,nctId,phase,recruitment,therapies,title,Indications_id
0,NCT02834013,Phase 0,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab in Treating Patients With Rare Tumors,3025
0,NCT03095248,Phase II,Recruiting,"[{'id': 913, 'therapyName': 'Selumetinib'}]",Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors,12689
0,NCT02731729,Phase II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy,6367
1,NCT02879162,Phase II,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours,6367
2,NCT02978443,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab,6367
0,NCT00602693,Phase I,Completed,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 2311, 'therapyName': 'Allopurinol + Cyclophosphamide + Fludarabine'}]",T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer,12603
1,NCT00990249,Phase II,Completed,"[{'id': 2469, 'therapyName': 'Busulfan + Clofarabine + Thymoglobulin'}]",Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation,12603
2,NCT01822509,Phase I,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant,12603
3,NCT02141828,Phase I,Completed,"[{'id': 2855, 'therapyName': 'EPZ-5676'}]",A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene,12603
4,NCT02158858,Phase I,Recruiting,"[{'id': 2033, 'therapyName': 'CPI-0610'}]","A Phase 1 Study Evaluating CPI-0610 in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelodysplastic/Myeloproliferative Neoplasms",12603
5,NCT02208037,Phase II,"Active, not recruiting",[],Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203),12603
6,NCT02212561,Phase Ib/II,Completed,"[{'id': 1749, 'therapyName': 'Selinexor'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 2345, 'therapyName': 'Cytarabine + Dexamethasone+ Methotrexate '}, {'id': 1166, 'therapyName': 'Fludarabine'}]",Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome,12603
7,NCT02225574,Phase Ib/II,Completed,"[{'id': 2219, 'therapyName': 'MEK162 + Nilotinib'}]","An Open-Label, Phase I/II Study of Nilotinib (Tasigna) and MEK-162 (ARRY-162) Used in Combination for Patients With Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia (Protocol CAMN107AUS41T)",12603
8,NCT02270788,Phase I,Completed,"[{'id': 1865, 'therapyName': 'Methotrexate + Cytarabine + Leucovorin'}, {'id': 1864, 'therapyName': 'Crenolanib + Sorafenib'}]",Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies,12603
9,NCT02345382,Phase I,Completed,"[{'id': 4027, 'therapyName': 'BAY1143572'}]",Phase I Dose Escalation of BAY1143572 in Subjects With Acute Leukemia,12603
10,NCT02390752,Phase Ib/II,Recruiting,"[{'id': 874, 'therapyName': 'PLX3397'}]",PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN),12603
11,NCT02392572,Phase Ib/II,Recruiting,"[{'id': 1687, 'therapyName': 'ONC201'}]",ONC201 in Relapsed/Refractory Acute Leukemias and High-risk Myelodysplastic Syndromes (HR-MDS),12603
12,NCT02484261,Phase I,Recruiting,"[{'id': 3191, 'therapyName': 'Bortezomib + Pravastatin'}]",Monitoring and Treatment of Relapsed Leukemia Following Allogeneic Hematopoietic Stem Cell Transplantation in Children,12603
13,NCT02551718,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,12603
14,NCT02722668,Phase II,Recruiting,"[{'id': 2281, 'therapyName': 'Cyclophosphamide + Fludarabine + Mycophenolate mofetil'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}]",UCB Transplant for Hematological DIseases Using a Non Myeloablative Prep,12603
15,NCT02793544,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 5682, 'therapyName': 'Mesna'}, {'id': 1166, 'therapyName': 'Fludarabine'}]",HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide,12603
16,NCT02879695,Phase I,Recruiting,"[{'id': 4613, 'therapyName': 'Blinatumomab + Ipilimumab + Nivolumab'}]",Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia,12603
17,NCT03267186,Phase II,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant,12603
0,NCT00084695,Phase II,Unknown status,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases,9952
1,NCT00513474,Phase I,Completed,"[{'id': 2313, 'therapyName': 'Rasburicase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2314, 'therapyName': 'Busulfan + Cyclophosphamide + Etoposide'}]",Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant,9952
2,NCT00549848,Phase III,"Active, not recruiting","[{'id': 1781, 'therapyName': 'Vincristine + Pegaspargase + Daunorubicin'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1782, 'therapyName': 'Clofarabine + Etoposide + Cyclophosphamide'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]",Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia,9952
3,NCT00550992,Phase I,Unknown status,"[{'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}, {'id': 1848, 'therapyName': 'Cyclophosphamide + Methotrexate + Vincristine + Pegaspargase '}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia,9952
4,NCT00679536,Phase Ib/II,Unknown status,"[{'id': 1846, 'therapyName': 'Busulfan + Fludarabine + anti-thymocyte globulin'}]",Allogeneic Transplantation for Pediatric Leukemias With Unrelated Donors,9952
5,NCT00857389,Phase II,"Active, not recruiting","[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 2469, 'therapyName': 'Busulfan + Clofarabine + Thymoglobulin'}, {'id': 1639, 'therapyName': 'Methotrexate'}]",Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies,9952
6,NCT00866281,Phase Ib/II,Terminated,"[{'id': 810, 'therapyName': 'Midostaurin'}]",A Study of the Safety and Preliminary Efficacy of Oral Midostaurin (PKC412) in Relapsed or Refractory Pediatric Leukemia,9952
7,NCT00908167,Phase I,Completed,"[{'id': 2374, 'therapyName': 'Clofarabine + Cytarabine + Sorafenib'}]",Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies,9952
8,NCT00990249,Phase II,Completed,"[{'id': 2469, 'therapyName': 'Busulfan + Clofarabine + Thymoglobulin'}]",Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation,9952
9,NCT01077544,Phase I,Completed,"[{'id': 829, 'therapyName': 'Nilotinib'}]",A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL),9952
10,NCT01162551,Phase II,Completed,"[{'id': 2304, 'therapyName': 'Sirolimus + Methotrexate'}]",Trial of Sirolimus and Methotrexate in Relapsed/Refractory Lymphoblastic Leukemia and Lymphoma,9952
11,NCT01187810,Phase I,"Active, not recruiting","[{'id': 2731, 'therapyName': 'Fenretinide'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1639, 'therapyName': 'Methotrexate'}]","Fenretinide in Children With Recurrent/Resistant ALL, AML, and NHL",9952
12,NCT01251575,Phase II,Recruiting,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 2270, 'therapyName': 'Cyclosporine + Mycophenolate mofetil + Sirolimus'}]","Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant",9952
13,NCT01256398,Phase II,"Active, not recruiting","[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1824, 'therapyName': 'Vincristine + Methotrexate + Mercaptopurine'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 2391, 'therapyName': 'Cytarabine + Daunorubicin + Etoposide'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1205, 'therapyName': 'Alemtuzumab'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,9952
14,NCT01266083,Phase II,"Active, not recruiting","[{'id': 2893, 'therapyName': 'WT1 vaccine'}]",Trial of a WT-1 Analog Peptide Vaccine in Patients With Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL),9952
15,NCT01319981,Phase II,Recruiting,"[{'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia,9952
16,NCT01321346,Phase I,Completed,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1080, 'therapyName': 'Panobinostat'}]",A Study Of Panobinostat In Children With Refractory Hematologic Malignancies,9952
17,NCT01324180,Phase I,Completed,"[{'id': 1031, 'therapyName': 'Metformin'}, {'id': 1830, 'therapyName': 'Vincristine + Dexamethasone + Pegaspargase + Doxorubicin'}]","Vincristine, Dexamethasone, Doxorubicin, and PEG-asparaginase (VPLD) and Metformin for Relapsed Childhood Acute Lymphoblastic Leukemia (ALL)",9952
18,NCT01338987,Phase II,"Active, not recruiting","[{'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",Pilot Study of Lupron to Improve Immune Function After Allogeneic Bone Marrow Transplantation,9952
19,NCT01424982,Phase II,Recruiting,"[{'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 2048, 'therapyName': 'Cytarabine + Methotrexate + Ponatinib'}, {'id': 2049, 'therapyName': 'Ponatinib + Vincristine'}, {'id': 2046, 'therapyName': 'Cyclophosphamide + Dexamethasone + Doxorubicin + Vincristine '}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Hyper-CVAD and Ponatinib in Ph-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL),9952
20,NCT01483690,Phase Ib/II,Terminated,"[{'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}]",A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL,9952
21,NCT01523977,Phase I,"Active, not recruiting","[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1638, 'therapyName': 'Pegaspargase'}]",Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL,9952
22,NCT01614197,Phase I,Recruiting,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1639, 'therapyName': 'Methotrexate'}]",A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma,9952
23,NCT01620216,Phase II,Recruiting,"[{'id': 930, 'therapyName': 'Sunitinib'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 920, 'therapyName': 'Sorafenib'}]",Validation of an in Vitro Assay to Predict Targeted Therapies for Acute Leukemia Patients,9952
24,NCT01621477,Phase II,Terminated,"[{'id': 1756, 'therapyName': 'Plerixafor'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 2469, 'therapyName': 'Busulfan + Clofarabine + Thymoglobulin'}, {'id': 1783, 'therapyName': 'Cyclophosphamide + Cytarabine'}]",T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant,9952
25,NCT01634217,Phase I,"Active, not recruiting",[],Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation,9952
26,NCT01658007,Phase I,Terminated,"[{'id': 917, 'therapyName': 'Sirolimus'}]",Pilot Study Of Sirolimus Plus Multiagent Chemotherapy For Relapsed/Refractory Acute Lymphoblastic Leukemia/Lymphoma,9952
27,NCT01744223,Phase Ib/II,Recruiting,"[{'id': 5992, 'therapyName': 'Rimiducid'}, {'id': 6053, 'therapyName': 'BPX-501'}]",Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant,9952
28,NCT01746849,Phase II,Recruiting,"[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 2373, 'therapyName': 'Palifermin'}]",Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation,9952
29,NCT01769209,Phase II,Terminated,"[{'id': 688, 'therapyName': 'Bortezomib'}, {'id': 3195, 'therapyName': 'Cytarabine + Methotrexate '}, {'id': 1830, 'therapyName': 'Vincristine + Dexamethasone + Pegaspargase + Doxorubicin'}]",Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia,9952
30,NCT01829971,Phase I,Terminated,"[{'id': 1035, 'therapyName': 'MRX34'}]","A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection",9952
31,NCT01841333,Phase II,Recruiting,"[{'id': 1748, 'therapyName': 'PF-04449913'}]",PF-04449913 For Patients With Acute Leukemia at High Risk of Relapse After Donor Stem Cell Transplant,9952
32,NCT01885689,Phase II,Recruiting,"[{'id': 2236, 'therapyName': 'Clofarabine + Melphalan'}]",Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia or Acute Leukemia in Remission,9952
33,NCT01885897,Phase Ib/II,Recruiting,"[{'id': 3060, 'therapyName': 'ALT-803'}]",IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT,9952
34,NCT01925131,Phase I,Recruiting,"[{'id': 3221, 'therapyName': 'Cyclophosphamide + Prednisone + Vincristine'}, {'id': 3199, 'therapyName': 'inotuzumab ozogamicin'}]","S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia",9952
35,NCT01943682,Phase I,Recruiting,"[{'id': 4341, 'therapyName': 'CPX-351'}]",Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma,9952
36,NCT02043587,Phase II,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1136, 'therapyName': 'Etoposide'}]",Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia &amp; Lymphoblastic Lymphoma,9952
37,NCT02071927,Phase I,Completed,"[{'id': 1667, 'therapyName': 'CB-839'}]",Study of the Glutaminase Inhibitor CB-839 in Leukemia,9952
38,NCT02083250,Phase I,Recruiting,"[{'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 3201, 'therapyName': 'Busulfan + Clofarabine + Fludarabine'}]",Fludarabine/Clofarabine/Busulfan Combined With SAHA in Acute Leukemia,9952
39,NCT02089230,Phase Ib/II,Recruiting,"[{'id': 807, 'therapyName': 'Binimetinib'}]","Phase I/II MEK162 Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Poor Prognosis, Not Suitable for or Unwilling to Receive Standard Therapy",9952
40,NCT02091245,Phase I,Recruiting,"[{'id': 1749, 'therapyName': 'Selinexor'}]","Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML",9952
41,NCT02101853,Phase III,Recruiting,"[{'id': 1876, 'therapyName': 'Blinatumomab '}, {'id': 2347, 'therapyName': 'Leucovorin + Pegaspargase  + Vincristine'}, {'id': 2346, 'therapyName': 'Mercaptopurine + Thioguanine'}, {'id': 2348, 'therapyName': 'Asparaginase + Cyclophosphamide + Etoposide'}, {'id': 2345, 'therapyName': 'Cytarabine + Dexamethasone+ Methotrexate '}]",Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia,9952
42,NCT02129062,Phase II,Terminated,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia,9952
43,NCT02141828,Phase I,Completed,"[{'id': 2855, 'therapyName': 'EPZ-5676'}]",A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene,9952
44,NCT02143635,Phase I,Recruiting,"[{'id': 2186, 'therapyName': 'HDM201'}]",Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt,9952
45,NCT02146924,Phase I,Recruiting,[],Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia,9952
46,NCT02158858,Phase I,Recruiting,"[{'id': 2033, 'therapyName': 'CPI-0610'}]","A Phase 1 Study Evaluating CPI-0610 in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelodysplastic/Myeloproliferative Neoplasms",9952
47,NCT02181478,Phase I,Recruiting,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",Intra-Osseous Co-Transplant of UCB and hMSC,9952
48,NCT02200380,Phase II,Terminated,"[{'id': 1756, 'therapyName': 'Plerixafor'}, {'id': 3007, 'therapyName': 'CDX-301'}]",A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs,9952
49,NCT02212561,Phase Ib/II,Completed,"[{'id': 1749, 'therapyName': 'Selinexor'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 2345, 'therapyName': 'Cytarabine + Dexamethasone+ Methotrexate '}, {'id': 1166, 'therapyName': 'Fludarabine'}]",Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome,9952
50,NCT02269579,Phase II,Recruiting,"[{'id': 4341, 'therapyName': 'CPX-351'}]",Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment,9952
51,NCT02311998,Phase Ib/II,Recruiting,"[{'id': 3200, 'therapyName': 'Bosutinib + inotuzumab ozogamicin'}]",Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive Philadelphia-Chromosome (PC) Positive Acute Lymphoblastic Leukemia (ALL) and Chronic Myeloid Leukemia (CML),9952
52,NCT02319369,Phase I,Recruiting,"[{'id': 2079, 'therapyName': 'DS-3032b'}]","Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-3032b in Hematological Malignancies",9952
53,NCT02356159,Phase Ib/II,Recruiting,"[{'id': 2294, 'therapyName': 'Cytarabine + Fludarabine'}, {'id': 2373, 'therapyName': 'Palifermin'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2238, 'therapyName': 'Sirolimus + Tacrolimus + Methotrexate'}, {'id': 2292, 'therapyName': 'Doxorubicin + Etoposide + Fludarabine + Vincristine '}, {'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 897, 'therapyName': 'Rituximab'}]",Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation,9952
54,NCT02420717,Phase II,Recruiting,"[{'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 3195, 'therapyName': 'Cytarabine + Methotrexate '}, {'id': 2046, 'therapyName': 'Cyclophosphamide + Dexamethasone + Doxorubicin + Vincristine '}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 3194, 'therapyName': 'Mercaptopurine + Methotrexate + Prednisone + Vincristine'}]",Ruxolitinib or Dasatinib With Chemotherapy in Patients With Philadelphia Chromosome (Ph)-Like Acute Lymphoblastic Leukemia (ALL),9952
55,NCT02454270,Phase II,"Active, not recruiting","[{'id': 4166, 'therapyName': 'JNJ-64052781'}]",A Dose Escalation Study of JNJ-64052781 in Participants With Relapsed or Refractory B-cell Malignancies,9952
56,NCT02484430,Phase II,Recruiting,"[{'id': 1282, 'therapyName': 'Sapanisertib'}]",TORC1/2 Inhibitor INK128 in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia,9952
57,NCT02487459,Phase I,Not yet recruiting,"[{'id': 6053, 'therapyName': 'BPX-501'}, {'id': 5992, 'therapyName': 'Rimiducid'}]",Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies,9952
58,NCT02518750,Phase II,Recruiting,"[{'id': 1604, 'therapyName': 'Panobinostat + Bortezomib + Dexamethasone'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 3217, 'therapyName': 'Cyclophosphamide + Etoposide'}, {'id': 3216, 'therapyName': 'Cytarabine + Methotrexate + Prednisone'}, {'id': 1746, 'therapyName': 'Clofarabine'}]",Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma,9952
59,NCT02535806,Phase II,Terminated,"[{'id': 1631, 'therapyName': 'Vincristine'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults,9952
60,NCT02538926,Phase II,Not yet recruiting,"[{'id': 770, 'therapyName': 'Imatinib'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 3212, 'therapyName': 'Doxorubicin + Etoposide + Vincristine '}, {'id': 2206, 'therapyName': 'Asparaginase'}]","Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma",9952
61,NCT02553460,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I,9952
62,NCT02614066,Phase Ib/II,Recruiting,"[{'id': 4829, 'therapyName': 'KTE-C19'}]",A Study Evaluating KTE-C19 in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) (ZUMA-3) (ZUMA-3),9952
63,NCT02625480,Phase Ib/II,Recruiting,"[{'id': 4829, 'therapyName': 'KTE-C19'}]",A Multi-Center Study Evaluating KTE-C19 in Pediatric and Adolescent Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-4),9952
64,NCT02723994,Phase II,Recruiting,"[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 4685, 'therapyName': 'Dexamethasone + Doxorubicin'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 2346, 'therapyName': 'Mercaptopurine + Thioguanine'}, {'id': 2394, 'therapyName': 'Asparaginase + Cytarabine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1848, 'therapyName': 'Cyclophosphamide + Methotrexate + Vincristine + Pegaspargase '}]",A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia,9952
65,NCT02746952,Phase I,Recruiting,"[{'id': 5997, 'therapyName': 'UCART19'}]",Dose Escalation Study of UCART19 in Adult Patients With Relapsed / Refractory B-cell Acute Lymphoblastic Leukaemia (CALM),9952
66,NCT02767934,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia,9952
67,NCT02790515,Phase II,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1876, 'therapyName': 'Blinatumomab '}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 5682, 'therapyName': 'Mesna'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Provision of TCR?? T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation,9952
68,NCT02793544,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 5682, 'therapyName': 'Mesna'}, {'id': 1166, 'therapyName': 'Fludarabine'}]",HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide,9952
69,NCT02815059,Phase I,Recruiting,"[{'id': 4438, 'therapyName': 'Dasatinib + Ibrutinib + Prednisone'}]","Study of Pts With Philadelphia Chromosome-Pos ALL With Comb of Ibrutinib, Dasatinib, and Prednisone",9952
70,NCT02819804,Phase I,Recruiting,"[{'id': 1813, 'therapyName': 'Dasatinib + Nivolumab'}]",Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia,9952
71,NCT02861040,Phase I,Withdrawn,"[{'id': 4781, 'therapyName': 'Vincristine + Volasertib'}]",Volasertib and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia,9952
72,NCT02879695,Phase I,Recruiting,"[{'id': 4613, 'therapyName': 'Blinatumomab + Ipilimumab + Nivolumab'}]",Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia,9952
73,NCT02906371,Phase I,Recruiting,"[{'id': 5647, 'therapyName': 'Tocilizumab'}]",Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome,9952
74,NCT02935543,Phase II,Recruiting,"[{'id': 5999, 'therapyName': 'CART19 cells'}]",CART19 in Patient With ALL,9952
75,NCT02997761,Phase II,Recruiting,"[{'id': 5125, 'therapyName': 'Blinatumomab + Ibrutinib'}]",Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia,9952
76,NCT03007147,Phase III,Recruiting,"[{'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 5167, 'therapyName': 'Methylprednisolone'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 5168, 'therapyName': 'Prednisolone'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia,9952
77,NCT03016377,Phase I,Not yet recruiting,"[{'id': 3585, 'therapyName': 'Anti-CD19 CAR T'}]",Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia,9952
78,NCT03020030,Phase III,Recruiting,"[{'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents,9952
79,NCT03023046,Phase II,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1631, 'therapyName': 'Vincristine'}]","Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma",9952
80,NCT03056339,Phase Ib/II,Recruiting,"[{'id': 6217, 'therapyName': 'Cyclophosphamide + Fludarabine phosphate + iC9/CAR.19/IL15-Transduced CB-NK'}]",Umbilical & Cord Blood (CB)- Derived CAR-Engineered NK Cells for B Lymphoid Malignancies,9952
81,NCT03069469,Phase I,Recruiting,"[{'id': 5760, 'therapyName': 'DCC-3014'}]",Study of DCC-3014 in Patients With Advanced Malignancies,9952
82,NCT03071276,Phase II,Recruiting,"[{'id': 5448, 'therapyName': 'Selinexor + Fludarabine phosphate + Cytarabine + Methotrexate + Prednisone'}]",Selinexor in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Acute Myeloid Leukemia,9952
83,NCT03094611,Phase II,Not yet recruiting,"[{'id': 3199, 'therapyName': 'inotuzumab ozogamicin'}]",Study of Low Dose Inotuzumab Ozogamicin in Patients With Relapsed and Refractory CD22 Positive Acute Lymphocytic Leukemia,9952
84,NCT03104491,Phase Ib/II,Recruiting,"[{'id': 3199, 'therapyName': 'inotuzumab ozogamicin'}]",Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia,9952
85,NCT03110354,Phase I,Recruiting,"[{'id': 5691, 'therapyName': 'DS-3201b'}]",DS-3201b for Acute Myelogenous Leukemia (AML) or Acute Lymphocytic Leukemia (ALL),9952
86,NCT03117751,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1876, 'therapyName': 'Blinatumomab '}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}]",Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma,9952
87,NCT03128034,Phase Ib/II,Recruiting,"[{'id': 5714, 'therapyName': 'Cyclosporine + Fludarabine phosphate + Mycophenolate mofetil + Sirolimus'}]","211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome",9952
88,NCT03132454,Phase I,Recruiting,"[{'id': 5637, 'therapyName': 'Palbociclib + Decitabine'}, {'id': 5636, 'therapyName': 'Palbociclib + Dexamethasone'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 5638, 'therapyName': 'Palbociclib + Sorafenib'}]",Study of Palbociclib Alone and in Combination in Patients With Relapsed and Refractory (R/R) Leukemias,9952
89,NCT03147612,Phase II,Not yet recruiting,"[{'id': 5682, 'therapyName': 'Mesna'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}]",Study of the Combination of Low-Intensity Chemotherapy and Ponatinib in Patients With Philadelphia Chromosome (Ph)-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL),9952
90,NCT03150693,Phase III,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1783, 'therapyName': 'Cyclophosphamide + Cytarabine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 3628, 'therapyName': 'Allopurinol'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 3199, 'therapyName': 'inotuzumab ozogamicin'}]",Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia,9952
91,NCT03160079,Phase Ib/II,Recruiting,"[{'id': 5839, 'therapyName': 'Blinatumomab + Pembrolizumab'}]",Blinatumomab and Pembrolizumab for Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia With High Marrow Lymphoblasts,9952
92,NCT03181126,Phase I,Not yet recruiting,"[{'id': 6187, 'therapyName': 'Navitoclax + Venetoclax'}]",A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed Acute Lymphoblastic Leukemia,9952
93,NCT03263572,Phase II,Not yet recruiting,"[{'id': 6155, 'therapyName': 'Blinatumomab + Cytarabine + Dexamethasone + Methotrexate + Ponatinib'}, {'id': 6156, 'therapyName': 'Blinatumomab + Dexamethasone + Ponatinib'}]",Blinatumomab and Ponatinib in Patients With Philadelphia Chromosome (Ph)-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL),9952
94,NCT03267186,Phase II,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant,9952
95,NCT03286114,Phase I,Not yet recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab,9952
0,NCT01627041,Phase II,"Active, not recruiting","[{'id': 1739, 'therapyName': 'Daunorubicin + Cytarabine + Decitabine'}, {'id': 1738, 'therapyName': 'Daunorubicin + Cytarabine'}]","Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia",8864
0,NCT00084695,Phase II,Unknown status,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases,9119
1,NCT00513474,Phase I,Completed,"[{'id': 2313, 'therapyName': 'Rasburicase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2314, 'therapyName': 'Busulfan + Cyclophosphamide + Etoposide'}]",Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant,9119
2,NCT00679536,Phase Ib/II,Unknown status,"[{'id': 1846, 'therapyName': 'Busulfan + Fludarabine + anti-thymocyte globulin'}]",Allogeneic Transplantation for Pediatric Leukemias With Unrelated Donors,9119
3,NCT00857389,Phase II,"Active, not recruiting","[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 2469, 'therapyName': 'Busulfan + Clofarabine + Thymoglobulin'}, {'id': 1639, 'therapyName': 'Methotrexate'}]",Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies,9119
4,NCT00866281,Phase Ib/II,Terminated,"[{'id': 810, 'therapyName': 'Midostaurin'}]",A Study of the Safety and Preliminary Efficacy of Oral Midostaurin (PKC412) in Relapsed or Refractory Pediatric Leukemia,9119
5,NCT00887068,Phase III,"Active, not recruiting","[{'id': 651, 'therapyName': 'Azacitidine'}]",Randomized Allogeneic Azacitidine Study,9119
6,NCT00892190,Phase I,Completed,"[{'id': 717, 'therapyName': 'Dasatinib'}]",Study of Dasatinib and All-Trans Retinoic Acid for Relapsed/Refractory and/or Elderly Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome,9119
7,NCT00908167,Phase I,Completed,"[{'id': 2374, 'therapyName': 'Clofarabine + Cytarabine + Sorafenib'}]",Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies,9119
8,NCT00946647,Phase II,"Active, not recruiting","[{'id': 1080, 'therapyName': 'Panobinostat'}, {'id': 651, 'therapyName': 'Azacitidine'}]","A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).",9119
9,NCT01093573,Phase Ib/II,"Active, not recruiting","[{'id': 2471, 'therapyName': 'Azacitidine + Midostaurin'}]",Midostaurin and Azacitidine in Treating Elderly Patients With Acute Myelogenous Leukemia,9119
10,NCT01187810,Phase I,"Active, not recruiting","[{'id': 2731, 'therapyName': 'Fenretinide'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1639, 'therapyName': 'Methotrexate'}]","Fenretinide in Children With Recurrent/Resistant ALL, AML, and NHL",9119
11,NCT01222143,Phase Ib/II,Terminated,"[{'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}]","Safety and Efficacy Study of Nilotinib Combined With Mitoxantrone, Etoposide, and High-dose Cytarabine Induction Chemotherapy Followed by Consolidation for Patients With C-kit Positive Acute Myeloid Leukemia",9119
12,NCT01251575,Phase II,Recruiting,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 2270, 'therapyName': 'Cyclosporine + Mycophenolate mofetil + Sirolimus'}]","Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant",9119
13,NCT01252667,Phase II,Recruiting,"[{'id': 2272, 'therapyName': 'Cyclosporine + Mycophenolate mofetil'}, {'id': 1746, 'therapyName': 'Clofarabine'}]",Clofarabine and Low-Dose Total-Body Irradiation in Treating Patients With Acute Myeloid Leukemia Undergoing Donor Peripheral Blood Stem Cell Transplant,9119
14,NCT01266083,Phase II,"Active, not recruiting","[{'id': 2893, 'therapyName': 'WT1 vaccine'}]",Trial of a WT-1 Analog Peptide Vaccine in Patients With Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL),9119
15,NCT01303796,Phase III,Unknown status,"[{'id': 1747, 'therapyName': 'Decitabine + Sapacitabine'}, {'id': 650, 'therapyName': 'Decitabine'}]",A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (SEAMLESS),9119
16,NCT01321346,Phase I,Completed,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1080, 'therapyName': 'Panobinostat'}]",A Study Of Panobinostat In Children With Refractory Hematologic Malignancies,9119
17,NCT01338987,Phase II,"Active, not recruiting","[{'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",Pilot Study of Lupron to Improve Immune Function After Allogeneic Bone Marrow Transplantation,9119
18,NCT01352650,Phase I,"Active, not recruiting","[{'id': 1770, 'therapyName': 'Plerixafor + Decitabine'}]",Decitabine and Plerixafor in Elderly Acute Myeloid Leukemia (AML),9119
19,NCT01371981,Phase III,"Active, not recruiting","[{'id': 2391, 'therapyName': 'Cytarabine + Daunorubicin + Etoposide'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2392, 'therapyName': 'Cytarabine + Etoposide'}, {'id': 2393, 'therapyName': 'Cytarabine + Mitoxantrone'}, {'id': 2394, 'therapyName': 'Asparaginase + Cytarabine'}, {'id': 688, 'therapyName': 'Bortezomib'}]",Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,9119
20,NCT01398462,Phase I,Completed,"[{'id': 3081, 'therapyName': 'CWP232291'}]",Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients,9119
21,NCT01449058,Phase Ib/II,Completed,"[{'id': 1311, 'therapyName': 'BYL719 + MEK162'}]",A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors,9119
22,NCT01463046,Phase I,"Active, not recruiting","[{'id': 3185, 'therapyName': 'Cytarabine + Daunorubicin + Panobinostat'}]",Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome,9119
23,NCT01483274,Phase I,Withdrawn,"[{'id': 650, 'therapyName': 'Decitabine'}]",Decitabine and Vaccine Therapy for Patients With Relapsed AML Following Allogeneic Stem Cell Transplantation,9119
24,NCT01498445,Phase Ib/II,Recruiting,"[{'id': 1760, 'therapyName': 'Dasatinib + Decitabine '}]",Phase I/II - Dasatinib and Decitabine,9119
25,NCT01515527,Phase II,Recruiting,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 650, 'therapyName': 'Decitabine'}]",Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS),9119
26,NCT01534260,Phase Ib/II,Recruiting,"[{'id': 2366, 'therapyName': 'Bortezomib + Sorafenib + vorinostat'}]","Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype",9119
27,NCT01546038,Phase Ib/II,"Active, not recruiting","[{'id': 1748, 'therapyName': 'PF-04449913'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 1738, 'therapyName': 'Daunorubicin + Cytarabine'}]",A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,9119
28,NCT01578109,Phase I,"Active, not recruiting","[{'id': 920, 'therapyName': 'Sorafenib'}]",Sorafenib Tosylate Before and After Donor Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia,9119
29,NCT01606579,Phase Ib/II,Completed,"[{'id': 2466, 'therapyName': 'Cytarabine + Pri-724'}, {'id': 2465, 'therapyName': 'Dasatinib + Pri-724'}, {'id': 1083, 'therapyName': 'Pri-724'}]",Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies,9119
30,NCT01620216,Phase II,Recruiting,"[{'id': 930, 'therapyName': 'Sunitinib'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 920, 'therapyName': 'Sorafenib'}]",Validation of an in Vitro Assay to Predict Targeted Therapies for Acute Leukemia Patients,9119
31,NCT01621477,Phase II,Terminated,"[{'id': 1756, 'therapyName': 'Plerixafor'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 2469, 'therapyName': 'Busulfan + Clofarabine + Thymoglobulin'}, {'id': 1783, 'therapyName': 'Cyclophosphamide + Cytarabine'}]",T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant,9119
32,NCT01621542,Phase I,Completed,"[{'id': 2893, 'therapyName': 'WT1 vaccine'}]",Clinical Study of WT2725 in Patients With Advanced Malignancies,9119
33,NCT01627041,Phase II,"Active, not recruiting","[{'id': 1739, 'therapyName': 'Daunorubicin + Cytarabine + Decitabine'}, {'id': 1738, 'therapyName': 'Daunorubicin + Cytarabine'}]","Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia",9119
34,NCT01634217,Phase I,"Active, not recruiting",[],Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation,9119
35,NCT01640301,Phase Ib/II,Suspended,"[{'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 2901, 'therapyName': 'WT1 senstized T cells'}]","Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant",9119
36,NCT01657682,Phase II,Recruiting,"[{'id': 705, 'therapyName': 'Crenolanib'}]",A Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients With FLT3 Activating Mutations,9119
37,NCT01687400,Phase II,"Active, not recruiting","[{'id': 650, 'therapyName': 'Decitabine'}]",Genomic Predictors of Decitabine Response in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes,9119
38,NCT01707004,Phase I,"Active, not recruiting","[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1206, 'therapyName': 'Busulfan'}]",Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia,9119
39,NCT01729845,Phase Ib/II,"Active, not recruiting","[{'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}, {'id': 650, 'therapyName': 'Decitabine'}]","Decitabine Followed By Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes",9119
40,NCT01736943,Phase II,Recruiting,"[{'id': 3184, 'therapyName': 'Bortezomib + pegylated liposomal-doxorubicin'}]",Bortezomib and Doxil for the Treatment of Patients With Acute Myelogenous Leukemia,9119
41,NCT01744223,Phase Ib/II,Recruiting,"[{'id': 5992, 'therapyName': 'Rimiducid'}, {'id': 6053, 'therapyName': 'BPX-501'}]",Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant,9119
42,NCT01746849,Phase II,Recruiting,"[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 2373, 'therapyName': 'Palifermin'}]",Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation,9119
43,NCT01786343,Phase II,Recruiting,"[{'id': 650, 'therapyName': 'Decitabine'}]",Decitabine for Older or Unfit Patients With Acute Myeloid Leukemia (AML),9119
44,NCT01794702,Phase Ib/II,"Active, not recruiting","[{'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 650, 'therapyName': 'Decitabine'}]","Decitabine Followed by Clofarabine, Idarubicin, and Cytarabine in Acute Leukemia",9119
45,NCT01798901,Phase I,"Active, not recruiting","[{'id': 1751, 'therapyName': 'AR-42 + Decitabine'}]",AR-42 and Decitabine in Treating Patients With Acute Myeloid Leukemia,9119
46,NCT01804101,Phase I,"Active, not recruiting","[{'id': 4341, 'therapyName': 'CPX-351'}]",Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia,9119
47,NCT01806571,Phase II,Recruiting,"[{'id': 1738, 'therapyName': 'Daunorubicin + Cytarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}]","Daunorubicin Hydrochloride, Cytarabine, and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia",9119
48,NCT01814826,Phase I,"Active, not recruiting","[{'id': 1688, 'therapyName': 'MLN4924'}, {'id': 651, 'therapyName': 'Azacitidine'}]",Study of MLN4924 Plus Azacitidine in Treatment-Naïve Patients With Acute Myelogenous Leukemia (AML) Who Are 60 Years or Older,9119
49,NCT01822015,Phase I,"Active, not recruiting","[{'id': 2232, 'therapyName': 'Cytarabine + Idarubicin + Sirolimus'}]","Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia",9119
50,NCT01823198,Phase Ib/II,Recruiting,"[{'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1846, 'therapyName': 'Busulfan + Fludarabine + anti-thymocyte globulin'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Natural Killer (NK) Cells With HLA Compatible Hematopoietic Transplantation for High Risk Myeloid Malignancies,9119
51,NCT01829503,Phase II,"Active, not recruiting","[{'id': 1736, 'therapyName': 'Decitabine + Cytarabine'}]",Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML),9119
52,NCT01834248,Phase I,Completed,"[{'id': 1795, 'therapyName': 'DEC-205-NY-ESO-1 + Decitabine '}]",DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia,9119
53,NCT01835288,Phase II,Withdrawn,"[{'id': 640, 'therapyName': 'Arsenic trioxide'}]",Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia,9119
54,NCT01838395,Phase II,Completed,"[{'id': 3168, 'therapyName': 'BKT140 + Cytarabine'}]",Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML Patients,9119
55,NCT01841333,Phase II,Recruiting,"[{'id': 1748, 'therapyName': 'PF-04449913'}]",PF-04449913 For Patients With Acute Leukemia at High Risk of Relapse After Donor Stem Cell Transplant,9119
56,NCT01842646,Phase II,"Active, not recruiting","[{'id': 1748, 'therapyName': 'PF-04449913'}]",Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS),9119
57,NCT01846624,Phase II,"Active, not recruiting","[{'id': 1769, 'therapyName': 'Decitabine + Midostaurin'}]",Decitabine and Midostaurin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,9119
58,NCT01849276,Phase I,"Active, not recruiting","[{'id': 1792, 'therapyName': 'Metformin + Cytarabine'}]",Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML,9119
59,NCT01861314,Phase I,"Active, not recruiting","[{'id': 1793, 'therapyName': 'Bortezomib + Sorafenib + Decitabine   '}]","Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia",9119
60,NCT01869114,Phase II,Recruiting,"[{'id': 2233, 'therapyName': 'Azacitidine + Sirolimus'}]",Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy,9119
61,NCT01869803,Phase I,Suspended,"[{'id': 756, 'therapyName': 'Gemtuzumab ozogamicin'}]",Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia,9119
62,NCT01870596,Phase II,Completed,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 2027, 'therapyName': 'MK-8776'}]",Cytarabine With or Without SCH 900776 in Treating Adult Patients With Relapsed Acute Myeloid Leukemia,9119
63,NCT01876953,Phase Ib/II,"Active, not recruiting","[{'id': 1850, 'therapyName': 'Cytarabine + Idarubicin + Dasatinib'}]","Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia",9119
64,NCT01880437,Phase II,Terminated,"[{'id': 1802, 'therapyName': 'Cytarabine + Vismodegib'}]",A Study of Vismodegib in Patients With Relapsed/Refractory Acute Myelogenous Leukemia and Relapsed Refractory High-Risk Myleodysplastic Syndrome,9119
65,NCT01883362,Phase II,Recruiting,"[{'id': 810, 'therapyName': 'Midostaurin'}]",Standard of Care +/- Midostaurin to Prevent Relapse Post Stem Cell Transplant in Patients With FLT3-ITD Mutated AML,9119
66,NCT01885689,Phase II,Recruiting,"[{'id': 2236, 'therapyName': 'Clofarabine + Melphalan'}]",Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia or Acute Leukemia in Remission,9119
67,NCT01885897,Phase Ib/II,Recruiting,"[{'id': 3060, 'therapyName': 'ALT-803'}]",IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT,9119
68,NCT01892371,Phase Ib/II,Recruiting,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 882, 'therapyName': 'Quizartinib'}]",AC220 With 5-Aza or Low Dose Cytarabine,9119
69,NCT01893320,Phase Ib/II,"Active, not recruiting","[{'id': 1766, 'therapyName': 'Decitabine + Vosaroxin'}]",Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome,9119
70,NCT01898793,Phase Ib/II,Recruiting,"[{'id': 3409, 'therapyName': 'Aldesleukin + Cyclophosphamide + Fludarabine '}, {'id': 5300, 'therapyName': 'ALT-803 + Cyclophosphamide + Fludarabine phosphate'}]",Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS),9119
71,NCT01907815,Phase II,"Active, not recruiting","[{'id': 1298, 'therapyName': 'Trametinib + GSK2141795'}]",Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia,9119
72,NCT01926587,Phase Ib/II,Recruiting,"[{'id': 2320, 'therapyName': 'Azacitidine + Regorafenib'}]",Oral Rigosertib in Combination With Azacitidine,9119
73,NCT01943682,Phase I,Recruiting,"[{'id': 4341, 'therapyName': 'CPX-351'}]",Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma,9119
74,NCT01961765,Phase I,Completed,"[{'id': 998, 'therapyName': 'cabozantinib'}]",Phase I Trial of Cabozantinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia,9119
75,NCT02003573,Phase I,Terminated,"[{'id': 1745, 'therapyName': 'Volasertib + Decitabine'}]",Volasertib + Decitabine in Patients With Acute Myeloid Leukemia (AML),9119
76,NCT02010645,Phase II,"Active, not recruiting","[{'id': 1763, 'therapyName': 'Eltrombopag + Decitabine'}]",Eltrombopag With Decitabine in Advanced Myelodysplastic Syndrome (MDS),9119
77,NCT02016729,Phase I,Completed,"[{'id': 2, 'therapyName': 'Trametinib'}, {'id': 1452, 'therapyName': 'AMG 232'}]",A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia,9119
78,NCT02019069,Phase II,Recruiting,"[{'id': 4341, 'therapyName': 'CPX-351'}]",CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome,9119
79,NCT02029417,Phase II,Terminated,"[{'id': 1794, 'therapyName': 'Omacetaxine + Cytarabine + Decitabine'}]","Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia",9119
80,NCT02039726,Phase III,"Active, not recruiting","[{'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 3193, 'therapyName': 'Cytarabine + Fludarabine + Idarubicin'}, {'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}, {'id': 882, 'therapyName': 'Quizartinib'}]",An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects,9119
81,NCT02046122,Phase I,Recruiting,"[{'id': 1606, 'therapyName': 'Cytarabine + Idarubicin'}]",Adoptive Transfer of Haplo-identical DLI for AML and MDS,9119
82,NCT02049801,Phase I,"Active, not recruiting","[{'id': 2220, 'therapyName': 'MEK162 + Idarubicin + Cytarabine'}]","MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia",9119
83,NCT02057770,Phase I,Recruiting,"[{'id': 5724, 'therapyName': 'Busulfan + Fludarabine phosphate + Cyclophosphamide'}, {'id': 5647, 'therapyName': 'Tocilizumab'}]",Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia,9119
84,NCT02071927,Phase I,Completed,"[{'id': 1667, 'therapyName': 'CB-839'}]",Study of the Glutaminase Inhibitor CB-839 in Leukemia,9119
85,NCT02073838,Phase II,Recruiting,"[{'id': 650, 'therapyName': 'Decitabine'}, {'id': 3179, 'therapyName': 'Vismodegib + Ribavirin'}]",Ribavirin and Hedgehog Inhibitor With or Without Decitabine in AML,9119
86,NCT02078609,Phase I,Recruiting,"[{'id': 2402, 'therapyName': 'LGH447 '}]",A Safety and Efficacy Study of LGH447 in Patients With Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS),9119
87,NCT02083250,Phase I,Recruiting,"[{'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 3201, 'therapyName': 'Busulfan + Clofarabine + Fludarabine'}]",Fludarabine/Clofarabine/Busulfan Combined With SAHA in Acute Leukemia,9119
88,NCT02085408,Phase III,Recruiting,"[{'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1738, 'therapyName': 'Daunorubicin + Cytarabine'}]",Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,9119
89,NCT02088541,Phase II,"Active, not recruiting","[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 1749, 'therapyName': 'Selinexor'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}]",Selinexor (KPT-330) in Older Patients With Relapsed AML,9119
90,NCT02089230,Phase Ib/II,Recruiting,"[{'id': 807, 'therapyName': 'Binimetinib'}]","Phase I/II MEK162 Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Poor Prognosis, Not Suitable for or Unwilling to Receive Standard Therapy",9119
91,NCT02091245,Phase I,Recruiting,"[{'id': 1749, 'therapyName': 'Selinexor'}]","Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML",9119
92,NCT02093403,Phase I,"Active, not recruiting","[{'id': 1768, 'therapyName': 'Decitabine + Selinexor'}]",Decitabine and Selinexor in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia,9119
93,NCT02096055,Phase II,Recruiting,"[{'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1949, 'therapyName': 'SGI-110'}, {'id': 1022, 'therapyName': 'Idarubicin'}]",4-Arm Phase II Study of SGI-110 in Elderly Acute Myeloid Leukemia (AML),9119
94,NCT02098967,Phase I,"Active, not recruiting","[{'id': 2155, 'therapyName': 'RO6839921'}]","A Study of the Safety and Pharmacokinetics of RO6839921, An MDM2 Antagonist, in Patients With Advanced Cancers, Including Acute Myeloid Leukemia.",9119
95,NCT02109627,Phase I,Recruiting,"[{'id': 3183, 'therapyName': 'Cytarabine + Ficlatuzumab'}]",Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML,9119
96,NCT02109744,Phase Ib/II,Recruiting,"[{'id': 1796, 'therapyName': 'Decitabine + Sirolimus'}, {'id': 1797, 'therapyName': 'Decitabine + Ribavirin'}]",Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients,9119
97,NCT02117297,Phase II,Recruiting,"[{'id': 756, 'therapyName': 'Gemtuzumab ozogamicin'}]",SCT Plus Immune Therapy in Average Risk AML/MDS,9119
98,NCT02121418,Phase I,"Active, not recruiting","[{'id': 1736, 'therapyName': 'Decitabine + Cytarabine'}]","Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm",9119
99,NCT02126553,Phase II,Recruiting,"[{'id': 1164, 'therapyName': 'lenalidomide'}]",Lenalidomide Maintenance With High Risk (HR) Acute Myeloid Leukemia (AML) in Remission,9119
100,NCT02141477,Phase II,Terminated,"[{'id': 1762, 'therapyName': 'Omacetaxine + Decitabine'}]",Omacetaxine and Decitabine in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS),9119
101,NCT02141828,Phase I,Completed,"[{'id': 2855, 'therapyName': 'EPZ-5676'}]",A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene,9119
102,NCT02143635,Phase I,Recruiting,"[{'id': 2186, 'therapyName': 'HDM201'}]",Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt,9119
103,NCT02158858,Phase I,Recruiting,"[{'id': 2033, 'therapyName': 'CPI-0610'}]","A Phase 1 Study Evaluating CPI-0610 in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelodysplastic/Myeloproliferative Neoplasms",9119
104,NCT02159495,Phase I,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}]",Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia,9119
105,NCT02177812,Phase I,Recruiting,"[{'id': 3014, 'therapyName': 'GSK2879552 '}]",A Phase I Dose Escalation Study of GSK2879552 in Subjects With Acute Myeloid Leukemia (AML),9119
106,NCT02181478,Phase I,Recruiting,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",Intra-Osseous Co-Transplant of UCB and hMSC,9119
107,NCT02190695,Phase II,Recruiting,"[{'id': 1608, 'therapyName': 'Decitabine + Carboplatin'}, {'id': 1609, 'therapyName': 'Decitabine + Arsenic trioxide '}]","A Safety and Efficacy Study Using Decitabine, Decitabine/Carboplatin, Decitabine/Arsenic for the Treatment of Relapsed, Refractory, and Elderly Acute Myeloid Leukemia , Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia",9119
108,NCT02196857,Phase II,Recruiting,"[{'id': 1633, 'therapyName': 'Sorafenib + Azacitidine'}]",Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation,9119
109,NCT02200380,Phase II,Terminated,"[{'id': 1756, 'therapyName': 'Plerixafor'}, {'id': 3007, 'therapyName': 'CDX-301'}]",A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs,9119
110,NCT02203773,Phase I,"Active, not recruiting","[{'id': 1636, 'therapyName': 'GDC-0199 + Decitabine'}, {'id': 1637, 'therapyName': 'GDC-0199 + Azacitidine'}]",Phase 1b Acute Myelogenous Leukemia (AML) Study With ABT-199 + Decitabine or Azacitidine (Chemo Combo),9119
111,NCT02204020,Phase II,Withdrawn,"[{'id': 651, 'therapyName': 'Azacitidine'}]",Phase II Study of 5-azacytidine Maintenance After Transplant for AML or MDS,9119
112,NCT02204085,Phase Ib/II,Recruiting,"[{'id': 3426, 'therapyName': 'GO-203-2C'}]","A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia",9119
113,NCT02212561,Phase Ib/II,Completed,"[{'id': 1749, 'therapyName': 'Selinexor'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 2345, 'therapyName': 'Cytarabine + Dexamethasone+ Methotrexate '}, {'id': 1166, 'therapyName': 'Fludarabine'}]",Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome,9119
114,NCT02221310,Phase II,Recruiting,"[{'id': 3932, 'therapyName': 'Busulfan + Cyclophosphamide + Gemtuzumab ozogamicin'}]",Immunochemotherapy and AlloSCT in Patients With High Risk CD33+ AML/MDS,9119
115,NCT02236013,Phase I,Recruiting,"[{'id': 1606, 'therapyName': 'Cytarabine + Idarubicin'}, {'id': 2865, 'therapyName': 'Gilteritinib'}]",A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia,9119
116,NCT02238522,Phase I,Withdrawn,[],Phase 1 Study Evaluating ZEN003365 in Relapsed/Refractory Lymphoproliferative Malignancies or Relapsed/Refractory AML,9119
117,NCT02257138,Phase Ib/II,Recruiting,"[{'id': 1735, 'therapyName': 'Ruxolitinib + Decitabine'}]",Study of Ruxolitinib Plus Decitabine in Patients With Acute Myeloid Leukemia (AML),9119
118,NCT02269579,Phase II,Recruiting,"[{'id': 4341, 'therapyName': 'CPX-351'}]",Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment,9119
119,NCT02270463,Phase Ib/II,Recruiting,"[{'id': 2005, 'therapyName': 'SL-401'}]",SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete Remission,9119
120,NCT02270788,Phase I,Completed,"[{'id': 1865, 'therapyName': 'Methotrexate + Cytarabine + Leucovorin'}, {'id': 1864, 'therapyName': 'Crenolanib + Sorafenib'}]",Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies,9119
121,NCT02273102,Phase I,Recruiting,"[{'id': 6126, 'therapyName': 'Tranylcypromine + Tretinoin '}]",Phase 1 Study of TCP-ATRA for Adult Patients With AML and MDS (TCP-ATRA),9119
122,NCT02275533,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab in Eliminating Minimal Residual Disease and Preventing Relapse in Patients With Acute Myeloid Leukemia in Remission After Chemotherapy,9119
123,NCT02283177,Phase II,Recruiting,"[{'id': 2637, 'therapyName': 'Crenolanib + Cytarabine + Daunorubicin'}]",A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations,9119
124,NCT02286726,Phase II,Recruiting,"[{'id': 4341, 'therapyName': 'CPX-351'}]",Phase II CPX-351 in Acute Myeloid Leukemia (AML),9119
125,NCT02287233,Phase I,"Active, not recruiting","[{'id': 3182, 'therapyName': 'Cytarabine + GDC-0199'}]",A Study Evaluating ABT-199 in Combination With Low-Dose Cytarabine in Treatment-Naïve Subjects With Acute Myelogenous Leukemia (AML),9119
126,NCT02296242,Phase Ib/II,Completed,"[{'id': 997, 'therapyName': 'BVD-523'}]",Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes,9119
127,NCT02299518,Phase I,Recruiting,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1749, 'therapyName': 'Selinexor'}, {'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}]",Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia,9119
128,NCT02305563,Phase Ib/II,Recruiting,"[{'id': 6259, 'therapyName': 'Cytarabine + Ulocuplumab'}]",An Investigational Immuno-therapy Study of Ulocuplumab in Combination With Low Dose Cytarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia,9119
129,NCT02306291,Phase Ib/II,Recruiting,"[{'id': 1606, 'therapyName': 'Cytarabine + Idarubicin'}, {'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}, {'id': 4402, 'therapyName': 'GMI-1271'}]","Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML",9119
130,NCT02308761,Phase I,Recruiting,"[{'id': 937, 'therapyName': 'TEN-010'}]",A Dose Escalation and Cohort Expansion Study of TEN-010 in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome,9119
131,NCT02312102,Phase I,Recruiting,"[{'id': 3220, 'therapyName': 'Bortezomib + lenalidomide'}]",Phase I Study of Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell Transplantation,9119
132,NCT02319369,Phase I,Recruiting,"[{'id': 2079, 'therapyName': 'DS-3032b'}]","Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-3032b in Hematological Malignancies",9119
133,NCT02323113,Phase Ib/II,Recruiting,"[{'id': 3146, 'therapyName': 'TAK-659'}]","Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (AML)",9119
134,NCT02323607,Phase I,Suspended,"[{'id': 3219, 'therapyName': 'Cytarabine + Daunorubicin + Pacritinib'}, {'id': 3177, 'therapyName': 'Pacritinib + Decitabine'}]",Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations,9119
135,NCT02333162,Phase I,Recruiting,"[{'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}]","Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant",9119
136,NCT02335814,Phase I,Terminated,"[{'id': 2529, 'therapyName': 'FLX925  '}]",First-in-Human Study of FLX925 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia,9119
137,NCT02343939,Phase Ib/II,Recruiting,"[{'id': 650, 'therapyName': 'Decitabine'}, {'id': 1738, 'therapyName': 'Daunorubicin + Cytarabine'}, {'id': 2522, 'therapyName': 'Entospletinib  '}]",Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),9119
138,NCT02348489,Phase III,"Active, not recruiting","[{'id': 1949, 'therapyName': 'SGI-110'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 650, 'therapyName': 'Decitabine'}]","SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction",9119
139,NCT02351037,Phase II,Terminated,"[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 712, 'therapyName': 'Cytarabine'}]",A Multicenter Open-Label Phase 2a Study of Ibrutinib With or Without Cytarabine in Subjects With Acute Myeloid Leukemia,9119
140,NCT02356159,Phase Ib/II,Recruiting,"[{'id': 2294, 'therapyName': 'Cytarabine + Fludarabine'}, {'id': 2373, 'therapyName': 'Palifermin'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2238, 'therapyName': 'Sirolimus + Tacrolimus + Methotrexate'}, {'id': 2292, 'therapyName': 'Doxorubicin + Etoposide + Fludarabine + Vincristine '}, {'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 897, 'therapyName': 'Rituximab'}]",Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation,9119
141,NCT02367456,Phase Ib/II,Recruiting,"[{'id': 4177, 'therapyName': 'Azacitidine + PF-04449913'}]","A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In 1st Line MDS, AML and CMML Patients",9119
142,NCT02381548,Phase I,"Active, not recruiting","[{'id': 3197, 'therapyName': 'Belinostat + MK-1775'}]",Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia,9119
143,NCT02391480,Phase I,Recruiting,"[{'id': 4028, 'therapyName': 'ABBV-075'}]",A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer,9119
144,NCT02397720,Phase II,Recruiting,"[{'id': 3196, 'therapyName': 'Azacitidine + Nivolumab'}]",A Study of Nivolumab (BMS-936558) in Combination With 5-azacytidine (Vidaza) for the Treatment of Patients With Refractory/ Relapsed Acute Myeloid Leukemia,9119
145,NCT02400255,Phase II,Recruiting,"[{'id': 705, 'therapyName': 'Crenolanib'}]",Crenolanib Maintenance Following Allogeneic Stem Cell Transplantation in FLT3-positive Acute Myeloid Leukemia Patients,9119
146,NCT02400281,Phase Ib/II,Recruiting,"[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 705, 'therapyName': 'Crenolanib'}, {'id': 1606, 'therapyName': 'Cytarabine + Idarubicin'}]",Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients,9119
147,NCT02403310,Phase I,"Active, not recruiting","[{'id': 1738, 'therapyName': 'Daunorubicin + Cytarabine'}, {'id': 1749, 'therapyName': 'Selinexor'}]",A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AML,9119
148,NCT02412475,Phase I,"Active, not recruiting","[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 650, 'therapyName': 'Decitabine'}]",Epigenetic Reprogramming in Relapse AML,9119
149,NCT02416908,Phase Ib/II,Recruiting,"[{'id': 1749, 'therapyName': 'Selinexor'}, {'id': 3178, 'therapyName': 'Cladribine + Cytarabine + Plerixafor'}]",Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia,9119
150,NCT02418000,Phase Ib/II,Terminated,"[{'id': 1011, 'therapyName': 'E6201'}]",A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 Mutation,9119
151,NCT02421939,Phase III,Recruiting,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 3193, 'therapyName': 'Cytarabine + Fludarabine + Idarubicin'}, {'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 2865, 'therapyName': 'Gilteritinib'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,9119
152,NCT02464657,Phase Ib/II,Recruiting,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 3192, 'therapyName': 'Cytarabine + Idarubicin + Nivolumab'}]",Nivolumab in Acute Myeloid Leukemia (AML),9119
153,NCT02472145,Phase III,"Active, not recruiting","[{'id': 650, 'therapyName': 'Decitabine'}, {'id': 5909, 'therapyName': 'Decitabine + Talacotuzumab'}]",An Efficacy and Safety Study of Decitabine (DACOGEN) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus Decitabine (DACOGEN) Alone in Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy,9119
154,NCT02485535,Phase I,Recruiting,"[{'id': 1749, 'therapyName': 'Selinexor'}]",Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant,9119
155,NCT02487459,Phase I,Not yet recruiting,"[{'id': 6053, 'therapyName': 'BPX-501'}, {'id': 5992, 'therapyName': 'Rimiducid'}]",Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies,9119
156,NCT02488408,Phase I,Recruiting,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 2660, 'therapyName': 'BGB-324'}]",Multicenter Open-label Study of BGB324 as a Single Agent and in Combination With Cytarabine in Patients With AML,9119
157,NCT02498665,Phase I,Recruiting,"[{'id': 4320, 'therapyName': 'DSP-7888'}]",A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies,9119
158,NCT02520011,Phase II,Recruiting,"[{'id': 628, 'therapyName': 'Alvocidib'}, {'id': 2393, 'therapyName': 'Cytarabine + Mitoxantrone'}]",Alvocidib Biomarker-driven Phase 2 AML Study,9119
159,NCT02521493,Phase III,Recruiting,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 5912, 'therapyName': 'Asparaginase Erwinia chrysanthemi'}, {'id': 5215, 'therapyName': 'mitoxantrone hydrochloride'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2206, 'therapyName': 'Asparaginase'}]",Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome,9119
160,NCT02527174,Phase I,Withdrawn,"[{'id': 3213, 'therapyName': 'Cytarabine + Idarubicin + Volasertib'}]",A Study of Volasertib Plus Induction Chemotherapy for Acute Myeloid Leukemia (VIAC),9119
161,NCT02528877,Phase I,Withdrawn,"[{'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}, {'id': 3181, 'therapyName': 'Ruxolitinib + Sirolimus + Tacrolimus'}]","Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis",9119
162,NCT02530476,Phase Ib/II,Recruiting,"[{'id': 3189, 'therapyName': 'Selinexor + Sorafenib'}]","Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia",9119
163,NCT02532010,Phase II,"Active, not recruiting","[{'id': 3177, 'therapyName': 'Pacritinib + Decitabine'}, {'id': 3176, 'therapyName': 'Pacritinib + Cytarabine'}]",Pacritinib Combined With Decitabine or Cytarabine in Older Patients With AML,9119
164,NCT02532231,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab in Acute Myeloid Leukemia (AML) in Remission at High Risk for Relapse,9119
165,NCT02533115,Expanded access,Approved for marketing,"[{'id': 4341, 'therapyName': 'CPX-351'}]",EAP of CPX-351 (VYXEOS) for Patients 60-75 Years of Age With Secondary AML,9119
166,NCT02545283,Phase III,Recruiting,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 4395, 'therapyName': 'Cytarabine + Idasanutlin'}]",A Study of Idasanutlin With Cytarabine Versus Cytarabine Plus Placebo in Patients With Relapsed or Refractory Acute Myeloid Leukemia,9119
167,NCT02560025,Phase II,"Active, not recruiting","[{'id': 626, 'therapyName': 'Alisertib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 712, 'therapyName': 'Cytarabine'}]",Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML,9119
168,NCT02561455,Phase Ib/II,"Active, not recruiting","[{'id': 2865, 'therapyName': 'Gilteritinib'}]",Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial,9119
169,NCT02573363,Phase I,Recruiting,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 1749, 'therapyName': 'Selinexor'}]",Selinexor With Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia,9119
170,NCT02576301,Phase Ib/II,Recruiting,"[{'id': 3524, 'therapyName': 'OXi4503'}, {'id': 3887, 'therapyName': 'Cytarabine + OXi4503'}]",Dose Escalation of OXi4503 as Single Agent and Combination With Cytarabine w/Subsequent Ph 2 Cohorts for AML and MDS,9119
171,NCT02577406,Phase III,Recruiting,"[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 2982, 'therapyName': 'Enasidenib'}]",An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation (IDHENTIFY),9119
172,NCT02583893,Phase II,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}]",Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients With High-Risk Acute Myeloid Leukemia,9119
173,NCT02610777,Phase II,"Active, not recruiting","[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 1688, 'therapyName': 'MLN4924'}]","An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)",9119
174,NCT02624570,Phase I,Available,"[{'id': 810, 'therapyName': 'Midostaurin'}]",Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy.,9119
175,NCT02626338,Phase Ib/II,Recruiting,"[{'id': 4024, 'therapyName': 'Crenolanib + Cytarabine + Mitoxantrone'}]",Pilot Study of Crenolanib Combined With Cytarabine and Mitoxantrone in Subjects With R/R AML,9119
176,NCT02632708,Phase I,Recruiting,"[{'id': 1491, 'therapyName': 'AG-120'}, {'id': 2982, 'therapyName': 'Enasidenib'}, {'id': 3431, 'therapyName': 'Cytarabine + Daunorubicin + Etoposide + Mitoxantrone'}]",Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia With an IDH1 and/or IDH2 Mutation,9119
177,NCT02632721,Phase II,Recruiting,"[{'id': 5540, 'therapyName': 'BI 836858 + Decitabine'}, {'id': 650, 'therapyName': 'Decitabine'}]",A Study to Find and Investigate a Safe Dose of BI 836858 in Combination With Decitabine for Patients With Acute Myeloid Leukemia (AML),9119
178,NCT02634827,Phase II,Recruiting,"[{'id': 1769, 'therapyName': 'Decitabine + Midostaurin'}]",Midostaurin and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia and FLT3 Mutation,9119
179,NCT02635074,Phase I,Recruiting,"[{'id': 3573, 'therapyName': 'Cytarabine + Idarubicin + Ibrutinib'}]","Ibrutinib, Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia",9119
180,NCT02642965,Phase Ib/II,Recruiting,"[{'id': 4391, 'therapyName': 'CPX-351 + Cytarabine + Filgrastim + Fludarabine '}]","Liposomal Cytarabine-Daunorubicin CPX-351, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia",9119
181,NCT02649764,Phase I,Recruiting,"[{'id': 3535, 'therapyName': 'Cytarabine + Fludarabine + Prexasertib'}]",LY2606368 in Combination With Cytarabine and Fludarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HRMDS),9119
182,NCT02652871,Phase I,Recruiting,"[{'id': 3470, 'therapyName': 'Cytarabine + Idarubicin + LY2510924'}]","A Phase 1b, Open-label Study of LY2510924, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia",9119
183,NCT02665143,Phase Ib/II,Recruiting,"[{'id': 1606, 'therapyName': 'Cytarabine + Idarubicin'}, {'id': 831, 'therapyName': 'Nintedanib'}]",A Randomized Trial of a Combination of Nintedanib/Placebo in Combination With Induction Chemotherapy for Patients With Refractory or First Relapse Acute Myeloid Leukemia,9119
184,NCT02666950,Phase II,Recruiting,"[{'id': 822, 'therapyName': 'MK-1775'}, {'id': 712, 'therapyName': 'Cytarabine'}]",WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome,9119
185,NCT02668653,Phase III,Recruiting,"[{'id': 3543, 'therapyName': 'Cytarabine + Daunorubicin + Idarubicin'}, {'id': 882, 'therapyName': 'Quizartinib'}]",Quizartinib With Standard of Care Chemotherapy and as Maintenance Therapy in Patients With Newly Diagnosed FLT3-ITD (+) AML,9119
186,NCT02670044,Phase Ib/II,Recruiting,"[{'id': 4171, 'therapyName': 'Cobimetinib + Venetoclax'}, {'id': 4172, 'therapyName': 'RO5503781 + Venetoclax'}]",A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy,9119
187,NCT02676323,Phase Ib/II,Recruiting,"[{'id': 3732, 'therapyName': 'Cytarabine + Fludarabine + Leucovorin + Panobinostat'}]",Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome,9119
188,NCT02677922,Phase Ib/II,Recruiting,"[{'id': 4002, 'therapyName': 'AG-120 + Azacitidine'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 4003, 'therapyName': 'Azacitidine + Enasidenib'}]",A Safety and Efficacy Study of Oral AG-120 Plus Subcutaneous Azacitidine and Oral AG-221 Plus Subcutaneous Azacitidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML),9119
189,NCT02680951,Phase I,Recruiting,"[{'id': 3731, 'therapyName': 'Cytarabine + Dasatinib + Fludarabine  + Idarubicin'}]",Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia,9119
190,NCT02684162,Phase II,Recruiting,"[{'id': 1949, 'therapyName': 'SGI-110'}]",SGI-110 With Donor Lymphocyte Infusion (DLI) for Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing Post Allogeneic Stem Cell Transplantation (AlloSCT),9119
191,NCT02698189,Phase I,"Active, not recruiting","[{'id': 2034, 'therapyName': 'OTX015'}]",A Dose Exploration Study With MK-8628 in Participants With Selected Hematologic Malignancies (MK-8628-005),9119
192,NCT02708641,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Phase II Study of Pembrolizumab as Post-Remission Treatment of Patients 60 With AML,9119
193,NCT02719574,Phase I,Recruiting,"[{'id': 4336, 'therapyName': 'FT-2102'}, {'id': 4449, 'therapyName': 'FT-2102 + Azacitidine'}]",Dose-Escalation Study of FT-2102 as a Single Agent and in Combination With Azacitidine in Patients With AML or MDS With an IDH1 Mutation,9119
194,NCT02721875,Phase I,Terminated,"[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 957, 'therapyName': 'Volasertib'}]",Trial of Volasertib With or Without Azacitidine in Patients With Myelodysplastic Syndromes,9119
195,NCT02723435,Phase II,Not yet recruiting,"[{'id': 810, 'therapyName': 'Midostaurin'}]",Midostaurin in Treating Older Patients With Mutated Acute Myeloid Leukemia Post-Transplant,9119
196,NCT02728050,Phase Ib/II,Recruiting,"[{'id': 920, 'therapyName': 'Sorafenib'}, {'id': 4363, 'therapyName': 'Cladribine + Cytarabine + Filgrastim + Mitoxantrone'}]","Filgrastim, Cladribine, Cytarabine and Mitoxantrone With or Without Sorafenib Tosylate in Treating Patients With Newly-Diagnosed, High-Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome",9119
197,NCT02743611,Phase I,Recruiting,"[{'id': 5992, 'therapyName': 'Rimiducid'}, {'id': 5991, 'therapyName': 'BPX-701'}]",Dose Finding Study Evaluating Safety and Feasibility in Patients With Relapsed or Refractory Myeloid Neoplasms,9119
198,NCT02752035,Phase II,Recruiting,"[{'id': 2865, 'therapyName': 'Gilteritinib'}, {'id': 651, 'therapyName': 'Azacitidine'}]","A Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation in Patients Not Eligible for Intensive Induction Chemotherapy",9119
199,NCT02756572,Phase I,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 5215, 'therapyName': 'mitoxantrone hydrochloride'}, {'id': 1166, 'therapyName': 'Fludarabine'}]",Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myelodysplastic Syndrome or Acute Myeloid Leukemia,9119
200,NCT02756962,Phase II,Recruiting,"[{'id': 810, 'therapyName': 'Midostaurin'}, {'id': 712, 'therapyName': 'Cytarabine'}]",Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance,9119
201,NCT02768792,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",High Dose Cytarabine Followed by Pembrolizumab in Relapsed/Refractory AML,9119
202,NCT02771197,Phase II,Recruiting,"[{'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in AML Patient Not Eligible for Transplant,9119
203,NCT02775903,Phase II,Recruiting,"[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 4178, 'therapyName': 'Azacitidine + MEDI4736'}]",An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Subjects With Acute Myeloid Leukemia (AML),9119
204,NCT02779283,Phase I,Recruiting,"[{'id': 717, 'therapyName': 'Dasatinib'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1606, 'therapyName': 'Cytarabine + Idarubicin'}, {'id': 930, 'therapyName': 'Sunitinib'}]",Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,9119
205,NCT02782546,Phase II,Recruiting,[],Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation,9119
206,NCT02790515,Phase II,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1876, 'therapyName': 'Blinatumomab '}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 5682, 'therapyName': 'Mesna'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Provision of TCR?? T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation,9119
207,NCT02791919,Phase I,Withdrawn,"[{'id': 822, 'therapyName': 'MK-1775'}, {'id': 4271, 'therapyName': 'Cytarabine + Filgrastim + Fludarabine'}]","Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia",9119
208,NCT02793544,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 5682, 'therapyName': 'Mesna'}, {'id': 1166, 'therapyName': 'Fludarabine'}]",HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide,9119
209,NCT02829840,Phase Ib/II,Withdrawn,"[{'id': 4464, 'therapyName': 'Azacitidine + Ponatinib'}]","Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML)",9119
210,NCT02835729,Phase Ib/II,Recruiting,"[{'id': 1606, 'therapyName': 'Cytarabine + Idarubicin'}, {'id': 4499, 'therapyName': 'Cytarabine + Idarubicin + indoximod'}]",A Study of Indoximod in Combination With (7+3) Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia,9119
211,NCT02845297,Phase II,Recruiting,"[{'id': 2496, 'therapyName': 'Azacitidine + Pembrolizumab'}]",Phase 2 Study of Azacitidine in Combination With Pembrolizumab in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients and in Newly Diagnosed Older (?65 Years) AML Patients,9119
212,NCT02846376,Phase I,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant (CPIT-002),9119
213,NCT02878785,Phase Ib/II,Recruiting,"[{'id': 5531, 'therapyName': 'Decitabine + Talazoparib'}]",Decitabine and Talazoparib in Untreated AML and R/R AML (1565GCC) ,9119
214,NCT02882321,Phase I,Recruiting,"[{'id': 6267, 'therapyName': 'IACS-010759'}]",Study of IACS-010759 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML),9119
215,NCT02890329,Phase I,Recruiting,"[{'id': 5738, 'therapyName': 'Decitabine + Ipilimumab'}]",Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia,9119
216,NCT02892318,Phase I,Recruiting,"[{'id': 4693, 'therapyName': 'Atezolizumab + SGI-110'}]",A Study Evaluating the Safety and Pharmacology of Atezolizumab Administered in Combination With Immunomodulatory Agents in Participants With Acute Myeloid Leukemia (AML),9119
217,NCT02905994,Phase I,Withdrawn,"[{'id': 3213, 'therapyName': 'Cytarabine + Idarubicin + Volasertib'}]",Volasertib Combined With Induction Chemotherapy in Acute Myeloid Leukemia,9119
218,NCT02909972,Phase I,Recruiting,"[{'id': 4755, 'therapyName': 'ALRN-6924 + Cytarabine'}, {'id': 2273, 'therapyName': 'ALRN-6924'}]",Safety Study of ALRN-6924 in Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome,9119
219,NCT02920008,Phase III,Recruiting,"[{'id': 650, 'therapyName': 'Decitabine'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1949, 'therapyName': 'SGI-110'}]","Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia",9119
220,NCT02927262,Phase III,Recruiting,"[{'id': 2865, 'therapyName': 'Gilteritinib'}]","A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission",9119
221,NCT02936752,Phase I,Recruiting,"[{'id': 3354, 'therapyName': 'Entinostat + Pembrolizumab'}]",Entinostat and Pembrolizumab in Treating Patients With Myelodysplastic Syndrome After DNMTi Therapy Failure,9119
222,NCT02953561,Phase Ib/II,Recruiting,"[{'id': 5372, 'therapyName': 'Avelumab + Azacitidine'}]",Avelumab (antiPDL1) and Azacytidine in Acute Myeloid Leukemia (AML),9119
223,NCT02954653,Phase I,Recruiting,"[{'id': 6087, 'therapyName': 'PF-06747143'}, {'id': 6092, 'therapyName': 'Cytarabine + Daunorubicin + PF-06747143'}, {'id': 6093, 'therapyName': 'Azacitidine + Decitabine + PF-06747143'}]","A Study Of PF-06747143, As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia",9119
224,NCT02981914,Phase 0,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation,9119
225,NCT02989844,Phase II,Recruiting,"[{'id': 3060, 'therapyName': 'ALT-803'}]",QUILT-3.035: Relapse Prophylaxis With ALT-803 for AML and MDS Pts Following Allo HSCT,9119
226,NCT02993523,Phase III,Recruiting,"[{'id': 1637, 'therapyName': 'GDC-0199 + Azacitidine'}, {'id': 651, 'therapyName': 'Azacitidine'}]",A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Elderly Subjects With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy,9119
227,NCT02996474,Phase Ib/II,Recruiting,"[{'id': 5127, 'therapyName': 'Pembrolizumab + Decitabine'}]",Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia,9119
228,NCT03008187,Phase Ib/II,Suspended,"[{'id': 3693, 'therapyName': 'SEL24-B489'}]",SEL24 in Patients With AML,9119
229,NCT03009240,Phase I,Recruiting,"[{'id': 5214, 'therapyName': 'Decitabine + MLN4924'}]",Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia,9119
230,NCT03013998,Phase Ib/II,Recruiting,"[{'id': 4003, 'therapyName': 'Azacitidine + Enasidenib'}, {'id': 5539, 'therapyName': 'Azacitidine + Entospletinib'}, {'id': 5536, 'therapyName': 'Cytarabine + Daunorubicin + Samalizumab'}, {'id': 5538, 'therapyName': 'Azacitidine + BI 836858'}]",Study of Biomarker-Based Treatment of Acute Myeloid Leukemia,9119
231,NCT03018405,Phase I,Recruiting,"[{'id': 5998, 'therapyName': 'NKR-2 cells'}]",A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications (THINK),9119
232,NCT03041688,Phase I,Not yet recruiting,"[{'id': 6185, 'therapyName': 'AMG 232 + Decitabine'}]","MDM2 Inhibitor AMG-232 and Decitabine in Treating Patients With Relapsed, Refractory, or Newly-Diagnosed Acute Myeloid Leukemia",9119
233,NCT03042689,Phase I,Not yet recruiting,"[{'id': 890, 'therapyName': 'Regorafenib'}]",Study of Regorafenib in Patients With Advanced Myeloid Malignancies,9119
234,NCT03050216,Phase II,Recruiting,"[{'id': 5300, 'therapyName': 'ALT-803 + Cyclophosphamide + Fludarabine phosphate'}]",Haplo NK With SQ ALT-803 for Adults With Relapsed or Refractory AML,9119
235,NCT03059485,Phase II,Recruiting,"[{'id': 5369, 'therapyName': 'DC/AML Vaccine'}, {'id': 5370, 'therapyName': 'DC/AML Vaccine + MEDI4736'}]",DC/AML Fusion Cell Vaccine vs DC/AML Fusion Cell Vaccine Plus Durvalumab vs Observation in Patients Who Achieve a Chemotherapy-induced Remission,9119
236,NCT03063944,Phase I,"Active, not recruiting","[{'id': 5794, 'therapyName': 'Decitabine + OPB-111077'}]",STAT Inhibitor OPB-111077 and Decitabine in Treating Patients With Acute Myeloid Leukemia That Is Refractory or Newly Diagnosed and Ineligible for Intensive Chemotherapy,9119
237,NCT03069352,Phase III,Recruiting,"[{'id': 3182, 'therapyName': 'Cytarabine + GDC-0199'}, {'id': 712, 'therapyName': 'Cytarabine'}]",A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naïve Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy,9119
238,NCT03069469,Phase I,Recruiting,"[{'id': 5760, 'therapyName': 'DCC-3014'}]",Study of DCC-3014 in Patients With Advanced Malignancies,9119
239,NCT03070093,Expanded access,Available,"[{'id': 2865, 'therapyName': 'Gilteritinib'}]",Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD),9119
240,NCT03071276,Phase II,Recruiting,"[{'id': 5448, 'therapyName': 'Selinexor + Fludarabine phosphate + Cytarabine + Methotrexate + Prednisone'}]",Selinexor in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Acute Myeloid Leukemia,9119
241,NCT03072043,Phase Ib/II,Recruiting,"[{'id': 5445, 'therapyName': 'APR-246 + Azacitidine'}]",Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms,9119
242,NCT03082209,Phase I,Recruiting,"[{'id': 5756, 'therapyName': 'ABBV-621'}]",A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously Treated Solid Tumors and Hematologic Malignancies,9119
243,NCT03092674,Phase II,Not yet recruiting,"[{'id': 1736, 'therapyName': 'Decitabine + Cytarabine'}, {'id': 2471, 'therapyName': 'Azacitidine + Midostaurin'}, {'id': 3196, 'therapyName': 'Azacitidine + Nivolumab'}, {'id': 651, 'therapyName': 'Azacitidine'}]","Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome",9119
244,NCT03106428,Phase I,Recruiting,"[{'id': 5762, 'therapyName': 'MEDI7247'}]",A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies,9119
245,NCT03110354,Phase I,Recruiting,"[{'id': 5691, 'therapyName': 'DS-3201b'}]",DS-3201b for Acute Myelogenous Leukemia (AML) or Acute Lymphocytic Leukemia (ALL),9119
246,NCT03125239,Phase I,Recruiting,"[{'id': 5744, 'therapyName': 'LY2801653 + LY2874455'}]",Combination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid Leukemia,9119
247,NCT03127735,Phase I,Recruiting,"[{'id': 5698, 'therapyName': 'BAY1436032'}]",BAY1436032 in Patients With Mutant IDH1(mIDH1) Advanced Acute Myeloid Leukemia (AML),9119
248,NCT03128034,Phase Ib/II,Recruiting,"[{'id': 5714, 'therapyName': 'Cyclosporine + Fludarabine phosphate + Mycophenolate mofetil + Sirolimus'}]","211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome",9119
249,NCT03132454,Phase I,Recruiting,"[{'id': 5637, 'therapyName': 'Palbociclib + Decitabine'}, {'id': 5636, 'therapyName': 'Palbociclib + Dexamethasone'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 5638, 'therapyName': 'Palbociclib + Sorafenib'}]",Study of Palbociclib Alone and in Combination in Patients With Relapsed and Refractory (R/R) Leukemias,9119
250,NCT03144245,Phase I,Recruiting,"[{'id': 5711, 'therapyName': 'AMV-564'}]",Study of AMV564 in Patients With AML,9119
251,NCT03151408,Phase III,Recruiting,"[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 5987, 'therapyName': 'Azacitidine + Pracinostat'}]",An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia,9119
252,NCT03164057,Phase II,Recruiting,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 651, 'therapyName': 'Azacitidine'}]",A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia,9119
253,NCT03173248,Phase III,Recruiting,"[{'id': 4002, 'therapyName': 'AG-120 + Azacitidine'}, {'id': 1491, 'therapyName': 'AG-120'}]",Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Patients With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation (AGILE),9119
254,NCT03187288,Phase I,Not yet recruiting,"[{'id': 4029, 'therapyName': 'CFI-400945'}]",A Study of CFI-400945 Fumarate in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome,9119
255,NCT03190278,Phase I,Suspended,"[{'id': 5994, 'therapyName': 'UCART123'}]",Study Evaluating Safety and Efficacy of UCART123 in Patients With Acute Myeloid Leukemia,9119
256,NCT03194932,Phase I,Recruiting,"[{'id': 712, 'therapyName': 'Cytarabine'}]",Study of Venetoclax in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia,9119
257,NCT03207334,Phase II,Not yet recruiting,"[{'id': 6095, 'therapyName': 'Cytarabine + Midostaurin'}]",iCare4: Genomic Signatures With Midostaurin in Acute Myeloid Leukemia (UF-BMT-AML-001),9119
258,NCT03214562,Phase Ib/II,Recruiting,"[{'id': 1562, 'therapyName': 'Venetoclax'}, {'id': 6329, 'therapyName': 'Cytarabine + Filgrastim + Fludarabine + Idarubicin + Venetoclax'}]",Study of the BCL-2 Inhibitor Venetoclax in Combination With Standard Intensive Acute Myeloid Leukemia (AML) Induction/Consolidation Therapy With FLAG-IDA in Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia (AML),9119
259,NCT03217838,Phase Ib/II,Recruiting,"[{'id': 3547, 'therapyName': 'AZD2811'}]","Safety, Tolerability, and Efficacy of AZD2811 Nanoparticles in Patients With Relapsed AML/High-Risk Myelodysplastic Syndrome or Treatment-Naïve Patients.",9119
260,NCT03247088,Phase Ib/II,Recruiting,"[{'id': 6122, 'therapyName': 'Busulfan + Sorafenib + Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Study Of Sorafenib Added To Busulfan And Fludarabine Conditioning Regimen In Patients With Relapsed/Refractory AML Undergoing Stem Cell Transplantation,9119
261,NCT03248479,Phase I,Not yet recruiting,"[{'id': 6133, 'therapyName': 'Azacitidine + Hu5F9-G4'}, {'id': 4947, 'therapyName': 'Hu5F9-G4'}]",Hu5F9-G4 Monotherapy or Hu5F9-G4 in Combination With Azacitidine in Patients With Hematological Malignancies,9119
262,NCT03263936,Phase I,Recruiting,"[{'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Epigenetic Reprogramming in Relapse/Refractory AML,9119
263,NCT03267186,Phase II,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant,9119
264,NCT03286114,Phase I,Not yet recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab,9119
265,NCT03286530,Phase II,Not yet recruiting,"[{'id': 907, 'therapyName': 'Ruxolitinib'}]",Ruxolitinib + Allogeneic Stem Cell Transplantation in AML,9119
266,NCT03298984,Phase I,Not yet recruiting,"[{'id': 6300, 'therapyName': 'Alvocidib + Cytarabine + Daunorubicin'}]",Ph I Study of Alvocidib and Cytarabine/Duanorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML).,9119
0,NCT01409161,Phase II,Recruiting,"[{'id': 3685, 'therapyName': 'Arsenic trioxide + Gemtuzumab ozogamicin + Tretinoin'}]","Acute Promyelocytic Leukemia (APL) Treated With ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin",60318
1,NCT01869803,Phase I,Suspended,"[{'id': 756, 'therapyName': 'Gemtuzumab ozogamicin'}]",Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia,60318
2,NCT02339740,Phase III,Recruiting,"[{'id': 3686, 'therapyName': 'Cytarabine + Dexamethasone + Idarubicin + Mitoxantrone'}, {'id': 3685, 'therapyName': 'Arsenic trioxide + Gemtuzumab ozogamicin + Tretinoin'}]",Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia,60318
0,NCT02112916,Phase III,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma,5603
1,NCT02518113,Phase Ib/II,Recruiting,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2958, 'therapyName': 'LY3039478'}]",A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL,5603
0,NCT02831179,Phase I,Withdrawn,"[{'id': 4463, 'therapyName': 'Capecitabine + Veliparib + Temozolomide'}]","Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor",3950
0,NCT01396408,Phase II,"Active, not recruiting","[{'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 930, 'therapyName': 'Sunitinib'}]",A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours,660
1,NCT02673333,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma,660
2,NCT02834013,Phase 0,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab in Treating Patients With Rare Tumors,660
3,NCT02867592,Phase II,Recruiting,"[{'id': 998, 'therapyName': 'cabozantinib'}]","Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors",660
0,NCT02834013,Phase 0,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab in Treating Patients With Rare Tumors,50892
1,NCT03008369,Phase II,Recruiting,"[{'id': 792, 'therapyName': 'Lenvatinib'}]",Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery,50892
2,NCT03165721,Phase II,Recruiting,"[{'id': 1949, 'therapyName': 'SGI-110'}]","A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer",50892
0,NCT00843037,Phase II,Completed,"[{'id': 930, 'therapyName': 'Sunitinib'}]",Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma,5719
1,NCT01396408,Phase II,"Active, not recruiting","[{'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 930, 'therapyName': 'Sunitinib'}]",A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours,5719
2,NCT01967576,Phase II,"Active, not recruiting","[{'id': 649, 'therapyName': 'Axitinib'}]","Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma",5719
3,NCT02302833,Phase I,Recruiting,"[{'id': 998, 'therapyName': 'cabozantinib'}]",Cabozantinib for Malignant Pheochromocytoma,5719
4,NCT02721732,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors,5719
5,NCT02831179,Phase I,Withdrawn,"[{'id': 4463, 'therapyName': 'Capecitabine + Veliparib + Temozolomide'}]","Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor",5719
6,NCT02936323,,Recruiting,"[{'id': 5819, 'therapyName': 'PEN-221'}]",PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers,5719
0,NCT03274258,Phase II,Not yet recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma,7379
0,NCT01898715,Phase I,Recruiting,"[{'id': 4296, 'therapyName': 'ATR-101'}]",Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma,3948
1,NCT02720484,Phase II,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab in Treating Patients With Metastatic Adrenocortical Cancer,3948
2,NCT02721732,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors,3948
0,NCT02186509,Phase I,Recruiting,"[{'id': 626, 'therapyName': 'Alisertib'}]",Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas,4813
0,NCT01446809,Phase I,"Active, not recruiting","[{'id': 1472, 'therapyName': 'Doxorubicin + Ifosfamide'}, {'id': 1471, 'therapyName': 'Pazopanib + Doxorubicin + Ifosfamide'}]",Pazopanib Hydrochloride Followed By Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma,8282
0,NCT01446809,Phase I,"Active, not recruiting","[{'id': 1472, 'therapyName': 'Doxorubicin + Ifosfamide'}, {'id': 1471, 'therapyName': 'Pazopanib + Doxorubicin + Ifosfamide'}]",Pazopanib Hydrochloride Followed By Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma,3516
0,NCT01446809,Phase I,"Active, not recruiting","[{'id': 1472, 'therapyName': 'Doxorubicin + Ifosfamide'}, {'id': 1471, 'therapyName': 'Pazopanib + Doxorubicin + Ifosfamide'}]",Pazopanib Hydrochloride Followed By Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma,5693
0,NCT02214147,Phase I,Completed,"[{'id': 626, 'therapyName': 'Alisertib'}]",Pharmacokinetics of Alisertib in Adults With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Function,5825
0,NCT01446809,Phase I,"Active, not recruiting","[{'id': 1472, 'therapyName': 'Doxorubicin + Ifosfamide'}, {'id': 1471, 'therapyName': 'Pazopanib + Doxorubicin + Ifosfamide'}]",Pazopanib Hydrochloride Followed By Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma,6332
0,NCT01266031,Phase Ib/II,Completed,"[{'id': 2110, 'therapyName': 'Bevacizumab + Vorinostat'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma,3186
0,NCT01712659,Phase II,Recruiting,"[{'id': 907, 'therapyName': 'Ruxolitinib'}]",Ruxolitinib for Adult T-Cell Leukemia,50523
1,NCT02737046,Phase II,Recruiting,"[{'id': 1299, 'therapyName': 'Interferon alfa-2b '}, {'id': 2624, 'therapyName': 'peginterferon alfa-2b'}, {'id': 4361, 'therapyName': 'Belinostat + Zidovudine'}]",Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma,50523
2,NCT03075553,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma,50523
0,NCT00006199,Phase I,Unknown status,"[{'id': 938, 'therapyName': 'Tipifarnib'}, {'id': 942, 'therapyName': 'Topotecan'}]","Study of the Farnesyl Transferase Inhibitor, R115777, in Combination With Topotecan (NYU 99-32)",10000003
1,NCT00084695,Phase II,Unknown status,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases,10000003
2,NCT00463060,Phase Ib/II,Unknown status,"[{'id': 930, 'therapyName': 'Sunitinib'}]",Sutent and Radiation as Treatment for Limited Extent Metastatic Cancer,10000003
3,NCT00576654,Phase I,Recruiting,"[{'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 954, 'therapyName': 'Veliparib'}]",Irinotecan Hydrochloride and Veliparib in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery,10000003
4,NCT00585195,Phase I,Recruiting,"[{'id': 1526, 'therapyName': 'Crizotinib + Itraconazole\t'}, {'id': 1483, 'therapyName': 'Crizotinib + Rifampin'}]","A Study Of Oral PF-02341066, A c-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer",10000003
5,NCT00610948,Phase I,Completed,"[{'id': 735, 'therapyName': 'Everolimus'}, {'id': 845, 'therapyName': 'Panitumumab'}]","Everolimus, Fluorouracil, Leucovorin, Panitumumab, and Oxaliplatin in Treating Patients With Solid Tumors That Did Not Respond to Treatment",10000003
6,NCT00625378,Phase III,Recruiting,"[{'id': 920, 'therapyName': 'Sorafenib'}]",Sorafenib Long Term Extension Program (STEP),10000003
7,NCT00658658,Phase I,Completed,"[{'id': 845, 'therapyName': 'Panitumumab'}]",Panitumumab Pediatric Study,10000003
8,NCT00665990,Phase I,Completed,"[{'id': 1119, 'therapyName': 'Sorafenib + Avastin + Cyclophosphamide'}]",Phase I Study of Bevacizumab and Sorafenib Combined With Low Dose Cyclophosphamide in Patients With Refractory Solid Tumors and Leukemia,10000003
9,NCT00697632,Phase I,Recruiting,"[{'id': 809, 'therapyName': 'MGCD265'}]",Safety Study of Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies,10000003
10,NCT00740805,Phase I,"Active, not recruiting","[{'id': 2989, 'therapyName': 'Aldoxorubicin + Cyclophosphamide + Veliparib'}]","Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma",10000003
11,NCT00756340,Phase I,Completed,"[{'id': 1120, 'therapyName': 'Everolimus + Bevacizumab'}]",A Trial of Everolimus and Bevacizumab in Children With Recurrent Solid Tumors,10000003
12,NCT00761644,Phase I,"Active, not recruiting","[{'id': 1121, 'therapyName': 'Bevacizumab + Temsirolimus + Doxil'}]","Doxil, Bevacizumab and Temsirolimus Trial",10000003
13,NCT00776867,Phase I,Completed,"[{'id': 855, 'therapyName': 'Perifosine'}]",Study of Single Agent Perifosine for Recurrent Pediatric Solid Tumors,10000003
14,NCT00781612,Phase II,Recruiting,"[{'id': 5471, 'therapyName': 'Trastuzumab + trastuzumab emtansine'}, {'id': 5470, 'therapyName': 'Paclitaxel + trastuzumab emtansine'}, {'id': 1402, 'therapyName': 'trastuzumab emtansine'}, {'id': 3930, 'therapyName': 'Docetaxel + T-DM1'}, {'id': 1976, 'therapyName': 'trastuzumab emtansine + Capecitabine'}, {'id': 1492, 'therapyName': 'T-DM1 + Pertuzumab'}]",A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies,10000003
15,NCT00790816,Phase I,Completed,"[{'id': 1410, 'therapyName': 'Lapatinib + Paclitaxel'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1414, 'therapyName': 'Trastuzumab + Lapatinib'}, {'id': 1399, 'therapyName': 'Lapatinib + Capecitabine'}, {'id': 1497, 'therapyName': 'Lapatinib + Letrozole'}, {'id': 1498, 'therapyName': 'Lapatinib + Oxaliplatin + Capecitabine'}, {'id': 1499, 'therapyName': 'Lapatinib + Gemcitabine'}, {'id': 1500, 'therapyName': 'Lapatinib + Docetaxel'}, {'id': 1501, 'therapyName': 'Lapatinib + Oxaliplatin + Leucovorin + Fluorouracil'}, {'id': 1502, 'therapyName': 'Lapatinib + Irinotecan + Leucovorin + Fluorouracil'}]",Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents,10000003
16,NCT00858377,Phase I,"Active, not recruiting","[{'id': 983, 'therapyName': 'AMG 900'}]",A Phase 1 First-in-Human Study Evaluating AMG 900 in Advanced Solid Tumors,10000003
17,NCT00889954,Phase I,"Active, not recruiting","[{'id': 1403, 'therapyName': 'Autologous TGF beta resistant HER2 EBV CTLs'}]",Her2 and TGFBeta CTLs in Treatment of Her2 Positive Malignancy,10000003
18,NCT00909831,Phase I,"Active, not recruiting","[{'id': 2302, 'therapyName': 'Hydroxychloroquine + Temsirolimus '}]",Hydroxychloroquine and Temsirolimus in Treating Patients With Metastatic Solid Tumors That Have Not Responded to Treatment,10000003
19,NCT00926640,Phase I,Completed,"[{'id': 1123, 'therapyName': 'Belinostat + Cisplatin + Etoposide'}]",A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers,10000003
20,NCT00981890,Phase I,"Active, not recruiting","[{'id': 930, 'therapyName': 'Sunitinib'}]",Stereotactic Radiosurgery With Sunitinib for Brain Metastases,10000003
21,NCT00999401,Phase I,Recruiting,"[{'id': 1130, 'therapyName': 'Sapacitabine + Seliciclib'}]",A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors,10000003
22,NCT01004224,Phase I,"Active, not recruiting","[{'id': 674, 'therapyName': 'BGJ398'}]",A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies,10000003
23,NCT01004861,Phase I,"Active, not recruiting","[{'id': 874, 'therapyName': 'PLX3397'}]",Safety Study of PLX108-01 in Patients With Solid Tumors,10000003
24,NCT01012817,Phase Ib/II,Recruiting,"[{'id': 1132, 'therapyName': 'Veliparib + Topotecan'}]","Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer",10000003
25,NCT01014936,,Completed,"[{'id': 726, 'therapyName': 'EMD 1214063'}]"," First-in-Man, Dose-escalation Trial of C-met Kinase Inhibitor MSC2156119J in Subjects With Advanced Solid Tumors",10000003
26,NCT01015222,Phase I,"Active, not recruiting","[{'id': 1032, 'therapyName': 'methylnaltrexone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 667, 'therapyName': 'Bevacizumab'}]","Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies",10000003
27,NCT01017640,Phase I,Completed,"[{'id': 954, 'therapyName': 'Veliparib'}, {'id': 1134, 'therapyName': 'Veliparib + Mitomycin C'}]"," Veliparib With or Without Mitomycin C in Treating Patients With Metastatic, Unresectable, or Recurrent Solid Tumors",10000003
28,NCT01023737,Phase I,Recruiting,"[{'id': 1135, 'therapyName': 'Vorinostat + Hydroxychloroquine'}]",Hydroxychloroquine + Vorinostat in Advanced Solid Tumors,10000003
29,NCT01058707,Phase I,"Active, not recruiting","[{'id': 1282, 'therapyName': 'Sapanisertib'}]",Dose Escalation Study of MLN0128 in Subjects With Advanced Malignancies,10000003
30,NCT01061788,Phase I,Recruiting,"[{'id': 1138, 'therapyName': 'AMG479 + Everolimus + Panitumumab'}]","A Trial of AMG 479, Everolimus (RAD001) and Panitumumab in Patients With Advanced Cancer",10000003
31,NCT01063075,Phase II,Completed,"[{'id': 1914, 'therapyName': 'Cetuximab + Carboplatin + Fluorouracil'}]",A Study in Advanced Solid Tumors,10000003
32,NCT01081808,Phase I,Terminated,"[{'id': 1012, 'therapyName': 'EGFRBi-armed autologous activated T cells'}]","Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid Tumors",10000003
33,NCT01087554,Phase I,"Active, not recruiting","[{'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}]",Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer,10000003
34,NCT01087983,Phase I,Completed,"[{'id': 1139, 'therapyName': 'Lapatinib + Sirolimus'}, {'id': 1140, 'therapyName': 'Lapatinib + Metformin'}]",Lapatinib With Sirolimus or Metformin,10000003
35,NCT01099358,Phase II,Completed,"[{'id': 1915, 'therapyName': 'Cetuximab + Cisplatin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}]",Study in Advanced Solid Tumors,10000003
36,NCT01106599,Phase I,Completed,"[{'id': 748, 'therapyName': 'GDC-0623'}]","A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0623 in Patients With Locally Advanced or Metastatic Solid Tumors",10000003
37,NCT01107522,Phase I,"Active, not recruiting","[{'id': 1142, 'therapyName': 'CTO + Temozolomide'}, {'id': 999, 'therapyName': 'Carboxyamidotriazole Orotate'}]",Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar&#174; in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar&#174; and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas,10000003
38,NCT01113476,Phase I,Recruiting,"[{'id': 1144, 'therapyName': 'Abraxane + Avastin + Gemcitabine'}]","Nab-paclitaxel, Gemcitabine, and Bevacizumab in Advanced Malignancies",10000003
39,NCT01122199,Phase I,Completed,"[{'id': 1145, 'therapyName': 'Everolimus + AMG479'}]",Study of RAD001 + AMG479 for Patients With Advanced Solid Tumors,10000003
40,NCT01138085,Phase I,Completed,"[{'id': 1150, 'therapyName': 'GSK1120212 + GSK2141795'}]","Safety, Pharmacokinetics (PK) of AKT and MEK Combination",10000003
41,NCT01139723,Phase I,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1616, 'therapyName': 'MINT1526A'}]","A Study of the Safety and Pharmacokinetics of MINT1526A, Administered Intravenously As a Single Agent and in Combination With Bevacizumab to Patients With Advanced Solid Tumors",10000003
42,NCT01164163,Phase I,Completed,"[{'id': 907, 'therapyName': 'Ruxolitinib'}]","INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease",10000003
43,NCT01177397,Phase Ib/II,Completed,"[{'id': 693, 'therapyName': 'CC-223'}]","Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma",10000003
44,NCT01184326,Phase I,Completed,"[{'id': 1806, 'therapyName': 'everolimus + pazopanib'}]",An Expanded Phase I Study of Pazopanib and Everolimus in Patients With Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer,10000003
45,NCT01187199,Phase I,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 936, 'therapyName': 'Temsirolimus'}]","Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer",10000003
46,NCT01197170,Phase I,"Active, not recruiting","[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Hormone Blockade in Combination With Targeted Agents,10000003
47,NCT01213238,Phase I,"Active, not recruiting","[{'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 667, 'therapyName': 'Bevacizumab'}]","Hepatic Arterial Infusion Oxaliplatin, Capecitabine With or Without Bevacizumab",10000003
48,NCT01218555,Phase I,"Active, not recruiting","[{'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 735, 'therapyName': 'Everolimus'}]",Study of Everolimus (RAD001)in Combination With Lenalidomide,10000003
49,NCT01218867,Phase Ib/II,Completed,"[{'id': 984, 'therapyName': 'Anti-VEGFR2 CAR CD8 lymphocytes'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1167, 'therapyName': 'Aldesleukin'}]",Treating Metastatic Cancer With Anti-VEGFR2 Gene Engineered CD8+ Lymphocytes,10000003
50,NCT01219699,Phase I,"Active, not recruiting","[{'id': 691, 'therapyName': 'BYL719'}, {'id': 744, 'therapyName': 'Fulvestrant'}]"," A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene",10000003
51,NCT01226316,Phase I,Recruiting,"[{'id': 655, 'therapyName': 'AZD5363'}]","Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules",10000003
52,NCT01231594,Phase I,Recruiting,"[{'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 2, 'therapyName': 'Trametinib'}]",A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors,10000003
53,NCT01237236,Phase I,Completed,"[{'id': 790, 'therapyName': 'Ribociclib'}]",A Trial of LEE011 in Patients With Advanced Solid Tumors or Lymphoma.,10000003
54,NCT01239134,Phase I,Recruiting,"[{'id': 3613, 'therapyName': 'TRX518'}]",Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors,10000003
55,NCT01240590,Phase Ib/II,Completed,"[{'id': 1461, 'therapyName': 'Crolibulin + Cisplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}]",A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC),10000003
56,NCT01248949,Phase I,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1176, 'therapyName': 'MEDI3617'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors,10000003
57,NCT01249443,Phase I,Terminated,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Vorinostat in Combination With Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection,10000003
58,NCT01253707,Phase I,Completed,"[{'id': 1064, 'therapyName': 'AMG 337'}]",A Study of AMG 337 in Subjects With Advanced Solid Tumors,10000003
59,NCT01264432,Phase I,"Active, not recruiting","[{'id': 954, 'therapyName': 'Veliparib'}]","Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer",10000003
60,NCT01266057,Phase I,"Active, not recruiting","[{'id': 1135, 'therapyName': 'Vorinostat + Hydroxychloroquine'}, {'id': 1177, 'therapyName': 'Sirolimus + Hydroxychloroquine'}]",Sirolimus or Vorinostat and Hydroxychloroquine in Advanced Cancer,10000003
61,NCT01273155,Phase I,Recruiting,"[{'id': 1078, 'therapyName': 'Belinostat'}]",Belinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction,10000003
62,NCT01276210,Phase I,Completed,"[{'id': 920, 'therapyName': 'Sorafenib'}]",Sorafenib Tosylate and Stereotactic Radiosurgery in Treating Patients With Brain Metastases,10000003
63,NCT01281150,Phase I,Completed,"[{'id': 954, 'therapyName': 'Veliparib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors,10000003
64,NCT01281176,,"Active, not recruiting","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",High-Dose or Low-Dose Vorinostat in Combination With Carboplatin or Paclitaxel in Treating Patients With Advanced Solid Tumors,10000003
65,NCT01283945,Phase Ib/II,Completed,"[{'id': 1029, 'therapyName': 'Lucitanib'}]","Study of Oral Lucitanib (E-3810), a Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, in Patients With Solid Tumors",10000003
66,NCT01285037,Phase I,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 1030, 'therapyName': 'LY2801653'}]",A Study of LY2801653 in Advanced Cancer,10000003
67,NCT01286987,Phase I,Completed,"[{'id': 682, 'therapyName': 'Talazoparib'}]","Study of BMN 673, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors",10000003
68,NCT01287546,Phase I,Completed,"[{'id': 1179, 'therapyName': 'Emibetuzumab + Erlotinib'}, {'id': 1180, 'therapyName': 'Emibetuzumab + Trametinib'}, {'id': 803, 'therapyName': 'Emibetuzumab'}]",A Study of LY2875358 in Participants With Advanced Cancer,10000003
69,NCT01288430,Phase I,Terminated,"[{'id': 1181, 'therapyName': 'DS-2248'}]","A Study of DS-2248, in Subjects With Advanced Solid Tumors",10000003
70,NCT01292655,Phase I,Completed,"[{'id': 2545, 'therapyName': 'BMS-906024'}]",Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors,10000003
71,NCT01294670,Phase Ib/II,"Active, not recruiting","[{'id': 1182, 'therapyName': 'Vorinostat + Etoposide'}]",Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients &lt; 21 Years at Diagnosis With Refractory Solid Tumors,10000003
72,NCT01296555,Phase I,Recruiting,"[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 1016, 'therapyName': 'GDC-0032'}, {'id': 794, 'therapyName': 'Letrozole'}]",A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Patients With Locally Advanced or Metastatic Solid Tumors And in Combination With Endocrine Therapy in Patients With Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer,10000003
73,NCT01296581,Phase I,"Active, not recruiting","[{'id': 962, 'therapyName': 'X-82'}]", Safety Study of X-82 in Patients With Advanced Solid Tumors,10000003
74,NCT01297452,Phase I,Completed,"[{'id': 1183, 'therapyName': 'BKM120 + Carboplatin + Paclitaxel'}]",BKM120 + Carboplatin + Paclitaxel for Patients With Advanced Solid Tumors,10000003
75,NCT01299636,Phase I,Completed,"[{'id': 1459, 'therapyName': 'PM060184'}]",Study of PM060184 in Patients With Advanced Solid Tumors,10000003
76,NCT01302405,Phase I,Terminated,"[{'id': 1083, 'therapyName': 'Pri-724'}]",Safety and Efficacy Study of PRI-724 in Subjects With Advanced Solid Tumors,10000003
77,NCT01303341,Phase I,"Active, not recruiting","[{'id': 1724, 'therapyName': 'Rilutek + Sorafenib'}]",Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma,10000003
78,NCT01307267,Phase I,Recruiting,"[{'id': 6111, 'therapyName': 'Utomilumab + Rituximab'}, {'id': 5086, 'therapyName': 'Utomilumab'}]",A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab,10000003
79,NCT01324479,Phase I,Completed,"[{'id': 1065, 'therapyName': 'Capmatinib'}]",Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors,10000003
80,NCT01325441,Phase Ib/II,Recruiting,"[{'id': 2586, 'therapyName': 'BBI608 + Paclitaxel'}]",A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies,10000003
81,NCT01326702,Phase Ib/II,Completed,"[{'id': 954, 'therapyName': 'Veliparib'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1231, 'therapyName': 'Bendamustine'}]"," Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors",10000003
82,NCT01327612,Phase II,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 746, 'therapyName': 'Ganitumab'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1458, 'therapyName': 'Conatumumab'}]",Open Label Extension Study of Conatumumab and AMG 479,10000003
83,NCT01328054,,Completed,"[{'id': 787, 'therapyName': 'Lapatinib'}]",A Study in Cancer Patients to Evaluate the Effect of Lapatinib on the QTc Interval,10000003
84,NCT01336842,Phase I,Completed,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1080, 'therapyName': 'Panobinostat'}, {'id': 854, 'therapyName': 'Pemetrexed'}]",Study of Cisplatin and Pemetrexed in Combination With Panobinostat in Solid Tumors,10000003
85,NCT01339871,Phase I,Completed,"[{'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 848, 'therapyName': 'Pazopanib'}]",Phase I Study of Pazopanib and Vorinostat,10000003
86,NCT01346358,Phase I,"Active, not recruiting","[{'id': 2004, 'therapyName': 'LY3022855'}]",A Study of IMC-CS4 in Subjects With Advanced Solid Tumors,10000003
87,NCT01347866,Phase I,Terminated,"[{'id': 1040, 'therapyName': 'PF-05212384'}, {'id': 849, 'therapyName': 'PD-0325901'}, {'id': 1074, 'therapyName': 'Irinotecan'}]",Clinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer,10000003
88,NCT01349660,Phase Ib/II,"Active, not recruiting","[{'id': 1178, 'therapyName': 'BKM120 + Bevacizumab'}]",Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme,10000003
89,NCT01351103,Phase I,Recruiting,"[{'id': 1937, 'therapyName': 'LGK974'}]",A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands,10000003
90,NCT01353625,Phase I,"Active, not recruiting","[{'id': 1000, 'therapyName': 'CC-115'}]","Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.",10000003
91,NCT01362374,Phase I,"Active, not recruiting","[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 747, 'therapyName': 'Ipatasertib'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]","Safety and Pharmacology Of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Patients With Advanced Solid Tumors",10000003
92,NCT01366144,Phase I,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 954, 'therapyName': 'Veliparib'}, {'id': 1092, 'therapyName': 'Carboplatin'}]","Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction",10000003
93,NCT01375699,Phase I,"Active, not recruiting","[{'id': 1009, 'therapyName': 'Doxorubicin'}]","Doxorubicin With or Without Sildenafil, With Analysis of Cardiac Markers",10000003
94,NCT01375829,Phase I,"Active, not recruiting","[{'id': 1263, 'therapyName': 'ixabepilone + temsirolimus'}]",Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery,10000003
95,NCT01375842,Phase I,"Active, not recruiting","[{'id': 1201, 'therapyName': 'Atezolizumab'}]",A Phase 1 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors,10000003
96,NCT01376310,Phase II,"Active, not recruiting","[{'id': 1264, 'therapyName': 'Docetaxel + Trametinib'}, {'id': 1265, 'therapyName': 'Erlotinib + Trametinib'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 1266, 'therapyName': 'Pemetrexed + GSK1120212'}, {'id': 1267, 'therapyName': 'Carboplatin + GSK1120212'}, {'id': 1268, 'therapyName': 'nab-paclitaxel + GSK1120212'}, {'id': 1269, 'therapyName': 'Gemcitabine + GSK1120212'}, {'id': 1271, 'therapyName': 'Everolimus + GSK1120212'}]",GSK1120212 Rollover Study,10000003
97,NCT01376505,Phase I,Recruiting,"[{'id': 1404, 'therapyName': 'HER2 Vaccine'}]",Vaccine Therapy in Treating Patients With Metastatic Solid Tumors,10000003
98,NCT01391533,Phase I,Completed,"[{'id': 2159, 'therapyName': 'SAR125844'}]",Study of SAR125844 Single Agent Administered as Slow Intravenous Infusion in Adult Patients With Advanced Malignant Solid Tumors,10000003
99,NCT01393509,Phase I,"Active, not recruiting","[{'id': 1162, 'therapyName': 'PU-H71'}]",The First-in-human Phase I Trial of PU-H71 in Patients With Advanced Malignancies,10000003
100,NCT01405391,Phase I,Completed,"[{'id': 1195, 'therapyName': 'Lurbinectedin'}]",Study of PM01183 in Non-Colorectal Cancer Patients as a Days 1 and 8 Intravenous Short Infusion Every 3 Weeks,10000003
101,NCT01407562,Phase I,"Active, not recruiting","[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}]","Study of Pazopanib, Paclitaxel, and Carboplatin in Patients With Advanced Solid Tumors",10000003
102,NCT01411410,Phase I,Completed,"[{'id': 1276, 'therapyName': 'Copanlisib + Paclitaxel'}]",Phase I Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With Paclitaxel in Patients With Advanced Cancer,10000003
103,NCT01425008,Phase I,"Active, not recruiting","[{'id': 1034, 'therapyName': 'MLN2480'}]",Study of MLN2480 in Patients With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Patients With Metastatic Melanoma,10000003
104,NCT01427322,,Terminated,"[{'id': 787, 'therapyName': 'Lapatinib'}]",Randomized RT +/- Lapatinib for Advanced Solid Tumor Cancer Patients Receiving Radiation Therapy for Metastatic Disease,10000003
105,NCT01433991,Phase Ib/II,"Active, not recruiting","[{'id': 1019, 'therapyName': 'Golvatinib'}, {'id': 792, 'therapyName': 'Lenvatinib'}]",E7050 in Combination With E7080 in Subjects With Advanced Solid Tumors (Dose Escalation) and in Subjects With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2),10000003
106,NCT01434316,Phase I,Recruiting,"[{'id': 1277, 'therapyName': 'Veliparib + Dinaciclib'}, {'id': 1278, 'therapyName': 'Veliparib + Dinaciclib + carboplatin'}]",Veliparib and Dinaciclib With or Without Carboplatin in Treating Patients With Advanced Solid Tumors,10000003
107,NCT01438554,Phase I,"Active, not recruiting","[{'id': 1310, 'therapyName': 'Pazopanib + Trametinib'}]","Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma",10000003
108,NCT01443481,Phase I,Completed,"[{'id': 721, 'therapyName': 'Dovitinib'}]",Pharmacokinetics (PK) of TKI258 in Cancer Patients With Normal and Impaired Hepatic Function,10000003
109,NCT01445509,Phase I,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 717, 'therapyName': 'Dasatinib'}]",Dasatinib in Combination With Bevacizumab to Treat Advanced Solid Tumors,10000003
110,NCT01449058,Phase Ib/II,Completed,"[{'id': 1311, 'therapyName': 'BYL719 + MEK162'}]",A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors,10000003
111,NCT01449370,Phase I,Completed,"[{'id': 1033, 'therapyName': 'MLN1117'}]",Dose Escalation Study of MLN1117 in Subjects With Advanced Cancer,10000003
112,NCT01449461,Phase Ib/II,"Active, not recruiting","[{'id': 634, 'therapyName': 'AP26113'}]",A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113,10000003
113,NCT01450384,Phase I,Completed,"[{'id': 1482, 'therapyName': 'Pemetrexed + Sorafenib'}]",Pemetrexed Disodium and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors,10000003
114,NCT01458067,Phase I,Completed,"[{'id': 765, 'therapyName': 'GSK2636771'}]"," A Phase I/IIa, First Time in Human, Study of GSK2636771 in Subjects With Advanced Solid Tumors With Phosphatase and Tensin Homolog (PTEN) Deficiency",10000003
115,NCT01468922,Phase I,Completed,"[{'id': 636, 'therapyName': 'Tivantinib'}, {'id': 848, 'therapyName': 'Pazopanib'}]",Pazopanib and ARQ 197 for Advanced Solid Tumors,10000003
116,NCT01470209,Phase I,"Active, not recruiting","[{'id': 1314, 'therapyName': 'BKM120 + Everolimus'}]",A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies,10000003
117,NCT01472016,Phase I,Completed,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1063, 'therapyName': 'ABT-700'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",Study of ABT-700 in Subjects With Advanced Solid Tumors,10000003
118,NCT01473095,Phase I,"Active, not recruiting","[{'id': 635, 'therapyName': 'ARQ092'}]",Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma,10000003
119,NCT01480154,Phase I,"Active, not recruiting","[{'id': 1393, 'therapyName': 'MK2206 + hydroxychloroquine'}]","Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer",10000003
120,NCT01485042,Phase I,Completed,"[{'id': 1318, 'therapyName': 'Evofosfamide + Pazopanib'}]",Dose Escalation Study of Pazopanib Plus TH-302,10000003
121,NCT01494688,Phase I,"Active, not recruiting","[{'id': 2843, 'therapyName': 'Emactuzumab'}, {'id': 4249, 'therapyName': 'Emactuzumab + Paclitaxel'}]",A Study of RO5509554 as Monotherapy and in Combination With Paclitaxel in Patients With Advanced Solid Tumors,10000003
122,NCT01497392,Phase I,Completed,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 721, 'therapyName': 'Dovitinib'}, {'id': 1105, 'therapyName': 'Capecitabine'}]"," Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors, Pancreatic Cancer and Biliary Cancers",10000003
123,NCT01497626,Phase I,Terminated,"[{'id': 1394, 'therapyName': 'Lapatinib + bortezomib'}]",Lapatinib and Bortezomib in Patients With Advanced Malignancies,10000003
124,NCT01497704,Phase Ib/II,Completed,"[{'id': 986, 'therapyName': 'Apatinib'}]",Dose-Escalation and Safety Trial of YN968D1,10000003
125,NCT01498484,Phase II,"Active, not recruiting","[{'id': 5057, 'therapyName': 'EB-VST cells'}]",Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies,10000003
126,NCT01505569,Phase I,Recruiting,"[{'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 2101, 'therapyName': 'Etoposide + Ifosfamide'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",Auto Transplant for High Risk or Relapsed Solid or CNS Tumors,10000003
127,NCT01508104,Phase Ib/II,Terminated,"[{'id': 1321, 'therapyName': 'BEZ235 + Everolimus'}, {'id': 735, 'therapyName': 'Everolimus'}]",Safety Study of BEZ235 With Everolimus in Subjects With Advanced Solid Tumors,10000003
128,NCT01520389,Phase I,Completed,"[{'id': 821, 'therapyName': 'MM-151'}, {'id': 1074, 'therapyName': 'Irinotecan'}]",Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment,10000003
129,NCT01522820,Phase I,Completed,"[{'id': 1324, 'therapyName': 'DEC-205-NY-ESO-1 fusion protein vaccine'}, {'id': 917, 'therapyName': 'Sirolimus'}]",Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors,10000003
130,NCT01522989,Phase I,"Active, not recruiting","[{'id': 1703, 'therapyName': 'Palbociclib + Fluorouracil + Oxaliplatin'}]","PD-0332991, 5-FU, and Oxaliplatin for Advanced Solid Tumor Malignancies",10000003
131,NCT01524978,Phase II,"Active, not recruiting","[{'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 694, 'therapyName': 'Cetuximab'}]",A Study of Zelboraf (Vemurafenib) in Patients With BRAF V600 Mutation-Positive Cancers,10000003
132,NCT01525602,Phase I,"Active, not recruiting","[{'id': 1395, 'therapyName': 'PLX3397 + Paclitaxel'}]",Safety Study of PLX3397 and Paclitaxel in Patients With Advanced Solid Tumors,10000003
133,NCT01526473,Phase I,"Active, not recruiting","[{'id': 1068, 'therapyName': 'AVX901'}]",A Phase I Study To Evaluate The Antitumor Activity And Safety Of AVX901,10000003
134,NCT01528046,Phase I,Recruiting,"[{'id': 1031, 'therapyName': 'Metformin'}, {'id': 1826, 'therapyName': 'Vincristine + Irinotecan + Temozolomide '}]",Metformin in Children With Relapsed or Refractory Solid Tumors,10000003
135,NCT01529593,Phase I,Recruiting,"[{'id': 1325, 'therapyName': 'Temsirolimus + Metformin'}]",Temsirolimus in Combination With Metformin in Patients With Advanced Cancers,10000003
136,NCT01531361,Phase I,Recruiting,"[{'id': 706, 'therapyName': 'Crizotinib'}, {'id': 1326, 'therapyName': 'Vemurafenib + Sorafenib'}]",Sorafenib or Crizotinib and Vemurafenib in Advanced Cancer,10000003
137,NCT01531894,Phase II,"Active, not recruiting","[{'id': 625, 'therapyName': 'Afuresertib'}]",Continuation Study of the Oral AKT Inhibitor GSK2110183,10000003
138,NCT01532011,Phase I,Completed,"[{'id': 1328, 'therapyName': 'Erlotinib + Pralatrexate'}]",Erlotinib in Combination With Pralatrexate in Advanced Malignancies,10000003
139,NCT01534598,Phase I,Recruiting,"[{'id': 3789, 'therapyName': 'FdCyd + THU'}]",FdCyd and THU for Advanced Solid Tumors,10000003
140,NCT01537107,Phase I,Suspended,"[{'id': 1329, 'therapyName': 'Sirolimus + Vismodegib'}]",Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery,10000003
141,NCT01537744,Phase I,Completed,"[{'id': 1396, 'therapyName': 'Azacitidine + Romidepsin'}]","A Trial of Oral 5-azacitidine in Combination With Romidepsin in Advanced Solid Tumors, With an Expansion Cohort in Non-small Cell Lung Cancer",10000003
142,NCT01540253,Phase I,Completed,"[{'id': 1330, 'therapyName': 'BKM120 + Docetaxel'}]","PI3K Inhibitor BKM120 and Docetaxel in Treating Patients With Advanced Solid Tumor That is Locally Advanced, Cannot Be Removed By Surgery, or Metastatic",10000003
143,NCT01540526,Phase I,Completed,"[{'id': 649, 'therapyName': 'Axitinib'}]",Pharmacodynamic Study With FLT-PET/CT in Patients With Prostate/Other Solid Malignancies Treated With High Dose Axitinib,10000003
144,NCT01543763,Phase I,"Active, not recruiting","[{'id': 3046, 'therapyName': 'Panobinostat + Pazopanib'}]","Phase I Tolerability, Efficacy, and Safety Study of Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors",10000003
145,NCT01548144,Phase I,"Active, not recruiting","[{'id': 1153, 'therapyName': 'Crizotinib + Pazopanib'}, {'id': 1151, 'therapyName': 'Crizotinib + Pemetrexed'}, {'id': 1156, 'therapyName': 'Pazopanib + Pemetrexed'}, {'id': 1155, 'therapyName': 'Crizotinib + Pazopanib + Pemetrexed'}]",Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer,10000003
146,NCT01552356,Phase I,"Active, not recruiting","[{'id': 848, 'therapyName': 'Pazopanib'}]",Pazopanib Hydrochloride in Treating Patients With Advanced or Refractory Solid Tumors,10000003
147,NCT01552434,Phase I,Recruiting,"[{'id': 1376, 'therapyName': 'Temsirolimus + Bevacizumab + Valproic Acid + Cetuximab'}]","Bevacizumab, Temsirolimus, Valproic Acid, Cetuximab",10000003
148,NCT01553071,Phase I,Recruiting,"[{'id': 1049, 'therapyName': 'Safingol'}, {'id': 2731, 'therapyName': 'Fenretinide'}]",Phase I Trial of IV Fenretinide (4-HPR) Plus IV Safingol for Patients With Relapsed Malignancies,10000003
149,NCT01562275,Phase I,Completed,"[{'id': 1160, 'therapyName': 'Cobimetinib + GDC-0068'}]"," A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0973 in Combination With GDC-0068 When Administered in Patients With Locally Advanced or Metastatic Solid Tumors",10000003
150,NCT01564251,Phase I,"Active, not recruiting","[{'id': 2113, 'therapyName': 'GDC-0575 + Gemcitabine'}, {'id': 2024, 'therapyName': 'GDC-0575'}]",A Study of GDC-0575 Alone And in Combination With Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma,10000003
151,NCT01571024,Phase I,Completed,"[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 680, 'therapyName': 'BKM120'}]", BKM120 + mFOLFOX6 in Advanced Solid Tumors With Expansion Cohort Pancreatic Cancer,10000003
152,NCT01576406,Phase I,Completed,"[{'id': 706, 'therapyName': 'Crizotinib'}]",Hepatic Impairment Study For Crizotinib In Advanced Cancer Patients,10000003
153,NCT01576666,Phase Ib/II,Completed,"[{'id': 1547, 'therapyName': 'BKM120 + Sonidegib'}]","Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors",10000003
154,NCT01577745,Phase I,Completed,"[{'id': 2546, 'therapyName': 'MEDI0639'}]","A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI0639 in Advanced Solid Tumors",10000003
155,NCT01581541,Phase I,Terminated,"[{'id': 1162, 'therapyName': 'PU-H71'}]", PU-H71 in Patients With Solid Tumors and Low-Grade Non-Hodgkin s Lymphoma That Have Not Responded to Standard Treatment,10000003
156,NCT01582191,Phase I,Recruiting,"[{'id': 1163, 'therapyName': 'Vandetanib + Everolimus'}]",Vandetanib With Everolimus,10000003
157,NCT01587040,Phase Ib/II,"Active, not recruiting","[{'id': 1050, 'therapyName': 'XL147'}, {'id': 1051, 'therapyName': 'SAR245409'}]",Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen,10000003
158,NCT01587703,Phase I,Recruiting,"[{'id': 784, 'therapyName': 'GSK525762'}]","A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers",10000003
159,NCT01588184,Phase III,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",An Extension Study to Provide Continued Avastin Therapy to Patients With Solid Tumours Who Were Previously Enrolled in a Roche/Genentech Sponsored Study,10000003
160,NCT01588678,Phase I,Completed,"[{'id': 1010, 'therapyName': 'DS-3078a'}]"," A Open-Label, Multiple Ascending Dose Study of DS-3078a, an Oral TORC1/2 Kinase Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas",10000003
161,NCT01588821,Phase II,"Active, not recruiting","[{'id': 998, 'therapyName': 'cabozantinib'}]",Cabozantinib in Advanced Solid Malignancies,10000003
162,NCT01593228,Phase III,Completed,"[{'id': 1173, 'therapyName': 'Iniparib + doxorubicin + carboplatin'}, {'id': 1172, 'therapyName': 'Iniparib + Paclitaxel'}, {'id': 1171, 'therapyName': 'Iniparib + Irinotecan'}, {'id': 1170, 'therapyName': 'Iniparib + Topotecan'}, {'id': 1169, 'therapyName': 'Iniparib + Gemcitabine + Carboplatin'}, {'id': 1168, 'therapyName': 'Iniparib'}]", Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial,10000003
163,NCT01596140,Phase I,"Active, not recruiting","[{'id': 1175, 'therapyName': 'Vemurafenib + Temsirolimus'}, {'id': 1174, 'therapyName': 'Vemurafenib + Everolimus'}]",Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer,10000003
164,NCT01596270,Phase I,Completed,"[{'id': 1051, 'therapyName': 'SAR245409'}]",A Study of the Safety and Pharmacokinetics of SAR245409 Tablets in Patients With Solid Tumors or Lymphoma,10000003
165,NCT01606878,Phase I,Recruiting,"[{'id': 2952, 'therapyName': 'Dexamethasone + Doxorubicin + Vincristine'}, {'id': 2590, 'therapyName': 'Cyclophosphamide + Topotecan'}, {'id': 706, 'therapyName': 'Crizotinib'}]",Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma,10000003
166,NCT01607905,Phase I,Completed,"[{'id': 1749, 'therapyName': 'Selinexor'}]",Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced or Metastatic Solid Tumor Cancer,10000003
167,NCT01609556,Phase I,"Active, not recruiting","[{'id': 3232, 'therapyName': 'IMGN853'}]","First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IMGN853 in Adults With Ovarian Cancer and Other FOLR1-Positive Solid Tumors",10000003
168,NCT01610570,Phase Ib/II,Terminated,"[{'id': 1397, 'therapyName': 'Mithramycin'}]",Mithramycin for Children and Adults With Solid Tumors or Ewing Sarcoma,10000003
169,NCT01624467,Phase II,Completed,"[{'id': 826, 'therapyName': 'Necitumumab'}]",A Study of Necitumumab Monotherapy and the QT/QTc Interval in Patient With Advanced Solid Tumors,10000003
170,NCT01624766,Phase I,Recruiting,"[{'id': 1199, 'therapyName': 'Everolimus + Denosumab'}, {'id': 1192, 'therapyName': 'Anakinra + Everolimus'}]",Anakinra or Denosumab and Everolimus in Advanced Cancer,10000003
171,NCT01625156,Phase I,Completed,"[{'id': 1200, 'therapyName': 'Tivantinib + Temsirolimus'}]",Tivantinib and Temsirolimus in Treating Patients With Solid Tumors That is Metastatic or Cannot be Removed By Surgery,10000003
172,NCT01625234,Phase Ib/II,Recruiting,"[{'id': 961, 'therapyName': 'X-396'}]","Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer",10000003
173,NCT01633970,Phase I,"Active, not recruiting","[{'id': 1203, 'therapyName': 'Atezolizumab + Carboplatin + Paclitaxel'}, {'id': 1204, 'therapyName': 'Atezolizumab + Carboplatin + Pemetrexed'}, {'id': 1202, 'therapyName': 'Atezolizumab + Bevacizumab + Capecitabine'}]",A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Avastin (Bevacizumab) and/or With Chemotherapy in Patients With Locally Advanced or Metastatic Solid Tumors,10000003
174,NCT01634893,Phase I,Completed,"[{'id': 1208, 'therapyName': 'Sorafenib + Hydroxychloroquine'}]",Oral Hydroxychloroquine Plus Oral Sorafenib to Treat Patients With Refractory or Relapsed Solid Tumors,10000003
175,NCT01636479,Phase I,"Active, not recruiting","[{'id': 2078, 'therapyName': 'SAR405838'}]",Phase 1 Safety Testing of SAR405838,10000003
176,NCT01636622,Phase I,"Active, not recruiting","[{'id': 1209, 'therapyName': 'Vemurafenib + Carboplatin + Paclitaxel '}]"," Study of Vemurafenib, Carboplatin, and Paclitaxel",10000003
177,NCT01638533,Phase I,Recruiting,"[{'id': 1075, 'therapyName': 'romidepsin'}]","Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction",10000003
178,NCT01639911,Phase I,Completed,"[{'id': 1212, 'therapyName': 'Alisertib + Pazopanib'}]",MLN8237 and Pazopanib in Combination for Solid Tumors,10000003
179,NCT01642342,Phase I,Recruiting,"[{'id': 3013, 'therapyName': 'sEphB4-HSA'}]",Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors,10000003
180,NCT01653470,Phase I,"Active, not recruiting","[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 2545, 'therapyName': 'BMS-906024'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]","Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors",10000003
181,NCT01654965,Phase I,"Active, not recruiting","[{'id': 1477, 'therapyName': 'Tivantinib + Topotecan + Pegfilgrastim'}]",Tivantinib and Topotecan Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors,10000003
182,NCT01655225,Phase I,Recruiting,"[{'id': 1214, 'therapyName': 'LY3023414 + Midazolam '}, {'id': 1215, 'therapyName': ' LY3023414 + Letrozole '}, {'id': 1069, 'therapyName': 'LY3023414'}]",A Study of LY3023414 in Participants With Advanced Cancer,10000003
183,NCT01661400,Phase I,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1475, 'therapyName': 'Thalidomide'}]",Anti-Angiogenic Therapy Post Transplant (ASCR) for Relapsed and Refractory Pediatric Solid Tumors,10000003
184,NCT01661972,Phase Ib/II,Completed,"[{'id': 2368, 'therapyName': 'Aflibercept + Capecitabine'}]",Phase I/II Study of Capecitabine Plus Aflibercept to Treat Metastatic Colorectal Cancer,10000003
185,NCT01664000,Phase I,Completed,"[{'id': 2999, 'therapyName': 'thioureidobutyronitrile'}]","A Safety, Pharmacokinetic and Pharmacodynamic Study of Kevetrin in Patients With Advanced Solid Tumors",10000003
186,NCT01670175,Phase I,Completed,"[{'id': 1224, 'therapyName': 'Sirolimus + Cyclophosphamide + Topotecan'}]",Sirolimus With Cyclophosphamide and Topotecan for Pediatric/Adolescent Relapsed and Refractory Solid Tumors,10000003
187,NCT01673737,Phase I,Completed,"[{'id': 1052, 'therapyName': 'SAR260301'}, {'id': 1225, 'therapyName': 'SAR260301 + Vemurafenib'}]", A Phase I/Ib Trial for the Evaluation of SAR260301 in Monotherapy or in Combination With Vemurafenib in Patients With Various Advanced Cancer,10000003
188,NCT01677559,Phase I,"Active, not recruiting","[{'id': 1226, 'therapyName': 'Alisertib + Abraxane'}]",Combining MLN8237 With Nab-Paclitaxel in Patients With Advanced Solid Malignancies,10000003
189,NCT01677741,Phase I,Recruiting,"[{'id': 3, 'therapyName': 'Dabrafenib'}]"," The Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Pediatric Subjects",10000003
190,NCT01683149,Phase I,Completed,"[{'id': 1228, 'therapyName': 'Topotecan + Sorafenib'}]", Sorafenib and Topotecan in Refractory/Recurrent Pediatric Malignancies,10000003
191,NCT01693562,Phase Ib/II,"Active, not recruiting","[{'id': 1356, 'therapyName': 'Durvalumab'}]",A Phase 1/2 Study to Evaluate MEDI4736,10000003
192,NCT01695005,Phase I,Recruiting,"[{'id': 2958, 'therapyName': 'LY3039478'}]",A Study of LY3039478 in Participants With Advanced Cancer,10000003
193,NCT01700270,Phase I,Completed,"[{'id': 1232, 'therapyName': 'Dovitinib + Fluvoxamine'}]", Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors.,10000003
194,NCT01703481,Phase I,"Active, not recruiting","[{'id': 1028, 'therapyName': 'JNJ-42756493'}]","A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Adult Patients With Advanced or Refractory Solid Tumors or Lymphoma",10000003
195,NCT01708161,Phase I,Completed,"[{'id': 1109, 'therapyName': 'BYL719 + AMG 479'}]",A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors,10000003
196,NCT01709435,Phase I,"Active, not recruiting","[{'id': 998, 'therapyName': 'cabozantinib'}]", Cabozantinib in Treating Younger Patients With Recurrent or Refractory Solid Tumors,10000003
197,NCT01713972,Phase I,"Active, not recruiting","[{'id': 1233, 'therapyName': 'Dabrafenib + Pazopanib'}]", Dabrafenib and Pazopanib Hydrochloride in Treating Patients With Advanced Malignant Tumors,10000003
198,NCT01714739,Phase I,Recruiting,"[{'id': 2584, 'therapyName': 'Lirilumab + Nivolumab'}]",A Phase I Study of an Anti-KIR Antibody in Combination With an Anti-PD1 Antibody in Patients With Advanced Solid Tumors,10000003
199,NCT01723020,Phase I,Completed,"[{'id': 1452, 'therapyName': 'AMG 232'}]",A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma,10000003
200,NCT01725100,Phase I,Completed,"[{'id': 2, 'therapyName': 'Trametinib'}]","A Study to Determine the Relative Bioavailability of the MEK Inhibitor, Trametinib, in Subjects With Solid Tumor Malignancies",10000003
201,NCT01727869,Phase I,Completed,"[{'id': 1246, 'therapyName': 'REGN1400 + Erlotinib'}, {'id': 1247, 'therapyName': 'REGN1400 + Cetuximab'}, {'id': 1072, 'therapyName': 'REGN1400'}]", Study of REGN1400 Alone and in Combination With Erlotinib or Cetuximab in Patients With Certain Types of Cancer,10000003
202,NCT01728311,Phase I,Completed,"[{'id': 666, 'therapyName': 'BAY1082439'}]",Open Label Study of BAY1082439 in Patients With Advanced Cancer,10000003
203,NCT01730118,Phase I,Recruiting,"[{'id': 1404, 'therapyName': 'HER2 Vaccine'}]",Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing,10000003
204,NCT01733004,Phase I,Completed,"[{'id': 1248, 'therapyName': 'MM-141 + Everolimus'}, {'id': 1073, 'therapyName': 'MM-141'}, {'id': 1249, 'therapyName': 'MM-141 + Abraxane + Gemcitabine'}]",A Phase 1 Study of MM-141 in Patients With Advanced Solid Tumors,10000003
205,NCT01738139,Phase I,Recruiting,"[{'id': 1250, 'therapyName': 'Ipilimumab + Imatinib Mesylate'}]",Ipilimumab and Imatinib Mesylate in Advanced Cancer,10000003
206,NCT01738451,Phase I,Completed,"[{'id': 3, 'therapyName': 'Dabrafenib'}]", A Study to Evaluate the Effect of Repeat Oral Dosing of GSK2118436 on Cardiac Repolarization in Subjects With V600 BRAF Mutation-Positive Tumors,10000003
207,NCT01739764,Phase III,Recruiting,"[{'id': 342, 'therapyName': 'Vemurafenib'}]", An Extension (Rollover) Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol,10000003
208,NCT01741727,Phase II,Completed,"[{'id': 976, 'therapyName': 'ABT-414'}]",A Study of ABT-414 in Subjects With Solid Tumors,10000003
209,NCT01742286,Phase I,Recruiting,"[{'id': 789, 'therapyName': 'Ceritinib'}]","Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)",10000003
210,NCT01744652,Phase I,"Active, not recruiting","[{'id': 1252, 'therapyName': 'Crizotinib + Dasatinib'}]",Dasatinib and Crizotinib in Advanced Cancer,10000003
211,NCT01748825,Phase I,Recruiting,"[{'id': 822, 'therapyName': 'MK-1775'}]",MK-1775 for Advanced Solid Tumors,10000003
212,NCT01749384,Phase I,Completed,"[{'id': 1254, 'therapyName': 'Bevacizumab + Tivantinib'}]",Tivantinib and Bevacizumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery,10000003
213,NCT01750983,Phase I,"Active, not recruiting","[{'id': 2992, 'therapyName': 'Ipilimumab + lenalidomide'}]",Ipilimumab and Lenalidomide in Advanced Cancer,10000003
214,NCT01752920,Phase I,"Active, not recruiting","[{'id': 2900, 'therapyName': 'ARQ 087'}]",Phase 1 Dose Escalation Study of ARQ 087 in Adult Subjects With Advanced Solid Tumors,10000003
215,NCT01760525,Phase I,"Active, not recruiting","[{'id': 2077, 'therapyName': 'CGM097'}]",A Phase I Dose Escalation Study of CGM097 in Adult Patients With Selected Advanced Solid Tumors,10000003
216,NCT01765543,Phase I,Completed,"[{'id': 1256, 'therapyName': 'Rifampin + Vemurafenib'}]",A Pharmacokinetics Study to Investigate the Effect of Rifampin on Vemurafenib in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy,10000003
217,NCT01767623,Phase I,"Active, not recruiting","[{'id': 342, 'therapyName': 'Vemurafenib'}]", A Study of The Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation-Positive Cancer Patients,10000003
218,NCT01769768,Phase I,Completed,"[{'id': 1428, 'therapyName': 'Sonidegib'}, {'id': 2505, 'therapyName': 'Warfarin'}, {'id': 2506, 'therapyName': 'Bupropion'}]",Phase I Study to Evaluate the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in Patients,10000003
219,NCT01772004,Phase I,Recruiting,"[{'id': 3144, 'therapyName': 'Avelumab'}]",Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor),10000003
220,NCT01775423,Phase Ib/II,Unknown status,"[{'id': 2057, 'therapyName': 'BBI608'}]",A Study of BBI608 in Adult Patients With Advanced Malignancies,10000003
221,NCT01778439,Phase I,Completed,"[{'id': 839, 'therapyName': 'Brontictuzumab'}]",A Dose Escalation Study of OMP-52M51 in Subjects With Solid Tumors,10000003
222,NCT01781429,Phase Ib/II,"Active, not recruiting","[{'id': 997, 'therapyName': 'BVD-523'}]","Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies",10000003
223,NCT01781455,Phase Ib/II,Recruiting,"[{'id': 1945, 'therapyName': 'BBI503'}]",A Study of BBI503 in Adult Patients With Advanced Solid Tumors,10000003
224,NCT01784861,Phase Ib/II,"Active, not recruiting","[{'id': 1272, 'therapyName': 'X-82 + Everolimus'}]",VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors,10000003
225,NCT01787500,Phase I,"Active, not recruiting","[{'id': 1331, 'therapyName': 'Vemurafenib + Cetuximab + Irinotecan '}]","Vemurafenib, Cetuximab, and Irinotecan in Advanced Solid Cancers",10000003
226,NCT01789281,Phase III,Recruiting,"[{'id': 1333, 'therapyName': 'Everolimus + Sandostatin LAR Depot'}]",Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.,10000003
227,NCT01791088,Phase I,"Active, not recruiting","[{'id': 917, 'therapyName': 'Sirolimus'}]",Sirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery,10000003
228,NCT01803282,Phase I,Recruiting,"[{'id': 3320, 'therapyName': 'GS-5745'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Safety and Tolerability Study in Solid Tumors,10000003
229,NCT01804530,Phase I,"Active, not recruiting","[{'id': 2651, 'therapyName': 'PLX7486'}, {'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}]",Phase 1 Study of PLX7486 as Single Agent and With Gemcitabine Plus Nab-Paclitaxel in Patients With Advanced Solid Tumors,10000003
230,NCT01804634,Phase II,Recruiting,"[{'id': 1373, 'therapyName': 'Cyclophosphamide + Fludarabine + Melphalan + Sirolimus'}]",A Phase II Trial of Reduced Intensity Conditioning and Haploidentical BMT for High-risk Solid Tumors,10000003
231,NCT01815294,Phase I,Completed,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1008, 'therapyName': 'Doxil'}]", A Pivotal Bioequivalence Study of DOXIL/CAELYX (Doxorubicin HCL) in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer,10000003
232,NCT01822522,Phase I,Recruiting,"[{'id': 998, 'therapyName': 'cabozantinib'}]",Cabozantinib-S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency Virus,10000003
233,NCT01822756,Phase I,Terminated,"[{'id': 907, 'therapyName': 'Ruxolitinib'}]",An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors,10000003
234,NCT01827384,Phase II,Recruiting,"[{'id': 1194, 'therapyName': 'MK-1775 + Carboplatin '}, {'id': 1193, 'therapyName': 'Veliparib + Temozolomide'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 2, 'therapyName': 'Trametinib'}]",Molecular Profiling-Based Targeted Therapy in Treating Patients With Advanced Solid Tumors,10000003
235,NCT01828554,Phase III,Recruiting,"[{'id': 1105, 'therapyName': 'Capecitabine'}]",Capecitabine Pharmacokinetics(PK)-Actual Versus Ideal Body Weight,10000003
236,NCT01829971,Phase I,Terminated,"[{'id': 1035, 'therapyName': 'MRX34'}]","A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection",10000003
237,NCT01831726,Phase II,Completed,"[{'id': 721, 'therapyName': 'Dovitinib'}]",Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib,10000003
238,NCT01833169,Phase II,Completed,"[{'id': 680, 'therapyName': 'BKM120'}]",BKM120 for Patients With PI3K-activated Tumors,10000003
239,NCT01835184,Phase I,Terminated,"[{'id': 1235, 'therapyName': 'Cabozantinib + Vemurafenib'}]",Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery,10000003
240,NCT01837667,Phase I,Completed,"[{'id': 3683, 'therapyName': 'Docetaxel + LB-100'}]",Phase I Study of LB-100 With Docetaxel in Solid Tumors,10000003
241,NCT01844583,Phase I,Completed,"[{'id': 1239, 'therapyName': 'Alisertib  + Esomeprazole'}, {'id': 1240, 'therapyName': 'Alisertib + Rifampin'}, {'id': 626, 'therapyName': 'Alisertib'}]","Safety, Tolerability and PK of Concomitant Esomeprazole and Rifampin, and QT Study on Single and Multiple-doses of Alisertib",10000003
242,NCT01844674,Phase I,Completed,"[{'id': 1241, 'therapyName': 'Vemurafenib + Tizanidine'}]",A Study on the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine in Patients With BRAFV600 Mutation-Positive Metastatic Malignancies,10000003
243,NCT01849744,Phase I,Terminated,"[{'id': 1933, 'therapyName': 'VS-4718'}]",Phase I Dose Escalation Study of VS-4718 in Subjects With Metastatic Non-Hematologic Malignancies,10000003
244,NCT01853046,Phase I,Completed,"[{'id': 890, 'therapyName': 'Regorafenib'}]",Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment,10000003
245,NCT01858883,Phase I,Completed,"[{'id': 619, 'therapyName': 'Abraxane'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2406, 'therapyName': 'INCB039110'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",Safety Study of INCB039110 in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors,10000003
246,NCT01875705,Phase I,Completed,"[{'id': 2149, 'therapyName': 'GDC-0994'}]",A Dose-Escalation Study of GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors,10000003
247,NCT01876511,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Phase 2 Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors,10000003
248,NCT01877382,Phase I,Recruiting,"[{'id': 2079, 'therapyName': 'DS-3032b'}]","A Phase 1 Multiple Ascending Dose Study of DS-3032b, an Oral Murine Double Minute 2 (MDM2) Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas",10000003
249,NCT01877811,Phase Ib/II,"Active, not recruiting","[{'id': 1002, 'therapyName': 'CEP-32496'}]",CEP-32496 in Patients With Advanced Solid Tumors in Phase 1 and Advanced Melanoma and Metastatic Colorectal Cancer in Phase 2,10000003
250,NCT01884285,Phase I,Recruiting,"[{'id': 992, 'therapyName': 'AZD8186'}]",AZD8186 First Time In Patient Ascending Dose Study,10000003
251,NCT01885195,Phase II,Completed,"[{'id': 807, 'therapyName': 'Binimetinib'}]",MEK162 for Patients With RAS/RAF/MEK Activated Tumors,10000003
252,NCT01898078,Phase I,"Active, not recruiting","[{'id': 626, 'therapyName': 'Alisertib'}]", Food Effect Study of Alisertib (MLN8237) in Patients With Advanced Solid Tumors or Lymphomas,10000003
253,NCT01898130,Phase II,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}]",Bevacizumab in Pats w/ Recurrent ST Brain Metas Who Have Failed Whole Brain Radiation Therapy,10000003
254,NCT01899053,Phase I,"Active, not recruiting","[{'id': 1283, 'therapyName': 'MLN1117 + Sapanisertib'}]",Phase 1b Study of MLN0128 in Combination With MLN1117 in Adult Patients With Advanced Nonhematologic Malignancies,10000003
255,NCT01902173,Phase Ib/II,Suspended,"[{'id': 2, 'therapyName': 'Trametinib'}, {'id': 2200, 'therapyName': 'Dabrafenib + GSK2141795'}]","GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer",10000003
256,NCT01905228,Phase I,Recruiting,"[{'id': 3940, 'therapyName': 'CBL0137 '}]",A Phase 1 Trial of CBL0137 in Patients With Metastatic or Unresectable Advanced Solid Neoplasm or Refractory Lymphomas,10000003
257,NCT01907802,Phase I,"Active, not recruiting","[{'id': 3, 'therapyName': 'Dabrafenib'}]",Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction,10000003
258,NCT01908413,Phase I,Terminated,"[{'id': 3639, 'therapyName': 'GDC-0917'}]","Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-427 When Given to Patients With Advanced and Refractory Solid Tumors or Lymphoma",10000003
259,NCT01910545,Phase I,Completed,"[{'id': 3951, 'therapyName': 'OTS167'}]",Phase 1 Study of OTS167 in Patients With Solid Tumors,10000003
260,NCT01915576,Phase I,Completed,"[{'id': 994, 'therapyName': 'BAY1125976'}]",Phase I Dose Escalation Study With an Allosteric AKT 1/2 Inhibitor in Patients,10000003
261,NCT01922752,Phase I,Completed,"[{'id': 2147, 'therapyName': 'CEP-37440'}]",To Determine the Maximum Tolerated Dose of Oral CEP-37440 in Patients With Advanced or Metastatic Solid Tumors,10000003
262,NCT01923337,Phase I,"Active, not recruiting","[{'id': 1288, 'therapyName': 'Irinotecan + Alisertib'}]",Irinotecan and Alisertib in Treating Patients With Advanced Solid Tumors or Colorectal Cancer,10000003
263,NCT01924260,Phase I,"Active, not recruiting","[{'id': 1289, 'therapyName': 'Alisertib + Gemcitabine'}]",Alisertib and Gemcitabine Hydrochloride in Treating Patients With Solid Tumors or Pancreatic Cancer,10000003
264,NCT01928459,Phase I,Completed,"[{'id': 1293, 'therapyName': 'BGJ398 + BYL719'}]",Phase 1b Trial of BGJ398/BYL719 in Solid Tumors,10000003
265,NCT01948297,Phase I,Recruiting,"[{'id': 1014, 'therapyName': 'FF-284'}]",Debio 1347-101 Phase I Trial in Advanced Solid Tumours With Fibroblast Growth Factor Receptor (FGFR) Alterations,10000003
266,NCT01953926,Phase II,Recruiting,"[{'id': 828, 'therapyName': 'Neratinib'}]","An Open-label, Phase 2 Study of Neratinib in Patients With Solid Tumors With Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification",10000003
267,NCT01954043,Phase I,Completed,"[{'id': 1302, 'therapyName': 'Dabrafenib + Rabeprazole + Rifampin'}]",A Pharmacokinetics (PK) Study of the Effects Rabeprazole and Rifampin on Dabrafenib in Subjects With BRAF V600 Mutation Positive Tumors,10000003
268,NCT01954316,Phase I,Recruiting,"[{'id': 4029, 'therapyName': 'CFI-400945'}]",A Study of CFI-400945 Fumarate in Patients With Advanced Cancer,10000003
269,NCT01971489,Phase I,Withdrawn,"[{'id': 1304, 'therapyName': 'BKM120 + Gemcitabine + Cisplatin'}]","PI3K Inhibitor BKM120, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors",10000003
270,NCT01971515,Phase I,Recruiting,"[{'id': 1037, 'therapyName': 'MSC2363318A'}]",First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies,10000003
271,NCT01973868,Phase I,"Active, not recruiting","[{'id': 1305, 'therapyName': 'Regorafenib + Cetuximab'}]",Safety and Pharmacokinetics of Regorafenib and Cetuximab in Combination,10000003
272,NCT01974258,Phase I,Withdrawn,"[{'id': 1306, 'therapyName': 'Onartuzumab + Vemurafenib'}, {'id': 1307, 'therapyName': 'Onartuzumab + Cobimetinib'}, {'id': 1308, 'therapyName': 'Onartuzumab + Cobimetinib + Vemurafenib'}]","Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients",10000003
273,NCT01975831,Phase I,"Active, not recruiting","[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab,10000003
274,NCT01976741,Phase I,Recruiting,"[{'id': 2030, 'therapyName': 'Rogaratinib'}]",Phase I Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor,10000003
275,NCT01981187,Phase II,Completed,"[{'id': 796, 'therapyName': 'Encorafenib'}]",LGX818 for Patients With BRAFV600 Mutated Tumors,10000003
276,NCT01986166,Phase I,Completed,"[{'id': 1342, 'therapyName': 'MEHD7945A + Cobimetinib'}]",A Study of MEHD7945A and Cobimetinib (GDC-0973) in Patients With Locally Advanced or Metastatic Cancers With Mutant KRAS,10000003
277,NCT01987362,Phase I,"Active, not recruiting","[{'id': 937, 'therapyName': 'TEN-010'}]","A Two Part, Multicenter, Open-label Study of TEN-010 Given Subcutaneously",10000003
278,NCT01988896,Phase I,"Active, not recruiting","[{'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}]",A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors,10000003
279,NCT01989546,Phase Ib/II,Completed,"[{'id': 682, 'therapyName': 'Talazoparib'}]","Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations",10000003
280,NCT01989585,Phase Ib/II,Recruiting,"[{'id': 1303, 'therapyName': 'Trametinib + Dabrafenib + Navitoclax'}, {'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}]","Dabrafenib, Trametinib, and Navitoclax in Treating Patients With Solid Tumors That Are Metastatic or Cannot be Removed by Surgery",10000003
281,NCT01991938,Phase I,Terminated,"[{'id': 960, 'therapyName': 'VS-5584'}]",Phase I Dose Escalation Study of VS-5584 in Subjects With Advanced Non-Hematologic Malignancies or Lymphoma,10000003
282,NCT01992874,Phase I,Completed,"[{'id': 871, 'therapyName': 'Pimasertib'}]",Relative Bioavailability of Pimasertib in Cancer Patients,10000003
283,NCT01999738,Phase I,"Active, not recruiting","[{'id': 1603, 'therapyName': 'EC1456'}]",Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors,10000003
284,NCT01999972,Phase I,"Active, not recruiting","[{'id': 1350, 'therapyName': 'Axitinib + Crizotinib'}]",A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors,10000003
285,NCT02000934,Phase I,Recruiting,"[{'id': 3146, 'therapyName': 'TAK-659'}]",A Study of TAK-659 in Adult Patients With Advanced Solid Tumor and Lymphoma Malignancies,10000003
286,NCT02002689,Phase II,Terminated,"[{'id': 1428, 'therapyName': 'Sonidegib'}]",LDE225 for Patients With PTCH1 or SMO Mutated Tumors,10000003
287,NCT02004106,Phase I,Completed,"[{'id': 2886, 'therapyName': 'RO6895882'}]",A Study of RO6895882 in Patients With Advanced and/or Metastatic Solid Tumors,10000003
288,NCT02009631,Phase I,Completed,"[{'id': 954, 'therapyName': 'Veliparib'}]",A Study to Evaluate the Effects of Veliparib on Heart Rhythms in Patients With Solid Tumors,10000003
289,NCT02012231,Phase Ib/II,Terminated,"[{'id': 1041, 'therapyName': 'PLX8394'}]","Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.",10000003
290,NCT02014116,Phase I,"Active, not recruiting","[{'id': 3268, 'therapyName': 'LY3009120'}]",A Study of LY3009120 in Participants With Advanced Cancer or Cancer That Has Spread to Other Parts of Their Body,10000003
291,NCT02014909,Phase I,Completed,"[{'id': 2054, 'therapyName': 'CDX-3379'}, {'id': 2063, 'therapyName': 'CDX-3379 + Vemurafenib'}, {'id': 2064, 'therapyName': 'CDX-3379 + Trastuzumab'}, {'id': 2061, 'therapyName': 'Cetuximab + CDX-3379'}, {'id': 2062, 'therapyName': 'CDX-3379 + Erlotinib'}]",A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors,10000003
292,NCT02015117,Phase I,"Active, not recruiting","[{'id': 2, 'therapyName': 'Trametinib'}]",Trametinib With or Without Whole Brain Radiation Therapy in Treating Patients With Brain Metastases,10000003
293,NCT02022982,Phase Ib/II,Recruiting,"[{'id': 1823, 'therapyName': 'PD-0325901 + Palbociclib'}]",PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors,10000003
294,NCT02025803,Phase I,"Active, not recruiting","[{'id': 4335, 'therapyName': 'Capecitabine + TAS-114'}]","A Safety, Tolerability and Pharmacokinetic Study of TAS-114 in Combination With Capecitabine in Patients With Advanced Solid Tumors",10000003
295,NCT02033148,Phase I,Withdrawn,"[{'id': 769, 'therapyName': 'Icotinib'}]",Icotinib Hydrochloride in Treating Patients With Advanced Cancers,10000003
296,NCT02038673,Phase I,Completed,"[{'id': 3584, 'therapyName': 'ASP5878'}]",An Open-label Phase I Study of Oral ASP5878 at Single and Multiple Doses in Patients With Solid Tumors,10000003
297,NCT02042989,Phase I,"Active, not recruiting","[{'id': 1360, 'therapyName': 'Ixazomib + Vorinostat'}]",MLN9708 and Vorinostat in Patients With Advanced p53 Mutant Malignancies,10000003
298,NCT02048488,Phase Ib/II,"Active, not recruiting","[{'id': 949, 'therapyName': 'TSR-011'}]","A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas",10000003
299,NCT02048709,Phase I,Completed,"[{'id': 2888, 'therapyName': 'GDC-0919'}]",IDO Inhibitor in Advanced Solid Tumors,10000003
300,NCT02048943,Phase I,Withdrawn,"[{'id': 1372, 'therapyName': 'Dovitinib + Gemcitabine + Abraxane'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 721, 'therapyName': 'Dovitinib'}]","Dovitinib Lactate, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Solid Tumors or Pancreatic Cancer",10000003
301,NCT02049593,Phase I,"Active, not recruiting","[{'id': 1377, 'therapyName': 'Talazoparib + Temozolomide'}, {'id': 1378, 'therapyName': 'Irinotecan + Talazoparib'}]",PARP Inhibitor BMN-673 and Temozolomide or Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic Solid Tumors,10000003
302,NCT02051751,Phase I,Completed,"[{'id': 1379, 'therapyName': 'BYL719 + Paclitaxel'}]",A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer,10000003
303,NCT02052778,Phase Ib/II,Recruiting,"[{'id': 1053, 'therapyName': 'TAS-120'}]",A Dose Finding Study Followed by a Safety and Efficacy Study in Patients With Advanced Solid Tumors or Multiple Myeloma With FGF/FGFR-Related Abnormalities,10000003
304,NCT02054806,Phase I,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-028/KEYNOTE-28),10000003
305,NCT02065063,Phase I,Completed,"[{'id': 1368, 'therapyName': 'Palbociclib + Trametinib'}]","A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid Tumors",10000003
306,NCT02069730,Phase I,Recruiting,"[{'id': 1749, 'therapyName': 'Selinexor'}]",A Study of Drug Therapies for Salivary Gland Cancers Based on Testing of Genes,10000003
307,NCT02070406,Phase I,Recruiting,"[{'id': 3409, 'therapyName': 'Aldesleukin + Cyclophosphamide + Fludarabine '}, {'id': 2696, 'therapyName': 'NY-ESO-1 peptide vaccine'}]","Gene-Modified T Cells, Vaccine Therapy, and Ipilimumab in Treating Patients With Locally Advanced or Metastatic Malignancies",10000003
308,NCT02070549,Phase I,Recruiting,"[{'id': 2, 'therapyName': 'Trametinib'}]",Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction,10000003
309,NCT02071862,Phase I,Recruiting,"[{'id': 1667, 'therapyName': 'CB-839'}]",Study of the Glutaminase Inhibitor CB-839 in Solid Tumors,10000003
310,NCT02073994,Phase I,"Active, not recruiting","[{'id': 1491, 'therapyName': 'AG-120'}]","Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation",10000003
311,NCT02076997,Phase I,Recruiting,"[{'id': 1639, 'therapyName': 'Methotrexate'}]",Individualized High Dose Methotrexate to Treat Cancer in Children Who Have a Significant Risk for Side Effects to Methotrexate,10000003
312,NCT02077933,Phase I,"Active, not recruiting","[{'id': 1384, 'therapyName': 'BYL719 + Everolimus'}, {'id': 1385, 'therapyName': 'BYL719 + Everolimus + Exemestane'}]","Study of Safety and Efficacy of BYL719 With Everolimus or BYL719 With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors",10000003
313,NCT02078752,Phase I,Completed,"[{'id': 4324, 'therapyName': 'PF-06647263 '}]",A Study Of PF-06647263 In Patients With Advanced Solid Tumors,10000003
314,NCT02079740,Phase Ib/II,Recruiting,"[{'id': 1386, 'therapyName': 'Trametinib + Navitoclax'}]",Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors,10000003
315,NCT02080078,Phase I,Recruiting,"[{'id': 2436, 'therapyName': 'Erlotinib + Theophylline'}]",A Phase I Dose Escalation Study of Erlotinib in Combination With Theophylline,10000003
316,NCT02081495,Phase I,Completed,"[{'id': 1008, 'therapyName': 'Doxil'}]",A Study of DOXIL/CAELYX in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer,10000003
317,NCT02082210,Phase Ib/II,"Active, not recruiting","[{'id': 1387, 'therapyName': 'Emibetuzumab + Ramucirumab'}]",A Study of LY2875358 in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer,10000003
318,NCT02082665,Phase I,Completed,"[{'id': 1388, 'therapyName': 'Dabrafenib + Rosuvastatin + Midazolam'}]",Effects of Dabrafenib on the Single Dose Pharmacokinetics (PK) of Rosuvastatin and Midazolam,10000003
319,NCT02091141,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 698, 'therapyName': 'Alectinib'}, {'id': 1657, 'therapyName': 'Vemurafenib + Cobimetinib'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]","My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors",10000003
320,NCT02095054,Phase I,"Active, not recruiting","[{'id': 1305, 'therapyName': 'Regorafenib + Cetuximab'}]",Regorafenib and Cetuximab in Patients With Advanced Malignancy,10000003
321,NCT02095132,Phase Ib/II,Recruiting,"[{'id': 1361, 'therapyName': 'MK-1775 + Irinotecan'}]",WEE1 Inhibitor MK-1775 and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors,10000003
322,NCT02097810,Phase Ib/II,Recruiting,"[{'id': 1455, 'therapyName': 'Entrectinib'}]","A Phase 1/2a Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer; Study Targeting ALK, ROS1, or TRKA/B/C",10000003
323,NCT02098967,Phase I,"Active, not recruiting","[{'id': 2155, 'therapyName': 'RO6839921'}]","A Study of the Safety and Pharmacokinetics of RO6839921, An MDM2 Antagonist, in Patients With Advanced Cancers, Including Acute Myeloid Leukemia.",10000003
324,NCT02099058,Phase I,Recruiting,"[{'id': 1743, 'therapyName': 'ABBV-399 + Carboplatin'}, {'id': 1364, 'therapyName': 'ABBV-399 + Erlotinib'}, {'id': 1363, 'therapyName': 'ABBV-399'}, {'id': 1366, 'therapyName': 'ABBV-399 + Bevacizumab'}, {'id': 1365, 'therapyName': 'ABBV-399 + Cetuximab'}]","A Phase 1/1b Study With ABBV-399, an Antibody Drug Conjugate, in Subjects With Advanced Solid Cancer Tumors",10000003
325,NCT02110563,Phase I,Terminated,"[{'id': 3122, 'therapyName': 'DCR-MYC'}]","Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma",10000003
326,NCT02116777,Phase Ib/II,Recruiting,"[{'id': 1377, 'therapyName': 'Talazoparib + Temozolomide'}]",BMN-673 and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies,10000003
327,NCT02116803,Phase III,Completed,"[{'id': 721, 'therapyName': 'Dovitinib'}]",An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled the Requirements for the Primary Objective,10000003
328,NCT02117648,,Completed,"[{'id': 1690, 'therapyName': 'Abemaciclib + Clarithromycin'}, {'id': 802, 'therapyName': 'Abemaciclib'}]", A Study of LY2835219 in Participants With Cancer,10000003
329,NCT02118337,Phase I,Recruiting,"[{'id': 3121, 'therapyName': 'MEDI0680 + MEDI4736'}]","A Phase 1, Open-label Study to Evaluate the Safety and Tolerability of MEDI0680 (AMP-514) in Combination With MEDI4736 in Subjects With Advanced Malignancies",10000003
330,NCT02122770,Phase I,"Active, not recruiting","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1026, 'therapyName': 'Itraconazole'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1688, 'therapyName': 'MLN4924'}, {'id': 1689, 'therapyName': 'Fluconazole'}]","Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Patients With Advanced Solid Tumors",10000003
331,NCT02122809,Phase I,Completed,"[{'id': 1998, 'therapyName': 'Chiauranib'}]",Phase I Study of Chiauranib in Patients With Advanced Solid Tumors,10000003
332,NCT02122913,Phase I,Recruiting,"[{'id': 2650, 'therapyName': 'LOXO-101'}]",Oral TRK Inhibitor LOXO-101 for Treatment of Advanced Adult Solid Tumors,10000003
333,NCT02124148,Phase I,Recruiting,"[{'id': 1994, 'therapyName': 'Cisplatin + Prexasertib'}, {'id': 1993, 'therapyName': 'Cetuximab + Prexasertib'}, {'id': 6248, 'therapyName': 'Pemetrexed + Prexasertib'}, {'id': 6247, 'therapyName': 'LY3023414 + Prexasertib'}, {'id': 6246, 'therapyName': 'Fluoruracil + Leucovorin + Prexasertib'}]",A Study of LY2606368 With Cisplatin or Cetuximab in Participants With Advanced Cancer,10000003
334,NCT02124772,Phase I,Recruiting,"[{'id': 2, 'therapyName': 'Trametinib'}, {'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}]","Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations",10000003
335,NCT02132754,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2829, 'therapyName': 'MK-4166'}]",Study of MK-4166 and MK-4166 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4166-001),10000003
336,NCT02134067,Phase I,Recruiting,"[{'id': 1400, 'therapyName': 'TAS-119'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]","Dose-escalating, Safety, Tolerability and PK Study of TAS-119 in Combination With Paclitaxel in Patients With Advanced Solid Tumors",10000003
337,NCT02138812,Phase I,"Active, not recruiting","[{'id': 3448, 'therapyName': 'BAY1161909 + Paclitaxel'}]",Phase I Dose Escalation of Oral BAY1161909 in Combination With Intravenous Paclitaxel,10000003
338,NCT02142803,Phase I,Recruiting,"[{'id': 1444, 'therapyName': 'MLN0128 + Bevacizumab'}]",MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors,10000003
339,NCT02143401,Phase I,Recruiting,"[{'id': 1872, 'therapyName': 'Navitoclax + Sorafenib'}]",Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors,10000003
340,NCT02143635,Phase I,Recruiting,"[{'id': 2186, 'therapyName': 'HDM201'}]",Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt,10000003
341,NCT02145559,Phase I,"Active, not recruiting","[{'id': 1593, 'therapyName': 'Sirolimus + Metformin'}, {'id': 917, 'therapyName': 'Sirolimus'}]",A Pharmacodynamic Study of Sirolimus and Metformin in Patients With Advanced Solid Tumors,10000003
342,NCT02146222,Phase I,"Active, not recruiting","[{'id': 1442, 'therapyName': 'X-82 + Docetaxel'}]",VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Docetaxel in Treating Patients With Solid Tumors,10000003
343,NCT02150733,Phase I,Completed,"[{'id': 636, 'therapyName': 'Tivantinib'}]",Pharmacokinetics of Tivantinib in Subjects With Advanced Solid Tumors and Hepatic Impairment,10000003
344,NCT02152943,Phase I,Recruiting,"[{'id': 1591, 'therapyName': 'Everolimus + Letrozole + Trastuzumab'}]","Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients",10000003
345,NCT02155582,Phase I,Completed,"[{'id': 995, 'therapyName': 'Copanlisib'}]",Copanlisib Pharmacodynamic Study,10000003
346,NCT02157792,Phase I,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 2879, 'therapyName': 'VX-970'}, {'id': 755, 'therapyName': 'Gemcitabine'}]","An Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics of VX-970 in Combination With Cytotoxic Chemotherapy",10000003
347,NCT02159989,Phase I,Recruiting,"[{'id': 1595, 'therapyName': 'Aflibercept + MLN0128'}]",MLN0128 and Ziv-Aflibercept in Treating Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery,10000003
348,NCT02160041,Phase II,Recruiting,"[{'id': 674, 'therapyName': 'BGJ398'}]",BGJ398 for Patients With Tumors With FGFR Genetic Alterations,10000003
349,NCT02160106,Phase I,Recruiting,"[{'id': 3011, 'therapyName': 'TEW 7197'}]",First in Human Dose Escalation Study of TEW-7197 in Subjects With Advanced Stage Solid Tumors,10000003
350,NCT02161770,Phase I,Completed,"[{'id': 660, 'therapyName': 'Osimertinib'}]",Study to Assess the Blood Levels and Safety of AZD9291 in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment,10000003
351,NCT02162888,Phase I,Completed,"[{'id': 1231, 'therapyName': 'Bendamustine'}]","A Phase I, Bioequivalence Study to Evaluate Two Formulations of Bendamustine (BDM) Hydrochloride (HCl) Administered to Cancer Patients",10000003
352,NCT02164838,Phase I,"Active, not recruiting","[{'id': 649, 'therapyName': 'Axitinib'}]",VEGF Receptor Tyrosine Kinase Inhibitor Axitinib in Children With Recurrent or Refractory Solid Tumors,10000003
353,NCT02168777,Phase Ib/II,Terminated,"[{'id': 1424, 'therapyName': 'Regorafenib + Refametinib'}, {'id': 888, 'therapyName': 'Refametinib'}]","Refametinib (BAY86-9766) in Combination With Regorafenib (Stivarga, BAY73-4506) in Patients With Advanced or Metastatic Cancer",10000003
354,NCT02173093,Phase Ib/II,Recruiting,"[{'id': 2058, 'therapyName': 'Aldesleukin + GD2Bi-a ATC + Sargramostim '}]",Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma,10000003
355,NCT02174172,Phase I,Recruiting,"[{'id': 6252, 'therapyName': 'Atezolizumab + Bevacizumab +Peg-interferon alfa-2a'}, {'id': 6253, 'therapyName': 'Atezolizumab + Interferon alfa-2b'}, {'id': 6250, 'therapyName': 'Atezolizumab + Peg-interferon alfa-2a'}, {'id': 6249, 'therapyName': 'Atezolizumab + Ipilimumab'}, {'id': 1975, 'therapyName': 'Atezolizumab + Obinutuzumab'}]",A Study to Assess the Safety and Tolerability of MPDL3280A in Combination With Other Immune-modulating Therapies in Patients With Locally Advanced or Metastatic Solid Tumors,10000003
356,NCT02179918,Phase I,Completed,"[{'id': 5086, 'therapyName': 'Utomilumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Study Of 4-1BB Agonist PF-05082566 Plus PD-1 Inhibitor MK-3475 In Patients With Solid Tumors (B1641003/KEYNOTE-0036),10000003
357,NCT02186821,Phase II,Completed,"[{'id': 789, 'therapyName': 'Ceritinib'}]",Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE),10000003
358,NCT02187783,Phase II,"Active, not recruiting","[{'id': 790, 'therapyName': 'Ribociclib'}]",LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE),10000003
359,NCT02188264,Phase I,"Active, not recruiting","[{'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 913, 'therapyName': 'Selumetinib'}]",Selumetinib and Cyclosporine in Treating Patients With Advanced Solid Tumors or Advanced or Metastatic Colorectal Cancer,10000003
360,NCT02189174,Phase Ib/II,Terminated,"[{'id': 1464, 'therapyName': 'CLR457'}]",Study of CLR457 Administered Orally in Adult Patients With Advanced Solid Malignancies,10000003
361,NCT02194049,Phase I,Completed,"[{'id': 1626, 'therapyName': 'BKM120 + Etoposide + Cisplatin'}]","Cisplatin, Etoposide and PI3K Inhibitor BKM120 in Treating Patients With Advanced Solid Tumors or Small Cell Lung Cancer",10000003
362,NCT02197572,Phase I,"Active, not recruiting","[{'id': 1282, 'therapyName': 'Sapanisertib'}]",Effect of MLN0128 on the QTc Interval in Participants With Advanced Solid Tumors,10000003
363,NCT02201212,Phase II,Recruiting,"[{'id': 735, 'therapyName': 'Everolimus'}]",Everolimus for Cancer With TSC1 or TSC2 Mutation,10000003
364,NCT02205333,Phase Ib/II,Terminated,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1653, 'therapyName': 'MEDI6469'}, {'id': 1652, 'therapyName': 'Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",A Phase 1b/2 Safety and Tolerability of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies,10000003
365,NCT02211755,Phase I,Recruiting,"[{'id': 3063, 'therapyName': 'Bortezomib + Clofarabine'}]",Trial of the Combination of Bortezomib and Clofarabine in Adults With Relapsed Solid Tumors,10000003
366,NCT02214147,Phase I,Completed,"[{'id': 626, 'therapyName': 'Alisertib'}]",Pharmacokinetics of Alisertib in Adults With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Function,10000003
367,NCT02216409,Phase I,Recruiting,"[{'id': 4947, 'therapyName': 'Hu5F9-G4'}]","Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody",10000003
368,NCT02219711,Phase I,Recruiting,"[{'id': 1655, 'therapyName': 'MGCD516'}]",Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer,10000003
369,NCT02219724,Phase I,"Active, not recruiting","[{'id': 2729, 'therapyName': 'MOXR0916'}]","A Phase I, Open-Label Study of MOXR0916 in Patients With Locally Advanced or Metastatic Solid Tumors",10000003
370,NCT02221882,Phase I,Completed,"[{'id': 1969, 'therapyName': 'LY3164530'}]",A Study of LY3164530 in Participants With Cancer,10000003
371,NCT02221960,Phase I,"Active, not recruiting","[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 3119, 'therapyName': 'MEDI6383'}]",A Phase 1 Study to Evaluate MEDI6383 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors,10000003
372,NCT02222922,Phase I,Recruiting,"[{'id': 1689, 'therapyName': 'Fluconazole'}, {'id': 4421, 'therapyName': 'PF-06647020'}]",A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors,10000003
373,NCT02223247,Phase I,Completed,"[{'id': 3611, 'therapyName': 'TVB-2640'}]","A Phase 1, First-In-Human Study of Escalating Doses of Oral TVB-2640 in Patients With Solid Tumors",10000003
374,NCT02227940,Phase I,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 2554, 'therapyName': 'Ceritinib + Gemcitabine'}]",Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or Metastatic Pancreatic Cancer,10000003
375,NCT02228811,Phase I,"Active, not recruiting","[{'id': 1656, 'therapyName': 'Altiratinib'}]",A Study of DCC-2701 in Participants With Advanced Solid Tumors,10000003
376,NCT02232243,Phase I,Recruiting,"[{'id': 1316, 'therapyName': 'Hydroxychloroquine'}]",HCQ on PAR-4 Levels in Patients With Resectable Solid Tumors,10000003
377,NCT02239900,Phase Ib/II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}]",Ipilimumab and Stereotactic Body Radiation Therapy (SBRT) in Advanced Solid Tumors,10000003
378,NCT02240238,Phase Ib/II,Recruiting,"[{'id': 5626, 'therapyName': 'Gemcitabine + NC-6004'}]","Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer",10000003
379,NCT02243917,Phase I,"Active, not recruiting","[{'id': 1944, 'therapyName': 'CB-5083'}]",A Phase 1 Study Evaluating CB-5083 in Patients With Advanced Solid Tumors,10000003
380,NCT02250781,Phase I,Recruiting,"[{'id': 1687, 'therapyName': 'ONC201'}]",Akt/ERK Inhibitor ONC201 in Treating Patients With Advanced Solid Tumors,10000003
381,NCT02253420,Phase I,Recruiting,"[{'id': 995, 'therapyName': 'Copanlisib'}, {'id': 1026, 'therapyName': 'Itraconazole'}]",COPANLISIB (BAY80-6946) Drug-drug Interaction Study in Advanced Solid Tumor Patients,10000003
382,NCT02253992,Phase Ib/II,Recruiting,"[{'id': 2567, 'therapyName': 'Nivolumab + Urelumab'}]",Study of the Safety and Tolerability of Urelumab Administered in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkins Lymphoma,10000003
383,NCT02259010,Phase I,"Active, not recruiting","[{'id': 626, 'therapyName': 'Alisertib'}, {'id': 1026, 'therapyName': 'Itraconazole'}]",A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Alisertib in Patients With Advanced Solid Tumors or Relapsed/Refractory Lymphoma,10000003
384,NCT02260661,Phase I,Completed,"[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 2013, 'therapyName': 'AZD8835'}]","Phase I, Dose Study to Look at the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid Tumours",10000003
385,NCT02261220,Phase I,"Active, not recruiting","[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors,10000003
386,NCT02264613,Phase Ib/II,Recruiting,"[{'id': 2273, 'therapyName': 'ALRN-6924'}]",Safety Study of ALRN-6924 in Patients With Advanced Solid Tumors,10000003
387,NCT02264678,Phase Ib/II,Recruiting,"[{'id': 2881, 'therapyName': 'AZD6738'}, {'id': 4737, 'therapyName': 'AZD6738 + Carboplatin'}, {'id': 4738, 'therapyName': 'AZD6738 + MEDI4736'}, {'id': 4739, 'therapyName': 'AZD6738 + Olaparib'}]",Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents,10000003
388,NCT02265510,Phase I,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 2747, 'therapyName': 'INCB052793'}, {'id': 688, 'therapyName': 'Bortezomib'}]","An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies",10000003
389,NCT02266745,Phase I,Recruiting,"[{'id': 2920, 'therapyName': 'PT-112'}]",A Phase 1 Study of PT-112 Injection in Subjects With Advanced Solid Tumors,10000003
390,NCT02272998,Phase II,Recruiting,"[{'id': 877, 'therapyName': 'Ponatinib'}]",Ponatinib Hydrochloride in Treating Patients With Refractory Metastatic Cancers and Genetic Alterations,10000003
391,NCT02273739,Phase Ib/II,Completed,"[{'id': 2982, 'therapyName': 'Enasidenib'}]","Study of Orally Administered AG-221 in Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation",10000003
392,NCT02279433,Phase I,"Active, not recruiting","[{'id': 4343, 'therapyName': 'DS6051b'}]","A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b",10000003
393,NCT02285439,Phase Ib/II,Recruiting,"[{'id': 807, 'therapyName': 'Binimetinib'}]",MEK 162 for Children w/Progressive/Recurrent Cancer/Study for Children w/Low-Grade Gliomas/Other Ras/Raf/MAP Pathway Activated Tumors,10000003
394,NCT02286687,Phase II,"Active, not recruiting","[{'id': 682, 'therapyName': 'Talazoparib'}]",Phase II Study of BMN 673,10000003
395,NCT02298387,Phase I,"Active, not recruiting","[{'id': 2732, 'therapyName': 'OMP-305B83 '}]",A Phase 1 Study of OMP-305B83 in Subjects With Solid Tumors,10000003
396,NCT02298959,Phase I,Recruiting,"[{'id': 2369, 'therapyName': 'Aflibercept + Pembrolizumab'}]",Pembrolizumab and Ziv-aflibercept in Treating Patients With Advanced Solid Tumors,10000003
397,NCT02301117,Phase I,Recruiting,"[{'id': 2426, 'therapyName': 'trifluridine/tipiracil hydrochloride'}]",A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment,10000003
398,NCT02301130,Phase I,"Active, not recruiting","[{'id': 2968, 'therapyName': 'Mogamulizumab '}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]",Study of Mogamulizumab + MEDI4736 and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid Tumors,10000003
399,NCT02303028,Phase Ib/II,Recruiting,"[{'id': 1469, 'therapyName': 'Topotecan + Pazopanib'}]",Phase I Dose Escalation Study of Topotecan and Pazopanib in Children With Recurrent/Refractory Solid and CNS Tumours,10000003
400,NCT02303990,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",RADVAX A Stratified Phase I Trial of Pembrolizumab With Hypofractionated Radiotherapy in Patients With Advanced and Metastatic Cancers,10000003
401,NCT02304393,Phase I,Recruiting,"[{'id': 2672, 'therapyName': 'RO7009789'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study of RO7009789 in Combination With MPDL3280A in Patients With Locally Advanced and Metastatic Solid Tumors,10000003
402,NCT02304419,Phase I,Completed,"[{'id': 2409, 'therapyName': 'Galunisertib'}]",A Study of Galunisertib on the Immune System in Participants With Cancer,10000003
403,NCT02304458,Phase Ib/II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas,10000003
404,NCT02307240,Phase I,Recruiting,"[{'id': 709, 'therapyName': 'CUDC-907'}]","Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors",10000003
405,NCT02312804,Phase I,Withdrawn,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 674, 'therapyName': 'BGJ398'}]",Ph Ib/BGJ398/Cervix and Other Solid Tumors,10000003
406,NCT02313012,Phase I,Terminated,"[{'id': 2874, 'therapyName': 'CC-90003'}]",Safety and PK Study of CC-90003 in Relapsed/Refractory Solid Tumors,10000003
407,NCT02317874,Phase I,Recruiting,"[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 682, 'therapyName': 'Talazoparib'}]","PARP Inhibitor BMN-673, Carboplatin, and Paclitaxel in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery",10000003
408,NCT02318277,Phase Ib/II,Recruiting,"[{'id': 3015, 'therapyName': 'INCB024360 + MEDI4736'}]",A Study of INCB024360 in Combination With MEDI4736 in Subjects With Selected Advanced Solid Tumors,10000003
409,NCT02318329,Phase I,Recruiting,"[{'id': 2933, 'therapyName': 'FPA144'}]","Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors",10000003
410,NCT02318394,Phase I,"Active, not recruiting","[{'id': 3838, 'therapyName': 'MEDI0562'}]",A Phase 1 Study of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors,10000003
411,NCT02318901,Phase Ib/II,"Active, not recruiting","[{'id': 1909, 'therapyName': 'Pembrolizumab + trastuzumab emtansine'}, {'id': 1908, 'therapyName': 'Pembrolizumab + Trastuzumab'}, {'id': 1910, 'therapyName': 'Pembrolizumab + Cetuximab'}]",Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer,10000003
412,NCT02321501,Phase I,Recruiting,"[{'id': 2295, 'therapyName': 'Ceritinib + Everolimus'}, {'id': 789, 'therapyName': 'Ceritinib'}]",Phase I/Ib Dose Escalation and Biomarker Study of Ceritinib (LDK378) + Everolimus for Locally Advanced or Metastatic Solid Tumors With an Expansion in Non-Small Cell Lung Cancer (NSCLC) Characterized by Abnormalities in Anaplastic Lymphoma Kinase (ALK) Expression,10000003
413,NCT02323880,Phase I,Recruiting,"[{'id': 1749, 'therapyName': 'Selinexor'}]",Study of Selinexor in Pediatric Solid Tumors,10000003
414,NCT02324621,Phase I,Recruiting,"[{'id': 1687, 'therapyName': 'ONC201'}]",Continuation of Oral ONC201 in Treating Patients With Advanced Solid Tumors,10000003
415,NCT02325739,Phase Ib/II,Recruiting,"[{'id': 2031, 'therapyName': 'FGF401'}]",Safety and Efficacy of FGF401 in Patients With Solid Malignancies,10000003
416,NCT02327169,Phase I,Recruiting,"[{'id': 2175, 'therapyName': 'MLN0128 + MLN2480'}, {'id': 2176, 'therapyName': 'MLN2480 + Alisertib'}, {'id': 2177, 'therapyName': 'MLN2480 + Paclitaxel'}]",A Phase 1B Study of MLN2480 in Combination With MLN0128 or Alisertib or Paclitaxel in Adult Patients With Advanced Nonhematologic Malignancies,10000003
417,NCT02331251,Phase Ib/II,"Active, not recruiting","[{'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 619, 'therapyName': 'Abraxane'}]",Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus),10000003
418,NCT02332668,Phase Ib/II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","A Study of Pembrolizumab (MK-3475) in Pediatric Participants With Advanced Melanoma or Advanced, Relapsed, or Refractory PD-L1-Positive Solid Tumors or Lymphoma (MK-3475-051/KEYNOTE-051)",10000003
419,NCT02341456,Phase I,"Active, not recruiting","[{'id': 822, 'therapyName': 'MK-1775'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Phase Ib Study AZD1775 in Combination With Carboplatin and Paclitaxel in Adult Asian Patients With Solid Tumours,10000003
420,NCT02343718,Phase I,"Active, not recruiting","[{'id': 2492, 'therapyName': 'Temsirolimus + Vinblastine'}]",Vinblastine and Temsirolimus in Pediatric Patients With Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours,10000003
421,NCT02350673,Phase I,Recruiting,"[{'id': 2886, 'therapyName': 'RO6895882'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study of Intravenous RO6895882 and MPDL3280A Combination in Patients With Locally Advanced and/or Metastatic Solid Tumors,10000003
422,NCT02352844,Phase II,"Active, not recruiting","[{'id': 735, 'therapyName': 'Everolimus'}]","Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations",10000003
423,NCT02354547,Phase I,Recruiting,"[{'id': 3617, 'therapyName': 'SGT-53 + Cyclophosphamide + Topotecan'}]",A Study of SGT-53 in Children With Refractory or Recurrent Solid Tumors,10000003
424,NCT02355535,Phase I,Recruiting,"[{'id': 4602, 'therapyName': 'PAC-1'}]",Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies,10000003
425,NCT02358200,Phase I,"Active, not recruiting","[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 682, 'therapyName': 'Talazoparib'}]",Study of BMN-673 With Carboplatin and Paclitaxel in Patients With Advanced BRCA-mutated Solid Tumor or Triple Negative Metastatic Breast Cancer,10000003
426,NCT02365662,Phase I,Recruiting,"[{'id': 2914, 'therapyName': 'ABBV-221'}]",A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor,10000003
427,NCT02366949,Phase I,Recruiting,"[{'id': 3447, 'therapyName': 'BAY1217389 + Paclitaxel'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel,10000003
428,NCT02368951,Phase I,Terminated,"[{'id': 2931, 'therapyName': 'BAY1187982'}]","Phase I, Dose-escalation Trial of BAY1187982 in Subjects With Advanced Solid Tumors Known to Express Fibroblast Growth Factor Receptor 2 (FGFR2)",10000003
429,NCT02369029,Phase I,Terminated,"[{'id': 2598, 'therapyName': 'BAY 1238097 '}]","BAY1238097, First in Man",10000003
430,NCT02376699,Phase I,Recruiting,"[{'id': 5781, 'therapyName': 'Pembrolizumab + SEA-CD40'}, {'id': 5780, 'therapyName': 'SEA-CD40'}]",Safety Study of SEA-CD40 in Cancer Patients,10000003
431,NCT02379416,Phase I,Recruiting,"[{'id': 2490, 'therapyName': 'Abraxane + Nilotinib'}]",Combination Nilotinib and Paclitaxel in Adults With Relapsed Solid Tumors,10000003
432,NCT02379520,Phase I,Recruiting,"[{'id': 5328, 'therapyName': 'Cyclophosphamide + Fludarabine phosphate + Nivolumab'}]","HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA (HESTIA)",10000003
433,NCT02381886,Phase I,Suspended,"[{'id': 2981, 'therapyName': 'IDH305'}]",A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations,10000003
434,NCT02383212,Phase I,"Active, not recruiting","[{'id': 5722, 'therapyName': 'REGN2810 + Carboplatin + Docetaxel'}, {'id': 5721, 'therapyName': 'REGN2810 + Carboplatin + Pemetrexed'}, {'id': 5723, 'therapyName': 'REGN2810 + GM-CSF + Cyclophosphamide'}, {'id': 5718, 'therapyName': 'REGN2810 + Cyclophosphamide'}, {'id': 5656, 'therapyName': 'REGN2810'}, {'id': 5720, 'therapyName': 'REGN2810 + Carboplatin + Paclitaxel'}, {'id': 5719, 'therapyName': 'REGN2810 + Docetaxel'}]",Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies,10000003
435,NCT02383927,Phase II,Recruiting,"[{'id': 938, 'therapyName': 'Tipifarnib'}]",Phase II Study of Tipifarnib in Advanced Cancers With HRAS Mutations,10000003
436,NCT02386501,,Recruiting,"[{'id': 4654, 'therapyName': 'ADXS31-164'}]",Dose Escalation Study of ADXS31-164 in Subjects With HER2 Expressing Solid Tumors,10000003
437,NCT02387125,Phase I,Recruiting,"[{'id': 4318, 'therapyName': 'CMB305'}]","A Phase 1b Safety Study of CMB305 (Sequentially Administered LV305 and G305) in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1",10000003
438,NCT02389309,Phase I,Recruiting,"[{'id': 2697, 'therapyName': 'Cyclophosphamide + Dasatinib + Temsirolimus'}]","A Trial of Dasatinib (PDGFR and SRC Inhibitor), Temsirolimus and Cyclophosphamide in Patients With Advanced Solid Tumors",10000003
439,NCT02390752,Phase Ib/II,Recruiting,"[{'id': 874, 'therapyName': 'PLX3397'}]",PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN),10000003
440,NCT02391480,Phase I,Recruiting,"[{'id': 4028, 'therapyName': 'ABBV-075'}]",A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer,10000003
441,NCT02391727,Phase I,Recruiting,"[{'id': 5330, 'therapyName': 'SYN004'}]","Safety, Immunogenicity and Pharmacokinetics of SYN004 in Patients With Solid Tumors (SYN004_Ph_1)",10000003
442,NCT02392611,Phase I,"Active, not recruiting","[{'id': 3561, 'therapyName': 'GS-5829 + Exemestane'}]","Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 in Adults With Advanced Solid Tumors and Lymphomas",10000003
443,NCT02392793,Phase I,Recruiting,"[{'id': 1378, 'therapyName': 'Irinotecan + Talazoparib'}, {'id': 1141, 'therapyName': 'Temozolomide'}]",Talazoparib Plus Irinotecan With or Without Temozolomide in Children With Refractory or Recurrent Solid Malignancies,10000003
444,NCT02393248,Phase Ib/II,Recruiting,"[{'id': 4176, 'therapyName': 'Cisplatin + Gemcitabine + INCB054828'}, {'id': 4174, 'therapyName': 'Docetaxel + INCB054828'}, {'id': 4088, 'therapyName': 'Epacadostat + Pembrolizumab'}]","Open-Label, Dose-Escalation Study of INCB054828 in Subjects With Advanced Malignancies",10000003
445,NCT02401815,Phase Ib/II,Recruiting,"[{'id': 874, 'therapyName': 'PLX3397'}, {'id': 2602, 'therapyName': 'PLX9486'}]",A Study of PLX9486 as a Single Agent and in Combination With PLX3397 in Patients With Advanced Solid Tumors Including GIST,10000003
446,NCT02404441,Phase Ib/II,Recruiting,"[{'id': 2659, 'therapyName': 'PDR001'}]",Phase I/II Study of PDR001 in Patients With Advanced Malignancies,10000003
447,NCT02404480,Phase I,Unknown status,"[{'id': 5407, 'therapyName': 'PTC596'}]",PTC596 in Patients With Advanced Solid Tumors,10000003
448,NCT02407990,Phase I,Recruiting,"[{'id': 5871, 'therapyName': 'BGB-A317'}]","Study of the Safety, Pharmacokinetics and Antitumor Activities of BGB-A317 in Subjects With Advanced Tumors",10000003
449,NCT02408861,Phase I,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab in Treating Patients With Advanced HIV Associated Solid Tumors,10000003
450,NCT02410512,Phase I,Recruiting,"[{'id': 2729, 'therapyName': 'MOXR0916'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",A Dose-Escalation Study of the Safety and Pharmacokinetics of MOXR0916 and MPDL3280A in Patients With Locally Advanced or Metastatic Solid Tumors,10000003
451,NCT02412462,Phase I,Completed,"[{'id': 4317, 'therapyName': 'AB-16B5'}]",Phase I Dose Escalation Study of AB-16B5 in Subjects With an Advanced Solid Malignancy,10000003
452,NCT02412722,Phase I,"Active, not recruiting","[{'id': 1282, 'therapyName': 'Sapanisertib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]","Safety, Tolerability, and Pharmacokinetics of MLN0128 as a Single Agent and in Combination With Paclitaxel in Adults With Advanced Nonhematologic Malignancies",10000003
453,NCT02414516,Phase I,Unknown status,"[{'id': 2906, 'therapyName': 'OBP-801'}]",A Dose-Escalation Study of OBP-801 in Patients With Advanced Solid Tumors,10000003
454,NCT02414724,Phase I,Terminated,"[{'id': 2898, 'therapyName': 'Gemcitabine + Ribociclib'}]",Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors or Lymphoma,10000003
455,NCT02419417,Phase Ib/II,Recruiting,"[{'id': 2811, 'therapyName': 'BMS986158'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Study of BMS-986158 in Subjects With Select Advanced Solid Tumors,10000003
456,NCT02419495,Phase I,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1749, 'therapyName': 'Selinexor'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Selinexor in Combination With Standard Chemotherapy,10000003
457,NCT02422589,Phase I,Recruiting,"[{'id': 2505, 'therapyName': 'Warfarin'}, {'id': 2685, 'therapyName': 'Midazolam'}, {'id': 789, 'therapyName': 'Ceritinib'}]","A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam in Patients With ALK-positive Advanced Tumors",10000003
458,NCT02423057,Phase I,Recruiting,"[{'id': 2907, 'therapyName': 'TdCyd'}]",Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors,10000003
459,NCT02423343,Phase Ib/II,Recruiting,"[{'id': 2409, 'therapyName': 'Galunisertib'}, {'id': 1312, 'therapyName': 'Nivolumab'}]","A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, Hepatocellular Carcinoma, or Glioma",10000003
460,NCT02423954,Phase Ib/II,"Active, not recruiting","[{'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1074, 'therapyName': 'Irinotecan'}]",Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus),10000003
461,NCT02428712,Phase Ib/II,Recruiting,"[{'id': 1041, 'therapyName': 'PLX8394'}]","A Study of PLX8394 as a Single Agent in Patients With Advanced, Unresectable Solid Tumors",10000003
462,NCT02431260,Phase I,"Active, not recruiting","[{'id': 2812, 'therapyName': 'INCB054329'}]","An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies",10000003
463,NCT02432274,Phase Ib/II,Recruiting,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 792, 'therapyName': 'Lenvatinib'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies,10000003
464,NCT02432326,Phase I,Recruiting,"[{'id': 1945, 'therapyName': 'BBI503'}, {'id': 2057, 'therapyName': 'BBI608'}]",A Study of BBI608 and BBI503 Administered in Combination to Adult Patients With Advanced Solid Tumors,10000003
465,NCT02432963,Phase I,Recruiting,"[{'id': 1038, 'therapyName': 'MVAp53'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy,10000003
466,NCT02439723,Phase I,Not yet recruiting,"[{'id': 890, 'therapyName': 'Regorafenib'}]",Effects of LBM and PPIs on Pharmacokinetics and Safety of Regorafenib (BAY 73-4506) in Cancer Patients,10000003
467,NCT02442414,Phase I,Unknown status,"[{'id': 2908, 'therapyName': 'Pirotinib'}]",A Phase 1 Study of KBP-5209 in Patients With Advanced Solid Tumors,10000003
468,NCT02444793,Phase I,Recruiting,"[{'id': 6332, 'therapyName': 'Mogamulizumab + Utomilumab'}]",A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors,10000003
469,NCT02448589,Phase I,Recruiting,"[{'id': 1400, 'therapyName': 'TAS-119'}]",An Investigation of TAS-119 Monotherapy and in Combination With Docetaxel,10000003
470,NCT02451553,Phase I,Recruiting,"[{'id': 623, 'therapyName': 'Afatinib'}, {'id': 1105, 'therapyName': 'Capecitabine'}]","Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer",10000003
471,NCT02452268,Phase I,Recruiting,"[{'id': 6032, 'therapyName': 'PDR001 + NIZ985'}]",A Phase I/Ib Study of NIZ985 in Combination With PDR001 in Adults With Metastatic Cancers,10000003
472,NCT02452424,Phase Ib/II,"Active, not recruiting","[{'id': 2736, 'therapyName': 'Pembrolizumab + PLX3397'}]",A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors,10000003
473,NCT02453620,Phase I,Recruiting,"[{'id': 1541, 'therapyName': 'Entinostat'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]","Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer",10000003
474,NCT02454010,Phase I,Recruiting,"[{'id': 3833, 'therapyName': 'FF-21101(90Y)'}]",A Dose Escalation Study of Radio-labeled Antibody for the Treatment of Advanced Cancer,10000003
475,NCT02456883,Phase I,Completed,"[{'id': 2865, 'therapyName': 'Gilteritinib'}]","Study to Investigate the Absorption, Metabolism and Excretion of [14C] ASP2215 in Patients With Advanced Solid Tumors",10000003
476,NCT02457351,Phase I,Completed,"[{'id': 663, 'therapyName': 'BAY1000394'}, {'id': 1026, 'therapyName': 'Itraconazole'}]",Roniciclib (BAY 1000394) Drug-Drug Interaction (DDI) Study,10000003
477,NCT02457793,Phase I,Completed,"[{'id': 1004, 'therapyName': 'Cobimetinib'}, {'id': 2149, 'therapyName': 'GDC-0994'}]","A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors",10000003
478,NCT02458638,Phase II,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}]",An Open Label Study of MPDL3280A in Advanced Solid Tumors,10000003
479,NCT02460224,Phase Ib/II,Recruiting,"[{'id': 2887, 'therapyName': 'LAG525'}, {'id': 2659, 'therapyName': 'PDR001'}]",Safety and Efficay of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies,10000003
480,NCT02465060,Phase II,Recruiting,"[{'id': 660, 'therapyName': 'Osimertinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 654, 'therapyName': 'AZD4547'}, {'id': 958, 'therapyName': 'VS-6063'}, {'id': 765, 'therapyName': 'GSK2636771'}]",NCI-MATCH Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,10000003
481,NCT02466802,Phase I,Recruiting,"[{'id': 890, 'therapyName': 'Regorafenib'}, {'id': 3066, 'therapyName': 'Sildenafil'}]",Study of Regorafenib and Sildenafil for Advanced Solid Tumors,10000003
482,NCT02467361,Phase Ib/II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 2057, 'therapyName': 'BBI608'}]",A Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Cancers,10000003
483,NCT02471846,Phase I,"Active, not recruiting","[{'id': 2888, 'therapyName': 'GDC-0919'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study of GDC-0919 and MPDL3280A Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors,10000003
484,NCT02473497,Expanded access,Available,"[{'id': 706, 'therapyName': 'Crizotinib'}]",Crizotinib (Xalkori) Expanded Access Protocol For The Treatment Of Adult Or Pediatric Patients,10000003
485,NCT02476955,Phase I,Recruiting,"[{'id': 635, 'therapyName': 'ARQ092'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Open-label Phase 1b Study of ARQ 092 in Combination With Carboplatin Plus Paclitaxel,10000003
486,NCT02478320,Phase II,Recruiting,"[{'id': 975, 'therapyName': 'ABT-348'}]",Phase II Study of Ilorasertib (ABT348) in Patients With CDKN2A Deficient Solid Tumors,10000003
487,NCT02481154,Phase I,Recruiting,"[{'id': 2995, 'therapyName': 'AG-881'}]","Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation",10000003
488,NCT02482168,Phase I,Recruiting,"[{'id': 3835, 'therapyName': 'APX005M'}]",Study of the CD40 Agonistic Monoclonal Antibody APX005M,10000003
489,NCT02482441,Phase I,Recruiting,"[{'id': 4401, 'therapyName': 'Rosmantuzumab'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]","A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10",10000003
490,NCT02483247,Phase Ib/II,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1945, 'therapyName': 'BBI503'}]",A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer,10000003
491,NCT02483858,Phase I,Recruiting,"[{'id': 2019, 'therapyName': 'PQR309'}]",Study of Oral PQR309 in Patients With Advanced Solid Tumors,10000003
492,NCT02484404,Phase Ib/II,Recruiting,"[{'id': 2895, 'therapyName': 'Cediranib + Durvalumab'}, {'id': 2894, 'therapyName': 'Durvalumab + Olaparib'}]",Phase 1 and 2 Study of MEDI4736 in Combination With Olaparib or Cediranib for Advanced Solid Tumors and Recurrent Ovarian Cancer,10000003
493,NCT02499328,Phase Ib/II,Recruiting,"[{'id': 3098, 'therapyName': 'AZD9150 + MEDI4736'}, {'id': 3099, 'therapyName': 'AZD5069 + MEDI4736'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 2782, 'therapyName': 'AZD9150 '}]",Study to Assess Combination of MEDI4736 With Either AZD9150 or AZD5069 in Patients With Metastatic Squamous Cell Carcinoma of Head and Neck,10000003
494,NCT02499861,Phase Ib/II,Recruiting,"[{'id': 1734, 'therapyName': 'Genistein + Decitabine'}]",Phase I/II a Study of Decitabine in Combination With Genistein in Pediatric Relapsed or Refractory Malignancies,10000003
495,NCT02503709,Phase I,Recruiting,"[{'id': 2727, 'therapyName': 'AT7519'}, {'id': 645, 'therapyName': 'AT13387'}]",Hsp90 Inhibitor AT13387 and CDKI AT7519 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery,10000003
496,NCT02503774,Phase I,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 3089, 'therapyName': 'MEDI9447'}]",MEDI9447 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors,10000003
497,NCT02506517,Phase II,Recruiting,"[{'id': 623, 'therapyName': 'Afatinib'}]",A Study of Afatinib in Patients With Advanced Cancer With Changes in the HER Gene,10000003
498,NCT02508532,Phase I,Recruiting,"[{'id': 2941, 'therapyName': 'BLU-285'}]",Phase 1 Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors,10000003
499,NCT02511795,Phase I,Recruiting,"[{'id': 822, 'therapyName': 'MK-1775'}, {'id': 837, 'therapyName': 'Olaparib'}]",AZD1775 Combined With Olaparib in Patients With Refractory Solid Tumors,10000003
500,NCT02516813,Phase I,Recruiting,"[{'id': 3616, 'therapyName': 'MSC2490484A '}]","Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy",10000003
501,NCT02517398,Phase I,Recruiting,"[{'id': 5860, 'therapyName': 'M7824'}]",MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors,10000003
502,NCT02518958,Phase I,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}]","A Phase I, Open-Label, Multiple Ascending Dose Study of RRx-001 and Nivolumab",10000003
503,NCT02520752,Phase I,Completed,"[{'id': 2685, 'therapyName': 'Midazolam'}, {'id': 1065, 'therapyName': 'Capmatinib'}]",A DDI Study to Assess the Effect of INC280 on the PK of Midazolam and Caffeine in Patients With cMET-dysregulated Advanced Solid Tumors,10000003
504,NCT02527434,Phase II,"Active, not recruiting","[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",Study of Tremelimumab in Patients With Advanced Solid Tumors,10000003
505,NCT02528357,Phase I,Recruiting,"[{'id': 5177, 'therapyName': 'GSK3174998'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",GSK3174998 Alone or With Pembrolizumab in Subjects With Advanced Solid Tumors,10000003
506,NCT02529553,Phase I,Recruiting,"[{'id': 3164, 'therapyName': 'LY3076226'}]",A Study of LY3076226 in Participants With Advanced or Metastatic Cancer,10000003
507,NCT02537418,Phase I,"Active, not recruiting","[{'id': 2585, 'therapyName': 'Cisplatin + Etoposide'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]",Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Receiving Standard Chemotherapy Regimens,10000003
508,NCT02537561,Phase I,Withdrawn,"[{'id': 682, 'therapyName': 'Talazoparib'}, {'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}]",Talazoparib in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors,10000003
509,NCT02540876,Phase I,Recruiting,"[{'id': 975, 'therapyName': 'ABT-348'}]",Ilorasertib in Treating Patients With CDKN2A-deficient Advanced or Metastatic Solid Cancers That Cannot Be Removed by Surgery,10000003
510,NCT02541604,Phase I,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}]","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of MPDL3280A (Anti-PD-L1 Antibody) in Pediatric and Young Adult Participants With Solid Tumors",10000003
511,NCT02546531,Phase I,Recruiting,"[{'id': 3083, 'therapyName': 'Defactinib + Gemcitabine + Pembrolizumab'}]",Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer,10000003
512,NCT02549937,Phase I,Recruiting,"[{'id': 3666, 'therapyName': 'Sulfatinib'}]","A Multi-Center, Open-Label Study of Sulfatinib(HMPL-012) in Patients With Advanced Solid Tumors",10000003
513,NCT02551055,Phase I,Terminated,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 626, 'therapyName': 'Alisertib'}, {'id': 3146, 'therapyName': 'TAK-659'}, {'id': 1033, 'therapyName': 'MLN1117'}]","MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal Adenocarcinoma",10000003
514,NCT02551185,Phase I,Recruiting,"[{'id': 3311, 'therapyName': 'Citarinostat'}]",ACY 241 in Combination With Paclitaxel in Patients With Advanced Solid Tumors,10000003
515,NCT02554812,Phase I,Recruiting,"[{'id': 6043, 'therapyName': 'Avelumab + Utomilumab'}]",A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley),10000003
516,NCT02556463,Phase I,Recruiting,"[{'id': 5457, 'therapyName': 'MEDI9197'}, {'id': 5458, 'therapyName': 'MEDI9197 + MEDI4736'}]",A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and Palliative Radiation in Subjects With Solid Tumors,10000003
517,NCT02558140,Phase I,Recruiting,"[{'id': 4330, 'therapyName': 'RO6874813'}]",A Dose Escalation Study of RO6874813 in Participants With Locally Advanced or Metastatic Solid Tumors,10000003
518,NCT02559492,Phase I,"Active, not recruiting","[{'id': 3096, 'therapyName': 'INCB039110 + INCB024360'}, {'id': 3097, 'therapyName': 'INCB039110 + INCB050465'}]",INCB039110 Combined With INCB024360 and/or INCB039110 Combined With INCB050465 in Advanced Solid Tumors,10000003
519,NCT02561455,Phase Ib/II,"Active, not recruiting","[{'id': 2865, 'therapyName': 'Gilteritinib'}]",Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial,10000003
520,NCT02564198,Phase I,Recruiting,"[{'id': 886, 'therapyName': 'Ramucirumab'}]",A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors,10000003
521,NCT02564900,Phase I,Recruiting,"[{'id': 4844, 'therapyName': 'DS-8201a'}]",Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors,10000003
522,NCT02565758,Phase I,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 3846, 'therapyName': 'ABBV-085'}]","ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Cancer Tumors",10000003
523,NCT02567396,Phase I,Withdrawn,"[{'id': 682, 'therapyName': 'Talazoparib'}]",Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction,10000003
524,NCT02568267,Phase II,Recruiting,"[{'id': 1455, 'therapyName': 'Entrectinib'}]","Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK1/2/3, ROS1, or ALK Gene Rearrangements  (STARTRK-2)",10000003
525,NCT02571036,Phase I,Recruiting,"[{'id': 4316, 'therapyName': 'DCC-2618'}]","A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies",10000003
526,NCT02574728,Phase II,Recruiting,"[{'id': 3143, 'therapyName': 'Celecoxib + Cyclophosphamide + Etoposide + Sirolimus'}]",Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors,10000003
527,NCT02575781,Phase I,Recruiting,"[{'id': 4026, 'therapyName': 'SAR428926'}]",A Study of SAR428926 in Patients With Advanced Solid Tumors,10000003
528,NCT02576431,Phase II,Recruiting,"[{'id': 2650, 'therapyName': 'LOXO-101'}]",Study of LOXO-101 in Subjects With NTRK Fusion Positive Solid Tumors,10000003
529,NCT02576444,Phase II,Recruiting,"[{'id': 3140, 'therapyName': 'MK-1775 + Olaparib'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 3141, 'therapyName': 'Olaparib + Vistusertib'}, {'id': 3139, 'therapyName': 'AZD5363 + Olaparib'}]",OLAParib COmbinations,10000003
530,NCT02576665,Phase I,Recruiting,"[{'id': 3211, 'therapyName': 'Toca 511 + Toca FC'}]","A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Solid Tumors (Toca6)",10000003
531,NCT02579226,Phase I,Recruiting,"[{'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 3547, 'therapyName': 'AZD2811'}]","A Phase I Study of Safety, Tolerability, and PK of AZD2811 in Patients With Advanced Solid Tumors",10000003
532,NCT02584933,FDA approved,Recruiting,"[{'id': 789, 'therapyName': 'Ceritinib'}]",Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study,10000003
533,NCT02586987,Phase I,Recruiting,"[{'id': 3162, 'therapyName': 'MEDI4736 + Selumetinib'}]","A Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 in Patients With Advanced Solid Tumours",10000003
534,NCT02587598,Phase Ib/II,Recruiting,"[{'id': 3696, 'therapyName': 'INCB053914'}]",Study of INCB053914 in Subjects With Advanced Malignancies,10000003
535,NCT02587962,Phase Ib/II,Recruiting,"[{'id': 6160, 'therapyName': 'Birinapant  + Pembrolizumab'}]",Dose-escalation Study of Birinapant and Pembrolizumab in Solid Tumors,10000003
536,NCT02588105,Phase I,Recruiting,"[{'id': 837, 'therapyName': 'Olaparib'}, {'id': 3557, 'therapyName': 'AZD0156'}]",Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer,10000003
537,NCT02593708,Phase I,Unknown status,"[{'id': 3187, 'therapyName': 'Neratinib + Paclitaxel + Pertuzumab + Trastuzumab'}]","Phase1 of Neratinib+Trastuzumab, Pertuzumab, Paclitaxel in Patients With Advanced Solid Tumors/HER2+",10000003
538,NCT02595866,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms",10000003
539,NCT02595931,Phase I,Recruiting,"[{'id': 2883, 'therapyName': 'VX-970 + Irinotecan'}]",VX-970 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery,10000003
540,NCT02597036,Phase I,"Active, not recruiting","[{'id': 3562, 'therapyName': 'LY3127804 '}, {'id': 886, 'therapyName': 'Ramucirumab'}]",A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors,10000003
541,NCT02598960,Phase Ib/II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 3559, 'therapyName': 'BMS-986156'}]",A Study of BMS-986156 Given Alone and in Combination With Nivolumab in Subjects With Advanced Solid Tumors,10000003
542,NCT02605083,Phase Ib/II,Recruiting,"[{'id': 4005, 'therapyName': 'eFT508'}]",A Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid Tumors,10000003
543,NCT02607813,Phase I,Recruiting,"[{'id': 4443, 'therapyName': 'LXH 254 + PDR001'}, {'id': 4442, 'therapyName': 'LXH 254'}]",Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations,10000003
544,NCT02608125,Phase I,Recruiting,"[{'id': 3583, 'therapyName': 'PRN1371'}]",A Dose Escalation and Dose Expansion Study of PRN1371 in Adult Patients With Advanced Solid Tumors,10000003
545,NCT02608268,Phase Ib/II,Recruiting,"[{'id': 2659, 'therapyName': 'PDR001'}, {'id': 3560, 'therapyName': 'MBG453'}]",Safety and Efficacy of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies,10000003
546,NCT02608385,Phase I,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors,10000003
547,NCT02610075,Phase I,Recruiting,"[{'id': 822, 'therapyName': 'MK-1775'}]",Study to Determine MTD of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours.,10000003
548,NCT02610361,Phase I,"Active, not recruiting","[{'id': 4025, 'therapyName': 'BGB-283'}]",Study of the Safety and Pharmacokinetics of BGB-283 in Patients With Solid Tumors,10000003
549,NCT02612285,Phase II,Terminated,"[{'id': 866, 'therapyName': 'SNX-5422'}]",Study of SNX-5422 in TP53 Null Cancers,10000003
550,NCT02614456,Phase I,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1733, 'therapyName': 'interferon gamma '}]",Combination of Interferon-gamma and Nivolumab for Advanced Solid Tumors,10000003
551,NCT02617277,Phase I,Recruiting,"[{'id': 3414, 'therapyName': 'MEDI4736 + MK-1775'}]","Safety, Tolerability and Pharmacokinetics of AZD1775 Plus MEDI4736 in Patients With Advanced Solid Tumours",10000003
552,NCT02620839,Phase I,Recruiting,"[{'id': 5627, 'therapyName': 'Alpelisib + Cisplatin'}]",Phase Ib Study of Alpelisib With Cisplatin in Patients With HPV+ Solid Tumor Malignancies,10000003
553,NCT02624388,Phase II,Recruiting,"[{'id': 757, 'therapyName': 'Genistein'}]",Study of Genistein in Pediatric Oncology Patients (UVA-Gen001),10000003
554,NCT02626234,Phase I,Completed,"[{'id': 1065, 'therapyName': 'Capmatinib'}]",A Drug-drug Interaction (DDI) Study to Assess the Effect of INC280 on the Pharmacokinetics of Digoxin and Rosuvastatin in Patients With cMET-dysregulated Advanced Solid Tumors,10000003
555,NCT02627274,Phase I,Recruiting,"[{'id': 5364, 'therapyName': 'RO6874281'}]","A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 in Participants With Advanced and/or Metastatic Solid Tumors",10000003
556,NCT02627430,Phase I,Withdrawn,"[{'id': 3317, 'therapyName': 'Onalespib + Talazoparib'}]","Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer",10000003
557,NCT02628067,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158),10000003
558,NCT02628574,Phase I,Recruiting,"[{'id': 3613, 'therapyName': 'TRX518'}]",Dose Escalation Study of TRX518 in Adults With Advanced Solid Tumors,10000003
559,NCT02632448,Phase Ib/II,Recruiting,"[{'id': 4420, 'therapyName': 'LY2880070 + Gemcitabine'}, {'id': 4315, 'therapyName': 'LY2880070'}]",A Study of LY2880070 in Patients With Advanced or Metastatic Cancer,10000003
560,NCT02637687,Phase I,Recruiting,"[{'id': 2650, 'therapyName': 'LOXO-101'}]",Oral TRK Inhibitor LOXO-101 for Treatment of Advanced Pediatric Solid or Primary Central Nervous System Tumors,10000003
561,NCT02642016,Phase I,Recruiting,"[{'id': 4037, 'therapyName': 'CDX-0158'}]",A Study to Evaluate the Safety and Pharmacokinetics of KTN0158 in Adult Patients With Advanced Solid Tumors,10000003
562,NCT02643303,Phase Ib/II,Recruiting,"[{'id': 3385, 'therapyName': 'MEDI4736 + poly ICLC '}, {'id': 1652, 'therapyName': 'Tremelimumab'}]","A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers",10000003
563,NCT02644369,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors,10000003
564,NCT02644460,Phase I,Recruiting,"[{'id': 802, 'therapyName': 'Abemaciclib'}]",Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors,10000003
565,NCT02646319,Phase II,"Active, not recruiting","[{'id': 3380, 'therapyName': 'Nab-Rapamycin'}]",Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations,10000003
566,NCT02646748,Phase I,Recruiting,"[{'id': 3088, 'therapyName': 'INCB050465 '}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2406, 'therapyName': 'INCB039110'}]",Pembrolizumab Combined With INCB039110 and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors,10000003
567,NCT02648490,Phase I,Recruiting,"[{'id': 3939, 'therapyName': 'Acetaminophen + Dexamethasone + Diphenhydramine + Ondansetron'}, {'id': 3938, 'therapyName': 'HLX07'}]","An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers",10000003
568,NCT02648711,Phase I,"Active, not recruiting","[{'id': 708, 'therapyName': 'CRLX101'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Alternative Dosing for CRLX101 Alone and With Avastin in Advanced Solid Tumors,10000003
569,NCT02648724,Phase Ib/II,Recruiting,"[{'id': 4322, 'therapyName': 'SYM015'}]",Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies,10000003
570,NCT02650401,Phase I,Recruiting,"[{'id': 1455, 'therapyName': 'Entrectinib'}]",Study of RXDX-101 in Children With Recurrent or Refractory Solid Tumors and Primary CNS Tumors,10000003
571,NCT02650635,Phase I,"Active, not recruiting","[{'id': 3413, 'therapyName': 'Cyclophosphamide + Pegfilgrastim + VTX-2337'}]","TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors",10000003
572,NCT02650713,Phase I,Recruiting,"[{'id': 3412, 'therapyName': 'Atezolizumab + RO6958688 '}]","A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors",10000003
573,NCT02651727,Phase I,Terminated,"[{'id': 4342, 'therapyName': 'Gemcitabine + nab-paclitaxel + VS-4718'}]","Ph 1 Study of VS-4718, a FAK Inhibitor, in Combination With Nab-paclitaxel and Gemcitabine in Advanced Cancer Subjects",10000003
574,NCT02653196,Phase II,Terminated,"[{'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1205, 'therapyName': 'Alemtuzumab'}, {'id': 2373, 'therapyName': 'Palifermin'}, {'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}, {'id': 3948, 'therapyName': 'Cyclosporine + Mycophenolate mofetil + Tacrolimus'}]",A Multi-Institutional Phase II Feasibility Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors,10000003
575,NCT02656849,Phase II,Withdrawn,"[{'id': 663, 'therapyName': 'BAY1000394'}]","BAY 1000394 for MCL-1-, MYC-, and CCNE1-Amplified Tumors",10000003
576,NCT02658890,Phase Ib/II,Recruiting,"[{'id': 3569, 'therapyName': 'BMS-986205 + Nivolumab'}]","Safety, Tolerability, Pharmacokinetic/Pharmacodynamic and Preliminary Efficacy Study of BMS-986205 Administered in Combination With Nivolumab in Advanced Cancers",10000003
577,NCT02665416,Phase I,Recruiting,"[{'id': 3468, 'therapyName': 'RO5520985 + RO7009789'}]","Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of RO7009789 With Vanucizumab in Metastatic Solid Tumors",10000003
578,NCT02667873,Phase I,Recruiting,"[{'id': 6223, 'therapyName': 'SL-801'}]",A Phase 1 Trial of a Novel XPO1 Inhibitor in Patients With Advanced Solid Tumors,10000003
579,NCT02668770,Phase I,Recruiting,"[{'id': 5741, 'therapyName': 'Ipilumumab + Lefitolimod'}]",Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies,10000003
580,NCT02669914,Phase II,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}]",MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors,10000003
581,NCT02671955,Phase I,Terminated,"[{'id': 3614, 'therapyName': 'JNJ-61610588 '}]","A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced Cancer",10000003
582,NCT02673736,Phase I,"Active, not recruiting","[{'id': 4332, 'therapyName': 'PLX73086'}]",A Study of PLX73086 in Advanced Solid Tumors and Locally Advanced or Refractory Tenosynovial Giant Cell Tumor,10000003
583,NCT02674555,Phase I,Withdrawn,"[{'id': 1082, 'therapyName': 'ASP8273'}]","A Study to Investigate the Absorption, Metabolism and Excretion of [14C]ASP8273 in Subjects With Solid Tumors",10000003
584,NCT02675829,Phase II,Recruiting,"[{'id': 1402, 'therapyName': 'trastuzumab emtansine'}]",Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers,10000003
585,NCT02677116,Phase I,Recruiting,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 3618, 'therapyName': 'Irinotecan + Vincristine'}, {'id': 3269, 'therapyName': 'Olaratumab'}]",A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer,10000003
586,NCT02679131,Phase I,Recruiting,"[{'id': 1078, 'therapyName': 'Belinostat'}]","To Evaluate Safety and Pharmacokinetics of Belinostat in Patients Who Have Mild, Moderate and Severe Renal Impairment.",10000003
587,NCT02680795,Phase I,Recruiting,"[{'id': 1078, 'therapyName': 'Belinostat'}]","To Evaluate the Safety and Pharmacokinetics of Belinostat in Patients Who Have Wild-type, Heterozygous, and Homozygous UGT1A1*28 Genotypes",10000003
588,NCT02686164,Phase I,"Active, not recruiting","[{'id': 3730, 'therapyName': 'Lenvatinib + Midazolam'}]",Phase 1 Study to Determine the Effect of Lenvatinib (E7080) on the Pharmacokinetics of Midazolam in Subjects With Advanced Solid Tumors,10000003
589,NCT02688088,Phase I,Recruiting,"[{'id': 802, 'therapyName': 'Abemaciclib'}, {'id': 3729, 'therapyName': 'Caffeine + Dextromethorphan + Midazolam + Warfarin'}]",A Study of Abemaciclib in Participants With Cancer That is Advanced or Has Spread to Another Part(s) of the Body,10000003
590,NCT02689336,Phase II,Recruiting,"[{'id': 3726, 'therapyName': 'Erlotinib + Temozolomide'}]",Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors,10000003
591,NCT02693535,Phase II,Recruiting,"[{'id': 1657, 'therapyName': 'Vemurafenib + Cobimetinib'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 690, 'therapyName': 'Bosutinib'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 4, 'therapyName': 'Erlotinib'}]",TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer,10000003
592,NCT02694822,Phase I,Recruiting,"[{'id': 5695, 'therapyName': 'AGEN1884'}]","AGEN-1884, an Anti-CTLA-4 Antibody, in Advanced Solid Cancers",10000003
593,NCT02697591,Phase Ib/II,Recruiting,"[{'id': 4321, 'therapyName': 'INCAGN01876'}]","An Open-Label, Dose-Escalation, Safety Study of INCAGN01876 in Subjects With Advanced or Metastatic Solid Tumors",10000003
594,NCT02702492,Phase I,Recruiting,"[{'id': 4662, 'therapyName': 'KPT-9274'}, {'id': 4688, 'therapyName': 'KPT-9274 + Niacin'}]",PAK4 and NAMPT in Patients With Solid MAlignancies or NHL (PANAMA) (PANAMA),10000003
595,NCT02703571,Phase Ib/II,Recruiting,"[{'id': 4472, 'therapyName': 'Ribociclib + Trametinib'}]",Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors,10000003
596,NCT02705105,Phase Ib/II,Recruiting,"[{'id': 3843, 'therapyName': 'Mogamulizumab + Nivolumab'}]",Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors,10000003
597,NCT02705482,Phase I,Recruiting,"[{'id': 3840, 'therapyName': 'MEDI0562 + Tremelimumab'}, {'id': 3839, 'therapyName': 'MEDI0562 + MEDI4736'}]",A Study to Evaluate MEDI0562 in Combination With Immune Therapeutic Agents in Adult Subjects With Advanced Solid Tumors,10000003
598,NCT02705963,Phase I,Recruiting,"[{'id': 2, 'therapyName': 'Trametinib'}]",A Drug-Drug Interaction Study to Assess the Effect of Trametinib on the Pharmacokinetics of an Oral Contraceptive in Female Patients With Solid Tumors,10000003
599,NCT02709889,Phase Ib/II,Recruiting,"[{'id': 3544, 'therapyName': 'Rovalpituzumab Tesirine'}]",Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors,10000003
600,NCT02711137,Phase Ib/II,Recruiting,"[{'id': 4319, 'therapyName': 'INCB057643 '}]","A Phase 1/2, Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies",10000003
601,NCT02712905,Phase Ib/II,Recruiting,"[{'id': 5464, 'therapyName': 'INCB059872'}]","An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies",10000003
602,NCT02718911,Phase I,Recruiting,"[{'id': 4216, 'therapyName': 'LY3022855 + Tremelimumab'}, {'id': 4215, 'therapyName': 'LY3022855 + MEDI4736'}]",A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors,10000003
603,NCT02719691,Phase I,Recruiting,"[{'id': 4214, 'therapyName': 'Alisertib + MLN0128'}]",Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,10000003
604,NCT02720068,Phase I,Recruiting,"[{'id': 4213, 'therapyName': 'MK-4280 + Pembrolizumab'}, {'id': 4212, 'therapyName': 'MK-4280'}]",Study of MK-4280 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-4280-001),10000003
605,NCT02722954,Phase I,"Active, not recruiting","[{'id': 3994, 'therapyName': 'Demcizumab + Pembrolizumab'}]",A Study of Demcizumab Plus Pembrolizumab +/- Chemotherapy,10000003
606,NCT02723864,Phase I,Recruiting,"[{'id': 3993, 'therapyName': 'Cisplatin + Veliparib + VX-970'}]","Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors",10000003
607,NCT02729298,Phase I,Recruiting,"[{'id': 3826, 'therapyName': 'TP-0903'}]",First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors,10000003
608,NCT02731742,Phase I,Recruiting,"[{'id': 4471, 'therapyName': 'MK-1966 + SD-101'}]",Dose Evaluation of MK-1966 in Combination With SD-101 in Participants With Advanced Malignancies (MK-1966-001),10000003
609,NCT02737072,Phase I,"Active, not recruiting","[{'id': 4210, 'therapyName': 'LY2510924 + MEDI4736'}]",A Study of LY2510924 and Durvalumab in Participants With Solid Tumors,10000003
610,NCT02737475,Phase Ib/II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 4030, 'therapyName': 'BMS-986178'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Study of BMS-986178 Monotherapy or in Combination With Nivolumab or Ipilimumab in Subjects With Advanced Solid Tumors,10000003
611,NCT02740270,Phase I,Recruiting,"[{'id': 4469, 'therapyName': 'GWN 323 + PDR001'}, {'id': 4468, 'therapyName': 'GWN 323'}]",Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas,10000003
612,NCT02740985,Phase I,Recruiting,"[{'id': 4223, 'therapyName': 'AZD4635'}, {'id': 4349, 'therapyName': 'AZD4635 + MEDI4736'}]",A Phase 1 Clinical Study of AZD4635 and Durvalumab in Patients With Advanced Solid Malignancies,10000003
613,NCT02743637,Phase I,Recruiting,"[{'id': 4326, 'therapyName': 'SDX-7320'}]",A Dose Escalation Study of SDX-7320 in Patients With Advanced Refractory or Late-Stage Solid Tumors (SDX-0101),10000003
614,NCT02746081,Phase I,Recruiting,"[{'id': 3987, 'therapyName': 'BAY 1436032'}]",Phase I Study of BAY1436032 in Isocitrate Dehydrogenase-1 (IDH1)-Mutant Advanced Solid Tumors,10000003
615,NCT02747537,Phase II,Recruiting,"[{'id': 1323, 'therapyName': 'Sorafenib + Irinotecan'}]",Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors With Sorafenib in Combination With Irinotecan,10000003
616,NCT02747797,Phase II,Withdrawn,"[{'id': 1029, 'therapyName': 'Lucitanib'}]","Lucitanib (E3810) in Patients With Advanced Cancer and FGFR, VEGFR, or PDGFR Pathway Aberrations",10000003
617,NCT02754141,Phase Ib/II,Recruiting,"[{'id': 4195, 'therapyName': 'BMS-986179 + Nivolumab'}]",A Study of BMS-986179 Administered in Combination With Nivolumab in Advanced Cancers,10000003
618,NCT02761694,Phase I,Recruiting,"[{'id': 4331, 'therapyName': 'ARQ 751'}]","Phase 1 Study of ARQ 751 in Solid Tumors With AKT1, 2, 3 Genetic Alterations, Activating PI3K Mutations or PTEN-null",10000003
619,NCT02769962,Phase Ib/II,Recruiting,"[{'id': 4348, 'therapyName': 'CRLX101 + Olaparib'}]","Trial of CRLX101, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer",10000003
620,NCT02771626,Phase Ib/II,Recruiting,"[{'id': 4274, 'therapyName': 'CB-839 + Nivolumab'}]",Study CB-839 in Combination With Nivolumab in Patients With ccRCC and Other Solid Tumors,10000003
621,NCT02775292,Phase I,Recruiting,"[{'id': 3409, 'therapyName': 'Aldesleukin + Cyclophosphamide + Fludarabine '}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 2696, 'therapyName': 'NY-ESO-1 peptide vaccine'}]","Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1",10000003
622,NCT02780011,Phase I,Not yet recruiting,"[{'id': 4301, 'therapyName': 'Alisertib + Brentuximab vedotin'}]",Alsertib (MLN8237) and Brentuximab Vedotin for Relapsed/Refractory CD30-Positive Lymphomas and Solid Malignancies,10000003
623,NCT02780804,Phase I,Recruiting,"[{'id': 1541, 'therapyName': 'Entinostat'}]",Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors,10000003
624,NCT02784795,Phase I,Recruiting,"[{'id': 4374, 'therapyName': 'Cisplatin + Gemcitabine + LY3039478'}, {'id': 4375, 'therapyName': 'Carboplatin + Gemcitabine + LY3039478'}, {'id': 4372, 'therapyName': 'LY3039478 + LY3023414'}, {'id': 4373, 'therapyName': 'Abemaciclib + LY3039478'}, {'id': 4371, 'therapyName': 'LY3039478 + Taladegib'}, {'id': 2958, 'therapyName': 'LY3039478'}, {'id': 1069, 'therapyName': 'LY3023414'}]",A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors,10000003
625,NCT02791334,Phase I,Recruiting,"[{'id': 4370, 'therapyName': 'LY3300054 + Necitumumab'}, {'id': 4369, 'therapyName': 'LY3300054 + Ramucirumab'}, {'id': 4368, 'therapyName': 'LY3300054'}]",A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors  (PACT),10000003
626,NCT02792465,Phase I,Recruiting,"[{'id': 5853, 'therapyName': 'CFI-402257'}]",A Study of Investigational Drug CFI-402257 in Patients With Advanced Cancers,10000003
627,NCT02793466,Phase I,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}]",Durvalumab in Pediatric and Adolescent Patients,10000003
628,NCT02794571,Phase I,Recruiting,"[{'id': 4269, 'therapyName': 'Atezolizumab + MTIG7192A '}, {'id': 4268, 'therapyName': 'MTIG7192A '}]",Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors,10000003
629,NCT02799095,Phase I,Recruiting,"[{'id': 4298, 'therapyName': 'ALKS 4230'}]",A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors,10000003
630,NCT02801097,Phase I,Recruiting,"[{'id': 4323, 'therapyName': 'Irinotecan + RRx-001'}]","A Phase I, Multiple Ascending Dose Study to Assess the Safety and Tolerability of RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer  (PAYLOAD) (PAYLOAD)",10000003
631,NCT02805660,Phase Ib/II,Recruiting,"[{'id': 4378, 'therapyName': 'MEDI4736 + Mocetinostat'}]",Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC,10000003
632,NCT02808650,Phase I,Recruiting,"[{'id': 1651, 'therapyName': 'Prexasertib'}]",Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors,10000003
633,NCT02811497,Phase II,Recruiting,"[{'id': 4178, 'therapyName': 'Azacitidine + MEDI4736'}]",Study of Azacitidine and Durvalumab in Advanced Solid Tumors (METADUR),10000003
634,NCT02812875,Phase I,Recruiting,"[{'id': 5885, 'therapyName': 'CA-170'}]","A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas",10000003
635,NCT02827968,Phase I,Recruiting,"[{'id': 6140, 'therapyName': 'KN035'}]",Phase 1 Study of Anti-PD-L1 Monoclonal Antibody KN035 to Treat Locally Advanced or Metastatic Solid Tumors,10000003
636,NCT02829723,Phase Ib/II,Recruiting,"[{'id': 2844, 'therapyName': 'BLZ945'}, {'id': 5071, 'therapyName': 'BLZ945 + PDR001'}]",Phase I/II Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors,10000003
637,NCT02834013,Phase 0,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab in Treating Patients With Rare Tumors,10000003
638,NCT02834247,Phase I,Recruiting,"[{'id': 4680, 'therapyName': 'Nivolumab + TAK-659'}]",A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors,10000003
639,NCT02840994,Phase Ib/II,Recruiting,"[{'id': 5244, 'therapyName': 'CV301 + Nivolumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",A Trial of CV301 in Combination With Nivolumab Versus Nivolumab in Subjects With Previously Treated Non-Small Cell Lung Cancer,10000003
640,NCT02842125,Phase I,Recruiting,"[{'id': 5879, 'therapyName': 'Ad5CMV-p53 gene + Capecitabine'}]",Safety and Efficacy of Intra-Arterial Ad-p53 in Liver Metastases of Solid Tumors,10000003
641,NCT02846766,Phase II,Not yet recruiting,"[{'id': 792, 'therapyName': 'Lenvatinib'}]",Study of Lenvatinib in Patients With Advanced Cancer and Aberrations in FGF/FGFR Signaling,10000003
642,NCT02857270,Phase I,Recruiting,"[{'id': 4588, 'therapyName': 'LY3214996'}, {'id': 4590, 'therapyName': 'LY3214996 + nab-paclitaxel + Gemcitabine'}, {'id': 4589, 'therapyName': 'LY3214996 + Midazolam'}, {'id': 4591, 'therapyName': 'LY3214996 + Abemaciclib'}]",A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer,10000003
643,NCT02858310,Phase I,Recruiting,"[{'id': 4562, 'therapyName': 'Aldesleukin + Cyclophosphamide + Fludarabine + Pembrolizumab'}]",E7 TCR T Cells With or Without PD-1 Blockade for Human Papillomavirus-Associated Cancers,10000003
644,NCT02860780,Phase I,Completed,"[{'id': 4587, 'therapyName': 'Prexasertib + Ralimetinib'}]",A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer,10000003
645,NCT02862275,Phase 0,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}]",Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer,10000003
646,NCT02864316,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Phase 2 Study of Nivolumab in Solid Tumors Induced by Prior Radiation Exposure,10000003
647,NCT02867592,Phase II,Recruiting,"[{'id': 998, 'therapyName': 'cabozantinib'}]","Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors",10000003
648,NCT02869295,Phase I,Recruiting,"[{'id': 5075, 'therapyName': 'NKTR-214'}]",A Phase 1 Dose Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors,10000003
649,NCT02873975,Phase II,Recruiting,"[{'id': 1651, 'therapyName': 'Prexasertib'}]",A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency,10000003
650,NCT02875548,Phase II,Recruiting,"[{'id': 2683, 'therapyName': 'Tazemetostat'}]",Tazemetostat Rollover Study (TRuST): An Open-Label Rollover Study,10000003
651,NCT02886585,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab In Central Nervous System Metastases,10000003
652,NCT02890368,Phase I,Recruiting,"[{'id': 5338, 'therapyName': 'TTI-621'}]",Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides,10000003
653,NCT02892123,Phase I,Recruiting,"[{'id': 6240, 'therapyName': 'ZW25'}]",Trial of ZW25 in Patients With Advanced HER2-expressing Cancers,10000003
654,NCT02896335,Phase II,Recruiting,"[{'id': 850, 'therapyName': 'Palbociclib'}]",Palbociclib In Progressive Brain Metastases,10000003
655,NCT02897778,Phase I,Completed,"[{'id': 1541, 'therapyName': 'Entinostat'}]",Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors,10000003
656,NCT02898207,Phase I,Recruiting,"[{'id': 4729, 'therapyName': 'Olaparib + Onalespib'}]","Olaparib and Hsp90 Inhibitor AT13387 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer",10000003
657,NCT02900157,Phase I,"Active, not recruiting","[{'id': 4727, 'therapyName': 'MEDI4736 + MEDI9090'}]",Study to Evaluate the Safety and Pharmacokinetics of MEDI9090 in Subjects With Advanced Solid Tumors,10000003
658,NCT02903914,Phase I,Recruiting,"[{'id': 4722, 'therapyName': 'CB-1158 + Nivolumab'}, {'id': 4721, 'therapyName': 'CB-1158'}]",Arginase Inhibitor CB-1158 in Patients With Solid Tumors,10000003
659,NCT02904226,Phase Ib/II,Recruiting,"[{'id': 4720, 'therapyName': 'JTX-2011 + Nivolumab'}, {'id': 4719, 'therapyName': 'JTX-2011'}]",Dose Escalation and Expansion of JTX-2011 Alone or in Combination With Anti-PD-1 in Subjects With Advanced Solid Tumors (ICONIC),10000003
660,NCT02906670,Phase Ib/II,Recruiting,"[{'id': 3885, 'therapyName': 'Pan-HER'}]",Sym013 (Pan-HER) in Patients With Advanced Epithelial Malignancies,10000003
661,NCT02909452,Phase I,Recruiting,"[{'id': 3354, 'therapyName': 'Entinostat + Pembrolizumab'}]",Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors,10000003
662,NCT02909777,Phase I,Recruiting,"[{'id': 709, 'therapyName': 'CUDC-907'}]","Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma",10000003
663,NCT02913313,Phase Ib/II,Recruiting,"[{'id': 4888, 'therapyName': 'BMS-986207 + Nivolumab'}, {'id': 4887, 'therapyName': 'BMS-986207 '}]",A Study to Evaluate the Safety and Tolerability of Monoclonal Antibody BMS-986207 Alone and in Combination With Nivolumab in Advanced (Solid Tumor) Cancers,10000003
664,NCT02915172,Phase I,Withdrawn,"[{'id': 4779, 'therapyName': 'Capecitabine + Lenvatinib'}]",Lenvatinib and Capecitabine in Patients With Advanced Malignancies,10000003
665,NCT02920996,Phase II,Recruiting,"[{'id': 1030, 'therapyName': 'LY2801653'}]",Merestinib In Non-Small Cell Lung Cancer And Solid Tumors,10000003
666,NCT02921919,Phase II,Recruiting,"[{'id': 682, 'therapyName': 'Talazoparib'}]",Open-Label Extension and Safety Study of Talazoparib,10000003
667,NCT02923349,Phase Ib/II,Recruiting,"[{'id': 5831, 'therapyName': 'INCAGN01949'}]","A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors",10000003
668,NCT02925104,Phase I,Recruiting,"[{'id': 1065, 'therapyName': 'Capmatinib'}]","A Dose Escalation Study to Assess PK, Safety and Tolerability of INC280 When Taken With Food in cMET Dysregulated Advanced Solid Tumors.",10000003
669,NCT02926768,Phase Ib/II,Recruiting,"[{'id': 5329, 'therapyName': 'CK-101'}]",Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors,10000003
670,NCT02929862,Phase Ib/II,Recruiting,"[{'id': 5812, 'therapyName': 'LYC-55716'}]",Study of LYC-55716 in Adult Subjects With Locally Advanced or Metastatic Cancer,10000003
671,NCT02932280,Phase Ib/II,Recruiting,"[{'id': 828, 'therapyName': 'Neratinib'}]",Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment,10000003
672,NCT02934568,Phase II,Recruiting,"[{'id': 790, 'therapyName': 'Ribociclib'}]",Ribociclib (LEE011) Rollover Study for Continued Access,10000003
673,NCT02935907,Phase I,Recruiting,"[{'id': 5826, 'therapyName': 'APG-115'}]",APG-115 in Patients With Advanced Solid Tumors or Lymphomas,10000003
674,NCT02936102,Phase I,Recruiting,"[{'id': 4971, 'therapyName': 'FAZ053'}, {'id': 4972, 'therapyName': 'FAZ053 + PDR001'}]",A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.,10000003
675,NCT02937272,Phase I,Recruiting,"[{'id': 5811, 'therapyName': 'LY3200882'}]",A Study of LY3200882 in Participants With Solid Tumors,10000003
676,NCT02938793,Phase II,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",Durvalumab in Combination With Tremelimumab in Subjects With Advanced Rare Solid Tumors,10000003
677,NCT02942095,Phase I,Recruiting,"[{'id': 4885, 'therapyName': 'Erlotinib + Ixazomib'}]",Phase I Study of Ixazomib and Erlotinib in Solid Tumors,10000003
678,NCT02947165,Phase I,Recruiting,"[{'id': 5632, 'therapyName': 'NIS793 + PDR001'}, {'id': 5631, 'therapyName': 'NIS793'}]",Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.,10000003
679,NCT02952248,Phase I,Recruiting,"[{'id': 5692, 'therapyName': 'BI 754091'}]",A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours,10000003
680,NCT02952989,Phase I,Recruiting,"[{'id': 5896, 'therapyName': 'SGN-2FF'}]",A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors,10000003
681,NCT02953782,Phase Ib/II,Recruiting,"[{'id': 4948, 'therapyName': 'Cetuximab + Hu5F9-G4'}]",Trial of Hu5F9-G4 in Combination With Cetuximab in Patients With Solid Tumors and Advanced Colorectal Cancer,10000003
682,NCT02955251,Phase I,Recruiting,"[{'id': 5051, 'therapyName': 'ABBV-428 + Nivolumab'}, {'id': 5050, 'therapyName': 'ABBV-428'}]","A Study Evaluating Safety and Pharmacokinetics, and the Recommended Phase 2 Dose (RPTD) of ABBV-428 in Participants With Advanced Solid Tumors",10000003
683,NCT02955446,Expanded access,No longer available,"[{'id': 859, 'therapyName': 'PF-03084014'}]",Compassionate Use Protocol for PF-03084014 in Patients With Advanced Solid Tumor Malignancies,10000003
684,NCT02959437,Phase Ib/II,Recruiting,"[{'id': 5477, 'therapyName': 'Azacitidine + INCB024360 + Pembrolizumab'}]",Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206),10000003
685,NCT02961283,Phase I,Recruiting,"[{'id': 5827, 'therapyName': 'ASN003'}]",Study of ASN003 in Subjects With Advanced Solid Tumors,10000003
686,NCT02963610,Phase Ib/II,Recruiting,"[{'id': 3322, 'therapyName': 'lenalidomide + Pembrolizumab'}]",Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer,10000003
687,NCT02964013,Phase I,Recruiting,"[{'id': 5218, 'therapyName': 'MK-7684'}, {'id': 5219, 'therapyName': 'MK-7684 + Pembrolizumab'}]",Study of MK-7684 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (MK-7684-001),10000003
688,NCT02972034,Phase I,Recruiting,"[{'id': 5269, 'therapyName': 'MK-8353 + Pembrolizumab'}]",Study of MK-8353 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Malignancies (MK-8353-013),10000003
689,NCT02974738,Phase I,Recruiting,"[{'id': 5820, 'therapyName': 'PT 2977'}]",A Trial of PT2977 Tablets In Patients With Advanced Solid Tumors,10000003
690,NCT02975882,Phase I,"Active, not recruiting","[{'id': 5030, 'therapyName': 'Nab-Rapamycin + Temozolomide + Irinotecan'}]","Nanoparticle Albumin-Bound Rapamycin, Temozolomide, and Irinotecan Hydrochloride in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors",10000003
691,NCT02982941,Phase I,Recruiting,"[{'id': 2863, 'therapyName': 'MGA271'}]",Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors,10000003
692,NCT02987166,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",HDCRT Plus Pembrolizumab in Advanced Malignancies (UVA-AM-001),10000003
693,NCT02987504,Phase I,Suspended,"[{'id': 5535, 'therapyName': 'Samalizumab'}]",Study of Samalizumab in Patients With Advanced Cancer,10000003
694,NCT02988817,Phase Ib/II,Recruiting,"[{'id': 5864, 'therapyName': 'HuMax-Axl-ADC'}]",HuMax-AXL-ADC Safety Study in Patients With Solid Tumors,10000003
695,NCT02988960,Phase I,Recruiting,"[{'id': 5143, 'therapyName': 'ABBV-927 + Nivolumab'}, {'id': 5142, 'therapyName': 'ABBV-927'}]","A Study of ABBV-927, an Immunotherapy, in Participants With Advanced Solid Tumors",10000003
696,NCT02990481,Phase I,Recruiting,"[{'id': 5835, 'therapyName': 'TRK-950'}]",A Study of TRK-950 in Patients With Advanced Solid Tumors,10000003
697,NCT02992964,Phase Ib/II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Pilot Study of Nivolumab in Pediatric Patients With Hypermutant Cancers,10000003
698,NCT02994953,Phase I,Recruiting,"[{'id': 5131, 'therapyName': 'Avelumab + NHS-IL12'}]","A Phase Ib Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Avelumab in Combination With M9241(NHS-IL12)",10000003
699,NCT02997163,Phase I,Recruiting,"[{'id': 682, 'therapyName': 'Talazoparib'}]",An Open-Label Pharmacokinetics and Safety Study of Talazoparib,10000003
700,NCT02997176,Phase I,Recruiting,"[{'id': 682, 'therapyName': 'Talazoparib'}]",An Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800),10000003
701,NCT03000257,Phase I,Recruiting,"[{'id': 5766, 'therapyName': 'ABBV-181'}]",A Study of ABBV-181 in Participants With Advanced Solid Tumors,10000003
702,NCT03005782,Phase I,Recruiting,"[{'id': 5736, 'therapyName': 'REGN3767 + REGN2810'}, {'id': 5735, 'therapyName': 'REGN3767'}]",Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers,10000003
703,NCT03006172,Phase I,Recruiting,"[{'id': 5182, 'therapyName': 'GDC-0077 + Letrozole + Palbociclib'}, {'id': 5181, 'therapyName': 'GDC-0077'}, {'id': 5184, 'therapyName': 'GDC-0077 + Fulvestrant'}, {'id': 5183, 'therapyName': 'GDC-0077 + Letrozole'}]","To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer",10000003
704,NCT03010176,Phase I,Recruiting,"[{'id': 5348, 'therapyName': 'MK-1454 + Pembrolizumab'}, {'id': 5347, 'therapyName': 'MK-1454'}]",Study of MK-1454 Alone or in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001),10000003
705,NCT03013218,Phase I,Recruiting,"[{'id': 5211, 'therapyName': 'ALX148'}, {'id': 5212, 'therapyName': 'ALX148 + Atezolizumab'}, {'id': 5213, 'therapyName': 'ALX148 + Trastuzumab'}]",A Study of ALX148 in Patients With Advanced Solid Tumors and Lymphoma,10000003
706,NCT03013491,Phase II,Recruiting,"[{'id': 5209, 'therapyName': 'CX-072 + Ipilimumab'}, {'id': 5210, 'therapyName': 'CX-072 + Vemurafenib'}, {'id': 5208, 'therapyName': 'CX-072'}]",A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas,10000003
707,NCT03017833,Phase I,Not yet recruiting,"[{'id': 5197, 'therapyName': 'MLN0128 + Metformin'}]",Study of TAK-228 (MLN0128) in Combination With Metformin in Patients With Advanced Cancers,10000003
708,NCT03030378,Phase I,Not yet recruiting,"[{'id': 5263, 'therapyName': 'Pembrolizumab + Interleukin-12'}]",Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors,10000003
709,NCT03030417,Phase I,Recruiting,"[{'id': 5749, 'therapyName': 'LMP744'}]",Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas,10000003
710,NCT03035253,Phase I,Recruiting,"[{'id': 5297, 'therapyName': 'FOLFIRI + OMP-305B83'}]",A Study of OMP-305B83 in Subjects With Metastatic Colorectal Cancer,10000003
711,NCT03037385,Phase I,Recruiting,"[{'id': 5530, 'therapyName': 'BLU-667'}]","Phase 1 Study of BLU-667 in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors",10000003
712,NCT03040973,FDA approved,Recruiting,"[{'id': 1065, 'therapyName': 'Capmatinib'}]",Roll-over Study for Patients With cMET-dependent Malignancies Who Previously Completed a Novartis Capmatinib Study,10000003
713,NCT03042910,Phase I,Completed,"[{'id': 682, 'therapyName': 'Talazoparib'}]",A Study to Assess the Effects of Talazoparib on Cardiac Repolarization in Patients With Advanced Solid Tumors,10000003
714,NCT03051035,Phase I,Recruiting,"[{'id': 5747, 'therapyName': 'KO-947'}]",First-in-Human Study of KO-947 in Non-Hematological Malignancies,10000003
715,NCT03052205,Phase I,Recruiting,"[{'id': 4243, 'therapyName': 'IMO-2125'}]",A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors,10000003
716,NCT03052569,Expanded access,Temporarily not available,"[{'id': 1002, 'therapyName': 'CEP-32496'}]",Expanded Access to RXDX-105 for Cancers With RET Alterations,10000003
717,NCT03057145,Phase I,Recruiting,"[{'id': 5332, 'therapyName': 'Olaparib + Prexasertib'}]",Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors,10000003
718,NCT03059823,Phase I,Recruiting,"[{'id': 5813, 'therapyName': 'MGA012'}]",A Phase 1 Study of MGA012 in Patients With Advanced Solid Tumors,10000003
719,NCT03061188,Phase I,Recruiting,"[{'id': 5368, 'therapyName': 'Veliparib + Nivolumab'}]",Nivolumab and Veliparib in Treating Patients With Recurrent or Refractory Stage IV Solid Tumors That Cannot Be Removed by Surgery or Lymphoma With or Without Alterations in DNA Repair Genes,10000003
720,NCT03065062,Phase I,Recruiting,"[{'id': 4034, 'therapyName': 'Gedatolisib + Palbociclib'}]","Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors",10000003
721,NCT03065387,Phase I,Not yet recruiting,"[{'id': 5401, 'therapyName': 'Neratinib + Everolimus'}, {'id': 5402, 'therapyName': 'Neratinib + Palbociclib'}, {'id': 5403, 'therapyName': 'Neratinib + Trametinib'}]","Study of the Pan-ERBB Inhibitor Neratinib Given in Combination With Everolimus, Palbociclib or Trametinib in Advanced Cancer Subjects With EGFR Mutation/Amplification, HER2 Mutation/Amplification or HER3/4 Mutation",10000003
722,NCT03066661,Expanded access,Available,"[{'id': 1455, 'therapyName': 'Entrectinib'}]","Expanded Access to Entrectinib for Cancers With NTRK1/2/3, ROS1, or ALK Gene Fusions",10000003
723,NCT03069469,Phase I,Recruiting,"[{'id': 5760, 'therapyName': 'DCC-3014'}]",Study of DCC-3014 in Patients With Advanced Malignancies,10000003
724,NCT03071757,Phase I,Recruiting,"[{'id': 5446, 'therapyName': 'ABBV-368'}, {'id': 5447, 'therapyName': 'ABBV-368 + Nivolumab'}]","A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors",10000003
725,NCT03080311,Phase I,Recruiting,"[{'id': 5757, 'therapyName': 'APG-1252'}]",A Study of APG-1252 in Patients With SCLC or Other Solid Tumors,10000003
726,NCT03082209,Phase I,Recruiting,"[{'id': 5756, 'therapyName': 'ABBV-621'}]",A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously Treated Solid Tumors and Hematologic Malignancies,10000003
727,NCT03085914,Phase Ib/II,Recruiting,"[{'id': 5483, 'therapyName': 'INCB024360 + Nivolumab + mFOLFOX6'}, {'id': 5484, 'therapyName': 'INCB024360 + Nivolumab + Gemcitabine + nab-paclitaxel'}, {'id': 5485, 'therapyName': 'INCB024360 + Pembrolizumab + Carboplatin + Paclitaxel'}, {'id': 5486, 'therapyName': 'INCB024360 + Pembrolizumab + Carboplatin + Pemetrexed'}, {'id': 5487, 'therapyName': 'INCB024360 + Pembrolizumab + Cyclophosphamide'}]",A Study of Epacadostat in Combination With a PD-1 Inhibitor and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207),10000003
728,NCT03087591,Phase I,Recruiting,"[{'id': 5751, 'therapyName': 'APN401'}]","APN401 in Treating Patients With Recurrent or Metastatic Pancreatic Cancer, Colorectal Cancer, or Other Solid Tumors That Cannot Be Removed by Surgery",10000003
729,NCT03089645,Phase I,Recruiting,"[{'id': 5588, 'therapyName': 'MEDI5083'}, {'id': 5589, 'therapyName': 'MEDI4736 + MEDI5083'}]",MEDI5083 Alone and in Combination With Durvalumab in Subjects With Select Advanced Solid Tumors,10000003
730,NCT03091478,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Patients With Leptomeningeal Disease,10000003
731,NCT03092934,Phase Ib/II,Recruiting,"[{'id': 5753, 'therapyName': 'AK-01'}]",A Study of AK-01 in Solid Tumors,10000003
732,NCT03093116,Phase Ib/II,Recruiting,"[{'id': 3950, 'therapyName': 'TPX-0005'}]","A Study of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements",10000003
733,NCT03098550,Phase Ib/II,Recruiting,"[{'id': 5520, 'therapyName': 'Daratumumab + Nivolumab '}]",A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Advanced Solid Tumors or Tumors That Have Spread,10000003
734,NCT03099109,Phase I,Recruiting,"[{'id': 5556, 'therapyName': 'LY3321367'}, {'id': 5557, 'therapyName': 'LY3300054 + LY3321367'}]",A Study of LY3321367 Alone or With LY3300054 in Participants With Advanced Relapsed/Refractory Solid Tumors,10000003
735,NCT03099161,Phase I,Recruiting,"[{'id': 5518, 'therapyName': 'Preladenant'}, {'id': 5519, 'therapyName': 'Pembrolizumab + Preladenant'}]",Study of Preladenant (MK-3814) Alone and With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3814A-062),10000003
736,NCT03099174,Phase I,Recruiting,"[{'id': 5514, 'therapyName': 'Abemaciclib + Xentuzumab'}, {'id': 5515, 'therapyName': 'Abemaciclib + Letrozole + Xentuzumab'}, {'id': 5516, 'therapyName': 'Abemaciclib + Anastrozole + Xentuzumab'}, {'id': 5517, 'therapyName': 'Abemaciclib + Fulvestrant + Xentuzumab'}]",This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer.,10000003
737,NCT03101839,Phase I,Recruiting,"[{'id': 5914, 'therapyName': 'AZD4785'}]",Phase I Dose-Escalation Study of AZD4785 in Patients With Advanced Solid Tumours,10000003
738,NCT03104699,Phase Ib/II,Recruiting,"[{'id': 5693, 'therapyName': 'AGEN2034'}]",Phase 1 / 2 Study of AGEN2034 in Advanced Tumors and Cervical Cancer,10000003
739,NCT03108131,Phase II,Recruiting,"[{'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}]",Cobimetinib and Atezolizumab in Advanced Rare Tumors,10000003
740,NCT03110107,Phase Ib/II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 5552, 'therapyName': 'BMS-986218 + Nivolumab'}, {'id': 5551, 'therapyName': 'BMS-986218'}]",First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Patients With Advanced Solid Tumors,10000003
741,NCT03113188,Phase I,Recruiting,"[{'id': 6186, 'therapyName': 'CBP501 + Cisplatin + Nivolumab'}]","CBP501, Cisplatin and Nivolumab in Advanced Refractory Tumors",10000003
742,NCT03118349,Phase I,Recruiting,"[{'id': 5801, 'therapyName': 'MVT-1075 + MVT-5873'}]",Study of 177Lu Human Monoclonal Antibody 5B1 (MVT-1075) in Combination With a Blocking Dose of MVT-5873 as Radioimmunotherapy,10000003
743,NCT03119428,Phase I,Recruiting,"[{'id': 5696, 'therapyName': 'OMP-313M32'}]",A Study of OMP-313M32 in Subjects With Locally Advanced or Metastatic Solid Tumors,10000003
744,NCT03123744,Phase II,Not yet recruiting,"[{'id': 850, 'therapyName': 'Palbociclib'}]",Histology-Independent Study of Palbociclib in Patients With Advanced Cancer,10000003
745,NCT03125200,Phase I,Recruiting,"[{'id': 5689, 'therapyName': 'ADCT-502'}]",Study of ADCT-502 in Patients With Advanced Solid Tumors With HER2 Expression,10000003
746,NCT03126110,Phase Ib/II,Recruiting,"[{'id': 5599, 'therapyName': 'INCAGN01876 + Nivolumab + Ipilimumab'}, {'id': 5598, 'therapyName': 'INCAGN01876 + Nivolumab'}, {'id': 5597, 'therapyName': 'INCAGN01876 + Ipilimumab'}]","Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies",10000003
747,NCT03127098,Phase Ib/II,"Active, not recruiting","[{'id': 6239, 'therapyName': 'ALT-803 + ETBX-011'}]","QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer",10000003
748,NCT03134638,Phase I,Recruiting,"[{'id': 5700, 'therapyName': 'SY-1365'}]",A Phase 1 Study of SY-1365 in Adult Patients With Advanced Solid Tumors,10000003
749,NCT03139370,Phase I,Recruiting,"[{'id': 5803, 'therapyName': 'KITE-718'}]",A Study Evaluating the Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Subjects With Advanced Cancers,10000003
750,NCT03144661,Phase I,Recruiting,"[{'id': 5832, 'therapyName': 'INCB062079'}]",An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies,10000003
751,NCT03148418,Phase II,Not yet recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study in Participants Previously Enrolled in a Genentech? and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study,10000003
752,NCT03149549,Phase Ib/II,Recruiting,"[{'id': 5709, 'therapyName': 'CX-2009'}]",PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors,10000003
753,NCT03150810,Phase Ib/II,Recruiting,"[{'id': 6124, 'therapyName': 'BGB-290 + Temozolomide'}]","Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Subjects With Locally Advanced or Metastatic Solid Tumors",10000003
754,NCT03154294,Phase I,Not yet recruiting,"[{'id': 5731, 'therapyName': 'Paclitaxel + MLN0128 + MLN1117'}]",Evaluation of the Safety and Tolerability of TAK-228 With TAK-117 and Paclitaxel in Advanced Solid Tumors,10000003
755,NCT03155620,Phase II,Recruiting,"[{'id': 2683, 'therapyName': 'Tazemetostat'}, {'id': 2650, 'therapyName': 'LOXO-101'}, {'id': 1069, 'therapyName': 'LY3023414'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 913, 'therapyName': 'Selumetinib'}, {'id': 961, 'therapyName': 'X-396'}]",Pediatric MATCH: Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Advanced Refractory Solid Tumors or Lymphomas,10000003
756,NCT03156114,Phase I,Recruiting,"[{'id': 5692, 'therapyName': 'BI 754091'}, {'id': 5690, 'therapyName': 'BI 754111'}]",This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment.,10000003
757,NCT03157128,Phase I,Recruiting,"[{'id': 5702, 'therapyName': 'LOXO-292'}]","Phase 1 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET-Fusion Lung Cancer and Medullary Thyroid Cancer",10000003
758,NCT03162627,Phase I,Recruiting,"[{'id': 5793, 'therapyName': 'Olaparib + Selumetinib'}]",Selumetinib and Olaparib in Solid Tumors,10000003
759,NCT03164603,Phase I,Recruiting,"[{'id': 5815, 'therapyName': 'NLG802'}]","NLG802 Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors",10000003
760,NCT03166631,Phase I,Recruiting,"[{'id': 6263, 'therapyName': 'BI 754091 + BI 891065'}, {'id': 6262, 'therapyName': 'BI 891065'}]",A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread,10000003
761,NCT03172936,Phase I,Recruiting,"[{'id': 6219, 'therapyName': 'MIW815 + PDR001'}]",Study of the Safety and Efficacy of MIW815 With PDR001 to Patients With Advanced/Metastatic Solid Tumors or Lymphomas,10000003
762,NCT03175224,Phase I,Recruiting,"[{'id': 5963, 'therapyName': 'CBT-101'}]",CBT-101 Study for Advanced Solid Tumors and c-Met Dysregulation,10000003
763,NCT03179436,Phase I,Recruiting,"[{'id': 6039, 'therapyName': 'MK-1308 + Pembrolizumab'}]","Safety, Pharmacokinetics (PK), and Efficacy of MK-1308 in Combination With Pembrolizumab in Advanced Solid Tumors (MK-1308-001)",10000003
764,NCT03188965,Phase I,Recruiting,"[{'id': 5962, 'therapyName': 'BAY1895344'}]",First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas,10000003
765,NCT03190941,Phase I,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 6061, 'therapyName': 'anti-KRAS G12V mTCR cells'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1167, 'therapyName': 'Aldesleukin'}]",Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*1101 Patients,10000003
766,NCT03192345,Phase I,Recruiting,"[{'id': 5934, 'therapyName': 'SAR439459 + REGN2810'}, {'id': 5933, 'therapyName': 'SAR439459'}]","A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and REGN2810 in Patients With Advanced Solid Tumors",10000003
767,NCT03194893,Phase III,Recruiting,"[{'id': 706, 'therapyName': 'Crizotinib'}, {'id': 698, 'therapyName': 'Alectinib'}]",A Roll Over Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer,10000003
768,NCT03195699,Phase I,Not yet recruiting,"[{'id': 5961, 'therapyName': 'C188-9'}]","Phase I Study of Oral STAT3 Inhibitor, C188-9, in Patients With Advanced Cancers",10000003
769,NCT03205176,Phase I,Recruiting,"[{'id': 4910, 'therapyName': 'AZD5153'}]",Phase I Study of AZD5153 in Patients With Relapsed or Refractory Solid Tumors and Lymphomas,10000003
770,NCT03207347,Phase II,Not yet recruiting,"[{'id': 832, 'therapyName': 'Niraparib'}]",A Trial of Niraparib in BAP1 and Other DNA Double-Strand Break Repair Deficient Neoplasms (UF-STO-ETI-001),10000003
771,NCT03209401,Phase I,Not yet recruiting,"[{'id': 5984, 'therapyName': 'Carboplatin + Niraparib'}]",Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignancies,10000003
772,NCT03210714,Phase II,Not yet recruiting,"[{'id': 1028, 'therapyName': 'JNJ-42756493'}]","Pediatric MATCH: Pan-FGFR Tyrosine Kinase Inhibitor JNJ-42756493 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations",10000003
773,NCT03212274,Phase II,Not yet recruiting,"[{'id': 837, 'therapyName': 'Olaparib'}]","Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations",10000003
774,NCT03213652,Phase II,Recruiting,"[{'id': 961, 'therapyName': 'X-396'}]","Pediatric MATCH: Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations",10000003
775,NCT03213665,Phase II,Recruiting,"[{'id': 2683, 'therapyName': 'Tazemetostat'}]","Pediatric MATCH: Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations",10000003
776,NCT03213678,Phase II,Recruiting,"[{'id': 1069, 'therapyName': 'LY3023414'}]","Pediatric MATCH: PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations",10000003
777,NCT03213691,Phase II,Recruiting,"[{'id': 913, 'therapyName': 'Selumetinib'}]","Pediatric MATCH: Selumetinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations",10000003
778,NCT03213704,Phase II,Recruiting,"[{'id': 2650, 'therapyName': 'LOXO-101'}]","Pediatric MATCH: Trk Inhibitor LOXO-101 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions",10000003
779,NCT03215511,Phase Ib/II,Recruiting,"[{'id': 5917, 'therapyName': 'LOXO-195'}]",Phase 1/2 Study of LOXO-195 in Patients With Previously Treated NTRK Fusions or Non-fusion NTRK Cancers,10000003
780,NCT03217253,Phase I,Not yet recruiting,"[{'id': 2683, 'therapyName': 'Tazemetostat'}]",Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver Dysfunction,10000003
781,NCT03217747,Phase Ib/II,Recruiting,"[{'id': 5052, 'therapyName': 'Avelumab + Cisplatin'}, {'id': 6044, 'therapyName': 'Avelumab + PF-04518600 + Utomilumab'}, {'id': 6043, 'therapyName': 'Avelumab + Utomilumab'}, {'id': 6045, 'therapyName': 'Avelumab + PF-04518600'}]",Study to Evaluate the Safety and Tolerability of Avelumab in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies,10000003
782,NCT03218826,Phase I,Not yet recruiting,"[{'id': 6046, 'therapyName': 'AZD8186 + Docetaxel'}]",PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery,10000003
783,NCT03219268,Phase I,Recruiting,"[{'id': 6060, 'therapyName': 'MGD013'}]",A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms,10000003
784,NCT03220035,Phase II,Recruiting,"[{'id': 342, 'therapyName': 'Vemurafenib'}]","Pediatric MATCH: Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations",10000003
785,NCT03221400,Phase Ib/II,Recruiting,"[{'id': 4842, 'therapyName': 'STA-8666'}]",PEN-866 in Patients With Advanced Solid Malignancies,10000003
786,NCT03225105,Phase I,Recruiting,"[{'id': 6059, 'therapyName': 'M3541'}]",M3541 in Combination With Radiotherapy in Subjects With Solid Tumors,10000003
787,NCT03229200,FDA approved,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.,10000003
788,NCT03229278,Phase I,Recruiting,"[{'id': 6055, 'therapyName': 'Nivolumab + Pembrolizumab + Trigriluzole'}]",Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma,10000003
789,NCT03233204,Phase II,Recruiting,"[{'id': 837, 'therapyName': 'Olaparib'}]","Pediatric MATCH: Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes",10000003
790,NCT03236857,Phase I,Not yet recruiting,"[{'id': 1562, 'therapyName': 'Venetoclax'}]",A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies,10000003
791,NCT03236935,Phase I,Not yet recruiting,"[{'id': 6097, 'therapyName': 'L-NMMA + Pembrolizumab'}]",Phase Ib of L-NMMA and Pembrolizumab,10000003
792,NCT03237390,Phase I,Recruiting,"[{'id': 2898, 'therapyName': 'Gemcitabine + Ribociclib'}]",Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors,10000003
793,NCT03239145,Phase I,Recruiting,"[{'id': 6102, 'therapyName': 'Pembrolizumab + Trebananib'}]",Phase Ib Study to Test the Safety and Potential Synergy of Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor,10000003
794,NCT03240861,Phase I,Not yet recruiting,"[{'id': 6116, 'therapyName': 'Busulfan + Fludarabine'}, {'id': 3933, 'therapyName': 'Filgrastim + Plerixafor'}, {'id': 1167, 'therapyName': 'Aldesleukin'}]",Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer (NYESO SCT),10000003
795,NCT03241173,Phase Ib/II,Not yet recruiting,"[{'id': 6120, 'therapyName': 'INCAGN01949 + Ipilimumab'}, {'id': 6119, 'therapyName': 'INCAGN01949 + Nivolumab'}, {'id': 6121, 'therapyName': 'INCAGN01949 + Ipilimumab + Nivolumab'}]",A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies,10000003
796,NCT03245151,Phase Ib/II,Not yet recruiting,"[{'id': 1713, 'therapyName': 'Everolimus + Lenvatinib'}]","Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors",10000003
797,NCT03245736,Phase II,Recruiting,"[{'id': 6113, 'therapyName': 'Tisotumab Vedotin'}]",Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.,10000003
798,NCT03249792,Phase I,Recruiting,"[{'id': 6131, 'therapyName': 'MK-2118 + Pembrolizumab'}, {'id': 6130, 'therapyName': 'MK-2118'}]",Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) in the Treatment of Adults With Advance/Metastatic Solid Tumors or Lymphomas (MK-2118-001),10000003
799,NCT03251924,Phase Ib/II,Recruiting,"[{'id': 6136, 'therapyName': 'BMS-986226 + Nivolumab'}, {'id': 6135, 'therapyName': 'BMS-986226 + Ipilimumab'}, {'id': 6134, 'therapyName': 'BMS-986226'}]",A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors,10000003
800,NCT03253679,Phase II,Not yet recruiting,"[{'id': 822, 'therapyName': 'MK-1775'}]",WEE1 Inhibitor AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification,10000003
801,NCT03270176,Phase I,Recruiting,"[{'id': 6178, 'therapyName': 'AT-406 + Avelumab'}]",A Dose-Finding Study of the Second Mitochondrial Activator of Caspases (SMAC) Mimetic Debio 1143 When Given in Combination With Avelumab to Participants With Advanced Solid Malignancies and to Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Platinum-Based Therapy,10000003
802,NCT03272464,Phase I,Not yet recruiting,"[{'id': 6176, 'therapyName': 'Dabrafenib + INCB039110 + Trametinib'}]",Phase I Study of INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors.,10000003
803,NCT03274661,Phase II,Not yet recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab Activity in Patients With HR Competent and Deficient Tumors,10000003
804,NCT03277352,Phase Ib/II,Not yet recruiting,"[{'id': 6277, 'therapyName': 'Epacadostat + INCAGN01876 + Pembrolizumab'}]",INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies,10000003
805,NCT03286296,Phase I,Recruiting,"[{'id': 6281, 'therapyName': 'LZM009'}]",LZM009 to Treat Patients With Advanced Solid Tumors,10000003
806,NCT03289962,Phase I,Not yet recruiting,"[{'id': 6234, 'therapyName': 'RO7198457'}, {'id': 6235, 'therapyName': 'Atezolizumab + RO7198457'}]",A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors,10000003
807,NCT03291938,Phase I,Not yet recruiting,"[{'id': 6267, 'therapyName': 'IACS-010759'}]",Study to Evaluate the Safety and Tolerability of IACS-010759 in Subjects With Advanced Solid Tumors and Lymphoma,10000003
808,NCT03295942,Phase I,Recruiting,"[{'id': 6264, 'therapyName': 'OMP-336B11'}]",A Study of OMP-336B11 in Subjects With Locally Advanced or Metastatic Tumors,10000003
809,NCT03297424,Phase Ib/II,Recruiting,"[{'id': 6324, 'therapyName': 'PLX2853'}]",A Study of PLX2853 in Advanced Malignancies.,10000003
810,NCT03301896,Phase I,Not yet recruiting,"[{'id': 6299, 'therapyName': 'LHC165 + PDR001'}, {'id': 6298, 'therapyName': 'LHC165'}]",Phase I/Ib Study of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies,10000003
811,NCT03306420,Phase I,Recruiting,"[{'id': 6317, 'therapyName': 'MS201408-0005A + MS201408-0005B'}, {'id': 6318, 'therapyName': 'MS201408-0005A + MS201408-0005C'}, {'id': 6314, 'therapyName': 'MS201408-0005A'}]",First-in-Human Study of MS201408-0005A as Single Agent and in Combinations,10000003
812,NCT03307785,Phase I,Recruiting,"[{'id': 6322, 'therapyName': 'Carboplatin + Paclitaxel + TSR-042'}, {'id': 6321, 'therapyName': 'Niraparib + TSR-042'}]",Study of Niraparib or Carboplatin-Paclitaxel in Combination With TSR-042,10000003
0,NCT02978625,Phase II,Recruiting,"[{'id': 5080, 'therapyName': 'Talimogene laherparepvec + Nivolumab'}]",Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers,5590
0,NCT02567435,Phase III,Suspended,"[{'id': 1435, 'therapyName': 'Vincristine + Dactinomycin + Cyclophosphamide'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1074, 'therapyName': 'Irinotecan'}]",Combination Chemotherapy and Irinotecan Hydrochloride or Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma,4051
1,NCT02748135,Phase Ib/II,Recruiting,"[{'id': 4704, 'therapyName': 'TB-403'}]",A Two-Part Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma,4051
2,NCT02978859,Phase II,Recruiting,"[{'id': 1655, 'therapyName': 'MGCD516'}]",MGCD516 in Advanced Liposarcoma and Other Soft Tissue Sarcomas,4051
3,NCT03041701,Phase Ib/II,Recruiting,"[{'id': 5287, 'therapyName': 'Dasatinib + Ganitumab'}]",Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma,4051
0,NCT00942877,Phase II,"Active, not recruiting","[{'id': 1001, 'therapyName': 'Cediranib'}]",Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma,4239
1,NCT01391962,Phase II,Recruiting,"[{'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1001, 'therapyName': 'Cediranib'}]",Sunitinib or Cediranib for Alveolar Soft Part Sarcoma,4239
2,NCT01446809,Phase I,"Active, not recruiting","[{'id': 1472, 'therapyName': 'Doxorubicin + Ifosfamide'}, {'id': 1471, 'therapyName': 'Pazopanib + Doxorubicin + Ifosfamide'}]",Pazopanib Hydrochloride Followed By Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma,4239
3,NCT02867592,Phase II,Recruiting,"[{'id': 998, 'therapyName': 'cabozantinib'}]","Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors",4239
4,NCT02978859,Phase II,Recruiting,"[{'id': 1655, 'therapyName': 'MGCD516'}]",MGCD516 in Advanced Liposarcoma and Other Soft Tissue Sarcomas,4239
5,NCT03141684,Phase II,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}]",Atezolizumab in Treating Patients With Newly Diagnosed and Metastatic Alveolar Soft Part Sarcoma That Cannot Be Removed by Surgery,4239
0,NCT01202409,Phase II,"Active, not recruiting","[{'id': 845, 'therapyName': 'Panitumumab'}]",CAPOX in KRAS Wild-Type Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater,3502
1,NCT01208103,Phase II,"Active, not recruiting","[{'id': 1601, 'therapyName': 'Capecitabine + Oxaliplatin + Bevacizumab'}]",Bevacizumab With Capecitabine and Oxaliplatin in Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater,3502
2,NCT02711553,Phase II,"Active, not recruiting","[{'id': 886, 'therapyName': 'Ramucirumab'}, {'id': 1030, 'therapyName': 'LY2801653'}, {'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}]",A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer,3502
0,NCT01825603,Phase I,Recruiting,"[{'id': 4952, 'therapyName': 'ADH-1 + Cisplatin + Gemcitabine'}]","ADH-1, Gemcitabine Hydrochloride and Cisplatin in Treating Patients With Metastatic Pancreatic or Biliary Tract Cancer That Cannot Be Removed By Surgery",4932
1,NCT02240238,Phase Ib/II,Recruiting,"[{'id': 5626, 'therapyName': 'Gemcitabine + NC-6004'}]","Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer",4932
2,NCT03000179,Phase II,Recruiting,"[{'id': 3144, 'therapyName': 'Avelumab'}]",Safety and Efficacy of Avelumab in Small Intestinal Adenocarcinoma,4932
3,NCT03093870,Phase II,Not yet recruiting,"[{'id': 5543, 'therapyName': 'Capecitabine + Varlitinib'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer,4932
4,NCT03111732,Phase II,Recruiting,"[{'id': 5549, 'therapyName': 'Capecitabine + Oxaliplatin + Pembrolizumab'}]","Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)",4932
0,NCT02399813,Phase Ib/II,"Active, not recruiting","[{'id': 3090, 'therapyName': 'ADXS11-001'}]",Phase 2 Study of ADXS11-001 in Subjects With Anal Cancer or Cancer of the Rectum,50688
1,NCT02404441,Phase Ib/II,Recruiting,"[{'id': 2659, 'therapyName': 'PDR001'}]",Phase I/II Study of PDR001 in Patients With Advanced Malignancies,50688
2,NCT02426892,Phase II,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab and HPV-16 Vaccination in Patients With HPV-16 Positive Incurable Solid Tumors,50688
0,NCT02628067,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158),6126
1,NCT02834013,Phase 0,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab in Treating Patients With Rare Tumors,6126
0,NCT02314169,Phase II,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab in Treating Patients With Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal,7177
1,NCT02879162,Phase II,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours,7177
2,NCT03074513,Phase II,Recruiting,"[{'id': 4595, 'therapyName': 'Atezolizumab + Bevacizumab'}]",Atezolizumab and Bevacizumab in Rare Solid Tumors,7177
0,NCT02051868,Phase II,Recruiting,"[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1833, 'therapyName': 'Cisplatin + Fluorouracil'}]",International Multicentre Study in Advanced Anal Cancer Comparing Cisplatin Plus 5 FU vs Carboplatin Plus Weekly Paclitaxel (InterAACT),4908
0,NCT03233711,Phase II,Not yet recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer,12239
0,NCT00316888,Phase II,"Active, not recruiting","[{'id': 1928, 'therapyName': 'Cetuximab + Cisplatin + Fluorouracil + Radiotherapy'}]","Cetuximab, Cisplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Anal Cancer",5525
0,NCT00585195,Phase I,Recruiting,"[{'id': 1526, 'therapyName': 'Crizotinib + Itraconazole\t'}, {'id': 1483, 'therapyName': 'Crizotinib + Rifampin'}]","A Study Of Oral PF-02341066, A c-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer",50744
1,NCT00671112,Phase I,Terminated,"[{'id': 2234, 'therapyName': 'Bortezomib + Everolimus'}]",Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma,50744
2,NCT00939770,Phase Ib/II,"Active, not recruiting","[{'id': 706, 'therapyName': 'Crizotinib'}]",Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma,50744
3,NCT01449461,Phase Ib/II,"Active, not recruiting","[{'id': 634, 'therapyName': 'AP26113'}]",A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113,50744
4,NCT01606878,Phase I,Recruiting,"[{'id': 2952, 'therapyName': 'Dexamethasone + Doxorubicin + Vincristine'}, {'id': 2590, 'therapyName': 'Cyclophosphamide + Topotecan'}, {'id': 706, 'therapyName': 'Crizotinib'}]",Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma,50744
5,NCT01686165,Phase II,"Active, not recruiting","[{'id': 1078, 'therapyName': 'Belinostat'}, {'id': 897, 'therapyName': 'Rituximab'}]",Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma,50744
6,NCT01979536,Phase II,Suspended,"[{'id': 706, 'therapyName': 'Crizotinib'}]",Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma,50744
7,NCT02420795,Phase Ib/II,Recruiting,"[{'id': 1687, 'therapyName': 'ONC201'}]",Study of Oral ONC201 in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma,50744
8,NCT02464228,Phase II,Recruiting,"[{'id': 938, 'therapyName': 'Tipifarnib'}]",Study of Tipifarnib in Subjects With Relapsed or Refractory Peripheral T-Cell Lymphoma,50744
9,NCT02568267,Phase II,Recruiting,"[{'id': 1455, 'therapyName': 'Entrectinib'}]","Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK1/2/3, ROS1, or ALK Gene Rearrangements  (STARTRK-2)",50744
10,NCT02572453,Phase II,Recruiting,"[{'id': 645, 'therapyName': 'AT13387'}]","AT13387 in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Diffuse Large B-cell Lymphoma",50744
11,NCT02722668,Phase II,Recruiting,"[{'id': 2281, 'therapyName': 'Cyclophosphamide + Fludarabine + Mycophenolate mofetil'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}]",UCB Transplant for Hematological DIseases Using a Non Myeloablative Prep,50744
12,NCT02729961,Phase Ib/II,Not yet recruiting,"[{'id': 4169, 'therapyName': 'Brentuximab vedotin + Ceritinib'}]",Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma,50744
13,NCT02978625,Phase II,Recruiting,"[{'id': 5080, 'therapyName': 'Talimogene laherparepvec + Nivolumab'}]",Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers,50744
14,NCT03075553,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma,50744
0,NCT01396408,Phase II,"Active, not recruiting","[{'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 930, 'therapyName': 'Sunitinib'}]",A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours,1816
1,NCT01446809,Phase I,"Active, not recruiting","[{'id': 1472, 'therapyName': 'Doxorubicin + Ifosfamide'}, {'id': 1471, 'therapyName': 'Pazopanib + Doxorubicin + Ifosfamide'}]",Pazopanib Hydrochloride Followed By Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma,1816
2,NCT01462630,Phase II,Recruiting,"[{'id': 848, 'therapyName': 'Pazopanib'}]",Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma,1816
3,NCT02048722,Phase II,Recruiting,"[{'id': 890, 'therapyName': 'Regorafenib'}]","Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma",1816
4,NCT02584309,Phase II,Recruiting,"[{'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 4140, 'therapyName': 'Doxorubicin + Olaratumab'}]",Doxorubicin With Upfront Dexrazoxane Plus Olaratumab for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma,1816
5,NCT02815995,Phase II,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes,1816
6,NCT02979899,Phase III,Recruiting,"[{'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1431, 'therapyName': 'TRC105 + Pazopanib'}]",A RANDOMIZED PHASE 3 TRIAL OF TRC105 AND PAZOPANIB VERSUS PAZOPANIB ALONE IN PATIENTS WITH ADVANCED ANGIOSARCOMA (TAPPAS),1816
7,NCT02987959,Phase II,Recruiting,"[{'id': 1282, 'therapyName': 'Sapanisertib'}]",Study of TAK-228 (MLN0128) in Soft Tissue Sarcomas,1816
8,NCT03009201,Phase I,Recruiting,"[{'id': 5179, 'therapyName': 'Doxorubicin + Ribociclib'}]",Ribociclib and Doxorubicin Hydrochloride in Treating Patients Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery,1816
9,NCT03282344,Phase II,Recruiting,"[{'id': 5076, 'therapyName': 'NKTR-214 + Nivolumab'}]",A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma,1816
0,NCT02199236,Phase I,Recruiting,"[{'id': 1619, 'therapyName': 'Capecitabine + Fluorouracil'}]",Dose Escalation Trial of Endoluminal High-Dose-Rate Brachytherapy With Concurrent Chemotherapy for Rectal or Anal Cancer in Patients With Recurrent Disease or Undergoing Non-Operative Management,14110
1,NCT02812056,Phase I,Withdrawn,"[{'id': 4214, 'therapyName': 'Alisertib + MLN0128'}]",Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated Malignancies,14110
2,NCT02919969,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Refractory Metastatic Anal Cancer,14110
3,NCT03289962,Phase I,Not yet recruiting,"[{'id': 6234, 'therapyName': 'RO7198457'}, {'id': 6235, 'therapyName': 'Atezolizumab + RO7198457'}]",A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors,14110
0,NCT02978625,Phase II,Recruiting,"[{'id': 5080, 'therapyName': 'Talimogene laherparepvec + Nivolumab'}]",Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers,4934
0,NCT01061515,Phase I,Recruiting,"[{'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}]",Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer,3608
1,NCT02834013,Phase 0,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab in Treating Patients With Rare Tumors,3608
2,NCT03074513,Phase II,Recruiting,"[{'id': 4595, 'therapyName': 'Atezolizumab + Bevacizumab'}]",Atezolizumab and Bevacizumab in Rare Solid Tumors,3608
3,NCT03108131,Phase II,Recruiting,"[{'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}]",Cobimetinib and Atezolizumab in Advanced Rare Tumors,3608
0,NCT01580410,Phase II,"Active, not recruiting","[{'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}]",Surgery and Oxaliplatin or Mitomycin C in Treating Patients With Tumors of the Appendix,11239
1,NCT02972034,Phase I,Recruiting,"[{'id': 5269, 'therapyName': 'MK-8353 + Pembrolizumab'}]",Study of MK-8353 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Malignancies (MK-8353-013),11239
0,NCT00301418,Phase Ib/II,Completed,"[{'id': 4, 'therapyName': 'Erlotinib'}]",Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma,3069
1,NCT00492687,Phase II,Unknown status,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 1456, 'therapyName': 'Tamoxifen'}]","Radiation Therapy, Temozolomide, Tamoxifen, and Carboplatin in Treating Patients With Malignant Gliomas",3069
2,NCT00906516,Phase II,Unknown status,"[{'id': 2146, 'therapyName': 'Neuradiab + Bevacizumab'}]",Neuradiab Combined With Bevacizumab (Avastin) Therapy in Patients With Recurrent Glioblastoma Multiforme,3069
3,NCT00968240,Phase I,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Super-Selective Intraarterial Intracranial Infusion of Avastin (Bevacizumab),3069
4,NCT01052363,Phase I,Withdrawn,"[{'id': 2109, 'therapyName': 'Bevacizumab + Fosbretabulin'}]",OXC401-PO1s/WVU 1309 - A Pilot Study of Fosbretabulin With Bevacizumab in Recurrent High-Grade Gliomas,3069
5,NCT01130077,Phase I,Recruiting,"[{'id': 2595, 'therapyName': 'poly ICLC  '}]",A Pilot Study of Glioma Associated Antigen Vaccines in Conjunction With Poly-ICLC in Pediatric Gliomas,3069
6,NCT01140568,Phase II,Recruiting,"[{'id': 829, 'therapyName': 'Nilotinib'}]",Study of Platelet Derived Growth Factor Receptor (PDGFR) in Recurrent Malignant Gliomas,3069
7,NCT01188096,Phase II,Recruiting,"[{'id': 2595, 'therapyName': 'poly ICLC  '}]",A Trial of Poly-ICLC in the Management of Recurrent Pediatric Low Grade Gliomas,3069
8,NCT01238237,Phase I,Completed,"[{'id': 694, 'therapyName': 'Cetuximab'}]",Super-Selective Intraarterial Cerebral Infusion of Cetuximab for the Treatment of Recurrent Glioblastoma Multiforme and Anaplastic Astrocytoma,3069
9,NCT01266031,Phase Ib/II,Completed,"[{'id': 2110, 'therapyName': 'Bevacizumab + Vorinostat'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma,3069
10,NCT01269853,Phase Ib/II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA,3069
11,NCT01331135,Phase I,"Active, not recruiting","[{'id': 917, 'therapyName': 'Sirolimus'}]",Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors,3069
12,NCT01339039,Phase I,Terminated,"[{'id': 2120, 'therapyName': 'Bevacizumab + Plerixafor'}]",Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma,3069
13,NCT01386710,Phase Ib/II,Suspended,"[{'id': 2074, 'therapyName': 'Bevacizumab + Carboplatin'}]",Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma,3069
14,NCT01392209,Phase I,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}]",Hypofractionated Stereotactic Radiotherapy With Bevacizumab in the Treatment of Recurrent Malignant Glioma,3069
15,NCT01403610,Phase II,Completed,"[{'id': 2144, 'therapyName': 'Bevacizumab + Evofosfamide'}, {'id': 1317, 'therapyName': 'Evofosfamide'}]",Safety and Efficacy Study of TH-302 CNS Penetration in Recurrent High Grade Astrocytoma Following Bevacizumab,3069
16,NCT01430351,Phase I,"Active, not recruiting","[{'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 1784, 'therapyName': 'Memantine'}, {'id': 1031, 'therapyName': 'Metformin'}, {'id': 1785, 'therapyName': 'Mefloquine'}]","Phase I Factorial Trial of Temozolomide, Memantine, Mefloquine, and Metformin for Post-Radiation Therapy (RT) Glioblastoma Multiforme (GBM)",3069
17,NCT01434602,Phase Ib/II,Recruiting,"[{'id': 2299, 'therapyName': 'Everolimus + Sorafenib'}]",Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas,3069
18,NCT01607905,Phase I,Completed,"[{'id': 1749, 'therapyName': 'Selinexor'}]",Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced or Metastatic Solid Tumor Cancer,3069
19,NCT01721577,Phase Ib/II,Unknown status,"[{'id': 2745, 'therapyName': 'AXL1717'}]",Phase I/II Trial of Safety and Anti-tumor Efficacy of AXL1717(Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas,3069
20,NCT01734512,Phase II,Recruiting,"[{'id': 735, 'therapyName': 'Everolimus'}]",PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children,3069
21,NCT01884740,Phase Ib/II,Recruiting,"[{'id': 1654, 'therapyName': 'Avastin + Cetuximab'}]",Phase I/II Trial Of Super-Selective Intraarterial Infusion Of Erbitux and Bevacizumab For Treatment Of Relapsed/Refractory Intracranial Glioma In Patients Under 22 Years Of Age,3069
22,NCT01891747,Phase Ib/II,"Active, not recruiting","[{'id': 2115, 'therapyName': 'Bevacizumab + Temozolomide'}]", A Phase I/II Study of High-dose L-methylfolate in Combination With Temozolomide and Bevacizumab in Recurrent High Grade Glioma,3069
23,NCT01999270,Phase I,Completed,"[{'id': 2112, 'therapyName': 'Bevacizumab + Irinotecan'}]",Evaluation of FDOPA-PET/MRI in Pediatric Patients With CNS Tumors,3069
24,NCT02101905,Phase I,Recruiting,"[{'id': 787, 'therapyName': 'Lapatinib'}]",Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma,3069
25,NCT02238496,Phase II,"Active, not recruiting","[{'id': 2194, 'therapyName': 'Perifosine + Temsirolimus'}]",Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas,3069
26,NCT02423525,Phase I,Recruiting,"[{'id': 623, 'therapyName': 'Afatinib'}]",Safety Study of Afatinib for Brain Cancer,3069
27,NCT02490930,Phase I,Completed,"[{'id': 3610, 'therapyName': 'Fingolimod'}]",A Safety Study of Fingolimod With Radiation and Temozolomide in Newly Diagnosed High Grade Glioma,3069
28,NCT02529072,Phase I,Terminated,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab With DC Vaccines for Recurrent Brain Tumors,3069
29,NCT02607124,Phase Ib/II,Recruiting,"[{'id': 790, 'therapyName': 'Ribociclib'}]",Administration of Ribociclib Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG),3069
30,NCT02885324,Phase II,Recruiting,"[{'id': 998, 'therapyName': 'cabozantinib'}]",Pilot Study of Cabozantinib for Recurrent or Progressive High-Grade Glioma in Children,3069
31,NCT02924038,Phase I,Recruiting,"[{'id': 4835, 'therapyName': 'IMA950 + poly ICLC '}, {'id': 2525, 'therapyName': 'Varlilumab'}]",A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG),3069
32,NCT02942264,Phase Ib/II,Recruiting,"[{'id': 5836, 'therapyName': 'TG02'}, {'id': 5851, 'therapyName': 'Temozolomide + TG02'}]",TG02 Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of TG02 Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma,3069
33,NCT03032484,Phase II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 5260, 'therapyName': 'Bevacizumab + TVB-2640'}]",TVB- 2640 in Combination With Bevacizumab in Patients With First Relapse of High Grade Astrocytoma,3069
34,NCT03220646,Phase II,Recruiting,"[{'id': 802, 'therapyName': 'Abemaciclib'}]",The Purpose of This Study is to Test Any Good and Bad Effects of a Study Drug Called Abemaciclib (LY2835219) in Patients With Recurrent Brain Tumors.,3069
35,NCT03295396,Phase II,Not yet recruiting,"[{'id': 1687, 'therapyName': 'ONC201'}]",ONC201 in Adults With Recurrent High-grade Glioma,3069
0,NCT00602667,Phase I,"Active, not recruiting","[{'id': 2449, 'therapyName': 'Methotrexate + Cisplatin + Cyclophosphamide + Vincristine'}, {'id': 2450, 'therapyName': 'Cyclophosphamide + Etoposide + Topotecan'}, {'id': 2451, 'therapyName': 'Erlotinib + Cyclophosphamide + Topotecan'}]","Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma",2129
1,NCT00983398,Phase Ib/II,Recruiting,"[{'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2587, 'therapyName': 'Carboplatin + Melphalan'}]","Melphalan, Carboplatin, and Sodium Thiosulfate for Patients With Central Nervous System (CNS) Embryonal or Germ Cell Tumors",2129
2,NCT01331135,Phase I,"Active, not recruiting","[{'id': 917, 'therapyName': 'Sirolimus'}]",Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors,2129
3,NCT02114229,Phase II,Recruiting,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 2449, 'therapyName': 'Methotrexate + Cisplatin + Cyclophosphamide + Vincristine'}, {'id': 626, 'therapyName': 'Alisertib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 942, 'therapyName': 'Topotecan'}]",Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors,2129
4,NCT02458339,Phase I,Recruiting,"[{'id': 1639, 'therapyName': 'Methotrexate'}]",Methotrexate Infusion Into Fourth Ventricle in Children With Recurrent Malignant Fourth Ventricular Brain Tumors,2129
5,NCT02639546,Phase I,Recruiting,"[{'id': 1004, 'therapyName': 'Cobimetinib'}]",iMATRIXcobi: Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Patients With Previously Treated Solid Tumors,2129
6,NCT03173950,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Immune Checkpoint Inhibitor Nivolumab in People With Select Rare CNS Cancers,2129
0,NCT02091245,Phase I,Recruiting,"[{'id': 1749, 'therapyName': 'Selinexor'}]","Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML",9953
0,NCT02228096,Phase II,Recruiting,"[{'id': 5981, 'therapyName': 'Tisagenlecleucel'}]",Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients,80146
1,NCT02435849,Phase II,Recruiting,"[{'id': 5981, 'therapyName': 'Tisagenlecleucel'}]",Determine Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell ALL (ELIANA),80146
2,NCT02981628,Phase II,Recruiting,"[{'id': 3199, 'therapyName': 'inotuzumab ozogamicin'}]",Inotuzumab Ozogamicin in Treating Younger Patients With Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia,80146
3,NCT03123939,Phase II,Available,"[{'id': 5981, 'therapyName': 'Tisagenlecleucel'}]",Expanded Treatment Protocol in Acute Lymphoblastic Leukemia,80146
0,NCT01307267,Phase I,Recruiting,"[{'id': 6111, 'therapyName': 'Utomilumab + Rituximab'}, {'id': 5086, 'therapyName': 'Utomilumab'}]",A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab,707
1,NCT01695941,Phase I,Recruiting,"[{'id': 3581, 'therapyName': 'Alisertib + Bortezomib + Rituximab'}]","Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma",707
2,NCT01799889,Phase II,"Active, not recruiting","[{'id': 2522, 'therapyName': 'Entospletinib  '}]",A Phase 2 of Entospletinib in Subjects With Relapsed or Refractory Hematologic Malignancies,707
3,NCT01976585,Phase Ib/II,Recruiting,"[{'id': 4337, 'therapyName': 'CDX-301 + poly ICLC '}]",In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy,707
4,NCT02006485,Phase I,Recruiting,"[{'id': 2319, 'therapyName': 'TGR-1202 + Ublituximab'}, {'id': 768, 'therapyName': 'Ibrutinib'}]",Ublituximab in Combination With TGR-1202 in Patients With B-cell Malignancies,707
5,NCT02018861,Phase I,"Active, not recruiting","[{'id': 2406, 'therapyName': 'INCB039110'}, {'id': 3097, 'therapyName': 'INCB039110 + INCB050465'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 2352, 'therapyName': 'Carboplatin + Etoposide + Ifosfamide '}, {'id': 3088, 'therapyName': 'INCB050465 '}]","A Phase 1, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 Monotherapy and in Combination With INCB039110 in Subjects With Previously Treated B-Cell Malignancies",707
6,NCT02153580,Phase I,"Active, not recruiting","[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 1231, 'therapyName': 'Bendamustine'}]","Cellular Immunotherapy Following Cyclophosphamide in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia or B-Cell Prolymphocytic Leukemia",707
7,NCT02207062,Phase I,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma,707
8,NCT02253992,Phase Ib/II,Recruiting,"[{'id': 2567, 'therapyName': 'Nivolumab + Urelumab'}]",Study of the Safety and Tolerability of Urelumab Administered in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkins Lymphoma,707
9,NCT02254772,Phase Ib/II,Completed,"[{'id': 3848, 'therapyName': 'Ipilimumab + SD-101'}]","TLR9 Agonist SD-101, Ipilimumab, and Radiation Therapy in Treating Patients With Low-Grade Recurrent B-cell Lymphoma",707
10,NCT02266147,Phase Ib/II,Completed,"[{'id': 3084, 'therapyName': 'SD-101'}]",Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma,707
11,NCT02272686,Phase II,"Active, not recruiting","[{'id': 768, 'therapyName': 'Ibrutinib'}]",Ibrutinib Post Stem Cell Transplantation (SCT) in Double-Hit B-Cell Lymphoma,707
12,NCT02290951,Phase I,Recruiting,"[{'id': 6151, 'therapyName': 'REGN1979'}]",A Phase 1 Study to Investigate the Safety and Tolerability of REGN1979 in Patients With CD20+ B-Cell Malignancies,707
13,NCT02328014,Phase Ib/II,Recruiting,"[{'id': 3265, 'therapyName': 'ACP-319'}, {'id': 1605, 'therapyName': 'Acalabrutinib'}]","ACP-196 in Combination With ACP-319, for Treatment of B-Cell Malignancies",707
14,NCT02343120,Phase I,Recruiting,"[{'id': 2544, 'therapyName': 'BGB-3111'}]",Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies,707
15,NCT02395601,Phase I,Recruiting,"[{'id': 2733, 'therapyName': 'CPI-1205'}]",A Study Evaluating CPI-1205 in Patients With B-Cell Lymphomas,707
16,NCT02436707,Phase II,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 3391, 'therapyName': 'Cisplatin + Dexamethasone + Gemcitabine + Rituximab'}]",Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma,707
17,NCT02443077,Phase III,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 3359, 'therapyName': 'Carmustine + Cytarabine + Etoposide + Melphalan'}, {'id': 768, 'therapyName': 'Ibrutinib'}]",Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma,707
18,NCT02500407,Phase I,Recruiting,"[{'id': 6305, 'therapyName': 'Atezolizumab + BTCT4465A'}]",A Safety and Pharmacokinetic Study of BTCT4465A as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL),707
19,NCT02569476,Phase I,Recruiting,"[{'id': 4682, 'therapyName': 'BGB-3111 + Obinutuzumab'}]",BGB 3111 in Combination With Obinutuzumab in Subjects With B-Cell Lymphoid Malignancies,707
20,NCT02600897,Phase Ib/II,Recruiting,"[{'id': 4394, 'therapyName': 'lenalidomide + Obinutuzumab + Polatuzumab Vedotin'}]","A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)",707
21,NCT02611323,Phase Ib/II,Recruiting,"[{'id': 4227, 'therapyName': 'Obinutuzumab + Polatuzumab Vedotin + Venetoclax'}]","A Study of Obinutuzumab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)",707
22,NCT02624986,Phase Ib/II,Recruiting,"[{'id': 4393, 'therapyName': 'Idasanutlin + Obinutuzumab'}]",A Study of Obinutuzumab With Idasanutlin in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL),707
23,NCT02631044,Phase I,Recruiting,"[{'id': 5980, 'therapyName': 'JCAR017'}]",Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (NHL),707
24,NCT02706405,Phase I,Recruiting,"[{'id': 4365, 'therapyName': 'Cyclophosphamide + JCAR014 + MEDI4736'}]",JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma,707
25,NCT02733042,Phase Ib/II,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 4278, 'therapyName': 'lenalidomide + MEDI4736 + Rituximab'}, {'id': 4279, 'therapyName': 'Bendamustine + MEDI4736 + Rituximab'}, {'id': 2573, 'therapyName': 'Ibrutinib + MEDI4736'}, {'id': 1356, 'therapyName': 'Durvalumab'}]","A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia (FUSION NHL 001)",707
26,NCT02846935,Phase 0,Recruiting,"[{'id': 3567, 'therapyName': 'Decitabine + Tetrahydrouridine'}]",p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies,707
27,NCT02875002,Phase I,Not yet recruiting,"[{'id': 4826, 'therapyName': 'Belinostat + Volasertib'}]",Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas,707
28,NCT02950220,Phase I,Recruiting,"[{'id': 4917, 'therapyName': 'Pembrolizumab + Ibrutinib'}]",Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma,707
29,NCT02973113,Phase I,Recruiting,"[{'id': 5058, 'therapyName': 'EB-VST cells + Nivolumab'}]","Nivolumab With Epstein Barr Virus Specific T Cells (EB-VSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE) (PREVALE)",707
30,NCT02992522,Phase I,Recruiting,"[{'id': 5133, 'therapyName': 'Lenalidomide + Obinutuzumab + Venetoclax'}]","Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma",707
31,NCT02997761,Phase II,Recruiting,"[{'id': 5125, 'therapyName': 'Blinatumomab + Ibrutinib'}]",Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia,707
32,NCT03028103,Phase I,Recruiting,"[{'id': 5267, 'therapyName': 'Tazemetostat + Fluconazole'}, {'id': 5285, 'therapyName': 'Repaglinide + Omeprazole + Tazemetostat'}]","Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, the Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and the Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma Subjects",707
33,NCT03036904,Phase I,Recruiting,"[{'id': 5294, 'therapyName': 'Venetoclax + DA-EPOCH-R'}]",Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas (V+DA-EPOCH-R),707
34,NCT03038672,Phase II,Not yet recruiting,"[{'id': 2526, 'therapyName': 'Nivolumab + Varlilumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas,707
35,NCT03133221,Phase II,Not yet recruiting,"[{'id': 1023, 'therapyName': 'Idelalisib'}]",1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation,707
36,NCT03153462,Expanded access,Available,"[{'id': 5098, 'therapyName': 'KTE-C19 + Fludarabine phosphate + Cyclophosphamide'}]",Axicabtagene Ciloleucel Expanded Access Study,707
37,NCT03217253,Phase I,Not yet recruiting,"[{'id': 2683, 'therapyName': 'Tazemetostat'}]",Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver Dysfunction,707
38,NCT03223610,Phase I,Not yet recruiting,"[{'id': 6189, 'therapyName': 'Ibrutinib + Lenalidomide + Obinutuzumab + Prednisone + Venetoclax'}]","Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma",707
39,NCT03274492,Phase III,Not yet recruiting,"[{'id': 4226, 'therapyName': 'Polatuzumab Vedotin'}, {'id': 6177, 'therapyName': 'R-CHP'}, {'id': 2195, 'therapyName': 'R-CHOP'}]","A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma",707
0,NCT02780310,Phase II,"Active, not recruiting","[{'id': 792, 'therapyName': 'Lenvatinib'}]",Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma,4879
1,NCT03087019,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma,4879
2,NCT03172624,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer,4879
0,NCT01367665,Phase II,Completed,"[{'id': 956, 'therapyName': 'Vismodegib'}]",STEVIE: A Study of Vismodegib in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma,2513
1,NCT01700049,Phase II,"Active, not recruiting","[{'id': 956, 'therapyName': 'Vismodegib'}]",Study Evaluating the Efficacy of Oral Vismodegib in Various Histologic Subtypes,2513
2,NCT01815840,Phase II,Completed,"[{'id': 956, 'therapyName': 'Vismodegib'}]",A Study of Two Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas,2513
3,NCT01898598,Phase II,Terminated,"[{'id': 956, 'therapyName': 'Vismodegib'}]",A Study of Vismodegib With Surgery in Patients With Previously Untreated Basal Cell Carcinoma,2513
4,NCT02067104,Phase II,Completed,"[{'id': 956, 'therapyName': 'Vismodegib'}]",Vismodegib in Basal Cell Carcinomas (BCC) Chemoprevention,2513
5,NCT02120677,Phase I,Recruiting,"[{'id': 1026, 'therapyName': 'Itraconazole'}]",Topical Itraconazole in the Treatment of Basal Cell Carcinoma,2513
6,NCT02303041,Phase I,"Active, not recruiting","[{'id': 1547, 'therapyName': 'BKM120 + Sonidegib'}]",Erismodegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma,2513
7,NCT02436408,FDA approved,Recruiting,"[{'id': 956, 'therapyName': 'Vismodegib'}]",VISmodegib for ORbital and Periocular Basal Cell Carcinoma,2513
8,NCT02639117,Phase I,Recruiting,"[{'id': 956, 'therapyName': 'Vismodegib'}]",Photodynamic Therapy and Vismodegib for Multiple Basal Cell Carcinomas,2513
9,NCT02690948,Phase II,Recruiting,"[{'id': 3727, 'therapyName': 'Pembrolizumab + Vismodegib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab With or Without Vismodegib in Treating Metastatic or Unresectable Basal Cell Skin Cancer,2513
10,NCT02699723,Phase I,Not yet recruiting,"[{'id': 3791, 'therapyName': 'Arsenic trioxide + Itraconazole'}]",Arsenic Trioxide and Itraconazole in Treating Patients With Advanced Basal Cell Cancer,2513
11,NCT02735356,Phase I,"Active, not recruiting","[{'id': 1026, 'therapyName': 'Itraconazole'}]",Topical Itraconazole in Treating Patients With Basal Cell Cancer,2513
12,NCT02978625,Phase II,Recruiting,"[{'id': 5080, 'therapyName': 'Talimogene laherparepvec + Nivolumab'}]",Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers,2513
13,NCT03132636,Phase II,Recruiting,"[{'id': 5656, 'therapyName': 'REGN2810'}]","PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy",2513
0,NCT02978625,Phase II,Recruiting,"[{'id': 5080, 'therapyName': 'Talimogene laherparepvec + Nivolumab'}]",Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers,5063
0,NCT01825603,Phase I,Recruiting,"[{'id': 4952, 'therapyName': 'ADH-1 + Cisplatin + Gemcitabine'}]","ADH-1, Gemcitabine Hydrochloride and Cisplatin in Treating Patients With Metastatic Pancreatic or Biliary Tract Cancer That Cannot Be Removed By Surgery",4896
0,NCT02042443,Phase II,Completed,"[{'id': 2278, 'therapyName': 'Fluorouracil + Leucovorin'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 2, 'therapyName': 'Trametinib'}]",Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery,4897
1,NCT02115542,Phase II,Recruiting,"[{'id': 890, 'therapyName': 'Regorafenib'}]",Single Agent Regorafenib in Refractory Advanced Biliary Cancers,4897
2,NCT02479178,Phase II,Terminated,"[{'id': 3640, 'therapyName': 'BIND-014'}]","A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck  (iNSITE2)",4897
3,NCT02628067,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158),4897
4,NCT02631590,Phase II,Recruiting,"[{'id': 3315, 'therapyName': 'BAY80-6946 + Cisplatin + Gemcitabine'}]",Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma,4897
0,NCT01828034,Phase Ib/II,"Active, not recruiting","[{'id': 2218, 'therapyName': 'MEK162 + Gemcitabine + Cisplatin'}]","First Line Gemcitabine, Cisplatin and MEK162 in Advanced Biliary Tract Carcinoma",4607
1,NCT01853618,Phase I,"Active, not recruiting","[{'id': 1652, 'therapyName': 'Tremelimumab'}]",Tremelimumab With Chemoembolization or Ablation for Liver Cancer,4607
2,NCT02034110,Phase II,Recruiting,"[{'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}]",Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers,4607
3,NCT02053376,Phase II,"Active, not recruiting","[{'id': 890, 'therapyName': 'Regorafenib'}]",A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy,4607
4,NCT02105350,Phase I,Suspended,"[{'id': 2210, 'therapyName': 'Gemcitabine + MEK162 + Oxaliplatin'}]",A Study of MEK162 With Gemcitabine and Oxaliplatin in Biliary Cancer,4607
5,NCT02151084,Phase II,Recruiting,"[{'id': 2222, 'therapyName': 'Selumetinib + Cisplatin + Gemcitabine'}]",A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer,4607
6,NCT02240238,Phase Ib/II,Recruiting,"[{'id': 5626, 'therapyName': 'Gemcitabine + NC-6004'}]","Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer",4607
7,NCT02265341,Phase II,"Active, not recruiting","[{'id': 877, 'therapyName': 'Ponatinib'}]",Ponatinib Hydrochloride in Treating Patients With Advanced Biliary Cancer With FGFR2 Fusions,4607
8,NCT02268825,Phase Ib/II,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Phase I/IIA Study MK-3475 With Chemotherapy in Patients With Advanced GI Cancers,4607
9,NCT02451553,Phase I,Recruiting,"[{'id': 623, 'therapyName': 'Afatinib'}, {'id': 1105, 'therapyName': 'Capecitabine'}]","Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer",4607
10,NCT02452970,Phase II,"Active, not recruiting","[{'id': 3680, 'therapyName': 'RRx-001'}, {'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}]",RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration of First-Line Therapy (EPIC),4607
11,NCT02454972,Phase II,Recruiting,"[{'id': 1195, 'therapyName': 'Lurbinectedin'}]",Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors,4607
12,NCT02576431,Phase II,Recruiting,"[{'id': 2650, 'therapyName': 'LOXO-101'}]",Study of LOXO-101 in Subjects With NTRK Fusion Positive Solid Tumors,4607
13,NCT02703714,Phase II,Recruiting,"[{'id': 4217, 'therapyName': 'Pembrolizumab + Sargramostim'}]",Pembrolizumab and GM-CSF in Biliary Cancer,4607
14,NCT02711553,Phase II,"Active, not recruiting","[{'id': 886, 'therapyName': 'Ramucirumab'}, {'id': 1030, 'therapyName': 'LY2801653'}, {'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}]",A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer,4607
15,NCT02795156,Phase II,Recruiting,"[{'id': 623, 'therapyName': 'Afatinib'}, {'id': 890, 'therapyName': 'Regorafenib'}]",Study to Assess the Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations,4607
16,NCT02821754,Phase Ib/II,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC),4607
17,NCT02897375,Phase I,Recruiting,"[{'id': 4734, 'therapyName': 'Cisplatin + Palbociclib'}, {'id': 4735, 'therapyName': 'Carboplatin + Palbociclib'}]",Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,4607
18,NCT03093870,Phase II,Not yet recruiting,"[{'id': 5543, 'therapyName': 'Capecitabine + Varlitinib'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer,4607
19,NCT03101566,Phase II,Recruiting,"[{'id': 5511, 'therapyName': 'Cisplatin + Gemcitabine + Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract Cancer,4607
20,NCT03111732,Phase II,Recruiting,"[{'id': 5549, 'therapyName': 'Capecitabine + Oxaliplatin + Pembrolizumab'}]","Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)",4607
0,NCT02829918,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers,50625
0,NCT02834013,Phase 0,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab in Treating Patients With Rare Tumors,3711
0,NCT00942331,Phase III,"Active, not recruiting","[{'id': 1295, 'therapyName': 'Gemcitabine + Bevacizumab + Cisplatin'}, {'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}]",Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer,4007
1,NCT01259063,Phase Ib/II,Completed,"[{'id': 2279, 'therapyName': 'Everolimus + Gemcitabine'}]",RAD001 and Intravesical Gemcitabine in BCG-Refractory Primary or Secondary Carcinoma In Situ of the Bladder,4007
2,NCT01366144,Phase I,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 954, 'therapyName': 'Veliparib'}, {'id': 1092, 'therapyName': 'Carboplatin'}]","Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction",4007
3,NCT01391143,Phase I,Recruiting,"[{'id': 2863, 'therapyName': 'MGA271'}]",Safety Study of MGA271 in Refractory Cancer,4007
4,NCT01438112,,Terminated,"[{'id': 2524, 'therapyName': 'Gemcitabine + interferon + Mitomycin C + Valrubicin '}, {'id': 2523, 'therapyName': 'CG0070'}]",Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer,4007
5,NCT01688999,Phase II,"Active, not recruiting","[{'id': 998, 'therapyName': 'cabozantinib'}]",Cabozantinib for Advanced Urothelial Cancer,4007
6,NCT01938573,Phase Ib/II,Completed,"[{'id': 2289, 'therapyName': 'Cisplatin + Gemcitabine + Sirolimus '}]","Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer",4007
7,NCT02169284,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}]",Erlotinib Hydrochloride in Treating Patients With Bladder Cancer Undergoing Surgery,4007
8,NCT02444793,Phase I,Recruiting,"[{'id': 6332, 'therapyName': 'Mogamulizumab + Utomilumab'}]",A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors,4007
9,NCT02636036,Phase I,Recruiting,"[{'id': 3620, 'therapyName': 'Enadenotucirev + Pembrolizumab'}]",Study of Enadenotucirev and Pembrolizumab in Subjects With Metastatic or Advanced Epithelial Tumors,4007
10,NCT02723955,Phase I,Recruiting,"[{'id': 4409, 'therapyName': 'GSK3359609'}, {'id': 4410, 'therapyName': 'GSK3359609 + Pembrolizumab'}]",Dose Escalation and Expansion Study of GSK3359609 in Subjects With Selected Advanced Solid Tumors (INDUCE-1),4007
11,NCT03171025,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Adjuvant Nivolumab Following Chemo-Radiation in Localized Muscle-Invasive Bladder Cancer (NEXT),4007
0,NCT03091660,Phase III,Recruiting,"[{'id': 5478, 'therapyName': 'BCG Tokyo-172 Strain Solution'}, {'id': 4455, 'therapyName': 'BCG solution'}]",Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer,9053
1,NCT03106610,Phase I,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Trial of Anti-PD-1 (Nivolumab) in Bladder Cancer Patients Recently Treated With Intravesical BCG Immunotherapy,9053
0,NCT00942331,Phase III,"Active, not recruiting","[{'id': 1295, 'therapyName': 'Gemcitabine + Bevacizumab + Cisplatin'}, {'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}]",Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer,4006
1,NCT01108055,Phase II,Completed,"[{'id': 1143, 'therapyName': 'Pazopanib + Paclitaxel'}]",Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer,4006
2,NCT01174121,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 1167, 'therapyName': 'Aldesleukin'}]",Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer,4006
3,NCT01215136,Phase II,"Active, not recruiting","[{'id': 735, 'therapyName': 'Everolimus'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma,4006
4,NCT01326871,Phase Ib/II,"Active, not recruiting","[{'id': 2187, 'therapyName': 'ALT-801'}]",A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer,4006
5,NCT01625260,Phase Ib/II,"Active, not recruiting","[{'id': 2187, 'therapyName': 'ALT-801'}, {'id': 2191, 'therapyName': 'ALT-801 + Gemcitabine'}]",A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer,4006
6,NCT01780545,Phase II,Completed,"[{'id': 1807, 'therapyName': 'OGX-427'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer,4006
7,NCT01916109,Phase II,Terminated,"[{'id': 1943, 'therapyName': 'Gemcitabine + Carboplatin + Panitumumab'}]","Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer",4006
8,NCT02009332,Phase Ib/II,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}]",Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer,4006
9,NCT02014337,Phase I,"Active, not recruiting","[{'id': 3053, 'therapyName': 'Eribulin + Mifepristone'}]",Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors,4006
10,NCT02108652,Phase II,"Active, not recruiting","[{'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study of MPDL3280A in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer,4006
11,NCT02122172,Phase II,Recruiting,"[{'id': 623, 'therapyName': 'Afatinib'}]",Afatinib in Advanced Refractory Urothelial Cancer,4006
12,NCT02178722,Phase Ib/II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2575, 'therapyName': 'Epacadostat'}]","A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Solid Tumors and Advanced NSCLC (INCB 24360-202 / MK-3475-037 / KEYNOTE-037)",4006
13,NCT02197897,Phase II,Recruiting,"[{'id': 1456, 'therapyName': 'Tamoxifen'}]",Evaluation the Treatment of Tamoxifen of Low/Intermediate Risk Bladder Tumors,4006
14,NCT02236195,Phase II,Completed,"[{'id': 3002, 'therapyName': 'Mocetinostat'}]",Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes,4006
15,NCT02240238,Phase Ib/II,Recruiting,"[{'id': 5626, 'therapyName': 'Gemcitabine + NC-6004'}]","Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer",4006
16,NCT02256436,Phase III,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045)",4006
17,NCT02300610,Phase I,"Active, not recruiting","[{'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]",Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer,4006
18,NCT02302807,Phase III,"Active, not recruiting","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 720, 'therapyName': 'Docetaxel'}]",A Study of MPDL3280A Compared With Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer,4006
19,NCT02315066,Phase I,Recruiting,"[{'id': 4333, 'therapyName': 'PF-04518600'}, {'id': 4448, 'therapyName': 'PF-04518600 + Utomilumab'}]",Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566,4006
20,NCT02324582,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",MK-3475/BCG in High Risk Superficial Bladder Cancer,4006
21,NCT02334527,Phase II,Recruiting,"[{'id': 850, 'therapyName': 'Palbociclib'}]",Phase II Trial of Palbociclib (PD-0332991) in Patients With Metastatic Urothelial Cancer (UC) After Failure of First-Line Chemotherapy,4006
22,NCT02335424,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-52),4006
23,NCT02351739,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1605, 'therapyName': 'Acalabrutinib'}]",Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum-refractory Metastatic Bladder Cancer,4006
24,NCT02365766,Phase Ib/II,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",Study of Neoadjuvant Pembrolizumab in Combination With Gemcitabine Based Therapy in Cis-eligible or -Ineligible Subjects With Urothelial Cancer,4006
25,NCT02365818,Phase II,"Active, not recruiting","[{'id': 2523, 'therapyName': 'CG0070'}]",Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade Non-Muscle Invasive Bladder Cancer After BCG Failure,4006
26,NCT02387996,Phase II,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}]",A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder Cancer,4006
27,NCT02401542,Phase II,Recruiting,"[{'id': 2934, 'therapyName': 'B-701'}, {'id': 720, 'therapyName': 'Docetaxel'}]",A Phase 2 Study of B-701 in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma,4006
28,NCT02426125,Phase III,"Active, not recruiting","[{'id': 886, 'therapyName': 'Ramucirumab'}, {'id': 720, 'therapyName': 'Docetaxel'}]",A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer,4006
29,NCT02437370,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer,4006
30,NCT02443324,Phase I,"Active, not recruiting","[{'id': 2896, 'therapyName': 'Pembrolizumab + Ramucirumab'}]","A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC or Transitional Cell Carcinoma of the Urothelium",4006
31,NCT02449239,Phase III,Recruiting,"[{'id': 6290, 'therapyName': 'Oportuzumab monatox'}]",Vicinium Treatment for Subjects With Non-muscle Invasive Bladder Cancer Previously Treated With BCG,4006
32,NCT02450331,Phase III,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}]","IMvigor 010 Study: Anti-Programmed Death-Ligand 1 (PD-L1) Antibody MPDL3280A Treatment Versus Observation as Adjuvant Therapy in Patients With PD-L1 Positive, High Risk Muscle Invasive Bladder Cancer After Cystectomy",4006
33,NCT02451423,Phase II,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}]",Study of MPDL3280A in Bladder Cancer,4006
34,NCT02459119,Phase II,Recruiting,"[{'id': 890, 'therapyName': 'Regorafenib'}]",Study of Regorafenib for Urothelial Cancer Following Chemotherapy (UAB 1477),4006
35,NCT02471846,Phase I,"Active, not recruiting","[{'id': 2888, 'therapyName': 'GDC-0919'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study of GDC-0919 and MPDL3280A Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors,4006
36,NCT02479178,Phase II,Terminated,"[{'id': 3640, 'therapyName': 'BIND-014'}]","A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck  (iNSITE2)",4006
37,NCT02496208,Phase I,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 2067, 'therapyName': 'Cabozantinib + Nivolumab'}]",Cabozantinib Plus Nivolumab (CaboNivo) Alone or in Combination With Ipilimumab (CaboNivoIpi) in Patients With Advanced/Metastatic Urothelial Carcinoma and Other Genitourinary Tumors,4006
38,NCT02500121,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Testing the PD-1 Inhibitor Pembrolizumab After Initial Chemotherapy in Patients With Metastatic Bladder Cancer,4006
39,NCT02516241,Phase III,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 4686, 'therapyName': 'Carboplatin + Cisplatin + Gemcitabine'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",Study of MEDI4736 With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer,4006
40,NCT02540291,Phase I,Recruiting,"[{'id': 5694, 'therapyName': 'E7046'}]",Study of E7046 in Subjects With Selected Advanced Malignancies,4006
41,NCT02553642,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260),4006
42,NCT02559492,Phase I,"Active, not recruiting","[{'id': 3096, 'therapyName': 'INCB039110 + INCB024360'}, {'id': 3097, 'therapyName': 'INCB039110 + INCB050465'}]",INCB039110 Combined With INCB024360 and/or INCB039110 Combined With INCB050465 in Advanced Solid Tumors,4006
43,NCT02567409,Phase II,Recruiting,"[{'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 3110, 'therapyName': 'Cisplatin + Gemcitabine + VX-970'}]",Cisplatin and Gemcitabine Hydrochloride With or Without ATR Kinase Inhibitor VX-970 in Treating Patients With Metastatic Urothelial Cancer,4006
44,NCT02581982,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer,4006
45,NCT02589717,FDA approved,Approved for marketing,"[{'id': 1201, 'therapyName': 'Atezolizumab'}]",An Expanded Access Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Urothelial Bladder Cancer After Failure With Platinum-Containing Chemotherapy,4006
46,NCT02612194,Phase II,Recruiting,"[{'id': 706, 'therapyName': 'Crizotinib'}]",LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer,4006
47,NCT02619253,Phase Ib/II,Recruiting,"[{'id': 3077, 'therapyName': 'Pembrolizumab + Vorinostat'}]",Phase I/Ib Study of Pembrolizumab With Vorinostat for Patients With Advanced Renal or Urothelial Cell Carcinoma,4006
48,NCT02621151,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 755, 'therapyName': 'Gemcitabine'}]","Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder",4006
49,NCT02625961,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057),4006
50,NCT02632409,Phase III,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",A Study of Adjuvant Nivolumab Versus Placebo Post-Surgical Removal of High Risk Invasive Urothelial Carcinoma,4006
51,NCT02646748,Phase I,Recruiting,"[{'id': 3088, 'therapyName': 'INCB050465 '}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2406, 'therapyName': 'INCB039110'}]",Pembrolizumab Combined With INCB039110 and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors,4006
52,NCT02657486,Phase I,Recruiting,"[{'id': 674, 'therapyName': 'BGJ398'}]",BGJ398 in Non-Muscle-Invasive Urothelial Carcinoma of the Bladder,4006
53,NCT02690558,Phase II,Recruiting,"[{'id': 3248, 'therapyName': 'Cisplatin + Gemcitabine + Pembrolizumab'}]",Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy,4006
54,NCT02710396,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Genetic Predictors of Benefit to Pembrolizumab,4006
55,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,4006
56,NCT02792192,Phase Ib/II,Recruiting,"[{'id': 4456, 'therapyName': 'Atezolizumab + BCG solution'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-risk Non-muscle-invasive Bladder Cancer (NMIBC) Participants,4006
57,NCT02807636,Phase III,Recruiting,"[{'id': 4450, 'therapyName': 'Atezolizumab + Carboplatin + Gemcitabine'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}]",The Effect of Atezolizumab in Combination With Gemcitabine/Carboplatin and Gemcitabine/Carboplatin Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-based Therapy,4006
58,NCT02812420,Phase I,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]","Pre-Surgical Study Evaluating Anti-PD-L1 Antibody (Durvalumab) Plus Anti-CTLA-4 (Tremelimumab) in Patients With Muscle-Invasive, High-Risk Urothelial Carcinoma Who Are Ineligible for Cisplatin-based Neoadjuvant Chemotherapy",4006
59,NCT02844816,Phase II,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}]",Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer,4006
60,NCT02845323,Phase II,Recruiting,"[{'id': 2055, 'therapyName': 'Urelumab'}, {'id': 2567, 'therapyName': 'Nivolumab + Urelumab'}]",Neoadjuvant Nivolumab With and Without Urelumab in Patients With Cisplatin-Ineligible Muscle-Invasive Urothelial Carcinoma of the Bladder,4006
61,NCT02853305,Phase III,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 4686, 'therapyName': 'Carboplatin + Cisplatin + Gemcitabine'}]",Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma (MK-3475-361/KEYNOTE-361),4006
62,NCT02872714,Phase II,Recruiting,"[{'id': 4173, 'therapyName': 'INCB054828'}]",A Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Urothelial Carcinoma,4006
63,NCT02891161,Phase Ib/II,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}]",Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 M0) of the Bladder,4006
64,NCT02897765,Phase I,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 4733, 'therapyName': 'NEO-PV-01 + poly ICLC'}]","A Personalized Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer",4006
65,NCT02901548,Phase II,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}]",Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder,4006
66,NCT02925533,Phase I,Terminated,"[{'id': 4831, 'therapyName': 'B-701 + Pembrolizumab'}]",Ph 1B B-701 in Combination With Pembrolizumab in Metastatic Transitional Cell Carcinoma of the Urothelial Tract,4006
67,NCT02989584,Phase Ib/II,Recruiting,"[{'id': 5140, 'therapyName': 'Atezolizumab + Cisplatin + Gemcitabine'}]",A Pilot Safety Study of Atezolizumab Combination With Cisplatin + Gemcitabine in Pts With Metastatic Bladder Cancer,4006
68,NCT03022825,Phase II,Recruiting,"[{'id': 5238, 'therapyName': 'ALT-803 + BCG solution'}]",QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer,4006
69,NCT03093922,Phase II,Recruiting,"[{'id': 5140, 'therapyName': 'Atezolizumab + Cisplatin + Gemcitabine'}]",A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer,4006
70,NCT03106610,Phase I,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Trial of Anti-PD-1 (Nivolumab) in Bladder Cancer Patients Recently Treated With Intravesical BCG Immunotherapy,4006
71,NCT03133390,Phase II,Recruiting,"[{'id': 4595, 'therapyName': 'Atezolizumab + Bevacizumab'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",Atezolizumab With or Without Bevacizumab in Cisplatin-ineligible Patients,4006
72,NCT03150836,Phase II,Withdrawn,"[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]","Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder Cancer",4006
73,NCT03170960,Phase Ib/II,Recruiting,"[{'id': 6094, 'therapyName': 'Atezolizumab + Cabozantinib'}]",Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors,4006
74,NCT03237780,Phase II,Not yet recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 6098, 'therapyName': 'Atezolizumab + Eribulin'}]",Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer,4006
75,NCT03258593,Phase I,Not yet recruiting,"[{'id': 6291, 'therapyName': 'Durvalumab + Oportuzumab monatox'}]",Durvalumab and Vicinium in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG),4006
0,NCT02574728,Phase II,Recruiting,"[{'id': 3143, 'therapyName': 'Celecoxib + Cyclophosphamide + Etoposide + Sirolimus'}]",Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors,184
0,NCT01353625,Phase I,"Active, not recruiting","[{'id': 1000, 'therapyName': 'CC-115'}]","Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.",3368
1,NCT01492673,Phase II,"Active, not recruiting","[{'id': 1479, 'therapyName': 'Cyclophosphamide + Topotecan + Bevacizumab'}]","Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma",3368
2,NCT01518413,Phase I,Completed,"[{'id': 1323, 'therapyName': 'Sorafenib + Irinotecan'}]",Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors,3368
3,NCT01610570,Phase Ib/II,Terminated,"[{'id': 1397, 'therapyName': 'Mithramycin'}]",Mithramycin for Children and Adults With Solid Tumors or Ewing Sarcoma,3368
4,NCT01625351,Phase I,"Active, not recruiting","[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1205, 'therapyName': 'Alemtuzumab'}]",A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas,3368
5,NCT01661400,Phase I,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1475, 'therapyName': 'Thalidomide'}]",Anti-Angiogenic Therapy Post Transplant (ASCR) for Relapsed and Refractory Pediatric Solid Tumors,3368
6,NCT02511132,Phase II,"Active, not recruiting","[{'id': 1157, 'therapyName': 'FANG vaccine'}, {'id': 1439, 'therapyName': 'Gemcitabine + Docetaxel'}]",Randomized Phase IIb Trial of Vigil Versus Gemcitabine + Docetaxel for Ewing's Sarcoma,3368
0,NCT00680992,Phase II,"Active, not recruiting","[{'id': 1198, 'therapyName': 'Denosumab'}]",Study of Denosumab in Subjects With Giant Cell Tumor of Bone,4305
0,NCT00084695,Phase II,Unknown status,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases,4960
1,NCT00513474,Phase I,Completed,"[{'id': 2313, 'therapyName': 'Rasburicase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2314, 'therapyName': 'Busulfan + Cyclophosphamide + Etoposide'}]",Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant,4960
2,NCT00602693,Phase I,Completed,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 2311, 'therapyName': 'Allopurinol + Cyclophosphamide + Fludarabine'}]",T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer,4960
3,NCT00620633,Phase I,"Active, not recruiting","[{'id': 2901, 'therapyName': 'WT1 senstized T cells'}]",Dose Escalation Trial of WT1-Sensitized T Cells for Residual or Relapsed Leukemia After Allogeneic Hematopoietic Progenitor Cell Transplantation,4960
4,NCT00679536,Phase Ib/II,Unknown status,"[{'id': 1846, 'therapyName': 'Busulfan + Fludarabine + anti-thymocyte globulin'}]",Allogeneic Transplantation for Pediatric Leukemias With Unrelated Donors,4960
5,NCT00857389,Phase II,"Active, not recruiting","[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 2469, 'therapyName': 'Busulfan + Clofarabine + Thymoglobulin'}, {'id': 1639, 'therapyName': 'Methotrexate'}]",Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies,4960
6,NCT00892190,Phase I,Completed,"[{'id': 717, 'therapyName': 'Dasatinib'}]",Study of Dasatinib and All-Trans Retinoic Acid for Relapsed/Refractory and/or Elderly Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome,4960
7,NCT00908167,Phase I,Completed,"[{'id': 2374, 'therapyName': 'Clofarabine + Cytarabine + Sorafenib'}]",Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies,4960
8,NCT01251575,Phase II,Recruiting,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 2270, 'therapyName': 'Cyclosporine + Mycophenolate mofetil + Sirolimus'}]","Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant",4960
9,NCT01338987,Phase II,"Active, not recruiting","[{'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",Pilot Study of Lupron to Improve Immune Function After Allogeneic Bone Marrow Transplantation,4960
10,NCT01584531,Phase II,Completed,"[{'id': 1046, 'therapyName': 'rigosertib'}]","Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome",4960
11,NCT01593670,Phase II,Terminated,"[{'id': 650, 'therapyName': 'Decitabine'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 1077, 'therapyName': 'Vorinostat'}]",Decitabine and Vorinostat Conditioning Followed by CD3-/CD19- NK Cells Infusion for High Risk Myelodysplastic Syndromes,4960
12,NCT01606579,Phase Ib/II,Completed,"[{'id': 2466, 'therapyName': 'Cytarabine + Pri-724'}, {'id': 2465, 'therapyName': 'Dasatinib + Pri-724'}, {'id': 1083, 'therapyName': 'Pri-724'}]",Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies,4960
13,NCT01621477,Phase II,Terminated,"[{'id': 1756, 'therapyName': 'Plerixafor'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 2469, 'therapyName': 'Busulfan + Clofarabine + Thymoglobulin'}, {'id': 1783, 'therapyName': 'Cyclophosphamide + Cytarabine'}]",T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant,4960
14,NCT01634217,Phase I,"Active, not recruiting",[],Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation,4960
15,NCT01640301,Phase Ib/II,Suspended,"[{'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 2901, 'therapyName': 'WT1 senstized T cells'}]","Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant",4960
16,NCT01687400,Phase II,"Active, not recruiting","[{'id': 650, 'therapyName': 'Decitabine'}]",Genomic Predictors of Decitabine Response in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes,4960
17,NCT01720225,Phase II,"Active, not recruiting","[{'id': 650, 'therapyName': 'Decitabine'}, {'id': 651, 'therapyName': 'Azacitidine'}]",Decitabine Versus Azacitidine in Myelodysplastic Syndrome Patients With Low and Intermediate-1 Risk,4960
18,NCT01746849,Phase II,Recruiting,"[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 2373, 'therapyName': 'Palifermin'}]",Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation,4960
19,NCT01812252,Phase II,Recruiting,"[{'id': 1606, 'therapyName': 'Cytarabine + Idarubicin'}, {'id': 1798, 'therapyName': 'Decitabine + Azacitidine'}]",Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant,4960
20,NCT01823198,Phase Ib/II,Recruiting,"[{'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1846, 'therapyName': 'Busulfan + Fludarabine + anti-thymocyte globulin'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Natural Killer (NK) Cells With HLA Compatible Hematopoietic Transplantation for High Risk Myeloid Malignancies,4960
21,NCT01834248,Phase I,Completed,"[{'id': 1795, 'therapyName': 'DEC-205-NY-ESO-1 + Decitabine '}]",DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia,4960
22,NCT01841333,Phase II,Recruiting,"[{'id': 1748, 'therapyName': 'PF-04449913'}]",PF-04449913 For Patients With Acute Leukemia at High Risk of Relapse After Donor Stem Cell Transplant,4960
23,NCT01842646,Phase II,"Active, not recruiting","[{'id': 1748, 'therapyName': 'PF-04449913'}]",Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS),4960
24,NCT01869114,Phase II,Recruiting,"[{'id': 2233, 'therapyName': 'Azacitidine + Sirolimus'}]",Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy,4960
25,NCT01880437,Phase II,Terminated,"[{'id': 1802, 'therapyName': 'Cytarabine + Vismodegib'}]",A Study of Vismodegib in Patients With Relapsed/Refractory Acute Myelogenous Leukemia and Relapsed Refractory High-Risk Myleodysplastic Syndrome,4960
26,NCT01885689,Phase II,Recruiting,"[{'id': 2236, 'therapyName': 'Clofarabine + Melphalan'}]",Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia or Acute Leukemia in Remission,4960
27,NCT01892371,Phase Ib/II,Recruiting,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 882, 'therapyName': 'Quizartinib'}]",AC220 With 5-Aza or Low Dose Cytarabine,4960
28,NCT01893320,Phase Ib/II,"Active, not recruiting","[{'id': 1766, 'therapyName': 'Decitabine + Vosaroxin'}]",Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome,4960
29,NCT01895842,Phase I,"Active, not recruiting","[{'id': 907, 'therapyName': 'Ruxolitinib'}]",Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS),4960
30,NCT01926587,Phase Ib/II,Recruiting,"[{'id': 2320, 'therapyName': 'Azacitidine + Regorafenib'}]",Oral Rigosertib in Combination With Azacitidine,4960
31,NCT01928537,Phase III,"Active, not recruiting","[{'id': 1046, 'therapyName': 'rigosertib'}]",Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine,4960
32,NCT01953692,Phase I,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013)(KEYNOTE-013),4960
33,NCT01993641,Phase II,Completed,"[{'id': 1758, 'therapyName': 'Pracinostat'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 650, 'therapyName': 'Decitabine'}]",Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA,4960
34,NCT02010645,Phase II,"Active, not recruiting","[{'id': 1763, 'therapyName': 'Eltrombopag + Decitabine'}]",Eltrombopag With Decitabine in Advanced Myelodysplastic Syndrome (MDS),4960
35,NCT02076191,Phase Ib/II,Recruiting,"[{'id': 1735, 'therapyName': 'Ruxolitinib + Decitabine'}]",Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML,4960
36,NCT02078609,Phase I,Recruiting,"[{'id': 2402, 'therapyName': 'LGH447 '}]",A Safety and Efficacy Study of LGH447 in Patients With Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS),4960
37,NCT02083250,Phase I,Recruiting,"[{'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 3201, 'therapyName': 'Busulfan + Clofarabine + Fludarabine'}]",Fludarabine/Clofarabine/Busulfan Combined With SAHA in Acute Leukemia,4960
38,NCT02092324,Phase II,Recruiting,"[{'id': 907, 'therapyName': 'Ruxolitinib'}]",Ruxolitinib Phosphate in Treating Patients With Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia,4960
39,NCT02103478,Phase Ib/II,"Active, not recruiting","[{'id': 1759, 'therapyName': 'ASTX727'}]",Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral CDAi in Patients With MDS,4960
40,NCT02121418,Phase I,"Active, not recruiting","[{'id': 1736, 'therapyName': 'Decitabine + Cytarabine'}]","Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm",4960
41,NCT02129101,Phase I,"Active, not recruiting","[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 1428, 'therapyName': 'Sonidegib'}]",Azacitidine and Sonidegib in Treating Patients With Myeloid Malignancies,4960
42,NCT02131597,Phase II,Recruiting,"[{'id': 1949, 'therapyName': 'SGI-110'}]",SGI-110 in Higher Risk Myelodysplastic Syndrome (MDS),4960
43,NCT02141477,Phase II,Terminated,"[{'id': 1762, 'therapyName': 'Omacetaxine + Decitabine'}]",Omacetaxine and Decitabine in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS),4960
44,NCT02158858,Phase I,Recruiting,"[{'id': 2033, 'therapyName': 'CPI-0610'}]","A Phase 1 Study Evaluating CPI-0610 in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelodysplastic/Myeloproliferative Neoplasms",4960
45,NCT02200380,Phase II,Terminated,"[{'id': 1756, 'therapyName': 'Plerixafor'}, {'id': 3007, 'therapyName': 'CDX-301'}]",A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs,4960
46,NCT02212561,Phase Ib/II,Completed,"[{'id': 1749, 'therapyName': 'Selinexor'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 2345, 'therapyName': 'Cytarabine + Dexamethasone+ Methotrexate '}, {'id': 1166, 'therapyName': 'Fludarabine'}]",Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome,4960
47,NCT02296242,Phase Ib/II,Completed,"[{'id': 997, 'therapyName': 'BVD-523'}]",Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes,4960
48,NCT02308761,Phase I,Recruiting,"[{'id': 937, 'therapyName': 'TEN-010'}]",A Dose Escalation and Cohort Expansion Study of TEN-010 in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome,4960
49,NCT02312102,Phase I,Recruiting,"[{'id': 3220, 'therapyName': 'Bortezomib + lenalidomide'}]",Phase I Study of Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell Transplantation,4960
50,NCT02319369,Phase I,Recruiting,"[{'id': 2079, 'therapyName': 'DS-3032b'}]","Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-3032b in Hematological Malignancies",4960
51,NCT02333162,Phase I,Recruiting,"[{'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}]","Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant",4960
52,NCT02381548,Phase I,"Active, not recruiting","[{'id': 3197, 'therapyName': 'Belinostat + MK-1775'}]",Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia,4960
53,NCT02392572,Phase Ib/II,Recruiting,"[{'id': 1687, 'therapyName': 'ONC201'}]",ONC201 in Relapsed/Refractory Acute Leukemias and High-risk Myelodysplastic Syndromes (HR-MDS),4960
54,NCT02393248,Phase Ib/II,Recruiting,"[{'id': 4176, 'therapyName': 'Cisplatin + Gemcitabine + INCB054828'}, {'id': 4174, 'therapyName': 'Docetaxel + INCB054828'}, {'id': 4088, 'therapyName': 'Epacadostat + Pembrolizumab'}]","Open-Label, Dose-Escalation Study of INCB054828 in Subjects With Advanced Malignancies",4960
55,NCT02400281,Phase Ib/II,Recruiting,"[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 705, 'therapyName': 'Crenolanib'}, {'id': 1606, 'therapyName': 'Cytarabine + Idarubicin'}]",Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients,4960
56,NCT02418000,Phase Ib/II,Terminated,"[{'id': 1011, 'therapyName': 'E6201'}]",A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 Mutation,4960
57,NCT02464657,Phase Ib/II,Recruiting,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 3192, 'therapyName': 'Cytarabine + Idarubicin + Nivolumab'}]",Nivolumab in Acute Myeloid Leukemia (AML),4960
58,NCT02469415,Phase II,Terminated,"[{'id': 650, 'therapyName': 'Decitabine'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 2006, 'therapyName': 'Pacritinib'}]",Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS),4960
59,NCT02472145,Phase III,"Active, not recruiting","[{'id': 650, 'therapyName': 'Decitabine'}, {'id': 5909, 'therapyName': 'Decitabine + Talacotuzumab'}]",An Efficacy and Safety Study of Decitabine (DACOGEN) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus Decitabine (DACOGEN) Alone in Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy,4960
60,NCT02485535,Phase I,Recruiting,"[{'id': 1749, 'therapyName': 'Selinexor'}]",Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant,4960
61,NCT02527174,Phase I,Withdrawn,"[{'id': 3213, 'therapyName': 'Cytarabine + Idarubicin + Volasertib'}]",A Study of Volasertib Plus Induction Chemotherapy for Acute Myeloid Leukemia (VIAC),4960
62,NCT02530476,Phase Ib/II,Recruiting,"[{'id': 3189, 'therapyName': 'Selinexor + Sorafenib'}]","Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia",4960
63,NCT02577406,Phase III,Recruiting,"[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 2982, 'therapyName': 'Enasidenib'}]",An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation (IDHENTIFY),4960
64,NCT02599649,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 2583, 'therapyName': 'Lirilumab '}]",Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS),4960
65,NCT02610777,Phase II,"Active, not recruiting","[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 1688, 'therapyName': 'MLN4924'}]","An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)",4960
66,NCT02721875,Phase I,Terminated,"[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 957, 'therapyName': 'Volasertib'}]",Trial of Volasertib With or Without Azacitidine in Patients With Myelodysplastic Syndromes,4960
67,NCT02722668,Phase II,Recruiting,"[{'id': 2281, 'therapyName': 'Cyclophosphamide + Fludarabine + Mycophenolate mofetil'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}]",UCB Transplant for Hematological DIseases Using a Non Myeloablative Prep,4960
68,NCT02728050,Phase Ib/II,Recruiting,"[{'id': 920, 'therapyName': 'Sorafenib'}, {'id': 4363, 'therapyName': 'Cladribine + Cytarabine + Filgrastim + Mitoxantrone'}]","Filgrastim, Cladribine, Cytarabine and Mitoxantrone With or Without Sorafenib Tosylate in Treating Patients With Newly-Diagnosed, High-Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome",4960
69,NCT03011372,Phase II,Recruiting,"[{'id': 4173, 'therapyName': 'INCB054828'}]",A Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement,4960
70,NCT03065400,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",PD-1 Inhibition in Advanced Myeloproliferative Neoplasms,4960
0,NCT01386580,Phase Ib/II,Completed,"[{'id': 974, 'therapyName': '2B3-101'}, {'id': 1274, 'therapyName': '2B3-101 + Trastuzumab'}]","An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.",1319
1,NCT01518413,Phase I,Completed,"[{'id': 1323, 'therapyName': 'Sorafenib + Irinotecan'}]",Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors,1319
2,NCT01753713,Phase II,"Active, not recruiting","[{'id': 721, 'therapyName': 'Dovitinib'}]",Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma,1319
3,NCT02015728,Phase I,"Active, not recruiting","[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1804, 'therapyName': 'Temozolomide + Etoposide'}, {'id': 920, 'therapyName': 'Sorafenib'}]",Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors,1319
4,NCT02130869,Phase I,Recruiting,"[{'id': 2378, 'therapyName': 'Bendamustine + Cytarabine + Etoposide'}, {'id': 2460, 'therapyName': 'Busulfan + Hu14.18K322A'}, {'id': 2459, 'therapyName': 'Aldesleukin + Melphalan + Sargramostim'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}]",A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas,1319
5,NCT02502708,Phase I,Recruiting,"[{'id': 2976, 'therapyName': 'indoximod'}, {'id': 1141, 'therapyName': 'Temozolomide'}]","Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Primary Malignant Brain Tumors",1319
6,NCT02574728,Phase II,Recruiting,"[{'id': 3143, 'therapyName': 'Celecoxib + Cyclophosphamide + Etoposide + Sirolimus'}]",Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors,1319
7,NCT02644460,Phase I,Recruiting,"[{'id': 802, 'therapyName': 'Abemaciclib'}]",Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors,1319
0,NCT01295944,Phase II,Recruiting,"[{'id': 2074, 'therapyName': 'Bevacizumab + Carboplatin'}]",Carboplatin and Bevacizumab for Recurrent Ependymoma,7497
1,NCT02458339,Phase I,Recruiting,"[{'id': 1639, 'therapyName': 'Methotrexate'}]",Methotrexate Infusion Into Fourth Ventricle in Children With Recurrent Malignant Fourth Ventricular Brain Tumors,7497
0,NCT01112527,Phase II,"Active, not recruiting","[{'id': 714, 'therapyName': 'Dacomitinib'}]",PF-00299804 in Adult Patients With Relapsed/Recurrent Glioblastoma,3073
1,NCT01837862,Phase Ib/II,Recruiting,"[{'id': 2134, 'therapyName': 'Mebendazole + Vincristine + Carboplatin + Temozolomide'}, {'id': 2133, 'therapyName': 'Mebendazole + Bevacizumab + Irinotecan'}]",A Phase I/II Study of Mebendazole for the Treatment of Pediatric Gliomas,3073
2,NCT01891747,Phase Ib/II,"Active, not recruiting","[{'id': 2115, 'therapyName': 'Bevacizumab + Temozolomide'}]", A Phase I/II Study of High-dose L-methylfolate in Combination With Temozolomide and Bevacizumab in Recurrent High Grade Glioma,3073
3,NCT01954576,Phase II,Recruiting,[],NovoTTF Therapy in Treating Patients With Recurrent Glioblastoma Multiforme,3073
4,NCT02052648,Phase Ib/II,Recruiting,"[{'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 2976, 'therapyName': 'indoximod'}]",Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors,3073
0,NCT00602667,Phase I,"Active, not recruiting","[{'id': 2449, 'therapyName': 'Methotrexate + Cisplatin + Cyclophosphamide + Vincristine'}, {'id': 2450, 'therapyName': 'Cyclophosphamide + Etoposide + Topotecan'}, {'id': 2451, 'therapyName': 'Erlotinib + Cyclophosphamide + Topotecan'}]","Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma",60108
1,NCT00660621,Phase II,Unknown status,"[{'id': 2115, 'therapyName': 'Bevacizumab + Temozolomide'}]","A Phase II Study Of Gliadel, Concomitant Temozolomide And Radiation, Followed By Dose Dense Therapy With Temozolomide Plus Bevacizumab For Newly Diagnosed Malignant High Grade Glioma",60108
2,NCT00823459,Phase II,Completed,"[{'id': 735, 'therapyName': 'Everolimus'}]",Phase II Trial of RAD001 in Patients With Recurrent Low Grade Glioma,60108
3,NCT01390948,Phase II,"Active, not recruiting","[{'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",A Study of Avastin (Bevacizumab) in Combination With Temolozomide (TMZ) and Radiotherapy in Paediatric and Adolescent Patients With High-Grade Glioma,60108
4,NCT01580969,Phase Ib/II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}]","Repeat Radiation, Minocycline and Bevacizumab in Patients With Recurrent Glioma",60108
5,NCT01661400,Phase I,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1475, 'therapyName': 'Thalidomide'}]",Anti-Angiogenic Therapy Post Transplant (ASCR) for Relapsed and Refractory Pediatric Solid Tumors,60108
6,NCT01774253,Phase II,Terminated,"[{'id': 956, 'therapyName': 'Vismodegib'}]",Erivedge (Vismodegib) in the Treatment of Pediatric Patients With Refractory Pontine Glioma,60108
7,NCT01967810,Phase II,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 2053, 'therapyName': 'GRN1005'}]",ANG1005 in Patients With Recurrent High-Grade Glioma,60108
8,NCT03122197,Phase I,Recruiting,"[{'id': 794, 'therapyName': 'Letrozole'}]",Study of Letrozole in Recurrent Gliomas,60108
0,NCT01891747,Phase Ib/II,"Active, not recruiting","[{'id': 2115, 'therapyName': 'Bevacizumab + Temozolomide'}]", A Phase I/II Study of High-dose L-methylfolate in Combination With Temozolomide and Bevacizumab in Recurrent High Grade Glioma,3187
0,NCT03173950,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Immune Checkpoint Inhibitor Nivolumab in People With Select Rare CNS Cancers,2132
0,NCT01922076,Phase I,Recruiting,"[{'id': 822, 'therapyName': 'MK-1775'}]",WEE1 Inhibitor MK-1775 and Local Radiation Therapy in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas,4860
0,NCT01514201,Phase Ib/II,"Active, not recruiting","[{'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 954, 'therapyName': 'Veliparib'}]","Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas",4203
0,NCT00879437,Phase II,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1076, 'therapyName': 'Valproic acid'}]",Valproic Acid and Radiation Followed by Maintenance Valproic Acid and Bevacizumab in Children With High Grade Gliomas,4202
1,NCT01130077,Phase I,Recruiting,"[{'id': 2595, 'therapyName': 'poly ICLC  '}]",A Pilot Study of Glioma Associated Antigen Vaccines in Conjunction With Poly-ICLC in Pediatric Gliomas,4202
2,NCT01514201,Phase Ib/II,"Active, not recruiting","[{'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 954, 'therapyName': 'Veliparib'}]","Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas",4202
3,NCT01884740,Phase Ib/II,Recruiting,"[{'id': 1654, 'therapyName': 'Avastin + Cetuximab'}]",Phase I/II Trial Of Super-Selective Intraarterial Infusion Of Erbitux and Bevacizumab For Treatment Of Relapsed/Refractory Intracranial Glioma In Patients Under 22 Years Of Age,4202
4,NCT01922076,Phase I,Recruiting,"[{'id': 822, 'therapyName': 'MK-1775'}]",WEE1 Inhibitor MK-1775 and Local Radiation Therapy in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas,4202
5,NCT02372006,Phase I,Recruiting,"[{'id': 623, 'therapyName': 'Afatinib'}]",Phase I Trial of Afatinib in Pediatric Tumours,4202
6,NCT02420613,Phase I,Recruiting,"[{'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 936, 'therapyName': 'Temsirolimus'}]",Study of Suberoylanilide Hydroxamic Acid (SAHA) With Temsirolimus in Children With Diffuse Intrinsic Pontine Glioma (DIPG),4202
7,NCT02607124,Phase Ib/II,Recruiting,"[{'id': 790, 'therapyName': 'Ribociclib'}]",Administration of Ribociclib Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG),4202
8,NCT02717455,Phase I,Recruiting,"[{'id': 1080, 'therapyName': 'Panobinostat'}]",Trial of Panobinostat in Children With Diffuse Intrinsic Pontine Glioma,4202
9,NCT03173950,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Immune Checkpoint Inhibitor Nivolumab in People With Select Rare CNS Cancers,4202
0,NCT00461773,Phase II,Unknown status,"[{'id': 794, 'therapyName': 'Letrozole'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Randomized Phase II Study of Preoperative Letrozole (Femara) in Combination With Avastin in Hormone Receptor Positive Breast Cancer,3458
1,NCT00796978,Phase II,Unknown status,"[{'id': 947, 'therapyName': 'Trastuzumab'}]",Trastuzumab in Treating Older Women With Early-Stage Breast Cancer,3458
2,NCT00826085,Phase Ib/II,Completed,"[{'id': 1054, 'therapyName': 'ThermoDox'}]",Phase 1/2 Study of ThermoDox With Approved Hyperthermia in Treatment of Breast Cancer Recurrence at the Chest Wall,3458
3,NCT01007695,Phase I,Terminated,"[{'id': 1076, 'therapyName': 'Valproic acid'}]",Molecular Signature of Valproic Acid in Breast Cancer With Functional Imaging Assessment - a Pilot,3458
4,NCT01111825,Phase Ib/II,Completed,"[{'id': 1527, 'therapyName': 'Temsirolimus + Neratinib'}]",Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer,3458
5,NCT01124695,Phase II,Unknown status,"[{'id': 1456, 'therapyName': 'Tamoxifen'}]",Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer,3458
6,NCT01283789,Phase II,"Active, not recruiting","[{'id': 1539, 'therapyName': 'Everolimus + Lapatinib'}]",Lapatinib and RAD-001 for HER2 Positive Metastatic Breast Cancer,3458
7,NCT01572038,Phase III,"Active, not recruiting","[{'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) and A Taxane in First-Line Treatment in Patients With HER2-Positive Advanced Breast Cancer (PERUSE),3458
8,NCT01621906,,Recruiting,"[{'id': 920, 'therapyName': 'Sorafenib'}]",18F-FLT-PET Imaging of the Brain in Patients With Metastatic Breast Cancer to the Brain Treated With Whole Brain Radiation Therapy With or Without Sorafenib,3458
9,NCT01697293,Phase Ib/II,Recruiting,"[{'id': 3054, 'therapyName': 'Paclitaxel + Triciribine'}, {'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}]","Triciribine Phosphate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer",3458
10,NCT01724606,Phase I,Recruiting,"[{'id': 920, 'therapyName': 'Sorafenib'}]",Whole Brain Radiotherapy (WBRT) With Sorafenib for Breast Cancer Brain Metastases (BCBM),3458
11,NCT01824836,Phase I,Recruiting,"[{'id': 633, 'therapyName': 'Anastrozole'}]",Anastrozole in Treating Aromatase Inhibitor Musculoskeletal Symptoms in Female Patients With Stage I-III Breast Cancer,3458
12,NCT01862081,Phase I,Completed,"[{'id': 2321, 'therapyName': 'Docetaxel + GDC-0032 '}, {'id': 2322, 'therapyName': 'GDC-0032 + Paclitaxel'}]","A Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer",3458
13,NCT01897441,Phase I,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1551, 'therapyName': 'Trastuzumab + Paclitaxel'}, {'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}]",Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast Cancer,3458
14,NCT01928589,Phase Ib/II,Recruiting,[],Partial Breast Irradiation With Concurrent Chemotherapy for Women With Breast Cancer,3458
15,NCT01959490,Phase II,Completed,"[{'id': 1486, 'therapyName': 'Bevacizumab + Doxorubicin + Cyclophosphamide + Paclitaxel '}, {'id': 1485, 'therapyName': 'Trastuzumab + Docetaxel + Carboplatin'}]",Trastuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer,3458
16,NCT01973309,Phase I,"Active, not recruiting","[{'id': 4398, 'therapyName': 'Vantictumab + Paclitaxel'}]",A Study of Vantictumab (OMP-18R5) in Combination With Paclitaxel in Locally Recurrent or Metastatic Breast Cancer,3458
17,NCT02053636,Phase II,Completed,"[{'id': 1029, 'therapyName': 'Lucitanib'}]",A Phase II Trial Testing Oral Administration of Lucitanib in Patients With Fibroblast Growth Factor Receptor (FGFR)1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast Cancer,3458
18,NCT02115282,Phase III,Recruiting,"[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 1541, 'therapyName': 'Entinostat'}, {'id': 738, 'therapyName': 'Exemestane'}]",Exemestane With or Without Entinostat in Treating Postmenopausal Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,3458
19,NCT02322814,Phase II,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1004, 'therapyName': 'Cobimetinib'}]",A Study of Cobimetinib in Combination With Paclitaxel as First-line Treatment for Patients With Metastatic Triple-negative Breast Cancer,3458
20,NCT02423902,Phase Ib/II,"Active, not recruiting","[{'id': 4250, 'therapyName': 'Ad-RTS-IL-12 plus AL'}]",A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Breast Cancer,3458
21,NCT02450175,Phase I,Unknown status,"[{'id': 794, 'therapyName': 'Letrozole'}, {'id': 735, 'therapyName': 'Everolimus'}]","Etiology of the Platelet-Cancer Metastatic Pathway - A Study of Inflammatory Markers, Platelet Characteristics and Metastatic Surrogates in Cancer Patients and Controls",3458
22,NCT02632071,Phase I,Recruiting,"[{'id': 3313, 'therapyName': 'ACY-1215 + nab-paclitaxel'}]",Phase I of ACY-1215 + Nab-paclitaxel in Breast Cancer,3458
23,NCT02833233,Phase I,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Study of Pre-Operative Treatment With Cryoablation and Immune Therapy in Early Stage Breast Cancer,3458
24,NCT02952729,Phase I,Recruiting,"[{'id': 5834, 'therapyName': 'XMT-1522'}]",Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2,3458
25,NCT02964507,Phase II,Recruiting,"[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 5242, 'therapyName': 'GSK525762 + Fulvestrant'}]",Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Subjects With Estrogen Receptor Positive (ER+) Breast Cancer,3458
26,NCT03094052,Phase II,Recruiting,"[{'id': 828, 'therapyName': 'Neratinib'}, {'id': 2700, 'therapyName': 'Loperamide'}, {'id': 5906, 'therapyName': 'Crofelemer'}, {'id': 4359, 'therapyName': 'Neratinib + Trastuzumab'}]","Diarrhea Prophylaxis in Patients With HER2+ Breast Cancer Treated With Trastuzumab and Neratinib, Followed by Neratinib Monotherapy",3458
27,NCT03199885,Phase III,Not yet recruiting,"[{'id': 1549, 'therapyName': 'Pertuzumab + Trastuzumab + Paclitaxel'}, {'id': 5956, 'therapyName': 'Paclitaxel + Pembrolizumab + Pertuzumab + Trastuzumab'}]","Paclitaxel, Trastuzumab, and Pertuzumab With or Without Pembrolizumab in Treating Patients With Metastatic Breast Cancer",3458
28,NCT03284957,Phase Ib/II,Recruiting,"[{'id': 6293, 'therapyName': 'SAR439859'}, {'id': 6294, 'therapyName': 'Palbociclib + SAR439859'}]",Phase 1 / 2 Study of SAR439859 Single Agent and in Combination With Palbociclib in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer,3458
0,NCT02780310,Phase II,"Active, not recruiting","[{'id': 792, 'therapyName': 'Lenvatinib'}]",Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma,4877
1,NCT03087019,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma,4877
2,NCT03172624,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer,4877
0,NCT00378638,Phase II,Unknown status,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Dose-Dense Chemotherapy Plus Bevacizumab in High Risk Lymph Node Positive Breast Cancer,1612
1,NCT00570323,Phase II,"Active, not recruiting","[{'id': 1911, 'therapyName': 'Anastrozole  + Fulvestrant'}, {'id': 633, 'therapyName': 'Anastrozole'}]",Arimidex With or Without Faslodex In Postmenopausal Women With HR Positive Breast Cancer,1612
2,NCT00618657,Phase II,"Active, not recruiting","[{'id': 1490, 'therapyName': 'Nab-paclitaxel + Carboplatin + Trastuzumab'}, {'id': 1489, 'therapyName': 'Nab-paclitaxel + Carboplatin + Bevacizumab'}]","Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting",1612
3,NCT00651976,Phase I,Suspended,"[{'id': 794, 'therapyName': 'Letrozole'}]","Letrozole in Treating Postmenopausal Women With Stage I, II or III Breast Cancer That Can Be Removed by Surgery",1612
4,NCT00719875,Phase Ib/II,Completed,"[{'id': 1077, 'therapyName': 'Vorinostat'}]",HDAC Inhibitor Vorinostat (SAHA) With Capecitabine (Xeloda) Using a New Weekly Dose Regimen for Advanced Breast Cancer,1612
5,NCT00733408,Phase II,"Active, not recruiting","[{'id': 1496, 'therapyName': 'Abraxane + Bevacizumab + Erlotinib'}]",Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab Followed By Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic Breast Cancer,1612
6,NCT00740805,Phase I,"Active, not recruiting","[{'id': 2989, 'therapyName': 'Aldoxorubicin + Cyclophosphamide + Veliparib'}]","Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma",1612
7,NCT00892736,Phase I,"Active, not recruiting","[{'id': 954, 'therapyName': 'Veliparib'}]",Veliparib in Treating Patients With Malignant Solid Tumors That Did Not Respond to Previous Therapy,1612
8,NCT00912340,Phase II,"Active, not recruiting","[{'id': 735, 'therapyName': 'Everolimus'}, {'id': 947, 'therapyName': 'Trastuzumab'}]",Randomized Phase II Trial of Trastuzumab or EVEROLIMUS in Hormone-refractory Metastatic Breast Cancer,1612
9,NCT00968968,Phase III,"Active, not recruiting","[{'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1414, 'therapyName': 'Trastuzumab + Lapatinib'}]",Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone,1612
10,NCT00978250,Phase II,Recruiting,"[{'id': 3789, 'therapyName': 'FdCyd + THU'}]",A Multi-Histology Phase II Study of 5-Fluoro-2-Deoxycytidine With Tetrahydrouridine (FdCyd + THU),1612
11,NCT01008150,Phase II,Unknown status,"[{'id': 1504, 'therapyName': 'Paclitaxel + Trastuzumab + Neratinib + Doxorubicin + Cyclophosphamide'}, {'id': 1503, 'therapyName': 'Paclitaxel + Trastuzumab + Doxorubicin + Cyclophosphamide'}, {'id': 1505, 'therapyName': 'Paclitaxel + Neratinib + Doxorubicin + Cyclophosphamide'}]",Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer,1612
12,NCT01035099,Phase I,Recruiting,"[{'id': 794, 'therapyName': 'Letrozole'}]",RCT of Fixed vs Titrated Letrozole in Breast Cancer Patient Undergoing IVF,1612
13,NCT01037790,Phase II,Recruiting,"[{'id': 850, 'therapyName': 'Palbociclib'}]",PD 0332991 in Treating Patients With Refractory Solid Tumors,1612
14,NCT01042379,Phase II,Recruiting,"[{'id': 1218, 'therapyName': 'Trebananib'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 746, 'therapyName': 'Ganitumab'}, {'id': 1495, 'therapyName': 'Paclitaxel + Doxorubicin + Cyclophosphamide'}, {'id': 1494, 'therapyName': 'MK2206 + Trastuzumab'}, {'id': 1493, 'therapyName': 'Trebananib + Trastuzumab'}, {'id': 1492, 'therapyName': 'T-DM1 + Pertuzumab'}]",I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer,1612
15,NCT01106898,Phase II,Unknown status,"[{'id': 1980, 'therapyName': 'Cyclophosphamide + Paclitaxel'}, {'id': 947, 'therapyName': 'Trastuzumab'}]",Cyclophosphamide and Paclitaxel With or Without Trastuzumab in Treating Women With Stage I or Stage II Breast Cancer Who Have Undergone Surgery,1612
16,NCT01194869,Phase II,Terminated,"[{'id': 1534, 'therapyName': 'Sorafenib + Cisplatin + Paclitaxel'}]","Preoperative Clinical Trial of Sorafenib in Combination With Cisplatin Followed by Paclitaxel for Triple Negative (ER-, PR-, Her2-)Early Stage Breast Cancer",1612
17,NCT01216176,Phase Ib/II,"Active, not recruiting","[{'id': 633, 'therapyName': 'Anastrozole'}, {'id': 912, 'therapyName': 'Saracatinib'}]",A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZDO530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer,1612
18,NCT01262027,Phase II,"Active, not recruiting","[{'id': 721, 'therapyName': 'Dovitinib'}]", TKI258 for Metastatic Inflammatory Breast Cancer Patients,1612
19,NCT01275677,Phase III,"Active, not recruiting","[{'id': 1503, 'therapyName': 'Paclitaxel + Trastuzumab + Doxorubicin + Cyclophosphamide'}, {'id': 1881, 'therapyName': 'Docetaxel + Cyclophosphamide'}, {'id': 1882, 'therapyName': 'Docetaxel + Cyclophosphamide + Trastuzumab'}, {'id': 1495, 'therapyName': 'Paclitaxel + Doxorubicin + Cyclophosphamide'}]",Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,1612
20,NCT01281150,Phase I,Completed,"[{'id': 954, 'therapyName': 'Veliparib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors,1612
21,NCT01283789,Phase II,"Active, not recruiting","[{'id': 1539, 'therapyName': 'Everolimus + Lapatinib'}]",Lapatinib and RAD-001 for HER2 Positive Metastatic Breast Cancer,1612
22,NCT01286987,Phase I,Completed,"[{'id': 682, 'therapyName': 'Talazoparib'}]","Study of BMN 673, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors",1612
23,NCT01293032,Phase I,Completed,"[{'id': 1456, 'therapyName': 'Tamoxifen'}]",Hormone Therapy Or Chemotherapy Before Surgery Based on Gene Expression Analysis in Treating Patients With Breast Cancer,1612
24,NCT01300962,Phase I,"Active, not recruiting","[{'id': 1538, 'therapyName': 'BKM120 + Capecitabine + Lapatinib'}, {'id': 1537, 'therapyName': 'BKM120 + Capecitabine + Trastuzumab'}, {'id': 1536, 'therapyName': 'BKM120 + Capecitabine'}, {'id': 1535, 'therapyName': 'BYL719 + Capecitabine'}]",Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer,1612
25,NCT01302379,Phase I,"Active, not recruiting","[{'id': 1031, 'therapyName': 'Metformin'}]",Reach for Health Study: Obesity-related Mechanisms and Mortality in Breast Cancer Survivors,1612
26,NCT01310231,Phase II,"Active, not recruiting","[{'id': 1031, 'therapyName': 'Metformin'}]",A Trial of Standard Chemotherapy With Metformin (vs Placebo) in Women With Metastatic Breast Cancer,1612
27,NCT01320592,Phase I,"Active, not recruiting","[{'id': 850, 'therapyName': 'Palbociclib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",PD0332991/Paclitaxel in Advanced Breast Cancer,1612
28,NCT01325441,Phase Ib/II,Recruiting,"[{'id': 2586, 'therapyName': 'BBI608 + Paclitaxel'}]",A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies,1612
29,NCT01340300,Phase II,"Active, not recruiting","[{'id': 1031, 'therapyName': 'Metformin'}]",Exercise and Metformin in Colorectal and Breast Cancer Survivors,1612
30,NCT01358877,Phase III,"Active, not recruiting","[{'id': 856, 'therapyName': 'Pertuzumab'}, {'id': 947, 'therapyName': 'Trastuzumab'}]",A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer,1612
31,NCT01366144,Phase I,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 954, 'therapyName': 'Veliparib'}, {'id': 1092, 'therapyName': 'Carboplatin'}]","Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction",1612
32,NCT01384253,Phase I,Completed,"[{'id': 1540, 'therapyName': '212Pb-TCMC-Trastuzumab + Trastuzumab '}]",Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy,1612
33,NCT01386580,Phase Ib/II,Completed,"[{'id': 974, 'therapyName': '2B3-101'}, {'id': 1274, 'therapyName': '2B3-101 + Trastuzumab'}]","An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.",1612
34,NCT01401959,Phase II,"Active, not recruiting","[{'id': 728, 'therapyName': 'Eribulin'}, {'id': 1981, 'therapyName': 'Eribulin + Trastuzumab'}]",Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy,1612
35,NCT01407562,Phase I,"Active, not recruiting","[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}]","Study of Pazopanib, Paclitaxel, and Carboplatin in Patients With Advanced Solid Tumors",1612
36,NCT01480583,Phase II,Completed,"[{'id': 947, 'therapyName': 'Trastuzumab'}]",GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases,1612
37,NCT01501487,FDA approved,"Active, not recruiting","[{'id': 1902, 'therapyName': 'Docetaxel + Doxorubicin + Cyclophosphamide'}, {'id': 1982, 'therapyName': 'Fluorouracil + Epirubicin + Cyclophosphamide'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1881, 'therapyName': 'Docetaxel + Cyclophosphamide'}, {'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}, {'id': 1485, 'therapyName': 'Trastuzumab + Docetaxel + Carboplatin'}, {'id': 1978, 'therapyName': 'Pertuzumab + Trastuzumab + Docetaxel'}]",MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I,1612
38,NCT01506609,Phase II,"Active, not recruiting","[{'id': 1193, 'therapyName': 'Veliparib + Temozolomide'}, {'id': 1544, 'therapyName': 'Carboplatin + Etoposide + Veliparib'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer,1612
39,NCT01517802,Phase III,Recruiting,"[{'id': 1805, 'therapyName': 'Abiraterone'}]",A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate,1612
40,NCT01525589,Phase II,Recruiting,"[{'id': 1195, 'therapyName': 'Lurbinectedin'}]",A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer,1612
41,NCT01532960,Phase I,Terminated,"[{'id': 2595, 'therapyName': 'poly ICLC  '}]",Pilot Study of a Breast Cancer Vaccine Plus Poly-ICLC for Breast Cancer (Breast 41),1612
42,NCT01545648,Phase II,"Active, not recruiting","[{'id': 1198, 'therapyName': 'Denosumab'}]",Pilot Study to Evaluate the Impact of Denosumab on Disseminated Tumor Cells (DTC) in Patients With Early Stage Breast Cancer,1612
43,NCT01562873,,Terminated,"[{'id': 907, 'therapyName': 'Ruxolitinib'}]", Ruxolitinib in Patients With Breast Cancer,1612
44,NCT01570036,Phase II,Recruiting,"[{'id': 3766, 'therapyName': 'E75'}, {'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 947, 'therapyName': 'Trastuzumab'}]",Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax,1612
45,NCT01576666,Phase Ib/II,Completed,"[{'id': 1547, 'therapyName': 'BKM120 + Sonidegib'}]","Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors",1612
46,NCT01596751,Phase Ib/II,"Active, not recruiting","[{'id': 728, 'therapyName': 'Eribulin'}, {'id': 874, 'therapyName': 'PLX3397'}]",Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer,1612
47,NCT01597388,Phase I,"Active, not recruiting","[{'id': 2199, 'therapyName': 'Vistusertib + Fulvestrant'}]",AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer,1612
48,NCT01625286,Phase Ib/II,"Active, not recruiting","[{'id': 2192, 'therapyName': 'AZD5363 + Paclitaxel'}]","Investigating Safety, Tolerability and Efficacy of AZD5363 When Combined With Paclitaxel in Breast Cancer Patients",1612
49,NCT01640665,Phase I,Completed,"[{'id': 2428, 'therapyName': 'Sorafenib + Capecitabine'}]",Pilot Study of Sorafenib and Bi-weekly Capecitabine in Patients With Advanced Breast and Gastrointestinal Tumors,1612
50,NCT01650506,Phase I,Completed,"[{'id': 1828, 'therapyName': 'Metformin + Erlotinib'}]",Study of Erlotinib and Metformin in Triple Negative Breast Cancer,1612
51,NCT01656538,Phase II,"Active, not recruiting","[{'id': 893, 'therapyName': 'Reolysin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",A Study of Reolysin For Patients With Advanced/Metastatic Breast Cancer,1612
52,NCT01669343,Phase I,"Active, not recruiting","[{'id': 794, 'therapyName': 'Letrozole'}]",Aromatase Inhibitor Host Factors Study,1612
53,NCT01676753,Phase Ib/II,Recruiting,"[{'id': 4225, 'therapyName': 'Dinaciclib + Pembrolizumab'}]",Phase 1b Dose De-escalation Trial of Dinaciclib With Pembrolizumab for Advanced Breast Cancer,1612
54,NCT01723774,Phase II,Recruiting,"[{'id': 850, 'therapyName': 'Palbociclib'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 759, 'therapyName': 'Goserelin'}]",PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer,1612
55,NCT01730833,Phase II,Recruiting,"[{'id': 1549, 'therapyName': 'Pertuzumab + Trastuzumab + Paclitaxel'}]","Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Metastatic Breast Cancer",1612
56,NCT01750073,Phase II,Recruiting,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1980, 'therapyName': 'Cyclophosphamide + Paclitaxel'}]",Paclitaxel and Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Patients With Previously Untreated Stage I-III Breast Cancer,1612
57,NCT01831089,Phase I,Completed,"[{'id': 1196, 'therapyName': 'Lurbinectedin + Paclitaxel + Bevacizumab'}, {'id': 1197, 'therapyName': 'Lurbinectedin + Paclitaxel'}]","Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors",1612
58,NCT01837602,Phase I,"Active, not recruiting",[],cMet CAR RNA T Cells Targeting Breast Cancer,1612
59,NCT01847001,Phase II,"Active, not recruiting","[{'id': 1912, 'therapyName': 'Propranolol'}, {'id': 1549, 'therapyName': 'Pertuzumab + Trastuzumab + Paclitaxel'}]",Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy,1612
60,NCT01853306,Phase I,Completed,"[{'id': 954, 'therapyName': 'Veliparib'}]","A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors",1612
61,NCT01862900,Phase Ib/II,"Active, not recruiting","[{'id': 1653, 'therapyName': 'MEDI6469'}]",Stereotactic Body Radiation and Monoclonal Antibody to OX40 (MEDI6469) in Breast Cancer Patients With Metastatic Lesions,1612
62,NCT01868503,Phase II,Terminated,"[{'id': 787, 'therapyName': 'Lapatinib'}]",Lapatinib Ditosylate and Radiation Therapy in Treating Patients With Locally Advanced or Locally Recurrent Breast Cancer,1612
63,NCT01870505,Phase I,"Active, not recruiting","[{'id': 2318, 'therapyName': 'BYL719 + Exemestane'}, {'id': 1553, 'therapyName': 'Letrozole + BYL719'}]",BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer,1612
64,NCT01920061,Phase I,Recruiting,"[{'id': 1287, 'therapyName': 'PF-05212384 + Dacomitinib'}, {'id': 1286, 'therapyName': 'PF-05212384 + Cisplatin'}, {'id': 1285, 'therapyName': 'PF-05212384 + Docetaxel'}]",A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents,1612
65,NCT01934335,Phase I,Recruiting,"[{'id': 953, 'therapyName': 'Vandetanib'}]",Effect of Vandetanib on Cellular Markers in Invasive Breast Cancer,1612
66,NCT01966445,Phase I,Completed,"[{'id': 2919, 'therapyName': 'GSK2849330'}]","Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors",1612
67,NCT01980823,Phase I,Recruiting,"[{'id': 1576, 'therapyName': 'Atorvastatin + Metformin'}]",Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer,1612
68,NCT01990209,Phase II,Recruiting,"[{'id': 2671, 'therapyName': 'Orteronel '}]",Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR),1612
69,NCT01990352,Phase II,Suspended,"[{'id': 1008, 'therapyName': 'Doxil'}]",Correlate BRCA1 Protein Expression With Response to DNA Damaging Chemotherapy,1612
70,NCT02000622,Phase III,"Active, not recruiting","[{'id': 837, 'therapyName': 'Olaparib'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.,1612
71,NCT02007512,Phase II,"Active, not recruiting","[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 738, 'therapyName': 'Exemestane'}]",Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer,1612
72,NCT02014337,Phase I,"Active, not recruiting","[{'id': 3053, 'therapyName': 'Eribulin + Mifepristone'}]",Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors,1612
73,NCT02025803,Phase I,"Active, not recruiting","[{'id': 4335, 'therapyName': 'Capecitabine + TAS-114'}]","A Safety, Tolerability and Pharmacokinetic Study of TAS-114 in Combination With Capecitabine in Patients With Advanced Solid Tumors",1612
74,NCT02040857,Phase II,"Active, not recruiting","[{'id': 738, 'therapyName': 'Exemestane'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 633, 'therapyName': 'Anastrozole'}]",Palbociclib + Endocrine Therapy for HR + BrCa,1612
75,NCT02041429,Phase Ib/II,"Active, not recruiting","[{'id': 1369, 'therapyName': 'Ruxolitinib + Paclitaxel'}]",Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca,1612
76,NCT02046421,Phase I,"Active, not recruiting","[{'id': 2603, 'therapyName': 'Mifepristone'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}]","Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer",1612
77,NCT02047747,Phase II,Terminated,"[{'id': 714, 'therapyName': 'Dacomitinib'}]",A Phase II Study of Dacomitinib in Progressive Brain Metastases,1612
78,NCT02048059,Phase II,Completed,"[{'id': 2053, 'therapyName': 'GRN1005'}]",ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases,1612
79,NCT02051751,Phase I,Completed,"[{'id': 1379, 'therapyName': 'BYL719 + Paclitaxel'}]",A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer,1612
80,NCT02077933,Phase I,"Active, not recruiting","[{'id': 1384, 'therapyName': 'BYL719 + Everolimus'}, {'id': 1385, 'therapyName': 'BYL719 + Everolimus + Exemestane'}]","Study of Safety and Efficacy of BYL719 With Everolimus or BYL719 With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors",1612
81,NCT02122861,Phase I,"Active, not recruiting","[{'id': 3271, 'therapyName': 'ID-LV305'}]","A Phase 1 Safety Study of Intradermal ID-LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1",1612
82,NCT02124148,Phase I,Recruiting,"[{'id': 1994, 'therapyName': 'Cisplatin + Prexasertib'}, {'id': 1993, 'therapyName': 'Cetuximab + Prexasertib'}, {'id': 6248, 'therapyName': 'Pemetrexed + Prexasertib'}, {'id': 6247, 'therapyName': 'LY3023414 + Prexasertib'}, {'id': 6246, 'therapyName': 'Fluoruracil + Leucovorin + Prexasertib'}]",A Study of LY2606368 With Cisplatin or Cetuximab in Participants With Advanced Cancer,1612
83,NCT02168777,Phase Ib/II,Terminated,"[{'id': 1424, 'therapyName': 'Regorafenib + Refametinib'}, {'id': 888, 'therapyName': 'Refametinib'}]","Refametinib (BAY86-9766) in Combination With Regorafenib (Stivarga, BAY73-4506) in Patients With Advanced or Metastatic Cancer",1612
84,NCT02202746,Phase II,"Active, not recruiting","[{'id': 1029, 'therapyName': 'Lucitanib'}]","A Study to Assess the Safety and Efficacy of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With FGF Aberrant Metastatic Breast Cancer",1612
85,NCT02203513,Phase II,Recruiting,"[{'id': 1651, 'therapyName': 'Prexasertib'}]","Chk1/2 Inhibitor (LY2606368) in Women With BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Non-High Risk Triple Negative Breast Cancer, and Grade Serous Ovarian Cancer at Low Genetic Risk",1612
86,NCT02230319,Phase II,Unknown status,"[{'id': 1103, 'therapyName': 'Paclitaxel'}]",Prevention of Paclitaxel Neuropathy With Cryotherapy,1612
87,NCT02260531,Phase II,Recruiting,"[{'id': 998, 'therapyName': 'cabozantinib'}, {'id': 947, 'therapyName': 'Trastuzumab'}]",Cabozantinib + / - Trastuzumab In Breast Cancer Patients w/ Brain Metastases,1612
88,NCT02265536,Phase I,Recruiting,"[{'id': 2004, 'therapyName': 'LY3022855'}]",A Study of LY3022855 In Participants With Breast or Prostate Cancer,1612
89,NCT02303990,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",RADVAX A Stratified Phase I Trial of Pembrolizumab With Hypofractionated Radiotherapy in Patients With Advanced and Metastatic Cancers,1612
90,NCT02308020,Phase II,Recruiting,"[{'id': 802, 'therapyName': 'Abemaciclib'}]",A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer That Has Spread to the Brain,1612
91,NCT02314156,Phase II,Recruiting,"[{'id': 2820, 'therapyName': 'Telapristone'}]",Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy,1612
92,NCT02340221,Phase III,Recruiting,"[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 1016, 'therapyName': 'GDC-0032'}]",SANDPIPER Study: A Study Of Taselisib + Fulvestrant Versus Placebo + Fulvestrant In Patients With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy,1612
93,NCT02366130,Phase II,Recruiting,"[{'id': 2001, 'therapyName': 'radium Ra 223 dichloride'}, {'id': 1198, 'therapyName': 'Denosumab'}]",Phase II Trial of Ra-223 Dichloride and Hormonal Treatment,1612
94,NCT02379585,Phase Ib/II,Terminated,"[{'id': 1495, 'therapyName': 'Paclitaxel + Doxorubicin + Cyclophosphamide'}, {'id': 1978, 'therapyName': 'Pertuzumab + Trastuzumab + Docetaxel'}]",Study of Short-term Fasting on Neoadjuvant Chemotherapy in Patients With Newly Diagnosed Breast Cancer,1612
95,NCT02391480,Phase I,Recruiting,"[{'id': 4028, 'therapyName': 'ABBV-075'}]",A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer,1612
96,NCT02393248,Phase Ib/II,Recruiting,"[{'id': 4176, 'therapyName': 'Cisplatin + Gemcitabine + INCB054828'}, {'id': 4174, 'therapyName': 'Docetaxel + INCB054828'}, {'id': 4088, 'therapyName': 'Epacadostat + Pembrolizumab'}]","Open-Label, Dose-Escalation Study of INCB054828 in Subjects With Advanced Malignancies",1612
97,NCT02393794,Phase Ib/II,"Active, not recruiting","[{'id': 2993, 'therapyName': 'Cisplatin + Romidepsin '}]",Romidepsin Plus Cisplatin in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC),1612
98,NCT02432963,Phase I,Recruiting,"[{'id': 1038, 'therapyName': 'MVAp53'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy,1612
99,NCT02540330,Phase II,Recruiting,"[{'id': 744, 'therapyName': 'Fulvestrant'}]",PK Study of Pre-Surgical Intramuscular and Intraductal Fulvestrant in Women With Invasive Breast Cancer or DCIS Undergoing Mastectomy,1612
100,NCT02563925,Phase I,"Active, not recruiting","[{'id': 1652, 'therapyName': 'Tremelimumab'}]",Brain Irradiation and Tremelimumab in Metastatic Breast Cancer,1612
101,NCT02564900,Phase I,Recruiting,"[{'id': 4844, 'therapyName': 'DS-8201a'}]",Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors,1612
102,NCT02576665,Phase I,Recruiting,"[{'id': 3211, 'therapyName': 'Toca 511 + Toca FC'}]","A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Solid Tumors (Toca6)",1612
103,NCT02586675,Phase I,"Active, not recruiting","[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 3175, 'therapyName': 'LEE001 + Tamoxifen'}]",TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer,1612
104,NCT02595905,Phase I,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 954, 'therapyName': 'Veliparib'}]",Cisplatin With or Without Veliparib in Treating Patients With Stage IV Triple-Negative and/or BRCA Mutation-Associated Breast Cancer,1612
105,NCT02599363,Phase I,Recruiting,"[{'id': 3206, 'therapyName': 'Paclitaxel + Ribociclib'}]",A Trial of Ribocilcib (LEE011) and Weekly Paclitaxel in Patients With Rb+ Advanced Breast Cancer,1612
106,NCT02605486,Phase Ib/II,Recruiting,"[{'id': 3252, 'therapyName': 'Bicalutamide + Palbociclib'}]",Palbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC),1612
107,NCT02639026,Phase I,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]","Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers",1612
108,NCT02640508,Phase II,Recruiting,"[{'id': 3352, 'therapyName': 'Eribulin + Lenvatinib'}]",Eribulin and Lenvatinib in Advanced Solid Tumors,1612
109,NCT02643303,Phase Ib/II,Recruiting,"[{'id': 3385, 'therapyName': 'MEDI4736 + poly ICLC '}, {'id': 1652, 'therapyName': 'Tremelimumab'}]","A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers",1612
110,NCT02646319,Phase II,"Active, not recruiting","[{'id': 3380, 'therapyName': 'Nab-Rapamycin'}]",Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations,1612
111,NCT02650635,Phase I,"Active, not recruiting","[{'id': 3413, 'therapyName': 'Cyclophosphamide + Pegfilgrastim + VTX-2337'}]","TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors",1612
112,NCT02673398,Phase II,Recruiting,"[{'id': 828, 'therapyName': 'Neratinib'}]",Neratinib in Treating Older Patients With Locally Advanced or Metastatic HER2-Positive Breast Cancer,1612
113,NCT02721433,FDA approved,Recruiting,"[{'id': 4784, 'therapyName': 'Denosumab + pamidronate + Zoledronic acid'}]",4-weekly Versus 12-weekly Administration of Bone-targeted Agents in Patients With Bone Metastases (REaCT-BTA),1612
114,NCT02725541,Phase II,Withdrawn,"[{'id': 1402, 'therapyName': 'trastuzumab emtansine'}]",Trial of Neoadjuvant Trastuzumab Emtansine in Patients With HER2-Equivocal Breast Cancer,1612
115,NCT02734004,Phase Ib/II,"Active, not recruiting","[{'id': 2894, 'therapyName': 'Durvalumab + Olaparib'}]",A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. (MEDIOLA),1612
116,NCT02746328,Phase II,"Active, not recruiting","[{'id': 5026, 'therapyName': 'enobosarm'}]",Add-on Study for Protocol G200802 (NCT02463032): Effect of GTx-024 on Maximal Neuromuscular Function and Lean Body Mass,1612
117,NCT02784795,Phase I,Recruiting,"[{'id': 4374, 'therapyName': 'Cisplatin + Gemcitabine + LY3039478'}, {'id': 4375, 'therapyName': 'Carboplatin + Gemcitabine + LY3039478'}, {'id': 4372, 'therapyName': 'LY3039478 + LY3023414'}, {'id': 4373, 'therapyName': 'Abemaciclib + LY3039478'}, {'id': 4371, 'therapyName': 'LY3039478 + Taladegib'}, {'id': 2958, 'therapyName': 'LY3039478'}, {'id': 1069, 'therapyName': 'LY3023414'}]",A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors,1612
118,NCT02874430,Phase II,Recruiting,"[{'id': 4610, 'therapyName': 'Metformin + Doxycycline'}]",Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer,1612
119,NCT02900469,Phase 0,Recruiting,"[{'id': 1198, 'therapyName': 'Denosumab'}]",Safety Study of Denosumab to Treat Breast Cancer,1612
120,NCT02939274,Phase II,Recruiting,"[{'id': 3319, 'therapyName': 'Verteporfin'}]","An Open Label, Phase II Trial of Continuous Low-Irradiance Photodynamic Therapy (CLIPT) Using Verteporfin (Visudyne) for the Treatment of Cutaneous Metastases of Breast Cancer",1612
121,NCT02953782,Phase Ib/II,Recruiting,"[{'id': 4948, 'therapyName': 'Cetuximab + Hu5F9-G4'}]",Trial of Hu5F9-G4 in Combination With Cetuximab in Patients With Solid Tumors and Advanced Colorectal Cancer,1612
122,NCT02965885,Phase I,Recruiting,"[{'id': 2768, 'therapyName': 'TAS-116'}]",A Study of TAS-116 in Patients With Solid Tumors,1612
123,NCT02985658,Phase I,Available,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 954, 'therapyName': 'Veliparib'}, {'id': 1685, 'therapyName': 'Vinorelbine'}]",Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer,1612
124,NCT02999477,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 619, 'therapyName': 'Abraxane'}]",A Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast Cancer,1612
125,NCT03006172,Phase I,Recruiting,"[{'id': 5182, 'therapyName': 'GDC-0077 + Letrozole + Palbociclib'}, {'id': 5181, 'therapyName': 'GDC-0077'}, {'id': 5184, 'therapyName': 'GDC-0077 + Fulvestrant'}, {'id': 5183, 'therapyName': 'GDC-0077 + Letrozole'}]","To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer",1612
126,NCT03025035,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Advanced BRCA-mutated Breast Cancer,1612
127,NCT03032107,Phase I,Recruiting,"[{'id': 1909, 'therapyName': 'Pembrolizumab + trastuzumab emtansine'}]",A Study Of Pembrolizumab In Combination With Trastuzumab-DM1,1612
128,NCT03032406,Phase II,Recruiting,"[{'id': 2231, 'therapyName': 'Everolimus + Hydroxychloroquine'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 1316, 'therapyName': 'Hydroxychloroquine'}]","CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer",1612
129,NCT03044730,Phase II,Recruiting,"[{'id': 4022, 'therapyName': 'Capecitabine + Pembrolizumab'}]",Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery,1612
130,NCT03050398,Phase III,Recruiting,"[{'id': 1568, 'therapyName': 'LEE011 + Letrozole'}]",A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib,1612
131,NCT03095352,Phase II,Recruiting,"[{'id': 5265, 'therapyName': 'Carboplatin + Pembrolizumab'}]","A Randomized Phase II Study of Pembrolizumab, an Anti-PD (Programmed Cell Death)-1 Antibody, in Combination With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease",1612
132,NCT03099174,Phase I,Recruiting,"[{'id': 5514, 'therapyName': 'Abemaciclib + Xentuzumab'}, {'id': 5515, 'therapyName': 'Abemaciclib + Letrozole + Xentuzumab'}, {'id': 5516, 'therapyName': 'Abemaciclib + Anastrozole + Xentuzumab'}, {'id': 5517, 'therapyName': 'Abemaciclib + Fulvestrant + Xentuzumab'}]",This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer.,1612
133,NCT03101748,Phase Ib/II,Not yet recruiting,"[{'id': 3187, 'therapyName': 'Neratinib + Paclitaxel + Pertuzumab + Trastuzumab'}, {'id': 1505, 'therapyName': 'Paclitaxel + Neratinib + Doxorubicin + Cyclophosphamide'}]",3HT With Taxol for Metastatic Breast Cancer,1612
134,NCT03102606,Phase II,Recruiting,"[{'id': 3678, 'therapyName': 'Plinabulin'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}]",Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy (Protective-1),1612
135,NCT03150810,Phase Ib/II,Recruiting,"[{'id': 6124, 'therapyName': 'BGB-290 + Temozolomide'}]","Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Subjects With Locally Advanced or Metastatic Solid Tumors",1612
136,NCT03154281,Phase I,Not yet recruiting,"[{'id': 5732, 'therapyName': 'Niraparib + Everolimus'}]",Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Ovarian and Breast,1612
137,NCT03179904,Phase II,Recruiting,"[{'id': 5874, 'therapyName': 'Paclitaxel + Trastuzumab + TVB-2640'}]","FASN Inhibitor TVB-2640, Paclitaxel, and Trastuzumab in Treating Patients With HER2 Positive Advanced Breast Cancer",1612
138,NCT03207529,Phase I,Not yet recruiting,"[{'id': 3751, 'therapyName': 'BYL719 + Enzalutamide'}]",Study of BYL719 (Alpelisib) in Combination With Androgen Receptor Inhibitor (Enzalutamide) in Patients With Androgen Receptor (AR)-Positive and PTEN Positive Metastatic Breast Cancer,1612
139,NCT03237572,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Focused Ultrasound and Pembrolizumab in Metastatic Breast Cancer (Breast-48),1612
140,NCT03248492,Phase II,Recruiting,"[{'id': 4844, 'therapyName': 'DS-8201a'}]",DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer,1612
141,NCT03310541,,Recruiting,"[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 655, 'therapyName': 'AZD5363'}]",AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations,1612
0,NCT01174121,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 1167, 'therapyName': 'Aldesleukin'}]",Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer,3459
1,NCT01293032,Phase I,Completed,"[{'id': 1456, 'therapyName': 'Tamoxifen'}]",Hormone Therapy Or Chemotherapy Before Surgery Based on Gene Expression Analysis in Treating Patients With Breast Cancer,3459
2,NCT01466972,Phase II,"Active, not recruiting","[{'id': 848, 'therapyName': 'Pazopanib'}]",Reversing Hormone Resistance in Advanced Breast Cancer With Pazopanib,3459
3,NCT01864746,Phase III,Recruiting,"[{'id': 850, 'therapyName': 'Palbociclib'}]",A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery,3459
4,NCT01945775,Phase III,"Active, not recruiting","[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 682, 'therapyName': 'Talazoparib'}, {'id': 728, 'therapyName': 'Eribulin'}]","A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)",3459
5,NCT01952054,Phase II,Recruiting,"[{'id': 1198, 'therapyName': 'Denosumab'}]",Denosumab for Breast Cancer With Bone Mets,3459
6,NCT02034916,Phase II,"Active, not recruiting","[{'id': 682, 'therapyName': 'Talazoparib'}]","A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study)",3459
7,NCT02270372,Phase I,Completed,"[{'id': 2525, 'therapyName': 'Varlilumab'}, {'id': 3051, 'therapyName': 'ONT-10'}]",Study of ONT-10 and Varlilumab to Treat Advanced Ovarian or Breast Cancer,3459
8,NCT02278965,Phase I,"Active, not recruiting","[{'id': 1031, 'therapyName': 'Metformin'}]",Metformin and Omega-3 Fatty Acids in Woman With a History of Early Stage Breast Cancer,3459
9,NCT02411656,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",MK-3475 for Metastatic Inflammatory Breast Cancer (MIBC),3459
10,NCT02436993,Phase II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Breast Cancer Treatment Using Weekly Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting,3459
11,NCT02454972,Phase II,Recruiting,"[{'id': 1195, 'therapyName': 'Lurbinectedin'}]",Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors,3459
12,NCT02960594,Phase I,Recruiting,"[{'id': 5844, 'therapyName': 'INO-1400 + INO-9012'}, {'id': 5807, 'therapyName': 'INO-1400'}]",hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse,3459
13,NCT03004534,Phase 0,Recruiting,"[{'id': 836, 'therapyName': 'ODM-201'}]",A Study to Evaluate Changes in Human Breast Cancer Tissue Following Short-Term Use of ODM-201,3459
14,NCT03238196,Phase I,Recruiting,"[{'id': 6099, 'therapyName': 'JNJ-42756493 + Fulvestrant + Palbociclib'}]","Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer",3459
15,NCT03238495,Phase II,Recruiting,"[{'id': 1879, 'therapyName': 'Pertuzumab + Trastuzumab + Carboplatin + Docetaxel'}, {'id': 6101, 'therapyName': 'Metformin + Pertuzumab + Trastuzumab + Carboplatin + Docetaxel'}]",Randomized Trial of Neo-adjuvant Chemotherapy With or Without Metformin for HER2 Positive Operable Breast Cancer,3459
16,NCT03238703,FDA approved,Not yet recruiting,"[{'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 794, 'therapyName': 'Letrozole'}]","Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer",3459
0,NCT02834013,Phase 0,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab in Treating Patients With Rare Tumors,4926
0,NCT00084695,Phase II,Unknown status,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases,8584
1,NCT01897012,Phase I,Recruiting,"[{'id': 1075, 'therapyName': 'romidepsin'}, {'id': 626, 'therapyName': 'Alisertib'}]",Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas,8584
2,NCT02532192,Phase I,Withdrawn,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1689, 'therapyName': 'Fluconazole'}, {'id': 1078, 'therapyName': 'Belinostat'}]","A Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in Adults With Relapsed or Refractory Diffuse Large B-cell Lymphoma",8584
3,NCT02700022,Phase I,"Active, not recruiting","[{'id': 626, 'therapyName': 'Alisertib'}, {'id': 3395, 'therapyName': 'R-EPOCH'}]",A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas,8584
4,NCT02701673,Phase Ib/II,Withdrawn,"[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 3277, 'therapyName': 'Pyridoxine'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1078, 'therapyName': 'Belinostat'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}]",Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma,8584
5,NCT02722668,Phase II,Recruiting,"[{'id': 2281, 'therapyName': 'Cyclophosphamide + Fludarabine + Mycophenolate mofetil'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}]",UCB Transplant for Hematological DIseases Using a Non Myeloablative Prep,8584
6,NCT02875002,Phase I,Not yet recruiting,"[{'id': 4826, 'therapyName': 'Belinostat + Volasertib'}]",Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas,8584
7,NCT02909777,Phase I,Recruiting,"[{'id': 709, 'therapyName': 'CUDC-907'}]","Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma",8584
8,NCT02950220,Phase I,Recruiting,"[{'id': 4917, 'therapyName': 'Pembrolizumab + Ibrutinib'}]",Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma,8584
9,NCT03015896,Phase Ib/II,Suspended,"[{'id': 5239, 'therapyName': 'Lenalidomide + Nivolumab'}]",Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma,8584
10,NCT03136146,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1090, 'therapyName': 'Ofatumumab'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}]","Study of Clofarabine, Etoposide, Cyclophosphamide [CEC], Liposomal Vincristine (VCR), Dexamethasone and Bortezomib in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL)",8584
0,NCT03247283,,Recruiting,"[{'id': 3568, 'therapyName': 'BMS-986205'}]",Pharmacokinetics and Metabolism Study in Healthy Male Participants,162
1,NCT03310879,,Not yet recruiting,"[{'id': 802, 'therapyName': 'Abemaciclib'}]",A Phase II Study of the CDK4/6 Inhibitor Abemaciclib in Patients With Solid Tumors Harboring Genetic Alterations in Genes Encoding D-type Cyclins or Amplification of CDK4 or CDK6,162
0,NCT01148849,Phase I,"Active, not recruiting","[{'id': 808, 'therapyName': 'MGAH22'}]",Safety Study of MGAH22 in HER2-positive Carcinomas,305
1,NCT02259114,Phase I,Completed,"[{'id': 2034, 'therapyName': 'OTX015'}]","A Phase IB Trial With OTX015, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Patients With Selected Advanced Solid Tumors",305
2,NCT02454972,Phase II,Recruiting,"[{'id': 1195, 'therapyName': 'Lurbinectedin'}]",Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors,305
3,NCT02637531,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 3363, 'therapyName': 'IPI-549'}]","A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549",305
4,NCT02648490,Phase I,Recruiting,"[{'id': 3939, 'therapyName': 'Acetaminophen + Dexamethasone + Diphenhydramine + Ondansetron'}, {'id': 3938, 'therapyName': 'HLX07'}]","An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers",305
5,NCT02721732,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors,305
6,NCT02879162,Phase II,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours,305
7,NCT03094169,Phase I,Recruiting,"[{'id': 5755, 'therapyName': 'AVID100'}]",AVID100 in Advanced Epithelial Carcinomas,305
0,NCT02834013,Phase 0,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab in Treating Patients With Rare Tumors,4236
1,NCT03206177,Phase I,Recruiting,"[{'id': 6265, 'therapyName': 'Carboplatin + Galunisertib + Paclitaxel'}]",Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary,4236
0,NCT00939770,Phase Ib/II,"Active, not recruiting","[{'id': 706, 'therapyName': 'Crizotinib'}]",Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma,3620
1,NCT02255461,Phase I,Recruiting,"[{'id': 850, 'therapyName': 'Palbociclib'}]","Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors",3620
2,NCT02303028,Phase Ib/II,Recruiting,"[{'id': 1469, 'therapyName': 'Topotecan + Pazopanib'}]",Phase I Dose Escalation Study of Topotecan and Pazopanib in Children With Recurrent/Refractory Solid and CNS Tumours,3620
3,NCT02390752,Phase Ib/II,Recruiting,"[{'id': 874, 'therapyName': 'PLX3397'}]",PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN),3620
4,NCT02564198,Phase I,Recruiting,"[{'id': 886, 'therapyName': 'Ramucirumab'}]",A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors,3620
5,NCT02576431,Phase II,Recruiting,"[{'id': 2650, 'therapyName': 'LOXO-101'}]",Study of LOXO-101 in Subjects With NTRK Fusion Positive Solid Tumors,3620
6,NCT02637687,Phase I,Recruiting,"[{'id': 2650, 'therapyName': 'LOXO-101'}]",Oral TRK Inhibitor LOXO-101 for Treatment of Advanced Pediatric Solid or Primary Central Nervous System Tumors,3620
7,NCT02650401,Phase I,Recruiting,"[{'id': 1455, 'therapyName': 'Entrectinib'}]",Study of RXDX-101 in Children With Recurrent or Refractory Solid Tumors and Primary CNS Tumors,3620
8,NCT02653196,Phase II,Terminated,"[{'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1205, 'therapyName': 'Alemtuzumab'}, {'id': 2373, 'therapyName': 'Palifermin'}, {'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}, {'id': 3948, 'therapyName': 'Cyclosporine + Mycophenolate mofetil + Tacrolimus'}]",A Multi-Institutional Phase II Feasibility Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors,3620
9,NCT02677116,Phase I,Recruiting,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 3618, 'therapyName': 'Irinotecan + Vincristine'}, {'id': 3269, 'therapyName': 'Olaratumab'}]",A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer,3620
10,NCT02780804,Phase I,Recruiting,"[{'id': 1541, 'therapyName': 'Entinostat'}]",Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors,3620
11,NCT02793466,Phase I,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}]",Durvalumab in Pediatric and Adolescent Patients,3620
12,NCT02808650,Phase I,Recruiting,"[{'id': 1651, 'therapyName': 'Prexasertib'}]",Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors,3620
13,NCT02867592,Phase II,Recruiting,"[{'id': 998, 'therapyName': 'cabozantinib'}]","Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors",3620
14,NCT02932280,Phase Ib/II,Recruiting,"[{'id': 828, 'therapyName': 'Neratinib'}]",Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment,3620
15,NCT03050450,Phase I,Recruiting,"[{'id': 5337, 'therapyName': 'Lenalidomide + Vorinostat'}]",Study of Lenalidomide With Vorinostat in Pediatric Patients With High Grade or Progressive CNS Tumors,3620
16,NCT03130959,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",An Investigational Immuno-therapy Study of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Patients With High Grade Primary CNS Malignancies (CheckMate 908),3620
17,NCT03155620,Phase II,Recruiting,"[{'id': 2683, 'therapyName': 'Tazemetostat'}, {'id': 2650, 'therapyName': 'LOXO-101'}, {'id': 1069, 'therapyName': 'LY3023414'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 913, 'therapyName': 'Selumetinib'}, {'id': 961, 'therapyName': 'X-396'}]",Pediatric MATCH: Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Advanced Refractory Solid Tumors or Lymphomas,3620
0,NCT00267865,Phase II,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma,3234
1,NCT00293475,Phase Ib/II,Recruiting,"[{'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 2669, 'therapyName': 'Carboplatin + Methotrexate + Rituximab'}]",Rituximab and Methotrexate Chemotherapy w/Blood-Brain Barrier Disruption (BBBD) &amp; Sodium Thiosulfate Chemoprotection for Patients With Newly Diagnosed PCNSL,3234
2,NCT00621036,Phase II,Unknown status,"[{'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 1873, 'therapyName': 'Sargramostim'}]",Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma,3234
3,NCT02203526,Phase I,Suspended,"[{'id': 1607, 'therapyName': 'Temozolomide + Etoposide + Doxil + Dexamethasone + Ibrutinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 897, 'therapyName': 'Rituximab'}]","Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Dose-Adjusted-Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (DA-TEDDI-R) in Primary CNS Lymphoma",3234
4,NCT02301364,Phase II,Completed,"[{'id': 680, 'therapyName': 'BKM120'}]",Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL),3234
5,NCT02315326,Phase Ib/II,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}]","Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)",3234
6,NCT02669511,Phase II,Recruiting,"[{'id': 2019, 'therapyName': 'PQR309'}]",PQR309 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma,3234
7,NCT02857426,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",A Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Relapsed/Refractory Primary Testicular Lymphoma (PTL) (CheckMate 647),3234
8,NCT03220646,Phase II,Recruiting,"[{'id': 802, 'therapyName': 'Abemaciclib'}]",The Purpose of This Study is to Test Any Good and Bad Effects of a Study Drug Called Abemaciclib (LY2835219) in Patients With Recurrent Brain Tumors.,3234
0,NCT02257528,Phase II,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}]","Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer",3702
1,NCT02348398,Phase II,Withdrawn,"[{'id': 1469, 'therapyName': 'Topotecan + Pazopanib'}]",Phase II Study of Pazopanib and Topotecan in Cervical Cancer,3702
2,NCT02834013,Phase 0,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab in Treating Patients With Rare Tumors,3702
3,NCT02853604,Phase III,Recruiting,"[{'id': 3090, 'therapyName': 'ADXS11-001'}]",Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer (AIM2CERV),3702
0,NCT02780310,Phase II,"Active, not recruiting","[{'id': 792, 'therapyName': 'Lenvatinib'}]",Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma,4867
1,NCT03087019,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma,4867
2,NCT03172624,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer,4867
0,NCT02257528,Phase II,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}]","Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer",5636
1,NCT02348398,Phase II,Withdrawn,"[{'id': 1469, 'therapyName': 'Topotecan + Pazopanib'}]",Phase II Study of Pazopanib and Topotecan in Cervical Cancer,5636
2,NCT02853604,Phase III,Recruiting,"[{'id': 3090, 'therapyName': 'ADXS11-001'}]",Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer (AIM2CERV),5636
0,NCT00292955,Phase II,Unknown status,"[{'id': 694, 'therapyName': 'Cetuximab'}, {'id': 700, 'therapyName': 'Cisplatin'}]","Cetuximab, Cisplatin, and Radiotherapy in Women With Locally Advanced Cervical Carcinoma",4362
1,NCT00980954,Phase III,Recruiting,"[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy,4362
2,NCT01711515,Phase I,"Active, not recruiting","[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Chemoradiation Therapy and Ipilimumab in Treating Patients With Locally Advanced Cervical Cancer,4362
3,NCT01958112,Phase II,Terminated,"[{'id': 1150, 'therapyName': 'GSK1120212 + GSK2141795'}]",GSK1120212+GSK2141795 for Cervical Cancer,4362
4,NCT01958658,Phase I,Suspended,"[{'id': 1725, 'therapyName': 'MK-1775 + Cisplatin'}]","AZD1775, Cisplatin, and Radiation Therapy in Treating Patients With Cervical Cancer",4362
5,NCT01966445,Phase I,Completed,"[{'id': 2919, 'therapyName': 'GSK2849330'}]","Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors",4362
6,NCT01968109,Phase I,Recruiting,"[{'id': 4197, 'therapyName': 'BMS-986016 + Nivolumab'}, {'id': 4196, 'therapyName': 'BMS-986016'}]",Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors,4362
7,NCT02100007,Phase Ib/II,Terminated,"[{'id': 2174, 'therapyName': 'ME-344 + Topotecan'}]",ME-344 Given in Combination With Hycamtin in Patients With Solid Tumors,4362
8,NCT02312804,Phase I,Withdrawn,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 674, 'therapyName': 'BGJ398'}]",Ph Ib/BGJ398/Cervix and Other Solid Tumors,4362
9,NCT02426892,Phase II,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab and HPV-16 Vaccination in Patients With HPV-16 Positive Incurable Solid Tumors,4362
10,NCT02479178,Phase II,Terminated,"[{'id': 3640, 'therapyName': 'BIND-014'}]","A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck  (iNSITE2)",4362
11,NCT02487095,Phase Ib/II,Recruiting,"[{'id': 2879, 'therapyName': 'VX-970'}, {'id': 942, 'therapyName': 'Topotecan'}]","Trial of Topotecan With VX-970, an ATR Kinase Inhibitor, in Small Cell Lung Cancer",4362
12,NCT02488759,Phase Ib/II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",A Study to Investigate the Safety and Efficacy of Nivolumab in Virus-associated Tumors (CheckMate358),4362
13,NCT02540291,Phase I,Recruiting,"[{'id': 5694, 'therapyName': 'E7046'}]",Study of E7046 in Subjects With Selected Advanced Malignancies,4362
14,NCT02631733,Phase I,Recruiting,"[{'id': 3314, 'therapyName': 'Irinotecan + Veliparib'}]",Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery,4362
15,NCT02635360,Phase II,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab and Chemoradiation Treatment for Advanced Cervical Cancer,4362
16,NCT02661815,Phase I,"Active, not recruiting","[{'id': 3469, 'therapyName': 'ACY-1215 + Paclitaxel'}, {'id': 667, 'therapyName': 'Bevacizumab'}]","A Phase 1b Study of Weekly Paclitaxel And Oral Ricolinostat For The Treatment Of Recurrent Platinum Resistant Ovarian, Primary Peritoneal, Or Fallopian Tube Cancer",4362
17,NCT02665416,Phase I,Recruiting,"[{'id': 3468, 'therapyName': 'RO5520985 + RO7009789'}]","Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of RO7009789 With Vanucizumab in Metastatic Solid Tumors",4362
18,NCT02671955,Phase I,Terminated,"[{'id': 3614, 'therapyName': 'JNJ-61610588 '}]","A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced Cancer",4362
19,NCT02812056,Phase I,Withdrawn,"[{'id': 4214, 'therapyName': 'Alisertib + MLN0128'}]",Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated Malignancies,4362
20,NCT02963831,Phase Ib/II,Recruiting,"[{'id': 4978, 'therapyName': 'ONCOS-102 + MEDI4736'}]","A Phase 1/2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies",4362
21,NCT03023319,Phase I,Recruiting,"[{'id': 5237, 'therapyName': 'Bosutinib + Pemetrexed'}]",Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors,4362
22,NCT03074513,Phase II,Recruiting,"[{'id': 4595, 'therapyName': 'Atezolizumab + Bevacizumab'}]",Atezolizumab and Bevacizumab in Rare Solid Tumors,4362
23,NCT03104699,Phase Ib/II,Recruiting,"[{'id': 5693, 'therapyName': 'AGEN2034'}]",Phase 1 / 2 Study of AGEN2034 in Advanced Tumors and Cervical Cancer,4362
24,NCT03188965,Phase I,Recruiting,"[{'id': 5962, 'therapyName': 'BAY1895344'}]",First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas,4362
25,NCT03217747,Phase Ib/II,Recruiting,"[{'id': 5052, 'therapyName': 'Avelumab + Cisplatin'}, {'id': 6044, 'therapyName': 'Avelumab + PF-04518600 + Utomilumab'}, {'id': 6043, 'therapyName': 'Avelumab + Utomilumab'}, {'id': 6045, 'therapyName': 'Avelumab + PF-04518600'}]",Study to Evaluate the Safety and Tolerability of Avelumab in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies,4362
26,NCT03257267,Phase III,Recruiting,"[{'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 5656, 'therapyName': 'REGN2810'}, {'id': 942, 'therapyName': 'Topotecan'}]",Study of REGN2810 in Adults With Cervical Cancer,4362
27,NCT03289962,Phase I,Not yet recruiting,"[{'id': 6234, 'therapyName': 'RO7198457'}, {'id': 6235, 'therapyName': 'Atezolizumab + RO7198457'}]",A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors,4362
0,NCT02257528,Phase II,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}]","Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer",3744
1,NCT02348398,Phase II,Withdrawn,"[{'id': 1469, 'therapyName': 'Topotecan + Pazopanib'}]",Phase II Study of Pazopanib and Topotecan in Cervical Cancer,3744
2,NCT02646319,Phase II,"Active, not recruiting","[{'id': 3380, 'therapyName': 'Nab-Rapamycin'}]",Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations,3744
3,NCT02834013,Phase 0,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab in Treating Patients With Rare Tumors,3744
4,NCT02853604,Phase III,Recruiting,"[{'id': 3090, 'therapyName': 'ADXS11-001'}]",Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer (AIM2CERV),3744
0,NCT01607905,Phase I,Completed,"[{'id': 1749, 'therapyName': 'Selinexor'}]",Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced or Metastatic Solid Tumor Cancer,2893
1,NCT02164461,Phase Ib/II,"Active, not recruiting","[{'id': 3090, 'therapyName': 'ADXS11-001'}]",ADXS11-001 High Dose HPV+ Cervical Cancer,2893
2,NCT02291055,Phase Ib/II,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 3090, 'therapyName': 'ADXS11-001'}]",Phase 1-2 Study of ADXS11-001 or MEDI4736 Alone or Combo In Cervical or HPV+ Head &amp; Neck Cancer,2893
3,NCT02315066,Phase I,Recruiting,"[{'id': 4333, 'therapyName': 'PF-04518600'}, {'id': 4448, 'therapyName': 'PF-04518600 + Utomilumab'}]",Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566,2893
4,NCT02394652,Phase II,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1031, 'therapyName': 'Metformin'}]",The Potential for Metformin to Improve Tumor Oxygenation in Locally Advanced Cervix Cancer,2893
5,NCT02628067,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158),2893
6,NCT02723955,Phase I,Recruiting,"[{'id': 4409, 'therapyName': 'GSK3359609'}, {'id': 4410, 'therapyName': 'GSK3359609 + Pembrolizumab'}]",Dose Escalation and Expansion Study of GSK3359609 in Subjects With Selected Advanced Solid Tumors (INDUCE-1),2893
7,NCT02835833,Phase I,Recruiting,"[{'id': 4498, 'therapyName': 'Bevacizumab + Nintedanib'}]",Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors,2893
8,NCT02921269,Phase II,Suspended,"[{'id': 4595, 'therapyName': 'Atezolizumab + Bevacizumab'}]","Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer",2893
0,NCT01182350,Phase II,"Active, not recruiting","[{'id': 2115, 'therapyName': 'Bevacizumab + Temozolomide'}, {'id': 2116, 'therapyName': 'Bevacizumab + Erlotinib + Temozolomide'}, {'id': 1146, 'therapyName': 'Bevacizumab + Erlotinib'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG),6383
1,NCT01661400,Phase I,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1475, 'therapyName': 'Thalidomide'}]",Anti-Angiogenic Therapy Post Transplant (ASCR) for Relapsed and Refractory Pediatric Solid Tumors,6383
0,NCT01625351,Phase I,"Active, not recruiting","[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1205, 'therapyName': 'Alemtuzumab'}]",A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas,3675
0,NCT00665990,Phase I,Completed,"[{'id': 1119, 'therapyName': 'Sorafenib + Avastin + Cyclophosphamide'}]",Phase I Study of Bevacizumab and Sorafenib Combined With Low Dose Cyclophosphamide in Patients With Refractory Solid Tumors and Leukemia,7757
1,NCT01164163,Phase I,Completed,"[{'id': 907, 'therapyName': 'Ruxolitinib'}]","INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease",7757
0,NCT00602667,Phase I,"Active, not recruiting","[{'id': 2449, 'therapyName': 'Methotrexate + Cisplatin + Cyclophosphamide + Vincristine'}, {'id': 2450, 'therapyName': 'Cyclophosphamide + Etoposide + Topotecan'}, {'id': 2451, 'therapyName': 'Erlotinib + Cyclophosphamide + Topotecan'}]","Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma",3869
1,NCT01661400,Phase I,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1475, 'therapyName': 'Thalidomide'}]",Anti-Angiogenic Therapy Post Transplant (ASCR) for Relapsed and Refractory Pediatric Solid Tumors,3869
2,NCT02095132,Phase Ib/II,Recruiting,"[{'id': 1361, 'therapyName': 'MK-1775 + Irinotecan'}]",WEE1 Inhibitor MK-1775 and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors,3869
0,NCT01174121,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 1167, 'therapyName': 'Aldesleukin'}]",Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer,4947
1,NCT01438554,Phase I,"Active, not recruiting","[{'id': 1310, 'therapyName': 'Pazopanib + Trametinib'}]","Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma",4947
2,NCT01642342,Phase I,Recruiting,"[{'id': 3013, 'therapyName': 'sEphB4-HSA'}]",Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors,4947
3,NCT01695005,Phase I,Recruiting,"[{'id': 2958, 'therapyName': 'LY3039478'}]",A Study of LY3039478 in Participants With Advanced Cancer,4947
4,NCT01825603,Phase I,Recruiting,"[{'id': 4952, 'therapyName': 'ADH-1 + Cisplatin + Gemcitabine'}]","ADH-1, Gemcitabine Hydrochloride and Cisplatin in Treating Patients With Metastatic Pancreatic or Biliary Tract Cancer That Cannot Be Removed By Surgery",4947
5,NCT01888302,Phase I,Completed,"[{'id': 2289, 'therapyName': 'Cisplatin + Gemcitabine + Sirolimus '}]","Sirolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients At High Risk for Cholangiocarcinoma Recurrence After Liver Transplant or Surgery",4947
6,NCT02024607,Phase Ib/II,"Active, not recruiting","[{'id': 1597, 'therapyName': 'Capecitabine + Oxaliplatin'}, {'id': 2093, 'therapyName': 'BBI608 + Bevacizumab'}, {'id': 2094, 'therapyName': 'BBI608 + Regorafenib'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 2057, 'therapyName': 'BBI608'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer,4947
7,NCT02053376,Phase II,"Active, not recruiting","[{'id': 890, 'therapyName': 'Regorafenib'}]",A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy,4947
8,NCT02128282,Phase Ib/II,Recruiting,"[{'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 6091, 'therapyName': 'Cisplatin + Gemcitabine + Silmitasertib'}]",Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma,4947
9,NCT02150967,Phase II,Recruiting,"[{'id': 674, 'therapyName': 'BGJ398'}]","A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma",4947
10,NCT02232633,Phase II,Recruiting,"[{'id': 1945, 'therapyName': 'BBI503'}]",A Study of BBI503 in Adult Patients With Advanced Hepatobiliary Cancer,4947
11,NCT02240238,Phase Ib/II,Recruiting,"[{'id': 5626, 'therapyName': 'Gemcitabine + NC-6004'}]","Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer",4947
12,NCT02393248,Phase Ib/II,Recruiting,"[{'id': 4176, 'therapyName': 'Cisplatin + Gemcitabine + INCB054828'}, {'id': 4174, 'therapyName': 'Docetaxel + INCB054828'}, {'id': 4088, 'therapyName': 'Epacadostat + Pembrolizumab'}]","Open-Label, Dose-Escalation Study of INCB054828 in Subjects With Advanced Malignancies",4947
13,NCT02452970,Phase II,"Active, not recruiting","[{'id': 3680, 'therapyName': 'RRx-001'}, {'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}]",RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration of First-Line Therapy (EPIC),4947
14,NCT02479178,Phase II,Terminated,"[{'id': 3640, 'therapyName': 'BIND-014'}]","A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck  (iNSITE2)",4947
15,NCT02508467,Phase I,Recruiting,"[{'id': 3165, 'therapyName': 'BLU-554'}]",A Phase 1 Study of BLU-554 in Patients With Hepatocellular Carcinoma and Cholangiocarcinoma,4947
16,NCT02520141,Phase II,Recruiting,"[{'id': 886, 'therapyName': 'Ramucirumab'}]",Ramucirumab for Advanced Pre-treated Biliary Cancers,4947
17,NCT02628067,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158),4947
18,NCT02638909,Phase II,Recruiting,"[{'id': 789, 'therapyName': 'Ceritinib'}]",Study of Oral Ceritinib in Patients With ALK-Activated Gastrointestinal Malignancies,4947
19,NCT02711553,Phase II,"Active, not recruiting","[{'id': 886, 'therapyName': 'Ramucirumab'}, {'id': 1030, 'therapyName': 'LY2801653'}, {'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}]",A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer,4947
20,NCT02784795,Phase I,Recruiting,"[{'id': 4374, 'therapyName': 'Cisplatin + Gemcitabine + LY3039478'}, {'id': 4375, 'therapyName': 'Carboplatin + Gemcitabine + LY3039478'}, {'id': 4372, 'therapyName': 'LY3039478 + LY3023414'}, {'id': 4373, 'therapyName': 'Abemaciclib + LY3039478'}, {'id': 4371, 'therapyName': 'LY3039478 + Taladegib'}, {'id': 2958, 'therapyName': 'LY3039478'}, {'id': 1069, 'therapyName': 'LY3023414'}]",A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors,4947
21,NCT02834013,Phase 0,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab in Treating Patients With Rare Tumors,4947
22,NCT02856568,Phase I,Withdrawn,"[{'id': 4526, 'therapyName': 'ACY-1215 + Cisplatin + Gemcitabine'}]","Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable or Metastatic Cholangiocarcinoma",4947
23,NCT02924376,Phase II,Recruiting,"[{'id': 4173, 'therapyName': 'INCB054828'}]",Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy,4947
24,NCT02963831,Phase Ib/II,Recruiting,"[{'id': 4978, 'therapyName': 'ONCOS-102 + MEDI4736'}]","A Phase 1/2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies",4947
25,NCT02982720,Phase II,Recruiting,"[{'id': 2625, 'therapyName': 'peginterferon alfa-2b + Pembrolizumab'}]",Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and PEG-Intron,4947
26,NCT02989857,Phase III,Recruiting,"[{'id': 1491, 'therapyName': 'AG-120'}]",Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy),4947
27,NCT03093870,Phase II,Not yet recruiting,"[{'id': 5543, 'therapyName': 'Capecitabine + Varlitinib'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer,4947
28,NCT03095781,Phase I,Recruiting,"[{'id': 5533, 'therapyName': 'Pembrolizumab + XL888'}]",Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer,4947
29,NCT03144661,Phase I,Recruiting,"[{'id': 5832, 'therapyName': 'INCB062079'}]",An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies,4947
30,NCT03201458,Phase II,Not yet recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}]",Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery,4947
31,NCT03207347,Phase II,Not yet recruiting,"[{'id': 832, 'therapyName': 'Niraparib'}]",A Trial of Niraparib in BAP1 and Other DNA Double-Strand Break Repair Deficient Neoplasms (UF-STO-ETI-001),4947
32,NCT03212274,Phase II,Not yet recruiting,"[{'id': 837, 'therapyName': 'Olaparib'}]","Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations",4947
33,NCT03230318,Phase III,Recruiting,"[{'id': 2900, 'therapyName': 'ARQ 087'}]",ARQ 087 in Subjects With FGFR2 Gene Fusion Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma,4947
34,NCT03250273,Phase II,Not yet recruiting,"[{'id': 6114, 'therapyName': 'Entinostat + Nivolumab'}]",A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma,4947
35,NCT03257761,Phase I,Not yet recruiting,"[{'id': 6146, 'therapyName': 'Durvalumab + SGI-110'}]","Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer",4947
0,NCT02834013,Phase 0,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab in Treating Patients With Rare Tumors,2602
0,NCT01446809,Phase I,"Active, not recruiting","[{'id': 1472, 'therapyName': 'Doxorubicin + Ifosfamide'}, {'id': 1471, 'therapyName': 'Pazopanib + Doxorubicin + Ifosfamide'}]",Pazopanib Hydrochloride Followed By Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma,3371
1,NCT03190174,Phase Ib/II,Recruiting,"[{'id': 5931, 'therapyName': 'Nab-Rapamycin + Nivolumab'}]",Nivolumab (Opdivo) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma,3371
2,NCT03282344,Phase II,Recruiting,"[{'id': 5076, 'therapyName': 'NKTR-214 + Nivolumab'}]",A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma,3371
0,NCT01407198,Phase I,"Active, not recruiting","[{'id': 829, 'therapyName': 'Nilotinib'}]",Nilotinib With Radiation for High Risk Chordoma,3302
1,NCT02989636,Phase I,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]","Nivolumab With or Without Stereotactic Radiosurgery in Treating Patients With Recurrent, Advanced, or Metastatic Chordoma",3302
2,NCT03173950,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Immune Checkpoint Inhibitor Nivolumab in People With Select Rare CNS Cancers,3302
0,NCT01535053,Phase III,"Active, not recruiting","[{'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 1639, 'therapyName': 'Methotrexate'}]",Methotrexate or Dactinomycin in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia,3594
0,NCT02458339,Phase I,Recruiting,"[{'id': 1639, 'therapyName': 'Methotrexate'}]",Methotrexate Infusion Into Fourth Ventricle in Children With Recurrent Malignant Fourth Ventricular Brain Tumors,5648
1,NCT03173950,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Immune Checkpoint Inhibitor Nivolumab in People With Select Rare CNS Cancers,5648
0,NCT03173950,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Immune Checkpoint Inhibitor Nivolumab in People With Select Rare CNS Cancers,2626
0,NCT00831480,Phase II,Terminated,"[{'id': 735, 'therapyName': 'Everolimus'}]",Everolimus(RAD001) For Advanced Renal Cell Carcinoma(RCC)Before Kidney Removal,4471
1,NCT02915783,Phase II,Recruiting,"[{'id': 1713, 'therapyName': 'Everolimus + Lenvatinib'}]",A Phase 2 Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease,4471
0,NCT00513474,Phase I,Completed,"[{'id': 2313, 'therapyName': 'Rasburicase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2314, 'therapyName': 'Busulfan + Cyclophosphamide + Etoposide'}]",Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant,1040
1,NCT00577278,Phase II,"Active, not recruiting","[{'id': 767, 'therapyName': 'Ibritumomab'}, {'id': 2238, 'therapyName': 'Sirolimus + Tacrolimus + Methotrexate'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}]","Yttrium Y 90 Ibritumomab Tiuxetan, Rituximab, Indium In-111 Ibritumomab Tiuxetan, Fludarabine, Melphalan, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin Lymphoma",1040
2,NCT00602693,Phase I,Completed,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 2311, 'therapyName': 'Allopurinol + Cyclophosphamide + Fludarabine'}]",T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer,1040
3,NCT00671112,Phase I,Terminated,"[{'id': 2234, 'therapyName': 'Bortezomib + Everolimus'}]",Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma,1040
4,NCT00829647,Phase Ib/II,Withdrawn,"[{'id': 1825, 'therapyName': 'Dasatinib + lenalidomide'}]",A Study Using Two Oral Chemotherapy Agents for Chronic Lymphocytic Leukemia,1040
5,NCT00857389,Phase II,"Active, not recruiting","[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 2469, 'therapyName': 'Busulfan + Clofarabine + Thymoglobulin'}, {'id': 1639, 'therapyName': 'Methotrexate'}]",Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies,1040
6,NCT01173679,Phase II,Terminated,"[{'id': 1821, 'therapyName': 'Dasatinib + Rituximab + Fludarabine'}]",Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL),1040
7,NCT01193842,Phase Ib/II,"Active, not recruiting","[{'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 3395, 'therapyName': 'R-EPOCH'}]",Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,1040
8,NCT01251575,Phase II,Recruiting,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 2270, 'therapyName': 'Cyclosporine + Mycophenolate mofetil + Sirolimus'}]","Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant",1040
9,NCT01296932,Phase I,Completed,"[{'id': 4276, 'therapyName': 'BI 836826'}]",BI836826 Dose Escalation in Relapsed Chronic Lymphocytic Leukaemia (CLL),1040
10,NCT01353625,Phase I,"Active, not recruiting","[{'id': 1000, 'therapyName': 'CC-115'}]","Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.",1040
11,NCT01441882,Phase II,"Active, not recruiting","[{'id': 717, 'therapyName': 'Dasatinib'}]",A Study of Dasatinib in Chronic Lymphocytic Leukemia in Patients Who Exhibit in Vitro Dasatinib Sensitivity,1040
12,NCT01459211,Phase II,Completed,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1164, 'therapyName': 'lenalidomide'}]",Pilot Study to Establish Safety and Efficacy of a Combination of Dexamethasone and Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukaemia (CLL),1040
13,NCT01532700,Phase II,"Active, not recruiting","[{'id': 1091, 'therapyName': 'Ofatumumab + GSK2110183'}]", An Open-Label Phase 2 Study of Ofatumumab (Arzerra) in Combination With Oral GSK2110183 in the Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL),1040
14,NCT01556776,Phase III,Terminated,"[{'id': 1164, 'therapyName': 'lenalidomide'}]",A Study of Lenalidomide Maintenance for High-risk Patients With CLL Following First-line Therapy,1040
15,NCT01604031,Phase Ib/II,Terminated,"[{'id': 1164, 'therapyName': 'lenalidomide'}]",Treatment of B-CLL With Autologous IL2 and CD40 Ligand-Expressing Tumor Cells + Lenalidomide,1040
16,NCT01638533,Phase I,Recruiting,"[{'id': 1075, 'therapyName': 'romidepsin'}]","Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction",1040
17,NCT01644253,Phase I,Recruiting,"[{'id': 4745, 'therapyName': 'Idelalisib + Otlertuzumab + Rituximab'}, {'id': 4742, 'therapyName': 'Otlertuzumab + Rituximab'}, {'id': 4743, 'therapyName': 'Obinutuzumab + Otlertuzumab'}, {'id': 4744, 'therapyName': 'Ibrutinib + Otlertuzumab'}]","Phase 1b Safety and Efficacy Study of TRU-016 and Rituximab, Obinutuzumab, Idelalisib, or Ibrutinib in Chronic Lymphocytic Leukemia",1040
18,NCT01660451,Phase II,"Active, not recruiting","[{'id': 995, 'therapyName': 'Copanlisib'}]","Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas",1040
19,NCT01671904,Phase I,"Active, not recruiting","[{'id': 3638, 'therapyName': 'Bendamustine + GDC-0199 + Obinutuzumab'}, {'id': 3637, 'therapyName': 'Bendamustine + GDC-0199 + Rituximab'}]","A Study of Venetoclax (GDC-0199, ABT-199) in Combination With Bendamustine And MabThera/Rituxan in Participants With Chronic Lymphocytic Leukemia",1040
20,NCT01685892,Phase I,"Active, not recruiting","[{'id': 3636, 'therapyName': 'GDC-0199 + Obinutuzumab'}]",A Study of Venetoclax (GDC-0199; ABT-199) in Combination With Obinutuzumab in Participants With Chronic Lymphocytic Leukemia,1040
21,NCT01695005,Phase I,Recruiting,"[{'id': 2958, 'therapyName': 'LY3039478'}]",A Study of LY3039478 in Participants With Advanced Cancer,1040
22,NCT01732913,Phase III,Terminated,"[{'id': 1023, 'therapyName': 'Idelalisib'}, {'id': 897, 'therapyName': 'Rituximab'}]",Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas,1040
23,NCT01732926,Phase III,Terminated,"[{'id': 1023, 'therapyName': 'Idelalisib'}, {'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}]",Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas,1040
24,NCT01750567,Phase II,Recruiting,"[{'id': 1031, 'therapyName': 'Metformin'}]",A Pilot Study of Metformin Therapy in Patients With Relapsed Chronic Lymphocytic Leukemia (CLL) and Untreated CLL,1040
25,NCT01799889,Phase II,"Active, not recruiting","[{'id': 2522, 'therapyName': 'Entospletinib  '}]",A Phase 2 of Entospletinib in Subjects With Relapsed or Refractory Hematologic Malignancies,1040
26,NCT01804686,Phase III,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",A Long-term Extension Study of PCI-32765 (Ibrutinib),1040
27,NCT01822509,Phase I,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant,1040
28,NCT01829971,Phase I,Terminated,"[{'id': 1035, 'therapyName': 'MRX34'}]","A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection",1040
29,NCT01849276,Phase I,"Active, not recruiting","[{'id': 1792, 'therapyName': 'Metformin + Cytarabine'}]",Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML,1040
30,NCT01885897,Phase Ib/II,Recruiting,"[{'id': 3060, 'therapyName': 'ALT-803'}]",IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT,1040
31,NCT01889186,Phase II,"Active, not recruiting","[{'id': 1562, 'therapyName': 'Venetoclax'}]",A Study of the Efficacy of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia With the 17p Deletion,1040
32,NCT01905813,Phase I,"Active, not recruiting","[{'id': 2420, 'therapyName': 'INCB039110 + INCB040093'}, {'id': 2021, 'therapyName': 'INCB040093'}]",Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies,1040
33,NCT01980875,Phase III,Terminated,"[{'id': 1647, 'therapyName': 'Idelalisib + Obinutuzumab'}, {'id': 1648, 'therapyName': 'Obinutuzumab + Chlorambucil'}]",Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia,1040
34,NCT01980888,Phase III,Terminated,"[{'id': 2324, 'therapyName': 'Bendamustine + Idelalisib + Rituximab'}]",Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia,1040
35,NCT02000934,Phase I,Recruiting,"[{'id': 3146, 'therapyName': 'TAK-659'}]",A Study of TAK-659 in Adult Patients With Advanced Solid Tumor and Lymphoma Malignancies,1040
36,NCT02004522,Phase III,"Active, not recruiting","[{'id': 1024, 'therapyName': 'Duvelisib'}, {'id': 1090, 'therapyName': 'Ofatumumab'}]",A Phase 3 Study of IPI-145 Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO),1040
37,NCT02005289,Phase II,Recruiting,"[{'id': 5843, 'therapyName': 'Lenalidomide + MOR208'}, {'id': 5847, 'therapyName': 'Ibrutinib + MOR208'}]","Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL",1040
38,NCT02005471,Phase III,"Active, not recruiting","[{'id': 1562, 'therapyName': 'Venetoclax'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 897, 'therapyName': 'Rituximab'}]",A Study of GDC-0199 (ABT-199) Plus MabThera/Rituxan (Rituximab) Compared With Bendamustine Plus MabThera/Rituxan (Rituximab) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia,1040
39,NCT02015208,Phase Ib/II,Completed,"[{'id': 907, 'therapyName': 'Ruxolitinib'}]",Ruxolitinib in the Treatment of Chronic Lymphocytic Leukemia,1040
40,NCT02018861,Phase I,"Active, not recruiting","[{'id': 2406, 'therapyName': 'INCB039110'}, {'id': 3097, 'therapyName': 'INCB039110 + INCB050465'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 2352, 'therapyName': 'Carboplatin + Etoposide + Ifosfamide '}, {'id': 3088, 'therapyName': 'INCB050465 '}]","A Phase 1, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 Monotherapy and in Combination With INCB039110 in Subjects With Previously Treated B-Cell Malignancies",1040
41,NCT02044822,Phase II,Terminated,"[{'id': 2325, 'therapyName': 'Idelalisib + Rituximab'}]",Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion,1040
42,NCT02049515,Phase III,Enrolling by invitation,"[{'id': 1090, 'therapyName': 'Ofatumumab'}, {'id': 1024, 'therapyName': 'Duvelisib'}]",A Phase 3 Extension Study of IPI-145 and Ofatumumab in Patients With CLL/SLL Previously Enrolled in Study IPI-145-07,1040
43,NCT02061761,Phase Ib/II,Recruiting,"[{'id': 4197, 'therapyName': 'BMS-986016 + Nivolumab'}, {'id': 4196, 'therapyName': 'BMS-986016'}]",Safety Study of Anti-LAG-3 in Relapsed or Refractory Hematologic Malignancies,1040
44,NCT02100423,Phase II,"Active, not recruiting",[],Curcumin and Cholecalciferol in Treating Patients With Previously Untreated Stage 0-II Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma,1040
45,NCT02100852,Phase I,"Active, not recruiting","[{'id': 2342, 'therapyName': 'Chlorambucil + Obinutuzumab + TGR-1202'}]","TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL)",1040
46,NCT02131584,Phase II,"Active, not recruiting","[{'id': 907, 'therapyName': 'Ruxolitinib'}]",Administration of Jakafi (Ruxolitinib) for Symptom Control of Patients With Chronic Lymphocytic Leukemia (CLL),1040
47,NCT02135133,Phase II,Suspended,"[{'id': 2326, 'therapyName': 'Idelalisib + Ofatumumab'}]","A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL",1040
48,NCT02141282,Phase II,"Active, not recruiting","[{'id': 1562, 'therapyName': 'Venetoclax'}]",A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy,1040
49,NCT02158091,Phase Ib/II,"Active, not recruiting","[{'id': 2339, 'therapyName': 'Cyclophosphamide + Fludarabine + Rituximab '}, {'id': 1024, 'therapyName': 'Duvelisib'}]","A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL",1040
50,NCT02160015,Phase I,"Active, not recruiting","[{'id': 1610, 'therapyName': 'Rituximab + Lenalidomide + Ibrutinib'}]","Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",1040
51,NCT02200380,Phase II,Terminated,"[{'id': 1756, 'therapyName': 'Plerixafor'}, {'id': 3007, 'therapyName': 'CDX-301'}]",A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs,1040
52,NCT02200848,Phase I,Terminated,"[{'id': 1610, 'therapyName': 'Rituximab + Lenalidomide + Ibrutinib'}]","Phase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory CLL",1040
53,NCT02208037,Phase II,"Active, not recruiting",[],Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203),1040
54,NCT02222688,Phase I,Recruiting,"[{'id': 4312, 'therapyName': 'Cirmtuzumab'}]",UC-961 (Cirmtuzumab) in Relapsed or Refractory Chronic Lymphocytic Leukemia,1040
55,NCT02242942,Phase III,"Active, not recruiting","[{'id': 1648, 'therapyName': 'Obinutuzumab + Chlorambucil'}, {'id': 3636, 'therapyName': 'GDC-0199 + Obinutuzumab'}]",A Study to Compare the Efficacy and Safety of Obinutuzumab + GDC-0199 Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia,1040
56,NCT02249429,Phase Ib/II,Recruiting,"[{'id': 2019, 'therapyName': 'PQR309'}]","Open-Label, Non Randomized Phase 2 Study With Safety Run-In",1040
57,NCT02251548,Phase II,Recruiting,"[{'id': 2185, 'therapyName': 'Ibrutinib + Rituximab + Cyclophosphamide + Fludarabine'}]","A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia",1040
58,NCT02268851,Phase I,Recruiting,"[{'id': 2044, 'therapyName': 'Ibrutinib + TGR-1202'}]",A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL,1040
59,NCT02285244,Phase II,Withdrawn,"[{'id': 621, 'therapyName': 'AEB071'}]","Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Prolymphocytic Leukemia, or Richter's Transformation",1040
60,NCT02292225,Phase I,Terminated,"[{'id': 2341, 'therapyName': 'Duvelisib + Obinutuzumab'}]",IPI-145 With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi,1040
61,NCT02296918,Phase I,"Active, not recruiting","[{'id': 3477, 'therapyName': 'Acalabrutinib + Obinutuzumab'}]",ACP-196 in Combination With Obinutuzumab in Relapsed/Refractory or Untreated CLL/SLL/PLL,1040
62,NCT02301156,Phase III,"Active, not recruiting","[{'id': 2287, 'therapyName': 'Ublituximab'}, {'id': 768, 'therapyName': 'Ibrutinib'}]",Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL),1040
63,NCT02303392,Phase I,Recruiting,"[{'id': 3579, 'therapyName': 'Ibrutinib + Selinexor'}]",Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma,1040
64,NCT02315768,Phase Ib/II,Recruiting,"[{'id': 3476, 'therapyName': 'Ibrutinib + Obinutuzumab'}]",Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.,1040
65,NCT02319369,Phase I,Recruiting,"[{'id': 2079, 'therapyName': 'DS-3032b'}]","Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-3032b in Hematological Malignancies",1040
66,NCT02332980,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Phase II Study of Anti-PD-1 Antibody (MK-3475) in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Other Low Grade B Cell Non-Hodgkin Lymphoma,1040
67,NCT02340780,Phase II,"Active, not recruiting","[{'id': 680, 'therapyName': 'BKM120'}]",Buparlisib in Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia,1040
68,NCT02369016,Phase III,"Active, not recruiting","[{'id': 995, 'therapyName': 'Copanlisib'}]",Phase III Copanlisib in Rituximab-refractory iNHL,1040
69,NCT02420912,Phase II,Recruiting,"[{'id': 3198, 'therapyName': 'Ibrutinib + Nivolumab'}]","Nivolumab With Ibrutinib for Relapsed, Refractory or High-Risk Untreated Patients With Chronic Lymphocytic Leukemia (CLL)",1040
70,NCT02427451,Phase Ib/II,"Active, not recruiting","[{'id': 3472, 'therapyName': 'GDC-0199 + Ibrutinib + Obinutuzumab'}]","Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia",1040
71,NCT02454270,Phase II,"Active, not recruiting","[{'id': 4166, 'therapyName': 'JNJ-64052781'}]",A Dose Escalation Study of JNJ-64052781 in Participants With Relapsed or Refractory B-cell Malignancies,1040
72,NCT02475681,Phase III,"Active, not recruiting","[{'id': 1605, 'therapyName': 'Acalabrutinib'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 1646, 'therapyName': 'Obinutuzumab'}]","Elevate CLL TN: Study of Obinutuzumab + Chlorambucil, ACP-196 + Obinutuzumab, and ACP-196 in Subjects With Previously Untreated CLL",1040
73,NCT02477696,Phase III,Recruiting,"[{'id': 1605, 'therapyName': 'Acalabrutinib'}, {'id': 768, 'therapyName': 'Ibrutinib'}]",Elevate CLL R/R: Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia,1040
74,NCT02535286,Phase Ib/II,Recruiting,"[{'id': 3475, 'therapyName': 'Pembrolizumab + TGR-1202 + Ublituximab'}]",Study of Pembrolizumab in Combination With Ublituximab and TGR-1202 in Patients With Relapsed-refractory CLL,1040
75,NCT02537613,Phase I,Recruiting,"[{'id': 3476, 'therapyName': 'Ibrutinib + Obinutuzumab'}]",A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia,1040
76,NCT02538614,Phase Ib/II,Terminated,"[{'id': 4396, 'therapyName': 'BI 836826 + Idelalisib '}]",Study of Idelalisib in Combination With BI 836826 in Participants With Chronic Lymphocytic Leukemia,1040
77,NCT02557516,Phase Ib/II,Recruiting,"[{'id': 3382, 'therapyName': 'IPH2201'}]",Combination Study of IPH2201 With Ibrutinib in Patients With Relapse or Refractory Chronic Lymphocytic Leukemia,1040
78,NCT02611908,Phase I,Recruiting,"[{'id': 3476, 'therapyName': 'Ibrutinib + Obinutuzumab'}]",Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib.,1040
79,NCT02612311,Phase III,"Active, not recruiting","[{'id': 2287, 'therapyName': 'Ublituximab'}, {'id': 1648, 'therapyName': 'Obinutuzumab + Chlorambucil'}, {'id': 2022, 'therapyName': 'TGR-1202'}]",Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia,1040
80,NCT02639910,Phase II,Recruiting,"[{'id': 5785, 'therapyName': 'MOR208 + Venetoclax'}, {'id': 5784, 'therapyName': 'Idelalisib + MOR208'}]",Study to Evaluate Efficacy and Safety of MOR208 With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi (COSMOS),1040
81,NCT02649387,Phase II,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",Ibrutinib in Treating Minimal Residual Disease in Patients With Chronic Lymphocytic Leukemia After Front-Line Therapy (MERIT),1040
82,NCT02656303,Phase II,Recruiting,"[{'id': 2319, 'therapyName': 'TGR-1202 + Ublituximab'}]",An Open-Label Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304,1040
83,NCT02684617,Phase I,Recruiting,"[{'id': 4225, 'therapyName': 'Dinaciclib + Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies  (MK-3475-155) (KEYNOTE-155),1040
84,NCT02717611,Phase II,"Active, not recruiting","[{'id': 1605, 'therapyName': 'Acalabrutinib'}]",A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy,1040
85,NCT02733042,Phase Ib/II,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 4278, 'therapyName': 'lenalidomide + MEDI4736 + Rituximab'}, {'id': 4279, 'therapyName': 'Bendamustine + MEDI4736 + Rituximab'}, {'id': 2573, 'therapyName': 'Ibrutinib + MEDI4736'}, {'id': 1356, 'therapyName': 'Durvalumab'}]","A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia (FUSION NHL 001)",1040
86,NCT02742090,Phase II,Recruiting,"[{'id': 2022, 'therapyName': 'TGR-1202'}]",Evaluate the Efficacy and Safety of TGR-1202 in Patients With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior Therapy,1040
87,NCT02743546,Phase I,Withdrawn,"[{'id': 4167, 'therapyName': 'Ibrutinib + JNJ-64052781'}]","Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of JNJ-64052781 Plus Ibrutinib in Lymphoma",1040
88,NCT02756611,Phase III,Recruiting,"[{'id': 1562, 'therapyName': 'Venetoclax'}]",A Study to Evaluate the Efficacy of Venetoclax in Relapsed/Refractory Participants With Chronic Lymphocytic Leukemia (CLL) Including Those With 17p Deletion or TP53 Mutation or Those Who Are Refractory or Intolerant to B-cell Receptor Inhibitors,1040
89,NCT02793544,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 5682, 'therapyName': 'Mesna'}, {'id': 1166, 'therapyName': 'Fludarabine'}]",HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide,1040
90,NCT02801578,Phase I,"Active, not recruiting","[{'id': 768, 'therapyName': 'Ibrutinib'}]",A Study of Different Doses of Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL),1040
91,NCT02846623,Phase II,Recruiting,"[{'id': 1975, 'therapyName': 'Atezolizumab + Obinutuzumab'}]",Atezolizumab (PD-L1 mAb) in Combination With Obinutuzumab and Ibrutinib in Patients With Relapsed Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL),1040
92,NCT02860676,Phase I,Enrolling by invitation,"[{'id': 4312, 'therapyName': 'Cirmtuzumab'}]",Extension Study of UC-961 (Cirmtuzumab) for Patients With Chronic Lymphocytic Leukemia Treated Previously With UC-961,1040
93,NCT02869633,Phase II,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant,1040
94,NCT02912754,Phase Ib/II,Not yet recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 4768, 'therapyName': 'Ibrutinib + Ruxolitinib'}]",Ruxolitinib Combined With Ibrutinib in Chronic Lymphocytic Leukemia Patients,1040
95,NCT02914327,Phase I,Recruiting,"[{'id': 4780, 'therapyName': 'Ibrutinib + SNX-5422'}]",Safety and Activity of SNX-5422 Plus Ibrutinib in CLL,1040
96,NCT02948283,Phase 0,Recruiting,"[{'id': 4919, 'therapyName': 'Metformin + Ritonavir'}]",Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia,1040
97,NCT02970318,Phase III,Recruiting,"[{'id': 2324, 'therapyName': 'Bendamustine + Idelalisib + Rituximab'}, {'id': 1605, 'therapyName': 'Acalabrutinib'}]",A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL,1040
98,NCT02973399,Phase I,Recruiting,"[{'id': 4780, 'therapyName': 'Ibrutinib + SNX-5422'}]",Efficacy and Safety of SNX-5422 Added to an Established Dose of Ibrutinib in CLL,1040
99,NCT03037645,Phase Ib/II,Recruiting,"[{'id': 5281, 'therapyName': 'SNS-062'}]","Safety, PK, PD, and Antitumor Activity of SNS-062 in B Lymphoid Cancers",1040
100,NCT03041636,Phase II,Recruiting,"[{'id': 907, 'therapyName': 'Ruxolitinib'}]",Administration of Jakafi (Ruxolitinib) to Patients With High-Risk Chronic Lymphocytic Leukemia (CLL),1040
101,NCT03045328,Phase Ib/II,Recruiting,"[{'id': 3392, 'therapyName': 'GDC-0199 + Ibrutinib'}]",Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL,1040
102,NCT03056339,Phase Ib/II,Recruiting,"[{'id': 6217, 'therapyName': 'Cyclophosphamide + Fludarabine phosphate + iC9/CAR.19/IL15-Transduced CB-NK'}]",Umbilical & Cord Blood (CB)- Derived CAR-Engineered NK Cells for B Lymphoid Malignancies,1040
103,NCT03069469,Phase I,Recruiting,"[{'id': 5760, 'therapyName': 'DCC-3014'}]",Study of DCC-3014 in Patients With Advanced Malignancies,1040
104,NCT03128879,Phase II,"Active, not recruiting","[{'id': 5876, 'therapyName': 'Allopurinol + Ibrutinib + Venetoclax'}]",Study of Venetoclax (ABT-199) Added to Ibrutinib in Patients With High-Risk Chronic Lymphocytic Leukemia (CLL),1040
105,NCT03133221,Phase II,Not yet recruiting,"[{'id': 1023, 'therapyName': 'Idelalisib'}]",1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation,1040
106,NCT03153202,Phase Ib/II,Recruiting,"[{'id': 4917, 'therapyName': 'Pembrolizumab + Ibrutinib'}]",Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL),1040
107,NCT03162536,Phase I,Recruiting,"[{'id': 5224, 'therapyName': 'ARQ 531'}]","Safety, PK, PD, and Antitumor Activity of ARQ 531 in Hematologic Malignancies",1040
108,NCT03207555,Phase II,Not yet recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL),1040
109,NCT03283137,Phase I,Not yet recruiting,"[{'id': 6237, 'therapyName': 'Pembrolizumab + TGR-1202'}]",Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL,1040
0,NCT00084695,Phase II,Unknown status,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases,8552
1,NCT00129740,Phase II,"Active, not recruiting","[{'id': 829, 'therapyName': 'Nilotinib'}]",Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML),8552
2,NCT00513474,Phase I,Completed,"[{'id': 2313, 'therapyName': 'Rasburicase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2314, 'therapyName': 'Busulfan + Cyclophosphamide + Etoposide'}]",Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant,8552
3,NCT00573378,Phase II,Withdrawn,"[{'id': 2467, 'therapyName': 'Imatinib + Interferon alfa-2b '}, {'id': 2468, 'therapyName': 'Interferon alfa-2b + Nilotinib '}]",Imatinib or Nilotinib With Pegylated Interferon-alpha2b in Chronic Myeloid Leukemia,8552
4,NCT00602693,Phase I,Completed,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 2311, 'therapyName': 'Allopurinol + Cyclophosphamide + Fludarabine'}]",T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer,8552
5,NCT00679536,Phase Ib/II,Unknown status,"[{'id': 1846, 'therapyName': 'Busulfan + Fludarabine + anti-thymocyte globulin'}]",Allogeneic Transplantation for Pediatric Leukemias With Unrelated Donors,8552
6,NCT00718263,Phase III,Recruiting,"[{'id': 770, 'therapyName': 'Imatinib'}, {'id': 829, 'therapyName': 'Nilotinib'}]",Efficacy and Safety of Nilotinib Patients With Newly Diagnosed CML - CP (Chronic Myelogenous Leukemia - Chronic Phase),8552
7,NCT00857389,Phase II,"Active, not recruiting","[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 2469, 'therapyName': 'Busulfan + Clofarabine + Thymoglobulin'}, {'id': 1639, 'therapyName': 'Methotrexate'}]",Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies,8552
8,NCT01077544,Phase I,Completed,"[{'id': 829, 'therapyName': 'Nilotinib'}]",A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL),8552
9,NCT01188889,Phase Ib/II,Withdrawn,"[{'id': 2198, 'therapyName': 'Everolimus + Imatinib'}]",RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease,8552
10,NCT01244750,Phase I,"Active, not recruiting","[{'id': 770, 'therapyName': 'Imatinib'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 829, 'therapyName': 'Nilotinib'}]",Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting,8552
11,NCT01251575,Phase II,Recruiting,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 2270, 'therapyName': 'Cyclosporine + Mycophenolate mofetil + Sirolimus'}]","Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant",8552
12,NCT01397734,Phase I,"Active, not recruiting","[{'id': 640, 'therapyName': 'Arsenic trioxide'}]",Arsenic Trioxide and Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia (CML),8552
13,NCT01498445,Phase Ib/II,Recruiting,"[{'id': 1760, 'therapyName': 'Dasatinib + Decitabine '}]",Phase I/II - Dasatinib and Decitabine,8552
14,NCT01570868,Phase II,Terminated,"[{'id': 877, 'therapyName': 'Ponatinib'}]",Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP),8552
15,NCT01592370,Phase I,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 2583, 'therapyName': 'Lirilumab '}]",Safety Study in Nivolumab Alone and in Combination With Ipilimumab or Lirilumab in Lymphoma and Multiple Myeloma,8552
16,NCT01593254,Phase II,"Active, not recruiting","[{'id': 770, 'therapyName': 'Imatinib'}, {'id': 717, 'therapyName': 'Dasatinib'}]",Phase IIb Study of Dasatinib Versus Imatinib in Patients With CML-CP Who Have Not Achieved an Early Optimal Response to Imatinib,8552
17,NCT01606579,Phase Ib/II,Completed,"[{'id': 2466, 'therapyName': 'Cytarabine + Pri-724'}, {'id': 2465, 'therapyName': 'Dasatinib + Pri-724'}, {'id': 1083, 'therapyName': 'Pri-724'}]",Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies,8552
18,NCT01621477,Phase II,Terminated,"[{'id': 1756, 'therapyName': 'Plerixafor'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 2469, 'therapyName': 'Busulfan + Clofarabine + Thymoglobulin'}, {'id': 1783, 'therapyName': 'Cyclophosphamide + Cytarabine'}]",T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant,8552
19,NCT01634217,Phase I,"Active, not recruiting",[],Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation,8552
20,NCT01640301,Phase Ib/II,Suspended,"[{'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 2901, 'therapyName': 'WT1 senstized T cells'}]","Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant",8552
21,NCT01660906,Phase III,Completed,"[{'id': 717, 'therapyName': 'Dasatinib'}]","This Study Will be a Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib",8552
22,NCT01698905,Phase II,"Active, not recruiting","[{'id': 829, 'therapyName': 'Nilotinib'}]",Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop),8552
23,NCT01702064,Phase I,"Active, not recruiting","[{'id': 1116, 'therapyName': 'Ruxolitinib + Nilotinib'}]",Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Patients,8552
24,NCT01744665,Phase II,"Active, not recruiting","[{'id': 829, 'therapyName': 'Nilotinib'}]",Safety and Efficacy of CML Patients Who Switch to Nilotinib and Stop Treatment After Achieving and Sustaining MR4.5.,8552
25,NCT01746849,Phase II,Recruiting,"[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 2373, 'therapyName': 'Palifermin'}]",Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation,8552
26,NCT01751425,Phase II,Recruiting,"[{'id': 907, 'therapyName': 'Ruxolitinib'}]",Ruxolitinib for Chronic Myeloid Leukemia (CML) With Minimal Residual Disease (MRD),8552
27,NCT01776723,Phase II,"Active, not recruiting","[{'id': 907, 'therapyName': 'Ruxolitinib'}]",A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib,8552
28,NCT01784068,Phase II,"Active, not recruiting","[{'id': 829, 'therapyName': 'Nilotinib'}]",Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients,8552
29,NCT01822509,Phase I,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant,8552
30,NCT01823198,Phase Ib/II,Recruiting,"[{'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1846, 'therapyName': 'Busulfan + Fludarabine + anti-thymocyte globulin'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Natural Killer (NK) Cells With HLA Compatible Hematopoietic Transplantation for High Risk Myeloid Malignancies,8552
31,NCT01829971,Phase I,Terminated,"[{'id': 1035, 'therapyName': 'MRX34'}]","A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection",8552
32,NCT01844765,Phase II,"Active, not recruiting","[{'id': 829, 'therapyName': 'Nilotinib'}]","Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients.",8552
33,NCT01850004,Phase II,"Active, not recruiting","[{'id': 717, 'therapyName': 'Dasatinib'}]",Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response,8552
34,NCT01885897,Phase Ib/II,Recruiting,"[{'id': 3060, 'therapyName': 'ALT-803'}]",IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT,8552
35,NCT01892371,Phase Ib/II,Recruiting,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 882, 'therapyName': 'Quizartinib'}]",AC220 With 5-Aza or Low Dose Cytarabine,8552
36,NCT01903733,Phase I,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}]",Bosutinib Treatment Extension Study Only For Subjects With Chronic Myeloid Leukemia (CML) Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008,8552
37,NCT01914484,Phase II,Recruiting,"[{'id': 1116, 'therapyName': 'Ruxolitinib + Nilotinib'}]",Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia,8552
38,NCT01926587,Phase Ib/II,Recruiting,"[{'id': 2320, 'therapyName': 'Azacitidine + Regorafenib'}]",Oral Rigosertib in Combination With Azacitidine,8552
39,NCT02011945,Phase I,"Active, not recruiting","[{'id': 1813, 'therapyName': 'Dasatinib + Nivolumab'}]",A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia,8552
40,NCT02047149,Phase I,Terminated,"[{'id': 1789, 'therapyName': 'Zileuton + Dasatinib'}]",Evaluating the Safety of Zileuton (Zyflo(R)) in Combination With Dasatinib (Sprycel (R) in Chronic Myelogenous Leukemia,8552
41,NCT02081378,Phase I,Recruiting,"[{'id': 2484, 'therapyName': 'ABL001'}, {'id': 829, 'therapyName': 'Nilotinib'}]","A Phase I, Multicenter, Open-label Study of Oral ABL001 in Patients With Chronic Myelogenous Leukemia (CML) or Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL)",8552
42,NCT02091245,Phase I,Recruiting,"[{'id': 1749, 'therapyName': 'Selinexor'}]","Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML",8552
43,NCT02092324,Phase II,Recruiting,"[{'id': 907, 'therapyName': 'Ruxolitinib'}]",Ruxolitinib Phosphate in Treating Patients With Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia,8552
44,NCT02130557,Phase III,"Active, not recruiting","[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 770, 'therapyName': 'Imatinib'}]","A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia",8552
45,NCT02158858,Phase I,Recruiting,"[{'id': 2033, 'therapyName': 'CPI-0610'}]","A Phase 1 Study Evaluating CPI-0610 in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelodysplastic/Myeloproliferative Neoplasms",8552
46,NCT02200380,Phase II,Terminated,"[{'id': 1756, 'therapyName': 'Plerixafor'}, {'id': 3007, 'therapyName': 'CDX-301'}]",A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs,8552
47,NCT02208037,Phase II,"Active, not recruiting",[],Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203),8552
48,NCT02225574,Phase Ib/II,Completed,"[{'id': 2219, 'therapyName': 'MEK162 + Nilotinib'}]","An Open-Label, Phase I/II Study of Nilotinib (Tasigna) and MEK-162 (ARRY-162) Used in Combination for Patients With Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia (Protocol CAMN107AUS41T)",8552
49,NCT02228382,FDA approved,"Active, not recruiting","[{'id': 690, 'therapyName': 'Bosutinib'}]",Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors,8552
50,NCT02268370,Phase II,Recruiting,"[{'id': 717, 'therapyName': 'Dasatinib'}]",Treatment-free Remission Accomplished With Dasatinib in Patients With CML (TRAD),8552
51,NCT02311998,Phase Ib/II,Recruiting,"[{'id': 3200, 'therapyName': 'Bosutinib + inotuzumab ozogamicin'}]",Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive Philadelphia-Chromosome (PC) Positive Acute Lymphoblastic Leukemia (ALL) and Chronic Myeloid Leukemia (CML),8552
52,NCT02353728,Phase II,Not yet recruiting,"[{'id': 829, 'therapyName': 'Nilotinib'}]",Stem Cell Monitoring for CML Patients Undergoing Nilotinib Therapy,8552
53,NCT02381548,Phase I,"Active, not recruiting","[{'id': 3197, 'therapyName': 'Belinostat + MK-1775'}]",Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia,8552
54,NCT02467270,Phase II,Recruiting,"[{'id': 877, 'therapyName': 'Ponatinib'}]",Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia (CML) to Characterize the Efficacy and Safety of a Range of Doses,8552
55,NCT02487459,Phase I,Not yet recruiting,"[{'id': 6053, 'therapyName': 'BPX-501'}, {'id': 5992, 'therapyName': 'Rimiducid'}]",Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies,8552
56,NCT02556931,Phase II,Recruiting,"[{'id': 4228, 'therapyName': 'Cyclophosphamide + Fludarabine + Melphalan + Tacrolimus'}]","Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies",8552
57,NCT02689440,FDA approved,Recruiting,"[{'id': 717, 'therapyName': 'Dasatinib'}]",Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Dasatinib,8552
58,NCT02709083,Phase II,Recruiting,"[{'id': 717, 'therapyName': 'Dasatinib'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 770, 'therapyName': 'Imatinib'}]","Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia",8552
59,NCT02722668,Phase II,Recruiting,"[{'id': 2281, 'therapyName': 'Cyclophosphamide + Fludarabine + Mycophenolate mofetil'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}]",UCB Transplant for Hematological DIseases Using a Non Myeloablative Prep,8552
60,NCT02730195,Phase II,Recruiting,"[{'id': 3125, 'therapyName': 'Pioglitazone'}]",Pioglitazone and Tyrosine Kinase Inhibitor in Treating Patients With Relapsed Chronic Myeloid Leukemia,8552
61,NCT02759016,Phase I,Recruiting,"[{'id': 4277, 'therapyName': 'BI 836826 + Ibrutinib'}]","Intravenous BI 836826 in Combination With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Patients Who Have Received at Least One Prior Systemic Therapy, and Who Are Eligible for Treatment With Ibrutinib",8552
62,NCT02782403,Phase Ib/II,Recruiting,"[{'id': 4241, 'therapyName': 'Axitinib + Bosutinib'}]","Axitinib and Bosutinib for Patients With Chronic Myeloid Leukemia in Chronic, Accelerated or Blastic Phases",8552
63,NCT02790515,Phase II,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1876, 'therapyName': 'Blinatumomab '}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 5682, 'therapyName': 'Mesna'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Provision of TCR?? T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation,8552
64,NCT02906696,Phase II,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}]",Bosutinib Dose-Optimization Study in Chronic Myeloid Leukemia (CML),8552
65,NCT02973711,Phase Ib/II,Recruiting,"[{'id': 1116, 'therapyName': 'Ruxolitinib + Nilotinib'}]",A Phase I/II Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CML,8552
66,NCT03075826,Phase II,Recruiting,"[{'id': 1949, 'therapyName': 'SGI-110'}]",A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms,8552
67,NCT03106779,Phase III,Recruiting,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 2484, 'therapyName': 'ABL001'}]","Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs",8552
68,NCT03267186,Phase II,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant,8552
0,NCT01331135,Phase I,"Active, not recruiting","[{'id': 917, 'therapyName': 'Sirolimus'}]",Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors,4233
1,NCT02867592,Phase II,Recruiting,"[{'id': 998, 'therapyName': 'cabozantinib'}]","Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors",4233
0,NCT01253460,Phase II,"Active, not recruiting","[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 3215, 'therapyName': 'Rituximab + sapacitabine'}]","Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23)",6354
1,NCT01353625,Phase I,"Active, not recruiting","[{'id': 1000, 'therapyName': 'CC-115'}]","Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.",6354
2,NCT01804686,Phase III,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",A Long-term Extension Study of PCI-32765 (Ibrutinib),6354
3,NCT01886859,Phase I,"Active, not recruiting","[{'id': 3580, 'therapyName': 'Ibrutinib + lenalidomide'}]",Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma,6354
4,NCT01976585,Phase Ib/II,Recruiting,"[{'id': 4337, 'therapyName': 'CDX-301 + poly ICLC '}]",In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy,6354
5,NCT01994382,Phase I,Recruiting,"[{'id': 2531, 'therapyName': 'Cerdulatinib'}]",Phase 1 Dose Escalation Study in Chronic Lymphocytic Leukemia and Non-hodgkin Lymphoma,6354
6,NCT02000934,Phase I,Recruiting,"[{'id': 3146, 'therapyName': 'TAK-659'}]",A Study of TAK-659 in Adult Patients With Advanced Solid Tumor and Lymphoma Malignancies,6354
7,NCT02005289,Phase II,Recruiting,"[{'id': 5843, 'therapyName': 'Lenalidomide + MOR208'}, {'id': 5847, 'therapyName': 'Ibrutinib + MOR208'}]","Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL",6354
8,NCT02006485,Phase I,Recruiting,"[{'id': 2319, 'therapyName': 'TGR-1202 + Ublituximab'}, {'id': 768, 'therapyName': 'Ibrutinib'}]",Ublituximab in Combination With TGR-1202 in Patients With B-cell Malignancies,6354
9,NCT02007044,Phase II,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 897, 'therapyName': 'Rituximab'}]",Ibrutinib Versus Ibrutinib + Rituximab (i vs iR) in Patients With Relapsed Chronic Lymphocytic Leukemia (CLL),6354
10,NCT02029443,Phase Ib/II,"Active, not recruiting","[{'id': 1605, 'therapyName': 'Acalabrutinib'}]","ACP-196, a Novel Bruton Tyrosine Kinase (Btk) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia",6354
11,NCT02160015,Phase I,"Active, not recruiting","[{'id': 1610, 'therapyName': 'Rituximab + Lenalidomide + Ibrutinib'}]","Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",6354
12,NCT02254772,Phase Ib/II,Completed,"[{'id': 3848, 'therapyName': 'Ipilimumab + SD-101'}]","TLR9 Agonist SD-101, Ipilimumab, and Radiation Therapy in Treating Patients With Low-Grade Recurrent B-cell Lymphoma",6354
13,NCT02266147,Phase Ib/II,Completed,"[{'id': 3084, 'therapyName': 'SD-101'}]",Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma,6354
14,NCT02296918,Phase I,"Active, not recruiting","[{'id': 3477, 'therapyName': 'Acalabrutinib + Obinutuzumab'}]",ACP-196 in Combination With Obinutuzumab in Relapsed/Refractory or Untreated CLL/SLL/PLL,6354
15,NCT02329847,Phase Ib/II,Recruiting,"[{'id': 3198, 'therapyName': 'Ibrutinib + Nivolumab'}]",Pharmacokinetic and Pharmacodynamic Study to Evaluate Safety and Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic Malignancies,6354
16,NCT02337829,Phase II,Recruiting,"[{'id': 1605, 'therapyName': 'Acalabrutinib'}]",ACP-196 in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL,6354
17,NCT02381080,Phase I,Completed,"[{'id': 3793, 'therapyName': 'Erythromycin + Ibrutinib + Voriconazole'}]",Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy,6354
18,NCT02384954,Phase Ib/II,Recruiting,"[{'id': 3936, 'therapyName': 'ALT-803 + Rituximab'}]",ALT-803 in Patients With Relapse/Refractory Indolent B Cell Non-Hodgkin Lymphoma (iNHL) in Conjunction With Rituximab,6354
19,NCT02406742,Phase Ib/II,Recruiting,"[{'id': 1646, 'therapyName': 'Obinutuzumab'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 2358, 'therapyName': 'CC-122'}]","A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Rituximab, Ibrutinib and Obinutuzumab in Subjects With Relapsed/Refractory CLL/SLL (ENHANCE)",6354
20,NCT02420912,Phase II,Recruiting,"[{'id': 3198, 'therapyName': 'Ibrutinib + Nivolumab'}]","Nivolumab With Ibrutinib for Relapsed, Refractory or High-Risk Untreated Patients With Chronic Lymphocytic Leukemia (CLL)",6354
21,NCT02514083,Phase II,Recruiting,"[{'id': 3633, 'therapyName': 'Fludarabine + Ibrutinib'}]",A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Previously Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL),6354
22,NCT02518555,Phase II,"Active, not recruiting","[{'id': 768, 'therapyName': 'Ibrutinib'}]","Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",6354
23,NCT02556931,Phase II,Recruiting,"[{'id': 4228, 'therapyName': 'Cyclophosphamide + Fludarabine + Melphalan + Tacrolimus'}]","Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies",6354
24,NCT02576275,Phase III,Withdrawn,"[{'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}, {'id': 1024, 'therapyName': 'Duvelisib'}]",A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA),6354
25,NCT02614508,Phase I,"Active, not recruiting","[{'id': 3630, 'therapyName': 'BKM120 + Ibrutinib'}, {'id': 3629, 'therapyName': 'BKM120 + Ofatumumab'}]",Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia,6354
26,NCT02626455,Phase III,Recruiting,"[{'id': 1631, 'therapyName': 'Vincristine'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 3388, 'therapyName': 'Aldoxorubicin +Cyclophosphamide + Prednisone + Rituximab + Vincristine'}, {'id': 995, 'therapyName': 'Copanlisib'}, {'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}, {'id': 897, 'therapyName': 'Rituximab'}]",Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL),6354
27,NCT02629809,Phase II,Recruiting,"[{'id': 3628, 'therapyName': 'Allopurinol'}, {'id': 3627, 'therapyName': 'Cyclophosphamide + Fludarabine + Obinutuzumab'}, {'id': 768, 'therapyName': 'Ibrutinib'}]","First-line Therapy With Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA-101) (iFCG) for Patients With Chronic Lymphocytic Leukemia (CLL)",6354
28,NCT02639910,Phase II,Recruiting,"[{'id': 5785, 'therapyName': 'MOR208 + Venetoclax'}, {'id': 5784, 'therapyName': 'Idelalisib + MOR208'}]",Study to Evaluate Efficacy and Safety of MOR208 With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi (COSMOS),6354
29,NCT02640209,Phase I,Recruiting,"[{'id': 5999, 'therapyName': 'CART19 cells'}]",Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL),6354
30,NCT02640833,Phase I,Withdrawn,"[{'id': 3624, 'therapyName': 'GDC-0199 + Duvelisib'}]","A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor",6354
31,NCT02662296,Phase II,Withdrawn,"[{'id': 1023, 'therapyName': 'Idelalisib'}, {'id': 768, 'therapyName': 'Ibrutinib'}]","Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant",6354
32,NCT02677948,Phase Ib/II,Withdrawn,"[{'id': 3623, 'therapyName': 'Ibrutinib + Pacritinib'}]",Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL),6354
33,NCT02722668,Phase II,Recruiting,"[{'id': 2281, 'therapyName': 'Cyclophosphamide + Fludarabine + Mycophenolate mofetil'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}]",UCB Transplant for Hematological DIseases Using a Non Myeloablative Prep,6354
34,NCT02756897,Phase II,Recruiting,"[{'id': 3392, 'therapyName': 'GDC-0199 + Ibrutinib'}]",Venetoclax and Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL),6354
35,NCT02787369,Phase I,"Active, not recruiting","[{'id': 4273, 'therapyName': 'ACY-1215 + Idelalisib '}, {'id': 4272, 'therapyName': 'ACY-1215 + Ibrutinib'}]",ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL,6354
36,NCT02846623,Phase II,Recruiting,"[{'id': 1975, 'therapyName': 'Atezolizumab + Obinutuzumab'}]",Atezolizumab (PD-L1 mAb) in Combination With Obinutuzumab and Ibrutinib in Patients With Relapsed Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL),6354
37,NCT02867618,Phase Ib/II,Recruiting,"[{'id': 4598, 'therapyName': 'Carfilzomib + TGR-1202'}]",Carfilzomib and TGR-1202 in Treatment of R/R Lymphoma,6354
38,NCT02910583,Phase II,"Active, not recruiting","[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 3392, 'therapyName': 'GDC-0199 + Ibrutinib'}]",Ibrutinib Plus Venetoclax in Patients With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma,6354
39,NCT03088878,Phase Ib/II,Not yet recruiting,"[{'id': 5480, 'therapyName': 'Cirmtuzumab + Ibrutinib'}, {'id': 768, 'therapyName': 'Ibrutinib'}]",A Study of the Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies,6354
40,NCT03133221,Phase II,Not yet recruiting,"[{'id': 1023, 'therapyName': 'Idelalisib'}]",1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation,6354
41,NCT03162536,Phase I,Recruiting,"[{'id': 5224, 'therapyName': 'ARQ 531'}]","Safety, PK, PD, and Antitumor Activity of ARQ 531 in Hematologic Malignancies",6354
42,NCT03204188,Phase II,Recruiting,"[{'id': 6154, 'therapyName': 'Fludarabine + Ibrutinib + Pembrolizumab'}]","Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma",6354
0,NCT02601937,Phase I,Recruiting,"[{'id': 2683, 'therapyName': 'Tazemetostat'}]",A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma,4464
1,NCT02915783,Phase II,Recruiting,"[{'id': 1713, 'therapyName': 'Everolimus + Lenvatinib'}]",A Phase 2 Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease,4464
0,NCT00602329,Phase II,Unknown status,"[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",MRI in Predicting Response in Patients Receiving Combination Chemotherapy and Bevacizumab For Advanced or Metastatic Colorectal Cancer,234
1,NCT01206530,Phase Ib/II,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1316, 'therapyName': 'Hydroxychloroquine'}]",FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer,234
2,NCT01298570,Phase II,"Active, not recruiting","[{'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 890, 'therapyName': 'Regorafenib'}]",Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer,234
3,NCT01442935,Phase II,"Active, not recruiting","[{'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}, {'id': 2180, 'therapyName': 'Cetuximab + FOLFIRI'}, {'id': 2181, 'therapyName': 'Bevacizumab + FOLFIRI'}, {'id': 2182, 'therapyName': 'Cetuximab + FOLFOX'}, {'id': 2183, 'therapyName': 'Bevacizumab + FOLFIRINOX'}, {'id': 2184, 'therapyName': 'Cetuximab + FOLFIRINOX'}]",Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases,234
4,NCT01471353,Phase II,"Active, not recruiting","[{'id': 2428, 'therapyName': 'Sorafenib + Capecitabine'}]",Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer,234
5,NCT01516216,Phase II,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Study of Vitamin D in Untreated Metastatic Colorectal Cancer,234
6,NCT01538680,Phase III,No longer available,"[{'id': 890, 'therapyName': 'Regorafenib'}]",Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy,234
7,NCT01571284,Phase III,Completed,"[{'id': 2095, 'therapyName': 'Aflibercept + FOLFIRI'}]",Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen,234
8,NCT01652482,Phase II,Completed,"[{'id': 694, 'therapyName': 'Cetuximab'}, {'id': 806, 'therapyName': 'MEHD7945A'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",A Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI in Second Line in Patients With KRAS Wild-Type Metastatic Colorectal Cancer,234
9,NCT01803282,Phase I,Recruiting,"[{'id': 3320, 'therapyName': 'GS-5745'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Safety and Tolerability Study in Solid Tumors,234
10,NCT01814501,Phase II,Recruiting,"[{'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 845, 'therapyName': 'Panitumumab'}]",Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab,234
11,NCT01896856,Phase Ib/II,Recruiting,"[{'id': 2015, 'therapyName': 'SGI-110 + Irinotecan'}, {'id': 890, 'therapyName': 'Regorafenib'}]",Phase I Study of SGI-110 With Irinotecan Followed by Randomized Phase II Study of SGI-110 With Irinotecan Versus Regorafenib in Previously Treated Metastatic Colorectal Cancer,234
12,NCT01939223,Phase III,Completed,"[{'id': 890, 'therapyName': 'Regorafenib'}]","COlorectal Cancer Treated With Adjuvant Regorafenib Versus Placebo After Curative Treatment of Liver Metastases in a Randomized, Double-blind, Placebo?Controlled Phase-III STudy (COAST)",234
13,NCT01949194,Phase II,Recruiting,"[{'id': 890, 'therapyName': 'Regorafenib'}]",Study to Determine the Efficacy of Regorafenib in Metastatic Colorectal Cancer Patients and to Discover Biomarkers,234
14,NCT02008383,Phase I,Recruiting,"[{'id': 1985, 'therapyName': 'Panitumumab + cabozantinib'}]",Cabozantinib and Panitumumab to Treat KRAS Wild-Type Metastatic Colorectal Cancer,234
15,NCT02045030,Phase II,Terminated,"[{'id': 2095, 'therapyName': 'Aflibercept + FOLFIRI'}]",Study to Identify Biomarkers of Clinical Response to Aflibercept in Patients With Metastatic Colorectal Cancer,234
16,NCT02046538,Phase II,Withdrawn,"[{'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 624, 'therapyName': 'Aflibercept'}]",Phase II Study of Zaltrap and Chemotherapy for Advanced Resectable Colorectal Cancer,234
17,NCT02096354,Phase II,"Active, not recruiting","[{'id': 890, 'therapyName': 'Regorafenib'}]","A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer",234
18,NCT02119676,Phase II,Terminated,"[{'id': 890, 'therapyName': 'Regorafenib'}, {'id': 907, 'therapyName': 'Ruxolitinib'}]",Study of Ruxolitinib in Colorectal Cancer Patients,234
19,NCT02138617,Phase II,Recruiting,"[{'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1715, 'therapyName': 'Fluorouracil'}]",Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer,234
20,NCT02164916,Phase II,"Active, not recruiting","[{'id': 1874, 'therapyName': 'Cetuximab + Irinotecan'}, {'id': 1331, 'therapyName': 'Vemurafenib + Cetuximab + Irinotecan '}]",S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,234
21,NCT02195011,Phase II,"Active, not recruiting","[{'id': 890, 'therapyName': 'Regorafenib'}]",Safety Study of Regorafenib and SIR-Spheres® Microspheres Radioembolization in Patients With Refractory Metastatic Colorectal Cancer With Liver Metastases,234
22,NCT02305758,Phase II,Completed,"[{'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 954, 'therapyName': 'Veliparib'}]",Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal Cancer,234
23,NCT02368886,Phase II,"Active, not recruiting","[{'id': 2350, 'therapyName': 'Clobetasol + Regorafenib'}]",Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer,234
24,NCT02393755,Phase Ib/II,"Active, not recruiting","[{'id': 2589, 'therapyName': 'Capecitabine + Nintedanib'}]",Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer,234
25,NCT02450175,Phase I,Unknown status,"[{'id': 794, 'therapyName': 'Letrozole'}, {'id': 735, 'therapyName': 'Everolimus'}]","Etiology of the Platelet-Cancer Metastatic Pathway - A Study of Inflammatory Markers, Platelet Characteristics and Metastatic Surrogates in Cancer Patients and Controls",234
26,NCT02575508,Phase Ib/II,Withdrawn,"[{'id': 3142, 'therapyName': 'BGJ398 + Fluorouracil + Irinotecan + Oxaliplatin'}]",Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer,234
27,NCT02581059,Phase II,Recruiting,"[{'id': 890, 'therapyName': 'Regorafenib'}]",Efficacy of Ginseng for Patients on Regorafenib,234
28,NCT02651415,Phase II,"Active, not recruiting","[{'id': 3410, 'therapyName': 'Perindopril + Regorafenib'}]",Phase II Study of Perindopril and Regorafenib in mCRC,234
29,NCT02664077,Phase III,Recruiting,"[{'id': 890, 'therapyName': 'Regorafenib'}]",A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer (ARGO),234
30,NCT02687009,Phase I,Recruiting,"[{'id': 3072, 'therapyName': 'Niclosamide'}]",A Study of Niclosamide in Patients With Resectable Colon Cancer,234
31,NCT02788279,Phase III,"Active, not recruiting","[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}, {'id': 890, 'therapyName': 'Regorafenib'}]",A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma,234
32,NCT02912559,Phase III,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair or Microsatellite Instability,234
33,NCT02972034,Phase I,Recruiting,"[{'id': 5269, 'therapyName': 'MK-8353 + Pembrolizumab'}]",Study of MK-8353 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Malignancies (MK-8353-013),234
34,NCT02997228,Phase III,Not yet recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}, {'id': 5126, 'therapyName': 'Bevacizumab + Atezolizumab + Fluorouracil + Leucovorin + Oxaliplatin'}]","Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Microsatellite Instability-High Metastatic Colorectal Cancer",234
35,NCT03043313,Phase II,Recruiting,"[{'id': 1560, 'therapyName': 'ARRY-380 + Trastuzumab'}]",Tucatinib (ONT-380) and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer (MOUNTAINEER)Tucatinib (ONT-380) and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer (MOUNTAINEER) (MOUNTAINEER),234
0,NCT01274624,Phase I,"Active, not recruiting","[{'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 2099, 'therapyName': 'Bevacizumab + Reolysin'}]",Study of REOLYSIN; in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer,219
1,NCT01730118,Phase I,Recruiting,"[{'id': 1404, 'therapyName': 'HER2 Vaccine'}]",Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing,219
2,NCT01966289,Phase I,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1949, 'therapyName': 'SGI-110'}, {'id': 2977, 'therapyName': 'GVAX colorectal cancer vaccine'}]",SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC),219
3,NCT02014909,Phase I,Completed,"[{'id': 2054, 'therapyName': 'CDX-3379'}, {'id': 2063, 'therapyName': 'CDX-3379 + Vemurafenib'}, {'id': 2064, 'therapyName': 'CDX-3379 + Trastuzumab'}, {'id': 2061, 'therapyName': 'Cetuximab + CDX-3379'}, {'id': 2062, 'therapyName': 'CDX-3379 + Erlotinib'}]",A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors,219
4,NCT02041481,Phase I,"Active, not recruiting","[{'id': 2217, 'therapyName': 'MEK162 + FOLFOX'}]","MEK Inhibitor MEK162 in Combination With Leucovorin Calcium, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Metastatic Colorectal Cancer",219
5,NCT02508077,Phase II,Terminated,"[{'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 845, 'therapyName': 'Panitumumab'}]",FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer,219
6,NCT02784795,Phase I,Recruiting,"[{'id': 4374, 'therapyName': 'Cisplatin + Gemcitabine + LY3039478'}, {'id': 4375, 'therapyName': 'Carboplatin + Gemcitabine + LY3039478'}, {'id': 4372, 'therapyName': 'LY3039478 + LY3023414'}, {'id': 4373, 'therapyName': 'Abemaciclib + LY3039478'}, {'id': 4371, 'therapyName': 'LY3039478 + Taladegib'}, {'id': 2958, 'therapyName': 'LY3039478'}, {'id': 1069, 'therapyName': 'LY3023414'}]",A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors,219
7,NCT02834052,Phase Ib/II,Not yet recruiting,"[{'id': 4458, 'therapyName': 'Pembrolizumab + poly ICLC '}]",Pembrolizumab + Poly-ICLC in MRP Colon Cancer,219
8,NCT02860780,Phase I,Completed,"[{'id': 4587, 'therapyName': 'Prexasertib + Ralimetinib'}]",A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer,219
9,NCT02980029,Phase I,Recruiting,"[{'id': 3611, 'therapyName': 'TVB-2640'}]",Pharmacodynamic Effects of Fatty Acid Synthase (FASN) Inhibition With TVB-2640 in Resectable Colon Cancer,219
10,NCT03127098,Phase Ib/II,"Active, not recruiting","[{'id': 6239, 'therapyName': 'ALT-803 + ETBX-011'}]","QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer",219
0,NCT01309126,Phase III,Terminated,"[{'id': 694, 'therapyName': 'Cetuximab'}, {'id': 2065, 'therapyName': 'Cetuximab + Imprime PGG'}]",Study of Imprime PGG in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer,1520
1,NCT01985763,Phase Ib/II,Completed,"[{'id': 757, 'therapyName': 'Genistein'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Genistein in Treatment of Metastatic Colorectal Cancer,1520
2,NCT02723955,Phase I,Recruiting,"[{'id': 4409, 'therapyName': 'GSK3359609'}, {'id': 4410, 'therapyName': 'GSK3359609 + Pembrolizumab'}]",Dose Escalation and Expansion Study of GSK3359609 in Subjects With Selected Advanced Solid Tumors (INDUCE-1),1520
0,NCT00408772,Phase II,Withdrawn,"[{'id': 1601, 'therapyName': 'Capecitabine + Oxaliplatin + Bevacizumab'}]","Oxaliplatin, Capecitabine, and Bevacizumab Followed By Surgery and/or Radiofrequency Ablation in Treating Patients With Colorectal Cancer That Has Spread to the Liver and Cannot Be Removed By Surgery",50861
1,NCT00842257,Phase II,Completed,"[{'id': 845, 'therapyName': 'Panitumumab'}]",Panitumumab in Cetuximab Refractory KRAS Wild-Type Colorectal Cancer,50861
2,NCT01061515,Phase I,Recruiting,"[{'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}]",Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer,50861
3,NCT01079780,Phase II,Unknown status,"[{'id': 1920, 'therapyName': 'Irinotecan + Cetuximab + Ramucirumab'}, {'id': 1874, 'therapyName': 'Cetuximab + Irinotecan'}]",Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy,50861
4,NCT01420874,Phase I,"Active, not recruiting","[{'id': 1012, 'therapyName': 'EGFRBi-armed autologous activated T cells'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Anti-CD3 x Anti-Erbitux Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer),50861
5,NCT01442935,Phase II,"Active, not recruiting","[{'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}, {'id': 2180, 'therapyName': 'Cetuximab + FOLFIRI'}, {'id': 2181, 'therapyName': 'Bevacizumab + FOLFIRI'}, {'id': 2182, 'therapyName': 'Cetuximab + FOLFOX'}, {'id': 2183, 'therapyName': 'Bevacizumab + FOLFIRINOX'}, {'id': 2184, 'therapyName': 'Cetuximab + FOLFIRINOX'}]",Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases,50861
6,NCT01471353,Phase II,"Active, not recruiting","[{'id': 2428, 'therapyName': 'Sorafenib + Capecitabine'}]",Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer,50861
7,NCT01571284,Phase III,Completed,"[{'id': 2095, 'therapyName': 'Aflibercept + FOLFIRI'}]",Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen,50861
8,NCT01622543,Phase II,"Active, not recruiting","[{'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}, {'id': 893, 'therapyName': 'Reolysin'}]",Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Metastatic Colorectal Cancer,50861
9,NCT01642342,Phase I,Recruiting,"[{'id': 3013, 'therapyName': 'sEphB4-HSA'}]",Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors,50861
10,NCT01652196,Phase II,"Active, not recruiting","[{'id': 2367, 'therapyName': 'Aflibercept + mFOLFOX-6'}]",Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer,50861
11,NCT01652482,Phase II,Completed,"[{'id': 694, 'therapyName': 'Cetuximab'}, {'id': 806, 'therapyName': 'MEHD7945A'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",A Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI in Second Line in Patients With KRAS Wild-Type Metastatic Colorectal Cancer,50861
12,NCT01802320,Phase II,"Active, not recruiting","[{'id': 816, 'therapyName': 'MK2206'}]",Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery,50861
13,NCT01814501,Phase II,Recruiting,"[{'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 845, 'therapyName': 'Panitumumab'}]",Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab,50861
14,NCT01949194,Phase II,Recruiting,"[{'id': 890, 'therapyName': 'Regorafenib'}]",Study to Determine the Efficacy of Regorafenib in Metastatic Colorectal Cancer Patients and to Discover Biomarkers,50861
15,NCT02023333,Phase II,Recruiting,"[{'id': 890, 'therapyName': 'Regorafenib'}]",Regorafenib in Good Performance Status Patients With Newly Diagnosed Metastatic Colorectal Adenocarcinoma,50861
16,NCT02024607,Phase Ib/II,"Active, not recruiting","[{'id': 1597, 'therapyName': 'Capecitabine + Oxaliplatin'}, {'id': 2093, 'therapyName': 'BBI608 + Bevacizumab'}, {'id': 2094, 'therapyName': 'BBI608 + Regorafenib'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 2057, 'therapyName': 'BBI608'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer,50861
17,NCT02116894,Phase I,Completed,"[{'id': 2035, 'therapyName': 'PF-03446962 + Regorafenib'}]",Safety Study of Regorafenib With PF-03446962 to Treat Colorectal Cancer,50861
18,NCT02149108,Phase III,Completed,"[{'id': 831, 'therapyName': 'Nintedanib'}]",Nintedanib (BIBF 1120) vs Placebo in Refractory Colorectal Cancer,50861
19,NCT02235324,Phase II,Withdrawn,"[{'id': 1841, 'therapyName': 'Aflibercept + Leucovorin + Fluorouracil'}, {'id': 624, 'therapyName': 'Aflibercept'}]","Ziv-Aflibercept Followed by Ziv-Aflibercept, Fluorouracil, and Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer",50861
20,NCT02248805,Phase I,Recruiting,"[{'id': 3093, 'therapyName': 'MGD007'}]",Phase 1 Study of MGD007 in Relapsed/Refractory Metastatic Colorectal Carcinoma,50861
21,NCT02292758,Phase II,Recruiting,"[{'id': 1923, 'therapyName': 'Bevacizumab + Cetuximab + Irinotecan'}, {'id': 1874, 'therapyName': 'Cetuximab + Irinotecan'}]","Phase II Trial of Irinotecan, Cetuximab, and Bevacizumab Compared With Irinotecan, Cetuximab, and Placebo in KRAS-Wildtype, Irinotecan-Refractory, Metastatic Colorectal Cancer",50861
22,NCT02368886,Phase II,"Active, not recruiting","[{'id': 2350, 'therapyName': 'Clobetasol + Regorafenib'}]",Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer,50861
23,NCT02375672,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Study of Pembrolizumab in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer,50861
24,NCT02413853,Phase II,Withdrawn,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1083, 'therapyName': 'Pri-724'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Combination Chemotherapy and Bevacizumab With or Without PRI-724 in Treating Patients With Newly Diagnosed Metastatic Colorectal Cancer,50861
25,NCT02466009,Phase II,Recruiting,"[{'id': 890, 'therapyName': 'Regorafenib'}]",Regorafenib in Metastatic Colorectal Cancer,50861
26,NCT02574663,Phase I,"Active, not recruiting","[{'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 2022, 'therapyName': 'TGR-1202'}]",TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors,50861
27,NCT02602327,Phase I,Recruiting,"[{'id': 2426, 'therapyName': 'trifluridine/tipiracil hydrochloride'}]",Tas-102 and Radioembolization With 90Y Resin Microspheres for Chemo-refractory Colorectal Liver Metastases,50861
28,NCT02638909,Phase II,Recruiting,"[{'id': 789, 'therapyName': 'Ceritinib'}]",Study of Oral Ceritinib in Patients With ALK-Activated Gastrointestinal Malignancies,50861
29,NCT02650635,Phase I,"Active, not recruiting","[{'id': 3413, 'therapyName': 'Cyclophosphamide + Pegfilgrastim + VTX-2337'}]","TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors",50861
30,NCT02651415,Phase II,"Active, not recruiting","[{'id': 3410, 'therapyName': 'Perindopril + Regorafenib'}]",Phase II Study of Perindopril and Regorafenib in mCRC,50861
31,NCT02780700,Phase II,Terminated,"[{'id': 2589, 'therapyName': 'Capecitabine + Nintedanib'}, {'id': 831, 'therapyName': 'Nintedanib'}]",Nintedanib Alone or in Combination With Capecitabine in Refractory Metastatic Colorectal Cancer [LUME-Colon 2],50861
32,NCT02835833,Phase I,Recruiting,"[{'id': 4498, 'therapyName': 'Bevacizumab + Nintedanib'}]",Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors,50861
33,NCT02860546,Phase II,"Active, not recruiting","[{'id': 4560, 'therapyName': 'Nivolumab + trifluridine/tipiracil hydrochloride'}]",A Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRC,50861
34,NCT02876224,Phase I,Recruiting,"[{'id': 4609, 'therapyName': 'Cobimetinib + Bevacizumab + Atezolizumab'}]",Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors,50861
35,NCT03007407,Phase II,Recruiting,"[{'id': 1652, 'therapyName': 'Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Progressing on Chemotherapy,50861
36,NCT03069950,Phase II,Recruiting,"[{'id': 5476, 'therapyName': 'Floxiuridine + Panitumumab + Dexamethasone + FOLFIRI'}]",Study of Chemotherapy With or Without Hepatic Arterial Infusion for Patients With Unresectable Metastatic Colorectal Cancer to the Liver,50861
37,NCT03081494,Phase I,Recruiting,"[{'id': 5930, 'therapyName': 'PDR001 + Regorafenib'}]",Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic Colorectal Cancer,50861
38,NCT03087071,Phase II,Not yet recruiting,"[{'id': 845, 'therapyName': 'Panitumumab'}, {'id': 2, 'therapyName': 'Trametinib'}]",Panitumumab in Combination With Trametinib in Cetuximab-Refractory Stage IV Colorectal Cancer,50861
39,NCT03095781,Phase I,Recruiting,"[{'id': 5533, 'therapyName': 'Pembrolizumab + XL888'}]",Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer,50861
40,NCT03104439,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer,50861
41,NCT03192345,Phase I,Recruiting,"[{'id': 5934, 'therapyName': 'SAR439459 + REGN2810'}, {'id': 5933, 'therapyName': 'SAR439459'}]","A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and REGN2810 in Patients With Advanced Solid Tumors",50861
42,NCT03258398,Phase II,Recruiting,"[{'id': 6238, 'therapyName': 'Avelumab + eFT508'}, {'id': 4005, 'therapyName': 'eFT508'}]",A Study to Evaluate eFT508 Alone and in Combination With Avelumab in Subjects With MSS Colorectal Cancer,50861
43,NCT03277209,Phase I,Recruiting,"[{'id': 1756, 'therapyName': 'Plerixafor'}]","To Assess the Safety of Continuous IV Administration of Plerixafor and Assess Impact on the Immune Microenvironment in Patients With Pancreatic, Ovarian and Colorectal Adenocarcinomas",50861
0,NCT00730158,Phase II,Suspended,"[{'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1699, 'therapyName': 'KD018'}]","A Phase II Multicenter, Randomized, Placebo Controlled, Double Blinded Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients With Metastatic Colorectal Cancer",9256
1,NCT00940316,Phase II,"Active, not recruiting","[{'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1940, 'therapyName': 'Panitumumab + Erlotinib'}]",Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer,9256
2,NCT01006369,Phase II,Completed,"[{'id': 1316, 'therapyName': 'Hydroxychloroquine'}, {'id': 1601, 'therapyName': 'Capecitabine + Oxaliplatin + Bevacizumab'}, {'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}]","Hydroxychloroquine, Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer",9256
3,NCT01037790,Phase II,Recruiting,"[{'id': 850, 'therapyName': 'Palbociclib'}]",PD 0332991 in Treating Patients With Refractory Solid Tumors,9256
4,NCT01174121,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 1167, 'therapyName': 'Aldesleukin'}]",Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer,9256
5,NCT01218867,Phase Ib/II,Completed,"[{'id': 984, 'therapyName': 'Anti-VEGFR2 CAR CD8 lymphocytes'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1167, 'therapyName': 'Aldesleukin'}]",Treating Metastatic Cancer With Anti-VEGFR2 Gene Engineered CD8+ Lymphocytes,9256
6,NCT01260415,Phase II,Completed,"[{'id': 845, 'therapyName': 'Panitumumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",A Study of Perioperative Chemotherapy Plus Panitumumab in Patients With Colorectal Cancer Liver Metastases,9256
7,NCT01294826,Phase I,Completed,"[{'id': 1996, 'therapyName': 'AUY922 + Cetuximab'}]",Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer,9256
8,NCT01312857,Phase II,Recruiting,"[{'id': 845, 'therapyName': 'Panitumumab'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 1941, 'therapyName': 'Floxuridine'}]","Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type KRAS Who Have Resected Hepatic Metastases From Colorectal Cancer",9256
9,NCT01327612,Phase II,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 746, 'therapyName': 'Ganitumab'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1458, 'therapyName': 'Conatumumab'}]",Open Label Extension Study of Conatumumab and AMG 479,9256
10,NCT01340300,Phase II,"Active, not recruiting","[{'id': 1031, 'therapyName': 'Metformin'}]",Exercise and Metformin in Colorectal and Breast Cancer Survivors,9256
11,NCT01351103,Phase I,Recruiting,"[{'id': 1937, 'therapyName': 'LGK974'}]",A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands,9256
12,NCT01436656,Phase I,"Active, not recruiting","[{'id': 796, 'therapyName': 'Encorafenib'}]",A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma,9256
13,NCT01543698,Phase Ib/II,"Active, not recruiting","[{'id': 1100, 'therapyName': 'Binimetinib + Encorafenib'}, {'id': 1101, 'therapyName': 'Binimetinib + Encorafenib + Ribociclib'}]",A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors,9256
14,NCT01569984,Phase II,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Radiosensitization of AVASTIN; (Bevacizumab) With Stereotactic Body Radiotherapy for Colorectal Liver Metastasis,9256
15,NCT01576666,Phase Ib/II,Completed,"[{'id': 1547, 'therapyName': 'BKM120 + Sonidegib'}]","Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors",9256
16,NCT01587703,Phase I,Recruiting,"[{'id': 784, 'therapyName': 'GSK525762'}]","A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers",9256
17,NCT01591421,Phase Ib/II,"Active, not recruiting","[{'id': 1990, 'therapyName': 'BKM120 + Panitumumab'}]",P13Kinase Inhibitor BKM120 in Combination With Panitumumab in Patients With Metastatic or Advanced RAS-Wild Type Colorectal Cancer.,9256
18,NCT01607905,Phase I,Completed,"[{'id': 1749, 'therapyName': 'Selinexor'}]",Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced or Metastatic Solid Tumor Cancer,9256
19,NCT01661972,Phase Ib/II,Completed,"[{'id': 2368, 'therapyName': 'Aflibercept + Capecitabine'}]",Phase I/II Study of Capecitabine Plus Aflibercept to Treat Metastatic Colorectal Cancer,9256
20,NCT01669720,Phase II,Terminated,"[{'id': 624, 'therapyName': 'Aflibercept'}]",Adjuvant Aflibercept for Metastatic Colorectal Cancer,9256
21,NCT01676714,Phase II,Completed,"[{'id': 721, 'therapyName': 'Dovitinib'}]",Study of Dovitinib and Biomarkers in Advanced Non-Small Cell Lung Cancer or Advanced Colorectal Cancer,9256
22,NCT01703390,Phase II,Unknown status,"[{'id': 2182, 'therapyName': 'Cetuximab + FOLFOX'}, {'id': 2180, 'therapyName': 'Cetuximab + FOLFIRI'}]",Biomarker Directed Treatment in Metastatic Colorectal Cancer,9256
23,NCT01719380,Phase Ib/II,"Active, not recruiting","[{'id': 1916, 'therapyName': 'Cetuximab + Encorafenib'}, {'id': 1917, 'therapyName': 'LGX818 + Cetuximab + BYL719'}]","Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer",9256
24,NCT01722162,Phase II,Completed,"[{'id': 2097, 'therapyName': 'Bevacizumab + Capecitabine'}]",Levocetirizine + Capecitabine + Bevacizumab for Patients With Refractory Colorectal Cancer,9256
25,NCT01729923,Phase II,Terminated,"[{'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 2124, 'therapyName': 'Celecoxib'}]",A Trial of Maintenance ADAPT Therapy With Capecitabine and Celecoxib in Patients With Metastatic Colorectal Cancer,9256
26,NCT01750918,Phase II,"Active, not recruiting","[{'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1718, 'therapyName': 'Panitumumab + Dabrafenib'}, {'id': 1992, 'therapyName': 'Panitumumab + Trametinib + Dabrafenib'}, {'id': 1991, 'therapyName': 'Panitumumab + Trametinib'}]",BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC),9256
27,NCT01765582,Phase II,Terminated,"[{'id': 1523, 'therapyName': 'Fluorouracil + Capecitabine + Irinotecan + Leucovorin + Oxaliplatin'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}]",STEAM: A Study of Sequential and Concurrent FOLFOXIRI/Avastin (Bevacizumab) Regimens Versus FOLFOX/Avastin in First-Line in Patients With Metastatic Colorectal Cancer,9256
28,NCT01776307,Phase II,Recruiting,"[{'id': 2090, 'therapyName': 'BBI608 + Cetuximab'}, {'id': 2091, 'therapyName': 'BBI608 + Capecitabine'}, {'id': 2092, 'therapyName': 'BBI608 + Panitumumab'}]",A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer,9256
29,NCT01871311,Phase I,Recruiting,"[{'id': 1929, 'therapyName': 'Nilotinib + Cetuximab'}]",A Phase I Study of the BCR-ABL Tyrosine Kinase Inhibitor Nilontinib and Cetuximab in Patients With Solid Tumors That Can be Treated With Cetuximab,9256
30,NCT01874860,Phase I,Recruiting,"[{'id': 1391, 'therapyName': 'Doxycycline'}]",Skin Rash Study Before Chemotherapy in Colorectal &amp; Head and Neck Cancer Patients,9256
31,NCT01876511,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Phase 2 Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors,9256
32,NCT01888965,Phase II,Terminated,"[{'id': 721, 'therapyName': 'Dovitinib'}]",Maintenance Dovitinib for Colorectal and Pancreas Cancer,9256
33,NCT01923337,Phase I,"Active, not recruiting","[{'id': 1288, 'therapyName': 'Irinotecan + Alisertib'}]",Irinotecan and Alisertib in Treating Patients With Advanced Solid Tumors or Colorectal Cancer,9256
34,NCT01927341,Phase Ib/II,Completed,"[{'id': 807, 'therapyName': 'Binimetinib'}, {'id': 845, 'therapyName': 'Panitumumab'}]","Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors",9256
35,NCT01937715,Phase II,Terminated,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1040, 'therapyName': 'PF-05212384'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer,9256
36,NCT01939223,Phase III,Completed,"[{'id': 890, 'therapyName': 'Regorafenib'}]","COlorectal Cancer Treated With Adjuvant Regorafenib Versus Placebo After Curative Treatment of Liver Metastases in a Randomized, Double-blind, Placebo?Controlled Phase-III STudy (COAST)",9256
37,NCT01960023,Phase Ib/II,"Active, not recruiting","[{'id': 1118, 'therapyName': 'Cetuximab + Neratinib'}]",Safety and Efficacy Study of Neratinib and Cetuximab to Treat Patients With Quadruple Wild-Type Metastatic Colorectal Cancer,9256
38,NCT01966445,Phase I,Completed,"[{'id': 2919, 'therapyName': 'GSK2849330'}]","Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors",9256
39,NCT01968109,Phase I,Recruiting,"[{'id': 4197, 'therapyName': 'BMS-986016 + Nivolumab'}, {'id': 4196, 'therapyName': 'BMS-986016'}]",Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors,9256
40,NCT01974258,Phase I,Withdrawn,"[{'id': 1306, 'therapyName': 'Onartuzumab + Vemurafenib'}, {'id': 1307, 'therapyName': 'Onartuzumab + Cobimetinib'}, {'id': 1308, 'therapyName': 'Onartuzumab + Cobimetinib + Vemurafenib'}]","Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients",9256
41,NCT01988896,Phase I,"Active, not recruiting","[{'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}]",A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors,9256
42,NCT02004106,Phase I,Completed,"[{'id': 2886, 'therapyName': 'RO6895882'}]",A Study of RO6895882 in Patients With Advanced and/or Metastatic Solid Tumors,9256
43,NCT02009449,Phase I,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 2621, 'therapyName': 'AM0010 '}, {'id': 619, 'therapyName': 'Abraxane'}]",A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors,9256
44,NCT02025803,Phase I,"Active, not recruiting","[{'id': 4335, 'therapyName': 'Capecitabine + TAS-114'}]","A Safety, Tolerability and Pharmacokinetic Study of TAS-114 in Combination With Capecitabine in Patients With Advanced Solid Tumors",9256
45,NCT02038699,Phase Ib/II,Withdrawn,"[{'id': 1687, 'therapyName': 'ONC201'}]",A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer,9256
46,NCT02041481,Phase I,"Active, not recruiting","[{'id': 2217, 'therapyName': 'MEK162 + FOLFOX'}]","MEK Inhibitor MEK162 in Combination With Leucovorin Calcium, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Metastatic Colorectal Cancer",9256
47,NCT02060188,Phase Ib/II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",A Study of Nivolumab and Nivolumab Plus Ipilimumab in Recurrent and Metastatic Colon Cancer (CheckMate 142),9256
48,NCT02083653,Phase II,"Active, not recruiting","[{'id': 931, 'therapyName': 'SYM004'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer,9256
49,NCT02110082,Phase I,Completed,"[{'id': 2066, 'therapyName': 'Cetuximab + Urelumab'}]",Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer,9256
50,NCT02122809,Phase I,Completed,"[{'id': 1998, 'therapyName': 'Chiauranib'}]",Phase I Study of Chiauranib in Patients With Advanced Solid Tumors,9256
51,NCT02124148,Phase I,Recruiting,"[{'id': 1994, 'therapyName': 'Cisplatin + Prexasertib'}, {'id': 1993, 'therapyName': 'Cetuximab + Prexasertib'}, {'id': 6248, 'therapyName': 'Pemetrexed + Prexasertib'}, {'id': 6247, 'therapyName': 'LY3023414 + Prexasertib'}, {'id': 6246, 'therapyName': 'Fluoruracil + Leucovorin + Prexasertib'}]",A Study of LY2606368 With Cisplatin or Cetuximab in Participants With Advanced Cancer,9256
52,NCT02141295,Phase II,Completed,"[{'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}, {'id': 1598, 'therapyName': 'RO5520985'}, {'id': 1599, 'therapyName': 'Bevacizumab + Fluorouracil + Leucovorin'}, {'id': 1600, 'therapyName': 'RO5520985 + Leucovorin + Fluorouracil'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",A Study Comparing the Efficacy and Safety of RO5520985 and FOLFOX With Bevacizumab and FOLFOX in Patients With Untreated Metastatic Colorectal Cancer (McCAVE),9256
53,NCT02168777,Phase Ib/II,Terminated,"[{'id': 1424, 'therapyName': 'Regorafenib + Refametinib'}, {'id': 888, 'therapyName': 'Refametinib'}]","Refametinib (BAY86-9766) in Combination With Regorafenib (Stivarga, BAY73-4506) in Patients With Advanced or Metastatic Cancer",9256
54,NCT02199223,Phase I,Terminated,"[{'id': 1617, 'therapyName': 'Regorafenib + Panitumumab'}]",Regorafenib + Panitumumab,9256
55,NCT02205398,Phase Ib/II,Terminated,"[{'id': 1618, 'therapyName': 'INC280 + Cetuximab '}]","Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy",9256
56,NCT02227667,Phase II,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}]",Evaluate the Efficacy of MEDI4736 in Immunological Subsets of Advanced Colorectal Cancer,9256
57,NCT02260440,Phase II,"Active, not recruiting","[{'id': 2496, 'therapyName': 'Azacitidine + Pembrolizumab'}]",A Phase 2 Study of MK-3475 in Combination With Azacitidine in Subjects With Chemo-refractory Metastatic Colorectal Cancer,9256
58,NCT02268825,Phase Ib/II,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Phase I/IIA Study MK-3475 With Chemotherapy in Patients With Advanced GI Cancers,9256
59,NCT02277093,Phase II,Terminated,"[{'id': 2006, 'therapyName': 'Pacritinib'}]",Pacritinib to Inhibit JAK/STAT Signaling in Refractory Colorectal Cancer,9256
60,NCT02278133,Phase Ib/II,Completed,"[{'id': 2008, 'therapyName': 'LGK974 + LGX818 + Cetuximab'}]",Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations,9256
61,NCT02279433,Phase I,"Active, not recruiting","[{'id': 4343, 'therapyName': 'DS6051b'}]","A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b",9256
62,NCT02287025,FDA approved,Terminated,"[{'id': 890, 'therapyName': 'Regorafenib'}]",A Phase 4 Study of Regorafenib in Metastatic Colorectal Cancer - Does Educating Physicians Change Patient Out Comes?,9256
63,NCT02298959,Phase I,Recruiting,"[{'id': 2369, 'therapyName': 'Aflibercept + Pembrolizumab'}]",Pembrolizumab and Ziv-aflibercept in Treating Patients With Advanced Solid Tumors,9256
64,NCT02316340,Phase II,Recruiting,"[{'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1316, 'therapyName': 'Hydroxychloroquine'}, {'id': 890, 'therapyName': 'Regorafenib'}]",Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer,9256
65,NCT02318901,Phase Ib/II,"Active, not recruiting","[{'id': 1909, 'therapyName': 'Pembrolizumab + trastuzumab emtansine'}, {'id': 1908, 'therapyName': 'Pembrolizumab + Trastuzumab'}, {'id': 1910, 'therapyName': 'Pembrolizumab + Cetuximab'}]",Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer,9256
66,NCT02327078,Phase Ib/II,Recruiting,"[{'id': 3059, 'therapyName': 'INCB024360 + Nivolumab'}]","A Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination With Nivolumab in Select Advanced Cancers",9256
67,NCT02335918,Phase Ib/II,Recruiting,"[{'id': 2526, 'therapyName': 'Nivolumab + Varlilumab'}]",A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors,9256
68,NCT02346955,Phase I,Terminated,"[{'id': 4246, 'therapyName': 'CM-24'}, {'id': 4247, 'therapyName': 'CM-24 + Pembrolizumab'}]",Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001),9256
69,NCT02365662,Phase I,Recruiting,"[{'id': 2914, 'therapyName': 'ABBV-221'}]",A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor,9256
70,NCT02386826,Phase I,Recruiting,"[{'id': 2600, 'therapyName': 'Bevacizumab + INC280'}]","INC280 Combined With Bevacizumab to Evaluate Glioblastoma Multiforme, Metastatic Colorectal Cancer, and Metastatic Renal Cell Carcinoma Patients",9256
71,NCT02399943,Phase II,Recruiting,"[{'id': 1991, 'therapyName': 'Panitumumab + Trametinib'}]",A Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Advanced Colorectal Cancer,9256
72,NCT02402036,Phase II,"Active, not recruiting","[{'id': 890, 'therapyName': 'Regorafenib'}]",A Biomarker Study in Patients Getting Regorafenib for Metastatic Colorectal Cancer,9256
73,NCT02425683,Phase II,"Active, not recruiting","[{'id': 890, 'therapyName': 'Regorafenib'}]",Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX,9256
74,NCT02437071,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Assess the Efficacy of Pembrolizumab Plus Radiotherapy or Ablation in Metastatic Colorectal Cancer Patients,9256
75,NCT02444793,Phase I,Recruiting,"[{'id': 6332, 'therapyName': 'Mogamulizumab + Utomilumab'}]",A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors,9256
76,NCT02448810,Phase II,Terminated,"[{'id': 2278, 'therapyName': 'Fluorouracil + Leucovorin'}, {'id': 2996, 'therapyName': 'Imalumab'}, {'id': 845, 'therapyName': 'Panitumumab'}]",Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer,9256
77,NCT02460198,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164),9256
78,NCT02460224,Phase Ib/II,Recruiting,"[{'id': 2887, 'therapyName': 'LAG525'}, {'id': 2659, 'therapyName': 'PDR001'}]",Safety and Efficay of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies,9256
79,NCT02512172,Phase I,Recruiting,"[{'id': 2496, 'therapyName': 'Azacitidine + Pembrolizumab'}, {'id': 5728, 'therapyName': 'Romidepsin + Pembrolizumab'}, {'id': 5782, 'therapyName': 'Azacitidine + Pembrolizumab + Romidepsin'}]",A Study of Enhancing Response to MK-3475 in Advanced Colorectal Cancer,9256
80,NCT02526017,Phase I,Recruiting,"[{'id': 2840, 'therapyName': 'FPA008'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Study of FPA008 in Combination With Nivolumab in Patients With Selected Advance Cancers,9256
81,NCT02528357,Phase I,Recruiting,"[{'id': 5177, 'therapyName': 'GSK3174998'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",GSK3174998 Alone or With Pembrolizumab in Subjects With Advanced Solid Tumors,9256
82,NCT02538627,Phase I,Terminated,"[{'id': 820, 'therapyName': 'Seribantumab'}, {'id': 821, 'therapyName': 'MM-151'}]",Phase 1 Combination Study of MM-151 and MM-121,9256
83,NCT02540291,Phase I,Recruiting,"[{'id': 5694, 'therapyName': 'E7046'}]",Study of E7046 in Subjects With Selected Advanced Malignancies,9256
84,NCT02559024,Phase I,"Active, not recruiting","[{'id': 1653, 'therapyName': 'MEDI6469'}]",Anti-OX40 Antibody (MEDI6469) in Patients With Metastatic Colorectal Cancer,9256
85,NCT02559492,Phase I,"Active, not recruiting","[{'id': 3096, 'therapyName': 'INCB039110 + INCB024360'}, {'id': 3097, 'therapyName': 'INCB039110 + INCB050465'}]",INCB039110 Combined With INCB024360 and/or INCB039110 Combined With INCB050465 in Advanced Solid Tumors,9256
86,NCT02563002,Phase III,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177),9256
87,NCT02568046,Phase Ib/II,"Active, not recruiting","[{'id': 3949, 'therapyName': 'FOLFIRI + SYM004'}]",Sym004 in Combination With FOLFIRI in Metastatic Colorectal Cancer Patients,9256
88,NCT02568267,Phase II,Recruiting,"[{'id': 1455, 'therapyName': 'Entrectinib'}]","Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK1/2/3, ROS1, or ALK Gene Rearrangements  (STARTRK-2)",9256
89,NCT02573220,Phase I,Withdrawn,"[{'id': 2180, 'therapyName': 'Cetuximab + FOLFIRI'}]",Irinotecan Hydrochloride With FOLFIRI and Cetuximab as First-Line Therapy in Treating Patients With RAS Wild-Type Colorectal Cancer,9256
90,NCT02575781,Phase I,Recruiting,"[{'id': 4026, 'therapyName': 'SAR428926'}]",A Study of SAR428926 in Patients With Advanced Solid Tumors,9256
91,NCT02576431,Phase II,Recruiting,"[{'id': 2650, 'therapyName': 'LOXO-101'}]",Study of LOXO-101 in Subjects With NTRK Fusion Positive Solid Tumors,9256
92,NCT02576665,Phase I,Recruiting,"[{'id': 3211, 'therapyName': 'Toca 511 + Toca FC'}]","A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Solid Tumors (Toca6)",9256
93,NCT02599324,Phase Ib/II,Recruiting,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 694, 'therapyName': 'Cetuximab'}]",A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors,9256
94,NCT02605044,Phase III,Recruiting,"[{'id': 804, 'therapyName': 'Masitinib'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",Study to Compare the Efficacy and Safety of Masitinib in Combination With FOLFIRI to Placebo in Combination With FOLFIRI in Second Line Treatment of Patients With Metastatic Colorectal Cancer,9256
95,NCT02613650,Phase I,Recruiting,"[{'id': 3247, 'therapyName': 'Binimetinib + FOLFIRI'}]",A Trial of FOLFIRI With MEK162 in Patients With Advanced KRAS Positive Metastatic Colorectal Cancers,9256
96,NCT02630420,Phase I,Not yet recruiting,"[{'id': 3790, 'therapyName': 'Cetuximab + Savolitinib'}]",Cetuximab and Savolitinib Treatment of Ras Wild-Type Colorectal Cancer,9256
97,NCT02632448,Phase Ib/II,Recruiting,"[{'id': 4420, 'therapyName': 'LY2880070 + Gemcitabine'}, {'id': 4315, 'therapyName': 'LY2880070'}]",A Study of LY2880070 in Patients With Advanced or Metastatic Cancer,9256
98,NCT02636036,Phase I,Recruiting,"[{'id': 3620, 'therapyName': 'Enadenotucirev + Pembrolizumab'}]",Study of Enadenotucirev and Pembrolizumab in Subjects With Metastatic or Advanced Epithelial Tumors,9256
99,NCT02646748,Phase I,Recruiting,"[{'id': 3088, 'therapyName': 'INCB050465 '}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2406, 'therapyName': 'INCB039110'}]",Pembrolizumab Combined With INCB039110 and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors,9256
100,NCT02654639,Phase II,"Active, not recruiting","[{'id': 3682, 'therapyName': 'Bevacizumab + trifluridine/tipiracil hydrochloride'}]",Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer,9256
101,NCT02655822,Phase I,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 3571, 'therapyName': 'CPI-444 '}]",Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers,9256
102,NCT02665416,Phase I,Recruiting,"[{'id': 3468, 'therapyName': 'RO5520985 + RO7009789'}]","Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of RO7009789 With Vanucizumab in Metastatic Solid Tumors",9256
103,NCT02671955,Phase I,Terminated,"[{'id': 3614, 'therapyName': 'JNJ-61610588 '}]","A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced Cancer",9256
104,NCT02703571,Phase Ib/II,Recruiting,"[{'id': 4472, 'therapyName': 'Ribociclib + Trametinib'}]",Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors,9256
105,NCT02713373,Phase Ib/II,Recruiting,"[{'id': 1910, 'therapyName': 'Pembrolizumab + Cetuximab'}]",Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery,9256
106,NCT02713529,Phase Ib/II,Recruiting,"[{'id': 4170, 'therapyName': 'AMG820 + Pembrolizumab'}]",Safety Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer,9256
107,NCT02723955,Phase I,Recruiting,"[{'id': 4409, 'therapyName': 'GSK3359609'}, {'id': 4410, 'therapyName': 'GSK3359609 + Pembrolizumab'}]",Dose Escalation and Expansion Study of GSK3359609 in Subjects With Selected Advanced Solid Tumors (INDUCE-1),9256
108,NCT02745769,Phase I,Recruiting,"[{'id': 4208, 'therapyName': 'LY2801653 + Ramucirumab'}, {'id': 4209, 'therapyName': 'Abemaciclib + Ramucirumab'}]",A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents,9256
109,NCT02753127,Phase III,Recruiting,"[{'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 2057, 'therapyName': 'BBI608'}]",A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer (CanStem303C),9256
110,NCT02754856,Phase I,Recruiting,"[{'id': 4097, 'therapyName': 'Bevacizumab + MEDI4736 + Tremelimumab + FOLFOX'}]",Tremelimumab (Anti-CTLA-4) Plus MEDI4736 (Anti-PD-L1) in Resectable Colorectal Cancer Liver Metastases.,9256
111,NCT02760797,Phase I,Recruiting,"[{'id': 4181, 'therapyName': 'Emactuzumab + RO7009789'}]",A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors,9256
112,NCT02785068,Phase I,Withdrawn,"[{'id': 4532, 'therapyName': 'Fluorouracil + Irinotecan + Leucovorin + MM-151'}]",Evaluation of MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal Cancer,9256
113,NCT02811497,Phase II,Recruiting,"[{'id': 4178, 'therapyName': 'Azacitidine + MEDI4736'}]",Study of Azacitidine and Durvalumab in Advanced Solid Tumors (METADUR),9256
114,NCT02837263,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",PI Pembro in Combination With Stereotactic Body Radiotherapy for Liver Metastatic Colorectal Cancer,9256
115,NCT02857270,Phase I,Recruiting,"[{'id': 4588, 'therapyName': 'LY3214996'}, {'id': 4590, 'therapyName': 'LY3214996 + nab-paclitaxel + Gemcitabine'}, {'id': 4589, 'therapyName': 'LY3214996 + Midazolam'}, {'id': 4591, 'therapyName': 'LY3214996 + Abemaciclib'}]",A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer,9256
116,NCT02870920,Phase II,"Active, not recruiting","[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care Alone in Patients With Advanced Colorectal Adenocarcinoma Refractory to Standard Therapies,9256
117,NCT02873195,Phase II,Recruiting,"[{'id': 2097, 'therapyName': 'Bevacizumab + Capecitabine'}, {'id': 1202, 'therapyName': 'Atezolizumab + Bevacizumab + Capecitabine'}]",Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer,9256
118,NCT02880371,Phase Ib/II,Recruiting,"[{'id': 4608, 'therapyName': 'ARRY-382 + Pembrolizumab'}]",A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors,9256
119,NCT02888743,Phase II,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer,9256
120,NCT02890069,Phase I,Recruiting,"[{'id': 5311, 'therapyName': 'PDR001 + LCL161'}, {'id': 5312, 'therapyName': 'PDR001 + Everolimus'}, {'id': 5313, 'therapyName': 'PDR001 + Panobinostat'}]","A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat",9256
121,NCT02900664,Phase I,Recruiting,"[{'id': 5399, 'therapyName': 'PDR001 + EGF816'}, {'id': 5397, 'therapyName': 'PDR001 + CJM112'}, {'id': 5398, 'therapyName': 'PDR001 + Trametinib'}, {'id': 5395, 'therapyName': 'PDR001 + Canakinumab'}]","A Study of PDR001 in Combination With CJM112, EGF816, Ilaris (Canakinumab) or Mekinist (Trametinib)",9256
122,NCT02906059,Phase I,Recruiting,"[{'id': 1361, 'therapyName': 'MK-1775 + Irinotecan'}]","Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer",9256
123,NCT02928224,Phase III,Recruiting,"[{'id': 1916, 'therapyName': 'Cetuximab + Encorafenib'}, {'id': 4886, 'therapyName': 'Binimetinib + Cetuximab + LGX818'}, {'id': 1874, 'therapyName': 'Cetuximab + Irinotecan'}, {'id': 2180, 'therapyName': 'Cetuximab + FOLFIRI'}]",Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer (BEACON CRC),9256
124,NCT02947165,Phase I,Recruiting,"[{'id': 5632, 'therapyName': 'NIS793 + PDR001'}, {'id': 5631, 'therapyName': 'NIS793'}]",Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.,9256
125,NCT02953782,Phase Ib/II,Recruiting,"[{'id': 4948, 'therapyName': 'Cetuximab + Hu5F9-G4'}]",Trial of Hu5F9-G4 in Combination With Cetuximab in Patients With Solid Tumors and Advanced Colorectal Cancer,9256
126,NCT02959437,Phase Ib/II,Recruiting,"[{'id': 5477, 'therapyName': 'Azacitidine + INCB024360 + Pembrolizumab'}]",Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206),9256
127,NCT02960594,Phase I,Recruiting,"[{'id': 5844, 'therapyName': 'INO-1400 + INO-9012'}, {'id': 5807, 'therapyName': 'INO-1400'}]",hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse,9256
128,NCT02961283,Phase I,Recruiting,"[{'id': 5827, 'therapyName': 'ASN003'}]",Study of ASN003 in Subjects With Advanced Solid Tumors,9256
129,NCT02963831,Phase Ib/II,Recruiting,"[{'id': 4978, 'therapyName': 'ONCOS-102 + MEDI4736'}]","A Phase 1/2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies",9256
130,NCT02965417,Phase II,Withdrawn,"[{'id': 931, 'therapyName': 'SYM004'}]",Sym004 in Metastatic Colorectal Cancer and ECD-EGFR Patients,9256
131,NCT02981524,Phase II,Recruiting,"[{'id': 5079, 'therapyName': 'Cyclophosphamide + GVAX colorectal cancer vaccine + Pembrolizumab'}]",Phase 2 Study of GVAX (With CY) and Pembrolizumab in MMR-p Advanced Colorectal Cancer,9256
132,NCT02983578,Phase II,Recruiting,"[{'id': 3098, 'therapyName': 'AZD9150 + MEDI4736'}]","AZD9150 With MEDI4736 in Patients With Advanced Pancreatic, Non-Small Lung and Colorectal Cancer",9256
133,NCT02991196,Phase I,Terminated,"[{'id': 5078, 'therapyName': 'DS-8273a + Nivolumab'}]",Antibody DS-8273a Administered in Combination With Nivolumab in Subjects With Advanced Colorectal Cancer,9256
134,NCT03005002,Phase I,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",Durvalumab and Tremelimumab in Treating Patients With Microsatellite Stable Metastatic Colorectal Cancer to the Liver,9256
135,NCT03018405,Phase I,Recruiting,"[{'id': 5998, 'therapyName': 'NKR-2 cells'}]",A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications (THINK),9256
136,NCT03031691,Phase I,"Active, not recruiting","[{'id': 5261, 'therapyName': 'Brontictuzumab + Trifluridine'}]",A Study of Brontictuzumab With Chemotherapy for Subjects With Previously Treated Metastatic Colorectal Cancer,9256
137,NCT03035279,Phase I,Recruiting,"[{'id': 5748, 'therapyName': 'SC-006'}]",A Study of SC-006 in Subjects With Advanced Cancer,9256
138,NCT03050814,Phase II,Suspended,"[{'id': 1524, 'therapyName': 'Fluorouracil + Bevacizumab + Capecitabine + Leucovorin + Oxaliplatin'}, {'id': 5336, 'therapyName': 'Ad-CEA + Bevacizumab + FOLFOX'}]",Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer,9256
139,NCT03087591,Phase I,Recruiting,"[{'id': 5751, 'therapyName': 'APN401'}]","APN401 in Treating Patients With Recurrent or Metastatic Pancreatic Cancer, Colorectal Cancer, or Other Solid Tumors That Cannot Be Removed by Surgery",9256
140,NCT03122509,Phase II,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]","A Clinical Trial of Durvalumab and Tremelimumab, Administered With Radiation Therapy or Ablation in Patients With Colorectal Cancer",9256
141,NCT03184870,Phase Ib/II,Recruiting,"[{'id': 5905, 'therapyName': 'BMS-813160 + Fluorouracil + Irinotecan + Leucovorin'}, {'id': 5903, 'therapyName': 'BMS-813160 + Nivolumab'}, {'id': 5904, 'therapyName': 'BMS-813160 + Gemcitabine + nab-paclitaxel'}, {'id': 5902, 'therapyName': 'BMS-813160'}]",A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Patients With Advanced Solid Tumors,9256
142,NCT03188965,Phase I,Recruiting,"[{'id': 5962, 'therapyName': 'BAY1895344'}]",First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas,9256
143,NCT03206073,Phase Ib/II,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer,9256
144,NCT03215264,Phase Ib/II,Not yet recruiting,"[{'id': 6052, 'therapyName': 'Entinostat + Hydroxychloroquine + Regorafenib'}]","Phase I/II Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal Cancer",9256
145,NCT03223779,Phase Ib/II,Not yet recruiting,"[{'id': 4586, 'therapyName': 'Trifluridine'}]",Study of TAS-102 Plus Radiation Therapy for the Treatment of the Liver in Patients With Hepatic Metastases From Colorectal Cancer,9256
146,NCT03239145,Phase I,Recruiting,"[{'id': 6102, 'therapyName': 'Pembrolizumab + Trebananib'}]",Phase Ib Study to Test the Safety and Potential Synergy of Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor,9256
147,NCT03259867,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Combination of TATE and PD-1 Inhibitor in Liver Cancer,9256
148,NCT03263429,Phase Ib/II,Recruiting,"[{'id': 6158, 'therapyName': 'CB-839 + Irinotecan + Panitumumab'}]",Novel PET/CT Imaging Biomarkers of CB-839 in Combination With Panitumumab and Irinotecan in Patients With Metastatic and Refractory RAS Wildtype Colorectal Cancer,9256
149,NCT03271047,Phase Ib/II,Recruiting,"[{'id': 6326, 'therapyName': 'Binimetinib + Ipilimumab + Nivolumab'}, {'id': 6325, 'therapyName': 'Binimetinib + Nivolumab'}]",Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation,9256
150,NCT03289962,Phase I,Not yet recruiting,"[{'id': 6234, 'therapyName': 'RO7198457'}, {'id': 6235, 'therapyName': 'Atezolizumab + RO7198457'}]",A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors,9256
151,NCT03290937,Phase I,Not yet recruiting,"[{'id': 6288, 'therapyName': 'Cetuximab + Irinotecan + Utomilumab'}]","Clinical Trial Evaluating the Safety and Response With PF-05082566, Cetuximab and Irinotecan in Patients With Advanced Colorectal Cancer",9256
152,NCT03307603,Phase Ib/II,Not yet recruiting,"[{'id': 6319, 'therapyName': 'Yttrium-90 + Nivolumab'}]",Yttrium-90 Radioembolization + Nivolumab for Liver + Extra-hepatic Metastases From Colorectal Cancer,9256
0,NCT02637687,Phase I,Recruiting,"[{'id': 2650, 'therapyName': 'LOXO-101'}]",Oral TRK Inhibitor LOXO-101 for Treatment of Advanced Pediatric Solid or Primary Central Nervous System Tumors,8418
0,NCT01964300,Phase II,Recruiting,"[{'id': 2624, 'therapyName': 'peginterferon alfa-2b'}]",Peginterferon Alfa-2b in Treating Younger Patients With Craniopharyngioma That is Recurrent or Cannot Be Removed By Surgery,3840
0,NCT02978625,Phase II,Recruiting,"[{'id': 5080, 'therapyName': 'Talimogene laherparepvec + Nivolumab'}]",Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers,4871
1,NCT03172624,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer,4871
0,NCT02978625,Phase II,Recruiting,"[{'id': 5080, 'therapyName': 'Talimogene laherparepvec + Nivolumab'}]",Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers,3450
0,NCT00671112,Phase I,Terminated,"[{'id': 2234, 'therapyName': 'Bortezomib + Everolimus'}]",Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma,60061
1,NCT01637090,Phase II,Terminated,"[{'id': 735, 'therapyName': 'Everolimus'}]",Everolimus in Treating Cutaneous T-cell Lymphoma,60061
2,NCT01843998,Phase II,Withdrawn,"[{'id': 917, 'therapyName': 'Sirolimus'}]",Therapeutic Efficacy of Topical Sirolimus in Early Stage Cutaneous T-cell Lymphoma (CTCL),60061
3,NCT01902225,Phase I,Unknown status,"[{'id': 3393, 'therapyName': 'Doxil + romidepsin '}]",Phase I Dose-finding and Preliminary Efficacy Study of the Istodax in Combination With Doxil for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma,60061
4,NCT01976585,Phase Ib/II,Recruiting,"[{'id': 4337, 'therapyName': 'CDX-301 + poly ICLC '}]",In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy,60061
5,NCT02192021,Phase I,Recruiting,"[{'id': 1009, 'therapyName': 'Doxorubicin'}]",Micro Needle Array-Doxorubicin (MNA-D) in Patients With Cutaneous T-cell Lymphoma (CTCL),60061
6,NCT02556463,Phase I,Recruiting,"[{'id': 5457, 'therapyName': 'MEDI9197'}, {'id': 5458, 'therapyName': 'MEDI9197 + MEDI4736'}]",A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and Palliative Radiation in Subjects With Solid Tumors,60061
7,NCT02567656,Phase I,Recruiting,"[{'id': 2020, 'therapyName': 'RP6530'}]",Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma,60061
8,NCT02643303,Phase Ib/II,Recruiting,"[{'id': 3385, 'therapyName': 'MEDI4736 + poly ICLC '}, {'id': 1652, 'therapyName': 'Tremelimumab'}]","A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers",60061
9,NCT02974647,Phase II,Recruiting,"[{'id': 907, 'therapyName': 'Ruxolitinib'}]",Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma,60061
10,NCT02978625,Phase II,Recruiting,"[{'id': 5080, 'therapyName': 'Talimogene laherparepvec + Nivolumab'}]",Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers,60061
11,NCT03011814,Phase Ib/II,"Active, not recruiting","[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 3934, 'therapyName': 'lenalidomide + MEDI4736'}]",Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma,60061
12,NCT03235869,Phase I,Not yet recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}]",Radiation Therapy Plus Durvalumab for Tumor-Stage Cutaneous T-Cell Lymphoma,60061
0,NCT01446809,Phase I,"Active, not recruiting","[{'id': 1472, 'therapyName': 'Doxorubicin + Ifosfamide'}, {'id': 1471, 'therapyName': 'Pazopanib + Doxorubicin + Ifosfamide'}]",Pazopanib Hydrochloride Followed By Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma,3507
0,NCT00671112,Phase I,Terminated,"[{'id': 2234, 'therapyName': 'Bortezomib + Everolimus'}]",Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma,50745
1,NCT00918463,Phase II,Completed,"[{'id': 717, 'therapyName': 'Dasatinib'}]",A Study to Evaluate the Safety and Efficacy of Dasatinib (Sprycel) in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),50745
2,NCT00978432,Phase II,Terminated,"[{'id': 1964, 'therapyName': 'Panobinostat + Everolimus'}]",Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL),50745
3,NCT01177397,Phase Ib/II,Completed,"[{'id': 693, 'therapyName': 'CC-223'}]","Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma",50745
4,NCT01193842,Phase Ib/II,"Active, not recruiting","[{'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 3395, 'therapyName': 'R-EPOCH'}]",Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,50745
5,NCT01251575,Phase II,Recruiting,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 2270, 'therapyName': 'Cyclosporine + Mycophenolate mofetil + Sirolimus'}]","Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant",50745
6,NCT01307267,Phase I,Recruiting,"[{'id': 6111, 'therapyName': 'Utomilumab + Rituximab'}, {'id': 5086, 'therapyName': 'Utomilumab'}]",A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab,50745
7,NCT01334502,Phase I,Completed,"[{'id': 735, 'therapyName': 'Everolimus'}, {'id': 2195, 'therapyName': 'R-CHOP'}]","Everolimus, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Untreated Diffuse Large B-Cell Lymphoma",50745
8,NCT01421524,Phase I,Recruiting,"[{'id': 2358, 'therapyName': 'CC-122'}]","Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma",50745
9,NCT01431209,Phase II,Recruiting,"[{'id': 907, 'therapyName': 'Ruxolitinib'}]",Ruxolitinib Phosphate (Oral JAK Inhibitor INCB18424) in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma,50745
10,NCT01449461,Phase Ib/II,"Active, not recruiting","[{'id': 634, 'therapyName': 'AP26113'}]",A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113,50745
11,NCT01453205,Phase II,Completed,"[{'id': 2354, 'therapyName': 'Cisplatin + Cytarabine + Dexamethasone'}, {'id': 2352, 'therapyName': 'Carboplatin + Etoposide + Ifosfamide '}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 2407, 'therapyName': 'MEDI-551'}]","A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)",50745
12,NCT01686165,Phase II,"Active, not recruiting","[{'id': 1078, 'therapyName': 'Belinostat'}, {'id': 897, 'therapyName': 'Rituximab'}]",Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma,50745
13,NCT01691898,Phase Ib/II,"Active, not recruiting","[{'id': 4415, 'therapyName': 'Obinutuzumab + Pinatuzumab Vedotin + Rituximab'}, {'id': 4416, 'therapyName': 'Polatuzumab Vedotin + Pinatuzumab Vedotin + Rituximab'}, {'id': 4417, 'therapyName': 'Obinutuzumab + Polatuzumab Vedotin'}]",A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (ROMULUS),50745
14,NCT01719250,Phase I,Completed,"[{'id': 680, 'therapyName': 'BKM120'}]",Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma,50745
15,NCT01799889,Phase II,"Active, not recruiting","[{'id': 2522, 'therapyName': 'Entospletinib  '}]",A Phase 2 of Entospletinib in Subjects With Relapsed or Refractory Hematologic Malignancies,50745
16,NCT01804686,Phase III,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",A Long-term Extension Study of PCI-32765 (Ibrutinib),50745
17,NCT01854606,Phase Ib/II,Completed,"[{'id': 1951, 'therapyName': 'AEB071 + Everolimus'}]",Safety and Efficacy of AEB071 and EVEROLIMUS in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma,50745
18,NCT01855750,Phase III,"Active, not recruiting","[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 3266, 'therapyName': 'Cyclophosphamide + Doxorubicin + Prednisone + Vincristine '}]","A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma",50745
19,NCT01897012,Phase I,Recruiting,"[{'id': 1075, 'therapyName': 'romidepsin'}, {'id': 626, 'therapyName': 'Alisertib'}]",Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas,50745
20,NCT01938638,Phase I,Completed,"[{'id': 4027, 'therapyName': 'BAY1143572'}]",Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer,50745
21,NCT01953692,Phase I,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013)(KEYNOTE-013),50745
22,NCT01955499,Phase I,"Active, not recruiting","[{'id': 3580, 'therapyName': 'Ibrutinib + lenalidomide'}]",Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma,50745
23,NCT01959698,Phase Ib/II,Recruiting,"[{'id': 2351, 'therapyName': 'Carfilzomib + Rituximab'}, {'id': 2352, 'therapyName': 'Carboplatin + Etoposide + Ifosfamide '}]","Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma",50745
24,NCT01992653,Phase I,"Active, not recruiting","[{'id': 4248, 'therapyName': 'Cyclophosphamide + Doxorubicin + Prednisone'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 4226, 'therapyName': 'Polatuzumab Vedotin'}, {'id': 1646, 'therapyName': 'Obinutuzumab'}]","A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma",50745
25,NCT01994382,Phase I,Recruiting,"[{'id': 2531, 'therapyName': 'Cerdulatinib'}]",Phase 1 Dose Escalation Study in Chronic Lymphocytic Leukemia and Non-hodgkin Lymphoma,50745
26,NCT02000934,Phase I,Recruiting,"[{'id': 3146, 'therapyName': 'TAK-659'}]",A Study of TAK-659 in Adult Patients With Advanced Solid Tumor and Lymphoma Malignancies,50745
27,NCT02029443,Phase Ib/II,"Active, not recruiting","[{'id': 1605, 'therapyName': 'Acalabrutinib'}]","ACP-196, a Novel Bruton Tyrosine Kinase (Btk) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia",50745
28,NCT02031419,Phase I,Recruiting,"[{'id': 2376, 'therapyName': 'CC-122 + CC-292'}, {'id': 2377, 'therapyName': 'CC-223 + CC-292'}, {'id': 2375, 'therapyName': 'CC-122 + CC-223'}, {'id': 897, 'therapyName': 'Rituximab'}]","Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma",50745
29,NCT02055820,Phase I,"Active, not recruiting","[{'id': 1562, 'therapyName': 'Venetoclax'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 3266, 'therapyName': 'Cyclophosphamide + Doxorubicin + Prednisone + Vincristine '}, {'id': 1646, 'therapyName': 'Obinutuzumab'}]",A Safety and Pharmacokinetics Study of GDC-0199 (ABT-199) in Patients With Non-Hodgkin's Lymphoma,50745
30,NCT02061761,Phase Ib/II,Recruiting,"[{'id': 4197, 'therapyName': 'BMS-986016 + Nivolumab'}, {'id': 4196, 'therapyName': 'BMS-986016'}]",Safety Study of Anti-LAG-3 in Relapsed or Refractory Hematologic Malignancies,50745
31,NCT02073097,Phase Ib/II,Recruiting,"[{'id': 2351, 'therapyName': 'Carfilzomib + Rituximab'}, {'id': 2353, 'therapyName': 'Cyclophosphamide + Doxorubicin + Vincristine '}]","Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma",50745
32,NCT02077166,Phase Ib/II,Recruiting,"[{'id': 1610, 'therapyName': 'Rituximab + Lenalidomide + Ibrutinib'}]",Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma,50745
33,NCT02082977,Phase I,Terminated,"[{'id': 2734, 'therapyName': 'GSK2816126'}]","A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell and Transformed Follicular Lymphoma",50745
34,NCT02138786,Phase II,Terminated,"[{'id': 1749, 'therapyName': 'Selinexor'}]",Study of Selinexor (KPT-330) in Patients With Refractory and/or Relapsed Richter's Transformation (RT),50745
35,NCT02181218,Phase I,Recruiting,"[{'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1611, 'therapyName': 'Gemcitabine + Oxaliplatin + Dexamethasone'}]","Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas",50745
36,NCT02203526,Phase I,Suspended,"[{'id': 1607, 'therapyName': 'Temozolomide + Etoposide + Doxil + Dexamethasone + Ibrutinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 897, 'therapyName': 'Rituximab'}]","Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Dose-Adjusted-Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (DA-TEDDI-R) in Primary CNS Lymphoma",50745
37,NCT02208037,Phase II,"Active, not recruiting",[],Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203),50745
38,NCT02219737,Phase I,"Active, not recruiting","[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 3360, 'therapyName': 'Carboplatin + Etoposide + Ifosfamide + Rituximab'}]",Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma,50745
39,NCT02220842,Phase I,Recruiting,"[{'id': 1975, 'therapyName': 'Atezolizumab + Obinutuzumab'}]",A Safety and Pharmacology Study of MPDL3280A Administered With Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma,50745
40,NCT02226965,Phase II,"Active, not recruiting","[{'id': 2581, 'therapyName': 'PNT2258'}]",Wolverine: PNT2258 for Treatment of Patients With r/r DLBCL,50745
41,NCT02227251,Phase II,Recruiting,"[{'id': 1749, 'therapyName': 'Selinexor'}]",Study of Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (SADAL),50745
42,NCT02229981,Phase Ib/II,Recruiting,"[{'id': 3301, 'therapyName': 'ABC294640'}]",An Early-Phase Clinical Trial Evaluating ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma,50745
43,NCT02252146,Phase Ib/II,Completed,"[{'id': 2866, 'therapyName': 'IMO-8400'}]",Dose Escalation Study in Patients With Relapsed or Refractory DLBCL and MyD88L265P Mutation,50745
44,NCT02257567,Phase Ib/II,"Active, not recruiting","[{'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}, {'id': 4226, 'therapyName': 'Polatuzumab Vedotin'}, {'id': 1646, 'therapyName': 'Obinutuzumab'}]",A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma,50745
45,NCT02282358,Phase Ib/II,"Active, not recruiting","[{'id': 3002, 'therapyName': 'Mocetinostat'}]",Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma,50745
46,NCT02303392,Phase I,Recruiting,"[{'id': 3579, 'therapyName': 'Ibrutinib + Selinexor'}]",Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma,50745
47,NCT02315326,Phase Ib/II,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}]","Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)",50745
48,NCT02323230,Phase II,"Active, not recruiting","[{'id': 4280, 'therapyName': 'Cyclophosphamide + DPX-Survivac'}]",A Study of DPX-Survivac Vaccine Therapy in Patients With Recurrent Survivin-expressing DLBCL,50745
49,NCT02327078,Phase Ib/II,Recruiting,"[{'id': 3059, 'therapyName': 'INCB024360 + Nivolumab'}]","A Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination With Nivolumab in Select Advanced Cancers",50745
50,NCT02343536,Phase I,Recruiting,"[{'id': 2488, 'therapyName': 'Cyclophosphamide + Prednisone + Rituximab + Vincristine'}, {'id': 651, 'therapyName': 'Azacitidine'}]","A Phase 1, Open-label,Trial of Oral Azacitidine (CC-486) Plus R-CHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma",50745
51,NCT02348216,Phase Ib/II,Recruiting,"[{'id': 4829, 'therapyName': 'KTE-C19'}]",A Phase 1-2 Multi-Center Study Evaluating KTE-C19 in Subjects With Refractory Aggressive Non-Hodgkin Lymphoma (ZUMA-1),50745
52,NCT02362997,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab After ASCT for Hodgkin Lymphoma and DLBCL,50745
53,NCT02376699,Phase I,Recruiting,"[{'id': 5781, 'therapyName': 'Pembrolizumab + SEA-CD40'}, {'id': 5780, 'therapyName': 'SEA-CD40'}]",Safety Study of SEA-CD40 in Cancer Patients,50745
54,NCT02391116,Phase II,"Active, not recruiting","[{'id': 995, 'therapyName': 'Copanlisib'}]",Phase II Copanlisib in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL),50745
55,NCT02399085,Phase II,Recruiting,"[{'id': 5843, 'therapyName': 'Lenalidomide + MOR208'}]",A Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL,50745
56,NCT02401048,Phase Ib/II,"Active, not recruiting","[{'id': 2573, 'therapyName': 'Ibrutinib + MEDI4736'}]",A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas,50745
57,NCT02408042,Phase Ib/II,Withdrawn,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 2352, 'therapyName': 'Carboplatin + Etoposide + Ifosfamide '}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2486, 'therapyName': 'Brentuximab vedotin'}]",Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme),50745
58,NCT02420795,Phase Ib/II,Recruiting,"[{'id': 1687, 'therapyName': 'ONC201'}]",Study of Oral ONC201 in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma,50745
59,NCT02436707,Phase II,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 3391, 'therapyName': 'Cisplatin + Dexamethasone + Gemcitabine + Rituximab'}]",Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma,50745
60,NCT02443077,Phase III,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 3359, 'therapyName': 'Carmustine + Cytarabine + Etoposide + Melphalan'}, {'id': 768, 'therapyName': 'Ibrutinib'}]",Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma,50745
61,NCT02445248,Phase II,Recruiting,"[{'id': 5981, 'therapyName': 'Tisagenlecleucel'}]",Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients (JULIET),50745
62,NCT02454270,Phase II,"Active, not recruiting","[{'id': 4166, 'therapyName': 'JNJ-64052781'}]",A Dose Escalation Study of JNJ-64052781 in Participants With Relapsed or Refractory B-cell Malignancies,50745
63,NCT02471911,Phase I,Recruiting,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 3360, 'therapyName': 'Carboplatin + Etoposide + Ifosfamide + Rituximab'}, {'id': 1749, 'therapyName': 'Selinexor'}]",KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma,50745
64,NCT02530125,Phase II,"Active, not recruiting","[{'id': 3338, 'therapyName': 'Pidilizumab'}]",Pidilizumab in Treating Patients With Stage III-IV Diffuse Large B-Cell Lymphoma Following First Remission,50745
65,NCT02531308,Phase II,Terminated,"[{'id': 1031, 'therapyName': 'Metformin'}, {'id': 3266, 'therapyName': 'Cyclophosphamide + Doxorubicin + Prednisone + Vincristine '}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 897, 'therapyName': 'Rituximab'}]",Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL),50745
66,NCT02532192,Phase I,Withdrawn,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1689, 'therapyName': 'Fluconazole'}, {'id': 1078, 'therapyName': 'Belinostat'}]","A Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in Adults With Relapsed or Refractory Diffuse Large B-cell Lymphoma",50745
67,NCT02541565,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 3266, 'therapyName': 'Cyclophosphamide + Doxorubicin + Prednisone + Vincristine '}, {'id': 897, 'therapyName': 'Rituximab'}]",Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma,50745
68,NCT02549651,Phase I,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 3098, 'therapyName': 'AZD9150 + MEDI4736'}]",MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Diffuse Large B-cell Lymphoma (D4190C00023),50745
69,NCT02570542,Phase II,Recruiting,"[{'id': 1756, 'therapyName': 'Plerixafor'}, {'id': 3359, 'therapyName': 'Carmustine + Cytarabine + Etoposide + Melphalan'}]",Impact of CD34+ Cell Dose on Progression-free Survival Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL),50745
70,NCT02572453,Phase II,Recruiting,"[{'id': 645, 'therapyName': 'AT13387'}]","AT13387 in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Diffuse Large B-cell Lymphoma",50745
71,NCT02576990,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) in Participants With Advanced Primary Mediastinal Large B-cell Lymphoma (MK-3475-170/KEYNOTE-170),50745
72,NCT02581631,Phase Ib/II,Recruiting,"[{'id': 3263, 'therapyName': 'Brentuximab vedotin + Nivolumab'}]",A Safety and Efficacy Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas (CheckMate 436),50745
73,NCT02589145,Phase Ib/II,Recruiting,"[{'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 3277, 'therapyName': 'Pyridoxine'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 3278, 'therapyName': 'Enoxaparin'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 2373, 'therapyName': 'Palifermin'}]",Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype,50745
74,NCT02596971,Phase I,Recruiting,"[{'id': 1975, 'therapyName': 'Atezolizumab + Obinutuzumab'}, {'id': 3266, 'therapyName': 'Cyclophosphamide + Doxorubicin + Prednisone + Vincristine '}, {'id': 1231, 'therapyName': 'Bendamustine'}]",Safety and Efficacy of MPDL3280A in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus CHOP in Patients With Follicular Lymphoma or Diffuse Large B-Cell Lymphoma,50745
75,NCT02600897,Phase Ib/II,Recruiting,"[{'id': 4394, 'therapyName': 'lenalidomide + Obinutuzumab + Polatuzumab Vedotin'}]","A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)",50745
76,NCT02611323,Phase Ib/II,Recruiting,"[{'id': 4227, 'therapyName': 'Obinutuzumab + Polatuzumab Vedotin + Venetoclax'}]","A Study of Obinutuzumab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)",50745
77,NCT02624986,Phase Ib/II,Recruiting,"[{'id': 4393, 'therapyName': 'Idasanutlin + Obinutuzumab'}]",A Study of Obinutuzumab With Idasanutlin in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL),50745
78,NCT02631044,Phase I,Recruiting,"[{'id': 5980, 'therapyName': 'JCAR017'}]",Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (NHL),50745
79,NCT02636322,Phase II,Recruiting,"[{'id': 2482, 'therapyName': 'Cyclophosphamide + Doxorubicin + Etoposide + Vincristine '}, {'id': 1610, 'therapyName': 'Rituximab + Lenalidomide + Ibrutinib'}, {'id': 2188, 'therapyName': 'Prednisone'}]","A Study of Rituximab, Lenalidomide, and Ibrutinib Combined With Dose Adjusted Chemotherapy For Patients With High Risk Diffuse Large B-Cell Lymphoma",50745
80,NCT02650999,Phase Ib/II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab in Patients Failing to Respond to or Relapsing After Anti-CD19 Chimeric Antigen Receptor Modified T Cell Therapy for Relapsed or Refractory CD19+ Lymphomas,50745
81,NCT02674750,Phase II,Recruiting,"[{'id': 4447, 'therapyName': 'CUDC-907 + Rituximab'}, {'id': 709, 'therapyName': 'CUDC-907'}]",Study to Evaluate the Efficacy and Safety of CUDC-907 With and Without Rituximab in Patients With RR MYC-Altered DLBCL,50745
82,NCT02681302,Phase Ib/II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study of Combined Check Point Inhibition After Autologous Hematopoietic Stem Cell Transplantation in Patients at High Risk for Post-transplant Recurrence (CPIT001),50745
83,NCT02684617,Phase I,Recruiting,"[{'id': 4225, 'therapyName': 'Dinaciclib + Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies  (MK-3475-155) (KEYNOTE-155),50745
84,NCT02698189,Phase I,"Active, not recruiting","[{'id': 2034, 'therapyName': 'OTX015'}]",A Dose Exploration Study With MK-8628 in Participants With Selected Hematologic Malignancies (MK-8628-005),50745
85,NCT02700022,Phase I,"Active, not recruiting","[{'id': 626, 'therapyName': 'Alisertib'}, {'id': 3395, 'therapyName': 'R-EPOCH'}]",A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas,50745
86,NCT02701673,Phase Ib/II,Withdrawn,"[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 3277, 'therapyName': 'Pyridoxine'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1078, 'therapyName': 'Belinostat'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}]",Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma,50745
87,NCT02706405,Phase I,Recruiting,"[{'id': 4365, 'therapyName': 'Cyclophosphamide + JCAR014 + MEDI4736'}]",JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma,50745
88,NCT02729896,Phase Ib/II,Recruiting,"[{'id': 4362, 'therapyName': 'Atezolizumab + Obinutuzumab + Polatuzumab Vedotin'}]","A Study of Obinutuzumab, Polatuzumab Vedotin, and Atezolizumab in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)",50745
89,NCT02743546,Phase I,Withdrawn,"[{'id': 4167, 'therapyName': 'Ibrutinib + JNJ-64052781'}]","Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of JNJ-64052781 Plus Ibrutinib in Lymphoma",50745
90,NCT02756247,Phase I,Recruiting,"[{'id': 3630, 'therapyName': 'BKM120 + Ibrutinib'}]",A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma,50745
91,NCT02760485,Phase Ib/II,Recruiting,"[{'id': 5151, 'therapyName': 'Ibrutinib + INCB039110'}]",A Study of INCB039110 in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma,50745
92,NCT02793583,Phase II,Recruiting,"[{'id': 2022, 'therapyName': 'TGR-1202'}, {'id': 2319, 'therapyName': 'TGR-1202 + Ublituximab'}]",Study to Assess the Efficacy and Safety of Ublituximab + TGR-1202 and TGR-1202 Alone in Patients With Previously Treated Diffuse Large B-Cell Lymphoma (UNITY-DLBCL),50745
93,NCT02815397,Phase II,Recruiting,"[{'id': 1031, 'therapyName': 'Metformin'}]",DA-EPOCH-Rituximab/Metformin (RM) for Double Hit Lymphoma,50745
94,NCT02874404,Phase II,Recruiting,"[{'id': 2044, 'therapyName': 'Ibrutinib + TGR-1202'}]",TGR-1202 and Ibrutinib in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma,50745
95,NCT02875002,Phase I,Not yet recruiting,"[{'id': 4826, 'therapyName': 'Belinostat + Volasertib'}]",Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas,50745
96,NCT02909777,Phase I,Recruiting,"[{'id': 709, 'therapyName': 'CUDC-907'}]","Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma",50745
97,NCT02926833,Phase Ib/II,Recruiting,"[{'id': 4830, 'therapyName': 'Atezolizumab + KTE-C19'}]",A Study Evaluating KTE-C19 in Combination With Atezolizumab in Subjects With Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (ZUMA-6),50745
98,NCT02950220,Phase I,Recruiting,"[{'id': 4917, 'therapyName': 'Pembrolizumab + Ibrutinib'}]",Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma,50745
99,NCT02951156,Phase III,Recruiting,"[{'id': 5088, 'therapyName': 'Avelumab + Azacitidine + Utomilumab'}, {'id': 5087, 'therapyName': 'Avelumab + Rituximab + Utomilumab'}, {'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}, {'id': 5090, 'therapyName': 'Gemcitabine + Oxaliplatin + Rituximab'}, {'id': 5089, 'therapyName': 'Avelumab + Bendamustine + Rituximab'}]","Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)",50745
100,NCT02953509,Phase Ib/II,Recruiting,"[{'id': 4955, 'therapyName': 'Hu5F9-G4 + Rituximab'}]",Trial of Hu5F9-G4 in Combination With Rituximab in Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma,50745
101,NCT02961816,Phase II,Withdrawn,"[{'id': 3277, 'therapyName': 'Pyridoxine'}, {'id': 4976, 'therapyName': 'Busulfan + Gemcitabine + Melphalan + Panobinostat'}, {'id': 4977, 'therapyName': 'Dexamethasone + Filgrastim + Palifermin + Rituximab'}]",Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma,50745
102,NCT02998476,Phase II,Recruiting,"[{'id': 3088, 'therapyName': 'INCB050465 '}]",A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202),50745
103,NCT03003520,Phase II,Recruiting,"[{'id': 5350, 'therapyName': 'MEDI4736 + R2-CHOP'}, {'id': 5349, 'therapyName': 'MEDI4736 + Rituximab + Doxorubicin + Vincristine + Cyclophosphamide + Prednisone'}]",A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma,50745
104,NCT03015896,Phase Ib/II,Suspended,"[{'id': 5239, 'therapyName': 'Lenalidomide + Nivolumab'}]",Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma,50745
105,NCT03028103,Phase I,Recruiting,"[{'id': 5267, 'therapyName': 'Tazemetostat + Fluconazole'}, {'id': 5285, 'therapyName': 'Repaglinide + Omeprazole + Tazemetostat'}]","Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, the Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and the Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma Subjects",50745
106,NCT03036904,Phase I,Recruiting,"[{'id': 5294, 'therapyName': 'Venetoclax + DA-EPOCH-R'}]",Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas (V+DA-EPOCH-R),50745
107,NCT03064867,Phase I,Recruiting,"[{'id': 5404, 'therapyName': 'Venetoclax + Rituximab + Ifosfamide + Carboplatin + Etoposide'}]",Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma,50745
108,NCT03106428,Phase I,Recruiting,"[{'id': 5762, 'therapyName': 'MEDI7247'}]",A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies,50745
109,NCT03135262,Phase Ib/II,Recruiting,"[{'id': 5646, 'therapyName': 'Idasanutlin + Rituximab + Venetoclax'}, {'id': 5644, 'therapyName': 'Idasanutlin + Obinutuzumab + Venetoclax'}, {'id': 5645, 'therapyName': 'Idasanutlin + Obinutuzumab + Rituximab + Venetoclax'}]",A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL),50745
110,NCT03136497,Phase I,Recruiting,"[{'id': 5777, 'therapyName': 'Ibrutinib + Rituximab + Venetoclax'}]",A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL),50745
111,NCT03147885,Phase Ib/II,Recruiting,"[{'id': 1749, 'therapyName': 'Selinexor'}]",Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma,50745
112,NCT03150329,Phase I,Recruiting,"[{'id': 3077, 'therapyName': 'Pembrolizumab + Vorinostat'}]","Pembrolizumab and Vorinostat in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, or Hodgkin Lymphoma",50745
113,NCT03153462,Expanded access,Available,"[{'id': 5098, 'therapyName': 'KTE-C19 + Fludarabine phosphate + Cyclophosphamide'}]",Axicabtagene Ciloleucel Expanded Access Study,50745
114,NCT03162536,Phase I,Recruiting,"[{'id': 5224, 'therapyName': 'ARQ 531'}]","Safety, PK, PD, and Antitumor Activity of ARQ 531 in Hematologic Malignancies",50745
115,NCT03188965,Phase I,Recruiting,"[{'id': 5962, 'therapyName': 'BAY1895344'}]",First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas,50745
116,NCT03205046,Phase Ib/II,Recruiting,"[{'id': 6188, 'therapyName': 'Acalabrutinib + Vistusertib'}]",A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies,50745
117,NCT03255018,Phase II,Not yet recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extra-Nodal Diffuse Large B-cell Lymphomas",50745
118,NCT03255096,Phase I,Recruiting,"[{'id': 6179, 'therapyName': 'Rituximab + TEN-010 + Venetoclax'}]","A Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of the Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)",50745
119,NCT03259503,Phase Ib/II,Not yet recruiting,"[{'id': 1206, 'therapyName': 'Busulfan'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 2373, 'therapyName': 'Palifermin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 3277, 'therapyName': 'Pyridoxine'}, {'id': 897, 'therapyName': 'Rituximab'}]",Olaparib Combined With High-Dose Chemotherapy for Refractory Lymphomas,50745
120,NCT03263026,Phase III,Not yet recruiting,"[{'id': 2195, 'therapyName': 'R-CHOP'}, {'id': 1682, 'therapyName': 'Enzastaurin'}]",Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1,50745
121,NCT03274492,Phase III,Not yet recruiting,"[{'id': 4226, 'therapyName': 'Polatuzumab Vedotin'}, {'id': 6177, 'therapyName': 'R-CHP'}, {'id': 2195, 'therapyName': 'R-CHOP'}]","A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma",50745
122,NCT03297424,Phase Ib/II,Recruiting,"[{'id': 6324, 'therapyName': 'PLX2853'}]",A Study of PLX2853 in Advanced Malignancies.,50745
123,NCT03305445,Phase Ib/II,Not yet recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCL,50745
0,NCT02521493,Phase III,Recruiting,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 5912, 'therapyName': 'Asparaginase Erwinia chrysanthemi'}, {'id': 5215, 'therapyName': 'mitoxantrone hydrochloride'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2206, 'therapyName': 'Asparaginase'}]",Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome,14250
0,NCT02636582,Phase II,Recruiting,"[{'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 5152, 'therapyName': 'Nelipepimut-S Plus GM-CSF'}]",Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer,60074
1,NCT02694809,Phase II,Recruiting,"[{'id': 5928, 'therapyName': 'Conjugated estrogens/bazedoxifene'}]",Conjugated Estrogens/Bazedoxifene in Treating Patients With Ductal Carcinoma in Situ Undergoing Surgery,60074
2,NCT02928978,Phase II,Not yet recruiting,"[{'id': 907, 'therapyName': 'Ruxolitinib'}]",Ruxolitinib for Premalignant Breast Disease,60074
3,NCT02993159,Phase II,Recruiting,"[{'id': 5132, 'therapyName': 'Afimoxifene'}, {'id': 1456, 'therapyName': 'Tamoxifen'}]",Tamoxifen Citrate or Afimoxifene in Treating Patients With Estrogen Receptor Positive Breast Cancer,60074
0,NCT02949219,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Treating Patients With Small Bowel Adenocarcinoma That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery,10816
0,NCT03000179,Phase II,Recruiting,"[{'id': 3144, 'therapyName': 'Avelumab'}]",Safety and Efficacy of Avelumab in Small Intestinal Adenocarcinoma,10021
0,NCT02978625,Phase II,Recruiting,"[{'id': 5080, 'therapyName': 'Talimogene laherparepvec + Nivolumab'}]",Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers,7566
0,NCT02567435,Phase III,Suspended,"[{'id': 1435, 'therapyName': 'Vincristine + Dactinomycin + Cyclophosphamide'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1074, 'therapyName': 'Irinotecan'}]",Combination Chemotherapy and Irinotecan Hydrochloride or Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma,3246
1,NCT02639546,Phase I,Recruiting,"[{'id': 1004, 'therapyName': 'Cobimetinib'}]",iMATRIXcobi: Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Patients With Previously Treated Solid Tumors,3246
2,NCT03041701,Phase Ib/II,Recruiting,"[{'id': 5287, 'therapyName': 'Dasatinib + Ganitumab'}]",Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma,3246
0,NCT02780011,Phase I,Not yet recruiting,"[{'id': 4301, 'therapyName': 'Alisertib + Brentuximab vedotin'}]",Alsertib (MLN8237) and Brentuximab Vedotin for Relapsed/Refractory CD30-Positive Lymphomas and Solid Malignancies,5680
0,NCT01482728,Phase I,Completed,"[{'id': 717, 'therapyName': 'Dasatinib'}]",Bristol-Myers Squibb Dasatinib Src Inhibition in Endometrial Cancer,2870
1,NCT01877564,Phase II,Recruiting,"[{'id': 1031, 'therapyName': 'Metformin'}]",A Randomized Pilot Study to Evaluate the Effects of a Short Course of Metformin Versus No Therapy in the Period Prior to Hysterectomy for Grade 1-2 Adenocarcinoma of the Endometrium in Obese Non-Diabetic Women,2870
2,NCT02065687,Phase III,Recruiting,"[{'id': 1381, 'therapyName': 'Paclitaxel + Carboplatin + Metformin'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]","Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer",2870
3,NCT02178722,Phase Ib/II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2575, 'therapyName': 'Epacadostat'}]","A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Solid Tumors and Advanced NSCLC (INCB 24360-202 / MK-3475-037 / KEYNOTE-037)",2870
4,NCT02208375,Phase Ib/II,Recruiting,"[{'id': 837, 'therapyName': 'Olaparib'}, {'id': 655, 'therapyName': 'AZD5363'}, {'id': 991, 'therapyName': 'Vistusertib'}]",mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian Cancer,2870
5,NCT02335203,Phase II,"Active, not recruiting","[{'id': 2401, 'therapyName': 'Medroxyprogesterone'}]",The Effect of Neoadjuvant DMPA on Glandular Cellularity in Women Awaiting Hysterectomy,2870
6,NCT02697591,Phase Ib/II,Recruiting,"[{'id': 4321, 'therapyName': 'INCAGN01876'}]","An Open-Label, Dose-Escalation, Safety Study of INCAGN01876 in Subjects With Advanced or Metastatic Solid Tumors",2870
7,NCT02834013,Phase 0,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab in Treating Patients With Rare Tumors,2870
8,NCT02923349,Phase Ib/II,Recruiting,"[{'id': 5831, 'therapyName': 'INCAGN01949'}]","A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors",2870
9,NCT03018249,Phase II,Recruiting,"[{'id': 2401, 'therapyName': 'Medroxyprogesterone'}, {'id': 5203, 'therapyName': 'Medroxyprogesterone + Entinostat'}]",Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial Cancer,2870
0,NCT01366144,Phase I,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 954, 'therapyName': 'Veliparib'}, {'id': 1092, 'therapyName': 'Carboplatin'}]","Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction",1380
1,NCT01697566,Phase III,"Active, not recruiting","[{'id': 1031, 'therapyName': 'Metformin'}]",An Endometrial Cancer Chemoprevention Study of Metformin,1380
2,NCT01797523,Phase II,"Active, not recruiting","[{'id': 794, 'therapyName': 'Letrozole'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 1031, 'therapyName': 'Metformin'}]",RAD/Letrozole/Metformin,1380
3,NCT01874353,Phase III,"Active, not recruiting","[{'id': 837, 'therapyName': 'Olaparib'}]",Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy,1380
4,NCT01935934,Phase II,Suspended,"[{'id': 998, 'therapyName': 'cabozantinib'}]",Cabozantinib-S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer,1380
5,NCT02035787,Phase I,Recruiting,"[{'id': 1031, 'therapyName': 'Metformin'}]",Metformin With the Levonorgestrel-Releasing Intrauterine Device for the Treatment of Complex Atypical Hyperplasia (CAH) and Endometrial Cancer (EC) in Non-surgical Patients,1380
6,NCT02042495,Phase II,Withdrawn,"[{'id': 1031, 'therapyName': 'Metformin'}]",Endometrial Cancer Biomarker Changes Following Exposure to Metformin,1380
7,NCT02188550,Phase II,Unknown status,"[{'id': 1621, 'therapyName': 'Everolimus + Letrozole'}]",Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer,1380
8,NCT02269293,Phase I,Recruiting,"[{'id': 2640, 'therapyName': 'Carboplatin + Paclitaxel + Selinexor'}]","Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers",1380
9,NCT02393248,Phase Ib/II,Recruiting,"[{'id': 4176, 'therapyName': 'Cisplatin + Gemcitabine + INCB054828'}, {'id': 4174, 'therapyName': 'Docetaxel + INCB054828'}, {'id': 4088, 'therapyName': 'Epacadostat + Pembrolizumab'}]","Open-Label, Dose-Escalation Study of INCB054828 in Subjects With Advanced Malignancies",1380
10,NCT02501096,Phase Ib/II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 792, 'therapyName': 'Lenvatinib'}]",Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors,1380
11,NCT02559492,Phase I,"Active, not recruiting","[{'id': 3096, 'therapyName': 'INCB039110 + INCB024360'}, {'id': 3097, 'therapyName': 'INCB039110 + INCB050465'}]",INCB039110 Combined With INCB024360 and/or INCB039110 Combined With INCB050465 in Advanced Solid Tumors,1380
12,NCT02606305,Phase I,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 3232, 'therapyName': 'IMGN853'}]","Study of IMGN853 in Comb. With Bevacizumab, Carboplatin or PLD in Adults With FRa + Adv. EOC, Primary Peritoneal, Fallopian Tube, or Endometrial Cancer",1380
13,NCT02630823,Phase I,Recruiting,"[{'id': 2103, 'therapyName': 'Carboplatin + Paclitaxel + Pembrolizumab'}]",MK-3475 Immunotherapy in Endometrial Carcinoma,1380
14,NCT02646319,Phase II,"Active, not recruiting","[{'id': 3380, 'therapyName': 'Nab-Rapamycin'}]",Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations,1380
15,NCT02646748,Phase I,Recruiting,"[{'id': 3088, 'therapyName': 'INCB050465 '}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2406, 'therapyName': 'INCB039110'}]",Pembrolizumab Combined With INCB039110 and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors,1380
16,NCT02657928,Phase II,Recruiting,"[{'id': 1568, 'therapyName': 'LEE011 + Letrozole'}]","Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal or Endometrial Cancer",1380
17,NCT02661815,Phase I,"Active, not recruiting","[{'id': 3469, 'therapyName': 'ACY-1215 + Paclitaxel'}, {'id': 667, 'therapyName': 'Bevacizumab'}]","A Phase 1b Study of Weekly Paclitaxel And Oral Ricolinostat For The Treatment Of Recurrent Platinum Resistant Ovarian, Primary Peritoneal, Or Fallopian Tube Cancer",1380
18,NCT02684227,Phase II,Recruiting,"[{'id': 3681, 'therapyName': 'Carboplatin + Enzalutamide + Paclitaxel'}]",Enzalutamide in Combination With Carboplatin and Paclitaxel in Endometrial Cancer,1380
19,NCT02728258,Phase II,Suspended,"[{'id': 995, 'therapyName': 'Copanlisib'}]",Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer,1380
20,NCT02728830,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers,1380
21,NCT02788708,Phase I,Recruiting,"[{'id': 4236, 'therapyName': 'Lenvatinib + Paclitaxel'}]",Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer,1380
22,NCT02899793,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Ultramutated and Hypermutated Endometrial Cancer,1380
23,NCT02912572,Phase II,Recruiting,"[{'id': 3144, 'therapyName': 'Avelumab'}]","Study of Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer",1380
24,NCT02936102,Phase I,Recruiting,"[{'id': 4971, 'therapyName': 'FAZ053'}, {'id': 4972, 'therapyName': 'FAZ053 + PDR001'}]",A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.,1380
25,NCT02963831,Phase Ib/II,Recruiting,"[{'id': 4978, 'therapyName': 'ONCOS-102 + MEDI4736'}]","A Phase 1/2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies",1380
26,NCT03016338,Phase II,Not yet recruiting,"[{'id': 832, 'therapyName': 'Niraparib'}]",Study of Niraparib in Recurrent Endometrial Cancer,1380
27,NCT03065062,Phase I,Recruiting,"[{'id': 4034, 'therapyName': 'Gedatolisib + Palbociclib'}]","Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors",1380
28,NCT03099499,Phase II,Recruiting,"[{'id': 1687, 'therapyName': 'ONC201'}]",Single Agent ONC201 in Recurrent or Metastatic Endometrial Cancer,1380
29,NCT03126110,Phase Ib/II,Recruiting,"[{'id': 5599, 'therapyName': 'INCAGN01876 + Nivolumab + Ipilimumab'}, {'id': 5598, 'therapyName': 'INCAGN01876 + Nivolumab'}, {'id': 5597, 'therapyName': 'INCAGN01876 + Ipilimumab'}]","Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies",1380
30,NCT03162627,Phase I,Recruiting,"[{'id': 5793, 'therapyName': 'Olaparib + Selumetinib'}]",Selumetinib and Olaparib in Solid Tumors,1380
31,NCT03188965,Phase I,Recruiting,"[{'id': 5962, 'therapyName': 'BAY1895344'}]",First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas,1380
32,NCT03300557,Phase II,Not yet recruiting,"[{'id': 738, 'therapyName': 'Exemestane'}]",Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Grade 1 Endometrial Cancer,1380
0,NCT01174121,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 1167, 'therapyName': 'Aldesleukin'}]",Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer,2871
1,NCT01440998,Phase I,"Active, not recruiting","[{'id': 1819, 'therapyName': 'Dasatinib + Paclitaxel + Carboplatin'}]","Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer",2871
2,NCT01504126,Phase I,"Active, not recruiting","[{'id': 1912, 'therapyName': 'Propranolol'}]",Beta-Blocker / Ovarian,2871
3,NCT01888562,Phase I,Withdrawn,"[{'id': 877, 'therapyName': 'Ponatinib'}]",Ponatinib in the Treatment of FGFR Mutation Positive Recurrent or Persistent Endometrial Carcinoma,2871
4,NCT01935973,Phase II,"Active, not recruiting","[{'id': 2, 'therapyName': 'Trametinib'}, {'id': 1298, 'therapyName': 'Trametinib + GSK2141795'}]",Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer,2871
5,NCT02059265,Phase II,"Active, not recruiting","[{'id': 717, 'therapyName': 'Dasatinib'}]","Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer",2871
6,NCT02065687,Phase III,Recruiting,"[{'id': 1381, 'therapyName': 'Paclitaxel + Carboplatin + Metformin'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]","Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer",2871
7,NCT02117817,Phase I,Withdrawn,"[{'id': 1367, 'therapyName': 'BKM120 + Abraxane'}]","Phase I BKM120/Abraxane in Solid Tumors, Expansion Phase Recurrent Endometrial or Ovarian Cancer",2871
8,NCT02228681,Phase II,"Active, not recruiting","[{'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 2401, 'therapyName': 'Medroxyprogesterone'}, {'id': 1621, 'therapyName': 'Everolimus + Letrozole'}]",Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer,2871
9,NCT02272790,Phase II,Recruiting,"[{'id': 1194, 'therapyName': 'MK-1775 + Carboplatin '}, {'id': 1279, 'therapyName': 'MK-1775 + Gemcitabine'}, {'id': 1567, 'therapyName': 'MK-1775 + Paclitaxel'}]","A Phase II Study Comparing AZD1775 + Chemotherapy Versus Chemotherapy Alone in Patients to Treat Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.",2871
10,NCT02397083,Phase II,Recruiting,"[{'id': 735, 'therapyName': 'Everolimus'}]",Phase II Study of Intrauterine Device (IUD) Alone or in Combination With Everolimus in Endometrial Cancer,2871
11,NCT02454972,Phase II,Recruiting,"[{'id': 1195, 'therapyName': 'Lurbinectedin'}]",Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors,2871
12,NCT02549209,Phase II,Recruiting,"[{'id': 2103, 'therapyName': 'Carboplatin + Paclitaxel + Pembrolizumab'}]",Pembro/Carbo/Taxol in Endometrial Cancer,2871
13,NCT02549989,Phase II,Recruiting,"[{'id': 1069, 'therapyName': 'LY3023414'}]",Study of LY3023414 for the Treatment of Recurrent,2871
14,NCT02628067,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158),2871
15,NCT02725268,Phase II,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1282, 'therapyName': 'Sapanisertib'}, {'id': 1283, 'therapyName': 'MLN1117 + Sapanisertib'}]","Phase 2 Study of MLN0128, Combination of MLN0128 With MLN1117, Paclitaxel and Combination of MLN0128 With Paclitaxel in Women With Endometrial Cancer",2871
16,NCT02807844,Phase Ib/II,Recruiting,"[{'id': 5072, 'therapyName': 'MCS110 + PDR001'}]",Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies,2871
17,NCT03008408,Phase II,Recruiting,"[{'id': 5180, 'therapyName': 'Ribociclib + Everolimus + Letrozole'}]","Phase II Ribociclib, Everolimus and Letrozole in Endometrial Cancer",2871
18,NCT03015129,Phase II,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer,2871
19,NCT03076372,Phase I,Recruiting,"[{'id': 5758, 'therapyName': 'MM-310'}]",A Study Evaluating MM-310 in Patients With Solid Tumors,2871
20,NCT03241745,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",A Study of Nivolumab in Selected Uterine Cancer Patients,2871
0,NCT01396408,Phase II,"Active, not recruiting","[{'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 930, 'therapyName': 'Sunitinib'}]",A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours,5299
1,NCT02065687,Phase III,Recruiting,"[{'id': 1381, 'therapyName': 'Paclitaxel + Carboplatin + Metformin'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]","Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer",5299
0,NCT02963831,Phase Ib/II,Recruiting,"[{'id': 4978, 'therapyName': 'ONCOS-102 + MEDI4736'}]","A Phase 1/2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies",4226
1,NCT03241745,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",A Study of Nivolumab in Selected Uterine Cancer Patients,4226
0,NCT02282020,Phase III,Recruiting,"[{'id': 837, 'therapyName': 'Olaparib'}]",Olaparib Treatment in Relapsed Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments.,5828
1,NCT02345265,Phase II,"Active, not recruiting","[{'id': 1971, 'therapyName': 'Cediranib + Olaparib'}]","Olaparib and Cediranib Maleate in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer",5828
2,NCT02889900,Phase II,Recruiting,"[{'id': 1971, 'therapyName': 'Cediranib + Olaparib'}]",Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer (CONCERTO),5828
0,NCT00602667,Phase I,"Active, not recruiting","[{'id': 2449, 'therapyName': 'Methotrexate + Cisplatin + Cyclophosphamide + Vincristine'}, {'id': 2450, 'therapyName': 'Cyclophosphamide + Etoposide + Topotecan'}, {'id': 2451, 'therapyName': 'Erlotinib + Cyclophosphamide + Topotecan'}]","Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma",4794
1,NCT00983398,Phase Ib/II,Recruiting,"[{'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2587, 'therapyName': 'Carboplatin + Melphalan'}]","Melphalan, Carboplatin, and Sodium Thiosulfate for Patients With Central Nervous System (CNS) Embryonal or Germ Cell Tumors",4794
0,NCT02601937,Phase I,Recruiting,"[{'id': 2683, 'therapyName': 'Tazemetostat'}]",A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma,8353
0,NCT02584309,Phase II,Recruiting,"[{'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 4140, 'therapyName': 'Doxorubicin + Olaratumab'}]",Doxorubicin With Upfront Dexrazoxane Plus Olaratumab for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma,6193
1,NCT02601937,Phase I,Recruiting,"[{'id': 2683, 'therapyName': 'Tazemetostat'}]",A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma,6193
2,NCT02834013,Phase 0,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab in Treating Patients With Rare Tumors,6193
3,NCT03009201,Phase I,Recruiting,"[{'id': 5179, 'therapyName': 'Doxorubicin + Ribociclib'}]",Ribociclib and Doxorubicin Hydrochloride in Treating Patients Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery,6193
0,NCT02780310,Phase II,"Active, not recruiting","[{'id': 792, 'therapyName': 'Lenvatinib'}]",Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma,4878
1,NCT03087019,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma,4878
2,NCT03172624,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer,4878
0,NCT03143153,Phase III,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 1833, 'therapyName': 'Cisplatin + Fluorouracil'}, {'id': 5799, 'therapyName': 'Nivolumab + Cisplatin + Fluorouacil'}]",A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin (CheckMate 648),5625
0,NCT01037790,Phase II,Recruiting,"[{'id': 850, 'therapyName': 'Palbociclib'}]",PD 0332991 in Treating Patients With Refractory Solid Tumors,5041
1,NCT01128387,Phase Ib/II,Completed,"[{'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 845, 'therapyName': 'Panitumumab'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Trial of Panitumumab/Cisplatin/Fluorouracil With XRT in Esophageal Cancer,5041
2,NCT01325441,Phase Ib/II,Recruiting,"[{'id': 2586, 'therapyName': 'BBI608 + Paclitaxel'}]",A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies,5041
3,NCT01366144,Phase I,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 954, 'therapyName': 'Veliparib'}, {'id': 1092, 'therapyName': 'Carboplatin'}]","Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction",5041
4,NCT01522768,Phase II,Recruiting,"[{'id': 1106, 'therapyName': 'Afatinib + Trastuzumab'}]", Afatinib (BIBW 2992) and Trastuzumab in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer,5041
5,NCT01848756,Phase Ib/II,Terminated,"[{'id': 866, 'therapyName': 'SNX-5422'}]",Safety and Efficacy of SNX-5422 in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Cancers,5041
6,NCT01928290,Phase II,Recruiting,"[{'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1903, 'therapyName': 'FOLFIRINOX'}]","Combination Chemotherapy in Treating Patients With Advanced Stomach, Gastroesophageal, or Esophageal Cancer",5041
7,NCT02569242,Phase III,"Active, not recruiting","[{'id': 3045, 'therapyName': 'Docetaxel + Paclitaxel'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer,5041
8,NCT02749513,Phase I,Recruiting,"[{'id': 1026, 'therapyName': 'Itraconazole'}]",Itraconazole as a Targeted Therapy for Inhibiting Hedgehog Pathway Signaling in Esophageal Cancer Patients,5041
9,NCT02795156,Phase II,Recruiting,"[{'id': 623, 'therapyName': 'Afatinib'}, {'id': 890, 'therapyName': 'Regorafenib'}]",Study to Assess the Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations,5041
10,NCT02960594,Phase I,Recruiting,"[{'id': 5844, 'therapyName': 'INO-1400 + INO-9012'}, {'id': 5807, 'therapyName': 'INO-1400'}]",hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse,5041
11,NCT02963831,Phase Ib/II,Recruiting,"[{'id': 4978, 'therapyName': 'ONCOS-102 + MEDI4736'}]","A Phase 1/2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies",5041
12,NCT02970539,Phase I,Recruiting,"[{'id': 5032, 'therapyName': 'Oraxol + Ramucirumab'}]","Ph1b Study of Oraxol in Comb. w. Ramucirumab in Patients w. Gastric, Gastro-esophageal, or Esophageal Cancers",5041
13,NCT03044613,Phase I,Recruiting,"[{'id': 5304, 'therapyName': 'Nivolumab + Ipilimumab + Carboplatin + Paclitaxel'}, {'id': 5303, 'therapyName': 'Nivolumab + Carboplatin + Paclitaxel'}]",Nivolumab or Nivolumab/Ipilimumab Prior to Chemoradiation Plus Nivolumab With II/III Gastro/Esophageal Cancer,5041
14,NCT03126110,Phase Ib/II,Recruiting,"[{'id': 5599, 'therapyName': 'INCAGN01876 + Nivolumab + Ipilimumab'}, {'id': 5598, 'therapyName': 'INCAGN01876 + Nivolumab'}, {'id': 5597, 'therapyName': 'INCAGN01876 + Ipilimumab'}]","Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies",5041
15,NCT03144661,Phase I,Recruiting,"[{'id': 5832, 'therapyName': 'INCB062079'}]",An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies,5041
0,NCT00702884,Phase II,Completed,"[{'id': 930, 'therapyName': 'Sunitinib'}]",Sunitinib in Treating Patients With Relapsed or Refractory Esophageal or Gastroesophageal Junction Cancer,1107
1,NCT01183559,Phase I,Unknown status,"[{'id': 2071, 'therapyName': 'Carboplatin + Fluorouracil + Paclitaxel + Vandetanib'}]","A Trial of ZD6474 (Zactima), Paclitaxel, Carboplatin, 5-Fluorouracil, and XRT Followed by Surgery",1107
2,NCT01191697,Phase II,"Active, not recruiting","[{'id': 1596, 'therapyName': 'Trastuzumab + Bevacizumab'}, {'id': 1597, 'therapyName': 'Capecitabine + Oxaliplatin'}]","CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer",1107
3,NCT01212822,Phase II,"Active, not recruiting","[{'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}]",Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer,1107
4,NCT02274012,Phase II,Withdrawn,"[{'id': 2441, 'therapyName': 'Afatinib + Paclitaxel'}]","Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line Treatment of HER2 Amplified Advanced Gastric, Gastroesophageal Junction and Esophageal Cancer",1107
5,NCT02344810,Phase Ib/II,Withdrawn,"[{'id': 1064, 'therapyName': 'AMG 337'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]","C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer",1107
6,NCT02723955,Phase I,Recruiting,"[{'id': 4409, 'therapyName': 'GSK3359609'}, {'id': 4410, 'therapyName': 'GSK3359609 + Pembrolizumab'}]",Dose Escalation and Expansion Study of GSK3359609 in Subjects With Selected Advanced Solid Tumors (INDUCE-1),1107
7,NCT02743494,Phase III,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Study of Adjuvant Nivolumab or Placebo in Subjects With Resected Esophageal or Gastroesophageal Junction Cancer (CheckMate 577),1107
8,NCT02830594,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer",1107
9,NCT02834013,Phase 0,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab in Treating Patients With Rare Tumors,1107
10,NCT03076372,Phase I,Recruiting,"[{'id': 5758, 'therapyName': 'MM-310'}]",A Study Evaluating MM-310 in Patients With Solid Tumors,1107
11,NCT03165994,Phase II,Recruiting,"[{'id': 5797, 'therapyName': 'APX005M + Paclitaxel + Carboplatin'}]",APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers,1107
12,NCT03288350,Phase II,Not yet recruiting,"[{'id': 1930, 'therapyName': 'Cisplatin + Docetaxel + Fluorouracil'}, {'id': 3144, 'therapyName': 'Avelumab'}]",mDCF + Avelumab in Resectable Esophago-gastric Adenocarcinoma (EGA),1107
0,NCT01196390,Phase III,"Active, not recruiting","[{'id': 1887, 'therapyName': 'Paclitaxel + Carboplatin + Trastuzumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]","Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer",4914
1,NCT01307956,Phase II,Unknown status,"[{'id': 1986, 'therapyName': 'Panitumumab + FOLFOX'}]","Panitumumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Advanced Esophageal or Gastroesophageal Junction Cancer",4914
2,NCT01490749,Phase I,"Active, not recruiting","[{'id': 1924, 'therapyName': 'Everolimus + Paclitaxel + Carboplatin + Cetuximab'}]",Trial of XELOX Followed by Radiation Combined With Carboplatin and RAD001 for Esophageal Cancer,4914
3,NCT01526473,Phase I,"Active, not recruiting","[{'id': 1068, 'therapyName': 'AVX901'}]",A Phase I Study To Evaluate The Antitumor Activity And Safety Of AVX901,4914
4,NCT01747551,Phase II,"Active, not recruiting","[{'id': 624, 'therapyName': 'Aflibercept'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer,4914
5,NCT01774851,Phase II,Terminated,"[{'id': 1892, 'therapyName': 'Paclitaxel + Trastuzumab + MM-111'}, {'id': 1551, 'therapyName': 'Trastuzumab + Paclitaxel'}]","A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach",4914
6,NCT01913639,Phase II,"Active, not recruiting","[{'id': 2014, 'therapyName': 'Regorafenib + FOLFOX'}]",FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer,4914
7,NCT02013154,Phase I,Recruiting,"[{'id': 6254, 'therapyName': 'DKN-01 + Paclitaxel'}]",A Study of DKN-01 in Combination With Paclitaxel,4914
8,NCT02016534,Phase II,Terminated,"[{'id': 1064, 'therapyName': 'AMG 337'}]",Phase 2 Study of AMG 337 in MET Amplified Gastric/Esophageal Adenocarcinoma or Other Solid Tumors,4914
9,NCT02024607,Phase Ib/II,"Active, not recruiting","[{'id': 1597, 'therapyName': 'Capecitabine + Oxaliplatin'}, {'id': 2093, 'therapyName': 'BBI608 + Bevacizumab'}, {'id': 2094, 'therapyName': 'BBI608 + Regorafenib'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 2057, 'therapyName': 'BBI608'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer,4914
10,NCT02138929,Phase I,"Active, not recruiting","[{'id': 1871, 'therapyName': 'Everolimus + Sonidegib'}]",LDE225 + Everolimus in Advanced Gastroesophageal Adenocarcinoma,4914
11,NCT02234180,Phase II,Completed,"[{'id': 890, 'therapyName': 'Regorafenib'}]",Study of Adjuvant Regorafenib vs Placebo in Patients With Node Positive Esophageal Cancer That Completed Pre-operative Therapy,4914
12,NCT02234596,Phase II,"Active, not recruiting","[{'id': 831, 'therapyName': 'Nintedanib'}]",Nintedanib in Patients With Advanced Esophagogastric Cancer,4914
13,NCT02241720,Phase II,Terminated,"[{'id': 890, 'therapyName': 'Regorafenib'}]",Regorafenib Second Line Treatment of Metastatic or Advanced Upper GI Cancers,4914
14,NCT02283359,Phase I,Terminated,"[{'id': 2588, 'therapyName': 'Irinotecan + Selinexor'}]",Selinexor in Combination With Irinotecan in Adenocarcinoma of Stomach and Distal Esophagus,4914
15,NCT02317991,Phase II,Recruiting,"[{'id': 2039, 'therapyName': 'Abraxane + Ramucirumab'}]",Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer,4914
16,NCT02389751,Phase I,"Active, not recruiting","[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 745, 'therapyName': 'Ganetespib'}]",A Study of Ganetespib in Combination With Chemoradiation,4914
17,NCT02404441,Phase Ib/II,Recruiting,"[{'id': 2659, 'therapyName': 'PDR001'}]",Phase I/II Study of PDR001 in Patients With Advanced Malignancies,4914
18,NCT02460224,Phase Ib/II,Recruiting,"[{'id': 2887, 'therapyName': 'LAG525'}, {'id': 2659, 'therapyName': 'PDR001'}]",Safety and Efficay of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies,4914
19,NCT02530437,Phase Ib/II,Recruiting,"[{'id': 1587, 'therapyName': 'Taladegib'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]","A Phase 1B/2 Study of LY2940680 in Combination With Weekly Paclitaxel, Carboplatin, and Radiation in Localized Adenocarcinoma of the Esophagus or Gastroesophageal Junction",4914
20,NCT02559687,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) in Previously-Treated Participants With Advanced Carcinoma of the Esophagus or Esophagogastric Junction (MK-3475-180/KEYNOTE-180),4914
21,NCT02564263,Phase III,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2282, 'therapyName': 'Docetaxel + Irinotecan + Paclitaxel'}]",Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181),4914
22,NCT02638909,Phase II,Recruiting,"[{'id': 789, 'therapyName': 'Ceritinib'}]",Study of Oral Ceritinib in Patients With ALK-Activated Gastrointestinal Malignancies,4914
23,NCT02639065,Phase II,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}]",A Study of Durvalumab (MEDI4736) in Esophageal Cancer,4914
24,NCT02642809,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab With Locally Delivered Radiation Therapy for the Initial Treatment of Metastatic Esophageal Cancers,4914
25,NCT02954536,Phase II,Recruiting,"[{'id': 4945, 'therapyName': 'Capecitabine + Cisplatin + Pembrolizumab + Trastuzumab'}]",Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer,4914
26,NCT02962063,Phase Ib/II,Recruiting,"[{'id': 3997, 'therapyName': 'Carboplatin + Durvalumab + Paclitaxel'}]","Durvalumab, an Anti-PD-L1 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer",4914
27,NCT02971956,Phase II,Not yet recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Phase II Study of Pembrolizumab in Refractory Advanced Esophageal Cancer,4914
28,NCT02998268,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Study of Pembrolizumab in Locally Advanced Esophageal Adenocarcinoma,4914
29,NCT03064490,Phase II,Recruiting,"[{'id': 2103, 'therapyName': 'Carboplatin + Paclitaxel + Pembrolizumab'}]","Pembrolizumab, Radiotherapy, and Chemotherapy in Neoadjuvant Treatment of Malignant Esophago-gastric Diseases (PROCEED)",4914
30,NCT03122548,Phase II,Recruiting,"[{'id': 5716, 'therapyName': 'CRS-207 + Pembrolizumab'}]","Safety and Efficacy of CRS-207 With Pembrolizumab in Gastric, Gastroesophageal Junction or Esophageal Cancers",4914
31,NCT03165994,Phase II,Recruiting,"[{'id': 5797, 'therapyName': 'APX005M + Paclitaxel + Carboplatin'}]",APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers,4914
32,NCT03189719,Phase III,Recruiting,"[{'id': 1833, 'therapyName': 'Cisplatin + Fluorouracil'}, {'id': 6051, 'therapyName': 'Cisplatin + Fluorouracil + Pembrolizumab'}]",First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590),4914
33,NCT03193918,Phase I,Recruiting,"[{'id': 5943, 'therapyName': 'Crenolanib + Paclitaxel + Ramucirumab'}]",Study of Crenolanib With Ramucirumab and Paclitaxel for Advanced Esophagogastric Adenocarcinoma,4914
34,NCT03196232,Phase II,Recruiting,"[{'id': 4088, 'therapyName': 'Epacadostat + Pembrolizumab'}]",Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer,4914
0,NCT01490749,Phase I,"Active, not recruiting","[{'id': 1924, 'therapyName': 'Everolimus + Paclitaxel + Carboplatin + Cetuximab'}]",Trial of XELOX Followed by Radiation Combined With Carboplatin and RAD001 for Esophageal Cancer,3748
1,NCT01822613,Phase Ib/II,Completed,"[{'id': 2282, 'therapyName': 'Docetaxel + Irinotecan + Paclitaxel'}, {'id': 2283, 'therapyName': 'BYL719 + LJM716'}]",Study of Safety and Efficacy of the Combination of LJM716 and BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC),3748
2,NCT02013154,Phase I,Recruiting,"[{'id': 6254, 'therapyName': 'DKN-01 + Paclitaxel'}]",A Study of DKN-01 in Combination With Paclitaxel,3748
3,NCT02389751,Phase I,"Active, not recruiting","[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 745, 'therapyName': 'Ganetespib'}]",A Study of Ganetespib in Combination With Chemoradiation,3748
4,NCT02559687,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) in Previously-Treated Participants With Advanced Carcinoma of the Esophagus or Esophagogastric Junction (MK-3475-180/KEYNOTE-180),3748
5,NCT02564263,Phase III,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2282, 'therapyName': 'Docetaxel + Irinotecan + Paclitaxel'}]",Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181),3748
6,NCT02710396,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Genetic Predictors of Benefit to Pembrolizumab,3748
7,NCT02971956,Phase II,Not yet recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Phase II Study of Pembrolizumab in Refractory Advanced Esophageal Cancer,3748
8,NCT03143153,Phase III,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 1833, 'therapyName': 'Cisplatin + Fluorouracil'}, {'id': 5799, 'therapyName': 'Nivolumab + Cisplatin + Fluorouacil'}]",A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin (CheckMate 648),3748
9,NCT03165994,Phase II,Recruiting,"[{'id': 5797, 'therapyName': 'APX005M + Paclitaxel + Carboplatin'}]",APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers,3748
10,NCT03189719,Phase III,Recruiting,"[{'id': 1833, 'therapyName': 'Cisplatin + Fluorouracil'}, {'id': 6051, 'therapyName': 'Cisplatin + Fluorouracil + Pembrolizumab'}]",First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590),3748
0,NCT03065400,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",PD-1 Inhibition in Advanced Myeloproliferative Neoplasms,2224
0,NCT01471106,Phase II,Recruiting,"[{'id': 717, 'therapyName': 'Dasatinib'}]",Phase II Short-term Adjuvant Therapy and Biomarker Studies With Targeted Agents in Women With Estrogen Receptor Negative Breast Cancer,60076
0,NCT00570323,Phase II,"Active, not recruiting","[{'id': 1911, 'therapyName': 'Anastrozole  + Fulvestrant'}, {'id': 633, 'therapyName': 'Anastrozole'}]",Arimidex With or Without Faslodex In Postmenopausal Women With HR Positive Breast Cancer,60075
1,NCT00759642,Phase II,"Active, not recruiting","[{'id': 787, 'therapyName': 'Lapatinib'}]",Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy,60075
2,NCT01027416,Phase I,Completed,"[{'id': 1456, 'therapyName': 'Tamoxifen'}]",Analyzing a New Mechanism in Response to Tamoxifen Therapy in Breast Cancer Patients,60075
3,NCT01177397,Phase Ib/II,Completed,"[{'id': 693, 'therapyName': 'CC-223'}]","Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma",60075
4,NCT01219699,Phase I,"Active, not recruiting","[{'id': 691, 'therapyName': 'BYL719'}, {'id': 744, 'therapyName': 'Fulvestrant'}]"," A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene",60075
5,NCT01594216,Phase II,"Active, not recruiting","[{'id': 1108, 'therapyName': 'Ruxolitinib + Exemestane'}]", Ruxolitinib in Estrogen Receptor Positive Breast Cancer,60075
6,NCT01857193,Phase Ib/II,Recruiting,"[{'id': 2265, 'therapyName': 'LEE011 + Everolimus + Exemestane'}, {'id': 1966, 'therapyName': 'Exemestane + Everolimus'}, {'id': 2266, 'therapyName': 'LEE011 + Exemestane'}]",Phase Ib/II Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of ER+ Her2- Advanced Breast Cancer,60075
7,NCT01872260,Phase Ib/II,Recruiting,"[{'id': 1553, 'therapyName': 'Letrozole + BYL719'}, {'id': 1569, 'therapyName': 'LEE011 + BYL719 + Letrozole'}, {'id': 1568, 'therapyName': 'LEE011 + Letrozole'}]","Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer",60075
8,NCT01990209,Phase II,Recruiting,"[{'id': 2671, 'therapyName': 'Orteronel '}]",Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR),60075
9,NCT02049957,Phase Ib/II,Recruiting,"[{'id': 1581, 'therapyName': 'MLN0128 + Fulvestrant'}, {'id': 1580, 'therapyName': 'MLN0128 + Exemestane'}]",Safety and Efficacy Study of MLN0128 in Combination With Exemestane or Fulvestrant in Postmenopausal Women With ER/PR+ Metastatic Breast Cancer,60075
10,NCT02219789,Phase I,"Active, not recruiting","[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 626, 'therapyName': 'Alisertib'}]",Alisertib and Fulvestrant in Treating Patients With Hormone Receptor Positive Breast Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery,60075
11,NCT02395627,Phase II,Recruiting,"[{'id': 3114, 'therapyName': 'Pembrolizumab + Tamoxifen + vorinostat'}]",Reversing Hormone Therapy Resistance With Epigenetic-Immune Modification,60075
12,NCT02569801,Phase II,"Active, not recruiting","[{'id': 2150, 'therapyName': 'GDC-0810'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",A Study of GDC-0810 Versus Fulvestrant in Women With Advanced or Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy,60075
13,NCT02580448,Phase Ib/II,Recruiting,"[{'id': 2822, 'therapyName': 'VT-464'}]","A Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of VT-464 in Patients With Advanced Breast Cancer",60075
14,NCT02598557,Phase II,Recruiting,"[{'id': 738, 'therapyName': 'Exemestane'}]",Alternative Dosing of Exemestane Before Surgery in Treating Postmenopausal Patients With Stage 0-II Estrogen Positive Breast Cancer,60075
15,NCT02676986,Phase II,Recruiting,"[{'id': 6183, 'therapyName': 'Enzalutamide + Exemestane'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]","Short-term Preoperative Treatment With Enzalutamide, Alone or in Combination With Exemestane in Primary Breast Cancer (ARB)",60075
16,NCT02734615,Phase I,Recruiting,"[{'id': 4441, 'therapyName': 'Alpelisib + LSZ 102'}, {'id': 4440, 'therapyName': 'LSZ 102 + Ribociclib'}, {'id': 4439, 'therapyName': 'LSZ 102'}]",Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers,60075
17,NCT02820961,Phase I,Recruiting,"[{'id': 4437, 'therapyName': 'Entinostat + Exemestane'}]",Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer,60075
18,NCT02913430,Phase II,Recruiting,"[{'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",Phase II Treatment of Metastatic Breast Cancer With Fulvestrant or Tamoxifen,60075
19,NCT02988986,Phase II,Recruiting,"[{'id': 5141, 'therapyName': 'MLN0128 + Tamoxifen'}]","TAK-228 Plus Tamoxifen in Patients With ER-Positive, HER2-negative Breast Cancer",60075
20,NCT03092635,Phase I,Recruiting,"[{'id': 5908, 'therapyName': 'OPC + Metformin'}]",AGE Levels in ER+ Metastatic Breast Cancer Patients Receiving Endocrine Therapy,60075
21,NCT03201913,Phase I,Not yet recruiting,"[{'id': 5960, 'therapyName': 'TTC-352'}]",Study of TTC-352 in Patients With Metastatic Breast Cancer Progressing on Endocrine Therapy,60075
22,NCT03250676,Phase Ib/II,Recruiting,"[{'id': 6150, 'therapyName': 'H3B-6545'}]","Trial of H3B-6545, a Covalent Antagonist of Estrogen Receptor Alpha, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer",60075
23,NCT03289039,,Not yet recruiting,"[{'id': 828, 'therapyName': 'Neratinib'}, {'id': 5705, 'therapyName': 'Fulvestrant + Neratinib'}]","A Phase 2 Study of Neratinib With or Without Fulvestrant in HER2-Positive, ER-Positive Metastatic Breast Cancer",60075
0,NCT02780310,Phase II,"Active, not recruiting","[{'id': 792, 'therapyName': 'Lenvatinib'}]",Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma,2764
1,NCT03087019,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma,2764
2,NCT03172624,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer,2764
0,NCT00020566,Phase III,Unknown status,"[{'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 2670, 'therapyName': 'Vincristine + Doxorubicin + Dactinomycin + Ifosfamide + Etoposide'}]","Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma",3369
1,NCT00084695,Phase II,Unknown status,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases,3369
2,NCT01241162,Phase I,Completed,"[{'id': 650, 'therapyName': 'Decitabine'}]",Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma,3369
3,NCT01286987,Phase I,Completed,"[{'id': 682, 'therapyName': 'Talazoparib'}]","Study of BMN 673, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors",3369
4,NCT01331135,Phase I,"Active, not recruiting","[{'id': 917, 'therapyName': 'Sirolimus'}]",Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors,3369
5,NCT01396408,Phase II,"Active, not recruiting","[{'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 930, 'therapyName': 'Sunitinib'}]",A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours,3369
6,NCT01661400,Phase I,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1475, 'therapyName': 'Thalidomide'}]",Anti-Angiogenic Therapy Post Transplant (ASCR) for Relapsed and Refractory Pediatric Solid Tumors,3369
7,NCT01858168,Phase I,Recruiting,"[{'id': 1438, 'therapyName': 'Olaparib + Temozolomide'}]",Phase I Study of Olaprib and Temozolomide for Ewings Sarcoma,3369
8,NCT01946529,Phase II,"Active, not recruiting","[{'id': 1433, 'therapyName': 'Vincristine + Doxorubicin + Cyclophosphamide + Ifosfamide + Etoposide'}, {'id': 1434, 'therapyName': 'Vincristine + Doxorubicin + Cyclophosphamide + Ifosfamide + Etoposide + others'}]",Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors,3369
9,NCT02044120,Phase I,Recruiting,"[{'id': 1437, 'therapyName': 'Niraparib + Temozolomide'}]","ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide in Patients With Previously Treated, Incurable Ewing Sarcoma",3369
10,NCT02048371,Phase II,Recruiting,"[{'id': 890, 'therapyName': 'Regorafenib'}]","A Blanket Protocol to Study Oral Regorafenib in Patients With Refractory Liposarcoma, Osteogenic Sarcoma, and Ewing/Ewing-like Sarcomas",3369
11,NCT02116777,Phase Ib/II,Recruiting,"[{'id': 1377, 'therapyName': 'Talazoparib + Temozolomide'}]",BMN-673 and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies,3369
12,NCT02173093,Phase Ib/II,Recruiting,"[{'id': 2058, 'therapyName': 'Aldesleukin + GD2Bi-a ATC + Sargramostim '}]",Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma,3369
13,NCT02306161,Phase II,Recruiting,"[{'id': 1433, 'therapyName': 'Vincristine + Doxorubicin + Cyclophosphamide + Ifosfamide + Etoposide'}, {'id': 746, 'therapyName': 'Ganitumab'}]",Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma,3369
14,NCT02644460,Phase I,Recruiting,"[{'id': 802, 'therapyName': 'Abemaciclib'}]",Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors,3369
15,NCT02657005,Phase I,Recruiting,"[{'id': 4314, 'therapyName': 'TK216'}]",TK216 in Patients With Relapsed or Refractory Ewing Sarcoma,3369
16,NCT02748135,Phase Ib/II,Recruiting,"[{'id': 4704, 'therapyName': 'TB-403'}]",A Two-Part Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma,3369
17,NCT02867592,Phase II,Recruiting,"[{'id': 998, 'therapyName': 'cabozantinib'}]","Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors",3369
18,NCT02982941,Phase I,Recruiting,"[{'id': 2863, 'therapyName': 'MGA271'}]",Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors,3369
19,NCT03139331,Phase I,Recruiting,"[{'id': 5635, 'therapyName': 'Pazopanib + Irinotecan + Temozolomide'}]",PAZIT Study for Children and Young Adults With Relapsed or Refractory Sarcoma,3369
20,NCT03190174,Phase Ib/II,Recruiting,"[{'id': 5931, 'therapyName': 'Nab-Rapamycin + Nivolumab'}]",Nivolumab (Opdivo) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma,3369
21,NCT03221400,Phase Ib/II,Recruiting,"[{'id': 4842, 'therapyName': 'STA-8666'}]",PEN-866 in Patients With Advanced Solid Malignancies,3369
22,NCT03245151,Phase Ib/II,Not yet recruiting,"[{'id': 1713, 'therapyName': 'Everolimus + Lenvatinib'}]","Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors",3369
0,NCT03008369,Phase II,Recruiting,"[{'id': 792, 'therapyName': 'Lenvatinib'}]",Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery,50936
1,NCT03165721,Phase II,Recruiting,"[{'id': 1949, 'therapyName': 'SGI-110'}]","A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer",50936
0,NCT02834013,Phase 0,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab in Treating Patients With Rare Tumors,4682
0,NCT01492673,Phase II,"Active, not recruiting","[{'id': 1479, 'therapyName': 'Cyclophosphamide + Topotecan + Bevacizumab'}]","Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma",4232
1,NCT01518413,Phase I,Completed,"[{'id': 1323, 'therapyName': 'Sorafenib + Irinotecan'}]",Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors,4232
2,NCT01610570,Phase Ib/II,Terminated,"[{'id': 1397, 'therapyName': 'Mithramycin'}]",Mithramycin for Children and Adults With Solid Tumors or Ewing Sarcoma,4232
3,NCT01625351,Phase I,"Active, not recruiting","[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1205, 'therapyName': 'Alemtuzumab'}]",A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas,4232
4,NCT01661400,Phase I,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1475, 'therapyName': 'Thalidomide'}]",Anti-Angiogenic Therapy Post Transplant (ASCR) for Relapsed and Refractory Pediatric Solid Tumors,4232
5,NCT02511132,Phase II,"Active, not recruiting","[{'id': 1157, 'therapyName': 'FANG vaccine'}, {'id': 1439, 'therapyName': 'Gemcitabine + Docetaxel'}]",Randomized Phase IIb Trial of Vigil Versus Gemcitabine + Docetaxel for Ewing's Sarcoma,4232
0,NCT02987959,Phase II,Recruiting,"[{'id': 1282, 'therapyName': 'Sapanisertib'}]",Study of TAK-228 (MLN0128) in Soft Tissue Sarcomas,3357
0,NCT02834013,Phase 0,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab in Treating Patients With Rare Tumors,3706
1,NCT03162562,Phase I,Recruiting,"[{'id': 5792, 'therapyName': 'Oregovomab + poly ICLC '}]",The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer,3706
0,NCT00565851,Phase III,"Active, not recruiting","[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 3045, 'therapyName': 'Docetaxel + Paclitaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 667, 'therapyName': 'Bevacizumab'}]","Carboplatin, Paclitaxel and Gemcitabine With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",1964
1,NCT00993655,Phase III,Completed,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}]"," Comparing Combination Chemotherapy Regimens in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer",1964
2,NCT01031381,Phase II,Completed,"[{'id': 1120, 'therapyName': 'Everolimus + Bevacizumab'}]","Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer",1964
3,NCT01116648,Phase Ib/II,"Active, not recruiting","[{'id': 837, 'therapyName': 'Olaparib'}, {'id': 1971, 'therapyName': 'Cediranib + Olaparib'}]","Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer",1964
4,NCT01132014,Phase I,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1154, 'therapyName': 'Dacarbazine'}]",Autologous OC-DC Vaccine in Ovarian Cancer,1964
5,NCT01146795,Phase II,Terminated,"[{'id': 1152, 'therapyName': 'Bevacizumab + Carboplatin + Paclitaxel'}]",Neoadjuvant Therapy for Ovarian Cancer,1964
6,NCT01264432,Phase I,"Active, not recruiting","[{'id': 954, 'therapyName': 'Veliparib'}]","Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer",1964
7,NCT01305213,Phase Ib/II,Completed,"[{'id': 1186, 'therapyName': 'Fosbretabulin'}, {'id': 667, 'therapyName': 'Bevacizumab'}]","Bevacizumab With or Without Fosbretabulin Tromethamine in Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer",1964
8,NCT01312376,Phase I,"Active, not recruiting","[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1227, 'therapyName': 'CD3/CD28 costimulated vaccine-primed autologous T-cells'}, {'id': 1222, 'therapyName': 'OC-DC vaccine'}]",Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer,1964
9,NCT01325441,Phase Ib/II,Recruiting,"[{'id': 2586, 'therapyName': 'BBI608 + Paclitaxel'}]",A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies,1964
10,NCT01357161,Phase II,Completed,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 822, 'therapyName': 'MK-1775'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]", A Study of MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004),1964
11,NCT01445418,Phase I,"Active, not recruiting","[{'id': 837, 'therapyName': 'Olaparib'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer,1964
12,NCT01459380,Phase I,Completed,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 954, 'therapyName': 'Veliparib'}, {'id': 667, 'therapyName': 'Bevacizumab'}]","Veliparib, Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer",1964
13,NCT01493505,Phase III,Terminated,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1218, 'therapyName': 'Trebananib'}]", TRINOVA-3,1964
14,NCT01579812,Phase II,"Active, not recruiting","[{'id': 1031, 'therapyName': 'Metformin'}]","Evaluation of Metformin, Targeting Cancer Stem Cells for Prevention of Relapse in Gynecologic Patients",1964
15,NCT01610206,Phase II,"Active, not recruiting","[{'id': 1478, 'therapyName': 'Gemcitabine + Pazopanib'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer,1964
16,NCT01649336,Phase I,Completed,"[{'id': 2010, 'therapyName': 'MEK162 + Paclitaxel'}]","A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer",1964
17,NCT01652079,Phase II,"Active, not recruiting","[{'id': 1213, 'therapyName': 'CRLX101 + Bevacizumab'}]",CRLX101 in Combination With Bevacizumab for Recurrent Ovarian/Tubal/Peritoneal Cancer,1964
18,NCT01663857,Phase Ib/II,"Active, not recruiting","[{'id': 3296, 'therapyName': 'Ralimetinib'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}]",A Study of LY2228820 for Recurrent Ovarian Cancer,1964
19,NCT01690468,Phase Ib/II,Recruiting,"[{'id': 4566, 'therapyName': 'Carboplatin + Triciribine'}]",PTX-200 and Carboplatin in Ovarian Cancer,1964
20,NCT01749397,Phase I,Recruiting,"[{'id': 2009, 'therapyName': 'Floxuridine + Veliparib'}]","Veliparib and Floxuridine in Treating Patients With Metastatic Epithelial Ovarian, Primary Peritoneal Cavity, or Fallopian Tube Cancer",1964
21,NCT01844986,Phase III,"Active, not recruiting","[{'id': 837, 'therapyName': 'Olaparib'}]",Olaparib Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.,1964
22,NCT01846611,Phase III,Recruiting,"[{'id': 1008, 'therapyName': 'Doxil'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]","A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",1964
23,NCT01847274,Phase III,Completed,"[{'id': 832, 'therapyName': 'Niraparib'}]",A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer,1964
24,NCT01853306,Phase I,Completed,"[{'id': 954, 'therapyName': 'Veliparib'}]","A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors",1964
25,NCT01853644,Phase II,Recruiting,"[{'id': 1055, 'therapyName': 'Tivozanib'}]","Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer",1964
26,NCT01874353,Phase III,"Active, not recruiting","[{'id': 837, 'therapyName': 'Olaparib'}]",Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy,1964
27,NCT01891344,Phase II,"Active, not recruiting","[{'id': 906, 'therapyName': 'Rucaparib'}]","A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)",1964
28,NCT01940172,Phase I,Completed,"[{'id': 1458, 'therapyName': 'Conatumumab'}, {'id': 2647, 'therapyName': 'Birinapant  '}]",Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer,1964
29,NCT01952249,Phase Ib/II,Completed,"[{'id': 2007, 'therapyName': 'Demcizumab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",A Study of Demcizumab Plus Paclitaxel in Subjects With Platinum Resistant Ovarian,1964
30,NCT01962948,Phase II,"Active, not recruiting","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 745, 'therapyName': 'Ganetespib'}]","Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",1964
31,NCT01968213,Phase III,"Active, not recruiting","[{'id': 906, 'therapyName': 'Rucaparib'}]","A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer",1964
32,NCT01972516,Phase II,Terminated,"[{'id': 1055, 'therapyName': 'Tivozanib'}]",Tivozanib As Maintenance Therapy In GYN,1964
33,NCT01991210,Phase II,Terminated,"[{'id': 1345, 'therapyName': 'DNIB0600A'}, {'id': 1008, 'therapyName': 'Doxil'}]",A Randomized Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin in Patients With Platinum-Resistant Ovarian Cancer,1964
34,NCT01995188,Phase I,Completed,"[{'id': 1347, 'therapyName': 'DNIB0600A + Carboplatin + Bevacizumab'}, {'id': 1346, 'therapyName': 'DNIB0600A + Carboplatin'}]",A Study to Evaluate the Safety and Pharmacology of DNIB0600A in Patients With Ovarian Cancer,1964
35,NCT02014337,Phase I,"Active, not recruiting","[{'id': 3053, 'therapyName': 'Eribulin + Mifepristone'}]",Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors,1964
36,NCT02046421,Phase I,"Active, not recruiting","[{'id': 2603, 'therapyName': 'Mifepristone'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}]","Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer",1964
37,NCT02050009,Phase I,Withdrawn,"[{'id': 1381, 'therapyName': 'Paclitaxel + Carboplatin + Metformin'}]","Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",1964
38,NCT02118285,Phase I,Completed,"[{'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 2575, 'therapyName': 'Epacadostat'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1166, 'therapyName': 'Fludarabine'}]","Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer",1964
39,NCT02124421,Phase II,Recruiting,"[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1812, 'therapyName': 'Cisplatin + Paclitaxel'}]","Outcomes in CRS/HIPEC as Initial Treatment of Ovarian, Fallopian Tube and Primary Peritoneal Cancer",1964
40,NCT02199171,Phase I,Unknown status,"[{'id': 1092, 'therapyName': 'Carboplatin'}]","Heated Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Peritoneal Cancer",1964
41,NCT02203513,Phase II,Recruiting,"[{'id': 1651, 'therapyName': 'Prexasertib'}]","Chk1/2 Inhibitor (LY2606368) in Women With BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Non-High Risk Triple Negative Breast Cancer, and Grade Serous Ovarian Cancer at Low Genetic Risk",1964
42,NCT02269293,Phase I,Recruiting,"[{'id': 2640, 'therapyName': 'Carboplatin + Paclitaxel + Selinexor'}]","Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers",1964
43,NCT02278783,Phase II,Terminated,"[{'id': 890, 'therapyName': 'Regorafenib'}]","Phase 2 Trial of Regorafenib in Patients With Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancer",1964
44,NCT02282020,Phase III,Recruiting,"[{'id': 837, 'therapyName': 'Olaparib'}]",Olaparib Treatment in Relapsed Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments.,1964
45,NCT02289950,Phase II,Recruiting,"[{'id': 3230, 'therapyName': 'Farletuzumab'}]",A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Subjects With Low CA125 Platinum-Sensitive Ovarian Cancer,1964
46,NCT02312245,Phase II,Recruiting,"[{'id': 942, 'therapyName': 'Topotecan'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 755, 'therapyName': 'Gemcitabine'}]","Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",1964
47,NCT02346747,Phase II,"Active, not recruiting","[{'id': 1157, 'therapyName': 'FANG vaccine'}]",Phase II/III Trial of Maintenance Vigil for High Risk Stage III/IV Ovarian Cancer (VITAL),1964
48,NCT02354131,Phase Ib/II,Recruiting,"[{'id': 832, 'therapyName': 'Niraparib'}, {'id': 4254, 'therapyName': 'Bevacizumab + Niraparib'}]",Niraparib Versus Niraparib-bevacizumab Combination in Women With Platinum-sensitive Epithelial Ovarian Cancer (AVANOVA),1964
49,NCT02392676,Phase III,Withdrawn,"[{'id': 837, 'therapyName': 'Olaparib'}]",Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations,1964
50,NCT02432690,Phase II,"Active, not recruiting","[{'id': 1945, 'therapyName': 'BBI503'}]",A Study of BBI503 in Asymptomatic Recurrent Ovarian Cancer Patients With CA-125 Elevation,1964
51,NCT02437812,Phase II,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1031, 'therapyName': 'Metformin'}]","Study of Paclitaxel, Carboplatin and Oral Metformin in the Treatment of Advanced Stage Ovarian Carcinoma",1964
52,NCT02446600,Phase III,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 1001, 'therapyName': 'Cediranib'}]","Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",1964
53,NCT02452775,Phase I,Recruiting,"[{'id': 3008, 'therapyName': 'OC-L'}]",Autologous OC-L Vaccine and Ovarian Cancer,1964
54,NCT02489006,Phase II,Recruiting,"[{'id': 837, 'therapyName': 'Olaparib'}]","A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer",1964
55,NCT02498600,Phase II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]","Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",1964
56,NCT02502266,Phase II,Suspended,"[{'id': 942, 'therapyName': 'Topotecan'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 1001, 'therapyName': 'Cediranib'}]","Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",1964
57,NCT02575807,Phase Ib/II,Recruiting,"[{'id': 2575, 'therapyName': 'Epacadostat'}, {'id': 2641, 'therapyName': 'CRS-207'}]","Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian, or Peritoneal Cancer",1964
58,NCT02580058,Phase III,"Active, not recruiting","[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 3144, 'therapyName': 'Avelumab'}]",A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer,1964
59,NCT02595892,Phase II,Recruiting,"[{'id': 2879, 'therapyName': 'VX-970'}, {'id': 755, 'therapyName': 'Gemcitabine'}]","Gemcitabine Hydrochloride Alone or With VX-970 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",1964
60,NCT02606305,Phase I,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 3232, 'therapyName': 'IMGN853'}]","Study of IMGN853 in Comb. With Bevacizumab, Carboplatin or PLD in Adults With FRa + Adv. EOC, Primary Peritoneal, Fallopian Tube, or Endometrial Cancer",1964
61,NCT02627430,Phase I,Withdrawn,"[{'id': 3317, 'therapyName': 'Onalespib + Talazoparib'}]","Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer",1964
62,NCT02627443,Phase II,Recruiting,"[{'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}, {'id': 2879, 'therapyName': 'VX-970'}]","Carboplatin and Gemcitabine Hydrochloride With or Without ATR Kinase Inhibitor VX-970 in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",1964
63,NCT02631876,Phase II,Recruiting,"[{'id': 3574, 'therapyName': 'Doxil + Paclitaxel'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3232, 'therapyName': 'IMGN853'}]","PH2 Study of IMGN853 vs Investigator's Choice of Chemo in Adults With FRa+ Adv. EOC, Primary Peritoneal or Primary Fallopian Tube Cancer",1964
64,NCT02649673,Phase Ib/II,Recruiting,"[{'id': 3845, 'therapyName': 'LCL161 + Topotecan'}]",LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies,1964
65,NCT02655016,Phase III,Recruiting,"[{'id': 832, 'therapyName': 'Niraparib'}]",A Study of Niraparib Maintenance Treatment in Patients With HRD-Positive Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy,1964
66,NCT02657889,Phase Ib/II,Recruiting,"[{'id': 3935, 'therapyName': 'Niraparib + Pembrolizumab'}]",Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Triple-negative Breast Cancer or Ovarian Cancer (KEYNOTE-162),1964
67,NCT02658214,Phase I,Recruiting,"[{'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}, {'id': 2634, 'therapyName': 'Carboplatin + nab-paclitaxel'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}]",Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors,1964
68,NCT02674061,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Efficacy and Safety Study of Pembrolizumab (MK-3475) in Women With Advanced Recurrent Ovarian Cancer (MK-3475-100/KEYNOTE-100),1964
69,NCT02713386,Phase Ib/II,Recruiting,"[{'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]","Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",1964
70,NCT02718417,Phase III,Recruiting,"[{'id': 3144, 'therapyName': 'Avelumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100),1964
71,NCT02726997,Phase Ib/II,Recruiting,"[{'id': 3997, 'therapyName': 'Carboplatin + Durvalumab + Paclitaxel'}]",Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer,1964
72,NCT02728830,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers,1964
73,NCT02737787,Phase I,Recruiting,"[{'id': 4020, 'therapyName': 'Nivolumab + WT1 vaccine'}]",A Study of WT1 Vaccine and Nivolumab For Recurrent Ovarian Cancer,1964
74,NCT02766582,Phase II,Recruiting,"[{'id': 2103, 'therapyName': 'Carboplatin + Paclitaxel + Pembrolizumab'}]",Phase II: Pembrolizumab/Carboplatin/Taxol in Epithelial Ovary Cancer,1964
75,NCT02785250,Phase I,Recruiting,"[{'id': 4238, 'therapyName': 'Cyclophosphamide + DPX-Survivac + INCB024360 '}]",Study of DPX-Survivac Vaccine Therapy and Epacadostat in Patients With Recurrent Ovarian Cancer,1964
76,NCT02788708,Phase I,Recruiting,"[{'id': 4236, 'therapyName': 'Lenvatinib + Paclitaxel'}]",Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer,1964
77,NCT02824042,Phase I,Recruiting,"[{'id': 4594, 'therapyName': 'Anetumab ravtansine + Itraconazole'}, {'id': 4593, 'therapyName': 'Anetumab ravtansine'}]",Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole,1964
78,NCT02853318,Phase II,Recruiting,"[{'id': 4528, 'therapyName': 'Bevacizumab + Cyclophosphamide + Pembrolizumab'}]","Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",1964
79,NCT02855944,Phase III,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 906, 'therapyName': 'Rucaparib'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]","ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients",1964
80,NCT02865811,Phase II,"Active, not recruiting","[{'id': 4558, 'therapyName': 'Doxil + Pembrolizumab'}]","Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer",1964
81,NCT02873962,Phase II,Recruiting,"[{'id': 2111, 'therapyName': 'Bevacizumab + Nivolumab'}]",A Phase II Study Of Nivolumab/ Bevacizumab,1964
82,NCT02884648,Phase II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Bevacizumab in Ovarian Cancer Patients With Disease at Second-look Surgery,1964
83,NCT02900560,Phase II,Recruiting,"[{'id': 2496, 'therapyName': 'Azacitidine + Pembrolizumab'}]",Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer,1964
84,NCT02901899,Phase II,Recruiting,"[{'id': 4725, 'therapyName': 'Pembrolizumab + SGI-110'}]","Guadecitabine and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",1964
85,NCT02915523,Phase Ib/II,Recruiting,"[{'id': 3144, 'therapyName': 'Avelumab'}, {'id': 5559, 'therapyName': 'Avelumab + Entinostat'}]",Phase 1b/2 Study of Avelumab With or Without Entinostat in Patients With Advanced Epithelial Ovarian Cancer,1964
86,NCT02923739,Phase II,Recruiting,"[{'id': 4836, 'therapyName': 'Bevacizumab + Emactuzumab + Paclitaxel'}, {'id': 2123, 'therapyName': 'Bevacizumab + Paclitaxel'}]","Induction Discontinuation Trial of Emactuzumab Following Paclitaxel and Bevacizumab in Patients With Platinum-Resistant, Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer - REDIRECT",1964
87,NCT02943317,Phase I,Recruiting,"[{'id': 958, 'therapyName': 'VS-6063'}, {'id': 3144, 'therapyName': 'Avelumab'}]","Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian Cancer",1964
88,NCT02948101,Phase II,Not yet recruiting,"[{'id': 5848, 'therapyName': 'Cyclophosphamide + PD 0360324'}]",Pre-Conditioning Effects of Anti-Macrophage Therapy Using PD 0360324 in Recurrent Platinum-Resistant Epithelial Ovarian Cancer,1964
89,NCT02948426,Phase I,Recruiting,"[{'id': 4975, 'therapyName': 'interferon gamma + peginterferon alfa-2b'}]","Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer",1964
90,NCT02963831,Phase Ib/II,Recruiting,"[{'id': 4978, 'therapyName': 'ONCOS-102 + MEDI4736'}]","A Phase 1/2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies",1964
91,NCT02983799,Phase II,Recruiting,"[{'id': 837, 'therapyName': 'Olaparib'}]",Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status,1964
92,NCT02996825,Phase I,Recruiting,"[{'id': 3232, 'therapyName': 'IMGN853'}]","Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRa-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer",1964
93,NCT03026062,Phase II,Recruiting,"[{'id': 1652, 'therapyName': 'Tremelimumab'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",Durvalumab and Tremelimumab in Combo Versus Sequential,1964
94,NCT03029598,Phase Ib/II,Recruiting,"[{'id': 5265, 'therapyName': 'Carboplatin + Pembrolizumab'}]","Pembrolizumab and Carboplatin in Treating Patients With Relapsed or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",1964
95,NCT03030287,Phase I,Recruiting,"[{'id': 5264, 'therapyName': 'OMP-305B83 + Paclitaxel'}]","A Phase 1b Study of OMP-305B83 Plus Paclitaxel in Subjects With Ovarian, Peritoneal or Fallopian Tube Cancer",1964
96,NCT03038100,Phase III,Recruiting,"[{'id': 2370, 'therapyName': 'Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel'}, {'id': 1152, 'therapyName': 'Bevacizumab + Carboplatin + Paclitaxel'}]","A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (IMagyn050)",1964
97,NCT03056833,Phase I,Recruiting,"[{'id': 5333, 'therapyName': 'LEE011 + Carboplatin + Paclitaxel'}]",Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer,1964
98,NCT03079687,Expanded access,Approved for marketing,"[{'id': 837, 'therapyName': 'Olaparib'}]","Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer.",1964
99,NCT03093155,Phase II,Recruiting,"[{'id': 1122, 'therapyName': 'Bevacizumab + Ixabepilone'}, {'id': 781, 'therapyName': 'Ixabepilone'}]",Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab,1964
100,NCT03113487,Phase II,Not yet recruiting,"[{'id': 5547, 'therapyName': 'MVAp53 + Pembrolizumab'}]","P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",1964
101,NCT03206177,Phase I,Recruiting,"[{'id': 6265, 'therapyName': 'Carboplatin + Galunisertib + Paclitaxel'}]",Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary,1964
102,NCT03245892,Phase I,Recruiting,"[{'id': 5303, 'therapyName': 'Nivolumab + Carboplatin + Paclitaxel'}]",A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab in Patients With Ovarian Cancer,1964
103,NCT03283943,Phase I,Not yet recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}]",PDL-1 Inhibition and Focal Sensitizing Radiotherapy in Recurrent Ovarian/Primary Peritoneal/Fallopian Tube Cancers.,1964
104,NCT03294694,Phase I,Not yet recruiting,"[{'id': 6285, 'therapyName': 'Fulvestrant + PDR001 + Ribociclib'}, {'id': 6284, 'therapyName': 'PDR001 + Ribociclib'}]",Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer,1964
0,NCT00989651,Phase I,"Active, not recruiting","[{'id': 3047, 'therapyName': 'Bevacizumab + Veliparib'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}]","Carboplatin, Paclitaxel, Bevacizumab, and ABT-888 in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer",1963
1,NCT01145430,Phase I,"Active, not recruiting","[{'id': 2167, 'therapyName': 'pegylated liposomal doxorubicin + Veliparib'}]","Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer",1963
2,NCT01239732,Phase III,Completed,"[{'id': 1152, 'therapyName': 'Bevacizumab + Carboplatin + Paclitaxel'}]",A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian Cancer,1963
3,NCT01248962,Phase II,"Active, not recruiting","[{'id': 1092, 'therapyName': 'Carboplatin'}]","Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in Patients With Patients With Recurrent, Ovary, Fallopian Tube, and Primary Peritoneal Cancer",1963
4,NCT01281514,Phase I,Recruiting,"[{'id': 2168, 'therapyName': 'Carboplatin + Doxil + Everolimus'}]","Carboplatin, Pegylated Liposomal Doxorubicin Hydrochloride, and Everolimus in Treating Patients With Relapsed Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer",1963
5,NCT01504126,Phase I,"Active, not recruiting","[{'id': 1912, 'therapyName': 'Propranolol'}]",Beta-Blocker / Ovarian,1963
6,NCT01519869,Phase I,"Active, not recruiting",[],"Trial of Chemotherapy in Ovarian, Fallopian Tube and Peritoneal Carcinoma",1963
7,NCT01607905,Phase I,Completed,"[{'id': 1749, 'therapyName': 'Selinexor'}]",Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced or Metastatic Solid Tumor Cancer,1963
8,NCT01669798,Phase II,Recruiting,"[{'id': 831, 'therapyName': 'Nintedanib'}]","BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer",1963
9,NCT01849874,Phase III,"Active, not recruiting","[{'id': 807, 'therapyName': 'Binimetinib'}]","A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer",1963
10,NCT01936974,Phase II,Terminated,"[{'id': 1295, 'therapyName': 'Gemcitabine + Bevacizumab + Cisplatin'}, {'id': 1296, 'therapyName': 'Gemcitabine + Bevacizumab + Oxaliplatin'}, {'id': 1294, 'therapyName': 'Gemcitabine + Bevacizumab + Carboplatin'}, {'id': 1297, 'therapyName': 'Gemcitabine + Bevacizumab'}]","(PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma",1963
11,NCT01974765,Phase II,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}]","Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies",1963
12,NCT02042430,Phase I,"Active, not recruiting","[{'id': 2575, 'therapyName': 'Epacadostat'}]","INCB024360 Before Surgery in Treating Patients With Newly Diagnosed Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",1963
13,NCT02059265,Phase II,"Active, not recruiting","[{'id': 717, 'therapyName': 'Dasatinib'}]","Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer",1963
14,NCT02101775,Phase II,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1279, 'therapyName': 'MK-1775 + Gemcitabine'}]","Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",1963
15,NCT02121990,Phase I,"Active, not recruiting","[{'id': 1451, 'therapyName': 'Cisplatin + Paclitaxel + Bevacizumab + Olaparib '}]","Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer",1963
16,NCT02122185,Phase II,Recruiting,"[{'id': 1031, 'therapyName': 'Metformin'}, {'id': 1827, 'therapyName': 'Paclitaxel + Carboplatin + Docetaxel'}]","Metformin Hydrochloride and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",1963
17,NCT02122861,Phase I,"Active, not recruiting","[{'id': 3271, 'therapyName': 'ID-LV305'}]","A Phase 1 Safety Study of Intradermal ID-LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1",1963
18,NCT02166905,Phase Ib/II,Recruiting,"[{'id': 2595, 'therapyName': 'poly ICLC  '}, {'id': 1324, 'therapyName': 'DEC-205-NY-ESO-1 fusion protein vaccine'}, {'id': 2575, 'therapyName': 'Epacadostat'}]","DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission",1963
19,NCT02188550,Phase II,Unknown status,"[{'id': 1621, 'therapyName': 'Everolimus + Letrozole'}]",Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer,1963
20,NCT02195973,Phase Ib/II,"Active, not recruiting","[{'id': 1620, 'therapyName': 'Paclitaxel + Sonidegib'}]",Phase IB/II Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer,1963
21,NCT02208375,Phase Ib/II,Recruiting,"[{'id': 837, 'therapyName': 'Olaparib'}, {'id': 655, 'therapyName': 'AZD5363'}, {'id': 991, 'therapyName': 'Vistusertib'}]",mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian Cancer,1963
22,NCT02272790,Phase II,Recruiting,"[{'id': 1194, 'therapyName': 'MK-1775 + Carboplatin '}, {'id': 1279, 'therapyName': 'MK-1775 + Gemcitabine'}, {'id': 1567, 'therapyName': 'MK-1775 + Paclitaxel'}]","A Phase II Study Comparing AZD1775 + Chemotherapy Versus Chemotherapy Alone in Patients to Treat Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.",1963
23,NCT02275039,Phase I,"Active, not recruiting","[{'id': 1038, 'therapyName': 'MVAp53'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer,1963
24,NCT02283658,Phase II,"Active, not recruiting","[{'id': 1621, 'therapyName': 'Everolimus + Letrozole'}]","Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer",1963
25,NCT02316834,Phase I,"Active, not recruiting","[{'id': 682, 'therapyName': 'Talazoparib'}]",POSITION: A PilOt Study of InducTion PARP InhibitiON in Ovarian Cancer,1963
26,NCT02387125,Phase I,Recruiting,"[{'id': 4318, 'therapyName': 'CMB305'}]","A Phase 1b Safety Study of CMB305 (Sequentially Administered LV305 and G305) in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1",1963
27,NCT02431559,Phase Ib/II,Recruiting,"[{'id': 3101, 'therapyName': 'Aldoxorubicin + MEDI4736 + Motolimod'}]","A Phase 1/2 Study of Motolimod (VTX-2337) and MEDI4736 in Subjects With Recurrent, Platinum-Resistant Ovarian Cancer for Whom Pegylated Liposomal Doxorubicin (PLD) is Indicated",1963
28,NCT02440425,Phase II,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer,1963
29,NCT02459301,Phase I,"Active, not recruiting","[{'id': 3382, 'therapyName': 'IPH2201'}]","Dose-Ranging Study of IPH2201 in Patients With High Grade Serious CA of Ovarian, Fallopian Tube or Peritoneal Origin",1963
30,NCT02470585,Phase III,"Active, not recruiting","[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 954, 'therapyName': 'Veliparib'}]","Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Subjects With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",1963
31,NCT02485990,Phase Ib/II,Recruiting,"[{'id': 837, 'therapyName': 'Olaparib'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]","Study of Tremelimumab Alone or Combined With Olaparib for Patients With Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma)",1963
32,NCT02537444,Phase II,"Active, not recruiting","[{'id': 1605, 'therapyName': 'Acalabrutinib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Recurrent Ovarian Cancer (KEYNOTE191),1963
33,NCT02571725,Phase Ib/II,Recruiting,"[{'id': 1652, 'therapyName': 'Tremelimumab'}, {'id': 837, 'therapyName': 'Olaparib'}]",PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer,1963
34,NCT02608684,Phase II,Recruiting,"[{'id': 3248, 'therapyName': 'Cisplatin + Gemcitabine + Pembrolizumab'}]",A Study of Pembrolizumab With Standard Treatment in Patients With Recurrent Platinum-resistant Ovarian Cancer,1963
35,NCT02657928,Phase II,Recruiting,"[{'id': 1568, 'therapyName': 'LEE011 + Letrozole'}]","Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal or Endometrial Cancer",1963
36,NCT02659241,Phase I,Recruiting,"[{'id': 822, 'therapyName': 'MK-1775'}]",A Pilot Study of Induction Wee1 Inhibition in Ovarian Cancer,1963
37,NCT02661815,Phase I,"Active, not recruiting","[{'id': 3469, 'therapyName': 'ACY-1215 + Paclitaxel'}, {'id': 667, 'therapyName': 'Bevacizumab'}]","A Phase 1b Study of Weekly Paclitaxel And Oral Ricolinostat For The Treatment Of Recurrent Platinum Resistant Ovarian, Primary Peritoneal, Or Fallopian Tube Cancer",1963
38,NCT02764333,Phase II,Recruiting,"[{'id': 4180, 'therapyName': 'MEDI4736 + TPIV 200'}]",TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian Cancer,1963
39,NCT02833506,Phase I,Not yet recruiting,"[{'id': 4460, 'therapyName': 'NY-ESO-1 peptide vaccine + Sirolimus'}, {'id': 2696, 'therapyName': 'NY-ESO-1 peptide vaccine'}]","Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",1963
40,NCT02834975,Phase II,Recruiting,"[{'id': 2103, 'therapyName': 'Carboplatin + Paclitaxel + Pembrolizumab'}]","Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Epithelial Ovarian Cancer (EOC).",1963
41,NCT02889900,Phase II,Recruiting,"[{'id': 1971, 'therapyName': 'Cediranib + Olaparib'}]",Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer (CONCERTO),1963
42,NCT02953457,Phase Ib/II,Recruiting,"[{'id': 4949, 'therapyName': 'MEDI4736 + Olaparib + Tremelimumab'}]","Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRAC2 Mutation",1963
43,NCT03018405,Phase I,Recruiting,"[{'id': 5998, 'therapyName': 'NKR-2 cells'}]",A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications (THINK),1963
44,NCT03029403,Phase II,Not yet recruiting,"[{'id': 5266, 'therapyName': 'Pembrolizumab + DPX-Survivac + Cyclophosphamide'}]","Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer",1963
45,NCT03054909,Phase I,Not yet recruiting,"[{'id': 3060, 'therapyName': 'ALT-803'}]",QUILT-2.021: Phase I of IP Followed by SQ ALT-803 for Ovarian Cancer,1963
46,NCT03206047,Phase Ib/II,Recruiting,"[{'id': 4693, 'therapyName': 'Atezolizumab + SGI-110'}, {'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 5982, 'therapyName': 'Atezolizumab + SGI-110 + DEC-205-NY-ESO-1 fusion protein vaccine'}]","Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",1963
47,NCT03206645,Phase I,Recruiting,"[{'id': 6266, 'therapyName': 'Carboplatin + Paclitaxel + PTC596'}]",PTC-596 in Women With Ovarian Cancer Receiving Neoadjuvant Chemotherapy,1963
0,NCT00989651,Phase I,"Active, not recruiting","[{'id': 3047, 'therapyName': 'Bevacizumab + Veliparib'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}]","Carboplatin, Paclitaxel, Bevacizumab, and ABT-888 in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer",1970
1,NCT03241745,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",A Study of Nivolumab in Selected Uterine Cancer Patients,1970
0,NCT03206645,Phase I,Recruiting,"[{'id': 6266, 'therapyName': 'Carboplatin + Paclitaxel + PTC596'}]",PTC-596 in Women With Ovarian Cancer Receiving Neoadjuvant Chemotherapy,5301
0,NCT02345265,Phase II,"Active, not recruiting","[{'id': 1971, 'therapyName': 'Cediranib + Olaparib'}]","Olaparib and Cediranib Maleate in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer",5831
1,NCT03206645,Phase I,Recruiting,"[{'id': 6266, 'therapyName': 'Carboplatin + Paclitaxel + PTC596'}]",PTC-596 in Women With Ovarian Cancer Receiving Neoadjuvant Chemotherapy,5831
0,NCT02345265,Phase II,"Active, not recruiting","[{'id': 1971, 'therapyName': 'Cediranib + Olaparib'}]","Olaparib and Cediranib Maleate in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer",5598
1,NCT02354586,Phase II,Recruiting,"[{'id': 832, 'therapyName': 'Niraparib'}]",A Study of Niraparib in Patients With Ovarian Cancer Who Have Received at Least Three Previous Chemotherapy Regimens,5598
2,NCT02898207,Phase I,Recruiting,"[{'id': 4729, 'therapyName': 'Olaparib + Onalespib'}]","Olaparib and Hsp90 Inhibitor AT13387 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer",5598
3,NCT03206645,Phase I,Recruiting,"[{'id': 6266, 'therapyName': 'Carboplatin + Paclitaxel + PTC596'}]",PTC-596 in Women With Ovarian Cancer Receiving Neoadjuvant Chemotherapy,5598
0,NCT00800345,Phase I,Completed,"[{'id': 1469, 'therapyName': 'Topotecan + Pazopanib'}]",Phase I Trial of Oral Metronomic Topotecan and Oral Pazopanib to Treat Recurrent/Persistent Gynecologic Tumors,120
1,NCT01831089,Phase I,Completed,"[{'id': 1196, 'therapyName': 'Lurbinectedin + Paclitaxel + Bevacizumab'}, {'id': 1197, 'therapyName': 'Lurbinectedin + Paclitaxel'}]","Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors",120
2,NCT03073525,Phase II,Recruiting,"[{'id': 5558, 'therapyName': 'Atezolizumab + FANG vaccine'}]",Trial of Atezolizumab and Vigil for Advanced Gynecological Cancers (A Companion Study to CL-PTL-119),120
3,NCT03277482,Phase I,Not yet recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]","Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer",120
0,NCT01734512,Phase II,Recruiting,"[{'id': 735, 'therapyName': 'Everolimus'}]",PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children,6726
1,NCT01837862,Phase Ib/II,Recruiting,"[{'id': 2134, 'therapyName': 'Mebendazole + Vincristine + Carboplatin + Temozolomide'}, {'id': 2133, 'therapyName': 'Mebendazole + Bevacizumab + Irinotecan'}]",A Phase I/II Study of Mebendazole for the Treatment of Pediatric Gliomas,6726
2,NCT02607124,Phase Ib/II,Recruiting,"[{'id': 790, 'therapyName': 'Ribociclib'}]",Administration of Ribociclib Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG),6726
0,NCT01396408,Phase II,"Active, not recruiting","[{'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 930, 'therapyName': 'Sunitinib'}]",A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours,5015
1,NCT02234986,Phase II,"Active, not recruiting","[{'id': 727, 'therapyName': 'ENMD-2076'}]","A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma",5015
0,NCT00356031,Phase II,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Bevacizumab and Radiation Therapy for Sarcomas,3355
1,NCT01981551,Phase II,"Active, not recruiting","[{'id': 859, 'therapyName': 'PF-03084014'}]",Phase II Trial of the Gamma-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors/Aggressive Fibromatosis,3355
2,NCT02584309,Phase II,Recruiting,"[{'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 4140, 'therapyName': 'Doxorubicin + Olaratumab'}]",Doxorubicin With Upfront Dexrazoxane Plus Olaratumab for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma,3355
3,NCT03009201,Phase I,Recruiting,"[{'id': 5179, 'therapyName': 'Doxorubicin + Ribociclib'}]",Ribociclib and Doxorubicin Hydrochloride in Treating Patients Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery,3355
4,NCT03092323,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity (SU2C-SARC032),3355
0,NCT00356031,Phase II,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Bevacizumab and Radiation Therapy for Sarcomas,4415
1,NCT01446809,Phase I,"Active, not recruiting","[{'id': 1472, 'therapyName': 'Doxorubicin + Ifosfamide'}, {'id': 1471, 'therapyName': 'Pazopanib + Doxorubicin + Ifosfamide'}]",Pazopanib Hydrochloride Followed By Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma,4415
2,NCT02301039,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas,4415
3,NCT02601209,Phase Ib/II,Suspended,"[{'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1282, 'therapyName': 'Sapanisertib'}]",Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma,4415
4,NCT02987959,Phase II,Recruiting,"[{'id': 1282, 'therapyName': 'Sapanisertib'}]",Study of TAK-228 (MLN0128) in Soft Tissue Sarcomas,4415
0,NCT00577278,Phase II,"Active, not recruiting","[{'id': 767, 'therapyName': 'Ibritumomab'}, {'id': 2238, 'therapyName': 'Sirolimus + Tacrolimus + Methotrexate'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}]","Yttrium Y 90 Ibritumomab Tiuxetan, Rituximab, Indium In-111 Ibritumomab Tiuxetan, Fludarabine, Melphalan, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin Lymphoma",50873
1,NCT00602693,Phase I,Completed,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 2311, 'therapyName': 'Allopurinol + Cyclophosphamide + Fludarabine'}]",T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer,50873
2,NCT00671112,Phase I,Terminated,"[{'id': 2234, 'therapyName': 'Bortezomib + Everolimus'}]",Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma,50873
3,NCT01216683,Phase II,Unknown status,"[{'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1164, 'therapyName': 'lenalidomide'}]","Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma",50873
4,NCT01286272,Phase II,"Active, not recruiting","[{'id': 3909, 'therapyName': 'Bendamustine + Ofatumumab'}, {'id': 3910, 'therapyName': 'Bendamustine + Bortezomib + Ofatumumab'}]",Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma,50873
5,NCT01307267,Phase I,Recruiting,"[{'id': 6111, 'therapyName': 'Utomilumab + Rituximab'}, {'id': 5086, 'therapyName': 'Utomilumab'}]",A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab,50873
6,NCT01691898,Phase Ib/II,"Active, not recruiting","[{'id': 4415, 'therapyName': 'Obinutuzumab + Pinatuzumab Vedotin + Rituximab'}, {'id': 4416, 'therapyName': 'Polatuzumab Vedotin + Pinatuzumab Vedotin + Rituximab'}, {'id': 4417, 'therapyName': 'Obinutuzumab + Polatuzumab Vedotin'}]",A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (ROMULUS),50873
7,NCT01719250,Phase I,Completed,"[{'id': 680, 'therapyName': 'BKM120'}]",Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma,50873
8,NCT01732913,Phase III,Terminated,"[{'id': 1023, 'therapyName': 'Idelalisib'}, {'id': 897, 'therapyName': 'Rituximab'}]",Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas,50873
9,NCT01732926,Phase III,Terminated,"[{'id': 1023, 'therapyName': 'Idelalisib'}, {'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}]",Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas,50873
10,NCT01804686,Phase III,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",A Long-term Extension Study of PCI-32765 (Ibrutinib),50873
11,NCT01897012,Phase I,Recruiting,"[{'id': 1075, 'therapyName': 'romidepsin'}, {'id': 626, 'therapyName': 'Alisertib'}]",Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas,50873
12,NCT01953692,Phase I,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013)(KEYNOTE-013),50873
13,NCT01955499,Phase I,"Active, not recruiting","[{'id': 3580, 'therapyName': 'Ibrutinib + lenalidomide'}]",Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma,50873
14,NCT01974440,Phase III,"Active, not recruiting","[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}, {'id': 3266, 'therapyName': 'Cyclophosphamide + Doxorubicin + Prednisone + Vincristine '}]","A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma",50873
15,NCT01976585,Phase Ib/II,Recruiting,"[{'id': 4337, 'therapyName': 'CDX-301 + poly ICLC '}]",In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy,50873
16,NCT01994382,Phase I,Recruiting,"[{'id': 2531, 'therapyName': 'Cerdulatinib'}]",Phase 1 Dose Escalation Study in Chronic Lymphocytic Leukemia and Non-hodgkin Lymphoma,50873
17,NCT02038946,Phase II,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}]",Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140),50873
18,NCT02049541,Phase I,"Active, not recruiting","[{'id': 2502, 'therapyName': 'BKM120 + Rituximab'}]",Study of BKM120; Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma,50873
19,NCT02082977,Phase I,Terminated,"[{'id': 2734, 'therapyName': 'GSK2816126'}]","A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell and Transformed Follicular Lymphoma",50873
20,NCT02187861,Phase II,"Active, not recruiting","[{'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}, {'id': 3637, 'therapyName': 'Bendamustine + GDC-0199 + Rituximab'}, {'id': 3937, 'therapyName': 'GDC-0199 + Rituximab'}]",A Study Evaluating the Safety and Efficacy of GDC-0199 (ABT-199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or GDC-0199 Plus Rituximab in Patients With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma,50873
21,NCT02208037,Phase II,"Active, not recruiting",[],Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203),50873
22,NCT02220842,Phase I,Recruiting,"[{'id': 1975, 'therapyName': 'Atezolizumab + Obinutuzumab'}]",A Safety and Pharmacology Study of MPDL3280A Administered With Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma,50873
23,NCT02254772,Phase Ib/II,Completed,"[{'id': 3848, 'therapyName': 'Ipilimumab + SD-101'}]","TLR9 Agonist SD-101, Ipilimumab, and Radiation Therapy in Treating Patients With Low-Grade Recurrent B-cell Lymphoma",50873
24,NCT02257567,Phase Ib/II,"Active, not recruiting","[{'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}, {'id': 4226, 'therapyName': 'Polatuzumab Vedotin'}, {'id': 1646, 'therapyName': 'Obinutuzumab'}]",A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma,50873
25,NCT02266147,Phase Ib/II,Completed,"[{'id': 3084, 'therapyName': 'SD-101'}]",Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma,50873
26,NCT02282358,Phase Ib/II,"Active, not recruiting","[{'id': 3002, 'therapyName': 'Mocetinostat'}]",Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma,50873
27,NCT02343536,Phase I,Recruiting,"[{'id': 2488, 'therapyName': 'Cyclophosphamide + Prednisone + Rituximab + Vincristine'}, {'id': 651, 'therapyName': 'Azacitidine'}]","A Phase 1, Open-label,Trial of Oral Azacitidine (CC-486) Plus R-CHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma",50873
28,NCT02348216,Phase Ib/II,Recruiting,"[{'id': 4829, 'therapyName': 'KTE-C19'}]",A Phase 1-2 Multi-Center Study Evaluating KTE-C19 in Subjects With Refractory Aggressive Non-Hodgkin Lymphoma (ZUMA-1),50873
29,NCT02367040,Phase III,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 995, 'therapyName': 'Copanlisib'}]",Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL),50873
30,NCT02369016,Phase III,"Active, not recruiting","[{'id': 995, 'therapyName': 'Copanlisib'}]",Phase III Copanlisib in Rituximab-refractory iNHL,50873
31,NCT02376699,Phase I,Recruiting,"[{'id': 5781, 'therapyName': 'Pembrolizumab + SEA-CD40'}, {'id': 5780, 'therapyName': 'SEA-CD40'}]",Safety Study of SEA-CD40 in Cancer Patients,50873
32,NCT02381080,Phase I,Completed,"[{'id': 3793, 'therapyName': 'Erythromycin + Ibrutinib + Voriconazole'}]",Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy,50873
33,NCT02384954,Phase Ib/II,Recruiting,"[{'id': 3936, 'therapyName': 'ALT-803 + Rituximab'}]",ALT-803 in Patients With Relapse/Refractory Indolent B Cell Non-Hodgkin Lymphoma (iNHL) in Conjunction With Rituximab,50873
34,NCT02401048,Phase Ib/II,"Active, not recruiting","[{'id': 2573, 'therapyName': 'Ibrutinib + MEDI4736'}]",A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas,50873
35,NCT02446457,Phase II,"Active, not recruiting","[{'id': 3279, 'therapyName': 'Pembrolizumab + Rituximab'}]",Study of Rituximab Plus Pembrolizumab (MK-3475) in Subjects With Relapsed Follicular Lymphoma,50873
36,NCT02454270,Phase II,"Active, not recruiting","[{'id': 4166, 'therapyName': 'JNJ-64052781'}]",A Dose Escalation Study of JNJ-64052781 in Participants With Relapsed or Refractory B-cell Malignancies,50873
37,NCT02471911,Phase I,Recruiting,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 3360, 'therapyName': 'Carboplatin + Etoposide + Ifosfamide + Rituximab'}, {'id': 1749, 'therapyName': 'Selinexor'}]",KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma,50873
38,NCT02501473,Phase Ib/II,Recruiting,"[{'id': 3577, 'therapyName': 'GLA-SE + Pembrolizumab'}]",Study of Intratumoral G100 Therapy in Patients With Or Without Pembrolizumab With Follicular Non-Hodgkin's Lymphoma,50873
39,NCT02532192,Phase I,Withdrawn,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1689, 'therapyName': 'Fluconazole'}, {'id': 1078, 'therapyName': 'Belinostat'}]","A Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in Adults With Relapsed or Refractory Diffuse Large B-cell Lymphoma",50873
40,NCT02532257,Phase II,Recruiting,"[{'id': 1610, 'therapyName': 'Rituximab + Lenalidomide + Ibrutinib'}]",Study of Ibrutinib in Combination With Rituximab and Lenalidomide,50873
41,NCT02576275,Phase III,Withdrawn,"[{'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}, {'id': 1024, 'therapyName': 'Duvelisib'}]",A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA),50873
42,NCT02596971,Phase I,Recruiting,"[{'id': 1975, 'therapyName': 'Atezolizumab + Obinutuzumab'}, {'id': 3266, 'therapyName': 'Cyclophosphamide + Doxorubicin + Prednisone + Vincristine '}, {'id': 1231, 'therapyName': 'Bendamustine'}]",Safety and Efficacy of MPDL3280A in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus CHOP in Patients With Follicular Lymphoma or Diffuse Large B-Cell Lymphoma,50873
43,NCT02600897,Phase Ib/II,Recruiting,"[{'id': 4394, 'therapyName': 'lenalidomide + Obinutuzumab + Polatuzumab Vedotin'}]","A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)",50873
44,NCT02605694,Phase II,Withdrawn,"[{'id': 3389, 'therapyName': 'Duvelisib + Rituximab'}, {'id': 2195, 'therapyName': 'R-CHOP'}]",Duvelisib With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO),50873
45,NCT02611323,Phase Ib/II,Recruiting,"[{'id': 4227, 'therapyName': 'Obinutuzumab + Polatuzumab Vedotin + Venetoclax'}]","A Study of Obinutuzumab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)",50873
46,NCT02624986,Phase Ib/II,Recruiting,"[{'id': 4393, 'therapyName': 'Idasanutlin + Obinutuzumab'}]",A Study of Obinutuzumab With Idasanutlin in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL),50873
47,NCT02626455,Phase III,Recruiting,"[{'id': 1631, 'therapyName': 'Vincristine'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 3388, 'therapyName': 'Aldoxorubicin +Cyclophosphamide + Prednisone + Rituximab + Vincristine'}, {'id': 995, 'therapyName': 'Copanlisib'}, {'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}, {'id': 897, 'therapyName': 'Rituximab'}]",Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL),50873
48,NCT02631044,Phase I,Recruiting,"[{'id': 5980, 'therapyName': 'JCAR017'}]",Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (NHL),50873
49,NCT02631577,Phase I,Suspended,"[{'id': 3387, 'therapyName': 'Atezolizumab + lenalidomide + Obinutuzumab'}]",A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma,50873
50,NCT02650999,Phase Ib/II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab in Patients Failing to Respond to or Relapsing After Anti-CD19 Chimeric Antigen Receptor Modified T Cell Therapy for Relapsed or Refractory CD19+ Lymphomas,50873
51,NCT02700022,Phase I,"Active, not recruiting","[{'id': 626, 'therapyName': 'Alisertib'}, {'id': 3395, 'therapyName': 'R-EPOCH'}]",A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas,50873
52,NCT02722668,Phase II,Recruiting,"[{'id': 2281, 'therapyName': 'Cyclophosphamide + Fludarabine + Mycophenolate mofetil'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}]",UCB Transplant for Hematological DIseases Using a Non Myeloablative Prep,50873
53,NCT02729896,Phase Ib/II,Recruiting,"[{'id': 4362, 'therapyName': 'Atezolizumab + Obinutuzumab + Polatuzumab Vedotin'}]","A Study of Obinutuzumab, Polatuzumab Vedotin, and Atezolizumab in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)",50873
54,NCT02743546,Phase I,Withdrawn,"[{'id': 4167, 'therapyName': 'Ibrutinib + JNJ-64052781'}]","Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of JNJ-64052781 Plus Ibrutinib in Lymphoma",50873
55,NCT02756247,Phase I,Recruiting,"[{'id': 3630, 'therapyName': 'BKM120 + Ibrutinib'}]",A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma,50873
56,NCT02869633,Phase II,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant,50873
57,NCT02927964,Phase Ib/II,Recruiting,"[{'id': 4828, 'therapyName': 'Ibrutinib + SD-101 + Radiotherapy'}]","TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma",50873
58,NCT02947347,Phase III,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 3280, 'therapyName': 'Ibrutinib + Rituximab'}]",Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma,50873
59,NCT02950220,Phase I,Recruiting,"[{'id': 4917, 'therapyName': 'Pembrolizumab + Ibrutinib'}]",Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma,50873
60,NCT02953509,Phase Ib/II,Recruiting,"[{'id': 4955, 'therapyName': 'Hu5F9-G4 + Rituximab'}]",Trial of Hu5F9-G4 in Combination With Rituximab in Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma,50873
61,NCT02956382,Phase Ib/II,Recruiting,"[{'id': 3392, 'therapyName': 'GDC-0199 + Ibrutinib'}]",Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma,50873
62,NCT02966730,Phase I,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",Ibrutinib for Patients With Follicular Lymphoma Without Complete Response to Initial Chemoimmunotherapy,50873
63,NCT02992522,Phase I,Recruiting,"[{'id': 5133, 'therapyName': 'Lenalidomide + Obinutuzumab + Venetoclax'}]","Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma",50873
64,NCT03015896,Phase Ib/II,Suspended,"[{'id': 5239, 'therapyName': 'Lenalidomide + Nivolumab'}]",Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma,50873
65,NCT03039114,Phase I,Recruiting,"[{'id': 6260, 'therapyName': 'Bendamustine + INCB050465 + Obinutuzumab'}]",Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102),50873
66,NCT03105336,Phase II,Recruiting,"[{'id': 4829, 'therapyName': 'KTE-C19'}]",A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (ZUMA-5),50873
67,NCT03121677,Phase I,Not yet recruiting,"[{'id': 5592, 'therapyName': 'Nivolumab + poly ICLC + Rituximab'}]",Personalized Synthetic Long Peptide Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma,50873
68,NCT03126019,Phase II,Recruiting,"[{'id': 3088, 'therapyName': 'INCB050465 '}, {'id': 1023, 'therapyName': 'Idelalisib'}]","An Open-Label, Randomized Study Comparing INCB050465 to Idelalisib in Relapsed or Refractory Follicular Lymphoma (CITADEL-203)",50873
69,NCT03133221,Phase II,Not yet recruiting,"[{'id': 1023, 'therapyName': 'Idelalisib'}]",1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation,50873
70,NCT03135262,Phase Ib/II,Recruiting,"[{'id': 5646, 'therapyName': 'Idasanutlin + Rituximab + Venetoclax'}, {'id': 5644, 'therapyName': 'Idasanutlin + Obinutuzumab + Venetoclax'}, {'id': 5645, 'therapyName': 'Idasanutlin + Obinutuzumab + Rituximab + Venetoclax'}]",A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL),50873
71,NCT03147885,Phase Ib/II,Recruiting,"[{'id': 1749, 'therapyName': 'Selinexor'}]",Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma,50873
72,NCT03150329,Phase I,Recruiting,"[{'id': 3077, 'therapyName': 'Pembrolizumab + Vorinostat'}]","Pembrolizumab and Vorinostat in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, or Hodgkin Lymphoma",50873
73,NCT03153462,Expanded access,Available,"[{'id': 5098, 'therapyName': 'KTE-C19 + Fludarabine phosphate + Cyclophosphamide'}]",Axicabtagene Ciloleucel Expanded Access Study,50873
74,NCT03156114,Phase I,Recruiting,"[{'id': 5692, 'therapyName': 'BI 754091'}, {'id': 5690, 'therapyName': 'BI 754111'}]",This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment.,50873
75,NCT03178201,Phase II,Recruiting,"[{'id': 2022, 'therapyName': 'TGR-1202'}]",TGR1202 in Relapsed and Refractory Follicular Lymphoma,50873
76,NCT03179930,Phase II,Recruiting,"[{'id': 3354, 'therapyName': 'Entinostat + Pembrolizumab'}]",Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas,50873
77,NCT03269669,Phase II,Recruiting,"[{'id': 6257, 'therapyName': 'Obinutuzumab + CHOP'}, {'id': 6302, 'therapyName': 'Lenalidomide + Obinutuzumab\t'}, {'id': 6301, 'therapyName': 'Obinutuzumab + TGR-1202'}, {'id': 2188, 'therapyName': 'Prednisone'}]","Obinutuzumab With or Without PI3K-delta Inhibitor TGR-1202, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma",50873
78,NCT03297424,Phase Ib/II,Recruiting,"[{'id': 6324, 'therapyName': 'PLX2853'}]",A Study of PLX2853 in Advanced Malignancies.,50873
0,NCT01723202,Phase II,"Active, not recruiting","[{'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}, {'id': 3, 'therapyName': 'Dabrafenib'}]",Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer,3962
1,NCT02145143,Phase I,"Active, not recruiting","[{'id': 342, 'therapyName': 'Vemurafenib'}]","Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib",3962
2,NCT02152995,Phase II,Recruiting,"[{'id': 2, 'therapyName': 'Trametinib'}]",Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer,3962
3,NCT02211222,Phase I,Approved for marketing,"[{'id': 792, 'therapyName': 'Lenvatinib'}]",An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer,3962
4,NCT02393690,Phase II,Recruiting,"[{'id': 913, 'therapyName': 'Selumetinib'}]",Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer,3962
5,NCT02456701,Phase I,Completed,"[{'id': 2063, 'therapyName': 'CDX-3379 + Vemurafenib'}]",Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379,3962
6,NCT02702388,Phase II,Recruiting,"[{'id': 792, 'therapyName': 'Lenvatinib'}]","Phase 2 Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 20 mg or 14 mg Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile",3962
7,NCT02973997,Phase II,Not yet recruiting,"[{'id': 4782, 'therapyName': 'Lenvatinib + Pembrolizumab'}]",Pembrolizumab and Lenvatinib in Treating Metastatic or Recurrent Differentiated Thyroid Cancer That Cannot Be Removed by Surgery,3962
8,NCT03215095,Phase I,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}]",RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid Cancers,3962
0,NCT01825603,Phase I,Recruiting,"[{'id': 4952, 'therapyName': 'ADH-1 + Cisplatin + Gemcitabine'}]","ADH-1, Gemcitabine Hydrochloride and Cisplatin in Treating Patients With Metastatic Pancreatic or Biliary Tract Cancer That Cannot Be Removed By Surgery",3500
1,NCT02628067,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158),3500
0,NCT01642342,Phase I,Recruiting,"[{'id': 3013, 'therapyName': 'sEphB4-HSA'}]",Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors,3121
1,NCT02240238,Phase Ib/II,Recruiting,"[{'id': 5626, 'therapyName': 'Gemcitabine + NC-6004'}]","Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer",3121
2,NCT02520141,Phase II,Recruiting,"[{'id': 886, 'therapyName': 'Ramucirumab'}]",Ramucirumab for Advanced Pre-treated Biliary Cancers,3121
3,NCT02711553,Phase II,"Active, not recruiting","[{'id': 886, 'therapyName': 'Ramucirumab'}, {'id': 1030, 'therapyName': 'LY2801653'}, {'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}]",A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer,3121
4,NCT03093870,Phase II,Not yet recruiting,"[{'id': 5543, 'therapyName': 'Capecitabine + Varlitinib'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer,3121
0,NCT01174121,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 1167, 'therapyName': 'Aldesleukin'}]",Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer,4948
1,NCT02042443,Phase II,Completed,"[{'id': 2278, 'therapyName': 'Fluorouracil + Leucovorin'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 2, 'therapyName': 'Trametinib'}]",Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery,4948
2,NCT02115542,Phase II,Recruiting,"[{'id': 890, 'therapyName': 'Regorafenib'}]",Single Agent Regorafenib in Refractory Advanced Biliary Cancers,4948
3,NCT02151084,Phase II,Recruiting,"[{'id': 2222, 'therapyName': 'Selumetinib + Cisplatin + Gemcitabine'}]",A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer,4948
4,NCT02631590,Phase II,Recruiting,"[{'id': 3315, 'therapyName': 'BAY80-6946 + Cisplatin + Gemcitabine'}]",Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma,4948
5,NCT02829918,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers,4948
0,NCT01999270,Phase I,Completed,"[{'id': 2112, 'therapyName': 'Bevacizumab + Irinotecan'}]",Evaluation of FDOPA-PET/MRI in Pediatric Patients With CNS Tumors,5078
0,NCT01175356,Phase I,Completed,"[{'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 2590, 'therapyName': 'Cyclophosphamide + Topotecan'}, {'id': 1425, 'therapyName': '131I-MIBG'}, {'id': 2353, 'therapyName': 'Cyclophosphamide + Doxorubicin + Vincristine '}, {'id': 2585, 'therapyName': 'Cisplatin + Etoposide'}]","Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin",4163
1,NCT02559778,Phase I,Recruiting,"[{'id': 688, 'therapyName': 'Bortezomib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 2629, 'therapyName': 'Eflornithine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 717, 'therapyName': 'Dasatinib'}]",Pediatric Precision Laboratory Advanced Neuroblastoma Therapy,4163
0,NCT01999270,Phase I,Completed,"[{'id': 2112, 'therapyName': 'Bevacizumab + Irinotecan'}]",Evaluation of FDOPA-PET/MRI in Pediatric Patients With CNS Tumors,4817
0,NCT00780494,Phase II,Unknown status,"[{'id': 2096, 'therapyName': 'Bevacizumab + Capecitabine + Carboplatin'}]","Ph II of Capecitabine, Carboplatin and Bevacizumab for Gastroesophageal Junction and Gastric Carcinoma",3717
1,NCT01191697,Phase II,"Active, not recruiting","[{'id': 1596, 'therapyName': 'Trastuzumab + Bevacizumab'}, {'id': 1597, 'therapyName': 'Capecitabine + Oxaliplatin'}]","CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer",3717
2,NCT01450696,Phase III,Terminated,"[{'id': 1899, 'therapyName': 'Capecitabine + Cisplatin + Trastuzumab'}]",HELOISE Study: A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer,3717
3,NCT01526473,Phase I,"Active, not recruiting","[{'id': 1068, 'therapyName': 'AVX901'}]",A Phase I Study To Evaluate The Antitumor Activity And Safety Of AVX901,3717
4,NCT01662869,Phase III,Completed,"[{'id': 838, 'therapyName': 'Onartuzumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric),3717
5,NCT01747551,Phase II,"Active, not recruiting","[{'id': 624, 'therapyName': 'Aflibercept'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer,3717
6,NCT01774786,Phase III,"Active, not recruiting","[{'id': 856, 'therapyName': 'Pertuzumab'}, {'id': 1894, 'therapyName': 'Capecitabine + Fluorouracil + Cisplatin + Trastuzumab'}]",A Study of Perjeta (Pertuzumab) in Combination With Herceptin (Trastuzumab) and Chemotherapy in Patients With HER2-Positive Metastatic Gastroesophageal Junction or Gastric Cancer,3717
7,NCT01774851,Phase II,Terminated,"[{'id': 1892, 'therapyName': 'Paclitaxel + Trastuzumab + MM-111'}, {'id': 1551, 'therapyName': 'Trastuzumab + Paclitaxel'}]","A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach",3717
8,NCT01803282,Phase I,Recruiting,"[{'id': 3320, 'therapyName': 'GS-5745'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Safety and Tolerability Study in Solid Tumors,3717
9,NCT01896531,Phase II,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 747, 'therapyName': 'Ipatasertib'}]",A Study of GDC-0068 in Combination With Fluoropyrimidine Plus Oxaliplatin in Patients With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer,3717
10,NCT01913639,Phase II,"Active, not recruiting","[{'id': 2014, 'therapyName': 'Regorafenib + FOLFOX'}]",FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer,3717
11,NCT02016534,Phase II,Terminated,"[{'id': 1064, 'therapyName': 'AMG 337'}]",Phase 2 Study of AMG 337 in MET Amplified Gastric/Esophageal Adenocarcinoma or Other Solid Tumors,3717
12,NCT02024607,Phase Ib/II,"Active, not recruiting","[{'id': 1597, 'therapyName': 'Capecitabine + Oxaliplatin'}, {'id': 2093, 'therapyName': 'BBI608 + Bevacizumab'}, {'id': 2094, 'therapyName': 'BBI608 + Regorafenib'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 2057, 'therapyName': 'BBI608'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer,3717
13,NCT02065765,Phase II,No longer available,"[{'id': 886, 'therapyName': 'Ramucirumab'}]",International Expanded Access Program to Provide Ramucirumab for the Treatment of Metastatic Gastric Cancer,3717
14,NCT02082210,Phase Ib/II,"Active, not recruiting","[{'id': 1387, 'therapyName': 'Emibetuzumab + Ramucirumab'}]",A Study of LY2875358 in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer,3717
15,NCT02178956,Phase III,"Active, not recruiting","[{'id': 2057, 'therapyName': 'BBI608'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer,3717
16,NCT02213289,Phase Ib/II,Recruiting,"[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1913, 'therapyName': 'FOLTAX'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 629, 'therapyName': 'AMG102'}]",PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression,3717
17,NCT02234596,Phase II,"Active, not recruiting","[{'id': 831, 'therapyName': 'Nintedanib'}]",Nintedanib in Patients With Advanced Esophagogastric Cancer,3717
18,NCT02241720,Phase II,Terminated,"[{'id': 890, 'therapyName': 'Regorafenib'}]",Regorafenib Second Line Treatment of Metastatic or Advanced Upper GI Cancers,3717
19,NCT02264678,Phase Ib/II,Recruiting,"[{'id': 2881, 'therapyName': 'AZD6738'}, {'id': 4737, 'therapyName': 'AZD6738 + Carboplatin'}, {'id': 4738, 'therapyName': 'AZD6738 + MEDI4736'}, {'id': 4739, 'therapyName': 'AZD6738 + Olaparib'}]",Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents,3717
20,NCT02283359,Phase I,Terminated,"[{'id': 2588, 'therapyName': 'Irinotecan + Selinexor'}]",Selinexor in Combination With Irinotecan in Adenocarcinoma of Stomach and Distal Esophagus,3717
21,NCT02317991,Phase II,Recruiting,"[{'id': 2039, 'therapyName': 'Abraxane + Ramucirumab'}]",Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer,3717
22,NCT02335411,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1833, 'therapyName': 'Cisplatin + Fluorouracil'}]",A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059),3717
23,NCT02340975,Phase Ib/II,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]","A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma",3717
24,NCT02443324,Phase I,"Active, not recruiting","[{'id': 2896, 'therapyName': 'Pembrolizumab + Ramucirumab'}]","A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC or Transitional Cell Carcinoma of the Urothelium",3717
25,NCT02494583,Phase III,"Active, not recruiting","[{'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1833, 'therapyName': 'Cisplatin + Fluorouracil'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062),3717
26,NCT02500043,Phase III,Recruiting,"[{'id': 2426, 'therapyName': 'trifluridine/tipiracil hydrochloride'}]",Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer,3717
27,NCT02514551,Phase II,"Active, not recruiting","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 886, 'therapyName': 'Ramucirumab'}]",A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer,3717
28,NCT02545504,Phase III,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 3320, 'therapyName': 'GS-5745'}]",GS-5745 With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma,3717
29,NCT02551055,Phase I,Terminated,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 626, 'therapyName': 'Alisertib'}, {'id': 3146, 'therapyName': 'TAK-659'}, {'id': 1033, 'therapyName': 'MLN1117'}]","MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal Adenocarcinoma",3717
30,NCT02563548,Phase I,Recruiting,"[{'id': 5779, 'therapyName': 'PEGPH20 + Pembrolizumab'}]",Phase 1b Open-Label Study of PEGPH20 With Pembrolizumab,3717
31,NCT02564900,Phase I,Recruiting,"[{'id': 4844, 'therapyName': 'DS-8201a'}]",Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors,3717
32,NCT02572687,Phase I,Recruiting,"[{'id': 3257, 'therapyName': 'MEDI4736 + Ramucirumab'}]",A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies,3717
33,NCT02574663,Phase I,"Active, not recruiting","[{'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 2022, 'therapyName': 'TGR-1202'}]",TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors,3717
34,NCT02597036,Phase I,"Active, not recruiting","[{'id': 3562, 'therapyName': 'LY3127804 '}, {'id': 886, 'therapyName': 'Ramucirumab'}]",A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors,3717
35,NCT02599324,Phase Ib/II,Recruiting,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 694, 'therapyName': 'Cetuximab'}]",A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors,3717
36,NCT02625610,Phase III,Recruiting,"[{'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 3144, 'therapyName': 'Avelumab'}, {'id': 1597, 'therapyName': 'Capecitabine + Oxaliplatin'}]",Avelumab in First-Line Gastric Cancer (JAVELIN Gastric 100),3717
37,NCT02625623,Phase III,"Active, not recruiting","[{'id': 3144, 'therapyName': 'Avelumab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1074, 'therapyName': 'Irinotecan'}]",Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300),3717
38,NCT02638909,Phase II,Recruiting,"[{'id': 789, 'therapyName': 'Ceritinib'}]",Study of Oral Ceritinib in Patients With ALK-Activated Gastrointestinal Malignancies,3717
39,NCT02689284,Phase Ib/II,Recruiting,"[{'id': 3728, 'therapyName': 'MGAH22 + Pembrolizumab'}]","Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer",3717
40,NCT02715531,Phase I,Recruiting,"[{'id': 3947, 'therapyName': 'Atezolizumab + Gemcitabine + nab-paclitaxel'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1202, 'therapyName': 'Atezolizumab + Bevacizumab + Capecitabine'}]",A Study of the Safety and Tolerability of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors,3717
41,NCT02864381,Phase II,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 4736, 'therapyName': 'GS-5745 + Nivolumab'}]",GS-5745 Combined With Nivolumab Versus Nivolumab Alone in Adults With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma,3717
42,NCT02918162,Phase II,Recruiting,"[{'id': 4776, 'therapyName': 'Capecitabine + Epirubicin + Oxaliplatin + Pembrolizumab'}]",Perioperative Chemo and Pembrolizumab in Gastric Cancer,3717
43,NCT02943603,Phase II,Withdrawn,"[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",A Study of Perioperative mFOLFOX6 Plus Pembrolizumab in Patients With Potentially Resectable Adenocarcinoma of the Gastroesophageal Junction (GEJ) and Stomach,3717
44,NCT02954536,Phase II,Recruiting,"[{'id': 4945, 'therapyName': 'Capecitabine + Cisplatin + Pembrolizumab + Trastuzumab'}]",Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer,3717
45,NCT03042611,Phase III,Recruiting,"[{'id': 986, 'therapyName': 'Apatinib'}]",Efficacy and Safety Trial of Apatinib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Patients With Gastric Cancer,3717
46,NCT03064490,Phase II,Recruiting,"[{'id': 2103, 'therapyName': 'Carboplatin + Paclitaxel + Pembrolizumab'}]","Pembrolizumab, Radiotherapy, and Chemotherapy in Neoadjuvant Treatment of Malignant Esophago-gastric Diseases (PROCEED)",3717
47,NCT03095781,Phase I,Recruiting,"[{'id': 5533, 'therapyName': 'Pembrolizumab + XL888'}]",Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer,3717
48,NCT03122548,Phase II,Recruiting,"[{'id': 5716, 'therapyName': 'CRS-207 + Pembrolizumab'}]","Safety and Efficacy of CRS-207 With Pembrolizumab in Gastric, Gastroesophageal Junction or Esophageal Cancers",3717
49,NCT03141034,Phase II,Not yet recruiting,"[{'id': 5633, 'therapyName': 'Irinotecan + Ramucirumab'}]",Ramucirumab Plus Irinotecan for Previously Treated Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma,3717
50,NCT03193918,Phase I,Recruiting,"[{'id': 5943, 'therapyName': 'Crenolanib + Paclitaxel + Ramucirumab'}]",Study of Crenolanib With Ramucirumab and Paclitaxel for Advanced Esophagogastric Adenocarcinoma,3717
51,NCT03196232,Phase II,Recruiting,"[{'id': 4088, 'therapyName': 'Epacadostat + Pembrolizumab'}]",Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer,3717
52,NCT03221400,Phase Ib/II,Recruiting,"[{'id': 4842, 'therapyName': 'STA-8666'}]",PEN-866 in Patients With Advanced Solid Malignancies,3717
53,NCT03221426,Phase III,Recruiting,"[{'id': 3999, 'therapyName': 'Capecitabine + Cisplatin'}, {'id': 6050, 'therapyName': 'Capecitabine + Cisplatin + Pembrolizumab'}, {'id': 6051, 'therapyName': 'Cisplatin + Fluorouracil + Pembrolizumab'}, {'id': 1833, 'therapyName': 'Cisplatin + Fluorouracil'}]",Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585),3717
54,NCT03257163,Phase II,Recruiting,"[{'id': 4022, 'therapyName': 'Capecitabine + Pembrolizumab'}]","Pembrolizumab, Capecitabine, and Radiation Therapy in Treating Patients With Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer",3717
55,NCT03281369,Phase Ib/II,Not yet recruiting,"[{'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}, {'id': 6274, 'therapyName': 'mFOLFOX-6 + Atezolizumab + Cobimetinib'}, {'id': 6275, 'therapyName': 'mFOLFOX-6 + Atezolizumab'}, {'id': 6276, 'therapyName': 'Atezolizumab + Linagliptin'}, {'id': 5941, 'therapyName': 'Atezolizumab + PEGPH20'}, {'id': 5942, 'therapyName': 'Atezolizumab + BKT140'}, {'id': 1721, 'therapyName': 'Ramucirumab + Paclitaxel'}, {'id': 5850, 'therapyName': 'mFOLFOX-6'}]",A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) (UMBRELLA),3717
0,NCT02730546,Phase Ib/II,Suspended,"[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]","Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery",6271
0,NCT01212822,Phase II,"Active, not recruiting","[{'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}]",Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer,6270
0,NCT02834013,Phase 0,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab in Treating Patients With Rare Tumors,4715
0,NCT03150810,Phase Ib/II,Recruiting,"[{'id': 6124, 'therapyName': 'BGB-290 + Temozolomide'}]","Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Subjects With Locally Advanced or Metastatic Solid Tumors",6552
0,NCT02834013,Phase 0,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab in Treating Patients With Rare Tumors,5516
0,NCT02831179,Phase I,Withdrawn,"[{'id': 4463, 'therapyName': 'Capecitabine + Veliparib + Temozolomide'}]","Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor",5577
0,NCT00702884,Phase II,Completed,"[{'id': 930, 'therapyName': 'Sunitinib'}]",Sunitinib in Treating Patients With Relapsed or Refractory Esophageal or Gastroesophageal Junction Cancer,4944
1,NCT00780494,Phase II,Unknown status,"[{'id': 2096, 'therapyName': 'Bevacizumab + Capecitabine + Carboplatin'}]","Ph II of Capecitabine, Carboplatin and Bevacizumab for Gastroesophageal Junction and Gastric Carcinoma",4944
2,NCT01174121,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 1167, 'therapyName': 'Aldesleukin'}]",Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer,4944
3,NCT01183559,Phase I,Unknown status,"[{'id': 2071, 'therapyName': 'Carboplatin + Fluorouracil + Paclitaxel + Vandetanib'}]","A Trial of ZD6474 (Zactima), Paclitaxel, Carboplatin, 5-Fluorouracil, and XRT Followed by Surgery",4944
4,NCT01191697,Phase II,"Active, not recruiting","[{'id': 1596, 'therapyName': 'Trastuzumab + Bevacizumab'}, {'id': 1597, 'therapyName': 'Capecitabine + Oxaliplatin'}]","CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer",4944
5,NCT01196390,Phase III,"Active, not recruiting","[{'id': 1887, 'therapyName': 'Paclitaxel + Carboplatin + Trastuzumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]","Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer",4944
6,NCT01212822,Phase II,"Active, not recruiting","[{'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}]",Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer,4944
7,NCT01307956,Phase II,Unknown status,"[{'id': 1986, 'therapyName': 'Panitumumab + FOLFOX'}]","Panitumumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Advanced Esophageal or Gastroesophageal Junction Cancer",4944
8,NCT01325441,Phase Ib/II,Recruiting,"[{'id': 2586, 'therapyName': 'BBI608 + Paclitaxel'}]",A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies,4944
9,NCT01450696,Phase III,Terminated,"[{'id': 1899, 'therapyName': 'Capecitabine + Cisplatin + Trastuzumab'}]",HELOISE Study: A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer,4944
10,NCT01490749,Phase I,"Active, not recruiting","[{'id': 1924, 'therapyName': 'Everolimus + Paclitaxel + Carboplatin + Cetuximab'}]",Trial of XELOX Followed by Radiation Combined With Carboplatin and RAD001 for Esophageal Cancer,4944
11,NCT01526473,Phase I,"Active, not recruiting","[{'id': 1068, 'therapyName': 'AVX901'}]",A Phase I Study To Evaluate The Antitumor Activity And Safety Of AVX901,4944
12,NCT01576666,Phase Ib/II,Completed,"[{'id': 1547, 'therapyName': 'BKM120 + Sonidegib'}]","Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors",4944
13,NCT01641939,Phase III,Terminated,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1402, 'therapyName': 'trastuzumab emtansine'}]",A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer,4944
14,NCT01662869,Phase III,Completed,"[{'id': 838, 'therapyName': 'Onartuzumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric),4944
15,NCT01747551,Phase II,"Active, not recruiting","[{'id': 624, 'therapyName': 'Aflibercept'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer,4944
16,NCT01774786,Phase III,"Active, not recruiting","[{'id': 856, 'therapyName': 'Pertuzumab'}, {'id': 1894, 'therapyName': 'Capecitabine + Fluorouracil + Cisplatin + Trastuzumab'}]",A Study of Perjeta (Pertuzumab) in Combination With Herceptin (Trastuzumab) and Chemotherapy in Patients With HER2-Positive Metastatic Gastroesophageal Junction or Gastric Cancer,4944
17,NCT01774851,Phase II,Terminated,"[{'id': 1892, 'therapyName': 'Paclitaxel + Trastuzumab + MM-111'}, {'id': 1551, 'therapyName': 'Trastuzumab + Paclitaxel'}]","A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach",4944
18,NCT01803282,Phase I,Recruiting,"[{'id': 3320, 'therapyName': 'GS-5745'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Safety and Tolerability Study in Solid Tumors,4944
19,NCT01896531,Phase II,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 747, 'therapyName': 'Ipatasertib'}]",A Study of GDC-0068 in Combination With Fluoropyrimidine Plus Oxaliplatin in Patients With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer,4944
20,NCT01913639,Phase II,"Active, not recruiting","[{'id': 2014, 'therapyName': 'Regorafenib + FOLFOX'}]",FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer,4944
21,NCT01920061,Phase I,Recruiting,"[{'id': 1287, 'therapyName': 'PF-05212384 + Dacomitinib'}, {'id': 1286, 'therapyName': 'PF-05212384 + Cisplatin'}, {'id': 1285, 'therapyName': 'PF-05212384 + Docetaxel'}]",A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents,4944
22,NCT01928290,Phase II,Recruiting,"[{'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1903, 'therapyName': 'FOLFIRINOX'}]","Combination Chemotherapy in Treating Patients With Advanced Stomach, Gastroesophageal, or Esophageal Cancer",4944
23,NCT02013154,Phase I,Recruiting,"[{'id': 6254, 'therapyName': 'DKN-01 + Paclitaxel'}]",A Study of DKN-01 in Combination With Paclitaxel,4944
24,NCT02016534,Phase II,Terminated,"[{'id': 1064, 'therapyName': 'AMG 337'}]",Phase 2 Study of AMG 337 in MET Amplified Gastric/Esophageal Adenocarcinoma or Other Solid Tumors,4944
25,NCT02024607,Phase Ib/II,"Active, not recruiting","[{'id': 1597, 'therapyName': 'Capecitabine + Oxaliplatin'}, {'id': 2093, 'therapyName': 'BBI608 + Bevacizumab'}, {'id': 2094, 'therapyName': 'BBI608 + Regorafenib'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 2057, 'therapyName': 'BBI608'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer,4944
26,NCT02065765,Phase II,No longer available,"[{'id': 886, 'therapyName': 'Ramucirumab'}]",International Expanded Access Program to Provide Ramucirumab for the Treatment of Metastatic Gastric Cancer,4944
27,NCT02082210,Phase Ib/II,"Active, not recruiting","[{'id': 1387, 'therapyName': 'Emibetuzumab + Ramucirumab'}]",A Study of LY2875358 in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer,4944
28,NCT02138929,Phase I,"Active, not recruiting","[{'id': 1871, 'therapyName': 'Everolimus + Sonidegib'}]",LDE225 + Everolimus in Advanced Gastroesophageal Adenocarcinoma,4944
29,NCT02178956,Phase III,"Active, not recruiting","[{'id': 2057, 'therapyName': 'BBI608'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer,4944
30,NCT02213289,Phase Ib/II,Recruiting,"[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1913, 'therapyName': 'FOLTAX'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 629, 'therapyName': 'AMG102'}]",PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression,4944
31,NCT02234180,Phase II,Completed,"[{'id': 890, 'therapyName': 'Regorafenib'}]",Study of Adjuvant Regorafenib vs Placebo in Patients With Node Positive Esophageal Cancer That Completed Pre-operative Therapy,4944
32,NCT02234596,Phase II,"Active, not recruiting","[{'id': 831, 'therapyName': 'Nintedanib'}]",Nintedanib in Patients With Advanced Esophagogastric Cancer,4944
33,NCT02241720,Phase II,Terminated,"[{'id': 890, 'therapyName': 'Regorafenib'}]",Regorafenib Second Line Treatment of Metastatic or Advanced Upper GI Cancers,4944
34,NCT02264678,Phase Ib/II,Recruiting,"[{'id': 2881, 'therapyName': 'AZD6738'}, {'id': 4737, 'therapyName': 'AZD6738 + Carboplatin'}, {'id': 4738, 'therapyName': 'AZD6738 + MEDI4736'}, {'id': 4739, 'therapyName': 'AZD6738 + Olaparib'}]",Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents,4944
35,NCT02268825,Phase Ib/II,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Phase I/IIA Study MK-3475 With Chemotherapy in Patients With Advanced GI Cancers,4944
36,NCT02274012,Phase II,Withdrawn,"[{'id': 2441, 'therapyName': 'Afatinib + Paclitaxel'}]","Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line Treatment of HER2 Amplified Advanced Gastric, Gastroesophageal Junction and Esophageal Cancer",4944
37,NCT02283359,Phase I,Terminated,"[{'id': 2588, 'therapyName': 'Irinotecan + Selinexor'}]",Selinexor in Combination With Irinotecan in Adenocarcinoma of Stomach and Distal Esophagus,4944
38,NCT02314117,Phase III,"Active, not recruiting","[{'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 886, 'therapyName': 'Ramucirumab'}]",A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer,4944
39,NCT02317991,Phase II,Recruiting,"[{'id': 2039, 'therapyName': 'Abraxane + Ramucirumab'}]",Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer,4944
40,NCT02318901,Phase Ib/II,"Active, not recruiting","[{'id': 1909, 'therapyName': 'Pembrolizumab + trastuzumab emtansine'}, {'id': 1908, 'therapyName': 'Pembrolizumab + Trastuzumab'}, {'id': 1910, 'therapyName': 'Pembrolizumab + Cetuximab'}]",Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer,4944
41,NCT02335411,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1833, 'therapyName': 'Cisplatin + Fluorouracil'}]",A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059),4944
42,NCT02340975,Phase Ib/II,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]","A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma",4944
43,NCT02344810,Phase Ib/II,Withdrawn,"[{'id': 1064, 'therapyName': 'AMG 337'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]","C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer",4944
44,NCT02358863,Phase I,Terminated,"[{'id': 4311, 'therapyName': 'Docetaxel + Irinotecan'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1835, 'therapyName': 'Docetaxel + Cisplatin'}, {'id': 1406, 'therapyName': 'Camptosar + Cisplatin'}, {'id': 4310, 'therapyName': 'Epirubicin + Docetaxel'}, {'id': 4309, 'therapyName': 'Capecitabine + Docetaxel'}]",Molecularly Tailored Therapy for Patients With Metastatic Cancer of the Esophagus and Stomach (mEGA),4944
45,NCT02389751,Phase I,"Active, not recruiting","[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 745, 'therapyName': 'Ganetespib'}]",A Study of Ganetespib in Combination With Chemoradiation,4944
46,NCT02443324,Phase I,"Active, not recruiting","[{'id': 2896, 'therapyName': 'Pembrolizumab + Ramucirumab'}]","A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC or Transitional Cell Carcinoma of the Urothelium",4944
47,NCT02443883,Phase II,"Active, not recruiting","[{'id': 886, 'therapyName': 'Ramucirumab'}]",A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer,4944
48,NCT02460224,Phase Ib/II,Recruiting,"[{'id': 2887, 'therapyName': 'LAG525'}, {'id': 2659, 'therapyName': 'PDR001'}]",Safety and Efficay of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies,4944
49,NCT02488759,Phase Ib/II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",A Study to Investigate the Safety and Efficacy of Nivolumab in Virus-associated Tumors (CheckMate358),4944
50,NCT02494583,Phase III,"Active, not recruiting","[{'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1833, 'therapyName': 'Cisplatin + Fluorouracil'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062),4944
51,NCT02500043,Phase III,Recruiting,"[{'id': 2426, 'therapyName': 'trifluridine/tipiracil hydrochloride'}]",Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer,4944
52,NCT02514551,Phase II,"Active, not recruiting","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 886, 'therapyName': 'Ramucirumab'}]",A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer,4944
53,NCT02530437,Phase Ib/II,Recruiting,"[{'id': 1587, 'therapyName': 'Taladegib'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]","A Phase 1B/2 Study of LY2940680 in Combination With Weekly Paclitaxel, Carboplatin, and Radiation in Localized Adenocarcinoma of the Esophagus or Gastroesophageal Junction",4944
54,NCT02545504,Phase III,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 3320, 'therapyName': 'GS-5745'}]",GS-5745 With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma,4944
55,NCT02551055,Phase I,Terminated,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 626, 'therapyName': 'Alisertib'}, {'id': 3146, 'therapyName': 'TAK-659'}, {'id': 1033, 'therapyName': 'MLN1117'}]","MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal Adenocarcinoma",4944
56,NCT02559687,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) in Previously-Treated Participants With Advanced Carcinoma of the Esophagus or Esophagogastric Junction (MK-3475-180/KEYNOTE-180),4944
57,NCT02564263,Phase III,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2282, 'therapyName': 'Docetaxel + Irinotecan + Paclitaxel'}]",Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181),4944
58,NCT02564900,Phase I,Recruiting,"[{'id': 4844, 'therapyName': 'DS-8201a'}]",Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors,4944
59,NCT02572687,Phase I,Recruiting,"[{'id': 3257, 'therapyName': 'MEDI4736 + Ramucirumab'}]",A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies,4944
60,NCT02574663,Phase I,"Active, not recruiting","[{'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 2022, 'therapyName': 'TGR-1202'}]",TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors,4944
61,NCT02597036,Phase I,"Active, not recruiting","[{'id': 3562, 'therapyName': 'LY3127804 '}, {'id': 886, 'therapyName': 'Ramucirumab'}]",A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors,4944
62,NCT02599324,Phase Ib/II,Recruiting,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 694, 'therapyName': 'Cetuximab'}]",A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors,4944
63,NCT02625610,Phase III,Recruiting,"[{'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 3144, 'therapyName': 'Avelumab'}, {'id': 1597, 'therapyName': 'Capecitabine + Oxaliplatin'}]",Avelumab in First-Line Gastric Cancer (JAVELIN Gastric 100),4944
64,NCT02625623,Phase III,"Active, not recruiting","[{'id': 3144, 'therapyName': 'Avelumab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1074, 'therapyName': 'Irinotecan'}]",Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300),4944
65,NCT02658214,Phase I,Recruiting,"[{'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}, {'id': 2634, 'therapyName': 'Carboplatin + nab-paclitaxel'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}]",Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors,4944
66,NCT02689284,Phase Ib/II,Recruiting,"[{'id': 3728, 'therapyName': 'MGAH22 + Pembrolizumab'}]","Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer",4944
67,NCT02715531,Phase I,Recruiting,"[{'id': 3947, 'therapyName': 'Atezolizumab + Gemcitabine + nab-paclitaxel'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1202, 'therapyName': 'Atezolizumab + Bevacizumab + Capecitabine'}]",A Study of the Safety and Tolerability of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors,4944
68,NCT02726399,Phase II,Recruiting,"[{'id': 3999, 'therapyName': 'Capecitabine + Cisplatin'}, {'id': 3998, 'therapyName': 'Ramucirumab + Trastuzumab'}]",Ramucirumab With Trastuzumab and Capecitabine/Cisplatin in Patients With Metastatic HER2-Positive Gastroesophageal Junction and Gastric Cancer,4944
69,NCT02730546,Phase Ib/II,Suspended,"[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]","Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery",4944
70,NCT02743494,Phase III,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Study of Adjuvant Nivolumab or Placebo in Subjects With Resected Esophageal or Gastroesophageal Junction Cancer (CheckMate 577),4944
71,NCT02749513,Phase I,Recruiting,"[{'id': 1026, 'therapyName': 'Itraconazole'}]",Itraconazole as a Targeted Therapy for Inhibiting Hedgehog Pathway Signaling in Esophageal Cancer Patients,4944
72,NCT02795156,Phase II,Recruiting,"[{'id': 623, 'therapyName': 'Afatinib'}, {'id': 890, 'therapyName': 'Regorafenib'}]",Study to Assess the Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations,4944
73,NCT02830594,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer",4944
74,NCT02864381,Phase II,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 4736, 'therapyName': 'GS-5745 + Nivolumab'}]",GS-5745 Combined With Nivolumab Versus Nivolumab Alone in Adults With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma,4944
75,NCT02872116,Phase III,Recruiting,"[{'id': 1597, 'therapyName': 'Capecitabine + Oxaliplatin'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Efficacy Study of Nivolumab Plus Ipilimumab Against Chemotherapy Standard of Care in Stomach Cancer or Stomach/Esophagus Junction Cancer (CheckMate649),4944
76,NCT02892123,Phase I,Recruiting,"[{'id': 6240, 'therapyName': 'ZW25'}]",Trial of ZW25 in Patients With Advanced HER2-expressing Cancers,4944
77,NCT02918162,Phase II,Recruiting,"[{'id': 4776, 'therapyName': 'Capecitabine + Epirubicin + Oxaliplatin + Pembrolizumab'}]",Perioperative Chemo and Pembrolizumab in Gastric Cancer,4944
78,NCT02943603,Phase II,Withdrawn,"[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",A Study of Perioperative mFOLFOX6 Plus Pembrolizumab in Patients With Potentially Resectable Adenocarcinoma of the Gastroesophageal Junction (GEJ) and Stomach,4944
79,NCT02954536,Phase II,Recruiting,"[{'id': 4945, 'therapyName': 'Capecitabine + Cisplatin + Pembrolizumab + Trastuzumab'}]",Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer,4944
80,NCT02962063,Phase Ib/II,Recruiting,"[{'id': 3997, 'therapyName': 'Carboplatin + Durvalumab + Paclitaxel'}]","Durvalumab, an Anti-PD-L1 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer",4944
81,NCT02970539,Phase I,Recruiting,"[{'id': 5032, 'therapyName': 'Oraxol + Ramucirumab'}]","Ph1b Study of Oraxol in Comb. w. Ramucirumab in Patients w. Gastric, Gastro-esophageal, or Esophageal Cancers",4944
82,NCT02998268,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Study of Pembrolizumab in Locally Advanced Esophageal Adenocarcinoma,4944
83,NCT03008278,Phase Ib/II,Not yet recruiting,"[{'id': 5165, 'therapyName': 'Olaparib + Ramucirumab'}]",Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery,4944
84,NCT03042611,Phase III,Recruiting,"[{'id': 986, 'therapyName': 'Apatinib'}]",Efficacy and Safety Trial of Apatinib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Patients With Gastric Cancer,4944
85,NCT03044613,Phase I,Recruiting,"[{'id': 5304, 'therapyName': 'Nivolumab + Ipilimumab + Carboplatin + Paclitaxel'}, {'id': 5303, 'therapyName': 'Nivolumab + Carboplatin + Paclitaxel'}]",Nivolumab or Nivolumab/Ipilimumab Prior to Chemoradiation Plus Nivolumab With II/III Gastro/Esophageal Cancer,4944
86,NCT03064490,Phase II,Recruiting,"[{'id': 2103, 'therapyName': 'Carboplatin + Paclitaxel + Pembrolizumab'}]","Pembrolizumab, Radiotherapy, and Chemotherapy in Neoadjuvant Treatment of Malignant Esophago-gastric Diseases (PROCEED)",4944
87,NCT03076372,Phase I,Recruiting,"[{'id': 5758, 'therapyName': 'MM-310'}]",A Study Evaluating MM-310 in Patients With Solid Tumors,4944
88,NCT03095781,Phase I,Recruiting,"[{'id': 5533, 'therapyName': 'Pembrolizumab + XL888'}]",Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer,4944
89,NCT03122548,Phase II,Recruiting,"[{'id': 5716, 'therapyName': 'CRS-207 + Pembrolizumab'}]","Safety and Efficacy of CRS-207 With Pembrolizumab in Gastric, Gastroesophageal Junction or Esophageal Cancers",4944
90,NCT03126110,Phase Ib/II,Recruiting,"[{'id': 5599, 'therapyName': 'INCAGN01876 + Nivolumab + Ipilimumab'}, {'id': 5598, 'therapyName': 'INCAGN01876 + Nivolumab'}, {'id': 5597, 'therapyName': 'INCAGN01876 + Ipilimumab'}]","Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies",4944
91,NCT03141034,Phase II,Not yet recruiting,"[{'id': 5633, 'therapyName': 'Irinotecan + Ramucirumab'}]",Ramucirumab Plus Irinotecan for Previously Treated Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma,4944
92,NCT03165994,Phase II,Recruiting,"[{'id': 5797, 'therapyName': 'APX005M + Paclitaxel + Carboplatin'}]",APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers,4944
93,NCT03175224,Phase I,Recruiting,"[{'id': 5963, 'therapyName': 'CBT-101'}]",CBT-101 Study for Advanced Solid Tumors and c-Met Dysregulation,4944
94,NCT03189719,Phase III,Recruiting,"[{'id': 1833, 'therapyName': 'Cisplatin + Fluorouracil'}, {'id': 6051, 'therapyName': 'Cisplatin + Fluorouracil + Pembrolizumab'}]",First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590),4944
95,NCT03193918,Phase I,Recruiting,"[{'id': 5943, 'therapyName': 'Crenolanib + Paclitaxel + Ramucirumab'}]",Study of Crenolanib With Ramucirumab and Paclitaxel for Advanced Esophagogastric Adenocarcinoma,4944
96,NCT03196232,Phase II,Recruiting,"[{'id': 4088, 'therapyName': 'Epacadostat + Pembrolizumab'}]",Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer,4944
97,NCT03221426,Phase III,Recruiting,"[{'id': 3999, 'therapyName': 'Capecitabine + Cisplatin'}, {'id': 6050, 'therapyName': 'Capecitabine + Cisplatin + Pembrolizumab'}, {'id': 6051, 'therapyName': 'Cisplatin + Fluorouracil + Pembrolizumab'}, {'id': 1833, 'therapyName': 'Cisplatin + Fluorouracil'}]",Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585),4944
98,NCT03281369,Phase Ib/II,Not yet recruiting,"[{'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}, {'id': 6274, 'therapyName': 'mFOLFOX-6 + Atezolizumab + Cobimetinib'}, {'id': 6275, 'therapyName': 'mFOLFOX-6 + Atezolizumab'}, {'id': 6276, 'therapyName': 'Atezolizumab + Linagliptin'}, {'id': 5941, 'therapyName': 'Atezolizumab + PEGPH20'}, {'id': 5942, 'therapyName': 'Atezolizumab + BKT140'}, {'id': 1721, 'therapyName': 'Ramucirumab + Paclitaxel'}, {'id': 5850, 'therapyName': 'mFOLFOX-6'}]",A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) (UMBRELLA),4944
99,NCT03288350,Phase II,Not yet recruiting,"[{'id': 1930, 'therapyName': 'Cisplatin + Docetaxel + Fluorouracil'}, {'id': 3144, 'therapyName': 'Avelumab'}]",mDCF + Avelumab in Resectable Esophago-gastric Adenocarcinoma (EGA),4944
0,NCT02250885,Phase II,Completed,"[{'id': 1749, 'therapyName': 'Selinexor'}]",KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors,50626
1,NCT02315625,Phase II,Recruiting,"[{'id': 735, 'therapyName': 'Everolimus'}, {'id': 930, 'therapyName': 'Sunitinib'}]",Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery,50626
2,NCT02834013,Phase 0,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab in Treating Patients With Rare Tumors,50626
3,NCT02955069,Phase II,Recruiting,"[{'id': 2659, 'therapyName': 'PDR001'}]","Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin",50626
4,NCT02963831,Phase Ib/II,Recruiting,"[{'id': 4978, 'therapyName': 'ONCOS-102 + MEDI4736'}]","A Phase 1/2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies",50626
5,NCT03043664,Phase Ib/II,Recruiting,"[{'id': 6129, 'therapyName': 'Lanreotide Depot + Pembrolizumab'}]",Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors (PLANET),50626
6,NCT03278379,Phase II,Not yet recruiting,"[{'id': 3144, 'therapyName': 'Avelumab'}]",Avelumab in G2-3 NET (NET-002),50626
7,NCT03278405,Phase Ib/II,Not yet recruiting,"[{'id': 3144, 'therapyName': 'Avelumab'}]",Avelumab in G3 NEC (NET-001),50626
0,NCT00290485,Phase II,Unknown status,"[{'id': 770, 'therapyName': 'Imatinib'}]",Gleevec Administered Preoperatively to Reduce Gastrointestinal Stromal Tumor (GIST),9253
1,NCT00812240,Phase III,Unknown status,"[{'id': 804, 'therapyName': 'Masitinib'}, {'id': 770, 'therapyName': 'Imatinib'}]",A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Comparison to Imatinib in Patients With Gastro-Intestinal Stromal Tumour in First Line Medical Treatment,9253
2,NCT01396148,Phase II,Completed,"[{'id': 930, 'therapyName': 'Sunitinib'}]",A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor,9253
3,NCT01643278,Phase I,Completed,"[{'id': 1803, 'therapyName': 'Dasatinib + Ipilimumab'}]",Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are Metastatic,9253
4,NCT01738139,Phase I,Recruiting,"[{'id': 1250, 'therapyName': 'Ipilimumab + Imatinib Mesylate'}]",Ipilimumab and Imatinib Mesylate in Advanced Cancer,9253
5,NCT01874665,Phase II,Completed,"[{'id': 877, 'therapyName': 'Ponatinib'}]",A Phase 2 Trial of Ponatinib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor,9253
6,NCT01991379,Phase Ib/II,Recruiting,"[{'id': 1430, 'therapyName': 'MEK162 + Imatinib mesylate'}]",MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST),9253
7,NCT02015065,Phase II,"Active, not recruiting","[{'id': 953, 'therapyName': 'Vandetanib'}]",Phase II Trial of Vandetanib in Children and Adults With Wild-Type Gastrointestinal Stromal Tumors,9253
8,NCT02034110,Phase II,Recruiting,"[{'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}]",Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers,9253
9,NCT02071862,Phase I,Recruiting,"[{'id': 1667, 'therapyName': 'CB-839'}]",Study of the Glutaminase Inhibitor CB-839 in Solid Tumors,9253
10,NCT02122809,Phase I,Completed,"[{'id': 1998, 'therapyName': 'Chiauranib'}]",Phase I Study of Chiauranib in Patients With Advanced Solid Tumors,9253
11,NCT02164240,Phase I,"Active, not recruiting","[{'id': 930, 'therapyName': 'Sunitinib'}, {'id': 890, 'therapyName': 'Regorafenib'}]",Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable GIST,9253
12,NCT02232620,Phase II,Recruiting,"[{'id': 1945, 'therapyName': 'BBI503'}]",A Study of BBI503 in Adult Patients With Advanced Gastrointestinal Stromal Tumors,9253
13,NCT02257541,Phase Ib/II,"Active, not recruiting","[{'id': 2284, 'therapyName': 'BGJ398 + Imatinib'}]",BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST),9253
14,NCT02401815,Phase Ib/II,Recruiting,"[{'id': 874, 'therapyName': 'PLX3397'}, {'id': 2602, 'therapyName': 'PLX9486'}]",A Study of PLX9486 as a Single Agent and in Combination With PLX3397 in Patients With Advanced Solid Tumors Including GIST,9253
15,NCT02508532,Phase I,Recruiting,"[{'id': 2941, 'therapyName': 'BLU-285'}]",Phase 1 Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors,9253
16,NCT02574663,Phase I,"Active, not recruiting","[{'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 2022, 'therapyName': 'TGR-1202'}]",TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors,9253
17,NCT02847429,Phase III,Recruiting,"[{'id': 705, 'therapyName': 'Crenolanib'}]",Randomized Trial of Crenolanib in Subjects With D842V Mutated GIST,9253
18,NCT02880020,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab With or Without Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumor That Is Metastatic or Cannot Be Removed by Surgery,9253
19,NCT03109301,Phase II,Recruiting,"[{'id': 913, 'therapyName': 'Selumetinib'}]",A Phase II Trial of the Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Patients With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST),9253
20,NCT03158103,Phase I,Recruiting,"[{'id': 5730, 'therapyName': 'Binimetinib + PLX3397'}]",A Study of MEK162 (Binimetinib) in Combination With Pexidartinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST),9253
21,NCT03165721,Phase II,Recruiting,"[{'id': 1949, 'therapyName': 'SGI-110'}]","A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer",9253
22,NCT03291054,Phase II,Not yet recruiting,"[{'id': 4088, 'therapyName': 'Epacadostat + Pembrolizumab'}]",Epacadostat and Pembrolizumab in Patients With GIST,9253
0,NCT01384253,Phase I,Completed,"[{'id': 1540, 'therapyName': '212Pb-TCMC-Trastuzumab + Trastuzumab '}]",Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy,3119
1,NCT01625351,Phase I,"Active, not recruiting","[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1205, 'therapyName': 'Alemtuzumab'}]",A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas,3119
2,NCT01640665,Phase I,Completed,"[{'id': 2428, 'therapyName': 'Sorafenib + Capecitabine'}]",Pilot Study of Sorafenib and Bi-weekly Capecitabine in Patients With Advanced Breast and Gastrointestinal Tumors,3119
3,NCT01916447,Phase I,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 2426, 'therapyName': 'trifluridine/tipiracil hydrochloride'}, {'id': 1074, 'therapyName': 'Irinotecan'}]",A Phase I Study of TAS-102 in Patients With Advanced Gastrointestinal Tumors.,3119
4,NCT02192541,Phase I,Completed,"[{'id': 1665, 'therapyName': 'Ganetespib + Aflibercept'}]","Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas",3119
5,NCT02319018,Phase I,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 626, 'therapyName': 'Alisertib'}]",Alisertib and Combination Chemotherapy in Treating Patients With Gastrointestinal Tumors,3119
6,NCT02344810,Phase Ib/II,Withdrawn,"[{'id': 1064, 'therapyName': 'AMG 337'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]","C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer",3119
7,NCT02417753,Phase II,Terminated,"[{'id': 2782, 'therapyName': 'AZD9150 '}]","AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant Ascites",3119
8,NCT02757391,Phase I,Not yet recruiting,"[{'id': 4193, 'therapyName': 'Aldesleukin + Cyclophosphamide + Pembrolizumab'}]",T Cell Immunotherapy Plus Anti-PD1 Antibody in Advanced Solid Malignancies,3119
0,NCT00936936,Phase II,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 2101, 'therapyName': 'Etoposide + Ifosfamide'}, {'id': 2100, 'therapyName': 'Docetaxel + Gemcitabine + Melphalan'}, {'id': 2074, 'therapyName': 'Bevacizumab + Carboplatin'}]",High-dose Chemotherapy for Poor-prognosis Relapsed Germ-Cell Tumors,2994
1,NCT00983398,Phase Ib/II,Recruiting,"[{'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2587, 'therapyName': 'Carboplatin + Melphalan'}]","Melphalan, Carboplatin, and Sodium Thiosulfate for Patients With Central Nervous System (CNS) Embryonal or Germ Cell Tumors",2994
2,NCT01037790,Phase II,Recruiting,"[{'id': 850, 'therapyName': 'Palbociclib'}]",PD 0332991 in Treating Patients With Refractory Solid Tumors,2994
3,NCT01331135,Phase I,"Active, not recruiting","[{'id': 917, 'therapyName': 'Sirolimus'}]",Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors,2994
4,NCT01625351,Phase I,"Active, not recruiting","[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1205, 'therapyName': 'Alemtuzumab'}]",A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas,2994
5,NCT01962896,Phase II,Recruiting,"[{'id': 2253, 'therapyName': 'Erlotinib + Sirolimus'}]",A Phase II Study of Sirolimus and Erlotinib in Recurrent/Refractory Germ Cell Tumors,2994
6,NCT02034110,Phase II,Recruiting,"[{'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}]",Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers,2994
7,NCT02130869,Phase I,Recruiting,"[{'id': 2378, 'therapyName': 'Bendamustine + Cytarabine + Etoposide'}, {'id': 2460, 'therapyName': 'Busulfan + Hu14.18K322A'}, {'id': 2459, 'therapyName': 'Aldesleukin + Melphalan + Sargramostim'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}]",A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas,2994
8,NCT02300987,Phase II,"Active, not recruiting","[{'id': 790, 'therapyName': 'Ribociclib'}]","A Randomized, Blinded, Placebo-controlled, Phase II Trial of LEE011 in Patients With Relapsed, Refractory, Incurable Teratoma With Recent Progression",2994
9,NCT02429466,Phase I,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1949, 'therapyName': 'SGI-110'}]",Study of the Hypomethylating Drug SGI-110 Plus Cisplatin in Relapsed Refractory Germ Cell Tumors,2994
10,NCT02454972,Phase II,Recruiting,"[{'id': 1195, 'therapyName': 'Lurbinectedin'}]",Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors,2994
11,NCT02499952,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors,2994
12,NCT02839694,Phase I,Withdrawn,"[{'id': 3567, 'therapyName': 'Decitabine + Tetrahydrouridine'}, {'id': 4592, 'therapyName': 'Decitabine + Tetrahydrouridine + Celecoxib'}]",Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in People Undergoing Pulmonary Metastasectomy,2994
13,NCT02988843,Phase II,Recruiting,"[{'id': 5144, 'therapyName': 'Bevacizumab + Brentuximab vedotin'}]",Study of Brentuximab Vedotin And Bevacizumab In Refractory CD-30 Positive Germ Cell Tumors,2994
14,NCT03158064,Phase II,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]","Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors",2994
0,NCT01535053,Phase III,"Active, not recruiting","[{'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 1639, 'therapyName': 'Methotrexate'}]",Methotrexate or Dactinomycin in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia,3590
0,NCT01730950,Phase II,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}]",Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma,3074
1,NCT02078648,Phase Ib/II,"Active, not recruiting","[{'id': 3010, 'therapyName': 'SL-701'}, {'id': 2595, 'therapyName': 'poly ICLC  '}, {'id': 667, 'therapyName': 'Bevacizumab'}]","Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme",3074
2,NCT02366728,,Recruiting,"[{'id': 5985, 'therapyName': 'Basiliximab'}, {'id': 1141, 'therapyName': 'Temozolomide'}]",DC Migration Study for Newly-Diagnosed GBM,3074
3,NCT02743078,Phase II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Optune Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma,3074
0,NCT01643850,Phase II,Recruiting,"[{'id': 2838, 'therapyName': 'MCS110'}]",MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCTTS),200
1,NCT02834013,Phase 0,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab in Treating Patients With Rare Tumors,200
0,NCT00054496,Phase II,Unknown status,"[{'id': 4, 'therapyName': 'Erlotinib'}]",Erlotinib in Treating Patients With Recurrent or Progressive Glioblastoma Multiforme,3068
1,NCT00301418,Phase Ib/II,Completed,"[{'id': 4, 'therapyName': 'Erlotinib'}]",Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma,3068
2,NCT00492687,Phase II,Unknown status,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 1456, 'therapyName': 'Tamoxifen'}]","Radiation Therapy, Temozolomide, Tamoxifen, and Carboplatin in Treating Patients With Malignant Gliomas",3068
3,NCT00669669,Phase Ib/II,"Active, not recruiting","[{'id': 2556, 'therapyName': 'O6-benzylguanine'}, {'id': 2555, 'therapyName': 'Carmustine + Filgrastim + Plerixafor + Temozolomide'}]",Dose-Intensive Chemotherapy in Combination With Chemoprotected Autologous Stem Cells in Treating Patients With Malignant Gliomas,3068
4,NCT00906516,Phase II,Unknown status,"[{'id': 2146, 'therapyName': 'Neuradiab + Bevacizumab'}]",Neuradiab Combined With Bevacizumab (Avastin) Therapy in Patients With Recurrent Glioblastoma Multiforme,3068
5,NCT00968240,Phase I,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Super-Selective Intraarterial Intracranial Infusion of Avastin (Bevacizumab),3068
6,NCT00998010,Phase II,"Active, not recruiting","[{'id': 3055, 'therapyName': 'Bortezomib + Temozolomide'}]","Bortezomib, Temozolomide, and Regional Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma",3068
7,NCT01052363,Phase I,Withdrawn,"[{'id': 2109, 'therapyName': 'Bevacizumab + Fosbretabulin'}]",OXC401-PO1s/WVU 1309 - A Pilot Study of Fosbretabulin With Bevacizumab in Recurrent High-Grade Gliomas,3068
8,NCT01067469,Phase II,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 2118, 'therapyName': 'Bevacizumab + Lomustine'}]",Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastoma Multiforme (GBM),3068
9,NCT01107522,Phase I,"Active, not recruiting","[{'id': 1142, 'therapyName': 'CTO + Temozolomide'}, {'id': 999, 'therapyName': 'Carboxyamidotriazole Orotate'}]",Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar&#174; in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar&#174; and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas,3068
10,NCT01112527,Phase II,"Active, not recruiting","[{'id': 714, 'therapyName': 'Dacomitinib'}]",PF-00299804 in Adult Patients With Relapsed/Recurrent Glioblastoma,3068
11,NCT01130077,Phase I,Recruiting,"[{'id': 2595, 'therapyName': 'poly ICLC  '}]",A Pilot Study of Glioma Associated Antigen Vaccines in Conjunction With Poly-ICLC in Pediatric Gliomas,3068
12,NCT01140568,Phase II,Recruiting,"[{'id': 829, 'therapyName': 'Nilotinib'}]",Study of Platelet Derived Growth Factor Receptor (PDGFR) in Recurrent Malignant Gliomas,3068
13,NCT01149850,Phase II,"Active, not recruiting","[{'id': 2115, 'therapyName': 'Bevacizumab + Temozolomide'}]",Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma,3068
14,NCT01177397,Phase Ib/II,Completed,"[{'id': 693, 'therapyName': 'CC-223'}]","Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma",3068
15,NCT01238237,Phase I,Completed,"[{'id': 694, 'therapyName': 'Cetuximab'}]",Super-Selective Intraarterial Cerebral Infusion of Cetuximab for the Treatment of Recurrent Glioblastoma Multiforme and Anaplastic Astrocytoma,3068
16,NCT01260506,Phase Ib/II,Unknown status,"[{'id': 2277, 'therapyName': 'Bevacizumab + VB-111'}]",Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme,3068
17,NCT01266031,Phase Ib/II,Completed,"[{'id': 2110, 'therapyName': 'Bevacizumab + Vorinostat'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma,3068
18,NCT01269424,Phase I,Suspended,"[{'id': 2972, 'therapyName': 'O6-benzylguanine + Temozolomide'}]",O6-Benzylguanine and Temozolomide With MGMTP140K Genetically Modified Blood Stem Cells in Untreated Glioblastoma,3068
19,NCT01269853,Phase Ib/II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA,3068
20,NCT01290263,Phase Ib/II,Completed,"[{'id': 1219, 'therapyName': 'Trebananib + Bevacizumab'}, {'id': 1218, 'therapyName': 'Trebananib'}]",Amgen 386 for Recurrent Glioblastoma,3068
21,NCT01331291,Phase II,Completed,"[{'id': 690, 'therapyName': 'Bosutinib'}]",Bosutinib in Adult Patients With Recurrent Glioblastoma,3068
22,NCT01331616,Phase I,Unknown status,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Optic Neuropathy in 10 Patients With Glioblastoma Receiving Bevacizumab,3068
23,NCT01339039,Phase I,Terminated,"[{'id': 2120, 'therapyName': 'Bevacizumab + Plerixafor'}]",Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma,3068
24,NCT01349660,Phase Ib/II,"Active, not recruiting","[{'id': 1178, 'therapyName': 'BKM120 + Bevacizumab'}]",Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme,3068
25,NCT01386710,Phase Ib/II,Suspended,"[{'id': 2074, 'therapyName': 'Bevacizumab + Carboplatin'}]",Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma,3068
26,NCT01421524,Phase I,Recruiting,"[{'id': 2358, 'therapyName': 'CC-122'}]","Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma",3068
27,NCT01434602,Phase Ib/II,Recruiting,"[{'id': 2299, 'therapyName': 'Everolimus + Sorafenib'}]",Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas,3068
28,NCT01435395,Phase I,Completed,"[{'id': 2122, 'therapyName': 'Bevacizumab + Bortezomib + Temozolomide'}]","Trial of Temozolomide, Bevacizumab Plus Bortezomib for Recurrent Glioblastoma Multiforme",3068
29,NCT01473901,Phase I,Completed,"[{'id': 4474, 'therapyName': 'BKM120 + Temozolomide'}]",A Phase I Dose Escalation Study of BKM120 With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma,3068
30,NCT01478178,Phase Ib/II,Completed,"[{'id': 2921, 'therapyName': 'VAL-083'}]",Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma or Progressive Secondary Brain Tumor,3068
31,NCT01478321,Phase II,"Active, not recruiting","[{'id': 2115, 'therapyName': 'Bevacizumab + Temozolomide'}]",Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas,3068
32,NCT01508117,Phase II,Terminated,"[{'id': 649, 'therapyName': 'Axitinib'}]",Phase II Axitinib (AG-013736) in Elderly Glioblastoma Multiforme (GBM) Patients,3068
33,NCT01526837,Phase I,Terminated,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Bevacizumab (Avastin) Into the Tumor Resection Cavity in Subjects With Glioblastoma Multiforme at First Recurrence,3068
34,NCT01576666,Phase Ib/II,Completed,"[{'id': 1547, 'therapyName': 'BKM120 + Sonidegib'}]","Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors",3068
35,NCT01591577,Phase II,Recruiting,"[{'id': 2440, 'therapyName': 'Lapatinib + Temozolomide'}]",Lapatinib With Temozolomide and Regional Radiation Therapy for Patients With Newly-Diagnosed Glioblastoma Multiforme,3068
36,NCT01607905,Phase I,Completed,"[{'id': 1749, 'therapyName': 'Selinexor'}]",Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced or Metastatic Solid Tumor Cancer,3068
37,NCT01621542,Phase I,Completed,"[{'id': 2893, 'therapyName': 'WT1 vaccine'}]",Clinical Study of WT2725 in Patients With Advanced Malignancies,3068
38,NCT01721577,Phase Ib/II,Unknown status,"[{'id': 2745, 'therapyName': 'AXL1717'}]",Phase I/II Trial of Safety and Anti-tumor Efficacy of AXL1717(Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas,3068
39,NCT01730950,Phase II,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}]",Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma,3068
40,NCT01753713,Phase II,"Active, not recruiting","[{'id': 721, 'therapyName': 'Dovitinib'}]",Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma,3068
41,NCT01756352,Phase II,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}]",FET-PET for Evaluation of Response of Recurrent GBM to Avastin,3068
42,NCT01788280,Phase I,Not yet recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Preliminary Assessment of [18F] Fluciclatide (GE [18F]AH111585) in Glioblastoma Multiforme Treated With Bevacizumab,3068
43,NCT01790503,Phase Ib/II,"Active, not recruiting","[{'id': 874, 'therapyName': 'PLX3397'}, {'id': 1141, 'therapyName': 'Temozolomide'}]",A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma,3068
44,NCT01800695,Phase I,Completed,"[{'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 976, 'therapyName': 'ABT-414'}]",Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Glioblastoma Multiforme,3068
45,NCT01811498,Phase Ib/II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Repeated Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Newly Diagnosed GBM,3068
46,NCT01814813,Phase II,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}]",Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery,3068
47,NCT01837862,Phase Ib/II,Recruiting,"[{'id': 2134, 'therapyName': 'Mebendazole + Vincristine + Carboplatin + Temozolomide'}, {'id': 2133, 'therapyName': 'Mebendazole + Bevacizumab + Irinotecan'}]",A Phase I/II Study of Mebendazole for the Treatment of Pediatric Gliomas,3068
48,NCT01849146,Phase I,Suspended,"[{'id': 2713, 'therapyName': 'MK-1775 + Temozolomide'}]","WEE1 Inhibitor MK-1775, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme",3068
49,NCT01860638,Phase III,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 2075, 'therapyName': 'Lomustine'}]",A Comparison of Continuous Avastin (Bevacizumab) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Patients With Glioblastoma,3068
50,NCT01870726,Phase Ib/II,Completed,"[{'id': 2461, 'therapyName': 'BKM120 + INC280'}]",Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Gliobastoma,3068
51,NCT01884740,Phase Ib/II,Recruiting,"[{'id': 1654, 'therapyName': 'Avastin + Cetuximab'}]",Phase I/II Trial Of Super-Selective Intraarterial Infusion Of Erbitux and Bevacizumab For Treatment Of Relapsed/Refractory Intracranial Glioma In Patients Under 22 Years Of Age,3068
52,NCT01891747,Phase Ib/II,"Active, not recruiting","[{'id': 2115, 'therapyName': 'Bevacizumab + Temozolomide'}]", A Phase I/II Study of High-dose L-methylfolate in Combination With Temozolomide and Bevacizumab in Recurrent High Grade Glioma,3068
53,NCT01894061,Phase II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma,3068
54,NCT01903330,Phase II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1873, 'therapyName': 'Sargramostim'}]",ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme,3068
55,NCT01904123,Phase I,Not yet recruiting,"[{'id': 2784, 'therapyName': 'WP1066'}]",A Phase I Trial of WP1066,3068
56,NCT01925573,Phase I,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",NOVOTTF-100A+ Bevacizumab+ Hypofractionated Stereotactic Irradiation Bevacizumab-Naive Recurrent Glioblastoma (GCC 1344),3068
57,NCT01931098,Phase II,Not yet recruiting,"[{'id': 1469, 'therapyName': 'Topotecan + Pazopanib'}]",Phase II Pazopanib Plus Topotecan for Recurrent Glioblastoma Multiforme (GBM),3068
58,NCT01933815,Phase Ib/II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 2274, 'therapyName': 'TPI 287'}]",Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma,3068
59,NCT01934361,Phase Ib/II,Completed,"[{'id': 2500, 'therapyName': 'BKM120 + Lomustine'}, {'id': 2501, 'therapyName': 'BKM120 + Carboplatin'}]",Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme,3068
60,NCT01954576,Phase II,Recruiting,[],NovoTTF Therapy in Treating Patients With Recurrent Glioblastoma Multiforme,3068
61,NCT01975701,Phase II,"Active, not recruiting","[{'id': 674, 'therapyName': 'BGJ398'}]",A Phase 2 Study of BGJ398 in Patients With Recurrent GBM,3068
62,NCT01977677,Phase Ib/II,"Active, not recruiting","[{'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 1756, 'therapyName': 'Plerixafor'}]",Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma,3068
63,NCT01986348,Phase II,"Active, not recruiting","[{'id': 1749, 'therapyName': 'Selinexor'}]",Phase 2 Study of Selinexor (KPT-330) in Patients With Recurrent Glioblastoma After Failure of Radiation and Temozolomide,3068
64,NCT01989052,Phase Ib/II,Terminated,"[{'id': 2075, 'therapyName': 'Lomustine'}, {'id': 999, 'therapyName': 'Carboxyamidotriazole Orotate'}]",Ph 1/2 CTO With Lomustine for Bevacizumab-Naive Recurrent Glioma,3068
65,NCT01999270,Phase I,Completed,"[{'id': 2112, 'therapyName': 'Bevacizumab + Irinotecan'}]",Evaluation of FDOPA-PET/MRI in Pediatric Patients With CNS Tumors,3068
66,NCT02010606,Phase I,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1141, 'therapyName': 'Temozolomide'}]",Phase I Study of a Dendritic Cell Vaccine for Patients With Either Newly Diagnosed or Recurrent Glioblastoma,3068
67,NCT02017717,Phase III,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Randomized Study of Nivolumab Versus Bevacizumab and a Safety Study of Nivolumab in Adult Subjects With Recurrent Glioblastoma (GBM) (CheckMate 143),3068
68,NCT02038699,Phase Ib/II,Withdrawn,"[{'id': 1687, 'therapyName': 'ONC201'}]",A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer,3068
69,NCT02047214,Phase II,Terminated,"[{'id': 2123, 'therapyName': 'Bevacizumab + Paclitaxel'}]",Safety and Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy,3068
70,NCT02067156,Phase II,Completed,"[{'id': 4338, 'therapyName': 'mipsagargin'}]","Efficacy, Safety and CNS Exposure of G-202 (Mipsagargin) in Patients With Recurrent or Progressive Glioblastoma",3068
71,NCT02101905,Phase I,Recruiting,"[{'id': 787, 'therapyName': 'Lapatinib'}]",Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma,3068
72,NCT02120287,Phase II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Border Zone Stereotactic Radiosurgery With Bevacizumab in Patients With Glioblastoma Multiforme,3068
73,NCT02133183,Phase I,Recruiting,"[{'id': 1282, 'therapyName': 'Sapanisertib'}]",TORC1/2 Inhibitor INK128 Before and After Surgery in Treating Patients With Recurrent Glioblastoma,3068
74,NCT02137759,Phase II,Recruiting,"[{'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1141, 'therapyName': 'Temozolomide'}]",MRSI to Predict Response to RT/TMZ and Vorinostat in GBM,3068
75,NCT02146066,Expanded access,Available,"[{'id': 5205, 'therapyName': 'DCVax-L'}]",Expanded Access Protocol for GBM Patients With Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221,3068
76,NCT02152982,Phase II,Recruiting,"[{'id': 954, 'therapyName': 'Veliparib'}, {'id': 1141, 'therapyName': 'Temozolomide'}]",Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme,3068
77,NCT02157103,Phase II,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}]",A Study of Subcutaneous Bevacizumab in Relapsed / Progressive Glioblastoma,3068
78,NCT02179086,Phase II,Recruiting,"[{'id': 1141, 'therapyName': 'Temozolomide'}]",Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma,3068
79,NCT02197169,Phase I,"Active, not recruiting","[{'id': 4407, 'therapyName': 'DNX-2401'}, {'id': 4444, 'therapyName': 'DNX-2401 + interferon gamma '}]",DNX-2401 With Interferon Gamma (IFN-gamma) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors (TARGET-I),3068
80,NCT02238496,Phase II,"Active, not recruiting","[{'id': 2194, 'therapyName': 'Perifosine + Temsirolimus'}]",Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas,3068
81,NCT02285959,Phase I,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Super-Selective Intraarterial Intracranial Infusion of Bevacizumab (Avastin) for Glioblastoma Multiforme,3068
82,NCT02311582,Phase Ib/II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",MK-3475 in Combination With MRI-guided Laser Ablation in Recurrent Malignant Gliomas,3068
83,NCT02311920,Phase I,"Active, not recruiting","[{'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Temozolomide in Combination With Ipilimumab and/or Nivolumab in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma,3068
84,NCT02315534,Phase Ib/II,Recruiting,"[{'id': 2057, 'therapyName': 'BBI608'}, {'id': 1141, 'therapyName': 'Temozolomide'}]",A Study of BBI608 in Combination With Temozolomide in Adult Patients With Recurrent or Progressed Glioblastoma,3068
85,NCT02327078,Phase Ib/II,Recruiting,"[{'id': 3059, 'therapyName': 'INCB024360 + Nivolumab'}]","A Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination With Nivolumab in Select Advanced Cancers",3068
86,NCT02336165,Phase II,"Active, not recruiting","[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 2117, 'therapyName': 'Bevacizumab + MEDI4736'}]",Phase 2 Study of MEDI4736 in Patients With Glioblastoma,3068
87,NCT02337491,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2119, 'therapyName': 'Bevacizumab + Pembrolizumab'}]",Pembrolizumab +/- Bevacizumab for Recurrent GBM,3068
88,NCT02340156,Phase II,Recruiting,"[{'id': 2518, 'therapyName': 'SGT-53'}, {'id': 1141, 'therapyName': 'Temozolomide'}]",Phase II Study of Combined Temozolomide and SGT-53 for Treatment of Recurrent Glioblastoma,3068
89,NCT02342379,Phase II,"Active, not recruiting","[{'id': 2144, 'therapyName': 'Bevacizumab + Evofosfamide'}]",TH-302 in Combination With Bevacizumab for Glioblastoma,3068
90,NCT02343406,Phase II,Recruiting,"[{'id': 2075, 'therapyName': 'Lomustine'}, {'id': 976, 'therapyName': 'ABT-414'}, {'id': 1141, 'therapyName': 'Temozolomide'}]",ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma,3068
91,NCT02343549,Phase II,Recruiting,"[{'id': 2115, 'therapyName': 'Bevacizumab + Temozolomide'}]",LCI-NEU-NOV-001 Study of a Device Worn on the Head in Combination With Chemo to Treat Brain Cancer,3068
92,NCT02345824,Phase I,Recruiting,"[{'id': 790, 'therapyName': 'Ribociclib'}]",Early-Phase Study to Assess Inhibitor LEE011 in Patients With Recurrent Glioblastoma or Anaplastic Glioma,3068
93,NCT02348255,Phase II,Withdrawn,"[{'id': 2371, 'therapyName': 'Bevacizumab + Carmustine'}]",NovoTTF-100A in Combination With Bevacizumab and Carmustine in Treating Patients With Glioblastoma Multiforme in First Relapse,3068
94,NCT02365662,Phase I,Recruiting,"[{'id': 2914, 'therapyName': 'ABBV-221'}]",A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor,3068
95,NCT02366728,,Recruiting,"[{'id': 5985, 'therapyName': 'Basiliximab'}, {'id': 1141, 'therapyName': 'Temozolomide'}]",DC Migration Study for Newly-Diagnosed GBM,3068
96,NCT02386826,Phase I,Recruiting,"[{'id': 2600, 'therapyName': 'Bevacizumab + INC280'}]","INC280 Combined With Bevacizumab to Evaluate Glioblastoma Multiforme, Metastatic Colorectal Cancer, and Metastatic Renal Cell Carcinoma Patients",3068
97,NCT02414165,Phase II,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 3211, 'therapyName': 'Toca 511 + Toca FC'}, {'id': 1141, 'therapyName': 'Temozolomide'}]",P2/3 Randomized Study of Toca 511 & Toca FC Versus SOC in Subjects Undergoing Surgery for Recurrent GBM/AA (Toca5),3068
98,NCT02423525,Phase I,Recruiting,"[{'id': 623, 'therapyName': 'Afatinib'}]",Safety Study of Afatinib for Brain Cancer,3068
99,NCT02442297,Phase I,Recruiting,"[{'id': 2940, 'therapyName': 'HER2 sensitized T-cells'}]",T Cells Expressing HER2-specific Chimeric Antigen Receptors(CAR) for Patients With Glioblastoma,3068
100,NCT02478164,Phase II,"Active, not recruiting","[{'id': 877, 'therapyName': 'Ponatinib'}]",Trial of Ponatinib in Patients With Bevacizumab-Refractory Glioblastoma,3068
101,NCT02498665,Phase I,Recruiting,"[{'id': 4320, 'therapyName': 'DSP-7888'}]",A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies,3068
102,NCT02510950,Phase I,Recruiting,"[{'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 2595, 'therapyName': 'poly ICLC  '}, {'id': 1141, 'therapyName': 'Temozolomide'}]",Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma,3068
103,NCT02511405,Phase III,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 2276, 'therapyName': 'VB-111'}]","A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE)",3068
104,NCT02521090,Phase Ib/II,Withdrawn,"[{'id': 1012, 'therapyName': 'EGFRBi-armed autologous activated T cells'}]",EGFRBi-Armed Autologous T Cells in Treating Patients With Recurrent or Refractory Glioblastoma,3068
105,NCT02525692,Phase II,Recruiting,"[{'id': 1687, 'therapyName': 'ONC201'}]",Oral ONC201 in Adult Recurrent Glioblastoma,3068
106,NCT02526017,Phase I,Recruiting,"[{'id': 2840, 'therapyName': 'FPA008'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Study of FPA008 in Combination With Nivolumab in Patients With Selected Advance Cancers,3068
107,NCT02530502,Phase Ib/II,"Active, not recruiting","[{'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Radiation Therapy With Temozolomide and Pembrolizumab in Treating Patients With Newly Diagnosed Glioblastoma,3068
108,NCT02573324,Phase II,Recruiting,"[{'id': 976, 'therapyName': 'ABT-414'}, {'id': 1141, 'therapyName': 'Temozolomide'}]",A Study of ABT-414 in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification,3068
109,NCT02586857,Phase Ib/II,Recruiting,"[{'id': 1605, 'therapyName': 'Acalabrutinib'}]","A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)",3068
110,NCT02605746,Phase I,Recruiting,"[{'id': 789, 'therapyName': 'Ceritinib'}]",Preoperative Ceritinib (LDK378) in Glioblastoma Multiforme and CNS Metastasis,3068
111,NCT02607124,Phase Ib/II,Recruiting,"[{'id': 790, 'therapyName': 'Ribociclib'}]",Administration of Ribociclib Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG),3068
112,NCT02617589,Phase III,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1141, 'therapyName': 'Temozolomide'}]","Study of Nivolumab Versus Temozolomide, Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) (CheckMate 498)",3068
113,NCT02619864,Phase Ib/II,Recruiting,"[{'id': 991, 'therapyName': 'Vistusertib'}]",mTORC1/mTORC2 Kinase Inhibitor AZD2014 in Previously Treated Glioblastoma Multiforme,3068
114,NCT02626364,Phase II,Recruiting,"[{'id': 705, 'therapyName': 'Crenolanib'}]",Study of Crenolanib in Recurrent/Refractory Glioblastoma With PDGFRA Gene Amplification,3068
115,NCT02648633,Phase I,Terminated,"[{'id': 4219, 'therapyName': 'Nivolumab + Valproic acid'}]",Stereotactic Radiosurgery With Nivolumab and Valproate in Patients With Recurrent Glioblastoma,3068
116,NCT02663271,Phase II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma,3068
117,NCT02667587,Phase II,Recruiting,"[{'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 3724, 'therapyName': 'Nivolumab + Temozolomide'}]","Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer).",3068
118,NCT02743078,Phase II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Optune Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma,3068
119,NCT02754362,Phase II,Enrolling by invitation,"[{'id': 2595, 'therapyName': 'poly ICLC  '}, {'id': 667, 'therapyName': 'Bevacizumab'}]",A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma,3068
120,NCT02766699,Phase I,Recruiting,"[{'id': 5331, 'therapyName': 'EGFR(V)-EDV-Dox'}]","A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent Glioblastoma Multiforme (GBM) (CerebralEDV)",3068
121,NCT02768389,Phase I,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Feasibility Trial of the Modified Atkins Diet and Bevacizumab for Recurrent Glioblastoma,3068
122,NCT02780024,Phase II,Recruiting,"[{'id': 1031, 'therapyName': 'Metformin'}]","Metformin, Neo-adjuvant Temozolomide and Hypo- Accelerated Radiotherapy Followed by Adjuvant TMZ in Patients With GBM",3068
123,NCT02798406,Phase II,Recruiting,"[{'id': 4408, 'therapyName': 'DNX-2401 + Pembrolizumab'}]",Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects (CAPTIVE),3068
124,NCT02800486,Phase II,Recruiting,"[{'id': 694, 'therapyName': 'Cetuximab'}]","Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA",3068
125,NCT02829723,Phase Ib/II,Recruiting,"[{'id': 2844, 'therapyName': 'BLZ945'}, {'id': 5071, 'therapyName': 'BLZ945 + PDR001'}]",Phase I/II Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors,3068
126,NCT02844439,Phase II,"Active, not recruiting","[{'id': 967, 'therapyName': 'XL647'}]",Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma,3068
127,NCT02852655,Phase 0,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma",3068
128,NCT02861898,Phase Ib/II,Recruiting,"[{'id': 4559, 'therapyName': 'Cetuximab + Mannitol'}]",Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma,3068
129,NCT02871843,Phase I,Recruiting,"[{'id': 4596, 'therapyName': 'RRx-001 + Temozolomide'}]",Phase 1 Two Part Dose Escalation Trial of RRx-001 + Radiation + Temozolomide and RRx-001 + Temozolomide Post-RT In Newly Diagnosed Glioblastoma and Anaplastic Gliomas (G-FORCE-1),3068
130,NCT02876003,Phase II,Withdrawn,"[{'id': 4338, 'therapyName': 'mipsagargin'}]",Efficacy and Safety of G-202 in PSMA-Positive Glioblastoma,3068
131,NCT02885324,Phase II,Recruiting,"[{'id': 998, 'therapyName': 'cabozantinib'}]",Pilot Study of Cabozantinib for Recurrent or Progressive High-Grade Glioma in Children,3068
132,NCT02928575,Phase II,Recruiting,"[{'id': 4905, 'therapyName': 'Sunitinib + Temozolomide'}]","Combining Sunitinib, Temozolomide and Radiation to Treat Patients Diagnosed With Glioblastoma",3068
133,NCT02942264,Phase Ib/II,Recruiting,"[{'id': 5836, 'therapyName': 'TG02'}, {'id': 5851, 'therapyName': 'Temozolomide + TG02'}]",TG02 Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of TG02 Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma,3068
134,NCT02968940,Phase III,Recruiting,"[{'id': 3144, 'therapyName': 'Avelumab'}]",Avelumab With Hypofractionated Radiation Therapy in Adults With Isocitrate Dehydrogenase (IDH) Mutant Glioblastoma,3068
135,NCT02974621,Phase II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1971, 'therapyName': 'Cediranib + Olaparib'}]",Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma,3068
136,NCT02977780,Phase II,Recruiting,"[{'id': 1000, 'therapyName': 'CC-115'}, {'id': 5028, 'therapyName': 'Abemaciclib + Temozolomide'}, {'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 5029, 'therapyName': 'Neratinib + Temozolomide'}]",INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT),3068
137,NCT02981940,Phase II,Recruiting,"[{'id': 802, 'therapyName': 'Abemaciclib'}]",A Study of Abemaciclib in Recurrent Glioblastoma,3068
138,NCT03014804,Phase II,Not yet recruiting,"[{'id': 5205, 'therapyName': 'DCVax-L'}, {'id': 5206, 'therapyName': 'DCVax-L + Nivolumab'}]",Dendritic Cell-Autologous Lung Tumor Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma,3068
139,NCT03018288,Phase II,Recruiting,"[{'id': 5221, 'therapyName': 'Pembrolizumab + Temozolomide'}, {'id': 5220, 'therapyName': 'Pembrolizumab + Temozolomide + Vitespen'}]",Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM),3068
140,NCT03027388,Phase I,Not yet recruiting,"[{'id': 3514, 'therapyName': 'LB-100'}]","Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma",3068
141,NCT03047473,Phase II,Recruiting,"[{'id': 3144, 'therapyName': 'Avelumab'}]",Avelumab in Patients With Newly Diagnosed Glioblastoma Multiforme (SEJ),3068
142,NCT03107780,Phase I,Not yet recruiting,"[{'id': 1452, 'therapyName': 'AMG 232'}]",MDM2 Inhibitor AMG-232 in Treating Patients With Recurrent or Newly Diagnosed Glioblastoma,3068
143,NCT03128047,Phase I,Recruiting,"[{'id': 2115, 'therapyName': 'Bevacizumab + Temozolomide'}]",HUMC 1612: Optune NovoTTF-200A System,3068
144,NCT03139916,Phase II,Recruiting,"[{'id': 5634, 'therapyName': 'Bavituximab + Temozolomide'}]",Phase II Clinical Trial of Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed Glioblastoma,3068
145,NCT03149003,Phase II,Recruiting,"[{'id': 5986, 'therapyName': 'Bevicizumab + DSP-7888'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy (WIZARD201G),3068
146,NCT03150862,Phase Ib/II,Recruiting,"[{'id': 2947, 'therapyName': 'BGB-290'}, {'id': 6124, 'therapyName': 'BGB-290 + Temozolomide'}]",A Study Assessing BGB-290 With Radiation and/or Temozolomide (TMZ) in Subjects With Newly Diagnosed or Recurrent Glioblastoma,3068
147,NCT03174197,Phase Ib/II,Recruiting,"[{'id': 5872, 'therapyName': 'Atezolizumab + Temozolomide'}]",Atezolizumab (aPDL1) + Temozolomide and Radiation for Newly Diagnosed Glioblastoma (GBM),3068
148,NCT03197506,Phase II,Recruiting,"[{'id': 5221, 'therapyName': 'Pembrolizumab + Temozolomide'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma,3068
149,NCT03216499,Phase II,Recruiting,"[{'id': 4146, 'therapyName': 'PT2385'}]",HIF-2 Alpha Inhibitor PT2385 in Treating Patients With Recurrent Glioblastoma,3068
150,NCT03250299,Phase I,Recruiting,"[{'id': 4908, 'therapyName': 'BAL101553'}]",Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma,3068
151,NCT03277638,Phase Ib/II,Not yet recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Laser Interstitial Thermotherapy Combined With Checkpoint Inhibitor for Recurrent Glioblastoma,3068
152,NCT03295396,Phase II,Not yet recruiting,"[{'id': 1687, 'therapyName': 'ONC201'}]",ONC201 in Adults With Recurrent High-grade Glioma,3068
153,NCT03296696,Phase I,Not yet recruiting,"[{'id': 6261, 'therapyName': 'AMG 596'}]",Study of AMG 596 in Patients With EGFRvIII Positive Glioblastoma,3068
0,NCT00879437,Phase II,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1076, 'therapyName': 'Valproic acid'}]",Valproic Acid and Radiation Followed by Maintenance Valproic Acid and Bevacizumab in Children With High Grade Gliomas,6128
1,NCT03173950,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Immune Checkpoint Inhibitor Nivolumab in People With Select Rare CNS Cancers,6128
0,NCT00602667,Phase I,"Active, not recruiting","[{'id': 2449, 'therapyName': 'Methotrexate + Cisplatin + Cyclophosphamide + Vincristine'}, {'id': 2450, 'therapyName': 'Cyclophosphamide + Etoposide + Topotecan'}, {'id': 2451, 'therapyName': 'Erlotinib + Cyclophosphamide + Topotecan'}]","Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma",3071
1,NCT00669669,Phase Ib/II,"Active, not recruiting","[{'id': 2556, 'therapyName': 'O6-benzylguanine'}, {'id': 2555, 'therapyName': 'Carmustine + Filgrastim + Plerixafor + Temozolomide'}]",Dose-Intensive Chemotherapy in Combination With Chemoprotected Autologous Stem Cells in Treating Patients With Malignant Gliomas,3071
2,NCT00998010,Phase II,"Active, not recruiting","[{'id': 3055, 'therapyName': 'Bortezomib + Temozolomide'}]","Bortezomib, Temozolomide, and Regional Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma",3071
3,NCT01130077,Phase I,Recruiting,"[{'id': 2595, 'therapyName': 'poly ICLC  '}]",A Pilot Study of Glioma Associated Antigen Vaccines in Conjunction With Poly-ICLC in Pediatric Gliomas,3071
4,NCT01149850,Phase II,"Active, not recruiting","[{'id': 2115, 'therapyName': 'Bevacizumab + Temozolomide'}]",Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma,3071
5,NCT01260506,Phase Ib/II,Unknown status,"[{'id': 2277, 'therapyName': 'Bevacizumab + VB-111'}]",Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme,3071
6,NCT01266031,Phase Ib/II,Completed,"[{'id': 2110, 'therapyName': 'Bevacizumab + Vorinostat'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma,3071
7,NCT01339039,Phase I,Terminated,"[{'id': 2120, 'therapyName': 'Bevacizumab + Plerixafor'}]",Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma,3071
8,NCT01421524,Phase I,Recruiting,"[{'id': 2358, 'therapyName': 'CC-122'}]","Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma",3071
9,NCT01434602,Phase Ib/II,Recruiting,"[{'id': 2299, 'therapyName': 'Everolimus + Sorafenib'}]",Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas,3071
10,NCT01435395,Phase I,Completed,"[{'id': 2122, 'therapyName': 'Bevacizumab + Bortezomib + Temozolomide'}]","Trial of Temozolomide, Bevacizumab Plus Bortezomib for Recurrent Glioblastoma Multiforme",3071
11,NCT01591577,Phase II,Recruiting,"[{'id': 2440, 'therapyName': 'Lapatinib + Temozolomide'}]",Lapatinib With Temozolomide and Regional Radiation Therapy for Patients With Newly-Diagnosed Glioblastoma Multiforme,3071
12,NCT01721577,Phase Ib/II,Unknown status,"[{'id': 2745, 'therapyName': 'AXL1717'}]",Phase I/II Trial of Safety and Anti-tumor Efficacy of AXL1717(Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas,3071
13,NCT01730950,Phase II,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}]",Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma,3071
14,NCT01753713,Phase II,"Active, not recruiting","[{'id': 721, 'therapyName': 'Dovitinib'}]",Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma,3071
15,NCT01790503,Phase Ib/II,"Active, not recruiting","[{'id': 874, 'therapyName': 'PLX3397'}, {'id': 1141, 'therapyName': 'Temozolomide'}]",A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma,3071
16,NCT01837862,Phase Ib/II,Recruiting,"[{'id': 2134, 'therapyName': 'Mebendazole + Vincristine + Carboplatin + Temozolomide'}, {'id': 2133, 'therapyName': 'Mebendazole + Bevacizumab + Irinotecan'}]",A Phase I/II Study of Mebendazole for the Treatment of Pediatric Gliomas,3071
17,NCT01894061,Phase II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma,3071
18,NCT01903330,Phase II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1873, 'therapyName': 'Sargramostim'}]",ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme,3071
19,NCT01931098,Phase II,Not yet recruiting,"[{'id': 1469, 'therapyName': 'Topotecan + Pazopanib'}]",Phase II Pazopanib Plus Topotecan for Recurrent Glioblastoma Multiforme (GBM),3071
20,NCT01977677,Phase Ib/II,"Active, not recruiting","[{'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 1756, 'therapyName': 'Plerixafor'}]",Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma,3071
21,NCT01989052,Phase Ib/II,Terminated,"[{'id': 2075, 'therapyName': 'Lomustine'}, {'id': 999, 'therapyName': 'Carboxyamidotriazole Orotate'}]",Ph 1/2 CTO With Lomustine for Bevacizumab-Naive Recurrent Glioma,3071
22,NCT02052648,Phase Ib/II,Recruiting,"[{'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 2976, 'therapyName': 'indoximod'}]",Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors,3071
23,NCT02078648,Phase Ib/II,"Active, not recruiting","[{'id': 3010, 'therapyName': 'SL-701'}, {'id': 2595, 'therapyName': 'poly ICLC  '}, {'id': 667, 'therapyName': 'Bevacizumab'}]","Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme",3071
24,NCT02101905,Phase I,Recruiting,"[{'id': 787, 'therapyName': 'Lapatinib'}]",Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma,3071
25,NCT02133183,Phase I,Recruiting,"[{'id': 1282, 'therapyName': 'Sapanisertib'}]",TORC1/2 Inhibitor INK128 Before and After Surgery in Treating Patients With Recurrent Glioblastoma,3071
26,NCT02137759,Phase II,Recruiting,"[{'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1141, 'therapyName': 'Temozolomide'}]",MRSI to Predict Response to RT/TMZ and Vorinostat in GBM,3071
27,NCT02152982,Phase II,Recruiting,"[{'id': 954, 'therapyName': 'Veliparib'}, {'id': 1141, 'therapyName': 'Temozolomide'}]",Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme,3071
28,NCT02197169,Phase I,"Active, not recruiting","[{'id': 4407, 'therapyName': 'DNX-2401'}, {'id': 4444, 'therapyName': 'DNX-2401 + interferon gamma '}]",DNX-2401 With Interferon Gamma (IFN-gamma) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors (TARGET-I),3071
29,NCT02238496,Phase II,"Active, not recruiting","[{'id': 2194, 'therapyName': 'Perifosine + Temsirolimus'}]",Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas,3071
30,NCT02311920,Phase I,"Active, not recruiting","[{'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Temozolomide in Combination With Ipilimumab and/or Nivolumab in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma,3071
31,NCT02337491,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2119, 'therapyName': 'Bevacizumab + Pembrolizumab'}]",Pembrolizumab +/- Bevacizumab for Recurrent GBM,3071
32,NCT02340156,Phase II,Recruiting,"[{'id': 2518, 'therapyName': 'SGT-53'}, {'id': 1141, 'therapyName': 'Temozolomide'}]",Phase II Study of Combined Temozolomide and SGT-53 for Treatment of Recurrent Glioblastoma,3071
33,NCT02386826,Phase I,Recruiting,"[{'id': 2600, 'therapyName': 'Bevacizumab + INC280'}]","INC280 Combined With Bevacizumab to Evaluate Glioblastoma Multiforme, Metastatic Colorectal Cancer, and Metastatic Renal Cell Carcinoma Patients",3071
34,NCT02521090,Phase Ib/II,Withdrawn,"[{'id': 1012, 'therapyName': 'EGFRBi-armed autologous activated T cells'}]",EGFRBi-Armed Autologous T Cells in Treating Patients With Recurrent or Refractory Glioblastoma,3071
35,NCT02607124,Phase Ib/II,Recruiting,"[{'id': 790, 'therapyName': 'Ribociclib'}]",Administration of Ribociclib Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG),3071
36,NCT02626364,Phase II,Recruiting,"[{'id': 705, 'therapyName': 'Crenolanib'}]",Study of Crenolanib in Recurrent/Refractory Glioblastoma With PDGFRA Gene Amplification,3071
37,NCT02648633,Phase I,Terminated,"[{'id': 4219, 'therapyName': 'Nivolumab + Valproic acid'}]",Stereotactic Radiosurgery With Nivolumab and Valproate in Patients With Recurrent Glioblastoma,3071
38,NCT02743078,Phase II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Optune Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma,3071
39,NCT02798406,Phase II,Recruiting,"[{'id': 4408, 'therapyName': 'DNX-2401 + Pembrolizumab'}]",Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects (CAPTIVE),3071
40,NCT02852655,Phase 0,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma",3071
41,NCT02871843,Phase I,Recruiting,"[{'id': 4596, 'therapyName': 'RRx-001 + Temozolomide'}]",Phase 1 Two Part Dose Escalation Trial of RRx-001 + Radiation + Temozolomide and RRx-001 + Temozolomide Post-RT In Newly Diagnosed Glioblastoma and Anaplastic Gliomas (G-FORCE-1),3071
42,NCT02942264,Phase Ib/II,Recruiting,"[{'id': 5836, 'therapyName': 'TG02'}, {'id': 5851, 'therapyName': 'Temozolomide + TG02'}]",TG02 Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of TG02 Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma,3071
43,NCT02977780,Phase II,Recruiting,"[{'id': 1000, 'therapyName': 'CC-115'}, {'id': 5028, 'therapyName': 'Abemaciclib + Temozolomide'}, {'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 5029, 'therapyName': 'Neratinib + Temozolomide'}]",INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT),3071
44,NCT03027388,Phase I,Not yet recruiting,"[{'id': 3514, 'therapyName': 'LB-100'}]","Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma",3071
45,NCT03107780,Phase I,Not yet recruiting,"[{'id': 1452, 'therapyName': 'AMG 232'}]",MDM2 Inhibitor AMG-232 in Treating Patients With Recurrent or Newly Diagnosed Glioblastoma,3071
46,NCT03139916,Phase II,Recruiting,"[{'id': 5634, 'therapyName': 'Bavituximab + Temozolomide'}]",Phase II Clinical Trial of Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed Glioblastoma,3071
47,NCT03173950,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Immune Checkpoint Inhibitor Nivolumab in People With Select Rare CNS Cancers,3071
48,NCT03174197,Phase Ib/II,Recruiting,"[{'id': 5872, 'therapyName': 'Atezolizumab + Temozolomide'}]",Atezolizumab (aPDL1) + Temozolomide and Radiation for Newly Diagnosed Glioblastoma (GBM),3071
49,NCT03197506,Phase II,Recruiting,"[{'id': 5221, 'therapyName': 'Pembrolizumab + Temozolomide'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma,3071
50,NCT03277638,Phase Ib/II,Not yet recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Laser Interstitial Thermotherapy Combined With Checkpoint Inhibitor for Recurrent Glioblastoma,3071
0,NCT02800486,Phase II,Recruiting,"[{'id': 694, 'therapyName': 'Cetuximab'}]","Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA",3078
1,NCT03128047,Phase I,Recruiting,"[{'id': 2115, 'therapyName': 'Bevacizumab + Temozolomide'}]",HUMC 1612: Optune NovoTTF-200A System,3078
0,NCT03255018,Phase II,Not yet recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extra-Nodal Diffuse Large B-cell Lymphomas",5822
0,NCT00671112,Phase I,Terminated,"[{'id': 2234, 'therapyName': 'Bortezomib + Everolimus'}]",Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma,285
1,NCT01711632,Phase II,"Active, not recruiting","[{'id': 342, 'therapyName': 'Vemurafenib'}]","BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia",285
2,NCT01841723,Phase II,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia,285
3,NCT01905813,Phase I,"Active, not recruiting","[{'id': 2420, 'therapyName': 'INCB039110 + INCB040093'}, {'id': 2021, 'therapyName': 'INCB040093'}]",Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies,285
4,NCT02012231,Phase Ib/II,Terminated,"[{'id': 1041, 'therapyName': 'PLX8394'}]","Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.",285
5,NCT02018861,Phase I,"Active, not recruiting","[{'id': 2406, 'therapyName': 'INCB039110'}, {'id': 3097, 'therapyName': 'INCB039110 + INCB050465'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 2352, 'therapyName': 'Carboplatin + Etoposide + Ifosfamide '}, {'id': 3088, 'therapyName': 'INCB050465 '}]","A Phase 1, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 Monotherapy and in Combination With INCB039110 in Subjects With Previously Treated B-Cell Malignancies",285
6,NCT02034110,Phase II,Recruiting,"[{'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}]",Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers,285
7,NCT02328014,Phase Ib/II,Recruiting,"[{'id': 3265, 'therapyName': 'ACP-319'}, {'id': 1605, 'therapyName': 'Acalabrutinib'}]","ACP-196 in Combination With ACP-319, for Treatment of B-Cell Malignancies",285
0,NCT00903461,Phase Ib/II,Terminated,"[{'id': 2130, 'therapyName': 'EGFR Antisense DNA'}]",Safety and Efficacy of Radiation/Cetuximab Plus EGFR Antisense DNA for Head and Neck Squamous Cell Carcinoma,11934
1,NCT00970502,Phase Ib/II,Completed,"[{'id': 2125, 'therapyName': 'Celecoxib + Erlotinib'}]","Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer",11934
2,NCT00978250,Phase II,Recruiting,"[{'id': 3789, 'therapyName': 'FdCyd + THU'}]",A Multi-Histology Phase II Study of 5-Fluoro-2-Deoxycytidine With Tetrahydrouridine (FdCyd + THU),11934
3,NCT01218048,Phase II,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 694, 'therapyName': 'Cetuximab'}]",ERBITUX; Followed by Adjuvant Treatment With Chemoradiation and ERBITUX; for Locally Advanced Head and Neck Squamous Cell Carcinoma,11934
4,NCT01391143,Phase I,Recruiting,"[{'id': 2863, 'therapyName': 'MGA271'}]",Safety Study of MGA271 in Refractory Cancer,11934
5,NCT01588431,Phase II,"Active, not recruiting","[{'id': 1987, 'therapyName': 'Cisplatin + Docetaxel + Cetuximab'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Bevacizumab/Ph 2 for Locally Advanced Head and Neck Cancer,11934
6,NCT01831089,Phase I,Completed,"[{'id': 1196, 'therapyName': 'Lurbinectedin + Paclitaxel + Bevacizumab'}, {'id': 1197, 'therapyName': 'Lurbinectedin + Paclitaxel'}]","Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors",11934
7,NCT01835626,Phase II,Recruiting,"[{'id': 956, 'therapyName': 'Vismodegib'}]",Phase II Study of Radiation Therapy and Vismodegib for Advanced Head/Neck Basal Cell Carcinoma,11934
8,NCT01860430,Phase I,"Active, not recruiting","[{'id': 1926, 'therapyName': 'Cetuximab + Ipilimumab'}]",A Phase Ib Trial of Concurrent Cetuximab (ERBITUX) and Intensity Modulated Radiotherapy (IMRT) With Ipilimumab (YERVOY) in Locally Advanced Head and Neck Cancer,11934
9,NCT01874860,Phase I,Recruiting,"[{'id': 1391, 'therapyName': 'Doxycycline'}]",Skin Rash Study Before Chemotherapy in Colorectal &amp; Head and Neck Cancer Patients,11934
10,NCT01935921,Phase I,"Active, not recruiting","[{'id': 1926, 'therapyName': 'Cetuximab + Ipilimumab'}]","Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer",11934
11,NCT01968109,Phase I,Recruiting,"[{'id': 4197, 'therapyName': 'BMS-986016 + Nivolumab'}, {'id': 4196, 'therapyName': 'BMS-986016'}]",Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors,11934
12,NCT01976741,Phase I,Recruiting,"[{'id': 2030, 'therapyName': 'Rogaratinib'}]",Phase I Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor,11934
13,NCT02004106,Phase I,Completed,"[{'id': 2886, 'therapyName': 'RO6895882'}]",A Study of RO6895882 in Patients With Advanced and/or Metastatic Solid Tumors,11934
14,NCT02014909,Phase I,Completed,"[{'id': 2054, 'therapyName': 'CDX-3379'}, {'id': 2063, 'therapyName': 'CDX-3379 + Vemurafenib'}, {'id': 2064, 'therapyName': 'CDX-3379 + Trastuzumab'}, {'id': 2061, 'therapyName': 'Cetuximab + CDX-3379'}, {'id': 2062, 'therapyName': 'CDX-3379 + Erlotinib'}]",A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors,11934
15,NCT02051751,Phase I,Completed,"[{'id': 1379, 'therapyName': 'BYL719 + Paclitaxel'}]",A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer,11934
16,NCT02107235,Phase I,Completed,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1046, 'therapyName': 'rigosertib'}]",Platinum-based Chemoradiotherapy and Rigosertib in Head and Neck Cancer,11934
17,NCT02113878,Phase I,Recruiting,"[{'id': 1691, 'therapyName': 'BKM120 + Cisplatin'}]",Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck,11934
18,NCT02318771,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Urothelial Cancer, Melanoma, and Non-Small Cell Lung Cancer",11934
19,NCT02454972,Phase II,Recruiting,"[{'id': 1195, 'therapyName': 'Lurbinectedin'}]",Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors,11934
20,NCT02471846,Phase I,"Active, not recruiting","[{'id': 2888, 'therapyName': 'GDC-0919'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study of GDC-0919 and MPDL3280A Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors,11934
21,NCT02488759,Phase Ib/II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",A Study to Investigate the Safety and Efficacy of Nivolumab in Virus-associated Tumors (CheckMate358),11934
22,NCT02538627,Phase I,Terminated,"[{'id': 820, 'therapyName': 'Seribantumab'}, {'id': 821, 'therapyName': 'MM-151'}]",Phase 1 Combination Study of MM-151 and MM-121,11934
23,NCT02543645,Phase Ib/II,Terminated,"[{'id': 3086, 'therapyName': 'Atezolizumab + Varlilumab'}]",A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer,11934
24,NCT02646319,Phase II,"Active, not recruiting","[{'id': 3380, 'therapyName': 'Nab-Rapamycin'}]",Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations,11934
25,NCT02655822,Phase I,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 3571, 'therapyName': 'CPI-444 '}]",Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers,11934
26,NCT02671955,Phase I,Terminated,"[{'id': 3614, 'therapyName': 'JNJ-61610588 '}]","A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced Cancer",11934
27,NCT02710396,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Genetic Predictors of Benefit to Pembrolizumab,11934
28,NCT02841748,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study",11934
29,NCT02953782,Phase Ib/II,Recruiting,"[{'id': 4948, 'therapyName': 'Cetuximab + Hu5F9-G4'}]",Trial of Hu5F9-G4 in Combination With Cetuximab in Patients With Solid Tumors and Advanced Colorectal Cancer,11934
30,NCT03109873,Phase I,Recruiting,"[{'id': 1031, 'therapyName': 'Metformin'}]",Metformin Hydrochloride in Affecting Cytokines and Exosomes in Patients With Head and Neck Cancer,11934
0,NCT02723955,Phase I,Recruiting,"[{'id': 4409, 'therapyName': 'GSK3359609'}, {'id': 4410, 'therapyName': 'GSK3359609 + Pembrolizumab'}]",Dose Escalation and Expansion Study of GSK3359609 in Subjects With Selected Advanced Solid Tumors (INDUCE-1),1542
0,NCT00573989,Phase Ib/II,Terminated,"[{'id': 1290, 'therapyName': 'Erlotinib + Pemetrexed'}]","Intensity-Modulated Radiation Therapy, Pemetrexed, and Erlotinib in Treating Patients With Recurrent or Second Primary Head and Neck Cancer",5520
1,NCT00588770,Phase III,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1835, 'therapyName': 'Docetaxel + Cisplatin'}, {'id': 1833, 'therapyName': 'Cisplatin + Fluorouracil'}, {'id': 1834, 'therapyName': 'Docetaxel + Carboplatin'}, {'id': 1832, 'therapyName': 'Carboplatin + Fluorouracil\t'}]",Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer,5520
2,NCT00660218,Phase Ib/II,Unknown status,"[{'id': 1988, 'therapyName': 'Paclitaxel + Cetuximab'}]","A Phase I/II Study of Radiation Therapy, Paclitaxel Poliglumex and Cetuximab in Advanced Head and Neck Cancer",5520
3,NCT00904345,Phase II,"Active, not recruiting","[{'id': 694, 'therapyName': 'Cetuximab'}]",Study of Radiation (RT) Concurrent With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (SCC),5520
4,NCT00956007,Phase III,Recruiting,"[{'id': 694, 'therapyName': 'Cetuximab'}]",Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer,5520
5,NCT00957853,Phase II,"Active, not recruiting","[{'id': 694, 'therapyName': 'Cetuximab'}, {'id': 701, 'therapyName': 'Cixutumumab'}]",Preoperative Treatment With Cetuximab and/or IMC-A12,5520
6,NCT01037790,Phase II,Recruiting,"[{'id': 850, 'therapyName': 'Palbociclib'}]",PD 0332991 in Treating Patients With Refractory Solid Tumors,5520
7,NCT01064479,Phase II,"Active, not recruiting","[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Docetaxel And Cisplatin With or Without Erlotinib For Metastatic Or Recurrent Squamous Cell Carcinoma Of Head And Neck,5520
8,NCT01104922,Phase II,"Active, not recruiting","[{'id': 694, 'therapyName': 'Cetuximab'}]",Re-irradiation With Fractionated Stereotactic Radiosurgery Plus Cetuximab in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck,5520
9,NCT01111058,Phase II,"Active, not recruiting","[{'id': 735, 'therapyName': 'Everolimus'}]",Everolimus Versus Placebo in Head and Neck Cancer,5520
10,NCT01116336,Phase I,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}]",Phase I Chemoprevention Trial With Green Tea Polyphenon E and Erlotinib in Patients With Premalignant Lesions of the Head and Neck,5520
11,NCT01133678,Phase II,"Active, not recruiting","[{'id': 1790, 'therapyName': 'Cetuximab + Cisplatin + Paclitaxel'}, {'id': 735, 'therapyName': 'Everolimus'}]",Study in Locally Advanced Squamous Cell Carcinoma of Head and Neck,5520
12,NCT01307267,Phase I,Recruiting,"[{'id': 6111, 'therapyName': 'Utomilumab + Rituximab'}, {'id': 5086, 'therapyName': 'Utomilumab'}]",A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab,5520
13,NCT01316757,Phase II,"Active, not recruiting","[{'id': 1921, 'therapyName': 'Cetuximab + Paclitaxel + Carboplatin + Erlotinib'}]","Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer",5520
14,NCT01345669,Phase III,Terminated,"[{'id': 623, 'therapyName': 'Afatinib'}]",LUX-Head&Neck 2: A Phase III Trial of Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy,5520
15,NCT01412229,Phase II,"Active, not recruiting","[{'id': 1957, 'therapyName': 'Abraxane + Carboplatin + Cetuximab'}]",Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck,5520
16,NCT01437449,Phase II,"Active, not recruiting","[{'id': 1987, 'therapyName': 'Cisplatin + Docetaxel + Cetuximab'}, {'id': 1092, 'therapyName': 'Carboplatin'}]","Weekly Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN)",5520
17,NCT01467115,Phase II,Completed,"[{'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1930, 'therapyName': 'Cisplatin + Docetaxel + Fluorouracil'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 694, 'therapyName': 'Cetuximab'}]",INDUCTION CHEMOTHERAPY FOLLOWED BY CETUXIMAB AND RADIATION THERAPY FOR HEAD AND NECK CANCER,5520
18,NCT01468896,Phase Ib/II,"Active, not recruiting","[{'id': 694, 'therapyName': 'Cetuximab'}]","Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery",5520
19,NCT01488318,Phase II,Terminated,"[{'id': 1820, 'therapyName': 'Cetuximab + Dasatinib'}]",Cetuximab and Dasatinib in Recurrent Squamous Cell Carcinoma,5520
20,NCT01577173,Phase II,Completed,"[{'id': 694, 'therapyName': 'Cetuximab'}, {'id': 806, 'therapyName': 'MEHD7945A'}]",A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck,5520
21,NCT01581970,Phase II,Completed,"[{'id': 1997, 'therapyName': 'Cyclophosphamide + Cetuximab'}]",Potentiation of Cetuximab by Tregs Depletion With CSA in Advanced Head &amp; Neck Cancer,5520
22,NCT01602315,Phase Ib/II,Terminated,"[{'id': 1837, 'therapyName': 'BYL719 + Cetuximab'}]",A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma,5520
23,NCT01607905,Phase I,Completed,"[{'id': 1749, 'therapyName': 'Selinexor'}]",Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced or Metastatic Solid Tumor Cancer,5520
24,NCT01612351,Phase II,"Active, not recruiting","[{'id': 2477, 'therapyName': 'Lapatinib + Carboplatin + Cisplatin + Paclitaxel'}, {'id': 2476, 'therapyName': 'Lapatinib + Carboplatin + Paclitaxel'}]",Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery,5520
25,NCT01642342,Phase I,Recruiting,"[{'id': 3013, 'therapyName': 'sEphB4-HSA'}]",Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors,5520
26,NCT01711541,Phase Ib/II,Suspended,"[{'id': 1544, 'therapyName': 'Carboplatin + Etoposide + Veliparib'}, {'id': 1849, 'therapyName': 'Cisplatin + Fluorouracil + Hydroxyurea'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer,5520
27,NCT01711658,Phase II,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 2475, 'therapyName': 'Lapatinib + Cisplatin'}]",TRYHARD: Radiation Therapy Plus Cisplatin With or Without Lapatinib in Treating Patients With Head and Neck Cancer,5520
28,NCT01716416,Phase I,"Active, not recruiting","[{'id': 1838, 'therapyName': 'Pazopanib + Cetuximab'}]",Pazopanib Plus Cetuximab for Incurable Head and Neck Squamous Cell Carcinoma (HNSCC),5520
29,NCT01737008,Phase I,Completed,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 714, 'therapyName': 'Dacomitinib'}]",Study of Dacomitinib With Radiotherapy With and Without Cisplatin in Patients With Squamous Cell Carcinoma of the Head and Neck,5520
30,NCT01744340,Phase Ib/II,Completed,"[{'id': 728, 'therapyName': 'Eribulin'}, {'id': 694, 'therapyName': 'Cetuximab'}]",A Dose Finding Study of Eribulin Mesylate and Cetuximab For Patients With Advanced Head and Neck and Colon Cancer,5520
31,NCT01783587,Phase I,Recruiting,"[{'id': 623, 'therapyName': 'Afatinib'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Safety Study of Afatinib and Postoperative Radiation Therapy to Treat Head and Neck Cancer,5520
32,NCT01794845,Phase II,Terminated,"[{'id': 1925, 'therapyName': 'Docetaxel + Cetuximab'}]",Phase II Trial Using Erbitux+ Taxotere With Low Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma,5520
33,NCT01810913,Phase II,"Active, not recruiting","[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1925, 'therapyName': 'Docetaxel + Cetuximab'}]","Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer",5520
34,NCT01816984,Phase Ib/II,"Active, not recruiting","[{'id': 694, 'therapyName': 'Cetuximab'}, {'id': 680, 'therapyName': 'BKM120'}]",PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer,5520
35,NCT01824823,Phase II,Terminated,"[{'id': 623, 'therapyName': 'Afatinib'}]",Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence,5520
36,NCT01836029,Phase II,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 2000, 'therapyName': 'Fluorouracil + Cetuximab'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck,5520
37,NCT01852292,Phase II,Completed,"[{'id': 1545, 'therapyName': 'BKM120 + Paclitaxel'}]",Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy,5520
38,NCT01871311,Phase I,Recruiting,"[{'id': 1929, 'therapyName': 'Nilotinib + Cetuximab'}]",A Phase I Study of the BCR-ABL Tyrosine Kinase Inhibitor Nilontinib and Cetuximab in Patients With Solid Tumors That Can be Treated With Cetuximab,5520
39,NCT01920061,Phase I,Recruiting,"[{'id': 1287, 'therapyName': 'PF-05212384 + Dacomitinib'}, {'id': 1286, 'therapyName': 'PF-05212384 + Cisplatin'}, {'id': 1285, 'therapyName': 'PF-05212384 + Docetaxel'}]",A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents,5520
40,NCT01946789,Phase I,Recruiting,"[{'id': 3060, 'therapyName': 'ALT-803'}]",A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors,5520
41,NCT01966445,Phase I,Completed,"[{'id': 2919, 'therapyName': 'GSK2849330'}]","Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors",5520
42,NCT01979211,Phase II,Recruiting,"[{'id': 694, 'therapyName': 'Cetuximab'}]",Post-operative Radiation With Cetuximab for Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck,5520
43,NCT02035527,Phase Ib/II,"Active, not recruiting","[{'id': 2431, 'therapyName': 'Sorafenib + Cisplatin + Docetaxel'}]","Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck",5520
44,NCT02057107,Phase II,Recruiting,"[{'id': 694, 'therapyName': 'Cetuximab'}, {'id': 720, 'therapyName': 'Docetaxel'}]","Stereotactic Body Radiation Therapy (SBRT) With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated Squamous Cell Carcinoma of the Head and Neck (SCCHN)",5520
45,NCT02083692,,Completed,"[{'id': 1031, 'therapyName': 'Metformin'}]",Pilot Study of Metformin in Head and Neck Squamous Cell Cancer and Its Effects on Stromal-epithelial Metabolic Uncoupling,5520
46,NCT02101034,Phase Ib/II,Recruiting,"[{'id': 1705, 'therapyName': 'Palbociclib + Cetuximab'}]",PD 0332991 and Cetuximab in Patients With Incurable SCCHN,5520
47,NCT02105636,Phase III,"Active, not recruiting","[{'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141),5520
48,NCT02110082,Phase I,Completed,"[{'id': 2066, 'therapyName': 'Cetuximab + Urelumab'}]",Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer,5520
49,NCT02124707,Phase II,Recruiting,"[{'id': 1989, 'therapyName': 'Carboplatin + Cetuximab + Paclitaxel'}]","Weekly Carboplatin, Paclitaxel and Cetuximab Treatment for Patients With Recurrent or Metastatic SCCHN",5520
50,NCT02124850,Phase I,Recruiting,"[{'id': 694, 'therapyName': 'Cetuximab'}]",A Phase Ib Study of Neoadjuvant Immune Biomarker Modulation With ERBITUX&#174; (Cetuximab) and VTX-2337,5520
51,NCT02128906,Phase II,Recruiting,"[{'id': 1925, 'therapyName': 'Docetaxel + Cetuximab'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC,5520
52,NCT02174172,Phase I,Recruiting,"[{'id': 6252, 'therapyName': 'Atezolizumab + Bevacizumab +Peg-interferon alfa-2a'}, {'id': 6253, 'therapyName': 'Atezolizumab + Interferon alfa-2b'}, {'id': 6250, 'therapyName': 'Atezolizumab + Peg-interferon alfa-2a'}, {'id': 6249, 'therapyName': 'Atezolizumab + Ipilimumab'}, {'id': 1975, 'therapyName': 'Atezolizumab + Obinutuzumab'}]",A Study to Assess the Safety and Tolerability of MPDL3280A in Combination With Other Immune-modulating Therapies in Patients With Locally Advanced or Metastatic Solid Tumors,5520
53,NCT02178072,Phase II,Recruiting,"[{'id': 651, 'therapyName': 'Azacitidine'}]","Window Trial 5-aza in HNSCC, T-tare",5520
54,NCT02178722,Phase Ib/II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2575, 'therapyName': 'Epacadostat'}]","A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Solid Tumors and Advanced NSCLC (INCB 24360-202 / MK-3475-037 / KEYNOTE-037)",5520
55,NCT02196168,Phase II,Terminated,"[{'id': 822, 'therapyName': 'MK-1775'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer,5520
56,NCT02205398,Phase Ib/II,Terminated,"[{'id': 1618, 'therapyName': 'INC280 + Cetuximab '}]","Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy",5520
57,NCT02207530,Phase II,"Active, not recruiting","[{'id': 1356, 'therapyName': 'Durvalumab'}]",Phase II Study of MEDI4736 Monotherapy in the Treatment of Patients With Recurrent or Metastatic SCCHN.,5520
58,NCT02241369,Phase I,Recruiting,"[{'id': 5846, 'therapyName': 'INO-3106 + INO-9012'}]",Immunotherapy in Subjects With HPV-6 Associated Aerodigestive Precancerous Lesions and Malignancies,5520
59,NCT02252042,Phase III,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040),5520
60,NCT02255097,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055),5520
61,NCT02262741,Phase I,"Active, not recruiting","[{'id': 1652, 'therapyName': 'Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]","A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 With Tremelimumab or Tremelimumab Alone in Head and Neck Cancer",5520
62,NCT02264678,Phase Ib/II,Recruiting,"[{'id': 2881, 'therapyName': 'AZD6738'}, {'id': 4737, 'therapyName': 'AZD6738 + Carboplatin'}, {'id': 4738, 'therapyName': 'AZD6738 + MEDI4736'}, {'id': 4739, 'therapyName': 'AZD6738 + Olaparib'}]",Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents,5520
63,NCT02270814,Phase II,Recruiting,"[{'id': 1957, 'therapyName': 'Abraxane + Carboplatin + Cetuximab'}, {'id': 1956, 'therapyName': 'Abraxane + Cisplatin + Cetuximab'}]","Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma",5520
64,NCT02277184,Phase I,Terminated,"[{'id': 1955, 'therapyName': 'Ficlatuzumab + Cisplatin'}]","Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma",5520
65,NCT02277197,Phase I,"Active, not recruiting","[{'id': 1959, 'therapyName': 'Ficlatuzumab + Cetuximab'}]",Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC),5520
66,NCT02282371,Phase I,Recruiting,"[{'id': 1837, 'therapyName': 'BYL719 + Cetuximab'}]",Cetuximab + BYL719 + IMRT (Intensity-Modulated Radiation Therapy) in Stage III/IVB Head and Neck Squamous Cell Cancer (HNSCC),5520
67,NCT02289209,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Reirradiation With MK-3475 in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck,5520
68,NCT02291055,Phase Ib/II,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 3090, 'therapyName': 'ADXS11-001'}]",Phase 1-2 Study of ADXS11-001 or MEDI4736 Alone or Combo In Cervical or HPV+ Head &amp; Neck Cancer,5520
69,NCT02296684,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma,5520
70,NCT02315066,Phase I,Recruiting,"[{'id': 4333, 'therapyName': 'PF-04518600'}, {'id': 4448, 'therapyName': 'PF-04518600 + Utomilumab'}]",Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566,5520
71,NCT02318901,Phase Ib/II,"Active, not recruiting","[{'id': 1909, 'therapyName': 'Pembrolizumab + trastuzumab emtansine'}, {'id': 1908, 'therapyName': 'Pembrolizumab + Trastuzumab'}, {'id': 1910, 'therapyName': 'Pembrolizumab + Cetuximab'}]",Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer,5520
72,NCT02319044,Phase II,"Active, not recruiting","[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]","Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck",5520
73,NCT02325401,Phase I,Recruiting,"[{'id': 2205, 'therapyName': 'Cisplatin + Metformin'}]",Dose-finding Study of Metformin With Chemoradiation in Locally Advanced Head and Neck Squamous Cell Carcinoma,5520
74,NCT02327078,Phase Ib/II,Recruiting,"[{'id': 3059, 'therapyName': 'INCB024360 + Nivolumab'}]","A Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination With Nivolumab in Select Advanced Cancers",5520
75,NCT02334319,Phase I,Terminated,"[{'id': 745, 'therapyName': 'Ganetespib'}]",Ganetespib Window of Opportunity Study in Head and Neck Cancers,5520
76,NCT02335918,Phase Ib/II,Recruiting,"[{'id': 2526, 'therapyName': 'Nivolumab + Varlilumab'}]",A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors,5520
77,NCT02358031,Phase III,"Active, not recruiting","[{'id': 694, 'therapyName': 'Cetuximab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}]",A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048),5520
78,NCT02365662,Phase I,Recruiting,"[{'id': 2914, 'therapyName': 'ABBV-221'}]",A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor,5520
79,NCT02369874,Phase III,"Active, not recruiting","[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer,5520
80,NCT02381314,Phase I,Recruiting,"[{'id': 3058, 'therapyName': 'Ipilimumab + MGA271'}]",Safety Study of MGA271 in Combination With Ipilimumab in Refractory Cancer,5520
81,NCT02381535,Phase I,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 645, 'therapyName': 'AT13387'}]",Hsp90 Inhibitor AT13387 in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Radiation Therapy and Cisplatin,5520
82,NCT02402348,Phase I,Terminated,"[{'id': 1031, 'therapyName': 'Metformin'}]","Pilot Study of Metformin in HNSCC to Investigate the Effects of MF, Tumor Genotype and MF-genotype Interactions, on Tumor Metabolism and Anoikis",5520
83,NCT02415881,Phase I,Recruiting,"[{'id': 845, 'therapyName': 'Panitumumab'}]",Phase I Panitumumab IRDye800 Optical Imaging Study,5520
84,NCT02422979,Phase I,Recruiting,"[{'id': 2918, 'therapyName': 'RM-1929'}]",Study of RM-1929 and Photoimmunotherapy in Patients With Recurrent Head and Neck Cancer,5520
85,NCT02423863,Phase II,Recruiting,"[{'id': 2595, 'therapyName': 'poly ICLC  '}]","In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol",5520
86,NCT02444793,Phase I,Recruiting,"[{'id': 6332, 'therapyName': 'Mogamulizumab + Utomilumab'}]",A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors,5520
87,NCT02449681,Phase II,Terminated,"[{'id': 2910, 'therapyName': 'TH-4000'}]",Study for Treatment of Patients With Recurrent or Metastatic SCCHN or SCCS,5520
88,NCT02452424,Phase Ib/II,"Active, not recruiting","[{'id': 2736, 'therapyName': 'Pembrolizumab + PLX3397'}]",A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors,5520
89,NCT02454179,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1605, 'therapyName': 'Acalabrutinib'}]",Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Advanced Head and Neck Squamous Cell Carcinoma,5520
90,NCT02473731,Phase I,Completed,"[{'id': 2054, 'therapyName': 'CDX-3379'}]",A Window of Opportunity Study of KTN3379 in Surgically Resectable Head and Neck Cancer Patients,5520
91,NCT02475213,Phase I,Recruiting,"[{'id': 2864, 'therapyName': 'MGA271 + Pembrolizumab'}]",Safety Study of MGA271 in Combination With Pembrolizumab in Refractory Cancer,5520
92,NCT02479178,Phase II,Terminated,"[{'id': 3640, 'therapyName': 'BIND-014'}]","A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck  (iNSITE2)",5520
93,NCT02499120,Phase II,Recruiting,"[{'id': 850, 'therapyName': 'Palbociclib'}, {'id': 694, 'therapyName': 'Cetuximab'}]",Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer,5520
94,NCT02499328,Phase Ib/II,Recruiting,"[{'id': 3098, 'therapyName': 'AZD9150 + MEDI4736'}, {'id': 3099, 'therapyName': 'AZD5069 + MEDI4736'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 2782, 'therapyName': 'AZD9150 '}]",Study to Assess Combination of MEDI4736 With Either AZD9150 or AZD5069 in Patients With Metastatic Squamous Cell Carcinoma of Head and Neck,5520
95,NCT02501096,Phase Ib/II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 792, 'therapyName': 'Lenvatinib'}]",Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors,5520
96,NCT02508246,Phase I,Recruiting,"[{'id': 822, 'therapyName': 'MK-1775'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}]","AZD1775, Docetaxel, and Cisplatin Before Surgery in Treating Patients With Borderline Resectable Stage III-IVB Squamous Cell Carcinoma of the Head and Neck",5520
97,NCT02526017,Phase I,Recruiting,"[{'id': 2840, 'therapyName': 'FPA008'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Study of FPA008 in Combination With Nivolumab in Patients With Selected Advance Cancers,5520
98,NCT02528357,Phase I,Recruiting,"[{'id': 5177, 'therapyName': 'GSK3174998'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",GSK3174998 Alone or With Pembrolizumab in Subjects With Advanced Solid Tumors,5520
99,NCT02537223,Phase I,Recruiting,"[{'id': 691, 'therapyName': 'BYL719'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Phase I Study of BYL719 in Combination With Cisplatin and Radiotherapy in Patients With Squamous Cell Head and Neck Cancer,5520
100,NCT02538510,Phase Ib/II,"Active, not recruiting","[{'id': 3077, 'therapyName': 'Pembrolizumab + Vorinostat'}]",Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer and Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery,5520
101,NCT02540291,Phase I,Recruiting,"[{'id': 5694, 'therapyName': 'E7046'}]",Study of E7046 in Subjects With Selected Advanced Malignancies,5520
102,NCT02551159,Phase III,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 1914, 'therapyName': 'Cetuximab + Carboplatin + Fluorouracil'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]",Phase III Open Label First Line Therapy Study of MEDI 4736 With or Without Tremelimumab Versus Standard of Care (SOC) in SCCHN,5520
103,NCT02554812,Phase I,Recruiting,"[{'id': 6043, 'therapyName': 'Avelumab + Utomilumab'}]",A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley),5520
104,NCT02555644,Phase I,Recruiting,"[{'id': 1651, 'therapyName': 'Prexasertib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 694, 'therapyName': 'Cetuximab'}]",A Study of LY2606368 With Chemotherapy and Radiation in Participants With Head and Neck Cancer,5520
105,NCT02559492,Phase I,"Active, not recruiting","[{'id': 3096, 'therapyName': 'INCB039110 + INCB024360'}, {'id': 3097, 'therapyName': 'INCB039110 + INCB050465'}]",INCB039110 Combined With INCB024360 and/or INCB039110 Combined With INCB050465 in Advanced Solid Tumors,5520
106,NCT02567422,Phase I,Recruiting,"[{'id': 3109, 'therapyName': 'Cisplatin + VX-970'}]","VX-970, Cisplatin, and Radiation Therapy in Treating Patients With Locally Advanced HPV-Negative Head and Neck Squamous Cell Carcinoma",5520
107,NCT02573493,Phase II,Recruiting,"[{'id': 3126, 'therapyName': 'Cisplatin + nab-paclitaxel'}, {'id': 3127, 'therapyName': 'Cetuximab + nab-paclitaxel'}]",Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC),5520
108,NCT02585973,Phase I,Recruiting,"[{'id': 1725, 'therapyName': 'MK-1775 + Cisplatin'}]",Dose-escalating AZD1775 + Concurrent Radiation + Cisplatin for Intermediate/High Risk HNSCC,5520
109,NCT02586207,Phase I,Recruiting,"[{'id': 3256, 'therapyName': 'Cisplatin + Pembrolizumab'}]",Pembrolizumab in Combination With CRT for LA-SCCHN,5520
110,NCT02609503,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab + Radiation for Locally Adv SCC of the Head and Neck (SCCHN) Not Eligible Cisplatin,5520
111,NCT02626000,Phase Ib/II,Recruiting,"[{'id': 4035, 'therapyName': 'Pembrolizumab + talimogene laherparepvec '}]",Talimogene Laherparepvec With Pembrolizumab for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck,5520
112,NCT02630420,Phase I,Not yet recruiting,"[{'id': 3790, 'therapyName': 'Cetuximab + Savolitinib'}]",Cetuximab and Savolitinib Treatment of Ras Wild-Type Colorectal Cancer,5520
113,NCT02636036,Phase I,Recruiting,"[{'id': 3620, 'therapyName': 'Enadenotucirev + Pembrolizumab'}]",Study of Enadenotucirev and Pembrolizumab in Subjects With Metastatic or Advanced Epithelial Tumors,5520
114,NCT02641093,Phase II,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Phase II Trial of Adjuvant Cisplatin and Radiation With Pembrolizumab in Resected Head and Neck Squamous Cell Carcinoma,5520
115,NCT02643303,Phase Ib/II,Recruiting,"[{'id': 3385, 'therapyName': 'MEDI4736 + poly ICLC '}, {'id': 1652, 'therapyName': 'Tremelimumab'}]","A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers",5520
116,NCT02643550,Phase Ib/II,Recruiting,"[{'id': 3383, 'therapyName': 'Cetuximab + IPH2201'}]",Study of IPH2201 (Monalizumab) and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck,5520
117,NCT02644122,Phase II,Recruiting,"[{'id': 915, 'therapyName': 'SF1126'}]",SF1126 in Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway Genes,5520
118,NCT02644369,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors,5520
119,NCT02646748,Phase I,Recruiting,"[{'id': 3088, 'therapyName': 'INCB050465 '}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2406, 'therapyName': 'INCB039110'}]",Pembrolizumab Combined With INCB039110 and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors,5520
120,NCT02649530,Phase II,Withdrawn,"[{'id': 1937, 'therapyName': 'LGK974'}]","An Open Label, Non-randomized Phase II Trial Evaluating WNT974 in Patients With Metastatic Head and Neck Squamous Cell Carcinoma",5520
121,NCT02658214,Phase I,Recruiting,"[{'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}, {'id': 2634, 'therapyName': 'Carboplatin + nab-paclitaxel'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}]",Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors,5520
122,NCT02684253,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]","Screening Trial of Nivolumab With Image Guided, Stereotactic Body Radiotherapy (SBRT) Versus Nivolumab Alone in Patients With Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)",5520
123,NCT02706691,Phase II,Not yet recruiting,"[{'id': 674, 'therapyName': 'BGJ398'}]","Pan FGFR Kinase Inhibitor BGJ398 in Treating Patients With FGFR1-3 Translocated, Mutated, or Amplified Recurrent Head and Neck Cancer",5520
124,NCT02741570,Phase III,Recruiting,"[{'id': 4168, 'therapyName': 'Carboplatin + Cetuximab + Cisplatin + Fluorouracil'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Study Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck,5520
125,NCT02762513,Phase II,Recruiting,"[{'id': 649, 'therapyName': 'Axitinib'}]",Expansion Trial for Axitinib In Head And Neck Cancer,5520
126,NCT02764593,Phase I,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 4760, 'therapyName': 'Cisplatin + Nivolumab'}, {'id': 4761, 'therapyName': 'Cetuximab + Nivolumab'}]",Chemotherapy +/- Nivolumab in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma,5520
127,NCT02769520,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","Efficacy Study of Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Cancer of the Head and Neck",5520
128,NCT02775812,Phase I,Recruiting,"[{'id': 3256, 'therapyName': 'Cisplatin + Pembrolizumab'}]","Cisplatin, Radiation Therapy, and Pembrolizumab in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma",5520
129,NCT02777385,Phase II,Recruiting,"[{'id': 3256, 'therapyName': 'Cisplatin + Pembrolizumab'}]",Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Head and Neck Cancer,5520
130,NCT02812524,Phase I,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}]",Ipilimumab for Head and Neck Cancer Patients,5520
131,NCT02823574,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck,5520
132,NCT02827838,Phase I,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}]",Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx Cancer,5520
133,NCT02834247,Phase I,Recruiting,"[{'id': 4680, 'therapyName': 'Nivolumab + TAK-659'}]",A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors,5520
134,NCT02880371,Phase Ib/II,Recruiting,"[{'id': 4608, 'therapyName': 'ARRY-382 + Pembrolizumab'}]",A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors,5520
135,NCT02892201,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in HNSCC With Residual Disease After Radiation,5520
136,NCT02949700,Phase Ib/II,Recruiting,"[{'id': 2205, 'therapyName': 'Cisplatin + Metformin'}]",Phase I/II Study OF Metformin in Combination With Cisplatin and Radiation in Head and Neck Squamous Cell Carcinoma,5520
137,NCT02952586,Phase III,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 5052, 'therapyName': 'Avelumab + Cisplatin'}]",Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100),5520
138,NCT02960594,Phase I,Recruiting,"[{'id': 5844, 'therapyName': 'INO-1400 + INO-9012'}, {'id': 5807, 'therapyName': 'INO-1400'}]",hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse,5520
139,NCT02979977,Phase II,Recruiting,"[{'id': 4190, 'therapyName': 'Afatinib + Cetuximab'}]",Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Recurrent or Metastatic Squamous Cell Cancers of the Head and Neck,5520
140,NCT02990468,Phase I,Recruiting,"[{'id': 5840, 'therapyName': 'BMX-001 + Cisplatin'}]","A Trial of Concurrent Radiation Therapy, Cisplatin, and BMX-001 in Locally Advanced Head and Neck Cancer (BMX-HN)",5520
141,NCT03019003,Phase Ib/II,Recruiting,"[{'id': 5199, 'therapyName': 'MEDI4736 + Azacitidine + Tremelimumab'}]","A Phase IB/II Study With Azacitidine, Durvalumab, and Tremelimumab in Recurrent and/or Metastatic Head and Neck Cancer Patients",5520
142,NCT03022409,Phase I,Not yet recruiting,"[{'id': 837, 'therapyName': 'Olaparib'}, {'id': 2881, 'therapyName': 'AZD6738'}]",A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC),5520
143,NCT03049618,Phase II,Recruiting,"[{'id': 3944, 'therapyName': 'sEphB4-HSA + Pembrolizumab'}]","Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475",5520
144,NCT03057613,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Study of the Addition of Pembrolizumab to Postoperative Radiotherapy in Resected High Risk Cutaneous Squamous Cell Cancer of the Head and Neck,5520
145,NCT03065062,Phase I,Recruiting,"[{'id': 4034, 'therapyName': 'Gedatolisib + Palbociclib'}]","Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors",5520
146,NCT03071757,Phase I,Recruiting,"[{'id': 5446, 'therapyName': 'ABBV-368'}, {'id': 5447, 'therapyName': 'ABBV-368 + Nivolumab'}]","A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors",5520
147,NCT03076281,Phase II,Recruiting,"[{'id': 1391, 'therapyName': 'Doxycycline'}, {'id': 4610, 'therapyName': 'Metformin + Doxycycline'}, {'id': 1031, 'therapyName': 'Metformin'}]",Metformin Hydrochloride and Doxycycline in Treating Patients With Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery,5520
148,NCT03076372,Phase I,Recruiting,"[{'id': 5758, 'therapyName': 'MM-310'}]",A Study Evaluating MM-310 in Patients With Solid Tumors,5520
149,NCT03082534,Phase II,Recruiting,"[{'id': 1910, 'therapyName': 'Pembrolizumab + Cetuximab'}]",Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma,5520
150,NCT03085719,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Targeting PD-1 Therapy Resistance With Focused High or High and Low Dose Radiation in SCCHN,5520
151,NCT03098160,Phase I,Recruiting,"[{'id': 5745, 'therapyName': 'Evofosfamide + Ipilimumab'}]",Immunotherapy Study of Evofosfamide in Combination With Ipilimumab,5520
152,NCT03109158,Phase Ib/II,Recruiting,"[{'id': 5578, 'therapyName': 'Cetuximab + Fluorouracil + NC-6004'}]",NC-6004 With 5-FU and Cetuximab for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck,5520
153,NCT03126110,Phase Ib/II,Recruiting,"[{'id': 5599, 'therapyName': 'INCAGN01876 + Nivolumab + Ipilimumab'}, {'id': 5598, 'therapyName': 'INCAGN01876 + Nivolumab'}, {'id': 5597, 'therapyName': 'INCAGN01876 + Ipilimumab'}]","Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies",5520
154,NCT03153982,Phase II,Not yet recruiting,"[{'id': 907, 'therapyName': 'Ruxolitinib'}]",Ruxolitinib in Operable Head and Neck Cancer,5520
155,NCT03162224,Phase Ib/II,Recruiting,"[{'id': 5791, 'therapyName': 'Durvalumab + MEDI0457'}]",Safety and Efficacy of MEDI0457 and Durvalumab in Patients With HPV Associated Recurrent/Metastatic Head and Neck Cancer,5520
156,NCT03162731,Phase I,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]","Nivolumab, Ipilimumab, and Radiation Therapy in Treating Patients With Stage IVA-B Head and Neck Cancer",5520
157,NCT03174275,Phase II,Not yet recruiting,"[{'id': 5873, 'therapyName': 'Carboplatin + Cisplatin + Durvalumab + Paclitaxel'}, {'id': 3997, 'therapyName': 'Carboplatin + Durvalumab + Paclitaxel'}]","Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma",5520
158,NCT03194373,Phase II,Recruiting,"[{'id': 4735, 'therapyName': 'Carboplatin + Palbociclib'}]",Phase II Trial Evaluating the Efficacy of Palbociclib in Combination With Carboplatin for the Treatment of Unresectable Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma,5520
159,NCT03236935,Phase I,Not yet recruiting,"[{'id': 6097, 'therapyName': 'L-NMMA + Pembrolizumab'}]",Phase Ib of L-NMMA and Pembrolizumab,5520
160,NCT03238638,Phase II,Not yet recruiting,"[{'id': 4088, 'therapyName': 'Epacadostat + Pembrolizumab'}]","A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy",5520
161,NCT03247712,Phase Ib/II,Not yet recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Neoadjuvant Immunoradiotherapy in Head & Neck Cancer,5520
162,NCT03254927,Phase II,Not yet recruiting,"[{'id': 2061, 'therapyName': 'Cetuximab + CDX-3379'}]",A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma,5520
163,NCT03258554,Phase II,Not yet recruiting,"[{'id': 694, 'therapyName': 'Cetuximab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Stage III-IVB Head and Neck Cancer Who Cannot Take Cisplatin,5520
164,NCT03264066,Phase II,Not yet recruiting,"[{'id': 6094, 'therapyName': 'Atezolizumab + Cabozantinib'}]",A Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Participants With Solid Tumors,5520
165,NCT03283605,Phase Ib/II,Not yet recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",Immunotherapy and SBRT for Metastatic Head and Neck Carcinomas,5520
166,NCT03289962,Phase I,Not yet recruiting,"[{'id': 6234, 'therapyName': 'RO7198457'}, {'id': 6235, 'therapyName': 'Atezolizumab + RO7198457'}]",A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors,5520
167,NCT03301896,Phase I,Not yet recruiting,"[{'id': 6299, 'therapyName': 'LHC165 + PDR001'}, {'id': 6298, 'therapyName': 'LHC165'}]",Phase I/Ib Study of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies,5520
0,NCT02815995,Phase II,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes,255
0,NCT01396408,Phase II,"Active, not recruiting","[{'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 930, 'therapyName': 'Sunitinib'}]",A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours,264
0,NCT00074490,Phase II,Completed,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1166, 'therapyName': 'Fludarabine'}]",Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,2531
1,NCT00167180,Phase II,Completed,"[{'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}]",Post Transplant Donor Lymphocyte Infusion,2531
2,NCT00305682,Phase II,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1166, 'therapyName': 'Fludarabine'}]",Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant,2531
3,NCT00520130,Phase Ib/II,"Active, not recruiting","[{'id': 2294, 'therapyName': 'Cytarabine + Fludarabine'}, {'id': 2305, 'therapyName': 'Alemtuzumab + Cyclosporine'}, {'id': 2306, 'therapyName': 'Rituximab + Fludarabine + EPOCH'}, {'id': 2307, 'therapyName': 'Fludarabine + EPOCH'}, {'id': 2238, 'therapyName': 'Sirolimus + Tacrolimus + Methotrexate'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,2531
4,NCT00697632,Phase I,Recruiting,"[{'id': 809, 'therapyName': 'MGCD265'}]",Safety Study of Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies,2531
5,NCT01203722,Phase Ib/II,Recruiting,"[{'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 2281, 'therapyName': 'Cyclophosphamide + Fludarabine + Mycophenolate mofetil'}]","Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies",2531
6,NCT01231412,Phase III,"Active, not recruiting","[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 2272, 'therapyName': 'Cyclosporine + Mycophenolate mofetil'}]",Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant,2531
7,NCT01339871,Phase I,Completed,"[{'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 848, 'therapyName': 'Pazopanib'}]",Phase I Study of Pazopanib and Vorinostat,2531
8,NCT01375842,Phase I,"Active, not recruiting","[{'id': 1201, 'therapyName': 'Atezolizumab'}]",A Phase 1 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors,2531
9,NCT01376310,Phase II,"Active, not recruiting","[{'id': 1264, 'therapyName': 'Docetaxel + Trametinib'}, {'id': 1265, 'therapyName': 'Erlotinib + Trametinib'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 1266, 'therapyName': 'Pemetrexed + GSK1120212'}, {'id': 1267, 'therapyName': 'Carboplatin + GSK1120212'}, {'id': 1268, 'therapyName': 'nab-paclitaxel + GSK1120212'}, {'id': 1269, 'therapyName': 'Gemcitabine + GSK1120212'}, {'id': 1271, 'therapyName': 'Everolimus + GSK1120212'}]",GSK1120212 Rollover Study,2531
10,NCT01529827,Phase II,"Active, not recruiting","[{'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1166, 'therapyName': 'Fludarabine'}]","Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies",2531
11,NCT01531894,Phase II,"Active, not recruiting","[{'id': 625, 'therapyName': 'Afuresertib'}]",Continuation Study of the Oral AKT Inhibitor GSK2110183,2531
12,NCT01619761,Phase I,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1847, 'therapyName': 'lenalidomide + Fludarabine + Melphalan'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1843, 'therapyName': 'Tacrolimus'}]",Natural Killer (NK) Cells in Cord Blood Transplantation,2531
13,NCT01635712,Phase I,Completed,"[{'id': 866, 'therapyName': 'SNX-5422'}]",Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Hematological Malignancies,2531
14,NCT01643603,Phase Ib/II,Recruiting,"[{'id': 717, 'therapyName': 'Dasatinib'}]",Dasatinib in Treating Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant,2531
15,NCT01760655,Phase II,Recruiting,"[{'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1842, 'therapyName': 'Fludarabine + Thiotepa + Cyclophosphamide'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}]",Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies,2531
16,NCT01767766,Phase I,"Active, not recruiting","[{'id': 2022, 'therapyName': 'TGR-1202'}]",Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies,2531
17,NCT01822509,Phase I,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant,2531
18,NCT01831726,Phase II,Completed,"[{'id': 721, 'therapyName': 'Dovitinib'}]",Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib,2531
19,NCT01833169,Phase II,Completed,"[{'id': 680, 'therapyName': 'BKM120'}]",BKM120 for Patients With PI3K-activated Tumors,2531
20,NCT01885195,Phase II,Completed,"[{'id': 807, 'therapyName': 'Binimetinib'}]",MEK162 for Patients With RAS/RAF/MEK Activated Tumors,2531
21,NCT01915498,Phase I,"Active, not recruiting","[{'id': 2982, 'therapyName': 'Enasidenib'}]",Phase 1 Study of AG-221 in Subjects With Advanced Hematologic Malignancies With an IDH2 Mutation,2531
22,NCT01954316,Phase I,Recruiting,"[{'id': 4029, 'therapyName': 'CFI-400945'}]",A Study of CFI-400945 Fumarate in Patients With Advanced Cancer,2531
23,NCT01981187,Phase II,Completed,"[{'id': 796, 'therapyName': 'Encorafenib'}]",LGX818 for Patients With BRAFV600 Mutated Tumors,2531
24,NCT02002689,Phase II,Terminated,"[{'id': 1428, 'therapyName': 'Sonidegib'}]",LDE225 for Patients With PTCH1 or SMO Mutated Tumors,2531
25,NCT02065869,Phase Ib/II,Recruiting,"[{'id': 6053, 'therapyName': 'BPX-501'}, {'id': 5992, 'therapyName': 'Rimiducid'}]",Safety Study of Gene Modified Donor T-cells Following TCR Alpha Beta Depleted Stem Cell Transplant,2531
26,NCT02074839,Phase I,"Active, not recruiting","[{'id': 1491, 'therapyName': 'AG-120'}]",Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation,2531
27,NCT02076997,Phase I,Recruiting,"[{'id': 1639, 'therapyName': 'Methotrexate'}]",Individualized High Dose Methotrexate to Treat Cancer in Children Who Have a Significant Risk for Side Effects to Methotrexate,2531
28,NCT02118311,Phase II,Withdrawn,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",T Regulatory Cell for Suppression of Acute Graft-vs-Host-Disease After a Non-Myeloablative Umbilical Cord Blood Transplantation,2531
29,NCT02160041,Phase II,Recruiting,"[{'id': 674, 'therapyName': 'BGJ398'}]",BGJ398 for Patients With Tumors With FGFR Genetic Alterations,2531
30,NCT02162888,Phase I,Completed,"[{'id': 1231, 'therapyName': 'Bendamustine'}]","A Phase I, Bioequivalence Study to Evaluate Two Formulations of Bendamustine (BDM) Hydrochloride (HCl) Administered to Cancer Patients",2531
31,NCT02186821,Phase II,Completed,"[{'id': 789, 'therapyName': 'Ceritinib'}]",Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE),2531
32,NCT02187783,Phase II,"Active, not recruiting","[{'id': 790, 'therapyName': 'Ribociclib'}]",LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE),2531
33,NCT02223598,Phase I,Terminated,"[{'id': 1944, 'therapyName': 'CB-5083'}, {'id': 4513, 'therapyName': 'CB-5083 + Dexamethasone'}]",A Phase 1 Study Evaluating CB-5083 in Subjects With Lymphoid Hematological Malignancies  (CLC-102),2531
34,NCT02272998,Phase II,Recruiting,"[{'id': 877, 'therapyName': 'Ponatinib'}]",Ponatinib Hydrochloride in Treating Patients With Refractory Metastatic Cancers and Genetic Alterations,2531
35,NCT02286687,Phase II,"Active, not recruiting","[{'id': 682, 'therapyName': 'Talazoparib'}]",Phase II Study of BMN 673,2531
36,NCT02333162,Phase I,Recruiting,"[{'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}]","Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant",2531
37,NCT02343679,Phase II,Withdrawn,"[{'id': 789, 'therapyName': 'Ceritinib'}]",Novartis PhII Ceritinib (LDK378) in R/R ALK+ Hem Malignancies,2531
38,NCT02352558,Phase I,"Active, not recruiting","[{'id': 770, 'therapyName': 'Imatinib'}, {'id': 2057, 'therapyName': 'BBI608'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]","A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies",2531
39,NCT02362035,Phase Ib/II,"Active, not recruiting","[{'id': 1605, 'therapyName': 'Acalabrutinib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]","ACP-196 in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies (KEYNOTE145)",2531
40,NCT02369029,Phase I,Terminated,"[{'id': 2598, 'therapyName': 'BAY 1238097 '}]","BAY1238097, First in Man",2531
41,NCT02381886,Phase I,Suspended,"[{'id': 2981, 'therapyName': 'IDH305'}]",A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations,2531
42,NCT02418000,Phase Ib/II,Terminated,"[{'id': 1011, 'therapyName': 'E6201'}]",A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 Mutation,2531
43,NCT02419755,Phase II,Terminated,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies,2531
44,NCT02423915,Phase Ib/II,Recruiting,"[{'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 2281, 'therapyName': 'Cyclophosphamide + Fludarabine + Mycophenolate mofetil'}, {'id': 917, 'therapyName': 'Sirolimus'}]",Fucosylated T Cells for Graft Versus Host Disease (GVHD) Prevention,2531
45,NCT02492737,Phase I,"Active, not recruiting","[{'id': 2995, 'therapyName': 'AG-881'}]",Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation,2531
46,NCT02508038,Phase I,Recruiting,"[{'id': 2971, 'therapyName': 'Zoledronic acid'}, {'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}]", Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa,2531
47,NCT02561988,Phase I,Recruiting,"[{'id': 2941, 'therapyName': 'BLU-285'}]",Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (advSM) and Relapsed or Refractory Myeloid Malignancies,2531
48,NCT02571036,Phase I,Recruiting,"[{'id': 4316, 'therapyName': 'DCC-2618'}]","A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies",2531
49,NCT02576496,Phase I,Recruiting,"[{'id': 6104, 'therapyName': 'EDO-S101'}]","Study of EDO-S101, A First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies",2531
50,NCT02584933,FDA approved,Recruiting,"[{'id': 789, 'therapyName': 'Ceritinib'}]",Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study,2531
51,NCT02588105,Phase I,Recruiting,"[{'id': 837, 'therapyName': 'Olaparib'}, {'id': 3557, 'therapyName': 'AZD0156'}]",Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer,2531
52,NCT02611063,Phase I,Recruiting,"[{'id': 1528, 'therapyName': 'Fostamatinib'}]",Evaluation of Fostamatinib in Patients With cGVHD After Allogeneic Stem Cell Transplant,2531
53,NCT02612285,Phase II,Terminated,"[{'id': 866, 'therapyName': 'SNX-5422'}]",Study of SNX-5422 in TP53 Null Cancers,2531
54,NCT02639559,Phase II,Recruiting,"[{'id': 2849, 'therapyName': 'BKT140'}]",Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies,2531
55,NCT02658890,Phase Ib/II,Recruiting,"[{'id': 3569, 'therapyName': 'BMS-986205 + Nivolumab'}]","Safety, Tolerability, Pharmacokinetic/Pharmacodynamic and Preliminary Efficacy Study of BMS-986205 Administered in Combination With Nivolumab in Advanced Cancers",2531
56,NCT02663518,Phase I,Recruiting,"[{'id': 5338, 'therapyName': 'TTI-621'}]",A Trial of TTI-621 for Patients With Hematologic Malignancies,2531
57,NCT02679131,Phase I,Recruiting,"[{'id': 1078, 'therapyName': 'Belinostat'}]","To Evaluate Safety and Pharmacokinetics of Belinostat in Patients Who Have Mild, Moderate and Severe Renal Impairment.",2531
58,NCT02680795,Phase I,Recruiting,"[{'id': 1078, 'therapyName': 'Belinostat'}]","To Evaluate the Safety and Pharmacokinetics of Belinostat in Patients Who Have Wild-type, Heterozygous, and Homozygous UGT1A1*28 Genotypes",2531
59,NCT02711137,Phase Ib/II,Recruiting,"[{'id': 4319, 'therapyName': 'INCB057643 '}]","A Phase 1/2, Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies",2531
60,NCT02862275,Phase 0,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}]",Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer,2531
61,NCT02921919,Phase II,Recruiting,"[{'id': 682, 'therapyName': 'Talazoparib'}]",Open-Label Extension and Safety Study of Talazoparib,2531
62,NCT02937675,Phase Ib/II,Recruiting,"[{'id': 4005, 'therapyName': 'eFT508'}]",A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Hematological Malignancies,2531
63,NCT02985554,Phase I,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Phase I Study to Assess the Tolerability and Efficacy of Nivolumab in Patients With Hematologic Malignancies,2531
64,NCT03011372,Phase II,Recruiting,"[{'id': 4173, 'therapyName': 'INCB054828'}]",A Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement,2531
65,NCT03075696,Phase I,Recruiting,"[{'id': 6162, 'therapyName': 'Obinutuzumab + RO7082859 + Tocilizumab'}]","A Dose Escalation Study of RO7082859, Administered After a Fixed, Single Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma",2531
66,NCT03219268,Phase I,Recruiting,"[{'id': 6060, 'therapyName': 'MGD013'}]",A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms,2531
67,NCT03236857,Phase I,Not yet recruiting,"[{'id': 1562, 'therapyName': 'Venetoclax'}]",A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies,2531
0,NCT00980460,Phase III,Recruiting,"[{'id': 2298, 'therapyName': 'Irinotecan + Temsirolimus + Vincristine'}, {'id': 2297, 'therapyName': 'Cisplatin + Fluorouracil + Vincristine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer,687
1,NCT01331135,Phase I,"Active, not recruiting","[{'id': 917, 'therapyName': 'Sirolimus'}]",Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors,687
2,NCT01956669,Phase II,Recruiting,"[{'id': 848, 'therapyName': 'Pazopanib'}]",Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors,687
3,NCT02867592,Phase II,Recruiting,"[{'id': 998, 'therapyName': 'cabozantinib'}]","Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors",687
0,NCT00986661,Phase I,Recruiting,"[{'id': 879, 'therapyName': 'PV-10'}]",A Study to Assess PV-10 Chemoablation of Cancer of the Liver,684
1,NCT01015833,Phase III,"Active, not recruiting","[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 920, 'therapyName': 'Sorafenib'}]",Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,684
2,NCT01075113,Phase I,"Active, not recruiting","[{'id': 2356, 'therapyName': 'Sorafenib + Vorinostat'}]",Sorafenib and Vorinostat in Treating Patients With Advanced Liver Cancer,684
3,NCT01141478,Phase I,Recruiting,"[{'id': 920, 'therapyName': 'Sorafenib'}]",Proton Beam Radiotherapy Plus Sorafenib Versus Sorafenib for Patients With Hepatocellular Carcinoma Exceeding San Francisco Criteria,684
4,NCT01174121,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 1167, 'therapyName': 'Aldesleukin'}]",Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer,684
5,NCT01177397,Phase Ib/II,Completed,"[{'id': 693, 'therapyName': 'CC-223'}]","Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma",684
6,NCT01246986,Phase II,"Active, not recruiting","[{'id': 2421, 'therapyName': 'Galunisertib + Sorafenib'}, {'id': 2409, 'therapyName': 'Galunisertib'}]",A Study of LY2157299 in Participants With Hepatocellular Carcinoma,684
7,NCT01306058,Phase Ib/II,"Active, not recruiting","[{'id': 2389, 'therapyName': 'Carotuximab + Sorafenib'}]",Sorafenib and TRC105 in Hepatocellular Cancer,684
8,NCT01356628,Phase II,"Active, not recruiting","[{'id': 850, 'therapyName': 'Palbociclib'}]",A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer,684
9,NCT01421524,Phase I,Recruiting,"[{'id': 2358, 'therapyName': 'CC-122'}]","Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma",684
10,NCT01556490,Phase III,Recruiting,[],Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer,684
11,NCT01567930,Phase II,Unknown status,"[{'id': 936, 'therapyName': 'Temsirolimus'}]",Temsirolimus as Second-line Therapy in HCC,684
12,NCT01624285,Phase II,Recruiting,"[{'id': 920, 'therapyName': 'Sorafenib'}]",Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer,684
13,NCT01628640,Phase I,Recruiting,"[{'id': 2423, 'therapyName': 'VSV-IFN-beta'}]",Viral Therapy in Treating Patient With Liver Cancer,684
14,NCT01642342,Phase I,Recruiting,"[{'id': 3013, 'therapyName': 'sEphB4-HSA'}]",Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors,684
15,NCT01655693,Phase III,"Active, not recruiting","[{'id': 1009, 'therapyName': 'Doxorubicin'}]",Efficacy and Safety Doxorubicin Transdrug Study in Patients Suffering From Advanced Hepatocellular Carcinoma (ReLive),684
16,NCT01658878,Phase I,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]","Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab in Subjects With Advanced Liver Cancer Anti-PD-1 HCC (Anti-Programmed-Death-1 Hepatocellular Carcinoma)",684
17,NCT01666756,Phase I,"Active, not recruiting","[{'id': 2387, 'therapyName': 'Sorafenib + KD018'}]",Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer,684
18,NCT01687673,Phase II,"Active, not recruiting","[{'id': 2388, 'therapyName': 'Sorafenib + Temsirolimus'}]",Phase II Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma,684
19,NCT01695005,Phase I,Recruiting,"[{'id': 2958, 'therapyName': 'LY3039478'}]",A Study of LY3039478 in Participants With Advanced Cancer,684
20,NCT01730937,Phase III,Recruiting,"[{'id': 920, 'therapyName': 'Sorafenib'}]",Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer,684
21,NCT01754987,Phase Ib/II,Completed,"[{'id': 920, 'therapyName': 'Sorafenib'}]",A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective,684
22,NCT01755767,Phase III,Completed,"[{'id': 636, 'therapyName': 'Tivantinib'}]",Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma Who Have Been Treated With One Prior Therapy,684
23,NCT01761266,Phase III,"Active, not recruiting","[{'id': 792, 'therapyName': 'Lenvatinib'}, {'id': 920, 'therapyName': 'Sorafenib'}]","A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma",684
24,NCT01774344,Phase III,"Active, not recruiting","[{'id': 890, 'therapyName': 'Regorafenib'}]",Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma (RESORCE),684
25,NCT01775501,Phase II,Recruiting,"[{'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Sorafenib + mFOLFOX for Hepatocellular Carcinoma,684
26,NCT01801163,Phase I,Withdrawn,"[{'id': 920, 'therapyName': 'Sorafenib'}]",A Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) Plus Sorafenib in Patients With Unresectable Hepatocellular Carcinoma (HCC),684
27,NCT01835223,Phase Ib/II,"Active, not recruiting","[{'id': 1055, 'therapyName': 'Tivozanib'}]",Tivozanib in Treating Patients With Liver Cancer That is Metastatic or Cannot Be Removed by Surgery,684
28,NCT01840592,Phase II,"Active, not recruiting","[{'id': 2363, 'therapyName': 'Doxorubicin + Sorafenib'}]",Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib,684
29,NCT01849588,FDA approved,Terminated,"[{'id': 920, 'therapyName': 'Sorafenib'}]",Sorafenib for Hepatocellular Cancer With Chronic Hepatitis C,684
30,NCT01853618,Phase I,"Active, not recruiting","[{'id': 1652, 'therapyName': 'Tremelimumab'}]",Tremelimumab With Chemoembolization or Ablation for Liver Cancer,684
31,NCT01887717,Phase III,"Active, not recruiting","[{'id': 920, 'therapyName': 'Sorafenib'}]",Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein,684
32,NCT01900002,Phase II,"Active, not recruiting","[{'id': 920, 'therapyName': 'Sorafenib'}]",Sorafenib and Yttrium-90 Glass Microspheres for Advanced Hepatocellular Carcinoma (HCC),684
33,NCT01908426,Phase III,"Active, not recruiting","[{'id': 998, 'therapyName': 'cabozantinib'}]",Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib,684
34,NCT01915602,Phase II,Completed,"[{'id': 2221, 'therapyName': 'Refametinib + Sorafenib'}]",Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC),684
35,NCT01966445,Phase I,Completed,"[{'id': 2919, 'therapyName': 'GSK2849330'}]","Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors",684
36,NCT01968109,Phase I,Recruiting,"[{'id': 4197, 'therapyName': 'BMS-986016 + Nivolumab'}, {'id': 4196, 'therapyName': 'BMS-986016'}]",Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors,684
37,NCT01999738,Phase I,"Active, not recruiting","[{'id': 1603, 'therapyName': 'EC1456'}]",Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors,684
38,NCT02024087,Phase Ib/II,"Active, not recruiting","[{'id': 2364, 'therapyName': 'Dalantercept + Sorafenib'}]",Study of Dalantercept and Sorafenib in Patients With Advanced Hepatocellular Carcinoma,684
39,NCT02024607,Phase Ib/II,"Active, not recruiting","[{'id': 1597, 'therapyName': 'Capecitabine + Oxaliplatin'}, {'id': 2093, 'therapyName': 'BBI608 + Bevacizumab'}, {'id': 2094, 'therapyName': 'BBI608 + Regorafenib'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 2057, 'therapyName': 'BBI608'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer,684
40,NCT02069145,Phase I,Completed,"[{'id': 2413, 'therapyName': 'Ipafricept + Sorafenib'}]",Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer,684
41,NCT02072486,Phase I,"Active, not recruiting","[{'id': 920, 'therapyName': 'Sorafenib'}]",Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery,684
42,NCT02081755,,Recruiting,"[{'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 735, 'therapyName': 'Everolimus'}]",Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer,684
43,NCT02082210,Phase Ib/II,"Active, not recruiting","[{'id': 1387, 'therapyName': 'Emibetuzumab + Ramucirumab'}]",A Study of LY2875358 in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer,684
44,NCT02101593,Phase I,Completed,"[{'id': 2424, 'therapyName': 'ADI-PEG 20'}]",Ph 1 Trial of ADI PEG 20 Plus Sorafenib to Treat Patients With Liver Cancer,684
45,NCT02143401,Phase I,Recruiting,"[{'id': 1872, 'therapyName': 'Navitoclax + Sorafenib'}]",Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors,684
46,NCT02151864,Phase I,"Active, not recruiting","[{'id': 1428, 'therapyName': 'Sonidegib'}]",LDE225 in Patients With Advanced or Metastatic Hepatocellular Carcinoma and Child-Pugh A Cirrhosis,684
47,NCT02174549,Phase I,Recruiting,"[{'id': 3028, 'therapyName': 'tirapazamine'}]",Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer,684
48,NCT02227914,Phase Ib/II,Withdrawn,"[{'id': 2422, 'therapyName': 'Oprozomib'}, {'id': 920, 'therapyName': 'Sorafenib'}]",Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma,684
49,NCT02232633,Phase II,Recruiting,"[{'id': 1945, 'therapyName': 'BBI503'}]",A Study of BBI503 in Adult Patients With Advanced Hepatobiliary Cancer,684
50,NCT02279719,Phase Ib/II,Recruiting,"[{'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2361, 'therapyName': 'BBI503 + Sorafenib'}, {'id': 2362, 'therapyName': 'BBI608 + Sorafenib'}]","A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma",684
51,NCT02288507,Phase I,Unknown status,"[{'id': 920, 'therapyName': 'Sorafenib'}]",Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With Advanced Hepatocellular Cancer,684
52,NCT02292173,Phase I,Recruiting,"[{'id': 2197, 'therapyName': 'Sorafenib + Trametinib'}]",Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular Cancer,684
53,NCT02314052,Phase Ib/II,Terminated,"[{'id': 3122, 'therapyName': 'DCR-MYC'}]","Phase Ib/2, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Hepatocellular Carcinoma",684
54,NCT02315066,Phase I,Recruiting,"[{'id': 4333, 'therapyName': 'PF-04518600'}, {'id': 4448, 'therapyName': 'PF-04518600 + Utomilumab'}]",Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566,684
55,NCT02323906,Phase Ib/II,Terminated,"[{'id': 2430, 'therapyName': 'Sorafenib + CC-122'}]",Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer,684
56,NCT02406508,Phase II,Recruiting,"[{'id': 1207, 'therapyName': 'Melphalan'}, {'id': 920, 'therapyName': 'Sorafenib'}]",Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable HCC,684
57,NCT02423343,Phase Ib/II,Recruiting,"[{'id': 2409, 'therapyName': 'Galunisertib'}, {'id': 1312, 'therapyName': 'Nivolumab'}]","A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, Hepatocellular Carcinoma, or Glioma",684
58,NCT02435433,Phase III,Recruiting,"[{'id': 886, 'therapyName': 'Ramucirumab'}]",A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (REACH-2),684
59,NCT02460991,Phase I,Terminated,"[{'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma,684
60,NCT02508467,Phase I,Recruiting,"[{'id': 3165, 'therapyName': 'BLU-554'}]",A Phase 1 Study of BLU-554 in Patients With Hepatocellular Carcinoma and Cholangiocarcinoma,684
61,NCT02519348,Phase II,Recruiting,"[{'id': 1652, 'therapyName': 'Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]","A Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Unresectable Hepatocellular Carcinoma",684
62,NCT02524119,Phase II,Recruiting,"[{'id': 790, 'therapyName': 'Ribociclib'}]",LEE001 and Chemoembolization In Patients With Advanced Hepatocellular Carcinoma (LEE001),684
63,NCT02528643,Phase II,"Active, not recruiting","[{'id': 1262, 'therapyName': 'Enzalutamide'}]",A Study to Assess the Efficacy and Safety of Enzalutamide in Subjects With Advanced Hepatocellular Carcinoma,684
64,NCT02540291,Phase I,Recruiting,"[{'id': 5694, 'therapyName': 'E7046'}]",Study of E7046 in Subjects With Selected Advanced Malignancies,684
65,NCT02560779,Phase Ib/II,Recruiting,"[{'id': 2389, 'therapyName': 'Carotuximab + Sorafenib'}]",Trial of TRC105 and Sorafenib in Patients With HCC,684
66,NCT02562755,Phase III,Recruiting,"[{'id': 3341, 'therapyName': 'JX-594'}, {'id': 920, 'therapyName': 'Sorafenib'}]",Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone,684
67,NCT02564614,Phase I,"Active, not recruiting","[{'id': 3612, 'therapyName': 'EZN-2968'}]","A Study of Hypoxia-inducible Factor 1a (HIF1A) Messenger Ribonucleic Acid (mRNA) Antagonist (RO7070179), to Demonstrate Proof-of-mechanism in Adult Participants With Hepatocellular Carcinoma (HCC)",684
68,NCT02572687,Phase I,Recruiting,"[{'id': 3257, 'therapyName': 'MEDI4736 + Ramucirumab'}]",A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies,684
69,NCT02575339,Phase Ib/II,Recruiting,"[{'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1282, 'therapyName': 'Sapanisertib'}]",MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma,684
70,NCT02576509,Phase III,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 920, 'therapyName': 'Sorafenib'}]",A Study of Nivolumab Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma,684
71,NCT02595866,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms",684
72,NCT02597036,Phase I,"Active, not recruiting","[{'id': 3562, 'therapyName': 'LY3127804 '}, {'id': 886, 'therapyName': 'Ramucirumab'}]",A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors,684
73,NCT02638909,Phase II,Recruiting,"[{'id': 789, 'therapyName': 'Ceritinib'}]",Study of Oral Ceritinib in Patients With ALK-Activated Gastrointestinal Malignancies,684
74,NCT02642913,Phase Ib/II,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 920, 'therapyName': 'Sorafenib'}]",Study of Enzalutamide With and Without Sorafenib in Advanced Hepatocellular Carcinoma Patients,684
75,NCT02658019,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab (Keytruda) in Advanced Hepatocellular Carcinoma,684
76,NCT02702401,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240),684
77,NCT02702414,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) as Monotherapy in Adults With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-224/KEYNOTE-224),684
78,NCT02715531,Phase I,Recruiting,"[{'id': 3947, 'therapyName': 'Atezolizumab + Gemcitabine + nab-paclitaxel'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1202, 'therapyName': 'Atezolizumab + Bevacizumab + Capecitabine'}]",A Study of the Safety and Tolerability of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors,684
79,NCT02795429,Phase Ib/II,Recruiting,"[{'id': 2659, 'therapyName': 'PDR001'}, {'id': 4492, 'therapyName': 'INC280 + PDR001'}]",Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC,684
80,NCT02821754,Phase Ib/II,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC),684
81,NCT02837029,Phase I,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab and Yttrium Y 90 Glass Microspheres in Treating Patients With Advanced Liver Cancer,684
82,NCT02842125,Phase I,Recruiting,"[{'id': 5879, 'therapyName': 'Ad5CMV-p53 gene + Capecitabine'}]",Safety and Efficacy of Intra-Arterial Ad-p53 in Liver Metastases of Solid Tumors,684
83,NCT02859324,Phase Ib/II,Recruiting,"[{'id': 4611, 'therapyName': 'CC-122 + Nivolumab'}]",A Safety and Efficacy Study of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellular Carcinoma (HCC),684
84,NCT02867592,Phase II,Recruiting,"[{'id': 998, 'therapyName': 'cabozantinib'}]","Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors",684
85,NCT02906397,Phase I,Recruiting,"[{'id': 2409, 'therapyName': 'Galunisertib'}]",A Phase I Study of Galunisertib (LY2157299) Plus Stereotactic Body Radiotherapy (SBRT) in Patients With Advanced Hepatocellular Carcinoma (HCC),684
86,NCT02939807,Phase II,Recruiting,"[{'id': 3301, 'therapyName': 'ABC294640'}]",A Phase II Study of ABC294640 as Second-Line Monotherapy in Patients With Advanced Hepatocellular Carcinoma,684
87,NCT02940496,Phase Ib/II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab (MK-3475) in Hepatocellular Carcinoma,684
88,NCT02947165,Phase I,Recruiting,"[{'id': 5632, 'therapyName': 'NIS793 + PDR001'}, {'id': 5631, 'therapyName': 'NIS793'}]",Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.,684
89,NCT02960594,Phase I,Recruiting,"[{'id': 5844, 'therapyName': 'INO-1400 + INO-9012'}, {'id': 5807, 'therapyName': 'INO-1400'}]",hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse,684
90,NCT02988440,Phase I,Recruiting,"[{'id': 5590, 'therapyName': 'PDR001 + Sorafenib'}]",Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients,684
91,NCT02989870,Phase I,Recruiting,"[{'id': 5138, 'therapyName': 'Bavituximab + Sorafenib'}]",Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma,684
92,NCT03006926,Phase I,Recruiting,"[{'id': 4782, 'therapyName': 'Lenvatinib + Pembrolizumab'}]",A Trial of Lenvatinib Plus Pembrolizumab in Subjects With Hepatocellular Carcinoma,684
93,NCT03059147,Phase I,Recruiting,"[{'id': 915, 'therapyName': 'SF1126'}]",A Study of Single Agent SF1126 Inhibitor in Patients With Advanced Hepatocellular Carcinoma,684
94,NCT03095781,Phase I,Recruiting,"[{'id': 5533, 'therapyName': 'Pembrolizumab + XL888'}]",Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer,684
95,NCT03099564,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab Plus Y90 Radioembolization in HCC Subjects,684
96,NCT03143270,Phase I,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",A Study to Test the Safety and Feasibility of Nivolumab With Drug Eluting Bead Transarterial Chemoembolization in Patients With Liver Cancer,684
97,NCT03144661,Phase I,Recruiting,"[{'id': 5832, 'therapyName': 'INCB062079'}]",An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies,684
98,NCT03145558,Phase II,Not yet recruiting,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 3028, 'therapyName': 'tirapazamine'}]",TATE Versus TACE in Intermediate Stage HCC (TATE),684
99,NCT03203304,Phase I,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study of Stereotactic Body Radiotherapy (SBRT) Followed by Nivolumab or Ipilimumab With Nivolumab in Unresectable Hepatocellular Carcinoma,684
100,NCT03211416,Phase Ib/II,Recruiting,"[{'id': 6041, 'therapyName': 'Pembrolizumab + Sorafenib'}]",Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver Cancer,684
101,NCT03222076,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Study Evaluating Nivolumab (Anti-PD-1 Antibody) Alone Versus Nivolumab Plus Ipilimumab (Anti-CTLA-4 Antibody) in Patients With Resectable and Potentially Resectable Hepatocellular Carcinoma (HCC) (CA209-956),684
102,NCT03257761,Phase I,Not yet recruiting,"[{'id': 6146, 'therapyName': 'Durvalumab + SGI-110'}]","Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer",684
103,NCT03259867,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Combination of TATE and PD-1 Inhibitor in Liver Cancer,684
104,NCT03289962,Phase I,Not yet recruiting,"[{'id': 6234, 'therapyName': 'RO7198457'}, {'id': 6235, 'therapyName': 'Atezolizumab + RO7198457'}]",A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors,684
105,NCT03298451,Phase III,Not yet recruiting,"[{'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma,684
106,NCT03299946,Phase I,Not yet recruiting,"[{'id': 2067, 'therapyName': 'Cabozantinib + Nivolumab'}]",Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC),684
0,NCT00764972,Phase Ib/II,Unknown status,"[{'id': 2357, 'therapyName': 'Sorafenib + Vinorelbine'}]",Phase IB/II Trial Combining Vinorelbine With Sorafenib as First-Line Treatment in Patients With Metastatic Breast Cancer,60080
1,NCT00921115,Phase II,"Active, not recruiting","[{'id': 633, 'therapyName': 'Anastrozole'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer.,60080
2,NCT00971737,Phase II,Unknown status,"[{'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",Cyclophosphamide and Vaccine Therapy With or Without Trastuzumab in Treating Patients With Metastatic Breast Cancer,60080
3,NCT01036087,Phase II,"Active, not recruiting","[{'id': 1984, 'therapyName': 'Panitumumab + Abraxane + Carboplatin'}, {'id': 1982, 'therapyName': 'Fluorouracil + Epirubicin + Cyclophosphamide'}]","Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer",60080
4,NCT01116648,Phase Ib/II,"Active, not recruiting","[{'id': 837, 'therapyName': 'Olaparib'}, {'id': 1971, 'therapyName': 'Cediranib + Olaparib'}]","Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer",60080
5,NCT01145430,Phase I,"Active, not recruiting","[{'id': 2167, 'therapyName': 'pegylated liposomal doxorubicin + Veliparib'}]","Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer",60080
6,NCT01262027,Phase II,"Active, not recruiting","[{'id': 721, 'therapyName': 'Dovitinib'}]", TKI258 for Metastatic Inflammatory Breast Cancer Patients,60080
7,NCT01272037,Phase III,Recruiting,"[{'id': 633, 'therapyName': 'Anastrozole'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 738, 'therapyName': 'Exemestane'}]","Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",60080
8,NCT01292655,Phase I,Completed,"[{'id': 2545, 'therapyName': 'BMS-906024'}]",Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors,60080
9,NCT01351909,Phase Ib/II,"Active, not recruiting","[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 954, 'therapyName': 'Veliparib'}]",Cyclophosphamide With or Without Veliparib in Treating Patients With Locally Advanced or Metastatic Breast Cancer,60080
10,NCT01437566,Phase II,Completed,"[{'id': 750, 'therapyName': 'GDC-0980'}, {'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 749, 'therapyName': 'GDC-0941'}]",Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy,60080
11,NCT01441947,Phase II,"Active, not recruiting","[{'id': 1965, 'therapyName': 'cabozantinib + Fulvestrant'}]",Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer,60080
12,NCT01467310,Phase I,Completed,"[{'id': 2, 'therapyName': 'Trametinib'}]",Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,60080
13,NCT01479244,Phase III,Completed,"[{'id': 3766, 'therapyName': 'E75'}, {'id': 1873, 'therapyName': 'Sargramostim'}]",Efficacy and Safety Study of NeuVax (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence,60080
14,NCT01484041,Phase Ib/II,Terminated,"[{'id': 721, 'therapyName': 'Dovitinib'}]",Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer,60080
15,NCT01528345,Phase II,Terminated,"[{'id': 2189, 'therapyName': 'Fulvestrant + Dovitinib'}, {'id': 744, 'therapyName': 'Fulvestrant'}]","Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer",60080
16,NCT01560416,Phase II,"Active, not recruiting","[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 745, 'therapyName': 'Ganetespib'}]",Fulvestrant With or Without Ganetespib in HR+ Breast Cancer,60080
17,NCT01572727,Phase II,Completed,"[{'id': 1545, 'therapyName': 'BKM120 + Paclitaxel'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]","A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation",60080
18,NCT01610284,Phase III,"Active, not recruiting","[{'id': 1546, 'therapyName': 'Fulvestrant + BKM120'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor,60080
19,NCT01633060,Phase III,"Active, not recruiting","[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 1546, 'therapyName': 'Fulvestrant + BKM120'}]","A Phase III Study of BKM120 With Fulvestrant in Patients With HR+, HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi",60080
20,NCT01670877,Phase II,Recruiting,"[{'id': 828, 'therapyName': 'Neratinib'}]",Neratinib in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer,60080
21,NCT01674140,Phase III,Recruiting,"[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 795, 'therapyName': 'Leuprolide'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 738, 'therapyName': 'Exemestane'}]",S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,60080
22,NCT01698918,Phase II,"Active, not recruiting","[{'id': 1966, 'therapyName': 'Exemestane + Everolimus'}, {'id': 1621, 'therapyName': 'Everolimus + Letrozole'}]","Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer",60080
23,NCT01757327,Phase II,Withdrawn,"[{'id': 1428, 'therapyName': 'Sonidegib'}]",LDE225 in Treating Patients With Stage II-III Estrogen Receptor- and HER2-Negative Breast Cancer,60080
24,NCT01776008,Phase II,"Active, not recruiting","[{'id': 1548, 'therapyName': 'Goserelin + MK2206'}]",Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer,60080
25,NCT01779050,Phase II,"Active, not recruiting","[{'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1087, 'therapyName': 'Epirubicin + Cyclophosphamide'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1982, 'therapyName': 'Fluorouracil + Epirubicin + Cyclophosphamide'}, {'id': 1834, 'therapyName': 'Docetaxel + Carboplatin'}, {'id': 1881, 'therapyName': 'Docetaxel + Cyclophosphamide'}]",Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells,60080
26,NCT01791478,Phase I,"Active, not recruiting","[{'id': 1553, 'therapyName': 'Letrozole + BYL719'}]",BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer,60080
27,NCT01792050,Phase II,"Active, not recruiting","[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 2976, 'therapyName': 'indoximod'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer,60080
28,NCT01797120,Phase II,Completed,"[{'id': 1589, 'therapyName': 'Fulvestrant + Everolimus'}, {'id': 744, 'therapyName': 'Fulvestrant'}]","Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI",60080
29,NCT01803282,Phase I,Recruiting,"[{'id': 3320, 'therapyName': 'GS-5745'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Safety and Tolerability Study in Solid Tumors,60080
30,NCT01823835,Phase II,"Active, not recruiting","[{'id': 2150, 'therapyName': 'GDC-0810'}]",A Study of ARN-810 (GDC-0810) in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer,60080
31,NCT01837602,Phase I,"Active, not recruiting",[],cMet CAR RNA T Cells Targeting Breast Cancer,60080
32,NCT01894451,Phase I,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Pilot Study of Zirconium-89 Bevacizumab Positron Emission Tomography for Imaging Angiogenesis in Patients With Inflammatory Breast Carcinoma Receiving Preoperative Chemotherapy,60080
33,NCT01905592,Phase III,"Active, not recruiting","[{'id': 832, 'therapyName': 'Niraparib'}]","A Phase III Trial of Niraparib Versus Physician's Choice in Her2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients",60080
34,NCT01918306,Phase Ib/II,Terminated,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1554, 'therapyName': 'GDC-0941 + Cisplatin'}]",GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer,60080
35,NCT01923168,Phase II,Completed,"[{'id': 1570, 'therapyName': 'BKM120 + Letrozole'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 1553, 'therapyName': 'Letrozole + BYL719'}]","Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women",60080
36,NCT01928394,Phase Ib/II,"Active, not recruiting","[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]","A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab in Subjects With Advanced or Metastatic Solid Tumors",60080
37,NCT01953588,Phase III,Recruiting,"[{'id': 633, 'therapyName': 'Anastrozole'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery,60080
38,NCT01958021,Phase III,"Active, not recruiting","[{'id': 790, 'therapyName': 'Ribociclib'}, {'id': 794, 'therapyName': 'Letrozole'}]",Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2),60080
39,NCT01963481,Phase II,Completed,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 738, 'therapyName': 'Exemestane'}]",Exemestane and Cyclophosphamide for Metastatic Breast Cancer,60080
40,NCT01964924,Phase II,"Active, not recruiting","[{'id': 1298, 'therapyName': 'Trametinib + GSK2141795'}]",Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer,60080
41,NCT01969643,Phase I,Recruiting,"[{'id': 3615, 'therapyName': 'SGN-LIV1A '}]",A Safety Study of SGN-LIV1A in Breast Cancer Patients,60080
42,NCT02010021,Phase I,"Active, not recruiting","[{'id': 794, 'therapyName': 'Letrozole'}]",Presurgical Treatment With Letrozole in Patients With Early-stage Breast Cancer.,60080
43,NCT02032277,Phase III,"Active, not recruiting","[{'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}, {'id': 954, 'therapyName': 'Veliparib'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer,60080
44,NCT02032823,Phase III,Recruiting,"[{'id': 837, 'therapyName': 'Olaparib'}]",Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer,60080
45,NCT02038699,Phase Ib/II,Withdrawn,"[{'id': 1687, 'therapyName': 'ONC201'}]",A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer,60080
46,NCT02049957,Phase Ib/II,Recruiting,"[{'id': 1581, 'therapyName': 'MLN0128 + Fulvestrant'}, {'id': 1580, 'therapyName': 'MLN0128 + Exemestane'}]",Safety and Efficacy Study of MLN0128 in Combination With Exemestane or Fulvestrant in Postmenopausal Women With ER/PR+ Metastatic Breast Cancer,60080
47,NCT02057133,Phase I,Recruiting,"[{'id': 2254, 'therapyName': 'Abemaciclib + Letrozole'}, {'id': 2257, 'therapyName': 'Abemaciclib + Exemestane'}, {'id': 2258, 'therapyName': 'Everolimus + Exemestane + LY2835219'}, {'id': 2255, 'therapyName': 'Abemaciclib + Anastrozole'}, {'id': 2256, 'therapyName': 'Abemaciclib + Tamoxifen'}, {'id': 2259, 'therapyName': 'Abemaciclib + Trastuzumab'}]",A Study of LY2835219 in Combination With Hormone Therapies for Breast Cancer That Has Spread,60080
48,NCT02074878,Phase I,Terminated,"[{'id': 1962, 'therapyName': 'Sunitinib + Crizotinib'}]",CRIZENT: Crizotinib and Sunitinib in Metastatic Breast Cancer,60080
49,NCT02088684,Phase Ib/II,"Active, not recruiting","[{'id': 2315, 'therapyName': 'BKM120 + Fulvestrant + LEE011'}, {'id': 2316, 'therapyName': 'Fulvestrant + LEE011'}, {'id': 2317, 'therapyName': 'BYL719 + Fulvestrant + LEE011'}]",Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer,60080
50,NCT02095184,Phase I,Recruiting,"[{'id': 633, 'therapyName': 'Anastrozole'}, {'id': 794, 'therapyName': 'Letrozole'}]",GCC 1366 Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients,60080
51,NCT02107703,Phase III,"Active, not recruiting","[{'id': 802, 'therapyName': 'Abemaciclib'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer,60080
52,NCT02115048,Phase II,"Active, not recruiting","[{'id': 623, 'therapyName': 'Afatinib'}, {'id': 794, 'therapyName': 'Letrozole'}]",Clinical Study for the Treatment of Breast Cancer the Patient Will Receive Afatinib Plus Letrozole or Letrozole Alone,60080
53,NCT02120417,Phase II,Terminated,"[{'id': 1615, 'therapyName': 'Ruxolitinib + Capecitabine'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer,60080
54,NCT02137837,Phase III,"Active, not recruiting","[{'id': 1589, 'therapyName': 'Fulvestrant + Everolimus'}, {'id': 1590, 'therapyName': 'Fulvestrant + Everolimus + Anastrozole'}, {'id': 744, 'therapyName': 'Fulvestrant'}]","S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer",60080
55,NCT02142868,Phase III,No longer available,"[{'id': 2922, 'therapyName': 'Palbociclib + Letrozole'}]","Expanded Access Study Of Palbociclib (PD-0332991) In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR-Positive, Her2-Negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed Appropriate",60080
56,NCT02154776,Phase I,Completed,"[{'id': 1594, 'therapyName': 'LEE011 + BKM120 + Letrozole'}]","Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer. (LeeBLet)",60080
57,NCT02157051,Phase I,Recruiting,[],Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer,60080
58,NCT02163694,Phase III,Recruiting,"[{'id': 954, 'therapyName': 'Veliparib'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]","A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer",60080
59,NCT02178722,Phase Ib/II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2575, 'therapyName': 'Epacadostat'}]","A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Solid Tumors and Advanced NSCLC (INCB 24360-202 / MK-3475-037 / KEYNOTE-037)",60080
60,NCT02187991,Phase II,Recruiting,"[{'id': 626, 'therapyName': 'Alisertib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer,60080
61,NCT02188745,Phase II,Recruiting,"[{'id': 738, 'therapyName': 'Exemestane'}, {'id': 1643, 'therapyName': 'Estradiol'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 794, 'therapyName': 'Letrozole'}]",ER Reactivation Therapy for Breast Cancer,60080
62,NCT02204098,Phase I,Recruiting,"[{'id': 794, 'therapyName': 'Letrozole'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1456, 'therapyName': 'Tamoxifen'}]",Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy,60080
63,NCT02236572,Phase II,"Active, not recruiting","[{'id': 735, 'therapyName': 'Everolimus'}]","Neoadj ph 2 AI Plus Everolimus in Postmenopausal Women w/ ER Pos/HER2 Neg, Low Risk Score",60080
64,NCT02246621,Phase III,"Active, not recruiting","[{'id': 1854, 'therapyName': 'Abemaciclib + Anastrozole + Letrozole'}, {'id': 1853, 'therapyName': 'Anastrozole + Letrozole'}]",A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer,60080
65,NCT02248090,Phase I,"Active, not recruiting","[{'id': 2997, 'therapyName': 'AZD9496'}]",AZD9496 First Time in Patients Ascending Dose Study,60080
66,NCT02258451,Phase II,Recruiting,"[{'id': 1966, 'therapyName': 'Exemestane + Everolimus'}, {'id': 2001, 'therapyName': 'radium Ra 223 dichloride'}]",Study of Radium-223 Dichloride Versus Placebo and Treatment With Exemestane / Everolimus in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer,60080
67,NCT02258464,Phase II,Recruiting,"[{'id': 2001, 'therapyName': 'radium Ra 223 dichloride'}]",Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer,60080
68,NCT02259114,Phase I,Completed,"[{'id': 2034, 'therapyName': 'OTX015'}]","A Phase IB Trial With OTX015, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Patients With Selected Advanced Solid Tumors",60080
69,NCT02260661,Phase I,Completed,"[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 2013, 'therapyName': 'AZD8835'}]","Phase I, Dose Study to Look at the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid Tumours",60080
70,NCT02269670,Phase II,"Active, not recruiting","[{'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 1869, 'therapyName': 'Megestrol'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 633, 'therapyName': 'Anastrozole'}]",Everolimus and Hormone Therapy in Treating Patients With Advanced Hormone Receptor Positive Breast Cancer That Has Progressed or Recurred on Everolimus and Exemestane Therapy,60080
71,NCT02273752,Phase II,Terminated,"[{'id': 735, 'therapyName': 'Everolimus'}]","Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer",60080
72,NCT02273973,Phase II,Completed,"[{'id': 1016, 'therapyName': 'GDC-0032'}]",Study of Neoadjuvant Letrozole + GDC-0032 Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI),60080
73,NCT02276443,,Recruiting,[],Molecular Triaging and Diagnostic Imaging to Guide Neoadjuvant Therapy,60080
74,NCT02278120,Phase III,"Active, not recruiting","[{'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 790, 'therapyName': 'Ribociclib'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 633, 'therapyName': 'Anastrozole'}]","Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer",60080
75,NCT02282345,Phase II,Recruiting,"[{'id': 682, 'therapyName': 'Talazoparib'}]",Neoadjuvant BMN673 for Patients With a BRCA Deleterious Mutation,60080
76,NCT02286843,Phase I,Recruiting,"[{'id': 947, 'therapyName': 'Trastuzumab'}]","Can HER2 Targeted 89Zr-trastuzumab PET/CT Identify Unsuspected HER2 Positive Breast Cancer Metastases, Which Are Amenable to HER2 Targeted Therapy?",60080
77,NCT02291913,Phase II,"Active, not recruiting","[{'id': 2267, 'therapyName': 'Everolimus + Tamoxifen'}, {'id': 2268, 'therapyName': 'Anastrozole + Everolimus'}, {'id': 1589, 'therapyName': 'Fulvestrant + Everolimus'}, {'id': 1621, 'therapyName': 'Everolimus + Letrozole'}, {'id': 2269, 'therapyName': 'Everolimus + Toremifene'}, {'id': 1966, 'therapyName': 'Exemestane + Everolimus'}]",Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer,60080
78,NCT02296801,Phase II,Recruiting,"[{'id': 850, 'therapyName': 'Palbociclib'}, {'id': 794, 'therapyName': 'Letrozole'}]",A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer,60080
79,NCT02301988,Phase II,"Active, not recruiting","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 747, 'therapyName': 'Ipatasertib'}]",A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Patients With Early Stage Triple Negative Breast Cancer,60080
80,NCT02307240,Phase I,Recruiting,"[{'id': 709, 'therapyName': 'CUDC-907'}]","Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors",60080
81,NCT02309177,Phase I,Recruiting,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 2489, 'therapyName': 'Abraxane + Nivolumab'}]","Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer",60080
82,NCT02311933,Phase II,"Active, not recruiting","[{'id': 3076, 'therapyName': 'Z-endoxifen HCl'}, {'id': 1456, 'therapyName': 'Tamoxifen'}]","Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer",60080
83,NCT02323191,Phase I,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 2004, 'therapyName': 'LY3022855'}]",A Study of RO5509554 and MPDL3280A Administered in Combination in Patients With Advanced Solid Tumors,60080
84,NCT02352025,Phase I,Recruiting,"[{'id': 2596, 'therapyName': 'S-equol  '}]",S-equol in Women With Triple Negative Breast Cancer,60080
85,NCT02374099,Phase II,"Active, not recruiting","[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant,60080
86,NCT02379247,Phase Ib/II,Recruiting,"[{'id': 2503, 'therapyName': 'BYL719 + nab-paclitaxel'}]",BYL719 and Nab-Paclitaxel in Locally Recurrent or Metastatic HER-2 Negative Breast Cancer,60080
87,NCT02384239,Phase II,Recruiting,"[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}]",A Study of Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Metastatic Breast Cancer,60080
88,NCT02384746,Phase I,Recruiting,"[{'id': 2568, 'therapyName': 'Fulvestrant + Ixazomib'}]",Phase I Study of the Combination of MLN9708 and Fulvestrant,60080
89,NCT02389764,Phase II,Recruiting,"[{'id': 831, 'therapyName': 'Nintedanib'}]",Nintedanib For HER2-negative Metastatic Inflammatory Breast Cancer (MIBC),60080
90,NCT02401347,Phase II,Recruiting,"[{'id': 682, 'therapyName': 'Talazoparib'}]",Talazoparib Beyond BRCA (TBB) Trial,60080
91,NCT02402764,Phase II,"Active, not recruiting","[{'id': 1749, 'therapyName': 'Selinexor'}]",Phase 2 Trial of Selinexor (KPT-330) for Metastatic TNBC,60080
92,NCT02403271,Phase Ib/II,Completed,"[{'id': 2573, 'therapyName': 'Ibrutinib + MEDI4736'}]",A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors,60080
93,NCT02422615,Phase III,"Active, not recruiting","[{'id': 790, 'therapyName': 'Ribociclib'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.,60080
94,NCT02437318,Phase III,Recruiting,"[{'id': 691, 'therapyName': 'BYL719'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.,60080
95,NCT02441946,Phase II,Completed,"[{'id': 802, 'therapyName': 'Abemaciclib'}, {'id': 2700, 'therapyName': 'Loperamide'}, {'id': 633, 'therapyName': 'Anastrozole'}]","A Phase 2 Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer",60080
96,NCT02448771,Phase Ib/II,Recruiting,"[{'id': 2738, 'therapyName': 'Bazedoxifene + Palbociclib'}]",A Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast Cancer,60080
97,NCT02453620,Phase I,Recruiting,"[{'id': 1541, 'therapyName': 'Entinostat'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]","Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer",60080
98,NCT02457910,Phase Ib/II,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1016, 'therapyName': 'GDC-0032'}]",Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer,60080
99,NCT02463032,Phase II,"Active, not recruiting","[{'id': 5026, 'therapyName': 'enobosarm'}]",Efficacy and Safety of GTx-024 in Patients With ER+/AR+ Breast Cancer,60080
100,NCT02476786,Phase II,Recruiting,"[{'id': 633, 'therapyName': 'Anastrozole'}, {'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 738, 'therapyName': 'Exemestane'}]",Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score,60080
101,NCT02481050,Phase II,"Active, not recruiting","[{'id': 728, 'therapyName': 'Eribulin'}]",Study to Evaluate the Efficacy and Safety of Eribulin Mesylate Administered Biweekly (Q2W) for Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer,60080
102,NCT02513394,Phase III,Recruiting,"[{'id': 850, 'therapyName': 'Palbociclib'}]",PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer (PALLAS),60080
103,NCT02520063,Phase Ib/II,Recruiting,"[{'id': 794, 'therapyName': 'Letrozole'}, {'id': 1242, 'therapyName': 'Carotuximab'}, {'id': 735, 'therapyName': 'Everolimus'}]","Preoperative Combination of Letrozole, Everolimus, and TRC105 in Postmenopausal Hormone-Receptor Positive and Her2 Negative Breast Cancer",60080
104,NCT02536794,Phase II,Suspended,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer,60080
105,NCT02561832,Phase I,Completed,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 1092, 'therapyName': 'Carboplatin'}]","A Study to Assess the Safety, Tolerability and Efficacy of Olaparib in Combination With Carboplatin in Patients With HER-2 Negative Breast Cancer",60080
106,NCT02575781,Phase I,Recruiting,"[{'id': 4026, 'therapyName': 'SAR428926'}]",A Study of SAR428926 in Patients With Advanced Solid Tumors,60080
107,NCT02599714,Phase Ib/II,Recruiting,"[{'id': 3205, 'therapyName': 'Fulvestrant + Palbociclib'}, {'id': 991, 'therapyName': 'Vistusertib'}]",Study of AZD2014 and Palbociclib in Patients With Estrogen Receptor Positive (ER+) Metastatic Breast Cancer (PASTOR),60080
108,NCT02619669,Phase I,Recruiting,"[{'id': 1282, 'therapyName': 'Sapanisertib'}, {'id': 794, 'therapyName': 'Letrozole'}]",Neoadjuvant Run-In Study With TAK-228 (MLN0128) Followed by Letrozole/TAK-228 (MLN0128) in Women With High-Risk ER+/HER2- Breast Cancer,60080
109,NCT02626507,Phase I,Recruiting,"[{'id': 850, 'therapyName': 'Palbociclib'}, {'id': 1040, 'therapyName': 'PF-05212384'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer,60080
110,NCT02630693,Phase II,"Active, not recruiting","[{'id': 850, 'therapyName': 'Palbociclib'}, {'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 1456, 'therapyName': 'Tamoxifen'}]","Study Comparing Two Different Schedules of Palbociclib Plus Second Line Endocrine Therapy in Women With Estrogen Receptor Positive, HER2 Negative Advanced/Metastatic Breast Cancer",60080
111,NCT02632045,Phase II,Recruiting,"[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 790, 'therapyName': 'Ribociclib'}]",Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ H2N- Advanced Breast Cancer,60080
112,NCT02648477,Phase II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer,60080
113,NCT02651610,Phase II,Withdrawn,"[{'id': 3545, 'therapyName': 'Bavituximab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer,60080
114,NCT02668666,Phase II,Recruiting,"[{'id': 3542, 'therapyName': 'Palbociclib + Tamoxifen'}]",Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer,60080
115,NCT02684032,Phase I,Recruiting,"[{'id': 794, 'therapyName': 'Letrozole'}, {'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 4034, 'therapyName': 'Gedatolisib + Palbociclib'}]",A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer,60080
116,NCT02692755,Phase II,Recruiting,"[{'id': 2922, 'therapyName': 'Palbociclib + Letrozole'}]",Palbociclib / Letrozole in African American Women With HR+ HER2- Breast Cancer (PALINA),60080
117,NCT02712723,Phase II,Recruiting,"[{'id': 1568, 'therapyName': 'LEE011 + Letrozole'}]","Letrozole Plus Ribociclib or Placebo as Neo-adjuvant Therapy in ER-positive, HER2-negative Early Breast Cancer",60080
118,NCT02732119,Phase Ib/II,Recruiting,"[{'id': 2265, 'therapyName': 'LEE011 + Everolimus + Exemestane'}]",Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor. (TRINITI-1),60080
119,NCT02738866,Phase II,Recruiting,"[{'id': 3205, 'therapyName': 'Fulvestrant + Palbociclib'}]",Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor,60080
120,NCT02747004,Phase II,Recruiting,"[{'id': 4387, 'therapyName': 'Abemaciclib + Loperamide'}, {'id': 802, 'therapyName': 'Abemaciclib'}, {'id': 2256, 'therapyName': 'Abemaciclib + Tamoxifen'}]",A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer (nextMONARCH 1),60080
121,NCT02752685,Phase II,Recruiting,"[{'id': 4023, 'therapyName': 'nab-paclitaxel + Pembrolizumab'}]",Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer,60080
122,NCT02753686,Phase I,Recruiting,"[{'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 1966, 'therapyName': 'Exemestane + Everolimus'}]",Treatment of Canadian Postmenopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy (Treat ER+ight),60080
123,NCT02756364,Phase II,Recruiting,"[{'id': 1581, 'therapyName': 'MLN0128 + Fulvestrant'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",MLN0128 in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy,60080
124,NCT02760030,Phase II,Recruiting,"[{'id': 3205, 'therapyName': 'Fulvestrant + Palbociclib'}]",Fulvestrant and Palbociclib in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery,60080
125,NCT02764541,Phase II,Recruiting,"[{'id': 850, 'therapyName': 'Palbociclib'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 1456, 'therapyName': 'Tamoxifen'}]",Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS),60080
126,NCT02776917,Phase I,Not yet recruiting,"[{'id': 4313, 'therapyName': 'Cirmtuzumab + Paclitaxel'}]","Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer",60080
127,NCT02778685,Phase II,Recruiting,"[{'id': 4222, 'therapyName': 'Letrozole + Palbociclib + Pembrolizumab'}]","Pembrolizumab, Letrozole, and Palbociclib in Treating Patients With Stage IV Estrogen Receptor Positive Breast Cancer With Stable Disease That Has Not Responded to Letrozole and Palbociclib",60080
128,NCT02779751,Phase II,Recruiting,"[{'id': 4242, 'therapyName': 'Abemaciclib + Pembrolizumab'}]",A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer,60080
129,NCT02792114,Phase I,Recruiting,"[{'id': 5992, 'therapyName': 'Rimiducid'}, {'id': 6029, 'therapyName': 'Mesothelin CAR-T cells'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",T-Cell Therapy for Advanced Breast Cancer,60080
130,NCT02792725,Expanded access,Available,"[{'id': 802, 'therapyName': 'Abemaciclib'}]",Expanded Access Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer,60080
131,NCT02811497,Phase II,Recruiting,"[{'id': 4178, 'therapyName': 'Azacitidine + MEDI4736'}]",Study of Azacitidine and Durvalumab in Advanced Solid Tumors (METADUR),60080
132,NCT02824575,Phase I,Recruiting,"[{'id': 4433, 'therapyName': 'Paclitaxel + Rebastinib'}, {'id': 4434, 'therapyName': 'Eribulin + Rebastinib'}]",Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer,60080
133,NCT02860000,Phase II,Recruiting,"[{'id': 4561, 'therapyName': 'Alisertib + Fulvestrant'}, {'id': 626, 'therapyName': 'Alisertib'}]","Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer",60080
134,NCT02871791,Phase Ib/II,Recruiting,"[{'id': 4597, 'therapyName': 'Exemestane + Everolimus + Palbociclib'}]",Palbociclib With Everolimus + Exemestane In BC,60080
135,NCT02892734,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer,60080
136,NCT02936206,Phase I,Recruiting,"[{'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",Examination of Breast Cancer Cells of Pre-menopausal Women Before and After Exposure to Tamoxifen or Fulvestrant.,60080
137,NCT02941926,Phase III,Recruiting,"[{'id': 5310, 'therapyName': 'Ribociclib + Letrozole + Goserelin'}]",Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC,60080
138,NCT02942355,Phase II,Recruiting,"[{'id': 4974, 'therapyName': 'Anastrozole + Palbociclib'}]",Trial of Anastrozole and Palbociclib in Metastatic HER2-Negative Breast Cancer,60080
139,NCT02953860,Phase II,Recruiting,"[{'id': 4940, 'therapyName': 'Enzalutamide + Fulvestrant'}]",Fulvestrant Plus Enzalutamide in ER+/Her2- Advanced Breast Cancer,60080
140,NCT02955394,Phase II,Recruiting,"[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 4940, 'therapyName': 'Enzalutamide + Fulvestrant'}]",Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer,60080
141,NCT02957968,Phase II,Recruiting,"[{'id': 1495, 'therapyName': 'Paclitaxel + Doxorubicin + Cyclophosphamide'}, {'id': 5729, 'therapyName': 'Doxorubicin + Cyclophosphamide + Paclitaxel + Carboplatin'}]",Neoadj Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca,60080
142,NCT02983604,Phase Ib/II,Recruiting,"[{'id': 738, 'therapyName': 'Exemestane'}, {'id': 5074, 'therapyName': 'GS-5829 + Fulvestrant'}, {'id': 3561, 'therapyName': 'GS-5829 + Exemestane'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",GS-5829 in Combination With Exemestane or Fulvestrant Comparing With Exemestane or Fulvestrant Alone in Women With Advanced Estrogen Receptor Positive HER2- Breast Cancer,60080
143,NCT03007979,Phase II,Recruiting,"[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 3205, 'therapyName': 'Fulvestrant + Palbociclib'}, {'id': 2922, 'therapyName': 'Palbociclib + Letrozole'}]",Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer,60080
144,NCT03018080,Phase II,Recruiting,"[{'id': 4021, 'therapyName': 'Paclitaxel + Pembrolizumab'}]",Pilot Study of Paclitaxel Plus Pembrolizumab in Metastatic HER2-Negative Breast Cancer (PePPy),60080
145,NCT03044730,Phase II,Recruiting,"[{'id': 4022, 'therapyName': 'Capecitabine + Pembrolizumab'}]",Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery,60080
146,NCT03051659,Phase II,Recruiting,"[{'id': 728, 'therapyName': 'Eribulin'}, {'id': 3080, 'therapyName': 'Eribulin + Pembrolizumab'}]",A Randomized Phase II Study Of Eribulin Mesylate With or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast Cancer,60080
147,NCT03051672,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Phase II PEMBROLIZUMAB + PALLIATIVE RADIOTHERAPY IN BC,60080
148,NCT03056755,Phase II,Recruiting,"[{'id': 5929, 'therapyName': 'Alpelisib + Fulvestrant'}, {'id': 1553, 'therapyName': 'Letrozole + BYL719'}]","Efficacy and Safety of Treatment With Alpelisib Plus Endocrine Therapy in Patients With HR+, HER2-negative aBC, With PIK3CA Mutations, Whose Disease Has Progressed on or After CDK 4/6 Treatment With an Aromatase Inhibitor (AI) or Fulvestrant",60080
149,NCT03070002,Phase II,Recruiting,"[{'id': 1198, 'therapyName': 'Denosumab'}]","Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor Cells",60080
150,NCT03078751,Phase III,Recruiting,"[{'id': 790, 'therapyName': 'Ribociclib'}]",Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer (EarLEE-1),60080
151,NCT03092934,Phase Ib/II,Recruiting,"[{'id': 5753, 'therapyName': 'AK-01'}]",A Study of AK-01 in Solid Tumors,60080
152,NCT03128619,Phase Ib/II,Recruiting,"[{'id': 5594, 'therapyName': 'Copanlisib + Palbociclib + Letrozole'}, {'id': 5593, 'therapyName': 'Copanlisib + Letrozole'}]","Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer",60080
153,NCT03132467,Phase I,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",Evaluating Anti-PD-L1 Antibody (Durvalumab) Plus Anti-CTLA-4 Antibody (Tremelimumab) in HR+/HER2- Breast Cancer,60080
154,NCT03147287,Phase II,Recruiting,"[{'id': 850, 'therapyName': 'Palbociclib'}, {'id': 3205, 'therapyName': 'Fulvestrant + Palbociclib'}, {'id': 5684, 'therapyName': 'Fulvestrant + Palbociclib + Avelumab'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",Palbociclib After CDK and Endocrine Therapy (PACE),60080
155,NCT03166085,Phase I,Recruiting,"[{'id': 5796, 'therapyName': 'PU-H71 + nab-paclitaxel'}]",PU-H71 With Nab-paclitaxel (Abraxane) in Metastatic Breast Cancer,60080
156,NCT03225547,Phase II,Not yet recruiting,"[{'id': 6030, 'therapyName': 'Mifepristone + Pembrolizumab'}]",Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer,60080
157,NCT03241810,Phase II,Recruiting,"[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 6327, 'therapyName': 'Fulvestrant + Seribantumab'}]",Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer (SHERBOC),60080
158,NCT03280563,Phase Ib/II,Not yet recruiting,"[{'id': 6269, 'therapyName': 'Atezolizumab + Ipatasertib'}, {'id': 6270, 'therapyName': 'Atezolizumab + Bevacizumab + Exemestane'}, {'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}, {'id': 6271, 'therapyName': 'Atezolizumab + Bevacizumab + Fulvestrant'}, {'id': 6272, 'therapyName': 'Atezolizumab + Bevacizumab + Tamoxifen'}, {'id': 6273, 'therapyName': 'Atezolizumab + Ipatasertib + Fulvestrant'}, {'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 6268, 'therapyName': 'Atezolizumab + Fulvestrant'}]",A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer,60080
159,NCT03285412,,Not yet recruiting,"[{'id': 790, 'therapyName': 'Ribociclib'}]","CDK 4/6 Inhibitor, LEE011 (Ribociclib), in Combination With Adjuvant Endocrine Therapy at Varying Duration for ER-positive Breast Cancer",60080
160,NCT03285607,Phase I,Not yet recruiting,"[{'id': 6236, 'therapyName': 'Cyclophosphamide + Doxorubicin + Paclitaxel + MCS110'}]","MCS110 Combined With Neoadjuvant Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast Cancer",60080
161,NCT03294694,Phase I,Not yet recruiting,"[{'id': 6285, 'therapyName': 'Fulvestrant + PDR001 + Ribociclib'}, {'id': 6284, 'therapyName': 'PDR001 + Ribociclib'}]",Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer,60080
0,NCT00411788,Phase II,Completed,"[{'id': 1979, 'therapyName': 'Sirolimus + Trastuzumab'}]",A Phase II Study of Rapamycin and Trastuzumab for Patients With HER-2 Receptor Positive Metastatic Breast Cancer,60079
1,NCT00574587,Phase Ib/II,Unknown status,"[{'id': 1983, 'therapyName': 'vorinostat + Paclitaxel'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}]","Trial for Locally Advanced Her2 Positive Breast Cancer Using Paclitaxel, Trastuzumab, Doxorubicin and Cyclophasmide on a Weekly Basis",60079
2,NCT01016886,Phase Ib/II,"Active, not recruiting","[{'id': 1897, 'therapyName': 'Bisoprolol'}, {'id': 1896, 'therapyName': 'Perindopril'}]",Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research,60079
3,NCT01160211,Phase III,"Active, not recruiting","[{'id': 1414, 'therapyName': 'Trastuzumab + Lapatinib'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 738, 'therapyName': 'Exemestane'}]","A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer",60079
4,NCT01177397,Phase Ib/II,Completed,"[{'id': 693, 'therapyName': 'CC-223'}]","Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma",60079
5,NCT01273610,Phase II,"Active, not recruiting","[{'id': 1414, 'therapyName': 'Trastuzumab + Lapatinib'}]",Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Metastatic Breast Cancer,60079
6,NCT01276041,Phase II,"Active, not recruiting","[{'id': 1549, 'therapyName': 'Pertuzumab + Trastuzumab + Paclitaxel'}]","Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer",60079
7,NCT01305941,Phase II,"Active, not recruiting","[{'id': 1411, 'therapyName': 'Trastuzumab + Everolimus + Vinorelbine'}]","A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases",60079
8,NCT01325207,Phase Ib/II,"Active, not recruiting","[{'id': 947, 'therapyName': 'Trastuzumab'}]",Intrathecal Trastuzumab for Leptomeningeal Metastases in HER2+ Breast Cancer,60079
9,NCT01434303,Phase I,"Active, not recruiting","[{'id': 1542, 'therapyName': 'Entinostat + Lapatinib + Trastuzumab'}]","Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only",60079
10,NCT01491737,Phase II,"Active, not recruiting","[{'id': 633, 'therapyName': 'Anastrozole'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}]","A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer",60079
11,NCT01494662,Phase II,"Active, not recruiting","[{'id': 1543, 'therapyName': 'Capecitabine + Neratinib'}, {'id': 828, 'therapyName': 'Neratinib'}]",HKI-272 for HER2-Positive Breast Cancer and Brain Metastases,60079
12,NCT01513083,Phase I,Completed,"[{'id': 1402, 'therapyName': 'trastuzumab emtansine'}]",A Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function,60079
13,NCT01526473,Phase I,"Active, not recruiting","[{'id': 1068, 'therapyName': 'AVX901'}]",A Phase I Study To Evaluate The Antitumor Activity And Safety Of AVX901,60079
14,NCT01565083,Phase II,Completed,"[{'id': 1666, 'therapyName': 'Pertuzumab + Trastuzumab + Vinorelbine'}]",A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer,60079
15,NCT01566721,Phase III,"Active, not recruiting","[{'id': 947, 'therapyName': 'Trastuzumab'}]",A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer),60079
16,NCT01602406,Phase I,Completed,"[{'id': 2037, 'therapyName': 'LJM716 + Trastuzumab'}]",Phase I Study LJM716 Combined With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast or Gastric Cancer,60079
17,NCT01622868,Phase II,Recruiting,"[{'id': 787, 'therapyName': 'Lapatinib'}]",Whole-Brain Radiation Therapy With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer,60079
18,NCT01702558,Phase II,Completed,"[{'id': 1402, 'therapyName': 'trastuzumab emtansine'}, {'id': 1976, 'therapyName': 'trastuzumab emtansine + Capecitabine'}]",A Combination Study of Kadcyla (Trastuzumab Emtansine) and Capecitabine in Patients With HER2-Positive Metastatic Breast Cancer and Patients With HER2-Positive Locally Advanced / Metastatic Gastric Cancer,60079
19,NCT01702571,Phase III,"Active, not recruiting","[{'id': 1402, 'therapyName': 'trastuzumab emtansine'}]",A Study of Kadcyla (Trastuzumab Emtansine) in Patients With HER2 Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment,60079
20,NCT01730118,Phase I,Recruiting,"[{'id': 1404, 'therapyName': 'HER2 Vaccine'}]",Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing,60079
21,NCT01772472,Phase III,"Active, not recruiting","[{'id': 1402, 'therapyName': 'trastuzumab emtansine'}, {'id': 947, 'therapyName': 'Trastuzumab'}]",A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE),60079
22,NCT01783756,Phase Ib/II,"Active, not recruiting","[{'id': 1552, 'therapyName': 'Lapatinib + Capecitabine + Everolimus'}]","Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis",60079
23,NCT01796197,Phase II,"Active, not recruiting","[{'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa,60079
24,NCT01808573,Phase III,"Active, not recruiting","[{'id': 1399, 'therapyName': 'Lapatinib + Capecitabine'}, {'id': 1543, 'therapyName': 'Capecitabine + Neratinib'}]",A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting,60079
25,NCT01816035,Phase I,Completed,"[{'id': 1402, 'therapyName': 'trastuzumab emtansine'}]",Ado-Trastuzumab Emtansine in Treating Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed by Surgery,60079
26,NCT01828021,Phase II,Completed,"[{'id': 808, 'therapyName': 'MGAH22'}]",Phase 2 Study of the Monoclonal Antibody MGAH22(Margetuximab)in Patients With Relapsed or Refractory Advanced Breast Cancer,60079
27,NCT01848756,Phase Ib/II,Terminated,"[{'id': 866, 'therapyName': 'SNX-5422'}]",Safety and Efficacy of SNX-5422 in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Cancers,60079
28,NCT01853748,Phase II,Recruiting,"[{'id': 1551, 'therapyName': 'Trastuzumab + Paclitaxel'}, {'id': 1402, 'therapyName': 'trastuzumab emtansine'}]",T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial),60079
29,NCT01855828,Phase II,Recruiting,"[{'id': 1549, 'therapyName': 'Pertuzumab + Trastuzumab + Paclitaxel'}, {'id': 1550, 'therapyName': 'Pertuzumab + Trastuzumab + Fluorouracil + Epirubicin + Cyclophosphamide'}]",Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer,60079
30,NCT01873833,Phase II,Recruiting,"[{'id': 1559, 'therapyName': 'Capecitabine + Cyclophosphamide + Lapatinib + Trastuzumab'}]","Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer",60079
31,NCT01875666,Phase I,"Active, not recruiting","[{'id': 1414, 'therapyName': 'Trastuzumab + Lapatinib'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 856, 'therapyName': 'Pertuzumab'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}]","Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib",60079
32,NCT01901146,Phase III,Completed,"[{'id': 1087, 'therapyName': 'Epirubicin + Cyclophosphamide'}, {'id': 1551, 'therapyName': 'Trastuzumab + Paclitaxel'}]",Efficacy and Safety Study of ABP 980 Compared With Trastuzumab in Subjects With HER2 Positive Early Breast Cancer (Lilac),60079
33,NCT01904903,Phase II,Recruiting,"[{'id': 856, 'therapyName': 'Pertuzumab'}, {'id': 1402, 'therapyName': 'trastuzumab emtansine'}, {'id': 947, 'therapyName': 'Trastuzumab'}]",Cardiac Safety Study in Patients With HER2+ Breast Cancer (SAFE-HEaRt),60079
34,NCT01912963,Phase II,"Active, not recruiting","[{'id': 728, 'therapyName': 'Eribulin'}, {'id': 856, 'therapyName': 'Pertuzumab'}, {'id': 947, 'therapyName': 'Trastuzumab'}]","Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer",60079
35,NCT01921335,Phase I,"Active, not recruiting","[{'id': 1560, 'therapyName': 'ARRY-380 + Trastuzumab'}]",Phase I Dose-escalation Trial of ARRY-380 in Combination With Trastuzumab in Participants With Brain Metastases From HER2+ Breast Cancer,60079
36,NCT01922921,Phase Ib/II,"Active, not recruiting","[{'id': 1556, 'therapyName': 'HER-2/neu intracellular domain protein + Trastuzumab '}, {'id': 1558, 'therapyName': 'HER-2/neu intracellular domain protein + Trastuzumab + Polysaccharide-K'}]",Vaccine Therapy and Trastuzumab With or Without Polysaccharide-K in Treating Patients With Stage IV HER2 Positive Breast Cancer,60079
37,NCT01924351,Phase II,Withdrawn,[],HER2-positive Breast Cancer With Brain Metastasis (GCC 1345),60079
38,NCT01934894,Phase II,Terminated,"[{'id': 1572, 'therapyName': 'Cabazitaxel + Lapatinib'}]",Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases,60079
39,NCT01937117,Phase II,"Active, not recruiting","[{'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}]",Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer,60079
40,NCT01966471,Phase III,"Active, not recruiting","[{'id': 1492, 'therapyName': 'T-DM1 + Pertuzumab'}, {'id': 1978, 'therapyName': 'Pertuzumab + Trastuzumab + Docetaxel'}, {'id': 1549, 'therapyName': 'Pertuzumab + Trastuzumab + Paclitaxel'}]",A Study of Kadcyla (Trastuzumab Emtansine) Plus Perjeta (Pertuzumab) Following Anthracyclines in Comparison With Herceptin (Trastuzumab) Plus Perjeta and a Taxane Following Anthracyclines as Adjuvant Therapy in Patients With Operable HER2-Positive Primary Breast Cancer,60079
41,NCT01976169,Phase I,Recruiting,"[{'id': 1731, 'therapyName': 'PD-0332991 + T-DM1'}]",Phase 1b Study of PD-0332991 in Combination With T-DM1(Trastuzumab-DM1),60079
42,NCT01983501,Phase I,"Active, not recruiting","[{'id': 1573, 'therapyName': 'ARRY-380 + Trastuzumab emtansine'}]",A Phase 1b Study of ONT-380 Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer,60079
43,NCT01989676,Phase III,"Active, not recruiting","[{'id': 1551, 'therapyName': 'Trastuzumab + Paclitaxel'}]",A Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin® [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02),60079
44,NCT02000596,Phase II,Terminated,"[{'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 1911, 'therapyName': 'Anastrozole  + Fulvestrant'}]",Trastuzmab and Pertuzumab Alone or in Combination With Hormonal Therapy or Chemotherapy With Eribulin in Women Aged 60 and Over With HER2/Neu Overexpressed Locally Advanced or MBC,60079
45,NCT02003209,Phase III,"Active, not recruiting","[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 1879, 'therapyName': 'Pertuzumab + Trastuzumab + Carboplatin + Docetaxel'}]","Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",60079
46,NCT02014909,Phase I,Completed,"[{'id': 2054, 'therapyName': 'CDX-3379'}, {'id': 2063, 'therapyName': 'CDX-3379 + Vemurafenib'}, {'id': 2064, 'therapyName': 'CDX-3379 + Trastuzumab'}, {'id': 2061, 'therapyName': 'Cetuximab + CDX-3379'}, {'id': 2062, 'therapyName': 'CDX-3379 + Erlotinib'}]",A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors,60079
47,NCT02025192,Phase I,"Active, not recruiting","[{'id': 1560, 'therapyName': 'ARRY-380 + Trastuzumab'}, {'id': 1577, 'therapyName': 'ARRY-380 + Capecitabine'}]",A Phase 1b Study of ONT-380 Combined With Capecitabine and/or Trastuzumab in Patients With HER2+ Metastatic Breast Cancer,60079
48,NCT02038010,Phase I,"Active, not recruiting","[{'id': 1575, 'therapyName': 'BYL719 + Trastuzumab emtansine'}]",BYL719 + T-DM1 in HER2(+) Metastatic Breast Cancer Pts Who Progress on Prior Trastuzumab & Taxane Tx,60079
49,NCT02060253,Phase I,"Active, not recruiting","[{'id': 1579, 'therapyName': 'Ganetespib + Paclitaxel + Trastuzumab'}]","Ganetespib, Paclitaxel and Trastuzumab for Advanced or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Cancer",60079
50,NCT02061332,Phase Ib/II,"Active, not recruiting","[{'id': 5222, 'therapyName': 'HER2-pulsed DC1 vaccine'}]",DC Vaccine for Patients With Ductal Carcinoma In Situ,60079
51,NCT02063724,Phase I,"Active, not recruiting","[{'id': 5222, 'therapyName': 'HER2-pulsed DC1 vaccine'}]",HER-2 Pulsed DC Vaccine to Prevent Recurrence of Invasive Breast Cancer (Adjuvant),60079
52,NCT02066532,Phase Ib/II,Recruiting,"[{'id': 1578, 'therapyName': 'Ruxolitinib + Trastuzumab'}]",Phase I/II Trial of Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer,60079
53,NCT02073487,Phase II,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1583, 'therapyName': 'Trastuzumab emtansine + Lapatinib'}, {'id': 1414, 'therapyName': 'Trastuzumab + Lapatinib'}, {'id': 619, 'therapyName': 'Abraxane'}]",Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab With Lapatinib and Paclitaxel,60079
54,NCT02073916,Phase I,Recruiting,"[{'id': 1907, 'therapyName': 'T-DM1 + Lapatinib + Abraxane'}]",TDM1 With Abraxane and Lapatinib for Metastatic HER2 Positive Breast Cancer,60079
55,NCT02091960,Phase II,"Active, not recruiting","[{'id': 1878, 'therapyName': 'Enzalutamide + Trastuzumab'}]","A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Subjects With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) and Estrogen Receptor Negative (ER-) Metastatic or Locally Advanced Breast Cancer",60079
56,NCT02131064,Phase III,"Active, not recruiting","[{'id': 1492, 'therapyName': 'T-DM1 + Pertuzumab'}, {'id': 1879, 'therapyName': 'Pertuzumab + Trastuzumab + Carboplatin + Docetaxel'}]",A Study Comparing Kadcyla Plus Perjeta Treatment to Chemotherapy Combined With Herceptin Plus Perjeta in Patients With HER2-Positive Breast Cancer,60079
57,NCT02132949,Phase II,"Active, not recruiting","[{'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 1495, 'therapyName': 'Paclitaxel + Doxorubicin + Cyclophosphamide'}, {'id': 1895, 'therapyName': 'Cyclophosphamide + Fluorouracil + Docetaxel + Epirubicin  '}]","A Study Evaluating Perjeta (Pertuzumab) Combined With Herceptin (Trastuzumab) and Standard Anthracycline-based Chemotherapy in Patients With HER2-positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer.",60079
58,NCT02139358,Phase Ib/II,"Active, not recruiting","[{'id': 1592, 'therapyName': 'Gemcitabine + Trastuzumab + Pertuzumab'}]",Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer,60079
59,NCT02152943,Phase I,Recruiting,"[{'id': 1591, 'therapyName': 'Everolimus + Letrozole + Trastuzumab'}]","Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients",60079
60,NCT02154529,Phase Ib/II,Terminated,"[{'id': 1880, 'therapyName': 'XL647 + Trastuzumab'}]",Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer,60079
61,NCT02167854,Phase I,Recruiting,"[{'id': 2059, 'therapyName': 'BYL719 + LJM716 + Trastuzumab'}]","Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer",60079
62,NCT02187744,Phase III,Completed,"[{'id': 1485, 'therapyName': 'Trastuzumab + Docetaxel + Carboplatin'}]",A Study Of PF-05280014 Or Trastuzumab Plus Taxotere&#174; And Carboplatin In HER2 Positive Breast Cancer In The Neoadjuvant Setting (REFLECTIONS B327-04),60079
63,NCT02213042,Phase II,"Active, not recruiting","[{'id': 1414, 'therapyName': 'Trastuzumab + Lapatinib'}, {'id': 947, 'therapyName': 'Trastuzumab'}]",Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer,60079
64,NCT02213744,Phase II,Terminated,"[{'id': 1890, 'therapyName': 'Vinorelbine + Trastuzumab'}, {'id': 1409, 'therapyName': 'Capecitabine + Trastuzumab'}, {'id': 1889, 'therapyName': 'Gemcitabine + Trastuzumab'}, {'id': 1888, 'therapyName': 'MM-302 + Trastuzumab'}]",MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients,60079
65,NCT02229149,Phase II,"Active, not recruiting","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1105, 'therapyName': 'Capecitabine'}]","Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer",60079
66,NCT02236000,Phase Ib/II,Recruiting,"[{'id': 1906, 'therapyName': 'Neratinib + trastuzumab emtansine'}]",A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer,60079
67,NCT02252887,Phase II,"Active, not recruiting","[{'id': 1592, 'therapyName': 'Gemcitabine + Trastuzumab + Pertuzumab'}]","Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab-Based Therapy, TDM-1, and TDM-1 + Pertuzumab",60079
68,NCT02297230,Phase Ib/II,Completed,"[{'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1551, 'therapyName': 'Trastuzumab + Paclitaxel'}]",Locally Advanced Breast Cancer: Individualized Treatment Based On Tumor Molecular Characteristics,60079
69,NCT02297698,Phase II,Recruiting,"[{'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 3766, 'therapyName': 'E75'}]",Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients,60079
70,NCT02318901,Phase Ib/II,"Active, not recruiting","[{'id': 1909, 'therapyName': 'Pembrolizumab + trastuzumab emtansine'}, {'id': 1908, 'therapyName': 'Pembrolizumab + Trastuzumab'}, {'id': 1910, 'therapyName': 'Pembrolizumab + Cetuximab'}]",Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer,60079
71,NCT02326974,Phase II,Recruiting,"[{'id': 1492, 'therapyName': 'T-DM1 + Pertuzumab'}]",T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA,60079
72,NCT02336984,Phase Ib/II,"Active, not recruiting","[{'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 5222, 'therapyName': 'HER2-pulsed DC1 vaccine'}]",A Phase I/II Trial of HER-2/Neu Pulsed DC1 Vaccine Combined With Trastuzumab for Patients With DCIS,60079
73,NCT02345772,Phase I,Terminated,"[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 1978, 'therapyName': 'Pertuzumab + Trastuzumab + Docetaxel'}]","Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy (Taxotere, Trastuzumab and Pertuzumab) in Patients With HER2-positive and ER-Positive Breast Cancer",60079
74,NCT02390427,Phase I,Recruiting,"[{'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 856, 'therapyName': 'Pertuzumab'}, {'id': 1016, 'therapyName': 'GDC-0032'}]",Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer,60079
75,NCT02400476,Phase II,Recruiting,"[{'id': 828, 'therapyName': 'Neratinib'}]",A Study Looking the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide,60079
76,NCT02402712,Phase III,"Active, not recruiting","[{'id': 1978, 'therapyName': 'Pertuzumab + Trastuzumab + Docetaxel'}]",Phase IIIb Study to Evaluate the Safety and Tolerability of Herceptin SC With Perjeta and Docetaxel in Patients With HER2-positive Advanced Breast Cancer,60079
77,NCT02403271,Phase Ib/II,Completed,"[{'id': 2573, 'therapyName': 'Ibrutinib + MEDI4736'}]",A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors,60079
78,NCT02414646,Phase II,Recruiting,"[{'id': 947, 'therapyName': 'Trastuzumab'}]",Trastuzumab Emtansine in Treating Older Patients With Human Epidermal Growth Factor Receptor 2-Positive Stage I-III Breast Cancer,60079
79,NCT02492711,Phase III,Recruiting,"[{'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 808, 'therapyName': 'MGAH22'}]",Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer,60079
80,NCT02500199,Phase I,Recruiting,"[{'id': 3082, 'therapyName': 'Pyrotinib'}]",Open Label Oral Use of Pyrotinib in Patients With HER2 Positive Solid Tumors Who Failed Prior HER2 Targeted Therapy,60079
81,NCT02536339,Phase II,"Active, not recruiting","[{'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}]",Pertuzumab With High-Dose Trastuzumab in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy,60079
82,NCT02571530,Phase I,Recruiting,"[{'id': 947, 'therapyName': 'Trastuzumab'}]",Super-selective Intra-arterial Cerebral Infusion of Trastuzumab for the Treatment of Cerebral Metastases of HER2/Neu Positive Breast Cancer,60079
83,NCT02598427,Phase I,Recruiting,"[{'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}]",Intrathecal Pertuzumab and Trastuzumab in Patients With New Untreated Asymptomatic or Low Symptomatic Brain Metastasis in HER2 Positive Breast Cancer,60079
84,NCT02605915,Phase I,Recruiting,"[{'id': 3250, 'therapyName': 'Atezolizumab + Trastuzumab'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 856, 'therapyName': 'Pertuzumab'}]",Safety and Pharmacokinetics of Atezolizumab in Combination With Trastuzumab Emtansine or With Trastuzumab and Pertuzumab in Participants With HER2-Positive Breast Cancer,60079
85,NCT02614794,Phase II,Recruiting,"[{'id': 3340, 'therapyName': 'ARRY-380 + Capecitabine + Trastuzumab'}, {'id': 1409, 'therapyName': 'Capecitabine + Trastuzumab'}]",Study of ONT-380 vs Placebo in Combo w/ Capecitabine & Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer,60079
86,NCT02649686,Phase I,"Active, not recruiting","[{'id': 4218, 'therapyName': 'MEDI4736 + Trastuzumab'}]",Durvalumab in Patients With HER-2 Positive Metastatic Breast Cancer Receiving Trastuzumab,60079
87,NCT02650752,Phase I,Recruiting,"[{'id': 1399, 'therapyName': 'Lapatinib + Capecitabine'}]",Intermittent High-Dose Lapatinib in Tandem With Capecitabine for HER2 Overexpressed/Amplified Metastatic Breast Cancer With Central Nervous System (CNS) Metastases,60079
88,NCT02654119,Phase II,Recruiting,"[{'id': 1898, 'therapyName': 'Cyclophosphamide + Paclitaxel + Trastuzumab '}]","Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Patients With Stage I-II HER2/Neu Positive Breast Cancer After Surgery",60079
89,NCT02657343,Phase Ib/II,Recruiting,"[{'id': 790, 'therapyName': 'Ribociclib'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1402, 'therapyName': 'trastuzumab emtansine'}]","An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.",60079
90,NCT02658084,Phase Ib/II,Recruiting,"[{'id': 3429, 'therapyName': 'Trastuzumab emtansine + Vinorelbine'}]",Vinorelbine With Trastuzumab Emtansine in Pre-Treated HER2-Positive Metastatic Breast Cancer,60079
91,NCT02659514,Phase II,Recruiting,"[{'id': 1042, 'therapyName': 'poziotinib'}]",Study of Poziotinib in Patients With HER2-Positive Metastatic Breast Cancer,60079
92,NCT02675231,Phase II,Recruiting,"[{'id': 802, 'therapyName': 'Abemaciclib'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 744, 'therapyName': 'Fulvestrant'}]","A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer",60079
93,NCT02689921,Phase II,Recruiting,"[{'id': 633, 'therapyName': 'Anastrozole'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 738, 'therapyName': 'Exemestane'}]",NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer (NEOADAPT),60079
94,NCT02774681,Phase II,Recruiting,"[{'id': 3041, 'therapyName': 'Palbociclib + Trastuzumab'}]",Palbociclib in Treating Patients With Metastatic HER-2 Positive or Triple-Negative Breast Cancer With Brain Metastasis,60079
95,NCT02789657,Phase II,Recruiting,"[{'id': 4235, 'therapyName': 'Carboplatin + Pertuzumab + Trastuzumab + Paclitaxel'}, {'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}]",BrUOG 308: Efficacy of wPCbTP and Switching to an AC in Non-responding Patients as Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer.,60079
96,NCT02827877,Phase I,Recruiting,"[{'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}]",Copper (Cu) 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Trastuzumab and Pertuzumab Before Surgery in Patients With HER2 Positive Breast Cancer,60079
97,NCT02892123,Phase I,Recruiting,"[{'id': 6240, 'therapyName': 'ZW25'}]",Trial of ZW25 in Patients With Advanced HER2-expressing Cancers,60079
98,NCT02907918,Phase II,Recruiting,"[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 4756, 'therapyName': 'Letrozole + Palbociclib + Trastuzumab'}]",Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer (PALTAN),60079
99,NCT02924883,Phase II,"Active, not recruiting","[{'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 3250, 'therapyName': 'Atezolizumab + Trastuzumab'}]",A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab and Taxane Based Therapy,60079
100,NCT02947685,Phase III,Recruiting,"[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 856, 'therapyName': 'Pertuzumab'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 947, 'therapyName': 'Trastuzumab'}]","Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer (PATINA)",60079
101,NCT03054363,Phase Ib/II,Not yet recruiting,"[{'id': 5334, 'therapyName': 'ARRY-380 + Palbociclib + Letrozole'}]","Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer",60079
102,NCT03112590,Phase Ib/II,Recruiting,"[{'id': 5548, 'therapyName': 'Interferon gamma + Paclitaxel + Pertuzumab + Trastuzumab'}]",Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer,60079
103,NCT03125928,Phase II,Recruiting,"[{'id': 5600, 'therapyName': 'Atezolizumab + Paclitaxel + Trastuzumab + Pertuzumab'}]","Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer",60079
104,NCT03135171,Phase I,Recruiting,"[{'id': 5648, 'therapyName': 'Pertuzumab + Tocilizumab + Trastuzumab'}]",Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to Trastuzumab,60079
105,NCT03155997,Phase III,Recruiting,"[{'id': 802, 'therapyName': 'Abemaciclib'}]",A Study to Compare Treatment After Surgery of Abemaciclib (LY2835219) Combined With Standard Endocrine Therapy Versus Endocrine Therapy Alone in Participants With Breast Cancer,60079
106,NCT03190967,Phase Ib/II,Recruiting,"[{'id': 1402, 'therapyName': 'trastuzumab emtansine'}, {'id': 5932, 'therapyName': 'Temozolomide + Trastuzumab emtansine'}]",T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery,60079
107,NCT03304080,Phase Ib/II,Not yet recruiting,"[{'id': 6323, 'therapyName': 'Anastrozole + Palbociclib + Pertuzumab + Trastuzumab'}]","Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in Her-positive, Her2-positive Metastatic Breast",60079
0,NCT02978625,Phase II,Recruiting,"[{'id': 5080, 'therapyName': 'Talimogene laherparepvec + Nivolumab'}]",Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers,3896
0,NCT01446809,Phase I,"Active, not recruiting","[{'id': 1472, 'therapyName': 'Doxorubicin + Ifosfamide'}, {'id': 1471, 'therapyName': 'Pazopanib + Doxorubicin + Ifosfamide'}]",Pazopanib Hydrochloride Followed By Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma,4231
0,NCT03210714,Phase II,Not yet recruiting,"[{'id': 1028, 'therapyName': 'JNJ-42756493'}]","Pediatric MATCH: Pan-FGFR Tyrosine Kinase Inhibitor JNJ-42756493 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations",3405
1,NCT03213652,Phase II,Recruiting,"[{'id': 961, 'therapyName': 'X-396'}]","Pediatric MATCH: Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations",3405
2,NCT03213665,Phase II,Recruiting,"[{'id': 2683, 'therapyName': 'Tazemetostat'}]","Pediatric MATCH: Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations",3405
3,NCT03213691,Phase II,Recruiting,"[{'id': 913, 'therapyName': 'Selumetinib'}]","Pediatric MATCH: Selumetinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations",3405
4,NCT03220035,Phase II,Recruiting,"[{'id': 342, 'therapyName': 'Vemurafenib'}]","Pediatric MATCH: Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations",3405
5,NCT03233204,Phase II,Recruiting,"[{'id': 837, 'therapyName': 'Olaparib'}]","Pediatric MATCH: Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes",3405
0,NCT00513474,Phase I,Completed,"[{'id': 2313, 'therapyName': 'Rasburicase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2314, 'therapyName': 'Busulfan + Cyclophosphamide + Etoposide'}]",Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant,8567
1,NCT00576654,Phase I,Recruiting,"[{'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 954, 'therapyName': 'Veliparib'}]",Irinotecan Hydrochloride and Veliparib in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery,8567
2,NCT00602693,Phase I,Completed,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 2311, 'therapyName': 'Allopurinol + Cyclophosphamide + Fludarabine'}]",T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer,8567
3,NCT00838955,Phase II,Unknown status,"[{'id': 936, 'therapyName': 'Temsirolimus'}]",Temsirolimus for Relapsed/Refractory Hodgkin's Lymphoma,8567
4,NCT00857389,Phase II,"Active, not recruiting","[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 2469, 'therapyName': 'Busulfan + Clofarabine + Thymoglobulin'}, {'id': 1639, 'therapyName': 'Methotrexate'}]",Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies,8567
5,NCT01032148,Phase I,Terminated,"[{'id': 1080, 'therapyName': 'Panobinostat'}]","Study of LBH589, A Deacetylase Inhibitor in Patients With Recurrent or Refractory Hodgkin or Non-Hodgkin's Lymphoma",8567
6,NCT01076543,Phase Ib/II,"Active, not recruiting","[{'id': 2280, 'therapyName': 'Temsirolimus + Lenalidomide'}]",Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma,8567
7,NCT01169636,Phase Ib/II,Completed,"[{'id': 1080, 'therapyName': 'Panobinostat'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 2352, 'therapyName': 'Carboplatin + Etoposide + Ifosfamide '}]","Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma",8567
8,NCT01251575,Phase II,Recruiting,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 2270, 'therapyName': 'Cyclosporine + Mycophenolate mofetil + Sirolimus'}]","Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant",8567
9,NCT01476839,Phase I,Recruiting,"[{'id': 6258, 'therapyName': 'Basiliximab + 90Y basiliximab + Carmustine + Cytarbine + Etoposide + Melphalan'}]",Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma,8567
10,NCT01592370,Phase I,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 2583, 'therapyName': 'Lirilumab '}]",Safety Study in Nivolumab Alone and in Combination With Ipilimumab or Lirilumab in Lymphoma and Multiple Myeloma,8567
11,NCT01609816,Phase Ib/II,Recruiting,"[{'id': 717, 'therapyName': 'Dasatinib'}]","Dasatinib in Treating Patients With Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma Previously Treated With Autologous Stem Cell Transplant",8567
12,NCT01621477,Phase II,Terminated,"[{'id': 1756, 'therapyName': 'Plerixafor'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 2469, 'therapyName': 'Busulfan + Clofarabine + Thymoglobulin'}, {'id': 1783, 'therapyName': 'Cyclophosphamide + Cytarabine'}]",T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant,8567
13,NCT01701986,Phase Ib/II,Recruiting,"[{'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 3992, 'therapyName': 'Busulfan + Clofarabine + Gemcitabine'}]",Gemcitabine/Clofarabine/Busulfan and Allogeneic Transplantation for Aggressive Lymphomas,8567
14,NCT01716806,Phase II,Recruiting,"[{'id': 3263, 'therapyName': 'Brentuximab vedotin + Nivolumab'}, {'id': 5055, 'therapyName': 'Brentuximab vedotin + Bendamustine'}, {'id': 5056, 'therapyName': 'Brentuximab vedotin + Dacarbazine'}, {'id': 2486, 'therapyName': 'Brentuximab vedotin'}]",A Study of Brentuximab Vedotin in Adults Age 60 and Above With Newly Diagnosed Hodgkin Lymphoma (HL),8567
15,NCT01745354,Phase I,Terminated,"[{'id': 3084, 'therapyName': 'SD-101'}]",Immunostimulatory CpG SD-101 + RT in Recurrent/Progressive Lymphoma After Allogeneic Hematopoietic Cell Transplantation (HCT),8567
16,NCT01822509,Phase I,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant,8567
17,NCT01896999,Phase I,Recruiting,"[{'id': 2487, 'therapyName': 'Brentuximab vedotin + Ipilimumab'}]",Ipilimumab and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma,8567
18,NCT01897012,Phase I,Recruiting,"[{'id': 1075, 'therapyName': 'romidepsin'}, {'id': 626, 'therapyName': 'Alisertib'}]",Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas,8567
19,NCT01905813,Phase I,"Active, not recruiting","[{'id': 2420, 'therapyName': 'INCB039110 + INCB040093'}, {'id': 2021, 'therapyName': 'INCB040093'}]",Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies,8567
20,NCT01949883,Phase I,Recruiting,"[{'id': 2033, 'therapyName': 'CPI-0610'}]",A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma,8567
21,NCT01953692,Phase I,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013)(KEYNOTE-013),8567
22,NCT01983969,Phase Ib/II,"Active, not recruiting","[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 2557, 'therapyName': 'Azacitidine + Gemcitabine + vorinostat'}]",Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma,8567
23,NCT02018861,Phase I,"Active, not recruiting","[{'id': 2406, 'therapyName': 'INCB039110'}, {'id': 3097, 'therapyName': 'INCB039110 + INCB050465'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 2352, 'therapyName': 'Carboplatin + Etoposide + Ifosfamide '}, {'id': 3088, 'therapyName': 'INCB050465 '}]","A Phase 1, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 Monotherapy and in Combination With INCB039110 in Subjects With Previously Treated B-Cell Malignancies",8567
24,NCT02061761,Phase Ib/II,Recruiting,"[{'id': 4197, 'therapyName': 'BMS-986016 + Nivolumab'}, {'id': 4196, 'therapyName': 'BMS-986016'}]",Safety Study of Anti-LAG-3 in Relapsed or Refractory Hematologic Malignancies,8567
25,NCT02091063,Phase Ib/II,Recruiting,"[{'id': 1613, 'therapyName': 'ACY-1215'}]",ACY-1215 for Relapsed/Refractory Lymphoid Malignancies,8567
26,NCT02104427,Phase II,Completed,"[{'id': 2853, 'therapyName': 'TG-0054'}, {'id': 1632, 'therapyName': 'Filgrastim'}]","PD and Safety of TG-0054 Combined With G-CSF in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients",8567
27,NCT02130869,Phase I,Recruiting,"[{'id': 2378, 'therapyName': 'Bendamustine + Cytarabine + Etoposide'}, {'id': 2460, 'therapyName': 'Busulfan + Hu14.18K322A'}, {'id': 2459, 'therapyName': 'Aldesleukin + Melphalan + Sargramostim'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}]",A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas,8567
28,NCT02164006,Phase I,"Active, not recruiting","[{'id': 2022, 'therapyName': 'TGR-1202'}]","Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma Patients",8567
29,NCT02181218,Phase I,Recruiting,"[{'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1611, 'therapyName': 'Gemcitabine + Oxaliplatin + Dexamethasone'}]","Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas",8567
30,NCT02181738,Phase II,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}]",Study of Nivolumab in Subjects With Hodgkin's Lymphoma (Registrational) (CheckMate 205),8567
31,NCT02200380,Phase II,Terminated,"[{'id': 1756, 'therapyName': 'Plerixafor'}, {'id': 3007, 'therapyName': 'CDX-301'}]",A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs,8567
32,NCT02208037,Phase II,"Active, not recruiting",[],Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203),8567
33,NCT02254239,Phase I,"Active, not recruiting","[{'id': 735, 'therapyName': 'Everolimus'}]",Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma,8567
34,NCT02304458,Phase Ib/II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas,8567
35,NCT02327078,Phase Ib/II,Recruiting,"[{'id': 3059, 'therapyName': 'INCB024360 + Nivolumab'}]","A Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination With Nivolumab in Select Advanced Cancers",8567
36,NCT02343666,Phase I,Recruiting,"[{'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1756, 'therapyName': 'Plerixafor'}, {'id': 2556, 'therapyName': 'O6-benzylguanine'}]",HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV Infection,8567
37,NCT02362997,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab After ASCT for Hodgkin Lymphoma and DLBCL,8567
38,NCT02376699,Phase I,Recruiting,"[{'id': 5781, 'therapyName': 'Pembrolizumab + SEA-CD40'}, {'id': 5780, 'therapyName': 'SEA-CD40'}]",Safety Study of SEA-CD40 in Cancer Patients,8567
39,NCT02408042,Phase Ib/II,Withdrawn,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 2352, 'therapyName': 'Carboplatin + Etoposide + Ifosfamide '}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2486, 'therapyName': 'Brentuximab vedotin'}]",Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme),8567
40,NCT02429375,Phase Ib/II,"Active, not recruiting","[{'id': 3264, 'therapyName': 'Brentuximab vedotin + Mocetinostat'}]",Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma,8567
41,NCT02453594,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087),8567
42,NCT02541604,Phase I,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}]","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of MPDL3280A (Anti-PD-L1 Antibody) in Pediatric and Young Adult Participants With Solid Tumors",8567
43,NCT02572167,Phase Ib/II,"Active, not recruiting","[{'id': 3263, 'therapyName': 'Brentuximab vedotin + Nivolumab'}]",A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma,8567
44,NCT02576496,Phase I,Recruiting,"[{'id': 6104, 'therapyName': 'EDO-S101'}]","Study of EDO-S101, A First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies",8567
45,NCT02595866,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms",8567
46,NCT02603419,Phase I,Recruiting,"[{'id': 3144, 'therapyName': 'Avelumab'}]",Avelumab In Patients With Previously Treated Advanced Stage Classical Hodgkin's Lymphoma (JAVELIN HODGKINS),8567
47,NCT02613598,Phase I,Recruiting,"[{'id': 3262, 'therapyName': 'Bortezomib + Ruxolitinib'}]",Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma,8567
48,NCT02624258,Phase I,Recruiting,"[{'id': 6000, 'therapyName': 'RNA CART19 cells'}]","Pilot Study of Non-Viral, RNA-Redirected Autologous T Cells in Patients With Refractory or Relapsed Hodgkin Lymphoma",8567
49,NCT02651662,Phase I,Recruiting,"[{'id': 5656, 'therapyName': 'REGN2810'}, {'id': 6152, 'therapyName': 'REGN1979 + REGN2810'}]",Study of REGN2810 and REGN1979 in Patients With Lymphoma,8567
50,NCT02665650,Phase I,Recruiting,"[{'id': 4390, 'therapyName': 'AFM13 + Pembrolizumab'}]",Study of the Combination of AFM13 and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma,8567
51,NCT02684292,Phase III,Recruiting,"[{'id': 2486, 'therapyName': 'Brentuximab vedotin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204),8567
52,NCT02701673,Phase Ib/II,Withdrawn,"[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 3277, 'therapyName': 'Pyridoxine'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1078, 'therapyName': 'Belinostat'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}]",Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma,8567
53,NCT02722668,Phase II,Recruiting,"[{'id': 2281, 'therapyName': 'Cyclophosphamide + Fludarabine + Mycophenolate mofetil'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}]",UCB Transplant for Hematological DIseases Using a Non Myeloablative Prep,8567
54,NCT02744612,Phase II,Recruiting,"[{'id': 4300, 'therapyName': 'Brentuximab vedotin + Ibrutinib'}]",Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma,8567
55,NCT02758717,Phase II,Recruiting,"[{'id': 3263, 'therapyName': 'Brentuximab vedotin + Nivolumab'}]",Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma,8567
56,NCT02824029,Phase II,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma,8567
57,NCT02867618,Phase Ib/II,Recruiting,"[{'id': 4598, 'therapyName': 'Carfilzomib + TGR-1202'}]",Carfilzomib and TGR-1202 in Treatment of R/R Lymphoma,8567
58,NCT02869633,Phase II,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant,8567
59,NCT02875067,Phase Ib/II,Recruiting,"[{'id': 3322, 'therapyName': 'lenalidomide + Pembrolizumab'}]","Safety & Efficacy Study of Combination of Pembrolizumab and Lenalidomide, in Patients With Relapsed Non-Hodgkin and Hodgkin Lymphoma",8567
60,NCT02927769,Phase II,Recruiting,"[{'id': 3263, 'therapyName': 'Brentuximab vedotin + Nivolumab'}, {'id': 5055, 'therapyName': 'Brentuximab vedotin + Bendamustine'}]","A Study of Nivolumab + Brentuximab Vedotin in Children, Adolescents, and Young Adults With Classic Hodgkin Lymphoma (cHL) After Failure of First Line Therapy, Followed by Brentuximab Vedotin + Bendamustine for Participants With a Suboptimal Response (CheckMate 744)",8567
61,NCT02940301,Phase II,Recruiting,"[{'id': 3198, 'therapyName': 'Ibrutinib + Nivolumab'}]",Ibrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma,8567
62,NCT02961816,Phase II,Withdrawn,"[{'id': 3277, 'therapyName': 'Pyridoxine'}, {'id': 4976, 'therapyName': 'Busulfan + Gemcitabine + Melphalan + Panobinostat'}, {'id': 4977, 'therapyName': 'Dexamethasone + Filgrastim + Palifermin + Rituximab'}]",Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma,8567
63,NCT02973113,Phase I,Recruiting,"[{'id': 5058, 'therapyName': 'EB-VST cells + Nivolumab'}]","Nivolumab With Epstein Barr Virus Specific T Cells (EB-VSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE) (PREVALE)",8567
64,NCT03015896,Phase Ib/II,Suspended,"[{'id': 5239, 'therapyName': 'Lenalidomide + Nivolumab'}]",Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma,8567
65,NCT03016871,Phase II,Recruiting,"[{'id': 5198, 'therapyName': 'Nivolumab + Etoposide + Ifosfamide + Carboplatin'}]","Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed Hodgkin Lymphoma",8567
66,NCT03033914,Phase I,Recruiting,"[{'id': 5296, 'therapyName': 'Dacarbazine + Doxorubicin + Vinblastine + Nivolumab'}, {'id': 5295, 'therapyName': 'Bleomycin + Dacarbazine + Doxorubicin + Vinblastine + Nivolumab'}]",A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma,8567
67,NCT03057795,Phase II,Recruiting,"[{'id': 3263, 'therapyName': 'Brentuximab vedotin + Nivolumab'}]",Nivolumab and Brentuximab Vedotin After Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Classical Hodgkin Lymphoma,8567
68,NCT03077828,Phase II,Recruiting,"[{'id': 5435, 'therapyName': 'Pembrolizumab + Etoposide + Carboplatin + Ifosfamide'}]",Pembrolizumab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma,8567
69,NCT03120676,Phase II,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}]",Study of Atezolizumab in Relapsed or Refractory Hodgkin Lymphoma,8567
70,NCT03138499,Phase III,Recruiting,"[{'id': 2486, 'therapyName': 'Brentuximab vedotin'}, {'id': 3263, 'therapyName': 'Brentuximab vedotin + Nivolumab'}]","Phase III Trial of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant,",8567
71,NCT03150329,Phase I,Recruiting,"[{'id': 3077, 'therapyName': 'Pembrolizumab + Vorinostat'}]","Pembrolizumab and Vorinostat in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, or Hodgkin Lymphoma",8567
72,NCT03179917,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab and Involved Site Radiation Therapy for Early Stage Relapsed or Primary Refractory Hodgkin Lymphoma,8567
73,NCT03179930,Phase II,Recruiting,"[{'id': 3354, 'therapyName': 'Entinostat + Pembrolizumab'}]",Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas,8567
74,NCT03226249,Phase II,Not yet recruiting,"[{'id': 6157, 'therapyName': 'Dacarbazine + Doxorubicin + Pembrolizumab +Vinblastine'}]",PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma,8567
75,NCT03233347,Phase II,Not yet recruiting,"[{'id': 6328, 'therapyName': 'Brentuximab vedotin + Dacarbazine + Doxorubicin + Nivolumab + Vinblastine'}]","Doxorubicin Hydrochloride, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma",8567
76,NCT03236935,Phase I,Not yet recruiting,"[{'id': 6097, 'therapyName': 'L-NMMA + Pembrolizumab'}]",Phase Ib of L-NMMA and Pembrolizumab,8567
77,NCT03259503,Phase Ib/II,Not yet recruiting,"[{'id': 1206, 'therapyName': 'Busulfan'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 2373, 'therapyName': 'Palifermin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 3277, 'therapyName': 'Pyridoxine'}, {'id': 897, 'therapyName': 'Rituximab'}]",Olaparib Combined With High-Dose Chemotherapy for Refractory Lymphomas,8567
0,NCT03015896,Phase Ib/II,Suspended,"[{'id': 5239, 'therapyName': 'Lenalidomide + Nivolumab'}]",Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma,8543
0,NCT00904345,Phase II,"Active, not recruiting","[{'id': 694, 'therapyName': 'Cetuximab'}]",Study of Radiation (RT) Concurrent With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (SCC),8533
1,NCT01218048,Phase II,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 694, 'therapyName': 'Cetuximab'}]",ERBITUX; Followed by Adjuvant Treatment With Chemoradiation and ERBITUX; for Locally Advanced Head and Neck Squamous Cell Carcinoma,8533
2,NCT01467115,Phase II,Completed,"[{'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1930, 'therapyName': 'Cisplatin + Docetaxel + Fluorouracil'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 694, 'therapyName': 'Cetuximab'}]",INDUCTION CHEMOTHERAPY FOLLOWED BY CETUXIMAB AND RADIATION THERAPY FOR HEAD AND NECK CANCER,8533
3,NCT01732640,Phase Ib/II,Completed,"[{'id': 2442, 'therapyName': 'Afatinib + Carboplatin + Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}]",A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy In HPV-Negative HNSCC.,8533
4,NCT01758731,Phase I,"Active, not recruiting","[{'id': 1999, 'therapyName': 'Olaparib + Cetuximab'}]",Study of Olaparib With Radiation Therapy and Cetuximab in Advanced Head and Neck Cancer With Heavy Smoking History,8533
5,NCT01783587,Phase I,Recruiting,"[{'id': 623, 'therapyName': 'Afatinib'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Safety Study of Afatinib and Postoperative Radiation Therapy to Treat Head and Neck Cancer,8533
6,NCT01810913,Phase II,"Active, not recruiting","[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1925, 'therapyName': 'Docetaxel + Cetuximab'}]","Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer",8533
7,NCT01824823,Phase II,Terminated,"[{'id': 623, 'therapyName': 'Afatinib'}]",Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence,8533
8,NCT01860430,Phase I,"Active, not recruiting","[{'id': 1926, 'therapyName': 'Cetuximab + Ipilimumab'}]",A Phase Ib Trial of Concurrent Cetuximab (ERBITUX) and Intensity Modulated Radiotherapy (IMRT) With Ipilimumab (YERVOY) in Locally Advanced Head and Neck Cancer,8533
9,NCT01935921,Phase I,"Active, not recruiting","[{'id': 1926, 'therapyName': 'Cetuximab + Ipilimumab'}]","Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer",8533
10,NCT02107235,Phase I,Completed,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1046, 'therapyName': 'rigosertib'}]",Platinum-based Chemoradiotherapy and Rigosertib in Head and Neck Cancer,8533
11,NCT02113878,Phase I,Recruiting,"[{'id': 1691, 'therapyName': 'BKM120 + Cisplatin'}]",Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck,8533
12,NCT02124850,Phase I,Recruiting,"[{'id': 694, 'therapyName': 'Cetuximab'}]",A Phase Ib Study of Neoadjuvant Immune Biomarker Modulation With ERBITUX&#174; (Cetuximab) and VTX-2337,8533
13,NCT02128906,Phase II,Recruiting,"[{'id': 1925, 'therapyName': 'Docetaxel + Cetuximab'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC,8533
14,NCT02177838,Phase II,Suspended,"[{'id': 1915, 'therapyName': 'Cetuximab + Cisplatin'}]",Cetuximab and Radiation Therapy in Treating Patients With Stage III-IV Head and Neck Cancer,8533
15,NCT02196168,Phase II,Terminated,"[{'id': 822, 'therapyName': 'MK-1775'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer,8533
16,NCT02201355,Phase I,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}]","Reduced-Volume Hypofractionated, PET-directed Intensity Modulated Radiotherapy Concurrent With Weekly Cisplatin Chemotherapy for Squamous Cell Carcinoma of the Head and Neck",8533
17,NCT02262741,Phase I,"Active, not recruiting","[{'id': 1652, 'therapyName': 'Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]","A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 With Tremelimumab or Tremelimumab Alone in Head and Neck Cancer",8533
18,NCT02289209,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Reirradiation With MK-3475 in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck,8533
19,NCT02296684,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma,8533
20,NCT02334319,Phase I,Terminated,"[{'id': 745, 'therapyName': 'Ganetespib'}]",Ganetespib Window of Opportunity Study in Head and Neck Cancers,8533
21,NCT02358031,Phase III,"Active, not recruiting","[{'id': 694, 'therapyName': 'Cetuximab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}]",A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048),8533
22,NCT02381535,Phase I,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 645, 'therapyName': 'AT13387'}]",Hsp90 Inhibitor AT13387 in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Radiation Therapy and Cisplatin,8533
23,NCT02449681,Phase II,Terminated,"[{'id': 2910, 'therapyName': 'TH-4000'}]",Study for Treatment of Patients With Recurrent or Metastatic SCCHN or SCCS,8533
24,NCT02454179,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1605, 'therapyName': 'Acalabrutinib'}]",Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Advanced Head and Neck Squamous Cell Carcinoma,8533
25,NCT02473731,Phase I,Completed,"[{'id': 2054, 'therapyName': 'CDX-3379'}]",A Window of Opportunity Study of KTN3379 in Surgically Resectable Head and Neck Cancer Patients,8533
26,NCT02499120,Phase II,Recruiting,"[{'id': 850, 'therapyName': 'Palbociclib'}, {'id': 694, 'therapyName': 'Cetuximab'}]",Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer,8533
27,NCT02499328,Phase Ib/II,Recruiting,"[{'id': 3098, 'therapyName': 'AZD9150 + MEDI4736'}, {'id': 3099, 'therapyName': 'AZD5069 + MEDI4736'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 2782, 'therapyName': 'AZD9150 '}]",Study to Assess Combination of MEDI4736 With Either AZD9150 or AZD5069 in Patients With Metastatic Squamous Cell Carcinoma of Head and Neck,8533
28,NCT02551159,Phase III,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 1914, 'therapyName': 'Cetuximab + Carboplatin + Fluorouracil'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]",Phase III Open Label First Line Therapy Study of MEDI 4736 With or Without Tremelimumab Versus Standard of Care (SOC) in SCCHN,8533
29,NCT02555644,Phase I,Recruiting,"[{'id': 1651, 'therapyName': 'Prexasertib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 694, 'therapyName': 'Cetuximab'}]",A Study of LY2606368 With Chemotherapy and Radiation in Participants With Head and Neck Cancer,8533
30,NCT02573493,Phase II,Recruiting,"[{'id': 3126, 'therapyName': 'Cisplatin + nab-paclitaxel'}, {'id': 3127, 'therapyName': 'Cetuximab + nab-paclitaxel'}]",Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC),8533
31,NCT02585973,Phase I,Recruiting,"[{'id': 1725, 'therapyName': 'MK-1775 + Cisplatin'}]",Dose-escalating AZD1775 + Concurrent Radiation + Cisplatin for Intermediate/High Risk HNSCC,8533
32,NCT02586207,Phase I,Recruiting,"[{'id': 3256, 'therapyName': 'Cisplatin + Pembrolizumab'}]",Pembrolizumab in Combination With CRT for LA-SCCHN,8533
33,NCT02643550,Phase Ib/II,Recruiting,"[{'id': 3383, 'therapyName': 'Cetuximab + IPH2201'}]",Study of IPH2201 (Monalizumab) and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck,8533
34,NCT02741570,Phase III,Recruiting,"[{'id': 4168, 'therapyName': 'Carboplatin + Cetuximab + Cisplatin + Fluorouracil'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Study Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck,8533
35,NCT02764593,Phase I,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 4760, 'therapyName': 'Cisplatin + Nivolumab'}, {'id': 4761, 'therapyName': 'Cetuximab + Nivolumab'}]",Chemotherapy +/- Nivolumab in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma,8533
36,NCT02769520,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","Efficacy Study of Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Cancer of the Head and Neck",8533
37,NCT02775812,Phase I,Recruiting,"[{'id': 3256, 'therapyName': 'Cisplatin + Pembrolizumab'}]","Cisplatin, Radiation Therapy, and Pembrolizumab in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma",8533
38,NCT02777385,Phase II,Recruiting,"[{'id': 3256, 'therapyName': 'Cisplatin + Pembrolizumab'}]",Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Head and Neck Cancer,8533
39,NCT02892201,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in HNSCC With Residual Disease After Radiation,8533
40,NCT03040999,Phase III,Recruiting,"[{'id': 3256, 'therapyName': 'Cisplatin + Pembrolizumab'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412),8533
41,NCT03162731,Phase I,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]","Nivolumab, Ipilimumab, and Radiation Therapy in Treating Patients With Stage IVA-B Head and Neck Cancer",8533
42,NCT03238365,Phase I,Recruiting,"[{'id': 6100, 'therapyName': 'Nivolumab + Tadalafil'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab With or Without Tadalafil in Treating Patients With Recurrent Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery,8533
0,NCT02949219,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Treating Patients With Small Bowel Adenocarcinoma That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery,10153
0,NCT01326871,Phase Ib/II,"Active, not recruiting","[{'id': 2187, 'therapyName': 'ALT-801'}]",A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer,50620
0,NCT01326871,Phase Ib/II,"Active, not recruiting","[{'id': 2187, 'therapyName': 'ALT-801'}]",A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer,6845
0,NCT02971748,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Study of Anti-PD-1 (Pembrolizumab) + Hormonal Therapy in HR-positive Localized IBC Patients With Non-pCR to Neoadjuvant Chemotherapy,6263
1,NCT03202316,Phase II,Recruiting,"[{'id': 5970, 'therapyName': 'Atezolizumab + Cobimetinib + Eribulin'}]",Study of Triple Combination of Atezolizumab + Cobimetinib + Eribulin (ACE) in Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer,6263
0,NCT02831179,Phase I,Withdrawn,"[{'id': 4463, 'therapyName': 'Capecitabine + Veliparib + Temozolomide'}]","Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor",3892
0,NCT02428855,Phase II,"Active, not recruiting","[{'id': 717, 'therapyName': 'Dasatinib'}]",Phase II Trial of Dasatinib in Patients With Isocitrate Dehydrogenase (IDH)-Mutant Advanced Intrahepatic Cholangiocarcinoma,4928
1,NCT02834013,Phase 0,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab in Treating Patients With Rare Tumors,4928
2,NCT03230318,Phase III,Recruiting,"[{'id': 2900, 'therapyName': 'ARQ 087'}]",ARQ 087 in Subjects With FGFR2 Gene Fusion Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma,4928
0,NCT02097134,Phase I,"Active, not recruiting","[{'id': 1207, 'therapyName': 'Melphalan'}]",Intra-arterial Melphalan in Treating Younger Patients With Unilateral Retinoblastoma,4653
1,NCT02116959,Phase I,Unknown status,"[{'id': 2559, 'therapyName': 'Carboplatin + Etoposide + Melphalan + Vincristine'}]",Alternating Systemic Chemotherapy and Intra-Arterial Melphalan Chemotherapy in Children With Intra-Ocular Retinoblastoma,4653
0,NCT01326871,Phase Ib/II,"Active, not recruiting","[{'id': 2187, 'therapyName': 'ALT-801'}]",A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer,6477
1,NCT03244384,Phase III,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Treating Patients With Locally Advanced Bladder Cancer,6477
0,NCT02206984,Phase I,Recruiting,"[{'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",Endocrine Response in Women With Invasive Lobular Breast Cancer,3457
0,NCT01465659,Phase Ib/II,Recruiting,"[{'id': 2040, 'therapyName': 'Pazopanib + Temozolomide'}]",Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery,1799
1,NCT01525082,Phase II,"Active, not recruiting","[{'id': 2073, 'therapyName': 'Bevacizumab + Capecitabine + Temozolomide'}]","Capecitabine, Temozolomide and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors",1799
2,NCT01525550,FDA approved,"Active, not recruiting","[{'id': 930, 'therapyName': 'Sunitinib'}]",A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors,1799
3,NCT01603004,Phase I,Recruiting,"[{'id': 735, 'therapyName': 'Everolimus'}, {'id': 930, 'therapyName': 'Sunitinib'}]",Potential Imaging and Molecular Predictors of Response to Novel Therapies in Metastatic Pancreatic Neuroendocrine Tumors,1799
4,NCT01784861,Phase Ib/II,"Active, not recruiting","[{'id': 1272, 'therapyName': 'X-82 + Everolimus'}]",VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors,1799
5,NCT02031536,Phase II,Terminated,"[{'id': 735, 'therapyName': 'Everolimus'}]",Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery,1799
6,NCT02101918,Phase II,"Active, not recruiting","[{'id': 624, 'therapyName': 'Aflibercept'}]",Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery,1799
7,NCT02315625,Phase II,Recruiting,"[{'id': 735, 'therapyName': 'Everolimus'}, {'id': 930, 'therapyName': 'Sunitinib'}]",Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery,1799
8,NCT02831179,Phase I,Withdrawn,"[{'id': 4463, 'therapyName': 'Capecitabine + Veliparib + Temozolomide'}]","Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor",1799
0,NCT02949219,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Treating Patients With Small Bowel Adenocarcinoma That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery,50926
0,NCT00084695,Phase II,Unknown status,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases,50458
1,NCT01621477,Phase II,Terminated,"[{'id': 1756, 'therapyName': 'Plerixafor'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 2469, 'therapyName': 'Busulfan + Clofarabine + Thymoglobulin'}, {'id': 1783, 'therapyName': 'Cyclophosphamide + Cytarabine'}]",T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant,50458
2,NCT02564536,Phase I,Withdrawn,"[{'id': 3177, 'therapyName': 'Pacritinib + Decitabine'}]",Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS),50458
3,NCT02790515,Phase II,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1876, 'therapyName': 'Blinatumomab '}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 5682, 'therapyName': 'Mesna'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Provision of TCR?? T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation,50458
4,NCT03190915,Phase II,Recruiting,"[{'id': 2, 'therapyName': 'Trametinib'}]",Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia,50458
0,NCT01188096,Phase II,Recruiting,"[{'id': 2595, 'therapyName': 'poly ICLC  '}]",A Trial of Poly-ICLC in the Management of Recurrent Pediatric Low Grade Gliomas,6811
0,NCT00092222,Phase II,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1187, 'therapyName': 'Alpha 2 Interferon'}, {'id': 2211, 'therapyName': 'EPOCH'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1008, 'therapyName': 'Doxil'}]",Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity,8632
1,NCT00923936,Phase II,"Active, not recruiting","[{'id': 1673, 'therapyName': 'Doxil + Bevacizamub'}]",Pilot Study of Liposomal Doxorubicin Combined With Bevacizumab Followed by Bevacizumab Monotherapy in Adults With Advanced Kaposi s Sarcoma,8632
2,NCT02137564,Phase II,Withdrawn,"[{'id': 859, 'therapyName': 'PF-03084014'}]",Gamma Secretase Inhibitor PF-03084014 in Treating Patients With AIDS-Associated Kaposi Sarcoma,8632
3,NCT02408861,Phase I,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab in Treating Patients With Advanced HIV Associated Solid Tumors,8632
4,NCT02595866,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms",8632
0,NCT02978625,Phase II,Recruiting,"[{'id': 5080, 'therapyName': 'Talimogene laherparepvec + Nivolumab'}]",Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers,3149
0,NCT00184015,,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 688, 'therapyName': 'Bortezomib'}]","Bortezomib and Bevacizumab (""BB-mib-mab"") in Patients With Advanced or Recurrent Renal Cell Cancer (RCC)",263
1,NCT00375674,,"Active, not recruiting","[{'id': 930, 'therapyName': 'Sunitinib'}]", A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer,263
2,NCT00923130,Phase II,Completed,"[{'id': 1122, 'therapyName': 'Bevacizumab + Ixabepilone'}]",Bevacizumab Plus Ixabepilone to Treat Patients With Advanced Kidney Cancer,263
3,NCT01005797,Phase I,Completed,"[{'id': 1131, 'therapyName': 'Panobinostat + Sorafenib'}]","Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers",263
4,NCT01184326,Phase I,Completed,"[{'id': 1806, 'therapyName': 'everolimus + pazopanib'}]",An Expanded Phase I Study of Pazopanib and Everolimus in Patients With Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer,263
5,NCT01217931,Phase II,"Active, not recruiting","[{'id': 735, 'therapyName': 'Everolimus'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy,263
6,NCT01218867,Phase Ib/II,Completed,"[{'id': 984, 'therapyName': 'Anti-VEGFR2 CAR CD8 lymphocytes'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1167, 'therapyName': 'Aldesleukin'}]",Treating Metastatic Cancer With Anti-VEGFR2 Gene Engineered CD8+ Lymphocytes,263
7,NCT01480154,Phase I,"Active, not recruiting","[{'id': 1393, 'therapyName': 'MK2206 + hydroxychloroquine'}]","Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer",263
8,NCT01497444,Phase Ib/II,Suspended,"[{'id': 1320, 'therapyName': 'Evofosfamide + Sorafenib'}]",Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery,263
9,NCT01727089,Phase II,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1243, 'therapyName': 'Bevacizumab + TRC105'}]", Bevacizumab With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Kidney Cancer,263
10,NCT02077933,Phase I,"Active, not recruiting","[{'id': 1384, 'therapyName': 'BYL719 + Everolimus'}, {'id': 1385, 'therapyName': 'BYL719 + Everolimus + Exemestane'}]","Study of Safety and Efficacy of BYL719 With Everolimus or BYL719 With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors",263
11,NCT02318771,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Urothelial Cancer, Melanoma, and Non-Small Cell Lung Cancer",263
12,NCT02460224,Phase Ib/II,Recruiting,"[{'id': 2887, 'therapyName': 'LAG525'}, {'id': 2659, 'therapyName': 'PDR001'}]",Safety and Efficay of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies,263
13,NCT02504892,Phase II,Recruiting,"[{'id': 735, 'therapyName': 'Everolimus'}]",Everolimus Therapy in People With Birt-Hogg-Dube Syndrome (BHD)-Associated Kidney Cancer or Sporadic Chromophobe Renal Cancer,263
14,NCT02643303,Phase Ib/II,Recruiting,"[{'id': 3385, 'therapyName': 'MEDI4736 + poly ICLC '}, {'id': 1652, 'therapyName': 'Tremelimumab'}]","A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers",263
15,NCT02655822,Phase I,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 3571, 'therapyName': 'CPI-444 '}]",Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers,263
16,NCT02899078,Phase Ib/II,Recruiting,"[{'id': 3198, 'therapyName': 'Ibrutinib + Nivolumab'}]",Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer,263
17,NCT02964078,Phase II,Recruiting,"[{'id': 4165, 'therapyName': 'Aldesleukin + Pembrolizumab'}]",Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer,263
0,NCT02831179,Phase I,Withdrawn,"[{'id': 4463, 'therapyName': 'Capecitabine + Veliparib + Temozolomide'}]","Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor",7402
0,NCT02780310,Phase II,"Active, not recruiting","[{'id': 792, 'therapyName': 'Lenvatinib'}]",Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma,4870
1,NCT03087019,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma,4870
2,NCT03172624,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer,4870
0,NCT02936323,,Recruiting,"[{'id': 5819, 'therapyName': 'PEN-221'}]",PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers,50872
0,NCT02780310,Phase II,"Active, not recruiting","[{'id': 792, 'therapyName': 'Lenvatinib'}]",Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma,4869
1,NCT03087019,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma,4869
2,NCT03172624,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer,4869
0,NCT01860430,Phase I,"Active, not recruiting","[{'id': 1926, 'therapyName': 'Cetuximab + Ipilimumab'}]",A Phase Ib Trial of Concurrent Cetuximab (ERBITUX) and Intensity Modulated Radiotherapy (IMRT) With Ipilimumab (YERVOY) in Locally Advanced Head and Neck Cancer,2600
0,NCT00904345,Phase II,"Active, not recruiting","[{'id': 694, 'therapyName': 'Cetuximab'}]",Study of Radiation (RT) Concurrent With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (SCC),2876
1,NCT01467115,Phase II,Completed,"[{'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1930, 'therapyName': 'Cisplatin + Docetaxel + Fluorouracil'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 694, 'therapyName': 'Cetuximab'}]",INDUCTION CHEMOTHERAPY FOLLOWED BY CETUXIMAB AND RADIATION THERAPY FOR HEAD AND NECK CANCER,2876
2,NCT01612351,Phase II,"Active, not recruiting","[{'id': 2477, 'therapyName': 'Lapatinib + Carboplatin + Cisplatin + Paclitaxel'}, {'id': 2476, 'therapyName': 'Lapatinib + Carboplatin + Paclitaxel'}]",Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery,2876
3,NCT01633541,Phase II,Recruiting,"[{'id': 644, 'therapyName': 'AT-101'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Chemotherapy AND Bcl-xL Inhibitor (AT-101) For Organ Preservation In Adults With Advanced Laryngeal Cancer,2876
4,NCT01711658,Phase II,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 2475, 'therapyName': 'Lapatinib + Cisplatin'}]",TRYHARD: Radiation Therapy Plus Cisplatin With or Without Lapatinib in Treating Patients With Head and Neck Cancer,2876
5,NCT01732640,Phase Ib/II,Completed,"[{'id': 2442, 'therapyName': 'Afatinib + Carboplatin + Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}]",A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy In HPV-Negative HNSCC.,2876
6,NCT01758731,Phase I,"Active, not recruiting","[{'id': 1999, 'therapyName': 'Olaparib + Cetuximab'}]",Study of Olaparib With Radiation Therapy and Cetuximab in Advanced Head and Neck Cancer With Heavy Smoking History,2876
7,NCT01783587,Phase I,Recruiting,"[{'id': 623, 'therapyName': 'Afatinib'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Safety Study of Afatinib and Postoperative Radiation Therapy to Treat Head and Neck Cancer,2876
8,NCT01810913,Phase II,"Active, not recruiting","[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1925, 'therapyName': 'Docetaxel + Cetuximab'}]","Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer",2876
9,NCT01824823,Phase II,Terminated,"[{'id': 623, 'therapyName': 'Afatinib'}]",Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence,2876
10,NCT02107235,Phase I,Completed,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1046, 'therapyName': 'rigosertib'}]",Platinum-based Chemoradiotherapy and Rigosertib in Head and Neck Cancer,2876
11,NCT02196168,Phase II,Terminated,"[{'id': 822, 'therapyName': 'MK-1775'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer,2876
12,NCT02201355,Phase I,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}]","Reduced-Volume Hypofractionated, PET-directed Intensity Modulated Radiotherapy Concurrent With Weekly Cisplatin Chemotherapy for Squamous Cell Carcinoma of the Head and Neck",2876
13,NCT02262741,Phase I,"Active, not recruiting","[{'id': 1652, 'therapyName': 'Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]","A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 With Tremelimumab or Tremelimumab Alone in Head and Neck Cancer",2876
14,NCT02289209,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Reirradiation With MK-3475 in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck,2876
15,NCT02296684,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma,2876
16,NCT02334319,Phase I,Terminated,"[{'id': 745, 'therapyName': 'Ganetespib'}]",Ganetespib Window of Opportunity Study in Head and Neck Cancers,2876
17,NCT02358031,Phase III,"Active, not recruiting","[{'id': 694, 'therapyName': 'Cetuximab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}]",A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048),2876
18,NCT02381535,Phase I,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 645, 'therapyName': 'AT13387'}]",Hsp90 Inhibitor AT13387 in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Radiation Therapy and Cisplatin,2876
19,NCT02449681,Phase II,Terminated,"[{'id': 2910, 'therapyName': 'TH-4000'}]",Study for Treatment of Patients With Recurrent or Metastatic SCCHN or SCCS,2876
20,NCT02454179,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1605, 'therapyName': 'Acalabrutinib'}]",Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Advanced Head and Neck Squamous Cell Carcinoma,2876
21,NCT02473731,Phase I,Completed,"[{'id': 2054, 'therapyName': 'CDX-3379'}]",A Window of Opportunity Study of KTN3379 in Surgically Resectable Head and Neck Cancer Patients,2876
22,NCT02499120,Phase II,Recruiting,"[{'id': 850, 'therapyName': 'Palbociclib'}, {'id': 694, 'therapyName': 'Cetuximab'}]",Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer,2876
23,NCT02499328,Phase Ib/II,Recruiting,"[{'id': 3098, 'therapyName': 'AZD9150 + MEDI4736'}, {'id': 3099, 'therapyName': 'AZD5069 + MEDI4736'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 2782, 'therapyName': 'AZD9150 '}]",Study to Assess Combination of MEDI4736 With Either AZD9150 or AZD5069 in Patients With Metastatic Squamous Cell Carcinoma of Head and Neck,2876
24,NCT02551159,Phase III,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 1914, 'therapyName': 'Cetuximab + Carboplatin + Fluorouracil'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]",Phase III Open Label First Line Therapy Study of MEDI 4736 With or Without Tremelimumab Versus Standard of Care (SOC) in SCCHN,2876
25,NCT02555644,Phase I,Recruiting,"[{'id': 1651, 'therapyName': 'Prexasertib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 694, 'therapyName': 'Cetuximab'}]",A Study of LY2606368 With Chemotherapy and Radiation in Participants With Head and Neck Cancer,2876
26,NCT02573493,Phase II,Recruiting,"[{'id': 3126, 'therapyName': 'Cisplatin + nab-paclitaxel'}, {'id': 3127, 'therapyName': 'Cetuximab + nab-paclitaxel'}]",Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC),2876
27,NCT02585973,Phase I,Recruiting,"[{'id': 1725, 'therapyName': 'MK-1775 + Cisplatin'}]",Dose-escalating AZD1775 + Concurrent Radiation + Cisplatin for Intermediate/High Risk HNSCC,2876
28,NCT02586207,Phase I,Recruiting,"[{'id': 3256, 'therapyName': 'Cisplatin + Pembrolizumab'}]",Pembrolizumab in Combination With CRT for LA-SCCHN,2876
29,NCT02643550,Phase Ib/II,Recruiting,"[{'id': 3383, 'therapyName': 'Cetuximab + IPH2201'}]",Study of IPH2201 (Monalizumab) and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck,2876
30,NCT02741570,Phase III,Recruiting,"[{'id': 4168, 'therapyName': 'Carboplatin + Cetuximab + Cisplatin + Fluorouracil'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Study Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck,2876
31,NCT02759575,Phase Ib/II,Recruiting,"[{'id': 3256, 'therapyName': 'Cisplatin + Pembrolizumab'}]",A Study of Chemoradiation Plus Pembrolizumab for Locally Advanced Laryngeal Squamous Cell Carcinoma,2876
32,NCT02764593,Phase I,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 4760, 'therapyName': 'Cisplatin + Nivolumab'}, {'id': 4761, 'therapyName': 'Cetuximab + Nivolumab'}]",Chemotherapy +/- Nivolumab in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma,2876
33,NCT02769520,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","Efficacy Study of Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Cancer of the Head and Neck",2876
34,NCT02775812,Phase I,Recruiting,"[{'id': 3256, 'therapyName': 'Cisplatin + Pembrolizumab'}]","Cisplatin, Radiation Therapy, and Pembrolizumab in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma",2876
35,NCT02892201,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in HNSCC With Residual Disease After Radiation,2876
36,NCT03162731,Phase I,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]","Nivolumab, Ipilimumab, and Radiation Therapy in Treating Patients With Stage IVA-B Head and Neck Cancer",2876
37,NCT03238365,Phase I,Recruiting,"[{'id': 6100, 'therapyName': 'Nivolumab + Tadalafil'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab With or Without Tadalafil in Treating Patients With Recurrent Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery,2876
0,NCT01218048,Phase II,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 694, 'therapyName': 'Cetuximab'}]",ERBITUX; Followed by Adjuvant Treatment With Chemoradiation and ERBITUX; for Locally Advanced Head and Neck Squamous Cell Carcinoma,2596
1,NCT01935921,Phase I,"Active, not recruiting","[{'id': 1926, 'therapyName': 'Cetuximab + Ipilimumab'}]","Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer",2596
2,NCT02113878,Phase I,Recruiting,"[{'id': 1691, 'therapyName': 'BKM120 + Cisplatin'}]",Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck,2596
3,NCT02124850,Phase I,Recruiting,"[{'id': 694, 'therapyName': 'Cetuximab'}]",A Phase Ib Study of Neoadjuvant Immune Biomarker Modulation With ERBITUX&#174; (Cetuximab) and VTX-2337,2596
4,NCT02128906,Phase II,Recruiting,"[{'id': 1925, 'therapyName': 'Docetaxel + Cetuximab'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC,2596
5,NCT02177838,Phase II,Suspended,"[{'id': 1915, 'therapyName': 'Cetuximab + Cisplatin'}]",Cetuximab and Radiation Therapy in Treating Patients With Stage III-IV Head and Neck Cancer,2596
6,NCT02777385,Phase II,Recruiting,"[{'id': 3256, 'therapyName': 'Cisplatin + Pembrolizumab'}]",Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Head and Neck Cancer,2596
7,NCT02795156,Phase II,Recruiting,"[{'id': 623, 'therapyName': 'Afatinib'}, {'id': 890, 'therapyName': 'Regorafenib'}]",Study to Assess the Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations,2596
8,NCT03040999,Phase III,Recruiting,"[{'id': 3256, 'therapyName': 'Cisplatin + Pembrolizumab'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412),2596
0,NCT01316757,Phase II,"Active, not recruiting","[{'id': 1921, 'therapyName': 'Cetuximab + Paclitaxel + Carboplatin + Erlotinib'}]","Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer",3752
0,NCT03165721,Phase II,Recruiting,"[{'id': 1949, 'therapyName': 'SGI-110'}]","A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer",5138
0,NCT00356031,Phase II,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Bevacizumab and Radiation Therapy for Sarcomas,1967
1,NCT01446809,Phase I,"Active, not recruiting","[{'id': 1472, 'therapyName': 'Doxorubicin + Ifosfamide'}, {'id': 1471, 'therapyName': 'Pazopanib + Doxorubicin + Ifosfamide'}]",Pazopanib Hydrochloride Followed By Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma,1967
2,NCT01498484,Phase II,"Active, not recruiting","[{'id': 5057, 'therapyName': 'EB-VST cells'}]",Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies,1967
3,NCT02301039,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas,1967
4,NCT02303262,Phase II,Completed,"[{'id': 3128, 'therapyName': 'Gemcitabine + Mocetinostat'}]",A Study of Mocetinostat and Gemcitabine in Patients With Metastatic Leiomyosarcoma,1967
5,NCT02584309,Phase II,Recruiting,"[{'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 4140, 'therapyName': 'Doxorubicin + Olaratumab'}]",Doxorubicin With Upfront Dexrazoxane Plus Olaratumab for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma,1967
6,NCT02601209,Phase Ib/II,Suspended,"[{'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1282, 'therapyName': 'Sapanisertib'}]",Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma,1967
7,NCT02815995,Phase II,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes,1967
8,NCT02987959,Phase II,Recruiting,"[{'id': 1282, 'therapyName': 'Sapanisertib'}]",Study of TAK-228 (MLN0128) in Soft Tissue Sarcomas,1967
9,NCT03009201,Phase I,Recruiting,"[{'id': 5179, 'therapyName': 'Doxorubicin + Ribociclib'}]",Ribociclib and Doxorubicin Hydrochloride in Treating Patients Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery,1967
10,NCT03074318,Phase Ib/II,Recruiting,"[{'id': 5444, 'therapyName': 'Avelumab + trabectedin'}]",Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery,1967
11,NCT03114527,Phase II,Recruiting,"[{'id': 5073, 'therapyName': 'Ribociclib + Everolimus'}]",Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS),1967
12,NCT03282344,Phase II,Recruiting,"[{'id': 5076, 'therapyName': 'NKTR-214 + Nivolumab'}]",A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma,1967
0,NCT00620633,Phase I,"Active, not recruiting","[{'id': 2901, 'therapyName': 'WT1 senstized T cells'}]",Dose Escalation Trial of WT1-Sensitized T Cells for Residual or Relapsed Leukemia After Allogeneic Hematopoietic Progenitor Cell Transplantation,1240
1,NCT00777036,,"Active, not recruiting","[{'id': 717, 'therapyName': 'Dasatinib'}]",A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib,1240
2,NCT01396499,Phase I,Completed,"[{'id': 680, 'therapyName': 'BKM120'}]","Study to Assess Safety, Tolerability and Preliminary Efficacy of BKM120, PI3K Kinase Inhibitor, With Advanced Leukemias",1240
3,NCT01703572,Phase I,Completed,"[{'id': 839, 'therapyName': 'Brontictuzumab'}]",A Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid Malignancies,1240
4,NCT01751425,Phase II,Recruiting,"[{'id': 907, 'therapyName': 'Ruxolitinib'}]",Ruxolitinib for Chronic Myeloid Leukemia (CML) With Minimal Residual Disease (MRD),1240
5,NCT01787487,Phase III,Recruiting,"[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}]",Evaluation of RUX and AZA Combination as a Therapy For Patients With Myelofibrosis And Myelodysplastic Syndrome/ Myeloproliferative Neoplasm,1240
6,NCT02091245,Phase I,Recruiting,"[{'id': 1749, 'therapyName': 'Selinexor'}]","Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML",1240
7,NCT02188706,Phase II,"Active, not recruiting","[{'id': 650, 'therapyName': 'Decitabine'}, {'id': 1608, 'therapyName': 'Decitabine + Carboplatin'}, {'id': 1609, 'therapyName': 'Decitabine + Arsenic trioxide '}]","A Leukemia SPORE Phase II Clinical Trial Comparing Decitabine Versus Decitabine/Carboplatin and Decitabine/Arsenic for the Treatment of Relapsed, Refractory, and Elderly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)",1240
8,NCT02477878,Phase I,Recruiting,"[{'id': 5995, 'therapyName': 'BPX-601'}, {'id': 5992, 'therapyName': 'Rimiducid'}]",Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant,1240
9,NCT02499861,Phase Ib/II,Recruiting,"[{'id': 1734, 'therapyName': 'Genistein + Decitabine'}]",Phase I/II a Study of Decitabine in Combination With Genistein in Pediatric Relapsed or Refractory Malignancies,1240
10,NCT02512926,Phase I,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 1136, 'therapyName': 'Etoposide'}]",Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children,1240
11,NCT02569476,Phase I,Recruiting,"[{'id': 4682, 'therapyName': 'BGB-3111 + Obinutuzumab'}]",BGB 3111 in Combination With Obinutuzumab in Subjects With B-Cell Lymphoid Malignancies,1240
12,NCT02786485,Phase I,Not yet recruiting,"[{'id': 5992, 'therapyName': 'Rimiducid'}, {'id': 6053, 'therapyName': 'BPX-501'}]",Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT,1240
13,NCT02932280,Phase Ib/II,Recruiting,"[{'id': 828, 'therapyName': 'Neratinib'}]",Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment,1240
14,NCT03229200,FDA approved,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.,1240
0,NCT02815995,Phase II,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes,3315
0,NCT00356031,Phase II,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Bevacizumab and Radiation Therapy for Sarcomas,3382
1,NCT01037790,Phase II,Recruiting,"[{'id': 850, 'therapyName': 'Palbociclib'}]",PD 0332991 in Treating Patients With Refractory Solid Tumors,3382
2,NCT02048371,Phase II,Recruiting,"[{'id': 890, 'therapyName': 'Regorafenib'}]","A Blanket Protocol to Study Oral Regorafenib in Patients With Refractory Liposarcoma, Osteogenic Sarcoma, and Ewing/Ewing-like Sarcomas",3382
3,NCT02210104,Phase I,Withdrawn,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",Adoptive Therapy Using Antigen-Specific CD4 T-Cells,3382
4,NCT02301039,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas,3382
5,NCT02343172,Phase Ib/II,Recruiting,"[{'id': 2481, 'therapyName': 'HDM201 + LEE011'}]",Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With Liposarcoma,3382
6,NCT02357810,Phase II,Recruiting,"[{'id': 1469, 'therapyName': 'Topotecan + Pazopanib'}]",Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas,3382
7,NCT02606461,Phase II,Recruiting,"[{'id': 1749, 'therapyName': 'Selinexor'}]",KCP-330-020 SEAL (Selinexor in Advanced Liposarcoma) (SEAL),3382
8,NCT02846987,Phase II,Recruiting,"[{'id': 802, 'therapyName': 'Abemaciclib'}]",Study of Abemaciclib in Dedifferentiated Liposarcoma,3382
9,NCT02978859,Phase II,Recruiting,"[{'id': 1655, 'therapyName': 'MGCD516'}]",MGCD516 in Advanced Liposarcoma and Other Soft Tissue Sarcomas,3382
10,NCT03009201,Phase I,Recruiting,"[{'id': 5179, 'therapyName': 'Doxorubicin + Ribociclib'}]",Ribociclib and Doxorubicin Hydrochloride in Treating Patients Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery,3382
11,NCT03074318,Phase Ib/II,Recruiting,"[{'id': 5444, 'therapyName': 'Avelumab + trabectedin'}]",Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery,3382
12,NCT03114527,Phase II,Recruiting,"[{'id': 5073, 'therapyName': 'Ribociclib + Everolimus'}]",Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS),3382
13,NCT03190174,Phase Ib/II,Recruiting,"[{'id': 5931, 'therapyName': 'Nab-Rapamycin + Nivolumab'}]",Nivolumab (Opdivo) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma,3382
0,NCT01497444,Phase Ib/II,Suspended,"[{'id': 1320, 'therapyName': 'Evofosfamide + Sorafenib'}]",Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery,3571
1,NCT01625351,Phase I,"Active, not recruiting","[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1205, 'therapyName': 'Alemtuzumab'}]",A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas,3571
2,NCT01829971,Phase I,Terminated,"[{'id': 1035, 'therapyName': 'MRX34'}]","A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection",3571
3,NCT02795156,Phase II,Recruiting,"[{'id': 623, 'therapyName': 'Afatinib'}, {'id': 890, 'therapyName': 'Regorafenib'}]",Study to Assess the Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations,3571
4,NCT02828124,Phase Ib/II,"Active, not recruiting","[{'id': 5628, 'therapyName': 'BMS-986183'}, {'id': 5629, 'therapyName': 'BMS-986183 + Nivolumab'}]",A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer,3571
0,NCT02520141,Phase II,Recruiting,"[{'id': 886, 'therapyName': 'Ramucirumab'}]",Ramucirumab for Advanced Pre-treated Biliary Cancers,686
0,NCT02928978,Phase II,Not yet recruiting,"[{'id': 907, 'therapyName': 'Ruxolitinib'}]",Ruxolitinib for Premalignant Breast Disease,3010
0,NCT01579994,Phase I,"Active, not recruiting","[{'id': 2190, 'therapyName': 'Ganetespib + Crizotinib'}]",Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers,3910
1,NCT01737502,Phase II,Recruiting,"[{'id': 2301, 'therapyName': 'Auranofin + Sirolimus'}]",PKCi and mTOR Inhibition With Auranofin+Sirolimus for Squamous Cell Lung Cancer,3910
2,NCT01814553,Phase III,Completed,"[{'id': 1374, 'therapyName': 'Afatinib + Loperamide'}]", ADAM-Afatinib Diarrhea Assessment and Management,3910
3,NCT01877083,Phase II,"Active, not recruiting","[{'id': 792, 'therapyName': 'Lenvatinib'}]",Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the Lung,3910
4,NCT01877811,Phase Ib/II,"Active, not recruiting","[{'id': 1002, 'therapyName': 'CEP-32496'}]",CEP-32496 in Patients With Advanced Solid Tumors in Phase 1 and Advanced Melanoma and Metastatic Colorectal Cancer in Phase 2,3910
5,NCT01976741,Phase I,Recruiting,"[{'id': 2030, 'therapyName': 'Rogaratinib'}]",Phase I Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor,3910
6,NCT02185690,Phase I,Not yet recruiting,"[{'id': 2213, 'therapyName': 'MEK162 + Carboplatin + Pemetrexed'}]","A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the Lung",3910
7,NCT02231164,Phase III,Terminated,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 831, 'therapyName': 'Nintedanib'}]",LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational Research,3910
8,NCT02264678,Phase Ib/II,Recruiting,"[{'id': 2881, 'therapyName': 'AZD6738'}, {'id': 4737, 'therapyName': 'AZD6738 + Carboplatin'}, {'id': 4738, 'therapyName': 'AZD6738 + MEDI4736'}, {'id': 4739, 'therapyName': 'AZD6738 + Olaparib'}]",Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents,3910
9,NCT02285855,Phase II,Recruiting,"[{'id': 1031, 'therapyName': 'Metformin'}]",Metformin in Non Small Cell Lung Cancer (NSCLC),3910
10,NCT02450175,Phase I,Unknown status,"[{'id': 794, 'therapyName': 'Letrozole'}, {'id': 735, 'therapyName': 'Everolimus'}]","Etiology of the Platelet-Cancer Metastatic Pathway - A Study of Inflammatory Markers, Platelet Characteristics and Metastatic Surrogates in Cancer Patients and Controls",3910
11,NCT02450591,Phase I,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}]",Local Therapies for Oligometastatic Non-Small Cell Lung Cancer Harboring Sensitizing EGFR Mutations,3910
12,NCT02466568,Phase Ib/II,Not yet recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung,3910
13,NCT02513667,Phase II,Recruiting,"[{'id': 789, 'therapyName': 'Ceritinib'}]",Ceritinib in Combination With Stereotactic Ablative Radiation Metastatic Lung Adenocarcinoma,3910
14,NCT02705339,Phase II,Withdrawn,"[{'id': 1003, 'therapyName': 'CO1686'}]",Rociletinib Genomic Landscape in Non-small Cell Lung Cancer (NSCLC),3910
15,NCT02759835,Phase II,Recruiting,"[{'id': 660, 'therapyName': 'Osimertinib'}]","Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib",3910
16,NCT02839681,Phase II,Recruiting,"[{'id': 4593, 'therapyName': 'Anetumab ravtansine'}]",Anti-Mesothelin Antibody Drug Conjugate Anetumab Ravtansine for Mesothelin Expressing Lung Adenocarcinoma,3910
17,NCT02864992,Phase II,Recruiting,"[{'id': 1398, 'therapyName': 'MSC2156119J'}]",Tepotinib Phase II Study in Lung Adenocarcinoma Harbouring MET Exon 14 (METex14) Skipping Alterations,3910
18,NCT03076164,Phase Ib/II,Recruiting,"[{'id': 1265, 'therapyName': 'Erlotinib + Trametinib'}]",A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib,3910
0,NCT02780310,Phase II,"Active, not recruiting","[{'id': 792, 'therapyName': 'Lenvatinib'}]",Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma,4872
1,NCT03087019,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma,4872
2,NCT03172624,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer,4872
0,NCT01014598,Phase I,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}]",Cisplatin in Treating Patients With Lung Cancer,1324
1,NCT01218867,Phase Ib/II,Completed,"[{'id': 984, 'therapyName': 'Anti-VEGFR2 CAR CD8 lymphocytes'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1167, 'therapyName': 'Aldesleukin'}]",Treating Metastatic Cancer With Anti-VEGFR2 Gene Engineered CD8+ Lymphocytes,1324
2,NCT01366144,Phase I,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 954, 'therapyName': 'Veliparib'}, {'id': 1092, 'therapyName': 'Carboplatin'}]","Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction",1324
3,NCT01386580,Phase Ib/II,Completed,"[{'id': 974, 'therapyName': '2B3-101'}, {'id': 1274, 'therapyName': '2B3-101 + Trastuzumab'}]","An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.",1324
4,NCT01470209,Phase I,"Active, not recruiting","[{'id': 1314, 'therapyName': 'BKM120 + Everolimus'}]",A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies,1324
5,NCT01859026,Phase I,Recruiting,"[{'id': 1253, 'therapyName': 'MEK162 + Erlotinib'}]",A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation,1324
6,NCT01935336,Phase II,Recruiting,"[{'id': 877, 'therapyName': 'Ponatinib'}]",Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers,1324
7,NCT01999985,Phase I,"Active, not recruiting","[{'id': 1351, 'therapyName': 'Dasatinib + Afatinib'}]",Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC),1324
8,NCT02047747,Phase II,Terminated,"[{'id': 714, 'therapyName': 'Dacomitinib'}]",A Phase II Study of Dacomitinib in Progressive Brain Metastases,1324
9,NCT02155465,Phase Ib/II,Completed,"[{'id': 1858, 'therapyName': 'Ruxolitinib + Erlotinib'}]",Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib,1324
10,NCT02241369,Phase I,Recruiting,"[{'id': 5846, 'therapyName': 'INO-3106 + INO-9012'}]",Immunotherapy in Subjects With HPV-6 Associated Aerodigestive Precancerous Lesions and Malignancies,1324
11,NCT02429843,Phase I,Recruiting,"[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1242, 'therapyName': 'Carotuximab'}]",A Study of TRC105 in Combination With Paclitaxel/Carboplatin and Bevacizumab in Non-Squamous Cell Lung Cancer,1324
12,NCT02538627,Phase I,Terminated,"[{'id': 820, 'therapyName': 'Seribantumab'}, {'id': 821, 'therapyName': 'MM-151'}]",Phase 1 Combination Study of MM-151 and MM-121,1324
13,NCT02675829,Phase II,Recruiting,"[{'id': 1402, 'therapyName': 'trastuzumab emtansine'}]",Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers,1324
14,NCT03188965,Phase I,Recruiting,"[{'id': 5962, 'therapyName': 'BAY1895344'}]",First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas,1324
0,NCT02834013,Phase 0,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab in Treating Patients With Rare Tumors,3905
1,NCT02960594,Phase I,Recruiting,"[{'id': 5844, 'therapyName': 'INO-1400 + INO-9012'}, {'id': 5807, 'therapyName': 'INO-1400'}]",hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse,3905
0,NCT02185690,Phase I,Not yet recruiting,"[{'id': 2213, 'therapyName': 'MEK162 + Carboplatin + Pemetrexed'}]","A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the Lung",4556
0,NCT01014598,Phase I,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}]",Cisplatin in Treating Patients With Lung Cancer,2784
0,NCT00926640,Phase I,Completed,"[{'id': 1123, 'therapyName': 'Belinostat + Cisplatin + Etoposide'}]",A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers,5409
1,NCT01286987,Phase I,Completed,"[{'id': 682, 'therapyName': 'Talazoparib'}]","Study of BMN 673, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors",5409
2,NCT01306045,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 816, 'therapyName': 'MK2206'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 913, 'therapyName': 'Selumetinib'}]","Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies",5409
3,NCT01450761,Phase III,Completed,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1136, 'therapyName': 'Etoposide'}]",Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone,5409
4,NCT01579929,Phase I,Completed,"[{'id': 2504, 'therapyName': 'Cisplatin + Etoposide + Sonidegib'}]","Combination of the Hedgehog Inhibitor, LDE225, With Etoposide and Cisplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)",5409
5,NCT01587703,Phase I,Recruiting,"[{'id': 784, 'therapyName': 'GSK525762'}]","A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers",5409
6,NCT01638546,Phase II,Completed,"[{'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 954, 'therapyName': 'Veliparib'}]",Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer,5409
7,NCT01642251,Phase Ib/II,"Active, not recruiting","[{'id': 2585, 'therapyName': 'Cisplatin + Etoposide'}, {'id': 954, 'therapyName': 'Veliparib'}]",Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer or Metastatic Large Cell Neuroendocrine Non-small Cell Lung Cancer,5409
8,NCT01722292,Phase Ib/II,Terminated,"[{'id': 1587, 'therapyName': 'Taladegib'}, {'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}]",A Study of LY2940680 in Small Cell Lung Cancer,5409
9,NCT01737502,Phase II,Recruiting,"[{'id': 2301, 'therapyName': 'Auranofin + Sirolimus'}]",PKCi and mTOR Inhibition With Auranofin+Sirolimus for Squamous Cell Lung Cancer,5409
10,NCT01831089,Phase I,Completed,"[{'id': 1196, 'therapyName': 'Lurbinectedin + Paclitaxel + Bevacizumab'}, {'id': 1197, 'therapyName': 'Lurbinectedin + Paclitaxel'}]","Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors",5409
11,NCT01859741,Phase Ib/II,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 2547, 'therapyName': 'Tarextumab'}]",A Phase 1b/2 Study of OMP-59R5 in Combination With Etoposide and Platinum Therapy in Subjects With Untreated Extensive Stage Small Cell Lung Cancer (PINNACLE),5409
12,NCT01892046,Phase I,Completed,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 866, 'therapyName': 'SNX-5422'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors,5409
13,NCT01928394,Phase Ib/II,"Active, not recruiting","[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]","A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab in Subjects With Advanced or Metastatic Solid Tumors",5409
14,NCT02034123,Phase I,Terminated,"[{'id': 3014, 'therapyName': 'GSK2879552 '}]",Investigation of GSK2879552 in Subjects With Relapsed/Refractory Small Cell Lung Carcinoma,5409
15,NCT02038647,Phase II,"Active, not recruiting","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 626, 'therapyName': 'Alisertib'}]",Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC),5409
16,NCT02100007,Phase Ib/II,Terminated,"[{'id': 2174, 'therapyName': 'ME-344 + Topotecan'}]",ME-344 Given in Combination With Hycamtin in Patients With Solid Tumors,5409
17,NCT02152059,Phase II,Withdrawn,"[{'id': 831, 'therapyName': 'Nintedanib'}]",A Study to Evaluate the Good and Bad Effects of BIBF1120 in Small Cell Lung Cancer Patients Who Have Previously Benefited From First-line Platinum-based Chemotherapy,5409
18,NCT02157792,Phase I,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 2879, 'therapyName': 'VX-970'}, {'id': 755, 'therapyName': 'Gemcitabine'}]","An Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics of VX-970 in Combination With Cytotoxic Chemotherapy",5409
19,NCT02161419,Phase II,Terminated,"[{'id': 663, 'therapyName': 'BAY1000394'}]",RONICICLIB / Placebo in Combination With Chemotherapy in Small Cell Lung Cancer,5409
20,NCT02200757,Phase II,Recruiting,"[{'id': 1440, 'therapyName': 'Aldoxorubicin'}, {'id': 942, 'therapyName': 'Topotecan'}]",Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer,5409
21,NCT02247349,Phase Ib/II,"Active, not recruiting","[{'id': 4534, 'therapyName': 'BMS-986012'}, {'id': 4535, 'therapyName': 'BMS-986012 + Nivolumab'}]",BMS-986012 in Relapsed/Refractory SCLC,5409
22,NCT02250885,Phase II,Completed,"[{'id': 1749, 'therapyName': 'Selinexor'}]",KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors,5409
23,NCT02261805,Phase Ib/II,Terminated,"[{'id': 3052, 'therapyName': 'Aldoxorubicin + Ganetespib'}]",A Phase I/II Study of Ganetespib in Combination With Doxorubicin,5409
24,NCT02289690,Phase I,Recruiting,"[{'id': 1544, 'therapyName': 'Carboplatin + Etoposide + Veliparib'}]",Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer,5409
25,NCT02331251,Phase Ib/II,"Active, not recruiting","[{'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 619, 'therapyName': 'Abraxane'}]",Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus),5409
26,NCT02351505,Phase II,Terminated,"[{'id': 1749, 'therapyName': 'Selinexor'}]",Selinexor in Treating Patients With Relapsed Small Cell Lung Cancer,5409
27,NCT02359019,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Treating Patients With Extensive Stage Small Cell Lung Cancer After Completion of Combination Chemotherapy,5409
28,NCT02402920,Phase I,Recruiting,"[{'id': 2604, 'therapyName': 'Carboplatin + Etoposide + Pembrolizumab'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Phase I Trial of MK-3475 and Concurrent Chemo/Radiation for the Elimination of Small Cell Lung Cancer,5409
29,NCT02419417,Phase Ib/II,Recruiting,"[{'id': 2811, 'therapyName': 'BMS986158'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Study of BMS-986158 in Subjects With Select Advanced Solid Tumors,5409
30,NCT02446704,Phase Ib/II,"Active, not recruiting","[{'id': 837, 'therapyName': 'Olaparib'}, {'id': 1141, 'therapyName': 'Temozolomide'}]",Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy,5409
31,NCT02454972,Phase II,Recruiting,"[{'id': 1195, 'therapyName': 'Lurbinectedin'}]",Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors,5409
32,NCT02472977,Phase Ib/II,Terminated,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 2847, 'therapyName': 'Ulocuplumab'}]",Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors,5409
33,NCT02481830,Phase III,"Active, not recruiting","[{'id': 2951, 'therapyName': 'Amrubicin'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 942, 'therapyName': 'Topotecan'}]",Efficacy Study of Nivolumab or Chemotherapy in Subjects With Relapsed Small-cell Lung Cancer,5409
34,NCT02487095,Phase Ib/II,Recruiting,"[{'id': 2879, 'therapyName': 'VX-970'}, {'id': 942, 'therapyName': 'Topotecan'}]","Trial of Topotecan With VX-970, an ATR Kinase Inhibitor, in Small Cell Lung Cancer",5409
35,NCT02489903,Phase II,Recruiting,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 3680, 'therapyName': 'RRx-001'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 619, 'therapyName': 'Abraxane'}]","RRx-001 in Small, Non-small Cell Lung Cancer, and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens",5409
36,NCT02498613,Phase II,Recruiting,"[{'id': 1971, 'therapyName': 'Cediranib + Olaparib'}]",Cediranib Maleate and Olaparib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery,5409
37,NCT02499770,Phase Ib/II,"Active, not recruiting","[{'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}, {'id': 3074, 'therapyName': 'Trilaciclib'}]",G1T28 (CDK 4/6 Inhibitor) in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC),5409
38,NCT02514447,Phase Ib/II,Recruiting,"[{'id': 3074, 'therapyName': 'Trilaciclib'}, {'id': 942, 'therapyName': 'Topotecan'}]",Study of G1T28 in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy,5409
39,NCT02537418,Phase I,"Active, not recruiting","[{'id': 2585, 'therapyName': 'Cisplatin + Etoposide'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]",Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Receiving Standard Chemotherapy Regimens,5409
40,NCT02538666,Phase III,"Active, not recruiting","[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]","A Randomized, Multicenter, Double-Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination With Ipilimumab, or Placebo as Maintenance Therapy in Subjects With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based First Line Chemotherapy (CheckMate 451)",5409
41,NCT02579226,Phase I,Recruiting,"[{'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 3547, 'therapyName': 'AZD2811'}]","A Phase I Study of Safety, Tolerability, and PK of AZD2811 in Patients With Advanced Solid Tumors",5409
42,NCT02628067,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158),5409
43,NCT02631733,Phase I,Recruiting,"[{'id': 3314, 'therapyName': 'Irinotecan + Veliparib'}]",Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery,5409
44,NCT02649673,Phase Ib/II,Recruiting,"[{'id': 3845, 'therapyName': 'LCL161 + Topotecan'}]",LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies,5409
45,NCT02658214,Phase I,Recruiting,"[{'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}, {'id': 2634, 'therapyName': 'Carboplatin + nab-paclitaxel'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}]",Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors,5409
46,NCT02671955,Phase I,Terminated,"[{'id': 3614, 'therapyName': 'JNJ-61610588 '}]","A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced Cancer",5409
47,NCT02674568,Phase II,"Active, not recruiting","[{'id': 3544, 'therapyName': 'Rovalpituzumab Tesirine'}]",Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY),5409
48,NCT02701400,Phase II,Recruiting,"[{'id': 3840, 'therapyName': 'MEDI0562 + Tremelimumab'}]",Tremelimumab and Durvalumab With or Without Radiation Therapy in Patients With Relapsed Small Cell Lung Cancer,5409
49,NCT02734004,Phase Ib/II,"Active, not recruiting","[{'id': 2894, 'therapyName': 'Durvalumab + Olaparib'}]",A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. (MEDIOLA),5409
50,NCT02735980,Phase II,Recruiting,"[{'id': 1651, 'therapyName': 'Prexasertib'}]",A Study of LY2606368 in Participants With Extensive Stage Disease Small Cell Lung Cancer,5409
51,NCT02748889,Phase Ib/II,Terminated,"[{'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}, {'id': 4164, 'therapyName': 'Atezolizumab + Carboplatin + Etoposide'}]",Carboplatin Plus Etoposide With or Without MPDL3280A in Untreated Extensive Stage Small Cell Lung Cancer,5409
52,NCT02763579,Phase III,Recruiting,"[{'id': 4164, 'therapyName': 'Atezolizumab + Carboplatin + Etoposide'}, {'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}]",A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer (IMpower133),5409
53,NCT02815592,Phase Ib/II,"Active, not recruiting","[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 4563, 'therapyName': 'BMS-986012 + Cisplatin + Etoposide'}, {'id': 4564, 'therapyName': 'BMS-986012 + Carboplatin + Etoposide'}]",Trial of BMS-986012 in Combination With Platinum and Etoposide,5409
54,NCT02819999,Phase I,Recruiting,"[{'id': 4827, 'therapyName': 'Rovalpituzumab Tesirine + Cisplatin + Etoposide'}, {'id': 3544, 'therapyName': 'Rovalpituzumab Tesirine'}]",A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Delta-Like Protein 3-Expressing Extensive Stage Small Cell Lung Cancer,5409
55,NCT02874664,Phase I,Recruiting,"[{'id': 3544, 'therapyName': 'Rovalpituzumab Tesirine'}]",A Study of Rovalpituzumab Tesirine to Study Cardiac Ventricular Repolarization in Subjects With Small Cell Lung Cancer,5409
56,NCT02934503,Phase II,Recruiting,"[{'id': 6184, 'therapyName': 'Carboplatin + Cisplatin + Etoposide + Pembrolizumab'}]",Study of Pembrolizumab and Chemotherapy With or Without Radiation in Small Cell Lung Cancer (SCLC),5409
57,NCT02936323,,Recruiting,"[{'id': 5819, 'therapyName': 'PEN-221'}]",PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers,5409
58,NCT02963090,Phase II,Recruiting,"[{'id': 5532, 'therapyName': 'Pembrolizumab + Topotecan'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab vs Topotecan in Patients With Small Cell Lung Cancer,5409
59,NCT03026166,Phase I,Recruiting,"[{'id': 5640, 'therapyName': 'Rovalpituzumab Tesirine + Nivolumab + Ipilimumab'}, {'id': 5641, 'therapyName': 'Rovalpituzumab Tesirine + Nivolumab'}]",A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer,5409
60,NCT03033511,Phase III,Recruiting,"[{'id': 5307, 'therapyName': 'Rovalpituzumab Tesirine + Dexamethasone'}]",A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU) (MERU),5409
61,NCT03041311,Phase II,Recruiting,"[{'id': 5541, 'therapyName': 'Atezolizumab + Carboplatin + Etoposide + Trilaciclib'}, {'id': 4164, 'therapyName': 'Atezolizumab + Carboplatin + Etoposide'}]","Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Extensive Stage Small Cell Lung Cancer (SCLC)",5409
62,NCT03043599,Phase Ib/II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer,5409
63,NCT03043872,Phase III,Recruiting,"[{'id': 5305, 'therapyName': 'MEDI4736 + Tremelimumab + Carboplatin + Cisplatin + Etoposide'}, {'id': 5306, 'therapyName': 'MEDI4736 + Carboplatin + Cisplatin + Etoposide'}, {'id': 4728, 'therapyName': 'Carboplatin + Cisplatin + Etoposide'}]",Durvalumab+/- Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (Caspian),5409
64,NCT03061812,Phase III,Recruiting,"[{'id': 3544, 'therapyName': 'Rovalpituzumab Tesirine'}, {'id': 942, 'therapyName': 'Topotecan'}]",Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE) (TAHOE),5409
65,NCT03066778,Phase III,Recruiting,"[{'id': 2585, 'therapyName': 'Cisplatin + Etoposide'}, {'id': 5145, 'therapyName': 'Cisplatin + Etoposide + Pembrolizumab'}, {'id': 2604, 'therapyName': 'Carboplatin + Etoposide + Pembrolizumab'}, {'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}]",A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604),5409
66,NCT03076372,Phase I,Recruiting,"[{'id': 5758, 'therapyName': 'MM-310'}]",A Study Evaluating MM-310 in Patients With Solid Tumors,5409
67,NCT03080311,Phase I,Recruiting,"[{'id': 5757, 'therapyName': 'APG-1252'}]",A Study of APG-1252 in Patients With SCLC or Other Solid Tumors,5409
68,NCT03085849,Phase I,Recruiting,"[{'id': 5488, 'therapyName': 'SGI-110 + MEDI4736 + Tremelimumab'}]",SGI-110 Plus Durvalumab/Tremelimumab in SCLC,5409
69,NCT03092934,Phase Ib/II,Recruiting,"[{'id': 5753, 'therapyName': 'AK-01'}]",A Study of AK-01 in Solid Tumors,5409
70,NCT03116971,Phase Ib/II,Recruiting,"[{'id': 5546, 'therapyName': 'MSC2490484A  + Cisplatin + Etoposide'}, {'id': 3616, 'therapyName': 'MSC2490484A '}]",Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED),5409
71,NCT03134638,Phase I,Recruiting,"[{'id': 5700, 'therapyName': 'SY-1365'}]",A Phase 1 Study of SY-1365 in Adult Patients With Advanced Solid Tumors,5409
72,NCT03150810,Phase Ib/II,Recruiting,"[{'id': 6124, 'therapyName': 'BGB-290 + Temozolomide'}]","Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Subjects With Locally Advanced or Metastatic Solid Tumors",5409
73,NCT03179436,Phase I,Recruiting,"[{'id': 6039, 'therapyName': 'MK-1308 + Pembrolizumab'}]","Safety, Pharmacokinetics (PK), and Efficacy of MK-1308 in Combination With Pembrolizumab in Advanced Solid Tumors (MK-1308-001)",5409
74,NCT03221400,Phase Ib/II,Recruiting,"[{'id': 4842, 'therapyName': 'STA-8666'}]",PEN-866 in Patients With Advanced Solid Malignancies,5409
0,NCT01737502,Phase II,Recruiting,"[{'id': 2301, 'therapyName': 'Auranofin + Sirolimus'}]",PKCi and mTOR Inhibition With Auranofin+Sirolimus for Squamous Cell Lung Cancer,3907
1,NCT01741727,Phase II,Completed,"[{'id': 976, 'therapyName': 'ABT-414'}]",A Study of ABT-414 in Subjects With Solid Tumors,3907
2,NCT01820325,Phase II,Terminated,"[{'id': 680, 'therapyName': 'BKM120'}]", Safety and Efficacy of Buparlisib (BKM120) in Patients With Untreated Squamous Non-small Cell Lung Cancer,3907
3,NCT01877811,Phase Ib/II,"Active, not recruiting","[{'id': 1002, 'therapyName': 'CEP-32496'}]",CEP-32496 in Patients With Advanced Solid Tumors in Phase 1 and Advanced Melanoma and Metastatic Colorectal Cancer in Phase 2,3907
4,NCT01948141,Phase II,Completed,"[{'id': 831, 'therapyName': 'Nintedanib'}]",Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens,3907
5,NCT01976741,Phase I,Recruiting,"[{'id': 2030, 'therapyName': 'Rogaratinib'}]",Phase I Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor,3907
6,NCT02240238,Phase Ib/II,Recruiting,"[{'id': 5626, 'therapyName': 'Gemcitabine + NC-6004'}]","Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer",3907
7,NCT02403895,Phase II,Completed,"[{'id': 991, 'therapyName': 'Vistusertib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",AZD2014 and Weekly Paclitaxel in Squamous NSCLC,3907
8,NCT02417701,Phase II,Recruiting,"[{'id': 1282, 'therapyName': 'Sapanisertib'}]",TORC1/2 Inhibitor MLN0128 in Treating Patients With Stage IV or Recurrent Lung Cancer,3907
9,NCT02443337,Phase II,"Active, not recruiting","[{'id': 826, 'therapyName': 'Necitumumab'}, {'id': 1069, 'therapyName': 'LY3023414'}]",A Study of LY3023414 and Necitumumab in Squamous Lung Cancer,3907
10,NCT02444793,Phase I,Recruiting,"[{'id': 6332, 'therapyName': 'Mogamulizumab + Utomilumab'}]",A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors,3907
11,NCT02513563,Phase II,Recruiting,"[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 822, 'therapyName': 'MK-1775'}]",AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer,3907
12,NCT02536495,Phase Ib/II,Withdrawn,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1749, 'therapyName': 'Selinexor'}]",Selinexor and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Lung Cancer,3907
13,NCT02785913,Phase II,"Active, not recruiting","[{'id': 1016, 'therapyName': 'GDC-0032'}]",Lung-MAP: Taselisib as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches,3907
14,NCT02785939,Phase II,"Active, not recruiting","[{'id': 850, 'therapyName': 'Palbociclib'}]",Lung-MAP: Palbociclib as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches,3907
15,NCT02785952,Phase III,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers,3907
16,NCT02924233,Phase Ib/II,Withdrawn,"[{'id': 4833, 'therapyName': 'Nivolumab + SYM004'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Sym004 in Combination With Nivolumab Versus Nivolumab Monotherapy in EGFR-amplified Squamous Non-Small Cell Lung Cancer,3907
17,NCT03065062,Phase I,Recruiting,"[{'id': 4034, 'therapyName': 'Gedatolisib + Palbociclib'}]","Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors",3907
18,NCT03157089,Phase II,Not yet recruiting,"[{'id': 2435, 'therapyName': 'Afatinib + Pembrolizumab'}]",Testing Afatinib in Combination With Pembrolizumab in Patients With Squamous Cell Carcinoma of the Lung (LUX-Lung IO),3907
0,NCT02780310,Phase II,"Active, not recruiting","[{'id': 792, 'therapyName': 'Lenvatinib'}]",Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma,60219
1,NCT03087019,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma,60219
2,NCT03172624,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer,60219
0,NCT03155620,Phase II,Recruiting,"[{'id': 2683, 'therapyName': 'Tazemetostat'}, {'id': 2650, 'therapyName': 'LOXO-101'}, {'id': 1069, 'therapyName': 'LY3023414'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 913, 'therapyName': 'Selumetinib'}, {'id': 961, 'therapyName': 'X-396'}]",Pediatric MATCH: Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Advanced Refractory Solid Tumors or Lymphomas,60073
0,NCT00990249,Phase II,Completed,"[{'id': 2469, 'therapyName': 'Busulfan + Clofarabine + Thymoglobulin'}]",Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation,1037
1,NCT01319981,Phase II,Recruiting,"[{'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia,1037
2,NCT02116777,Phase Ib/II,Recruiting,"[{'id': 1377, 'therapyName': 'Talazoparib + Temozolomide'}]",BMN-673 and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies,1037
3,NCT02535806,Phase II,Terminated,"[{'id': 1631, 'therapyName': 'Vincristine'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults,1037
4,NCT03136146,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1090, 'therapyName': 'Ofatumumab'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}]","Study of Clofarabine, Etoposide, Cyclophosphamide [CEC], Liposomal Vincristine (VCR), Dexamethasone and Bortezomib in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL)",1037
0,NCT02793544,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 5682, 'therapyName': 'Mesna'}, {'id': 1166, 'therapyName': 'Fludarabine'}]",HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide,80147
1,NCT02906371,Phase I,Recruiting,"[{'id': 5647, 'therapyName': 'Tocilizumab'}]",Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome,80147
2,NCT03023046,Phase II,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1631, 'therapyName': 'Vincristine'}]","Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma",80147
3,NCT03117751,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1876, 'therapyName': 'Blinatumomab '}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}]",Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma,80147
4,NCT03136146,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1090, 'therapyName': 'Ofatumumab'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}]","Study of Clofarabine, Etoposide, Cyclophosphamide [CEC], Liposomal Vincristine (VCR), Dexamethasone and Bortezomib in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL)",80147
0,NCT00368082,Phase I,"Active, not recruiting",[],"Autologous/Allogeneic TGFbeta-resistant LMP2A-specific CTL, Lymphoma (TGF-beta)",5660
0,NCT00084695,Phase II,Unknown status,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases,60058
1,NCT00368082,Phase I,"Active, not recruiting",[],"Autologous/Allogeneic TGFbeta-resistant LMP2A-specific CTL, Lymphoma (TGF-beta)",60058
2,NCT00585195,Phase I,Recruiting,"[{'id': 1526, 'therapyName': 'Crizotinib + Itraconazole\t'}, {'id': 1483, 'therapyName': 'Crizotinib + Rifampin'}]","A Study Of Oral PF-02341066, A c-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer",60058
3,NCT00918333,Phase Ib/II,"Active, not recruiting","[{'id': 1964, 'therapyName': 'Panobinostat + Everolimus'}]","Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma",60058
4,NCT01237236,Phase I,Completed,"[{'id': 790, 'therapyName': 'Ribociclib'}]",A Trial of LEE011 in Patients With Advanced Solid Tumors or Lymphoma.,60058
5,NCT01273155,Phase I,Recruiting,"[{'id': 1078, 'therapyName': 'Belinostat'}]",Belinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction,60058
6,NCT01287546,Phase I,Completed,"[{'id': 1179, 'therapyName': 'Emibetuzumab + Erlotinib'}, {'id': 1180, 'therapyName': 'Emibetuzumab + Trametinib'}, {'id': 803, 'therapyName': 'Emibetuzumab'}]",A Study of LY2875358 in Participants With Advanced Cancer,60058
7,NCT01326702,Phase Ib/II,Completed,"[{'id': 954, 'therapyName': 'Veliparib'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1231, 'therapyName': 'Bendamustine'}]"," Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors",60058
8,NCT01327612,Phase II,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 746, 'therapyName': 'Ganitumab'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1458, 'therapyName': 'Conatumumab'}]",Open Label Extension Study of Conatumumab and AMG 479,60058
9,NCT01363817,Phase I,"Active, not recruiting","[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2545, 'therapyName': 'BMS-906024'}]",Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma,60058
10,NCT01393509,Phase I,"Active, not recruiting","[{'id': 1162, 'therapyName': 'PU-H71'}]",The First-in-human Phase I Trial of PU-H71 in Patients With Advanced Malignancies,60058
11,NCT01473095,Phase I,"Active, not recruiting","[{'id': 635, 'therapyName': 'ARQ092'}]",Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma,60058
12,NCT01498484,Phase II,"Active, not recruiting","[{'id': 5057, 'therapyName': 'EB-VST cells'}]",Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies,60058
13,NCT01564251,Phase I,"Active, not recruiting","[{'id': 2113, 'therapyName': 'GDC-0575 + Gemcitabine'}, {'id': 2024, 'therapyName': 'GDC-0575'}]",A Study of GDC-0575 Alone And in Combination With Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma,60058
14,NCT01576406,Phase I,Completed,"[{'id': 706, 'therapyName': 'Crizotinib'}]",Hepatic Impairment Study For Crizotinib In Advanced Cancer Patients,60058
15,NCT01596270,Phase I,Completed,"[{'id': 1051, 'therapyName': 'SAR245409'}]",A Study of the Safety and Pharmacokinetics of SAR245409 Tablets in Patients With Solid Tumors or Lymphoma,60058
16,NCT01625351,Phase I,"Active, not recruiting","[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1205, 'therapyName': 'Alemtuzumab'}]",A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas,60058
17,NCT01636479,Phase I,"Active, not recruiting","[{'id': 2078, 'therapyName': 'SAR405838'}]",Phase 1 Safety Testing of SAR405838,60058
18,NCT01638533,Phase I,Recruiting,"[{'id': 1075, 'therapyName': 'romidepsin'}]","Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction",60058
19,NCT01655225,Phase I,Recruiting,"[{'id': 1214, 'therapyName': 'LY3023414 + Midazolam '}, {'id': 1215, 'therapyName': ' LY3023414 + Letrozole '}, {'id': 1069, 'therapyName': 'LY3023414'}]",A Study of LY3023414 in Participants With Advanced Cancer,60058
20,NCT01665768,Phase II,"Active, not recruiting","[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 735, 'therapyName': 'Everolimus'}]",Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma,60058
21,NCT01670175,Phase I,Completed,"[{'id': 1224, 'therapyName': 'Sirolimus + Cyclophosphamide + Topotecan'}]",Sirolimus With Cyclophosphamide and Topotecan for Pediatric/Adolescent Relapsed and Refractory Solid Tumors,60058
22,NCT01673737,Phase I,Completed,"[{'id': 1052, 'therapyName': 'SAR260301'}, {'id': 1225, 'therapyName': 'SAR260301 + Vemurafenib'}]", A Phase I/Ib Trial for the Evaluation of SAR260301 in Monotherapy or in Combination With Vemurafenib in Patients With Various Advanced Cancer,60058
23,NCT01695005,Phase I,Recruiting,"[{'id': 2958, 'therapyName': 'LY3039478'}]",A Study of LY3039478 in Participants With Advanced Cancer,60058
24,NCT01703481,Phase I,"Active, not recruiting","[{'id': 1028, 'therapyName': 'JNJ-42756493'}]","A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Adult Patients With Advanced or Refractory Solid Tumors or Lymphoma",60058
25,NCT01703572,Phase I,Completed,"[{'id': 839, 'therapyName': 'Brontictuzumab'}]",A Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid Malignancies,60058
26,NCT01742988,Phase I,Recruiting,"[{'id': 709, 'therapyName': 'CUDC-907'}]","Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Patients With Lymphoma or Multiple Myeloma",60058
27,NCT01744223,Phase Ib/II,Recruiting,"[{'id': 5992, 'therapyName': 'Rimiducid'}, {'id': 6053, 'therapyName': 'BPX-501'}]",Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant,60058
28,NCT01829971,Phase I,Terminated,"[{'id': 1035, 'therapyName': 'MRX34'}]","A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection",60058
29,NCT01844583,Phase I,Completed,"[{'id': 1239, 'therapyName': 'Alisertib  + Esomeprazole'}, {'id': 1240, 'therapyName': 'Alisertib + Rifampin'}, {'id': 626, 'therapyName': 'Alisertib'}]","Safety, Tolerability and PK of Concomitant Esomeprazole and Rifampin, and QT Study on Single and Multiple-doses of Alisertib",60058
30,NCT01877382,Phase I,Recruiting,"[{'id': 2079, 'therapyName': 'DS-3032b'}]","A Phase 1 Multiple Ascending Dose Study of DS-3032b, an Oral Murine Double Minute 2 (MDM2) Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas",60058
31,NCT01885897,Phase Ib/II,Recruiting,"[{'id': 3060, 'therapyName': 'ALT-803'}]",IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT,60058
32,NCT01897012,Phase I,Recruiting,"[{'id': 1075, 'therapyName': 'romidepsin'}, {'id': 626, 'therapyName': 'Alisertib'}]",Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas,60058
33,NCT01898078,Phase I,"Active, not recruiting","[{'id': 626, 'therapyName': 'Alisertib'}]", Food Effect Study of Alisertib (MLN8237) in Patients With Advanced Solid Tumors or Lymphomas,60058
34,NCT01905228,Phase I,Recruiting,"[{'id': 3940, 'therapyName': 'CBL0137 '}]",A Phase 1 Trial of CBL0137 in Patients With Metastatic or Unresectable Advanced Solid Neoplasm or Refractory Lymphomas,60058
35,NCT01908413,Phase I,Terminated,"[{'id': 3639, 'therapyName': 'GDC-0917'}]","Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-427 When Given to Patients With Advanced and Refractory Solid Tumors or Lymphoma",60058
36,NCT01943682,Phase I,Recruiting,"[{'id': 4341, 'therapyName': 'CPX-351'}]",Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma,60058
37,NCT01991938,Phase I,Terminated,"[{'id': 960, 'therapyName': 'VS-5584'}]",Phase I Dose Escalation Study of VS-5584 in Subjects With Advanced Non-Hematologic Malignancies or Lymphoma,60058
38,NCT01992653,Phase I,"Active, not recruiting","[{'id': 4248, 'therapyName': 'Cyclophosphamide + Doxorubicin + Prednisone'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 4226, 'therapyName': 'Polatuzumab Vedotin'}, {'id': 1646, 'therapyName': 'Obinutuzumab'}]","A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma",60058
39,NCT02042989,Phase I,"Active, not recruiting","[{'id': 1360, 'therapyName': 'Ixazomib + Vorinostat'}]",MLN9708 and Vorinostat in Patients With Advanced p53 Mutant Malignancies,60058
40,NCT02216409,Phase I,Recruiting,"[{'id': 4947, 'therapyName': 'Hu5F9-G4'}]","Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody",60058
41,NCT02249429,Phase Ib/II,Recruiting,"[{'id': 2019, 'therapyName': 'PQR309'}]","Open-Label, Non Randomized Phase 2 Study With Safety Run-In",60058
42,NCT02259010,Phase I,"Active, not recruiting","[{'id': 626, 'therapyName': 'Alisertib'}, {'id': 1026, 'therapyName': 'Itraconazole'}]",A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Alisertib in Patients With Advanced Solid Tumors or Relapsed/Refractory Lymphoma,60058
43,NCT02309580,Phase I,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma,60058
44,NCT02318329,Phase I,Recruiting,"[{'id': 2933, 'therapyName': 'FPA144'}]","Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors",60058
45,NCT02323880,Phase I,Recruiting,"[{'id': 1749, 'therapyName': 'Selinexor'}]",Study of Selinexor in Pediatric Solid Tumors,60058
46,NCT02332668,Phase Ib/II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","A Study of Pembrolizumab (MK-3475) in Pediatric Participants With Advanced Melanoma or Advanced, Relapsed, or Refractory PD-L1-Positive Solid Tumors or Lymphoma (MK-3475-051/KEYNOTE-051)",60058
47,NCT02337985,Phase I,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 2482, 'therapyName': 'Cyclophosphamide + Doxorubicin + Etoposide + Vincristine '}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma,60058
48,NCT02343718,Phase I,"Active, not recruiting","[{'id': 2492, 'therapyName': 'Temsirolimus + Vinblastine'}]",Vinblastine and Temsirolimus in Pediatric Patients With Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours,60058
49,NCT02355535,Phase I,Recruiting,"[{'id': 4602, 'therapyName': 'PAC-1'}]",Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies,60058
50,NCT02356159,Phase Ib/II,Recruiting,"[{'id': 2294, 'therapyName': 'Cytarabine + Fludarabine'}, {'id': 2373, 'therapyName': 'Palifermin'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2238, 'therapyName': 'Sirolimus + Tacrolimus + Methotrexate'}, {'id': 2292, 'therapyName': 'Doxorubicin + Etoposide + Fludarabine + Vincristine '}, {'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 897, 'therapyName': 'Rituximab'}]",Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation,60058
51,NCT02376699,Phase I,Recruiting,"[{'id': 5781, 'therapyName': 'Pembrolizumab + SEA-CD40'}, {'id': 5780, 'therapyName': 'SEA-CD40'}]",Safety Study of SEA-CD40 in Cancer Patients,60058
52,NCT02392611,Phase I,"Active, not recruiting","[{'id': 3561, 'therapyName': 'GS-5829 + Exemestane'}]","Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 in Adults With Advanced Solid Tumors and Lymphomas",60058
53,NCT02414724,Phase I,Terminated,"[{'id': 2898, 'therapyName': 'Gemcitabine + Ribociclib'}]",Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors or Lymphoma,60058
54,NCT02431260,Phase I,"Active, not recruiting","[{'id': 2812, 'therapyName': 'INCB054329'}]","An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies",60058
55,NCT02465060,Phase II,Recruiting,"[{'id': 660, 'therapyName': 'Osimertinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 654, 'therapyName': 'AZD4547'}, {'id': 958, 'therapyName': 'VS-6063'}, {'id': 765, 'therapyName': 'GSK2636771'}]",NCI-MATCH Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,60058
56,NCT02477878,Phase I,Recruiting,"[{'id': 5995, 'therapyName': 'BPX-601'}, {'id': 5992, 'therapyName': 'Rimiducid'}]",Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant,60058
57,NCT02499861,Phase Ib/II,Recruiting,"[{'id': 1734, 'therapyName': 'Genistein + Decitabine'}]",Phase I/II a Study of Decitabine in Combination With Genistein in Pediatric Relapsed or Refractory Malignancies,60058
58,NCT02516813,Phase I,Recruiting,"[{'id': 3616, 'therapyName': 'MSC2490484A '}]","Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy",60058
59,NCT02518113,Phase Ib/II,Recruiting,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2958, 'therapyName': 'LY3039478'}]",A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL,60058
60,NCT02518750,Phase II,Recruiting,"[{'id': 1604, 'therapyName': 'Panobinostat + Bortezomib + Dexamethasone'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 3217, 'therapyName': 'Cyclophosphamide + Etoposide'}, {'id': 3216, 'therapyName': 'Cytarabine + Methotrexate + Prednisone'}, {'id': 1746, 'therapyName': 'Clofarabine'}]",Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma,60058
61,NCT02518958,Phase I,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}]","A Phase I, Open-Label, Multiple Ascending Dose Study of RRx-001 and Nivolumab",60058
62,NCT02538926,Phase II,Not yet recruiting,"[{'id': 770, 'therapyName': 'Imatinib'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 3212, 'therapyName': 'Doxorubicin + Etoposide + Vincristine '}, {'id': 2206, 'therapyName': 'Asparaginase'}]","Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma",60058
63,NCT02624388,Phase II,Recruiting,"[{'id': 757, 'therapyName': 'Genistein'}]",Study of Genistein in Pediatric Oncology Patients (UVA-Gen001),60058
64,NCT02663518,Phase I,Recruiting,"[{'id': 5338, 'therapyName': 'TTI-621'}]",A Trial of TTI-621 for Patients With Hematologic Malignancies,60058
65,NCT02681302,Phase Ib/II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study of Combined Check Point Inhibition After Autologous Hematopoietic Stem Cell Transplantation in Patients at High Risk for Post-transplant Recurrence (CPIT001),60058
66,NCT02694822,Phase I,Recruiting,"[{'id': 5695, 'therapyName': 'AGEN1884'}]","AGEN-1884, an Anti-CTLA-4 Antibody, in Advanced Solid Cancers",60058
67,NCT02729896,Phase Ib/II,Recruiting,"[{'id': 4362, 'therapyName': 'Atezolizumab + Obinutuzumab + Polatuzumab Vedotin'}]","A Study of Obinutuzumab, Polatuzumab Vedotin, and Atezolizumab in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)",60058
68,NCT02740270,Phase I,Recruiting,"[{'id': 4469, 'therapyName': 'GWN 323 + PDR001'}, {'id': 4468, 'therapyName': 'GWN 323'}]",Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas,60058
69,NCT02780011,Phase I,Not yet recruiting,"[{'id': 4301, 'therapyName': 'Alisertib + Brentuximab vedotin'}]",Alsertib (MLN8237) and Brentuximab Vedotin for Relapsed/Refractory CD30-Positive Lymphomas and Solid Malignancies,60058
70,NCT02780804,Phase I,Recruiting,"[{'id': 1541, 'therapyName': 'Entinostat'}]",Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors,60058
71,NCT02783625,Phase I,Recruiting,"[{'id': 4240, 'therapyName': 'Bortezomib + Duvelisib'}, {'id': 4239, 'therapyName': 'Duvelisib + romidepsin '}]",Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas,60058
72,NCT02784795,Phase I,Recruiting,"[{'id': 4374, 'therapyName': 'Cisplatin + Gemcitabine + LY3039478'}, {'id': 4375, 'therapyName': 'Carboplatin + Gemcitabine + LY3039478'}, {'id': 4372, 'therapyName': 'LY3039478 + LY3023414'}, {'id': 4373, 'therapyName': 'Abemaciclib + LY3039478'}, {'id': 4371, 'therapyName': 'LY3039478 + Taladegib'}, {'id': 2958, 'therapyName': 'LY3039478'}, {'id': 1069, 'therapyName': 'LY3023414'}]",A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors,60058
73,NCT02786485,Phase I,Not yet recruiting,"[{'id': 5992, 'therapyName': 'Rimiducid'}, {'id': 6053, 'therapyName': 'BPX-501'}]",Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT,60058
74,NCT02793466,Phase I,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}]",Durvalumab in Pediatric and Adolescent Patients,60058
75,NCT02793544,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 5682, 'therapyName': 'Mesna'}, {'id': 1166, 'therapyName': 'Fludarabine'}]",HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide,60058
76,NCT02812875,Phase I,Recruiting,"[{'id': 5885, 'therapyName': 'CA-170'}]","A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas",60058
77,NCT02846935,Phase 0,Recruiting,"[{'id': 3567, 'therapyName': 'Decitabine + Tetrahydrouridine'}]",p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies,60058
78,NCT02875548,Phase II,Recruiting,"[{'id': 2683, 'therapyName': 'Tazemetostat'}]",Tazemetostat Rollover Study (TRuST): An Open-Label Rollover Study,60058
79,NCT02909777,Phase I,Recruiting,"[{'id': 709, 'therapyName': 'CUDC-907'}]","Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma",60058
80,NCT02932280,Phase Ib/II,Recruiting,"[{'id': 828, 'therapyName': 'Neratinib'}]",Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment,60058
81,NCT02935907,Phase I,Recruiting,"[{'id': 5826, 'therapyName': 'APG-115'}]",APG-115 in Patients With Advanced Solid Tumors or Lymphomas,60058
82,NCT02992483,Phase I,Recruiting,"[{'id': 5814, 'therapyName': 'MIK665'}]","Phase I Study of MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple Myeloma",60058
83,NCT03005782,Phase I,Recruiting,"[{'id': 5736, 'therapyName': 'REGN3767 + REGN2810'}, {'id': 5735, 'therapyName': 'REGN3767'}]",Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers,60058
84,NCT03010176,Phase I,Recruiting,"[{'id': 5348, 'therapyName': 'MK-1454 + Pembrolizumab'}, {'id': 5347, 'therapyName': 'MK-1454'}]",Study of MK-1454 Alone or in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001),60058
85,NCT03011372,Phase II,Recruiting,"[{'id': 4173, 'therapyName': 'INCB054828'}]",A Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement,60058
86,NCT03013218,Phase I,Recruiting,"[{'id': 5211, 'therapyName': 'ALX148'}, {'id': 5212, 'therapyName': 'ALX148 + Atezolizumab'}, {'id': 5213, 'therapyName': 'ALX148 + Trastuzumab'}]",A Study of ALX148 in Patients With Advanced Solid Tumors and Lymphoma,60058
87,NCT03013491,Phase II,Recruiting,"[{'id': 5209, 'therapyName': 'CX-072 + Ipilimumab'}, {'id': 5210, 'therapyName': 'CX-072 + Vemurafenib'}, {'id': 5208, 'therapyName': 'CX-072'}]",A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas,60058
88,NCT03030417,Phase I,Recruiting,"[{'id': 5749, 'therapyName': 'LMP744'}]",Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas,60058
89,NCT03061188,Phase I,Recruiting,"[{'id': 5368, 'therapyName': 'Veliparib + Nivolumab'}]",Nivolumab and Veliparib in Treating Patients With Recurrent or Refractory Stage IV Solid Tumors That Cannot Be Removed by Surgery or Lymphoma With or Without Alterations in DNA Repair Genes,60058
90,NCT03155620,Phase II,Recruiting,"[{'id': 2683, 'therapyName': 'Tazemetostat'}, {'id': 2650, 'therapyName': 'LOXO-101'}, {'id': 1069, 'therapyName': 'LY3023414'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 913, 'therapyName': 'Selumetinib'}, {'id': 961, 'therapyName': 'X-396'}]",Pediatric MATCH: Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Advanced Refractory Solid Tumors or Lymphomas,60058
91,NCT03162536,Phase I,Recruiting,"[{'id': 5224, 'therapyName': 'ARQ 531'}]","Safety, PK, PD, and Antitumor Activity of ARQ 531 in Hematologic Malignancies",60058
92,NCT03172936,Phase I,Recruiting,"[{'id': 6219, 'therapyName': 'MIW815 + PDR001'}]",Study of the Safety and Efficacy of MIW815 With PDR001 to Patients With Advanced/Metastatic Solid Tumors or Lymphomas,60058
93,NCT03192202,Phase Ib/II,Recruiting,"[{'id': 4389, 'therapyName': 'AFM13'}]",AFM13 in Relapsed/Refractory Cutaneous Lymphomas,60058
94,NCT03194893,Phase III,Recruiting,"[{'id': 706, 'therapyName': 'Crizotinib'}, {'id': 698, 'therapyName': 'Alectinib'}]",A Roll Over Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer,60058
95,NCT03205176,Phase I,Recruiting,"[{'id': 4910, 'therapyName': 'AZD5153'}]",Phase I Study of AZD5153 in Patients With Relapsed or Refractory Solid Tumors and Lymphomas,60058
96,NCT03229200,FDA approved,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.,60058
97,NCT03229278,Phase I,Recruiting,"[{'id': 6055, 'therapyName': 'Nivolumab + Pembrolizumab + Trigriluzole'}]",Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma,60058
98,NCT03249792,Phase I,Recruiting,"[{'id': 6131, 'therapyName': 'MK-2118 + Pembrolizumab'}, {'id': 6130, 'therapyName': 'MK-2118'}]",Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) in the Treatment of Adults With Advance/Metastatic Solid Tumors or Lymphomas (MK-2118-001),60058
99,NCT03259503,Phase Ib/II,Not yet recruiting,"[{'id': 1206, 'therapyName': 'Busulfan'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 2373, 'therapyName': 'Palifermin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 3277, 'therapyName': 'Pyridoxine'}, {'id': 897, 'therapyName': 'Rituximab'}]",Olaparib Combined With High-Dose Chemotherapy for Refractory Lymphomas,60058
100,NCT03291938,Phase I,Not yet recruiting,"[{'id': 6267, 'therapyName': 'IACS-010759'}]",Study to Evaluate the Safety and Tolerability of IACS-010759 in Subjects With Advanced Solid Tumors and Lymphoma,60058
101,NCT03311412,,Not yet recruiting,[],Sym021 (Anti-PD-1) in Patients With Advanced Solid Tumor Malignancies or Lymphomas,60058
0,NCT00577278,Phase II,"Active, not recruiting","[{'id': 767, 'therapyName': 'Ibritumomab'}, {'id': 2238, 'therapyName': 'Sirolimus + Tacrolimus + Methotrexate'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}]","Yttrium Y 90 Ibritumomab Tiuxetan, Rituximab, Indium In-111 Ibritumomab Tiuxetan, Fludarabine, Melphalan, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin Lymphoma",50747
1,NCT00602693,Phase I,Completed,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 2311, 'therapyName': 'Allopurinol + Cyclophosphamide + Fludarabine'}]",T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer,50747
2,NCT00671112,Phase I,Terminated,"[{'id': 2234, 'therapyName': 'Bortezomib + Everolimus'}]",Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma,50747
3,NCT01732913,Phase III,Terminated,"[{'id': 1023, 'therapyName': 'Idelalisib'}, {'id': 897, 'therapyName': 'Rituximab'}]",Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas,50747
4,NCT01732926,Phase III,Terminated,"[{'id': 1023, 'therapyName': 'Idelalisib'}, {'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}]",Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas,50747
5,NCT01955499,Phase I,"Active, not recruiting","[{'id': 3580, 'therapyName': 'Ibrutinib + lenalidomide'}]",Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma,50747
6,NCT01994382,Phase I,Recruiting,"[{'id': 2531, 'therapyName': 'Cerdulatinib'}]",Phase 1 Dose Escalation Study in Chronic Lymphocytic Leukemia and Non-hodgkin Lymphoma,50747
7,NCT02000934,Phase I,Recruiting,"[{'id': 3146, 'therapyName': 'TAK-659'}]",A Study of TAK-659 in Adult Patients With Advanced Solid Tumor and Lymphoma Malignancies,50747
8,NCT02049541,Phase I,"Active, not recruiting","[{'id': 2502, 'therapyName': 'BKM120 + Rituximab'}]",Study of BKM120; Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma,50747
9,NCT02092909,Phase Ib/II,"Active, not recruiting","[{'id': 2866, 'therapyName': 'IMO-8400'}]",Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia (8400-401),50747
10,NCT02180724,Phase I,"Active, not recruiting","[{'id': 1605, 'therapyName': 'Acalabrutinib'}]","An Open-label, Phase 1b Study of ACP 196 in Subjects With Waldenström Macroglobulinemia",50747
11,NCT02367040,Phase III,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 995, 'therapyName': 'Copanlisib'}]",Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL),50747
12,NCT02369016,Phase III,"Active, not recruiting","[{'id': 995, 'therapyName': 'Copanlisib'}]",Phase III Copanlisib in Rituximab-refractory iNHL,50747
13,NCT02384954,Phase Ib/II,Recruiting,"[{'id': 3936, 'therapyName': 'ALT-803 + Rituximab'}]",ALT-803 in Patients With Relapse/Refractory Indolent B Cell Non-Hodgkin Lymphoma (iNHL) in Conjunction With Rituximab,50747
14,NCT02604511,Phase II,"Active, not recruiting","[{'id': 768, 'therapyName': 'Ibrutinib'}]","Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing",50747
15,NCT02626455,Phase III,Recruiting,"[{'id': 1631, 'therapyName': 'Vincristine'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 3388, 'therapyName': 'Aldoxorubicin +Cyclophosphamide + Prednisone + Rituximab + Vincristine'}, {'id': 995, 'therapyName': 'Copanlisib'}, {'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}, {'id': 897, 'therapyName': 'Rituximab'}]",Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL),50747
16,NCT02722668,Phase II,Recruiting,"[{'id': 2281, 'therapyName': 'Cyclophosphamide + Fludarabine + Mycophenolate mofetil'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}]",UCB Transplant for Hematological DIseases Using a Non Myeloablative Prep,50747
17,NCT02950220,Phase I,Recruiting,"[{'id': 4917, 'therapyName': 'Pembrolizumab + Ibrutinib'}]",Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma,50747
18,NCT03015896,Phase Ib/II,Suspended,"[{'id': 5239, 'therapyName': 'Lenalidomide + Nivolumab'}]",Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma,50747
19,NCT03037645,Phase Ib/II,Recruiting,"[{'id': 5281, 'therapyName': 'SNS-062'}]","Safety, PK, PD, and Antitumor Activity of SNS-062 in B Lymphoid Cancers",50747
20,NCT03053440,Phase III,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 2544, 'therapyName': 'BGB-3111'}]",A Study Comparing BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM),50747
21,NCT03133221,Phase II,Not yet recruiting,"[{'id': 1023, 'therapyName': 'Idelalisib'}]",1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation,50747
0,NCT02978625,Phase II,Recruiting,"[{'id': 5080, 'therapyName': 'Talimogene laherparepvec + Nivolumab'}]",Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers,5570
0,NCT01331135,Phase I,"Active, not recruiting","[{'id': 917, 'therapyName': 'Sirolimus'}]",Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors,5074
1,NCT01721577,Phase Ib/II,Unknown status,"[{'id': 2745, 'therapyName': 'AXL1717'}]",Phase I/II Trial of Safety and Anti-tumor Efficacy of AXL1717(Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas,5074
2,NCT02101905,Phase I,Recruiting,"[{'id': 787, 'therapyName': 'Lapatinib'}]",Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma,5074
3,NCT02502708,Phase I,Recruiting,"[{'id': 2976, 'therapyName': 'indoximod'}, {'id': 1141, 'therapyName': 'Temozolomide'}]","Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Primary Malignant Brain Tumors",5074
4,NCT02774421,Phase I,Recruiting,"[{'id': 1891, 'therapyName': 'Trastuzumab + Sargramostim'}]",Pilot Study of the Effect of Trastuzumab and GM-CSF on Children With Recurrent Ependymoma,5074
5,NCT03095248,Phase II,Recruiting,"[{'id': 913, 'therapyName': 'Selumetinib'}]",Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors,5074
6,NCT03130959,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",An Investigational Immuno-therapy Study of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Patients With High Grade Primary CNS Malignancies (CheckMate 908),5074
7,NCT03173950,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Immune Checkpoint Inhibitor Nivolumab in People With Select Rare CNS Cancers,5074
8,NCT03220646,Phase II,Recruiting,"[{'id': 802, 'therapyName': 'Abemaciclib'}]",The Purpose of This Study is to Test Any Good and Bad Effects of a Study Drug Called Abemaciclib (LY2835219) in Patients With Recurrent Brain Tumors.,5074
0,NCT02584309,Phase II,Recruiting,"[{'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 4140, 'therapyName': 'Doxorubicin + Olaratumab'}]",Doxorubicin With Upfront Dexrazoxane Plus Olaratumab for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma,1907
1,NCT03092323,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity (SU2C-SARC032),1907
2,NCT03190174,Phase Ib/II,Recruiting,"[{'id': 5931, 'therapyName': 'Nab-Rapamycin + Nivolumab'}]",Nivolumab (Opdivo) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma,1907
3,NCT03282344,Phase II,Recruiting,"[{'id': 5076, 'therapyName': 'NKTR-214 + Nivolumab'}]",A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma,1907
0,NCT02371369,Phase III,"Active, not recruiting","[{'id': 874, 'therapyName': 'PLX3397'}]",PLX3397 Phase 3 Study for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS),2704
0,NCT00876993,Phase I,Completed,"[{'id': 1463, 'therapyName': 'Temozolomide + Irinotecan + Bevacizumab'}]",Study of Irinotecan and Bevacizumab With Temozolomide in Refractory/Relapsed Central Nervous System (CNS) Tumors,3070
1,NCT00879437,Phase II,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1076, 'therapyName': 'Valproic acid'}]",Valproic Acid and Radiation Followed by Maintenance Valproic Acid and Bevacizumab in Children With High Grade Gliomas,3070
2,NCT01052363,Phase I,Withdrawn,"[{'id': 2109, 'therapyName': 'Bevacizumab + Fosbretabulin'}]",OXC401-PO1s/WVU 1309 - A Pilot Study of Fosbretabulin With Bevacizumab in Recurrent High-Grade Gliomas,3070
3,NCT01089101,Phase Ib/II,Recruiting,"[{'id': 913, 'therapyName': 'Selumetinib'}]",Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma,3070
4,NCT01107522,Phase I,"Active, not recruiting","[{'id': 1142, 'therapyName': 'CTO + Temozolomide'}, {'id': 999, 'therapyName': 'Carboxyamidotriazole Orotate'}]",Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar&#174; in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar&#174; and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas,3070
5,NCT01130077,Phase I,Recruiting,"[{'id': 2595, 'therapyName': 'poly ICLC  '}]",A Pilot Study of Glioma Associated Antigen Vaccines in Conjunction With Poly-ICLC in Pediatric Gliomas,3070
6,NCT01156584,Phase I,"Active, not recruiting","[{'id': 3211, 'therapyName': 'Toca 511 + Toca FC'}]",A Study of a Retroviral Replicating Vector Administered to Subjects With Recurrent Malignant Glioma,3070
7,NCT01188096,Phase II,Recruiting,"[{'id': 2595, 'therapyName': 'poly ICLC  '}]",A Trial of Poly-ICLC in the Management of Recurrent Pediatric Low Grade Gliomas,3070
8,NCT01266031,Phase Ib/II,Completed,"[{'id': 2110, 'therapyName': 'Bevacizumab + Vorinostat'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma,3070
9,NCT01331135,Phase I,"Active, not recruiting","[{'id': 917, 'therapyName': 'Sirolimus'}]",Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors,3070
10,NCT01386580,Phase Ib/II,Completed,"[{'id': 974, 'therapyName': '2B3-101'}, {'id': 1274, 'therapyName': '2B3-101 + Trastuzumab'}]","An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.",3070
11,NCT01392209,Phase I,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}]",Hypofractionated Stereotactic Radiotherapy With Bevacizumab in the Treatment of Recurrent Malignant Glioma,3070
12,NCT01434602,Phase Ib/II,Recruiting,"[{'id': 2299, 'therapyName': 'Everolimus + Sorafenib'}]",Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas,3070
13,NCT01435395,Phase I,Completed,"[{'id': 2122, 'therapyName': 'Bevacizumab + Bortezomib + Temozolomide'}]","Trial of Temozolomide, Bevacizumab Plus Bortezomib for Recurrent Glioblastoma Multiforme",3070
14,NCT01478178,Phase Ib/II,Completed,"[{'id': 2921, 'therapyName': 'VAL-083'}]",Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma or Progressive Secondary Brain Tumor,3070
15,NCT01478321,Phase II,"Active, not recruiting","[{'id': 2115, 'therapyName': 'Bevacizumab + Temozolomide'}]",Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas,3070
16,NCT01547546,Phase I,Completed,"[{'id': 2018, 'therapyName': 'GDC-0084'}]",A Study of GDC-0084 in Patients With Progressive or Recurrent High-Grade Glioma,3070
17,NCT01644773,Phase I,Recruiting,"[{'id': 1252, 'therapyName': 'Crizotinib + Dasatinib'}]",Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG),3070
18,NCT01648348,Phase Ib/II,"Active, not recruiting","[{'id': 1242, 'therapyName': 'Carotuximab'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme,3070
19,NCT01661400,Phase I,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1475, 'therapyName': 'Thalidomide'}]",Anti-Angiogenic Therapy Post Transplant (ASCR) for Relapsed and Refractory Pediatric Solid Tumors,3070
20,NCT01743950,Phase II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",A Phase II Study of Pulse Reduced Dose Rate Radiation Therapy With Bevacizumab,3070
21,NCT01748149,Phase I,Recruiting,"[{'id': 342, 'therapyName': 'Vemurafenib'}]",Vemurafenib in Children With Recurrent/Refractory BRAFV600E-mutant Gliomas,3070
22,NCT01817751,Phase II,Recruiting,"[{'id': 1076, 'therapyName': 'Valproic acid'}, {'id': 920, 'therapyName': 'Sorafenib'}]","Sorafenib Tosylate, Valproic Acid, and Sildenafil Citrate in Treating Patients With Recurrent High-Grade Glioma",3070
23,NCT01903330,Phase II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1873, 'therapyName': 'Sargramostim'}]",ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme,3070
24,NCT01925573,Phase I,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",NOVOTTF-100A+ Bevacizumab+ Hypofractionated Stereotactic Irradiation Bevacizumab-Naive Recurrent Glioblastoma (GCC 1344),3070
25,NCT01954030,Phase Ib/II,Terminated,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 999, 'therapyName': 'Carboxyamidotriazole Orotate'}]",Phase 1/2 CTO + Bevacizumab for Recurrent Glioma Post-Bevacizumab Failure,3070
26,NCT01977677,Phase Ib/II,"Active, not recruiting","[{'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 1756, 'therapyName': 'Plerixafor'}]",Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma,3070
27,NCT01985256,Phase I,"Active, not recruiting","[{'id': 3209, 'therapyName': 'Toca 511'}]",Study of a Retroviral Replicating Vector Given Intravenously to Patients Undergoing Surgery for Recurrent Brain Tumor,3070
28,NCT01989052,Phase Ib/II,Terminated,"[{'id': 2075, 'therapyName': 'Lomustine'}, {'id': 999, 'therapyName': 'Carboxyamidotriazole Orotate'}]",Ph 1/2 CTO With Lomustine for Bevacizumab-Naive Recurrent Glioma,3070
29,NCT02017717,Phase III,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Randomized Study of Nivolumab Versus Bevacizumab and a Safety Study of Nivolumab in Adult Subjects With Recurrent Glioblastoma (GBM) (CheckMate 143),3070
30,NCT02023905,Phase II,Recruiting,"[{'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 735, 'therapyName': 'Everolimus'}]",Everolimus With and Without Temozolomide in Adult Low Grade Glioma,3070
31,NCT02034110,Phase II,Recruiting,"[{'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}]",Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers,3070
32,NCT02052648,Phase Ib/II,Recruiting,"[{'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 2976, 'therapyName': 'indoximod'}]",Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors,3070
33,NCT02101905,Phase I,Recruiting,"[{'id': 787, 'therapyName': 'Lapatinib'}]",Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma,3070
34,NCT02186509,Phase I,Recruiting,"[{'id': 626, 'therapyName': 'Alisertib'}]",Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas,3070
35,NCT02193347,Phase I,Recruiting,"[{'id': 1635, 'therapyName': 'PEPIDH1M vaccine'}]",RESIST: Patients With IDH1 Positive Recurrent Grade II Glioma Enrolled in a Safety and Immunogenicity Study of Tumor-Specific Peptide Vaccine,3070
36,NCT02238496,Phase II,"Active, not recruiting","[{'id': 2194, 'therapyName': 'Perifosine + Temsirolimus'}]",Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas,3070
37,NCT02273739,Phase Ib/II,Completed,"[{'id': 2982, 'therapyName': 'Enasidenib'}]","Study of Orally Administered AG-221 in Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation",3070
38,NCT02311582,Phase Ib/II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",MK-3475 in Combination With MRI-guided Laser Ablation in Recurrent Malignant Gliomas,3070
39,NCT02313272,Phase I,Recruiting,"[{'id': 2119, 'therapyName': 'Bevacizumab + Pembrolizumab'}]",Phase I Trial of HFSRT With Pembrolizumab and Bevacizumab for Recurrent High Grade Gliomas,3070
40,NCT02323880,Phase I,Recruiting,"[{'id': 1749, 'therapyName': 'Selinexor'}]",Study of Selinexor in Pediatric Solid Tumors,3070
41,NCT02330562,Phase I,Recruiting,"[{'id': 2166, 'therapyName': 'Bevacizumab + Marizomib'}]",Study of Marizomib With Bevacizumab in Bevacizumab-Na&#239;ve Subjects With WHO Grade IV Malignant Glioma,3070
42,NCT02332889,Phase Ib/II,Terminated,"[{'id': 650, 'therapyName': 'Decitabine'}, {'id': 2595, 'therapyName': 'poly ICLC  '}]",Phase I/II Decitabine/Vaccine Therapy in Relapsed/Refractory Pediatric High Grade Gliomas/Medulloblastomas/CNS PNETs,3070
43,NCT02337491,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2119, 'therapyName': 'Bevacizumab + Pembrolizumab'}]",Pembrolizumab +/- Bevacizumab for Recurrent GBM,3070
44,NCT02337686,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pharmacodynamic Study of Pembrolizumab in Patients With Recurrent Glioblastoma,3070
45,NCT02343718,Phase I,"Active, not recruiting","[{'id': 2492, 'therapyName': 'Temsirolimus + Vinblastine'}]",Vinblastine and Temsirolimus in Pediatric Patients With Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours,3070
46,NCT02345824,Phase I,Recruiting,"[{'id': 790, 'therapyName': 'Ribociclib'}]",Early-Phase Study to Assess Inhibitor LEE011 in Patients With Recurrent Glioblastoma or Anaplastic Glioma,3070
47,NCT02358187,Phase II,Recruiting,"[{'id': 2595, 'therapyName': 'poly ICLC  '}]",A Vaccine Trial for Low Grade Gliomas,3070
48,NCT02359565,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas or Diffuse Intrinsic Pontine Gliomas",3070
49,NCT02372006,Phase I,Recruiting,"[{'id': 623, 'therapyName': 'Afatinib'}]",Phase I Trial of Afatinib in Pediatric Tumours,3070
50,NCT02390752,Phase Ib/II,Recruiting,"[{'id': 874, 'therapyName': 'PLX3397'}]",PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN),3070
51,NCT02423343,Phase Ib/II,Recruiting,"[{'id': 2409, 'therapyName': 'Galunisertib'}, {'id': 1312, 'therapyName': 'Nivolumab'}]","A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, Hepatocellular Carcinoma, or Glioma",3070
52,NCT02423525,Phase I,Recruiting,"[{'id': 623, 'therapyName': 'Afatinib'}]",Safety Study of Afatinib for Brain Cancer,3070
53,NCT02481154,Phase I,Recruiting,"[{'id': 2995, 'therapyName': 'AG-881'}]","Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation",3070
54,NCT02502708,Phase I,Recruiting,"[{'id': 2976, 'therapyName': 'indoximod'}, {'id': 1141, 'therapyName': 'Temozolomide'}]","Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Primary Malignant Brain Tumors",3070
55,NCT02507583,Phase I,Recruiting,"[{'id': 4325, 'therapyName': 'IGF-1R/AS ODN'}]",Antisense102: Pilot Immunotherapy for Newly Diagnosed Malignant Glioma,3070
56,NCT02529072,Phase I,Terminated,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab With DC Vaccines for Recurrent Brain Tumors,3070
57,NCT02540161,Phase II,Recruiting,"[{'id': 931, 'therapyName': 'SYM004'}]",Phase 2 Study of Sym004 for Adult Patients With Recurrent Glioblastoma,3070
58,NCT02607124,Phase Ib/II,Recruiting,"[{'id': 790, 'therapyName': 'Ribociclib'}]",Administration of Ribociclib Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG),3070
59,NCT02639546,Phase I,Recruiting,"[{'id': 1004, 'therapyName': 'Cobimetinib'}]",iMATRIXcobi: Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Patients With Previously Treated Solid Tumors,3070
60,NCT02644460,Phase I,Recruiting,"[{'id': 802, 'therapyName': 'Abemaciclib'}]",Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors,3070
61,NCT02655601,Phase Ib/II,Recruiting,"[{'id': 5841, 'therapyName': 'BMX-001 + Temozolomide'}, {'id': 1141, 'therapyName': 'Temozolomide'}]","Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001",3070
62,NCT02658279,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype,3070
63,NCT02669173,Phase I,Recruiting,"[{'id': 2097, 'therapyName': 'Bevacizumab + Capecitabine'}]",Capecitabine + Bevacizumab in Patients With Recurrent Glioblastoma,3070
64,NCT02743078,Phase II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Optune Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma,3070
65,NCT02768389,Phase I,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Feasibility Trial of the Modified Atkins Diet and Bevacizumab for Recurrent Glioblastoma,3070
66,NCT02794883,Phase II,Recruiting,"[{'id': 1652, 'therapyName': 'Tremelimumab'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma,3070
67,NCT02829931,Phase I,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Hypofractionated Stereotactic Irradiation With Nivolumab in Patients With Recurrent High Grade Gliomas,3070
68,NCT02833701,Phase I,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Bevacizumab and Ascorbic Acid in Patients Treating With Recurrent High Grade Glioma,3070
69,NCT02840409,Phase II,Recruiting,"[{'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 5178, 'therapyName': 'Bevacizumab + Vinblastine'}]",Vinblastine +/- Bevacizumab in Children With Unresectable or Progressive Low Grade Glioma (LGG),3070
70,NCT02852655,Phase 0,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma",3070
71,NCT02871843,Phase I,Recruiting,"[{'id': 4596, 'therapyName': 'RRx-001 + Temozolomide'}]",Phase 1 Two Part Dose Escalation Trial of RRx-001 + Radiation + Temozolomide and RRx-001 + Temozolomide Post-RT In Newly Diagnosed Glioblastoma and Anaplastic Gliomas (G-FORCE-1),3070
72,NCT02885324,Phase II,Recruiting,"[{'id': 998, 'therapyName': 'cabozantinib'}]",Pilot Study of Cabozantinib for Recurrent or Progressive High-Grade Glioma in Children,3070
73,NCT02924038,Phase I,Recruiting,"[{'id': 4835, 'therapyName': 'IMA950 + poly ICLC '}, {'id': 2525, 'therapyName': 'Varlilumab'}]",A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG),3070
74,NCT02933736,Phase 0,Recruiting,"[{'id': 790, 'therapyName': 'Ribociclib'}]",Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients,3070
75,NCT02968940,Phase III,Recruiting,"[{'id': 3144, 'therapyName': 'Avelumab'}]",Avelumab With Hypofractionated Radiation Therapy in Adults With Isocitrate Dehydrogenase (IDH) Mutant Glioblastoma,3070
76,NCT02977689,Phase II,Not yet recruiting,"[{'id': 2981, 'therapyName': 'IDH305'}]",Trial of IDH305 in IDH1 Mutant Grade II or III Glioma,3070
77,NCT03095248,Phase II,Recruiting,"[{'id': 913, 'therapyName': 'Selumetinib'}]",Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors,3070
78,NCT03130959,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",An Investigational Immuno-therapy Study of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Patients With High Grade Primary CNS Malignancies (CheckMate 908),3070
79,NCT03134131,Expanded access,Available,"[{'id': 1687, 'therapyName': 'ONC201'}]",Expanded Access Program for ONC201 to Treat Recurrent Histone H3 Mutant Glioma,3070
80,NCT03173950,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Immune Checkpoint Inhibitor Nivolumab in People With Select Rare CNS Cancers,3070
81,NCT03174197,Phase Ib/II,Recruiting,"[{'id': 5872, 'therapyName': 'Atezolizumab + Temozolomide'}]",Atezolizumab (aPDL1) + Temozolomide and Radiation for Newly Diagnosed Glioblastoma (GBM),3070
82,NCT03212274,Phase II,Not yet recruiting,"[{'id': 837, 'therapyName': 'Olaparib'}]","Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations",3070
83,NCT03220646,Phase II,Recruiting,"[{'id': 802, 'therapyName': 'Abemaciclib'}]",The Purpose of This Study is to Test Any Good and Bad Effects of a Study Drug Called Abemaciclib (LY2835219) in Patients With Recurrent Brain Tumors.,3070
84,NCT03245151,Phase Ib/II,Not yet recruiting,"[{'id': 1713, 'therapyName': 'Everolimus + Lenvatinib'}]","Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors",3070
85,NCT03295396,Phase II,Not yet recruiting,"[{'id': 1687, 'therapyName': 'ONC201'}]",ONC201 in Adults With Recurrent High-grade Glioma,3070
0,NCT02423525,Phase I,Recruiting,"[{'id': 623, 'therapyName': 'Afatinib'}]",Safety Study of Afatinib for Brain Cancer,6086
0,NCT01592383,Phase II,Completed,"[{'id': 4, 'therapyName': 'Erlotinib'}]",Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal Mesothelioma,1790
1,NCT01642342,Phase I,Recruiting,"[{'id': 3013, 'therapyName': 'sEphB4-HSA'}]",Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors,1790
2,NCT02293005,Phase II,"Active, not recruiting","[{'id': 626, 'therapyName': 'Alisertib'}]",Alisertib in Malignant Mesothelioma,1790
3,NCT02341625,Phase Ib/II,"Active, not recruiting","[{'id': 4923, 'therapyName': 'BMS-986148'}, {'id': 4924, 'therapyName': 'BMS-986148 + Nivolumab'}]",A Study of BMS-986148 in Patients With Select Advanced Solid Tumors,1790
4,NCT02349958,Phase II,Recruiting,"[{'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy,1790
5,NCT02357147,Phase II,"Active, not recruiting","[{'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}, {'id': 3513, 'therapyName': 'Amatuximab'}]",Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM). (ARTEMIS),1790
6,NCT02372227,Phase I,Terminated,"[{'id': 2464, 'therapyName': 'VS-5584 + VS-6063'}]","A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant Mesothelioma",1790
7,NCT02628067,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158),1790
8,NCT02760797,Phase I,Recruiting,"[{'id': 4181, 'therapyName': 'Emactuzumab + RO7009789'}]",A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors,1790
9,NCT02860286,Phase II,"Active, not recruiting","[{'id': 2683, 'therapyName': 'Tazemetostat'}]",Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma,1790
10,NCT02963831,Phase Ib/II,Recruiting,"[{'id': 4978, 'therapyName': 'ONCOS-102 + MEDI4736'}]","A Phase 1/2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies",1790
11,NCT03207347,Phase II,Not yet recruiting,"[{'id': 832, 'therapyName': 'Niraparib'}]",A Trial of Niraparib in BAP1 and Other DNA Double-Strand Break Repair Deficient Neoplasms (UF-STO-ETI-001),1790
0,NCT00565851,Phase III,"Active, not recruiting","[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 3045, 'therapyName': 'Docetaxel + Paclitaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 667, 'therapyName': 'Bevacizumab'}]","Carboplatin, Paclitaxel and Gemcitabine With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",4217
1,NCT01669798,Phase II,Recruiting,"[{'id': 831, 'therapyName': 'Nintedanib'}]","BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer",4217
0,NCT02301039,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas,5940
1,NCT02584309,Phase II,Recruiting,"[{'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 4140, 'therapyName': 'Doxorubicin + Olaratumab'}]",Doxorubicin With Upfront Dexrazoxane Plus Olaratumab for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma,5940
2,NCT02584647,Phase Ib/II,Recruiting,"[{'id': 3155, 'therapyName': 'PLX3397 + Sirolimus'}]",Combination of PLX3397 and Sirolimus in Unresectable Sarcoma (Phase 1) and Malignant Peripheral Nerve Sheath Tumors (Phase 2),5940
3,NCT02601209,Phase Ib/II,Suspended,"[{'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1282, 'therapyName': 'Sapanisertib'}]",Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma,5940
4,NCT02978859,Phase II,Recruiting,"[{'id': 1655, 'therapyName': 'MGCD516'}]",MGCD516 in Advanced Liposarcoma and Other Soft Tissue Sarcomas,5940
5,NCT02987959,Phase II,Recruiting,"[{'id': 1282, 'therapyName': 'Sapanisertib'}]",Study of TAK-228 (MLN0128) in Soft Tissue Sarcomas,5940
6,NCT03009201,Phase I,Recruiting,"[{'id': 5179, 'therapyName': 'Doxorubicin + Ribociclib'}]",Ribociclib and Doxorubicin Hydrochloride in Treating Patients Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery,5940
0,NCT03158064,Phase II,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]","Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors",1660
0,NCT00996385,Phase II,Unknown status,"[{'id': 3064, 'therapyName': 'Bortezomib + Oxaliplatin'}]",Velcade and Eloxatin for Patients With Malignant Pleural or Peritoneal Mesothelioma,7474
1,NCT01064648,Phase Ib/II,"Active, not recruiting","[{'id': 2432, 'therapyName': 'Cediranib + Cisplatin + Pemetrexed'}]",Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma,7474
2,NCT01265433,Phase II,Completed,"[{'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 2893, 'therapyName': 'WT1 vaccine'}]",Randomized Study of Adjuvant WT-1 Analog Peptide Vaccine in Patients With Malignant Pleural Mesothelioma (MPM) After Completion of Combined Modality Therapy,7474
3,NCT01769547,Phase II,Terminated,"[{'id': 721, 'therapyName': 'Dovitinib'}]",A Phase II Study of Single-agent DOVitinib in Advanced Malignant PlEural Mesothelioma Which Has Progressed Following Prior Platinum-Antifolate Chemotherapy,7474
4,NCT01868022,Phase I,"Active, not recruiting","[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}, {'id': 2899, 'therapyName': 'GSK3052230'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]","Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling",7474
5,NCT01870609,Phase II,Terminated,"[{'id': 958, 'therapyName': 'VS-6063'}]",Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma,7474
6,NCT01890980,Phase II,"Active, not recruiting","[{'id': 2893, 'therapyName': 'WT1 vaccine'}, {'id': 1873, 'therapyName': 'Sargramostim'}]",Phase II Study of Adjuvant WT-1 Analog Peptide Vaccine in MPM Patients After MSK10-134,7474
7,NCT01907100,Phase III,Recruiting,"[{'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}, {'id': 831, 'therapyName': 'Nintedanib'}]",Nintedanib (BIBF 1120) in Mesothelioma,7474
8,NCT02004028,Phase II,Completed,"[{'id': 958, 'therapyName': 'VS-6063'}]",Window of Opportunity Study of VS-6063 (Defactinib) in Participants With Surgical Resectable Malignant Pleural Mesothelioma.,7474
9,NCT02399371,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Treating Patients With Malignant Mesothelioma,7474
10,NCT02568449,Phase II,Recruiting,"[{'id': 831, 'therapyName': 'Nintedanib'}]",Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent,7474
11,NCT02592551,Phase II,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma,7474
12,NCT02639091,Phase I,Recruiting,"[{'id': 4617, 'therapyName': 'Anetumab ravtansine + Cisplatin + Pemetrexed'}]",Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors,7474
13,NCT02707666,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}]",A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma,7474
14,NCT02723955,Phase I,Recruiting,"[{'id': 4409, 'therapyName': 'GSK3359609'}, {'id': 4410, 'therapyName': 'GSK3359609 + Pembrolizumab'}]",Dose Escalation and Expansion Study of GSK3359609 in Subjects With Selected Advanced Solid Tumors (INDUCE-1),7474
15,NCT02784171,Phase II,Recruiting,"[{'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma,7474
16,NCT02824042,Phase I,Recruiting,"[{'id': 4594, 'therapyName': 'Anetumab ravtansine + Itraconazole'}, {'id': 4593, 'therapyName': 'Anetumab ravtansine'}]",Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole,7474
17,NCT02899195,Phase II,Recruiting,"[{'id': 5630, 'therapyName': 'Cisplatin + Durvalumab + Pemetrexed'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma (PrE0505),7474
18,NCT02899299,Phase III,Recruiting,"[{'id': 4616, 'therapyName': 'Carboplatin + Cisplatin + Pemetrexed'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients (CheckMate743),7474
19,NCT02959463,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Adjuvant Pembrolizumab After Radiation Therapy for Lung-Intact Malignant Pleural Mesothelioma,7474
20,NCT03023319,Phase I,Recruiting,"[{'id': 5237, 'therapyName': 'Bosutinib + Pemetrexed'}]",Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors,7474
21,NCT03074513,Phase II,Recruiting,"[{'id': 4595, 'therapyName': 'Atezolizumab + Bevacizumab'}]",Atezolizumab and Bevacizumab in Rare Solid Tumors,7474
22,NCT03075527,Phase II,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma,7474
23,NCT03126630,Phase Ib/II,Not yet recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 5596, 'therapyName': 'Pembrolizumab + Anetumab ravtansine'}]",Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma,7474
24,NCT03175172,Phase II,Recruiting,"[{'id': 5716, 'therapyName': 'CRS-207 + Pembrolizumab'}]",Evaluation of CRS-207 With Pembrolizumab in Previously Treated MPM,7474
25,NCT03228537,Phase I,Not yet recruiting,"[{'id': 6036, 'therapyName': 'Atezolizumab + Cisplatin + Pemetrexed'}]","Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma",7474
0,NCT02775851,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Treating Patients With Desmoplastic Melanoma That Can or Cannot Be Removed by Surgery,3162
0,NCT02978625,Phase II,Recruiting,"[{'id': 5080, 'therapyName': 'Talimogene laherparepvec + Nivolumab'}]",Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers,7960
0,NCT02978625,Phase II,Recruiting,"[{'id': 5080, 'therapyName': 'Talimogene laherparepvec + Nivolumab'}]",Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers,5569
0,NCT03147885,Phase Ib/II,Recruiting,"[{'id': 1749, 'therapyName': 'Selinexor'}]",Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma,50909
0,NCT00114738,Phase II,"Active, not recruiting","[{'id': 3395, 'therapyName': 'R-EPOCH'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 688, 'therapyName': 'Bortezomib'}]",EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma,50746
1,NCT00602693,Phase I,Completed,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 2311, 'therapyName': 'Allopurinol + Cyclophosphamide + Fludarabine'}]",T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer,50746
2,NCT00671112,Phase I,Terminated,"[{'id': 2234, 'therapyName': 'Bortezomib + Everolimus'}]",Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma,50746
3,NCT01111188,,"Active, not recruiting","[{'id': 1730, 'therapyName': 'Palbociclib + Velcade'}]", Trial of PD 0332991 Plus Bortezomib in Patients With Relapsed Mantle Cell Lymphoma,50746
4,NCT01180049,FDA approved,"Active, not recruiting","[{'id': 936, 'therapyName': 'Temsirolimus'}]",Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma,50746
5,NCT01251575,Phase II,Recruiting,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 2270, 'therapyName': 'Cyclosporine + Mycophenolate mofetil + Sirolimus'}]","Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant",50746
6,NCT01267812,Phase II,"Active, not recruiting","[{'id': 1649, 'therapyName': 'Rituximab + Bortezomib'}]",Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation,50746
7,NCT01415752,Phase II,Recruiting,"[{'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1164, 'therapyName': 'lenalidomide'}]","Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma",50746
8,NCT01439750,Phase Ib/II,"Active, not recruiting","[{'id': 3394, 'therapyName': 'Bortezomib + Cladribine + Rituximab'}]","Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma (PSHCI 10-011)",50746
9,NCT01686165,Phase II,"Active, not recruiting","[{'id': 1078, 'therapyName': 'Belinostat'}, {'id': 897, 'therapyName': 'Rituximab'}]",Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma,50746
10,NCT01695941,Phase I,Recruiting,"[{'id': 3581, 'therapyName': 'Alisertib + Bortezomib + Rituximab'}]","Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma",50746
11,NCT01719250,Phase I,Completed,"[{'id': 680, 'therapyName': 'BKM120'}]",Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma,50746
12,NCT01799889,Phase II,"Active, not recruiting","[{'id': 2522, 'therapyName': 'Entospletinib  '}]",A Phase 2 of Entospletinib in Subjects With Relapsed or Refractory Hematologic Malignancies,50746
13,NCT01804686,Phase III,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",A Long-term Extension Study of PCI-32765 (Ibrutinib),50746
14,NCT01880567,Phase II,Recruiting,"[{'id': 3280, 'therapyName': 'Ibrutinib + Rituximab'}]",Phase 2 Ibrutinib + Rituximab in Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL),50746
15,NCT01897012,Phase I,Recruiting,"[{'id': 1075, 'therapyName': 'romidepsin'}, {'id': 626, 'therapyName': 'Alisertib'}]",Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas,50746
16,NCT01905813,Phase I,"Active, not recruiting","[{'id': 2420, 'therapyName': 'INCB039110 + INCB040093'}, {'id': 2021, 'therapyName': 'INCB040093'}]",Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies,50746
17,NCT01955499,Phase I,"Active, not recruiting","[{'id': 3580, 'therapyName': 'Ibrutinib + lenalidomide'}]",Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma,50746
18,NCT01994382,Phase I,Recruiting,"[{'id': 2531, 'therapyName': 'Cerdulatinib'}]",Phase 1 Dose Escalation Study in Chronic Lymphocytic Leukemia and Non-hodgkin Lymphoma,50746
19,NCT02000934,Phase I,Recruiting,"[{'id': 3146, 'therapyName': 'TAK-659'}]",A Study of TAK-659 in Adult Patients With Advanced Solid Tumor and Lymphoma Malignancies,50746
20,NCT02018861,Phase I,"Active, not recruiting","[{'id': 2406, 'therapyName': 'INCB039110'}, {'id': 3097, 'therapyName': 'INCB039110 + INCB050465'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 2352, 'therapyName': 'Carboplatin + Etoposide + Ifosfamide '}, {'id': 3088, 'therapyName': 'INCB050465 '}]","A Phase 1, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 Monotherapy and in Combination With INCB039110 in Subjects With Previously Treated B-Cell Malignancies",50746
21,NCT02049541,Phase I,"Active, not recruiting","[{'id': 2502, 'therapyName': 'BKM120 + Rituximab'}]",Study of BKM120; Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma,50746
22,NCT02159755,Phase I,"Active, not recruiting","[{'id': 1729, 'therapyName': 'ibrutinib + palbociclib'}]",Ibrutinib and Palbociclib Isethionate in Treating Patients With Previously Treated Mantle Cell Lymphoma,50746
23,NCT02208037,Phase II,"Active, not recruiting",[],Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203),50746
24,NCT02213926,Phase II,"Active, not recruiting","[{'id': 1605, 'therapyName': 'Acalabrutinib'}]","An Open-label, Phase 2 Study of ACP 196 in Subjects With Mantle Cell Lymphoma",50746
25,NCT02242097,Phase II,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma,50746
26,NCT02268851,Phase I,Recruiting,"[{'id': 2044, 'therapyName': 'Ibrutinib + TGR-1202'}]",A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL,50746
27,NCT02269085,Phase Ib/II,"Active, not recruiting","[{'id': 3282, 'therapyName': 'Carfilzomib + Ibrutinib'}]",A Phase I/II Trial of PCI-32765 (BTK Inhibitor) in Combination With Carfilzomib in Relapse/Refractory Mantle Cell Lymphoma,50746
28,NCT02285244,Phase II,Withdrawn,"[{'id': 621, 'therapyName': 'AEB071'}]","Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Prolymphocytic Leukemia, or Richter's Transformation",50746
29,NCT02303392,Phase I,Recruiting,"[{'id': 3579, 'therapyName': 'Ibrutinib + Selinexor'}]",Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma,50746
30,NCT02328014,Phase Ib/II,Recruiting,"[{'id': 3265, 'therapyName': 'ACP-319'}, {'id': 1605, 'therapyName': 'Acalabrutinib'}]","ACP-196 in Combination With ACP-319, for Treatment of B-Cell Malignancies",50746
31,NCT02381080,Phase I,Completed,"[{'id': 3793, 'therapyName': 'Erythromycin + Ibrutinib + Voriconazole'}]",Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy,50746
32,NCT02419560,Phase I,Suspended,"[{'id': 3392, 'therapyName': 'GDC-0199 + Ibrutinib'}]",Optimal Dose Finding Study ABT-199 and Ibrutinib in MCL,50746
33,NCT02420795,Phase Ib/II,Recruiting,"[{'id': 1687, 'therapyName': 'ONC201'}]",Study of Oral ONC201 in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma,50746
34,NCT02427620,Phase II,Recruiting,"[{'id': 2353, 'therapyName': 'Cyclophosphamide + Doxorubicin + Vincristine '}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 3195, 'therapyName': 'Cytarabine + Methotrexate '}, {'id': 1642, 'therapyName': 'Leucovorin'}]",A Study of Ibrutinib Plus Rituximab With Hyper-CVAD Consolidation in Newly Diagnosed Young Patients With Mantle Cell Lymphoma,50746
35,NCT02446236,Phase I,Recruiting,"[{'id': 1610, 'therapyName': 'Rituximab + Lenalidomide + Ibrutinib'}]","Dose Finding Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma (MCL)",50746
36,NCT02454270,Phase II,"Active, not recruiting","[{'id': 4166, 'therapyName': 'JNJ-64052781'}]",A Dose Escalation Study of JNJ-64052781 in Participants With Relapsed or Refractory B-cell Malignancies,50746
37,NCT02455297,Phase II,Terminated,"[{'id': 995, 'therapyName': 'Copanlisib'}]",Phase IIa Study of Copanlisib in Relapsed or Refractory Mantle Cell Lymphoma (MCL),50746
38,NCT02489123,Phase I,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}]",Enzalutamide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma,50746
39,NCT02572453,Phase II,Recruiting,"[{'id': 645, 'therapyName': 'AT13387'}]","AT13387 in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Diffuse Large B-cell Lymphoma",50746
40,NCT02601313,Phase II,Recruiting,"[{'id': 5098, 'therapyName': 'KTE-C19 + Fludarabine phosphate + Cyclophosphamide'}]",A Phase 2 Multicenter Study Evaluating Subjects With Relapsed/Refractory Mantle Cell Lymphoma (ZUMA-2),50746
41,NCT02631044,Phase I,Recruiting,"[{'id': 5980, 'therapyName': 'JCAR017'}]",Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (NHL),50746
42,NCT02650999,Phase Ib/II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab in Patients Failing to Respond to or Relapsing After Anti-CD19 Chimeric Antigen Receptor Modified T Cell Therapy for Relapsed or Refractory CD19+ Lymphomas,50746
43,NCT02717624,Phase I,"Active, not recruiting","[{'id': 3996, 'therapyName': 'Acalabrutinib + Bendamustine + Rituximab'}]",A Study of ACP-196 in Combination With Bendamustine and Rituximab in Subjects With Mantle Cell Lymphoma,50746
44,NCT02722668,Phase II,Recruiting,"[{'id': 2281, 'therapyName': 'Cyclophosphamide + Fludarabine + Mycophenolate mofetil'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}]",UCB Transplant for Hematological DIseases Using a Non Myeloablative Prep,50746
45,NCT02736617,Phase II,Recruiting,"[{'id': 3476, 'therapyName': 'Ibrutinib + Obinutuzumab'}]",Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell Lymphoma,50746
46,NCT02743546,Phase I,Withdrawn,"[{'id': 4167, 'therapyName': 'Ibrutinib + JNJ-64052781'}]","Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of JNJ-64052781 Plus Ibrutinib in Lymphoma",50746
47,NCT02745769,Phase I,Recruiting,"[{'id': 4208, 'therapyName': 'LY2801653 + Ramucirumab'}, {'id': 4209, 'therapyName': 'Abemaciclib + Ramucirumab'}]",A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents,50746
48,NCT02756247,Phase I,Recruiting,"[{'id': 3630, 'therapyName': 'BKM120 + Ibrutinib'}]",A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma,50746
49,NCT02869633,Phase II,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant,50746
50,NCT02875002,Phase I,Not yet recruiting,"[{'id': 4826, 'therapyName': 'Belinostat + Volasertib'}]",Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas,50746
51,NCT02950220,Phase I,Recruiting,"[{'id': 4917, 'therapyName': 'Pembrolizumab + Ibrutinib'}]",Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma,50746
52,NCT02972840,Phase III,Recruiting,"[{'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}, {'id': 3996, 'therapyName': 'Acalabrutinib + Bendamustine + Rituximab'}]",A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma,50746
53,NCT03015896,Phase Ib/II,Suspended,"[{'id': 5239, 'therapyName': 'Lenalidomide + Nivolumab'}]",Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma,50746
54,NCT03028103,Phase I,Recruiting,"[{'id': 5267, 'therapyName': 'Tazemetostat + Fluconazole'}, {'id': 5285, 'therapyName': 'Repaglinide + Omeprazole + Tazemetostat'}]","Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, the Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and the Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma Subjects",50746
55,NCT03037645,Phase Ib/II,Recruiting,"[{'id': 5281, 'therapyName': 'SNS-062'}]","Safety, PK, PD, and Antitumor Activity of SNS-062 in B Lymphoid Cancers",50746
56,NCT03088878,Phase Ib/II,Not yet recruiting,"[{'id': 5480, 'therapyName': 'Cirmtuzumab + Ibrutinib'}, {'id': 768, 'therapyName': 'Ibrutinib'}]",A Study of the Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies,50746
57,NCT03112174,Phase III,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 3392, 'therapyName': 'GDC-0199 + Ibrutinib'}]",Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO),50746
58,NCT03147885,Phase Ib/II,Recruiting,"[{'id': 1749, 'therapyName': 'Selinexor'}]",Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma,50746
59,NCT03153202,Phase Ib/II,Recruiting,"[{'id': 4917, 'therapyName': 'Pembrolizumab + Ibrutinib'}]",Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL),50746
60,NCT03162536,Phase I,Recruiting,"[{'id': 5224, 'therapyName': 'ARQ 531'}]","Safety, PK, PD, and Antitumor Activity of ARQ 531 in Hematologic Malignancies",50746
61,NCT03188965,Phase I,Recruiting,"[{'id': 5962, 'therapyName': 'BAY1895344'}]",First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas,50746
62,NCT03219047,Phase I,Not yet recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",The EXPLORE Trial: Study Evaluating Xenografts to Personalize Therapies (PDX) in Relapsed Mantle Cell Lymphoma to Optimize Response,50746
63,NCT03232307,Phase II,Not yet recruiting,"[{'id': 1610, 'therapyName': 'Rituximab + Lenalidomide + Ibrutinib'}]",Ibrutinib Plus Rituximab and Lenalidomide in Elderly Patients With Newly Diagnosed Mantle Cell Lymphoma (MCL),50746
64,NCT03282396,Phase II,Not yet recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",Ibrutinib in Newly Diagnosed Mantle Cell Lymphoma With Low-Risk Disease,50746
0,NCT00602693,Phase I,Completed,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 2311, 'therapyName': 'Allopurinol + Cyclophosphamide + Fludarabine'}]",T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer,50748
1,NCT00671112,Phase I,Terminated,"[{'id': 2234, 'therapyName': 'Bortezomib + Everolimus'}]",Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma,50748
2,NCT01732913,Phase III,Terminated,"[{'id': 1023, 'therapyName': 'Idelalisib'}, {'id': 897, 'therapyName': 'Rituximab'}]",Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas,50748
3,NCT01732926,Phase III,Terminated,"[{'id': 1023, 'therapyName': 'Idelalisib'}, {'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}]",Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas,50748
4,NCT01955499,Phase I,"Active, not recruiting","[{'id': 3580, 'therapyName': 'Ibrutinib + lenalidomide'}]",Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma,50748
5,NCT01974440,Phase III,"Active, not recruiting","[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}, {'id': 3266, 'therapyName': 'Cyclophosphamide + Doxorubicin + Prednisone + Vincristine '}]","A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma",50748
6,NCT01976585,Phase Ib/II,Recruiting,"[{'id': 4337, 'therapyName': 'CDX-301 + poly ICLC '}]",In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy,50748
7,NCT01994382,Phase I,Recruiting,"[{'id': 2531, 'therapyName': 'Cerdulatinib'}]",Phase 1 Dose Escalation Study in Chronic Lymphocytic Leukemia and Non-hodgkin Lymphoma,50748
8,NCT02000934,Phase I,Recruiting,"[{'id': 3146, 'therapyName': 'TAK-659'}]",A Study of TAK-659 in Adult Patients With Advanced Solid Tumor and Lymphoma Malignancies,50748
9,NCT02049541,Phase I,"Active, not recruiting","[{'id': 2502, 'therapyName': 'BKM120 + Rituximab'}]",Study of BKM120; Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma,50748
10,NCT02208037,Phase II,"Active, not recruiting",[],Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203),50748
11,NCT02254772,Phase Ib/II,Completed,"[{'id': 3848, 'therapyName': 'Ipilimumab + SD-101'}]","TLR9 Agonist SD-101, Ipilimumab, and Radiation Therapy in Treating Patients With Low-Grade Recurrent B-cell Lymphoma",50748
12,NCT02266147,Phase Ib/II,Completed,"[{'id': 3084, 'therapyName': 'SD-101'}]",Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma,50748
13,NCT02367040,Phase III,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 995, 'therapyName': 'Copanlisib'}]",Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL),50748
14,NCT02369016,Phase III,"Active, not recruiting","[{'id': 995, 'therapyName': 'Copanlisib'}]",Phase III Copanlisib in Rituximab-refractory iNHL,50748
15,NCT02381080,Phase I,Completed,"[{'id': 3793, 'therapyName': 'Erythromycin + Ibrutinib + Voriconazole'}]",Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy,50748
16,NCT02384954,Phase Ib/II,Recruiting,"[{'id': 3936, 'therapyName': 'ALT-803 + Rituximab'}]",ALT-803 in Patients With Relapse/Refractory Indolent B Cell Non-Hodgkin Lymphoma (iNHL) in Conjunction With Rituximab,50748
17,NCT02576275,Phase III,Withdrawn,"[{'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}, {'id': 1024, 'therapyName': 'Duvelisib'}]",A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA),50748
18,NCT02626455,Phase III,Recruiting,"[{'id': 1631, 'therapyName': 'Vincristine'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 3388, 'therapyName': 'Aldoxorubicin +Cyclophosphamide + Prednisone + Rituximab + Vincristine'}, {'id': 995, 'therapyName': 'Copanlisib'}, {'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}, {'id': 897, 'therapyName': 'Rituximab'}]",Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL),50748
19,NCT02722668,Phase II,Recruiting,"[{'id': 2281, 'therapyName': 'Cyclophosphamide + Fludarabine + Mycophenolate mofetil'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}]",UCB Transplant for Hematological DIseases Using a Non Myeloablative Prep,50748
20,NCT02950220,Phase I,Recruiting,"[{'id': 4917, 'therapyName': 'Pembrolizumab + Ibrutinib'}]",Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma,50748
21,NCT02953509,Phase Ib/II,Recruiting,"[{'id': 4955, 'therapyName': 'Hu5F9-G4 + Rituximab'}]",Trial of Hu5F9-G4 in Combination With Rituximab in Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma,50748
22,NCT03015896,Phase Ib/II,Suspended,"[{'id': 5239, 'therapyName': 'Lenalidomide + Nivolumab'}]",Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma,50748
23,NCT03133221,Phase II,Not yet recruiting,"[{'id': 1023, 'therapyName': 'Idelalisib'}]",1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation,50748
24,NCT03144674,Phase II,Recruiting,"[{'id': 3088, 'therapyName': 'INCB050465 '}]",A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204),50748
25,NCT03147885,Phase Ib/II,Recruiting,"[{'id': 1749, 'therapyName': 'Selinexor'}]",Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma,50748
0,NCT02415608,Phase II,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis,3664
1,NCT02561988,Phase I,Recruiting,"[{'id': 2941, 'therapyName': 'BLU-285'}]",Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (advSM) and Relapsed or Refractory Myeloid Malignancies,3664
0,NCT02415608,Phase II,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis,9254
0,NCT00814073,Phase III,Unknown status,"[{'id': 804, 'therapyName': 'Masitinib'}]","A Phase 3 Study to Compare Efficacy and Safety of Masitinib to Placebo in the Treatment of Patients With Smouldering Systemic, Indolent Systemic or Cutaneous Mastocytosis With Handicap",350
0,NCT02328014,Phase Ib/II,Recruiting,"[{'id': 3265, 'therapyName': 'ACP-319'}, {'id': 1605, 'therapyName': 'Acalabrutinib'}]","ACP-196 in Combination With ACP-319, for Treatment of B-Cell Malignancies",706
1,NCT02981914,Phase 0,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation,706
0,NCT02342782,Phase I,Recruiting,"[{'id': 2485, 'therapyName': '90Y basiliximab'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 2392, 'therapyName': 'Cytarabine + Etoposide'}, {'id': 1207, 'therapyName': 'Melphalan'}]",Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma,50743
1,NCT02567656,Phase I,Recruiting,"[{'id': 2020, 'therapyName': 'RP6530'}]",Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma,50743
2,NCT02973113,Phase I,Recruiting,"[{'id': 5058, 'therapyName': 'EB-VST cells + Nivolumab'}]","Nivolumab With Epstein Barr Virus Specific T Cells (EB-VSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE) (PREVALE)",50743
3,NCT02974647,Phase II,Recruiting,"[{'id': 907, 'therapyName': 'Ruxolitinib'}]",Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma,50743
4,NCT02978625,Phase II,Recruiting,"[{'id': 5080, 'therapyName': 'Talimogene laherparepvec + Nivolumab'}]",Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers,50743
5,NCT03075553,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma,50743
0,NCT02780310,Phase II,"Active, not recruiting","[{'id': 792, 'therapyName': 'Lenvatinib'}]",Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma,7198
1,NCT03087019,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma,7198
2,NCT03172624,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer,7198
0,NCT00602667,Phase I,"Active, not recruiting","[{'id': 2449, 'therapyName': 'Methotrexate + Cisplatin + Cyclophosphamide + Vincristine'}, {'id': 2450, 'therapyName': 'Cyclophosphamide + Etoposide + Topotecan'}, {'id': 2451, 'therapyName': 'Erlotinib + Cyclophosphamide + Topotecan'}]","Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma",50902
1,NCT00876993,Phase I,Completed,"[{'id': 1463, 'therapyName': 'Temozolomide + Irinotecan + Bevacizumab'}]",Study of Irinotecan and Bevacizumab With Temozolomide in Refractory/Relapsed Central Nervous System (CNS) Tumors,50902
2,NCT00983398,Phase Ib/II,Recruiting,"[{'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2587, 'therapyName': 'Carboplatin + Melphalan'}]","Melphalan, Carboplatin, and Sodium Thiosulfate for Patients With Central Nervous System (CNS) Embryonal or Germ Cell Tumors",50902
3,NCT01217437,Phase II,"Active, not recruiting","[{'id': 1462, 'therapyName': 'Temozolomide + Irinotecan'}, {'id': 1463, 'therapyName': 'Temozolomide + Irinotecan + Bevacizumab'}]",Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors,50902
4,NCT01331135,Phase I,"Active, not recruiting","[{'id': 917, 'therapyName': 'Sirolimus'}]",Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors,50902
5,NCT01356290,Phase II,Recruiting,"[{'id': 1475, 'therapyName': 'Thalidomide'}, {'id': 4418, 'therapyName': 'Fenofibrate'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 2124, 'therapyName': 'Celecoxib'}, {'id': 1783, 'therapyName': 'Cyclophosphamide + Cytarabine'}]",Metronomic and Targeted Anti-angiogenesis Therapy for Children With Recurrent/Progressive Medulloblastoma (MEMMAT),50902
6,NCT01878617,Phase II,Recruiting,"[{'id': 956, 'therapyName': 'Vismodegib'}, {'id': 1800, 'therapyName': 'Cyclophosphamide + Cisplatin + Vincristine '}, {'id': 1801, 'therapyName': 'Pemetrexed + Gemcitabine'}]",A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma,50902
7,NCT01977677,Phase Ib/II,"Active, not recruiting","[{'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 1756, 'therapyName': 'Plerixafor'}]",Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma,50902
8,NCT01999270,Phase I,Completed,"[{'id': 2112, 'therapyName': 'Bevacizumab + Irinotecan'}]",Evaluation of FDOPA-PET/MRI in Pediatric Patients With CNS Tumors,50902
9,NCT02040376,Phase III,"Active, not recruiting","[{'id': 1031, 'therapyName': 'Metformin'}]",Placebo Controlled Double Blind Crossover Trial of Metformin for Brain Repair in Children With Cranial-Spinal Radiation for Medulloblastoma,50902
10,NCT02301039,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas,50902
11,NCT02304458,Phase Ib/II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas,50902
12,NCT02332889,Phase Ib/II,Terminated,"[{'id': 650, 'therapyName': 'Decitabine'}, {'id': 2595, 'therapyName': 'poly ICLC  '}]",Phase I/II Decitabine/Vaccine Therapy in Relapsed/Refractory Pediatric High Grade Gliomas/Medulloblastomas/CNS PNETs,50902
13,NCT02372006,Phase I,Recruiting,"[{'id': 623, 'therapyName': 'Afatinib'}]",Phase I Trial of Afatinib in Pediatric Tumours,50902
14,NCT02390752,Phase Ib/II,Recruiting,"[{'id': 874, 'therapyName': 'PLX3397'}]",PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN),50902
15,NCT02446431,Phase I,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1076, 'therapyName': 'Valproic acid'}]",Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence,50902
16,NCT02454972,Phase II,Recruiting,"[{'id': 1195, 'therapyName': 'Lurbinectedin'}]",Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors,50902
17,NCT02458339,Phase I,Recruiting,"[{'id': 1639, 'therapyName': 'Methotrexate'}]",Methotrexate Infusion Into Fourth Ventricle in Children With Recurrent Malignant Fourth Ventricular Brain Tumors,50902
18,NCT02472392,Phase I,Completed,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}]",Study To Examine Toxicity Of Allogeneic Stem Cell Transplantation For Relapsed Or Therapy Refractory Ewings Sarcoma,50902
19,NCT02502708,Phase I,Recruiting,"[{'id': 2976, 'therapyName': 'indoximod'}, {'id': 1141, 'therapyName': 'Temozolomide'}]","Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Primary Malignant Brain Tumors",50902
20,NCT02748135,Phase Ib/II,Recruiting,"[{'id': 4704, 'therapyName': 'TB-403'}]",A Two-Part Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma,50902
21,NCT03130959,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",An Investigational Immuno-therapy Study of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Patients With High Grade Primary CNS Malignancies (CheckMate 908),50902
22,NCT03173950,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Immune Checkpoint Inhibitor Nivolumab in People With Select Rare CNS Cancers,50902
0,NCT00983398,Phase Ib/II,Recruiting,"[{'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2587, 'therapyName': 'Carboplatin + Melphalan'}]","Melphalan, Carboplatin, and Sodium Thiosulfate for Patients With Central Nervous System (CNS) Embryonal or Germ Cell Tumors",4790
0,NCT02530619,Phase I,Recruiting,"[{'id': 626, 'therapyName': 'Alisertib'}]",Alisertib in Treating Patients With Myelofibrosis or Relapsed or Refractory Acute Megakaryoblastic Leukemia,8761
0,NCT00338377,Phase II,Recruiting,"[{'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 1167, 'therapyName': 'Aldesleukin'}]",Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization,1909
1,NCT00492505,Phase II,Unknown status,"[{'id': 2212, 'therapyName': 'Cisplatin + Sorafenib + Tamoxifen'}]","Sorafenib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Stage III Melanoma",1909
2,NCT00538005,Phase Ib/II,Unknown status,"[{'id': 2132, 'therapyName': 'Sorafenib + Bevacizumab + Oxaliplatin'}]","Sorafenib, Bevacizumab, and Oxaliplatin in Treating Patients With Metastatic Malignant Melanoma",1909
3,NCT00700882,Phase II,Unknown status,"[{'id': 717, 'therapyName': 'Dasatinib'}]","Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery",1909
4,NCT00925132,Phase Ib/II,Terminated,"[{'id': 1737, 'therapyName': 'Decitabine + Temozolomide + Panobinostat'}]","Treatment of Resistant Metastatic Melanoma Using Decitabine, Temozolomide and Panobinostat",1909
5,NCT00976573,,Completed,"[{'id': 735, 'therapyName': 'Everolimus'}, {'id': 667, 'therapyName': 'Bevacizumab'}]","Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma",1909
6,NCT01028222,Phase II,Completed,"[{'id': 829, 'therapyName': 'Nilotinib'}]",A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation,1909
7,NCT01037790,Phase II,Recruiting,"[{'id': 850, 'therapyName': 'Palbociclib'}]",PD 0332991 in Treating Patients With Refractory Solid Tumors,1909
8,NCT01176474,Phase I,"Active, not recruiting","[{'id': 2696, 'therapyName': 'NY-ESO-1 peptide vaccine'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",A Phase I Trial of a Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma,1909
9,NCT01218867,Phase Ib/II,Completed,"[{'id': 984, 'therapyName': 'Anti-VEGFR2 CAR CD8 lymphocytes'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1167, 'therapyName': 'Aldesleukin'}]",Treating Metastatic Cancer With Anti-VEGFR2 Gene Engineered CD8+ Lymphocytes,1909
10,NCT01239134,Phase I,Recruiting,"[{'id': 3613, 'therapyName': 'TRX518'}]",Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors,1909
11,NCT01258855,Phase II,"Active, not recruiting","[{'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 624, 'therapyName': 'Aflibercept'}]",Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,1909
12,NCT01274338,Phase III,"Active, not recruiting","[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1299, 'therapyName': 'Interferon alfa-2b '}]",Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,1909
13,NCT01292655,Phase I,Completed,"[{'id': 2545, 'therapyName': 'BMS-906024'}]",Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors,1909
14,NCT01303341,Phase I,"Active, not recruiting","[{'id': 1724, 'therapyName': 'Rilutek + Sorafenib'}]",Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma,1909
15,NCT01307267,Phase I,Recruiting,"[{'id': 6111, 'therapyName': 'Utomilumab + Rituximab'}, {'id': 5086, 'therapyName': 'Utomilumab'}]",A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab,1909
16,NCT01321437,Phase II,"Active, not recruiting","[{'id': 649, 'therapyName': 'Axitinib'}]",Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma,1909
17,NCT01323517,Phase II,Recruiting,"[{'id': 5900, 'therapyName': 'Dactinomycin + Ipilimumab + Melphalan'}]",Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity,1909
18,NCT01325441,Phase Ib/II,Recruiting,"[{'id': 2586, 'therapyName': 'BBI608 + Paclitaxel'}]",A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies,1909
19,NCT01366144,Phase I,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 954, 'therapyName': 'Veliparib'}, {'id': 1092, 'therapyName': 'Carboplatin'}]","Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction",1909
20,NCT01391143,Phase I,Recruiting,"[{'id': 2863, 'therapyName': 'MGA271'}]",Safety Study of MGA271 in Refractory Cancer,1909
21,NCT01409174,Phase Ib/II,Terminated,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 1299, 'therapyName': 'Interferon alfa-2b '}]",IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma,1909
22,NCT01425008,Phase I,"Active, not recruiting","[{'id': 1034, 'therapyName': 'MLN2480'}]",Study of MLN2480 in Patients With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Patients With Metastatic Melanoma,1909
23,NCT01436656,Phase I,"Active, not recruiting","[{'id': 796, 'therapyName': 'Encorafenib'}]",A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma,1909
24,NCT01449279,Phase I,"Active, not recruiting","[{'id': 779, 'therapyName': 'Ipilimumab'}]",Pilot Ipilimumab in Stage IV Melanoma Receiving Palliative Radiation Therapy,1909
25,NCT01480154,Phase I,"Active, not recruiting","[{'id': 1393, 'therapyName': 'MK2206 + hydroxychloroquine'}]","Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer",1909
26,NCT01495988,Phase II,Terminated,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 342, 'therapyName': 'Vemurafenib'}]",Trial of Vemurafenib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma,1909
27,NCT01497808,Phase Ib/II,"Active, not recruiting","[{'id': 779, 'therapyName': 'Ipilimumab'}]",RADVAX: A Stratified Phase I/II Dose Escalation Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Metastatic Melanoma,1909
28,NCT01512251,Phase Ib/II,Completed,"[{'id': 1322, 'therapyName': 'BKM120 + Vemurafenib'}]",BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma,1909
29,NCT01519323,Phase I,Terminated,"[{'id': 342, 'therapyName': 'Vemurafenib'}]", BRIM-P,1909
30,NCT01533948,Phase II,Terminated,"[{'id': 649, 'therapyName': 'Axitinib'}]",Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed By Surgery,1909
31,NCT01543698,Phase Ib/II,"Active, not recruiting","[{'id': 1100, 'therapyName': 'Binimetinib + Encorafenib'}, {'id': 1101, 'therapyName': 'Binimetinib + Encorafenib + Ribociclib'}]",A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors,1909
32,NCT01565837,Phase II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}]",Concurrent Ipilimumab and Stereotactic Ablative Radiation Therapy (SART) for Oligometastatic But Unresectable Melanoma,1909
33,NCT01585415,Phase I,Terminated,"[{'id': 953, 'therapyName': 'Vandetanib'}]", Vemurafenib and White Blood Cell Therapy for Advanced Melanoma,1909
34,NCT01586195,Phase II,Terminated,"[{'id': 342, 'therapyName': 'Vemurafenib'}]"," Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E",1909
35,NCT01603212,Phase Ib/II,Completed,"[{'id': 1188, 'therapyName': 'Aldesleukin + Vemurafenib + IFN A2b'}]"," Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor",1909
36,NCT01619774,Phase II,Completed,"[{'id': 1191, 'therapyName': 'GSK1120212 + Dabrafenib'}]", An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor,1909
37,NCT01621490,Phase I,"Active, not recruiting","[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma (PD-1),1909
38,NCT01625351,Phase I,"Active, not recruiting","[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1205, 'therapyName': 'Alemtuzumab'}]",A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas,1909
39,NCT01638676,Phase Ib/II,Recruiting,"[{'id': 1210, 'therapyName': 'Vemurafenib + Metformin '}]", A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients,1909
40,NCT01656642,Phase I,"Active, not recruiting","[{'id': 1216, 'therapyName': 'Atezolizumab + vemurafenib'}]", A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Vemurafinib (Zelboraf&#174;) in Patients With Previously Untreated BRAFV600-Mutation Positive Metastatic Melanoma,1909
41,NCT01657591,Phase I,"Active, not recruiting","[{'id': 1217, 'therapyName': 'XL888 + Vemurafenib'}]", Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma,1909
42,NCT01659151,Phase II,"Active, not recruiting","[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 342, 'therapyName': 'Vemurafenib'}]", Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer &amp; High Dose IL-2 Metastatic Melanoma,1909
43,NCT01667419,Phase III,"Active, not recruiting","[{'id': 342, 'therapyName': 'Vemurafenib'}]",BRIM8: A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma,1909
44,NCT01682083,Phase III,"Active, not recruiting","[{'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}]", A Study of the BRAF Inhibitor Dabrafenib in Combination With the MEK Inhibitor Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma After Surgical Resection.,1909
45,NCT01682213,Phase II,"Active, not recruiting","[{'id': 3, 'therapyName': 'Dabrafenib'}]",Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation,1909
46,NCT01683188,Phase III,Terminated,"[{'id': 1229, 'therapyName': 'Aldesleukin + Vemurafenib'}]", HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma,1909
47,NCT01689974,Phase II,Terminated,"[{'id': 779, 'therapyName': 'Ipilimumab'}]",Phase II Randomized Trial of Ipilimumab Versus Ipilimumab and Radiotherapy in Metastatic Melanoma,1909
48,NCT01696045,Phase II,Terminated,"[{'id': 779, 'therapyName': 'Ipilimumab'}]","Phase 2 Study of Ipilimumab in Children and Adolescents (12 to <18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma",1909
49,NCT01701037,Phase II,Terminated,"[{'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}, {'id': 3, 'therapyName': 'Dabrafenib'}]", Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery,1909
50,NCT01701674,Phase I,"Active, not recruiting","[{'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1167, 'therapyName': 'Aldesleukin'}]",Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts,1909
51,NCT01703507,Phase I,"Active, not recruiting","[{'id': 779, 'therapyName': 'Ipilimumab'}]",Ipilimumab and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Melanoma With Brain Metastases,1909
52,NCT01708941,Phase II,"Active, not recruiting","[{'id': 1299, 'therapyName': 'Interferon alfa-2b '}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,1909
53,NCT01721603,Phase II,Completed,"[{'id': 3, 'therapyName': 'Dabrafenib'}]", A Phase 2 Prospective Trial of Dabrafenib With Stereotactic Radiosurgery in BRAFV600E Melanoma Brain Metastases,1909
54,NCT01726738,Phase II,"Active, not recruiting","[{'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}]",LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations,1909
55,NCT01738139,Phase I,Recruiting,"[{'id': 1250, 'therapyName': 'Ipilimumab + Imatinib Mesylate'}]",Ipilimumab and Imatinib Mesylate in Advanced Cancer,1909
56,NCT01740297,Phase Ib/II,"Active, not recruiting","[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 2695, 'therapyName': 'talimogene laherparepvec '}]",Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma,1909
57,NCT01754376,Phase II,Terminated,"[{'id': 1229, 'therapyName': 'Aldesleukin + Vemurafenib'}]",Combined BRAF-Targeted Therapy and Immunotherapy for Melanoma,1909
58,NCT01763164,Phase III,"Active, not recruiting","[{'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 807, 'therapyName': 'Binimetinib'}]",Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma,1909
59,NCT01765543,Phase I,Completed,"[{'id': 1256, 'therapyName': 'Rifampin + Vemurafenib'}]",A Pharmacokinetics Study to Investigate the Effect of Rifampin on Vemurafenib in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy,1909
60,NCT01767454,Phase I,Completed,"[{'id': 1258, 'therapyName': 'Dabrafenib + Ipilimumab + Trametinib'}, {'id': 1257, 'therapyName': 'Dabrafenib + Ipilimumab'}]",Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma,1909
61,NCT01777776,Phase Ib/II,Terminated,"[{'id': 796, 'therapyName': 'Encorafenib'}, {'id': 1260, 'therapyName': 'Encorafenib + Ribociclib'}]",Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.,1909
62,NCT01781026,Phase II,Completed,"[{'id': 342, 'therapyName': 'Vemurafenib'}]",Phase 2 Study of Neoadjuvant Vemurafenib in Melanoma Patients With Untreated Brain Metastases,1909
63,NCT01781572,Phase Ib/II,"Active, not recruiting","[{'id': 5, 'therapyName': 'Binimetinib + Ribociclib'}]",A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant Melanoma,1909
64,NCT01810016,Phase I,Terminated,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 2696, 'therapyName': 'NY-ESO-1 peptide vaccine'}]",NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma,1909
65,NCT01813214,Phase II,Terminated,"[{'id': 342, 'therapyName': 'Vemurafenib'}]", The Effects of Vemurafenib on Immunity in Patients With Melanoma,1909
66,NCT01820364,Phase II,Terminated,"[{'id': 1100, 'therapyName': 'Binimetinib + Encorafenib'}, {'id': 1260, 'therapyName': 'Encorafenib + Ribociclib'}, {'id': 1337, 'therapyName': 'Encorafenib + BKM120'}, {'id': 1336, 'therapyName': 'BGJ398 + Encorafenib'}, {'id': 1338, 'therapyName': 'Capmatinib + Encorafenib'}]", LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma,1909
67,NCT01826448,Phase I,Terminated,"[{'id': 1339, 'therapyName': 'PLX3397 + Vemurafenib'}]"," A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma",1909
68,NCT01827111,Phase II,"Active, not recruiting","[{'id': 2978, 'therapyName': 'Ipilimumab + nab-paclitaxel'}]",Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma,1909
69,NCT01835184,Phase I,Terminated,"[{'id': 1235, 'therapyName': 'Cabozantinib + Vemurafenib'}]",Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery,1909
70,NCT01841463,Phase Ib/II,Suspended,"[{'id': 1238, 'therapyName': 'Vemurafenib + Voruciclib'}]",Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation,1909
71,NCT01843738,Phase I,Withdrawn,"[{'id': 342, 'therapyName': 'Vemurafenib'}]",Radiation Use During Vemurafenib Treatment,1909
72,NCT01844674,Phase I,Completed,"[{'id': 1241, 'therapyName': 'Vemurafenib + Tizanidine'}]",A Study on the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine in Patients With BRAFV600 Mutation-Positive Metastatic Malignancies,1909
73,NCT01876212,Phase II,Recruiting,"[{'id': 717, 'therapyName': 'Dasatinib'}]",Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma,1909
74,NCT01876641,Phase Ib/II,Recruiting,"[{'id': 1259, 'therapyName': 'Vemurafenib + Decitabine'}]",Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib,1909
75,NCT01894672,Phase II,Completed,"[{'id': 796, 'therapyName': 'Encorafenib'}]","BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation",1909
76,NCT01897116,Phase I,"Active, not recruiting","[{'id': 1281, 'therapyName': 'Vemurafenib + Hydroxychloroquine'}]", A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma,1909
77,NCT01904123,Phase I,Not yet recruiting,"[{'id': 2784, 'therapyName': 'WP1066'}]",A Phase I Trial of WP1066,1909
78,NCT01909453,Phase III,"Active, not recruiting","[{'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 796, 'therapyName': 'Encorafenib'}, {'id': 1100, 'therapyName': 'Binimetinib + Encorafenib'}]",Study Comparing Combination of LGX818 Plus MEK162 and LGX818 Monotherapy Versus Vemurafenib in BRAF Mutant Melanoma,1909
79,NCT01940809,Phase II,Recruiting,"[{'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 779, 'therapyName': 'Ipilimumab'}]","Ipilimumab With or Without Dabrafenib, and/or Trametinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed By Surgery",1909
80,NCT01941927,Phase II,Unknown status,"[{'id': 1298, 'therapyName': 'Trametinib + GSK2141795'}]",Trametinib With GSK2141795 in BRAF Wild-type Melanoma,1909
81,NCT01942993,Phase II,Terminated,"[{'id': 342, 'therapyName': 'Vemurafenib'}]",The Effects of Treatment With Vemurafenib on the Immune System in Advanced Melanoma,1909
82,NCT01943422,Phase Ib/II,"Active, not recruiting","[{'id': 1300, 'therapyName': 'Vemurafenib + Interferon alfa-2b'}]",Safety and Efficacy Study of Vemurafenib and High-dose Interferon Alfa-2b in Melanoma,1909
83,NCT01946789,Phase I,Recruiting,"[{'id': 3060, 'therapyName': 'ALT-803'}]",A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors,1909
84,NCT01950195,Phase I,Terminated,"[{'id': 779, 'therapyName': 'Ipilimumab'}]",SRS (Stereotactic Radiosurgery) Plus Ipilimumab,1909
85,NCT01950390,Phase II,"Active, not recruiting","[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1301, 'therapyName': 'Ipilimumab + Bevacizumab'}]",Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot be Removed by Surgery,1909
86,NCT01961115,Phase II,"Active, not recruiting","[{'id': 2575, 'therapyName': 'Epacadostat'}, {'id': 3016, 'therapyName': 'MELITAC 12.1 Peptide Vaccine '}]",INCB024360 and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma,1909
87,NCT01966445,Phase I,Completed,"[{'id': 2919, 'therapyName': 'GSK2849330'}]","Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors",1909
88,NCT01968109,Phase I,Recruiting,"[{'id': 4197, 'therapyName': 'BMS-986016 + Nivolumab'}, {'id': 4196, 'therapyName': 'BMS-986016'}]",Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors,1909
89,NCT01970358,Phase I,Recruiting,"[{'id': 3006, 'therapyName': 'NeoVax melanoma vaccine'}]",A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma,1909
90,NCT01970527,Phase II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}]",Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma,1909
91,NCT01974258,Phase I,Withdrawn,"[{'id': 1306, 'therapyName': 'Onartuzumab + Vemurafenib'}, {'id': 1307, 'therapyName': 'Onartuzumab + Cobimetinib'}, {'id': 1308, 'therapyName': 'Onartuzumab + Cobimetinib + Vemurafenib'}]","Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients",1909
92,NCT01978236,Phase II,Completed,"[{'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}, {'id': 3, 'therapyName': 'Dabrafenib'}]","Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites",1909
93,NCT01988896,Phase I,"Active, not recruiting","[{'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}]",A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors,1909
94,NCT01989585,Phase Ib/II,Recruiting,"[{'id': 1303, 'therapyName': 'Trametinib + Dabrafenib + Navitoclax'}, {'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}]","Dabrafenib, Trametinib, and Navitoclax in Treating Patients With Solid Tumors That Are Metastatic or Cannot be Removed by Surgery",1909
95,NCT01993719,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",Immunotherapy Using Tumor Infiltrating Lymphocytes Comparing 2 Different Conditioning Regimens for Patients With Metastatic Melanoma,1909
96,NCT02009397,Phase Ib/II,Recruiting,"[{'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients,1909
97,NCT02009449,Phase I,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 2621, 'therapyName': 'AM0010 '}, {'id': 619, 'therapyName': 'Abraxane'}]",A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors,1909
98,NCT02012231,Phase Ib/II,Terminated,"[{'id': 1041, 'therapyName': 'PLX8394'}]","Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.",1909
99,NCT02013804,Phase I,Completed,"[{'id': 3120, 'therapyName': 'MEDI0680'}]",A Phase 1 Multicenter Open-label Study to Evaluate the Safety Tolerability and PK of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies,1909
100,NCT02014909,Phase I,Completed,"[{'id': 2054, 'therapyName': 'CDX-3379'}, {'id': 2063, 'therapyName': 'CDX-3379 + Vemurafenib'}, {'id': 2064, 'therapyName': 'CDX-3379 + Trastuzumab'}, {'id': 2061, 'therapyName': 'Cetuximab + CDX-3379'}, {'id': 2062, 'therapyName': 'CDX-3379 + Erlotinib'}]",A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors,1909
101,NCT02020707,Phase I,Suspended,"[{'id': 619, 'therapyName': 'Abraxane'}]",Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery,1909
102,NCT02027935,Phase II,Recruiting,"[{'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells and Anti-CTLA4,1909
103,NCT02027961,Phase Ib/II,"Active, not recruiting","[{'id': 1357, 'therapyName': 'Dabrafenib + Durvalumab + Trametinib'}, {'id': 1358, 'therapyName': 'Durvalumab + Trametinib'}]",Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone,1909
104,NCT02032810,Phase I,"Active, not recruiting","[{'id': 1080, 'therapyName': 'Panobinostat'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma,1909
105,NCT02036086,Phase II,Recruiting,"[{'id': 1657, 'therapyName': 'Vemurafenib + Cobimetinib'}]",Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases,1909
106,NCT02039947,Phase II,"Active, not recruiting","[{'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}]",Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain,1909
107,NCT02043665,Phase I,Recruiting,"[{'id': 2974, 'therapyName': 'coxsackievirus A21'}]",Systemic Treatment Of Resistant Metastatic Disease Employing CVA21 and Pembrolizumab in Non-small Cell Lung Cancer and Bladder Cancer (STORM/ KEYNOTE-200) (STORM),1909
108,NCT02047747,Phase II,Terminated,"[{'id': 714, 'therapyName': 'Dacomitinib'}]",A Phase II Study of Dacomitinib in Progressive Brain Metastases,1909
109,NCT02050321,Phase II,Terminated,"[{'id': 1936, 'therapyName': 'Vemurafenib + Acitretin'}]",A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma,1909
110,NCT02054520,Phase II,Unknown status,"[{'id': 779, 'therapyName': 'Ipilimumab'}]",Immunotherapy Study for Patients With Stage IV Melanoma,1909
111,NCT02065466,Phase Ib/II,Withdrawn,"[{'id': 1380, 'therapyName': 'Abraxane + Temozolomide + Bevacizumab'}]","Combo of Abraxane, TMZ, Bevacizumab in Metastatic Melanoma With Brain Metastases",1909
112,NCT02068079,Phase I,Withdrawn,"[{'id': 1383, 'therapyName': 'Vemurafenib + Trientine'}]",A Pilot Study of Trientine With Vemurafenib for the Treatment BRAF Mutated Metastatic Melanoma,1909
113,NCT02073123,Phase Ib/II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 2976, 'therapyName': 'indoximod'}]",Study of IDO Inhibitor in Combination With Ipilimumab for Adult Patients With Metastatic Melanoma,1909
114,NCT02089685,Phase Ib/II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 2624, 'therapyName': 'peginterferon alfa-2b'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29),1909
115,NCT02094872,Phase II,"Active, not recruiting","[{'id': 1009, 'therapyName': 'Doxorubicin'}]",Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic,1909
116,NCT02097225,Phase I,Recruiting,"[{'id': 1362, 'therapyName': 'AT13387 + Dabrafenib + Trametinib'}]","Hsp90 Inhibitor AT13387, Dabrafenib, and Trametinib in Treating Patients With Recurrent Melanoma That is Metastatic or Cannot be Removed by Surgery",1909
117,NCT02097732,Phase II,"Active, not recruiting","[{'id': 779, 'therapyName': 'Ipilimumab'}]",Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic Radiosurgery,1909
118,NCT02107755,Phase II,"Active, not recruiting","[{'id': 779, 'therapyName': 'Ipilimumab'}]",Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma,1909
119,NCT02110355,Phase Ib/II,Recruiting,"[{'id': 1454, 'therapyName': 'AMG 232 + Trametinib'}, {'id': 1453, 'therapyName': 'AMG 232 + Trametinib + Dabrafenib'}, {'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}]",A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma,1909
120,NCT02112032,Phase I,"Active, not recruiting","[{'id': 2625, 'therapyName': 'peginterferon alfa-2b + Pembrolizumab'}]",Treatment of Advanced Melanoma With MK-3475 and Peginterferon,1909
121,NCT02115243,Phase I,"Active, not recruiting","[{'id': 779, 'therapyName': 'Ipilimumab'}]",Trial of Neoadjuvant Ipilimumab Followed by Melphalan Via Isolated Limb Infusion for Patients With Unresectable In-transit Extremity Melanoma,1909
122,NCT02117362,Phase I,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 2975, 'therapyName': 'GR-MD-02'}]",Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma,1909
123,NCT02120222,Phase I,Recruiting,"[{'id': 1749, 'therapyName': 'Selinexor'}]",Evaluating SINE KPT-330 in Treating Patients With Melanoma That Cannot Be Removed By Surgery,1909
124,NCT02122861,Phase I,"Active, not recruiting","[{'id': 3271, 'therapyName': 'ID-LV305'}]","A Phase 1 Safety Study of Intradermal ID-LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1",1909
125,NCT02126579,Phase Ib/II,Recruiting,"[{'id': 2595, 'therapyName': 'poly ICLC  '}, {'id': 3009, 'therapyName': 'Long peptide vaccine 7'}]",Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists,1909
126,NCT02129075,Phase II,"Active, not recruiting","[{'id': 3006, 'therapyName': 'NeoVax melanoma vaccine'}, {'id': 3007, 'therapyName': 'CDX-301'}, {'id': 1324, 'therapyName': 'DEC-205-NY-ESO-1 fusion protein vaccine'}]",CDX-1401 and Poly-ICLC Vaccine Therapy With or Without CDX-301in Treating Patients With Stage IIB-IV Melanoma,1909
127,NCT02130466,Phase Ib/II,Recruiting,"[{'id': 1450, 'therapyName': 'Pembrolizumab + Trametinib'}, {'id': 1448, 'therapyName': 'Pembrolizumab + Dabrafenib'}, {'id': 1449, 'therapyName': 'Pembrolizumab + Dabrafenib + Trametinib'}]",A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022),1909
128,NCT02138292,Phase I,"Active, not recruiting","[{'id': 1446, 'therapyName': 'Trametinib + Digoxin'}]",A Phase 1B Clinical Trial of Trametinib Plus Digoxin in Patients With Unresectable or Metastatic BRAF Wild-type Melanoma,1909
129,NCT02141542,Phase I,"Active, not recruiting","[{'id': 1652, 'therapyName': 'Tremelimumab'}, {'id': 1176, 'therapyName': 'MEDI3617'}]",Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma,1909
130,NCT02142218,Phase I,No longer available,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Expanded Access Program With Nivolumab to Treat Melanoma,1909
131,NCT02143050,Phase Ib/II,Recruiting,"[{'id': 1443, 'therapyName': 'Dabrafenib + Trametinib + Metformin'}]","Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients",1909
132,NCT02145910,Phase I,Withdrawn,"[{'id': 342, 'therapyName': 'Vemurafenib'}]",Vemurafenib Combined With Whole Brain Radiation Therapy or Radiosurgery in Patients With BRAF Mutation-Positive Melanoma and Brain Metastases,1909
133,NCT02156804,Phase II,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}]","A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody (CheckMate 172)",1909
134,NCT02158520,Phase II,"Active, not recruiting","[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1261, 'therapyName': 'Bevacizumab + Abraxane'}]",Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery,1909
135,NCT02159066,Phase II,"Active, not recruiting","[{'id': 1101, 'therapyName': 'Binimetinib + Encorafenib + Ribociclib'}, {'id': 1100, 'therapyName': 'Binimetinib + Encorafenib'}, {'id': 2216, 'therapyName': 'LGX818 + MEK162 + INC280'}, {'id': 2215, 'therapyName': 'LGX818 + MEK162 + BKM120'}, {'id': 2214, 'therapyName': 'LGX818 + MEK162 + BGJ398'}]","LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma",1909
136,NCT02173093,Phase Ib/II,Recruiting,"[{'id': 2058, 'therapyName': 'Aldesleukin + GD2Bi-a ATC + Sargramostim '}]",Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma,1909
137,NCT02174172,Phase I,Recruiting,"[{'id': 6252, 'therapyName': 'Atezolizumab + Bevacizumab +Peg-interferon alfa-2a'}, {'id': 6253, 'therapyName': 'Atezolizumab + Interferon alfa-2b'}, {'id': 6250, 'therapyName': 'Atezolizumab + Peg-interferon alfa-2a'}, {'id': 6249, 'therapyName': 'Atezolizumab + Ipilimumab'}, {'id': 1975, 'therapyName': 'Atezolizumab + Obinutuzumab'}]",A Study to Assess the Safety and Tolerability of MPDL3280A in Combination With Other Immune-modulating Therapies in Patients With Locally Advanced or Metastatic Solid Tumors,1909
138,NCT02178722,Phase Ib/II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2575, 'therapyName': 'Epacadostat'}]","A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Solid Tumors and Advanced NSCLC (INCB 24360-202 / MK-3475-037 / KEYNOTE-037)",1909
139,NCT02186249,Phase III,No longer available,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Expanded Access Program With Nivolumab (BMS-936558) in Combination With Ipilimumab (Yervoy®) in Anti-CTLA-4 Treatment-Naïve Subjects With Unresectable or Metastatic Melanoma (CheckMate 218),1909
140,NCT02196181,Phase II,Recruiting,"[{'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}]",Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery,1909
141,NCT02200562,Phase Ib/II,Terminated,"[{'id': 1257, 'therapyName': 'Dabrafenib + Ipilimumab'}]",Ipilimumab and Dabrafenib in the 1st Line Tx of Unresectable Stage III/IV Melanoma,1909
142,NCT02210104,Phase I,Withdrawn,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",Adoptive Therapy Using Antigen-Specific CD4 T-Cells,1909
143,NCT02224781,Phase III,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}]",Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma,1909
144,NCT02230306,Phase II,Terminated,"[{'id': 1657, 'therapyName': 'Vemurafenib + Cobimetinib'}]",Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases,1909
145,NCT02231775,Phase II,Recruiting,"[{'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}]",Combi-Neo Study for Stage IV Melanoma,1909
146,NCT02257424,Phase Ib/II,Recruiting,"[{'id': 2, 'therapyName': 'Trametinib'}]","The BAMM Trial: BRAF, Autophagy and MEK Inhibition in Metastatic Melanoma: A Phase I/2 Trial of Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma",1909
147,NCT02259231,Phase Ib/II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 3062, 'therapyName': 'RTA 408'}]",RTA 408 Capsules in Patients With Melanoma - REVEAL,1909
148,NCT02263508,Phase Ib/II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2695, 'therapyName': 'talimogene laherparepvec '}]",MK-3475 With or Without Talimogene Laherparepvec in Unresected Melanoma,1909
149,NCT02263898,Phase II,Withdrawn,"[{'id': 1100, 'therapyName': 'Binimetinib + Encorafenib'}]",Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations,1909
150,NCT02272855,Phase II,"Active, not recruiting","[{'id': 2003, 'therapyName': 'HF10 + Ipilimumab'}]",A Study of Combination Treatment With HF10 and Ipilimumab in Patients With Unresectable or Metastatic Melanoma,1909
151,NCT02296112,Phase II,Recruiting,"[{'id': 2, 'therapyName': 'Trametinib'}]",Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations,1909
152,NCT02298959,Phase I,Recruiting,"[{'id': 2369, 'therapyName': 'Aflibercept + Pembrolizumab'}]",Pembrolizumab and Ziv-aflibercept in Treating Patients With Advanced Solid Tumors,1909
153,NCT02300935,Phase I,Withdrawn,"[{'id': 1268, 'therapyName': 'nab-paclitaxel + GSK1120212'}]",Study of Trametinib and Nab-paclitaxel in Patients With Melanoma,1909
154,NCT02302339,Phase II,Recruiting,"[{'id': 3597, 'therapyName': 'Glembatumumab vedotin'}]",A Study of Glembatumumab Vedotin in Patients With Advanced Melanoma,1909
155,NCT02303990,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",RADVAX A Stratified Phase I Trial of Pembrolizumab With Hypofractionated Radiotherapy in Patients With Advanced and Metastatic Cancers,1909
156,NCT02306850,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma,1909
157,NCT02307149,Phase I,Recruiting,"[{'id': 2974, 'therapyName': 'coxsackievirus A21'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Study of Intratumoral CAVATAK (Coxsackievirus A21) and Ipilimumab in Patients With Advanced Melanoma,1909
158,NCT02315066,Phase I,Recruiting,"[{'id': 4333, 'therapyName': 'PF-04518600'}, {'id': 4448, 'therapyName': 'PF-04518600 + Utomilumab'}]",Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566,1909
159,NCT02318771,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Urothelial Cancer, Melanoma, and Non-Small Cell Lung Cancer",1909
160,NCT02320058,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Multi-Center Phase 2 Open-Label Study to Evaluate Safety and Efficacy in Subjects With Melanoma Metastatic to the Brain Treated With Nivolumab in Combination With Ipilimumab Followed by Nivolumab Monotherapy (CheckMate 204),1909
161,NCT02320305,Phase I,"Active, not recruiting","[{'id': 3787, 'therapyName': 'MART-1 antigen'}, {'id': 3889, 'therapyName': 'GLA-SE + MART-1 antigen'}]",MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery,1909
162,NCT02327078,Phase Ib/II,Recruiting,"[{'id': 3059, 'therapyName': 'INCB024360 + Nivolumab'}]","A Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination With Nivolumab in Select Advanced Cancers",1909
163,NCT02332668,Phase Ib/II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","A Study of Pembrolizumab (MK-3475) in Pediatric Participants With Advanced Melanoma or Advanced, Relapsed, or Refractory PD-L1-Positive Solid Tumors or Lymphoma (MK-3475-051/KEYNOTE-051)",1909
164,NCT02334735,Phase II,Recruiting,"[{'id': 2595, 'therapyName': 'poly ICLC  '}, {'id': 3012, 'therapyName': 'Melan-A/MART-1 peptide vaccine'}, {'id': 2696, 'therapyName': 'NY-ESO-1 peptide vaccine'}]",A Comparison of Matured Dendritic Cells and Montanide&#174; in Study Subjects With High Risk of Melanoma Recurrence,1909
165,NCT02335918,Phase Ib/II,Recruiting,"[{'id': 2526, 'therapyName': 'Nivolumab + Varlilumab'}]",A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors,1909
166,NCT02339324,Phase I,"Active, not recruiting","[{'id': 1299, 'therapyName': 'Interferon alfa-2b '}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Neoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN-alfa2b,1909
167,NCT02339571,Phase II,Suspended,"[{'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Nivolumab and Ipilimumab With or Without Sargramostim in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,1909
168,NCT02346955,Phase I,Terminated,"[{'id': 4246, 'therapyName': 'CM-24'}, {'id': 4247, 'therapyName': 'CM-24 + Pembrolizumab'}]",Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001),1909
169,NCT02362594,Phase III,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/KEYNOTE-054),1909
170,NCT02381314,Phase I,Recruiting,"[{'id': 3058, 'therapyName': 'Ipilimumab + MGA271'}]",Safety Study of MGA271 in Combination With Ipilimumab in Refractory Cancer,1909
171,NCT02382549,Phase Ib/II,Recruiting,"[{'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 2620, 'therapyName': '6MHP vaccine'}]",A Clinical Trial to Evaluate a Helper Peptide Vaccine Plus Vemurafenib in Melanoma,1909
172,NCT02385669,Phase Ib/II,Recruiting,"[{'id': 2620, 'therapyName': '6MHP vaccine'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma,1909
173,NCT02387125,Phase I,Recruiting,"[{'id': 4318, 'therapyName': 'CMB305'}]","A Phase 1b Safety Study of CMB305 (Sequentially Administered LV305 and G305) in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1",1909
174,NCT02388906,Phase III,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma (CheckMate 238),1909
175,NCT02400385,Phase II,Withdrawn,"[{'id': 2626, 'therapyName': 'Nivolumab + Sunitinib'}]",A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced Melanoma,1909
176,NCT02404441,Phase Ib/II,Recruiting,"[{'id': 2659, 'therapyName': 'PDR001'}]",Phase I/II Study of PDR001 in Patients With Advanced Malignancies,1909
177,NCT02407171,Phase Ib/II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic Melanoma or NSCLC,1909
178,NCT02413827,Phase Ib/II,Terminated,"[{'id': 2526, 'therapyName': 'Nivolumab + Varlilumab'}, {'id': 1324, 'therapyName': 'DEC-205-NY-ESO-1 fusion protein vaccine'}, {'id': 2595, 'therapyName': 'poly ICLC  '}]",A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma,1909
179,NCT02423863,Phase II,Recruiting,"[{'id': 2595, 'therapyName': 'poly ICLC  '}]","In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol",1909
180,NCT02425306,Phase Ib/II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2620, 'therapyName': '6MHP vaccine'}, {'id': 2595, 'therapyName': 'poly ICLC  '}]",Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma,1909
181,NCT02427893,Phase III,Withdrawn,"[{'id': 1004, 'therapyName': 'Cobimetinib'}, {'id': 342, 'therapyName': 'Vemurafenib'}]",Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma,1909
182,NCT02428712,Phase Ib/II,Recruiting,"[{'id': 1041, 'therapyName': 'PLX8394'}]","A Study of PLX8394 as a Single Agent in Patients With Advanced, Unresectable Solid Tumors",1909
183,NCT02434354,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Tissue Collection Study of Pembrolizumab (MK-3475) in Subjects With Resectable Advanced Melanoma,1909
184,NCT02437136,Phase Ib/II,Recruiting,"[{'id': 3354, 'therapyName': 'Entinostat + Pembrolizumab'}]",Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in NSCLC With Expansion Cohorts in NSCLC and Melanoma,1909
185,NCT02452281,Phase Ib/II,Withdrawn,"[{'id': 2973, 'therapyName': 'Vitespen'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma,1909
186,NCT02452424,Phase Ib/II,"Active, not recruiting","[{'id': 2736, 'therapyName': 'Pembrolizumab + PLX3397'}]",A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors,1909
187,NCT02460224,Phase Ib/II,Recruiting,"[{'id': 2887, 'therapyName': 'LAG525'}, {'id': 2659, 'therapyName': 'PDR001'}]",Safety and Efficay of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies,1909
188,NCT02471846,Phase I,"Active, not recruiting","[{'id': 2888, 'therapyName': 'GDC-0919'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study of GDC-0919 and MPDL3280A Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors,1909
189,NCT02475213,Phase I,Recruiting,"[{'id': 2864, 'therapyName': 'MGA271 + Pembrolizumab'}]",Safety Study of MGA271 in Combination With Pembrolizumab in Refractory Cancer,1909
190,NCT02493361,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2990, 'therapyName': 'IL-12 gene'}]",Trial of pIL-12/MK-3475 in Metastatic Melanoma,1909
191,NCT02498665,Phase I,Recruiting,"[{'id': 4320, 'therapyName': 'DSP-7888'}]",A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies,1909
192,NCT02500576,Phase II,Recruiting,"[{'id': 5683, 'therapyName': 'Aldesleukin + Cyclophosphamide + Fludarabine + Mesna + Pembrolizumab'}]","MK-3475 With Lymphodepletion, TIL and High or Low Dose Interleukin-2 (IL-2)",1909
193,NCT02501096,Phase Ib/II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 792, 'therapyName': 'Lenvatinib'}]",Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors,1909
194,NCT02506153,Phase III,"Active, not recruiting","[{'id': 1299, 'therapyName': 'Interferon alfa-2b '}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",High-Dose Recombinant Interferon Alfa-2B or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery,1909
195,NCT02519322,Phase II,"Active, not recruiting","[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Neoadjuvant and Adjuvant Checkpoint Blockade in Patients With Clinical Stage III or Oligometastatic Stage IV Melanoma,1909
196,NCT02521870,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 3084, 'therapyName': 'SD-101'}]",A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma,1909
197,NCT02526017,Phase I,Recruiting,"[{'id': 2840, 'therapyName': 'FPA008'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Study of FPA008 in Combination With Nivolumab in Patients With Selected Advance Cancers,1909
198,NCT02528357,Phase I,Recruiting,"[{'id': 5177, 'therapyName': 'GSK3174998'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",GSK3174998 Alone or With Pembrolizumab in Subjects With Advanced Solid Tumors,1909
199,NCT02543645,Phase Ib/II,Terminated,"[{'id': 3086, 'therapyName': 'Atezolizumab + Varlilumab'}]",A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer,1909
200,NCT02553642,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260),1909
201,NCT02554812,Phase I,Recruiting,"[{'id': 6043, 'therapyName': 'Avelumab + Utomilumab'}]",A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley),1909
202,NCT02557321,Phase Ib/II,Recruiting,"[{'id': 879, 'therapyName': 'PV-10'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma,1909
203,NCT02559492,Phase I,"Active, not recruiting","[{'id': 3096, 'therapyName': 'INCB039110 + INCB024360'}, {'id': 3097, 'therapyName': 'INCB039110 + INCB050465'}]",INCB039110 Combined With INCB024360 and/or INCB039110 Combined With INCB050465 in Advanced Solid Tumors,1909
204,NCT02565992,Phase I,Recruiting,"[{'id': 3136, 'therapyName': 'coxsackievirus A21 + Pembrolizumab'}]",Phase I Study of Intratumoral CAVATAK and Pembrolizumab in Subjects With Advanced Melanoma,1909
205,NCT02574533,Phase I,Completed,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1157, 'therapyName': 'FANG vaccine'}]",Pilot Study of Vigil + Pembrolizumab for Advanced Melanoma,1909
206,NCT02575404,Phase I,Recruiting,"[{'id': 2975, 'therapyName': 'GR-MD-02'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",GR-MD-02 Plus Pembrolizumab in Melanoma Patients,1909
207,NCT02576665,Phase I,Recruiting,"[{'id': 3211, 'therapyName': 'Toca 511 + Toca FC'}]","A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Solid Tumors (Toca6)",1909
208,NCT02591654,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",MRI/PET Imaging to Assess Response to Pembrolizumab in Metastatic Melanoma,1909
209,NCT02595866,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms",1909
210,NCT02599402,Phase III,"Active, not recruiting","[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma,1909
211,NCT02608268,Phase Ib/II,Recruiting,"[{'id': 2659, 'therapyName': 'PDR001'}, {'id': 3560, 'therapyName': 'MBG453'}]",Safety and Efficacy of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies,1909
212,NCT02617849,Phase II,Recruiting,"[{'id': 2103, 'therapyName': 'Carboplatin + Paclitaxel + Pembrolizumab'}]",Pembrolizumab With Carboplatin/Paclitaxel in Patients With Metastatic Melanoma,1909
213,NCT02621021,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1167, 'therapyName': 'Aldesleukin'}]",A Prospective Randomized and Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab,1909
214,NCT02637531,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 3363, 'therapyName': 'IPI-549'}]","A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549",1909
215,NCT02639026,Phase I,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]","Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers",1909
216,NCT02639546,Phase I,Recruiting,"[{'id': 1004, 'therapyName': 'Cobimetinib'}]",iMATRIXcobi: Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Patients With Previously Treated Solid Tumors,1909
217,NCT02643303,Phase Ib/II,Recruiting,"[{'id': 3385, 'therapyName': 'MEDI4736 + poly ICLC '}, {'id': 1652, 'therapyName': 'Tremelimumab'}]","A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers",1909
218,NCT02644369,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors,1909
219,NCT02644967,Phase Ib/II,Recruiting,"[{'id': 4244, 'therapyName': 'IMO-2125 + Ipilimumab'}, {'id': 4245, 'therapyName': 'IMO-2125 + Pembrolizumab'}]",A Study to Assess the Safety and Efficacy of Intratumoral IMO-2125 in Combination With Ipilimumab or Pembrolizumab in Patients With Metastatic Melanoma,1909
220,NCT02646748,Phase I,Recruiting,"[{'id': 3088, 'therapyName': 'INCB050465 '}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2406, 'therapyName': 'INCB039110'}]",Pembrolizumab Combined With INCB039110 and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors,1909
221,NCT02650635,Phase I,"Active, not recruiting","[{'id': 3413, 'therapyName': 'Cyclophosphamide + Pegfilgrastim + VTX-2337'}]","TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors",1909
222,NCT02652455,Phase I,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 3409, 'therapyName': 'Aldesleukin + Cyclophosphamide + Fludarabine '}, {'id': 2055, 'therapyName': 'Urelumab'}]","Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma",1909
223,NCT02655822,Phase I,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 3571, 'therapyName': 'CPI-444 '}]",Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers,1909
224,NCT02656706,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",BrUOG 324: Adjuvant Nivolumab and Low Dose Ipilimumab for Stage III and Resected Stage IV Melanoma: A Phase II Brown University Oncology Research Group Trial,1909
225,NCT02659540,Phase I,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Pilot Study to Evaluate the Safety and Efficacy of Combination Checkpoint Blockade Plus External Beam Radiotherapy in Subjects With Stage IV Melanoma,1909
226,NCT02681549,Phase II,Recruiting,"[{'id': 2119, 'therapyName': 'Bevacizumab + Pembrolizumab'}]",Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer,1909
227,NCT02697591,Phase Ib/II,Recruiting,"[{'id': 4321, 'therapyName': 'INCAGN01876'}]","An Open-Label, Dose-Escalation, Safety Study of INCAGN01876 in Subjects With Advanced or Metastatic Solid Tumors",1909
228,NCT02706353,Phase Ib/II,Recruiting,"[{'id': 3836, 'therapyName': 'APX005M + Pembrolizumab'}]",APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma,1909
229,NCT02714218,Phase III,"Active, not recruiting","[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]","A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma",1909
230,NCT02716948,Phase I,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Stereotactic Radiosurgery and Nivolumab in Treating Patients With Newly Diagnosed Melanoma Metastases in the Brain or Spine,1909
231,NCT02718066,Phase Ib/II,Recruiting,"[{'id': 4689, 'therapyName': 'Chidamide + Nivolumab'}]","Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer",1909
232,NCT02719015,Phase Ib/II,Not yet recruiting,"[{'id': 3943, 'therapyName': 'Pembrolizumab + rAd.CD40L'}]",Dose Escalation and Cohort Expansion of Safety and Tolerability Study of Intratumoral rAd.CD40L (ISF35) in Combination of Systemic Pembrolizumab in Patients With Refractory Metastatic Melanoma,1909
233,NCT02721459,Phase I,Recruiting,"[{'id': 3995, 'therapyName': 'Cobimetinib + XL888 + Vemurafenib'}]",XL888 + Vemurafenib + Cobimetinib for Unresectable B Rapidly Accelerated Fibrosarcoma (BRAF) Mutated Stage III/IV Melanoma,1909
234,NCT02723006,Phase I,Recruiting,"[{'id': 4198, 'therapyName': 'MLN2480 + Nivolumab'}, {'id': 4200, 'therapyName': 'MLN1202 + Nivolumab'}, {'id': 4202, 'therapyName': 'Ipilimumab + Nivolumab + Vedolizumab '}]","Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma",1909
235,NCT02723955,Phase I,Recruiting,"[{'id': 4409, 'therapyName': 'GSK3359609'}, {'id': 4410, 'therapyName': 'GSK3359609 + Pembrolizumab'}]",Dose Escalation and Expansion Study of GSK3359609 in Subjects With Selected Advanced Solid Tumors (INDUCE-1),1909
236,NCT02736123,Phase Ib/II,Withdrawn,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone,1909
237,NCT02740920,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Assessment of Response to Pembrolizumab in Metastatic Melanoma: Computed Tomography (CT) Texture Analysis as a Predictive Biomarker,1909
238,NCT02743819,Phase II,Recruiting,"[{'id': 2106, 'therapyName': 'Ipilimumab + Pembrolizumab '}]",Phase II Study of Pembrolizumab and Ipilimumab Following Initial Anti-PD1/L1 Antibody,1909
239,NCT02748564,Phase II,Recruiting,"[{'id': 4165, 'therapyName': 'Aldesleukin + Pembrolizumab'}]",Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma,1909
240,NCT02752074,Phase III,"Active, not recruiting","[{'id': 4088, 'therapyName': 'Epacadostat + Pembrolizumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma,1909
241,NCT02760797,Phase I,Recruiting,"[{'id': 4181, 'therapyName': 'Emactuzumab + RO7009789'}]",A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors,1909
242,NCT02796352,Phase II,Terminated,"[{'id': 1167, 'therapyName': 'Aldesleukin'}]",A Phase II Study of High Dose Bolus IL2 in Patients With Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy: Efficacy and Biomarker Study,1909
243,NCT02799095,Phase I,Recruiting,"[{'id': 4298, 'therapyName': 'ALKS 4230'}]",A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors,1909
244,NCT02807844,Phase Ib/II,Recruiting,"[{'id': 5072, 'therapyName': 'MCS110 + PDR001'}]",Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies,1909
245,NCT02812693,Phase Ib/II,Recruiting,"[{'id': 4376, 'therapyName': 'Imatinib + Pembrolizumab'}]",Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/Amplification,1909
246,NCT02816021,Phase II,Recruiting,"[{'id': 2496, 'therapyName': 'Azacitidine + Pembrolizumab'}]",Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma,1909
247,NCT02818023,Phase I,Recruiting,"[{'id': 4406, 'therapyName': 'Pembrolizumab + Vemurafenib'}]",Dose-seeking and Efficacy Study of Pembrolizumab Plus Vemurafenib Advanced Melanoma,1909
248,NCT02823405,Phase I,Recruiting,"[{'id': 4436, 'therapyName': 'Pembrolizumab + X4P-001'}]",Neoadjuvant X4P-001 and Pembrolizumab in Patients With Resectable Melanoma (X4P-001-MELA),1909
249,NCT02839694,Phase I,Withdrawn,"[{'id': 3567, 'therapyName': 'Decitabine + Tetrahydrouridine'}, {'id': 4592, 'therapyName': 'Decitabine + Tetrahydrouridine + Celecoxib'}]",Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in People Undergoing Pulmonary Metastasectomy,1909
250,NCT02857270,Phase I,Recruiting,"[{'id': 4588, 'therapyName': 'LY3214996'}, {'id': 4590, 'therapyName': 'LY3214996 + nab-paclitaxel + Gemcitabine'}, {'id': 4589, 'therapyName': 'LY3214996 + Midazolam'}, {'id': 4591, 'therapyName': 'LY3214996 + Abemaciclib'}]",A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer,1909
251,NCT02858869,Phase 0,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases,1909
252,NCT02880371,Phase Ib/II,Recruiting,"[{'id': 4608, 'therapyName': 'ARRY-382 + Pembrolizumab'}]",A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors,1909
253,NCT02889861,Phase Ib/II,Recruiting,"[{'id': 3847, 'therapyName': 'IMCgp100'}]",IMCgp100-401 Rollover Study,1909
254,NCT02897765,Phase I,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 4733, 'therapyName': 'NEO-PV-01 + poly ICLC'}]","A Personalized Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer",1909
255,NCT02908672,Phase III,Recruiting,"[{'id': 1657, 'therapyName': 'Vemurafenib + Cobimetinib'}, {'id': 4825, 'therapyName': 'Atezolizumab + Vemurafenib + Cobimetinib'}]",A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Participants With Metastatic or Unresectable Locally Advanced Melanoma,1909
256,NCT02910700,Phase II,Recruiting,"[{'id': 4753, 'therapyName': 'Nivolumab + Trametinib'}, {'id': 4754, 'therapyName': 'Dabrafenib + Nivolumab + Trametinib'}]",Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib in Patients With BRAF or NRAS-mutated Metastatic Melanoma,1909
257,NCT02915666,Phase I,Recruiting,"[{'id': 4778, 'therapyName': 'Dabrafenib + Digoxin + Trametinib'}]",A Clinical Trial of Patients With Melanoma,1909
258,NCT02923349,Phase Ib/II,Recruiting,"[{'id': 5831, 'therapyName': 'INCAGN01949'}]","A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors",1909
259,NCT02935790,Phase I,Completed,"[{'id': 3312, 'therapyName': 'ACY-241 + Ipilimumab + Nivolumab'}]",Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab,1909
260,NCT02939300,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Ipilimumab and Nivolumab in Leptomeningeal Metastases From Melanoma,1909
261,NCT02952248,Phase I,Recruiting,"[{'id': 5692, 'therapyName': 'BI 754091'}]",A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours,1909
262,NCT02961283,Phase I,Recruiting,"[{'id': 5827, 'therapyName': 'ASN003'}]",Study of ASN003 in Subjects With Advanced Solid Tumors,1909
263,NCT02965716,Phase II,Recruiting,"[{'id': 4035, 'therapyName': 'Pembrolizumab + talimogene laherparepvec '}]",Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma,1909
264,NCT02967692,Phase III,Recruiting,"[{'id': 6023, 'therapyName': 'Dabrafenib + Trametinib + PDR001'}, {'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}]","A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma",1909
265,NCT02970981,Phase II,Not yet recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma,1909
266,NCT02974803,Phase II,Not yet recruiting,"[{'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}]",Concurrent Dabrafenib and Trametinib With Sterotactic Radiation in Patients With BRAF Mutation-Positive Malignant Melanoma and Brain Metastases,1909
267,NCT02981303,Phase II,Recruiting,"[{'id': 5174, 'therapyName': 'Imprime PGG + Pembrolizumab'}]",Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer,1909
268,NCT02983006,Phase I,Recruiting,"[{'id': 5078, 'therapyName': 'DS-8273a + Nivolumab'}]",Study of DS-8273a With Nivolumab in Unresectable Stage III or Stage IV Melanoma,1909
269,NCT02983045,Phase Ib/II,Recruiting,"[{'id': 5076, 'therapyName': 'NKTR-214 + Nivolumab'}]",A Dose Escalation and Cohort Expansion Study of CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 Antibody (Nivolumab) in Patients With Select Advanced or Metastatic Solid Tumors (PIVOT-02),1909
270,NCT02990416,Phase Ib/II,Not yet recruiting,"[{'id': 5137, 'therapyName': 'A-dmDT390-bisFv(UCHT1) + Pembrolizumab'}]",A-dmDT390-bisFv(UCHT1) Fusion Protein With Ionizing Radiation and Pembrolizumab for the Treatment of Stage IV Melanoma,1909
271,NCT03003676,Phase I,Recruiting,"[{'id': 5173, 'therapyName': 'Cyclophosphamide + ONCOS-102 + Pembrolizumab'}]","A Pilot Study of Sequential ONCOS-102, an Engineered Oncolytic Adenovirus Expressing GMCSF, and Pembrolizumab in Patients With Advanced or Unresectable Melanoma Progressing After Programmed Cell Death Protein 1 (PD1) Blockade",1909
272,NCT03005639,Phase II,Recruiting,"[{'id': 1657, 'therapyName': 'Vemurafenib + Cobimetinib'}]",ML29255 Neoadjuvant Vemurafenib and Cobimetinib Melanoma,1909
273,NCT03021460,Phase II,Suspended,"[{'id': 4917, 'therapyName': 'Pembrolizumab + Ibrutinib'}]",Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,1909
274,NCT03025256,Phase I,Not yet recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Study of Concurrent Intravenous and Intrathecal Nivolumab for Patients With Leptomeningeal Disease (LMD),1909
275,NCT03026517,Phase I,Recruiting,"[{'id': 5270, 'therapyName': 'Dabrafenib + Trametinib + Phenformin'}]",Clinical Trial of Phenformin in Combination With Dabrafenib and Trametinib for Patients With BRAF-mutated Melanoma,1909
276,NCT03033576,Phase II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That is Stage IV or Stage III and Cannot Be Removed by Surgery,1909
277,NCT03050060,Phase II,Recruiting,"[{'id': 5301, 'therapyName': 'Nelfinavir + Nivolumab'}]","Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, and Nivolumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer",1909
278,NCT03068455,Phase III,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Study of Nivolumab in Combination With Ipilimumab Compared to Nivolumab or Ipilimumab Alone in Treatment of Patients After Complete Resection of Stage IIIb/c/d or Stage IV Melanoma (CheckMate 915),1909
279,NCT03088176,Phase I,Recruiting,"[{'id': 5481, 'therapyName': 'talimogene laherparepvec + Dabrafenib + Trametinib'}]",Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma,1909
280,NCT03089606,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab TX-naive Distant Mets Melanoma and Use of AMT (PET) at Baseline as Imaging Biomarker,1909
281,NCT03092453,Phase I,Recruiting,"[{'id': 4891, 'therapyName': 'Cyclophosphamide + Pembrolizumab'}]",Dendritic Cell Vaccination in Patients With Advanced Melamona,1909
282,NCT03098160,Phase I,Recruiting,"[{'id': 5745, 'therapyName': 'Evofosfamide + Ipilimumab'}]",Immunotherapy Study of Evofosfamide in Combination With Ipilimumab,1909
283,NCT03101254,Phase Ib/II,Recruiting,"[{'id': 5512, 'therapyName': 'Cobimetinib + LY3022855 + Vemurafenib'}]",LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma,1909
284,NCT03111901,Phase Ib/II,Not yet recruiting,"[{'id': 4165, 'therapyName': 'Aldesleukin + Pembrolizumab'}]",Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer,1909
285,NCT03126461,Phase II,Not yet recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma Patients,1909
286,NCT03131908,Phase Ib/II,Recruiting,"[{'id': 3518, 'therapyName': 'GSK2636771 + Pembrolizumab'}]",Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss,1909
287,NCT03149029,Phase II,Not yet recruiting,"[{'id': 1449, 'therapyName': 'Pembrolizumab + Dabrafenib + Trametinib'}, {'id': 1450, 'therapyName': 'Pembrolizumab + Trametinib'}]",Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma,1909
288,NCT03159117,Phase I,Recruiting,"[{'id': 5707, 'therapyName': ' PF-06688992'}]",Pfizer PF-06688992 in Patients With Stage III or Stage IV Melanoma,1909
289,NCT03161431,Phase I,Not yet recruiting,"[{'id': 5786, 'therapyName': 'SX-682'}, {'id': 5787, 'therapyName': 'Pembrolizumab + SX-682'}]",SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab,1909
290,NCT03175432,Phase II,Recruiting,"[{'id': 4595, 'therapyName': 'Atezolizumab + Bevacizumab'}]",Study of BEvacizumab in Combination With ATezolizumab in Patients With Untreated Melanoma Brain Metastases  (BEAT-MBM),1909
291,NCT03178851,Phase I,Recruiting,"[{'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}]",A Study Evaluating Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy,1909
292,NCT03192345,Phase I,Recruiting,"[{'id': 5934, 'therapyName': 'SAR439459 + REGN2810'}, {'id': 5933, 'therapyName': 'SAR439459'}]","A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and REGN2810 in Patients With Advanced Solid Tumors",1909
293,NCT03200847,Phase Ib/II,Not yet recruiting,"[{'id': 5988, 'therapyName': 'Pembrolizumab + Tretinoin'}]",Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma,1909
294,NCT03236935,Phase I,Not yet recruiting,"[{'id': 6097, 'therapyName': 'L-NMMA + Pembrolizumab'}]",Phase Ib of L-NMMA and Pembrolizumab,1909
295,NCT03239145,Phase I,Recruiting,"[{'id': 6102, 'therapyName': 'Pembrolizumab + Trebananib'}]",Phase Ib Study to Test the Safety and Potential Synergy of Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor,1909
296,NCT03241927,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab Effects on NK Cell Exhaustion in Melanoma (Merck NK-IIT),1909
297,NCT03259425,Phase II,Not yet recruiting,"[{'id': 6149, 'therapyName': 'HF10 + Nivolumab'}]","Neoadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1a Melanoma",1909
298,NCT03272464,Phase I,Not yet recruiting,"[{'id': 6176, 'therapyName': 'Dabrafenib + INCB039110 + Trametinib'}]",Phase I Study of INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors.,1909
299,NCT03273153,Phase III,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}]",A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma,1909
300,NCT03276832,Phase I,Not yet recruiting,"[{'id': 6220, 'therapyName': 'Imiquimod + Pembrolizumab'}]",Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma,1909
301,NCT03277352,Phase Ib/II,Not yet recruiting,"[{'id': 6277, 'therapyName': 'Epacadostat + INCAGN01876 + Pembrolizumab'}]",INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies,1909
302,NCT03289962,Phase I,Not yet recruiting,"[{'id': 6234, 'therapyName': 'RO7198457'}, {'id': 6235, 'therapyName': 'Atezolizumab + RO7198457'}]",A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors,1909
303,NCT03301896,Phase I,Not yet recruiting,"[{'id': 6299, 'therapyName': 'LHC165 + PDR001'}, {'id': 6298, 'therapyName': 'LHC165'}]",Phase I/Ib Study of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies,1909
0,NCT01880749,Phase I,"Active, not recruiting","[{'id': 735, 'therapyName': 'Everolimus'}]",Exploring the Activity of RAD001 in Vestibular Schwannomas and Meningiomas,3565
1,NCT02282917,Phase I,Recruiting,"[{'id': 987, 'therapyName': 'AR-42'}]",Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma,3565
2,NCT02423525,Phase I,Recruiting,"[{'id': 623, 'therapyName': 'Afatinib'}]",Safety Study of Afatinib for Brain Cancer,3565
3,NCT02523014,Phase II,Recruiting,"[{'id': 3078, 'therapyName': 'GSK2256098'}, {'id': 956, 'therapyName': 'Vismodegib'}]",A Study Looking at Targeted Therapy According to Tumor Markers for People With Meningiomas,3565
4,NCT02648997,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",A Study of Nivolumab in Adult Participants With Recurrent High-Grade Meningioma,3565
5,NCT02831257,Phase II,"Active, not recruiting","[{'id': 991, 'therapyName': 'Vistusertib'}]",AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas,3565
6,NCT02847559,Phase II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma,3565
7,NCT02933736,Phase 0,Recruiting,"[{'id': 790, 'therapyName': 'Ribociclib'}]",Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients,3565
8,NCT03071874,Phase II,Recruiting,"[{'id': 991, 'therapyName': 'Vistusertib'}]",Phase II Study Of Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas,3565
9,NCT03095248,Phase II,Recruiting,"[{'id': 913, 'therapyName': 'Selumetinib'}]",Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors,3565
10,NCT03173950,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Immune Checkpoint Inhibitor Nivolumab in People With Select Rare CNS Cancers,3565
11,NCT03220646,Phase II,Recruiting,"[{'id': 802, 'therapyName': 'Abemaciclib'}]",The Purpose of This Study is to Test Any Good and Bad Effects of a Study Drug Called Abemaciclib (LY2835219) in Patients With Recurrent Brain Tumors.,3565
12,NCT03267836,Phase I,Not yet recruiting,"[{'id': 3144, 'therapyName': 'Avelumab'}]",Neoadjuvant Avelumab and Hypofractionated Proton Radiation Therapy Followed by Surgery for Recurrent Radiation-refractory Meningioma,3565
13,NCT03279692,Phase II,Not yet recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Phase II Trial of Pembrolizumab in Recurrent or Residual High Grade Meningioma,3565
0,NCT02036476,Phase II,"Active, not recruiting","[{'id': 998, 'therapyName': 'cabozantinib'}]",Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma,3965
1,NCT02155647,Phase II,Recruiting,"[{'id': 3144, 'therapyName': 'Avelumab'}]",Avelumab in Subjects With Merkel Cell Carcinoma (JAVELIN Merkel 200),3965
2,NCT02267603,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer,3965
3,NCT02488759,Phase Ib/II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",A Study to Investigate the Safety and Efficacy of Nivolumab in Virus-associated Tumors (CheckMate358),3965
4,NCT02514824,Phase Ib/II,Recruiting,"[{'id': 1282, 'therapyName': 'Sapanisertib'}]",MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma,3965
5,NCT02584829,Phase Ib/II,Suspended,"[{'id': 3156, 'therapyName': 'IFN-B'}, {'id': 3144, 'therapyName': 'Avelumab'}]",Localized Radiation Therapy or Recombinant Interferon Beta and MSB0010718C With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma,3965
6,NCT02643303,Phase Ib/II,Recruiting,"[{'id': 3385, 'therapyName': 'MEDI4736 + poly ICLC '}, {'id': 1652, 'therapyName': 'Tremelimumab'}]","A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers",3965
7,NCT02831179,Phase I,Withdrawn,"[{'id': 4463, 'therapyName': 'Capecitabine + Veliparib + Temozolomide'}]","Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor",3965
8,NCT02936323,,Recruiting,"[{'id': 5819, 'therapyName': 'PEN-221'}]",PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers,3965
9,NCT02978625,Phase II,Recruiting,"[{'id': 5080, 'therapyName': 'Talimogene laherparepvec + Nivolumab'}]",Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers,3965
10,NCT03071406,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma,3965
11,NCT03074513,Phase II,Recruiting,"[{'id': 4595, 'therapyName': 'Atezolizumab + Bevacizumab'}]",Atezolizumab and Bevacizumab in Rare Solid Tumors,3965
12,NCT03271372,Phase III,Not yet recruiting,"[{'id': 3144, 'therapyName': 'Avelumab'}]",Adjuvant Avelumab in Merkel Cell Cancer (ADAM),3965
13,NCT03289962,Phase I,Not yet recruiting,"[{'id': 6234, 'therapyName': 'RO7198457'}, {'id': 6235, 'therapyName': 'Atezolizumab + RO7198457'}]",A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors,3965
14,NCT03304639,Phase II,Not yet recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Merkel Cell Cancer,3965
0,NCT02223819,Phase II,Recruiting,"[{'id': 706, 'therapyName': 'Crizotinib'}]",Adjuvant Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy,6522
0,NCT00303849,Phase Ib/II,Recruiting,"[{'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2562, 'therapyName': 'Etoposide + Melphalan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}]",Combination Chemotherapy With BBBD Followed By Sodium Thiosulfate in Treating Patients With Anaplastic Oligodendroglioma or Oligoastrocytoma,5076
1,NCT01392209,Phase I,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}]",Hypofractionated Stereotactic Radiotherapy With Bevacizumab in the Treatment of Recurrent Malignant Glioma,5076
2,NCT01999270,Phase I,Completed,"[{'id': 2112, 'therapyName': 'Bevacizumab + Irinotecan'}]",Evaluation of FDOPA-PET/MRI in Pediatric Patients With CNS Tumors,5076
3,NCT02101905,Phase I,Recruiting,"[{'id': 787, 'therapyName': 'Lapatinib'}]",Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma,5076
4,NCT02238496,Phase II,"Active, not recruiting","[{'id': 2194, 'therapyName': 'Perifosine + Temsirolimus'}]",Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas,5076
5,NCT02607124,Phase Ib/II,Recruiting,"[{'id': 790, 'therapyName': 'Ribociclib'}]",Administration of Ribociclib Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG),5076
6,NCT02800486,Phase II,Recruiting,"[{'id': 694, 'therapyName': 'Cetuximab'}]","Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA",5076
0,NCT01140568,Phase II,Recruiting,"[{'id': 829, 'therapyName': 'Nilotinib'}]",Study of Platelet Derived Growth Factor Receptor (PDGFR) in Recurrent Malignant Gliomas,7912
1,NCT01266031,Phase Ib/II,Completed,"[{'id': 2110, 'therapyName': 'Bevacizumab + Vorinostat'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma,7912
2,NCT01269853,Phase Ib/II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA,7912
3,NCT01339039,Phase I,Terminated,"[{'id': 2120, 'therapyName': 'Bevacizumab + Plerixafor'}]",Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma,7912
4,NCT01386710,Phase Ib/II,Suspended,"[{'id': 2074, 'therapyName': 'Bevacizumab + Carboplatin'}]",Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma,7912
5,NCT01434602,Phase Ib/II,Recruiting,"[{'id': 2299, 'therapyName': 'Everolimus + Sorafenib'}]",Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas,7912
6,NCT02423525,Phase I,Recruiting,"[{'id': 623, 'therapyName': 'Afatinib'}]",Safety Study of Afatinib for Brain Cancer,7912
0,NCT02834013,Phase 0,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab in Treating Patients With Rare Tumors,3030
1,NCT02978625,Phase II,Recruiting,"[{'id': 5080, 'therapyName': 'Talimogene laherparepvec + Nivolumab'}]",Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers,3030
0,NCT02834013,Phase 0,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab in Treating Patients With Rare Tumors,3603
0,NCT02748564,Phase II,Recruiting,"[{'id': 4165, 'therapyName': 'Aldesleukin + Pembrolizumab'}]",Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma,50929
1,NCT02818023,Phase I,Recruiting,"[{'id': 4406, 'therapyName': 'Pembrolizumab + Vemurafenib'}]",Dose-seeking and Efficacy Study of Pembrolizumab Plus Vemurafenib Advanced Melanoma,50929
2,NCT02879162,Phase II,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours,50929
3,NCT02978443,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab,50929
4,NCT03220009,Phase II,Not yet recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]","Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma",50929
0,NCT00602693,Phase I,Completed,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 2311, 'therapyName': 'Allopurinol + Cyclophosphamide + Fludarabine'}]",T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer,9538
1,NCT00734877,Phase III,Recruiting,"[{'id': 1851, 'therapyName': 'Cisplatin + Doxorubicin + Cyclophosphamide + Etoposide'}, {'id': 1852, 'therapyName': 'Melphalan + Bortezomib + Thalidomide + Dexamethasone'}]","UARK 2008-01, Total Therapy 4 - A Phase III Trial for Low Risk Myeloma",9538
2,NCT00903968,Phase Ib/II,Completed,"[{'id': 3348, 'therapyName': 'Bortezomib + Plerixafor'}]",Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma,9538
3,NCT00918333,Phase Ib/II,"Active, not recruiting","[{'id': 1964, 'therapyName': 'Panobinostat + Everolimus'}]","Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma",9538
4,NCT01146834,Phase III,Recruiting,"[{'id': 3345, 'therapyName': 'Bortezomib + Filgrastim'}, {'id': 5459, 'therapyName': 'Bortezomib + Cyclophosphamide + G-CSF'}, {'id': 5460, 'therapyName': 'Bortezomib + Cyclophosphamide'}]",Trial of Three Stem Cell Mobilization Regimens for Multiple Myeloma,9538
5,NCT01163357,Phase I,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 2288, 'therapyName': 'Bortezomib + Fludarabine + Melphalan'}]","Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma",9538
6,NCT01177397,Phase Ib/II,Completed,"[{'id': 693, 'therapyName': 'CC-223'}]","Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma",9538
7,NCT01177683,Phase Ib/II,"Active, not recruiting","[{'id': 3349, 'therapyName': 'Bendamustine + Bortezomib + pegylated liposomal-doxorubicin'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma,9538
8,NCT01208662,Phase III,Recruiting,"[{'id': 3342, 'therapyName': 'Bortezomib + Dexamethasone + lenalidomide'}]","Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65  (DFCI 10-106)",9538
9,NCT01239368,Phase I,Completed,[],Th1/Tc1 Immunotherapy Following Stem Cell Transplantation in Multiple Myeloma,9538
10,NCT01241708,Phase III,Recruiting,"[{'id': 688, 'therapyName': 'Bortezomib'}]",Tandem Auto Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma ((Mel/MelVel)),9538
11,NCT01251575,Phase II,Recruiting,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 2270, 'therapyName': 'Cyclosporine + Mycophenolate mofetil + Sirolimus'}]","Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant",9538
12,NCT01287546,Phase I,Completed,"[{'id': 1179, 'therapyName': 'Emibetuzumab + Erlotinib'}, {'id': 1180, 'therapyName': 'Emibetuzumab + Trametinib'}, {'id': 803, 'therapyName': 'Emibetuzumab'}]",A Study of LY2875358 in Participants With Advanced Cancer,9538
13,NCT01301807,Phase I,"Active, not recruiting","[{'id': 3438, 'therapyName': 'Carfilzomib + Panobinostat'}]",Carfilzomib Plus Panobinostat in Relapsed/Refractory Multiple Myeloma (MM),9538
14,NCT01313897,Phase II,Completed,"[{'id': 688, 'therapyName': 'Bortezomib'}]","UARK 2010-35, A Study of Expanded Natural Killer Cell Therapy for Multiple Myeloma (NK2010-35)",9538
15,NCT01323751,Phase Ib/II,Completed,"[{'id': 2470, 'therapyName': 'Bortezomib + Dexamethasone'}, {'id': 1613, 'therapyName': 'ACY-1215'}]",Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma,9538
16,NCT01326702,Phase Ib/II,Completed,"[{'id': 954, 'therapyName': 'Veliparib'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1231, 'therapyName': 'Bendamustine'}]"," Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors",9538
17,NCT01345019,Phase III,"Active, not recruiting","[{'id': 1198, 'therapyName': 'Denosumab'}, {'id': 2971, 'therapyName': 'Zoledronic acid'}]",Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma,9538
18,NCT01353625,Phase I,"Active, not recruiting","[{'id': 1000, 'therapyName': 'CC-115'}]","Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.",9538
19,NCT01421524,Phase I,Recruiting,"[{'id': 2358, 'therapyName': 'CC-122'}]","Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma",9538
20,NCT01428492,Phase I,Completed,"[{'id': 625, 'therapyName': 'Afuresertib'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]",Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma,9538
21,NCT01440582,Phase I,"Active, not recruiting","[{'id': 3362, 'therapyName': 'Bortezomib + Dexamethasone + lenalidomide + Panobinostat'}]",Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) Patients,9538
22,NCT01453088,Phase II,Recruiting,"[{'id': 1207, 'therapyName': 'Melphalan'}, {'id': 688, 'therapyName': 'Bortezomib'}]",Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older,9538
23,NCT01453101,Phase II,"Active, not recruiting","[{'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}, {'id': 688, 'therapyName': 'Bortezomib'}]",Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma,9538
24,NCT01456689,Phase I,"Active, not recruiting","[{'id': 2685, 'therapyName': 'Midazolam'}, {'id': 2402, 'therapyName': 'LGH447 '}]",A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma,9538
25,NCT01470131,Phase III,Unknown status,"[{'id': 804, 'therapyName': 'Masitinib'}, {'id': 2470, 'therapyName': 'Bortezomib + Dexamethasone'}]",A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma,9538
26,NCT01522872,Phase Ib/II,"Active, not recruiting","[{'id': 1317, 'therapyName': 'Evofosfamide'}, {'id': 688, 'therapyName': 'Bortezomib'}]",Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib in Subjects With Relapsed/Refractory Multiple Myeloma,9538
27,NCT01524978,Phase II,"Active, not recruiting","[{'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 694, 'therapyName': 'Cetuximab'}]",A Study of Zelboraf (Vemurafenib) in Patients With BRAF V600 Mutation-Positive Cancers,9538
28,NCT01526096,Phase I,Recruiting,"[{'id': 5985, 'therapyName': 'Basiliximab'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1756, 'therapyName': 'Plerixafor'}, {'id': 1207, 'therapyName': 'Melphalan'}]",Stem Cell Transplantation for Patients With Multiple Myeloma,9538
29,NCT01547806,Phase II,"Active, not recruiting","[{'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1756, 'therapyName': 'Plerixafor'}]",Collection of Transplant Stem Cells for Plasma Cell Myeloma,9538
30,NCT01582295,Phase I,Completed,"[{'id': 998, 'therapyName': 'cabozantinib'}]",XL184 For Relapsed/Refractory Multiple Myeloma (MM) With Bone Disease,9538
31,NCT01587703,Phase I,Recruiting,"[{'id': 784, 'therapyName': 'GSK525762'}]","A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers",9538
32,NCT01592370,Phase I,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 2583, 'therapyName': 'Lirilumab '}]",Safety Study in Nivolumab Alone and in Combination With Ipilimumab or Lirilumab in Lymphoma and Multiple Myeloma,9538
33,NCT01609816,Phase Ib/II,Recruiting,"[{'id': 717, 'therapyName': 'Dasatinib'}]","Dasatinib in Treating Patients With Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma Previously Treated With Autologous Stem Cell Transplant",9538
34,NCT01668719,Phase Ib/II,Recruiting,"[{'id': 3343, 'therapyName': 'Elotuzumab'}, {'id': 3342, 'therapyName': 'Bortezomib + Dexamethasone + lenalidomide'}]","S1211, Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma",9538
35,NCT01672736,Phase Ib/II,"Active, not recruiting","[{'id': 1831, 'therapyName': 'Linsitinib + Bortezomib + Dexamethasone'}]",A Trial of ASP7487 (OSI-906) in Combination With Bortezomib for the Treatment of Relapsed Multiple Myeloma,9538
36,NCT01689987,Phase I,Completed,"[{'id': 2385, 'therapyName': 'Sirolimus + Cyclophosphamide + Dexamethasone + Hydroxychloroquine'}]","Hydroxychloroquine, Cyclophosphamide, Dexamethasone, and Sirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma",9538
37,NCT01695330,Phase II,Terminated,"[{'id': 688, 'therapyName': 'Bortezomib'}]",Subcutaneous (SC) Bortezomib-Regimens for Patients With RR MM Failing Prior IV Bortezomib-Containing Regimens,9538
38,NCT01711528,Phase I,"Active, not recruiting","[{'id': 3437, 'therapyName': 'Bortezomib + Dexamethasone + Dinaciclib'}]","Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma",9538
39,NCT01723020,Phase I,Completed,"[{'id': 1452, 'therapyName': 'AMG 232'}]",A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma,9538
40,NCT01729091,Phase Ib/II,Recruiting,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 3343, 'therapyName': 'Elotuzumab'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1164, 'therapyName': 'lenalidomide'}]",Study of Umbilical Cord Blood-derived Natural Killer Cells in Conjunction With High Dose Chemotherapy and Autologous Stem Cell Transplant for Patients With Multiple Myeloma,9538
41,NCT01729338,Phase II,Terminated,"[{'id': 3358, 'therapyName': 'Bortezomib + Cyclophosphamide + lenalidomide'}]",Velcade + Cyclophosphamide in Newly Diagnosed Multiple Myeloma,9538
42,NCT01734928,Phase III,"Active, not recruiting","[{'id': 1622, 'therapyName': 'Pomalidomide'}, {'id': 2470, 'therapyName': 'Bortezomib + Dexamethasone'}]","Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma",9538
43,NCT01742988,Phase I,Recruiting,"[{'id': 709, 'therapyName': 'CUDC-907'}]","Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Patients With Lymphoma or Multiple Myeloma",9538
44,NCT01794507,Phase I,"Active, not recruiting","[{'id': 3436, 'therapyName': 'Bortezomib + Dexamethasone + GDC-0199\t'}]",A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy,9538
45,NCT01794520,Phase I,"Active, not recruiting","[{'id': 1562, 'therapyName': 'Venetoclax'}]",Study Evaluating ABT-199 in Subjects With Relapsed or Refractory Multiple Myeloma,9538
46,NCT01822509,Phase I,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant,9538
47,NCT01827137,Phase I,"Active, not recruiting","[{'id': 2893, 'therapyName': 'WT1 vaccine'}, {'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 1873, 'therapyName': 'Sargramostim'}]",WT1 Analog Peptide Vaccine in Patients With Multiple Myeloma Following Autologous Stem Cell Transplantation,9538
48,NCT01829971,Phase I,Terminated,"[{'id': 1035, 'therapyName': 'MRX34'}]","A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection",9538
49,NCT01849783,Phase II,Recruiting,"[{'id': 1852, 'therapyName': 'Melphalan + Bortezomib + Thalidomide + Dexamethasone'}, {'id': 3435, 'therapyName': 'Aldoxorubicin + Cisplatin + Cyclophosphamide + Dexamethasone + Etoposide'}]",Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma,9538
50,NCT01863550,Phase III,Recruiting,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 688, 'therapyName': 'Bortezomib'}]",Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma,9538
51,NCT01866293,Phase Ib/II,Completed,"[{'id': 998, 'therapyName': 'cabozantinib'}]",Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma,9538
52,NCT01889420,Phase I,Terminated,"[{'id': 2312, 'therapyName': 'Pomalidomide + Everolimus + Dexamethasone'}]","Phase I Trial of Everolimus, Pomalidomide and Dexamethasone Patients With Relapsed/Refractory Multiple Myeloma",9538
53,NCT01919086,Phase II,"Active, not recruiting","[{'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 2470, 'therapyName': 'Bortezomib + Dexamethasone'}]",Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma,9538
54,NCT01953692,Phase I,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013)(KEYNOTE-013),9538
55,NCT01954784,Phase I,Terminated,"[{'id': 3434, 'therapyName': 'Bortezomib + Cyclosporine + Mycophenolate'}, {'id': 1164, 'therapyName': 'lenalidomide'}]",Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple Myeloma,9538
56,NCT01955434,Phase II,Recruiting,"[{'id': 4019, 'therapyName': 'Cyclophosphamide + LCL161'}]",SMAC Mimetic LCL161 Alone or With Cyclophosphamide in Treating Patients With Relapsed or Refractory Multiple Myeloma,9538
57,NCT01962792,Phase Ib/II,Recruiting,"[{'id': 3282, 'therapyName': 'Carfilzomib + Ibrutinib'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]","Study of the Bruton's Tyrosine Kinase Inhibitor in Combination With Carfilzomib (Kyprolis), in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma",9538
58,NCT01965353,Phase I,"Active, not recruiting","[{'id': 3362, 'therapyName': 'Bortezomib + Dexamethasone + lenalidomide + Panobinostat'}]",A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma,9538
59,NCT01989598,Phase II,"Active, not recruiting","[{'id': 1298, 'therapyName': 'Trametinib + GSK2141795'}]",Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple Myeloma,9538
60,NCT01995708,Phase I,Recruiting,"[{'id': 2901, 'therapyName': 'WT1 senstized T cells'}]","CT7, MAGE-A3, and WT1 mRNA-electroporated Autologous Langerhans-type Dendritic Cells as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation",9538
61,NCT01997840,Phase Ib/II,"Active, not recruiting","[{'id': 1614, 'therapyName': 'ACY-1215 + Pomalidomide + Dexamethasone'}]",ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma,9538
62,NCT01998971,Phase I,Recruiting,"[{'id': 1622, 'therapyName': 'Pomalidomide'}, {'id': 2470, 'therapyName': 'Bortezomib + Dexamethasone'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1475, 'therapyName': 'Thalidomide'}, {'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1630, 'therapyName': 'Daratumumab'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 1275, 'therapyName': 'Diphenhydramine'}, {'id': 3323, 'therapyName': 'Montelukast'}]",A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma,9538
63,NCT02030483,Phase I,Terminated,"[{'id': 850, 'therapyName': 'Palbociclib'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1164, 'therapyName': 'lenalidomide'}]",Palbociclib in Combination With Lenalidomide and Dexamethasone for Multiple Myeloma,9538
64,NCT02034110,Phase II,Recruiting,"[{'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}]",Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers,9538
65,NCT02036502,Phase I,Recruiting,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 3322, 'therapyName': 'lenalidomide + Pembrolizumab'}]",A Study of Pembrolizumab (MK-3475) in Combination With Lenalidomide and Dexamethasone in Participants With Multiple Myeloma (MK-3475-023/KEYNOTE-023),9538
66,NCT02052778,Phase Ib/II,Recruiting,"[{'id': 1053, 'therapyName': 'TAS-120'}]",A Dose Finding Study Followed by a Safety and Efficacy Study in Patients With Advanced Solid Tumors or Multiple Myeloma With FGF/FGFR-Related Abnormalities,9538
67,NCT02057640,Phase Ib/II,"Active, not recruiting","[{'id': 4565, 'therapyName': 'Dexamethasone + Ixazomib + Panobinostat'}]",MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Multiple Myeloma,9538
68,NCT02061761,Phase Ib/II,Recruiting,"[{'id': 4197, 'therapyName': 'BMS-986016 + Nivolumab'}, {'id': 4196, 'therapyName': 'BMS-986016'}]",Safety Study of Anti-LAG-3 in Relapsed or Refractory Hematologic Malignancies,9538
69,NCT02077959,Phase Ib/II,"Active, not recruiting","[{'id': 3357, 'therapyName': 'lenalidomide + Pidilizumab'}]",Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma,9538
70,NCT02086552,Phase II,Recruiting,"[{'id': 4445, 'therapyName': 'lenalidomide + Sonidegib'}]",Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma,9538
71,NCT02098109,Phase II,Completed,"[{'id': 1756, 'therapyName': 'Plerixafor'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma,9538
72,NCT02099539,Phase Ib/II,Recruiting,"[{'id': 3060, 'therapyName': 'ALT-803'}]",A Study of ALT-803 in Patients With Relapsed or Refractory Multiple Myeloma,9538
73,NCT02101944,Phase I,Recruiting,"[{'id': 2463, 'therapyName': 'Carfilzomib + Dexamethasone + Reolysin'}]","Viral Protein Production After Dexamethasone, Wild-Type Reovirus, and Carfilzomib in Treating Patients With Multiple Myeloma",9538
74,NCT02104427,Phase II,Completed,"[{'id': 2853, 'therapyName': 'TG-0054'}, {'id': 1632, 'therapyName': 'Filgrastim'}]","PD and Safety of TG-0054 Combined With G-CSF in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients",9538
75,NCT02110563,Phase I,Terminated,"[{'id': 3122, 'therapyName': 'DCR-MYC'}]","Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma",9538
76,NCT02136134,Phase III,"Active, not recruiting","[{'id': 1630, 'therapyName': 'Daratumumab'}, {'id': 2470, 'therapyName': 'Bortezomib + Dexamethasone'}]",Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma,9538
77,NCT02140840,Phase II,Withdrawn,"[{'id': 2, 'therapyName': 'Trametinib'}]","A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered Trametinib",9538
78,NCT02144038,Phase Ib/II,Completed,"[{'id': 2419, 'therapyName': 'BYL719 + LGH447'}, {'id': 2402, 'therapyName': 'LGH447 '}]",Study of the Safety and Effectiveness of LGH447 and BYL719 in Patients With Relapsed and Refractory Multiple Myeloma,9538
79,NCT02157636,Phase I,Recruiting,"[{'id': 2033, 'therapyName': 'CPI-0610'}]",A Phase 1 Study Evaluating CPI-0610 in Patients With Previously Treated Multiple Myeloma,9538
80,NCT02159365,Phase II,"Active, not recruiting","[{'id': 3353, 'therapyName': 'Elotuzumab + Dexamethasone + Lenalidomide'}]",Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients,9538
81,NCT02186834,Phase Ib/II,"Active, not recruiting","[{'id': 3356, 'therapyName': 'Dexamethasone + pegylated liposomal-doxorubicin + Selinexor'}]",Selinexor (KPT-330) and Pegylated Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma,9538
82,NCT02188368,Phase II,Recruiting,"[{'id': 1625, 'therapyName': 'Bortezomib + Carfilzomib + Clarithromycin'}, {'id': 1674, 'therapyName': 'Doxil + Pomalidomide'}, {'id': 1622, 'therapyName': 'Pomalidomide'}]",Pomalidomide for Lenalidomide for Failures,9538
83,NCT02189343,Phase I,"Active, not recruiting","[{'id': 1614, 'therapyName': 'ACY-1215 + Pomalidomide + Dexamethasone'}]",Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed-and-Refractory Multiple Myeloma,9538
84,NCT02192775,Phase II,Recruiting,"[{'id': 6125, 'therapyName': 'MV-NIS'}]",UARK 2014-21 A Phase II Trial of Oncolytic Virotherapy by Systemic Administration of Edmonston Strain of Measles Virus,9538
85,NCT02195479,Phase III,Recruiting,"[{'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1630, 'therapyName': 'Daratumumab'}, {'id': 1207, 'therapyName': 'Melphalan'}]",A Study of Combination of Daratumumanb and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma,9538
86,NCT02199665,Phase I,"Active, not recruiting","[{'id': 2985, 'therapyName': 'Carfilzomib + Dexamethasone + Selinexor'}]","Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma",9538
87,NCT02204553,Phase I,No longer available,"[{'id': 1604, 'therapyName': 'Panobinostat + Bortezomib + Dexamethasone'}]",Expanded Treatment Prot of Panobinostat in Combo w/ Bortez and Dex in Pts w/ Relapsed and/or Refractory Multiple Myeloma,9538
88,NCT02211014,Phase I,"Active, not recruiting","[{'id': 1605, 'therapyName': 'Acalabrutinib'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]","An Open-Label, Phase 1b Study of ACP-196 With and Without Dexamethasone in Subjects With Multiple Myeloma",9538
89,NCT02220608,Phase I,Completed,"[{'id': 3345, 'therapyName': 'Bortezomib + Filgrastim'}]",Phase I Study of Bortezomib With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma,9538
90,NCT02223598,Phase I,Terminated,"[{'id': 1944, 'therapyName': 'CB-5083'}, {'id': 4513, 'therapyName': 'CB-5083 + Dexamethasone'}]",A Phase 1 Study Evaluating CB-5083 in Subjects With Lymphoid Hematological Malignancies  (CLC-102),9538
91,NCT02235740,Phase I,Terminated,"[{'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 1839, 'therapyName': 'Afuresertib + Carfilzomib'}]","A Study Conducted in Subjects With Relapsed/Refractory Multiple Myeloma (MM); to Determine Dose of Afuresertib in Combination With Carfilzomib (Part 1) and to Investigate the Safety, Pharmacokinetic and Clinical Activity of the Combination Compared With Carfilzomib Alone (Part 2)",9538
92,NCT02252263,Phase I,"Active, not recruiting","[{'id': 2055, 'therapyName': 'Urelumab'}, {'id': 2583, 'therapyName': 'Lirilumab '}, {'id': 3343, 'therapyName': 'Elotuzumab'}]",A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma,9538
93,NCT02254551,Phase II,Terminated,"[{'id': 1954, 'therapyName': 'Bortezomib + Sonidegib'}]",Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma,9538
94,NCT02289222,Phase Ib/II,"Active, not recruiting","[{'id': 3344, 'therapyName': 'Dexamethasone + Pembrolizumab + Pomalidomide'}]",Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma,9538
95,NCT02308280,Phase II,Recruiting,"[{'id': 688, 'therapyName': 'Bortezomib'}]",Nonmyeloablative Allogeneic Stem Cell Transplant Followed by Bortezomib in High-risk Multiple Myeloma Patients,9538
96,NCT02328014,Phase Ib/II,Recruiting,"[{'id': 3265, 'therapyName': 'ACP-319'}, {'id': 1605, 'therapyName': 'Acalabrutinib'}]","ACP-196 in Combination With ACP-319, for Treatment of B-Cell Malignancies",9538
97,NCT02331368,Phase II,"Active, not recruiting","[{'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma,9538
98,NCT02332850,,Recruiting,"[{'id': 1624, 'therapyName': 'Carfilzomib'}]",SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma,9538
99,NCT02336815,Phase II,Recruiting,"[{'id': 2479, 'therapyName': 'Dexamethasone + Selinexor'}]",Phase 2b Open-Label Single-Arm Selinexor (KPT-330) + Low-Dose Dexamethasone in Patients w/ Multiple Myeloma Quad-refractory to Previous Therapies,9538
100,NCT02343042,Phase Ib/II,Recruiting,"[{'id': 688, 'therapyName': 'Bortezomib'}, {'id': 2479, 'therapyName': 'Dexamethasone + Selinexor'}, {'id': 1622, 'therapyName': 'Pomalidomide'}]",Phase 1b/2 Study of Selinexor (KPT-330) in Combination w/ Backbone Treatments for Resistant/Refractory Multiple Myeloma,9538
101,NCT02356159,Phase Ib/II,Recruiting,"[{'id': 2294, 'therapyName': 'Cytarabine + Fludarabine'}, {'id': 2373, 'therapyName': 'Palifermin'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2238, 'therapyName': 'Sirolimus + Tacrolimus + Methotrexate'}, {'id': 2292, 'therapyName': 'Doxorubicin + Etoposide + Fludarabine + Vincristine '}, {'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 897, 'therapyName': 'Rituximab'}]",Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation,9538
102,NCT02368301,Phase I,Approved for marketing,"[{'id': 3353, 'therapyName': 'Elotuzumab + Dexamethasone + Lenalidomide'}]",Expanded Access Treatment Protocol CA204-143,9538
103,NCT02372240,Phase Ib/II,Suspended,"[{'id': 5099, 'therapyName': 'VLX1570 + Dexamethasone'}]",A Study of VLX1570 and Dexamethasone in Myeloma Patients,9538
104,NCT02375555,Phase II,"Active, not recruiting","[{'id': 3343, 'therapyName': 'Elotuzumab'}, {'id': 3342, 'therapyName': 'Bortezomib + Dexamethasone + lenalidomide'}]","Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM",9538
105,NCT02391480,Phase I,Recruiting,"[{'id': 4028, 'therapyName': 'ABBV-075'}]",A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer,9538
106,NCT02393248,Phase Ib/II,Recruiting,"[{'id': 4176, 'therapyName': 'Cisplatin + Gemcitabine + INCB054828'}, {'id': 4174, 'therapyName': 'Docetaxel + INCB054828'}, {'id': 4088, 'therapyName': 'Epacadostat + Pembrolizumab'}]","Open-Label, Dose-Escalation Study of INCB054828 in Subjects With Advanced Malignancies",9538
107,NCT02400242,Phase I,"Active, not recruiting","[{'id': 3311, 'therapyName': 'Citarinostat'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1622, 'therapyName': 'Pomalidomide'}]",Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma,9538
108,NCT02401295,Phase I,Completed,"[{'id': 3433, 'therapyName': 'Celecoxib + Itraconazole + Tretinoin '}]","ATRA, Celecoxib, and Itraconazole as Maintenance",9538
109,NCT02426723,Phase I,Recruiting,"[{'id': 3081, 'therapyName': 'CWP232291'}, {'id': 4036, 'therapyName': 'Dexamethasone + lenalidomide'}]",Clinical Study of CWP232291 in Relapsed or Refractory Myeloma Patients,9538
110,NCT02431208,Phase I,Suspended,"[{'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study of Atezolizumab (Anti-Programmed Death Ligand 1 [PD-L1] Antibody) Administered With or Without Lenalidomide in Participants With Multiple Myeloma (MM),9538
111,NCT02440464,Phase II,Recruiting,"[{'id': 3321, 'therapyName': 'Tacrolimus + Methotrexate'}, {'id': 1359, 'therapyName': 'Ixazomib'}, {'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}, {'id': 688, 'therapyName': 'Bortezomib'}]",Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302),9538
112,NCT02441686,Phase II,"Active, not recruiting","[{'id': 3342, 'therapyName': 'Bortezomib + Dexamethasone + lenalidomide'}]","Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma",9538
113,NCT02465060,Phase II,Recruiting,"[{'id': 660, 'therapyName': 'Osimertinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 654, 'therapyName': 'AZD4547'}, {'id': 958, 'therapyName': 'VS-6063'}, {'id': 765, 'therapyName': 'GSK2636771'}]",NCI-MATCH Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,9538
114,NCT02477878,Phase I,Recruiting,"[{'id': 5995, 'therapyName': 'BPX-601'}, {'id': 5992, 'therapyName': 'Rimiducid'}]",Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant,9538
115,NCT02514382,Phase I,Recruiting,"[{'id': 3432, 'therapyName': 'Bortezomib + Dexamethasone + Reolysin'}]","Wild-Type Reovirus, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma",9538
116,NCT02548962,Phase Ib/II,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 3792, 'therapyName': 'Dexamethasone + Pomalidomide'}]",Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma,9538
117,NCT02568943,Phase I,Available,"[{'id': 1604, 'therapyName': 'Panobinostat + Bortezomib + Dexamethasone'}]","An Expanded Treatment Protocol of Panobinostat in Combination Therapy for Relapsed, and Relapsed and Refractory Multiple Myeloma",9538
118,NCT02569320,Phase I,Suspended,"[{'id': 4299, 'therapyName': 'AR-42 + Dexamethasone + Pomalidomide'}]",HDAC Inhibitor AR-42 and Pomalidomide in Treating Patients With Relapsed Multiple Myeloma,9538
119,NCT02576496,Phase I,Recruiting,"[{'id': 6104, 'therapyName': 'EDO-S101'}]","Study of EDO-S101, A First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies",9538
120,NCT02576977,Phase III,Suspended,"[{'id': 1622, 'therapyName': 'Pomalidomide'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]",Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK-3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (MK-3475-183/KEYNOTE-183),9538
121,NCT02579824,Phase I,Recruiting,"[{'id': 2079, 'therapyName': 'DS-3032b'}]",DS-3032b for Relapsed and/or Refractory (RR) Myeloma,9538
122,NCT02579863,Phase III,Suspended,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1164, 'therapyName': 'lenalidomide'}]",Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185),9538
123,NCT02603887,Phase I,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab for Smoldering Multiple Myeloma (SMM),9538
124,NCT02605356,Phase Ib/II,Withdrawn,"[{'id': 2001, 'therapyName': 'radium Ra 223 dichloride'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]",Phase 1b/2 Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in Relapsed Multiple Myeloma,9538
125,NCT02612779,Phase II,"Active, not recruiting","[{'id': 3355, 'therapyName': 'Elotuzumab + Dexamethasone + Pomalidomide'}]",A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone (EPd) in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide,9538
126,NCT02616640,Phase I,"Active, not recruiting","[{'id': 1622, 'therapyName': 'Pomalidomide'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma,9538
127,NCT02628704,Phase II,Withdrawn,"[{'id': 2985, 'therapyName': 'Carfilzomib + Dexamethasone + Selinexor'}]","Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma",9538
128,NCT02633059,Phase Ib/II,Recruiting,"[{'id': 4392, 'therapyName': 'Dexamethasone + Idasanutlin + Ixazomib'}]","Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma",9538
129,NCT02649790,Phase Ib/II,Recruiting,"[{'id': 5687, 'therapyName': 'KPT-8602'}]","Study of the Safety, Tolerability and Efficacy of KPT-8602 in Patients With Relapsed/Refractory Multiple Myeloma",9538
130,NCT02654132,Phase II,"Active, not recruiting","[{'id': 3792, 'therapyName': 'Dexamethasone + Pomalidomide'}, {'id': 3343, 'therapyName': 'Elotuzumab'}]",Trial of Elotuzumab With or Without Pomalidomide and Low-dose Dexamethasone to Treat Refractory and Relapsed and Refractory Multiple Myeloma,9538
131,NCT02654990,Phase II,Recruiting,"[{'id': 1604, 'therapyName': 'Panobinostat + Bortezomib + Dexamethasone'}]",Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma,9538
132,NCT02655458,Phase I,Completed,"[{'id': 3430, 'therapyName': 'Elotuzumab + lenalidomide'}]",Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple Myeloma,9538
133,NCT02658396,Phase I,Withdrawn,"[{'id': 3427, 'therapyName': 'Bortezomib + GO-203-2C'}]",GO-203-2C + Bortezomib For Relapsed Or Refractory MM,9538
134,NCT02658929,Phase I,Recruiting,"[{'id': 5278, 'therapyName': 'bb2121'}]",Study of bb2121 in Multiple Myeloma,9538
135,NCT02666209,Phase I,No longer available,"[{'id': 3556, 'therapyName': 'Bortezomib + Dexamethasone + Ulocuplumab'}, {'id': 3555, 'therapyName': 'Dexamethasone + lenalidomide + Ulocuplumab'}]",Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma,9538
136,NCT02681302,Phase Ib/II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study of Combined Check Point Inhibition After Autologous Hematopoietic Stem Cell Transplantation in Patients at High Risk for Post-transplant Recurrence (CPIT001),9538
137,NCT02684617,Phase I,Recruiting,"[{'id': 4225, 'therapyName': 'Dinaciclib + Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies  (MK-3475-155) (KEYNOTE-155),9538
138,NCT02685826,Phase I,Suspended,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 3934, 'therapyName': 'lenalidomide + MEDI4736'}]",A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Subjects With Newly Diagnosed Multiple Myeloma,9538
139,NCT02693535,Phase II,Recruiting,"[{'id': 1657, 'therapyName': 'Vemurafenib + Cobimetinib'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 690, 'therapyName': 'Bosutinib'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 4, 'therapyName': 'Erlotinib'}]",TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer,9538
140,NCT02700841,Phase II,Recruiting,"[{'id': 5344, 'therapyName': 'Melphalan + PVX-410'}]",Enhancing Anti-Myeloma Vaccine Response After Autologous Stem Cell Transplantation,9538
141,NCT02703779,Phase II,Recruiting,"[{'id': 688, 'therapyName': 'Bortezomib'}, {'id': 3933, 'therapyName': 'Filgrastim + Plerixafor'}]",Exploratory Trial to Estimate Proportion of Patients With Tumor Cell Contaminated Leukapheresis Products With and Without Bortezomib With In-vivo Purging - Multiple Myeloma (MM),9538
142,NCT02716805,Phase I,"Active, not recruiting","[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]","Phase 1 Study to Assess Safety & Tolerability of Tremelimumab & Durvalumab, Administered With High Dose Chemotherapy and Autologous Stem Cell Transplant",9538
143,NCT02718833,Phase II,Recruiting,"[{'id': 4031, 'therapyName': 'Bortezomib + Dexamethasone + Elotuzumab + Panobinostat'}]","A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma",9538
144,NCT02719613,Phase II,Recruiting,"[{'id': 4533, 'therapyName': 'Bortezomib + Elotuzumab + Dexamethasone + lenalidomide'}]",Continuing Treatment for Subjects Who Have Participated in a Prior Protocol Investigating Elotuzumab,9538
145,NCT02720510,Phase II,Recruiting,"[{'id': 1080, 'therapyName': 'Panobinostat'}, {'id': 3342, 'therapyName': 'Bortezomib + Dexamethasone + lenalidomide'}]","A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM)",9538
146,NCT02722668,Phase II,Recruiting,"[{'id': 2281, 'therapyName': 'Cyclophosphamide + Fludarabine + Mycophenolate mofetil'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}]",UCB Transplant for Hematological DIseases Using a Non Myeloablative Prep,9538
147,NCT02722941,Phase II,Recruiting,"[{'id': 1080, 'therapyName': 'Panobinostat'}]",Panobinostat (LBH589): Multiple Myeloma - Autologous Hematopoietic Cell Transplantation (HCT),9538
148,NCT02726581,Phase III,"Active, not recruiting","[{'id': 3343, 'therapyName': 'Elotuzumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 3792, 'therapyName': 'Dexamethasone + Pomalidomide'}]","Study of Combinations of Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone in Multiple Myeloma",9538
149,NCT02755597,Phase III,Recruiting,"[{'id': 2470, 'therapyName': 'Bortezomib + Dexamethasone'}, {'id': 3436, 'therapyName': 'Bortezomib + Dexamethasone + GDC-0199\t'}]",A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy,9538
150,NCT02757326,Phase Ib/II,Recruiting,"[{'id': 3301, 'therapyName': 'ABC294640'}]",ABC294640 in Refractory / Relapsed Multiple Myeloma,9538
151,NCT02780609,Phase Ib/II,Recruiting,"[{'id': 4221, 'therapyName': 'Dexamethasone + Melphalan + Selinexor'}]",Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma,9538
152,NCT02784483,Phase I,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}]","Pilot Study Of Anti-Programmed Death Ligand-1 (Anti-PD-L1, Atezolizumab) In Asymptomatic Myeloma",9538
153,NCT02786485,Phase I,Not yet recruiting,"[{'id': 5992, 'therapyName': 'Rimiducid'}, {'id': 6053, 'therapyName': 'BPX-501'}]",Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT,9538
154,NCT02802163,Phase Ib/II,Withdrawn,"[{'id': 4367, 'therapyName': 'Carfilzomib + Dexamethasone + lenalidomide + Panobinostat'}]","Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,Panobinostat",9538
155,NCT02807454,Phase Ib/II,"Active, not recruiting","[{'id': 4531, 'therapyName': 'Daratumumab + Dexamethasone + MEDI4736 + Pomalidomide'}, {'id': 4530, 'therapyName': 'Daratumumab + MEDI4736'}]",A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma (FUSIONMM-003),9538
156,NCT02831686,Phase I,Recruiting,"[{'id': 4500, 'therapyName': 'Dexamethasone + Ixazomib + Selinexor'}]","A Study to Test the Combination of Selinexor (KPT-330), Ixazomib, and Dexamethasone in Patients With Myeloma",9538
157,NCT02833610,Phase II,Recruiting,"[{'id': 1198, 'therapyName': 'Denosumab'}]",A Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency,9538
158,NCT02863991,Phase II,Recruiting,"[{'id': 1687, 'therapyName': 'ONC201'}]",Oral ONC201 in Relapsed/Refractory Multiple Myeloma,9538
159,NCT02874742,Phase II,Recruiting,"[{'id': 1630, 'therapyName': 'Daratumumab'}, {'id': 3342, 'therapyName': 'Bortezomib + Dexamethasone + lenalidomide'}]","Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma",9538
160,NCT02880228,Phase II,"Active, not recruiting","[{'id': 4612, 'therapyName': 'Dexamethasone + lenalidomide + Pembrolizumab'}]","Pembrolizumab, Lenalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Eligible for Stem Cell Transplant",9538
161,NCT02899052,Phase II,Recruiting,"[{'id': 5268, 'therapyName': 'Carfilzomib + Dexamethasone + Venetoclax'}]",Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (MM),9538
162,NCT02906332,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]",Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM),9538
163,NCT02928029,Phase Ib/II,Recruiting,"[{'id': 6161, 'therapyName': 'Bortezomib + Dexamethasone + radium Ra 223 dichloride'}]",Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma,9538
164,NCT02943473,Phase II,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients,9538
165,NCT02948283,Phase 0,Recruiting,"[{'id': 4919, 'therapyName': 'Metformin + Ritonavir'}]",Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia,9538
166,NCT02951819,Phase II,Recruiting,"[{'id': 4951, 'therapyName': 'Bortezomib + Cyclophosphamide + Daratumumab + Dexamethasone'}]",A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma,9538
167,NCT02952573,Phase II,Recruiting,"[{'id': 4950, 'therapyName': 'Dexamethasone + JNJ-42756493'}]",Testing JNJ-42756493 In Combination With Dexamethasone in Multiple Myeloma That Came Back After a Period of Improvement,9538
168,NCT02978235,Phase Ib/II,Recruiting,"[{'id': 5897, 'therapyName': 'TAS4464'}]",A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma,9538
169,NCT02992483,Phase I,Recruiting,"[{'id': 5814, 'therapyName': 'MIK665'}]","Phase I Study of MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple Myeloma",9538
170,NCT03000452,Phase II,"Active, not recruiting","[{'id': 4530, 'therapyName': 'Daratumumab + MEDI4736'}]",A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION-MM-005),9538
171,NCT03004287,Phase II,Recruiting,"[{'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1630, 'therapyName': 'Daratumumab'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1475, 'therapyName': 'Thalidomide'}]",2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy,9538
172,NCT03015792,Phase Ib/II,Recruiting,"[{'id': 5240, 'therapyName': 'Ibrutinib + Lenalidomide + Dexamethasone'}]","Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for Transplant",9538
173,NCT03018405,Phase I,Recruiting,"[{'id': 5998, 'therapyName': 'NKR-2 cells'}]",A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications (THINK),9538
174,NCT03030261,Phase II,Not yet recruiting,"[{'id': 1207, 'therapyName': 'Melphalan'}, {'id': 3355, 'therapyName': 'Elotuzumab + Dexamethasone + Pomalidomide'}]","Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma",9538
175,NCT03068351,Phase I,Recruiting,"[{'id': 937, 'therapyName': 'TEN-010'}, {'id': 5957, 'therapyName': 'Daratumumab + TEN-010'}]",Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma,9538
176,NCT03091257,Phase I,Recruiting,"[{'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 2, 'therapyName': 'Trametinib'}]",A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma,9538
177,NCT03104270,Phase II,Recruiting,"[{'id': 5555, 'therapyName': 'Carfilzomib + Elotuzumab + Dexamethasone + Pomalidomide'}]",Combination Study for High Risk Multiple Myeloma Patients,9538
178,NCT03106428,Phase I,Recruiting,"[{'id': 5762, 'therapyName': 'MEDI7247'}]",A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies,9538
179,NCT03110562,Phase III,Recruiting,"[{'id': 5639, 'therapyName': 'Selinexor + Bortezomib + Dexamethasone'}, {'id': 2470, 'therapyName': 'Bortezomib + Dexamethasone'}]","Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma (BOSTON)",9538
180,NCT03110822,Phase I,Recruiting,"[{'id': 5550, 'therapyName': 'Methylprednisolone + Lenalidomide + Ruxolitinib'}]","A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients",9538
181,NCT03111992,Phase I,Recruiting,"[{'id': 5311, 'therapyName': 'PDR001 + LCL161'}, {'id': 5397, 'therapyName': 'PDR001 + CJM112'}, {'id': 2659, 'therapyName': 'PDR001'}]","Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma",9538
182,NCT03143985,Phase I,Recruiting,"[{'id': 5875, 'therapyName': 'Pomalidomide + TEW 7197'}]",TEW-7197 in Combination w/ Pomalidomide in Relapsed or Relapsed and Refractory Multiple Myeloma,9538
183,NCT03145181,Phase I,Recruiting,"[{'id': 5708, 'therapyName': 'JNJ-64007957'}]","Dose Escalation Study of JNJ-64007957, a Humanized BCMA CD3 DuoBody® Antibody, in Participants With Relapsed or Refractory Multiple Myeloma",9538
184,NCT03168100,Phase II,Recruiting,"[{'id': 3342, 'therapyName': 'Bortezomib + Dexamethasone + lenalidomide'}, {'id': 3353, 'therapyName': 'Elotuzumab + Dexamethasone + Lenalidomide'}]","2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 (Anti-SLAMF7) Monoclonal Antibody (mAb) Therapy After Autologous Stem Cell Transplant in Patients With Multiple Myeloma",9538
185,NCT03168438,Phase I,Recruiting,"[{'id': 5877, 'therapyName': 'NY-ESO-1-c259T'}, {'id': 5878, 'therapyName': 'NY-ESO-1-c259T + Pembrolizumab'}]",NY-ESO-1-c259T Alone and in Combination With Pembrolizumab for Multiple Myeloma,9538
186,NCT03194867,Phase Ib/II,Not yet recruiting,"[{'id': 6335, 'therapyName': 'Isatuximab + REGN2810'}]",Isatuximab in Combination With REGN2810 in Relapsed/Refractory Multiple Myeloma (RRMM) Patients,9538
187,NCT03201250,Phase Ib/II,Not yet recruiting,"[{'id': 6330, 'therapyName': 'Cabozantinib + Carfilzomib + Dexamethasone'}]",Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple Myeloma,9538
188,NCT03221634,Phase II,Not yet recruiting,"[{'id': 6115, 'therapyName': 'Daratumumab + Pembrolizumab'}]",Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668),9538
189,NCT03227432,Phase II,Not yet recruiting,"[{'id': 6118, 'therapyName': 'Dexamethasone + Elotuzumab + Nivolumab + Pomalidomide'}, {'id': 6117, 'therapyName': 'Elotuzumab + Nivolumab'}]",An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma,9538
190,NCT03256045,Phase II,Not yet recruiting,"[{'id': 6289, 'therapyName': 'Carfilzomib + Dexamethasone + Panobinostat'}]","Panobinostat, Carfilzomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma",9538
191,NCT03267888,Phase I,Not yet recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma,9538
192,NCT03288493,Phase I,Recruiting,"[{'id': 6280, 'therapyName': 'P-BCMA-101 CAR-T cells'}]",P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM),9538
193,NCT03315026,,Not yet recruiting,"[{'id': 3485, 'therapyName': 'siltuximab'}]",Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis,9538
0,NCT01330966,Phase II,"Active, not recruiting","[{'id': 848, 'therapyName': 'Pazopanib'}]",Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma,60100
0,NCT01976585,Phase Ib/II,Recruiting,"[{'id': 4337, 'therapyName': 'CDX-301 + poly ICLC '}]",In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy,8691
1,NCT02542124,Phase II,Recruiting,"[{'id': 5262, 'therapyName': 'Interleukin-12'}]",NM-IL-12 in Cutaneous T-Cell Lymphoma (CTCL) Undergoing Total Skin Electron Beam Therapy (TSEBT),8691
2,NCT02890368,Phase I,Recruiting,"[{'id': 5338, 'therapyName': 'TTI-621'}]",Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides,8691
3,NCT02978625,Phase II,Recruiting,"[{'id': 5080, 'therapyName': 'Talimogene laherparepvec + Nivolumab'}]",Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers,8691
4,NCT03011814,Phase Ib/II,"Active, not recruiting","[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 3934, 'therapyName': 'lenalidomide + MEDI4736'}]",Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma,8691
5,NCT03063632,Phase II,Recruiting,"[{'id': 5367, 'therapyName': 'Pembrolizumab + interferon gamma'}]",Pembrolizumab and Interferon Gamma-1b in Treating Patients With Stage IB-IVB Relapsed or Refractory Mycosis Fungoides and Sezary Syndrome,8691
6,NCT03075553,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma,8691
0,NCT01804101,Phase I,"Active, not recruiting","[{'id': 4341, 'therapyName': 'CPX-351'}]",Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia,50908
1,NCT01822509,Phase I,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant,50908
2,NCT01898793,Phase Ib/II,Recruiting,"[{'id': 3409, 'therapyName': 'Aldesleukin + Cyclophosphamide + Fludarabine '}, {'id': 5300, 'therapyName': 'ALT-803 + Cyclophosphamide + Fludarabine phosphate'}]",Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS),50908
3,NCT02019069,Phase II,Recruiting,"[{'id': 4341, 'therapyName': 'CPX-351'}]",CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome,50908
4,NCT02117219,Phase I,Recruiting,"[{'id': 4178, 'therapyName': 'Azacitidine + MEDI4736'}]",Phase 1 Study to Evaluate MEDI4736 in MDS,50908
5,NCT02117297,Phase II,Recruiting,"[{'id': 756, 'therapyName': 'Gemtuzumab ozogamicin'}]",SCT Plus Immune Therapy in Average Risk AML/MDS,50908
6,NCT02221310,Phase II,Recruiting,"[{'id': 3932, 'therapyName': 'Busulfan + Cyclophosphamide + Gemtuzumab ozogamicin'}]",Immunochemotherapy and AlloSCT in Patients With High Risk CD33+ AML/MDS,50908
7,NCT02228525,Phase II,Recruiting,"[{'id': 1749, 'therapyName': 'Selinexor'}]",Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Myelodysplastic Syndromes,50908
8,NCT02240706,Phase II,Recruiting,"[{'id': 5537, 'therapyName': 'BI 836858'}]",Phase I/II Trial to Investigate BI 836858 in Myelodysplastic Syndromes,50908
9,NCT02269579,Phase II,Recruiting,"[{'id': 4341, 'therapyName': 'CPX-351'}]",Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment,50908
10,NCT02273102,Phase I,Recruiting,"[{'id': 6126, 'therapyName': 'Tranylcypromine + Tretinoin '}]",Phase 1 Study of TCP-ATRA for Adult Patients With AML and MDS (TCP-ATRA),50908
11,NCT02281084,Phase II,Recruiting,"[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 4178, 'therapyName': 'Azacitidine + MEDI4736'}]",Safety and Efficacy Study of CC-486 and Durvalumab in Subjects With Myelodysplastic Syndromes,50908
12,NCT02367456,Phase Ib/II,Recruiting,"[{'id': 4177, 'therapyName': 'Azacitidine + PF-04449913'}]","A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In 1st Line MDS, AML and CMML Patients",50908
13,NCT02462252,Phase II,Recruiting,"[{'id': 4411, 'therapyName': 'anti-thymocyte globulin + BKT140 + Cyclosporine + Methylprednisolone'}]","Phase IIA Open Label Study to Evaluate Efficacy and Safety of BL-8040 Followed by (hATG), Cyclosporine and Methyprednisolone in Adult Subjects With Aplastic Anemia or Hypoplastic Myelodysplastic Syndrome",50908
14,NCT02472145,Phase III,"Active, not recruiting","[{'id': 650, 'therapyName': 'Decitabine'}, {'id': 5909, 'therapyName': 'Decitabine + Talacotuzumab'}]",An Efficacy and Safety Study of Decitabine (DACOGEN) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus Decitabine (DACOGEN) Alone in Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy,50908
15,NCT02477878,Phase I,Recruiting,"[{'id': 5995, 'therapyName': 'BPX-601'}, {'id': 5992, 'therapyName': 'Rimiducid'}]",Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant,50908
16,NCT02487459,Phase I,Not yet recruiting,"[{'id': 6053, 'therapyName': 'BPX-501'}, {'id': 5992, 'therapyName': 'Rimiducid'}]",Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies,50908
17,NCT02498665,Phase I,Recruiting,"[{'id': 4320, 'therapyName': 'DSP-7888'}]",A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies,50908
18,NCT02508870,Phase I,Recruiting,"[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]","A Safety and Pharmacology Study of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) Administered Alone or in Combination With Azacitidine in Patients With Myelodysplastic Syndromes",50908
19,NCT02530463,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Nivolumab and Ipilimumab With 5-azacitidine in Patients With Myelodysplastic Syndromes (MDS),50908
20,NCT02553941,Phase I,Recruiting,"[{'id': 3632, 'therapyName': 'Azacitidine + Ibrutinib'}]",Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome,50908
21,NCT02556931,Phase II,Recruiting,"[{'id': 4228, 'therapyName': 'Cyclophosphamide + Fludarabine + Melphalan + Tacrolimus'}]","Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies",50908
22,NCT02562443,Phase III,Recruiting,"[{'id': 1046, 'therapyName': 'rigosertib'}]",Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA (INSPIRE),50908
23,NCT02564536,Phase I,Withdrawn,"[{'id': 3177, 'therapyName': 'Pacritinib + Decitabine'}]",Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS),50908
24,NCT02576301,Phase Ib/II,Recruiting,"[{'id': 3524, 'therapyName': 'OXi4503'}, {'id': 3887, 'therapyName': 'Cytarabine + OXi4503'}]",Dose Escalation of OXi4503 as Single Agent and Combination With Cytarabine w/Subsequent Ph 2 Cohorts for AML and MDS,50908
25,NCT02598661,Phase III,Recruiting,"[{'id': 3710, 'therapyName': 'Imetelstat'}]",Study to Evaluate Imetelstat (JNJ-63935937) in Subjects With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS),50908
26,NCT02610777,Phase II,"Active, not recruiting","[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 1688, 'therapyName': 'MLN4924'}]","An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)",50908
27,NCT02666950,Phase II,Recruiting,"[{'id': 822, 'therapyName': 'MK-1775'}, {'id': 712, 'therapyName': 'Cytarabine'}]",WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome,50908
28,NCT02676323,Phase Ib/II,Recruiting,"[{'id': 3732, 'therapyName': 'Cytarabine + Fludarabine + Leucovorin + Panobinostat'}]",Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome,50908
29,NCT02677922,Phase Ib/II,Recruiting,"[{'id': 4002, 'therapyName': 'AG-120 + Azacitidine'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 4003, 'therapyName': 'Azacitidine + Enasidenib'}]",A Safety and Efficacy Study of Oral AG-120 Plus Subcutaneous Azacitidine and Oral AG-221 Plus Subcutaneous Azacitidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML),50908
30,NCT02684162,Phase II,Recruiting,"[{'id': 1949, 'therapyName': 'SGI-110'}]",SGI-110 With Donor Lymphocyte Infusion (DLI) for Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing Post Allogeneic Stem Cell Transplantation (AlloSCT),50908
31,NCT02719574,Phase I,Recruiting,"[{'id': 4336, 'therapyName': 'FT-2102'}, {'id': 4449, 'therapyName': 'FT-2102 + Azacitidine'}]",Dose-Escalation Study of FT-2102 as a Single Agent and in Combination With Azacitidine in Patients With AML or MDS With an IDH1 Mutation,50908
32,NCT02721875,Phase I,Terminated,"[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 957, 'therapyName': 'Volasertib'}]",Trial of Volasertib With or Without Azacitidine in Patients With Myelodysplastic Syndromes,50908
33,NCT02722668,Phase II,Recruiting,"[{'id': 2281, 'therapyName': 'Cyclophosphamide + Fludarabine + Mycophenolate mofetil'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}]",UCB Transplant for Hematological DIseases Using a Non Myeloablative Prep,50908
34,NCT02728050,Phase Ib/II,Recruiting,"[{'id': 920, 'therapyName': 'Sorafenib'}, {'id': 4363, 'therapyName': 'Cladribine + Cytarabine + Filgrastim + Mitoxantrone'}]","Filgrastim, Cladribine, Cytarabine and Mitoxantrone With or Without Sorafenib Tosylate in Treating Patients With Newly-Diagnosed, High-Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome",50908
35,NCT02743611,Phase I,Recruiting,"[{'id': 5992, 'therapyName': 'Rimiducid'}, {'id': 5991, 'therapyName': 'BPX-701'}]",Dose Finding Study Evaluating Safety and Feasibility in Patients With Relapsed or Refractory Myeloid Neoplasms,50908
36,NCT02756572,Phase I,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 5215, 'therapyName': 'mitoxantrone hydrochloride'}, {'id': 1166, 'therapyName': 'Fludarabine'}]",Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myelodysplastic Syndrome or Acute Myeloid Leukemia,50908
37,NCT02775903,Phase II,Recruiting,"[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 4178, 'therapyName': 'Azacitidine + MEDI4736'}]",An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Subjects With Acute Myeloid Leukemia (AML),50908
38,NCT02779777,Phase II,Recruiting,"[{'id': 938, 'therapyName': 'Tipifarnib'}]","Tipifarnib in Subjects With Transfusion-dependent, Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes",50908
39,NCT02786485,Phase I,Not yet recruiting,"[{'id': 5992, 'therapyName': 'Rimiducid'}, {'id': 6053, 'therapyName': 'BPX-501'}]",Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT,50908
40,NCT02790515,Phase II,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1876, 'therapyName': 'Blinatumomab '}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 5682, 'therapyName': 'Mesna'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Provision of TCR?? T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation,50908
41,NCT02793544,Phase II,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 5682, 'therapyName': 'Mesna'}, {'id': 1166, 'therapyName': 'Fludarabine'}]",HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide,50908
42,NCT02829840,Phase Ib/II,Withdrawn,"[{'id': 4464, 'therapyName': 'Azacitidine + Ponatinib'}]","Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML)",50908
43,NCT02890329,Phase I,Recruiting,"[{'id': 5738, 'therapyName': 'Decitabine + Ipilimumab'}]",Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia,50908
44,NCT02907359,Phase III,Recruiting,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1949, 'therapyName': 'SGI-110'}]",Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs,50908
45,NCT02909972,Phase I,Recruiting,"[{'id': 4755, 'therapyName': 'ALRN-6924 + Cytarabine'}, {'id': 2273, 'therapyName': 'ALRN-6924'}]",Safety Study of ALRN-6924 in Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome,50908
46,NCT02935361,Phase Ib/II,Recruiting,"[{'id': 4693, 'therapyName': 'Atezolizumab + SGI-110'}]",Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed,50908
47,NCT02936752,Phase I,Recruiting,"[{'id': 3354, 'therapyName': 'Entinostat + Pembrolizumab'}]",Entinostat and Pembrolizumab in Treating Patients With Myelodysplastic Syndrome After DNMTi Therapy Failure,50908
48,NCT02942290,Phase II,Recruiting,"[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 1637, 'therapyName': 'GDC-0199 + Azacitidine'}]",A Study Evaluating Venetoclax in Combination With Azacitidine Compared With Azacitidine Alone in Participants With Previously Untreated Higher-Risk Myelodysplastic Syndromes (MDS),50908
49,NCT02966782,Phase I,Recruiting,"[{'id': 1637, 'therapyName': 'GDC-0199 + Azacitidine'}, {'id': 1562, 'therapyName': 'Venetoclax'}]",A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) After Hypomethylating Agent-Failure,50908
50,NCT02981914,Phase 0,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation,50908
51,NCT02989844,Phase II,Recruiting,"[{'id': 3060, 'therapyName': 'ALT-803'}]",QUILT-3.035: Relapse Prophylaxis With ALT-803 for AML and MDS Pts Following Allo HSCT,50908
52,NCT03011034,Phase II,Recruiting,"[{'id': 5809, 'therapyName': 'Talacotuzumab'}, {'id': 1630, 'therapyName': 'Daratumumab'}]",Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Participants With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Who Are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment,50908
53,NCT03018405,Phase I,Recruiting,"[{'id': 5998, 'therapyName': 'NKR-2 cells'}]",A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications (THINK),50908
54,NCT03042689,Phase I,Not yet recruiting,"[{'id': 890, 'therapyName': 'Regorafenib'}]",Study of Regorafenib in Patients With Advanced Myeloid Malignancies,50908
55,NCT03069469,Phase I,Recruiting,"[{'id': 5760, 'therapyName': 'DCC-3014'}]",Study of DCC-3014 in Patients With Advanced Malignancies,50908
56,NCT03072043,Phase Ib/II,Recruiting,"[{'id': 5445, 'therapyName': 'APR-246 + Azacitidine'}]",Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms,50908
57,NCT03074006,Phase Ib/II,Not yet recruiting,"[{'id': 3011, 'therapyName': 'TEW 7197'}]",Dose Escalation and Proof-of-Concept Studies of TEW-7197 Monotherapy in Patients With Myelodysplastic Syndrome (MDS),50908
58,NCT03075826,Phase II,Recruiting,"[{'id': 1949, 'therapyName': 'SGI-110'}]",A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms,50908
59,NCT03092674,Phase II,Not yet recruiting,"[{'id': 1736, 'therapyName': 'Decitabine + Cytarabine'}, {'id': 2471, 'therapyName': 'Azacitidine + Midostaurin'}, {'id': 3196, 'therapyName': 'Azacitidine + Nivolumab'}, {'id': 651, 'therapyName': 'Azacitidine'}]","Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome",50908
60,NCT03094637,Phase II,Not yet recruiting,"[{'id': 2496, 'therapyName': 'Azacitidine + Pembrolizumab'}]",Azacitidine and Pembrolizumab for Patients With Myelodysplastic Syndrome (MDS),50908
61,NCT03128034,Phase Ib/II,Recruiting,"[{'id': 5714, 'therapyName': 'Cyclosporine + Fludarabine phosphate + Mycophenolate mofetil + Sirolimus'}]","211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome",50908
62,NCT03151304,Phase II,Recruiting,"[{'id': 5987, 'therapyName': 'Azacitidine + Pracinostat'}, {'id': 651, 'therapyName': 'Azacitidine'}]",A Safety and Efficacy Study of Pracinostat and Azacitidine in Patients With High Risk Myelodysplastic Syndromes,50908
63,NCT03164057,Phase II,Recruiting,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 651, 'therapyName': 'Azacitidine'}]",A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia,50908
64,NCT03187288,Phase I,Not yet recruiting,"[{'id': 4029, 'therapyName': 'CFI-400945'}]",A Study of CFI-400945 Fumarate in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome,50908
65,NCT03214562,Phase Ib/II,Recruiting,"[{'id': 1562, 'therapyName': 'Venetoclax'}, {'id': 6329, 'therapyName': 'Cytarabine + Filgrastim + Fludarabine + Idarubicin + Venetoclax'}]",Study of the BCL-2 Inhibitor Venetoclax in Combination With Standard Intensive Acute Myeloid Leukemia (AML) Induction/Consolidation Therapy With FLAG-IDA in Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia (AML),50908
66,NCT03238248,Phase II,Recruiting,"[{'id': 6164, 'therapyName': 'Azacitidine + MLN4924'}]",Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy With DNA Methyl Transferase Inhibitors,50908
67,NCT03248479,Phase I,Not yet recruiting,"[{'id': 6133, 'therapyName': 'Azacitidine + Hu5F9-G4'}, {'id': 4947, 'therapyName': 'Hu5F9-G4'}]",Hu5F9-G4 Monotherapy or Hu5F9-G4 in Combination With Azacitidine in Patients With Hematological Malignancies,50908
68,NCT03286114,Phase I,Not yet recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab,50908
0,NCT00946647,Phase II,"Active, not recruiting","[{'id': 1080, 'therapyName': 'Panobinostat'}, {'id': 651, 'therapyName': 'Azacitidine'}]","A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).",4972
1,NCT01164163,Phase I,Completed,"[{'id': 907, 'therapyName': 'Ruxolitinib'}]","INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease",4972
2,NCT01398462,Phase I,Completed,"[{'id': 3081, 'therapyName': 'CWP232291'}]",Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients,4972
3,NCT01449058,Phase Ib/II,Completed,"[{'id': 1311, 'therapyName': 'BYL719 + MEK162'}]",A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors,4972
4,NCT01746849,Phase II,Recruiting,"[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 2373, 'therapyName': 'Palifermin'}]",Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation,4972
5,NCT01822509,Phase I,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant,4972
6,NCT01829971,Phase I,Terminated,"[{'id': 1035, 'therapyName': 'MRX34'}]","A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection",4972
7,NCT02089230,Phase Ib/II,Recruiting,"[{'id': 807, 'therapyName': 'Binimetinib'}]","Phase I/II MEK162 Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Poor Prognosis, Not Suitable for or Unwilling to Receive Standard Therapy",4972
8,NCT02143635,Phase I,Recruiting,"[{'id': 2186, 'therapyName': 'HDM201'}]",Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt,4972
9,NCT02158858,Phase I,Recruiting,"[{'id': 2033, 'therapyName': 'CPI-0610'}]","A Phase 1 Study Evaluating CPI-0610 in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelodysplastic/Myeloproliferative Neoplasms",4972
10,NCT02530476,Phase Ib/II,Recruiting,"[{'id': 3189, 'therapyName': 'Selinexor + Sorafenib'}]","Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia",4972
11,NCT02564536,Phase I,Withdrawn,"[{'id': 3177, 'therapyName': 'Pacritinib + Decitabine'}]",Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS),4972
12,NCT02807272,Phase II,Recruiting,"[{'id': 938, 'therapyName': 'Tipifarnib'}]",Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia (CMML),4972
13,NCT02829840,Phase Ib/II,Withdrawn,"[{'id': 4464, 'therapyName': 'Azacitidine + Ponatinib'}]","Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML)",4972
14,NCT02907359,Phase III,Recruiting,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1949, 'therapyName': 'SGI-110'}]",Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs,4972
15,NCT02935361,Phase Ib/II,Recruiting,"[{'id': 4693, 'therapyName': 'Atezolizumab + SGI-110'}]",Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed,4972
16,NCT03072043,Phase Ib/II,Recruiting,"[{'id': 5445, 'therapyName': 'APR-246 + Azacitidine'}]",Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms,4972
17,NCT03075826,Phase II,Recruiting,"[{'id': 1949, 'therapyName': 'SGI-110'}]",A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms,4972
18,NCT03128034,Phase Ib/II,Recruiting,"[{'id': 5714, 'therapyName': 'Cyclosporine + Fludarabine phosphate + Mycophenolate mofetil + Sirolimus'}]","211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome",4972
19,NCT03238248,Phase II,Recruiting,"[{'id': 6164, 'therapyName': 'Azacitidine + MLN4924'}]",Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy With DNA Methyl Transferase Inhibitors,4972
0,NCT01398462,Phase I,Completed,"[{'id': 3081, 'therapyName': 'CWP232291'}]",Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients,4971
1,NCT02251821,Phase II,Recruiting,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 2006, 'therapyName': 'Pacritinib'}, {'id': 823, 'therapyName': 'Momelotinib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",JAK-2 Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis,4971
2,NCT02528877,Phase I,Withdrawn,"[{'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}, {'id': 3181, 'therapyName': 'Ruxolitinib + Sirolimus + Tacrolimus'}]","Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis",4971
3,NCT02530619,Phase I,Recruiting,"[{'id': 626, 'therapyName': 'Alisertib'}]",Alisertib in Treating Patients With Myelofibrosis or Relapsed or Refractory Acute Megakaryoblastic Leukemia,4971
4,NCT02564536,Phase I,Withdrawn,"[{'id': 3177, 'therapyName': 'Pacritinib + Decitabine'}]",Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS),4971
5,NCT02718300,Phase II,Recruiting,"[{'id': 4224, 'therapyName': 'INCB050465 + Ruxolitinib'}]",A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis,4971
6,NCT03042689,Phase I,Not yet recruiting,"[{'id': 890, 'therapyName': 'Regorafenib'}]",Study of Regorafenib in Patients With Advanced Myeloid Malignancies,4971
7,NCT03065400,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",PD-1 Inhibition in Advanced Myeloproliferative Neoplasms,4971
0,NCT02129101,Phase I,"Active, not recruiting","[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 1428, 'therapyName': 'Sonidegib'}]",Azacitidine and Sonidegib in Treating Patients With Myeloid Malignancies,8692
1,NCT03164057,Phase II,Recruiting,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 651, 'therapyName': 'Azacitidine'}]",A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia,8692
0,NCT01885897,Phase Ib/II,Recruiting,"[{'id': 3060, 'therapyName': 'ALT-803'}]",IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT,70004
1,NCT02420860,Phase II,Recruiting,"[{'id': 5972, 'therapyName': 'Famotidine'}, {'id': 3430, 'therapyName': 'Elotuzumab + lenalidomide'}, {'id': 1275, 'therapyName': 'Diphenhydramine'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]",Study of Elotuzumab With Lenalidomide as Maintenance After Autologous Stem Cell Transplant (ASCT),70004
2,NCT02506959,Phase II,Recruiting,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 3277, 'therapyName': 'Pyridoxine'}, {'id': 1080, 'therapyName': 'Panobinostat'}, {'id': 2373, 'therapyName': 'Palifermin'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Myeloma,70004
3,NCT02681302,Phase Ib/II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study of Combined Check Point Inhibition After Autologous Hematopoietic Stem Cell Transplantation in Patients at High Risk for Post-transplant Recurrence (CPIT001),70004
4,NCT02843074,Phase II,Recruiting,"[{'id': 3353, 'therapyName': 'Elotuzumab + Dexamethasone + Lenalidomide'}]","Elotuzumab, Lenalidomide and Dexamethasone (ERd) in the Induction, Consolidation and Maintenance Treatment of Transplant-Eligible, Newly Diagnosed Multiple Myeloma Patients",70004
5,NCT02969837,Phase II,Recruiting,"[{'id': 5033, 'therapyName': 'Carfilzomib + Elotuzumab + Dexamethasone + lenalidomide'}]","Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma",70004
0,NCT02790515,Phase II,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1876, 'therapyName': 'Blinatumomab '}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 5682, 'therapyName': 'Mesna'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Provision of TCR?? T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation,8683
1,NCT03164057,Phase II,Recruiting,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 651, 'therapyName': 'Azacitidine'}]",A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia,8683
0,NCT00074490,Phase II,Completed,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1166, 'therapyName': 'Fludarabine'}]",Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,2226
1,NCT02556931,Phase II,Recruiting,"[{'id': 4228, 'therapyName': 'Cyclophosphamide + Fludarabine + Melphalan + Tacrolimus'}]","Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies",2226
2,NCT02677922,Phase Ib/II,Recruiting,"[{'id': 4002, 'therapyName': 'AG-120 + Azacitidine'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 4003, 'therapyName': 'Azacitidine + Enasidenib'}]",A Safety and Efficacy Study of Oral AG-120 Plus Subcutaneous Azacitidine and Oral AG-221 Plus Subcutaneous Azacitidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML),2226
3,NCT02722668,Phase II,Recruiting,"[{'id': 2281, 'therapyName': 'Cyclophosphamide + Fludarabine + Mycophenolate mofetil'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}]",UCB Transplant for Hematological DIseases Using a Non Myeloablative Prep,2226
0,NCT02601937,Phase I,Recruiting,"[{'id': 2683, 'therapyName': 'Tazemetostat'}]",A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma,4838
0,NCT02601937,Phase I,Recruiting,"[{'id': 2683, 'therapyName': 'Tazemetostat'}]",A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma,5861
0,NCT02387125,Phase I,Recruiting,"[{'id': 4318, 'therapyName': 'CMB305'}]","A Phase 1b Safety Study of CMB305 (Sequentially Administered LV305 and G305) in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1",5363
1,NCT02609984,Phase II,"Active, not recruiting","[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 3273, 'therapyName': 'G305 + ID-LV305'}]",Trial of CMB305 and Atezolizumab in Patients With Sarcoma,5363
0,NCT03009201,Phase I,Recruiting,"[{'id': 5179, 'therapyName': 'Doxorubicin + Ribociclib'}]",Ribociclib and Doxorubicin Hydrochloride in Treating Patients Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery,4136
0,NCT02834013,Phase 0,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab in Treating Patients With Rare Tumors,4930
0,NCT02795156,Phase II,Recruiting,"[{'id': 623, 'therapyName': 'Afatinib'}, {'id': 890, 'therapyName': 'Regorafenib'}]",Study to Assess the Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations,10811
0,NCT02834013,Phase 0,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab in Treating Patients With Rare Tumors,4931
0,NCT02538510,Phase Ib/II,"Active, not recruiting","[{'id': 3077, 'therapyName': 'Pembrolizumab + Vorinostat'}]",Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer and Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery,5515
1,NCT03238365,Phase I,Recruiting,"[{'id': 6100, 'therapyName': 'Nivolumab + Tadalafil'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab With or Without Tadalafil in Treating Patients With Recurrent Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery,5515
0,NCT01498484,Phase II,"Active, not recruiting","[{'id': 5057, 'therapyName': 'EB-VST cells'}]",Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies,9261
1,NCT01966445,Phase I,Completed,"[{'id': 2919, 'therapyName': 'GSK2849330'}]","Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors",9261
2,NCT02113878,Phase I,Recruiting,"[{'id': 1691, 'therapyName': 'BKM120 + Cisplatin'}]",Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck,9261
3,NCT02269943,Phase II,"Active, not recruiting","[{'id': 651, 'therapyName': 'Azacitidine'}]",Safety and Efficacy of Oral Azacitidine in Previously Treated Subjects With Locally Advanced or Metastatic Nasopharyngeal Carcinoma,9261
4,NCT02339558,Phase II,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Cancer,9261
5,NCT02358031,Phase III,"Active, not recruiting","[{'id': 694, 'therapyName': 'Cetuximab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}]",A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048),9261
6,NCT02460224,Phase Ib/II,Recruiting,"[{'id': 2887, 'therapyName': 'LAG525'}, {'id': 2659, 'therapyName': 'PDR001'}]",Safety and Efficay of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies,9261
7,NCT02488759,Phase Ib/II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",A Study to Investigate the Safety and Efficacy of Nivolumab in Virus-associated Tumors (CheckMate358),9261
8,NCT02538510,Phase Ib/II,"Active, not recruiting","[{'id': 3077, 'therapyName': 'Pembrolizumab + Vorinostat'}]",Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer and Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery,9261
9,NCT02605967,Phase II,Recruiting,"[{'id': 2659, 'therapyName': 'PDR001'}]",Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma,9261
10,NCT02611960,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 4203, 'therapyName': 'Capecitabine + Docetaxel + Gemcitabine'}]","Study of Pembrolizumab (MK-3475) in Platinum Pre-treated Recurrent/Metastatic Nasopharyngeal Cancer (MK-3475-122, KEYNOTE-122)",9261
11,NCT02643550,Phase Ib/II,Recruiting,"[{'id': 3383, 'therapyName': 'Cetuximab + IPH2201'}]",Study of IPH2201 (Monalizumab) and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck,9261
12,NCT02706691,Phase II,Not yet recruiting,"[{'id': 674, 'therapyName': 'BGJ398'}]","Pan FGFR Kinase Inhibitor BGJ398 in Treating Patients With FGFR1-3 Translocated, Mutated, or Amplified Recurrent Head and Neck Cancer",9261
13,NCT02780011,Phase I,Not yet recruiting,"[{'id': 4301, 'therapyName': 'Alisertib + Brentuximab vedotin'}]",Alsertib (MLN8237) and Brentuximab Vedotin for Relapsed/Refractory CD30-Positive Lymphomas and Solid Malignancies,9261
14,NCT02795156,Phase II,Recruiting,"[{'id': 623, 'therapyName': 'Afatinib'}, {'id': 890, 'therapyName': 'Regorafenib'}]",Study to Assess the Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations,9261
15,NCT02834013,Phase 0,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab in Treating Patients With Rare Tumors,9261
16,NCT02875613,Phase II,Recruiting,"[{'id': 3144, 'therapyName': 'Avelumab'}]",Avelumab for Recurrent/Metastatic Nasopharyngeal Cancer,9261
17,NCT02892201,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in HNSCC With Residual Disease After Radiation,9261
18,NCT03074513,Phase II,Recruiting,"[{'id': 4595, 'therapyName': 'Atezolizumab + Bevacizumab'}]",Atezolizumab and Bevacizumab in Rare Solid Tumors,9261
19,NCT03144661,Phase I,Recruiting,"[{'id': 5832, 'therapyName': 'INCB062079'}]",An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies,9261
0,NCT02722668,Phase II,Recruiting,"[{'id': 2281, 'therapyName': 'Cyclophosphamide + Fludarabine + Mycophenolate mofetil'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}]",UCB Transplant for Hematological DIseases Using a Non Myeloablative Prep,1035
1,NCT03203369,Phase I,Suspended,"[{'id': 5994, 'therapyName': 'UCART123'}]",Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN (ABC123),1035
0,NCT02223819,Phase II,Recruiting,"[{'id': 706, 'therapyName': 'Crizotinib'}]",Adjuvant Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy,7808
0,NCT01331135,Phase I,"Active, not recruiting","[{'id': 917, 'therapyName': 'Sirolimus'}]",Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors,2154
1,NCT01661400,Phase I,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1475, 'therapyName': 'Thalidomide'}]",Anti-Angiogenic Therapy Post Transplant (ASCR) for Relapsed and Refractory Pediatric Solid Tumors,2154
2,NCT02982941,Phase I,Recruiting,"[{'id': 2863, 'therapyName': 'MGA271'}]",Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors,2154
0,NCT03095248,Phase II,Recruiting,"[{'id': 913, 'therapyName': 'Selumetinib'}]",Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors,3192
0,NCT00084695,Phase II,Unknown status,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases,769
1,NCT00602667,Phase I,"Active, not recruiting","[{'id': 2449, 'therapyName': 'Methotrexate + Cisplatin + Cyclophosphamide + Vincristine'}, {'id': 2450, 'therapyName': 'Cyclophosphamide + Etoposide + Topotecan'}, {'id': 2451, 'therapyName': 'Erlotinib + Cyclophosphamide + Topotecan'}]","Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma",769
2,NCT00885326,Phase I,"Active, not recruiting","[{'id': 2072, 'therapyName': 'Bevacizumab + Cyclophosphamide + Zoledronic acid'}]","N2007-02:Bevacizumab,Cyclophosphamide,and Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma",769
3,NCT00939770,Phase Ib/II,"Active, not recruiting","[{'id': 706, 'therapyName': 'Crizotinib'}]",Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma,769
4,NCT01175356,Phase I,Completed,"[{'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 2590, 'therapyName': 'Cyclophosphamide + Topotecan'}, {'id': 1425, 'therapyName': '131I-MIBG'}, {'id': 2353, 'therapyName': 'Cyclophosphamide + Doxorubicin + Vincristine '}, {'id': 2585, 'therapyName': 'Cisplatin + Etoposide'}]","Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin",769
5,NCT01241162,Phase I,Completed,"[{'id': 650, 'therapyName': 'Decitabine'}]",Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma,769
6,NCT01331135,Phase I,"Active, not recruiting","[{'id': 917, 'therapyName': 'Sirolimus'}]",Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors,769
7,NCT01492673,Phase II,"Active, not recruiting","[{'id': 1479, 'therapyName': 'Cyclophosphamide + Topotecan + Bevacizumab'}]","Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma",769
8,NCT01518413,Phase I,Completed,"[{'id': 1323, 'therapyName': 'Sorafenib + Irinotecan'}]",Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors,769
9,NCT01526603,Phase I,Recruiting,"[{'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1092, 'therapyName': 'Carboplatin'}]",High Dose Chemotherapy and Autologous Transplant for Neuroblastoma,769
10,NCT01587703,Phase I,Recruiting,"[{'id': 784, 'therapyName': 'GSK525762'}]","A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers",769
11,NCT01601535,Phase Ib/II,"Active, not recruiting","[{'id': 2628, 'therapyName': 'Alisertib + Irinotecan + Temozolomide'}]",Study of MLN8237 in Combination With Irinotecan and Temozolomide,769
12,NCT01625351,Phase I,"Active, not recruiting","[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1205, 'therapyName': 'Alemtuzumab'}]",A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas,769
13,NCT01747876,Phase I,Completed,"[{'id': 790, 'therapyName': 'Ribociclib'}]",Study of Safety and Efficacy in Patients With Malignant Rhabdoid Tumors (MRT) and Neuroblastoma,769
14,NCT01767194,Phase II,Suspended,"[{'id': 2286, 'therapyName': 'Dinutuximab  '}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1462, 'therapyName': 'Temozolomide + Irinotecan'}]",Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Monoclonal Antibody Ch14.18 in Treating Younger Patients With Refractory or Relapsed Neuroblastoma,769
15,NCT01822652,Phase I,"Active, not recruiting","[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]","3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN",769
16,NCT01857934,Phase II,Recruiting,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 2627, 'therapyName': 'Levetiracetam'}, {'id': 2585, 'therapyName': 'Cisplatin + Etoposide'}, {'id': 2458, 'therapyName': 'Hu14.18K322A'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 2590, 'therapyName': 'Cyclophosphamide + Topotecan'}]",Therapy for Children With Advanced Stage Neuroblastoma,769
17,NCT01956669,Phase II,Recruiting,"[{'id': 848, 'therapyName': 'Pazopanib'}]",Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors,769
18,NCT02030964,Phase I,"Active, not recruiting","[{'id': 2590, 'therapyName': 'Cyclophosphamide + Topotecan'}, {'id': 2124, 'therapyName': 'Celecoxib'}]",N2012-01 Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan,769
19,NCT02035137,,Recruiting,"[{'id': 1425, 'therapyName': '131I-MIBG'}, {'id': 1426, 'therapyName': '131I-MIBG + Irinotecan + Vincristine'}, {'id': 1427, 'therapyName': '131I-MIBG + Vorinostat'}]",131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinistat,769
20,NCT02075177,Phase I,Available,"[{'id': 2858, 'therapyName': 'Ketoconazole'}, {'id': 2731, 'therapyName': 'Fenretinide'}]",Expanded Access Study of Fenretinide Lym-X-Sorb Plus Ketoconazole in Neuroblastoma,769
21,NCT02095132,Phase Ib/II,Recruiting,"[{'id': 1361, 'therapyName': 'MK-1775 + Irinotecan'}]",WEE1 Inhibitor MK-1775 and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors,769
22,NCT02130869,Phase I,Recruiting,"[{'id': 2378, 'therapyName': 'Bendamustine + Cytarabine + Etoposide'}, {'id': 2460, 'therapyName': 'Busulfan + Hu14.18K322A'}, {'id': 2459, 'therapyName': 'Aldesleukin + Melphalan + Sargramostim'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}]",A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas,769
23,NCT02139397,Phase Ib/II,Recruiting,"[{'id': 2629, 'therapyName': 'Eflornithine'}, {'id': 688, 'therapyName': 'Bortezomib'}]",Study of DFMO in Combination With Bortezomib for Relapsed or Refractory Neuroblastoma,769
24,NCT02163356,Phase I,Recruiting,"[{'id': 1631, 'therapyName': 'Vincristine'}, {'id': 2731, 'therapyName': 'Fenretinide'}, {'id': 2858, 'therapyName': 'Ketoconazole'}]",Fenretinide Lym-X-Sorb + Ketoconazole + Vincristine for Recurrent or Resistant Neuroblastoma,769
25,NCT02173093,Phase Ib/II,Recruiting,"[{'id': 2058, 'therapyName': 'Aldesleukin + GD2Bi-a ATC + Sargramostim '}]",Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma,769
26,NCT02298348,Phase I,Recruiting,"[{'id': 2360, 'therapyName': 'Cyclophosphamide + Sorafenib + Topotecan'}]",Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma,769
27,NCT02303028,Phase Ib/II,Recruiting,"[{'id': 1469, 'therapyName': 'Topotecan + Pazopanib'}]",Phase I Dose Escalation Study of Topotecan and Pazopanib in Children With Recurrent/Refractory Solid and CNS Tumours,769
28,NCT02304458,Phase Ib/II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas,769
29,NCT02337309,Phase I,Recruiting,"[{'id': 915, 'therapyName': 'SF1126'}]",SF1126 for Patients With Relapsed or Refractory Neuroblastoma,769
30,NCT02372006,Phase I,Recruiting,"[{'id': 623, 'therapyName': 'Afatinib'}]",Phase I Trial of Afatinib in Pediatric Tumours,769
31,NCT02508038,Phase I,Recruiting,"[{'id': 2971, 'therapyName': 'Zoledronic acid'}, {'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}]", Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa,769
32,NCT02559778,Phase I,Recruiting,"[{'id': 688, 'therapyName': 'Bortezomib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 2629, 'therapyName': 'Eflornithine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 717, 'therapyName': 'Dasatinib'}]",Pediatric Precision Laboratory Advanced Neuroblastoma Therapy,769
33,NCT02574728,Phase II,Recruiting,"[{'id': 3143, 'therapyName': 'Celecoxib + Cyclophosphamide + Etoposide + Sirolimus'}]",Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors,769
34,NCT02639546,Phase I,Recruiting,"[{'id': 1004, 'therapyName': 'Cobimetinib'}]",iMATRIXcobi: Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Patients With Previously Treated Solid Tumors,769
35,NCT02644460,Phase I,Recruiting,"[{'id': 802, 'therapyName': 'Abemaciclib'}]",Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors,769
36,NCT02650401,Phase I,Recruiting,"[{'id': 1455, 'therapyName': 'Entrectinib'}]",Study of RXDX-101 in Children With Recurrent or Refractory Solid Tumors and Primary CNS Tumors,769
37,NCT02748135,Phase Ib/II,Recruiting,"[{'id': 4704, 'therapyName': 'TB-403'}]",A Two-Part Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma,769
38,NCT02780128,Phase I,Recruiting,"[{'id': 2186, 'therapyName': 'HDM201'}, {'id': 2638, 'therapyName': 'Ceritinib + LEE011'}, {'id': 2, 'therapyName': 'Trametinib'}]",Next Generation Personalized Neuroblastoma Therapy,769
39,NCT02909777,Phase I,Recruiting,"[{'id': 709, 'therapyName': 'CUDC-907'}]","Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma",769
40,NCT02982941,Phase I,Recruiting,"[{'id': 2863, 'therapyName': 'MGA271'}]",Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors,769
41,NCT03107988,Phase I,Recruiting,"[{'id': 5580, 'therapyName': 'PF-06463922 + Cyclophosphamide + Topotecan'}, {'id': 869, 'therapyName': 'PF-06463922'}]",Study of Lorlatinib (PF-06463922),769
42,NCT03126916,Phase III,Not yet recruiting,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1425, 'therapyName': '131I-MIBG'}, {'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 5595, 'therapyName': 'Isotretinoin'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 2286, 'therapyName': 'Dinutuximab  '}]",Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma,769
0,NCT03136055,Phase II,Recruiting,"[{'id': 5643, 'therapyName': 'Irinotecan + Pembrolizumab'}, {'id': 4021, 'therapyName': 'Paclitaxel + Pembrolizumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas,1800
1,NCT03190213,Phase II,Not yet recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab for the Treatment of Recurrent High Grade Neuroendocrine Carcinoma (Pembro NEC),1800
2,NCT03290079,Phase II,Not yet recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Advanced Poorly Differentiated and/or High Grade Neuroendocrine Tumors/Carcinomas,1800
0,NCT00926640,Phase I,Completed,"[{'id': 1123, 'therapyName': 'Belinostat + Cisplatin + Etoposide'}]",A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers,169
1,NCT01177397,Phase Ib/II,Completed,"[{'id': 693, 'therapyName': 'CC-223'}]","Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma",169
2,NCT01466036,Phase II,"Active, not recruiting","[{'id': 998, 'therapyName': 'cabozantinib'}]",Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors,169
3,NCT01841736,Phase II,"Active, not recruiting","[{'id': 848, 'therapyName': 'Pazopanib'}]",Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors,169
4,NCT02063958,Phase I,"Active, not recruiting","[{'id': 866, 'therapyName': 'SNX-5422'}]",Safety and Pharmacology of SNX-5422 Plus Everolimus in Subjects With Neuroendocrine Tumors,169
5,NCT02205515,Phase Ib/II,Recruiting,"[{'id': 735, 'therapyName': 'Everolimus'}]","An Open Label, Single-Centre, Phase II Study of Everolimus With EBRT for the Treatment of mNET Liver Metastasis",169
6,NCT02250885,Phase II,Completed,"[{'id': 1749, 'therapyName': 'Selinexor'}]",KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors,169
7,NCT02259725,Phase II,Recruiting,"[{'id': 890, 'therapyName': 'Regorafenib'}]",Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors,169
8,NCT02279433,Phase I,"Active, not recruiting","[{'id': 4343, 'therapyName': 'DS6051b'}]","A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b",169
9,NCT02399215,Phase II,Recruiting,"[{'id': 831, 'therapyName': 'Nintedanib'}]",Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors,169
10,NCT02402920,Phase I,Recruiting,"[{'id': 2604, 'therapyName': 'Carboplatin + Etoposide + Pembrolizumab'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Phase I Trial of MK-3475 and Concurrent Chemo/Radiation for the Elimination of Small Cell Lung Cancer,169
11,NCT02420691,Phase II,"Active, not recruiting","[{'id': 790, 'therapyName': 'Ribociclib'}]",LEE011 in Neuroendocrine Tumors of Foregut Origin,169
12,NCT02454972,Phase II,Recruiting,"[{'id': 1195, 'therapyName': 'Lurbinectedin'}]",Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors,169
13,NCT02487095,Phase Ib/II,Recruiting,"[{'id': 2879, 'therapyName': 'VX-970'}, {'id': 942, 'therapyName': 'Topotecan'}]","Trial of Topotecan With VX-970, an ATR Kinase Inhibitor, in Small Cell Lung Cancer",169
14,NCT02489903,Phase II,Recruiting,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 3680, 'therapyName': 'RRx-001'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 619, 'therapyName': 'Abraxane'}]","RRx-001 in Small, Non-small Cell Lung Cancer, and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens",169
15,NCT02628067,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158),169
16,NCT02631733,Phase I,Recruiting,"[{'id': 3314, 'therapyName': 'Irinotecan + Veliparib'}]",Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery,169
17,NCT02795858,Phase II,Recruiting,"[{'id': 4266, 'therapyName': 'Octreotide + Ramucirumab'}]","A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors",169
18,NCT02831179,Phase I,Withdrawn,"[{'id': 4463, 'therapyName': 'Capecitabine + Veliparib + Temozolomide'}]","Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor",169
19,NCT02936323,,Recruiting,"[{'id': 5819, 'therapyName': 'PEN-221'}]",PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers,169
20,NCT02939651,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Study of Pembrolizumab in Patients With Neuroendocrine Tumors,169
21,NCT02955069,Phase II,Recruiting,"[{'id': 2659, 'therapyName': 'PDR001'}]","Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin",169
22,NCT03014297,Phase I,Recruiting,"[{'id': 5207, 'therapyName': 'Everolimus + Fosbretabulin'}]",Fosbretabulin With Everolimus in Neuroendocrine Tumors With Progression,169
23,NCT03034200,Phase II,Recruiting,"[{'id': 1687, 'therapyName': 'ONC201'}]",Phase 2 Study of ONC201 in Neuroendocrine Tumors,169
24,NCT03070301,Phase II,Recruiting,"[{'id': 5073, 'therapyName': 'Ribociclib + Everolimus'}]",A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors,169
25,NCT03074513,Phase II,Recruiting,"[{'id': 4595, 'therapyName': 'Atezolizumab + Bevacizumab'}]",Atezolizumab and Bevacizumab in Rare Solid Tumors,169
26,NCT03211988,Phase II,Not yet recruiting,"[{'id': 1541, 'therapyName': 'Entinostat'}]",Entinostat Neuroendocrine (NE) Tumor,169
27,NCT03289741,FDA approved,Recruiting,"[{'id': 6279, 'therapyName': 'Lanreotide Depot + Octreotide'}]",A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide,169
28,NCT03290079,Phase II,Not yet recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Advanced Poorly Differentiated and/or High Grade Neuroendocrine Tumors/Carcinomas,169
0,NCT02096471,Phase II,"Active, not recruiting","[{'id': 849, 'therapyName': 'PD-0325901'}]",MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1,962
1,NCT02839720,Phase I,Recruiting,"[{'id': 913, 'therapyName': 'Selumetinib'}]",Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Dermal Neurofibroma,962
2,NCT03259633,Expanded access,Available,"[{'id': 913, 'therapyName': 'Selumetinib'}]",An Intermediate Access Protocol for Selumetinib for Treatment of Neurofibromatosis Type 1,962
0,NCT01446809,Phase I,"Active, not recruiting","[{'id': 1472, 'therapyName': 'Doxorubicin + Ifosfamide'}, {'id': 1471, 'therapyName': 'Pazopanib + Doxorubicin + Ifosfamide'}]",Pazopanib Hydrochloride Followed By Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma,3512
0,NCT03126916,Phase III,Not yet recruiting,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1425, 'therapyName': '131I-MIBG'}, {'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 5595, 'therapyName': 'Isotretinoin'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 2286, 'therapyName': 'Dinutuximab  '}]",Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma,5193
0,NCT02017964,Phase II,Completed,"[{'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}, {'id': 2673, 'therapyName': 'Cyclophosphamide + Methotrexate + Vincristine  '}]","Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed, Non-Metastatic Desmoplastic Medulloblastoma",3873
0,NCT00513474,Phase I,Completed,"[{'id': 2313, 'therapyName': 'Rasburicase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2314, 'therapyName': 'Busulfan + Cyclophosphamide + Etoposide'}]",Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant,60060
1,NCT00576654,Phase I,Recruiting,"[{'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 954, 'therapyName': 'Veliparib'}]",Irinotecan Hydrochloride and Veliparib in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery,60060
2,NCT00577278,Phase II,"Active, not recruiting","[{'id': 767, 'therapyName': 'Ibritumomab'}, {'id': 2238, 'therapyName': 'Sirolimus + Tacrolimus + Methotrexate'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}]","Yttrium Y 90 Ibritumomab Tiuxetan, Rituximab, Indium In-111 Ibritumomab Tiuxetan, Fludarabine, Melphalan, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin Lymphoma",60060
3,NCT00602693,Phase I,Completed,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 2311, 'therapyName': 'Allopurinol + Cyclophosphamide + Fludarabine'}]",T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer,60060
4,NCT00671112,Phase I,Terminated,"[{'id': 2234, 'therapyName': 'Bortezomib + Everolimus'}]",Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma,60060
5,NCT00740805,Phase I,"Active, not recruiting","[{'id': 2989, 'therapyName': 'Aldoxorubicin + Cyclophosphamide + Veliparib'}]","Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma",60060
6,NCT00857389,Phase II,"Active, not recruiting","[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 2469, 'therapyName': 'Busulfan + Clofarabine + Thymoglobulin'}, {'id': 1639, 'therapyName': 'Methotrexate'}]",Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies,60060
7,NCT01032148,Phase I,Terminated,"[{'id': 1080, 'therapyName': 'Panobinostat'}]","Study of LBH589, A Deacetylase Inhibitor in Patients With Recurrent or Refractory Hodgkin or Non-Hodgkin's Lymphoma",60060
8,NCT01058239,Phase II,"Active, not recruiting","[{'id': 1649, 'therapyName': 'Rituximab + Bortezomib'}]",Bortezomib Plus Rituximab for EBV+ PTLD,60060
9,NCT01076543,Phase Ib/II,"Active, not recruiting","[{'id': 2280, 'therapyName': 'Temsirolimus + Lenalidomide'}]",Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma,60060
10,NCT01162551,Phase II,Completed,"[{'id': 2304, 'therapyName': 'Sirolimus + Methotrexate'}]",Trial of Sirolimus and Methotrexate in Relapsed/Refractory Lymphoblastic Leukemia and Lymphoma,60060
11,NCT01187810,Phase I,"Active, not recruiting","[{'id': 2731, 'therapyName': 'Fenretinide'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1639, 'therapyName': 'Methotrexate'}]","Fenretinide in Children With Recurrent/Resistant ALL, AML, and NHL",60060
12,NCT01251575,Phase II,Recruiting,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 2270, 'therapyName': 'Cyclosporine + Mycophenolate mofetil + Sirolimus'}]","Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant",60060
13,NCT01306643,Phase Ib/II,Completed,"[{'id': 1023, 'therapyName': 'Idelalisib'}]","Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma",60060
14,NCT01307267,Phase I,Recruiting,"[{'id': 6111, 'therapyName': 'Utomilumab + Rituximab'}, {'id': 5086, 'therapyName': 'Utomilumab'}]",A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab,60060
15,NCT01321346,Phase I,Completed,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1080, 'therapyName': 'Panobinostat'}]",A Study Of Panobinostat In Children With Refractory Hematologic Malignancies,60060
16,NCT01324180,Phase I,Completed,"[{'id': 1031, 'therapyName': 'Metformin'}, {'id': 1830, 'therapyName': 'Vincristine + Dexamethasone + Pegaspargase + Doxorubicin'}]","Vincristine, Dexamethasone, Doxorubicin, and PEG-asparaginase (VPLD) and Metformin for Relapsed Childhood Acute Lymphoblastic Leukemia (ALL)",60060
17,NCT01353625,Phase I,"Active, not recruiting","[{'id': 1000, 'therapyName': 'CC-115'}]","Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.",60060
18,NCT01408043,Phase I,Terminated,"[{'id': 3222, 'therapyName': 'Etoposide + Filgrastim + Plerixafor'}]","Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma",60060
19,NCT01421524,Phase I,Recruiting,"[{'id': 2358, 'therapyName': 'CC-122'}]","Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma",60060
20,NCT01581541,Phase I,Terminated,"[{'id': 1162, 'therapyName': 'PU-H71'}]", PU-H71 in Patients With Solid Tumors and Low-Grade Non-Hodgkin s Lymphoma That Have Not Responded to Standard Treatment,60060
21,NCT01592370,Phase I,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 2583, 'therapyName': 'Lirilumab '}]",Safety Study in Nivolumab Alone and in Combination With Ipilimumab or Lirilumab in Lymphoma and Multiple Myeloma,60060
22,NCT01609816,Phase Ib/II,Recruiting,"[{'id': 717, 'therapyName': 'Dasatinib'}]","Dasatinib in Treating Patients With Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma Previously Treated With Autologous Stem Cell Transplant",60060
23,NCT01614197,Phase I,Recruiting,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1639, 'therapyName': 'Methotrexate'}]",A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma,60060
24,NCT01621477,Phase II,Terminated,"[{'id': 1756, 'therapyName': 'Plerixafor'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 2469, 'therapyName': 'Busulfan + Clofarabine + Thymoglobulin'}, {'id': 1783, 'therapyName': 'Cyclophosphamide + Cytarabine'}]",T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant,60060
25,NCT01634217,Phase I,"Active, not recruiting",[],Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation,60060
26,NCT01660451,Phase II,"Active, not recruiting","[{'id': 995, 'therapyName': 'Copanlisib'}]","Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas",60060
27,NCT01686165,Phase II,"Active, not recruiting","[{'id': 1078, 'therapyName': 'Belinostat'}, {'id': 897, 'therapyName': 'Rituximab'}]",Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma,60060
28,NCT01701986,Phase Ib/II,Recruiting,"[{'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 3992, 'therapyName': 'Busulfan + Clofarabine + Gemcitabine'}]",Gemcitabine/Clofarabine/Busulfan and Allogeneic Transplantation for Aggressive Lymphomas,60060
29,NCT01719250,Phase I,Completed,"[{'id': 680, 'therapyName': 'BKM120'}]",Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma,60060
30,NCT01732913,Phase III,Terminated,"[{'id': 1023, 'therapyName': 'Idelalisib'}, {'id': 897, 'therapyName': 'Rituximab'}]",Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas,60060
31,NCT01732926,Phase III,Terminated,"[{'id': 1023, 'therapyName': 'Idelalisib'}, {'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}]",Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas,60060
32,NCT01745354,Phase I,Terminated,"[{'id': 3084, 'therapyName': 'SD-101'}]",Immunostimulatory CpG SD-101 + RT in Recurrent/Progressive Lymphoma After Allogeneic Hematopoietic Cell Transplantation (HCT),60060
33,NCT01746849,Phase II,Recruiting,"[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 2373, 'therapyName': 'Palifermin'}]",Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation,60060
34,NCT01822509,Phase I,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant,60060
35,NCT01871675,Phase I,Completed,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1024, 'therapyName': 'Duvelisib'}, {'id': 1231, 'therapyName': 'Bendamustine'}]","Phase Ib Study of IPI-145 in Combination With Bendamustine, Rituximab or Bendamustine/Rituximab in Hematologic Malignancies",60060
36,NCT01882803,Phase II,"Active, not recruiting","[{'id': 1024, 'therapyName': 'Duvelisib'}]",A Phase 2 Study of IPI-145 in Subjects With Refractory Indolent Non-Hodgkin Lymphoma (DYNAMO),60060
37,NCT01905813,Phase I,"Active, not recruiting","[{'id': 2420, 'therapyName': 'INCB039110 + INCB040093'}, {'id': 2021, 'therapyName': 'INCB040093'}]",Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies,60060
38,NCT01949883,Phase I,Recruiting,"[{'id': 2033, 'therapyName': 'CPI-0610'}]",A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma,60060
39,NCT01953692,Phase I,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013)(KEYNOTE-013),60060
40,NCT01983969,Phase Ib/II,"Active, not recruiting","[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 2557, 'therapyName': 'Azacitidine + Gemcitabine + vorinostat'}]",Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma,60060
41,NCT01992653,Phase I,"Active, not recruiting","[{'id': 4248, 'therapyName': 'Cyclophosphamide + Doxorubicin + Prednisone'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 4226, 'therapyName': 'Polatuzumab Vedotin'}, {'id': 1646, 'therapyName': 'Obinutuzumab'}]","A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma",60060
42,NCT01994382,Phase I,Recruiting,"[{'id': 2531, 'therapyName': 'Cerdulatinib'}]",Phase 1 Dose Escalation Study in Chronic Lymphocytic Leukemia and Non-hodgkin Lymphoma,60060
43,NCT02000934,Phase I,Recruiting,"[{'id': 3146, 'therapyName': 'TAK-659'}]",A Study of TAK-659 in Adult Patients With Advanced Solid Tumor and Lymphoma Malignancies,60060
44,NCT02018861,Phase I,"Active, not recruiting","[{'id': 2406, 'therapyName': 'INCB039110'}, {'id': 3097, 'therapyName': 'INCB039110 + INCB050465'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 2352, 'therapyName': 'Carboplatin + Etoposide + Ifosfamide '}, {'id': 3088, 'therapyName': 'INCB050465 '}]","A Phase 1, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 Monotherapy and in Combination With INCB039110 in Subjects With Previously Treated B-Cell Malignancies",60060
45,NCT02043587,Phase II,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1136, 'therapyName': 'Etoposide'}]",Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia &amp; Lymphoblastic Lymphoma,60060
46,NCT02055820,Phase I,"Active, not recruiting","[{'id': 1562, 'therapyName': 'Venetoclax'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 3266, 'therapyName': 'Cyclophosphamide + Doxorubicin + Prednisone + Vincristine '}, {'id': 1646, 'therapyName': 'Obinutuzumab'}]",A Safety and Pharmacokinetics Study of GDC-0199 (ABT-199) in Patients With Non-Hodgkin's Lymphoma,60060
47,NCT02061761,Phase Ib/II,Recruiting,"[{'id': 4197, 'therapyName': 'BMS-986016 + Nivolumab'}, {'id': 4196, 'therapyName': 'BMS-986016'}]",Safety Study of Anti-LAG-3 in Relapsed or Refractory Hematologic Malignancies,60060
48,NCT02082977,Phase I,Terminated,"[{'id': 2734, 'therapyName': 'GSK2816126'}]","A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell and Transformed Follicular Lymphoma",60060
49,NCT02091063,Phase Ib/II,Recruiting,"[{'id': 1613, 'therapyName': 'ACY-1215'}]",ACY-1215 for Relapsed/Refractory Lymphoid Malignancies,60060
50,NCT02098109,Phase II,Completed,"[{'id': 1756, 'therapyName': 'Plerixafor'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma,60060
51,NCT02104427,Phase II,Completed,"[{'id': 2853, 'therapyName': 'TG-0054'}, {'id': 1632, 'therapyName': 'Filgrastim'}]","PD and Safety of TG-0054 Combined With G-CSF in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients",60060
52,NCT02110563,Phase I,Terminated,"[{'id': 3122, 'therapyName': 'DCR-MYC'}]","Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma",60060
53,NCT02130869,Phase I,Recruiting,"[{'id': 2378, 'therapyName': 'Bendamustine + Cytarabine + Etoposide'}, {'id': 2460, 'therapyName': 'Busulfan + Hu14.18K322A'}, {'id': 2459, 'therapyName': 'Aldesleukin + Melphalan + Sargramostim'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}]",A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas,60060
54,NCT02142530,Phase I,Recruiting,"[{'id': 1078, 'therapyName': 'Belinostat'}, {'id': 1624, 'therapyName': 'Carfilzomib'}]",Carfilzomib Plus Belinostat in Relapsed/Refractory NHL,60060
55,NCT02155582,Phase I,Completed,"[{'id': 995, 'therapyName': 'Copanlisib'}]",Copanlisib Pharmacodynamic Study,60060
56,NCT02180711,Phase I,"Active, not recruiting","[{'id': 1605, 'therapyName': 'Acalabrutinib'}]","An Open-label, Phase 1b Study of ACP 196 in Subjects With Follicular Lymphoma",60060
57,NCT02200380,Phase II,Terminated,"[{'id': 1756, 'therapyName': 'Plerixafor'}, {'id': 3007, 'therapyName': 'CDX-301'}]",A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs,60060
58,NCT02204982,Phase III,Terminated,"[{'id': 1024, 'therapyName': 'Duvelisib'}, {'id': 897, 'therapyName': 'Rituximab'}]",Study of IPI-145 in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma (DYNAMO + R),60060
59,NCT02281279,Phase Ib/II,Withdrawn,"[{'id': 2349, 'therapyName': 'Lenalidomide + Rituximab + Romidepsin '}]","Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma",60060
60,NCT02304458,Phase Ib/II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas,60060
61,NCT02327078,Phase Ib/II,Recruiting,"[{'id': 3059, 'therapyName': 'INCB024360 + Nivolumab'}]","A Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination With Nivolumab in Select Advanced Cancers",60060
62,NCT02329847,Phase Ib/II,Recruiting,"[{'id': 3198, 'therapyName': 'Ibrutinib + Nivolumab'}]",Pharmacokinetic and Pharmacodynamic Study to Evaluate Safety and Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic Malignancies,60060
63,NCT02343666,Phase I,Recruiting,"[{'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1756, 'therapyName': 'Plerixafor'}, {'id': 2556, 'therapyName': 'O6-benzylguanine'}]",HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV Infection,60060
64,NCT02348216,Phase Ib/II,Recruiting,"[{'id': 4829, 'therapyName': 'KTE-C19'}]",A Phase 1-2 Multi-Center Study Evaluating KTE-C19 in Subjects With Refractory Aggressive Non-Hodgkin Lymphoma (ZUMA-1),60060
65,NCT02367040,Phase III,Recruiting,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 995, 'therapyName': 'Copanlisib'}]",Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL),60060
66,NCT02408042,Phase Ib/II,Withdrawn,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 2352, 'therapyName': 'Carboplatin + Etoposide + Ifosfamide '}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2486, 'therapyName': 'Brentuximab vedotin'}]",Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme),60060
67,NCT02487459,Phase I,Not yet recruiting,"[{'id': 6053, 'therapyName': 'BPX-501'}, {'id': 5992, 'therapyName': 'Rimiducid'}]",Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies,60060
68,NCT02541604,Phase I,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}]","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of MPDL3280A (Anti-PD-L1 Antibody) in Pediatric and Young Adult Participants With Solid Tumors",60060
69,NCT02576496,Phase I,Recruiting,"[{'id': 6104, 'therapyName': 'EDO-S101'}]","Study of EDO-S101, A First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies",60060
70,NCT02595866,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms",60060
71,NCT02613598,Phase I,Recruiting,"[{'id': 3262, 'therapyName': 'Bortezomib + Ruxolitinib'}]",Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma,60060
72,NCT02651662,Phase I,Recruiting,"[{'id': 5656, 'therapyName': 'REGN2810'}, {'id': 6152, 'therapyName': 'REGN1979 + REGN2810'}]",Study of REGN2810 and REGN1979 in Patients With Lymphoma,60060
73,NCT02662296,Phase II,Withdrawn,"[{'id': 1023, 'therapyName': 'Idelalisib'}, {'id': 768, 'therapyName': 'Ibrutinib'}]","Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant",60060
74,NCT02693535,Phase II,Recruiting,"[{'id': 1657, 'therapyName': 'Vemurafenib + Cobimetinib'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 690, 'therapyName': 'Bosutinib'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 4, 'therapyName': 'Erlotinib'}]",TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer,60060
75,NCT02701673,Phase Ib/II,Withdrawn,"[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 3277, 'therapyName': 'Pyridoxine'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1078, 'therapyName': 'Belinostat'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}]",Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma,60060
76,NCT02702492,Phase I,Recruiting,"[{'id': 4662, 'therapyName': 'KPT-9274'}, {'id': 4688, 'therapyName': 'KPT-9274 + Niacin'}]",PAK4 and NAMPT in Patients With Solid MAlignancies or NHL (PANAMA) (PANAMA),60060
77,NCT02703272,Phase III,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 4307, 'therapyName': 'Carboplatin + Dexamethasone + Etoposide + Ifosfamide + Rituximab'}, {'id': 4308, 'therapyName': 'Carboplatin + Dexamethasone + Idarubicin + Ifosfamide + Rituximab + Vincristine'}]",A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma,60060
78,NCT02790515,Phase II,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1876, 'therapyName': 'Blinatumomab '}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 5682, 'therapyName': 'Mesna'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Provision of TCR?? T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation,60060
79,NCT02867618,Phase Ib/II,Recruiting,"[{'id': 4598, 'therapyName': 'Carfilzomib + TGR-1202'}]",Carfilzomib and TGR-1202 in Treatment of R/R Lymphoma,60060
80,NCT02875067,Phase Ib/II,Recruiting,"[{'id': 3322, 'therapyName': 'lenalidomide + Pembrolizumab'}]","Safety & Efficacy Study of Combination of Pembrolizumab and Lenalidomide, in Patients With Relapsed Non-Hodgkin and Hodgkin Lymphoma",60060
81,NCT02953509,Phase Ib/II,Recruiting,"[{'id': 4955, 'therapyName': 'Hu5F9-G4 + Rituximab'}]",Trial of Hu5F9-G4 in Combination With Rituximab in Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma,60060
82,NCT02954406,Phase I,Recruiting,"[{'id': 5150, 'therapyName': 'Lenalidomide + TAK-659'}, {'id': 5149, 'therapyName': 'Ibrutinib + TAK-659'}, {'id': 5148, 'therapyName': 'Gemcitabine + TAK-659'}, {'id': 5147, 'therapyName': 'Bendamustine + Rituximab + TAK-659'}, {'id': 5146, 'therapyName': 'Bendamustine + TAK-659'}]","A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma",60060
83,NCT02961816,Phase II,Withdrawn,"[{'id': 3277, 'therapyName': 'Pyridoxine'}, {'id': 4976, 'therapyName': 'Busulfan + Gemcitabine + Melphalan + Panobinostat'}, {'id': 4977, 'therapyName': 'Dexamethasone + Filgrastim + Palifermin + Rituximab'}]",Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma,60060
84,NCT02973113,Phase I,Recruiting,"[{'id': 5058, 'therapyName': 'EB-VST cells + Nivolumab'}]","Nivolumab With Epstein Barr Virus Specific T Cells (EB-VSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE) (PREVALE)",60060
85,NCT02978235,Phase Ib/II,Recruiting,"[{'id': 5897, 'therapyName': 'TAS4464'}]",A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma,60060
86,NCT03015896,Phase Ib/II,Suspended,"[{'id': 5239, 'therapyName': 'Lenalidomide + Nivolumab'}]",Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma,60060
87,NCT03035331,Phase Ib/II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma",60060
88,NCT03036904,Phase I,Recruiting,"[{'id': 5294, 'therapyName': 'Venetoclax + DA-EPOCH-R'}]",Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas (V+DA-EPOCH-R),60060
89,NCT03056339,Phase Ib/II,Recruiting,"[{'id': 6217, 'therapyName': 'Cyclophosphamide + Fludarabine phosphate + iC9/CAR.19/IL15-Transduced CB-NK'}]",Umbilical & Cord Blood (CB)- Derived CAR-Engineered NK Cells for B Lymphoid Malignancies,60060
90,NCT03082209,Phase I,Recruiting,"[{'id': 5756, 'therapyName': 'ABBV-621'}]",A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously Treated Solid Tumors and Hematologic Malignancies,60060
91,NCT03093116,Phase Ib/II,Recruiting,"[{'id': 3950, 'therapyName': 'TPX-0005'}]","A Study of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements",60060
92,NCT03105336,Phase II,Recruiting,"[{'id': 4829, 'therapyName': 'KTE-C19'}]",A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (ZUMA-5),60060
93,NCT03119467,Phase I,Recruiting,"[{'id': 5761, 'therapyName': 'RP4010'}]","Safety and Efficacy Study of RP4010, in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma",60060
94,NCT03133221,Phase II,Not yet recruiting,"[{'id': 1023, 'therapyName': 'Idelalisib'}]",1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation,60060
95,NCT03147885,Phase Ib/II,Recruiting,"[{'id': 1749, 'therapyName': 'Selinexor'}]",Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma,60060
96,NCT03153462,Expanded access,Available,"[{'id': 5098, 'therapyName': 'KTE-C19 + Fludarabine phosphate + Cyclophosphamide'}]",Axicabtagene Ciloleucel Expanded Access Study,60060
97,NCT03162536,Phase I,Recruiting,"[{'id': 5224, 'therapyName': 'ARQ 531'}]","Safety, PK, PD, and Antitumor Activity of ARQ 531 in Hematologic Malignancies",60060
98,NCT03188965,Phase I,Recruiting,"[{'id': 5962, 'therapyName': 'BAY1895344'}]",First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas,60060
99,NCT03210662,Phase II,Not yet recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab and Fractionated External Beam Radiotherapy (EBRT) in Patients With Non-Hodgkin Lymphoma (NHL),60060
100,NCT03210714,Phase II,Not yet recruiting,"[{'id': 1028, 'therapyName': 'JNJ-42756493'}]","Pediatric MATCH: Pan-FGFR Tyrosine Kinase Inhibitor JNJ-42756493 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations",60060
101,NCT03213652,Phase II,Recruiting,"[{'id': 961, 'therapyName': 'X-396'}]","Pediatric MATCH: Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations",60060
102,NCT03213665,Phase II,Recruiting,"[{'id': 2683, 'therapyName': 'Tazemetostat'}]","Pediatric MATCH: Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations",60060
103,NCT03213691,Phase II,Recruiting,"[{'id': 913, 'therapyName': 'Selumetinib'}]","Pediatric MATCH: Selumetinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations",60060
104,NCT03213704,Phase II,Recruiting,"[{'id': 2650, 'therapyName': 'LOXO-101'}]","Pediatric MATCH: Trk Inhibitor LOXO-101 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions",60060
105,NCT03220035,Phase II,Recruiting,"[{'id': 342, 'therapyName': 'Vemurafenib'}]","Pediatric MATCH: Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations",60060
106,NCT03233204,Phase II,Recruiting,"[{'id': 837, 'therapyName': 'Olaparib'}]","Pediatric MATCH: Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes",60060
107,NCT03259503,Phase Ib/II,Not yet recruiting,"[{'id': 1206, 'therapyName': 'Busulfan'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 2373, 'therapyName': 'Palifermin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 3277, 'therapyName': 'Pyridoxine'}, {'id': 897, 'therapyName': 'Rituximab'}]",Olaparib Combined With High-Dose Chemotherapy for Refractory Lymphomas,60060
108,NCT03283137,Phase I,Not yet recruiting,"[{'id': 6237, 'therapyName': 'Pembrolizumab + TGR-1202'}]",Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL,60060
109,NCT03297424,Phase Ib/II,Recruiting,"[{'id': 6324, 'therapyName': 'PLX2853'}]",A Study of PLX2853 in Advanced Malignancies.,60060
0,NCT00794950,Phase II,"Active, not recruiting","[{'id': 930, 'therapyName': 'Sunitinib'}]",Bacillus Calmette-Guerin Followed by Sunitinib for the Treatment of High Risk Non-muscle Invasive Lower Urinary Tract Urothelial Carcinoma,6571
0,NCT00150657,Phase II,Unknown status,"[{'id': 1294, 'therapyName': 'Gemcitabine + Bevacizumab + Carboplatin'}]",Study of Carboplatin/Gemcitabine Plus Bevacizumab in Advanced Lung Cancer,3908
1,NCT00254319,Phase II,Unknown status,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 2114, 'therapyName': 'Bevacizumab + Pemetrexed'}]",Previously Untreated Advanced Non-Small Cell Lung Cancer (NSCLC),3908
2,NCT00547105,Phase II,Unknown status,"[{'id': 4, 'therapyName': 'Erlotinib'}]",Erlotinib and Stereotactic Body Radiation Therapy in Treating Patients With Locally Advanced or Metastatic Non-Small Call Lung Cancer,3908
3,NCT00569296,,Terminated,"[{'id': 1012, 'therapyName': 'EGFRBi-armed autologous activated T cells'}]"," Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and GM-CSF in Treating Patients With Recurrent, Refractory, or Metastatic Non-Small Cell Lung Cancer",3908
4,NCT00585195,Phase I,Recruiting,"[{'id': 1526, 'therapyName': 'Crizotinib + Itraconazole\t'}, {'id': 1483, 'therapyName': 'Crizotinib + Rifampin'}]","A Study Of Oral PF-02341066, A c-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer",3908
5,NCT00828009,Phase II,Unknown status,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 2142, 'therapyName': 'Emepepimut-S  '}, {'id': 1092, 'therapyName': 'Carboplatin'}]",BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery,3908
6,NCT00932451,Phase II,Completed,"[{'id': 706, 'therapyName': 'Crizotinib'}]","An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene",3908
7,NCT00950365,Phase II,Unknown status,"[{'id': 1290, 'therapyName': 'Erlotinib + Pemetrexed'}, {'id': 854, 'therapyName': 'Pemetrexed'}]",Pharmacodynamic Separation of Pemetrexed and Erlotinib as Second-line Therapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC),3908
8,NCT00975767,Phase Ib/II,Terminated,"[{'id': 1127, 'therapyName': 'MGCD265 + Docetaxel'}, {'id': 1126, 'therapyName': 'MGCD265 + Erlotinib'}]",A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer,3908
9,NCT00978250,Phase II,Recruiting,"[{'id': 3789, 'therapyName': 'FdCyd + THU'}]",A Multi-Histology Phase II Study of 5-Fluoro-2-Deoxycytidine With Tetrahydrouridine (FdCyd + THU),3908
10,NCT00979212,Phase II,"Active, not recruiting","[{'id': 845, 'therapyName': 'Panitumumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer (Cetuximab Closed as of 05/14/10),3908
11,NCT00997334,Phase II,Completed,"[{'id': 4, 'therapyName': 'Erlotinib'}]",Erlotinib Therapy and Subsequent Development of Mechanisms of Secondary Resistance in Patients With NSCLC,3908
12,NCT01005797,Phase I,Completed,"[{'id': 1131, 'therapyName': 'Panobinostat + Sorafenib'}]","Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers",3908
13,NCT01014598,Phase I,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}]",Cisplatin in Treating Patients With Lung Cancer,3908
14,NCT01059552,Phase I,"Active, not recruiting","[{'id': 1077, 'therapyName': 'Vorinostat'}]",Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC),3908
15,NCT01061788,Phase I,Recruiting,"[{'id': 1138, 'therapyName': 'AMG479 + Everolimus + Panitumumab'}]","A Trial of AMG 479, Everolimus (RAD001) and Panitumumab in Patients With Advanced Cancer",3908
16,NCT01107626,Phase III,"Active, not recruiting","[{'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer,3908
17,NCT01177397,Phase Ib/II,Completed,"[{'id': 693, 'therapyName': 'CC-223'}]","Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma",3908
18,NCT01179269,Phase II,Withdrawn,"[{'id': 1143, 'therapyName': 'Pazopanib + Paclitaxel'}]",Stage IIIB/IV Non-Small Cell Lung Cancer,3908
19,NCT01210378,Phase II,Completed,"[{'id': 2924, 'therapyName': 'Nitroglycerin'}]",Nitroglycerin in Non-small Cell Lung Cancer,3908
20,NCT01233687,Phase Ib/II,Completed,"[{'id': 629, 'therapyName': 'AMG102'}, {'id': 4, 'therapyName': 'Erlotinib'}]",AMG 102 and Erlotinib for Advanced Non-Small Cell Lung Cancer,3908
21,NCT01248247,Phase I,"Active, not recruiting","[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1098, 'therapyName': 'MK2206 + Selumetinib'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1097, 'therapyName': 'Erlotinib + MK2206'}]",BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study,3908
22,NCT01263782,Phase II,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}, {'id': 701, 'therapyName': 'Cixutumumab'}]",BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non Small Cell Lung Cancer,3908
23,NCT01288430,Phase I,Terminated,"[{'id': 1181, 'therapyName': 'DS-2248'}]","A Study of DS-2248, in Subjects With Advanced Solid Tumors",3908
24,NCT01292655,Phase I,Completed,"[{'id': 2545, 'therapyName': 'BMS-906024'}]",Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors,3908
25,NCT01306045,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 816, 'therapyName': 'MK2206'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 913, 'therapyName': 'Selumetinib'}]","Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies",3908
26,NCT01307267,Phase I,Recruiting,"[{'id': 6111, 'therapyName': 'Utomilumab + Rituximab'}, {'id': 5086, 'therapyName': 'Utomilumab'}]",A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab,3908
27,NCT01325441,Phase Ib/II,Recruiting,"[{'id': 2586, 'therapyName': 'BBI608 + Paclitaxel'}]",A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies,3908
28,NCT01327612,Phase II,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 746, 'therapyName': 'Ganitumab'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1458, 'therapyName': 'Conatumumab'}]",Open Label Extension Study of Conatumumab and AMG 479,3908
29,NCT01336634,Phase II,"Active, not recruiting","[{'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}]",Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.,3908
30,NCT01336842,Phase I,Completed,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1080, 'therapyName': 'Panobinostat'}, {'id': 854, 'therapyName': 'Pemetrexed'}]",Study of Cisplatin and Pemetrexed in Combination With Panobinostat in Solid Tumors,3908
31,NCT01344824,Phase II,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 854, 'therapyName': 'Pemetrexed'}]","Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Who Are Light or Never Smokers",3908
32,NCT01351415,Phase III,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",A Study of Avastin (Bevacizumab) in Combination With Standard of Care Treatment in Patients With Lung Cancer,3908
33,NCT01383148,Phase Ib/II,Terminated,"[{'id': 1273, 'therapyName': 'MVA-MUC1-IL2 vaccine'}]",Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer,3908
34,NCT01386385,Phase Ib/II,Recruiting,"[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1544, 'therapyName': 'Carboplatin + Etoposide + Veliparib'}]","Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery",3908
35,NCT01391143,Phase I,Recruiting,"[{'id': 2863, 'therapyName': 'MGA271'}]",Safety Study of MGA271 in Refractory Cancer,3908
36,NCT01391533,Phase I,Completed,"[{'id': 2159, 'therapyName': 'SAR125844'}]",Study of SAR125844 Single Agent Administered as Slow Intravenous Infusion in Adult Patients With Advanced Malignant Solid Tumors,3908
37,NCT01449461,Phase Ib/II,"Active, not recruiting","[{'id': 634, 'therapyName': 'AP26113'}]",A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113,3908
38,NCT01454102,Phase I,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1312, 'therapyName': 'Nivolumab'}]","Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)",3908
39,NCT01455389,Phase Ib/II,Recruiting,"[{'id': 1313, 'therapyName': 'DOTAP:chol-Fus1'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1275, 'therapyName': 'Diphenhydramine'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]",FUS1-nanoparticles and Erlotinib in Stage IV Lung Cancer,3908
40,NCT01456325,Phase III,Completed,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 838, 'therapyName': 'Onartuzumab'}]",A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Patients With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung),3908
41,NCT01465802,Phase II,Completed,"[{'id': 714, 'therapyName': 'Dacomitinib'}, {'id': 1392, 'therapyName': 'Alclometasone'}, {'id': 1391, 'therapyName': 'Doxycycline'}]",Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO,3908
42,NCT01487265,Phase II,"Active, not recruiting","[{'id': 1319, 'therapyName': 'BKM120 + Erlotinib'}]",Trial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to Erlotinib,3908
43,NCT01493843,Phase II,Completed,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 749, 'therapyName': 'GDC-0941'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Study Evaluating the Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without GDC-0941 in Patients With Previously Untreated Advanced or Recurrent Non-small Cell Lung Cancer,3908
44,NCT01514864,Phase II,Terminated,"[{'id': 717, 'therapyName': 'Dasatinib'}]",Trial of Dasatinib in Subjects With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation,3908
45,NCT01526928,Phase Ib/II,"Active, not recruiting","[{'id': 1003, 'therapyName': 'CO1686'}]","Study to Evaluate Safety, Pharmacokinetics, and Efficacy of CO-1686 in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients",3908
46,NCT01532089,Phase II,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 4, 'therapyName': 'Erlotinib'}]",Erlotinib With or Without Bevacizumab in Treating Patients With Stage IV Non-Small Cell Lung Cancer With EGFR Mutations,3908
47,NCT01537744,Phase I,Completed,"[{'id': 1396, 'therapyName': 'Azacitidine + Romidepsin'}]","A Trial of Oral 5-azacitidine in Combination With Romidepsin in Advanced Solid Tumors, With an Expansion Cohort in Non-small Cell Lung Cancer",3908
48,NCT01545947,Phase I,Completed,"[{'id': 1149, 'therapyName': 'Azacitidine + CC-223'}, {'id': 1147, 'therapyName': 'Erlotinib + CC-223'}]"," Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer",3908
49,NCT01553942,Phase II,Recruiting,"[{'id': 623, 'therapyName': 'Afatinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 854, 'therapyName': 'Pemetrexed'}]",Afatinib With CT and RT for EGFR-Mutant NSCLC,3908
50,NCT01573702,Phase II,"Active, not recruiting","[{'id': 4, 'therapyName': 'Erlotinib'}]",Stereotactic Radiosurgery or Other Local Ablation Then Erlotinib in Epidermal Growth Factor Receptor (EGFR),3908
51,NCT01574729,Phase II,Unknown status,"[{'id': 1680, 'therapyName': 'rAD-p53'}]",Surgery Combined With rAd-p53 Gene in Treatment Advanced Non-small-cell Carcinoma,3908
52,NCT01578551,Phase II,"Active, not recruiting","[{'id': 1031, 'therapyName': 'Metformin'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",A Randomized Phase II Study of Metformin Plus Paclitaxel/Carboplatin/Bevacizumab in Patients With Adenocarcinoma.,3908
53,NCT01587703,Phase I,Recruiting,"[{'id': 784, 'therapyName': 'GSK525762'}]","A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers",3908
54,NCT01607905,Phase I,Completed,"[{'id': 1749, 'therapyName': 'Selinexor'}]",Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced or Metastatic Solid Tumor Cancer,3908
55,NCT01620190,Phase II,"Active, not recruiting","[{'id': 619, 'therapyName': 'Abraxane'}]",Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-Small Cell Lung Cancer,3908
56,NCT01621542,Phase I,Completed,"[{'id': 2893, 'therapyName': 'WT1 vaccine'}]",Clinical Study of WT2725 in Patients With Advanced Malignancies,3908
57,NCT01628471,Phase Ib/II,Completed,"[{'id': 1734, 'therapyName': 'Genistein + Decitabine'}]","MTD Determination, Safety and Efficacy of the Decitabine-Genistein Drug Combination in Advanced Solid Tumors and Non-Small Cell Lung Cancer",3908
58,NCT01630733,Phase III,Recruiting,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 3648, 'therapyName': 'Custirsen + Docetaxel'}]","A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer",3908
59,NCT01639508,Phase II,Recruiting,"[{'id': 998, 'therapyName': 'cabozantinib'}]",Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes,3908
60,NCT01642251,Phase Ib/II,"Active, not recruiting","[{'id': 2585, 'therapyName': 'Cisplatin + Etoposide'}, {'id': 954, 'therapyName': 'Veliparib'}]",Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer or Metastatic Large Cell Neuroendocrine Non-small Cell Lung Cancer,3908
61,NCT01642342,Phase I,Recruiting,"[{'id': 3013, 'therapyName': 'sEphB4-HSA'}]",Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors,3908
62,NCT01646125,,Terminated,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 647, 'therapyName': 'AUY922'}, {'id': 854, 'therapyName': 'Pemetrexed'}]"," An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations",3908
63,NCT01647711,Phase I,Completed,"[{'id': 623, 'therapyName': 'Afatinib'}]","A Study of Intermittent, High-dose Afatinib to Determine the Maximal Tolerated Dose and Assess Activity of This Dose Against Non-small Cell Lung Cancer With T790M Mutations",3908
64,NCT01649284,Phase I,Approved for marketing,"[{'id': 623, 'therapyName': 'Afatinib'}]",Afatinib Expanded Access Program,3908
65,NCT01649947,Phase II,Completed,"[{'id': 1487, 'therapyName': 'Bevacizumab + Carboplatin + Paclitaxel + Hydroxychloroquine'}, {'id': 1488, 'therapyName': 'Paclitaxel + Carboplatin + Hydroxychloroquine'}]",Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II,3908
66,NCT01653470,Phase I,"Active, not recruiting","[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 2545, 'therapyName': 'BMS-906024'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]","Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors",3908
67,NCT01664754,Phase I,"Active, not recruiting","[{'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 738, 'therapyName': 'Exemestane'}]","Exemestane, Pemetrexed Disodium, and Carboplatin in Treating Post-Menopausal Women With Stage IV Non-Small Cell Lung Cancer",3908
68,NCT01676714,Phase II,Completed,"[{'id': 721, 'therapyName': 'Dovitinib'}]",Study of Dovitinib and Biomarkers in Advanced Non-Small Cell Lung Cancer or Advanced Colorectal Cancer,3908
69,NCT01700400,Phase I,Completed,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}]"," Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab to Treat Stage IV Lung Cancer",3908
70,NCT01708993,Phase II,Completed,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1110, 'therapyName': 'Reolysin + Pemetrexed'}, {'id': 1111, 'therapyName': 'Reolysin + Docetaxel'}]"," Reolysin in Patients With Previously Treated Advanced or Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage Therapy",3908
71,NCT01712217,Phase Ib/II,"Active, not recruiting","[{'id': 706, 'therapyName': 'Crizotinib'}, {'id': 645, 'therapyName': 'AT13387'}]",A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib,3908
72,NCT01717482,Phase II,"Active, not recruiting","[{'id': 1031, 'therapyName': 'Metformin'}]",Metformin as a Chemoprevention Agent in Non-small Cell Lung Cancer,3908
73,NCT01723800,Phase I,Completed,"[{'id': 1112, 'therapyName': 'BKM120 + Pemetrexed + Carboplatin'}]"," PI3K Inhibitor BKM120, Carboplatin, and Pemetrexed Disodium in Treating Patients With Stage IV Non-Small Cell Lung Cancer",3908
74,NCT01725165,Phase II,"Active, not recruiting",[],Oligometastatic Disease,3908
75,NCT01730118,Phase I,Recruiting,"[{'id': 1404, 'therapyName': 'HER2 Vaccine'}]",Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing,3908
76,NCT01746251,Phase II,"Active, not recruiting","[{'id': 623, 'therapyName': 'Afatinib'}]",Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation,3908
77,NCT01750281,Phase II,"Active, not recruiting","[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1117, 'therapyName': 'Selumetinib + Docetaxel'}]",Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment.,3908
78,NCT01752400,Phase II,"Active, not recruiting","[{'id': 647, 'therapyName': 'AUY922'}]",AUY922 for Advanced ALK-positive NSCLC,3908
79,NCT01769391,Phase II,"Active, not recruiting","[{'id': 826, 'therapyName': 'Necitumumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",A Study of Necitumumab and Chemotherapy in Participants With Stage IV Squamous Non-Small Cell Lung Cancer,3908
80,NCT01772797,Phase I,Completed,"[{'id': 789, 'therapyName': 'Ceritinib'}, {'id': 647, 'therapyName': 'AUY922'}]",Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer,3908
81,NCT01783197,Phase I,"Active, not recruiting","[{'id': 913, 'therapyName': 'Selumetinib'}]", Study of Selumetinib in Patients With Previously Treated or Untreated Advanced/Metastatic NSCLC,3908
82,NCT01784640,Phase I,"Active, not recruiting","[{'id': 1270, 'therapyName': 'AUY922 + Pemetrexed'}]",Pemetrexed Disodium and Hsp90 Inhibitor AUY922 in Treating Patients With Previously Treated Stage IV Non-Small Cell Lung Cancer,3908
83,NCT01788566,Phase II,Completed,"[{'id': 2882, 'therapyName': 'Necitumumab + Gemcitabine + Cisplatin'}]",A Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab in the First-Line Treatment of Participants With Lung Cancer,3908
84,NCT01798485,Phase III,Terminated,"[{'id': 745, 'therapyName': 'Ganetespib'}, {'id': 720, 'therapyName': 'Docetaxel'}]",A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC,3908
85,NCT01801111,Phase II,"Active, not recruiting","[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 698, 'therapyName': 'Alectinib'}]",A Study of RO5424802 in Patients With Non-Small Cell Lung Cancer Who Have ALK Mutation and Failed Crizotinib Treatment,3908
86,NCT01802632,Phase Ib/II,"Active, not recruiting","[{'id': 660, 'therapyName': 'Osimertinib'}]", AZD9291 First Time In Patients Ascending Dose Study,3908
87,NCT01803282,Phase I,Recruiting,"[{'id': 3320, 'therapyName': 'GS-5745'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Safety and Tolerability Study in Solid Tumors,3908
88,NCT01813734,Phase II,Recruiting,"[{'id': 877, 'therapyName': 'Ponatinib'}]",Ponatinib in Advanced NSCLC w/ RET Translocations,3908
89,NCT01820754,Phase II,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During / After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSCLC),3908
90,NCT01822496,Phase II,Recruiting,"[{'id': 1375, 'therapyName': 'Cisplatin + Etoposide + Paclitaxel + Carboplatin + Erlotinib'}]",Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer,3908
91,NCT01828112,Phase III,"Active, not recruiting","[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 789, 'therapyName': 'Ceritinib'}]",LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib,3908
92,NCT01829217,Phase II,"Active, not recruiting","[{'id': 930, 'therapyName': 'Sunitinib'}]",Sunitinib in Never-Smokers With Lung Adenocarcinoma,3908
93,NCT01831089,Phase I,Completed,"[{'id': 1196, 'therapyName': 'Lurbinectedin + Paclitaxel + Bevacizumab'}, {'id': 1197, 'therapyName': 'Lurbinectedin + Paclitaxel'}]","Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors",3908
94,NCT01833143,Phase II,"Active, not recruiting","[{'id': 688, 'therapyName': 'Bortezomib'}]",Bortezomib in KRAS-Mutant Non-Small Cell Lung Cancer in Never Smokers or Those With KRAS G12D,3908
95,NCT01837329,Phase I,Recruiting,"[{'id': 3147, 'therapyName': 'Tetrathiomolybdate'}]",Phase I Study of Tetrathiomolybdate in Combination With Carboplatin/Pemetrexed in Metastatic Non-small Cell Lung Cancer,3908
96,NCT01839955,Phase Ib/II,Completed,"[{'id': 1237, 'therapyName': 'Erlotinib + Quinacrine'}]",Erlotinib Hydrochloride and Quinacrine Dihydrochloride in Stage IIIB-IV Non-Small Cell Lung Cancer,3908
97,NCT01848756,Phase Ib/II,Terminated,"[{'id': 866, 'therapyName': 'SNX-5422'}]",Safety and Efficacy of SNX-5422 in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Cancers,3908
98,NCT01854034,Phase II,Completed,"[{'id': 647, 'therapyName': 'AUY922'}]",Phase 2 Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR,3908
99,NCT01857271,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}]",Erlotinib Hydrochloride Before Surgery in Treating Patients With Stage III Non-Small Cell Lung Cancer,3908
100,NCT01858389,Phase II,Completed,"[{'id': 714, 'therapyName': 'Dacomitinib'}]",A Study Of Dacomitinib (PF-00299804) In Patients With Advanced Non-Small Cell Lung Cancer,3908
101,NCT01859026,Phase I,Recruiting,"[{'id': 1253, 'therapyName': 'MEK162 + Erlotinib'}]",A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation,3908
102,NCT01866410,Phase II,"Active, not recruiting","[{'id': 1255, 'therapyName': 'Cabozantinib + Erlotinib'}]",Cabozantinib-S-Malate and Erlotinib Hydrochloride in Treating Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer,3908
103,NCT01868022,Phase I,"Active, not recruiting","[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}, {'id': 2899, 'therapyName': 'GSK3052230'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]","Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling",3908
104,NCT01871805,Phase Ib/II,"Active, not recruiting","[{'id': 698, 'therapyName': 'Alectinib'}]",A Study of CH5424802/RO5424802 in Patients With ALK-Rearranged Non-Small Cell Lung Cancer,3908
105,NCT01884285,Phase I,Recruiting,"[{'id': 992, 'therapyName': 'AZD8186'}]",AZD8186 First Time In Patient Ascending Dose Study,3908
106,NCT01887886,Phase III,Completed,"[{'id': 1280, 'therapyName': 'Onartuzumab + Erlotinib'}]",A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating EGFR Mutation,3908
107,NCT01892046,Phase I,Completed,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 866, 'therapyName': 'SNX-5422'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors,3908
108,NCT01900652,Phase II,Completed,"[{'id': 1179, 'therapyName': 'Emibetuzumab + Erlotinib'}, {'id': 803, 'therapyName': 'Emibetuzumab'}]",A Study of LY2875358 in Non Small Cell Lung Cancer (NSCLC) Participants,3908
109,NCT01903993,Phase II,"Active, not recruiting","[{'id': 1201, 'therapyName': 'Atezolizumab'}]",A Randomized Phase 2 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) Compared With Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - &quot;POPLAR&quot;,3908
110,NCT01911325,Phase Ib/II,Terminated,"[{'id': 680, 'therapyName': 'BKM120'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients,3908
111,NCT01911507,Phase I,Recruiting,"[{'id': 1284, 'therapyName': 'INCB028060 + Erlotinib'}]",INC280 and Erlotinib Hydrochloride in Treating Patients With Non-small Cell Lung Cancer,3908
112,NCT01912625,Phase I,Recruiting,"[{'id': 2196, 'therapyName': 'Carboplatin + Paclitaxel + Trametinib'}]","Trametinib, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery",3908
113,NCT01920061,Phase I,Recruiting,"[{'id': 1287, 'therapyName': 'PF-05212384 + Dacomitinib'}, {'id': 1286, 'therapyName': 'PF-05212384 + Cisplatin'}, {'id': 1285, 'therapyName': 'PF-05212384 + Docetaxel'}]",A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents,3908
114,NCT01928160,Phase II,Withdrawn,"[{'id': 1290, 'therapyName': 'Erlotinib + Pemetrexed'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1291, 'therapyName': 'Erlotinib + Carboplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1292, 'therapyName': 'Erlotinib + Cisplatin'}]",Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib,3908
115,NCT01928576,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1541, 'therapyName': 'Entinostat'}, {'id': 651, 'therapyName': 'Azacitidine'}]",Phase II Anti-PD1 Epigenetic Priming Study in NSCLC.,3908
116,NCT01933932,Phase III,"Active, not recruiting","[{'id': 1117, 'therapyName': 'Selumetinib + Docetaxel'}]",Assess Efficacy and Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC,3908
117,NCT01935947,Phase II,Terminated,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 2645, 'therapyName': 'Azacitidine + Entinostat'}, {'id': 2646, 'therapyName': 'Docetaxel + Irinotecan + Pemetrexed '}]",Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer,3908
118,NCT01946789,Phase I,Recruiting,"[{'id': 3060, 'therapyName': 'ALT-803'}]",A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors,3908
119,NCT01947608,Phase I,Available,"[{'id': 789, 'therapyName': 'Ceritinib'}]",Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC,3908
120,NCT01951690,Phase II,Completed,"[{'id': 958, 'therapyName': 'VS-6063'}]",Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer,3908
121,NCT01957007,Phase I,Completed,"[{'id': 4413, 'therapyName': 'Docetaxel + Vantictumab'}]",A Study of Vantictumab (OMP-18R5) in Combination With Docetaxel in Patients With Previously Treated NSCLC,3908
122,NCT01966003,Phase III,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 2141, 'therapyName': 'Bevacizumab-awwb'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Subjects With Advanced Non-Small Cell Lung Cancer,3908
123,NCT01966445,Phase I,Completed,"[{'id': 2919, 'therapyName': 'GSK2849330'}]","Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors",3908
124,NCT01967095,Phase I,"Active, not recruiting","[{'id': 4, 'therapyName': 'Erlotinib'}]",Low Dose Daily Erlotinib in Combination With High Dose Twice Weekly Erlotinib in Patients With EGFR-Mutant Lung Cancer,3908
125,NCT01968109,Phase I,Recruiting,"[{'id': 4197, 'therapyName': 'BMS-986016 + Nivolumab'}, {'id': 4196, 'therapyName': 'BMS-986016'}]",Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors,3908
126,NCT01970865,Phase Ib/II,Recruiting,"[{'id': 869, 'therapyName': 'PF-06463922'}, {'id': 706, 'therapyName': 'Crizotinib'}]",A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations,3908
127,NCT01974258,Phase I,Withdrawn,"[{'id': 1306, 'therapyName': 'Onartuzumab + Vemurafenib'}, {'id': 1307, 'therapyName': 'Onartuzumab + Cobimetinib'}, {'id': 1308, 'therapyName': 'Onartuzumab + Cobimetinib + Vemurafenib'}]","Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients",3908
128,NCT01988896,Phase I,"Active, not recruiting","[{'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}]",A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors,3908
129,NCT01998126,Phase I,"Active, not recruiting","[{'id': 1348, 'therapyName': 'Ipilimumab + Erlotinib'}, {'id': 1349, 'therapyName': 'Ipilimumab + Crizotinib'}]",Ipilimumab Plus Targeted Inhibitor (Erlotinib or Crizotinib) for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer: Phase Ib With Expansion Cohorts,3908
130,NCT01999738,Phase I,"Active, not recruiting","[{'id': 1603, 'therapyName': 'EC1456'}]",Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors,3908
131,NCT01999985,Phase I,"Active, not recruiting","[{'id': 1351, 'therapyName': 'Dasatinib + Afatinib'}]",Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC),3908
132,NCT02000947,Phase Ib/II,"Active, not recruiting","[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer,3908
133,NCT02004106,Phase I,Completed,"[{'id': 2886, 'therapyName': 'RO6895882'}]",A Study of RO6895882 in Patients With Advanced and/or Metastatic Solid Tumors,3908
134,NCT02008227,Phase III,"Active, not recruiting","[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",A Randomized Phase 3 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) Compared to Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - OAK,3908
135,NCT02009449,Phase I,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 2621, 'therapyName': 'AM0010 '}, {'id': 619, 'therapyName': 'Abraxane'}]",A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors,3908
136,NCT02013219,Phase I,"Active, not recruiting","[{'id': 3490, 'therapyName': 'Alectinib + Atezolizumab'}, {'id': 1352, 'therapyName': 'Atezolizumab + Erlotinib'}]",A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer,3908
137,NCT02014337,Phase I,"Active, not recruiting","[{'id': 3053, 'therapyName': 'Eribulin + Mifepristone'}]",Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors,3908
138,NCT02014909,Phase I,Completed,"[{'id': 2054, 'therapyName': 'CDX-3379'}, {'id': 2063, 'therapyName': 'CDX-3379 + Vemurafenib'}, {'id': 2064, 'therapyName': 'CDX-3379 + Trastuzumab'}, {'id': 2061, 'therapyName': 'Cetuximab + CDX-3379'}, {'id': 2062, 'therapyName': 'CDX-3379 + Erlotinib'}]",A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors,3908
139,NCT02019979,Phase II,Terminated,"[{'id': 1031, 'therapyName': 'Metformin'}]",Metformin and Carbohydrate Restriction With Platinum Based Chemotherapy In Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NS-NSCLC) (METRO),3908
140,NCT02022982,Phase Ib/II,Recruiting,"[{'id': 1823, 'therapyName': 'PD-0325901 + Palbociclib'}]",PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors,3908
141,NCT02031458,Phase II,"Active, not recruiting","[{'id': 1201, 'therapyName': 'Atezolizumab'}]",A Phase 2 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Patients With PD-L1 Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer - BIRCH,3908
142,NCT02038699,Phase Ib/II,Withdrawn,"[{'id': 1687, 'therapyName': 'ONC201'}]",A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer,3908
143,NCT02039674,Phase Ib/II,"Active, not recruiting","[{'id': 2103, 'therapyName': 'Carboplatin + Paclitaxel + Pembrolizumab'}, {'id': 2104, 'therapyName': 'Bevacizumab + Carboplatin + Paclitaxel + Pembrolizumab'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}, {'id': 2106, 'therapyName': 'Ipilimumab + Pembrolizumab '}, {'id': 2107, 'therapyName': 'Erlotinib + Pembrolizumab '}, {'id': 2108, 'therapyName': 'Gefitinib + Pembrolizumab '}]",A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Lung Cancer (MK-3475-021/KEYNOTE-021),3908
144,NCT02041533,Phase III,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}]","An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)",3908
145,NCT02043665,Phase I,Recruiting,"[{'id': 2974, 'therapyName': 'coxsackievirus A21'}]",Systemic Treatment Of Resistant Metastatic Disease Employing CVA21 and Pembrolizumab in Non-small Cell Lung Cancer and Bladder Cancer (STORM/ KEYNOTE-200) (STORM),3908
146,NCT02044601,Phase Ib/II,Withdrawn,"[{'id': 1370, 'therapyName': 'Onartuzumab + Paclitaxel + Carboplatin'}, {'id': 1371, 'therapyName': 'Onartuzumab + Erlotinib + Paclitaxel + Carboplatin'}]",Biomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT),3908
147,NCT02045446,Phase II,"Active, not recruiting","[{'id': 1146, 'therapyName': 'Bevacizumab + Erlotinib'}, {'id': 1439, 'therapyName': 'Gemcitabine + Docetaxel'}]",Maintenance Chemotherapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Chemotherapy for Stage IV Non-Small Cell Lung Cancer (NSCLC),3908
148,NCT02047344,Phase II,Recruiting,"[{'id': 985, 'therapyName': 'Antroquinonol'}]","Efficacy, Safety and Pharmacokinetics Study of Antroquinonol to Treat NSCLC",3908
149,NCT02066636,Phase III,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}]",A Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen (CheckMate 153),3908
150,NCT02075840,Phase III,"Active, not recruiting","[{'id': 698, 'therapyName': 'Alectinib'}, {'id': 706, 'therapyName': 'Crizotinib'}]","ALEX Study: A Randomized, Phase III Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Patients",3908
151,NCT02079636,Phase I,Recruiting,"[{'id': 1069, 'therapyName': 'LY3023414'}, {'id': 802, 'therapyName': 'Abemaciclib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 886, 'therapyName': 'Ramucirumab'}]",A Study of LY2835219 in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC),3908
152,NCT02080078,Phase I,Recruiting,"[{'id': 2436, 'therapyName': 'Erlotinib + Theophylline'}]",A Phase I Dose Escalation Study of Erlotinib in Combination With Theophylline,3908
153,NCT02085070,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",MK-3475 in Melanoma and NSCLC Patients With Brain Metastases,3908
154,NCT02087176,Phase II,Terminated,"[{'id': 822, 'therapyName': 'MK-1775'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}]",A Placebo Controlled Study Comparing AZD1775+ Docetaxel Versus Placebo+Docetaxel to Treat Lung Cancer,3908
155,NCT02087241,Phase II,Terminated,"[{'id': 822, 'therapyName': 'MK-1775'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}]",Ph II Trial of Carboplatin and Pemetrexed With or Without AZD1775 for Untreated Lung Cancer,3908
156,NCT02087423,Phase II,"Active, not recruiting","[{'id': 1356, 'therapyName': 'Durvalumab'}]",A Global Study to Assess the Effects of MEDI4736 in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (ATLANTIC),3908
157,NCT02088112,Phase I,"Active, not recruiting","[{'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC),3908
158,NCT02094573,Phase II,"Active, not recruiting","[{'id': 634, 'therapyName': 'AP26113'}]","A Phase 2, Multicenter, Randomized Study of AP26113",3908
159,NCT02106546,Phase III,"Active, not recruiting","[{'id': 954, 'therapyName': 'Veliparib'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]","Randomized, Double-Blind, Multicenter, Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer",3908
160,NCT02108964,Phase Ib/II,Recruiting,"[{'id': 1309, 'therapyName': 'EGF816'}]","A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies",3908
161,NCT02109016,Phase II,Completed,"[{'id': 1029, 'therapyName': 'Lucitanib'}]","A Study to Assess the Efficacy of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With FGFR1-driven Lung Cancer",3908
162,NCT02113813,Phase I,"Active, not recruiting","[{'id': 1082, 'therapyName': 'ASP8273'}]",A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations,3908
163,NCT02115464,Phase II,Recruiting,"[{'id': 1031, 'therapyName': 'Metformin'}]",Advanced Lung Cancer Treatment With Metformin and Chemo-Radiotherapy,3908
164,NCT02117024,Phase II,"Active, not recruiting","[{'id': 2472, 'therapyName': 'HS-110 + Cyclophosphamide'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer,3908
165,NCT02119650,Phase II,Terminated,"[{'id': 1856, 'therapyName': 'Ruxolitinib + Cisplatin + Pemetrexed'}, {'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}]",Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer,3908
166,NCT02122809,Phase I,Completed,"[{'id': 1998, 'therapyName': 'Chiauranib'}]",Phase I Study of Chiauranib in Patients With Advanced Solid Tumors,3908
167,NCT02122861,Phase I,"Active, not recruiting","[{'id': 3271, 'therapyName': 'ID-LV305'}]","A Phase 1 Safety Study of Intradermal ID-LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1",3908
168,NCT02125461,Phase III,"Active, not recruiting","[{'id': 1356, 'therapyName': 'Durvalumab'}]",A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer (PACIFIC),3908
169,NCT02132598,Phase II,Recruiting,"[{'id': 998, 'therapyName': 'cabozantinib'}]",Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain Metastases,3908
170,NCT02134015,Phase III,Terminated,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2530, 'therapyName': 'Patritumab + Erlotinib'}]",Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung),3908
171,NCT02134886,Phase I,Terminated,"[{'id': 4, 'therapyName': 'Erlotinib'}]",Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV Infection,3908
172,NCT02134912,Phase II,Recruiting,"[{'id': 1151, 'therapyName': 'Crizotinib + Pemetrexed'}, {'id': 854, 'therapyName': 'Pemetrexed'}]",S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib,3908
173,NCT02142738,Phase III,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}]",Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024),3908
174,NCT02143466,Phase I,Recruiting,"[{'id': 2224, 'therapyName': 'Osimertinib + Savolitinib'}, {'id': 2225, 'therapyName': 'Osimertinib + Selumetinib'}, {'id': 2223, 'therapyName': 'AZD9291 + MEDI4736'}]",AZD9291 in Combination With Ascending Doses of Novel Therapeutics,3908
175,NCT02147990,Phase II,Unknown status,"[{'id': 1003, 'therapyName': 'CO1686'}]",Open Label Safety and Efficacy Study of Rociletinib (CO-1686) in Patients With T790M Positive NSCLC Who Have Failed One Previous EGFR-Directed TKI,3908
176,NCT02151981,Phase III,"Active, not recruiting","[{'id': 660, 'therapyName': 'Osimertinib'}]",AZD9291 Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer,3908
177,NCT02152631,Phase III,"Active, not recruiting","[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 802, 'therapyName': 'Abemaciclib'}]",A Study of LY2835219 in Participants With Previously Treated Lung Cancer,3908
178,NCT02154490,Phase II,Recruiting,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 654, 'therapyName': 'AZD4547'}, {'id': 1016, 'therapyName': 'GDC-0032'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 629, 'therapyName': 'AMG102'}]",Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,3908
179,NCT02157792,Phase I,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 2879, 'therapyName': 'VX-970'}, {'id': 755, 'therapyName': 'Gemcitabine'}]","An Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics of VX-970 in Combination With Cytotoxic Chemotherapy",3908
180,NCT02157883,Phase I,"Active, not recruiting","[{'id': 1026, 'therapyName': 'Itraconazole'}, {'id': 660, 'therapyName': 'Osimertinib'}]","Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)",3908
181,NCT02163733,Phase I,"Active, not recruiting","[{'id': 660, 'therapyName': 'Osimertinib'}]",Study to Determine the Effect of Food on the Blood Levels of AZD9291 Following Oral Dosing of a Tablet Formulation in Patients With Non-Small Cell Lung Cancer,3908
182,NCT02168777,Phase Ib/II,Terminated,"[{'id': 1424, 'therapyName': 'Regorafenib + Refametinib'}, {'id': 888, 'therapyName': 'Refametinib'}]","Refametinib (BAY86-9766) in Combination With Regorafenib (Stivarga, BAY73-4506) in Patients With Advanced or Metastatic Cancer",3908
183,NCT02174172,Phase I,Recruiting,"[{'id': 6252, 'therapyName': 'Atezolizumab + Bevacizumab +Peg-interferon alfa-2a'}, {'id': 6253, 'therapyName': 'Atezolizumab + Interferon alfa-2b'}, {'id': 6250, 'therapyName': 'Atezolizumab + Peg-interferon alfa-2a'}, {'id': 6249, 'therapyName': 'Atezolizumab + Ipilimumab'}, {'id': 1975, 'therapyName': 'Atezolizumab + Obinutuzumab'}]",A Study to Assess the Safety and Tolerability of MPDL3280A in Combination With Other Immune-modulating Therapies in Patients With Locally Advanced or Metastatic Solid Tumors,3908
184,NCT02178722,Phase Ib/II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2575, 'therapyName': 'Epacadostat'}]","A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Solid Tumors and Advanced NSCLC (INCB 24360-202 / MK-3475-037 / KEYNOTE-037)",3908
185,NCT02179671,Phase II,Completed,"[{'id': 1117, 'therapyName': 'Selumetinib + Docetaxel'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 660, 'therapyName': 'Osimertinib'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]","Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer",3908
186,NCT02186301,Phase II,Terminated,"[{'id': 1003, 'therapyName': 'CO1686'}, {'id': 4, 'therapyName': 'Erlotinib'}]",TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR Mutant NSCLC Who Have Not Had Any Previous EGFR Directed Therapy,3908
187,NCT02186847,Phase II,"Active, not recruiting","[{'id': 1031, 'therapyName': 'Metformin'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer,3908
188,NCT02192541,Phase I,Completed,"[{'id': 1665, 'therapyName': 'Ganetespib + Aflibercept'}]","Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas",3908
189,NCT02193152,Phase I,Recruiting,"[{'id': 848, 'therapyName': 'Pazopanib'}]",Pazopanib in Molecularly Selected Patients With Advanced NSCLC,3908
190,NCT02193282,Phase III,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}]",Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),3908
191,NCT02197234,Phase I,"Active, not recruiting","[{'id': 1645, 'therapyName': 'Osimertinib + Simvastatin'}, {'id': 660, 'therapyName': 'Osimertinib'}]",Study to Assess the Effect of AZD9291 on the Blood Levels of Simvastatin in Patients With EGFRm+ NSCLC,3908
192,NCT02197247,Phase I,"Active, not recruiting","[{'id': 1644, 'therapyName': 'Osimertinib + Rifampin'}, {'id': 660, 'therapyName': 'Osimertinib'}]","Study to Assess the Effect of Rifampicin on Blood Levels and Safety of AZD9291, in Patients With EGFRm+ NSCLC",3908
193,NCT02201992,Phase III,Recruiting,"[{'id': 706, 'therapyName': 'Crizotinib'}]",Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial),3908
194,NCT02206763,Phase I,Terminated,"[{'id': 2380, 'therapyName': 'Erlotinib + Momelotinib'}]",Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC),3908
195,NCT02220894,Phase III,Recruiting,"[{'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of MK-3475 (Pembrolizumab) Versus Platinum-based Chemotherapy for Participants With PD-L1-positive Advanced or Metastatic Non-small Cell Lung Cancer (MK-3475-042/KEYNOTE-042),3908
196,NCT02221739,Phase II,Completed,"[{'id': 779, 'therapyName': 'Ipilimumab'}]",Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC),3908
197,NCT02222922,Phase I,Recruiting,"[{'id': 1689, 'therapyName': 'Fluconazole'}, {'id': 4421, 'therapyName': 'PF-06647020'}]",A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors,3908
198,NCT02225405,Phase I,Recruiting,"[{'id': 2372, 'therapyName': 'Cisplatin + Docetaxel + Nintedanib'}]","Induction Study of Cisplatin, Docetaxel, and Nintedanib Stage IB-IIIA Non-Small Cell Lung Cancer (NCLC)",3908
199,NCT02228369,Phase I,"Active, not recruiting","[{'id': 660, 'therapyName': 'Osimertinib'}, {'id': 2912, 'therapyName': 'AZD3759'}]","Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung Cancer",3908
200,NCT02250326,Phase II,"Active, not recruiting","[{'id': 1950, 'therapyName': 'Abraxane + Azacitidine'}, {'id': 619, 'therapyName': 'Abraxane'}]",Safety and Efficacy Study of Nab-Paclitaxel With CC-486 and Nab-Paclitaxel Monotherapy as Second Line Treatment for Advanced Nonsquamous Non-small Cell Lung Cancer,3908
201,NCT02257619,Phase II,Terminated,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 2406, 'therapyName': 'INCB039110'}]",Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer,3908
202,NCT02258607,Phase I,Terminated,"[{'id': 823, 'therapyName': 'Momelotinib'}, {'id': 1860, 'therapyName': 'Momelotinib + Trametinib'}]",Efficacy and Safety of Momelotinib and Momelotinib Combined With Trametinib in Adults With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in Phase,3908
203,NCT02259114,Phase I,Completed,"[{'id': 2034, 'therapyName': 'OTX015'}]","A Phase IB Trial With OTX015, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Patients With Selected Advanced Solid Tumors",3908
204,NCT02259582,Phase II,"Active, not recruiting","[{'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}, {'id': 2007, 'therapyName': 'Demcizumab'}]","A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With Non-Squamous Non-Small Cell Lung Cancer",3908
205,NCT02259621,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]","Neoadjuvant Anti-PD-1, Nivolumab in Resectable NSCLC",3908
206,NCT02264678,Phase Ib/II,Recruiting,"[{'id': 2881, 'therapyName': 'AZD6738'}, {'id': 4737, 'therapyName': 'AZD6738 + Carboplatin'}, {'id': 4738, 'therapyName': 'AZD6738 + MEDI4736'}, {'id': 4739, 'therapyName': 'AZD6738 + Olaparib'}]",Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents,3908
207,NCT02264990,Phase III,"Active, not recruiting","[{'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 954, 'therapyName': 'Veliparib'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Subjects Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer Who Are Current or Former Smokers,3908
208,NCT02271139,Phase III,No longer available,"[{'id': 698, 'therapyName': 'Alectinib'}]",Expanded Access Study of Alectinib for Patients With ALK-Rearranged Non-Small Cell Lung Cancer Previously Treated With Crizotinib,3908
209,NCT02271906,Phase II,Terminated,"[{'id': 623, 'therapyName': 'Afatinib'}]",The ATTAIN Study: A Therapeutic Trial of Afatinib In the Neoadjuvant Setting,3908
210,NCT02272413,Phase III,"Active, not recruiting","[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Phase III Trial BI 695502 Plus Chemotherapy vs. Avastin Plus Chemotherapy in Patients With Lung Cancer,3908
211,NCT02273375,Phase III,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}]",Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC,3908
212,NCT02277457,Phase I,Withdrawn,"[{'id': 706, 'therapyName': 'Crizotinib'}, {'id': 4, 'therapyName': 'Erlotinib'}]","Personalized Adaptive Radiation Therapy With Individualized Systemic Targeted Therapy (PARTIST) for Locally Advanced, Non-small Cell Lung Cancer With Genomic Driver Mutations",3908
213,NCT02279433,Phase I,"Active, not recruiting","[{'id': 4343, 'therapyName': 'DS6051b'}]","A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b",3908
214,NCT02283320,Phase II,Completed,"[{'id': 720, 'therapyName': 'Docetaxel'}]",A Study of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy for Patients With KRAS Positive or Squamous Cell Non-Small Cell Lung Cancer,3908
215,NCT02289833,Phase II,"Active, not recruiting","[{'id': 1402, 'therapyName': 'trastuzumab emtansine'}]","A Study of Trastuzumab Emtansine in Patients With HER2 IHC-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer",3908
216,NCT02292550,Phase Ib/II,"Active, not recruiting","[{'id': 2638, 'therapyName': 'Ceritinib + LEE011'}]",Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer.,3908
217,NCT02296125,Phase III,"Active, not recruiting","[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 660, 'therapyName': 'Osimertinib'}, {'id': 751, 'therapyName': 'Gefitinib'}]",AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer,3908
218,NCT02298153,Phase I,"Active, not recruiting","[{'id': 2636, 'therapyName': 'Atezolizumab + Epacadostat'}]",A Study of MPDL3280A in Combination With INCB024360 in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer,3908
219,NCT02299141,Phase I,Recruiting,"[{'id': 831, 'therapyName': 'Nintedanib'}]",Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer,3908
220,NCT02299505,Phase I,Recruiting,"[{'id': 789, 'therapyName': 'Ceritinib'}]",Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC),3908
221,NCT02303990,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",RADVAX A Stratified Phase I Trial of Pembrolizumab With Hypofractionated Radiotherapy in Patients With Advanced and Metastatic Cancers,3908
222,NCT02309177,Phase I,Recruiting,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 2489, 'therapyName': 'Abraxane + Nivolumab'}]","Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer",3908
223,NCT02314364,Phase II,Recruiting,[],A Trial of Integrating SBRT With Targeted Therapy in Stage IV Oncogene-driven NSCLC,3908
224,NCT02315066,Phase I,Recruiting,"[{'id': 4333, 'therapyName': 'PF-04518600'}, {'id': 4448, 'therapyName': 'PF-04518600 + Utomilumab'}]",Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566,3908
225,NCT02316002,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Phase II Study of Pembrolizumab After Curative Intent Treatment for Oligometastatic Non-Small Cell Lung Cancer,3908
226,NCT02317016,Phase I,"Active, not recruiting","[{'id': 660, 'therapyName': 'Osimertinib'}, {'id': 2928, 'therapyName': 'Rosuvastatin'}]","Study to Assess the Effect of AZD9291 on the Blood Levels of Rosuvastatin, in Patients With EGFRm+ Non-small Cell Lung Cancer",3908
227,NCT02318368,Phase II,Terminated,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2169, 'therapyName': 'Ficlatuzumab + Erlotinib'}]","A Phase 2, Multicenter, Study of Ficlatuzumab Plus Erlotinib Versus Placebo Plus Erlotinib in Subjects Who Have Previously Untreated Metastatic, EGFR-mutated Non-small Cell Lung Cancer (NSCLC) and BDX004 Positive Label",3908
228,NCT02318771,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Urothelial Cancer, Melanoma, and Non-Small Cell Lung Cancer",3908
229,NCT02321293,Phase I,Unknown status,"[{'id': 2379, 'therapyName': 'Erlotinib + Gefitinib'}]",A Open-label Prospective Cohort Trial of Curcumin Plus Tyrosine Kinase Inhibitors (TKI) for EGFR -Mutant Advanced NSCLC,3908
230,NCT02321501,Phase I,Recruiting,"[{'id': 2295, 'therapyName': 'Ceritinib + Everolimus'}, {'id': 789, 'therapyName': 'Ceritinib'}]",Phase I/Ib Dose Escalation and Biomarker Study of Ceritinib (LDK378) + Everolimus for Locally Advanced or Metastatic Solid Tumors With an Expansion in Non-Small Cell Lung Cancer (NSCLC) Characterized by Abnormalities in Anaplastic Lymphoma Kinase (ALK) Expression,3908
231,NCT02321540,Phase Ib/II,"Active, not recruiting","[{'id': 768, 'therapyName': 'Ibrutinib'}]",A Phase I/II Study of Ibrutinib in Previously Treated Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer,3908
232,NCT02322281,Phase III,"Active, not recruiting","[{'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1003, 'therapyName': 'CO1686'}]","TIGER-3 Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy",3908
233,NCT02323126,Phase II,Recruiting,"[{'id': 2443, 'therapyName': 'EGF816 + Nivolumab'}, {'id': 2444, 'therapyName': 'INC280 + Nivolumab'}]",Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer,3908
234,NCT02327078,Phase Ib/II,Recruiting,"[{'id': 3059, 'therapyName': 'INCB024360 + Nivolumab'}]","A Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination With Nivolumab in Select Advanced Cancers",3908
235,NCT02335918,Phase Ib/II,Recruiting,"[{'id': 2526, 'therapyName': 'Nivolumab + Varlilumab'}]",A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors,3908
236,NCT02335944,Phase Ib/II,Recruiting,"[{'id': 2445, 'therapyName': 'EGF816 + INC280'}]",Study of Safety and Efficacy of EGF816 in Combination With INC280 in Non-small Cell Lung Cancer Patients With EGFR Mutation.,3908
237,NCT02336451,Phase II,Recruiting,"[{'id': 789, 'therapyName': 'Ceritinib'}]",A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges,3908
238,NCT02337530,Phase II,"Active, not recruiting","[{'id': 913, 'therapyName': 'Selumetinib'}, {'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}]",Selumetinib in Patients Receiving Pemetrexed and Cisplatin in Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous Non-Small Cell Lung Cancer,3908
239,NCT02342353,Phase Ib/II,Recruiting,"[{'id': 2382, 'therapyName': 'Erlotinib + Pacritinib'}]",Pacritinib in Patients With Endothelial Growth Factor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) After EGFR Tyrosine Kinase Inhibitor (TKI),3908
240,NCT02343952,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","Consolidation Pembrolizumab (MK-3475), Following Chemoradiation in Patients With Inoperable/Unresectable Stage III NSCLC",3908
241,NCT02346955,Phase I,Terminated,"[{'id': 4246, 'therapyName': 'CM-24'}, {'id': 4247, 'therapyName': 'CM-24 + Pembrolizumab'}]",Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001),3908
242,NCT02349633,Phase I,Recruiting,"[{'id': 2527, 'therapyName': 'PF-06747775  '}]",Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M),3908
243,NCT02350764,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Evaluate the Mediators of Sensitivity and Resistance to Nivolumab in Patients With Advanced NSCLCs,3908
244,NCT02352948,Phase III,"Active, not recruiting","[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 2438, 'therapyName': 'Erlotinib + Gemcitabine + Vinorelbine'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]","A Global Study to Assess the Effects of MEDI4736, Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer",3908
245,NCT02355431,Phase II,Withdrawn,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2406, 'therapyName': 'INCB039110'}]",INCB039110 in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations,3908
246,NCT02357836,Phase I,Recruiting,"[{'id': 1026, 'therapyName': 'Itraconazole'}]",Neoadjuvant Itraconazole in Non-small Cell Lung Cancer,3908
247,NCT02364609,Phase I,Recruiting,"[{'id': 2435, 'therapyName': 'Afatinib + Pembrolizumab'}]",Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib,3908
248,NCT02364999,Phase III,"Active, not recruiting","[{'id': 1152, 'therapyName': 'Bevacizumab + Carboplatin + Paclitaxel'}]",A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC,3908
249,NCT02365662,Phase I,Recruiting,"[{'id': 2914, 'therapyName': 'ABBV-221'}]",A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor,3908
250,NCT02366143,Phase III,"Active, not recruiting","[{'id': 2370, 'therapyName': 'Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel'}, {'id': 1489, 'therapyName': 'Nab-paclitaxel + Carboplatin + Bevacizumab'}, {'id': 1203, 'therapyName': 'Atezolizumab + Carboplatin + Paclitaxel'}]",TBAA Phase III Study of MPDL3280A (Anti-PD-L1 Antibody) in Combination With Carboplatin + Paclitaxel With or Without Bevacizumab in Patients With Stage IV Non-squamous Non-small Cell Lung Cancer,3908
251,NCT02367781,Phase III,"Active, not recruiting","[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 2634, 'therapyName': 'Carboplatin + nab-paclitaxel'}]",A Phase III Study of MPDL3280A (Anti-PD-L1 Antibody) in Combination With Carboplatin + Nab-Paclitaxel in Patients With Non-Squamous Non-Small Cell Lung Cancer,3908
252,NCT02367794,Phase III,"Active, not recruiting","[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",A Phase III Study of MPDL3280A (Anti-PD-L1) in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-paclitaxel Compared With Carboplatin + Nab-paclitaxel in Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC),3908
253,NCT02381314,Phase I,Recruiting,"[{'id': 3058, 'therapyName': 'Ipilimumab + MGA271'}]",Safety Study of MGA271 in Combination With Ipilimumab in Refractory Cancer,3908
254,NCT02382406,Phase Ib/II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2634, 'therapyName': 'Carboplatin + nab-paclitaxel'}]",Carboplatin/Nab-Paclitaxel and MK-3475 in NSCLC,3908
255,NCT02387125,Phase I,Recruiting,"[{'id': 4318, 'therapyName': 'CMB305'}]","A Phase 1b Safety Study of CMB305 (Sequentially Administered LV305 and G305) in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1",3908
256,NCT02387216,Phase II,Recruiting,"[{'id': 820, 'therapyName': 'Seribantumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 720, 'therapyName': 'Docetaxel'}]",A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC,3908
257,NCT02391480,Phase I,Recruiting,"[{'id': 4028, 'therapyName': 'ABBV-075'}]",A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer,3908
258,NCT02392507,Phase II,Recruiting,"[{'id': 2599, 'therapyName': 'Carboplatin + nab-paclitaxel + Necitumumab'}]",A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC,3908
259,NCT02393248,Phase Ib/II,Recruiting,"[{'id': 4176, 'therapyName': 'Cisplatin + Gemcitabine + INCB054828'}, {'id': 4174, 'therapyName': 'Docetaxel + INCB054828'}, {'id': 4088, 'therapyName': 'Epacadostat + Pembrolizumab'}]","Open-Label, Dose-Escalation Study of INCB054828 in Subjects With Advanced Malignancies",3908
260,NCT02393625,Phase I,Recruiting,"[{'id': 2565, 'therapyName': 'Ceritinib + Nivolumab'}]",Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer,3908
261,NCT02395172,Phase III,"Active, not recruiting","[{'id': 3144, 'therapyName': 'Avelumab'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200),3908
262,NCT02400814,Phase I,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}]",MPDL3280A and Stereotactic Ablative Radiotherapy in Patients With Non-small Cell Lung Cancer,3908
263,NCT02403193,Phase Ib/II,Recruiting,"[{'id': 4741, 'therapyName': 'PBF-509 + PDR001'}, {'id': 4740, 'therapyName': 'PBF-509'}]",Trial of PBF-509 and PDR001 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) (AdenONCO),3908
264,NCT02403271,Phase Ib/II,Completed,"[{'id': 2573, 'therapyName': 'Ibrutinib + MEDI4736'}]",A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors,3908
265,NCT02404441,Phase Ib/II,Recruiting,"[{'id': 2659, 'therapyName': 'PDR001'}]",Phase I/II Study of PDR001 in Patients With Advanced Malignancies,3908
266,NCT02407171,Phase Ib/II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic Melanoma or NSCLC,3908
267,NCT02409342,Phase III,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 700, 'therapyName': 'Cisplatin'}]",A Comparative Study of MPDL3280A (Anti-PDL1 Antibody) With Cisplatin or Carboplatin + Pemetrexed in Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC),3908
268,NCT02409355,Phase III,"Active, not recruiting","[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study of MPDL3280A Compared With Gemcitabine + Cisplatin or Carboplatin in Patients With Stage IV Squamous Non-Small Cell Lung Cancer,3908
269,NCT02411448,Phase III,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 886, 'therapyName': 'Ramucirumab'}]",A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Participants With EGFR Mutation-Positive Metastatic NSCLC,3908
270,NCT02412371,Phase II,Recruiting,"[{'id': 954, 'therapyName': 'Veliparib'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Subjects With Stage III Non-Small Cell Lung Cancer,3908
271,NCT02414139,Phase II,Recruiting,"[{'id': 1065, 'therapyName': 'Capmatinib'}]",Clinical Study of Oral cMET Inhibitor INC280 in Adult Patients With Advanced Non-small Cell Lung Cancer Who Have Received One or Two Prior Lines of Therapy,3908
272,NCT02422381,Phase Ib/II,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",MK-3475 and Gemcitabine in Non-Small Cell Lung Cancer (NSCLC),3908
273,NCT02422589,Phase I,Recruiting,"[{'id': 2505, 'therapyName': 'Warfarin'}, {'id': 2685, 'therapyName': 'Midazolam'}, {'id': 789, 'therapyName': 'Ceritinib'}]","A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam in Patients With ALK-positive Advanced Tumors",3908
274,NCT02423343,Phase Ib/II,Recruiting,"[{'id': 2409, 'therapyName': 'Galunisertib'}, {'id': 1312, 'therapyName': 'Nivolumab'}]","A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, Hepatocellular Carcinoma, or Glioma",3908
275,NCT02424617,Phase Ib/II,Recruiting,"[{'id': 2684, 'therapyName': 'BGB-324 + Erlotinib'}]",A Study of BGB324 in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer,3908
276,NCT02432963,Phase I,Recruiting,"[{'id': 1038, 'therapyName': 'MVAp53'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy,3908
277,NCT02435121,Phase II,Completed,"[{'id': 2159, 'therapyName': 'SAR125844'}]",A Study Assessing Efficacy and Safety of SAR125844 in NSCLC Patients With MET Amplification,3908
278,NCT02437136,Phase Ib/II,Recruiting,"[{'id': 3354, 'therapyName': 'Entinostat + Pembrolizumab'}]",Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in NSCLC With Expansion Cohorts in NSCLC and Melanoma,3908
279,NCT02438722,Phase II,Recruiting,"[{'id': 623, 'therapyName': 'Afatinib'}, {'id': 694, 'therapyName': 'Cetuximab'}]","S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer",3908
280,NCT02439450,Phase I,Recruiting,"[{'id': 2457, 'therapyName': 'HS-110'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer,3908
281,NCT02443324,Phase I,"Active, not recruiting","[{'id': 2896, 'therapyName': 'Pembrolizumab + Ramucirumab'}]","A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC or Transitional Cell Carcinoma of the Urothelium",3908
282,NCT02444741,Phase Ib/II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",MK-3475 and Hypofractionated Stereotactic Radiation Therapy in Patients With Non-Small Cell Lung Cancer (NSCLC),3908
283,NCT02448251,Phase Ib/II,Recruiting,"[{'id': 2909, 'therapyName': 'AC0010MA'}]","Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010MA in Advanced Non Small Cell Lung Cancer",3908
284,NCT02448303,Phase II,"Active, not recruiting","[{'id': 1605, 'therapyName': 'Acalabrutinib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab Alone and In Combination With ACP-196 in Subjects With Advanced Non-small Cell Lung Cancer,3908
285,NCT02450539,Phase II,"Active, not recruiting","[{'id': 802, 'therapyName': 'Abemaciclib'}, {'id': 720, 'therapyName': 'Docetaxel'}]",A Study of Abemaciclib (LY2835219) in Participants With Stage IV Squamous Non-small Cell Lung Cancer,3908
286,NCT02451852,Phase I,No longer available,"[{'id': 660, 'therapyName': 'Osimertinib'}]",AZD9291 US Expanded Access Program,3908
287,NCT02451865,Phase I,Withdrawn,"[{'id': 2740, 'therapyName': 'Binimetinib + Docetaxel'}]","Binimetinib With Docetaxel in Treating Patients With Previously Treated, Stage IV Non-small Cell Lung Cancer",3908
288,NCT02451930,Phase I,"Active, not recruiting","[{'id': 826, 'therapyName': 'Necitumumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Study of the Combination of Necitumumab (LY3012211) and Pembrolizumab (MK3475) in Participants With NSCLC,3908
289,NCT02452424,Phase Ib/II,"Active, not recruiting","[{'id': 2736, 'therapyName': 'Pembrolizumab + PLX3397'}]",A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors,3908
290,NCT02453282,Phase III,"Active, not recruiting","[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]",Phase III Open Label First Line Therapy Study of MEDI 4736 With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC).,3908
291,NCT02454842,Phase II,Terminated,"[{'id': 2910, 'therapyName': 'TH-4000'}]","Study for Treatment of Patients With EGFR Mutant, T790M-negative NSCLC",3908
292,NCT02454933,Phase III,"Active, not recruiting","[{'id': 660, 'therapyName': 'Osimertinib'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",Study of AZD9291 Plus MEDI4736 Versus AZD9291 Monotherapy in NSCLC After Previous EGFR TKI Therapy in T790M Mutation Positive Tumours,3908
293,NCT02460224,Phase Ib/II,Recruiting,"[{'id': 2887, 'therapyName': 'LAG525'}, {'id': 2659, 'therapyName': 'PDR001'}]",Safety and Efficay of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies,3908
294,NCT02460367,Phase Ib/II,Recruiting,"[{'id': 3578, 'therapyName': 'Docetaxel + Indoximod'}]",Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer,3908
295,NCT02463994,Phase I,"Active, not recruiting","[{'id': 1201, 'therapyName': 'Atezolizumab'}]",A Pilot Study of MPDL3280A and HIGRT in Metastatic NSCLC,3908
296,NCT02468661,Phase Ib/II,Recruiting,"[{'id': 1065, 'therapyName': 'Capmatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}]","A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification",3908
297,NCT02469701,Phase II,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}]",BrUOG 317: Nivolumab and Ablation For Patients With Advanced Non-Small Cell Lung Cancer Progressing After at Least One Prior Therapy For Metastatic Disease,3908
298,NCT02471846,Phase I,"Active, not recruiting","[{'id': 2888, 'therapyName': 'GDC-0919'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study of GDC-0919 and MPDL3280A Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors,3908
299,NCT02474355,Phase III,Recruiting,"[{'id': 660, 'therapyName': 'Osimertinib'}]",Real World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLC,3908
300,NCT02475213,Phase I,Recruiting,"[{'id': 2864, 'therapyName': 'MGA271 + Pembrolizumab'}]",Safety Study of MGA271 in Combination With Pembrolizumab in Refractory Cancer,3908
301,NCT02475382,Expanded access,No longer available,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Expanded Access Program With Nivolumab Therapy for Treatment of Advanced/Metastatic SqNSCLC or Non-SqNSCLC After One Prior Systemic Regimen (CheckMate 169),3908
302,NCT02477826,Phase III,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}]","An Open-Label, Trial of Nivolumab and Nivolumab Plus Ipilimumab Versus Platinum Doublet Chemotherapy in Subjects With Stage IV Non-Small Cell Lung Cancer (NSCLC)",3908
303,NCT02485652,Phase II,"Active, not recruiting","[{'id': 2137, 'therapyName': 'HM61713'}]",Phase II Trial of HM61713 (BI 1482694) for the Treatment of >2nd Line T790M Mutation Positive Adenocarcinoma of the Lung (NSCLC),3908
304,NCT02486718,Phase III,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}]",Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer,3908
305,NCT02487095,Phase Ib/II,Recruiting,"[{'id': 2879, 'therapyName': 'VX-970'}, {'id': 942, 'therapyName': 'Topotecan'}]","Trial of Topotecan With VX-970, an ATR Kinase Inhibitor, in Small Cell Lung Cancer",3908
306,NCT02489903,Phase II,Recruiting,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 3680, 'therapyName': 'RRx-001'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 619, 'therapyName': 'Abraxane'}]","RRx-001 in Small, Non-small Cell Lung Cancer, and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens",3908
307,NCT02495636,Phase II,Withdrawn,"[{'id': 4204, 'therapyName': 'Atezolizumab + DEC-205-NY-ESO-1 fusion protein vaccine'}]","Phase 2 Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent Non-Small Cell Lung Cancer",3908
308,NCT02496663,Phase I,Recruiting,"[{'id': 826, 'therapyName': 'Necitumumab'}, {'id': 660, 'therapyName': 'Osimertinib'}]",EGFR Inhibitor AZD9291 and Necitumumab in Treating Patients With EGFR-Positive Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor,3908
309,NCT02498613,Phase II,Recruiting,"[{'id': 1971, 'therapyName': 'Cediranib + Olaparib'}]",Cediranib Maleate and Olaparib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery,3908
310,NCT02498665,Phase I,Recruiting,"[{'id': 4320, 'therapyName': 'DSP-7888'}]",A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies,3908
311,NCT02501096,Phase Ib/II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 792, 'therapyName': 'Lenvatinib'}]",Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors,3908
312,NCT02503358,Phase I,Recruiting,"[{'id': 913, 'therapyName': 'Selumetinib'}, {'id': 619, 'therapyName': 'Abraxane'}]",Selumetinib and Nab-Paclitaxel (Albumin-stabilized Nanoparticle Formulation) as Second-Line Treatment in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer,3908
313,NCT02503722,Phase I,Recruiting,"[{'id': 2994, 'therapyName': 'AZD9291 + MLN0128'}]",TORC1/2 Inhibitor INK128 and EGFR Inhibitor AZD9291 in Treating Patients With Advanced EGFR Mutation Positive Non-small Cell Lung Cancer After Progression on a Previous EGFR Tyrosine Kinase Inhibitor,3908
314,NCT02504489,Phase III,Recruiting,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 3679, 'therapyName': 'Docetaxel + Plinabulin'}]",Plinabulin (P) + Docetaxel (D) vs D as 2nd-Line Chemo in Patients With Advanced NSCLC With at Least 1 Large Lung Lesion,3908
315,NCT02511106,Phase III,Recruiting,"[{'id': 660, 'therapyName': 'Osimertinib'}]","AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy",3908
316,NCT02511184,Phase I,Recruiting,"[{'id': 706, 'therapyName': 'Crizotinib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Crizotinib Plus Pembrolizumab In Alk-positive Advanced Non Small Cell Lung Cancer Patients,3908
317,NCT02514174,FDA approved,Recruiting,"[{'id': 623, 'therapyName': 'Afatinib'}]",Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older,3908
318,NCT02516813,Phase I,Recruiting,"[{'id': 3616, 'therapyName': 'MSC2490484A '}]","Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy",3908
319,NCT02520778,Phase I,Recruiting,"[{'id': 3065, 'therapyName': 'Navitoclax + Osimertinib'}]",EGFR Inhibitor AZD9291 and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer,3908
320,NCT02521051,Phase Ib/II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 698, 'therapyName': 'Alectinib'}]","Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer",3908
321,NCT02523469,Phase Ib/II,Recruiting,"[{'id': 3061, 'therapyName': 'ALT-803 + Nivolumab'}]","ALT-803 Plus Nivolumab in Patients With Pretreated, Advanced or Metastatic Non-Small Cell Lung Cancer",3908
322,NCT02525757,Phase II,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",MPDL3280A With Chemoradiation for Lung Cancer,3908
323,NCT02526017,Phase I,Recruiting,"[{'id': 2840, 'therapyName': 'FPA008'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Study of FPA008 in Combination With Nivolumab in Patients With Selected Advance Cancers,3908
324,NCT02528357,Phase I,Recruiting,"[{'id': 5177, 'therapyName': 'GSK3174998'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",GSK3174998 Alone or With Pembrolizumab in Subjects With Advanced Solid Tumors,3908
325,NCT02535338,Phase Ib/II,Recruiting,"[{'id': 3071, 'therapyName': 'Erlotinib + Onalespib'}]",Erlotinib Hydrochloride and Hsp90 Inhibitor AT13387 in Treating Patients With Recurrent or Metastatic Non-small Cell Lung Cancer,3908
326,NCT02537561,Phase I,Withdrawn,"[{'id': 682, 'therapyName': 'Talazoparib'}, {'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}]",Talazoparib in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors,3908
327,NCT02540291,Phase I,Recruiting,"[{'id': 5694, 'therapyName': 'E7046'}]",Study of E7046 in Subjects With Selected Advanced Malignancies,3908
328,NCT02542293,Phase III,Recruiting,"[{'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}]",Study of 1st Line Therapy Study of MEDI4736 With Tremelimumab Versus SoC in Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE).,3908
329,NCT02543645,Phase Ib/II,Terminated,"[{'id': 3086, 'therapyName': 'Atezolizumab + Varlilumab'}]",A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer,3908
330,NCT02544633,Phase II,Recruiting,"[{'id': 809, 'therapyName': 'MGCD265'}]",Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET,3908
331,NCT02546986,Phase II,"Active, not recruiting","[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer,3908
332,NCT02547675,Phase I,No longer available,"[{'id': 1003, 'therapyName': 'CO1686'}]",Rociletinib (CO-1686) USA Expanded Access Program,3908
333,NCT02554812,Phase I,Recruiting,"[{'id': 6043, 'therapyName': 'Avelumab + Utomilumab'}]",A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley),3908
334,NCT02563548,Phase I,Recruiting,"[{'id': 5779, 'therapyName': 'PEGPH20 + Pembrolizumab'}]",Phase 1b Open-Label Study of PEGPH20 With Pembrolizumab,3908
335,NCT02568267,Phase II,Recruiting,"[{'id': 1455, 'therapyName': 'Entrectinib'}]","Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK1/2/3, ROS1, or ALK Gene Rearrangements  (STARTRK-2)",3908
336,NCT02572687,Phase I,Recruiting,"[{'id': 3257, 'therapyName': 'MEDI4736 + Ramucirumab'}]",A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies,3908
337,NCT02574078,Phase I,Recruiting,"[{'id': 619, 'therapyName': 'Abraxane'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2114, 'therapyName': 'Bevacizumab + Pemetrexed'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",A Master Protocol Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) (CheckMate 370),3908
338,NCT02575781,Phase I,Recruiting,"[{'id': 4026, 'therapyName': 'SAR428926'}]",A Study of SAR428926 in Patients With Advanced Solid Tumors,3908
339,NCT02576431,Phase II,Recruiting,"[{'id': 2650, 'therapyName': 'LOXO-101'}]",Study of LOXO-101 in Subjects With NTRK Fusion Positive Solid Tumors,3908
340,NCT02576574,Phase III,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 3144, 'therapyName': 'Avelumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",Avelumab in First-line Non-Small Cell Lung Cancer (JAVELIN Lung 100),3908
341,NCT02576665,Phase I,Recruiting,"[{'id': 3211, 'therapyName': 'Toca 511 + Toca FC'}]","A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Solid Tumors (Toca6)",3908
342,NCT02578680,Phase III,"Active, not recruiting","[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Study of Platinum+Pemetrexed Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Non-squamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189),3908
343,NCT02580708,Phase Ib/II,Completed,"[{'id': 2, 'therapyName': 'Trametinib'}, {'id': 1003, 'therapyName': 'CO1686'}]",A Phase 1/2 Study of the Safety and Efficacy of Rociletinib When Administered in Combination With Trametinib in Patients With Activating EGFR Mutation-positive Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC),3908
344,NCT02581787,Phase Ib/II,Recruiting,"[{'id': 2707, 'therapyName': 'fresolimumab'}]",SABR-ATAC: A Trial of TGF-beta Inhibition and Stereotactic Ablative Radiotherapy for Early Stage Non-small Cell Lung Cancer,3908
345,NCT02581943,Phase II,Suspended,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",Effect of Pembrolizumab With or Without Carboplatin and Paclitaxel on Immune Response in Patients With Recurrent or Stage IIIB-IV Non-small Cell Lung Cancer,3908
346,NCT02584634,Phase I,Recruiting,"[{'id': 706, 'therapyName': 'Crizotinib'}, {'id': 3144, 'therapyName': 'Avelumab'}, {'id': 869, 'therapyName': 'PF-06463922'}]","Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101)",3908
347,NCT02588261,Phase III,"Active, not recruiting","[{'id': 1082, 'therapyName': 'ASP8273'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 4, 'therapyName': 'Erlotinib'}]",A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations,3908
348,NCT02589522,Phase I,Recruiting,"[{'id': 2879, 'therapyName': 'VX-970'}]",VX-970 and Whole Brain Radiation Therapy in Treating Patients With Brain Metastases From Non-Small Cell Lung Cancer,3908
349,NCT02591615,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}]",Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLC,3908
350,NCT02595866,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms",3908
351,NCT02595944,Phase III,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (ANVIL),3908
352,NCT02599454,Phase I,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}]",Atezolizumab and Stereotactic Body Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer,3908
353,NCT02605746,Phase I,Recruiting,"[{'id': 789, 'therapyName': 'Ceritinib'}]",Preoperative Ceritinib (LDK378) in Glioblastoma Multiforme and CNS Metastasis,3908
354,NCT02608268,Phase Ib/II,Recruiting,"[{'id': 2659, 'therapyName': 'PDR001'}, {'id': 3560, 'therapyName': 'MBG453'}]",Safety and Efficacy of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies,3908
355,NCT02608385,Phase I,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors,3908
356,NCT02616393,Phase II,Recruiting,"[{'id': 967, 'therapyName': 'XL647'}]","Study of Tesevatinib in Subjects With Non-Small Cell Lung Cancer, EGFR Activating Mutation, Prior Treatment With a Tyrosine Kinase Inhibitor, and Brain Metastases or Leptomeningeal Metastases",3908
357,NCT02621398,Phase I,Suspended,"[{'id': 2103, 'therapyName': 'Carboplatin + Paclitaxel + Pembrolizumab'}]","Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung Cancer",3908
358,NCT02630186,Phase Ib/II,"Active, not recruiting","[{'id': 3575, 'therapyName': 'Atezolizumab + CO1686'}]",A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLC,3908
359,NCT02631733,Phase I,Recruiting,"[{'id': 3314, 'therapyName': 'Irinotecan + Veliparib'}]",Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery,3908
360,NCT02635061,Phase I,Recruiting,"[{'id': 3312, 'therapyName': 'ACY-241 + Ipilimumab + Nivolumab'}]",Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non Small Cell Lung Cancer,3908
361,NCT02637531,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 3363, 'therapyName': 'IPI-549'}]","A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549",3908
362,NCT02638090,Phase Ib/II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1077, 'therapyName': 'Vorinostat'}]",Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC),3908
363,NCT02639026,Phase I,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]","Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers",3908
364,NCT02639091,Phase I,Recruiting,"[{'id': 4617, 'therapyName': 'Anetumab ravtansine + Cisplatin + Pemetrexed'}]",Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors,3908
365,NCT02639234,Phase II,Withdrawn,"[{'id': 3572, 'therapyName': 'FANG vaccine + Nivolumab'}]",Vigil + Nivolumab in Advanced Non-Small Cell Lung Cancer,3908
366,NCT02640508,Phase II,Recruiting,"[{'id': 3352, 'therapyName': 'Eribulin + Lenvatinib'}]",Eribulin and Lenvatinib in Advanced Solid Tumors,3908
367,NCT02642042,Phase II,Recruiting,"[{'id': 1264, 'therapyName': 'Docetaxel + Trametinib'}]",Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV Non-small Cell Lung Cancer,3908
368,NCT02642939,Phase II,Recruiting,"[{'id': 2603, 'therapyName': 'Mifepristone'}]",Study of Oral Mifepristone as Salvage Therapy in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer,3908
369,NCT02646748,Phase I,Recruiting,"[{'id': 3088, 'therapyName': 'INCB050465 '}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2406, 'therapyName': 'INCB039110'}]",Pembrolizumab Combined With INCB039110 and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors,3908
370,NCT02650635,Phase I,"Active, not recruiting","[{'id': 3413, 'therapyName': 'Cyclophosphamide + Pegfilgrastim + VTX-2337'}]","TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors",3908
371,NCT02654587,Phase III,"Active, not recruiting","[{'id': 4327, 'therapyName': 'OSE 2101 '}, {'id': 4328, 'therapyName': 'Docetaxel + Pemetrexed'}]",Study of OSE2101 Versus Standard Treatment as 2nd or 3rd Line in HLA-A2 Positive Patients With Advanced NSCLC (ATALANTE 1),3908
372,NCT02655822,Phase I,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 3571, 'therapyName': 'CPI-444 '}]",Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers,3908
373,NCT02657434,Phase III,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 854, 'therapyName': 'Pemetrexed'}]",A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer,3908
374,NCT02658097,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","A Randomized Two Arm Phase II Trial of Pembrolizumab Alone or Sequentially Following Single Fraction Non-ablative Radiation to One of the Target Lesions, in Previously Treated Patients With Stage IV NSCLC",3908
375,NCT02659059,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab Plus Ipilimumab to Treat First Line Stage IV Non-Small Cell Lung Cancer (CheckMate568),3908
376,NCT02664181,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 5910, 'therapyName': 'Decitabine + Nivolumab + Tetrahydrouridine'}]",Pharmacologically Rational EpigenetiC Immunotherapy for SEcond Line Therapy in Patients With Non-Small Cell Lung Cancer (PRECISE),3908
377,NCT02666105,Phase II,Recruiting,"[{'id': 738, 'therapyName': 'Exemestane'}]",Exemestane in Post-Menopausal Women With NSCLC,3908
378,NCT02669914,Phase II,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}]",MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors,3908
379,NCT02671955,Phase I,Terminated,"[{'id': 3614, 'therapyName': 'JNJ-61610588 '}]","A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced Cancer",3908
380,NCT02681549,Phase II,Recruiting,"[{'id': 2119, 'therapyName': 'Bevacizumab + Pembrolizumab'}]",Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer,3908
381,NCT02684461,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Phase II Trial of Sequential Consolidation With Pembrolizumab Followed by Nab-paclitaxel,3908
382,NCT02695290,Phase III,Terminated,"[{'id': 623, 'therapyName': 'Afatinib'}]",Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status (ECOG 2 or 3),3908
383,NCT02696993,Phase Ib/II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Phase I/II Trial of Nivolumab With Radiation or Nivolumab and Ipilimumab With Radiation for the Treatment of Intracranial Metastases From Non-small Cell Lung Cancer,3908
384,NCT02697591,Phase Ib/II,Recruiting,"[{'id': 4321, 'therapyName': 'INCAGN01876'}]","An Open-Label, Dose-Escalation, Safety Study of INCAGN01876 in Subjects With Advanced or Metastatic Solid Tumors",3908
385,NCT02698176,Phase I,Terminated,"[{'id': 2034, 'therapyName': 'OTX015'}]",A Dose Exploration Study With MK-8628 in Participants With Selected Advanced Solid Tumors (MK-8628-006),3908
386,NCT02706626,Phase II,Recruiting,"[{'id': 634, 'therapyName': 'AP26113'}]",Trial of Brigatinib After Treatment With Second-Generation ALK Inhibitors,3908
387,NCT02710396,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Genetic Predictors of Benefit to Pembrolizumab,3908
388,NCT02713529,Phase Ib/II,Recruiting,"[{'id': 4170, 'therapyName': 'AMG820 + Pembrolizumab'}]",Safety Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer,3908
389,NCT02713828,Phase Ib/II,Recruiting,"[{'id': 3597, 'therapyName': 'Glembatumumab vedotin'}]","Study of Glembatumumab Vedotin in gpNMB-Expressing, Advanced or Metastatic SCC of the Lung",3908
390,NCT02713867,Phase III,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]","A Dose Frequency Optimization,Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks (CheckMate 384)",3908
391,NCT02716038,Phase II,Recruiting,"[{'id': 3946, 'therapyName': 'Atezolizumab + Carboplatin + nab-Paclitaxel'}]","Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC",3908
392,NCT02716116,Phase Ib/II,Recruiting,"[{'id': 3981, 'therapyName': 'AP32788'}]",A Trial of AP32788 in Non-Small Cell Lung Cancer,3908
393,NCT02718066,Phase Ib/II,Recruiting,"[{'id': 4689, 'therapyName': 'Chidamide + Nivolumab'}]","Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer",3908
394,NCT02723955,Phase I,Recruiting,"[{'id': 4409, 'therapyName': 'GSK3359609'}, {'id': 4410, 'therapyName': 'GSK3359609 + Pembrolizumab'}]",Dose Escalation and Expansion Study of GSK3359609 in Subjects With Selected Advanced Solid Tumors (INDUCE-1),3908
395,NCT02730247,Phase II,Recruiting,"[{'id': 2039, 'therapyName': 'Abraxane + Ramucirumab'}]",Clinical Trial of the Safety and Efficacy of the Addition of Ramucirumab to Nab-paclitaxel in Previously Treated Patients With Advanced Non-small Cell Lung Cancer (NSCLC),3908
396,NCT02733250,Phase Ib/II,Recruiting,"[{'id': 4023, 'therapyName': 'nab-paclitaxel + Pembrolizumab'}]",Pembrolizumab With Nab-Paclitaxel in Non-Small Cell Lung Cancer (URCOH-PMS-001),3908
397,NCT02737501,Phase III,"Active, not recruiting","[{'id': 634, 'therapyName': 'AP26113'}, {'id': 706, 'therapyName': 'Crizotinib'}]",ALTA-1L Study: A Phase 3 Study of Brigatinib Versus Crizotinib in ALK-positive Advanced Non-Small Cell Lung Cancer Patients,3908
398,NCT02740985,Phase I,Recruiting,"[{'id': 4223, 'therapyName': 'AZD4635'}, {'id': 4349, 'therapyName': 'AZD4635 + MEDI4736'}]",A Phase 1 Clinical Study of AZD4635 and Durvalumab in Patients With Advanced Solid Malignancies,3908
399,NCT02750215,Phase II,"Active, not recruiting","[{'id': 1065, 'therapyName': 'Capmatinib'}]",A Study of Capmatinib (INC280) in NSCLC Patients With MET Exon 14 Alterations Who Have Received Prior MET Inhibitor,3908
400,NCT02750514,Phase II,Recruiting,"[{'id': 1813, 'therapyName': 'Dasatinib + Nivolumab'}, {'id': 4197, 'therapyName': 'BMS-986016 + Nivolumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",A Study to Test Combination Treatments in People With Advanced Non-Small Cell Lung Cancer,3908
401,NCT02767804,Phase III,Recruiting,"[{'id': 706, 'therapyName': 'Crizotinib'}, {'id': 961, 'therapyName': 'X-396'}]",eXalt3: Study Comparing X-396 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients,3908
402,NCT02768558,Phase III,Recruiting,"[{'id': 2585, 'therapyName': 'Cisplatin + Etoposide'}, {'id': 4922, 'therapyName': 'Cisplatin + Etoposide + Nivolumab'}]",Cisplatin and Etoposide Plus Radiation Followed By Nivolumab/Placebo For Locally Advanced NSCLC,3908
403,NCT02770014,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}]",Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer,3908
404,NCT02775435,Phase III,Recruiting,"[{'id': 2634, 'therapyName': 'Carboplatin + nab-paclitaxel'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407),3908
405,NCT02779751,Phase II,Recruiting,"[{'id': 4242, 'therapyName': 'Abemaciclib + Pembrolizumab'}]",A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer,3908
406,NCT02784158,Phase I,No longer available,"[{'id': 634, 'therapyName': 'AP26113'}]",An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer,3908
407,NCT02789345,Phase I,Recruiting,"[{'id': 4379, 'therapyName': 'Osimertinib + Ramucirumab'}, {'id': 4380, 'therapyName': 'Necitumumab + Osimertinib'}]",A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer,3908
408,NCT02795156,Phase II,Recruiting,"[{'id': 623, 'therapyName': 'Afatinib'}, {'id': 890, 'therapyName': 'Regorafenib'}]",Study to Assess the Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations,3908
409,NCT02803203,Phase Ib/II,Recruiting,"[{'id': 4366, 'therapyName': 'Bevacizumab + Osimertinib'}]",Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers,3908
410,NCT02805660,Phase Ib/II,Recruiting,"[{'id': 4378, 'therapyName': 'MEDI4736 + Mocetinostat'}]",Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC,3908
411,NCT02810457,Phase III,Recruiting,"[{'id': 1152, 'therapyName': 'Bevacizumab + Carboplatin + Paclitaxel'}]",Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer (AVANA),3908
412,NCT02812667,Phase I,Recruiting,"[{'id': 4512, 'therapyName': 'Nivolumab + Plinabulin'}]",Nivolumab in Combination With Plinabulin in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC),3908
413,NCT02818920,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Neoadjuvant Pembrolizumab,3908
414,NCT02823990,Phase II,Recruiting,"[{'id': 4435, 'therapyName': 'MVA-MUC1-IL2 vaccine + Nivolumab'}]",TG4010 and Nivolumab in Patients With Lung Cancer,3908
415,NCT02824042,Phase I,Recruiting,"[{'id': 4594, 'therapyName': 'Anetumab ravtansine + Itraconazole'}, {'id': 4593, 'therapyName': 'Anetumab ravtansine'}]",Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole,3908
416,NCT02826161,Phase III,Terminated,"[{'id': 2586, 'therapyName': 'BBI608 + Paclitaxel'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]","A Study of Napabucasin (BBI-608) Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Cancer (CanStem43L)",3908
417,NCT02831491,Phase II,Withdrawn,"[{'id': 1423, 'therapyName': 'Ramucirumab + Docetaxel'}]",A Study of Ramucirumab (LY3009806) in Combination With Weekly Docetaxel in Participants With Stage IV Non-Small Cell Lung Cancer,3908
418,NCT02831933,Phase II,Recruiting,"[{'id': 4462, 'therapyName': 'AdV-tk + Nivolumab'}]",Trial of Stereotactic Body Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung Carcinoma (ENSIGN),3908
419,NCT02834247,Phase I,Recruiting,"[{'id': 4680, 'therapyName': 'Nivolumab + TAK-659'}]",A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors,3908
420,NCT02835833,Phase I,Recruiting,"[{'id': 4498, 'therapyName': 'Bevacizumab + Nintedanib'}]",Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors,3908
421,NCT02840994,Phase Ib/II,Recruiting,"[{'id': 5244, 'therapyName': 'CV301 + Nivolumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",A Trial of CV301 in Combination With Nivolumab Versus Nivolumab in Subjects With Previously Treated Non-Small Cell Lung Cancer,3908
422,NCT02846792,Phase Ib/II,Recruiting,"[{'id': 4512, 'therapyName': 'Nivolumab + Plinabulin'}]","Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer",3908
423,NCT02848651,Phase II,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study of Atezolizumab (MPDL3280A) as First-line Monotherapy for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC): Clinical Evaluation of Novel Blood-Based Diagnostics [B-F1RST],3908
424,NCT02855125,Phase II,Recruiting,"[{'id': 1407, 'therapyName': 'TS-1'}, {'id': 4527, 'therapyName': 'TAS-114 + TS-1'}]",A Randomized Phase 2 Trial of TAS-114 in Combination With S-1 Versus S-1,3908
425,NCT02857270,Phase I,Recruiting,"[{'id': 4588, 'therapyName': 'LY3214996'}, {'id': 4590, 'therapyName': 'LY3214996 + nab-paclitaxel + Gemcitabine'}, {'id': 4589, 'therapyName': 'LY3214996 + Midazolam'}, {'id': 4591, 'therapyName': 'LY3214996 + Abemaciclib'}]",A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer,3908
426,NCT02858869,Phase 0,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases,3908
427,NCT02860780,Phase I,Completed,"[{'id': 4587, 'therapyName': 'Prexasertib + Ralimetinib'}]",A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer,3908
428,NCT02864251,Phase III,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 4616, 'therapyName': 'Carboplatin + Cisplatin + Pemetrexed'}]","A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Patients With EGFR Mutation, T790M Negative NSCLC Who Have Failed 1L EGFR TKI Therapy (CheckMate722)",3908
429,NCT02869789,Phase III,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Safety Study of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers,3908
430,NCT02879617,Phase II,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}]",A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients,3908
431,NCT02879760,Phase Ib/II,Recruiting,"[{'id': 5085, 'therapyName': 'Pembrolizumab + Ad-MAGEA3 + MG1-MAGEA3'}]",Oncolytic MG1-MAGEA3 With Ad-MAGEA3 Vaccine in Combination With Pembrolizumab for Non-Small Cell Lung Cancer Patients,3908
432,NCT02879994,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","Pembrolizumab in Treating Patients With EGFR Mutant, Tyrosine Kinase Inhibitor Naive Advanced Non-Small Cell Lung Cancer",3908
433,NCT02880371,Phase Ib/II,Recruiting,"[{'id': 4608, 'therapyName': 'ARRY-382 + Pembrolizumab'}]",A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors,3908
434,NCT02888743,Phase II,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer,3908
435,NCT02890069,Phase I,Recruiting,"[{'id': 5311, 'therapyName': 'PDR001 + LCL161'}, {'id': 5312, 'therapyName': 'PDR001 + Everolimus'}, {'id': 5313, 'therapyName': 'PDR001 + Panobinostat'}]","A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat",3908
436,NCT02897375,Phase I,Recruiting,"[{'id': 4734, 'therapyName': 'Cisplatin + Palbociclib'}, {'id': 4735, 'therapyName': 'Carboplatin + Palbociclib'}]",Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,3908
437,NCT02897765,Phase I,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 4733, 'therapyName': 'NEO-PV-01 + poly ICLC'}]","A Personalized Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer",3908
438,NCT02898116,Phase Ib/II,Recruiting,"[{'id': 4730, 'therapyName': 'MEDI4736 + X-396'}, {'id': 961, 'therapyName': 'X-396'}]","A Study of ALK Inhibitor, Ensartinib, and Anti-PD-L1, Durvalumab, in Subjects With ALK-rearranged Non-small Cell Lung Cancer",3908
439,NCT02900664,Phase I,Recruiting,"[{'id': 5399, 'therapyName': 'PDR001 + EGF816'}, {'id': 5397, 'therapyName': 'PDR001 + CJM112'}, {'id': 5398, 'therapyName': 'PDR001 + Trametinib'}, {'id': 5395, 'therapyName': 'PDR001 + Canakinumab'}]","A Study of PDR001 in Combination With CJM112, EGF816, Ilaris (Canakinumab) or Mekinist (Trametinib)",3908
440,NCT02904954,Phase II,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}]",Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage IB and II Non-small Cell Lung Cancer,3908
441,NCT02917993,Phase Ib/II,Recruiting,"[{'id': 4777, 'therapyName': 'INCB039110 + Osimertinib'}]",An Open-Label Phase 1/2 Study of INCB039110 in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer,3908
442,NCT02919449,Phase I,Recruiting,"[{'id': 6127, 'therapyName': 'MV-NIS + Atezolizumab'}]",Trial of Measles Virotherapy in Combination With Atezolizumab in Patients With Metastatic Non-Small Cell Lung Cancer,3908
443,NCT02920450,Phase Ib/II,Recruiting,"[{'id': 4785, 'therapyName': 'Gedatolisib + Paclitaxel + Carboplatin'}]","Study of Paclitaxel, Carboplatin, and PF-05212384 in Advanced or Metastatic NSCLC",3908
444,NCT02920996,Phase II,Recruiting,"[{'id': 1030, 'therapyName': 'LY2801653'}]",Merestinib In Non-Small Cell Lung Cancer And Solid Tumors,3908
445,NCT02922777,Phase I,Recruiting,"[{'id': 5973, 'therapyName': 'BGB-324 + Docetaxel'}]",Trial of Dose Escalated BGB324 in Previously Treated Non-small Cell Lung Cancer.,3908
446,NCT02923349,Phase Ib/II,Recruiting,"[{'id': 5831, 'therapyName': 'INCAGN01949'}]","A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors",3908
447,NCT02926768,Phase Ib/II,Recruiting,"[{'id': 5329, 'therapyName': 'CK-101'}]",Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors,3908
448,NCT02927301,Phase II,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}]","A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Stage IB, II, or IIIA Resectable and Untreated Non-Small Cell Lung Cancer (NSCLC)",3908
449,NCT02927340,Phase II,Recruiting,"[{'id': 869, 'therapyName': 'PF-06463922'}]",A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions,3908
450,NCT02936102,Phase I,Recruiting,"[{'id': 4971, 'therapyName': 'FAZ053'}, {'id': 4972, 'therapyName': 'FAZ053 + PDR001'}]",A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.,3908
451,NCT02941601,Phase II,Withdrawn,"[{'id': 4973, 'therapyName': 'Necitumumab + Gemcitabine + Carboplatin'}]",A Study of Gemcitabine-Carboplatin Plus Necitumumab (LY3012211) in Chemotherapy-Naïve Participants With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC),3908
452,NCT02942095,Phase I,Recruiting,"[{'id': 4885, 'therapyName': 'Erlotinib + Ixazomib'}]",Phase I Study of Ixazomib and Erlotinib in Solid Tumors,3908
453,NCT02944396,Phase II,Recruiting,"[{'id': 5054, 'therapyName': 'Carboplatin + Paclitaxel + Pemetrexed + Veliparib'}, {'id': 5053, 'therapyName': 'Carboplatin + Paclitaxel + Pemetrexed + Nivolumab + Veliparib'}]",Study of Veliparib in Combination With Nivolumab and Platinum Doublet Chemotherapy in Participants With Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC),3908
454,NCT02947165,Phase I,Recruiting,"[{'id': 5632, 'therapyName': 'NIS793 + PDR001'}, {'id': 5631, 'therapyName': 'NIS793'}]",Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.,3908
455,NCT02947386,Phase Ib/II,Recruiting,"[{'id': 4920, 'therapyName': 'Nimotuzumab + Nivolumab'}]",Nimotuzumab and Nivolumab in Treating Patients With Advanced Non-small Cell Lung Cancer,3908
456,NCT02949843,Phase II,Recruiting,"[{'id': 4918, 'therapyName': 'Nivolumab + Pembrolizumab'}]",Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations,3908
457,NCT02950038,Phase II,Withdrawn,"[{'id': 3198, 'therapyName': 'Ibrutinib + Nivolumab'}]",Study of Ibrutinib Followed by Ibrutinib in Combination With Nivolumab in Non-Small Cell Lung Cancer (NSCLC),3908
458,NCT02952248,Phase I,Recruiting,"[{'id': 5692, 'therapyName': 'BI 754091'}]",A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours,3908
459,NCT02952729,Phase I,Recruiting,"[{'id': 5834, 'therapyName': 'XMT-1522'}]",Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2,3908
460,NCT02952989,Phase I,Recruiting,"[{'id': 5896, 'therapyName': 'SGN-2FF'}]",A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors,3908
461,NCT02954523,Phase Ib/II,Recruiting,"[{'id': 4946, 'therapyName': 'Dasatinib + Osimertinib'}]",Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations,3908
462,NCT02954991,Phase II,Recruiting,"[{'id': 4943, 'therapyName': 'MGCD516 + Nivolumab'}, {'id': 4944, 'therapyName': 'Mocetinostat + Nivolumab'}, {'id': 4942, 'therapyName': 'MGCD265 + Nivolumab'}]","Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer",3908
463,NCT02955290,Phase Ib/II,Recruiting,"[{'id': 4941, 'therapyName': 'CIMAvax-EGF + Nivolumab'}]",CIMAvax Vaccine and Nivolumab in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer,3908
464,NCT02955758,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer,3908
465,NCT02959437,Phase Ib/II,Recruiting,"[{'id': 5477, 'therapyName': 'Azacitidine + INCB024360 + Pembrolizumab'}]",Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206),3908
466,NCT02963610,Phase Ib/II,Recruiting,"[{'id': 3322, 'therapyName': 'lenalidomide + Pembrolizumab'}]",Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer,3908
467,NCT02965885,Phase I,Recruiting,"[{'id': 2768, 'therapyName': 'TAS-116'}]",A Study of TAS-116 in Patients With Solid Tumors,3908
468,NCT02971501,Phase II,Recruiting,"[{'id': 660, 'therapyName': 'Osimertinib'}, {'id': 4366, 'therapyName': 'Bevacizumab + Osimertinib'}]",Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases,3908
469,NCT02978404,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases,3908
470,NCT02981108,Phase Ib/II,Recruiting,"[{'id': 5830, 'therapyName': 'HS-10296'}]","A Study to Evaluate Safety, PK and Efficacy of HS-10296 in Patients With NSCLC",3908
471,NCT02983045,Phase Ib/II,Recruiting,"[{'id': 5076, 'therapyName': 'NKTR-214 + Nivolumab'}]",A Dose Escalation and Cohort Expansion Study of CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 Antibody (Nivolumab) in Patients With Select Advanced or Metastatic Solid Tumors (PIVOT-02),3908
472,NCT02983578,Phase II,Recruiting,"[{'id': 3098, 'therapyName': 'AZD9150 + MEDI4736'}]","AZD9150 With MEDI4736 in Patients With Advanced Pancreatic, Non-Small Lung and Colorectal Cancer",3908
473,NCT02987998,Phase I,Recruiting,"[{'id': 5145, 'therapyName': 'Cisplatin + Etoposide + Pembrolizumab'}]",Neoadjuvant Chemoradiation Plus Pembrolizumab Followed By Consolidation Pembrolizumab in NSCLC,3908
474,NCT02991651,Phase I,Recruiting,"[{'id': 5135, 'therapyName': 'Erlotinib + IRX4204'}]",Study of IRX4204 With Erlotinib in Previously Treated Advanced NSCLC,3908
475,NCT02998528,Phase III,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 5241, 'therapyName': 'Cisplatin + Vinorelbine + Gemcitabine + Docetaxel + Pemetrexed + Carboplatin'}]",A Neoadjuvant Study of Nivolumab and Ipilimumab Compared to Chemotherapy Doublet in Early Stage Non-Small Cell Lung Cancer (NSCLC) (CheckMate 816),3908
476,NCT03001882,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC),3908
477,NCT03003468,Phase Ib/II,Recruiting,"[{'id': 5174, 'therapyName': 'Imprime PGG + Pembrolizumab'}]",Pembrolizumab + Imprime PGG for Metastatic Non-small Cell Lung Cancer After Progression on First-Line Chemotherapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017,3908
478,NCT03004105,Phase II,Not yet recruiting,"[{'id': 3162, 'therapyName': 'MEDI4736 + Selumetinib'}]",MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC),3908
479,NCT03004183,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 5172, 'therapyName': 'AdV-tk + Valacyclovir'}]",SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC,3908
480,NCT03014648,Phase II,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}]",Evaluating the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer (NSCLC),3908
481,NCT03023319,Phase I,Recruiting,"[{'id': 5237, 'therapyName': 'Bosutinib + Pemetrexed'}]",Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors,3908
482,NCT03023423,Phase Ib/II,Recruiting,"[{'id': 5236, 'therapyName': 'Atezolizumab + Daratumumab'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer (DARZALEX),3908
483,NCT03037385,Phase I,Recruiting,"[{'id': 5530, 'therapyName': 'BLU-667'}]","Phase 1 Study of BLU-667 in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors",3908
484,NCT03041181,Phase II,Recruiting,"[{'id': 5288, 'therapyName': 'Docetaxel + Nivolumab'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Docetaxel Plus Nivolumab or Docetaxel Alone in Patients With Advanced Non-squamous NSCLC Previously Treated With Nivolumab,3908
485,NCT03042013,Phase II,Withdrawn,"[{'id': 1082, 'therapyName': 'ASP8273'}]",A Study for Subjects Who Are Participating in an Astellas-sponsored ASP8273 Study,3908
486,NCT03048136,Phase III,Not yet recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer (CheckMate 955),3908
487,NCT03048500,Phase II,Not yet recruiting,"[{'id': 5302, 'therapyName': 'Metformin + Nivolumab'}]",Nivolumab and Metformin Hydrochloride in Treating Patients With Stage III-IV Non-small Cell Lung Cancer That Cannot Be Removed by Surgery,3908
488,NCT03049618,Phase II,Recruiting,"[{'id': 3944, 'therapyName': 'sEphB4-HSA + Pembrolizumab'}]","Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475",3908
489,NCT03050060,Phase II,Recruiting,"[{'id': 5301, 'therapyName': 'Nelfinavir + Nivolumab'}]","Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, and Nivolumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer",3908
490,NCT03050554,Phase Ib/II,Recruiting,"[{'id': 3144, 'therapyName': 'Avelumab'}]",Stereotactic Body Radiation Therapy (SBRT) Combined With Avelumab (Anti-PD-L1) for Management of Early Stage Non-Small Cell Lung Cancer (NSCLC),3908
491,NCT03052608,Phase III,Recruiting,"[{'id': 869, 'therapyName': 'PF-06463922'}, {'id': 706, 'therapyName': 'Crizotinib'}]",A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC,3908
492,NCT03054038,Phase I,Recruiting,"[{'id': 5363, 'therapyName': 'Afatinib + Necitumumab'}]",Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung Cancer,3908
493,NCT03057106,Phase II,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}]",Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC,3908
494,NCT03064854,Phase I,Recruiting,"[{'id': 6027, 'therapyName': 'Carboplatin + Paclitaxel + PDR001'}, {'id': 6026, 'therapyName': 'Cisplatin + Pemetrexed + PDR001'}, {'id': 6025, 'therapyName': 'Cisplatin + Gemcitabine + PDR001'}, {'id': 6024, 'therapyName': 'Pemetrexed + PDR001 + Cisplatin + Carboplatin'}]","PDR001 in Combination With Platinum-doublet Chemotherapy in PD-L1 Unselected, Metastatic NSCLC Patients (ElevatION:NSCLC-101 Trial)",3908
495,NCT03066206,Phase II,Recruiting,"[{'id': 1042, 'therapyName': 'poziotinib'}]",Poziotinib in EGFR Exon 20 Mutant Advanced Non-Small Cell Lung Cancer (NSCLC),3908
496,NCT03071757,Phase I,Recruiting,"[{'id': 5446, 'therapyName': 'ABBV-368'}, {'id': 5447, 'therapyName': 'ABBV-368 + Nivolumab'}]","A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors",3908
497,NCT03076372,Phase I,Recruiting,"[{'id': 5758, 'therapyName': 'MM-310'}]",A Study Evaluating MM-310 in Patients With Solid Tumors,3908
498,NCT03082300,Phase I,Terminated,"[{'id': 1082, 'therapyName': 'ASP8273'}]",A Study of ASP8273 in Subjects With Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations,3908
499,NCT03083808,Phase II,Recruiting,"[{'id': 5497, 'therapyName': 'Pembrolizumab + Gemcitabine'}, {'id': 5496, 'therapyName': 'Docetaxel + Pembrolizumab'}, {'id': 5498, 'therapyName': 'Pemetrexed + Pembrolizumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}]",Phase II Trial of Continuation Therapy in Advanced NSCLC,3908
500,NCT03086733,Phase II,Recruiting,"[{'id': 1031, 'therapyName': 'Metformin'}]",Phase II Lung Metcore - Preoperative Metformin for Lung Cancer (Metcore),3908
501,NCT03087448,Phase Ib/II,Recruiting,"[{'id': 6303, 'therapyName': 'Ceritinib + Trametinib'}]",Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC),3908
502,NCT03087760,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Trial of Consolidation Pembrolizumab After Concurrent Chemotherapy and Proton Reirradiation for Thoracic Recurrences of Non-Small Cell Lung Cancer,3908
503,NCT03088930,Phase II,Not yet recruiting,"[{'id': 706, 'therapyName': 'Crizotinib'}]",Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer,3908
504,NCT03090737,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Safety Study of Nivolumab to Treat Advanced or Metastatic Non-small Cell Lung Cancer (CheckMate 907),3908
505,NCT03095612,Phase Ib/II,Not yet recruiting,"[{'id': 5534, 'therapyName': 'Docetaxel + Selinexor'}]",Phase 1/2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung Cancer (NSCLC),3908
506,NCT03098550,Phase Ib/II,Recruiting,"[{'id': 5520, 'therapyName': 'Daratumumab + Nivolumab '}]",A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Advanced Solid Tumors or Tumors That Have Spread,3908
507,NCT03099174,Phase I,Recruiting,"[{'id': 5514, 'therapyName': 'Abemaciclib + Xentuzumab'}, {'id': 5515, 'therapyName': 'Abemaciclib + Letrozole + Xentuzumab'}, {'id': 5516, 'therapyName': 'Abemaciclib + Anastrozole + Xentuzumab'}, {'id': 5517, 'therapyName': 'Abemaciclib + Fulvestrant + Xentuzumab'}]",This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer.,3908
508,NCT03101839,Phase I,Recruiting,"[{'id': 5914, 'therapyName': 'AZD4785'}]",Phase I Dose-Escalation Study of AZD4785 in Patients With Advanced Solid Tumours,3908
509,NCT03102606,Phase II,Recruiting,"[{'id': 3678, 'therapyName': 'Plinabulin'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}]",Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy (Protective-1),3908
510,NCT03110978,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Clinical Trials Comparing Immunotherapy Plus Stereotactic Ablative Radiotherapy (I-SABR) Versus SABR Alone for Stage I or Isolated Lung Parenchymal Recurrent Non-small Cell Lung Cancer: I-SABR,3908
511,NCT03121417,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Biomarker-Driven Phase 2 Study of Nivolumab in Advanced Metastatic Non-small Cell Lung Cancer,3908
512,NCT03122717,Phase I,Recruiting,"[{'id': 5616, 'therapyName': 'Gefitinib + Osimertinib'}]",Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer,3908
513,NCT03123783,Phase Ib/II,Recruiting,"[{'id': 5608, 'therapyName': 'APX005M + Nivolumab'}]",CD40 Agonistic Antibody APX005M in Combination With Nivolumab,3908
514,NCT03130764,Phase II,Not yet recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",Durvalumab and Tremelimumab for Adjuvant Therapy of Resected NSCLC,3908
515,NCT03131037,Phase I,Recruiting,"[{'id': 5172, 'therapyName': 'AdV-tk + Valacyclovir'}]",Intratumoral Gene Mediated Cytotoxic Immunotherapy in Patients With Resectable Non-Small Cell Lung Cancer,3908
516,NCT03131206,Phase Ib/II,Recruiting,"[{'id': 698, 'therapyName': 'Alectinib'}]",A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer,3908
517,NCT03137771,Phase II,Recruiting,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 4, 'therapyName': 'Erlotinib'}]",Maintenance Chemotherapy With or Without Stereotactic Body Radiation Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer,3908
518,NCT03138889,Phase I,Recruiting,"[{'id': 5625, 'therapyName': 'NKTR-214 + Pembrolizumab'}]",A Study of a CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-L1 (Atezolizumab) in Patients With Metastatic Urothelial Bladder Cancer or Metastatic Non-Small Cell Lung Cancer,3908
519,NCT03156114,Phase I,Recruiting,"[{'id': 5692, 'therapyName': 'BI 754091'}, {'id': 5690, 'therapyName': 'BI 754111'}]",This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment.,3908
520,NCT03157128,Phase I,Recruiting,"[{'id': 5702, 'therapyName': 'LOXO-292'}]","Phase 1 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET-Fusion Lung Cancer and Medullary Thyroid Cancer",3908
521,NCT03158129,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study Of Induction Checkpoint Blockade For Untreated Stage I-IIIA Non-Small Cell Lung Cancers Amenable For Surgical Resection,3908
522,NCT03158883,Phase I,Recruiting,"[{'id': 3144, 'therapyName': 'Avelumab'}]",Avelumab and Stereotactic Ablative Radiotherapy in Non-responding and Progressing NSCLC Patients,3908
523,NCT03164616,Phase III,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}, {'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 2634, 'therapyName': 'Carboplatin + nab-paclitaxel'}]",Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON). (POSEIDON),3908
524,NCT03164772,Phase Ib/II,Not yet recruiting,"[{'id': 5818, 'therapyName': 'BI 1361849 + Durvalumab + Tremelimumab'}]",Phase 1/2 Study of Combination Immunotherapy and mRNA Vaccine in Subjects With NSCLC,3908
525,NCT03166254,Phase I,Not yet recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Combination of a Personalized Therapeutic Anti-tumor Vaccine With Pembrolizumab in Non-Small Cell Lung Cancer,3908
526,NCT03166631,Phase I,Recruiting,"[{'id': 6263, 'therapyName': 'BI 754091 + BI 891065'}, {'id': 6262, 'therapyName': 'BI 891065'}]",A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread,3908
527,NCT03168464,Phase Ib/II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Radiation and Immune Checkpoints Blockade in Metastatic NSCLC (BMS # CA209-632),3908
528,NCT03170206,Phase Ib/II,Recruiting,"[{'id': 850, 'therapyName': 'Palbociclib'}, {'id': 807, 'therapyName': 'Binimetinib'}, {'id': 5838, 'therapyName': 'Binimetinib + Palbociclib'}]",Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the MEK Inhibitor Binimetinib (MEK162) for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer,3908
529,NCT03175224,Phase I,Recruiting,"[{'id': 5963, 'therapyName': 'CBT-101'}]",CBT-101 Study for Advanced Solid Tumors and c-Met Dysregulation,3908
530,NCT03178071,Expanded access,Available,"[{'id': 869, 'therapyName': 'PF-06463922'}]",Expanded Access For Lorlatinib For Patients With Non Small Cell Lung Cancer Harboring Specific Molecular Alterations,3908
531,NCT03178552,Phase II,Recruiting,"[{'id': 4686, 'therapyName': 'Carboplatin + Cisplatin + Gemcitabine'}, {'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 4616, 'therapyName': 'Carboplatin + Cisplatin + Pemetrexed'}, {'id': 698, 'therapyName': 'Alectinib'}]",A Study to Evaluate Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) (B-FAST),3908
532,NCT03179436,Phase I,Recruiting,"[{'id': 6039, 'therapyName': 'MK-1308 + Pembrolizumab'}]","Safety, Pharmacokinetics (PK), and Efficacy of MK-1308 in Combination With Pembrolizumab in Advanced Solid Tumors (MK-1308-001)",3908
533,NCT03181308,Phase I,Recruiting,"[{'id': 6334, 'therapyName': 'Carotuximab + Nivolumab'}]",Study of Carotuximab (TRC105) Plus Nivolumab in Patients With Metastatic NSCLC,3908
534,NCT03184571,Phase II,Recruiting,"[{'id': 5964, 'therapyName': 'BGB-324 + Pembrolizumab'}]",BGB324 in Combination With Pembrolizumab in Patients With Advanced NSCLC,3908
535,NCT03191149,Phase II,Not yet recruiting,"[{'id': 660, 'therapyName': 'Osimertinib'}]",Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations,3908
536,NCT03191786,Phase III,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1685, 'therapyName': 'Vinorelbine'}]",A Study of Atezolizumab Compared With Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Containing Therapy,3908
537,NCT03202940,Phase Ib/II,Recruiting,"[{'id': 5971, 'therapyName': 'Alectinib + Cobimetinib'}]",A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC,3908
538,NCT03215706,Phase III,Recruiting,"[{'id': 6132, 'therapyName': 'Carboplatin + Cisplatin + Paclitaxel + Pemetrexed'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy by Itself as the First Treatment Given for Stage IV Non-Small Cell Lung Cancer (NSCLC) (CheckMate 9LA),3908
539,NCT03217071,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab With and Without Radiotherapy for Non-Small Cell Lung Cancer,3908
540,NCT03220477,Phase I,Recruiting,"[{'id': 6042, 'therapyName': 'Mocetinostat + Pembrolizumab + SGI-110'}]",Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer.,3908
541,NCT03223155,Phase I,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]","Evaluate Concurrent Or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV Non-Small Cell Lung Cancer",3908
542,NCT03224871,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",A Pilot Study of Interlesional IL-2 and RT in Patients With NSCLC.,3908
543,NCT03225664,Phase Ib/II,Not yet recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1450, 'therapyName': 'Pembrolizumab + Trametinib'}]",BATTLE-2 Program - A Biomarker-Integrated Targeted Therapy in Non-Small Cell Lung Cancer (NSCLC),3908
544,NCT03228186,Phase II,Not yet recruiting,"[{'id': 6033, 'therapyName': 'Docetaxel + MLN4924'}]",Trial of Pevonedistat Plus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer,3908
545,NCT03228667,Phase II,Not yet recruiting,"[{'id': 3061, 'therapyName': 'ALT-803 + Nivolumab'}, {'id': 6037, 'therapyName': 'ALT-803 + Pembrolizumab'}]","QUILT-3.055: A Phase IIb, Single-Arm, Open-Label Study of ALT-803 in Combination With Pembrolizumab or Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Disease Progression Following an Initial Response to Treatment With PD-1 Checkpoint Inhibitor Therapy",3908
546,NCT03233724,Phase Ib/II,Not yet recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","The Immune Checkpoint Inhibitor Pembrolizumab in Combination With Oral Decitabine and Tetrahydrouridine as First-Line Therapy for Inoperable, Locally Advanced or Metastatic Non-small Cell Lung Cancer",3908
547,NCT03236935,Phase I,Not yet recruiting,"[{'id': 6097, 'therapyName': 'L-NMMA + Pembrolizumab'}]",Phase Ib of L-NMMA and Pembrolizumab,3908
548,NCT03239340,Phase III,Not yet recruiting,"[{'id': 660, 'therapyName': 'Osimertinib'}]",A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib,3908
549,NCT03242915,Phase II,Recruiting,"[{'id': 2105, 'therapyName': 'Carboplatin +  Pembrolizumab + Pemetrexed '}]",Pembrolizumab in Combination With Platinum-based Doublet Chemotherapy in Patients With EGFR Mutation and ALK Positive NSCLC (Non-Small Cell Lung Cancer) With Progressive Disease Following Prior Tyrosine Kinase Inhibitors (TKIs),3908
550,NCT03256136,Phase II,Not yet recruiting,"[{'id': 6159, 'therapyName': 'Carboplatin + Nivolumab + Pemetrexed'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]","A Phase II Study of Nivolumab in Combination With Carboplatin and Pemetrexed, or Nivolumab in Combination With Ipilimumab, in Patients With Advanced, EGFR-mutant or ALK-rearranged, Non-Small Cell Lung Cancer",3908
551,NCT03257722,Phase Ib/II,Recruiting,"[{'id': 6145, 'therapyName': 'Idelalisib + Pembrolizumab'}]",Pembrolizumab + Idelalisib for Lung Cancer Study,3908
552,NCT03262779,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Ipilimumab and Nivolumab in Patients With Anti-PD-1-axis Therapy-resistant Advanced Non-small Cell Lung Cancer.,3908
553,NCT03268057,Phase Ib/II,Recruiting,"[{'id': 6153, 'therapyName': 'Avelumab + VX15/2503'}]",VX15/2503 in Combination With Avelumab in Advanced Non-small Cell Lung Cancer,3908
554,NCT03270176,Phase I,Recruiting,"[{'id': 6178, 'therapyName': 'AT-406 + Avelumab'}]",A Dose-Finding Study of the Second Mitochondrial Activator of Caspases (SMAC) Mimetic Debio 1143 When Given in Combination With Avelumab to Participants With Advanced Solid Malignancies and to Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Platinum-Based Therapy,3908
555,NCT03275597,Phase I,Not yet recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition,3908
556,NCT03285321,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC),3908
557,NCT03286296,Phase I,Recruiting,"[{'id': 6281, 'therapyName': 'LZM009'}]",LZM009 to Treat Patients With Advanced Solid Tumors,3908
558,NCT03289962,Phase I,Not yet recruiting,"[{'id': 6234, 'therapyName': 'RO7198457'}, {'id': 6235, 'therapyName': 'Atezolizumab + RO7198457'}]",A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors,3908
559,NCT03292133,Phase II,Not yet recruiting,"[{'id': 6287, 'therapyName': 'EGF816 + Gefitinib'}]",A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer,3908
560,NCT03299088,Phase I,Not yet recruiting,"[{'id': 1450, 'therapyName': 'Pembrolizumab + Trametinib'}]",Pembrolizumab and Trametinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer and KRAS Gene Mutations,3908
561,NCT03302234,Phase III,Not yet recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2106, 'therapyName': 'Ipilimumab + Pembrolizumab '}]",Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-small Cell Lung Cancer (MK-3475-598/KEYNOTE-598),3908
562,NCT03302247,Phase II,Not yet recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 6297, 'therapyName': 'Gemcitabine + Nivolumab'}]",Depletion of Myeloid Derived Suppressor Cells to Enhance Anti PD-1 Therapy,3908
0,NCT01987362,Phase I,"Active, not recruiting","[{'id': 937, 'therapyName': 'TEN-010'}]","A Two Part, Multicenter, Open-label Study of TEN-010 Given Subcutaneously",60463
1,NCT02698176,Phase I,Terminated,"[{'id': 2034, 'therapyName': 'OTX015'}]",A Dose Exploration Study With MK-8628 in Participants With Selected Advanced Solid Tumors (MK-8628-006),60463
0,NCT01252251,Phase II,Completed,"[{'id': 2261, 'therapyName': 'Everolimus + Pasireotide'}]",RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma,1752
1,NCT01801358,Phase Ib/II,Terminated,"[{'id': 807, 'therapyName': 'Binimetinib'}, {'id': 1114, 'therapyName': 'MEK162 + AEB071'}]", A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma,1752
0,NCT00303849,Phase Ib/II,Recruiting,"[{'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2562, 'therapyName': 'Etoposide + Melphalan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}]",Combination Chemotherapy With BBBD Followed By Sodium Thiosulfate in Treating Patients With Anaplastic Oligodendroglioma or Oligoastrocytoma,3181
1,NCT01052363,Phase I,Withdrawn,"[{'id': 2109, 'therapyName': 'Bevacizumab + Fosbretabulin'}]",OXC401-PO1s/WVU 1309 - A Pilot Study of Fosbretabulin With Bevacizumab in Recurrent High-Grade Gliomas,3181
2,NCT01140568,Phase II,Recruiting,"[{'id': 829, 'therapyName': 'Nilotinib'}]",Study of Platelet Derived Growth Factor Receptor (PDGFR) in Recurrent Malignant Gliomas,3181
3,NCT01188096,Phase II,Recruiting,"[{'id': 2595, 'therapyName': 'poly ICLC  '}]",A Trial of Poly-ICLC in the Management of Recurrent Pediatric Low Grade Gliomas,3181
4,NCT01339039,Phase I,Terminated,"[{'id': 2120, 'therapyName': 'Bevacizumab + Plerixafor'}]",Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma,3181
5,NCT01392209,Phase I,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}]",Hypofractionated Stereotactic Radiotherapy With Bevacizumab in the Treatment of Recurrent Malignant Glioma,3181
6,NCT01434602,Phase Ib/II,Recruiting,"[{'id': 2299, 'therapyName': 'Everolimus + Sorafenib'}]",Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas,3181
7,NCT01721577,Phase Ib/II,Unknown status,"[{'id': 2745, 'therapyName': 'AXL1717'}]",Phase I/II Trial of Safety and Anti-tumor Efficacy of AXL1717(Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas,3181
8,NCT01884740,Phase Ib/II,Recruiting,"[{'id': 1654, 'therapyName': 'Avastin + Cetuximab'}]",Phase I/II Trial Of Super-Selective Intraarterial Infusion Of Erbitux and Bevacizumab For Treatment Of Relapsed/Refractory Intracranial Glioma In Patients Under 22 Years Of Age,3181
9,NCT01891747,Phase Ib/II,"Active, not recruiting","[{'id': 2115, 'therapyName': 'Bevacizumab + Temozolomide'}]", A Phase I/II Study of High-dose L-methylfolate in Combination With Temozolomide and Bevacizumab in Recurrent High Grade Glioma,3181
10,NCT01977677,Phase Ib/II,"Active, not recruiting","[{'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 1756, 'therapyName': 'Plerixafor'}]",Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma,3181
11,NCT01999270,Phase I,Completed,"[{'id': 2112, 'therapyName': 'Bevacizumab + Irinotecan'}]",Evaluation of FDOPA-PET/MRI in Pediatric Patients With CNS Tumors,3181
12,NCT02078648,Phase Ib/II,"Active, not recruiting","[{'id': 3010, 'therapyName': 'SL-701'}, {'id': 2595, 'therapyName': 'poly ICLC  '}, {'id': 667, 'therapyName': 'Bevacizumab'}]","Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme",3181
13,NCT02101905,Phase I,Recruiting,"[{'id': 787, 'therapyName': 'Lapatinib'}]",Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma,3181
14,NCT02238496,Phase II,"Active, not recruiting","[{'id': 2194, 'therapyName': 'Perifosine + Temsirolimus'}]",Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas,3181
15,NCT02423525,Phase I,Recruiting,"[{'id': 623, 'therapyName': 'Afatinib'}]",Safety Study of Afatinib for Brain Cancer,3181
16,NCT02924038,Phase I,Recruiting,"[{'id': 4835, 'therapyName': 'IMA950 + poly ICLC '}, {'id': 2525, 'therapyName': 'Varlilumab'}]",A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG),3181
17,NCT03220646,Phase II,Recruiting,"[{'id': 802, 'therapyName': 'Abemaciclib'}]",The Purpose of This Study is to Test Any Good and Bad Effects of a Study Drug Called Abemaciclib (LY2835219) in Patients With Recurrent Brain Tumors.,3181
18,NCT03295396,Phase II,Not yet recruiting,"[{'id': 1687, 'therapyName': 'ONC201'}]",ONC201 in Adults With Recurrent High-grade Glioma,3181
0,NCT01089101,Phase Ib/II,Recruiting,"[{'id': 913, 'therapyName': 'Selumetinib'}]",Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma,4992
0,NCT01218048,Phase II,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 694, 'therapyName': 'Cetuximab'}]",ERBITUX; Followed by Adjuvant Treatment With Chemoradiation and ERBITUX; for Locally Advanced Head and Neck Squamous Cell Carcinoma,8618
1,NCT01316757,Phase II,"Active, not recruiting","[{'id': 1921, 'therapyName': 'Cetuximab + Paclitaxel + Carboplatin + Erlotinib'}]","Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer",8618
2,NCT01414426,Phase II,Recruiting,"[{'id': 953, 'therapyName': 'Vandetanib'}]",Vandetanib in Preventing Head and Neck Cancer in Patients With Precancerous Head and Neck Lesions,8618
3,NCT01467115,Phase II,Completed,"[{'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1930, 'therapyName': 'Cisplatin + Docetaxel + Fluorouracil'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 694, 'therapyName': 'Cetuximab'}]",INDUCTION CHEMOTHERAPY FOLLOWED BY CETUXIMAB AND RADIATION THERAPY FOR HEAD AND NECK CANCER,8618
4,NCT01790204,Phase Ib/II,Completed,"[{'id': 1457, 'therapyName': 'phenethyl isothiocyanate'}]",A Study of the Effects of PEITC on Oral Cells With Mutant p53,8618
5,NCT02124850,Phase I,Recruiting,"[{'id': 694, 'therapyName': 'Cetuximab'}]",A Phase Ib Study of Neoadjuvant Immune Biomarker Modulation With ERBITUX&#174; (Cetuximab) and VTX-2337,8618
6,NCT02262741,Phase I,"Active, not recruiting","[{'id': 1652, 'therapyName': 'Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]","A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 With Tremelimumab or Tremelimumab Alone in Head and Neck Cancer",8618
7,NCT02449681,Phase II,Terminated,"[{'id': 2910, 'therapyName': 'TH-4000'}]",Study for Treatment of Patients With Recurrent or Metastatic SCCHN or SCCS,8618
8,NCT02643550,Phase Ib/II,Recruiting,"[{'id': 3383, 'therapyName': 'Cetuximab + IPH2201'}]",Study of IPH2201 (Monalizumab) and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck,8618
9,NCT02795156,Phase II,Recruiting,"[{'id': 623, 'therapyName': 'Afatinib'}, {'id': 890, 'therapyName': 'Regorafenib'}]",Study to Assess the Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations,8618
10,NCT02834013,Phase 0,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab in Treating Patients With Rare Tumors,8618
11,NCT03040999,Phase III,Recruiting,"[{'id': 3256, 'therapyName': 'Cisplatin + Pembrolizumab'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412),8618
0,NCT02882282,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) for High Risk Oral Intra-Epithelial Neoplasias,50610
0,NCT00904345,Phase II,"Active, not recruiting","[{'id': 694, 'therapyName': 'Cetuximab'}]",Study of Radiation (RT) Concurrent With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (SCC),50866
1,NCT01195922,Phase Ib/II,Completed,"[{'id': 917, 'therapyName': 'Sirolimus'}]",Rapamycin Therapy in Head and Neck Squamous Cell Carcinoma,50866
2,NCT01553851,Phase II,Completed,"[{'id': 2, 'therapyName': 'Trametinib'}]",GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell Cancer,50866
3,NCT01612351,Phase II,"Active, not recruiting","[{'id': 2477, 'therapyName': 'Lapatinib + Carboplatin + Cisplatin + Paclitaxel'}, {'id': 2476, 'therapyName': 'Lapatinib + Carboplatin + Paclitaxel'}]",Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery,50866
4,NCT01732640,Phase Ib/II,Completed,"[{'id': 2442, 'therapyName': 'Afatinib + Carboplatin + Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}]",A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy In HPV-Negative HNSCC.,50866
5,NCT01783587,Phase I,Recruiting,"[{'id': 623, 'therapyName': 'Afatinib'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Safety Study of Afatinib and Postoperative Radiation Therapy to Treat Head and Neck Cancer,50866
6,NCT01810913,Phase II,"Active, not recruiting","[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1925, 'therapyName': 'Docetaxel + Cetuximab'}]","Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer",50866
7,NCT01824823,Phase II,Terminated,"[{'id': 623, 'therapyName': 'Afatinib'}]",Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence,50866
8,NCT01914900,Phase II,Unknown status,"[{'id': 1930, 'therapyName': 'Cisplatin + Docetaxel + Fluorouracil'}]",Preoperative TPF Chemotherapy in a Population of Molecularly Selected Locally Advanced Resectable Oral Cavity Squamous Cell Cancer,50866
9,NCT01927744,Phase II,Recruiting,"[{'id': 2474, 'therapyName': 'Erlotinib + Docetaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}]","Study of Chemotherapy With Cisplatin/CarboplatinAstellas Pharma Inc, OSI Pharmaceuticals, Kadoorie Foundation, and Docetaxel With or Without Erlotinib in Patients With Head and Neck Squamous Cell Carcinomas Amenable for Surgical Resection",50866
10,NCT02196168,Phase II,Terminated,"[{'id': 822, 'therapyName': 'MK-1775'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer,50866
11,NCT02289209,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Reirradiation With MK-3475 in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck,50866
12,NCT02296684,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma,50866
13,NCT02334319,Phase I,Terminated,"[{'id': 745, 'therapyName': 'Ganetespib'}]",Ganetespib Window of Opportunity Study in Head and Neck Cancers,50866
14,NCT02358031,Phase III,"Active, not recruiting","[{'id': 694, 'therapyName': 'Cetuximab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}]",A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048),50866
15,NCT02381535,Phase I,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 645, 'therapyName': 'AT13387'}]",Hsp90 Inhibitor AT13387 in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Radiation Therapy and Cisplatin,50866
16,NCT02454179,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1605, 'therapyName': 'Acalabrutinib'}]",Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Advanced Head and Neck Squamous Cell Carcinoma,50866
17,NCT02473731,Phase I,Completed,"[{'id': 2054, 'therapyName': 'CDX-3379'}]",A Window of Opportunity Study of KTN3379 in Surgically Resectable Head and Neck Cancer Patients,50866
18,NCT02499120,Phase II,Recruiting,"[{'id': 850, 'therapyName': 'Palbociclib'}, {'id': 694, 'therapyName': 'Cetuximab'}]",Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer,50866
19,NCT02499328,Phase Ib/II,Recruiting,"[{'id': 3098, 'therapyName': 'AZD9150 + MEDI4736'}, {'id': 3099, 'therapyName': 'AZD5069 + MEDI4736'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 2782, 'therapyName': 'AZD9150 '}]",Study to Assess Combination of MEDI4736 With Either AZD9150 or AZD5069 in Patients With Metastatic Squamous Cell Carcinoma of Head and Neck,50866
20,NCT02551159,Phase III,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 1914, 'therapyName': 'Cetuximab + Carboplatin + Fluorouracil'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]",Phase III Open Label First Line Therapy Study of MEDI 4736 With or Without Tremelimumab Versus Standard of Care (SOC) in SCCHN,50866
21,NCT02585973,Phase I,Recruiting,"[{'id': 1725, 'therapyName': 'MK-1775 + Cisplatin'}]",Dose-escalating AZD1775 + Concurrent Radiation + Cisplatin for Intermediate/High Risk HNSCC,50866
22,NCT02586207,Phase I,Recruiting,"[{'id': 3256, 'therapyName': 'Cisplatin + Pembrolizumab'}]",Pembrolizumab in Combination With CRT for LA-SCCHN,50866
23,NCT02741570,Phase III,Recruiting,"[{'id': 4168, 'therapyName': 'Carboplatin + Cetuximab + Cisplatin + Fluorouracil'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Study Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck,50866
24,NCT02764593,Phase I,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 4760, 'therapyName': 'Cisplatin + Nivolumab'}, {'id': 4761, 'therapyName': 'Cetuximab + Nivolumab'}]",Chemotherapy +/- Nivolumab in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma,50866
25,NCT02769520,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","Efficacy Study of Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Cancer of the Head and Neck",50866
26,NCT02775812,Phase I,Recruiting,"[{'id': 3256, 'therapyName': 'Cisplatin + Pembrolizumab'}]","Cisplatin, Radiation Therapy, and Pembrolizumab in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma",50866
27,NCT02777385,Phase II,Recruiting,"[{'id': 3256, 'therapyName': 'Cisplatin + Pembrolizumab'}]",Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Head and Neck Cancer,50866
28,NCT02827838,Phase I,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}]",Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx Cancer,50866
29,NCT02873819,Phase II,Recruiting,"[{'id': 4614, 'therapyName': 'MAGE-A3 vaccine'}, {'id': 4615, 'therapyName': 'Cyclophosphamide + poly ICLC  + Sargramostim'}]",Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity,50866
30,NCT02892201,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in HNSCC With Residual Disease After Radiation,50866
31,NCT02919683,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity,50866
32,NCT02993991,Phase I,Not yet recruiting,"[{'id': 4378, 'therapyName': 'MEDI4736 + Mocetinostat'}]",Pre-operative Mocetinostat (MGCD0103) and Durvalumab (MEDI4736) (PRIMED) for Squamous Cell Carcinoma of the Oral Cavity,50866
33,NCT03021993,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Trial of Nivolumab as a Novel Neoadjuvant Pre-Surgical Therapy for Locally Advanced Oral Cavity Cancer,50866
34,NCT03162731,Phase I,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]","Nivolumab, Ipilimumab, and Radiation Therapy in Treating Patients With Stage IVA-B Head and Neck Cancer",50866
35,NCT03238365,Phase I,Recruiting,"[{'id': 6100, 'therapyName': 'Nivolumab + Tadalafil'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab With or Without Tadalafil in Treating Patients With Recurrent Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery,50866
36,NCT03258008,Phase II,Not yet recruiting,"[{'id': 6148, 'therapyName': 'ISA101b + Utomilumab'}]",Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal Cancer,50866
0,NCT02436408,FDA approved,Recruiting,"[{'id': 956, 'therapyName': 'Vismodegib'}]",VISmodegib for ORbital and Periocular Basal Cell Carcinoma,4143
0,NCT00904345,Phase II,"Active, not recruiting","[{'id': 694, 'therapyName': 'Cetuximab'}]",Study of Radiation (RT) Concurrent With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (SCC),8557
1,NCT01064921,Phase I,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1077, 'therapyName': 'Vorinostat'}]",Ph I Vorinostat in the Treatment of Advanced Staged Oropharyngeal Squamous Cell Carcinoma,8557
2,NCT01195922,Phase Ib/II,Completed,"[{'id': 917, 'therapyName': 'Sirolimus'}]",Rapamycin Therapy in Head and Neck Squamous Cell Carcinoma,8557
3,NCT01218048,Phase II,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 694, 'therapyName': 'Cetuximab'}]",ERBITUX; Followed by Adjuvant Treatment With Chemoradiation and ERBITUX; for Locally Advanced Head and Neck Squamous Cell Carcinoma,8557
4,NCT01467115,Phase II,Completed,"[{'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1930, 'therapyName': 'Cisplatin + Docetaxel + Fluorouracil'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 694, 'therapyName': 'Cetuximab'}]",INDUCTION CHEMOTHERAPY FOLLOWED BY CETUXIMAB AND RADIATION THERAPY FOR HEAD AND NECK CANCER,8557
5,NCT01663259,Phase I,"Active, not recruiting","[{'id': 694, 'therapyName': 'Cetuximab'}]",Reduced-intensity Therapy for Oropharyngeal Cancer in Non-smoking HPV-16 Positive Patients,8557
6,NCT01732640,Phase Ib/II,Completed,"[{'id': 2442, 'therapyName': 'Afatinib + Carboplatin + Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}]",A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy In HPV-Negative HNSCC.,8557
7,NCT01758731,Phase I,"Active, not recruiting","[{'id': 1999, 'therapyName': 'Olaparib + Cetuximab'}]",Study of Olaparib With Radiation Therapy and Cetuximab in Advanced Head and Neck Cancer With Heavy Smoking History,8557
8,NCT01783587,Phase I,Recruiting,"[{'id': 623, 'therapyName': 'Afatinib'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Safety Study of Afatinib and Postoperative Radiation Therapy to Treat Head and Neck Cancer,8557
9,NCT01810913,Phase II,"Active, not recruiting","[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1925, 'therapyName': 'Docetaxel + Cetuximab'}]","Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer",8557
10,NCT01824823,Phase II,Terminated,"[{'id': 623, 'therapyName': 'Afatinib'}]",Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence,8557
11,NCT01860430,Phase I,"Active, not recruiting","[{'id': 1926, 'therapyName': 'Cetuximab + Ipilimumab'}]",A Phase Ib Trial of Concurrent Cetuximab (ERBITUX) and Intensity Modulated Radiotherapy (IMRT) With Ipilimumab (YERVOY) in Locally Advanced Head and Neck Cancer,8557
12,NCT01898494,Phase II,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer,8557
13,NCT01935921,Phase I,"Active, not recruiting","[{'id': 1926, 'therapyName': 'Cetuximab + Ipilimumab'}]","Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer",8557
14,NCT02002182,Phase II,Recruiting,"[{'id': 3090, 'therapyName': 'ADXS11-001'}]","ADXS 11-001 Vaccination Prior to Robotic Surgery, HPV-Positive Oropharyngeal Cancer",8557
15,NCT02107235,Phase I,Completed,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1046, 'therapyName': 'rigosertib'}]",Platinum-based Chemoradiotherapy and Rigosertib in Head and Neck Cancer,8557
16,NCT02124850,Phase I,Recruiting,"[{'id': 694, 'therapyName': 'Cetuximab'}]",A Phase Ib Study of Neoadjuvant Immune Biomarker Modulation With ERBITUX&#174; (Cetuximab) and VTX-2337,8557
17,NCT02128906,Phase II,Recruiting,"[{'id': 1925, 'therapyName': 'Docetaxel + Cetuximab'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC,8557
18,NCT02177838,Phase II,Suspended,"[{'id': 1915, 'therapyName': 'Cetuximab + Cisplatin'}]",Cetuximab and Radiation Therapy in Treating Patients With Stage III-IV Head and Neck Cancer,8557
19,NCT02196168,Phase II,Terminated,"[{'id': 822, 'therapyName': 'MK-1775'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer,8557
20,NCT02201355,Phase I,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}]","Reduced-Volume Hypofractionated, PET-directed Intensity Modulated Radiotherapy Concurrent With Weekly Cisplatin Chemotherapy for Squamous Cell Carcinoma of the Head and Neck",8557
21,NCT02254278,Phase II,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}]",Reduced-Dose Intensity-Modulated Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Oropharyngeal Cancer,8557
22,NCT02262741,Phase I,"Active, not recruiting","[{'id': 1652, 'therapyName': 'Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]","A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 With Tremelimumab or Tremelimumab Alone in Head and Neck Cancer",8557
23,NCT02281955,Phase II,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 694, 'therapyName': 'Cetuximab'}]",De-intensification of Radiation and Chemotherapy for Low-Risk HPV-related Oropharyngeal SCC,8557
24,NCT02289209,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Reirradiation With MK-3475 in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck,8557
25,NCT02296684,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma,8557
26,NCT02334319,Phase I,Terminated,"[{'id': 745, 'therapyName': 'Ganetespib'}]",Ganetespib Window of Opportunity Study in Head and Neck Cancers,8557
27,NCT02358031,Phase III,"Active, not recruiting","[{'id': 694, 'therapyName': 'Cetuximab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}]",A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048),8557
28,NCT02381535,Phase I,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 645, 'therapyName': 'AT13387'}]",Hsp90 Inhibitor AT13387 in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Radiation Therapy and Cisplatin,8557
29,NCT02426892,Phase II,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab and HPV-16 Vaccination in Patients With HPV-16 Positive Incurable Solid Tumors,8557
30,NCT02449681,Phase II,Terminated,"[{'id': 2910, 'therapyName': 'TH-4000'}]",Study for Treatment of Patients With Recurrent or Metastatic SCCHN or SCCS,8557
31,NCT02454179,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1605, 'therapyName': 'Acalabrutinib'}]",Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Advanced Head and Neck Squamous Cell Carcinoma,8557
32,NCT02473731,Phase I,Completed,"[{'id': 2054, 'therapyName': 'CDX-3379'}]",A Window of Opportunity Study of KTN3379 in Surgically Resectable Head and Neck Cancer Patients,8557
33,NCT02499120,Phase II,Recruiting,"[{'id': 850, 'therapyName': 'Palbociclib'}, {'id': 694, 'therapyName': 'Cetuximab'}]",Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer,8557
34,NCT02499328,Phase Ib/II,Recruiting,"[{'id': 3098, 'therapyName': 'AZD9150 + MEDI4736'}, {'id': 3099, 'therapyName': 'AZD5069 + MEDI4736'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 2782, 'therapyName': 'AZD9150 '}]",Study to Assess Combination of MEDI4736 With Either AZD9150 or AZD5069 in Patients With Metastatic Squamous Cell Carcinoma of Head and Neck,8557
35,NCT02551159,Phase III,"Active, not recruiting","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 1914, 'therapyName': 'Cetuximab + Carboplatin + Fluorouracil'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]",Phase III Open Label First Line Therapy Study of MEDI 4736 With or Without Tremelimumab Versus Standard of Care (SOC) in SCCHN,8557
36,NCT02555644,Phase I,Recruiting,"[{'id': 1651, 'therapyName': 'Prexasertib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 694, 'therapyName': 'Cetuximab'}]",A Study of LY2606368 With Chemotherapy and Radiation in Participants With Head and Neck Cancer,8557
37,NCT02573493,Phase II,Recruiting,"[{'id': 3126, 'therapyName': 'Cisplatin + nab-paclitaxel'}, {'id': 3127, 'therapyName': 'Cetuximab + nab-paclitaxel'}]",Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC),8557
38,NCT02585973,Phase I,Recruiting,"[{'id': 1725, 'therapyName': 'MK-1775 + Cisplatin'}]",Dose-escalating AZD1775 + Concurrent Radiation + Cisplatin for Intermediate/High Risk HNSCC,8557
39,NCT02586207,Phase I,Recruiting,"[{'id': 3256, 'therapyName': 'Cisplatin + Pembrolizumab'}]",Pembrolizumab in Combination With CRT for LA-SCCHN,8557
40,NCT02643550,Phase Ib/II,Recruiting,"[{'id': 3383, 'therapyName': 'Cetuximab + IPH2201'}]",Study of IPH2201 (Monalizumab) and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck,8557
41,NCT02741570,Phase III,Recruiting,"[{'id': 4168, 'therapyName': 'Carboplatin + Cetuximab + Cisplatin + Fluorouracil'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Study Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck,8557
42,NCT02764593,Phase I,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 4760, 'therapyName': 'Cisplatin + Nivolumab'}, {'id': 4761, 'therapyName': 'Cetuximab + Nivolumab'}]",Chemotherapy +/- Nivolumab in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma,8557
43,NCT02769520,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","Efficacy Study of Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Cancer of the Head and Neck",8557
44,NCT02775812,Phase I,Recruiting,"[{'id': 3256, 'therapyName': 'Cisplatin + Pembrolizumab'}]","Cisplatin, Radiation Therapy, and Pembrolizumab in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma",8557
45,NCT02777385,Phase II,Recruiting,"[{'id': 3256, 'therapyName': 'Cisplatin + Pembrolizumab'}]",Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Head and Neck Cancer,8557
46,NCT02795156,Phase II,Recruiting,"[{'id': 623, 'therapyName': 'Afatinib'}, {'id': 890, 'therapyName': 'Regorafenib'}]",Study to Assess the Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations,8557
47,NCT02812056,Phase I,Withdrawn,"[{'id': 4214, 'therapyName': 'Alisertib + MLN0128'}]",Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated Malignancies,8557
48,NCT02827838,Phase I,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}]",Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx Cancer,8557
49,NCT02834013,Phase 0,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab in Treating Patients With Rare Tumors,8557
50,NCT02892201,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in HNSCC With Residual Disease After Radiation,8557
51,NCT03040999,Phase III,Recruiting,"[{'id': 3256, 'therapyName': 'Cisplatin + Pembrolizumab'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412),8557
52,NCT03107182,Phase II,Recruiting,"[{'id': 5581, 'therapyName': 'Dexamethasone + Diphenhydramine + Famotidine + 5FU + Hydroxyurea + Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 5303, 'therapyName': 'Nivolumab + Carboplatin + Paclitaxel'}]",Oropharyngeal Tumor Induction Chemotherapy and Response-stratified Locoregional Therapy Trial in Order to Minimize Long-term Adverse Events,8557
53,NCT03144778,Phase I,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",Checkpoint Inhibitors Assessment in Oropharynx Carcinoma (CIAO),8557
54,NCT03162731,Phase I,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]","Nivolumab, Ipilimumab, and Radiation Therapy in Treating Patients With Stage IVA-B Head and Neck Cancer",8557
55,NCT03238365,Phase I,Recruiting,"[{'id': 6100, 'therapyName': 'Nivolumab + Tadalafil'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab With or Without Tadalafil in Treating Patients With Recurrent Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery,8557
56,NCT03254927,Phase II,Not yet recruiting,"[{'id': 2061, 'therapyName': 'Cetuximab + CDX-3379'}]",A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma,8557
0,NCT00902044,Phase I,Recruiting,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2940, 'therapyName': 'HER2 sensitized T-cells'}]",Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma,3347
1,NCT01241162,Phase I,Completed,"[{'id': 650, 'therapyName': 'Decitabine'}]",Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma,3347
2,NCT01331135,Phase I,"Active, not recruiting","[{'id': 917, 'therapyName': 'Sirolimus'}]",Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors,3347
3,NCT01518413,Phase I,Completed,"[{'id': 1323, 'therapyName': 'Sorafenib + Irinotecan'}]",Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors,3347
4,NCT01759303,Phase II,"Active, not recruiting","[{'id': 848, 'therapyName': 'Pazopanib'}]",Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung,3347
5,NCT01956669,Phase II,Recruiting,"[{'id': 848, 'therapyName': 'Pazopanib'}]",Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors,3347
6,NCT02048371,Phase II,Recruiting,"[{'id': 890, 'therapyName': 'Regorafenib'}]","A Blanket Protocol to Study Oral Regorafenib in Patients With Refractory Liposarcoma, Osteogenic Sarcoma, and Ewing/Ewing-like Sarcomas",3347
7,NCT02173093,Phase Ib/II,Recruiting,"[{'id': 2058, 'therapyName': 'Aldesleukin + GD2Bi-a ATC + Sargramostim '}]",Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma,3347
8,NCT02304458,Phase Ib/II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas,3347
9,NCT02357810,Phase II,Recruiting,"[{'id': 1469, 'therapyName': 'Topotecan + Pazopanib'}]",Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas,3347
10,NCT02432274,Phase Ib/II,Recruiting,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 792, 'therapyName': 'Lenvatinib'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies,3347
11,NCT02446431,Phase I,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1076, 'therapyName': 'Valproic acid'}]",Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence,3347
12,NCT02470091,Phase II,Recruiting,"[{'id': 1198, 'therapyName': 'Denosumab'}]",Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma,3347
13,NCT02487979,Phase II,"Active, not recruiting","[{'id': 3597, 'therapyName': 'Glembatumumab vedotin'}]",Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory Osteosarcoma,3347
14,NCT02644460,Phase I,Recruiting,"[{'id': 802, 'therapyName': 'Abemaciclib'}]",Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors,3347
15,NCT02815995,Phase II,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes,3347
16,NCT02879162,Phase II,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours,3347
17,NCT02982941,Phase I,Recruiting,"[{'id': 2863, 'therapyName': 'MGA271'}]",Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors,3347
18,NCT03006848,Phase II,Recruiting,"[{'id': 3144, 'therapyName': 'Avelumab'}]",A Phase II Trial of Avelumab in Patients With Recurrent or Progressive Osteosarcoma,3347
19,NCT03139331,Phase I,Recruiting,"[{'id': 5635, 'therapyName': 'Pazopanib + Irinotecan + Temozolomide'}]",PAZIT Study for Children and Young Adults With Relapsed or Refractory Sarcoma,3347
20,NCT03190174,Phase Ib/II,Recruiting,"[{'id': 5931, 'therapyName': 'Nab-Rapamycin + Nivolumab'}]",Nivolumab (Opdivo) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma,3347
21,NCT03282344,Phase II,Recruiting,"[{'id': 5076, 'therapyName': 'NKTR-214 + Nivolumab'}]",A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma,3347
0,NCT00565851,Phase III,"Active, not recruiting","[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 3045, 'therapyName': 'Docetaxel + Paclitaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 667, 'therapyName': 'Bevacizumab'}]","Carboplatin, Paclitaxel and Gemcitabine With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",2394
1,NCT00892736,Phase I,"Active, not recruiting","[{'id': 954, 'therapyName': 'Veliparib'}]",Veliparib in Treating Patients With Malignant Solid Tumors That Did Not Respond to Previous Therapy,2394
2,NCT00993655,Phase III,Completed,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}]"," Comparing Combination Chemotherapy Regimens in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer",2394
3,NCT01031381,Phase II,Completed,"[{'id': 1120, 'therapyName': 'Everolimus + Bevacizumab'}]","Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer",2394
4,NCT01132014,Phase I,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1154, 'therapyName': 'Dacarbazine'}]",Autologous OC-DC Vaccine in Ovarian Cancer,2394
5,NCT01218867,Phase Ib/II,Completed,"[{'id': 984, 'therapyName': 'Anti-VEGFR2 CAR CD8 lymphocytes'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1167, 'therapyName': 'Aldesleukin'}]",Treating Metastatic Cancer With Anti-VEGFR2 Gene Engineered CD8+ Lymphocytes,2394
6,NCT01248949,Phase I,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1176, 'therapyName': 'MEDI3617'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors,2394
7,NCT01264432,Phase I,"Active, not recruiting","[{'id': 954, 'therapyName': 'Veliparib'}]","Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer",2394
8,NCT01286987,Phase I,Completed,"[{'id': 682, 'therapyName': 'Talazoparib'}]","Study of BMN 673, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors",2394
9,NCT01292655,Phase I,Completed,"[{'id': 2545, 'therapyName': 'BMS-906024'}]",Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors,2394
10,NCT01305213,Phase Ib/II,Completed,"[{'id': 1186, 'therapyName': 'Fosbretabulin'}, {'id': 667, 'therapyName': 'Bevacizumab'}]","Bevacizumab With or Without Fosbretabulin Tromethamine in Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer",2394
11,NCT01312376,Phase I,"Active, not recruiting","[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1227, 'therapyName': 'CD3/CD28 costimulated vaccine-primed autologous T-cells'}, {'id': 1222, 'therapyName': 'OC-DC vaccine'}]",Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer,2394
12,NCT01325441,Phase Ib/II,Recruiting,"[{'id': 2586, 'therapyName': 'BBI608 + Paclitaxel'}]",A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies,2394
13,NCT01357161,Phase II,Completed,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 822, 'therapyName': 'MK-1775'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]", A Study of MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004),2394
14,NCT01366144,Phase I,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 954, 'therapyName': 'Veliparib'}, {'id': 1092, 'therapyName': 'Carboplatin'}]","Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction",2394
15,NCT01384253,Phase I,Completed,"[{'id': 1540, 'therapyName': '212Pb-TCMC-Trastuzumab + Trastuzumab '}]",Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy,2394
16,NCT01445418,Phase I,"Active, not recruiting","[{'id': 837, 'therapyName': 'Olaparib'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer,2394
17,NCT01459380,Phase I,Completed,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 954, 'therapyName': 'Veliparib'}, {'id': 667, 'therapyName': 'Bevacizumab'}]","Veliparib, Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer",2394
18,NCT01482715,,"Active, not recruiting","[{'id': 906, 'therapyName': 'Rucaparib'}]",A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II),2394
19,NCT01493505,Phase III,Terminated,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1218, 'therapyName': 'Trebananib'}]", TRINOVA-3,2394
20,NCT01551745,Phase II,Completed,"[{'id': 1158, 'therapyName': 'FANG vaccine + Bevacizumab'}]", Salvage Ovarian FANG Vaccine + Bevacizumab,2394
21,NCT01579812,Phase II,"Active, not recruiting","[{'id': 1031, 'therapyName': 'Metformin'}]","Evaluation of Metformin, Targeting Cancer Stem Cells for Prevention of Relapse in Gynecologic Patients",2394
22,NCT01610206,Phase II,"Active, not recruiting","[{'id': 1478, 'therapyName': 'Gemcitabine + Pazopanib'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer,2394
23,NCT01616303,Phase II,"Active, not recruiting","[{'id': 1190, 'therapyName': 'Oregovomab + Carboplatin + Paclitaxel'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]", A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer,2394
24,NCT01621542,Phase I,Completed,"[{'id': 2893, 'therapyName': 'WT1 vaccine'}]",Clinical Study of WT2725 in Patients With Advanced Malignancies,2394
25,NCT01623349,Phase I,"Active, not recruiting","[{'id': 2171, 'therapyName': 'BYL719 + Olaparib'}, {'id': 2170, 'therapyName': 'BKM120 + Olaparib'}]",Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer,2394
26,NCT01652079,Phase II,"Active, not recruiting","[{'id': 1213, 'therapyName': 'CRLX101 + Bevacizumab'}]",CRLX101 in Combination With Bevacizumab for Recurrent Ovarian/Tubal/Peritoneal Cancer,2394
27,NCT01663857,Phase Ib/II,"Active, not recruiting","[{'id': 3296, 'therapyName': 'Ralimetinib'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}]",A Study of LY2228820 for Recurrent Ovarian Cancer,2394
28,NCT01730118,Phase I,Recruiting,"[{'id': 1404, 'therapyName': 'HER2 Vaccine'}]",Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing,2394
29,NCT01831089,Phase I,Completed,"[{'id': 1196, 'therapyName': 'Lurbinectedin + Paclitaxel + Bevacizumab'}, {'id': 1197, 'therapyName': 'Lurbinectedin + Paclitaxel'}]","Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors",2394
30,NCT01847274,Phase III,Completed,"[{'id': 832, 'therapyName': 'Niraparib'}]",A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer,2394
31,NCT01874353,Phase III,"Active, not recruiting","[{'id': 837, 'therapyName': 'Olaparib'}]",Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy,2394
32,NCT01920061,Phase I,Recruiting,"[{'id': 1287, 'therapyName': 'PF-05212384 + Dacomitinib'}, {'id': 1286, 'therapyName': 'PF-05212384 + Cisplatin'}, {'id': 1285, 'therapyName': 'PF-05212384 + Docetaxel'}]",A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents,2394
33,NCT01952249,Phase Ib/II,Completed,"[{'id': 2007, 'therapyName': 'Demcizumab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",A Study of Demcizumab Plus Paclitaxel in Subjects With Platinum Resistant Ovarian,2394
34,NCT01962948,Phase II,"Active, not recruiting","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 745, 'therapyName': 'Ganetespib'}]","Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",2394
35,NCT01966445,Phase I,Completed,"[{'id': 2919, 'therapyName': 'GSK2849330'}]","Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors",2394
36,NCT01968109,Phase I,Recruiting,"[{'id': 4197, 'therapyName': 'BMS-986016 + Nivolumab'}, {'id': 4196, 'therapyName': 'BMS-986016'}]",Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors,2394
37,NCT01972516,Phase II,Terminated,"[{'id': 1055, 'therapyName': 'Tivozanib'}]",Tivozanib As Maintenance Therapy In GYN,2394
38,NCT01995188,Phase I,Completed,"[{'id': 1347, 'therapyName': 'DNIB0600A + Carboplatin + Bevacizumab'}, {'id': 1346, 'therapyName': 'DNIB0600A + Carboplatin'}]",A Study to Evaluate the Safety and Pharmacology of DNIB0600A in Patients With Ovarian Cancer,2394
39,NCT01999738,Phase I,"Active, not recruiting","[{'id': 1603, 'therapyName': 'EC1456'}]",Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors,2394
40,NCT02009449,Phase I,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 2621, 'therapyName': 'AM0010 '}, {'id': 619, 'therapyName': 'Abraxane'}]",A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors,2394
41,NCT02014337,Phase I,"Active, not recruiting","[{'id': 3053, 'therapyName': 'Eribulin + Mifepristone'}]",Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors,2394
42,NCT02035345,FDA approved,Terminated,"[{'id': 1092, 'therapyName': 'Carboplatin'}]",Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment,2394
43,NCT02046421,Phase I,"Active, not recruiting","[{'id': 2603, 'therapyName': 'Mifepristone'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}]","Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer",2394
44,NCT02050009,Phase I,Withdrawn,"[{'id': 1381, 'therapyName': 'Paclitaxel + Carboplatin + Metformin'}]","Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",2394
45,NCT02100007,Phase Ib/II,Terminated,"[{'id': 2174, 'therapyName': 'ME-344 + Topotecan'}]",ME-344 Given in Combination With Hycamtin in Patients With Solid Tumors,2394
46,NCT02117817,Phase I,Withdrawn,"[{'id': 1367, 'therapyName': 'BKM120 + Abraxane'}]","Phase I BKM120/Abraxane in Solid Tumors, Expansion Phase Recurrent Endometrial or Ovarian Cancer",2394
47,NCT02118285,Phase I,Completed,"[{'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 2575, 'therapyName': 'Epacadostat'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1166, 'therapyName': 'Fludarabine'}]","Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer",2394
48,NCT02122809,Phase I,Completed,"[{'id': 1998, 'therapyName': 'Chiauranib'}]",Phase I Study of Chiauranib in Patients With Advanced Solid Tumors,2394
49,NCT02122861,Phase I,"Active, not recruiting","[{'id': 3271, 'therapyName': 'ID-LV305'}]","A Phase 1 Safety Study of Intradermal ID-LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1",2394
50,NCT02124421,Phase II,Recruiting,"[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1812, 'therapyName': 'Cisplatin + Paclitaxel'}]","Outcomes in CRS/HIPEC as Initial Treatment of Ovarian, Fallopian Tube and Primary Peritoneal Cancer",2394
51,NCT02199171,Phase I,Unknown status,"[{'id': 1092, 'therapyName': 'Carboplatin'}]","Heated Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Peritoneal Cancer",2394
52,NCT02203513,Phase II,Recruiting,"[{'id': 1651, 'therapyName': 'Prexasertib'}]","Chk1/2 Inhibitor (LY2606368) in Women With BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Non-High Risk Triple Negative Breast Cancer, and Grade Serous Ovarian Cancer at Low Genetic Risk",2394
53,NCT02222922,Phase I,Recruiting,"[{'id': 1689, 'therapyName': 'Fluconazole'}, {'id': 4421, 'therapyName': 'PF-06647020'}]",A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors,2394
54,NCT02269293,Phase I,Recruiting,"[{'id': 2640, 'therapyName': 'Carboplatin + Paclitaxel + Selinexor'}]","Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers",2394
55,NCT02298959,Phase I,Recruiting,"[{'id': 2369, 'therapyName': 'Aflibercept + Pembrolizumab'}]",Pembrolizumab and Ziv-aflibercept in Treating Patients With Advanced Solid Tumors,2394
56,NCT02312245,Phase II,Recruiting,"[{'id': 942, 'therapyName': 'Topotecan'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 755, 'therapyName': 'Gemcitabine'}]","Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",2394
57,NCT02323191,Phase I,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 2004, 'therapyName': 'LY3022855'}]",A Study of RO5509554 and MPDL3280A Administered in Combination in Patients With Advanced Solid Tumors,2394
58,NCT02326844,Phase II,Terminated,"[{'id': 682, 'therapyName': 'Talazoparib'}]","BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor Treatment",2394
59,NCT02327078,Phase Ib/II,Recruiting,"[{'id': 3059, 'therapyName': 'INCB024360 + Nivolumab'}]","A Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination With Nivolumab in Select Advanced Cancers",2394
60,NCT02335918,Phase Ib/II,Recruiting,"[{'id': 2526, 'therapyName': 'Nivolumab + Varlilumab'}]",A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors,2394
61,NCT02340611,Phase II,Recruiting,"[{'id': 1971, 'therapyName': 'Cediranib + Olaparib'}]",A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib,2394
62,NCT02341625,Phase Ib/II,"Active, not recruiting","[{'id': 4923, 'therapyName': 'BMS-986148'}, {'id': 4924, 'therapyName': 'BMS-986148 + Nivolumab'}]",A Study of BMS-986148 in Patients With Select Advanced Solid Tumors,2394
63,NCT02346747,Phase II,"Active, not recruiting","[{'id': 1157, 'therapyName': 'FANG vaccine'}]",Phase II/III Trial of Maintenance Vigil for High Risk Stage III/IV Ovarian Cancer (VITAL),2394
64,NCT02346955,Phase I,Terminated,"[{'id': 4246, 'therapyName': 'CM-24'}, {'id': 4247, 'therapyName': 'CM-24 + Pembrolizumab'}]",Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001),2394
65,NCT02349958,Phase II,Recruiting,"[{'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy,2394
66,NCT02387125,Phase I,Recruiting,"[{'id': 4318, 'therapyName': 'CMB305'}]","A Phase 1b Safety Study of CMB305 (Sequentially Administered LV305 and G305) in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1",2394
67,NCT02417753,Phase II,Terminated,"[{'id': 2782, 'therapyName': 'AZD9150 '}]","AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant Ascites",2394
68,NCT02419417,Phase Ib/II,Recruiting,"[{'id': 2811, 'therapyName': 'BMS986158'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Study of BMS-986158 in Subjects With Select Advanced Solid Tumors,2394
69,NCT02432690,Phase II,"Active, not recruiting","[{'id': 1945, 'therapyName': 'BBI503'}]",A Study of BBI503 in Asymptomatic Recurrent Ovarian Cancer Patients With CA-125 Elevation,2394
70,NCT02432963,Phase I,Recruiting,"[{'id': 1038, 'therapyName': 'MVAp53'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy,2394
71,NCT02437812,Phase II,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1031, 'therapyName': 'Metformin'}]","Study of Paclitaxel, Carboplatin and Oral Metformin in the Treatment of Advanced Stage Ovarian Carcinoma",2394
72,NCT02446600,Phase III,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 1001, 'therapyName': 'Cediranib'}]","Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",2394
73,NCT02452424,Phase Ib/II,"Active, not recruiting","[{'id': 2736, 'therapyName': 'Pembrolizumab + PLX3397'}]",A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors,2394
74,NCT02452775,Phase I,Recruiting,"[{'id': 3008, 'therapyName': 'OC-L'}]",Autologous OC-L Vaccine and Ovarian Cancer,2394
75,NCT02476968,FDA approved,Recruiting,"[{'id': 837, 'therapyName': 'Olaparib'}]",To Assess Efficacy of Olaparib Maintenance Monotherapy at Preventing or Delaying the Return of the Cancer,2394
76,NCT02487095,Phase Ib/II,Recruiting,"[{'id': 2879, 'therapyName': 'VX-970'}, {'id': 942, 'therapyName': 'Topotecan'}]","Trial of Topotecan With VX-970, an ATR Kinase Inhibitor, in Small Cell Lung Cancer",2394
77,NCT02498600,Phase II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]","Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",2394
78,NCT02498665,Phase I,Recruiting,"[{'id': 4320, 'therapyName': 'DSP-7888'}]",A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies,2394
79,NCT02502266,Phase II,Suspended,"[{'id': 942, 'therapyName': 'Topotecan'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 1001, 'therapyName': 'Cediranib'}]","Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",2394
80,NCT02520154,Phase II,Recruiting,"[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Combination With Chemotherapy in Frontline Ovarian Cancer,2394
81,NCT02575781,Phase I,Recruiting,"[{'id': 4026, 'therapyName': 'SAR428926'}]",A Study of SAR428926 in Patients With Advanced Solid Tumors,2394
82,NCT02575807,Phase Ib/II,Recruiting,"[{'id': 2575, 'therapyName': 'Epacadostat'}, {'id': 2641, 'therapyName': 'CRS-207'}]","Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian, or Peritoneal Cancer",2394
83,NCT02580058,Phase III,"Active, not recruiting","[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 3144, 'therapyName': 'Avelumab'}]",A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer,2394
84,NCT02595892,Phase II,Recruiting,"[{'id': 2879, 'therapyName': 'VX-970'}, {'id': 755, 'therapyName': 'Gemcitabine'}]","Gemcitabine Hydrochloride Alone or With VX-970 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",2394
85,NCT02606305,Phase I,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 3232, 'therapyName': 'IMGN853'}]","Study of IMGN853 in Comb. With Bevacizumab, Carboplatin or PLD in Adults With FRa + Adv. EOC, Primary Peritoneal, Fallopian Tube, or Endometrial Cancer",2394
86,NCT02627430,Phase I,Withdrawn,"[{'id': 3317, 'therapyName': 'Onalespib + Talazoparib'}]","Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer",2394
87,NCT02627443,Phase II,Recruiting,"[{'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}, {'id': 2879, 'therapyName': 'VX-970'}]","Carboplatin and Gemcitabine Hydrochloride With or Without ATR Kinase Inhibitor VX-970 in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",2394
88,NCT02631733,Phase I,Recruiting,"[{'id': 3314, 'therapyName': 'Irinotecan + Veliparib'}]",Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery,2394
89,NCT02631876,Phase II,Recruiting,"[{'id': 3574, 'therapyName': 'Doxil + Paclitaxel'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3232, 'therapyName': 'IMGN853'}]","PH2 Study of IMGN853 vs Investigator's Choice of Chemo in Adults With FRa+ Adv. EOC, Primary Peritoneal or Primary Fallopian Tube Cancer",2394
90,NCT02632448,Phase Ib/II,Recruiting,"[{'id': 4420, 'therapyName': 'LY2880070 + Gemcitabine'}, {'id': 4315, 'therapyName': 'LY2880070'}]",A Study of LY2880070 in Patients With Advanced or Metastatic Cancer,2394
91,NCT02644369,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors,2394
92,NCT02646319,Phase II,"Active, not recruiting","[{'id': 3380, 'therapyName': 'Nab-Rapamycin'}]",Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations,2394
93,NCT02649673,Phase Ib/II,Recruiting,"[{'id': 3845, 'therapyName': 'LCL161 + Topotecan'}]",LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies,2394
94,NCT02655016,Phase III,Recruiting,"[{'id': 832, 'therapyName': 'Niraparib'}]",A Study of Niraparib Maintenance Treatment in Patients With HRD-Positive Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy,2394
95,NCT02657889,Phase Ib/II,Recruiting,"[{'id': 3935, 'therapyName': 'Niraparib + Pembrolizumab'}]",Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Triple-negative Breast Cancer or Ovarian Cancer (KEYNOTE-162),2394
96,NCT02658214,Phase I,Recruiting,"[{'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}, {'id': 2634, 'therapyName': 'Carboplatin + nab-paclitaxel'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}]",Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors,2394
97,NCT02681237,Phase I,Recruiting,"[{'id': 1971, 'therapyName': 'Cediranib + Olaparib'}]",A Study of Cediranib and Olaparib at Disease Worsening in Ovarian Cancer,2394
98,NCT02734004,Phase Ib/II,"Active, not recruiting","[{'id': 2894, 'therapyName': 'Durvalumab + Olaparib'}]",A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. (MEDIOLA),2394
99,NCT02737787,Phase I,Recruiting,"[{'id': 4020, 'therapyName': 'Nivolumab + WT1 vaccine'}]",A Study of WT1 Vaccine and Nivolumab For Recurrent Ovarian Cancer,2394
100,NCT02760797,Phase I,Recruiting,"[{'id': 4181, 'therapyName': 'Emactuzumab + RO7009789'}]",A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors,2394
101,NCT02799095,Phase I,Recruiting,"[{'id': 4298, 'therapyName': 'ALKS 4230'}]",A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors,2394
102,NCT02839707,Phase II,Recruiting,"[{'id': 4496, 'therapyName': 'Atezolizumab + Bevacizumab + Doxil'}, {'id': 4495, 'therapyName': 'Atezolizumab + Doxil'}, {'id': 1673, 'therapyName': 'Doxil + Bevacizamub'}]","Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",2394
103,NCT02880371,Phase Ib/II,Recruiting,"[{'id': 4608, 'therapyName': 'ARRY-382 + Pembrolizumab'}]",A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors,2394
104,NCT02923349,Phase Ib/II,Recruiting,"[{'id': 5831, 'therapyName': 'INCAGN01949'}]","A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors",2394
105,NCT02950064,Phase I,Recruiting,"[{'id': 6336, 'therapyName': 'BTP-114'}]",A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations,2394
106,NCT02952248,Phase I,Recruiting,"[{'id': 5692, 'therapyName': 'BI 754091'}]",A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours,2394
107,NCT02953782,Phase Ib/II,Recruiting,"[{'id': 4948, 'therapyName': 'Cetuximab + Hu5F9-G4'}]",Trial of Hu5F9-G4 in Combination With Cetuximab in Patients With Solid Tumors and Advanced Colorectal Cancer,2394
108,NCT02996825,Phase I,Recruiting,"[{'id': 3232, 'therapyName': 'IMGN853'}]","Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRa-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer",2394
109,NCT03023319,Phase I,Recruiting,"[{'id': 5237, 'therapyName': 'Bosutinib + Pemetrexed'}]",Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors,2394
110,NCT03026062,Phase II,Recruiting,"[{'id': 1652, 'therapyName': 'Tremelimumab'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",Durvalumab and Tremelimumab in Combo Versus Sequential,2394
111,NCT03029598,Phase Ib/II,Recruiting,"[{'id': 5265, 'therapyName': 'Carboplatin + Pembrolizumab'}]","Pembrolizumab and Carboplatin in Treating Patients With Relapsed or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",2394
112,NCT03030287,Phase I,Recruiting,"[{'id': 5264, 'therapyName': 'OMP-305B83 + Paclitaxel'}]","A Phase 1b Study of OMP-305B83 Plus Paclitaxel in Subjects With Ovarian, Peritoneal or Fallopian Tube Cancer",2394
113,NCT03056833,Phase I,Recruiting,"[{'id': 5333, 'therapyName': 'LEE011 + Carboplatin + Paclitaxel'}]",Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer,2394
114,NCT03076372,Phase I,Recruiting,"[{'id': 5758, 'therapyName': 'MM-310'}]",A Study Evaluating MM-310 in Patients With Solid Tumors,2394
115,NCT03134638,Phase I,Recruiting,"[{'id': 5700, 'therapyName': 'SY-1365'}]",A Phase 1 Study of SY-1365 in Adult Patients With Advanced Solid Tumors,2394
116,NCT03150810,Phase Ib/II,Recruiting,"[{'id': 6124, 'therapyName': 'BGB-290 + Temozolomide'}]","Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Subjects With Locally Advanced or Metastatic Solid Tumors",2394
117,NCT03154281,Phase I,Not yet recruiting,"[{'id': 5732, 'therapyName': 'Niraparib + Everolimus'}]",Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Ovarian and Breast,2394
118,NCT03162627,Phase I,Recruiting,"[{'id': 5793, 'therapyName': 'Olaparib + Selumetinib'}]",Selumetinib and Olaparib in Solid Tumors,2394
119,NCT03188965,Phase I,Recruiting,"[{'id': 5962, 'therapyName': 'BAY1895344'}]",First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas,2394
120,NCT03206177,Phase I,Recruiting,"[{'id': 6265, 'therapyName': 'Carboplatin + Galunisertib + Paclitaxel'}]",Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary,2394
121,NCT03239145,Phase I,Recruiting,"[{'id': 6102, 'therapyName': 'Pembrolizumab + Trebananib'}]",Phase Ib Study to Test the Safety and Potential Synergy of Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor,2394
122,NCT03283943,Phase I,Not yet recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}]",PDL-1 Inhibition and Focal Sensitizing Radiotherapy in Recurrent Ovarian/Primary Peritoneal/Fallopian Tube Cancers.,2394
123,NCT03292172,Phase I,Not yet recruiting,"[{'id': 6286, 'therapyName': 'Atezolizumab + TEN-010'}]","A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer",2394
124,NCT03294694,Phase I,Not yet recruiting,"[{'id': 6285, 'therapyName': 'Fulvestrant + PDR001 + Ribociclib'}, {'id': 6284, 'therapyName': 'PDR001 + Ribociclib'}]",Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer,2394
0,NCT00989651,Phase I,"Active, not recruiting","[{'id': 3047, 'therapyName': 'Bevacizumab + Veliparib'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}]","Carboplatin, Paclitaxel, Bevacizumab, and ABT-888 in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer",4001
1,NCT01174121,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 1167, 'therapyName': 'Aldesleukin'}]",Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer,4001
2,NCT01248962,Phase II,"Active, not recruiting","[{'id': 1092, 'therapyName': 'Carboplatin'}]","Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in Patients With Patients With Recurrent, Ovary, Fallopian Tube, and Primary Peritoneal Cancer",4001
3,NCT01281514,Phase I,Recruiting,"[{'id': 2168, 'therapyName': 'Carboplatin + Doxil + Everolimus'}]","Carboplatin, Pegylated Liposomal Doxorubicin Hydrochloride, and Everolimus in Treating Patients With Relapsed Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer",4001
4,NCT01504126,Phase I,"Active, not recruiting","[{'id': 1912, 'therapyName': 'Propranolol'}]",Beta-Blocker / Ovarian,4001
5,NCT01607905,Phase I,Completed,"[{'id': 1749, 'therapyName': 'Selinexor'}]",Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced or Metastatic Solid Tumor Cancer,4001
6,NCT01669798,Phase II,Recruiting,"[{'id': 831, 'therapyName': 'Nintedanib'}]","BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer",4001
7,NCT01849874,Phase III,"Active, not recruiting","[{'id': 807, 'therapyName': 'Binimetinib'}]","A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer",4001
8,NCT01936974,Phase II,Terminated,"[{'id': 1295, 'therapyName': 'Gemcitabine + Bevacizumab + Cisplatin'}, {'id': 1296, 'therapyName': 'Gemcitabine + Bevacizumab + Oxaliplatin'}, {'id': 1294, 'therapyName': 'Gemcitabine + Bevacizumab + Carboplatin'}, {'id': 1297, 'therapyName': 'Gemcitabine + Bevacizumab'}]","(PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma",4001
9,NCT01940172,Phase I,Completed,"[{'id': 1458, 'therapyName': 'Conatumumab'}, {'id': 2647, 'therapyName': 'Birinapant  '}]",Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer,4001
10,NCT01974765,Phase II,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}]","Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies",4001
11,NCT02042430,Phase I,"Active, not recruiting","[{'id': 2575, 'therapyName': 'Epacadostat'}]","INCB024360 Before Surgery in Treating Patients With Newly Diagnosed Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",4001
12,NCT02059265,Phase II,"Active, not recruiting","[{'id': 717, 'therapyName': 'Dasatinib'}]","Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer",4001
13,NCT02098343,Phase Ib/II,Recruiting,"[{'id': 1953, 'therapyName': 'Carboplatin + Doxorubicin'}, {'id': 1952, 'therapyName': 'APR-246 + Carboplatin + Doxorubicin'}]","p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246",4001
14,NCT02101775,Phase II,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1279, 'therapyName': 'MK-1775 + Gemcitabine'}]","Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",4001
15,NCT02101788,Phase II,Recruiting,"[{'id': 942, 'therapyName': 'Topotecan'}, {'id': 2173, 'therapyName': 'Doxil + Letrozole + Tamoxifen + Paclitaxel'}, {'id': 2, 'therapyName': 'Trametinib'}]",Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,4001
16,NCT02121990,Phase I,"Active, not recruiting","[{'id': 1451, 'therapyName': 'Cisplatin + Paclitaxel + Bevacizumab + Olaparib '}]","Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer",4001
17,NCT02122185,Phase II,Recruiting,"[{'id': 1031, 'therapyName': 'Metformin'}, {'id': 1827, 'therapyName': 'Paclitaxel + Carboplatin + Docetaxel'}]","Metformin Hydrochloride and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",4001
18,NCT02166905,Phase Ib/II,Recruiting,"[{'id': 2595, 'therapyName': 'poly ICLC  '}, {'id': 1324, 'therapyName': 'DEC-205-NY-ESO-1 fusion protein vaccine'}, {'id': 2575, 'therapyName': 'Epacadostat'}]","DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission",4001
19,NCT02208375,Phase Ib/II,Recruiting,"[{'id': 837, 'therapyName': 'Olaparib'}, {'id': 655, 'therapyName': 'AZD5363'}, {'id': 991, 'therapyName': 'Vistusertib'}]",mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian Cancer,4001
20,NCT02270372,Phase I,Completed,"[{'id': 2525, 'therapyName': 'Varlilumab'}, {'id': 3051, 'therapyName': 'ONT-10'}]",Study of ONT-10 and Varlilumab to Treat Advanced Ovarian or Breast Cancer,4001
21,NCT02272790,Phase II,Recruiting,"[{'id': 1194, 'therapyName': 'MK-1775 + Carboplatin '}, {'id': 1279, 'therapyName': 'MK-1775 + Gemcitabine'}, {'id': 1567, 'therapyName': 'MK-1775 + Paclitaxel'}]","A Phase II Study Comparing AZD1775 + Chemotherapy Versus Chemotherapy Alone in Patients to Treat Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.",4001
22,NCT02283658,Phase II,"Active, not recruiting","[{'id': 1621, 'therapyName': 'Everolimus + Letrozole'}]","Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer",4001
23,NCT02431559,Phase Ib/II,Recruiting,"[{'id': 3101, 'therapyName': 'Aldoxorubicin + MEDI4736 + Motolimod'}]","A Phase 1/2 Study of Motolimod (VTX-2337) and MEDI4736 in Subjects With Recurrent, Platinum-Resistant Ovarian Cancer for Whom Pegylated Liposomal Doxorubicin (PLD) is Indicated",4001
24,NCT02440425,Phase II,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer,4001
25,NCT02444793,Phase I,Recruiting,"[{'id': 6332, 'therapyName': 'Mogamulizumab + Utomilumab'}]",A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors,4001
26,NCT02459301,Phase I,"Active, not recruiting","[{'id': 3382, 'therapyName': 'IPH2201'}]","Dose-Ranging Study of IPH2201 in Patients With High Grade Serious CA of Ovarian, Fallopian Tube or Peritoneal Origin",4001
27,NCT02470585,Phase III,"Active, not recruiting","[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 954, 'therapyName': 'Veliparib'}]","Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Subjects With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",4001
28,NCT02485990,Phase Ib/II,Recruiting,"[{'id': 837, 'therapyName': 'Olaparib'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]","Study of Tremelimumab Alone or Combined With Olaparib for Patients With Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma)",4001
29,NCT02489006,Phase II,Recruiting,"[{'id': 837, 'therapyName': 'Olaparib'}]","A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer",4001
30,NCT02520115,Phase I,Recruiting,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1076, 'therapyName': 'Valproic acid'}]",Folate Receptor in Diagnosing Ovarian Cancer Using Serum Samples From Patients With Newly Diagnosed Pelvic Mass or Previously Diagnosed Ovarian Cancer,4001
31,NCT02571725,Phase Ib/II,Recruiting,"[{'id': 1652, 'therapyName': 'Tremelimumab'}, {'id': 837, 'therapyName': 'Olaparib'}]",PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer,4001
32,NCT02608684,Phase II,Recruiting,"[{'id': 3248, 'therapyName': 'Cisplatin + Gemcitabine + Pembrolizumab'}]",A Study of Pembrolizumab With Standard Treatment in Patients With Recurrent Platinum-resistant Ovarian Cancer,4001
33,NCT02657928,Phase II,Recruiting,"[{'id': 1568, 'therapyName': 'LEE011 + Letrozole'}]","Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal or Endometrial Cancer",4001
34,NCT02659241,Phase I,Recruiting,"[{'id': 822, 'therapyName': 'MK-1775'}]",A Pilot Study of Induction Wee1 Inhibition in Ovarian Cancer,4001
35,NCT02661815,Phase I,"Active, not recruiting","[{'id': 3469, 'therapyName': 'ACY-1215 + Paclitaxel'}, {'id': 667, 'therapyName': 'Bevacizumab'}]","A Phase 1b Study of Weekly Paclitaxel And Oral Ricolinostat For The Treatment Of Recurrent Platinum Resistant Ovarian, Primary Peritoneal, Or Fallopian Tube Cancer",4001
36,NCT02665416,Phase I,Recruiting,"[{'id': 3468, 'therapyName': 'RO5520985 + RO7009789'}]","Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of RO7009789 With Vanucizumab in Metastatic Solid Tumors",4001
37,NCT02764333,Phase II,Recruiting,"[{'id': 4180, 'therapyName': 'MEDI4736 + TPIV 200'}]",TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian Cancer,4001
38,NCT02835833,Phase I,Recruiting,"[{'id': 4498, 'therapyName': 'Bevacizumab + Nintedanib'}]",Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors,4001
39,NCT02960594,Phase I,Recruiting,"[{'id': 5844, 'therapyName': 'INO-1400 + INO-9012'}, {'id': 5807, 'therapyName': 'INO-1400'}]",hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse,4001
40,NCT03029403,Phase II,Not yet recruiting,"[{'id': 5266, 'therapyName': 'Pembrolizumab + DPX-Survivac + Cyclophosphamide'}]","Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer",4001
0,NCT00954174,Phase III,"Active, not recruiting","[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1125, 'therapyName': 'Paclitaxel + Ifosfamide'}]","Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritorium Cavity Cancer",6170
1,NCT00989651,Phase I,"Active, not recruiting","[{'id': 3047, 'therapyName': 'Bevacizumab + Veliparib'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}]","Carboplatin, Paclitaxel, Bevacizumab, and ABT-888 in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer",6170
2,NCT02269293,Phase I,Recruiting,"[{'id': 2640, 'therapyName': 'Carboplatin + Paclitaxel + Selinexor'}]","Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers",6170
3,NCT03241745,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",A Study of Nivolumab in Selected Uterine Cancer Patients,6170
0,NCT01396408,Phase II,"Active, not recruiting","[{'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 930, 'therapyName': 'Sunitinib'}]",A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours,5304
1,NCT01914510,Phase II,Recruiting,"[{'id': 727, 'therapyName': 'ENMD-2076'}]",A Study of ENMD-2076 in Ovarian Clear Cell Cancers,5304
2,NCT02315430,Phase II,"Active, not recruiting","[{'id': 998, 'therapyName': 'cabozantinib'}]","Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",5304
0,NCT02879162,Phase II,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours,50934
1,NCT02889900,Phase II,Recruiting,"[{'id': 1971, 'therapyName': 'Cediranib + Olaparib'}]",Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer (CONCERTO),50934
0,NCT00565851,Phase III,"Active, not recruiting","[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 3045, 'therapyName': 'Docetaxel + Paclitaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 667, 'therapyName': 'Bevacizumab'}]","Carboplatin, Paclitaxel and Gemcitabine With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",7438
0,NCT01844986,Phase III,"Active, not recruiting","[{'id': 837, 'therapyName': 'Olaparib'}]",Olaparib Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.,6212
1,NCT02345265,Phase II,"Active, not recruiting","[{'id': 1971, 'therapyName': 'Cediranib + Olaparib'}]","Olaparib and Cediranib Maleate in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer",6212
0,NCT02834013,Phase 0,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab in Treating Patients With Rare Tumors,2156
0,NCT02834013,Phase 0,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab in Treating Patients With Rare Tumors,3606
0,NCT00565851,Phase III,"Active, not recruiting","[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 3045, 'therapyName': 'Docetaxel + Paclitaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 667, 'therapyName': 'Bevacizumab'}]","Carboplatin, Paclitaxel and Gemcitabine With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",3604
0,NCT02540291,Phase I,Recruiting,"[{'id': 5694, 'therapyName': 'E7046'}]",Study of E7046 in Subjects With Selected Advanced Malignancies,50933
1,NCT02898207,Phase I,Recruiting,"[{'id': 4729, 'therapyName': 'Olaparib + Onalespib'}]","Olaparib and Hsp90 Inhibitor AT13387 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer",50933
2,NCT02983799,Phase II,Recruiting,"[{'id': 837, 'therapyName': 'Olaparib'}]",Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status,50933
3,NCT03042702,Phase II,Recruiting,"[{'id': 2999, 'therapyName': 'thioureidobutyronitrile'}]",A Phase 2 Study of Kevetrin in Subjects With Ovarian Cancer,50933
4,NCT03144661,Phase I,Recruiting,"[{'id': 5832, 'therapyName': 'INCB062079'}]",An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies,50933
5,NCT03205176,Phase I,Recruiting,"[{'id': 4910, 'therapyName': 'AZD5153'}]",Phase I Study of AZD5153 in Patients With Relapsed or Refractory Solid Tumors and Lymphomas,50933
0,NCT00565851,Phase III,"Active, not recruiting","[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 3045, 'therapyName': 'Docetaxel + Paclitaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 667, 'therapyName': 'Bevacizumab'}]","Carboplatin, Paclitaxel and Gemcitabine With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",5746
1,NCT02345265,Phase II,"Active, not recruiting","[{'id': 1971, 'therapyName': 'Cediranib + Olaparib'}]","Olaparib and Cediranib Maleate in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer",5746
0,NCT02834013,Phase 0,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab in Treating Patients With Rare Tumors,5531
0,NCT02834013,Phase 0,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab in Treating Patients With Rare Tumors,3713
0,NCT01012817,Phase Ib/II,Recruiting,"[{'id': 1132, 'therapyName': 'Veliparib + Topotecan'}]","Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer",2152
1,NCT01116648,Phase Ib/II,"Active, not recruiting","[{'id': 837, 'therapyName': 'Olaparib'}, {'id': 1971, 'therapyName': 'Cediranib + Olaparib'}]","Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer",2152
2,NCT01145430,Phase I,"Active, not recruiting","[{'id': 2167, 'therapyName': 'pegylated liposomal doxorubicin + Veliparib'}]","Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer",2152
3,NCT01146795,Phase II,Terminated,"[{'id': 1152, 'therapyName': 'Bevacizumab + Carboplatin + Paclitaxel'}]",Neoadjuvant Therapy for Ovarian Cancer,2152
4,NCT01239732,Phase III,Completed,"[{'id': 1152, 'therapyName': 'Bevacizumab + Carboplatin + Paclitaxel'}]",A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian Cancer,2152
5,NCT01519869,Phase I,"Active, not recruiting",[],"Trial of Chemotherapy in Ovarian, Fallopian Tube and Peritoneal Carcinoma",2152
6,NCT01535157,Phase Ib/II,"Active, not recruiting","[{'id': 2858, 'therapyName': 'Ketoconazole'}, {'id': 2731, 'therapyName': 'Fenretinide'}]",Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer,2152
7,NCT01536743,Phase II,"Active, not recruiting","[{'id': 850, 'therapyName': 'Palbociclib'}]",A Open Label Study of the Efficacy and Safety of PD0332991 a Selective Inhibitor of the Cyclin Dependent Kinases 4 and 6 in Patients With Recurrent Ovarian Cancer Demonstrating Rb-proficiency and Low p16 Expression,2152
8,NCT01649336,Phase I,Completed,"[{'id': 2010, 'therapyName': 'MEK162 + Paclitaxel'}]","A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer",2152
9,NCT01690468,Phase Ib/II,Recruiting,"[{'id': 4566, 'therapyName': 'Carboplatin + Triciribine'}]",PTX-200 and Carboplatin in Ovarian Cancer,2152
10,NCT01749397,Phase I,Recruiting,"[{'id': 2009, 'therapyName': 'Floxuridine + Veliparib'}]","Veliparib and Floxuridine in Treating Patients With Metastatic Epithelial Ovarian, Primary Peritoneal Cavity, or Fallopian Tube Cancer",2152
11,NCT01846611,Phase III,Recruiting,"[{'id': 1008, 'therapyName': 'Doxil'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]","A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",2152
12,NCT01853644,Phase II,Recruiting,"[{'id': 1055, 'therapyName': 'Tivozanib'}]","Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer",2152
13,NCT01891344,Phase II,"Active, not recruiting","[{'id': 906, 'therapyName': 'Rucaparib'}]","A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)",2152
14,NCT01968213,Phase III,"Active, not recruiting","[{'id': 906, 'therapyName': 'Rucaparib'}]","A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer",2152
15,NCT01991210,Phase II,Terminated,"[{'id': 1345, 'therapyName': 'DNIB0600A'}, {'id': 1008, 'therapyName': 'Doxil'}]",A Randomized Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin in Patients With Platinum-Resistant Ovarian Cancer,2152
16,NCT02188550,Phase II,Unknown status,"[{'id': 1621, 'therapyName': 'Everolimus + Letrozole'}]",Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer,2152
17,NCT02195973,Phase Ib/II,"Active, not recruiting","[{'id': 1620, 'therapyName': 'Paclitaxel + Sonidegib'}]",Phase IB/II Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer,2152
18,NCT02275039,Phase I,"Active, not recruiting","[{'id': 1038, 'therapyName': 'MVAp53'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer,2152
19,NCT02278783,Phase II,Terminated,"[{'id': 890, 'therapyName': 'Regorafenib'}]","Phase 2 Trial of Regorafenib in Patients With Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancer",2152
20,NCT02289950,Phase II,Recruiting,"[{'id': 3230, 'therapyName': 'Farletuzumab'}]",A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Subjects With Low CA125 Platinum-Sensitive Ovarian Cancer,2152
21,NCT02354131,Phase Ib/II,Recruiting,"[{'id': 832, 'therapyName': 'Niraparib'}, {'id': 4254, 'therapyName': 'Bevacizumab + Niraparib'}]",Niraparib Versus Niraparib-bevacizumab Combination in Women With Platinum-sensitive Epithelial Ovarian Cancer (AVANOVA),2152
22,NCT02392676,Phase III,Withdrawn,"[{'id': 837, 'therapyName': 'Olaparib'}]",Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations,2152
23,NCT02537444,Phase II,"Active, not recruiting","[{'id': 1605, 'therapyName': 'Acalabrutinib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Recurrent Ovarian Cancer (KEYNOTE191),2152
24,NCT02540356,Phase Ib/II,Terminated,"[{'id': 2996, 'therapyName': 'Imalumab'}]",Phase 1/2a Two-Arm Dose-Escalation Study of BAX69 in Subjects With Malignant Ascites of Ovarian Cancer,2152
25,NCT02674061,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Efficacy and Safety Study of Pembrolizumab (MK-3475) in Women With Advanced Recurrent Ovarian Cancer (MK-3475-100/KEYNOTE-100),2152
26,NCT02713386,Phase Ib/II,Recruiting,"[{'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]","Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",2152
27,NCT02718417,Phase III,Recruiting,"[{'id': 3144, 'therapyName': 'Avelumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100),2152
28,NCT02726997,Phase Ib/II,Recruiting,"[{'id': 3997, 'therapyName': 'Carboplatin + Durvalumab + Paclitaxel'}]",Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer,2152
29,NCT02728830,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers,2152
30,NCT02766582,Phase II,Recruiting,"[{'id': 2103, 'therapyName': 'Carboplatin + Paclitaxel + Pembrolizumab'}]",Phase II: Pembrolizumab/Carboplatin/Taxol in Epithelial Ovary Cancer,2152
31,NCT02785250,Phase I,Recruiting,"[{'id': 4238, 'therapyName': 'Cyclophosphamide + DPX-Survivac + INCB024360 '}]",Study of DPX-Survivac Vaccine Therapy and Epacadostat in Patients With Recurrent Ovarian Cancer,2152
32,NCT02788708,Phase I,Recruiting,"[{'id': 4236, 'therapyName': 'Lenvatinib + Paclitaxel'}]",Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer,2152
33,NCT02811497,Phase II,Recruiting,"[{'id': 4178, 'therapyName': 'Azacitidine + MEDI4736'}]",Study of Azacitidine and Durvalumab in Advanced Solid Tumors (METADUR),2152
34,NCT02824042,Phase I,Recruiting,"[{'id': 4594, 'therapyName': 'Anetumab ravtansine + Itraconazole'}, {'id': 4593, 'therapyName': 'Anetumab ravtansine'}]",Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole,2152
35,NCT02833506,Phase I,Not yet recruiting,"[{'id': 4460, 'therapyName': 'NY-ESO-1 peptide vaccine + Sirolimus'}, {'id': 2696, 'therapyName': 'NY-ESO-1 peptide vaccine'}]","Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",2152
36,NCT02834975,Phase II,Recruiting,"[{'id': 2103, 'therapyName': 'Carboplatin + Paclitaxel + Pembrolizumab'}]","Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Epithelial Ovarian Cancer (EOC).",2152
37,NCT02853318,Phase II,Recruiting,"[{'id': 4528, 'therapyName': 'Bevacizumab + Cyclophosphamide + Pembrolizumab'}]","Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",2152
38,NCT02855944,Phase III,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 906, 'therapyName': 'Rucaparib'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]","ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients",2152
39,NCT02865811,Phase II,"Active, not recruiting","[{'id': 4558, 'therapyName': 'Doxil + Pembrolizumab'}]","Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer",2152
40,NCT02873962,Phase II,Recruiting,"[{'id': 2111, 'therapyName': 'Bevacizumab + Nivolumab'}]",A Phase II Study Of Nivolumab/ Bevacizumab,2152
41,NCT02884648,Phase II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Bevacizumab in Ovarian Cancer Patients With Disease at Second-look Surgery,2152
42,NCT02900560,Phase II,Recruiting,"[{'id': 2496, 'therapyName': 'Azacitidine + Pembrolizumab'}]",Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer,2152
43,NCT02901899,Phase II,Recruiting,"[{'id': 4725, 'therapyName': 'Pembrolizumab + SGI-110'}]","Guadecitabine and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",2152
44,NCT02915523,Phase Ib/II,Recruiting,"[{'id': 3144, 'therapyName': 'Avelumab'}, {'id': 5559, 'therapyName': 'Avelumab + Entinostat'}]",Phase 1b/2 Study of Avelumab With or Without Entinostat in Patients With Advanced Epithelial Ovarian Cancer,2152
45,NCT02923739,Phase II,Recruiting,"[{'id': 4836, 'therapyName': 'Bevacizumab + Emactuzumab + Paclitaxel'}, {'id': 2123, 'therapyName': 'Bevacizumab + Paclitaxel'}]","Induction Discontinuation Trial of Emactuzumab Following Paclitaxel and Bevacizumab in Patients With Platinum-Resistant, Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer - REDIRECT",2152
46,NCT02943317,Phase I,Recruiting,"[{'id': 958, 'therapyName': 'VS-6063'}, {'id': 3144, 'therapyName': 'Avelumab'}]","Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian Cancer",2152
47,NCT02948101,Phase II,Not yet recruiting,"[{'id': 5848, 'therapyName': 'Cyclophosphamide + PD 0360324'}]",Pre-Conditioning Effects of Anti-Macrophage Therapy Using PD 0360324 in Recurrent Platinum-Resistant Epithelial Ovarian Cancer,2152
48,NCT02948426,Phase I,Recruiting,"[{'id': 4975, 'therapyName': 'interferon gamma + peginterferon alfa-2b'}]","Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer",2152
49,NCT02953457,Phase Ib/II,Recruiting,"[{'id': 4949, 'therapyName': 'MEDI4736 + Olaparib + Tremelimumab'}]","Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRAC2 Mutation",2152
50,NCT02963831,Phase Ib/II,Recruiting,"[{'id': 4978, 'therapyName': 'ONCOS-102 + MEDI4736'}]","A Phase 1/2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies",2152
51,NCT03018405,Phase I,Recruiting,"[{'id': 5998, 'therapyName': 'NKR-2 cells'}]",A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications (THINK),2152
52,NCT03038100,Phase III,Recruiting,"[{'id': 2370, 'therapyName': 'Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel'}, {'id': 1152, 'therapyName': 'Bevacizumab + Carboplatin + Paclitaxel'}]","A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (IMagyn050)",2152
53,NCT03054909,Phase I,Not yet recruiting,"[{'id': 3060, 'therapyName': 'ALT-803'}]",QUILT-2.021: Phase I of IP Followed by SQ ALT-803 for Ovarian Cancer,2152
54,NCT03078400,Phase I,Recruiting,"[{'id': 5763, 'therapyName': 'SPL-108'}]",Safety and Efficacy Study of Daily SPL-108 Injections In Conjunction With Paclitaxel in Women With Ovarian Cancer,2152
55,NCT03079687,Expanded access,Approved for marketing,"[{'id': 837, 'therapyName': 'Olaparib'}]","Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer.",2152
56,NCT03081702,Phase Ib/II,Not yet recruiting,"[{'id': 5495, 'therapyName': 'Hydroxychloroquine + Itraconazole'}]","A Study of the Safety, Tolerability and Effectiveness of Hydroxychloroquine and Itraconazole in Platinum-resistant Epithelial Ovarian Cancer",2152
57,NCT03093155,Phase II,Recruiting,"[{'id': 1122, 'therapyName': 'Bevacizumab + Ixabepilone'}, {'id': 781, 'therapyName': 'Ixabepilone'}]",Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab,2152
58,NCT03113487,Phase II,Not yet recruiting,"[{'id': 5547, 'therapyName': 'MVAp53 + Pembrolizumab'}]","P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",2152
59,NCT03162562,Phase I,Recruiting,"[{'id': 5792, 'therapyName': 'Oregovomab + poly ICLC '}]",The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer,2152
60,NCT03206047,Phase Ib/II,Recruiting,"[{'id': 4693, 'therapyName': 'Atezolizumab + SGI-110'}, {'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 5982, 'therapyName': 'Atezolizumab + SGI-110 + DEC-205-NY-ESO-1 fusion protein vaccine'}]","Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",2152
61,NCT03206645,Phase I,Recruiting,"[{'id': 6266, 'therapyName': 'Carboplatin + Paclitaxel + PTC596'}]",PTC-596 in Women With Ovarian Cancer Receiving Neoadjuvant Chemotherapy,2152
62,NCT03245892,Phase I,Recruiting,"[{'id': 5303, 'therapyName': 'Nivolumab + Carboplatin + Paclitaxel'}]",A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab in Patients With Ovarian Cancer,2152
0,NCT01853306,Phase I,Completed,"[{'id': 954, 'therapyName': 'Veliparib'}]","A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors",5744
1,NCT02282020,Phase III,Recruiting,"[{'id': 837, 'therapyName': 'Olaparib'}]",Olaparib Treatment in Relapsed Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments.,5744
2,NCT02316834,Phase I,"Active, not recruiting","[{'id': 682, 'therapyName': 'Talazoparib'}]",POSITION: A PilOt Study of InducTion PARP InhibitiON in Ovarian Cancer,5744
3,NCT02345265,Phase II,"Active, not recruiting","[{'id': 1971, 'therapyName': 'Cediranib + Olaparib'}]","Olaparib and Cediranib Maleate in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer",5744
4,NCT02354586,Phase II,Recruiting,"[{'id': 832, 'therapyName': 'Niraparib'}]",A Study of Niraparib in Patients With Ovarian Cancer Who Have Received at Least Three Previous Chemotherapy Regimens,5744
5,NCT03277209,Phase I,Recruiting,"[{'id': 1756, 'therapyName': 'Plerixafor'}]","To Assess the Safety of Continuous IV Administration of Plerixafor and Assess Impact on the Immune Microenvironment in Patients With Pancreatic, Ovarian and Colorectal Adenocarcinomas",5744
0,NCT01537107,Phase I,Suspended,"[{'id': 1329, 'therapyName': 'Sirolimus + Vismodegib'}]",Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery,5742
1,NCT02834013,Phase 0,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab in Treating Patients With Rare Tumors,5742
0,NCT00602602,Phase II,"Active, not recruiting","[{'id': 2102, 'therapyName': 'Bevacizumab + Fluorouracil + Oxaliplatin'}, {'id': 1296, 'therapyName': 'Gemcitabine + Bevacizumab + Oxaliplatin'}, {'id': 1297, 'therapyName': 'Gemcitabine + Bevacizumab'}]","Bevacizumab, Combination Chemotherapy, and Radiation Therapy in Treating Patients Undergoing Surgery For Locally Advanced Pancreatic Cancer",4074
1,NCT01013649,Phase II,Recruiting,"[{'id': 2381, 'therapyName': 'Erlotinib + Gemcitabine'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery,4074
2,NCT01088815,Phase II,Unknown status,"[{'id': 1799, 'therapyName': 'Vismodegib + Gemcitabine + Abraxane'}]",Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas,4074
3,NCT01351103,Phase I,Recruiting,"[{'id': 1937, 'therapyName': 'LGK974'}]",A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands,4074
4,NCT01383538,Phase I,Completed,"[{'id': 2498, 'therapyName': 'Fluorouracil + Leucovorin + Irinotecan + Oxaliplatin + Saridegib'}]",FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma,4074
5,NCT01420874,Phase I,"Active, not recruiting","[{'id': 1012, 'therapyName': 'EGFRBi-armed autologous activated T cells'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Anti-CD3 x Anti-Erbitux Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer),4074
6,NCT01431794,Phase Ib/II,"Active, not recruiting","[{'id': 2497, 'therapyName': 'Gemcitabine + nab-paclitaxel + Sonidegib'}]",Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma,4074
7,NCT01473940,Phase I,"Active, not recruiting","[{'id': 2970, 'therapyName': 'Gemcitabine + Ipilimumab'}]",Ipilimumab and Gemcitabine Hydrochloride in Treating Patients With Stage III-IV or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery,4074
8,NCT01485744,Phase I,"Active, not recruiting","[{'id': 1903, 'therapyName': 'FOLFIRINOX'}, {'id': 1428, 'therapyName': 'Sonidegib'}]","LDE225 With Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan for Untreated Advanced Pancreatic Cancer",4074
9,NCT01488552,Phase Ib/II,Completed,"[{'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 1031, 'therapyName': 'Metformin'}]",Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer,4074
10,NCT01489865,Phase Ib/II,Recruiting,"[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 954, 'therapyName': 'Veliparib'}]",ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer,4074
11,NCT01506973,Phase Ib/II,Recruiting,"[{'id': 1316, 'therapyName': 'Hydroxychloroquine'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",A Phase I/II/Pharmacodynamic Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane to Inhibit Autophagy in Pancreatic Cancer,4074
12,NCT01555489,Phase II,Completed,[],Assessing the Efficacy and Safety of IV Vitamin C in Combination With Standard Chemotherapy for Pancreatic Ca,4074
13,NCT01576666,Phase Ib/II,Completed,"[{'id': 1547, 'therapyName': 'BKM120 + Sonidegib'}]","Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors",4074
14,NCT01585805,Phase II,Recruiting,"[{'id': 954, 'therapyName': 'Veliparib'}, {'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}]",Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Patients With Locally Advanced or Metastatic Pancreatic Cancer,4074
15,NCT01586611,Phase III,Unknown status,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",A Study to See if hENT1 Testing on Tumour Tissue Can Predict Response to Treatment With Gemcitabine Chemotherapy and if a Different Chemotherapy Called FOLFOX is Better Than Gemcitabine in Metastatic Pancreas Cancer,4074
16,NCT01652976,Phase II,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 717, 'therapyName': 'Dasatinib'}]","Phase II Study of 5-FU, Oxaliplatin Plus Dasatinib in Metastatic Pancreatic Adenocarcinoma",4074
17,NCT01660971,Phase I,"Active, not recruiting","[{'id': 1816, 'therapyName': 'Gemcitabine + Dasatinib + Erlotinib'}]","Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery",4074
18,NCT01666730,Phase II,Recruiting,"[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1031, 'therapyName': 'Metformin'}]",Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer,4074
19,NCT01683422,Phase II,Recruiting,"[{'id': 2473, 'therapyName': 'Erlotinib + Capecitabine + Gemcitabine'}]",Chemotherapy Plus Proton-chemotherapy for Locally Advanced Pancreatic Cancer,4074
20,NCT01764477,Phase I,Completed,"[{'id': 2566, 'therapyName': 'Gemcitabine + Pri-724'}]",Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adenocarcinoma,4074
21,NCT01783171,Phase I,Completed,"[{'id': 2193, 'therapyName': 'Dinaciclib + MK2206'}]",Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed By Surgery,4074
22,NCT01803282,Phase I,Recruiting,"[{'id': 3320, 'therapyName': 'GS-5745'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Safety and Tolerability Study in Solid Tumors,4074
23,NCT01804530,Phase I,"Active, not recruiting","[{'id': 2651, 'therapyName': 'PLX7486'}, {'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}]",Phase 1 Study of PLX7486 as Single Agent and With Gemcitabine Plus Nab-Paclitaxel in Patients With Advanced Solid Tumors,4074
24,NCT01825603,Phase I,Recruiting,"[{'id': 4952, 'therapyName': 'ADH-1 + Cisplatin + Gemcitabine'}]","ADH-1, Gemcitabine Hydrochloride and Cisplatin in Treating Patients With Metastatic Pancreatic or Biliary Tract Cancer That Cannot Be Removed By Surgery",4074
25,NCT01858883,Phase I,Completed,"[{'id': 619, 'therapyName': 'Abraxane'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2406, 'therapyName': 'INCB039110'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",Safety Study of INCB039110 in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors,4074
26,NCT01896869,Phase II,Suspended,"[{'id': 1903, 'therapyName': 'FOLFIRINOX'}, {'id': 779, 'therapyName': 'Ipilimumab'}]","A Phase 2, Multicenter Study of FOLFIRINOX Followed by Ipilimumab With Allogenic GM-CSF Transfected Pancreatic Tumor Vaccine in the Treatment of Metastatic Pancreatic Cancer",4074
27,NCT01908478,Phase I,"Active, not recruiting","[{'id': 954, 'therapyName': 'Veliparib'}, {'id': 755, 'therapyName': 'Gemcitabine'}]","A Phase I Study of Veliparib (ABT-888) in Combination With Gemcitabine and Intensity Modulated Radiation Therapy in Patients With Locally Advanced, Unresectable Pancreatic Cancer",4074
28,NCT01921751,Phase II,Terminated,"[{'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",High or Standard Intensity Radiation Therapy After Gemcitabine Hydrochloride and Nab-paclitaxel in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery,4074
29,NCT01924260,Phase I,"Active, not recruiting","[{'id': 1289, 'therapyName': 'Alisertib + Gemcitabine'}]",Alisertib and Gemcitabine Hydrochloride in Treating Patients With Solid Tumors or Pancreatic Cancer,4074
30,NCT01956812,Phase III,Terminated,"[{'id': 3000, 'therapyName': 'Y90 clivatuzumab tetraxetan'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer (PANCRIT-1),4074
31,NCT01959672,Phase II,Recruiting,"[{'id': 827, 'therapyName': 'Nelfinavir'}, {'id': 1189, 'therapyName': 'Oregovomab'}, {'id': 2278, 'therapyName': 'Fluorouracil + Leucovorin'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",Combination Chemotherapy With or Without Oregovomab Followed by Stereotactic Body Radiation Therapy and Nelfinavir Mesylate in Treating Patients With Locally Advanced Pancreatic Cancer,4074
32,NCT02004262,Phase II,Completed,"[{'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2383, 'therapyName': 'Capecitabine + Fluorouracil + Gemcitabine '}]",Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting,4074
33,NCT02005315,Phase I,"Active, not recruiting","[{'id': 4412, 'therapyName': 'Gemcitabine + nab-paclitaxel + Vantictumab'}]",A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer,4074
34,NCT02024607,Phase Ib/II,"Active, not recruiting","[{'id': 1597, 'therapyName': 'Capecitabine + Oxaliplatin'}, {'id': 2093, 'therapyName': 'BBI608 + Bevacizumab'}, {'id': 2094, 'therapyName': 'BBI608 + Regorafenib'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 2057, 'therapyName': 'BBI608'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer,4074
35,NCT02037230,Phase Ib/II,Recruiting,"[{'id': 1279, 'therapyName': 'MK-1775 + Gemcitabine'}]",Dose Escalation Trial of MK1775 and Gemcitabine (+Radiation) for Unresectable Adenocarcinoma of the Pancreas,4074
36,NCT02048384,Phase Ib/II,Recruiting,"[{'id': 1593, 'therapyName': 'Sirolimus + Metformin'}, {'id': 1031, 'therapyName': 'Metformin'}]",A Study of Metformin With or Without Rapamycin as Maintenance Therapy After Induction Chemotherapy in Subjects With Pancreatic Cancer,4074
37,NCT02077881,Phase Ib/II,Recruiting,"[{'id': 2976, 'therapyName': 'indoximod'}, {'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}]",Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer,4074
38,NCT02080260,Phase II,"Active, not recruiting","[{'id': 890, 'therapyName': 'Regorafenib'}]",A Study of Regorafenib in Advanced Pancreatic Cancer Patients,4074
39,NCT02117479,Phase III,Terminated,"[{'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1),4074
40,NCT02119663,Phase III,Terminated,"[{'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1615, 'therapyName': 'Ruxolitinib + Capecitabine'}]",A Study of Ruxolitinib in Pancreatic Cancer Patients,4074
41,NCT02138383,Phase I,"Active, not recruiting","[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",Enzalutamide in Combination With Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced Pancreatic Cancer,4074
42,NCT02153450,Phase I,Recruiting,"[{'id': 1031, 'therapyName': 'Metformin'}]",Stereotactic Radiosurgery and Metformin Hydrochloride in Treating Patients With Borderline-Resectable or Locally-Advanced Pancreatic Cancer,4074
43,NCT02155088,Phase I,"Active, not recruiting","[{'id': 1870, 'therapyName': 'BYL719 + Gemcitabine + Abraxane'}]",BYL719 in Combination With Gemcitabine and (Nab)-Paclitaxel in Locally Advanced and Metastatic Pancreatic Cancer,4074
44,NCT02178436,Phase Ib/II,Suspended,"[{'id': 2560, 'therapyName': 'Gemcitabine + nab-paclitaxel + Selinexor'}]","Selinexor, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Pancreatic Cancer",4074
45,NCT02184195,Phase III,Recruiting,"[{'id': 837, 'therapyName': 'Olaparib'}]",Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy,4074
46,NCT02194829,Phase Ib/II,"Active, not recruiting","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 822, 'therapyName': 'MK-1775'}]",Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery,4074
47,NCT02227940,Phase I,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 2554, 'therapyName': 'Ceritinib + Gemcitabine'}]",Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or Metastatic Pancreatic Cancer,4074
48,NCT02231723,Phase I,"Active, not recruiting","[{'id': 2630, 'therapyName': 'BBI608 + Gemcitabine + nab-paclitaxel'}]",A Study of BBI608 in Combination With Gemcitabine and Nab-Paclitaxel in Adult Patients With Metastatic Pancreatic Adenocarcinoma,4074
49,NCT02243371,Phase II,"Active, not recruiting","[{'id': 2642, 'therapyName': 'GVAX pancreatic cancer vaccine  '}, {'id': 2641, 'therapyName': 'CRS-207'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab,4074
50,NCT02244489,Phase I,Terminated,"[{'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 823, 'therapyName': 'Momelotinib'}]",Momelotinib Combined With Capecitabine and Oxaliplatin in Adults With Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma,4074
51,NCT02309177,Phase I,Recruiting,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 2489, 'therapyName': 'Abraxane + Nivolumab'}]","Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer",4074
52,NCT02311361,Phase I,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]",Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer,4074
53,NCT02331251,Phase Ib/II,"Active, not recruiting","[{'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 619, 'therapyName': 'Abraxane'}]",Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus),4074
54,NCT02336087,Phase I,Recruiting,"[{'id': 2204, 'therapyName': 'Abraxane + Gemcitabine + Metformin'}]","Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride, and a Standardized Dietary Supplement in Treating Patients With Metastatic Pancreatic Cancer",4074
55,NCT02340117,Phase II,Recruiting,"[{'id': 2518, 'therapyName': 'SGT-53'}, {'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}]",Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer,4074
56,NCT02349867,Phase I,Recruiting,"[{'id': 2429, 'therapyName': 'Abraxane + Gemcitabine + Sorafenib + Vorinostat'}]","Gemcitabine Hydrochloride, Nab-Paclitaxel, Radiation Therapy, Sorafenib Tosylate,Vorinostat in Treating Previously Untreated Pancreatic Cancer Patients",4074
57,NCT02383433,Phase II,"Active, not recruiting","[{'id': 2491, 'therapyName': 'Gemcitabine + Regorafenib'}]",Regorafenib Plus Gemcitabine in Metastatic Pancreatic Cancer,4074
58,NCT02399137,Phase II,"Active, not recruiting","[{'id': 619, 'therapyName': 'Abraxane'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1073, 'therapyName': 'MM-141'}]",A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer,4074
59,NCT02403271,Phase Ib/II,Completed,"[{'id': 2573, 'therapyName': 'Ibrutinib + MEDI4736'}]",A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors,4074
60,NCT02428270,Phase II,Recruiting,"[{'id': 4205, 'therapyName': 'GSK2256098 + Trametinib'}]",A Study of GSK2256098 and Trametinib in Advanced Pancreatic Cancer,4074
61,NCT02436668,Phase II,"Active, not recruiting","[{'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 768, 'therapyName': 'Ibrutinib'}]","Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma",4074
62,NCT02451982,Phase Ib/II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 3622, 'therapyName': 'Cyclophosphamide + GVAX pancreatic cancer vaccine '}]",Neoadjuvant/Adjuvant GVAX Pancreas Vaccine (With CY) With or Without Nivolumab Trial for Surgically Resectable Pancreatic Cancer,4074
63,NCT02472977,Phase Ib/II,Terminated,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 2847, 'therapyName': 'Ulocuplumab'}]",Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors,4074
64,NCT02498613,Phase II,Recruiting,"[{'id': 1971, 'therapyName': 'Cediranib + Olaparib'}]",Cediranib Maleate and Olaparib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery,4074
65,NCT02540291,Phase I,Recruiting,"[{'id': 5694, 'therapyName': 'E7046'}]",Study of E7046 in Subjects With Selected Advanced Malignancies,4074
66,NCT02562898,Phase Ib/II,Recruiting,"[{'id': 3259, 'therapyName': 'Gemcitabine + Ibrutinib + Paclitaxel'}]",Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer,4074
67,NCT02570711,Phase II,Terminated,"[{'id': 1605, 'therapyName': 'Acalabrutinib'}, {'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}]",Study of Nab Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Previously Untreated Metastatic Pancreatic Cancer,4074
68,NCT02574663,Phase I,"Active, not recruiting","[{'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 2022, 'therapyName': 'TGR-1202'}]",TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors,4074
69,NCT02575508,Phase Ib/II,Withdrawn,"[{'id': 3142, 'therapyName': 'BGJ398 + Fluorouracil + Irinotecan + Oxaliplatin'}]",Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer,4074
70,NCT02608229,Phase I,Recruiting,"[{'id': 3249, 'therapyName': 'BVD-523 + Gemcitabine + nab-paclitaxel'}]",BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer,4074
71,NCT02620423,Phase I,"Active, not recruiting","[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 893, 'therapyName': 'Reolysin'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab With REOLYSIN and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma,4074
72,NCT02620800,Phase Ib/II,Recruiting,"[{'id': 3621, 'therapyName': 'FABLOx'}]","Study of 5-fluorouracil (5-FU), Nab-paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic Cancer",4074
73,NCT02620865,Phase Ib/II,Suspended,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 2278, 'therapyName': 'Fluorouracil + Leucovorin'}]",Bispecific Antibody Armed Activated T-cells With Aldesleukin and Sargramostim in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer,4074
74,NCT02638909,Phase II,Recruiting,"[{'id': 789, 'therapyName': 'Ceritinib'}]",Study of Oral Ceritinib in Patients With ALK-Activated Gastrointestinal Malignancies,4074
75,NCT02639026,Phase I,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]","Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers",4074
76,NCT02648282,Phase II,Recruiting,"[{'id': 4473, 'therapyName': 'Cyclophosphamide + GVAX pancreatic cancer vaccine + Pembrolizumab'}]","Study With CY, Pembrolizumab, GVAX, and SBRT in Patients With Locally Advanced Pancreatic Cancer",4074
77,NCT02650635,Phase I,"Active, not recruiting","[{'id': 3413, 'therapyName': 'Cyclophosphamide + Pegfilgrastim + VTX-2337'}]","TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors",4074
78,NCT02650804,Phase II,Recruiting,"[{'id': 5759, 'therapyName': 'BPM 31510'}, {'id': 5842, 'therapyName': 'BPM 31510 + Gemcitabine'}]",BPM31510 Administered Intravenously With or Without Gemcitabine in Advanced Pancreatic Cancer Patients,4074
79,NCT02651727,Phase I,Terminated,"[{'id': 4342, 'therapyName': 'Gemcitabine + nab-paclitaxel + VS-4718'}]","Ph 1 Study of VS-4718, a FAK Inhibitor, in Combination With Nab-paclitaxel and Gemcitabine in Advanced Cancer Subjects",4074
80,NCT02677038,Phase II,Recruiting,"[{'id': 837, 'therapyName': 'Olaparib'}]",Ph II Olaparib for BRCAness Phenotype in Pancreatic Cancer,4074
81,NCT02703571,Phase Ib/II,Recruiting,"[{'id': 4472, 'therapyName': 'Ribociclib + Trametinib'}]",Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors,4074
82,NCT02734160,Phase I,Recruiting,"[{'id': 4211, 'therapyName': 'Galunisertib + MEDI4736'}]",A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic Cancer,4074
83,NCT02824042,Phase I,Recruiting,"[{'id': 4594, 'therapyName': 'Anetumab ravtansine + Itraconazole'}, {'id': 4593, 'therapyName': 'Anetumab ravtansine'}]",Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole,4074
84,NCT02826486,Phase II,Recruiting,"[{'id': 4757, 'therapyName': 'BKT140 + Pembrolizumab'}, {'id': 2849, 'therapyName': 'BKT140'}]",Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients (COMBAT/KEYNOTE-202) (COMBAT),4074
85,NCT02847000,Phase 0,Recruiting,"[{'id': 3567, 'therapyName': 'Decitabine + Tetrahydrouridine'}]",p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Pancreatic Cancer,4074
86,NCT02868632,Phase I,Recruiting,"[{'id': 1652, 'therapyName': 'Tremelimumab'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]","Study of Immune Checkpoint Inhibition With Radiation Therapy in Unresectable, Non-metastatic Pancreatic Cancer",4074
87,NCT02890355,,Recruiting,"[{'id': 954, 'therapyName': 'Veliparib'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer,4074
88,NCT02902484,Phase Ib/II,Not yet recruiting,"[{'id': 4723, 'therapyName': 'Nintedanib + Gemcitabine + nab-paclitaxel'}, {'id': 831, 'therapyName': 'Nintedanib'}]",Study of Nintedanib and Chemotherapy for Advanced Pancreatic Cancer,4074
89,NCT02907099,Phase II,Recruiting,"[{'id': 4757, 'therapyName': 'BKT140 + Pembrolizumab'}]",Pembrolizumab and BL-8040 in Metastatic Pancreatic Cancer,4074
90,NCT02923921,Phase III,Recruiting,"[{'id': 5849, 'therapyName': 'AM0010 + mFOLFOX-6'}, {'id': 5850, 'therapyName': 'mFOLFOX-6'}]",Study of AM0010 With FOLFOX Compared to FOLFOX Alone Second-line Tx in Pts With Metastatic Pancreatic Cancer,4074
91,NCT02985125,Phase Ib/II,Recruiting,"[{'id': 5073, 'therapyName': 'Ribociclib + Everolimus'}]",LEE011 Plus Everolimus in Patients With Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy,4074
92,NCT03006302,Phase II,Not yet recruiting,"[{'id': 5169, 'therapyName': 'CRS-207 + INCB024360 + Pembrolizumab'}, {'id': 5170, 'therapyName': 'CRS-207 + Cyclophosphamide + GVAX panc vaccine + INCB024360 + Pembrolizumab'}]","Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer",4074
93,NCT03086369,Phase Ib/II,Recruiting,"[{'id': 5482, 'therapyName': 'Olaratumab + nab-paclitaxel + Gemcitabine'}, {'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}]",A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer,4074
94,NCT03095781,Phase I,Recruiting,"[{'id': 5533, 'therapyName': 'Pembrolizumab + XL888'}]",Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer,4074
95,NCT03098550,Phase Ib/II,Recruiting,"[{'id': 5520, 'therapyName': 'Daratumumab + Nivolumab '}]",A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Advanced Solid Tumors or Tumors That Have Spread,4074
96,NCT03104439,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer,4074
97,NCT03140670,Phase II,Recruiting,"[{'id': 906, 'therapyName': 'Rucaparib'}]",Rucaparib in BRCA1/2 or PALB2 Mutated Pancreatic Cancer,4074
98,NCT03153410,Phase I,Not yet recruiting,"[{'id': 5778, 'therapyName': 'Cyclophosphamide + GVAX pancreatic cancer vaccine + LY3022855 + Pembrolizumab'}]","Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas",4074
99,NCT03213626,Phase II,Not yet recruiting,"[{'id': 1255, 'therapyName': 'Cabozantinib + Erlotinib'}]",Cabozantinib and Erlotinib for Patients With EGFR and c-Met Co-expressing Metastatic Pancreatic Adenocarcinoma,4074
100,NCT03214250,Phase Ib/II,Recruiting,"[{'id': 6047, 'therapyName': 'Gemcitabine + nab-paclitaxel + Nivolumab'}, {'id': 6048, 'therapyName': 'APX005M + Gemcitabine + nab-paclitaxel'}, {'id': 6049, 'therapyName': 'APX005M + Gemcitabine + nab-paclitaxel + Nivolumab'}]",Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma,4074
101,NCT03245541,Phase Ib/II,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}]",Study of Durvalumab and Stereotactive Ablative Body Radiotherapy in Advanced Pancreatic Adenocarcinoma (DurvaRad),4074
102,NCT03250273,Phase II,Not yet recruiting,"[{'id': 6114, 'therapyName': 'Entinostat + Nivolumab'}]",A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma,4074
103,NCT03277209,Phase I,Recruiting,"[{'id': 1756, 'therapyName': 'Plerixafor'}]","To Assess the Safety of Continuous IV Administration of Plerixafor and Assess Impact on the Immune Microenvironment in Patients With Pancreatic, Ovarian and Colorectal Adenocarcinomas",4074
104,NCT03281382,Phase I,Recruiting,"[{'id': 6283, 'therapyName': 'Ad5-yCD/mutTKSR39rep-hIL12 '}]",Phase 1 Trial of Interleukin 12 Gene Therapy for Metastatic Pancreatic Cancer,4074
0,NCT00871169,Phase II,Completed,"[{'id': 1919, 'therapyName': 'Irinotecan + Oxaliplatin + Cetuximab'}]","Combination of Irinotecan, Oxaliplatin and Cetuximab for Locally Advanced or Metastatic Pancreatic Cancer",1793
1,NCT00892736,Phase I,"Active, not recruiting","[{'id': 954, 'therapyName': 'Veliparib'}]",Veliparib in Treating Patients With Malignant Solid Tumors That Did Not Respond to Previous Therapy,1793
2,NCT01286987,Phase I,Completed,"[{'id': 682, 'therapyName': 'Talazoparib'}]","Study of BMN 673, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors",1793
3,NCT01292655,Phase I,Completed,"[{'id': 2545, 'therapyName': 'BMS-906024'}]",Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors,1793
4,NCT01384253,Phase I,Completed,"[{'id': 1540, 'therapyName': '212Pb-TCMC-Trastuzumab + Trastuzumab '}]",Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy,1793
5,NCT01497392,Phase I,Completed,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 721, 'therapyName': 'Dovitinib'}, {'id': 1105, 'therapyName': 'Capecitabine'}]"," Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors, Pancreatic Cancer and Biliary Cancers",1793
6,NCT01642342,Phase I,Recruiting,"[{'id': 3013, 'therapyName': 'sEphB4-HSA'}]",Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors,1793
7,NCT01822756,Phase I,Terminated,"[{'id': 907, 'therapyName': 'Ruxolitinib'}]",An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors,1793
8,NCT01888965,Phase II,Terminated,"[{'id': 721, 'therapyName': 'Dovitinib'}]",Maintenance Dovitinib for Colorectal and Pancreas Cancer,1793
9,NCT01928394,Phase Ib/II,"Active, not recruiting","[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]","A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab in Subjects With Advanced or Metastatic Solid Tumors",1793
10,NCT01966445,Phase I,Completed,"[{'id': 2919, 'therapyName': 'GSK2849330'}]","Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors",1793
11,NCT02048943,Phase I,Withdrawn,"[{'id': 1372, 'therapyName': 'Dovitinib + Gemcitabine + Abraxane'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 721, 'therapyName': 'Dovitinib'}]","Dovitinib Lactate, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Solid Tumors or Pancreatic Cancer",1793
12,NCT02154737,Phase I,Recruiting,"[{'id': 2381, 'therapyName': 'Erlotinib + Gemcitabine'}]",Gemcitabine and Pulse Dose Erlotinib in Second Line Treatment of Advanced Pancreatic Cancer,1793
13,NCT02237157,Phase I,"Active, not recruiting","[{'id': 755, 'therapyName': 'Gemcitabine'}]",A Dose Escalation Safety Study of Locally-Delivered Gemcitabine in Pancreatic Cancer,1793
14,NCT02303990,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",RADVAX A Stratified Phase I Trial of Pembrolizumab With Hypofractionated Radiotherapy in Patients With Advanced and Metastatic Cancers,1793
15,NCT02305186,Phase Ib/II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",Safety and Immunological Effect of Pembrolizumab in Resectable or Borderline Resectable Pancreatic Cancer,1793
16,NCT02341625,Phase Ib/II,"Active, not recruiting","[{'id': 4923, 'therapyName': 'BMS-986148'}, {'id': 4924, 'therapyName': 'BMS-986148 + Nivolumab'}]",A Study of BMS-986148 in Patients With Select Advanced Solid Tumors,1793
17,NCT02451553,Phase I,Recruiting,"[{'id': 623, 'therapyName': 'Afatinib'}, {'id': 1105, 'therapyName': 'Capecitabine'}]","Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer",1793
18,NCT02498665,Phase I,Recruiting,"[{'id': 4320, 'therapyName': 'DSP-7888'}]",A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies,1793
19,NCT02526017,Phase I,Recruiting,"[{'id': 2840, 'therapyName': 'FPA008'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Study of FPA008 in Combination With Nivolumab in Patients With Selected Advance Cancers,1793
20,NCT02546531,Phase I,Recruiting,"[{'id': 3083, 'therapyName': 'Defactinib + Gemcitabine + Pembrolizumab'}]",Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer,1793
21,NCT02559674,Phase Ib/II,Recruiting,"[{'id': 3095, 'therapyName': 'ALT-803 + Gemcitabine + nab-paclitaxel'}]",ALT-803 in Patients With Advanced Pancreatic Cancer Conjunction With Gemcitabine and Nab-Paclitaxel,1793
22,NCT02576665,Phase I,Recruiting,"[{'id': 3211, 'therapyName': 'Toca 511 + Toca FC'}]","A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Solid Tumors (Toca6)",1793
23,NCT02581215,Phase II,Recruiting,"[{'id': 886, 'therapyName': 'Ramucirumab'}, {'id': 1903, 'therapyName': 'FOLFIRINOX'}]",Phase II Randomized Trial of FOLFIRINOX +/- Ramucirumab in Advanced Pancreatic Cancer,1793
24,NCT02671955,Phase I,Terminated,"[{'id': 3614, 'therapyName': 'JNJ-61610588 '}]","A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced Cancer",1793
25,NCT02713529,Phase Ib/II,Recruiting,"[{'id': 4170, 'therapyName': 'AMG820 + Pembrolizumab'}]",Safety Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer,1793
26,NCT02715531,Phase I,Recruiting,"[{'id': 3947, 'therapyName': 'Atezolizumab + Gemcitabine + nab-paclitaxel'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1202, 'therapyName': 'Atezolizumab + Bevacizumab + Capecitabine'}]",A Study of the Safety and Tolerability of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors,1793
27,NCT02760797,Phase I,Recruiting,"[{'id': 4181, 'therapyName': 'Emactuzumab + RO7009789'}]",A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors,1793
28,NCT02795156,Phase II,Recruiting,"[{'id': 623, 'therapyName': 'Afatinib'}, {'id': 890, 'therapyName': 'Regorafenib'}]",Study to Assess the Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations,1793
29,NCT02829723,Phase Ib/II,Recruiting,"[{'id': 2844, 'therapyName': 'BLZ945'}, {'id': 5071, 'therapyName': 'BLZ945 + PDR001'}]",Phase I/II Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors,1793
30,NCT02897375,Phase I,Recruiting,"[{'id': 4734, 'therapyName': 'Cisplatin + Palbociclib'}, {'id': 4735, 'therapyName': 'Carboplatin + Palbociclib'}]",Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,1793
31,NCT02947165,Phase I,Recruiting,"[{'id': 5632, 'therapyName': 'NIS793 + PDR001'}, {'id': 5631, 'therapyName': 'NIS793'}]",Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.,1793
32,NCT02950064,Phase I,Recruiting,"[{'id': 6336, 'therapyName': 'BTP-114'}]",A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations,1793
33,NCT02953782,Phase Ib/II,Recruiting,"[{'id': 4948, 'therapyName': 'Cetuximab + Hu5F9-G4'}]",Trial of Hu5F9-G4 in Combination With Cetuximab in Patients With Solid Tumors and Advanced Colorectal Cancer,1793
34,NCT02963831,Phase Ib/II,Recruiting,"[{'id': 4978, 'therapyName': 'ONCOS-102 + MEDI4736'}]","A Phase 1/2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies",1793
35,NCT02983578,Phase II,Recruiting,"[{'id': 3098, 'therapyName': 'AZD9150 + MEDI4736'}]","AZD9150 With MEDI4736 in Patients With Advanced Pancreatic, Non-Small Lung and Colorectal Cancer",1793
36,NCT03018405,Phase I,Recruiting,"[{'id': 5998, 'therapyName': 'NKR-2 cells'}]",A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications (THINK),1793
37,NCT03023722,Phase II,Recruiting,"[{'id': 4593, 'therapyName': 'Anetumab ravtansine'}]",Phase II Anetumab Ravtansine as 2nd Line Treatment for Pancreatic Cancer,1793
38,NCT03033225,Phase II,Recruiting,"[{'id': 3319, 'therapyName': 'Verteporfin'}]",EUS-guided PDT in Pancreatic Tumors,1793
39,NCT03040986,Phase II,Not yet recruiting,"[{'id': 913, 'therapyName': 'Selumetinib'}]",Selumetinib Sulfate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12R Mutations,1793
40,NCT03065062,Phase I,Recruiting,"[{'id': 4034, 'therapyName': 'Gedatolisib + Palbociclib'}]","Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors",1793
41,NCT03080974,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma,1793
42,NCT03087591,Phase I,Recruiting,"[{'id': 5751, 'therapyName': 'APN401'}]","APN401 in Treating Patients With Recurrent or Metastatic Pancreatic Cancer, Colorectal Cancer, or Other Solid Tumors That Cannot Be Removed by Surgery",1793
43,NCT03098160,Phase I,Recruiting,"[{'id': 5745, 'therapyName': 'Evofosfamide + Ipilimumab'}]",Immunotherapy Study of Evofosfamide in Combination With Ipilimumab,1793
44,NCT03136406,Phase Ib/II,Recruiting,"[{'id': 1018, 'therapyName': 'GI-4000'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 3144, 'therapyName': 'Avelumab'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 6163, 'therapyName': 'ETBX-011'}, {'id': 3060, 'therapyName': 'ALT-803'}]",QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy,1793
45,NCT03184870,Phase Ib/II,Recruiting,"[{'id': 5905, 'therapyName': 'BMS-813160 + Fluorouracil + Irinotecan + Leucovorin'}, {'id': 5903, 'therapyName': 'BMS-813160 + Nivolumab'}, {'id': 5904, 'therapyName': 'BMS-813160 + Gemcitabine + nab-paclitaxel'}, {'id': 5902, 'therapyName': 'BMS-813160'}]",A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Patients With Advanced Solid Tumors,1793
46,NCT03257761,Phase I,Not yet recruiting,"[{'id': 6146, 'therapyName': 'Durvalumab + SGI-110'}]","Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer",1793
0,NCT01174121,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 1167, 'therapyName': 'Aldesleukin'}]",Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer,4905
1,NCT01537107,Phase I,Suspended,"[{'id': 1329, 'therapyName': 'Sirolimus + Vismodegib'}]",Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery,4905
2,NCT01663272,Phase I,"Active, not recruiting","[{'id': 2070, 'therapyName': 'Cabozantinib + Gemcitabine'}]",A Trial of Cabozantinib (XL184) and Gemcitabine in Advanced Pancreatic Cancer,4905
3,NCT01954732,Phase I,Withdrawn,"[{'id': 1031, 'therapyName': 'Metformin'}]",Metformin Hydrochloride in Treating Patients With Pancreatic Cancer That Can be Removed by Surgery,4905
4,NCT02009449,Phase I,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 2621, 'therapyName': 'AM0010 '}, {'id': 619, 'therapyName': 'Abraxane'}]",A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors,4905
5,NCT02268825,Phase Ib/II,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Phase I/IIA Study MK-3475 With Chemotherapy in Patients With Advanced GI Cancers,4905
6,NCT02665416,Phase I,Recruiting,"[{'id': 3468, 'therapyName': 'RO5520985 + RO7009789'}]","Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of RO7009789 With Vanucizumab in Metastatic Solid Tumors",4905
7,NCT02807844,Phase Ib/II,Recruiting,"[{'id': 5072, 'therapyName': 'MCS110 + PDR001'}]",Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies,4905
8,NCT02847000,Phase 0,Recruiting,"[{'id': 3567, 'therapyName': 'Decitabine + Tetrahydrouridine'}]",p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Pancreatic Cancer,4905
9,NCT02930902,Phase I,Recruiting,"[{'id': 4903, 'therapyName': 'Pembrolizumab + Paricalcitol'}, {'id': 4904, 'therapyName': 'Pembrolizumab + Paricalcitol + Gemcitabine + nab-paclitaxel'}]",Preoperative Pilot Study to Assess Safety and Immunological Effect of Pembrolizumab (Keytruda) in Combination With Paricalcitol With or Without Chemotherapy in Patients With Resectable Pancreatic Cancer,4905
10,NCT02960594,Phase I,Recruiting,"[{'id': 5844, 'therapyName': 'INO-1400 + INO-9012'}, {'id': 5807, 'therapyName': 'INO-1400'}]",hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse,4905
0,NCT01647828,Phase Ib/II,Completed,"[{'id': 619, 'therapyName': 'Abraxane'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 2547, 'therapyName': 'Tarextumab'}]",A Phase 1b/2 Study of OMP-59R5 in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer,3498
1,NCT02042378,Phase II,Completed,"[{'id': 906, 'therapyName': 'Rucaparib'}]",A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation,3498
2,NCT02101021,Phase II,Terminated,"[{'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 823, 'therapyName': 'Momelotinib'}]",Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Participants With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma,3498
3,NCT02109445,Phase II,Terminated,"[{'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 859, 'therapyName': 'PF-03084014'}]",Study Of PF-03084014 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Adenocarcinoma Not Previously Treated With Anticancer Therapies,3498
4,NCT02241187,Phase I,Completed,"[{'id': 2145, 'therapyName': 'Cetuximab + PEGPH20'}]",Two Stage Study Of Single Dose PEGPH20 And Cetuximab In Patients With Pancreatic Adenocarcinoma Prior To Surgical Resection,3498
5,NCT02259114,Phase I,Completed,"[{'id': 2034, 'therapyName': 'OTX015'}]","A Phase IB Trial With OTX015, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Patients With Selected Advanced Solid Tumors",3498
6,NCT02289898,Phase II,"Active, not recruiting","[{'id': 2639, 'therapyName': 'Demcizumab + Gemcitabine + nab-paclitaxel'}]","Study of Gemcitabine, Abraxane Plus Placebo Versus Gemcitabine, Abraxane Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma",3498
7,NCT02362048,Phase II,"Active, not recruiting","[{'id': 1605, 'therapyName': 'Acalabrutinib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Pancreatic Cancer,3498
8,NCT02501902,Phase I,Recruiting,"[{'id': 3112, 'therapyName': 'nab-paclitaxel + Palbociclib'}]",Dose-Escalation Study Of Palbociclib + Nab-Paclitaxel In mPDAC,3498
9,NCT02559492,Phase I,"Active, not recruiting","[{'id': 3096, 'therapyName': 'INCB039110 + INCB024360'}, {'id': 3097, 'therapyName': 'INCB039110 + INCB050465'}]",INCB039110 Combined With INCB024360 and/or INCB039110 Combined With INCB050465 in Advanced Solid Tumors,3498
10,NCT02583477,Phase Ib/II,Recruiting,"[{'id': 3099, 'therapyName': 'AZD5069 + MEDI4736'}, {'id': 3163, 'therapyName': 'Gemcitabine + MEDI4736 + nab-paclitaxel'}]",Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma,3498
11,NCT02672917,Phase I,Recruiting,"[{'id': 5712, 'therapyName': 'MVT-5873'}]",Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies,3498
12,NCT02732938,Phase I,"Active, not recruiting","[{'id': 4340, 'therapyName': 'Gemcitabine + nab-paclitaxel + PF-04136309'}]",Ph1b/2 Study of PF-04136309 in Combination With Gem/Nab-P in First-line Metastatic Pancreatic Patients (CCR2i),3498
13,NCT02754726,Phase II,Recruiting,"[{'id': 4087, 'therapyName': 'Cisplatin + Gemcitabine + nab-paclitaxel + Nivolumab + Paricalcitol'}]",Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma,3498
14,NCT02857270,Phase I,Recruiting,"[{'id': 4588, 'therapyName': 'LY3214996'}, {'id': 4590, 'therapyName': 'LY3214996 + nab-paclitaxel + Gemcitabine'}, {'id': 4589, 'therapyName': 'LY3214996 + Midazolam'}, {'id': 4591, 'therapyName': 'LY3214996 + Abemaciclib'}]",A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer,3498
15,NCT02879318,Phase II,Recruiting,"[{'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]","Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Pancreatic Adenocarcinoma",3498
16,NCT02880371,Phase Ib/II,Recruiting,"[{'id': 4608, 'therapyName': 'ARRY-382 + Pembrolizumab'}]",A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors,3498
17,NCT02942095,Phase I,Recruiting,"[{'id': 4885, 'therapyName': 'Erlotinib + Ixazomib'}]",Phase I Study of Ixazomib and Erlotinib in Solid Tumors,3498
18,NCT02978547,Phase II,Not yet recruiting,"[{'id': 1031, 'therapyName': 'Metformin'}]",The Effects of Neoadjuvant Metformin on Tumour Cell Proliferation and Tumour Progression in Pancreatic Ductal Adenocarcinoma (Metformin 001),3498
19,NCT02981342,Phase II,Recruiting,"[{'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 802, 'therapyName': 'Abemaciclib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 5175, 'therapyName': 'Abemaciclib + LY3023414'}, {'id': 5176, 'therapyName': 'Abemaciclib + Galunisertib'}]",A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma,3498
20,NCT02993731,Phase III,Recruiting,"[{'id': 2630, 'therapyName': 'BBI608 + Gemcitabine + nab-paclitaxel'}, {'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}]",A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma (CanStem111P),3498
21,NCT03038477,Phase II,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}]",A Study of Durvalumab in Patients With Borderline Resectable Pancreas Adenocarcinoma Following Neoadjuvant Therapy and Successful Surgical Resection,3498
22,NCT03076372,Phase I,Recruiting,"[{'id': 5758, 'therapyName': 'MM-310'}]",A Study Evaluating MM-310 in Patients With Solid Tumors,3498
23,NCT03118349,Phase I,Recruiting,"[{'id': 5801, 'therapyName': 'MVT-1075 + MVT-5873'}]",Study of 177Lu Human Monoclonal Antibody 5B1 (MVT-1075) in Combination With a Blocking Dose of MVT-5873 as Radioimmunotherapy,3498
24,NCT03193190,Phase Ib/II,Recruiting,"[{'id': 5942, 'therapyName': 'Atezolizumab + BKT140'}, {'id': 5940, 'therapyName': 'Gemcitabine + Nab-Paclitaxel + mFOLFOX-6'}, {'id': 5941, 'therapyName': 'Atezolizumab + PEGPH20'}, {'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}]",A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC),3498
25,NCT03264404,Phase II,Recruiting,"[{'id': 2496, 'therapyName': 'Azacitidine + Pembrolizumab'}]",Azacitidine and Pembrolizumab in Pancreatic Cancer,3498
0,NCT01621243,Phase Ib/II,Terminated,"[{'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 4251, 'therapyName': 'Necuparanib'}]",M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer,3587
1,NCT01821729,Phase II,Recruiting,"[{'id': 1903, 'therapyName': 'FOLFIRINOX'}, {'id': 2998, 'therapyName': 'Losartan'}]",Proton w/FOLFIRINOX-Losartan for Pancreatic Cancer,3587
2,NCT02432963,Phase I,Recruiting,"[{'id': 1038, 'therapyName': 'MVAp53'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy,3587
3,NCT02452424,Phase Ib/II,"Active, not recruiting","[{'id': 2736, 'therapyName': 'Pembrolizumab + PLX3397'}]",A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors,3587
4,NCT02558894,Phase II,Completed,"[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]",Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma,3587
0,NCT01466036,Phase II,"Active, not recruiting","[{'id': 998, 'therapyName': 'cabozantinib'}]",Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors,1798
1,NCT02077933,Phase I,"Active, not recruiting","[{'id': 1384, 'therapyName': 'BYL719 + Everolimus'}, {'id': 1385, 'therapyName': 'BYL719 + Everolimus + Exemestane'}]","Study of Safety and Efficacy of BYL719 With Everolimus or BYL719 With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors",1798
2,NCT02101918,Phase II,"Active, not recruiting","[{'id': 624, 'therapyName': 'Aflibercept'}]",Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery,1798
3,NCT02108782,Phase II,Withdrawn,"[{'id': 721, 'therapyName': 'Dovitinib'}]",Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors,1798
4,NCT02273752,Phase II,Terminated,"[{'id': 735, 'therapyName': 'Everolimus'}]","Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer",1798
5,NCT02575300,Phase II,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors,1798
6,NCT02893930,Phase II,Recruiting,"[{'id': 1282, 'therapyName': 'Sapanisertib'}]",Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery,1798
7,NCT03043664,Phase Ib/II,Recruiting,"[{'id': 6129, 'therapyName': 'Lanreotide Depot + Pembrolizumab'}]",Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors (PLANET),1798
8,NCT03074513,Phase II,Recruiting,"[{'id': 4595, 'therapyName': 'Atezolizumab + Bevacizumab'}]",Atezolizumab and Bevacizumab in Rare Solid Tumors,1798
0,NCT03224767,Phase II,Recruiting,"[{'id': 1657, 'therapyName': 'Vemurafenib + Cobimetinib'}]",Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma,3847
0,NCT00831480,Phase II,Terminated,"[{'id': 735, 'therapyName': 'Everolimus'}]",Everolimus(RAD001) For Advanced Renal Cell Carcinoma(RCC)Before Kidney Removal,4465
1,NCT01130519,Phase II,Recruiting,"[{'id': 1146, 'therapyName': 'Bevacizumab + Erlotinib'}]",A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer,4465
2,NCT02019693,Phase II,Recruiting,"[{'id': 1065, 'therapyName': 'Capmatinib'}]",A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer,4465
3,NCT02127710,Phase II,"Active, not recruiting","[{'id': 2161, 'therapyName': 'Savolitinib'}]",A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC),4465
4,NCT02761057,Phase II,Recruiting,"[{'id': 2161, 'therapyName': 'Savolitinib'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 930, 'therapyName': 'Sunitinib'}]","Cabozantinib-S-Malate, Crizotinib, Volitinib, or Sunitinib Malate in Treating Patients With Locally Advanced or Metastatic Kidney Cancer",4465
5,NCT02837991,Phase Ib/II,Recruiting,"[{'id': 5774, 'therapyName': 'CDX-014'}]","A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Advanced or Metastatic Renal Cell Carcinoma",4465
6,NCT02915783,Phase II,Recruiting,"[{'id': 1713, 'therapyName': 'Everolimus + Lenvatinib'}]",A Phase 2 Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease,4465
7,NCT03091192,Phase III,Recruiting,"[{'id': 930, 'therapyName': 'Sunitinib'}, {'id': 2161, 'therapyName': 'Savolitinib'}]",Savolitinib vs. Sunitinib in MET-driven PRCC,4465
0,NCT01534897,Phase I,Completed,"[{'id': 3, 'therapyName': 'Dabrafenib'}]",Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436,3969
1,NCT01709292,Phase II,"Active, not recruiting","[{'id': 342, 'therapyName': 'Vemurafenib'}]",Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer,3969
2,NCT01723202,Phase II,"Active, not recruiting","[{'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}, {'id': 3, 'therapyName': 'Dabrafenib'}]",Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer,3969
3,NCT02145143,Phase I,"Active, not recruiting","[{'id': 342, 'therapyName': 'Vemurafenib'}]","Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib",3969
4,NCT02211222,Phase I,Approved for marketing,"[{'id': 792, 'therapyName': 'Lenvatinib'}]",An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer,3969
5,NCT02702388,Phase II,Recruiting,"[{'id': 792, 'therapyName': 'Lenvatinib'}]","Phase 2 Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 20 mg or 14 mg Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile",3969
6,NCT02973997,Phase II,Not yet recruiting,"[{'id': 4782, 'therapyName': 'Lenvatinib + Pembrolizumab'}]",Pembrolizumab and Lenvatinib in Treating Metastatic or Recurrent Differentiated Thyroid Cancer That Cannot Be Removed by Surgery,3969
7,NCT03002623,Phase II,Recruiting,"[{'id': 709, 'therapyName': 'CUDC-907'}]",CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer,3969
8,NCT03215095,Phase I,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}]",RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid Cancers,3969
0,NCT02632344,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","Study of Anti-PD-1 Therapy for HPV-associated Recurrent Respiratory Papilloma Patients With Laryngeal, Tracheal and/or Pulmonary Involvement",2615
1,NCT02859454,Phase II,Recruiting,"[{'id': 3144, 'therapyName': 'Avelumab'}]",Avelumab for People With Recurrent Respiratory Papillomatosis,2615
0,NCT00843037,Phase II,Completed,"[{'id': 930, 'therapyName': 'Sunitinib'}]",Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma,50773
1,NCT01396408,Phase II,"Active, not recruiting","[{'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 930, 'therapyName': 'Sunitinib'}]",A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours,50773
2,NCT01967576,Phase II,"Active, not recruiting","[{'id': 649, 'therapyName': 'Axitinib'}]","Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma",50773
3,NCT02302833,Phase I,Recruiting,"[{'id': 998, 'therapyName': 'cabozantinib'}]",Cabozantinib for Malignant Pheochromocytoma,50773
4,NCT02721732,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors,50773
5,NCT02834013,Phase 0,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab in Treating Patients With Rare Tumors,50773
6,NCT02936323,,Recruiting,"[{'id': 5819, 'therapyName': 'PEN-221'}]",PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers,50773
7,NCT03008369,Phase II,Recruiting,"[{'id': 792, 'therapyName': 'Lenvatinib'}]",Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery,50773
8,NCT03165721,Phase II,Recruiting,"[{'id': 1949, 'therapyName': 'SGI-110'}]","A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer",50773
0,NCT02196168,Phase II,Terminated,"[{'id': 822, 'therapyName': 'MK-1775'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer,50619
1,NCT02538510,Phase Ib/II,"Active, not recruiting","[{'id': 3077, 'therapyName': 'Pembrolizumab + Vorinostat'}]",Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer and Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery,50619
2,NCT02567422,Phase I,Recruiting,"[{'id': 3109, 'therapyName': 'Cisplatin + VX-970'}]","VX-970, Cisplatin, and Radiation Therapy in Treating Patients With Locally Advanced HPV-Negative Head and Neck Squamous Cell Carcinoma",50619
3,NCT02795156,Phase II,Recruiting,"[{'id': 623, 'therapyName': 'Afatinib'}, {'id': 890, 'therapyName': 'Regorafenib'}]",Study to Assess the Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations,50619
4,NCT02834013,Phase 0,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab in Treating Patients With Rare Tumors,50619
5,NCT03172624,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer,50619
6,NCT03238365,Phase I,Recruiting,"[{'id': 6100, 'therapyName': 'Nivolumab + Tadalafil'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab With or Without Tadalafil in Treating Patients With Recurrent Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery,50619
0,NCT02834013,Phase 0,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab in Treating Patients With Rare Tumors,1540
0,NCT02780310,Phase II,"Active, not recruiting","[{'id': 792, 'therapyName': 'Lenvatinib'}]",Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma,50931
1,NCT03087019,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma,50931
2,NCT03172624,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer,50931
0,NCT01966445,Phase I,Completed,"[{'id': 2919, 'therapyName': 'GSK2849330'}]","Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors",9036
0,NCT00876993,Phase I,Completed,"[{'id': 1463, 'therapyName': 'Temozolomide + Irinotecan + Bevacizumab'}]",Study of Irinotecan and Bevacizumab With Temozolomide in Refractory/Relapsed Central Nervous System (CNS) Tumors,5509
1,NCT01661400,Phase I,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1475, 'therapyName': 'Thalidomide'}]",Anti-Angiogenic Therapy Post Transplant (ASCR) for Relapsed and Refractory Pediatric Solid Tumors,5509
2,NCT01999270,Phase I,Completed,"[{'id': 2112, 'therapyName': 'Bevacizumab + Irinotecan'}]",Evaluation of FDOPA-PET/MRI in Pediatric Patients With CNS Tumors,5509
3,NCT02155920,Phase II,Recruiting,"[{'id': 735, 'therapyName': 'Everolimus'}]",Everolimus for Children With Recurrent or Progressive Ependymomaildren With Recurrent or Progressive Ependymoma,5509
4,NCT02372006,Phase I,Recruiting,"[{'id': 623, 'therapyName': 'Afatinib'}]",Phase I Trial of Afatinib in Pediatric Tumours,5509
0,NCT00939770,Phase Ib/II,"Active, not recruiting","[{'id': 706, 'therapyName': 'Crizotinib'}]",Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma,10000004
1,NCT01518413,Phase I,Completed,"[{'id': 1323, 'therapyName': 'Sorafenib + Irinotecan'}]",Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors,10000004
0,NCT02426892,Phase II,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab and HPV-16 Vaccination in Patients With HPV-16 Positive Incurable Solid Tumors,11615
1,NCT02721732,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors,11615
2,NCT02812056,Phase I,Withdrawn,"[{'id': 4214, 'therapyName': 'Alisertib + MLN0128'}]",Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated Malignancies,11615
3,NCT02834013,Phase 0,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab in Treating Patients With Rare Tumors,11615
0,NCT02541903,Phase II,Recruiting,"[{'id': 623, 'therapyName': 'Afatinib'}]",Trial Using Gilotrif for Advanced Penile Squamous Cell Carcinoma,5518
0,NCT01661283,Phase II,"Active, not recruiting","[{'id': 1120, 'therapyName': 'Everolimus + Bevacizumab'}]",Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors,3193
1,NCT02639546,Phase I,Recruiting,"[{'id': 1004, 'therapyName': 'Cobimetinib'}]",iMATRIXcobi: Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Patients With Previously Treated Solid Tumors,3193
2,NCT02834013,Phase 0,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab in Treating Patients With Rare Tumors,3193
0,NCT01431209,Phase II,Recruiting,"[{'id': 907, 'therapyName': 'Ruxolitinib'}]",Ruxolitinib Phosphate (Oral JAK Inhibitor INCB18424) in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma,50749
1,NCT02181218,Phase I,Recruiting,"[{'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1611, 'therapyName': 'Gemcitabine + Oxaliplatin + Dexamethasone'}]","Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas",50749
2,NCT02273739,Phase Ib/II,Completed,"[{'id': 2982, 'therapyName': 'Enasidenib'}]","Study of Orally Administered AG-221 in Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation",50749
3,NCT02464228,Phase II,Recruiting,"[{'id': 938, 'therapyName': 'Tipifarnib'}]",Study of Tipifarnib in Subjects With Relapsed or Refractory Peripheral T-Cell Lymphoma,50749
4,NCT02495415,Phase II,Recruiting,"[{'id': 2731, 'therapyName': 'Fenretinide'}]",Trial of Intravenous Fenretinide Emulsion for Patients With Relapsed/Refractory Peripheral T-cell Lymphomas,50749
5,NCT02520791,Phase I,Recruiting,"[{'id': 4762, 'therapyName': 'MEDI-570'}]",Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma,50749
6,NCT02535247,Phase II,Suspended,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of MK-3475 in Relapsed or Refractory Peripheral T-cell Non-Hodgkin Lymphoma,50749
7,NCT02567656,Phase I,Recruiting,"[{'id': 2020, 'therapyName': 'RP6530'}]",Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma,50749
8,NCT02576496,Phase I,Recruiting,"[{'id': 6104, 'therapyName': 'EDO-S101'}]","Study of EDO-S101, A First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies",50749
9,NCT02581631,Phase Ib/II,Recruiting,"[{'id': 3263, 'therapyName': 'Brentuximab vedotin + Nivolumab'}]",A Safety and Efficacy Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas (CheckMate 436),50749
10,NCT02875002,Phase I,Not yet recruiting,"[{'id': 4826, 'therapyName': 'Belinostat + Volasertib'}]",Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas,50749
11,NCT02978625,Phase II,Recruiting,"[{'id': 5080, 'therapyName': 'Talimogene laherparepvec + Nivolumab'}]",Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers,50749
12,NCT03011814,Phase Ib/II,"Active, not recruiting","[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 3934, 'therapyName': 'lenalidomide + MEDI4736'}]",Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma,50749
13,NCT03075553,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma,50749
14,NCT03161223,Phase Ib/II,Not yet recruiting,"[{'id': 5882, 'therapyName': 'Durvalumab + Romidepsin'}, {'id': 4178, 'therapyName': 'Azacitidine + MEDI4736'}, {'id': 5881, 'therapyName': 'Azacitidine + Durvalumab + Romidepsin'}, {'id': 5880, 'therapyName': 'Durvalumab + Pralatrexate + Romidepsin'}]","Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma",50749
15,NCT03278782,Phase Ib/II,Not yet recruiting,"[{'id': 1075, 'therapyName': 'romidepsin'}, {'id': 5728, 'therapyName': 'Romidepsin + Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) in Combination With Romidepsin,50749
0,NCT00565851,Phase III,"Active, not recruiting","[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 3045, 'therapyName': 'Docetaxel + Paclitaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 667, 'therapyName': 'Bevacizumab'}]","Carboplatin, Paclitaxel and Gemcitabine With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",1791
1,NCT00954174,Phase III,"Active, not recruiting","[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1125, 'therapyName': 'Paclitaxel + Ifosfamide'}]","Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritorium Cavity Cancer",1791
2,NCT00989651,Phase I,"Active, not recruiting","[{'id': 3047, 'therapyName': 'Bevacizumab + Veliparib'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}]","Carboplatin, Paclitaxel, Bevacizumab, and ABT-888 in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer",1791
3,NCT00993655,Phase III,Completed,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}]"," Comparing Combination Chemotherapy Regimens in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer",1791
4,NCT01012817,Phase Ib/II,Recruiting,"[{'id': 1132, 'therapyName': 'Veliparib + Topotecan'}]","Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer",1791
5,NCT01031381,Phase II,Completed,"[{'id': 1120, 'therapyName': 'Everolimus + Bevacizumab'}]","Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer",1791
6,NCT01061515,Phase I,Recruiting,"[{'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}]",Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer,1791
7,NCT01132014,Phase I,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1154, 'therapyName': 'Dacarbazine'}]",Autologous OC-DC Vaccine in Ovarian Cancer,1791
8,NCT01145430,Phase I,"Active, not recruiting","[{'id': 2167, 'therapyName': 'pegylated liposomal doxorubicin + Veliparib'}]","Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer",1791
9,NCT01146795,Phase II,Terminated,"[{'id': 1152, 'therapyName': 'Bevacizumab + Carboplatin + Paclitaxel'}]",Neoadjuvant Therapy for Ovarian Cancer,1791
10,NCT01239732,Phase III,Completed,"[{'id': 1152, 'therapyName': 'Bevacizumab + Carboplatin + Paclitaxel'}]",A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian Cancer,1791
11,NCT01248962,Phase II,"Active, not recruiting","[{'id': 1092, 'therapyName': 'Carboplatin'}]","Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in Patients With Patients With Recurrent, Ovary, Fallopian Tube, and Primary Peritoneal Cancer",1791
12,NCT01264432,Phase I,"Active, not recruiting","[{'id': 954, 'therapyName': 'Veliparib'}]","Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer",1791
13,NCT01281514,Phase I,Recruiting,"[{'id': 2168, 'therapyName': 'Carboplatin + Doxil + Everolimus'}]","Carboplatin, Pegylated Liposomal Doxorubicin Hydrochloride, and Everolimus in Treating Patients With Relapsed Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer",1791
14,NCT01305213,Phase Ib/II,Completed,"[{'id': 1186, 'therapyName': 'Fosbretabulin'}, {'id': 667, 'therapyName': 'Bevacizumab'}]","Bevacizumab With or Without Fosbretabulin Tromethamine in Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer",1791
15,NCT01312376,Phase I,"Active, not recruiting","[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1227, 'therapyName': 'CD3/CD28 costimulated vaccine-primed autologous T-cells'}, {'id': 1222, 'therapyName': 'OC-DC vaccine'}]",Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer,1791
16,NCT01357161,Phase II,Completed,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 822, 'therapyName': 'MK-1775'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]", A Study of MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004),1791
17,NCT01445418,Phase I,"Active, not recruiting","[{'id': 837, 'therapyName': 'Olaparib'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer,1791
18,NCT01459380,Phase I,Completed,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 954, 'therapyName': 'Veliparib'}, {'id': 667, 'therapyName': 'Bevacizumab'}]","Veliparib, Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer",1791
19,NCT01482715,,"Active, not recruiting","[{'id': 906, 'therapyName': 'Rucaparib'}]",A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II),1791
20,NCT01493505,Phase III,Terminated,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1218, 'therapyName': 'Trebananib'}]", TRINOVA-3,1791
21,NCT01519869,Phase I,"Active, not recruiting",[],"Trial of Chemotherapy in Ovarian, Fallopian Tube and Peritoneal Carcinoma",1791
22,NCT01535157,Phase Ib/II,"Active, not recruiting","[{'id': 2858, 'therapyName': 'Ketoconazole'}, {'id': 2731, 'therapyName': 'Fenretinide'}]",Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer,1791
23,NCT01579812,Phase II,"Active, not recruiting","[{'id': 1031, 'therapyName': 'Metformin'}]","Evaluation of Metformin, Targeting Cancer Stem Cells for Prevention of Relapse in Gynecologic Patients",1791
24,NCT01607905,Phase I,Completed,"[{'id': 1749, 'therapyName': 'Selinexor'}]",Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced or Metastatic Solid Tumor Cancer,1791
25,NCT01652079,Phase II,"Active, not recruiting","[{'id': 1213, 'therapyName': 'CRLX101 + Bevacizumab'}]",CRLX101 in Combination With Bevacizumab for Recurrent Ovarian/Tubal/Peritoneal Cancer,1791
26,NCT01669798,Phase II,Recruiting,"[{'id': 831, 'therapyName': 'Nintedanib'}]","BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer",1791
27,NCT01849874,Phase III,"Active, not recruiting","[{'id': 807, 'therapyName': 'Binimetinib'}]","A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer",1791
28,NCT01936974,Phase II,Terminated,"[{'id': 1295, 'therapyName': 'Gemcitabine + Bevacizumab + Cisplatin'}, {'id': 1296, 'therapyName': 'Gemcitabine + Bevacizumab + Oxaliplatin'}, {'id': 1294, 'therapyName': 'Gemcitabine + Bevacizumab + Carboplatin'}, {'id': 1297, 'therapyName': 'Gemcitabine + Bevacizumab'}]","(PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma",1791
29,NCT01974765,Phase II,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}]","Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies",1791
30,NCT02050009,Phase I,Withdrawn,"[{'id': 1381, 'therapyName': 'Paclitaxel + Carboplatin + Metformin'}]","Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",1791
31,NCT02059265,Phase II,"Active, not recruiting","[{'id': 717, 'therapyName': 'Dasatinib'}]","Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer",1791
32,NCT02101775,Phase II,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1279, 'therapyName': 'MK-1775 + Gemcitabine'}]","Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",1791
33,NCT02101788,Phase II,Recruiting,"[{'id': 942, 'therapyName': 'Topotecan'}, {'id': 2173, 'therapyName': 'Doxil + Letrozole + Tamoxifen + Paclitaxel'}, {'id': 2, 'therapyName': 'Trametinib'}]",Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,1791
34,NCT02121990,Phase I,"Active, not recruiting","[{'id': 1451, 'therapyName': 'Cisplatin + Paclitaxel + Bevacizumab + Olaparib '}]","Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer",1791
35,NCT02122185,Phase II,Recruiting,"[{'id': 1031, 'therapyName': 'Metformin'}, {'id': 1827, 'therapyName': 'Paclitaxel + Carboplatin + Docetaxel'}]","Metformin Hydrochloride and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",1791
36,NCT02166905,Phase Ib/II,Recruiting,"[{'id': 2595, 'therapyName': 'poly ICLC  '}, {'id': 1324, 'therapyName': 'DEC-205-NY-ESO-1 fusion protein vaccine'}, {'id': 2575, 'therapyName': 'Epacadostat'}]","DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission",1791
37,NCT02188550,Phase II,Unknown status,"[{'id': 1621, 'therapyName': 'Everolimus + Letrozole'}]",Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer,1791
38,NCT02203513,Phase II,Recruiting,"[{'id': 1651, 'therapyName': 'Prexasertib'}]","Chk1/2 Inhibitor (LY2606368) in Women With BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Non-High Risk Triple Negative Breast Cancer, and Grade Serous Ovarian Cancer at Low Genetic Risk",1791
39,NCT02208375,Phase Ib/II,Recruiting,"[{'id': 837, 'therapyName': 'Olaparib'}, {'id': 655, 'therapyName': 'AZD5363'}, {'id': 991, 'therapyName': 'Vistusertib'}]",mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian Cancer,1791
40,NCT02275039,Phase I,"Active, not recruiting","[{'id': 1038, 'therapyName': 'MVAp53'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer,1791
41,NCT02283658,Phase II,"Active, not recruiting","[{'id': 1621, 'therapyName': 'Everolimus + Letrozole'}]","Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer",1791
42,NCT02312245,Phase II,Recruiting,"[{'id': 942, 'therapyName': 'Topotecan'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 755, 'therapyName': 'Gemcitabine'}]","Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",1791
43,NCT02316834,Phase I,"Active, not recruiting","[{'id': 682, 'therapyName': 'Talazoparib'}]",POSITION: A PilOt Study of InducTion PARP InhibitiON in Ovarian Cancer,1791
44,NCT02392676,Phase III,Withdrawn,"[{'id': 837, 'therapyName': 'Olaparib'}]",Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations,1791
45,NCT02431559,Phase Ib/II,Recruiting,"[{'id': 3101, 'therapyName': 'Aldoxorubicin + MEDI4736 + Motolimod'}]","A Phase 1/2 Study of Motolimod (VTX-2337) and MEDI4736 in Subjects With Recurrent, Platinum-Resistant Ovarian Cancer for Whom Pegylated Liposomal Doxorubicin (PLD) is Indicated",1791
46,NCT02440425,Phase II,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer,1791
47,NCT02459301,Phase I,"Active, not recruiting","[{'id': 3382, 'therapyName': 'IPH2201'}]","Dose-Ranging Study of IPH2201 in Patients With High Grade Serious CA of Ovarian, Fallopian Tube or Peritoneal Origin",1791
48,NCT02470585,Phase III,"Active, not recruiting","[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 954, 'therapyName': 'Veliparib'}]","Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Subjects With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",1791
49,NCT02485990,Phase Ib/II,Recruiting,"[{'id': 837, 'therapyName': 'Olaparib'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]","Study of Tremelimumab Alone or Combined With Olaparib for Patients With Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma)",1791
50,NCT02537444,Phase II,"Active, not recruiting","[{'id': 1605, 'therapyName': 'Acalabrutinib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Recurrent Ovarian Cancer (KEYNOTE191),1791
51,NCT02571725,Phase Ib/II,Recruiting,"[{'id': 1652, 'therapyName': 'Tremelimumab'}, {'id': 837, 'therapyName': 'Olaparib'}]",PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer,1791
52,NCT02608684,Phase II,Recruiting,"[{'id': 3248, 'therapyName': 'Cisplatin + Gemcitabine + Pembrolizumab'}]",A Study of Pembrolizumab With Standard Treatment in Patients With Recurrent Platinum-resistant Ovarian Cancer,1791
53,NCT02657928,Phase II,Recruiting,"[{'id': 1568, 'therapyName': 'LEE011 + Letrozole'}]","Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal or Endometrial Cancer",1791
54,NCT02659241,Phase I,Recruiting,"[{'id': 822, 'therapyName': 'MK-1775'}]",A Pilot Study of Induction Wee1 Inhibition in Ovarian Cancer,1791
55,NCT02661815,Phase I,"Active, not recruiting","[{'id': 3469, 'therapyName': 'ACY-1215 + Paclitaxel'}, {'id': 667, 'therapyName': 'Bevacizumab'}]","A Phase 1b Study of Weekly Paclitaxel And Oral Ricolinostat For The Treatment Of Recurrent Platinum Resistant Ovarian, Primary Peritoneal, Or Fallopian Tube Cancer",1791
56,NCT02764333,Phase II,Recruiting,"[{'id': 4180, 'therapyName': 'MEDI4736 + TPIV 200'}]",TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian Cancer,1791
57,NCT02833506,Phase I,Not yet recruiting,"[{'id': 4460, 'therapyName': 'NY-ESO-1 peptide vaccine + Sirolimus'}, {'id': 2696, 'therapyName': 'NY-ESO-1 peptide vaccine'}]","Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",1791
58,NCT02834975,Phase II,Recruiting,"[{'id': 2103, 'therapyName': 'Carboplatin + Paclitaxel + Pembrolizumab'}]","Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Epithelial Ovarian Cancer (EOC).",1791
59,NCT02889900,Phase II,Recruiting,"[{'id': 1971, 'therapyName': 'Cediranib + Olaparib'}]",Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer (CONCERTO),1791
60,NCT02901899,Phase II,Recruiting,"[{'id': 4725, 'therapyName': 'Pembrolizumab + SGI-110'}]","Guadecitabine and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",1791
61,NCT02953457,Phase Ib/II,Recruiting,"[{'id': 4949, 'therapyName': 'MEDI4736 + Olaparib + Tremelimumab'}]","Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRAC2 Mutation",1791
62,NCT02983799,Phase II,Recruiting,"[{'id': 837, 'therapyName': 'Olaparib'}]",Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status,1791
63,NCT03029403,Phase II,Not yet recruiting,"[{'id': 5266, 'therapyName': 'Pembrolizumab + DPX-Survivac + Cyclophosphamide'}]","Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer",1791
64,NCT03038100,Phase III,Recruiting,"[{'id': 2370, 'therapyName': 'Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel'}, {'id': 1152, 'therapyName': 'Bevacizumab + Carboplatin + Paclitaxel'}]","A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (IMagyn050)",1791
65,NCT03054909,Phase I,Not yet recruiting,"[{'id': 3060, 'therapyName': 'ALT-803'}]",QUILT-2.021: Phase I of IP Followed by SQ ALT-803 for Ovarian Cancer,1791
66,NCT03079687,Expanded access,Approved for marketing,"[{'id': 837, 'therapyName': 'Olaparib'}]","Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer.",1791
67,NCT03162562,Phase I,Recruiting,"[{'id': 5792, 'therapyName': 'Oregovomab + poly ICLC '}]",The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer,1791
68,NCT03206047,Phase Ib/II,Recruiting,"[{'id': 4693, 'therapyName': 'Atezolizumab + SGI-110'}, {'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 5982, 'therapyName': 'Atezolizumab + SGI-110 + DEC-205-NY-ESO-1 fusion protein vaccine'}]","Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",1791
69,NCT03206645,Phase I,Recruiting,"[{'id': 6266, 'therapyName': 'Carboplatin + Paclitaxel + PTC596'}]",PTC-596 in Women With Ovarian Cancer Receiving Neoadjuvant Chemotherapy,1791
0,NCT00996385,Phase II,Unknown status,"[{'id': 3064, 'therapyName': 'Bortezomib + Oxaliplatin'}]",Velcade and Eloxatin for Patients With Malignant Pleural or Peritoneal Mesothelioma,1788
1,NCT02399371,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Treating Patients With Malignant Mesothelioma,1788
2,NCT02639091,Phase I,Recruiting,"[{'id': 4617, 'therapyName': 'Anetumab ravtansine + Cisplatin + Pemetrexed'}]",Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors,1788
3,NCT02824042,Phase I,Recruiting,"[{'id': 4594, 'therapyName': 'Anetumab ravtansine + Itraconazole'}, {'id': 4593, 'therapyName': 'Anetumab ravtansine'}]",Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole,1788
4,NCT03074513,Phase II,Recruiting,"[{'id': 4595, 'therapyName': 'Atezolizumab + Bevacizumab'}]",Atezolizumab and Bevacizumab in Rare Solid Tumors,1788
0,NCT02345265,Phase II,"Active, not recruiting","[{'id': 1971, 'therapyName': 'Cediranib + Olaparib'}]","Olaparib and Cediranib Maleate in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer",4901
1,NCT02354586,Phase II,Recruiting,"[{'id': 832, 'therapyName': 'Niraparib'}]",A Study of Niraparib in Patients With Ovarian Cancer Who Have Received at Least Three Previous Chemotherapy Regimens,4901
2,NCT02834013,Phase 0,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab in Treating Patients With Rare Tumors,4901
3,NCT02898207,Phase I,Recruiting,"[{'id': 4729, 'therapyName': 'Olaparib + Onalespib'}]","Olaparib and Hsp90 Inhibitor AT13387 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer",4901
4,NCT03206645,Phase I,Recruiting,"[{'id': 6266, 'therapyName': 'Carboplatin + Paclitaxel + PTC596'}]",PTC-596 in Women With Ovarian Cancer Receiving Neoadjuvant Chemotherapy,4901
0,NCT01116648,Phase Ib/II,"Active, not recruiting","[{'id': 837, 'therapyName': 'Olaparib'}, {'id': 1971, 'therapyName': 'Cediranib + Olaparib'}]","Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer",1725
1,NCT01325441,Phase Ib/II,Recruiting,"[{'id': 2586, 'therapyName': 'BBI608 + Paclitaxel'}]",A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies,1725
2,NCT01384253,Phase I,Completed,"[{'id': 1540, 'therapyName': '212Pb-TCMC-Trastuzumab + Trastuzumab '}]",Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy,1725
3,NCT01610206,Phase II,"Active, not recruiting","[{'id': 1478, 'therapyName': 'Gemcitabine + Pazopanib'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer,1725
4,NCT01649336,Phase I,Completed,"[{'id': 2010, 'therapyName': 'MEK162 + Paclitaxel'}]","A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer",1725
5,NCT01663857,Phase Ib/II,"Active, not recruiting","[{'id': 3296, 'therapyName': 'Ralimetinib'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}]",A Study of LY2228820 for Recurrent Ovarian Cancer,1725
6,NCT01690468,Phase Ib/II,Recruiting,"[{'id': 4566, 'therapyName': 'Carboplatin + Triciribine'}]",PTX-200 and Carboplatin in Ovarian Cancer,1725
7,NCT01749397,Phase I,Recruiting,"[{'id': 2009, 'therapyName': 'Floxuridine + Veliparib'}]","Veliparib and Floxuridine in Treating Patients With Metastatic Epithelial Ovarian, Primary Peritoneal Cavity, or Fallopian Tube Cancer",1725
8,NCT01844986,Phase III,"Active, not recruiting","[{'id': 837, 'therapyName': 'Olaparib'}]",Olaparib Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.,1725
9,NCT01846611,Phase III,Recruiting,"[{'id': 1008, 'therapyName': 'Doxil'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]","A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",1725
10,NCT01847274,Phase III,Completed,"[{'id': 832, 'therapyName': 'Niraparib'}]",A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer,1725
11,NCT01853306,Phase I,Completed,"[{'id': 954, 'therapyName': 'Veliparib'}]","A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors",1725
12,NCT01853644,Phase II,Recruiting,"[{'id': 1055, 'therapyName': 'Tivozanib'}]","Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer",1725
13,NCT01874353,Phase III,"Active, not recruiting","[{'id': 837, 'therapyName': 'Olaparib'}]",Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy,1725
14,NCT01891344,Phase II,"Active, not recruiting","[{'id': 906, 'therapyName': 'Rucaparib'}]","A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)",1725
15,NCT01940172,Phase I,Completed,"[{'id': 1458, 'therapyName': 'Conatumumab'}, {'id': 2647, 'therapyName': 'Birinapant  '}]",Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer,1725
16,NCT01952249,Phase Ib/II,Completed,"[{'id': 2007, 'therapyName': 'Demcizumab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",A Study of Demcizumab Plus Paclitaxel in Subjects With Platinum Resistant Ovarian,1725
17,NCT01962948,Phase II,"Active, not recruiting","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 745, 'therapyName': 'Ganetespib'}]","Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",1725
18,NCT01968213,Phase III,"Active, not recruiting","[{'id': 906, 'therapyName': 'Rucaparib'}]","A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer",1725
19,NCT01972516,Phase II,Terminated,"[{'id': 1055, 'therapyName': 'Tivozanib'}]",Tivozanib As Maintenance Therapy In GYN,1725
20,NCT01991210,Phase II,Terminated,"[{'id': 1345, 'therapyName': 'DNIB0600A'}, {'id': 1008, 'therapyName': 'Doxil'}]",A Randomized Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin in Patients With Platinum-Resistant Ovarian Cancer,1725
21,NCT01995188,Phase I,Completed,"[{'id': 1347, 'therapyName': 'DNIB0600A + Carboplatin + Bevacizumab'}, {'id': 1346, 'therapyName': 'DNIB0600A + Carboplatin'}]",A Study to Evaluate the Safety and Pharmacology of DNIB0600A in Patients With Ovarian Cancer,1725
22,NCT02014337,Phase I,"Active, not recruiting","[{'id': 3053, 'therapyName': 'Eribulin + Mifepristone'}]",Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors,1725
23,NCT02042430,Phase I,"Active, not recruiting","[{'id': 2575, 'therapyName': 'Epacadostat'}]","INCB024360 Before Surgery in Treating Patients With Newly Diagnosed Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",1725
24,NCT02046421,Phase I,"Active, not recruiting","[{'id': 2603, 'therapyName': 'Mifepristone'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}]","Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer",1725
25,NCT02118285,Phase I,Completed,"[{'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 2575, 'therapyName': 'Epacadostat'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1166, 'therapyName': 'Fludarabine'}]","Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer",1725
26,NCT02124421,Phase II,Recruiting,"[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1812, 'therapyName': 'Cisplatin + Paclitaxel'}]","Outcomes in CRS/HIPEC as Initial Treatment of Ovarian, Fallopian Tube and Primary Peritoneal Cancer",1725
27,NCT02195973,Phase Ib/II,"Active, not recruiting","[{'id': 1620, 'therapyName': 'Paclitaxel + Sonidegib'}]",Phase IB/II Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer,1725
28,NCT02199171,Phase I,Unknown status,"[{'id': 1092, 'therapyName': 'Carboplatin'}]","Heated Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Peritoneal Cancer",1725
29,NCT02269293,Phase I,Recruiting,"[{'id': 2640, 'therapyName': 'Carboplatin + Paclitaxel + Selinexor'}]","Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers",1725
30,NCT02278783,Phase II,Terminated,"[{'id': 890, 'therapyName': 'Regorafenib'}]","Phase 2 Trial of Regorafenib in Patients With Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancer",1725
31,NCT02282020,Phase III,Recruiting,"[{'id': 837, 'therapyName': 'Olaparib'}]",Olaparib Treatment in Relapsed Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments.,1725
32,NCT02289950,Phase II,Recruiting,"[{'id': 3230, 'therapyName': 'Farletuzumab'}]",A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Subjects With Low CA125 Platinum-Sensitive Ovarian Cancer,1725
33,NCT02312245,Phase II,Recruiting,"[{'id': 942, 'therapyName': 'Topotecan'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 755, 'therapyName': 'Gemcitabine'}]","Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",1725
34,NCT02346747,Phase II,"Active, not recruiting","[{'id': 1157, 'therapyName': 'FANG vaccine'}]",Phase II/III Trial of Maintenance Vigil for High Risk Stage III/IV Ovarian Cancer (VITAL),1725
35,NCT02349958,Phase II,Recruiting,"[{'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy,1725
36,NCT02354131,Phase Ib/II,Recruiting,"[{'id': 832, 'therapyName': 'Niraparib'}, {'id': 4254, 'therapyName': 'Bevacizumab + Niraparib'}]",Niraparib Versus Niraparib-bevacizumab Combination in Women With Platinum-sensitive Epithelial Ovarian Cancer (AVANOVA),1725
37,NCT02432690,Phase II,"Active, not recruiting","[{'id': 1945, 'therapyName': 'BBI503'}]",A Study of BBI503 in Asymptomatic Recurrent Ovarian Cancer Patients With CA-125 Elevation,1725
38,NCT02437812,Phase II,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1031, 'therapyName': 'Metformin'}]","Study of Paclitaxel, Carboplatin and Oral Metformin in the Treatment of Advanced Stage Ovarian Carcinoma",1725
39,NCT02446600,Phase III,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 1001, 'therapyName': 'Cediranib'}]","Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",1725
40,NCT02452775,Phase I,Recruiting,"[{'id': 3008, 'therapyName': 'OC-L'}]",Autologous OC-L Vaccine and Ovarian Cancer,1725
41,NCT02489006,Phase II,Recruiting,"[{'id': 837, 'therapyName': 'Olaparib'}]","A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer",1725
42,NCT02498600,Phase II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]","Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",1725
43,NCT02502266,Phase II,Suspended,"[{'id': 942, 'therapyName': 'Topotecan'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 1001, 'therapyName': 'Cediranib'}]","Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",1725
44,NCT02575807,Phase Ib/II,Recruiting,"[{'id': 2575, 'therapyName': 'Epacadostat'}, {'id': 2641, 'therapyName': 'CRS-207'}]","Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian, or Peritoneal Cancer",1725
45,NCT02580058,Phase III,"Active, not recruiting","[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 3144, 'therapyName': 'Avelumab'}]",A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer,1725
46,NCT02595892,Phase II,Recruiting,"[{'id': 2879, 'therapyName': 'VX-970'}, {'id': 755, 'therapyName': 'Gemcitabine'}]","Gemcitabine Hydrochloride Alone or With VX-970 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",1725
47,NCT02606305,Phase I,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 3232, 'therapyName': 'IMGN853'}]","Study of IMGN853 in Comb. With Bevacizumab, Carboplatin or PLD in Adults With FRa + Adv. EOC, Primary Peritoneal, Fallopian Tube, or Endometrial Cancer",1725
48,NCT02627430,Phase I,Withdrawn,"[{'id': 3317, 'therapyName': 'Onalespib + Talazoparib'}]","Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer",1725
49,NCT02627443,Phase II,Recruiting,"[{'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}, {'id': 2879, 'therapyName': 'VX-970'}]","Carboplatin and Gemcitabine Hydrochloride With or Without ATR Kinase Inhibitor VX-970 in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",1725
50,NCT02631876,Phase II,Recruiting,"[{'id': 3574, 'therapyName': 'Doxil + Paclitaxel'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3232, 'therapyName': 'IMGN853'}]","PH2 Study of IMGN853 vs Investigator's Choice of Chemo in Adults With FRa+ Adv. EOC, Primary Peritoneal or Primary Fallopian Tube Cancer",1725
51,NCT02649673,Phase Ib/II,Recruiting,"[{'id': 3845, 'therapyName': 'LCL161 + Topotecan'}]",LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies,1725
52,NCT02655016,Phase III,Recruiting,"[{'id': 832, 'therapyName': 'Niraparib'}]",A Study of Niraparib Maintenance Treatment in Patients With HRD-Positive Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy,1725
53,NCT02657889,Phase Ib/II,Recruiting,"[{'id': 3935, 'therapyName': 'Niraparib + Pembrolizumab'}]",Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Triple-negative Breast Cancer or Ovarian Cancer (KEYNOTE-162),1725
54,NCT02658214,Phase I,Recruiting,"[{'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}, {'id': 2634, 'therapyName': 'Carboplatin + nab-paclitaxel'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}]",Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors,1725
55,NCT02674061,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Efficacy and Safety Study of Pembrolizumab (MK-3475) in Women With Advanced Recurrent Ovarian Cancer (MK-3475-100/KEYNOTE-100),1725
56,NCT02713386,Phase Ib/II,Recruiting,"[{'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]","Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",1725
57,NCT02718417,Phase III,Recruiting,"[{'id': 3144, 'therapyName': 'Avelumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100),1725
58,NCT02726997,Phase Ib/II,Recruiting,"[{'id': 3997, 'therapyName': 'Carboplatin + Durvalumab + Paclitaxel'}]",Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer,1725
59,NCT02728830,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers,1725
60,NCT02737787,Phase I,Recruiting,"[{'id': 4020, 'therapyName': 'Nivolumab + WT1 vaccine'}]",A Study of WT1 Vaccine and Nivolumab For Recurrent Ovarian Cancer,1725
61,NCT02766582,Phase II,Recruiting,"[{'id': 2103, 'therapyName': 'Carboplatin + Paclitaxel + Pembrolizumab'}]",Phase II: Pembrolizumab/Carboplatin/Taxol in Epithelial Ovary Cancer,1725
62,NCT02785250,Phase I,Recruiting,"[{'id': 4238, 'therapyName': 'Cyclophosphamide + DPX-Survivac + INCB024360 '}]",Study of DPX-Survivac Vaccine Therapy and Epacadostat in Patients With Recurrent Ovarian Cancer,1725
63,NCT02788708,Phase I,Recruiting,"[{'id': 4236, 'therapyName': 'Lenvatinib + Paclitaxel'}]",Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer,1725
64,NCT02824042,Phase I,Recruiting,"[{'id': 4594, 'therapyName': 'Anetumab ravtansine + Itraconazole'}, {'id': 4593, 'therapyName': 'Anetumab ravtansine'}]",Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole,1725
65,NCT02853318,Phase II,Recruiting,"[{'id': 4528, 'therapyName': 'Bevacizumab + Cyclophosphamide + Pembrolizumab'}]","Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",1725
66,NCT02855944,Phase III,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 906, 'therapyName': 'Rucaparib'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]","ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients",1725
67,NCT02865811,Phase II,"Active, not recruiting","[{'id': 4558, 'therapyName': 'Doxil + Pembrolizumab'}]","Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer",1725
68,NCT02873962,Phase II,Recruiting,"[{'id': 2111, 'therapyName': 'Bevacizumab + Nivolumab'}]",A Phase II Study Of Nivolumab/ Bevacizumab,1725
69,NCT02884648,Phase II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Bevacizumab in Ovarian Cancer Patients With Disease at Second-look Surgery,1725
70,NCT02900560,Phase II,Recruiting,"[{'id': 2496, 'therapyName': 'Azacitidine + Pembrolizumab'}]",Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer,1725
71,NCT02915523,Phase Ib/II,Recruiting,"[{'id': 3144, 'therapyName': 'Avelumab'}, {'id': 5559, 'therapyName': 'Avelumab + Entinostat'}]",Phase 1b/2 Study of Avelumab With or Without Entinostat in Patients With Advanced Epithelial Ovarian Cancer,1725
72,NCT02923739,Phase II,Recruiting,"[{'id': 4836, 'therapyName': 'Bevacizumab + Emactuzumab + Paclitaxel'}, {'id': 2123, 'therapyName': 'Bevacizumab + Paclitaxel'}]","Induction Discontinuation Trial of Emactuzumab Following Paclitaxel and Bevacizumab in Patients With Platinum-Resistant, Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer - REDIRECT",1725
73,NCT02943317,Phase I,Recruiting,"[{'id': 958, 'therapyName': 'VS-6063'}, {'id': 3144, 'therapyName': 'Avelumab'}]","Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian Cancer",1725
74,NCT02948101,Phase II,Not yet recruiting,"[{'id': 5848, 'therapyName': 'Cyclophosphamide + PD 0360324'}]",Pre-Conditioning Effects of Anti-Macrophage Therapy Using PD 0360324 in Recurrent Platinum-Resistant Epithelial Ovarian Cancer,1725
75,NCT02948426,Phase I,Recruiting,"[{'id': 4975, 'therapyName': 'interferon gamma + peginterferon alfa-2b'}]","Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer",1725
76,NCT02963831,Phase Ib/II,Recruiting,"[{'id': 4978, 'therapyName': 'ONCOS-102 + MEDI4736'}]","A Phase 1/2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies",1725
77,NCT02996825,Phase I,Recruiting,"[{'id': 3232, 'therapyName': 'IMGN853'}]","Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRa-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer",1725
78,NCT03023319,Phase I,Recruiting,"[{'id': 5237, 'therapyName': 'Bosutinib + Pemetrexed'}]",Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors,1725
79,NCT03026062,Phase II,Recruiting,"[{'id': 1652, 'therapyName': 'Tremelimumab'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",Durvalumab and Tremelimumab in Combo Versus Sequential,1725
80,NCT03029598,Phase Ib/II,Recruiting,"[{'id': 5265, 'therapyName': 'Carboplatin + Pembrolizumab'}]","Pembrolizumab and Carboplatin in Treating Patients With Relapsed or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",1725
81,NCT03030287,Phase I,Recruiting,"[{'id': 5264, 'therapyName': 'OMP-305B83 + Paclitaxel'}]","A Phase 1b Study of OMP-305B83 Plus Paclitaxel in Subjects With Ovarian, Peritoneal or Fallopian Tube Cancer",1725
82,NCT03056833,Phase I,Recruiting,"[{'id': 5333, 'therapyName': 'LEE011 + Carboplatin + Paclitaxel'}]",Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer,1725
83,NCT03093155,Phase II,Recruiting,"[{'id': 1122, 'therapyName': 'Bevacizumab + Ixabepilone'}, {'id': 781, 'therapyName': 'Ixabepilone'}]",Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab,1725
84,NCT03113487,Phase II,Not yet recruiting,"[{'id': 5547, 'therapyName': 'MVAp53 + Pembrolizumab'}]","P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",1725
85,NCT03245892,Phase I,Recruiting,"[{'id': 5303, 'therapyName': 'Nivolumab + Carboplatin + Paclitaxel'}]",A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab in Patients With Ovarian Cancer,1725
86,NCT03283943,Phase I,Not yet recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}]",PDL-1 Inhibition and Focal Sensitizing Radiotherapy in Recurrent Ovarian/Primary Peritoneal/Fallopian Tube Cancers.,1725
87,NCT03294694,Phase I,Not yet recruiting,"[{'id': 6285, 'therapyName': 'Fulvestrant + PDR001 + Ribociclib'}, {'id': 6284, 'therapyName': 'PDR001 + Ribociclib'}]",Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer,1725
0,NCT02494570,Phase II,Recruiting,"[{'id': 3380, 'therapyName': 'Nab-Rapamycin'}]",A Phase 2 Study of ABI-009 in Patients With Advanced Malignant PEComa,2643
0,NCT03258008,Phase II,Not yet recruiting,"[{'id': 6148, 'therapyName': 'ISA101b + Utomilumab'}]",Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal Cancer,50921
0,NCT01089101,Phase Ib/II,Recruiting,"[{'id': 913, 'therapyName': 'Selumetinib'}]",Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma,4851
1,NCT01734512,Phase II,Recruiting,"[{'id': 735, 'therapyName': 'Everolimus'}]",PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children,4851
2,NCT01837862,Phase Ib/II,Recruiting,"[{'id': 2134, 'therapyName': 'Mebendazole + Vincristine + Carboplatin + Temozolomide'}, {'id': 2133, 'therapyName': 'Mebendazole + Bevacizumab + Irinotecan'}]",A Phase I/II Study of Mebendazole for the Treatment of Pediatric Gliomas,4851
3,NCT01999270,Phase I,Completed,"[{'id': 2112, 'therapyName': 'Bevacizumab + Irinotecan'}]",Evaluation of FDOPA-PET/MRI in Pediatric Patients With CNS Tumors,4851
0,NCT01837862,Phase Ib/II,Recruiting,"[{'id': 2134, 'therapyName': 'Mebendazole + Vincristine + Carboplatin + Temozolomide'}, {'id': 2133, 'therapyName': 'Mebendazole + Bevacizumab + Irinotecan'}]",A Phase I/II Study of Mebendazole for the Treatment of Pediatric Gliomas,4845
0,NCT01999270,Phase I,Completed,"[{'id': 2112, 'therapyName': 'Bevacizumab + Irinotecan'}]",Evaluation of FDOPA-PET/MRI in Pediatric Patients With CNS Tumors,5032
0,NCT00602667,Phase I,"Active, not recruiting","[{'id': 2449, 'therapyName': 'Methotrexate + Cisplatin + Cyclophosphamide + Vincristine'}, {'id': 2450, 'therapyName': 'Cyclophosphamide + Etoposide + Topotecan'}, {'id': 2451, 'therapyName': 'Erlotinib + Cyclophosphamide + Topotecan'}]","Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma",1664
1,NCT00983398,Phase Ib/II,Recruiting,"[{'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2587, 'therapyName': 'Carboplatin + Melphalan'}]","Melphalan, Carboplatin, and Sodium Thiosulfate for Patients With Central Nervous System (CNS) Embryonal or Germ Cell Tumors",1664
2,NCT01217437,Phase II,"Active, not recruiting","[{'id': 1462, 'therapyName': 'Temozolomide + Irinotecan'}, {'id': 1463, 'therapyName': 'Temozolomide + Irinotecan + Bevacizumab'}]",Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors,1664
3,NCT03173950,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Immune Checkpoint Inhibitor Nivolumab in People With Select Rare CNS Cancers,1664
0,NCT00939523,Phase II,Recruiting,"[{'id': 787, 'therapyName': 'Lapatinib'}]",Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy,1785
0,NCT02834013,Phase 0,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab in Treating Patients With Rare Tumors,4916
0,NCT02834013,Phase 0,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab in Treating Patients With Rare Tumors,2024
0,NCT02834013,Phase 0,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab in Treating Patients With Rare Tumors,3596
0,NCT02506959,Phase II,Recruiting,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 3277, 'therapyName': 'Pyridoxine'}, {'id': 1080, 'therapyName': 'Panobinostat'}, {'id': 2373, 'therapyName': 'Palifermin'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Myeloma,6536
1,NCT02556931,Phase II,Recruiting,"[{'id': 4228, 'therapyName': 'Cyclophosphamide + Fludarabine + Melphalan + Tacrolimus'}]","Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies",6536
0,NCT02506959,Phase II,Recruiting,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 3277, 'therapyName': 'Pyridoxine'}, {'id': 1080, 'therapyName': 'Panobinostat'}, {'id': 2373, 'therapyName': 'Palifermin'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Myeloma,3721
1,NCT03196401,Phase I,Suspended,"[{'id': 1356, 'therapyName': 'Durvalumab'}]",A Study of Immunotherapy Plus Radiation Therapy to Stimulate Immunity in Solitary Bone Plasmacytoma,3721
0,NCT02987959,Phase II,Recruiting,"[{'id': 1282, 'therapyName': 'Sapanisertib'}]",Study of TAK-228 (MLN0128) in Soft Tissue Sarcomas,5702
1,NCT03009201,Phase I,Recruiting,"[{'id': 5179, 'therapyName': 'Doxorubicin + Ribociclib'}]",Ribociclib and Doxorubicin Hydrochloride in Treating Patients Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery,5702
2,NCT03092323,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity (SU2C-SARC032),5702
3,NCT03282344,Phase II,Recruiting,"[{'id': 5076, 'therapyName': 'NKTR-214 + Nivolumab'}]",A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma,5702
0,NCT02987959,Phase II,Recruiting,"[{'id': 1282, 'therapyName': 'Sapanisertib'}]",Study of TAK-228 (MLN0128) in Soft Tissue Sarcomas,3250
1,NCT03009201,Phase I,Recruiting,"[{'id': 5179, 'therapyName': 'Doxorubicin + Ribociclib'}]",Ribociclib and Doxorubicin Hydrochloride in Treating Patients Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery,3250
0,NCT01837862,Phase Ib/II,Recruiting,"[{'id': 2134, 'therapyName': 'Mebendazole + Vincristine + Carboplatin + Temozolomide'}, {'id': 2133, 'therapyName': 'Mebendazole + Bevacizumab + Irinotecan'}]",A Phase I/II Study of Mebendazole for the Treatment of Pediatric Gliomas,4852
1,NCT01999270,Phase I,Completed,"[{'id': 2112, 'therapyName': 'Bevacizumab + Irinotecan'}]",Evaluation of FDOPA-PET/MRI in Pediatric Patients With CNS Tumors,4852
0,NCT00030264,Phase II,Completed,"[{'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 1639, 'therapyName': 'Methotrexate'}]",Combination Chemotherapy in Treating Patients With Neurofibromatosis and Progressive Plexiform Neurofibromas,5151
1,NCT01362803,Phase I,Recruiting,"[{'id': 913, 'therapyName': 'Selumetinib'}]",AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors,5151
2,NCT02101736,Phase II,"Active, not recruiting","[{'id': 998, 'therapyName': 'cabozantinib'}]",Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 (16 Years +),5151
3,NCT02390752,Phase Ib/II,Recruiting,"[{'id': 874, 'therapyName': 'PLX3397'}]",PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN),5151
4,NCT02407405,Phase II,Recruiting,"[{'id': 913, 'therapyName': 'Selumetinib'}]",Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas That Cannot Be Removed by Surgery,5151
5,NCT02639546,Phase I,Recruiting,"[{'id': 1004, 'therapyName': 'Cobimetinib'}]",iMATRIXcobi: Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Patients With Previously Treated Solid Tumors,5151
6,NCT03231306,Phase II,Not yet recruiting,"[{'id': 807, 'therapyName': 'Binimetinib'}]",Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas (NF108-BINI),5151
0,NCT02223819,Phase II,Recruiting,"[{'id': 706, 'therapyName': 'Crizotinib'}]",Adjuvant Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy,6566
0,NCT02251548,Phase II,Recruiting,"[{'id': 2185, 'therapyName': 'Ibrutinib + Rituximab + Cyclophosphamide + Fludarabine'}]","A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia",7230
0,NCT02143414,Phase II,Recruiting,"[{'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1824, 'therapyName': 'Vincristine + Methotrexate + Mercaptopurine'}]","Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia",7061
1,NCT02328014,Phase Ib/II,Recruiting,"[{'id': 3265, 'therapyName': 'ACP-319'}, {'id': 1605, 'therapyName': 'Acalabrutinib'}]","ACP-196 in Combination With ACP-319, for Treatment of B-Cell Malignancies",7061
2,NCT02494882,Phase I,Recruiting,"[{'id': 3218, 'therapyName': 'Dasatinib + Dexamethasone + Ruxolitinib'}]",Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older,7061
3,NCT02535806,Phase II,Terminated,"[{'id': 1631, 'therapyName': 'Vincristine'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults,7061
4,NCT02883049,Phase III,Suspended,"[{'id': 717, 'therapyName': 'Dasatinib'}, {'id': 4685, 'therapyName': 'Dexamethasone + Doxorubicin'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1746, 'therapyName': 'Clofarabine'}]",Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations,7061
0,NCT01658007,Phase I,Terminated,"[{'id': 917, 'therapyName': 'Sirolimus'}]",Pilot Study Of Sirolimus Plus Multiagent Chemotherapy For Relapsed/Refractory Acute Lymphoblastic Leukemia/Lymphoma,5600
0,NCT02112916,Phase III,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma,5599
0,NCT02763384,Phase II,Recruiting,"[{'id': 4275, 'therapyName': 'BKT140 + Nelarabine'}]",BL-8040 and Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma,7936
0,NCT02251548,Phase II,Recruiting,"[{'id': 2185, 'therapyName': 'Ibrutinib + Rituximab + Cyclophosphamide + Fludarabine'}]","A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia",8144
0,NCT00570323,Phase II,"Active, not recruiting","[{'id': 1911, 'therapyName': 'Anastrozole  + Fulvestrant'}, {'id': 633, 'therapyName': 'Anastrozole'}]",Arimidex With or Without Faslodex In Postmenopausal Women With HR Positive Breast Cancer,60077
1,NCT00759642,Phase II,"Active, not recruiting","[{'id': 787, 'therapyName': 'Lapatinib'}]",Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy,60077
2,NCT01177397,Phase Ib/II,Completed,"[{'id': 693, 'therapyName': 'CC-223'}]","Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma",60077
3,NCT01857193,Phase Ib/II,Recruiting,"[{'id': 2265, 'therapyName': 'LEE011 + Everolimus + Exemestane'}, {'id': 1966, 'therapyName': 'Exemestane + Everolimus'}, {'id': 2266, 'therapyName': 'LEE011 + Exemestane'}]",Phase Ib/II Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of ER+ Her2- Advanced Breast Cancer,60077
4,NCT01990209,Phase II,Recruiting,"[{'id': 2671, 'therapyName': 'Orteronel '}]",Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR),60077
0,NCT00939523,Phase II,Recruiting,"[{'id': 787, 'therapyName': 'Lapatinib'}]",Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy,5394
0,NCT00602693,Phase I,Completed,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 2311, 'therapyName': 'Allopurinol + Cyclophosphamide + Fludarabine'}]",T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer,1039
1,NCT01353625,Phase I,"Active, not recruiting","[{'id': 1000, 'therapyName': 'CC-115'}]","Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.",1039
2,NCT01886859,Phase I,"Active, not recruiting","[{'id': 3580, 'therapyName': 'Ibrutinib + lenalidomide'}]",Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma,1039
3,NCT02005289,Phase II,Recruiting,"[{'id': 5843, 'therapyName': 'Lenalidomide + MOR208'}, {'id': 5847, 'therapyName': 'Ibrutinib + MOR208'}]","Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL",1039
4,NCT02007044,Phase II,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 897, 'therapyName': 'Rituximab'}]",Ibrutinib Versus Ibrutinib + Rituximab (i vs iR) in Patients With Relapsed Chronic Lymphocytic Leukemia (CLL),1039
5,NCT02029443,Phase Ib/II,"Active, not recruiting","[{'id': 1605, 'therapyName': 'Acalabrutinib'}]","ACP-196, a Novel Bruton Tyrosine Kinase (Btk) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia",1039
6,NCT02285244,Phase II,Withdrawn,"[{'id': 621, 'therapyName': 'AEB071'}]","Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Prolymphocytic Leukemia, or Richter's Transformation",1039
7,NCT02296918,Phase I,"Active, not recruiting","[{'id': 3477, 'therapyName': 'Acalabrutinib + Obinutuzumab'}]",ACP-196 in Combination With Obinutuzumab in Relapsed/Refractory or Untreated CLL/SLL/PLL,1039
8,NCT02556931,Phase II,Recruiting,"[{'id': 4228, 'therapyName': 'Cyclophosphamide + Fludarabine + Melphalan + Tacrolimus'}]","Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies",1039
9,NCT02576496,Phase I,Recruiting,"[{'id': 6104, 'therapyName': 'EDO-S101'}]","Study of EDO-S101, A First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies",1039
10,NCT02722668,Phase II,Recruiting,"[{'id': 2281, 'therapyName': 'Cyclophosphamide + Fludarabine + Mycophenolate mofetil'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}]",UCB Transplant for Hematological DIseases Using a Non Myeloablative Prep,1039
0,NCT00002651,Phase III,Completed,"[{'id': 1507, 'therapyName': 'Bicalutamide'}, {'id': 759, 'therapyName': 'Goserelin'}]",Hormone Therapy in Treating Men With Stage IV Prostate Cancer,2526
1,NCT00223665,Phase II,Unknown status,"[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 742, 'therapyName': 'Flutamide'}]",Intermittent Hormone Therapy in Men With Localized Prostate Cancer After Radiation Therapy or Radical Prostatectomy,2526
2,NCT00536991,Phase Ib/II,Terminated,"[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 2889, 'therapyName': 'calcitriol'}, {'id': 2858, 'therapyName': 'Ketoconazole'}]","Calcitriol, Ketoconazole, and Hydrocortisone in Treating Patients With Advanced or Recurrent Prostate Cancer",2526
3,NCT00541047,Phase III,"Active, not recruiting","[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 1507, 'therapyName': 'Bicalutamide'}]",Radiation Therapy and Androgen Deprivation Therapy in Treating Patients Who Have Undergone Surgery for Prostate Cancer (RADICALS),2526
4,NCT00589420,Phase II,Unknown status,"[{'id': 2390, 'therapyName': 'Docetaxel + Sorafenib'}]",Sorafenib and Docetaxel in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy,2526
5,NCT00859781,Phase II,Recruiting,"[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 2858, 'therapyName': 'Ketoconazole'}]",177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer,2526
6,NCT00936390,Phase III,"Active, not recruiting","[{'id': 742, 'therapyName': 'Flutamide'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 795, 'therapyName': 'Leuprolide'}, {'id': 2050, 'therapyName': 'Triptorelin'}, {'id': 1507, 'therapyName': 'Bicalutamide'}]",Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer,2526
7,NCT01174199,Phase I,Terminated,"[{'id': 2263, 'therapyName': 'Temsirolimus + vorinostat'}]",Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer,2526
8,NCT01313559,Phase II,Terminated,"[{'id': 2261, 'therapyName': 'Everolimus + Pasireotide'}, {'id': 2260, 'therapyName': 'Pasireotide'}]","Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer",2526
9,NCT01342367,Phase I,Recruiting,"[{'id': 1507, 'therapyName': 'Bicalutamide'}, {'id': 2643, 'therapyName': 'Dutasteride'}, {'id': 2644, 'therapyName': 'Finasteride'}]",Feasibility of Hormones and Radiation for Intermediate or High Risk Prostate Cancer,2526
10,NCT01409200,Phase II,Recruiting,"[{'id': 649, 'therapyName': 'Axitinib'}]",Neoadjuvant Axitinib in Prostate Cancer,2526
11,NCT01420250,Phase I,"Active, not recruiting","[{'id': 1507, 'therapyName': 'Bicalutamide'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}]",Cabazitaxel With Radiation and Hormone Therapy for Prostate Cancer,2526
12,NCT01485861,Phase II,"Active, not recruiting","[{'id': 750, 'therapyName': 'GDC-0980'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 747, 'therapyName': 'Ipatasertib'}]",Study of GDC-0068 Or GDC-0980 With Abiraterone Acetate Versus Abiraterone Acetate in Patients With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy,2526
13,NCT01498978,Phase II,"Active, not recruiting","[{'id': 779, 'therapyName': 'Ipilimumab'}]",Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer,2526
14,NCT01503229,Phase II,"Active, not recruiting","[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1805, 'therapyName': 'Abiraterone'}]",Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer,2526
15,NCT01513733,Phase I,Completed,"[{'id': 2699, 'therapyName': 'Tasquinimod'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}]",The CATCH Prostate Cancer Trial Cabazitaxel And Tasquinimod in Men With Prostate Cancer,2526
16,NCT01548807,Phase I,Recruiting,"[{'id': 735, 'therapyName': 'Everolimus'}]",Phase 1 Trial of the Mammalian Target of Rapamycin (mTOR) Inhibitor Everolimus Plus Radiation Therapy (RT) for Salvage Treatment of Biochemical Recurrence in Prostate Cancer Patients Following Prostatectomy,2526
17,NCT01560923,Phase II,"Active, not recruiting","[{'id': 2648, 'therapyName': 'Sipuleucel-T'}]",Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer,2526
18,NCT01619813,Phase II,Completed,"[{'id': 2462, 'therapyName': 'Docetaxel + Prednisone'}, {'id': 893, 'therapyName': 'Reolysin'}]",Reolysin Combined With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Metastatic Castration Resistant Prostate Cancer,2526
19,NCT01630590,Phase II,"Active, not recruiting","[{'id': 998, 'therapyName': 'cabozantinib'}]",Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer,2526
20,NCT01681433,Phase II,Terminated,"[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 1807, 'therapyName': 'OGX-427'}]",OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone,2526
21,NCT01688492,Phase Ib/II,"Active, not recruiting","[{'id': 2748, 'therapyName': 'Abiraterone + Prednisone'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-na&#239;ve Patients With Progressive Metastatic Castration-resistant Prostate Cancer,2526
22,NCT01695473,Phase II,"Active, not recruiting","[{'id': 680, 'therapyName': 'BKM120'}]",Neoadjuvant BKM120 in High-risk Prostate Cancer,2526
23,NCT01703065,Phase I,"Active, not recruiting","[{'id': 998, 'therapyName': 'cabozantinib'}]",Cabozantinib in Treating Men With Castration-Resistant Prostate Cancer,2526
24,NCT01706458,Phase II,"Active, not recruiting","[{'id': 2698, 'therapyName': 'pTVG-HP plasmid DNA vaccine'}, {'id': 2648, 'therapyName': 'Sipuleucel-T'}]",Provenge With or Without pTVG-HP DNA Booster Vaccine in Prostate Cancer,2526
25,NCT01709734,Phase II,"Active, not recruiting","[{'id': 1508, 'therapyName': 'galeterone'}]","A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer",2526
26,NCT01786265,Phase II,"Active, not recruiting","[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 1814, 'therapyName': 'Degarelix'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 795, 'therapyName': 'Leuprolide'}]",Finite Androgen Ablation vs. Finite Androgen Ablation in Combination With Abiraterone Acetate and Prednisone,2526
27,NCT01787331,Phase II,"Active, not recruiting","[{'id': 1026, 'therapyName': 'Itraconazole'}]",A Phase II Study of Itraconazole in Biochemical Relapse,2526
28,NCT01790126,Phase II,"Active, not recruiting","[{'id': 1947, 'therapyName': 'ARN-509'}]",The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer,2526
29,NCT01804465,Phase II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}]",A Randomized Phase 2 Trial of Combining Sipuleucel-T With Immediate vs. Delayed CTLA-4 Blockade for Prostate Cancer,2526
30,NCT01807065,Phase II,"Active, not recruiting","[{'id': 2648, 'therapyName': 'Sipuleucel-T'}]",Sipuleucel-T With or Without Radiation Therapy in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer,2526
31,NCT01812668,Phase I,"Active, not recruiting","[{'id': 998, 'therapyName': 'cabozantinib'}]",Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer,2526
32,NCT01832259,Phase II,"Active, not recruiting","[{'id': 848, 'therapyName': 'Pazopanib'}]",A Study of VEGF Tyrosine Kinase Inhibitor (Pazopanib) in Men With High-Risk Prostate Cancer Followed by Radical Prostatectomy and Pelvic Lymph Node Dissection,2526
33,NCT01845792,Phase II,Completed,"[{'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 1805, 'therapyName': 'Abiraterone'}]",Study of Abiraterone Acetate and Prednisone in Combination With Cabazitaxel in Patients With Prostate Cancer,2526
34,NCT01848067,Phase Ib/II,"Active, not recruiting","[{'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 626, 'therapyName': 'Alisertib'}]","Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer",2526
35,NCT01885949,Phase II,"Active, not recruiting","[{'id': 2395, 'therapyName': 'Enzalutamide + Tivozanib'}]",Tivozanib + Enzalutamide in Adv Prostate Cancer,2526
36,NCT01927627,Phase II,"Active, not recruiting","[{'id': 1262, 'therapyName': 'Enzalutamide'}]",Enzalutamide in Patients With High-risk Prostate Cancer,2526
37,NCT01940276,Phase II,"Active, not recruiting","[{'id': 2748, 'therapyName': 'Abiraterone + Prednisone'}]",Abiraterone Race in Metastatic Castrate-resistant Prostate Cancer,2526
38,NCT01942837,Phase II,"Active, not recruiting","[{'id': 1262, 'therapyName': 'Enzalutamide'}]",Phase II Trial of Enzalutamide for Castrate-resistant Prostate Cancer With Correlative Assessment of Androgen Receptor Signaling,2526
39,NCT01946204,Phase III,"Active, not recruiting","[{'id': 1947, 'therapyName': 'ARN-509'}]",A Study of ARN-509 in Men With Non-Metastatic Castration-Resistant Prostate Cancer,2526
40,NCT01949337,Phase III,"Active, not recruiting","[{'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]",Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer,2526
41,NCT01961843,Phase I,"Active, not recruiting","[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1805, 'therapyName': 'Abiraterone'}]",Abiraterone Acetate for Castrate Resistant Prostate Cancer,2526
42,NCT01977651,FDA approved,"Active, not recruiting","[{'id': 1262, 'therapyName': 'Enzalutamide'}]",A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide,2526
43,NCT01996696,Phase II,Recruiting,"[{'id': 1031, 'therapyName': 'Metformin'}]","A Study With or Without Metformin to Determine if Metformin Can Prevent Weight Gain and Other Problems (i.e. Diabetes, Increased Cholesterol, Etc.) That Can Arise From the Use of Hormonal Therapy in Combination With Radiation Therapy When Treating Aggressive Localized Prostate Cancer.",2526
44,NCT02003924,Phase III,"Active, not recruiting","[{'id': 1262, 'therapyName': 'Enzalutamide'}]",Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer,2526
45,NCT02023463,Phase I,"Active, not recruiting","[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 795, 'therapyName': 'Leuprolide'}]","Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer",2526
46,NCT02025010,Phase II,"Active, not recruiting","[{'id': 1805, 'therapyName': 'Abiraterone'}]",Phase II Clinical Trial of Abiraterone Acetate Without Exogenous Glucocorticoids in Men With Castration-resistant Prostate Cancer With Correlative Assessment of Hormone Intermediates.,2526
47,NCT02034552,Phase II,"Active, not recruiting","[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 2001, 'therapyName': 'radium Ra 223 dichloride'}, {'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1805, 'therapyName': 'Abiraterone'}]",A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC),2526
48,NCT02036918,Phase I,Recruiting,"[{'id': 2648, 'therapyName': 'Sipuleucel-T'}]",Dendreon Lymph Node Biopsy in Metastatic Castrate-Resistant Prostate Cancer,2526
49,NCT02043678,Phase III,"Active, not recruiting","[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 2001, 'therapyName': 'radium Ra 223 dichloride'}]","Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms",2526
50,NCT02057939,Phase II,"Active, not recruiting","[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 795, 'therapyName': 'Leuprolide'}]",Salvage Therapeutic Radiation With Enzalutamide and ADT in Men With Recurrent Prostate Cancer (STREAM),2526
51,NCT02058706,Phase II,Recruiting,"[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 1507, 'therapyName': 'Bicalutamide'}, {'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 795, 'therapyName': 'Leuprolide'}]",LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer,2526
52,NCT02064036,Phase I,Recruiting,"[{'id': 1507, 'therapyName': 'Bicalutamide'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 795, 'therapyName': 'Leuprolide'}]",Stereotactic Boost and Long-Term Androgen Deprivation for Adenocarcinoma of the Prostate,2526
53,NCT02064582,Phase II,Recruiting,"[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]","Enzalutamide and Hormone Therapy Before, During, and After Radiation for High Risk Localized Prostate Cancer",2526
54,NCT02090114,Phase II,Recruiting,"[{'id': 2591, 'therapyName': 'Andriol'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]",RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistant (The RESTORE Study),2526
55,NCT02106507,Phase I,"Active, not recruiting","[{'id': 2303, 'therapyName': 'ARN-509 + Everolimus'}]",ARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone Acetate,2526
56,NCT02111187,Phase I,Completed,"[{'id': 1428, 'therapyName': 'Sonidegib'}]",A Pre-surgical Study of LDE225 in Men With High-risk Localized Prostate Cancer,2526
57,NCT02123758,Phase I,"Active, not recruiting","[{'id': 2649, 'therapyName': 'Abiraterone + ARN-509 + Prednisone'}]",A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer,2526
58,NCT02125084,Phase I,"Active, not recruiting","[{'id': 2264, 'therapyName': 'Enzalutamide + Everolimus'}]",Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer,2526
59,NCT02125357,Phase II,"Active, not recruiting","[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1805, 'therapyName': 'Abiraterone'}]",Sequencing Abiraterone and Enzalutamide in mCRPC,2526
60,NCT02146833,Phase II,Terminated,"[{'id': 1749, 'therapyName': 'Selinexor'}]",Study of Selinexor (KPT-330) in Metastatic Castrate Resistant Prostate Adenocarcinoma,2526
61,NCT02176161,Phase II,Recruiting,"[{'id': 1031, 'therapyName': 'Metformin'}]",Metformin Prostate Cancer Adjuvant Trial,2526
62,NCT02182622,Phase I,Unknown status,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1428, 'therapyName': 'Sonidegib'}]",LDE225 + Docetaxel/Prednisone for Adv/Met Castrate Resistant Prostate Cancer w/ Disease Progression After Docetaxel,2526
63,NCT02199197,Phase II,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}]",Radium Ra 223 With Enzalutamide in Men With Metastatic Castration Refractory Prostate Cancer,2526
64,NCT02200614,Phase III,Recruiting,"[{'id': 836, 'therapyName': 'ODM-201'}]",Efficacy and Safety Study of ODM-201 in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer,2526
65,NCT02203695,Phase II,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}]",Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy,2526
66,NCT02204072,Phase I,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 2916, 'therapyName': 'Xentuzumab'}]",BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC),2526
67,NCT02207504,Phase I,"Active, not recruiting","[{'id': 2446, 'therapyName': 'Crizotinib + Enzalutamide'}]",Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer,2526
68,NCT02213107,Phase II,"Active, not recruiting","[{'id': 3067, 'therapyName': 'Dutasteride + Enzalutamide'}]",Enzalutamide & Dutasteride as 1st Line Treatment for Patients =/&gt; 65 Years Old With Prostate Cancer.,2526
69,NCT02215096,Phase I,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 765, 'therapyName': 'GSK2636771'}]",Dose-finding Study of GSK2636771 When Administered in Combination With Enzalutamide in Male Subjects With Metastatic Castration-Resistant Prostate Cancer,2526
70,NCT02215161,Phase II,"Active, not recruiting","[{'id': 1749, 'therapyName': 'Selinexor'}]",Selinexor (KPT-330) in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Prior Therapy With Abiraterone and/or Enzalutamide,2526
71,NCT02217566,Phase II,"Active, not recruiting","[{'id': 1805, 'therapyName': 'Abiraterone'}]","Study of Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC), Chemo-Naive, Who Received a Prior Diethylstilbestrol Therapy",2526
72,NCT02254785,Phase II,Recruiting,"[{'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}]",Cabazitaxel vs Abiraterone or Enzalutamide in Patients With Poor Prognosis Metastatic Castration-resistant Prostate Cancer,2526
73,NCT02256111,Phase II,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}]",EXTEND Exercise Trial,2526
74,NCT02257736,Phase III,"Active, not recruiting","[{'id': 1948, 'therapyName': 'ARN-509 + Abiraterone'}, {'id': 1805, 'therapyName': 'Abiraterone'}]",An Efficacy and Safety Study of JNJ56021927 in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC),2526
75,NCT02262910,Phase I,Recruiting,"[{'id': 4651, 'therapyName': 'MOR209/ES414'}]",Study of MOR209/ES414 in Metastatic Castration-Resistant Prostate Cancer,2526
76,NCT02268175,Phase II,"Active, not recruiting","[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 795, 'therapyName': 'Leuprolide'}]",Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate,2526
77,NCT02284971,Phase I,Terminated,"[{'id': 2525, 'therapyName': 'Varlilumab'}]",Pilot Study of SBRT and CDX-1127 in Prostate Cancer (Prostate-04),2526
78,NCT02286921,Phase II,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 2591, 'therapyName': 'Andriol'}]","Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance",2526
79,NCT02319837,Phase III,Recruiting,"[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]",Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK),2526
80,NCT02346253,Phase Ib/II,Recruiting,"[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 2050, 'therapyName': 'Triptorelin'}, {'id': 1814, 'therapyName': 'Degarelix'}, {'id': 1507, 'therapyName': 'Bicalutamide'}, {'id': 759, 'therapyName': 'Goserelin'}]",High-Dose Brachytherapy in Treating Patients With Prostate Cancer,2526
81,NCT02349139,Phase Ib/II,"Active, not recruiting","[{'id': 2528, 'therapyName': 'CYP17 lyase inhibitor ASN001'}]","Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer",2526
82,NCT02353715,Phase I,Recruiting,"[{'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 2648, 'therapyName': 'Sipuleucel-T'}]","Men With Metastatic Castrate-Resistant Prostate Cancer Treated With Either Sipuleucel-T (Provenge), Abiraterone Acetate (Zytiga) or Enzalutamide (Xtandi) Undergoing Cardiopulmonary EXercise Testing",2526
83,NCT02376166,Phase I,Completed,"[{'id': 1031, 'therapyName': 'Metformin'}]",Metformin for Rising PSA Remote Trial,2526
84,NCT02379390,Phase II,Terminated,"[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}]",Cabazitaxel Versus the Switch to Alternative AR Targeted Therapy Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Primary Resistant Patients to Abiraterone or Enz (PRIMCAB),2526
85,NCT02381236,Phase II,Completed,"[{'id': 4338, 'therapyName': 'mipsagargin'}]",G-202 in the Neoadjuvant Setting Followed by Radical Prostatectomy in Patients With Prostate Cancer,2526
86,NCT02384382,Phase II,"Active, not recruiting","[{'id': 1262, 'therapyName': 'Enzalutamide'}]",A Positron Emission Tomography/Computed Tomography (PET/CT) Bone Imaging Study in Patients Receiving Enzalutamide for Castration-Resistant Prostate Cancer (CRPC),2526
87,NCT02396368,Phase I,Withdrawn,"[{'id': 2699, 'therapyName': 'Tasquinimod'}, {'id': 2001, 'therapyName': 'radium Ra 223 dichloride'}]",A Study of Radium-223 in Combination With Tasquinimod in Bone-only Metastatic Castration-Resistant Prostate Cancer,2526
88,NCT02407054,Phase II,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1069, 'therapyName': 'LY3023414'}]",A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer,2526
89,NCT02411786,Phase I,Recruiting,"[{'id': 4297, 'therapyName': 'pTVG-AR '}, {'id': 1873, 'therapyName': 'Sargramostim'}]",A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD) +/-GMCSF,2526
90,NCT02415621,Phase I,Recruiting,"[{'id': 1805, 'therapyName': 'Abiraterone'}]",Adaptive Abiraterone Therapy for Metastatic Castration Resistant Prostate Cancer,2526
91,NCT02441517,FDA approved,Terminated,"[{'id': 1262, 'therapyName': 'Enzalutamide'}]",A Study of Enzalutamide Re-treatment in Metastatic Castration-resistant Prostate Cancer After Docetaxel Treatment in Patients Who Have Previously Received Enzalutamide,2526
92,NCT02446405,Phase III,"Active, not recruiting","[{'id': 1262, 'therapyName': 'Enzalutamide'}]",Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer,2526
93,NCT02446444,Phase III,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}]","Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer",2526
94,NCT02463799,Phase II,Recruiting,"[{'id': 2001, 'therapyName': 'radium Ra 223 dichloride'}, {'id': 2648, 'therapyName': 'Sipuleucel-T'}]",Ph 2 Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC,2526
95,NCT02472275,Phase I,Recruiting,"[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 874, 'therapyName': 'PLX3397'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 1814, 'therapyName': 'Degarelix'}]","PLX3397, Radiation Therapy, and Antihormone Therapy in Treating Patients With Intermediate- or High-Risk Prostate Cancer",2526
96,NCT02489318,Phase III,"Active, not recruiting","[{'id': 1947, 'therapyName': 'ARN-509'}]",A Phase 3 Study of JNJ-56021927 Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With Low-Volume mHSPC,2526
97,NCT02491411,Phase I,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]",Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and Docetaxel,2526
98,NCT02494713,Phase II,Recruiting,"[{'id': 1814, 'therapyName': 'Degarelix'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 2858, 'therapyName': 'Ketoconazole'}]",Hormonal Therapy and Chemotherapy Followed by Prostatectomy in Patients With Prostate Cancer,2526
99,NCT02497638,Phase II,Recruiting,"[{'id': 1576, 'therapyName': 'Atorvastatin + Metformin'}]",LIpitor and biGuanide to Androgen Delay Trial,2526
100,NCT02499835,Phase Ib/II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer",2526
101,NCT02500901,Phase I,"Active, not recruiting","[{'id': 832, 'therapyName': 'Niraparib'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]",Enzalutamide and Niraparib in the Treatment of Metastatic Castrate-Resistant Prostate Cancer (CRPC),2526
102,NCT02506114,Phase II,Recruiting,"[{'id': 4892, 'therapyName': 'PROSTVAC-V/F'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 4895, 'therapyName': 'PROSTVAC-V/F + Ipilimumab'}]",Neoadjuvant PROSTVAC-VF With or Without Ipilimumab for Prostate Cancer,2526
103,NCT02508636,Phase II,Recruiting,"[{'id': 3180, 'therapyName': 'Enzalutamide + Leuprolide'}]",Trial of Radiotherapy With Leuprolide and Enzalutamide in High Risk Prostate,2526
104,NCT02532114,Phase I,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 3072, 'therapyName': 'Niclosamide'}]","Niclosamide and Enzalutamide in Treating Patients With Androgen Receptor Splice Variant-Positive, Castration-Resistant, Metastatic Prostate Cancer",2526
105,NCT02543255,Phase II,Recruiting,"[{'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 3079, 'therapyName': 'Abiraterone + Leuprolide + Prednisone'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}]",Anti-Androgens and Cabazitaxel in Defining Complete Response in Prostatectomy (ACDC Trial),2526
106,NCT02560051,Phase II,Recruiting,"[{'id': 1814, 'therapyName': 'Degarelix'}, {'id': 3087, 'therapyName': 'Aldoxorubicin + Docetaxel + Estramustine + Ketoconazole'}]",Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer,2526
107,NCT02578797,Phase I,"Active, not recruiting","[{'id': 1947, 'therapyName': 'ARN-509'}]",A JNJ-56021927 (ARN-509) QT/QTc Study,2526
108,NCT02582749,Phase II,Recruiting,"[{'id': 4618, 'therapyName': 'Bicalutamide + Ra 223'}, {'id': 1507, 'therapyName': 'Bicalutamide'}]",Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases,2526
109,NCT02601014,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7,2526
110,NCT02606123,Phase Ib/II,"Active, not recruiting","[{'id': 5611, 'therapyName': 'EPI-506'}]",Safety and Anti-Tumor Study of Oral EPI-506 for Patients With Metastatic Castration-Resistant Prostate Cancer,2526
111,NCT02625857,Phase I,"Active, not recruiting","[{'id': 4889, 'therapyName': 'JNJ-64041809'}]","Safety & Immunogenicity of JNJ-64041809, a Live Attenuated Double-deleted Listeria Immunotherapy, in Participants With Metastatic Castration-resistant Prostate Cancer",2526
112,NCT02643667,Phase Ib/II,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",A Study of Ibrutinib as Neoadjuvant Therapy in Localized Prostate Cancer,2526
113,NCT02677896,Phase III,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}]",A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC),2526
114,NCT02685267,Phase II,"Active, not recruiting","[{'id': 4681, 'therapyName': 'Docetaxel + Enzalutamide + Prednisone'}, {'id': 2462, 'therapyName': 'Docetaxel + Prednisone'}]",Docetaxel/Prednisone Versus Docetaxel/Prednisone and Enzalutamide in Castration-Resistant Prostate Cancer (Doce/Enza),2526
115,NCT02685397,Phase II,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 2050, 'therapyName': 'Triptorelin'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 795, 'therapyName': 'Leuprolide'}]",Management of Castration-Resistant Prostate Cancer With Oligometastases,2526
116,NCT02703623,Phase II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 2649, 'therapyName': 'Abiraterone + ARN-509 + Prednisone'}, {'id': 3844, 'therapyName': 'Cabazitaxel + Carboplatin'}]",A Dynamic Allocation Modular Sequential Trial of Approved and Promising Therapies in Men With Metastatic Castrate Resistant Prostate Cancer (DynaMO),2526
117,NCT02716974,Phase I,Recruiting,"[{'id': 3945, 'therapyName': 'Bicalutamide + Docetaxel + Leuprolide'}]",A Study of Definitive Therapy to Treat Prostate Cancer,2526
118,NCT02721979,Phase II,Not yet recruiting,"[{'id': 1947, 'therapyName': 'ARN-509'}]",ARN-509 in Treating Patients With Prostate Cancer Who Are in Active Surveillance,2526
119,NCT02758132,Phase I,Terminated,"[{'id': 4182, 'therapyName': 'Abiraterone + Denosumab + Enzalutamide + Prednisone'}, {'id': 4183, 'therapyName': 'Denosumab + Enzalutamide'}]","Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases",2526
120,NCT02768363,Phase II,Recruiting,"[{'id': 5172, 'therapyName': 'AdV-tk + Valacyclovir'}, {'id': 5171, 'therapyName': 'Valacyclovir'}]",Randomized Controlled Trial of ProstAtak Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES),2526
121,NCT02770391,Phase II,Recruiting,"[{'id': 4207, 'therapyName': 'ARN-509 + Leuprolide'}]",ARN-509 and Leuprolide in Intermediate and High-risk Prostate Cancer,2526
122,NCT02772588,Phase II,Recruiting,"[{'id': 4206, 'therapyName': 'Abiraterone + ARN-509 + Leuprolide'}]",AASUR in High Risk Prostate Cancer,2526
123,NCT02787005,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Chemotherapy (MK-3475-199/KEYNOTE-199),2526
124,NCT02788773,Phase II,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer,2526
125,NCT02793219,Phase II,Not yet recruiting,"[{'id': 4270, 'therapyName': 'Docetaxel + Sipuleucel-T'}]",Provenge Followed by Docetaxel in Castration-Resistant Prostate Cancer,2526
126,NCT02793765,Phase II,Not yet recruiting,"[{'id': 4270, 'therapyName': 'Docetaxel + Sipuleucel-T'}]",Docetaxel Followed by Provenge in Metastatic Prostate Cancer,2526
127,NCT02799602,Phase III,Recruiting,"[{'id': 836, 'therapyName': 'ODM-201'}, {'id': 4921, 'therapyName': 'Docetaxel + ODM-201'}]",ODM-201 in Addition to Standard ADT and Docetaxel in Metastatic Castration Sensitive Prostate Cancer (ARASENS),2526
128,NCT02799745,Phase II,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}]",A Randomized Study of Enzalutamide in Patients With Localized Prostate Cancer Undergoing Active Surveillance (ENACT) (ENACT),2526
129,NCT02811809,Phase II,Not yet recruiting,"[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 4207, 'therapyName': 'ARN-509 + Leuprolide'}]",Apalutamide Plus Intermittent Hormone Therapy Versus Intermittent Hormone Therapy Alone in Prostate Cancer,2526
130,NCT02814669,Phase I,Recruiting,"[{'id': 4881, 'therapyName': 'Atezolizumab + Ra 223'}]",Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor,2526
131,NCT02849990,Phase II,Recruiting,"[{'id': 4510, 'therapyName': 'Abiraterone + ARN-509 + Degarelix + Indomethacin + Prednisone'}]","Androgen Receptor Antagonist ARN-509, Abiraterone Acetate, Prednisone, Degarelix, and Indomethacin in Treating Patients With Localized Prostate Cancer Before Surgery",2526
132,NCT02861573,Phase I,Recruiting,"[{'id': 5343, 'therapyName': 'Dexamethasone + Docetaxel + Pembrolizumab + Prednisone'}, {'id': 5342, 'therapyName': 'Olaparib + Pembrolizumab'}, {'id': 2666, 'therapyName': 'Enzalutamide + Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365),2526
133,NCT02893917,Phase II,Recruiting,"[{'id': 1971, 'therapyName': 'Cediranib + Olaparib'}, {'id': 837, 'therapyName': 'Olaparib'}]",Olaparib With or Without Cediranib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer,2526
134,NCT02903160,Phase II,Recruiting,"[{'id': 4759, 'therapyName': 'Abiraterone + Cabazitaxel + Carboplatin + Enzalutamide + Prednisone'}]","Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)",2526
135,NCT02903368,Phase II,Recruiting,"[{'id': 3079, 'therapyName': 'Abiraterone + Leuprolide + Prednisone'}, {'id': 4758, 'therapyName': 'Abiraterone + ARN-509 + Leuprolide + Prednisone'}]",Neoadjuvant And Adjuvant Abiraterone Acetate + Aptilutamide Prostate Cancer Undergoing Prostatectomy,2526
136,NCT02905318,Phase II,Recruiting,"[{'id': 850, 'therapyName': 'Palbociclib'}]",Palbociclib in Patients With Metastatic Castration-Resistant Prostate Cancer,2526
137,NCT02906605,Phase II,Withdrawn,"[{'id': 1947, 'therapyName': 'ARN-509'}, {'id': 4890, 'therapyName': 'ARN-509 + JNJ-64041809'}]","A Study of the Clinical Activity and Safety of JNJ-64041809, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Apalutamide Versus Apalutamide in Subjects With Metastatic Castration-resistant Prostate Cancer",2526
138,NCT02913196,Phase I,Recruiting,"[{'id': 4767, 'therapyName': 'Abiraterone + ARN-509 + Docetaxel + Prednisone'}]","Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With mCRPC",2526
139,NCT02923180,Phase I,Recruiting,"[{'id': 2863, 'therapyName': 'MGA271'}]",Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer,2526
140,NCT02949284,Phase II,Recruiting,"[{'id': 1947, 'therapyName': 'ARN-509'}, {'id': 2649, 'therapyName': 'Abiraterone + ARN-509 + Prednisone'}]","Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery",2526
141,NCT02952534,Phase II,Recruiting,"[{'id': 906, 'therapyName': 'Rucaparib'}]",A Study of Rucaparib in Patients With MetA Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON2),2526
142,NCT02987829,Phase Ib/II,Recruiting,"[{'id': 5770, 'therapyName': 'TRC253'}]","A Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients",2526
143,NCT02991911,Phase I,Recruiting,"[{'id': 5217, 'therapyName': 'Enzalutamide + MEDI3726'}, {'id': 5216, 'therapyName': 'MEDI3726'}]",A Phase 1/1b Study of MEDI3726 in Adults Subjects With Metastatic Castration Resistant Prostate Cancer,2526
144,NCT03007732,Phase II,Suspended,"[{'id': 5166, 'therapyName': 'Pembrolizumab + SD-101'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Combination With Intratumoral SD-101 Therapy,2526
145,NCT03009981,Phase III,Recruiting,"[{'id': 5523, 'therapyName': 'Abiraterone + ARN-509 + Degarelix + Prednisone'}, {'id': 5524, 'therapyName': 'ARN-509 + Degarelix'}, {'id': 1814, 'therapyName': 'Degarelix'}]",A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer,2526
146,NCT03012321,Phase II,Recruiting,"[{'id': 5226, 'therapyName': 'Abiraterone + Prednisone + Olaparib'}, {'id': 2748, 'therapyName': 'Abiraterone + Prednisone'}, {'id': 837, 'therapyName': 'Olaparib'}]","Abiraterone Acetate, Olaparib, and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer With DNA Repair Defects",2526
147,NCT03016312,Phase III,Recruiting,"[{'id': 5204, 'therapyName': 'Atezolizumab + Enzalutamide'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]","IMbassador250: A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen",2526
148,NCT03024216,Phase I,Recruiting,"[{'id': 5642, 'therapyName': 'Atezolizumab + Sipuleucel-T'}]",Clinical Study of Atezolizumab (Anti-PD-L1) and Sipuleucel-T in Patients Who Have Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer,2526
149,NCT03030885,Phase I,Recruiting,"[{'id': 5804, 'therapyName': '131I-MIP-1095'}]",Use of an Experimental Radiopharmaceutical (131I-MIP-1095) in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC),2526
150,NCT03043807,Phase II,Recruiting,"[{'id': 3945, 'therapyName': 'Bicalutamide + Docetaxel + Leuprolide'}]",A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy,2526
151,NCT03047135,Phase II,Recruiting,"[{'id': 837, 'therapyName': 'Olaparib'}]","Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis",2526
152,NCT03070886,Phase III,Recruiting,"[{'id': 5450, 'therapyName': 'Bicalutamide + Docetaxel + Flutamide + Goserelin + Leuprolide + Nilutamide'}, {'id': 5449, 'therapyName': 'Bicalutamide + Flutamide + Goserelin + Leuprolide + Nilutamide'}]",Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery,2526
153,NCT03072238,Phase III,Recruiting,"[{'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 5438, 'therapyName': 'Abiraterone + Ipatasertib'}]","Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer",2526
154,NCT03076203,Phase I,Recruiting,"[{'id': 5436, 'therapyName': 'Niraparib + radium Ra 223 dichloride'}]",Radium Ra 223 Dichloride and Niraparib in Treating Patients With Hormone- Resistant Prostate Cancer Metastatic to the Bone,2526
155,NCT03085095,Phase III,Recruiting,"[{'id': 5492, 'therapyName': 'Relugolix'}, {'id': 795, 'therapyName': 'Leuprolide'}]",A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer (HERO),2526
156,NCT03093272,Phase II,Recruiting,"[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 5521, 'therapyName': 'ARN-509 + Docetaxel'}]",A Study of Docetaxel + ARN-509 in Castration-Resistant Prostate Cancer,2526
157,NCT03093428,Phase II,Recruiting,"[{'id': 5542, 'therapyName': 'Pembrolizumab + Ra 223'}, {'id': 2001, 'therapyName': 'radium Ra 223 dichloride'}]",Study Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPC,2526
158,NCT03098836,Phase II,Recruiting,"[{'id': 2649, 'therapyName': 'Abiraterone + ARN-509 + Prednisone'}]",Apalutamide and Abiraterone Acetate in African American and Caucasian Men With Metastatic Castrate Resistant Prostate Cancer,2526
159,NCT03147196,Phase II,Recruiting,"[{'id': 5686, 'therapyName': 'Raloxifene + Bicalutamide'}, {'id': 5685, 'therapyName': 'Raloxifene'}, {'id': 1507, 'therapyName': 'Bicalutamide'}]",Bicalutamide and Raloxifene Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery,2526
160,NCT03148795,Phase II,Recruiting,"[{'id': 682, 'therapyName': 'Talazoparib'}]",A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer,2526
161,NCT03150056,Phase I,Recruiting,"[{'id': 6034, 'therapyName': 'Abiraterone + GSK525762'}, {'id': 6035, 'therapyName': 'Enzalutamide + GSK525762'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy and Other Agents in Subjects With Castrate-resistant Prostate Cancer,2526
162,NCT03204812,Phase II,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",Tremelimumab + Durvalumab Chemotherapy Naive CRPC,2526
163,NCT03279250,Phase II,Recruiting,"[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 2050, 'therapyName': 'Triptorelin'}, {'id': 2649, 'therapyName': 'Abiraterone + ARN-509 + Prednisone'}, {'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1947, 'therapyName': 'ARN-509'}]",Effects of Apalutamide Plus LHRH Agonist or Apalutamide Plus Abiraterone Acetate Plus LHRH Agonist for Six Months for Prostate Cancer Patients at High Risk for Recurrence,2526
164,NCT03298087,Phase II,Not yet recruiting,"[{'id': 4206, 'therapyName': 'Abiraterone + ARN-509 + Leuprolide'}]",Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer,2526
0,NCT02780310,Phase II,"Active, not recruiting","[{'id': 792, 'therapyName': 'Lenvatinib'}]",Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma,4868
1,NCT03087019,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma,4868
2,NCT03172624,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer,4868
0,NCT00670046,Phase II,Unknown status,"[{'id': 1076, 'therapyName': 'Valproic acid'}]","Valproic Acid in Treating Patients With Progressive, Non-Metastatic Prostate Cancer",10283
1,NCT00892736,Phase I,"Active, not recruiting","[{'id': 954, 'therapyName': 'Veliparib'}]",Veliparib in Treating Patients With Malignant Solid Tumors That Did Not Respond to Previous Therapy,10283
2,NCT00942331,Phase III,"Active, not recruiting","[{'id': 1295, 'therapyName': 'Gemcitabine + Bevacizumab + Cisplatin'}, {'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}]",Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer,10283
3,NCT01254864,Phase II,"Active, not recruiting","[{'id': 1817, 'therapyName': 'Abiraterone + Sunitinib'}, {'id': 1818, 'therapyName': 'Abiraterone + Dasatinib\t'}]",Maximum Androgen Depletion,10283
4,NCT01286987,Phase I,Completed,"[{'id': 682, 'therapyName': 'Talazoparib'}]","Study of BMN 673, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors",10283
5,NCT01353625,Phase I,"Active, not recruiting","[{'id': 1000, 'therapyName': 'CC-115'}]","Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.",10283
6,NCT01436968,Phase III,Recruiting,"[{'id': 5171, 'therapyName': 'Valacyclovir'}, {'id': 5172, 'therapyName': 'AdV-tk + Valacyclovir'}]",Phase 3 Study of ProstAtak Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer,10283
7,NCT01480154,Phase I,"Active, not recruiting","[{'id': 1393, 'therapyName': 'MK2206 + hydroxychloroquine'}]","Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer",10283
8,NCT01517802,Phase III,Recruiting,"[{'id': 1805, 'therapyName': 'Abiraterone'}]",A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate,10283
9,NCT01530984,Phase II,Withdrawn,"[{'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Ipilimumab and GMCSF Immunotherapy for Prostate Cancer,10283
10,NCT01540526,Phase I,Completed,"[{'id': 649, 'therapyName': 'Axitinib'}]",Pharmacodynamic Study With FLT-PET/CT in Patients With Prostate/Other Solid Malignancies Treated With High Dose Axitinib,10283
11,NCT01543776,Phase II,"Active, not recruiting","[{'id': 1805, 'therapyName': 'Abiraterone'}]",Food Effect Study of Abiraterone Acetate for Treatment of Patients With Castration-Resistant Prostate Cancer,10283
12,NCT01553188,Phase II,"Active, not recruiting","[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 1218, 'therapyName': 'Trebananib'}]",AMG 386 and Abiraterone for Advanced Prostate Cancer,10283
13,NCT01576172,Phase II,"Active, not recruiting","[{'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 954, 'therapyName': 'Veliparib'}]",Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer,10283
14,NCT01607905,Phase I,Completed,"[{'id': 1749, 'therapyName': 'Selinexor'}]",Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced or Metastatic Solid Tumor Cancer,10283
15,NCT01620593,Phase II,Completed,"[{'id': 1031, 'therapyName': 'Metformin'}]",Castration Compared to Castration Plus Metformin as First Line Treatment for Patients With Advanced Prostate Cancer,10283
16,NCT01674270,Phase II,Completed,"[{'id': 1507, 'therapyName': 'Bicalutamide'}, {'id': 1814, 'therapyName': 'Degarelix'}]",Degarelix Neo-Adjuvant Radical Prostatectomy Trial,10283
17,NCT01683994,Phase I,"Active, not recruiting","[{'id': 2069, 'therapyName': 'cabozantinib + Docetaxel'}]",Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer,10283
18,NCT01685125,Phase II,"Active, not recruiting","[{'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1805, 'therapyName': 'Abiraterone'}]",Abiraterone Acetate and Prednisone With or Without Dasatinib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer,10283
19,NCT01715285,Phase III,"Active, not recruiting","[{'id': 2748, 'therapyName': 'Abiraterone + Prednisone'}]","A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)",10283
20,NCT01717053,Phase II,"Active, not recruiting","[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 759, 'therapyName': 'Goserelin'}]","Abiraterone, Radiotherapy and Short-Term Androgen Deprivation in Unfavorable Localized Prostate Cancer",10283
21,NCT01730118,Phase I,Recruiting,"[{'id': 1404, 'therapyName': 'HER2 Vaccine'}]",Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing,10283
22,NCT01741753,Phase I,Terminated,"[{'id': 2499, 'therapyName': 'Abiraterone + BKM120 + Prednisone'}]",BKM120+Abiraterone Acetate for Metastatic CRPC,10283
23,NCT01751451,Phase II,"Active, not recruiting","[{'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 1814, 'therapyName': 'Degarelix'}]","3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy",10283
24,NCT01809691,Phase III,"Active, not recruiting","[{'id': 2671, 'therapyName': 'Orteronel '}, {'id': 1507, 'therapyName': 'Bicalutamide'}]","S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer",10283
25,NCT01818986,Phase II,Recruiting,"[{'id': 2648, 'therapyName': 'Sipuleucel-T'}]",Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR) for Metastatic Castrate-resistant Prostate Cancer (mCRPC),10283
26,NCT01828476,Phase II,Terminated,"[{'id': 1316, 'therapyName': 'Hydroxychloroquine'}, {'id': 2597, 'therapyName': 'Abiraterone + Navitoclax'}]",Navitoclax and Abiraterone Acetate With or Without Hydroxychloroquine in Treating Patients With Progressive Metastatic Castrate Refractory Prostate Cancer,10283
27,NCT01834651,Phase II,Completed,"[{'id': 998, 'therapyName': 'cabozantinib'}]",A Phase II Study of Cabozantinib (XL184) Therapy in Castrate Resistant Prostate Cancer (CRPC) With Visceral Metastases,10283
28,NCT01864096,Phase III,Recruiting,"[{'id': 1031, 'therapyName': 'Metformin'}]",The Metformin Active Surveillance Trial (MAST) Study,10283
29,NCT01867333,Phase II,"Active, not recruiting","[{'id': 3069, 'therapyName': 'PROSTVAC-F/TRICOM '}, {'id': 1262, 'therapyName': 'Enzalutamide'}]",Enzalutamide With or Without Vaccine Therapy for Advanced Prostate Cancer,10283
30,NCT01875250,Phase II,"Active, not recruiting","[{'id': 4884, 'therapyName': 'Enzalutamide + PROSTVAC-F/TRICOM + PROSTVAC-V/TRICOM'}]",Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate Cancer,10283
31,NCT01884285,Phase I,Recruiting,"[{'id': 992, 'therapyName': 'AZD8186'}]",AZD8186 First Time In Patient Ascending Dose Study,10283
32,NCT01920061,Phase I,Recruiting,"[{'id': 1287, 'therapyName': 'PF-05212384 + Dacomitinib'}, {'id': 1286, 'therapyName': 'PF-05212384 + Cisplatin'}, {'id': 1285, 'therapyName': 'PF-05212384 + Docetaxel'}]",A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents,10283
33,NCT01966445,Phase I,Completed,"[{'id': 2919, 'therapyName': 'GSK2849330'}]","Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors",10283
34,NCT01972217,Phase II,"Active, not recruiting","[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 837, 'therapyName': 'Olaparib'}]",Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer,10283
35,NCT01990196,Phase II,Recruiting,"[{'id': 717, 'therapyName': 'Dasatinib'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 1815, 'therapyName': 'Degarelix + Enzalutamide'}]",Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer,10283
36,NCT01994590,Phase II,Terminated,"[{'id': 721, 'therapyName': 'Dovitinib'}]",Dovitinib (TKI258) and Abiraterone Acetate in Metastatic Castrate-Resistant Prostate Cancer (mCRPC),10283
37,NCT02009449,Phase I,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 2621, 'therapyName': 'AM0010 '}, {'id': 619, 'therapyName': 'Abraxane'}]",A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors,10283
38,NCT02012296,Phase Ib/II,Recruiting,"[{'id': 2603, 'therapyName': 'Mifepristone'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]",Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer,10283
39,NCT02014337,Phase I,"Active, not recruiting","[{'id': 3053, 'therapyName': 'Eribulin + Mifepristone'}]",Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors,10283
40,NCT02020070,Phase II,"Active, not recruiting","[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1814, 'therapyName': 'Degarelix'}]","Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy",10283
41,NCT02028988,Phase II,"Active, not recruiting","[{'id': 1262, 'therapyName': 'Enzalutamide'}]",Enzalutamide + External Beam Rt For Prostate,10283
42,NCT02043665,Phase I,Recruiting,"[{'id': 2974, 'therapyName': 'coxsackievirus A21'}]",Systemic Treatment Of Resistant Metastatic Disease Employing CVA21 and Pembrolizumab in Non-small Cell Lung Cancer and Bladder Cancer (STORM/ KEYNOTE-200) (STORM),10283
43,NCT02059213,Phase II,"Active, not recruiting","[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 1507, 'therapyName': 'Bicalutamide'}, {'id': 795, 'therapyName': 'Leuprolide'}]", A Phase II Study of Androgen Deprivation Therapy With or Without PD 0332991 in RB-Positive Metastatic Prostate Cancer,10283
44,NCT02091531,Phase II,"Active, not recruiting","[{'id': 1282, 'therapyName': 'Sapanisertib'}]",Dual mTOR Inhibitor MLN0128 in Advanced Castration-Resistant Prostate Cancer (CRPC) Patients,10283
45,NCT02115828,Phase I,"Active, not recruiting","[{'id': 956, 'therapyName': 'Vismodegib'}]",A Study of Vismodegib in Men With Metastatic CRPC With Accessible Metastatic Lesions for Tumor Biopsy,10283
46,NCT02159950,Phase II,Completed,"[{'id': 2648, 'therapyName': 'Sipuleucel-T'}, {'id': 2699, 'therapyName': 'Tasquinimod'}]",Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer,10283
47,NCT02218606,Phase II,Recruiting,"[{'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 2748, 'therapyName': 'Abiraterone + Prednisone'}]",Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in Treatment of Metastatic Castration Resistant Prostate Cancer,10283
48,NCT02234921,Phase I,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}]",Pilot Study of DRibble Vaccine for Prostate Cancer Patients,10283
49,NCT02259114,Phase I,Completed,"[{'id': 2034, 'therapyName': 'OTX015'}]","A Phase IB Trial With OTX015, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Patients With Selected Advanced Solid Tumors",10283
50,NCT02265536,Phase I,Recruiting,"[{'id': 2004, 'therapyName': 'LY3022855'}]",A Study of LY3022855 In Participants With Breast or Prostate Cancer,10283
51,NCT02278185,Phase II,Recruiting,"[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 1814, 'therapyName': 'Degarelix'}, {'id': 2047, 'therapyName': 'Histrelin acetate'}, {'id': 2050, 'therapyName': 'Triptorelin'}, {'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]",Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer,10283
52,NCT02279862,Phase II,Completed,"[{'id': 779, 'therapyName': 'Ipilimumab'}]",Safety and Efficacy Study of Ipilimumab 3 mg/kg Versus Ipilimumab 10 mg/kg in Subjects With Metastatic Castration Resistant Prostate Cancer Who Are Chemotherapy Naive,10283
53,NCT02312557,Phase II,Recruiting,"[{'id': 2666, 'therapyName': 'Enzalutamide + Pembrolizumab'}]",Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide,10283
54,NCT02325557,Phase Ib/II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 3050, 'therapyName': 'ADXS31-142 '}]",ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Patients With Prostate Cancer - KEYNOTE-046,10283
55,NCT02339168,Phase I,Recruiting,"[{'id': 2202, 'therapyName': 'Enzalutamide + Metformin'}]",Enzalutamide and Metformin Hydrochloride in Treating Patients With Hormone-Resistant Prostate Cancer,10283
56,NCT02366494,Phase I,Recruiting,"[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 2050, 'therapyName': 'Triptorelin'}, {'id': 1507, 'therapyName': 'Bicalutamide'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Micro RNAs to Predict Response to Androgen Deprivation Therapy,10283
57,NCT02403505,Phase II,"Active, not recruiting","[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1814, 'therapyName': 'Degarelix'}]",Discovery Stage Clinical Study About Oncology Drugs and Single Nucleotide Polymorphisms,10283
58,NCT02420652,Phase II,Recruiting,"[{'id': 1031, 'therapyName': 'Metformin'}]",Metformin Hydrochloride and Aspirin in Treating Patients With Hormone-Dependent Prostate Cancer That Has Progressed After Surgery or Radiation Therapy,10283
59,NCT02429193,Phase II,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 2748, 'therapyName': 'Abiraterone + Prednisone'}]",Biomarkers of Androgen Response and Resistance In Evolution During a Rising PSA (BARRIER-P),10283
60,NCT02430480,Phase II,Recruiting,"[{'id': 759, 'therapyName': 'Goserelin'}]",Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate Cancer,10283
61,NCT02438007,Phase III,Terminated,"[{'id': 1508, 'therapyName': 'galeterone'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]",A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC,10283
62,NCT02452008,Phase II,Recruiting,"[{'id': 2409, 'therapyName': 'Galunisertib'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]",Study of TGF-Beta Receptor Inhibitor LY2157299 and Enzalutamide in Metastatic Castration-resistant Prostate Cancer,10283
63,NCT02489357,Phase I,"Active, not recruiting","[{'id': 1814, 'therapyName': 'Degarelix'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]","Pembrolizumab and Cryosurgery in Treating Patients With Newly Diagnosed, Oligo-metastatic Prostate Cancer",10283
64,NCT02494921,Phase Ib/II,Recruiting,"[{'id': 3113, 'therapyName': 'Docetaxel + Filgrastim + Prednisone + Ribociclib'}]",LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC,10283
65,NCT02507570,Phase II,"Active, not recruiting","[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 2001, 'therapyName': 'radium Ra 223 dichloride'}]",Open Label Phase Two Study of Enzalutamide With Concurrent Administration of Radium Ra 223 Dichloride in Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Symptomatic Bone Metastasis,10283
66,NCT02522715,Phase Ib/II,Recruiting,"[{'id': 3056, 'therapyName': 'Cabazitaxel + Enzalutamide'}, {'id': 2188, 'therapyName': 'Prednisone'}]","Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Hormone-Resistant Prostate Cancer",10283
67,NCT02531516,Phase III,Recruiting,"[{'id': 2649, 'therapyName': 'Abiraterone + ARN-509 + Prednisone'}, {'id': 1507, 'therapyName': 'Bicalutamide'}]",An Efficacy and Safety Study of JNJ-56021927 (ARN-509) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy,10283
68,NCT02555189,Phase Ib/II,Recruiting,"[{'id': 790, 'therapyName': 'Ribociclib'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]","Enzalutamide With and Without Ribociclib for Metastatic, Castrate-Resistant, Chemotherapy-Naive Prostate Cancer That Retains RB Expression",10283
69,NCT02566772,Phase I,Recruiting,"[{'id': 4329, 'therapyName': 'TAS3681'}]",Study of TAS3681 in Metastatic Castration Resistant Prostate Cancer,10283
70,NCT02575781,Phase I,Recruiting,"[{'id': 4026, 'therapyName': 'SAR428926'}]",A Study of SAR428926 in Patients With Advanced Solid Tumors,10283
71,NCT02594072,Phase I,Recruiting,"[{'id': 759, 'therapyName': 'Goserelin'}]",Androgen Suppression With Stereotactic Body or External Beam Radiation Therapy (ASSERT) (ASSERT),10283
72,NCT02607228,Phase Ib/II,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 3561, 'therapyName': 'GS-5829 + Exemestane'}]","Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate Cancer",10283
73,NCT02614859,Phase II,Recruiting,"[{'id': 1507, 'therapyName': 'Bicalutamide'}, {'id': 1031, 'therapyName': 'Metformin'}]",Bicalutamide With or Without Metformin for Biochemical Recurrence in Overweight or Obese Prostate Cancer Patients,10283
74,NCT02616185,Phase I,Recruiting,"[{'id': 3565, 'therapyName': 'PF-06755990 + PF-06755992 + Sunitinib + Tremelimumab'}]",A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR),10283
75,NCT02655822,Phase I,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 3571, 'therapyName': 'CPI-444 '}]",Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers,10283
76,NCT02663908,Phase III,Recruiting,"[{'id': 1814, 'therapyName': 'Degarelix'}, {'id': 795, 'therapyName': 'Leuprolide'}]",A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease,10283
77,NCT02698176,Phase I,Terminated,"[{'id': 2034, 'therapyName': 'OTX015'}]",A Dose Exploration Study With MK-8628 in Participants With Selected Advanced Solid Tumors (MK-8628-006),10283
78,NCT02705469,Phase I,"Active, not recruiting","[{'id': 4032, 'therapyName': 'ZEN003694'}]",A Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer,10283
79,NCT02711956,Phase I,Recruiting,"[{'id': 4033, 'therapyName': 'Enzalutamide + ZEN003694'}]",A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer,10283
80,NCT02721433,FDA approved,Recruiting,"[{'id': 4784, 'therapyName': 'Denosumab + pamidronate + Zoledronic acid'}]",4-weekly Versus 12-weekly Administration of Bone-targeted Agents in Patients With Bone Metastases (REaCT-BTA),10283
81,NCT02766478,Phase II,Recruiting,"[{'id': 757, 'therapyName': 'Genistein'}]",Genistein Supplementation to Mitigate Cardiometabolic Dysfunction in Patients Undergoing Androgen Deprivation Therapy for Prostate Cancer,10283
82,NCT02796898,Phase Ib/II,Recruiting,"[{'id': 5866, 'therapyName': 'SM88'}]","Study of the Efficacy, Safety, and Pharmacokinetics of SM88 in Patients With Prostate Cancer",10283
83,NCT02807805,Phase II,Recruiting,"[{'id': 4377, 'therapyName': 'Abiraterone + Niclosamide + Prednisone'}]","Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer",10283
84,NCT02833883,Phase I,Recruiting,"[{'id': 4459, 'therapyName': 'CC-115 + Enzalutamide'}]","Use of an Experimental Drug, CC-115, With Enzalutamide in Men With Castration-Resistant Prostate Cancer",10283
85,NCT02854436,Phase II,Suspended,"[{'id': 832, 'therapyName': 'Niraparib'}]",An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies,10283
86,NCT02881242,Phase II,Not yet recruiting,"[{'id': 2, 'therapyName': 'Trametinib'}]",Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer,10283
87,NCT02887976,Phase III,Not yet recruiting,"[{'id': 4678, 'therapyName': 'Abiraterone + Methylprednisolone'}]",Extension of SoluMatrix TM Abiraterone Acetate in Patients Who Completed Study Number CHL-AA-201,10283
88,NCT02924766,Phase I,Recruiting,"[{'id': 4832, 'therapyName': 'ARN-509 + Niraparib'}]",A Safety and Pharmacokinetics Study of Niraparib Plus Apalutamide in Men With Metastatic Castration-Resistant Prostate Cancer (BEDIVERE),10283
89,NCT02933255,Phase Ib/II,Recruiting,"[{'id': 4895, 'therapyName': 'PROSTVAC-V/F + Ipilimumab'}, {'id': 4893, 'therapyName': 'PROSTVAC-V/F + Nivolumab + Ipilimumab'}, {'id': 4894, 'therapyName': 'PROSTVAC-V/F + Nivolumab'}]",PROSTVAC in Combination With Nivolumab and/or Ipilimumab in Men With Prostate Cancer,10283
90,NCT02935205,Phase Ib/II,Not yet recruiting,"[{'id': 4876, 'therapyName': 'Enzalutamide + Indomethacin'}]",Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate Cancer,10283
91,NCT02947165,Phase I,Recruiting,"[{'id': 5632, 'therapyName': 'NIS793 + PDR001'}, {'id': 5631, 'therapyName': 'NIS793'}]",Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.,10283
92,NCT02950064,Phase I,Recruiting,"[{'id': 6336, 'therapyName': 'BTP-114'}]",A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations,10283
93,NCT02960022,Phase II,Recruiting,"[{'id': 5371, 'therapyName': 'Enzalutamide + Abiraterone + Prednisone'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]",A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study,10283
94,NCT02966587,Phase II,Not yet recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}]",Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer,10283
95,NCT02985957,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Study to Evaluate Preliminary Safety and Efficacy of Nivolumab Plus Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer,10283
96,NCT02987543,Phase III,Recruiting,"[{'id': 837, 'therapyName': 'Olaparib'}, {'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1805, 'therapyName': 'Abiraterone'}]",Study of Olaparib (Lynparza) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study),10283
97,NCT03016741,FDA approved,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 2748, 'therapyName': 'Abiraterone + Prednisone'}]",Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer,10283
98,NCT03067051,Phase I,Recruiting,"[{'id': 3319, 'therapyName': 'Verteporfin'}]",Clinical Study to Assess the Safety and Adequacy of Effectiveness of the SpectraCure P18 System,10283
99,NCT03098160,Phase I,Recruiting,"[{'id': 5745, 'therapyName': 'Evofosfamide + Ipilimumab'}]",Immunotherapy Study of Evofosfamide in Combination With Ipilimumab,10283
100,NCT03102606,Phase II,Recruiting,"[{'id': 3678, 'therapyName': 'Plinabulin'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}]",Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy (Protective-1),10283
101,NCT03120832,Phase I,Recruiting,"[{'id': 5704, 'therapyName': 'PAN-301-1'}]",Phase 1 Trial of PAN-301-1 in Cancer Patients,10283
102,NCT03123978,Phase I,Recruiting,"[{'id': 5607, 'therapyName': 'Niclosamide + Enzalutamide'}]",Enzalutamide and Niclosamide in Treating Patients With Recurrent or Metastatic Castration-Resistant Prostate Cancer,10283
103,NCT03141671,Phase II,Not yet recruiting,"[{'id': 5742, 'therapyName': 'Bicalutamide + Gonadorelin'}, {'id': 5743, 'therapyName': 'Abiraterone + ARN-509 + Gonadorelin + Prednisone'}]",Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509),10283
104,NCT03150810,Phase Ib/II,Recruiting,"[{'id': 6124, 'therapyName': 'BGB-290 + Temozolomide'}]","Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Subjects With Locally Advanced or Metastatic Solid Tumors",10283
105,NCT03188965,Phase I,Recruiting,"[{'id': 5962, 'therapyName': 'BAY1895344'}]",First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas,10283
106,NCT03310541,,Recruiting,"[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 655, 'therapyName': 'AZD5363'}]",AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations,10283
0,NCT01385228,Phase I,Completed,"[{'id': 2042, 'therapyName': 'Docetaxel + Pazopanib + Pegfilgrastim'}]","Pazopanib, Docetaxel, Prednisone Prostate",10286
1,NCT01391143,Phase I,Recruiting,"[{'id': 2863, 'therapyName': 'MGA271'}]",Safety Study of MGA271 in Refractory Cancer,10286
2,NCT01561482,Phase II,Withdrawn,"[{'id': 1829, 'therapyName': 'Metformin + Simvastatin'}]",Study of Metformin With Simvastatin for Men With Prostate Carcinoma,10286
3,NCT02113657,Phase II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}]",T-Cell Responses to Neoantigens Post Treatment With Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer,10286
4,NCT02234115,Phase III,Completed,"[{'id': 795, 'therapyName': 'Leuprolide'}]","Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate in Subjects With Advanced Prostate Carcinoma",10286
5,NCT02565901,Phase Ib/II,Recruiting,"[{'id': 3111, 'therapyName': 'Carboplatin + Docetaxel + Sirolimus '}]","Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer",10286
6,NCT02723955,Phase I,Recruiting,"[{'id': 4409, 'therapyName': 'GSK3359609'}, {'id': 4410, 'therapyName': 'GSK3359609 + Pembrolizumab'}]",Dose Escalation and Expansion Study of GSK3359609 in Subjects With Selected Advanced Solid Tumors (INDUCE-1),10286
7,NCT02952534,Phase II,Recruiting,"[{'id': 906, 'therapyName': 'Rucaparib'}]",A Study of Rucaparib in Patients With MetA Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON2),10286
8,NCT02975934,Phase III,Recruiting,"[{'id': 906, 'therapyName': 'Rucaparib'}]",A Study of Rucaparib Verses Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency,10286
9,NCT03261999,Phase III,Recruiting,"[{'id': 795, 'therapyName': 'Leuprolide'}]","Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate (LMIS 25 mg) in Subjects With Prostate Cancer",10286
10,NCT03263650,Phase II,Recruiting,"[{'id': 3844, 'therapyName': 'Cabazitaxel + Carboplatin'}, {'id': 837, 'therapyName': 'Olaparib'}]",Randomized Phase II Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC,10286
0,NCT01799278,Phase II,"Active, not recruiting","[{'id': 626, 'therapyName': 'Alisertib'}]",A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer,2992
0,NCT00942331,Phase III,"Active, not recruiting","[{'id': 1295, 'therapyName': 'Gemcitabine + Bevacizumab + Cisplatin'}, {'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}]",Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer,4011
0,NCT00794950,Phase II,"Active, not recruiting","[{'id': 930, 'therapyName': 'Sunitinib'}]",Bacillus Calmette-Guerin Followed by Sunitinib for the Treatment of High Risk Non-muscle Invasive Lower Urinary Tract Urothelial Carcinoma,6166
1,NCT01688999,Phase II,"Active, not recruiting","[{'id': 998, 'therapyName': 'cabozantinib'}]",Cabozantinib for Advanced Urothelial Cancer,6166
2,NCT03106610,Phase I,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Trial of Anti-PD-1 (Nivolumab) in Bladder Cancer Patients Recently Treated With Intravesical BCG Immunotherapy,6166
0,NCT02834013,Phase 0,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab in Treating Patients With Rare Tumors,3559
0,NCT02279433,Phase I,"Active, not recruiting","[{'id': 4343, 'therapyName': 'DS6051b'}]","A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b",6658
0,NCT02834013,Phase 0,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab in Treating Patients With Rare Tumors,5410
1,NCT03278379,Phase II,Not yet recruiting,"[{'id': 3144, 'therapyName': 'Avelumab'}]",Avelumab in G2-3 NET (NET-002),5410
2,NCT03278405,Phase Ib/II,Not yet recruiting,"[{'id': 3144, 'therapyName': 'Avelumab'}]",Avelumab in G3 NEC (NET-001),5410
0,NCT02687009,Phase I,Recruiting,"[{'id': 3072, 'therapyName': 'Niclosamide'}]",A Study of Niclosamide in Patients With Resectable Colon Cancer,1984
0,NCT00602329,Phase II,Unknown status,"[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",MRI in Predicting Response in Patients Receiving Combination Chemotherapy and Bevacizumab For Advanced or Metastatic Colorectal Cancer,1996
1,NCT00967655,Phase II,Unknown status,"[{'id': 1960, 'therapyName': 'Capecitabine + Panitumumab'}, {'id': 1074, 'therapyName': 'Irinotecan'}]","Capecitabine, Panitumumab, and Radiation Therapy With or Without Irinotecan Hydrochloride in Treating Patients Undergoing Surgery for Localized Rectal Cancer",1996
2,NCT01206530,Phase Ib/II,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1316, 'therapyName': 'Hydroxychloroquine'}]",FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer,1996
3,NCT01282502,Phase I,"Active, not recruiting","[{'id': 810, 'therapyName': 'Midostaurin'}]",Midostaurin (PKC412) for Locally Advanced Rectal Cancer,1996
4,NCT01298570,Phase II,"Active, not recruiting","[{'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 890, 'therapyName': 'Regorafenib'}]",Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer,1996
5,NCT01442935,Phase II,"Active, not recruiting","[{'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}, {'id': 2180, 'therapyName': 'Cetuximab + FOLFIRI'}, {'id': 2181, 'therapyName': 'Bevacizumab + FOLFIRI'}, {'id': 2182, 'therapyName': 'Cetuximab + FOLFOX'}, {'id': 2183, 'therapyName': 'Bevacizumab + FOLFIRINOX'}, {'id': 2184, 'therapyName': 'Cetuximab + FOLFIRINOX'}]",Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases,1996
6,NCT01471353,Phase II,"Active, not recruiting","[{'id': 2428, 'therapyName': 'Sorafenib + Capecitabine'}]",Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer,1996
7,NCT01516216,Phase II,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Study of Vitamin D in Untreated Metastatic Colorectal Cancer,1996
8,NCT01538680,Phase III,No longer available,"[{'id': 890, 'therapyName': 'Regorafenib'}]",Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy,1996
9,NCT01571284,Phase III,Completed,"[{'id': 2095, 'therapyName': 'Aflibercept + FOLFIRI'}]",Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen,1996
10,NCT01634685,Phase I,"Active, not recruiting","[{'id': 3684, 'therapyName': 'Bavituximab + Capecitabine'}]","A Phase I Study of Bavituximab, Capecitabine, and Radiation for the Treatment of Rectal Adenocarcinoma",1996
11,NCT01652482,Phase II,Completed,"[{'id': 694, 'therapyName': 'Cetuximab'}, {'id': 806, 'therapyName': 'MEHD7945A'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",A Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI in Second Line in Patients With KRAS Wild-Type Metastatic Colorectal Cancer,1996
12,NCT01803282,Phase I,Recruiting,"[{'id': 3320, 'therapyName': 'GS-5745'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Safety and Tolerability Study in Solid Tumors,1996
13,NCT01814501,Phase II,Recruiting,"[{'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 845, 'therapyName': 'Panitumumab'}]",Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab,1996
14,NCT01871571,Phase II,Recruiting,"[{'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}]","Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating Patients With Stage II-III Rectal Cancer",1996
15,NCT01896856,Phase Ib/II,Recruiting,"[{'id': 2015, 'therapyName': 'SGI-110 + Irinotecan'}, {'id': 890, 'therapyName': 'Regorafenib'}]",Phase I Study of SGI-110 With Irinotecan Followed by Randomized Phase II Study of SGI-110 With Irinotecan Versus Regorafenib in Previously Treated Metastatic Colorectal Cancer,1996
16,NCT01939223,Phase III,Completed,"[{'id': 890, 'therapyName': 'Regorafenib'}]","COlorectal Cancer Treated With Adjuvant Regorafenib Versus Placebo After Curative Treatment of Liver Metastases in a Randomized, Double-blind, Placebo?Controlled Phase-III STudy (COAST)",1996
17,NCT01949194,Phase II,Recruiting,"[{'id': 890, 'therapyName': 'Regorafenib'}]",Study to Determine the Efficacy of Regorafenib in Metastatic Colorectal Cancer Patients and to Discover Biomarkers,1996
18,NCT02008383,Phase I,Recruiting,"[{'id': 1985, 'therapyName': 'Panitumumab + cabozantinib'}]",Cabozantinib and Panitumumab to Treat KRAS Wild-Type Metastatic Colorectal Cancer,1996
19,NCT02045030,Phase II,Terminated,"[{'id': 2095, 'therapyName': 'Aflibercept + FOLFIRI'}]",Study to Identify Biomarkers of Clinical Response to Aflibercept in Patients With Metastatic Colorectal Cancer,1996
20,NCT02046538,Phase II,Withdrawn,"[{'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 624, 'therapyName': 'Aflibercept'}]",Phase II Study of Zaltrap and Chemotherapy for Advanced Resectable Colorectal Cancer,1996
21,NCT02096354,Phase II,"Active, not recruiting","[{'id': 890, 'therapyName': 'Regorafenib'}]","A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer",1996
22,NCT02119676,Phase II,Terminated,"[{'id': 890, 'therapyName': 'Regorafenib'}, {'id': 907, 'therapyName': 'Ruxolitinib'}]",Study of Ruxolitinib in Colorectal Cancer Patients,1996
23,NCT02138617,Phase II,Recruiting,"[{'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1715, 'therapyName': 'Fluorouracil'}]",Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer,1996
24,NCT02164916,Phase II,"Active, not recruiting","[{'id': 1874, 'therapyName': 'Cetuximab + Irinotecan'}, {'id': 1331, 'therapyName': 'Vemurafenib + Cetuximab + Irinotecan '}]",S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,1996
25,NCT02178644,Phase I,Recruiting,"[{'id': 1699, 'therapyName': 'KD018'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",Pilot Trial of KD018 With Neo-Adjuvant Concurrent Chemo-Radiation Therapy in Patients With Locally Advanced Rectal Cancer,1996
26,NCT02195011,Phase II,"Active, not recruiting","[{'id': 890, 'therapyName': 'Regorafenib'}]",Safety Study of Regorafenib and SIR-Spheres® Microspheres Radioembolization in Patients With Refractory Metastatic Colorectal Cancer With Liver Metastases,1996
27,NCT02287727,Phase II,Withdrawn,"[{'id': 890, 'therapyName': 'Regorafenib'}]",Regorafenib in Reducing Recurrence in Patients With Non-metastatic Rectal Cancer Who Have Completed Curative-Intent Treatment,1996
28,NCT02305758,Phase II,Completed,"[{'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 954, 'therapyName': 'Veliparib'}]",Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal Cancer,1996
29,NCT02368886,Phase II,"Active, not recruiting","[{'id': 2350, 'therapyName': 'Clobetasol + Regorafenib'}]",Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer,1996
30,NCT02393755,Phase Ib/II,"Active, not recruiting","[{'id': 2589, 'therapyName': 'Capecitabine + Nintedanib'}]",Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer,1996
31,NCT02550743,Phase I,Recruiting,"[{'id': 1535, 'therapyName': 'BYL719 + Capecitabine'}]","BrUOG 302:BYL719, Capecitabine and Radiation for Rectal Cancer: A Brown University Oncology Research Group Study",1996
32,NCT02575508,Phase Ib/II,Withdrawn,"[{'id': 3142, 'therapyName': 'BGJ398 + Fluorouracil + Irinotecan + Oxaliplatin'}]",Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer,1996
33,NCT02651415,Phase II,"Active, not recruiting","[{'id': 3410, 'therapyName': 'Perindopril + Regorafenib'}]",Phase II Study of Perindopril and Regorafenib in mCRC,1996
34,NCT02688712,Phase II,Recruiting,"[{'id': 5788, 'therapyName': 'Capecitabine + Galunisertib'}, {'id': 5789, 'therapyName': 'Fluorouracil + Galunisertib'}, {'id': 2409, 'therapyName': 'Galunisertib'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer,1996
35,NCT02788279,Phase III,"Active, not recruiting","[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}, {'id': 890, 'therapyName': 'Regorafenib'}]",A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma,1996
36,NCT02921256,Phase II,Recruiting,"[{'id': 954, 'therapyName': 'Veliparib'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 4838, 'therapyName': 'Capecitabine + Veliparib'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",Veliparib and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer,1996
37,NCT02935309,Phase I,Recruiting,"[{'id': 4779, 'therapyName': 'Capecitabine + Lenvatinib'}]",Phase I Study of Capecitabine and Lenvatinib With External Radiation in Rectal Adenocarcinoma,1996
38,NCT02972034,Phase I,Recruiting,"[{'id': 5269, 'therapyName': 'MK-8353 + Pembrolizumab'}]",Study of MK-8353 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Malignancies (MK-8353-013),1996
39,NCT02997228,Phase III,Not yet recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}, {'id': 5126, 'therapyName': 'Bevacizumab + Atezolizumab + Fluorouracil + Leucovorin + Oxaliplatin'}]","Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Microsatellite Instability-High Metastatic Colorectal Cancer",1996
40,NCT03043313,Phase II,Recruiting,"[{'id': 1560, 'therapyName': 'ARRY-380 + Trastuzumab'}]",Tucatinib (ONT-380) and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer (MOUNTAINEER)Tucatinib (ONT-380) and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer (MOUNTAINEER) (MOUNTAINEER),1996
41,NCT03053544,Phase II,Recruiting,"[{'id': 1031, 'therapyName': 'Metformin'}]",Metformin With Neoadjuvant Chemoradiation to Improve Pathologic Responses in Rectal Cancer,1996
0,NCT01274624,Phase I,"Active, not recruiting","[{'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 2099, 'therapyName': 'Bevacizumab + Reolysin'}]",Study of REOLYSIN; in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer,1993
1,NCT01309126,Phase III,Terminated,"[{'id': 694, 'therapyName': 'Cetuximab'}, {'id': 2065, 'therapyName': 'Cetuximab + Imprime PGG'}]",Study of Imprime PGG in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer,1993
2,NCT01740648,Phase I,"Active, not recruiting","[{'id': 1113, 'therapyName': 'Trametinib + Fluorouracil'}]","Trametinib, Fluorouracil, and Radiation Therapy Before Surgery in Treating Patients With Stage II-III Rectal Cancer",1993
3,NCT01966289,Phase I,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1949, 'therapyName': 'SGI-110'}, {'id': 2977, 'therapyName': 'GVAX colorectal cancer vaccine'}]",SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC),1993
4,NCT01985763,Phase Ib/II,Completed,"[{'id': 757, 'therapyName': 'Genistein'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Genistein in Treatment of Metastatic Colorectal Cancer,1993
5,NCT02041481,Phase I,"Active, not recruiting","[{'id': 2217, 'therapyName': 'MEK162 + FOLFOX'}]","MEK Inhibitor MEK162 in Combination With Leucovorin Calcium, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Metastatic Colorectal Cancer",1993
6,NCT02199236,Phase I,Recruiting,"[{'id': 1619, 'therapyName': 'Capecitabine + Fluorouracil'}]",Dose Escalation Trial of Endoluminal High-Dose-Rate Brachytherapy With Concurrent Chemotherapy for Rectal or Anal Cancer in Patients With Recurrent Disease or Undergoing Non-Operative Management,1993
7,NCT02399813,Phase Ib/II,"Active, not recruiting","[{'id': 3090, 'therapyName': 'ADXS11-001'}]",Phase 2 Study of ADXS11-001 in Subjects With Anal Cancer or Cancer of the Rectum,1993
8,NCT02508077,Phase II,Terminated,"[{'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 845, 'therapyName': 'Panitumumab'}]",FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer,1993
9,NCT03127098,Phase Ib/II,"Active, not recruiting","[{'id': 6239, 'therapyName': 'ALT-803 + ETBX-011'}]","QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer",1993
10,NCT03152370,Phase I,Recruiting,"[{'id': 5798, 'therapyName': 'E7046 + mFOLFOX-6'}, {'id': 5805, 'therapyName': 'Capecitabine + E7046'}]",Preoperative Radiotherapy and E7046 in Rectum Cancer (PRAER 1),1993
0,NCT01943851,Phase I,Recruiting,"[{'id': 784, 'therapyName': 'GSK525762'}]","A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies",712
1,NCT02240719,Phase I,Recruiting,"[{'id': 2336, 'therapyName': 'Bendamustine + Everolimus'}]",Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer,712
0,NCT03050060,Phase II,Recruiting,"[{'id': 5301, 'therapyName': 'Nelfinavir + Nivolumab'}]","Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, and Nivolumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer",4451
0,NCT00003553,Phase II,Unknown status,"[{'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1639, 'therapyName': 'Methotrexate'}]",Peripheral Stem Cell Transplant in Treating Patients With Metastatic Kidney Cancer,4450
1,NCT00301990,Phase II,Unknown status,"[{'id': 2098, 'therapyName': 'Aldesleukin + Bevacizumab'}]",Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer,4450
2,NCT00717587,Phase II,Unknown status,"[{'id': 930, 'therapyName': 'Sunitinib'}, {'id': 2129, 'therapyName': 'girentuximab'}, {'id': 2128, 'therapyName': 'motexafin gadolinium'}]",Sunitinib Before and After Surgery in Treating Patients With Stage IV Kidney Cancer,4450
3,NCT00828919,Phase I,"Active, not recruiting","[{'id': 649, 'therapyName': 'Axitinib'}]",Continuing Access To AG- 013736 (A406) For Patients Previously Receiving AG 013736 In Clinical Trials,4450
4,NCT00915993,Phase I,Unknown status,"[{'id': 930, 'therapyName': 'Sunitinib'}]",MRI in Predicting Response to Sunitinib Malate in Patients With Stage IV Kidney Cancer,4450
5,NCT00923130,Phase II,Completed,"[{'id': 1122, 'therapyName': 'Bevacizumab + Ixabepilone'}]",Bevacizumab Plus Ixabepilone to Treat Patients With Advanced Kidney Cancer,4450
6,NCT00923845,Phase II,Completed,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 2308, 'therapyName': 'Cyclophosphamide + Pentostatin'}]",Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney Cancer,4450
7,NCT01014065,Phase II,Completed,"[{'id': 930, 'therapyName': 'Sunitinib'}]",A Prospective Study of Acute Cardiovascular Effects of First-line Sunitinib in Metastatic Renal Cell Carcinoma Patients (SUnitinib Prospective CardiovasculaR Effect),4450
8,NCT01026337,Phase I,"Active, not recruiting","[{'id': 930, 'therapyName': 'Sunitinib'}]",Magnetic Resonance Imaging (MRI) in Predicting Response to Sunitinib Malate in Patients With Locally Advanced or Metastatic Kidney Cancer,4450
9,NCT01120249,Phase III,"Active, not recruiting","[{'id': 735, 'therapyName': 'Everolimus'}]","S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",4450
10,NCT01164228,Phase II,Recruiting,"[{'id': 930, 'therapyName': 'Sunitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery,4450
11,NCT01221506,Phase I,Completed,"[{'id': 848, 'therapyName': 'Pazopanib'}]",Pazopanib/DCE-MRIs in Renal Cell Carcinoma (RCC),4450
12,NCT01283048,Phase I,Completed,"[{'id': 1178, 'therapyName': 'BKM120 + Bevacizumab'}]",Bevacizumab and BKM-120 in Patients With Metastatic Renal Cell Carcinoma,4450
13,NCT01307267,Phase I,Recruiting,"[{'id': 6111, 'therapyName': 'Utomilumab + Rituximab'}, {'id': 5086, 'therapyName': 'Utomilumab'}]",A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab,4450
14,NCT01331135,Phase I,"Active, not recruiting","[{'id': 917, 'therapyName': 'Sirolimus'}]",Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors,4450
15,NCT01361113,Phase II,Completed,"[{'id': 848, 'therapyName': 'Pazopanib'}]",Neoadjuvant Pazopanib in Renal Cell Carcinoma,4450
16,NCT01370109,Phase I,Recruiting,"[{'id': 930, 'therapyName': 'Sunitinib'}]",Cardiovascular Effects of Sunitinib Therapy (CREST),4450
17,NCT01391143,Phase I,Recruiting,"[{'id': 2863, 'therapyName': 'MGA271'}]",Safety Study of MGA271 in Refractory Cancer,4450
18,NCT01399918,Phase II,"Active, not recruiting","[{'id': 1120, 'therapyName': 'Everolimus + Bevacizumab'}]",Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC),4450
19,NCT01480154,Phase I,"Active, not recruiting","[{'id': 1393, 'therapyName': 'MK2206 + hydroxychloroquine'}]","Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer",4450
20,NCT01510119,Phase Ib/II,"Active, not recruiting","[{'id': 2231, 'therapyName': 'Everolimus + Hydroxychloroquine'}]",Autophagy Inhibition to Augment mTOR Inhibition: A Phase I/II Trial of RAD001 and Hydroxychloroquine in Patients With Previously Treated Renal Cell Carcinoma,4450
21,NCT01517243,Phase II,Unknown status,"[{'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 930, 'therapyName': 'Sunitinib'}]",Phase II Study of Alternating Sunitinib and Temsirolimus,4450
22,NCT01575548,Phase III,"Active, not recruiting","[{'id': 848, 'therapyName': 'Pazopanib'}]",Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery,4450
23,NCT01582009,Phase Ib/II,Terminated,"[{'id': 1964, 'therapyName': 'Panobinostat + Everolimus'}]",Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate,4450
24,NCT01582672,Phase III,"Active, not recruiting","[{'id': 930, 'therapyName': 'Sunitinib'}]",Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC),4450
25,NCT01625936,Phase I,Unknown status,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 708, 'therapyName': 'CRLX101'}]",CRLX101 Plus Bevacizumab in Advanced RCC,4450
26,NCT01649180,Phase II,Terminated,"[{'id': 649, 'therapyName': 'Axitinib'}]",NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma (PrE0801),4450
27,NCT01664182,Phase II,"Active, not recruiting","[{'id': 1223, 'therapyName': 'Trebananib + Sunitinib'}, {'id': 1220, 'therapyName': 'Trebananib + Pazopanib'}, {'id': 1221, 'therapyName': 'Trebananib + Sorafenib'}, {'id': 1218, 'therapyName': 'Trebananib'}, {'id': 1219, 'therapyName': 'Trebananib + Bevacizumab'}]","Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer",4450
28,NCT01727336,Phase II,"Active, not recruiting","[{'id': 1245, 'therapyName': 'Dalantercept + Axitinib'}, {'id': 649, 'therapyName': 'Axitinib'}]", Study of Dalantercept in Patients With Advanced Renal Cell Carcinoma,4450
29,NCT01730118,Phase I,Recruiting,"[{'id': 1404, 'therapyName': 'HER2 Vaccine'}]",Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing,4450
30,NCT01767636,Phase II,Recruiting,"[{'id': 848, 'therapyName': 'Pazopanib'}]",Pazopanib in Treating Patients With Metastatic Non-Clear Cell Kidney Cancer,4450
31,NCT01806064,Phase I,"Active, not recruiting","[{'id': 1243, 'therapyName': 'Bevacizumab + TRC105'}]", A Phase 1B Dose-escalation Study of TRC105 in Combination With Axitinib in Patients With Advanced Renal Cell Carcinoma,4450
32,NCT01835158,Phase II,"Active, not recruiting","[{'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1236, 'therapyName': 'Cabozantinib + Sunitinib'}]",Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer,4450
33,NCT01865747,Phase III,"Active, not recruiting","[{'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}]",A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma,4450
34,NCT01946789,Phase I,Recruiting,"[{'id': 3060, 'therapyName': 'ALT-803'}]",A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors,4450
35,NCT01984242,Phase II,"Active, not recruiting","[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1202, 'therapyName': 'Atezolizumab + Bevacizumab + Capecitabine'}]",A Phase 2 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) as Monotherapy or in Combination With Avastin (Bevacizumab) Compared to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma,4450
36,NCT02009449,Phase I,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 2621, 'therapyName': 'AM0010 '}, {'id': 619, 'therapyName': 'Abraxane'}]",A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors,4450
37,NCT02013804,Phase I,Completed,"[{'id': 3120, 'therapyName': 'MEDI0680'}]",A Phase 1 Multicenter Open-label Study to Evaluate the Safety Tolerability and PK of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies,4450
38,NCT02014636,Phase I,"Active, not recruiting","[{'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Safety and Efficacy Study of Pazopanib and MK 3475 in Advanced Renal Cell Carcinoma (RCC),4450
39,NCT02082210,Phase Ib/II,"Active, not recruiting","[{'id': 1387, 'therapyName': 'Emibetuzumab + Ramucirumab'}]",A Study of LY2875358 in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer,4450
40,NCT02089334,Phase Ib/II,Recruiting,"[{'id': 2262, 'therapyName': 'Everolimus + RX-0201'}, {'id': 735, 'therapyName': 'Everolimus'}]","Dose-Finding, Safety and Efficacy Study of RX-0201 Plus Everolimus in Metastatic Renal Cell Cancer",4450
41,NCT02089685,Phase Ib/II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 2624, 'therapyName': 'peginterferon alfa-2b'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29),4450
42,NCT02122809,Phase I,Completed,"[{'id': 1998, 'therapyName': 'Chiauranib'}]",Phase I Study of Chiauranib in Patients With Advanced Solid Tumors,4450
43,NCT02133742,Phase I,"Active, not recruiting","[{'id': 2494, 'therapyName': 'Axitinib + Pembrolizumab'}]","A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell Cancer",4450
44,NCT02164838,Phase I,"Active, not recruiting","[{'id': 649, 'therapyName': 'Axitinib'}]",VEGF Receptor Tyrosine Kinase Inhibitor Axitinib in Children With Recurrent or Refractory Solid Tumors,4450
45,NCT02170389,Phase I,Withdrawn,"[{'id': 4075, 'therapyName': 'AGS-003'}]",Vaccine Therapy Before Surgery in Treating Patients With Localized Kidney Cancer,4450
46,NCT02174172,Phase I,Recruiting,"[{'id': 6252, 'therapyName': 'Atezolizumab + Bevacizumab +Peg-interferon alfa-2a'}, {'id': 6253, 'therapyName': 'Atezolizumab + Interferon alfa-2b'}, {'id': 6250, 'therapyName': 'Atezolizumab + Peg-interferon alfa-2a'}, {'id': 6249, 'therapyName': 'Atezolizumab + Ipilimumab'}, {'id': 1975, 'therapyName': 'Atezolizumab + Obinutuzumab'}]",A Study to Assess the Safety and Tolerability of MPDL3280A in Combination With Other Immune-modulating Therapies in Patients With Locally Advanced or Metastatic Solid Tumors,4450
47,NCT02178722,Phase Ib/II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2575, 'therapyName': 'Epacadostat'}]","A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Solid Tumors and Advanced NSCLC (INCB 24360-202 / MK-3475-037 / KEYNOTE-037)",4450
48,NCT02187302,Phase II,Completed,"[{'id': 1213, 'therapyName': 'CRLX101 + Bevacizumab'}]",CRLX101 in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC),4450
49,NCT02212730,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Study Evaluating the Effect of Pembrolizumab (MK-3475) in Participants With Renal Cell Cancer (MK-3475-031),4450
50,NCT02231749,Phase III,"Active, not recruiting","[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 930, 'therapyName': 'Sunitinib'}]",Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214),4450
51,NCT02273752,Phase II,Terminated,"[{'id': 735, 'therapyName': 'Everolimus'}]","Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer",4450
52,NCT02298959,Phase I,Recruiting,"[{'id': 2369, 'therapyName': 'Aflibercept + Pembrolizumab'}]",Pembrolizumab and Ziv-aflibercept in Treating Patients With Advanced Solid Tumors,4450
53,NCT02386826,Phase I,Recruiting,"[{'id': 2600, 'therapyName': 'Bevacizumab + INC280'}]","INC280 Combined With Bevacizumab to Evaluate Glioblastoma Multiforme, Metastatic Colorectal Cancer, and Metastatic Renal Cell Carcinoma Patients",4450
54,NCT02404441,Phase Ib/II,Recruiting,"[{'id': 2659, 'therapyName': 'PDR001'}]",Phase I/II Study of PDR001 in Patients With Advanced Malignancies,4450
55,NCT02406521,Phase I,"Active, not recruiting","[{'id': 848, 'therapyName': 'Pazopanib'}, {'id': 2001, 'therapyName': 'radium Ra 223 dichloride'}, {'id': 920, 'therapyName': 'Sorafenib'}]",Exploratory Study of Radium-223 and Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Metastases,4450
56,NCT02420821,Phase III,"Active, not recruiting","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study of MPDL3280A (Anti-Programmed Death Ligand 1 [PD-L1] Antibody) in Combination With Bevacizumab Versus Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma,4450
57,NCT02432846,Phase II,Recruiting,"[{'id': 930, 'therapyName': 'Sunitinib'}]",Intratumoral Vaccination With Intuvax Pre-nephrectomy Followed by Sunitinib Post-nephrectomy vs Sunitinib Post-nephrectomy in Newly Diagnosed Metastatic Renal Cell Carcinoma (mRCC) (MERECA),4450
58,NCT02471846,Phase I,"Active, not recruiting","[{'id': 2888, 'therapyName': 'GDC-0919'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study of GDC-0919 and MPDL3280A Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors,4450
59,NCT02493751,Phase I,"Active, not recruiting","[{'id': 3145, 'therapyName': 'Avelumab + Axitinib'}]",A Study Of Avelumab In Combination With Axitinib In Advanced Renal Cell Cancer,4450
60,NCT02495103,Phase Ib/II,Recruiting,"[{'id': 2959, 'therapyName': 'Metformin + Vandetanib'}]",Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma,4450
61,NCT02498665,Phase I,Recruiting,"[{'id': 4320, 'therapyName': 'DSP-7888'}]",A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies,4450
62,NCT02501096,Phase Ib/II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 792, 'therapyName': 'Lenvatinib'}]",Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors,4450
63,NCT02543645,Phase Ib/II,Terminated,"[{'id': 3086, 'therapyName': 'Atezolizumab + Varlilumab'}]",A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer,4450
64,NCT02559492,Phase I,"Active, not recruiting","[{'id': 3096, 'therapyName': 'INCB039110 + INCB024360'}, {'id': 3097, 'therapyName': 'INCB039110 + INCB050465'}]",INCB039110 Combined With INCB024360 and/or INCB039110 Combined With INCB050465 in Advanced Solid Tumors,4450
65,NCT02560012,Phase II,Terminated,"[{'id': 735, 'therapyName': 'Everolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 848, 'therapyName': 'Pazopanib'}]",Personalized Targeted Inhibitors Treatment in Renal Cell Cancer,4450
66,NCT02576665,Phase I,Recruiting,"[{'id': 3211, 'therapyName': 'Toca 511 + Toca FC'}]","A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Solid Tumors (Toca6)",4450
67,NCT02596035,FDA approved,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}]",A Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374),4450
68,NCT02599779,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Proof of Principle Study of Pembrolizumab With SBRT in TKI mRCC Patients,4450
69,NCT02608268,Phase Ib/II,Recruiting,"[{'id': 2659, 'therapyName': 'PDR001'}, {'id': 3560, 'therapyName': 'MBG453'}]",Safety and Efficacy of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies,4450
70,NCT02608385,Phase I,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors,4450
71,NCT02619253,Phase Ib/II,Recruiting,"[{'id': 3077, 'therapyName': 'Pembrolizumab + Vorinostat'}]",Phase I/Ib Study of Pembrolizumab With Vorinostat for Patients With Advanced Renal or Urothelial Cell Carcinoma,4450
72,NCT02627963,Phase III,"Active, not recruiting","[{'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1055, 'therapyName': 'Tivozanib'}]",A Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced RCC,4450
73,NCT02639182,Phase II,Recruiting,"[{'id': 4220, 'therapyName': 'AGS-16C3F'}, {'id': 649, 'therapyName': 'Axitinib'}]",A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma,4450
74,NCT02646319,Phase II,"Active, not recruiting","[{'id': 3380, 'therapyName': 'Nab-Rapamycin'}]",Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations,4450
75,NCT02646748,Phase I,Recruiting,"[{'id': 3088, 'therapyName': 'INCB050465 '}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2406, 'therapyName': 'INCB039110'}]",Pembrolizumab Combined With INCB039110 and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors,4450
76,NCT02650635,Phase I,"Active, not recruiting","[{'id': 3413, 'therapyName': 'Cyclophosphamide + Pegfilgrastim + VTX-2337'}]","TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors",4450
77,NCT02684006,Phase III,Recruiting,"[{'id': 3145, 'therapyName': 'Avelumab + Axitinib'}, {'id': 930, 'therapyName': 'Sunitinib'}]",A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101),4450
78,NCT02697591,Phase Ib/II,Recruiting,"[{'id': 4321, 'therapyName': 'INCAGN01876'}]","An Open-Label, Dose-Escalation, Safety Study of INCAGN01876 in Subjects With Advanced or Metastatic Solid Tumors",4450
79,NCT02718066,Phase Ib/II,Recruiting,"[{'id': 4689, 'therapyName': 'Chidamide + Nivolumab'}]","Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer",4450
80,NCT02721732,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors,4450
81,NCT02724020,Phase II,Recruiting,"[{'id': 1283, 'therapyName': 'MLN1117 + Sapanisertib'}, {'id': 1282, 'therapyName': 'Sapanisertib'}, {'id': 735, 'therapyName': 'Everolimus'}]",MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma,4450
82,NCT02724878,Phase II,Recruiting,"[{'id': 1202, 'therapyName': 'Atezolizumab + Bevacizumab + Capecitabine'}]",Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma,4450
83,NCT02729194,Phase I,"Active, not recruiting","[{'id': 848, 'therapyName': 'Pazopanib'}]",Pilot Study of Pazopanib With Low Fat Meal (PALM) in Advanced Renal Cell Carcinoma,4450
84,NCT02762006,Phase I,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",Neoadjuvant MEDI 4736 +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma,4450
85,NCT02781506,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab and Stereotactic Ablative Radiation Therapy Versus Nivolumab Alone for Metastatic Renal Cancer,4450
86,NCT02795819,Phase I,Suspended,"[{'id': 4267, 'therapyName': 'AR-42 + Pazopanib'}]",Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer,4450
87,NCT02799095,Phase I,Recruiting,"[{'id': 4298, 'therapyName': 'ALKS 4230'}]",A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors,4450
88,NCT02811861,Phase III,Recruiting,"[{'id': 1713, 'therapyName': 'Everolimus + Lenvatinib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 4782, 'therapyName': 'Lenvatinib + Pembrolizumab'}]",Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma,4450
89,NCT02835833,Phase I,Recruiting,"[{'id': 4498, 'therapyName': 'Bevacizumab + Nintedanib'}]",Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors,4450
90,NCT02853331,Phase III,Recruiting,"[{'id': 2494, 'therapyName': 'Axitinib + Pembrolizumab'}, {'id': 930, 'therapyName': 'Sunitinib'}]",Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426),4450
91,NCT02853344,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427),4450
92,NCT02867592,Phase II,Recruiting,"[{'id': 998, 'therapyName': 'cabozantinib'}]","Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors",4450
93,NCT02915783,Phase II,Recruiting,"[{'id': 1713, 'therapyName': 'Everolimus + Lenvatinib'}]",A Phase 2 Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease,4450
94,NCT02923349,Phase Ib/II,Recruiting,"[{'id': 5831, 'therapyName': 'INCAGN01949'}]","A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors",4450
95,NCT02923531,Phase Ib/II,Recruiting,"[{'id': 4837, 'therapyName': 'Nivolumab + X4P-001'}]",Addition of X4P-001 to Nivolumab Treatment in Patients With Renal Cell Carcinoma,4450
96,NCT02952248,Phase I,Recruiting,"[{'id': 5692, 'therapyName': 'BI 754091'}]",A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours,4450
97,NCT02956798,Phase II,Not yet recruiting,"[{'id': 848, 'therapyName': 'Pazopanib'}]",Pazopanib Vs. Local Therapy for Renal Cancer With Metastases,4450
98,NCT02962804,Phase II,Not yet recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC),4450
99,NCT02982954,Phase III,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer (CHECKMATE 920),4450
100,NCT02983045,Phase Ib/II,Recruiting,"[{'id': 5076, 'therapyName': 'NKTR-214 + Nivolumab'}]",A Dose Escalation and Cohort Expansion Study of CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 Antibody (Nivolumab) in Patients With Select Advanced or Metastatic Solid Tumors (PIVOT-02),4450
101,NCT02996110,Phase II,Recruiting,"[{'id': 4197, 'therapyName': 'BMS-986016 + Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma (FRACTION-RCC),4450
102,NCT03015740,Phase Ib/II,Recruiting,"[{'id': 4943, 'therapyName': 'MGCD516 + Nivolumab'}]",MGCD516 Combined With Nivolumab in Renal Cell Cancer (RCC),4450
103,NCT03024437,Phase Ib/II,"Active, not recruiting","[{'id': 5129, 'therapyName': 'Entinostat + Atezolizumab'}, {'id': 5235, 'therapyName': 'Atezolizumab + Entinostat + Bevacizumab'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma,4450
104,NCT03024996,Phase III,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy (IMmotion010),4450
105,NCT03029780,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma,4450
106,NCT03055013,Phase III,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy (PROSPER),4450
107,NCT03063762,Phase I,Recruiting,"[{'id': 5365, 'therapyName': 'RO6874281 + Obinutuzumab + Atezolizumab'}, {'id': 5366, 'therapyName': 'RO6874281 + Obinutuzumab + Atezolizumab + Bevacizumab'}]","Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)",4450
108,NCT03065179,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Trial of SBRT in Combination With Nivolumab/Ipilimumab in RCC / Kidney Cancer Patients,4450
109,NCT03092856,Phase II,Recruiting,"[{'id': 649, 'therapyName': 'Axitinib'}, {'id': 5522, 'therapyName': 'Axitinib + PF-04518600'}]",Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer,4450
110,NCT03097328,Phase II,Recruiting,"[{'id': 1282, 'therapyName': 'Sapanisertib'}]",Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell Carcinoma,4450
111,NCT03109015,Phase II,Recruiting,"[{'id': 930, 'therapyName': 'Sunitinib'}]",Alternative Schedule Sunitinib in Metastatic Renal Cell Carcinoma: Cardiopulmonary Exercise Testing (ASSET),4450
112,NCT03111901,Phase Ib/II,Not yet recruiting,"[{'id': 4165, 'therapyName': 'Aldesleukin + Pembrolizumab'}]",Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer,4450
113,NCT03115801,Phase II,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers,4450
114,NCT03117309,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma,4450
115,NCT03126331,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Intermittent Nivolumab in Metastatic Renal Cell Carcinoma Patients,4450
116,NCT03138512,Phase III,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Study Comparing the Combination of Nivolumab and Ipilimumab Versus Placebo in Participants With Localized Renal Cell Carcinoma (CheckMate 914),4450
117,NCT03141177,Phase III,Recruiting,"[{'id': 2068, 'therapyName': 'Cabozantinib + Ipilimumab + Nivolumab'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 2067, 'therapyName': 'Cabozantinib + Nivolumab'}]",A Study of Nivolumab Combined With Cabozantinib or Nivolumab and Ipilimumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 9ER),4450
118,NCT03142334,Phase III,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564),4450
119,NCT03149822,Phase Ib/II,Not yet recruiting,"[{'id': 5680, 'therapyName': 'Pembrolizumab + Cabozantinib'}]",Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma,4450
120,NCT03165721,Phase II,Recruiting,"[{'id': 1949, 'therapyName': 'SGI-110'}]","A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer",4450
121,NCT03172754,Phase Ib/II,Recruiting,"[{'id': 5837, 'therapyName': 'Axitinib + Nivolumab'}]",Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma,4450
122,NCT03175224,Phase I,Recruiting,"[{'id': 5963, 'therapyName': 'CBT-101'}]",CBT-101 Study for Advanced Solid Tumors and c-Met Dysregulation,4450
123,NCT03189186,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Phase-I Trial of Pembrolizumab and Percutaneous Cryoablation Combination Followed by Nephron-Sparing Surgery or Cytoreductive Nephrectomy in Locally Advanced and Metastatic Renal Cell Carcinomas,4450
124,NCT03203473,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study),4450
125,NCT03207347,Phase II,Not yet recruiting,"[{'id': 832, 'therapyName': 'Niraparib'}]",A Trial of Niraparib in BAP1 and Other DNA Double-Strand Break Repair Deficient Neoplasms (UF-STO-ETI-001),4450
126,NCT03239145,Phase I,Recruiting,"[{'id': 6102, 'therapyName': 'Pembrolizumab + Trebananib'}]",Phase Ib Study to Test the Safety and Potential Synergy of Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor,4450
127,NCT03241173,Phase Ib/II,Not yet recruiting,"[{'id': 6120, 'therapyName': 'INCAGN01949 + Ipilimumab'}, {'id': 6119, 'therapyName': 'INCAGN01949 + Nivolumab'}, {'id': 6121, 'therapyName': 'INCAGN01949 + Ipilimumab + Nivolumab'}]",A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies,4450
128,NCT03260504,Phase I,Not yet recruiting,"[{'id': 4165, 'therapyName': 'Aldesleukin + Pembrolizumab'}]",Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer,4450
129,NCT03264066,Phase II,Not yet recruiting,"[{'id': 6094, 'therapyName': 'Atezolizumab + Cabozantinib'}]",A Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Participants With Solid Tumors,4450
130,NCT03277352,Phase Ib/II,Not yet recruiting,"[{'id': 6277, 'therapyName': 'Epacadostat + INCAGN01876 + Pembrolizumab'}]",INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies,4450
131,NCT03289962,Phase I,Not yet recruiting,"[{'id': 6234, 'therapyName': 'RO7198457'}, {'id': 6235, 'therapyName': 'Atezolizumab + RO7198457'}]",A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors,4450
0,NCT00747305,Phase I,Terminated,"[{'id': 930, 'therapyName': 'Sunitinib'}]",Sunitinib Before and After Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed By Surgery,4467
1,NCT00831480,Phase II,Terminated,"[{'id': 735, 'therapyName': 'Everolimus'}]",Everolimus(RAD001) For Advanced Renal Cell Carcinoma(RCC)Before Kidney Removal,4467
2,NCT01038778,Phase Ib/II,"Active, not recruiting","[{'id': 1541, 'therapyName': 'Entinostat'}, {'id': 1167, 'therapyName': 'Aldesleukin'}]",Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer,4467
3,NCT01099423,Phase III,"Active, not recruiting","[{'id': 930, 'therapyName': 'Sunitinib'}]",Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer,4467
4,NCT01158521,Phase II,Completed,"[{'id': 848, 'therapyName': 'Pazopanib'}]",Pazopanib Hydrochloride Before Surgery in Treating Patients With Kidney Cancer,4467
5,NCT01392183,Phase II,"Active, not recruiting","[{'id': 1275, 'therapyName': 'Diphenhydramine'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 848, 'therapyName': 'Pazopanib'}]",Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC),4467
6,NCT01499121,Phase II,"Active, not recruiting","[{'id': 930, 'therapyName': 'Sunitinib'}]",Study of Efficacy and Safety of Sunitinib Given on an Individualized Schedule,4467
7,NCT01582204,Phase I,Recruiting,"[{'id': 848, 'therapyName': 'Pazopanib'}, {'id': 930, 'therapyName': 'Sunitinib'}]",Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma,4467
8,NCT01599754,Phase III,"Active, not recruiting","[{'id': 649, 'therapyName': 'Axitinib'}]",Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients,4467
9,NCT01599832,Phase I,Terminated,"[{'id': 848, 'therapyName': 'Pazopanib'}]",Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Measuring Effects of Pazopanib Hydrochloride in Patients With Metastatic Kidney Cancer,4467
10,NCT01684397,Phase Ib/II,Recruiting,"[{'id': 1230, 'therapyName': 'Pazopanib + Bevacizumab'}]",Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer,4467
11,NCT01835158,Phase II,"Active, not recruiting","[{'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1236, 'therapyName': 'Cabozantinib + Sunitinib'}]",Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer,4467
12,NCT01999972,Phase I,"Active, not recruiting","[{'id': 1350, 'therapyName': 'Axitinib + Crizotinib'}]",A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors,4467
13,NCT02060370,Phase II,"Active, not recruiting","[{'id': 930, 'therapyName': 'Sunitinib'}]",Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC),4467
14,NCT02210117,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 2111, 'therapyName': 'Bevacizumab + Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab vs Nivolumab + Bevacizumab vs Nivolumab + Ipilimumab in Metastatic Renal Cell Carcinoma (mRCC),4467
15,NCT02293980,Phase I,"Active, not recruiting","[{'id': 4146, 'therapyName': 'PT2385'}, {'id': 4347, 'therapyName': 'PT2385 + Nivolumab'}]","A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma",4467
16,NCT02307474,Phase I,Withdrawn,"[{'id': 848, 'therapyName': 'Pazopanib'}]",A Pilot Study of SBRT With Adjuvant Pazopanib for Renal Cell Cancer,4467
17,NCT02315066,Phase I,Recruiting,"[{'id': 4333, 'therapyName': 'PF-04518600'}, {'id': 4448, 'therapyName': 'PF-04518600 + Utomilumab'}]",Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566,4467
18,NCT02348008,Phase Ib/II,"Active, not recruiting","[{'id': 2119, 'therapyName': 'Bevacizumab + Pembrolizumab'}]",Phase Ib and Phase II Studies of MK-3475 in Combination + for Renal Cell Carcinoma,4467
19,NCT02386111,Phase Ib/II,Terminated,"[{'id': 3057, 'therapyName': 'Sunitinib + Varlilumab'}]",A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma,4467
20,NCT02535533,Phase I,Recruiting,"[{'id': 3474, 'therapyName': 'Axitinib + Selenomethionine'}]",SLM + Axitinib for Clear Cell RCC,4467
21,NCT02540291,Phase I,Recruiting,"[{'id': 5694, 'therapyName': 'E7046'}]",Study of E7046 in Subjects With Selected Advanced Malignancies,4467
22,NCT02575222,Phase I,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Study of Neoadjuvant Nivolumab in Patients With Non-metastatic Stage II-IV Clear Cell Renal Cell Carcinoma,4467
23,NCT02579811,Phase II,Recruiting,"[{'id': 649, 'therapyName': 'Axitinib'}]",Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer,4467
24,NCT02595918,Phase I,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab in Treating Patients With HIgh-Risk Non-Metastatic Kidney Cancer,4467
25,NCT02599324,Phase Ib/II,Recruiting,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 694, 'therapyName': 'Cetuximab'}]",A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors,4467
26,NCT02607553,Phase II,Completed,"[{'id': 4338, 'therapyName': 'mipsagargin'}]",Safety and Activity of G-202 in Patients With Clear Cell Renal Cell Carcinoma That Expresses PSMA,4467
27,NCT02626130,Phase I,Recruiting,"[{'id': 1652, 'therapyName': 'Tremelimumab'}]",Pilot Study of Presurgical Tremelimumab With or Without Cryoablation in Patients With Metastatic Renal Cell Carcinoma (RCC),4467
28,NCT02667886,Phase Ib/II,Recruiting,"[{'id': 649, 'therapyName': 'Axitinib'}, {'id': 3570, 'therapyName': 'X4P-001'}]",Trial of X4P-001 in Patients With Advanced Renal Cell Carcinoma,4467
29,NCT02837991,Phase Ib/II,Recruiting,"[{'id': 5774, 'therapyName': 'CDX-014'}]","A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Advanced or Metastatic Renal Cell Carcinoma",4467
30,NCT02853344,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427),4467
31,NCT02885649,Phase 0,Not yet recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}]",Enzalutamide Before Surgery in Treating Patients With Kidney Cancer,4467
32,NCT02947165,Phase I,Recruiting,"[{'id': 5632, 'therapyName': 'NIS793 + PDR001'}, {'id': 5631, 'therapyName': 'NIS793'}]",Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.,4467
33,NCT02974738,Phase I,Recruiting,"[{'id': 5820, 'therapyName': 'PT 2977'}]",A Trial of PT2977 Tablets In Patients With Advanced Solid Tumors,4467
34,NCT02978404,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases,4467
35,NCT02989714,Phase Ib/II,Recruiting,"[{'id': 5139, 'therapyName': 'Aldesleukin + Nivolumab'}]","Phase Ib/II Trial of Interleukin-2 and PD-1 Checkpoint Inhibitor, Nivolumab In Metastatic Clear Cell Renal Cell Cancer",4467
36,NCT03015740,Phase Ib/II,Recruiting,"[{'id': 4943, 'therapyName': 'MGCD516 + Nivolumab'}]",MGCD516 Combined With Nivolumab in Renal Cell Cancer (RCC),4467
37,NCT03024996,Phase III,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy (IMmotion010),4467
38,NCT03035630,Phase II,Recruiting,"[{'id': 3144, 'therapyName': 'Avelumab'}, {'id': 930, 'therapyName': 'Sunitinib'}]",Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma,4467
39,NCT03108066,Phase II,"Active, not recruiting","[{'id': 4146, 'therapyName': 'PT2385'}]",PT2385 for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma,4467
40,NCT03138512,Phase III,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Study Comparing the Combination of Nivolumab and Ipilimumab Versus Placebo in Participants With Localized Renal Cell Carcinoma (CheckMate 914),4467
41,NCT03141177,Phase III,Recruiting,"[{'id': 2068, 'therapyName': 'Cabozantinib + Ipilimumab + Nivolumab'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 2067, 'therapyName': 'Cabozantinib + Nivolumab'}]",A Study of Nivolumab Combined With Cabozantinib or Nivolumab and Ipilimumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 9ER),4467
42,NCT03149159,Phase II,Not yet recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]","Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab",4467
43,NCT03170960,Phase Ib/II,Recruiting,"[{'id': 6094, 'therapyName': 'Atezolizumab + Cabozantinib'}]",Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors,4467
44,NCT03173560,Phase II,Recruiting,"[{'id': 1713, 'therapyName': 'Everolimus + Lenvatinib'}]",Trial to Assess Safety and Efficacy of Lenvatinib in Combination With Everolimus in Participants With Renal Cell Carcinoma,4467
45,NCT03260504,Phase I,Not yet recruiting,"[{'id': 4165, 'therapyName': 'Aldesleukin + Pembrolizumab'}]",Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer,4467
0,NCT01688999,Phase II,"Active, not recruiting","[{'id': 998, 'therapyName': 'cabozantinib'}]",Cabozantinib for Advanced Urothelial Cancer,4919
0,NCT00942331,Phase III,"Active, not recruiting","[{'id': 1295, 'therapyName': 'Gemcitabine + Bevacizumab + Cisplatin'}, {'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}]",Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer,5974
1,NCT01108055,Phase II,Completed,"[{'id': 1143, 'therapyName': 'Pazopanib + Paclitaxel'}]",Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer,5974
2,NCT01174121,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 1167, 'therapyName': 'Aldesleukin'}]",Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer,5974
3,NCT01215136,Phase II,"Active, not recruiting","[{'id': 735, 'therapyName': 'Everolimus'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma,5974
4,NCT01326871,Phase Ib/II,"Active, not recruiting","[{'id': 2187, 'therapyName': 'ALT-801'}]",A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer,5974
5,NCT01366144,Phase I,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 954, 'therapyName': 'Veliparib'}, {'id': 1092, 'therapyName': 'Carboplatin'}]","Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction",5974
6,NCT01780545,Phase II,Completed,"[{'id': 1807, 'therapyName': 'OGX-427'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer,5974
7,NCT02014337,Phase I,"Active, not recruiting","[{'id': 3053, 'therapyName': 'Eribulin + Mifepristone'}]",Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors,5974
8,NCT02108652,Phase II,"Active, not recruiting","[{'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study of MPDL3280A in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer,5974
9,NCT02178722,Phase Ib/II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2575, 'therapyName': 'Epacadostat'}]","A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Solid Tumors and Advanced NSCLC (INCB 24360-202 / MK-3475-037 / KEYNOTE-037)",5974
10,NCT02236195,Phase II,Completed,"[{'id': 3002, 'therapyName': 'Mocetinostat'}]",Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes,5974
11,NCT02240238,Phase Ib/II,Recruiting,"[{'id': 5626, 'therapyName': 'Gemcitabine + NC-6004'}]","Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer",5974
12,NCT02256436,Phase III,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045)",5974
13,NCT02300610,Phase I,"Active, not recruiting","[{'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]",Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer,5974
14,NCT02302807,Phase III,"Active, not recruiting","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 720, 'therapyName': 'Docetaxel'}]",A Study of MPDL3280A Compared With Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer,5974
15,NCT02334527,Phase II,Recruiting,"[{'id': 850, 'therapyName': 'Palbociclib'}]",Phase II Trial of Palbociclib (PD-0332991) in Patients With Metastatic Urothelial Cancer (UC) After Failure of First-Line Chemotherapy,5974
16,NCT02335424,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-52),5974
17,NCT02365766,Phase Ib/II,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",Study of Neoadjuvant Pembrolizumab in Combination With Gemcitabine Based Therapy in Cis-eligible or -Ineligible Subjects With Urothelial Cancer,5974
18,NCT02365818,Phase II,"Active, not recruiting","[{'id': 2523, 'therapyName': 'CG0070'}]",Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade Non-Muscle Invasive Bladder Cancer After BCG Failure,5974
19,NCT02387996,Phase II,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}]",A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder Cancer,5974
20,NCT02401542,Phase II,Recruiting,"[{'id': 2934, 'therapyName': 'B-701'}, {'id': 720, 'therapyName': 'Docetaxel'}]",A Phase 2 Study of B-701 in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma,5974
21,NCT02412670,Phase II,Recruiting,"[{'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}, {'id': 2668, 'therapyName': 'Aldoxorubicin + Cisplatin + Methotrexate + Vincristine'}]",Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer,5974
22,NCT02426125,Phase III,"Active, not recruiting","[{'id': 886, 'therapyName': 'Ramucirumab'}, {'id': 720, 'therapyName': 'Docetaxel'}]",A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer,5974
23,NCT02437370,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer,5974
24,NCT02443324,Phase I,"Active, not recruiting","[{'id': 2896, 'therapyName': 'Pembrolizumab + Ramucirumab'}]","A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC or Transitional Cell Carcinoma of the Urothelium",5974
25,NCT02459119,Phase II,Recruiting,"[{'id': 890, 'therapyName': 'Regorafenib'}]",Study of Regorafenib for Urothelial Cancer Following Chemotherapy (UAB 1477),5974
26,NCT02479178,Phase II,Terminated,"[{'id': 3640, 'therapyName': 'BIND-014'}]","A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck  (iNSITE2)",5974
27,NCT02496208,Phase I,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 2067, 'therapyName': 'Cabozantinib + Nivolumab'}]",Cabozantinib Plus Nivolumab (CaboNivo) Alone or in Combination With Ipilimumab (CaboNivoIpi) in Patients With Advanced/Metastatic Urothelial Carcinoma and Other Genitourinary Tumors,5974
28,NCT02500121,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Testing the PD-1 Inhibitor Pembrolizumab After Initial Chemotherapy in Patients With Metastatic Bladder Cancer,5974
29,NCT02516241,Phase III,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 4686, 'therapyName': 'Carboplatin + Cisplatin + Gemcitabine'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",Study of MEDI4736 With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer,5974
30,NCT02553642,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260),5974
31,NCT02559492,Phase I,"Active, not recruiting","[{'id': 3096, 'therapyName': 'INCB039110 + INCB024360'}, {'id': 3097, 'therapyName': 'INCB039110 + INCB050465'}]",INCB039110 Combined With INCB024360 and/or INCB039110 Combined With INCB050465 in Advanced Solid Tumors,5974
32,NCT02567409,Phase II,Recruiting,"[{'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 3110, 'therapyName': 'Cisplatin + Gemcitabine + VX-970'}]",Cisplatin and Gemcitabine Hydrochloride With or Without ATR Kinase Inhibitor VX-970 in Treating Patients With Metastatic Urothelial Cancer,5974
33,NCT02581982,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer,5974
34,NCT02589717,FDA approved,Approved for marketing,"[{'id': 1201, 'therapyName': 'Atezolizumab'}]",An Expanded Access Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Urothelial Bladder Cancer After Failure With Platinum-Containing Chemotherapy,5974
35,NCT02612194,Phase II,Recruiting,"[{'id': 706, 'therapyName': 'Crizotinib'}]",LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer,5974
36,NCT02619253,Phase Ib/II,Recruiting,"[{'id': 3077, 'therapyName': 'Pembrolizumab + Vorinostat'}]",Phase I/Ib Study of Pembrolizumab With Vorinostat for Patients With Advanced Renal or Urothelial Cell Carcinoma,5974
37,NCT02632409,Phase III,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",A Study of Adjuvant Nivolumab Versus Placebo Post-Surgical Removal of High Risk Invasive Urothelial Carcinoma,5974
38,NCT02646748,Phase I,Recruiting,"[{'id': 3088, 'therapyName': 'INCB050465 '}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2406, 'therapyName': 'INCB039110'}]",Pembrolizumab Combined With INCB039110 and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors,5974
39,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,5974
40,NCT02807636,Phase III,Recruiting,"[{'id': 4450, 'therapyName': 'Atezolizumab + Carboplatin + Gemcitabine'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}]",The Effect of Atezolizumab in Combination With Gemcitabine/Carboplatin and Gemcitabine/Carboplatin Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-based Therapy,5974
41,NCT02812420,Phase I,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]","Pre-Surgical Study Evaluating Anti-PD-L1 Antibody (Durvalumab) Plus Anti-CTLA-4 (Tremelimumab) in Patients With Muscle-Invasive, High-Risk Urothelial Carcinoma Who Are Ineligible for Cisplatin-based Neoadjuvant Chemotherapy",5974
42,NCT02853305,Phase III,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 4686, 'therapyName': 'Carboplatin + Cisplatin + Gemcitabine'}]",Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma (MK-3475-361/KEYNOTE-361),5974
43,NCT02872714,Phase II,Recruiting,"[{'id': 4173, 'therapyName': 'INCB054828'}]",A Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Urothelial Carcinoma,5974
44,NCT02897765,Phase I,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 4733, 'therapyName': 'NEO-PV-01 + poly ICLC'}]","A Personalized Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer",5974
45,NCT02925533,Phase I,Terminated,"[{'id': 4831, 'therapyName': 'B-701 + Pembrolizumab'}]",Ph 1B B-701 in Combination With Pembrolizumab in Metastatic Transitional Cell Carcinoma of the Urothelial Tract,5974
46,NCT02989584,Phase Ib/II,Recruiting,"[{'id': 5140, 'therapyName': 'Atezolizumab + Cisplatin + Gemcitabine'}]",A Pilot Safety Study of Atezolizumab Combination With Cisplatin + Gemcitabine in Pts With Metastatic Bladder Cancer,5974
47,NCT03093922,Phase II,Recruiting,"[{'id': 5140, 'therapyName': 'Atezolizumab + Cisplatin + Gemcitabine'}]",A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer,5974
48,NCT03133390,Phase II,Recruiting,"[{'id': 4595, 'therapyName': 'Atezolizumab + Bevacizumab'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",Atezolizumab With or Without Bevacizumab in Cisplatin-ineligible Patients,5974
49,NCT03170960,Phase Ib/II,Recruiting,"[{'id': 6094, 'therapyName': 'Atezolizumab + Cabozantinib'}]",Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors,5974
50,NCT03237780,Phase II,Not yet recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 6098, 'therapyName': 'Atezolizumab + Eribulin'}]",Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer,5974
0,NCT02130869,Phase I,Recruiting,"[{'id': 2378, 'therapyName': 'Bendamustine + Cytarabine + Etoposide'}, {'id': 2460, 'therapyName': 'Busulfan + Hu14.18K322A'}, {'id': 2459, 'therapyName': 'Aldesleukin + Melphalan + Sargramostim'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}]",A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas,5176
1,NCT02574728,Phase II,Recruiting,"[{'id': 3143, 'therapyName': 'Celecoxib + Cyclophosphamide + Etoposide + Sirolimus'}]",Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors,5176
2,NCT02867592,Phase II,Recruiting,"[{'id': 998, 'therapyName': 'cabozantinib'}]","Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors",5176
0,NCT01331135,Phase I,"Active, not recruiting","[{'id': 917, 'therapyName': 'Sirolimus'}]",Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors,768
1,NCT01661400,Phase I,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1475, 'therapyName': 'Thalidomide'}]",Anti-Angiogenic Therapy Post Transplant (ASCR) for Relapsed and Refractory Pediatric Solid Tumors,768
2,NCT02130869,Phase I,Recruiting,"[{'id': 2378, 'therapyName': 'Bendamustine + Cytarabine + Etoposide'}, {'id': 2460, 'therapyName': 'Busulfan + Hu14.18K322A'}, {'id': 2459, 'therapyName': 'Aldesleukin + Melphalan + Sargramostim'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}]",A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas,768
0,NCT01331135,Phase I,"Active, not recruiting","[{'id': 917, 'therapyName': 'Sirolimus'}]",Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors,3672
1,NCT01747876,Phase I,Completed,"[{'id': 790, 'therapyName': 'Ribociclib'}]",Study of Safety and Efficacy in Patients With Malignant Rhabdoid Tumors (MRT) and Neuroblastoma,3672
2,NCT02114229,Phase II,Recruiting,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 2449, 'therapyName': 'Methotrexate + Cisplatin + Cyclophosphamide + Vincristine'}, {'id': 626, 'therapyName': 'Alisertib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 942, 'therapyName': 'Topotecan'}]",Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors,3672
3,NCT02601937,Phase I,Recruiting,"[{'id': 2683, 'therapyName': 'Tazemetostat'}]",A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma,3672
4,NCT02601950,Phase II,Recruiting,"[{'id': 2683, 'therapyName': 'Tazemetostat'}]","A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma",3672
5,NCT02639546,Phase I,Recruiting,"[{'id': 1004, 'therapyName': 'Cobimetinib'}]",iMATRIXcobi: Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Patients With Previously Treated Solid Tumors,3672
6,NCT02644460,Phase I,Recruiting,"[{'id': 802, 'therapyName': 'Abemaciclib'}]",Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors,3672
0,NCT00084695,Phase II,Unknown status,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases,3247
1,NCT01241162,Phase I,Completed,"[{'id': 650, 'therapyName': 'Decitabine'}]",Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma,3247
2,NCT01331135,Phase I,"Active, not recruiting","[{'id': 917, 'therapyName': 'Sirolimus'}]",Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors,3247
3,NCT01446809,Phase I,"Active, not recruiting","[{'id': 1472, 'therapyName': 'Doxorubicin + Ifosfamide'}, {'id': 1471, 'therapyName': 'Pazopanib + Doxorubicin + Ifosfamide'}]",Pazopanib Hydrochloride Followed By Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma,3247
4,NCT01518413,Phase I,Completed,"[{'id': 1323, 'therapyName': 'Sorafenib + Irinotecan'}]",Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors,3247
5,NCT01661400,Phase I,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1475, 'therapyName': 'Thalidomide'}]",Anti-Angiogenic Therapy Post Transplant (ASCR) for Relapsed and Refractory Pediatric Solid Tumors,3247
6,NCT01871766,Phase II,Recruiting,"[{'id': 1119, 'therapyName': 'Sorafenib + Avastin + Cyclophosphamide'}, {'id': 1436, 'therapyName': 'Vincristine + Dactinomycin'}, {'id': 1435, 'therapyName': 'Vincristine + Dactinomycin + Cyclophosphamide'}]","Treatment of Localized Rhabdomyosarcoma With Chemotherapy, Radiotherapy, and Surgery",3247
7,NCT02303028,Phase Ib/II,Recruiting,"[{'id': 1469, 'therapyName': 'Topotecan + Pazopanib'}]",Phase I Dose Escalation Study of Topotecan and Pazopanib in Children With Recurrent/Refractory Solid and CNS Tumours,3247
8,NCT02304458,Phase Ib/II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas,3247
9,NCT02372006,Phase I,Recruiting,"[{'id': 623, 'therapyName': 'Afatinib'}]",Phase I Trial of Afatinib in Pediatric Tumours,3247
10,NCT02390752,Phase Ib/II,Recruiting,"[{'id': 874, 'therapyName': 'PLX3397'}]",PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN),3247
11,NCT02446431,Phase I,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1076, 'therapyName': 'Valproic acid'}]",Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence,3247
12,NCT02567435,Phase III,Suspended,"[{'id': 1435, 'therapyName': 'Vincristine + Dactinomycin + Cyclophosphamide'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1074, 'therapyName': 'Irinotecan'}]",Combination Chemotherapy and Irinotecan Hydrochloride or Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma,3247
13,NCT02574728,Phase II,Recruiting,"[{'id': 3143, 'therapyName': 'Celecoxib + Cyclophosphamide + Etoposide + Sirolimus'}]",Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors,3247
14,NCT02644460,Phase I,Recruiting,"[{'id': 802, 'therapyName': 'Abemaciclib'}]",Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors,3247
15,NCT02867592,Phase II,Recruiting,"[{'id': 998, 'therapyName': 'cabozantinib'}]","Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors",3247
16,NCT02982941,Phase I,Recruiting,"[{'id': 2863, 'therapyName': 'MGA271'}]",Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors,3247
17,NCT03139331,Phase I,Recruiting,"[{'id': 5635, 'therapyName': 'Pazopanib + Irinotecan + Temozolomide'}]",PAZIT Study for Children and Young Adults With Relapsed or Refractory Sarcoma,3247
18,NCT03221400,Phase Ib/II,Recruiting,"[{'id': 4842, 'therapyName': 'STA-8666'}]",PEN-866 in Patients With Advanced Solid Malignancies,3247
19,NCT03245151,Phase Ib/II,Not yet recruiting,"[{'id': 1713, 'therapyName': 'Everolimus + Lenvatinib'}]","Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors",3247
0,NCT02098538,Phase II,"Active, not recruiting","[{'id': 890, 'therapyName': 'Regorafenib'}]","Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma",4866
1,NCT02978625,Phase II,Recruiting,"[{'id': 5080, 'therapyName': 'Talimogene laherparepvec + Nivolumab'}]",Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers,4866
2,NCT03087019,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma,4866
3,NCT03146650,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab in Treating Patients With Metastatic Recurrent Major or Minor Salivary Gland Cancer,4866
4,NCT03172624,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer,4866
0,NCT01316757,Phase II,"Active, not recruiting","[{'id': 1921, 'therapyName': 'Cetuximab + Paclitaxel + Carboplatin + Erlotinib'}]","Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer",8850
1,NCT02538510,Phase Ib/II,"Active, not recruiting","[{'id': 3077, 'therapyName': 'Pembrolizumab + Vorinostat'}]",Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer and Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery,8850
2,NCT02576431,Phase II,Recruiting,"[{'id': 2650, 'therapyName': 'LOXO-101'}]",Study of LOXO-101 in Subjects With NTRK Fusion Positive Solid Tumors,8850
3,NCT02628067,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158),8850
4,NCT02636036,Phase I,Recruiting,"[{'id': 3620, 'therapyName': 'Enadenotucirev + Pembrolizumab'}]",Study of Enadenotucirev and Pembrolizumab in Subjects With Metastatic or Advanced Epithelial Tumors,8850
5,NCT02749903,Phase II,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}]",Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers,8850
6,NCT03172624,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer,8850
0,NCT02834013,Phase 0,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab in Treating Patients With Rare Tumors,50904
1,NCT02879162,Phase II,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours,50904
2,NCT03146650,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab in Treating Patients With Metastatic Recurrent Major or Minor Salivary Gland Cancer,50904
0,NCT00356031,Phase II,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Bevacizumab and Radiation Therapy for Sarcomas,1115
1,NCT00902044,Phase I,Recruiting,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2940, 'therapyName': 'HER2 sensitized T-cells'}]",Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma,1115
2,NCT01005797,Phase I,Completed,"[{'id': 1131, 'therapyName': 'Panobinostat + Sorafenib'}]","Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers",1115
3,NCT01010958,Phase I,Terminated,"[{'id': 1076, 'therapyName': 'Valproic acid'}]",Adjuvant Valproate for High Grade Sarcomas,1115
4,NCT01106872,Phase Ib/II,Completed,"[{'id': 1466, 'therapyName': 'Bevacizumab + Gemcitabine + Docetaxel + Valproic Acid '}]","Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas",1115
5,NCT01154452,Phase Ib/II,Completed,"[{'id': 956, 'therapyName': 'Vismodegib'}, {'id': 1096, 'therapyName': 'Vismodegib + RO4929097'}, {'id': 902, 'therapyName': 'RO4929097'}]",Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma,1115
6,NCT01189643,Phase I,"Active, not recruiting","[{'id': 1463, 'therapyName': 'Temozolomide + Irinotecan + Bevacizumab'}]","Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor",1115
7,NCT01294670,Phase Ib/II,"Active, not recruiting","[{'id': 1182, 'therapyName': 'Vorinostat + Etoposide'}]",Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients &lt; 21 Years at Diagnosis With Refractory Solid Tumors,1115
8,NCT01327612,Phase II,"Active, not recruiting","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 746, 'therapyName': 'Ganitumab'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1458, 'therapyName': 'Conatumumab'}]",Open Label Extension Study of Conatumumab and AMG 479,1115
9,NCT01418001,Phase Ib/II,Terminated,"[{'id': 1470, 'therapyName': 'Gemcitabine + Docetaxel + Pazopanib'}]",Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS),1115
10,NCT01438554,Phase I,"Active, not recruiting","[{'id': 1310, 'therapyName': 'Pazopanib + Trametinib'}]","Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma",1115
11,NCT01446809,Phase I,"Active, not recruiting","[{'id': 1472, 'therapyName': 'Doxorubicin + Ifosfamide'}, {'id': 1471, 'therapyName': 'Pazopanib + Doxorubicin + Ifosfamide'}]",Pazopanib Hydrochloride Followed By Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma,1115
12,NCT01468922,Phase I,Completed,"[{'id': 636, 'therapyName': 'Tivantinib'}, {'id': 848, 'therapyName': 'Pazopanib'}]",Pazopanib and ARQ 197 for Advanced Solid Tumors,1115
13,NCT01518413,Phase I,Completed,"[{'id': 1323, 'therapyName': 'Sorafenib + Irinotecan'}]",Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors,1115
14,NCT01532687,Phase II,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1478, 'therapyName': 'Gemcitabine + Pazopanib'}]",Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma,1115
15,NCT01593748,Phase II,"Active, not recruiting","[{'id': 1439, 'therapyName': 'Gemcitabine + Docetaxel'}, {'id': 1478, 'therapyName': 'Gemcitabine + Pazopanib'}]",A Treatment Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma,1115
16,NCT01625351,Phase I,"Active, not recruiting","[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1205, 'therapyName': 'Alemtuzumab'}]",A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas,1115
17,NCT01643278,Phase I,Completed,"[{'id': 1803, 'therapyName': 'Dasatinib + Ipilimumab'}]",Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are Metastatic,1115
18,NCT01695005,Phase I,Recruiting,"[{'id': 2958, 'therapyName': 'LY3039478'}]",A Study of LY3039478 in Participants With Advanced Cancer,1115
19,NCT01719302,Phase Ib/II,Completed,"[{'id': 1470, 'therapyName': 'Gemcitabine + Docetaxel + Pazopanib'}]","Docetaxel, Gemcitabine and Pazopanib as Treatment for Soft Tissue Sarcoma",1115
20,NCT01719744,,Completed,"[{'id': 727, 'therapyName': 'ENMD-2076'}]", Study of ENMD-2076 in Patients With Advanced/Metastatic Soft Tissue Sarcoma,1115
21,NCT01746238,Phase I,"Active, not recruiting","[{'id': 1473, 'therapyName': 'Doxorubicin + Bevacizumab'}]",Bevacizumab/Doxorubicin/Radiation for Sarcoma,1115
22,NCT01755195,Phase II,Recruiting,"[{'id': 998, 'therapyName': 'cabozantinib'}]",Cabozantinib for Adults With Advanced Soft Tissue Sarcoma,1115
23,NCT01879085,Phase Ib/II,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1077, 'therapyName': 'Vorinostat'}]",Phase 1b/2 Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma,1115
24,NCT01946529,Phase II,"Active, not recruiting","[{'id': 1433, 'therapyName': 'Vincristine + Doxorubicin + Cyclophosphamide + Ifosfamide + Etoposide'}, {'id': 1434, 'therapyName': 'Vincristine + Doxorubicin + Cyclophosphamide + Ifosfamide + Etoposide + others'}]",Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors,1115
25,NCT01975519,Phase I,"Active, not recruiting","[{'id': 1431, 'therapyName': 'TRC105 + Pazopanib'}]",A Phase 1B Dose-escalation Study of TRC105 in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma,1115
26,NCT02008877,Phase Ib/II,"Active, not recruiting","[{'id': 2271, 'therapyName': 'Ganetespib + Sirolimus'}]",A Trial of Ganetespib Plus Sirolimus: Phase 1 Includes Multiple Sarcoma Subtypes and Phase 2 MPNST,1115
27,NCT02014337,Phase I,"Active, not recruiting","[{'id': 3053, 'therapyName': 'Eribulin + Mifepristone'}]",Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors,1115
28,NCT02049905,Phase III,Completed,"[{'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1440, 'therapyName': 'Aldoxorubicin'}, {'id': 1439, 'therapyName': 'Gemcitabine + Docetaxel'}]",Phase 3 Study to Treat Patients With Soft Tissue Sarcomas,1115
29,NCT02050919,Phase II,Recruiting,"[{'id': 2365, 'therapyName': 'Epirubicin + Ifosfamide + Sorafenib'}]","Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma",1115
30,NCT02066181,Phase III,"Active, not recruiting","[{'id': 920, 'therapyName': 'Sorafenib'}]",Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis,1115
31,NCT02122861,Phase I,"Active, not recruiting","[{'id': 3271, 'therapyName': 'ID-LV305'}]","A Phase 1 Safety Study of Intradermal ID-LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1",1115
32,NCT02130869,Phase I,Recruiting,"[{'id': 2378, 'therapyName': 'Bendamustine + Cytarabine + Etoposide'}, {'id': 2460, 'therapyName': 'Busulfan + Hu14.18K322A'}, {'id': 2459, 'therapyName': 'Aldesleukin + Melphalan + Sargramostim'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}]",A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas,1115
33,NCT02173093,Phase Ib/II,Recruiting,"[{'id': 2058, 'therapyName': 'Aldesleukin + GD2Bi-a ATC + Sargramostim '}]",Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma,1115
34,NCT02180698,Phase I,Recruiting,"[{'id': 3576, 'therapyName': 'GLA-SE'}]",TLR4 Agonist GLA-SE and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma That Is Metastatic or Cannot Be Removed by Surgery,1115
35,NCT02180867,Phase II,Recruiting,"[{'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1472, 'therapyName': 'Doxorubicin + Ifosfamide'}]",Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can be Removed by Surgery (PAZNTIS),1115
36,NCT02192541,Phase I,Completed,"[{'id': 1665, 'therapyName': 'Ganetespib + Aflibercept'}]","Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas",1115
37,NCT02267083,Phase II,Completed,"[{'id': 2041, 'therapyName': 'GPX-150'}]",Efficacy and Safety Study of GPX-150 to Treat Soft Tissue Sarcoma,1115
38,NCT02300545,Phase II,Recruiting,"[{'id': 848, 'therapyName': 'Pazopanib'}]",Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy,1115
39,NCT02319824,Phase I,Completed,[],NY-ESO-1-Specific T-cells in Treating Patients With Advanced NY-ESO-1-Expressing Sarcomas Receiving Palliative Radiation Therapy,1115
40,NCT02323191,Phase I,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 2004, 'therapyName': 'LY3022855'}]",A Study of RO5509554 and MPDL3280A Administered in Combination in Patients With Advanced Solid Tumors,1115
41,NCT02331251,Phase Ib/II,"Active, not recruiting","[{'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 619, 'therapyName': 'Abraxane'}]",Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus),1115
42,NCT02349958,Phase II,Recruiting,"[{'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy,1115
43,NCT02357810,Phase II,Recruiting,"[{'id': 1469, 'therapyName': 'Topotecan + Pazopanib'}]",Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas,1115
44,NCT02387125,Phase I,Recruiting,"[{'id': 4318, 'therapyName': 'CMB305'}]","A Phase 1b Safety Study of CMB305 (Sequentially Administered LV305 and G305) in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1",1115
45,NCT02390752,Phase Ib/II,Recruiting,"[{'id': 874, 'therapyName': 'PLX3397'}]",PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN),1115
46,NCT02423863,Phase II,Recruiting,"[{'id': 2595, 'therapyName': 'poly ICLC  '}]","In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol",1115
47,NCT02432963,Phase I,Recruiting,"[{'id': 1038, 'therapyName': 'MVAp53'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy,1115
48,NCT02446431,Phase I,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1076, 'therapyName': 'Valproic acid'}]",Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence,1115
49,NCT02451943,Phase III,"Active, not recruiting","[{'id': 3269, 'therapyName': 'Olaratumab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma,1115
50,NCT02498665,Phase I,Recruiting,"[{'id': 4320, 'therapyName': 'DSP-7888'}]",A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies,1115
51,NCT02500797,Phase II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic or Unresectable Sarcoma,1115
52,NCT02508038,Phase I,Recruiting,"[{'id': 2971, 'therapyName': 'Zoledronic acid'}, {'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}]", Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa,1115
53,NCT02528357,Phase I,Recruiting,"[{'id': 5177, 'therapyName': 'GSK3174998'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",GSK3174998 Alone or With Pembrolizumab in Subjects With Advanced Solid Tumors,1115
54,NCT02558140,Phase I,Recruiting,"[{'id': 4330, 'therapyName': 'RO6874813'}]",A Dose Escalation Study of RO6874813 in Participants With Locally Advanced or Metastatic Solid Tumors,1115
55,NCT02574728,Phase II,Recruiting,"[{'id': 3143, 'therapyName': 'Celecoxib + Cyclophosphamide + Etoposide + Sirolimus'}]",Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors,1115
56,NCT02576431,Phase II,Recruiting,"[{'id': 2650, 'therapyName': 'LOXO-101'}]",Study of LOXO-101 in Subjects With NTRK Fusion Positive Solid Tumors,1115
57,NCT02584309,Phase II,Recruiting,"[{'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 4140, 'therapyName': 'Doxorubicin + Olaratumab'}]",Doxorubicin With Upfront Dexrazoxane Plus Olaratumab for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma,1115
58,NCT02584647,Phase Ib/II,Recruiting,"[{'id': 3155, 'therapyName': 'PLX3397 + Sirolimus'}]",Combination of PLX3397 and Sirolimus in Unresectable Sarcoma (Phase 1) and Malignant Peripheral Nerve Sheath Tumors (Phase 2),1115
59,NCT02601209,Phase Ib/II,Suspended,"[{'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1282, 'therapyName': 'Sapanisertib'}]",Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma,1115
60,NCT02636725,Phase II,Recruiting,"[{'id': 2494, 'therapyName': 'Axitinib + Pembrolizumab'}]",Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma and Other Soft Tissue Sarcomas,1115
61,NCT02639546,Phase I,Recruiting,"[{'id': 1004, 'therapyName': 'Cobimetinib'}]",iMATRIXcobi: Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Patients With Previously Treated Solid Tumors,1115
62,NCT02640508,Phase II,Recruiting,"[{'id': 3352, 'therapyName': 'Eribulin + Lenvatinib'}]",Eribulin and Lenvatinib in Advanced Solid Tumors,1115
63,NCT02643303,Phase Ib/II,Recruiting,"[{'id': 3385, 'therapyName': 'MEDI4736 + poly ICLC '}, {'id': 1652, 'therapyName': 'Tremelimumab'}]","A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers",1115
64,NCT02646319,Phase II,"Active, not recruiting","[{'id': 3380, 'therapyName': 'Nab-Rapamycin'}]",Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations,1115
65,NCT02659020,Phase Ib/II,Recruiting,"[{'id': 3269, 'therapyName': 'Olaratumab'}, {'id': 1439, 'therapyName': 'Gemcitabine + Docetaxel'}]",A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma,1115
66,NCT02783599,Phase I,Recruiting,"[{'id': 4140, 'therapyName': 'Doxorubicin + Olaratumab'}]",A Study of Olaratumab (LY3012207) in Participants With Soft Tissue Sarcoma,1115
67,NCT02784795,Phase I,Recruiting,"[{'id': 4374, 'therapyName': 'Cisplatin + Gemcitabine + LY3039478'}, {'id': 4375, 'therapyName': 'Carboplatin + Gemcitabine + LY3039478'}, {'id': 4372, 'therapyName': 'LY3039478 + LY3023414'}, {'id': 4373, 'therapyName': 'Abemaciclib + LY3039478'}, {'id': 4371, 'therapyName': 'LY3039478 + Taladegib'}, {'id': 2958, 'therapyName': 'LY3039478'}, {'id': 1069, 'therapyName': 'LY3023414'}]",A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors,1115
68,NCT02795819,Phase I,Suspended,"[{'id': 4267, 'therapyName': 'AR-42 + Pazopanib'}]",Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer,1115
69,NCT02815995,Phase II,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes,1115
70,NCT02839694,Phase I,Withdrawn,"[{'id': 3567, 'therapyName': 'Decitabine + Tetrahydrouridine'}, {'id': 4592, 'therapyName': 'Decitabine + Tetrahydrouridine + Celecoxib'}]",Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in People Undergoing Pulmonary Metastasectomy,1115
71,NCT02867592,Phase II,Recruiting,"[{'id': 998, 'therapyName': 'cabozantinib'}]","Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors",1115
72,NCT02879162,Phase II,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours,1115
73,NCT02888665,Phase Ib/II,Recruiting,"[{'id': 4690, 'therapyName': 'Doxorubicin + Pembrolizumab'}]",Pembrolizumab and Doxorubicin Hydrochloride in Treating Patients With Sarcoma That is Metastatic or Cannot Be Removed by Surgery,1115
74,NCT02987959,Phase II,Recruiting,"[{'id': 1282, 'therapyName': 'Sapanisertib'}]",Study of TAK-228 (MLN0128) in Soft Tissue Sarcomas,1115
75,NCT03009201,Phase I,Recruiting,"[{'id': 5179, 'therapyName': 'Doxorubicin + Ribociclib'}]",Ribociclib and Doxorubicin Hydrochloride in Treating Patients Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery,1115
76,NCT03042819,Phase I,Recruiting,"[{'id': 5286, 'therapyName': 'Selinexor + Doxorubicin'}]",Study of Selinexor and Doxorubicin in Advanced Soft Tissue Sarcomas,1115
77,NCT03056001,Phase II,Recruiting,"[{'id': 4690, 'therapyName': 'Doxorubicin + Pembrolizumab'}]","Safety, Tolerability, and Efficacy of Doxorubicin and Pembrolizumab for Sarcoma",1115
78,NCT03056599,,Recruiting,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1299, 'therapyName': 'Interferon alfa-2b '}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1733, 'therapyName': 'interferon gamma '}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 3420, 'therapyName': 'trabectedin'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO™ Device in Soft Tissue Sarcoma,1115
79,NCT03069378,Phase II,Recruiting,"[{'id': 4035, 'therapyName': 'Pembrolizumab + talimogene laherparepvec '}]",A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma,1115
80,NCT03076372,Phase I,Recruiting,"[{'id': 5758, 'therapyName': 'MM-310'}]",A Study Evaluating MM-310 in Patients With Solid Tumors,1115
81,NCT03092323,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity (SU2C-SARC032),1115
82,NCT03126591,Phase I,Recruiting,"[{'id': 5715, 'therapyName': 'Olaratumab + Pembrolizumab'}]",A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue Sarcoma,1115
83,NCT03138161,Phase Ib/II,Recruiting,"[{'id': 5800, 'therapyName': 'trabectedin + Ipilimumab + Nivolumab'}]","Trabectedin, Ipilimumab and Nivolumab as First Line Treatment for Advanced Soft Tissue Sarcoma",1115
84,NCT03139331,Phase I,Recruiting,"[{'id': 5635, 'therapyName': 'Pazopanib + Irinotecan + Temozolomide'}]",PAZIT Study for Children and Young Adults With Relapsed or Refractory Sarcoma,1115
85,NCT03149120,Phase II,Withdrawn,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 5681, 'therapyName': 'Nivolumab + Pazopanib'}]",Study of Nivolumab With or Without Pazopanib in Metastatic or Unresectable Soft Tissue Sarcomas,1115
86,NCT03217266,Phase I,Not yet recruiting,"[{'id': 1452, 'therapyName': 'AMG 232'}]",MDM2 Inhibitor AMG-232 and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma,1115
87,NCT03283696,Phase I,Recruiting,"[{'id': 6292, 'therapyName': 'Doxorubicin + Ifosfamide + Mesna + Olaratumab'}]","A Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma",1115
0,NCT02837042,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Trial of Pembrolizumab for Advanced Penile Squamous Cell Carcinoma,7958
1,NCT03074513,Phase II,Recruiting,"[{'id': 4595, 'therapyName': 'Atezolizumab + Bevacizumab'}]",Atezolizumab and Bevacizumab in Rare Solid Tumors,7958
0,NCT03024996,Phase III,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy (IMmotion010),4473
0,NCT02834013,Phase 0,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab in Treating Patients With Rare Tumors,13159
0,NCT02978625,Phase II,Recruiting,"[{'id': 5080, 'therapyName': 'Talimogene laherparepvec + Nivolumab'}]",Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers,4840
0,NCT02834013,Phase 0,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab in Treating Patients With Rare Tumors,14545
0,NCT02834013,Phase 0,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab in Treating Patients With Rare Tumors,4440
0,NCT02834013,Phase 0,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab in Treating Patients With Rare Tumors,3114
0,NCT01042522,Phase II,Recruiting,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1137, 'therapyName': 'Bleomycin'}]","Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors",192
0,NCT02834013,Phase 0,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab in Treating Patients With Rare Tumors,4757
0,NCT02542124,Phase II,Recruiting,"[{'id': 5262, 'therapyName': 'Interleukin-12'}]",NM-IL-12 in Cutaneous T-Cell Lymphoma (CTCL) Undergoing Total Skin Electron Beam Therapy (TSEBT),8541
1,NCT02581631,Phase Ib/II,Recruiting,"[{'id': 3263, 'therapyName': 'Brentuximab vedotin + Nivolumab'}]",A Safety and Efficacy Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas (CheckMate 436),8541
2,NCT02978625,Phase II,Recruiting,"[{'id': 5080, 'therapyName': 'Talimogene laherparepvec + Nivolumab'}]",Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers,8541
3,NCT03011814,Phase Ib/II,"Active, not recruiting","[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 3934, 'therapyName': 'lenalidomide + MEDI4736'}]",Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma,8541
4,NCT03063632,Phase II,Recruiting,"[{'id': 5367, 'therapyName': 'Pembrolizumab + interferon gamma'}]",Pembrolizumab and Interferon Gamma-1b in Treating Patients With Stage IB-IVB Relapsed or Refractory Mycosis Fungoides and Sezary Syndrome,8541
0,NCT02978625,Phase II,Recruiting,"[{'id': 5080, 'therapyName': 'Talimogene laherparepvec + Nivolumab'}]",Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers,4304
0,NCT02780011,Phase I,Not yet recruiting,"[{'id': 4301, 'therapyName': 'Alisertib + Brentuximab vedotin'}]",Alsertib (MLN8237) and Brentuximab Vedotin for Relapsed/Refractory CD30-Positive Lymphomas and Solid Malignancies,4517
0,NCT02423863,Phase II,Recruiting,"[{'id': 2595, 'therapyName': 'poly ICLC  '}]","In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol",4159
1,NCT02834013,Phase 0,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab in Treating Patients With Rare Tumors,4159
0,NCT01107665,Phase II,"Active, not recruiting","[{'id': 1143, 'therapyName': 'Pazopanib + Paclitaxel'}]",Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma,8923
1,NCT01693068,Phase II,Completed,"[{'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 871, 'therapyName': 'Pimasertib'}]",Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma,8923
2,NCT02203604,Phase II,"Active, not recruiting","[{'id': 1612, 'therapyName': 'Aldesleukin + Ipilimumab'}]",High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery,8923
3,NCT02346955,Phase I,Terminated,"[{'id': 4246, 'therapyName': 'CM-24'}, {'id': 4247, 'therapyName': 'CM-24 + Pembrolizumab'}]",Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001),8923
4,NCT02535078,Phase Ib/II,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 3847, 'therapyName': 'IMCgp100'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]",Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Cutaneous Melanoma,8923
5,NCT02581930,Phase II,Recruiting,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",Ibrutinib in Treating Patients With Refractory Stage IV Cutaneous Melanoma,8923
6,NCT02680184,Phase I,Recruiting,"[{'id': 4001, 'therapyName': 'Pembrolizumab + QbG10'}]",Clinical Study of CMP-001 in Combination With Pembrolizumab,8923
7,NCT02731729,Phase II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy,8923
8,NCT02748564,Phase II,Recruiting,"[{'id': 4165, 'therapyName': 'Aldesleukin + Pembrolizumab'}]",Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma,8923
9,NCT02818023,Phase I,Recruiting,"[{'id': 4406, 'therapyName': 'Pembrolizumab + Vemurafenib'}]",Dose-seeking and Efficacy Study of Pembrolizumab Plus Vemurafenib Advanced Melanoma,8923
10,NCT03084640,Phase Ib/II,Recruiting,"[{'id': 4001, 'therapyName': 'Pembrolizumab + QbG10'}]",Phase 1b Study Evaluating Alternative Routes of Administration of CMP-001 in Combination With Pembrolizumab in Subjects With Advanced Melanoma,8923
11,NCT03089606,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab TX-naive Distant Mets Melanoma and Use of AMT (PET) at Baseline as Imaging Biomarker,8923
0,NCT02324608,Phase I,Recruiting,"[{'id': 694, 'therapyName': 'Cetuximab'}]",Cetuximab Before Surgery in Treating Patients With Aggressive Locally Advanced Skin Cancer,3151
1,NCT02449681,Phase II,Terminated,"[{'id': 2910, 'therapyName': 'TH-4000'}]",Study for Treatment of Patients With Recurrent or Metastatic SCCHN or SCCS,3151
2,NCT02721732,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors,3151
3,NCT02760498,Phase II,Recruiting,"[{'id': 5656, 'therapyName': 'REGN2810'}]",Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma,3151
4,NCT02964559,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Patients With Locally Advanced or Metastatic Skin Cancer,3151
5,NCT02978625,Phase II,Recruiting,"[{'id': 5080, 'therapyName': 'Talimogene laherparepvec + Nivolumab'}]",Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers,3151
6,NCT03108131,Phase II,Recruiting,"[{'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}]",Cobimetinib and Atezolizumab in Advanced Rare Tumors,3151
7,NCT03289962,Phase I,Not yet recruiting,"[{'id': 6234, 'therapyName': 'RO7198457'}, {'id': 6235, 'therapyName': 'Atezolizumab + RO7198457'}]",A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors,3151
0,NCT01642251,Phase Ib/II,"Active, not recruiting","[{'id': 2585, 'therapyName': 'Cisplatin + Etoposide'}, {'id': 954, 'therapyName': 'Veliparib'}]",Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer or Metastatic Large Cell Neuroendocrine Non-small Cell Lung Cancer,50685
0,NCT02899728,Phase II,Suspended,"[{'id': 4728, 'therapyName': 'Carboplatin + Cisplatin + Etoposide'}, {'id': 1971, 'therapyName': 'Cediranib + Olaparib'}]","Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer",50875
0,NCT01202409,Phase II,"Active, not recruiting","[{'id': 845, 'therapyName': 'Panitumumab'}]",CAPOX in KRAS Wild-Type Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater,4906
1,NCT01208103,Phase II,"Active, not recruiting","[{'id': 1601, 'therapyName': 'Capecitabine + Oxaliplatin + Bevacizumab'}]",Bevacizumab With Capecitabine and Oxaliplatin in Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater,4906
2,NCT02034110,Phase II,Recruiting,"[{'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}]",Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers,4906
3,NCT02834013,Phase 0,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab in Treating Patients With Rare Tumors,4906
4,NCT03000179,Phase II,Recruiting,"[{'id': 3144, 'therapyName': 'Avelumab'}]",Safety and Efficacy of Avelumab in Small Intestinal Adenocarcinoma,4906
5,NCT03095781,Phase I,Recruiting,"[{'id': 5533, 'therapyName': 'Pembrolizumab + XL888'}]",Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer,4906
6,NCT03108131,Phase II,Recruiting,"[{'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}]",Cobimetinib and Atezolizumab in Advanced Rare Tumors,4906
0,NCT02831179,Phase I,Withdrawn,"[{'id': 4463, 'therapyName': 'Capecitabine + Veliparib + Temozolomide'}]","Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor",50925
0,NCT02638909,Phase II,Recruiting,"[{'id': 789, 'therapyName': 'Ceritinib'}]",Study of Oral Ceritinib in Patients With ALK-Activated Gastrointestinal Malignancies,4907
0,NCT02279394,Phase II,"Active, not recruiting","[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 3430, 'therapyName': 'Elotuzumab + lenalidomide'}]",Trial of Combination of Elotuzumab and Lenalidomide +/- Dexamethasone in High-Risk Smoldering Multiple Myeloma,9551
1,NCT02886065,Phase I,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 5082, 'therapyName': 'PVX-410 + MEDI4736'}, {'id': 5081, 'therapyName': 'PVX-410 + MEDI4736 + lenalidomide'}]","A Phase 1b Study of PVX-410, a Multi-Peptide Cancer Vaccine, and Durvalumab (Anti-PDL1) With and Without Lenalidomide for Patients With Smoldering Multiple Myeloma",9551
2,NCT02903381,Phase II,Recruiting,"[{'id': 5128, 'therapyName': 'Nivolumab + Lenalidomide + Dexamethasone'}]",Nivolumab + Lenalidomide + Dexamethasone In SMM,9551
0,NCT02831179,Phase I,Withdrawn,"[{'id': 4463, 'therapyName': 'Capecitabine + Veliparib + Temozolomide'}]","Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor",4430
0,NCT01295944,Phase II,Recruiting,"[{'id': 2074, 'therapyName': 'Bevacizumab + Carboplatin'}]",Carboplatin and Bevacizumab for Recurrent Ependymoma,5503
1,NCT02458339,Phase I,Recruiting,"[{'id': 1639, 'therapyName': 'Methotrexate'}]",Methotrexate Infusion Into Fourth Ventricle in Children With Recurrent Malignant Fourth Ventricular Brain Tumors,5503
0,NCT01661400,Phase I,Recruiting,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1475, 'therapyName': 'Thalidomide'}]",Anti-Angiogenic Therapy Post Transplant (ASCR) for Relapsed and Refractory Pediatric Solid Tumors,3185
1,NCT01837862,Phase Ib/II,Recruiting,"[{'id': 2134, 'therapyName': 'Mebendazole + Vincristine + Carboplatin + Temozolomide'}, {'id': 2133, 'therapyName': 'Mebendazole + Bevacizumab + Irinotecan'}]",A Phase I/II Study of Mebendazole for the Treatment of Pediatric Gliomas,3185
0,NCT02834013,Phase 0,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab in Treating Patients With Rare Tumors,4015
0,NCT03092323,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity (SU2C-SARC032),4235
0,NCT02723955,Phase I,Recruiting,"[{'id': 4409, 'therapyName': 'GSK3359609'}, {'id': 4410, 'therapyName': 'GSK3359609 + Pembrolizumab'}]",Dose Escalation and Expansion Study of GSK3359609 in Subjects With Selected Advanced Solid Tumors (INDUCE-1),1749
0,NCT01325441,Phase Ib/II,Recruiting,"[{'id': 2586, 'therapyName': 'BBI608 + Paclitaxel'}]",A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies,10534
1,NCT01468922,Phase I,Completed,"[{'id': 636, 'therapyName': 'Tivantinib'}, {'id': 848, 'therapyName': 'Pazopanib'}]",Pazopanib and ARQ 197 for Advanced Solid Tumors,10534
2,NCT01522768,Phase II,Recruiting,"[{'id': 1106, 'therapyName': 'Afatinib + Trastuzumab'}]", Afatinib (BIBW 2992) and Trastuzumab in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer,10534
3,NCT01576666,Phase Ib/II,Completed,"[{'id': 1547, 'therapyName': 'BKM120 + Sonidegib'}]","Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors",10534
4,NCT01602406,Phase I,Completed,"[{'id': 2037, 'therapyName': 'LJM716 + Trastuzumab'}]",Phase I Study LJM716 Combined With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast or Gastric Cancer,10534
5,NCT01641939,Phase III,Terminated,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1402, 'therapyName': 'trastuzumab emtansine'}]",A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer,10534
6,NCT01702558,Phase II,Completed,"[{'id': 1402, 'therapyName': 'trastuzumab emtansine'}, {'id': 1976, 'therapyName': 'trastuzumab emtansine + Capecitabine'}]",A Combination Study of Kadcyla (Trastuzumab Emtansine) and Capecitabine in Patients With HER2-Positive Metastatic Breast Cancer and Patients With HER2-Positive Locally Advanced / Metastatic Gastric Cancer,10534
7,NCT01928290,Phase II,Recruiting,"[{'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1903, 'therapyName': 'FOLFIRINOX'}]","Combination Chemotherapy in Treating Patients With Advanced Stomach, Gastroesophageal, or Esophageal Cancer",10534
8,NCT01928394,Phase Ib/II,"Active, not recruiting","[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]","A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab in Subjects With Advanced or Metastatic Solid Tumors",10534
9,NCT01938638,Phase I,Completed,"[{'id': 4027, 'therapyName': 'BAY1143572'}]",Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer,10534
10,NCT01968109,Phase I,Recruiting,"[{'id': 4197, 'therapyName': 'BMS-986016 + Nivolumab'}, {'id': 4196, 'therapyName': 'BMS-986016'}]",Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors,10534
11,NCT02014909,Phase I,Completed,"[{'id': 2054, 'therapyName': 'CDX-3379'}, {'id': 2063, 'therapyName': 'CDX-3379 + Vemurafenib'}, {'id': 2064, 'therapyName': 'CDX-3379 + Trastuzumab'}, {'id': 2061, 'therapyName': 'Cetuximab + CDX-3379'}, {'id': 2062, 'therapyName': 'CDX-3379 + Erlotinib'}]",A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors,10534
12,NCT02047747,Phase II,Terminated,"[{'id': 714, 'therapyName': 'Dacomitinib'}]",A Phase II Study of Dacomitinib in Progressive Brain Metastases,10534
13,NCT02122809,Phase I,Completed,"[{'id': 1998, 'therapyName': 'Chiauranib'}]",Phase I Study of Chiauranib in Patients With Advanced Solid Tumors,10534
14,NCT02314117,Phase III,"Active, not recruiting","[{'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 886, 'therapyName': 'Ramucirumab'}]",A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer,10534
15,NCT02315066,Phase I,Recruiting,"[{'id': 4333, 'therapyName': 'PF-04518600'}, {'id': 4448, 'therapyName': 'PF-04518600 + Utomilumab'}]",Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566,10534
16,NCT02318901,Phase Ib/II,"Active, not recruiting","[{'id': 1909, 'therapyName': 'Pembrolizumab + trastuzumab emtansine'}, {'id': 1908, 'therapyName': 'Pembrolizumab + Trastuzumab'}, {'id': 1910, 'therapyName': 'Pembrolizumab + Cetuximab'}]",Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer,10534
17,NCT02323191,Phase I,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 2004, 'therapyName': 'LY3022855'}]",A Study of RO5509554 and MPDL3280A Administered in Combination in Patients With Advanced Solid Tumors,10534
18,NCT02341625,Phase Ib/II,"Active, not recruiting","[{'id': 4923, 'therapyName': 'BMS-986148'}, {'id': 4924, 'therapyName': 'BMS-986148 + Nivolumab'}]",A Study of BMS-986148 in Patients With Select Advanced Solid Tumors,10534
19,NCT02346955,Phase I,Terminated,"[{'id': 4246, 'therapyName': 'CM-24'}, {'id': 4247, 'therapyName': 'CM-24 + Pembrolizumab'}]",Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001),10534
20,NCT02393248,Phase Ib/II,Recruiting,"[{'id': 4176, 'therapyName': 'Cisplatin + Gemcitabine + INCB054828'}, {'id': 4174, 'therapyName': 'Docetaxel + INCB054828'}, {'id': 4088, 'therapyName': 'Epacadostat + Pembrolizumab'}]","Open-Label, Dose-Escalation Study of INCB054828 in Subjects With Advanced Malignancies",10534
21,NCT02404441,Phase Ib/II,Recruiting,"[{'id': 2659, 'therapyName': 'PDR001'}]",Phase I/II Study of PDR001 in Patients With Advanced Malignancies,10534
22,NCT02443883,Phase II,"Active, not recruiting","[{'id': 886, 'therapyName': 'Ramucirumab'}]",A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer,10534
23,NCT02452424,Phase Ib/II,"Active, not recruiting","[{'id': 2736, 'therapyName': 'Pembrolizumab + PLX3397'}]",A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors,10534
24,NCT02460224,Phase Ib/II,Recruiting,"[{'id': 2887, 'therapyName': 'LAG525'}, {'id': 2659, 'therapyName': 'PDR001'}]",Safety and Efficay of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies,10534
25,NCT02471846,Phase I,"Active, not recruiting","[{'id': 2888, 'therapyName': 'GDC-0919'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study of GDC-0919 and MPDL3280A Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors,10534
26,NCT02500199,Phase I,Recruiting,"[{'id': 3082, 'therapyName': 'Pyrotinib'}]",Open Label Oral Use of Pyrotinib in Patients With HER2 Positive Solid Tumors Who Failed Prior HER2 Targeted Therapy,10534
27,NCT02559492,Phase I,"Active, not recruiting","[{'id': 3096, 'therapyName': 'INCB039110 + INCB024360'}, {'id': 3097, 'therapyName': 'INCB039110 + INCB050465'}]",INCB039110 Combined With INCB024360 and/or INCB039110 Combined With INCB050465 in Advanced Solid Tumors,10534
28,NCT02575781,Phase I,Recruiting,"[{'id': 4026, 'therapyName': 'SAR428926'}]",A Study of SAR428926 in Patients With Advanced Solid Tumors,10534
29,NCT02631733,Phase I,Recruiting,"[{'id': 3314, 'therapyName': 'Irinotecan + Veliparib'}]",Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery,10534
30,NCT02646748,Phase I,Recruiting,"[{'id': 3088, 'therapyName': 'INCB050465 '}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2406, 'therapyName': 'INCB039110'}]",Pembrolizumab Combined With INCB039110 and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors,10534
31,NCT02658214,Phase I,Recruiting,"[{'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}, {'id': 2634, 'therapyName': 'Carboplatin + nab-paclitaxel'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}]",Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors,10534
32,NCT02734004,Phase Ib/II,"Active, not recruiting","[{'id': 2894, 'therapyName': 'Durvalumab + Olaparib'}]",A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. (MEDIOLA),10534
33,NCT02760797,Phase I,Recruiting,"[{'id': 4181, 'therapyName': 'Emactuzumab + RO7009789'}]",A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors,10534
34,NCT02872116,Phase III,Recruiting,"[{'id': 1597, 'therapyName': 'Capecitabine + Oxaliplatin'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Efficacy Study of Nivolumab Plus Ipilimumab Against Chemotherapy Standard of Care in Stomach Cancer or Stomach/Esophagus Junction Cancer (CheckMate649),10534
35,NCT02880371,Phase Ib/II,Recruiting,"[{'id': 4608, 'therapyName': 'ARRY-382 + Pembrolizumab'}]",A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors,10534
36,NCT02935634,Phase II,Recruiting,"[{'id': 4197, 'therapyName': 'BMS-986016 + Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Study to Test Combination Treatments in Patients With Advanced Gastric Cancer (FRACTION-GC),10534
37,NCT02952248,Phase I,Recruiting,"[{'id': 5692, 'therapyName': 'BI 754091'}]",A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours,10534
38,NCT02952729,Phase I,Recruiting,"[{'id': 5834, 'therapyName': 'XMT-1522'}]",Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2,10534
39,NCT02960594,Phase I,Recruiting,"[{'id': 5844, 'therapyName': 'INO-1400 + INO-9012'}, {'id': 5807, 'therapyName': 'INO-1400'}]",hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse,10534
40,NCT02963831,Phase Ib/II,Recruiting,"[{'id': 4978, 'therapyName': 'ONCOS-102 + MEDI4736'}]","A Phase 1/2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies",10534
41,NCT02965885,Phase I,Recruiting,"[{'id': 2768, 'therapyName': 'TAS-116'}]",A Study of TAS-116 in Patients With Solid Tumors,10534
42,NCT02970539,Phase I,Recruiting,"[{'id': 5032, 'therapyName': 'Oraxol + Ramucirumab'}]","Ph1b Study of Oraxol in Comb. w. Ramucirumab in Patients w. Gastric, Gastro-esophageal, or Esophageal Cancers",10534
43,NCT03126110,Phase Ib/II,Recruiting,"[{'id': 5599, 'therapyName': 'INCAGN01876 + Nivolumab + Ipilimumab'}, {'id': 5598, 'therapyName': 'INCAGN01876 + Nivolumab'}, {'id': 5597, 'therapyName': 'INCAGN01876 + Ipilimumab'}]","Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies",10534
0,NCT01174121,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 1167, 'therapyName': 'Aldesleukin'}]",Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer,5517
1,NCT01183559,Phase I,Unknown status,"[{'id': 2071, 'therapyName': 'Carboplatin + Fluorouracil + Paclitaxel + Vandetanib'}]","A Trial of ZD6474 (Zactima), Paclitaxel, Carboplatin, 5-Fluorouracil, and XRT Followed by Surgery",5517
2,NCT02065765,Phase II,No longer available,"[{'id': 886, 'therapyName': 'Ramucirumab'}]",International Expanded Access Program to Provide Ramucirumab for the Treatment of Metastatic Gastric Cancer,5517
3,NCT02274012,Phase II,Withdrawn,"[{'id': 2441, 'therapyName': 'Afatinib + Paclitaxel'}]","Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line Treatment of HER2 Amplified Advanced Gastric, Gastroesophageal Junction and Esophageal Cancer",5517
4,NCT02344810,Phase Ib/II,Withdrawn,"[{'id': 1064, 'therapyName': 'AMG 337'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]","C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer",5517
5,NCT02488759,Phase Ib/II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",A Study to Investigate the Safety and Efficacy of Nivolumab in Virus-associated Tumors (CheckMate358),5517
6,NCT02665416,Phase I,Recruiting,"[{'id': 3468, 'therapyName': 'RO5520985 + RO7009789'}]","Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of RO7009789 With Vanucizumab in Metastatic Solid Tumors",5517
7,NCT02830594,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer",5517
8,NCT02892123,Phase I,Recruiting,"[{'id': 6240, 'therapyName': 'ZW25'}]",Trial of ZW25 in Patients With Advanced HER2-expressing Cancers,5517
9,NCT03008278,Phase Ib/II,Not yet recruiting,"[{'id': 5165, 'therapyName': 'Olaparib + Ramucirumab'}]",Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery,5517
10,NCT03076372,Phase I,Recruiting,"[{'id': 5758, 'therapyName': 'MM-310'}]",A Study Evaluating MM-310 in Patients With Solid Tumors,5517
11,NCT03175224,Phase I,Recruiting,"[{'id': 5963, 'therapyName': 'CBT-101'}]",CBT-101 Study for Advanced Solid Tumors and c-Met Dysregulation,5517
12,NCT03288350,Phase II,Not yet recruiting,"[{'id': 1930, 'therapyName': 'Cisplatin + Docetaxel + Fluorouracil'}, {'id': 3144, 'therapyName': 'Avelumab'}]",mDCF + Avelumab in Resectable Esophago-gastric Adenocarcinoma (EGA),5517
0,NCT01305499,Phase II,Recruiting,"[{'id': 2645, 'therapyName': 'Azacitidine + Entinostat'}]",A Trial to Evaluate Two Schedules of MS275 in Combination With 5AC in Elderly Patients With Acute Myeloid Leukemia (AML),8747
0,NCT02780310,Phase II,"Active, not recruiting","[{'id': 792, 'therapyName': 'Lenvatinib'}]",Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma,50930
1,NCT03087019,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma,50930
2,NCT03172624,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer,50930
0,NCT01489813,Phase II,Recruiting,"[{'id': 757, 'therapyName': 'Genistein'}]",Study of Genistein in Reducing Side Effects of Superficial Bladder Cancer Treatment,7371
0,NCT00602667,Phase I,"Active, not recruiting","[{'id': 2449, 'therapyName': 'Methotrexate + Cisplatin + Cyclophosphamide + Vincristine'}, {'id': 2450, 'therapyName': 'Cyclophosphamide + Etoposide + Topotecan'}, {'id': 2451, 'therapyName': 'Erlotinib + Cyclophosphamide + Topotecan'}]","Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma",4791
1,NCT02095132,Phase Ib/II,Recruiting,"[{'id': 1361, 'therapyName': 'MK-1775 + Irinotecan'}]",WEE1 Inhibitor MK-1775 and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors,4791
0,NCT02978625,Phase II,Recruiting,"[{'id': 5080, 'therapyName': 'Talimogene laherparepvec + Nivolumab'}]",Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers,2095
0,NCT02978625,Phase II,Recruiting,"[{'id': 5080, 'therapyName': 'Talimogene laherparepvec + Nivolumab'}]",Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers,5667
0,NCT00356031,Phase II,Completed,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Bevacizumab and Radiation Therapy for Sarcomas,5485
1,NCT01241162,Phase I,Completed,"[{'id': 650, 'therapyName': 'Decitabine'}]",Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma,5485
2,NCT01343043,Phase Ib/II,Recruiting,"[{'id': 5877, 'therapyName': 'NY-ESO-1-c259T'}]",A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1c259T in HLA-A2+ Patients With Synovial Sarcoma  (NY-ESO-1),5485
3,NCT01446809,Phase I,"Active, not recruiting","[{'id': 1472, 'therapyName': 'Doxorubicin + Ifosfamide'}, {'id': 1471, 'therapyName': 'Pazopanib + Doxorubicin + Ifosfamide'}]",Pazopanib Hydrochloride Followed By Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma,5485
4,NCT02210104,Phase I,Withdrawn,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",Adoptive Therapy Using Antigen-Specific CD4 T-Cells,5485
5,NCT02301039,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas,5485
6,NCT02387125,Phase I,Recruiting,"[{'id': 4318, 'therapyName': 'CMB305'}]","A Phase 1b Safety Study of CMB305 (Sequentially Administered LV305 and G305) in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1",5485
7,NCT02584309,Phase II,Recruiting,"[{'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 4140, 'therapyName': 'Doxorubicin + Olaratumab'}]",Doxorubicin With Upfront Dexrazoxane Plus Olaratumab for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma,5485
8,NCT02601209,Phase Ib/II,Suspended,"[{'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1282, 'therapyName': 'Sapanisertib'}]",Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma,5485
9,NCT02601937,Phase I,Recruiting,"[{'id': 2683, 'therapyName': 'Tazemetostat'}]",A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma,5485
10,NCT02601950,Phase II,Recruiting,"[{'id': 2683, 'therapyName': 'Tazemetostat'}]","A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma",5485
11,NCT02609984,Phase II,"Active, not recruiting","[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 3273, 'therapyName': 'G305 + ID-LV305'}]",Trial of CMB305 and Atezolizumab in Patients With Sarcoma,5485
12,NCT02815995,Phase II,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes,5485
13,NCT02978859,Phase II,Recruiting,"[{'id': 1655, 'therapyName': 'MGCD516'}]",MGCD516 in Advanced Liposarcoma and Other Soft Tissue Sarcomas,5485
14,NCT03009201,Phase I,Recruiting,"[{'id': 5179, 'therapyName': 'Doxorubicin + Ribociclib'}]",Ribociclib and Doxorubicin Hydrochloride in Treating Patients Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery,5485
0,NCT01363817,Phase I,"Active, not recruiting","[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2545, 'therapyName': 'BMS-906024'}]",Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma,5602
1,NCT02763384,Phase II,Recruiting,"[{'id': 4275, 'therapyName': 'BKT140 + Nelarabine'}]",BL-8040 and Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma,5602
0,NCT02535806,Phase II,Terminated,"[{'id': 1631, 'therapyName': 'Vincristine'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults,715
1,NCT02631746,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma,715
0,NCT03002623,Phase II,Recruiting,"[{'id': 709, 'therapyName': 'CUDC-907'}]",CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer,7089
0,NCT01207492,Phase II,"Active, not recruiting","[{'id': 829, 'therapyName': 'Nilotinib'}]",Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor,314
1,NCT02471716,Phase Ib/II,Recruiting,"[{'id': 2840, 'therapyName': 'FPA008'}]",Study of FPA008 in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor,314
2,NCT02673736,Phase I,"Active, not recruiting","[{'id': 4332, 'therapyName': 'PLX73086'}]",A Study of PLX73086 in Advanced Solid Tumors and Locally Advanced or Refractory Tenosynovial Giant Cell Tumor,314
0,NCT02834013,Phase 0,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab in Treating Patients With Rare Tumors,3307
0,NCT02721732,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors,2998
0,NCT01366144,Phase I,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 954, 'therapyName': 'Veliparib'}, {'id': 1092, 'therapyName': 'Carboplatin'}]","Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction",12253
1,NCT02857426,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",A Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Relapsed/Refractory Primary Testicular Lymphoma (PTL) (CheckMate 647),12253
0,NCT02834013,Phase 0,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab in Treating Patients With Rare Tumors,5345
0,NCT01011439,Phase II,"Active, not recruiting","[{'id': 2654, 'therapyName': 'PHA-848125AC'}]",Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma,3284
1,NCT01025089,Phase II,"Active, not recruiting","[{'id': 694, 'therapyName': 'Cetuximab'}, {'id': 1927, 'therapyName': 'Cisplatin + Doxorubicin + Cyclophosphamide'}]",Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma,3284
2,NCT01301391,Phase II,"Active, not recruiting","[{'id': 2654, 'therapyName': 'PHA-848125AC'}]",Study Of Oral PHA-848125AC In Patients With Malignant Thymoma Previously Treated With Multiple Lines Of Chemotherapy,3284
3,NCT01396408,Phase II,"Active, not recruiting","[{'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 930, 'therapyName': 'Sunitinib'}]",A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours,3284
4,NCT01621568,Phase II,"Active, not recruiting","[{'id': 930, 'therapyName': 'Sunitinib'}]",Sunitinib for Advanced Thymus Cancer Following Earlier Treatment,3284
5,NCT02364076,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",MK-3475 in Patients With Thymic Carcinoma,3284
6,NCT03076554,Phase II,Recruiting,"[{'id': 3144, 'therapyName': 'Avelumab'}]",A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy,3284
7,NCT03193437,Phase II,Not yet recruiting,"[{'id': 1749, 'therapyName': 'Selinexor'}]",Selinexor in Patients With Advanced Thymic Epithelial Tumor Progressing After Primary Chemotherapy,3284
8,NCT03295227,Phase I,Not yet recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Feasibility Trial of Pembrolizumab in Unresectable Thymoma and Thymic Carcinoma,3284
0,NCT01011439,Phase II,"Active, not recruiting","[{'id': 2654, 'therapyName': 'PHA-848125AC'}]",Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma,3275
1,NCT01025089,Phase II,"Active, not recruiting","[{'id': 694, 'therapyName': 'Cetuximab'}, {'id': 1927, 'therapyName': 'Cisplatin + Doxorubicin + Cyclophosphamide'}]",Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma,3275
2,NCT01301391,Phase II,"Active, not recruiting","[{'id': 2654, 'therapyName': 'PHA-848125AC'}]",Study Of Oral PHA-848125AC In Patients With Malignant Thymoma Previously Treated With Multiple Lines Of Chemotherapy,3275
3,NCT01621568,Phase II,"Active, not recruiting","[{'id': 930, 'therapyName': 'Sunitinib'}]",Sunitinib for Advanced Thymus Cancer Following Earlier Treatment,3275
4,NCT02220855,Phase II,Recruiting,"[{'id': 680, 'therapyName': 'BKM120'}]",A Study of BKM120 (Buparlisib) in Relapsed or Refractory Thymomas,3275
5,NCT02721732,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors,3275
6,NCT03023319,Phase I,Recruiting,"[{'id': 5237, 'therapyName': 'Bosutinib + Pemetrexed'}]",Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors,3275
7,NCT03076554,Phase II,Recruiting,"[{'id': 3144, 'therapyName': 'Avelumab'}]",A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy,3275
8,NCT03193437,Phase II,Not yet recruiting,"[{'id': 1749, 'therapyName': 'Selinexor'}]",Selinexor in Patients With Advanced Thymic Epithelial Tumor Progressing After Primary Chemotherapy,3275
9,NCT03295227,Phase I,Not yet recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Feasibility Trial of Pembrolizumab in Unresectable Thymoma and Thymic Carcinoma,3275
0,NCT01306045,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 816, 'therapyName': 'MK2206'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 913, 'therapyName': 'Selumetinib'}]","Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies",3277
1,NCT03023319,Phase I,Recruiting,"[{'id': 5237, 'therapyName': 'Bosutinib + Pemetrexed'}]",Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors,3277
0,NCT01182285,Phase II,Completed,"[{'id': 2674, 'therapyName': 'liothyronine sodium  '}, {'id': 1076, 'therapyName': 'Valproic acid'}]",A Phase II Trial of Valproic Acid in Patients With Advanced Thyroid Cancers of Follicular Cell Origin,1781
1,NCT01236547,Phase II,"Active, not recruiting","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}]",Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer,1781
2,NCT01240590,Phase Ib/II,Completed,"[{'id': 1461, 'therapyName': 'Crolibulin + Cisplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}]",A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC),1781
3,NCT01263951,Phase II,"Active, not recruiting","[{'id': 2299, 'therapyName': 'Everolimus + Sorafenib'}]",Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone,1781
4,NCT01270321,Phase II,"Active, not recruiting","[{'id': 2260, 'therapyName': 'Pasireotide'}, {'id': 735, 'therapyName': 'Everolimus'}]",A Trial of Pasireotide and Everolimus in Adult Patients With Radioiodine-Refractory Differentiated and Medullary Thyroid Cancer,1781
5,NCT01438554,Phase I,"Active, not recruiting","[{'id': 1310, 'therapyName': 'Pazopanib + Trametinib'}]","Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma",1781
6,NCT01811212,Phase II,"Active, not recruiting","[{'id': 998, 'therapyName': 'cabozantinib'}]",Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer,1781
7,NCT01843062,Phase III,"Active, not recruiting","[{'id': 913, 'therapyName': 'Selumetinib'}]",Study Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer,1781
8,NCT01876784,Phase III,Completed,"[{'id': 953, 'therapyName': 'Vandetanib'}]","Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer",1781
9,NCT01947023,Phase I,Recruiting,"[{'id': 2478, 'therapyName': 'Dabrafenib + Lapatinib'}]",Dabrafenib and Lapatinib Ditosylate in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery,1781
10,NCT02012231,Phase Ib/II,Terminated,"[{'id': 1041, 'therapyName': 'PLX8394'}]","Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.",1781
11,NCT02034110,Phase II,Recruiting,"[{'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}]",Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers,1781
12,NCT02041260,Phase II,Recruiting,"[{'id': 998, 'therapyName': 'cabozantinib'}]",A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting,1781
13,NCT02143726,Phase II,Recruiting,"[{'id': 920, 'therapyName': 'Sorafenib'}, {'id': 735, 'therapyName': 'Everolimus'}]","Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Thyroid Cancer",1781
14,NCT02244463,Phase II,Recruiting,"[{'id': 1282, 'therapyName': 'Sapanisertib'}]",A Phase II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer,1781
15,NCT02289144,Phase II,Recruiting,"[{'id': 789, 'therapyName': 'Ceritinib'}]",Ceritinib (LDK378) in Mutation and Oncogene Directed Therapy in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer,1781
16,NCT02383927,Phase II,Recruiting,"[{'id': 938, 'therapyName': 'Tipifarnib'}]",Phase II Study of Tipifarnib in Advanced Cancers With HRAS Mutations,1781
17,NCT02432274,Phase Ib/II,Recruiting,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 792, 'therapyName': 'Lenvatinib'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies,1781
18,NCT02576431,Phase II,Recruiting,"[{'id': 2650, 'therapyName': 'LOXO-101'}]",Study of LOXO-101 in Subjects With NTRK Fusion Positive Solid Tumors,1781
19,NCT02657369,Phase II,Recruiting,"[{'id': 792, 'therapyName': 'Lenvatinib'}]",A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC),1781
20,NCT02688608,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer,1781
21,NCT02721732,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors,1781
22,NCT02936102,Phase I,Recruiting,"[{'id': 4971, 'therapyName': 'FAZ053'}, {'id': 4972, 'therapyName': 'FAZ053 + PDR001'}]",A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.,1781
23,NCT02973997,Phase II,Not yet recruiting,"[{'id': 4782, 'therapyName': 'Lenvatinib + Pembrolizumab'}]",Pembrolizumab and Lenvatinib in Treating Metastatic or Recurrent Differentiated Thyroid Cancer That Cannot Be Removed by Surgery,1781
24,NCT03002623,Phase II,Recruiting,"[{'id': 709, 'therapyName': 'CUDC-907'}]",CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer,1781
25,NCT03085056,Phase I,Recruiting,"[{'id': 5493, 'therapyName': 'Trametinib + Paclitaxel'}]",Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer,1781
26,NCT03099356,Phase II,Recruiting,"[{'id': 5513, 'therapyName': 'Sirolimus + Cyclophosphamide'}]","Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer",1781
27,NCT03122496,Phase I,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer,1781
28,NCT03131206,Phase Ib/II,Recruiting,"[{'id': 698, 'therapyName': 'Alectinib'}]",A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer,1781
29,NCT03139747,Phase II,Recruiting,"[{'id': 1713, 'therapyName': 'Everolimus + Lenvatinib'}]",UPCC 36315 A Phase II Study Of Everolimus (RAD001) And Lenvatinib (E7080) In Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Lenvatinib Alone,1781
30,NCT03211117,Phase II,Recruiting,"[{'id': 6040, 'therapyName': 'Docetaxel + Doxorubicin + Pembrolizumab'}]","Pembrolizumab, Chemotherapy, and Radiation Therapy With or Without Surgery in Treating Patients With Anaplastic Thyroid Cancer",1781
31,NCT03246958,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab Plus Ipilimumab in Thyroid Cancer,1781
0,NCT01208051,Phase Ib/II,"Active, not recruiting","[{'id': 2437, 'therapyName': 'Cediranib + Lenalidomide'}, {'id': 1001, 'therapyName': 'Cediranib'}]",Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer,3963
1,NCT01655719,Phase II,Completed,"[{'id': 3125, 'therapyName': 'Pioglitazone'}]",Pioglitazone in Thyroid Cancers,3963
2,NCT02428712,Phase Ib/II,Recruiting,"[{'id': 1041, 'therapyName': 'PLX8394'}]","A Study of PLX8394 as a Single Agent in Patients With Advanced, Unresectable Solid Tumors",3963
3,NCT02628067,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158),3963
4,NCT02834013,Phase 0,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab in Treating Patients With Rare Tumors,3963
5,NCT03181100,Phase II,Recruiting,"[{'id': 619, 'therapyName': 'Abraxane'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}, {'id': 4595, 'therapyName': 'Atezolizumab + Bevacizumab'}, {'id': 3049, 'therapyName': 'Atezolizumab + nab-paclitaxel'}, {'id': 4825, 'therapyName': 'Atezolizumab + Vemurafenib + Cobimetinib'}, {'id': 5606, 'therapyName': 'Atezolizumab + Paclitaxel'}]",Atezolizumab Combinations With Chemotherapy for Anaplastic and Poorly Differentiated Thyroid Carcinomas,3963
0,NCT02973997,Phase II,Not yet recruiting,"[{'id': 4782, 'therapyName': 'Lenvatinib + Pembrolizumab'}]",Pembrolizumab and Lenvatinib in Treating Metastatic or Recurrent Differentiated Thyroid Cancer That Cannot Be Removed by Surgery,8161
1,NCT03002623,Phase II,Recruiting,"[{'id': 709, 'therapyName': 'CUDC-907'}]",CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer,8161
2,NCT03215095,Phase I,Recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}]",RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid Cancers,8161
0,NCT01396408,Phase II,"Active, not recruiting","[{'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 930, 'therapyName': 'Sunitinib'}]",A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours,3973
1,NCT01838642,Phase II,Terminated,"[{'id': 877, 'therapyName': 'Ponatinib'}]",Ponatinib for Advanced Medullary Thyroid Cancer,3973
2,NCT02657551,Phase II,Recruiting,"[{'id': 890, 'therapyName': 'Regorafenib'}]",A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer,3973
3,NCT02831179,Phase I,Withdrawn,"[{'id': 4463, 'therapyName': 'Capecitabine + Veliparib + Temozolomide'}]","Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor",3973
4,NCT02867592,Phase II,Recruiting,"[{'id': 998, 'therapyName': 'cabozantinib'}]","Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors",3973
5,NCT02936323,,Recruiting,"[{'id': 5819, 'therapyName': 'PEN-221'}]",PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers,3973
6,NCT03037385,Phase I,Recruiting,"[{'id': 5530, 'therapyName': 'BLU-667'}]","Phase 1 Study of BLU-667 in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors",3973
7,NCT03072160,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer,3973
8,NCT03157128,Phase I,Recruiting,"[{'id': 5702, 'therapyName': 'LOXO-292'}]","Phase 1 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET-Fusion Lung Cancer and Medullary Thyroid Cancer",3973
0,NCT02993991,Phase I,Not yet recruiting,"[{'id': 4378, 'therapyName': 'MEDI4736 + Mocetinostat'}]",Pre-operative Mocetinostat (MGCD0103) and Durvalumab (MEDI4736) (PRIMED) for Squamous Cell Carcinoma of the Oral Cavity,50865
0,NCT02780310,Phase II,"Active, not recruiting","[{'id': 792, 'therapyName': 'Lenvatinib'}]",Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma,4875
1,NCT03087019,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma,4875
2,NCT03172624,Phase II,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer,4875
0,NCT02834013,Phase 0,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab in Treating Patients With Rare Tumors,4876
0,NCT00978250,Phase II,Recruiting,"[{'id': 3789, 'therapyName': 'FdCyd + THU'}]",A Multi-Histology Phase II Study of 5-Fluoro-2-Deoxycytidine With Tetrahydrouridine (FdCyd + THU),2671
1,NCT01004224,Phase I,"Active, not recruiting","[{'id': 674, 'therapyName': 'BGJ398'}]",A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies,2671
2,NCT01920061,Phase I,Recruiting,"[{'id': 1287, 'therapyName': 'PF-05212384 + Dacomitinib'}, {'id': 1286, 'therapyName': 'PF-05212384 + Cisplatin'}, {'id': 1285, 'therapyName': 'PF-05212384 + Docetaxel'}]",A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents,2671
3,NCT02393248,Phase Ib/II,Recruiting,"[{'id': 4176, 'therapyName': 'Cisplatin + Gemcitabine + INCB054828'}, {'id': 4174, 'therapyName': 'Docetaxel + INCB054828'}, {'id': 4088, 'therapyName': 'Epacadostat + Pembrolizumab'}]","Open-Label, Dose-Escalation Study of INCB054828 in Subjects With Advanced Malignancies",2671
4,NCT02501096,Phase Ib/II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 792, 'therapyName': 'Lenvatinib'}]",Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors,2671
5,NCT02516241,Phase III,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 4686, 'therapyName': 'Carboplatin + Cisplatin + Gemcitabine'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",Study of MEDI4736 With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer,2671
6,NCT02599324,Phase Ib/II,Recruiting,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 694, 'therapyName': 'Cetuximab'}]",A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors,2671
7,NCT02603432,Phase III,Recruiting,"[{'id': 3144, 'therapyName': 'Avelumab'}]",A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100),2671
8,NCT02717156,Phase II,Recruiting,"[{'id': 3944, 'therapyName': 'sEphB4-HSA + Pembrolizumab'}]",Recombinant EphB4-HSA Fusion Protein and Pembrolizumab in Treating Patients With Metastatic or Recurrent Urothelial Cancer That Is Refractory to Certain Chemotherapy Drugs,2671
9,NCT02795156,Phase II,Recruiting,"[{'id': 623, 'therapyName': 'Afatinib'}, {'id': 890, 'therapyName': 'Regorafenib'}]",Study to Assess the Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations,2671
10,NCT02807636,Phase III,Recruiting,"[{'id': 4450, 'therapyName': 'Atezolizumab + Carboplatin + Gemcitabine'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}]",The Effect of Atezolizumab in Combination With Gemcitabine/Carboplatin and Gemcitabine/Carboplatin Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-based Therapy,2671
11,NCT02812420,Phase I,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]","Pre-Surgical Study Evaluating Anti-PD-L1 Antibody (Durvalumab) Plus Anti-CTLA-4 (Tremelimumab) in Patients With Muscle-Invasive, High-Risk Urothelial Carcinoma Who Are Ineligible for Cisplatin-based Neoadjuvant Chemotherapy",2671
12,NCT02834013,Phase 0,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab in Treating Patients With Rare Tumors,2671
13,NCT02872714,Phase II,Recruiting,"[{'id': 4173, 'therapyName': 'INCB054828'}]",A Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Urothelial Carcinoma,2671
14,NCT02880345,Phase 0,Not yet recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",RADVAX: A Trial of Combined Pembrolizumab and Hypofractionated Radiation in Patients With Advanced Urothelial Cancer Who Have Progressed on Anti-PD-1/PD-L1 Monotherapy,2671
15,NCT03018405,Phase I,Recruiting,"[{'id': 5998, 'therapyName': 'NKR-2 cells'}]",A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications (THINK),2671
16,NCT03029832,Phase II,"Active, not recruiting","[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 5451, 'therapyName': 'Atezolizumab + MOXR0916'}]",A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based Therapy,2671
17,NCT03036098,Phase III,Recruiting,"[{'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}]",Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care Chemotherapy in Treatment of Patients With Untreated Inoperable or Metastatic Urothelial Cancer,2671
18,NCT03047213,Phase II,Recruiting,"[{'id': 1282, 'therapyName': 'Sapanisertib'}]",Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations,2671
19,NCT03076372,Phase I,Recruiting,"[{'id': 5758, 'therapyName': 'MM-310'}]",A Study Evaluating MM-310 in Patients With Solid Tumors,2671
20,NCT03091660,Phase III,Recruiting,"[{'id': 5478, 'therapyName': 'BCG Tokyo-172 Strain Solution'}, {'id': 4455, 'therapyName': 'BCG solution'}]",Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer,2671
21,NCT03115801,Phase II,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers,2671
22,NCT03123055,Phase I,Recruiting,"[{'id': 5615, 'therapyName': 'B-701 + Atezolizumab'}]",A Study of B-701 in Combination With Atezolizumab in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma (U22),2671
23,NCT03208712,Phase I,Not yet recruiting,"[{'id': 4881, 'therapyName': 'Atezolizumab + Ra 223'}]",Radium-223 and Atezolizumab in Patients With Urothelial Carcinoma With Bone Metastases Who Have Had Disease Progression After Platinum-Based Chemotherapy,2671
24,NCT03219333,Phase II,Recruiting,"[{'id': 4125, 'therapyName': 'Enfortumab vedotin'}]",A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer (EV-201),2671
25,NCT03236935,Phase I,Not yet recruiting,"[{'id': 6097, 'therapyName': 'L-NMMA + Pembrolizumab'}]",Phase Ib of L-NMMA and Pembrolizumab,2671
26,NCT03240016,Phase II,Not yet recruiting,"[{'id': 4023, 'therapyName': 'nab-paclitaxel + Pembrolizumab'}]",Abraxane With Anti-PD1/PDL1 in Cisplatin-ineligible Patients With Advanced Urothelial Cancer,2671
27,NCT03241173,Phase Ib/II,Not yet recruiting,"[{'id': 6120, 'therapyName': 'INCAGN01949 + Ipilimumab'}, {'id': 6119, 'therapyName': 'INCAGN01949 + Nivolumab'}, {'id': 6121, 'therapyName': 'INCAGN01949 + Ipilimumab + Nivolumab'}]",A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies,2671
28,NCT03264066,Phase II,Not yet recruiting,"[{'id': 6094, 'therapyName': 'Atezolizumab + Cabozantinib'}]",A Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Participants With Solid Tumors,2671
29,NCT03277352,Phase Ib/II,Not yet recruiting,"[{'id': 6277, 'therapyName': 'Epacadostat + INCAGN01876 + Pembrolizumab'}]",INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies,2671
30,NCT03287050,Phase I,Not yet recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","Anti-PD(L)1 and SBRT in the Treatment of Advanced, Platinum-Refractory Urothelial Carcinoma",2671
31,NCT03289962,Phase I,Not yet recruiting,"[{'id': 6234, 'therapyName': 'RO7198457'}, {'id': 6235, 'therapyName': 'Atezolizumab + RO7198457'}]",A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors,2671
0,NCT00576654,Phase I,Recruiting,"[{'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 954, 'therapyName': 'Veliparib'}]",Irinotecan Hydrochloride and Veliparib in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery,60081
1,NCT00740805,Phase I,"Active, not recruiting","[{'id': 2989, 'therapyName': 'Aldoxorubicin + Cyclophosphamide + Veliparib'}]","Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma",60081
2,NCT01391143,Phase I,Recruiting,"[{'id': 2863, 'therapyName': 'MGA271'}]",Safety Study of MGA271 in Refractory Cancer,60081
3,NCT01623349,Phase I,"Active, not recruiting","[{'id': 2171, 'therapyName': 'BYL719 + Olaparib'}, {'id': 2170, 'therapyName': 'BKM120 + Olaparib'}]",Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer,60081
4,NCT01639248,,Completed,"[{'id': 727, 'therapyName': 'ENMD-2076'}]", A Phase II Study of the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced and Metastatic Triple-Negative Breast Cancer,60081
5,NCT01653470,Phase I,"Active, not recruiting","[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 2545, 'therapyName': 'BMS-906024'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]","Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors",60081
6,NCT01695005,Phase I,Recruiting,"[{'id': 2958, 'therapyName': 'LY3039478'}]",A Study of LY3039478 in Participants With Advanced Cancer,60081
7,NCT01876251,,Terminated,"[{'id': 1115, 'therapyName': 'PF-03084014 + Docetaxel'}]", A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer,60081
8,NCT01884285,Phase I,Recruiting,"[{'id': 992, 'therapyName': 'AZD8186'}]",AZD8186 First Time In Patient Ascending Dose Study,60081
9,NCT01920061,Phase I,Recruiting,"[{'id': 1287, 'therapyName': 'PF-05212384 + Dacomitinib'}, {'id': 1286, 'therapyName': 'PF-05212384 + Cisplatin'}, {'id': 1285, 'therapyName': 'PF-05212384 + Docetaxel'}]",A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents,60081
10,NCT01931163,Phase II,Recruiting,"[{'id': 735, 'therapyName': 'Everolimus'}]",NECTAR Everolimus Plus Cisplatin in Triple (-) Breast Cancer,60081
11,NCT01938638,Phase I,Completed,"[{'id': 4027, 'therapyName': 'BAY1143572'}]",Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer,60081
12,NCT01969643,Phase I,Recruiting,"[{'id': 3615, 'therapyName': 'SGN-LIV1A '}]",A Safety Study of SGN-LIV1A in Breast Cancer Patients,60081
13,NCT01982448,Phase II,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Cisplatin vs Paclitaxel for Triple Neg,60081
14,NCT01990209,Phase II,Recruiting,"[{'id': 2671, 'therapyName': 'Orteronel '}]",Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR),60081
15,NCT01997333,Phase II,"Active, not recruiting","[{'id': 3597, 'therapyName': 'Glembatumumab vedotin'}, {'id': 1105, 'therapyName': 'Capecitabine'}]","Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer",60081
16,NCT01999738,Phase I,"Active, not recruiting","[{'id': 1603, 'therapyName': 'EC1456'}]",Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors,60081
17,NCT02000882,Phase II,"Active, not recruiting","[{'id': 1536, 'therapyName': 'BKM120 + Capecitabine'}]",Capecitabine + BKM120 TNBC BC Brain Met,60081
18,NCT02003092,Phase I,Recruiting,"[{'id': 6224, 'therapyName': 'RX-5902'}]",RX-5902 Treatment of Subjects With Solid Tumors,60081
19,NCT02014337,Phase I,"Active, not recruiting","[{'id': 3053, 'therapyName': 'Eribulin + Mifepristone'}]",Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors,60081
20,NCT02078752,Phase I,Completed,"[{'id': 4324, 'therapyName': 'PF-06647263 '}]",A Study Of PF-06647263 In Patients With Advanced Solid Tumors,60081
21,NCT02101385,Phase II,Recruiting,[],Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer,60081
22,NCT02120469,Phase I,Recruiting,"[{'id': 2252, 'therapyName': 'Eribulin + Everolimus'}]",Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer,60081
23,NCT02138812,Phase I,"Active, not recruiting","[{'id': 3448, 'therapyName': 'BAY1161909 + Paclitaxel'}]",Phase I Dose Escalation of Oral BAY1161909 in Combination With Intravenous Paclitaxel,60081
24,NCT02157792,Phase I,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 2879, 'therapyName': 'VX-970'}, {'id': 755, 'therapyName': 'Gemcitabine'}]","An Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics of VX-970 in Combination With Cytotoxic Chemotherapy",60081
25,NCT02158507,Phase I,"Active, not recruiting","[{'id': 2543, 'therapyName': 'Lapatinib + Veliparib'}]","Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer",60081
26,NCT02162719,Phase II,"Active, not recruiting","[{'id': 1588, 'therapyName': 'Ipatasertib + Paclitaxel'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Front-line Treatment for Patients With Metastatic Triple-Negative Breast Cancer,60081
27,NCT02208375,Phase Ib/II,Recruiting,"[{'id': 837, 'therapyName': 'Olaparib'}, {'id': 655, 'therapyName': 'AZD5363'}, {'id': 991, 'therapyName': 'Vistusertib'}]",mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian Cancer,60081
28,NCT02222922,Phase I,Recruiting,"[{'id': 1689, 'therapyName': 'Fluconazole'}, {'id': 4421, 'therapyName': 'PF-06647020'}]",A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors,60081
29,NCT02299635,Phase II,Terminated,"[{'id': 859, 'therapyName': 'PF-03084014'}]",A Study Evaluating PF-03084014 In Patients With Advanced Breast Cancer With Or Without Notch Alterations,60081
30,NCT02358200,Phase I,"Active, not recruiting","[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 682, 'therapyName': 'Talazoparib'}]",Study of BMN-673 With Carboplatin and Paclitaxel in Patients With Advanced BRCA-mutated Solid Tumor or Triple Negative Metastatic Breast Cancer,60081
31,NCT02365662,Phase I,Recruiting,"[{'id': 2914, 'therapyName': 'ABBV-221'}]",A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor,60081
32,NCT02366949,Phase I,Recruiting,"[{'id': 3447, 'therapyName': 'BAY1217389 + Paclitaxel'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel,60081
33,NCT02368691,Phase II,Terminated,"[{'id': 5026, 'therapyName': 'enobosarm'}]",Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC),60081
34,NCT02370238,Phase II,Recruiting,"[{'id': 2930, 'therapyName': 'Reparixin'}]",A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast Cancer,60081
35,NCT02393794,Phase Ib/II,"Active, not recruiting","[{'id': 2993, 'therapyName': 'Cisplatin + Romidepsin '}]",Romidepsin Plus Cisplatin in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC),60081
36,NCT02401347,Phase II,Recruiting,"[{'id': 682, 'therapyName': 'Talazoparib'}]",Talazoparib Beyond BRCA (TBB) Trial,60081
37,NCT02419417,Phase Ib/II,Recruiting,"[{'id': 2811, 'therapyName': 'BMS986158'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Study of BMS-986158 in Subjects With Select Advanced Solid Tumors,60081
38,NCT02425891,Phase III,"Active, not recruiting","[{'id': 619, 'therapyName': 'Abraxane'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study of MPDL3280A in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Patients With Previously Untreated Metastatic Triple Negative Breast Cancer,60081
39,NCT02427581,Phase I,Recruiting,"[{'id': 2595, 'therapyName': 'poly ICLC  '}]",Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy,60081
40,NCT02435680,Phase II,"Active, not recruiting","[{'id': 2838, 'therapyName': 'MCS110'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}]",Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC),60081
41,NCT02447003,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) Monotherapy for Metastatic Triple-Negative Breast Cancer (MK-3475-086/KEYNOTE-086),60081
42,NCT02452424,Phase Ib/II,"Active, not recruiting","[{'id': 2736, 'therapyName': 'Pembrolizumab + PLX3397'}]",A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors,60081
43,NCT02456857,Phase II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 936, 'therapyName': 'Temsirolimus'}]","Liposomal Doxorubicin, Bevacizumab and Temsirolimus (DAT) in Triple-Negative Breast Cancer (TNBC) Insensitive to Standard Neoadjuvant Chemotherapy",60081
44,NCT02457910,Phase Ib/II,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1016, 'therapyName': 'GDC-0032'}]",Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer,60081
45,NCT02471846,Phase I,"Active, not recruiting","[{'id': 2888, 'therapyName': 'GDC-0919'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study of GDC-0919 and MPDL3280A Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors,60081
46,NCT02474173,Phase I,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 645, 'therapyName': 'AT13387'}]",HSP90 Inhibitor AT13387 and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer,60081
47,NCT02489448,Phase Ib/II,Recruiting,"[{'id': 3100, 'therapyName': 'MEDI4736 + nab-paclitaxel'}, {'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}]",Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast Cancer,60081
48,NCT02498613,Phase II,Recruiting,"[{'id': 1971, 'therapyName': 'Cediranib + Olaparib'}]",Cediranib Maleate and Olaparib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery,60081
49,NCT02513472,Phase Ib/II,"Active, not recruiting","[{'id': 3080, 'therapyName': 'Eribulin + Pembrolizumab'}]",Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC),60081
50,NCT02528357,Phase I,Recruiting,"[{'id': 5177, 'therapyName': 'GSK3174998'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",GSK3174998 Alone or With Pembrolizumab in Subjects With Advanced Solid Tumors,60081
51,NCT02530489,Phase II,Recruiting,"[{'id': 3049, 'therapyName': 'Atezolizumab + nab-paclitaxel'}]",Neoadjuvant Trial of Nab-Paclitaxel and MPDL3280A,60081
52,NCT02531932,Phase II,Recruiting,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 735, 'therapyName': 'Everolimus'}]",Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer,60081
53,NCT02540291,Phase I,Recruiting,"[{'id': 5694, 'therapyName': 'E7046'}]",Study of E7046 in Subjects With Selected Advanced Malignancies,60081
54,NCT02543645,Phase Ib/II,Terminated,"[{'id': 3086, 'therapyName': 'Atezolizumab + Varlilumab'}]",A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer,60081
55,NCT02555657,Phase III,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119),60081
56,NCT02559492,Phase I,"Active, not recruiting","[{'id': 3096, 'therapyName': 'INCB039110 + INCB024360'}, {'id': 3097, 'therapyName': 'INCB039110 + INCB050465'}]",INCB039110 Combined With INCB024360 and/or INCB039110 Combined With INCB050465 in Advanced Solid Tumors,60081
57,NCT02575781,Phase I,Recruiting,"[{'id': 4026, 'therapyName': 'SAR428926'}]",A Study of SAR428926 in Patients With Advanced Solid Tumors,60081
58,NCT02580448,Phase Ib/II,Recruiting,"[{'id': 2822, 'therapyName': 'VT-464'}]","A Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of VT-464 in Patients With Advanced Breast Cancer",60081
59,NCT02593175,Phase II,Recruiting,"[{'id': 3386, 'therapyName': 'Carboplatin + Paclitaxel + Panitumumab'}]","Women's Triple-Negative First-Line Study: A Phase II Trial of Panitumumab, Carboplatin and Paclitaxel (PaCT) in Patients With Localized Triple-Negative Breast Cancer (TNBC) With Tumors Predicted Insensitive to Standard Neoadjuvant Chemotherapy",60081
60,NCT02624700,Phase II,Recruiting,"[{'id': 1482, 'therapyName': 'Pemetrexed + Sorafenib'}]",Study of Pemetrexed and Sorafenib for Recurrent or Metastatic Triple Negative Breast Cancer,60081
61,NCT02627430,Phase I,Withdrawn,"[{'id': 3317, 'therapyName': 'Onalespib + Talazoparib'}]","Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer",60081
62,NCT02631733,Phase I,Recruiting,"[{'id': 3314, 'therapyName': 'Irinotecan + Veliparib'}]",Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery,60081
63,NCT02632448,Phase Ib/II,Recruiting,"[{'id': 4420, 'therapyName': 'LY2880070 + Gemcitabine'}, {'id': 4315, 'therapyName': 'LY2880070'}]",A Study of LY2880070 in Patients With Advanced or Metastatic Cancer,60081
64,NCT02637375,Phase I,Withdrawn,"[{'id': 1495, 'therapyName': 'Paclitaxel + Doxorubicin + Cyclophosphamide'}, {'id': 745, 'therapyName': 'Ganetespib'}]",A Pilot Preoperative Trial of Ganetespib With Paclitaxel for Triple-Negative Breast Cancer,60081
65,NCT02644369,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors,60081
66,NCT02646748,Phase I,Recruiting,"[{'id': 3088, 'therapyName': 'INCB050465 '}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2406, 'therapyName': 'INCB039110'}]",Pembrolizumab Combined With INCB039110 and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors,60081
67,NCT02648477,Phase II,Recruiting,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer,60081
68,NCT02655822,Phase I,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 3571, 'therapyName': 'CPI-444 '}]",Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers,60081
69,NCT02657889,Phase Ib/II,Recruiting,"[{'id': 3935, 'therapyName': 'Niraparib + Pembrolizumab'}]",Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Triple-negative Breast Cancer or Ovarian Cancer (KEYNOTE-162),60081
70,NCT02658214,Phase I,Recruiting,"[{'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}, {'id': 2634, 'therapyName': 'Carboplatin + nab-paclitaxel'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}]",Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors,60081
71,NCT02665416,Phase I,Recruiting,"[{'id': 3468, 'therapyName': 'RO5520985 + RO7009789'}]","Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of RO7009789 With Vanucizumab in Metastatic Solid Tumors",60081
72,NCT02672475,Phase I,Recruiting,"[{'id': 3541, 'therapyName': 'Galunisertib + Paclitaxel'}]",Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer,60081
73,NCT02676986,Phase II,Recruiting,"[{'id': 6183, 'therapyName': 'Enzalutamide + Exemestane'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]","Short-term Preoperative Treatment With Enzalutamide, Alone or in Combination With Exemestane in Primary Breast Cancer (ARB)",60081
74,NCT02689427,Phase II,Recruiting,"[{'id': 3725, 'therapyName': 'Enzalutamide + Paclitaxel'}]",Phase IIB Neoadjuvant Enzalutamide (ZT) Plus Taxol for Androgen Receptor (AR)-Positive Triple-Negative Breast Cancer (AR+ TNBC),60081
75,NCT02698176,Phase I,Terminated,"[{'id': 2034, 'therapyName': 'OTX015'}]",A Dose Exploration Study With MK-8628 in Participants With Selected Advanced Solid Tumors (MK-8628-006),60081
76,NCT02708680,Phase Ib/II,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 5129, 'therapyName': 'Entinostat + Atezolizumab'}]",Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In,60081
77,NCT02719691,Phase I,Recruiting,"[{'id': 4214, 'therapyName': 'Alisertib + MLN0128'}]",Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,60081
78,NCT02720185,Phase II,Recruiting,"[{'id': 717, 'therapyName': 'Dasatinib'}]",The Window of Opportunity of Dasatinib in Operable Triple Negative Breast Cancers With nEGFR,60081
79,NCT02725489,Phase II,Recruiting,"[{'id': 4388, 'therapyName': 'FANG vaccine + MEDI4736'}]",Pilot Study of Durvalumab (MEDI4736) in Combination With Vigil in Advanced Breast Cancer,60081
80,NCT02730130,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study to Assess the Efficacy of Pembrolizumab Plus Radiotherapy in Metastatic Triple Negative Breast Cancer Patients,60081
81,NCT02734290,Phase Ib/II,Recruiting,"[{'id': 4022, 'therapyName': 'Capecitabine + Pembrolizumab'}, {'id': 4021, 'therapyName': 'Paclitaxel + Pembrolizumab'}]",Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer,60081
82,NCT02750358,Phase II,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}]",Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR (+) Triple Negative Breast Cancer,60081
83,NCT02752685,Phase II,Recruiting,"[{'id': 4023, 'therapyName': 'nab-paclitaxel + Pembrolizumab'}]",Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer,60081
84,NCT02755272,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}]",A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer,60081
85,NCT02760797,Phase I,Recruiting,"[{'id': 4181, 'therapyName': 'Emactuzumab + RO7009789'}]",A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors,60081
86,NCT02768701,Phase II,Recruiting,"[{'id': 4891, 'therapyName': 'Cyclophosphamide + Pembrolizumab'}]",Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast Cancer,60081
87,NCT02774681,Phase II,Recruiting,"[{'id': 3041, 'therapyName': 'Palbociclib + Trastuzumab'}]",Palbociclib in Treating Patients With Metastatic HER-2 Positive or Triple-Negative Breast Cancer With Brain Metastasis,60081
88,NCT02788981,Phase II,Recruiting,"[{'id': 4350, 'therapyName': 'Mifepristone + Nab-paclitaxel'}, {'id': 619, 'therapyName': 'Abraxane'}]","A Trial of Nanoparticle Albumin-Bound Paclitaxel (Nab-Paclitaxel, Abraxane) With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer",60081
89,NCT02807844,Phase Ib/II,Recruiting,"[{'id': 5072, 'therapyName': 'MCS110 + PDR001'}]",Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies,60081
90,NCT02819518,Phase III,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}]",Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355),60081
91,NCT02824042,Phase I,Recruiting,"[{'id': 4594, 'therapyName': 'Anetumab ravtansine + Itraconazole'}, {'id': 4593, 'therapyName': 'Anetumab ravtansine'}]",Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole,60081
92,NCT02826434,Phase I,Recruiting,"[{'id': 4466, 'therapyName': 'MEDI4736 + PVX-410 + poly ICLC '}]",Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer,60081
93,NCT02829723,Phase Ib/II,Recruiting,"[{'id': 2844, 'therapyName': 'BLZ945'}, {'id': 5071, 'therapyName': 'BLZ945 + PDR001'}]",Phase I/II Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors,60081
94,NCT02834247,Phase I,Recruiting,"[{'id': 4680, 'therapyName': 'Nivolumab + TAK-659'}]",A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors,60081
95,NCT02834403,Phase Ib/II,Recruiting,"[{'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 6123, 'therapyName': 'Docetaxel + L-NMMA'}, {'id': 6096, 'therapyName': 'L-NMMA'}]",L-NMMA Plus Docetaxel in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients,60081
96,NCT02849496,Phase II,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 4511, 'therapyName': 'Atezolizumab + Veliparib'}, {'id': 954, 'therapyName': 'Veliparib'}]",Veliparib and Atezolizumab Either Alone or in Combination in Treating Patients With Stage III-IV Triple Negative Breast Cancer,60081
97,NCT02876107,Phase II,Recruiting,"[{'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}, {'id': 3386, 'therapyName': 'Carboplatin + Paclitaxel + Panitumumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",A Phase II Study of Using Panitumumab/Carboplatin/Paclitaxel (PaCT) Followed by Anthracycline-Containing Regimen (AC) for New Triple-Negative Inflammatory Breast Cancer (TN-IBC),60081
98,NCT02876302,Phase II,Recruiting,"[{'id': 4679, 'therapyName': 'Cyclophosphamide + Doxorubicin + Paclitaxel + Ruxolitinib'}]",Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer,60081
99,NCT02880371,Phase Ib/II,Recruiting,"[{'id': 4608, 'therapyName': 'ARRY-382 + Pembrolizumab'}]",A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors,60081
100,NCT02883062,Phase II,Not yet recruiting,"[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1203, 'therapyName': 'Atezolizumab + Carboplatin + Paclitaxel'}]","Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer",60081
101,NCT02890069,Phase I,Recruiting,"[{'id': 5311, 'therapyName': 'PDR001 + LCL161'}, {'id': 5312, 'therapyName': 'PDR001 + Everolimus'}, {'id': 5313, 'therapyName': 'PDR001 + Panobinostat'}]","A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat",60081
102,NCT02898207,Phase I,Recruiting,"[{'id': 4729, 'therapyName': 'Olaparib + Onalespib'}]","Olaparib and Hsp90 Inhibitor AT13387 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer",60081
103,NCT02900664,Phase I,Recruiting,"[{'id': 5399, 'therapyName': 'PDR001 + EGF816'}, {'id': 5397, 'therapyName': 'PDR001 + CJM112'}, {'id': 5398, 'therapyName': 'PDR001 + Trametinib'}, {'id': 5395, 'therapyName': 'PDR001 + Canakinumab'}]","A Study of PDR001 in Combination With CJM112, EGF816, Ilaris (Canakinumab) or Mekinist (Trametinib)",60081
104,NCT02929576,Phase III,Withdrawn,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 3725, 'therapyName': 'Enzalutamide + Paclitaxel'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]","Efficacy and Safety Study of Enzalutamide in Combination With Paclitaxel Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in Patients With Advanced, Diagnostic-Positive, Triple-Negative Breast Cancer (ENDEAR)",60081
105,NCT02936102,Phase I,Recruiting,"[{'id': 4971, 'therapyName': 'FAZ053'}, {'id': 4972, 'therapyName': 'FAZ053 + PDR001'}]",A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.,60081
106,NCT02947165,Phase I,Recruiting,"[{'id': 5632, 'therapyName': 'NIS793 + PDR001'}, {'id': 5631, 'therapyName': 'NIS793'}]",Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.,60081
107,NCT02950064,Phase I,Recruiting,"[{'id': 6336, 'therapyName': 'BTP-114'}]",A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations,60081
108,NCT02952248,Phase I,Recruiting,"[{'id': 5692, 'therapyName': 'BI 754091'}]",A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours,60081
109,NCT02954874,Phase III,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer,60081
110,NCT02971761,Phase II,Recruiting,"[{'id': 5027, 'therapyName': 'enobosarm + Pembrolizumab'}]",Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer,60081
111,NCT02977468,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer (Pembro/IORT),60081
112,NCT02978716,Phase II,Recruiting,"[{'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}, {'id': 5737, 'therapyName': 'Carboplatin + Gemcitabine + Trilaciclib'}]","Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)",60081
113,NCT02981303,Phase II,Recruiting,"[{'id': 5174, 'therapyName': 'Imprime PGG + Pembrolizumab'}]",Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer,60081
114,NCT02984683,Phase II,Recruiting,"[{'id': 5825, 'therapyName': 'SAR566658'}]",Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast Cancer,60081
115,NCT02985658,Phase I,Available,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 954, 'therapyName': 'Veliparib'}, {'id': 1685, 'therapyName': 'Vinorelbine'}]",Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer,60081
116,NCT02996825,Phase I,Recruiting,"[{'id': 3232, 'therapyName': 'IMGN853'}]","Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRa-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer",60081
117,NCT03004183,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 5172, 'therapyName': 'AdV-tk + Valacyclovir'}]",SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC,60081
118,NCT03012230,Phase I,Not yet recruiting,"[{'id': 5227, 'therapyName': 'Pembrolizumab + Ruxolitinib'}]",Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast Cancer,60081
119,NCT03012477,Phase II,Recruiting,"[{'id': 1725, 'therapyName': 'MK-1775 + Cisplatin'}]",CISPLATIN + AZD-1775 In Breast Cancer,60081
120,NCT03018405,Phase I,Recruiting,"[{'id': 5998, 'therapyName': 'NKR-2 cells'}]",A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications (THINK),60081
121,NCT03036488,Phase III,Recruiting,"[{'id': 1087, 'therapyName': 'Epirubicin + Cyclophosphamide'}, {'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522),60081
122,NCT03044730,Phase II,Recruiting,"[{'id': 4022, 'therapyName': 'Capecitabine + Pembrolizumab'}]",Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery,60081
123,NCT03076372,Phase I,Recruiting,"[{'id': 5758, 'therapyName': 'MM-310'}]",A Study Evaluating MM-310 in Patients With Solid Tumors,60081
124,NCT03090165,Phase Ib/II,Recruiting,"[{'id': 5479, 'therapyName': 'Ribociclib + Bicalutamide'}]",Ribociclib and Bicalutamide in AR+ TNBC,60081
125,NCT03098550,Phase Ib/II,Recruiting,"[{'id': 5520, 'therapyName': 'Daratumumab + Nivolumab '}]",A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Advanced Solid Tumors or Tumors That Have Spread,60081
126,NCT03106077,Phase II,Recruiting,"[{'id': 3232, 'therapyName': 'IMGN853'}]",Mirvetuximab Soravtansine in Localized Triple-Negative Breast Cancer (TNBC),60081
127,NCT03106415,Phase Ib/II,Recruiting,"[{'id': 5568, 'therapyName': 'Binimetinib + Pembrolizumab'}]",Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer,60081
128,NCT03121352,Phase I,Recruiting,"[{'id': 5591, 'therapyName': 'Carboplatin + nab-paclitaxel + Pembrolizumab'}]","Pilot Study of Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer",60081
129,NCT03125902,Phase III,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 5606, 'therapyName': 'Atezolizumab + Paclitaxel'}]",A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC) (IMpassion131),60081
130,NCT03130439,Phase II,Recruiting,"[{'id': 802, 'therapyName': 'Abemaciclib'}]","Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast Cancer",60081
131,NCT03134638,Phase I,Recruiting,"[{'id': 5700, 'therapyName': 'SY-1365'}]",A Phase 1 Study of SY-1365 in Adult Patients With Advanced Solid Tumors,60081
132,NCT03150810,Phase Ib/II,Recruiting,"[{'id': 6124, 'therapyName': 'BGB-290 + Temozolomide'}]","Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Subjects With Locally Advanced or Metastatic Solid Tumors",60081
133,NCT03184558,Phase II,Recruiting,"[{'id': 5964, 'therapyName': 'BGB-324 + Pembrolizumab'}]",BGB324 in Combination With Pembrolizumab in Patients With TNBC,60081
134,NCT03193853,Phase II,Recruiting,"[{'id': 3126, 'therapyName': 'Cisplatin + nab-paclitaxel'}, {'id': 1283, 'therapyName': 'MLN1117 + Sapanisertib'}]",TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast Cancer,60081
135,NCT03197935,Phase III,Recruiting,"[{'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer (IMpassion031),60081
136,NCT03199040,Phase I,Not yet recruiting,"[{'id': 1356, 'therapyName': 'Durvalumab'}]",Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy,60081
137,NCT03206203,Phase II,Recruiting,"[{'id': 5983, 'therapyName': 'Atezolizumab + Carboplatin'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer,60081
138,NCT03213041,Phase II,Recruiting,"[{'id': 5265, 'therapyName': 'Carboplatin + Pembrolizumab'}]",Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer,60081
139,NCT03221400,Phase Ib/II,Recruiting,"[{'id': 4842, 'therapyName': 'STA-8666'}]",PEN-866 in Patients With Advanced Solid Malignancies,60081
140,NCT03225547,Phase II,Not yet recruiting,"[{'id': 6030, 'therapyName': 'Mifepristone + Pembrolizumab'}]",Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer,60081
141,NCT03243331,Phase I,Not yet recruiting,"[{'id': 6110, 'therapyName': 'Gedatolisib + PF-06647020'}]",An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer,60081
142,NCT03289962,Phase I,Not yet recruiting,"[{'id': 6234, 'therapyName': 'RO7198457'}, {'id': 6235, 'therapyName': 'Atezolizumab + RO7198457'}]",A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors,60081
143,NCT03292172,Phase I,Not yet recruiting,"[{'id': 6286, 'therapyName': 'Atezolizumab + TEN-010'}]","A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer",60081
0,NCT02664961,Phase II,Recruiting,"[{'id': 1243, 'therapyName': 'Bevacizumab + TRC105'}]",Study of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN),4085
0,NCT02834013,Phase 0,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab in Treating Patients With Rare Tumors,4938
0,NCT00942331,Phase III,"Active, not recruiting","[{'id': 1295, 'therapyName': 'Gemcitabine + Bevacizumab + Cisplatin'}, {'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}]",Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer,11819
1,NCT01366144,Phase I,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 954, 'therapyName': 'Veliparib'}, {'id': 1092, 'therapyName': 'Carboplatin'}]","Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction",11819
0,NCT01688999,Phase II,"Active, not recruiting","[{'id': 998, 'therapyName': 'cabozantinib'}]",Cabozantinib for Advanced Urothelial Cancer,4939
1,NCT03171025,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Adjuvant Nivolumab Following Chemo-Radiation in Localized Muscle-Invasive Bladder Cancer (NEXT),4939
0,NCT02834013,Phase 0,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab in Treating Patients With Rare Tumors,5539
0,NCT00942331,Phase III,"Active, not recruiting","[{'id': 1295, 'therapyName': 'Gemcitabine + Bevacizumab + Cisplatin'}, {'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}]",Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer,6888
1,NCT01108055,Phase II,Completed,"[{'id': 1143, 'therapyName': 'Pazopanib + Paclitaxel'}]",Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer,6888
2,NCT01174121,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 1167, 'therapyName': 'Aldesleukin'}]",Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer,6888
3,NCT01215136,Phase II,"Active, not recruiting","[{'id': 735, 'therapyName': 'Everolimus'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma,6888
4,NCT01326871,Phase Ib/II,"Active, not recruiting","[{'id': 2187, 'therapyName': 'ALT-801'}]",A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer,6888
5,NCT01366144,Phase I,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 954, 'therapyName': 'Veliparib'}, {'id': 1092, 'therapyName': 'Carboplatin'}]","Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction",6888
6,NCT01780545,Phase II,Completed,"[{'id': 1807, 'therapyName': 'OGX-427'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer,6888
7,NCT02014337,Phase I,"Active, not recruiting","[{'id': 3053, 'therapyName': 'Eribulin + Mifepristone'}]",Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors,6888
8,NCT02108652,Phase II,"Active, not recruiting","[{'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study of MPDL3280A in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer,6888
9,NCT02122172,Phase II,Recruiting,"[{'id': 623, 'therapyName': 'Afatinib'}]",Afatinib in Advanced Refractory Urothelial Cancer,6888
10,NCT02178722,Phase Ib/II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2575, 'therapyName': 'Epacadostat'}]","A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Solid Tumors and Advanced NSCLC (INCB 24360-202 / MK-3475-037 / KEYNOTE-037)",6888
11,NCT02236195,Phase II,Completed,"[{'id': 3002, 'therapyName': 'Mocetinostat'}]",Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes,6888
12,NCT02240238,Phase Ib/II,Recruiting,"[{'id': 5626, 'therapyName': 'Gemcitabine + NC-6004'}]","Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer",6888
13,NCT02256436,Phase III,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045)",6888
14,NCT02300610,Phase I,"Active, not recruiting","[{'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]",Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer,6888
15,NCT02302807,Phase III,"Active, not recruiting","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 720, 'therapyName': 'Docetaxel'}]",A Study of MPDL3280A Compared With Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer,6888
16,NCT02334527,Phase II,Recruiting,"[{'id': 850, 'therapyName': 'Palbociclib'}]",Phase II Trial of Palbociclib (PD-0332991) in Patients With Metastatic Urothelial Cancer (UC) After Failure of First-Line Chemotherapy,6888
17,NCT02335424,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-52),6888
18,NCT02365766,Phase Ib/II,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",Study of Neoadjuvant Pembrolizumab in Combination With Gemcitabine Based Therapy in Cis-eligible or -Ineligible Subjects With Urothelial Cancer,6888
19,NCT02365818,Phase II,"Active, not recruiting","[{'id': 2523, 'therapyName': 'CG0070'}]",Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade Non-Muscle Invasive Bladder Cancer After BCG Failure,6888
20,NCT02387996,Phase II,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}]",A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder Cancer,6888
21,NCT02401542,Phase II,Recruiting,"[{'id': 2934, 'therapyName': 'B-701'}, {'id': 720, 'therapyName': 'Docetaxel'}]",A Phase 2 Study of B-701 in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma,6888
22,NCT02412670,Phase II,Recruiting,"[{'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}, {'id': 2668, 'therapyName': 'Aldoxorubicin + Cisplatin + Methotrexate + Vincristine'}]",Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer,6888
23,NCT02426125,Phase III,"Active, not recruiting","[{'id': 886, 'therapyName': 'Ramucirumab'}, {'id': 720, 'therapyName': 'Docetaxel'}]",A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer,6888
24,NCT02437370,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer,6888
25,NCT02443324,Phase I,"Active, not recruiting","[{'id': 2896, 'therapyName': 'Pembrolizumab + Ramucirumab'}]","A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC or Transitional Cell Carcinoma of the Urothelium",6888
26,NCT02459119,Phase II,Recruiting,"[{'id': 890, 'therapyName': 'Regorafenib'}]",Study of Regorafenib for Urothelial Cancer Following Chemotherapy (UAB 1477),6888
27,NCT02479178,Phase II,Terminated,"[{'id': 3640, 'therapyName': 'BIND-014'}]","A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck  (iNSITE2)",6888
28,NCT02496208,Phase I,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 2067, 'therapyName': 'Cabozantinib + Nivolumab'}]",Cabozantinib Plus Nivolumab (CaboNivo) Alone or in Combination With Ipilimumab (CaboNivoIpi) in Patients With Advanced/Metastatic Urothelial Carcinoma and Other Genitourinary Tumors,6888
29,NCT02500121,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Testing the PD-1 Inhibitor Pembrolizumab After Initial Chemotherapy in Patients With Metastatic Bladder Cancer,6888
30,NCT02516241,Phase III,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 4686, 'therapyName': 'Carboplatin + Cisplatin + Gemcitabine'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",Study of MEDI4736 With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer,6888
31,NCT02553642,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260),6888
32,NCT02559492,Phase I,"Active, not recruiting","[{'id': 3096, 'therapyName': 'INCB039110 + INCB024360'}, {'id': 3097, 'therapyName': 'INCB039110 + INCB050465'}]",INCB039110 Combined With INCB024360 and/or INCB039110 Combined With INCB050465 in Advanced Solid Tumors,6888
33,NCT02567409,Phase II,Recruiting,"[{'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 3110, 'therapyName': 'Cisplatin + Gemcitabine + VX-970'}]",Cisplatin and Gemcitabine Hydrochloride With or Without ATR Kinase Inhibitor VX-970 in Treating Patients With Metastatic Urothelial Cancer,6888
34,NCT02581982,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer,6888
35,NCT02589717,FDA approved,Approved for marketing,"[{'id': 1201, 'therapyName': 'Atezolizumab'}]",An Expanded Access Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Urothelial Bladder Cancer After Failure With Platinum-Containing Chemotherapy,6888
36,NCT02612194,Phase II,Recruiting,"[{'id': 706, 'therapyName': 'Crizotinib'}]",LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer,6888
37,NCT02619253,Phase Ib/II,Recruiting,"[{'id': 3077, 'therapyName': 'Pembrolizumab + Vorinostat'}]",Phase I/Ib Study of Pembrolizumab With Vorinostat for Patients With Advanced Renal or Urothelial Cell Carcinoma,6888
38,NCT02632409,Phase III,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",A Study of Adjuvant Nivolumab Versus Placebo Post-Surgical Removal of High Risk Invasive Urothelial Carcinoma,6888
39,NCT02646748,Phase I,Recruiting,"[{'id': 3088, 'therapyName': 'INCB050465 '}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2406, 'therapyName': 'INCB039110'}]",Pembrolizumab Combined With INCB039110 and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors,6888
40,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,6888
41,NCT02807636,Phase III,Recruiting,"[{'id': 4450, 'therapyName': 'Atezolizumab + Carboplatin + Gemcitabine'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}]",The Effect of Atezolizumab in Combination With Gemcitabine/Carboplatin and Gemcitabine/Carboplatin Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-based Therapy,6888
42,NCT02812420,Phase I,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]","Pre-Surgical Study Evaluating Anti-PD-L1 Antibody (Durvalumab) Plus Anti-CTLA-4 (Tremelimumab) in Patients With Muscle-Invasive, High-Risk Urothelial Carcinoma Who Are Ineligible for Cisplatin-based Neoadjuvant Chemotherapy",6888
43,NCT02853305,Phase III,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 4686, 'therapyName': 'Carboplatin + Cisplatin + Gemcitabine'}]",Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma (MK-3475-361/KEYNOTE-361),6888
44,NCT02872714,Phase II,Recruiting,"[{'id': 4173, 'therapyName': 'INCB054828'}]",A Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Urothelial Carcinoma,6888
45,NCT02897765,Phase I,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 4733, 'therapyName': 'NEO-PV-01 + poly ICLC'}]","A Personalized Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer",6888
46,NCT02925533,Phase I,Terminated,"[{'id': 4831, 'therapyName': 'B-701 + Pembrolizumab'}]",Ph 1B B-701 in Combination With Pembrolizumab in Metastatic Transitional Cell Carcinoma of the Urothelial Tract,6888
47,NCT02989584,Phase Ib/II,Recruiting,"[{'id': 5140, 'therapyName': 'Atezolizumab + Cisplatin + Gemcitabine'}]",A Pilot Safety Study of Atezolizumab Combination With Cisplatin + Gemcitabine in Pts With Metastatic Bladder Cancer,6888
48,NCT03093922,Phase II,Recruiting,"[{'id': 5140, 'therapyName': 'Atezolizumab + Cisplatin + Gemcitabine'}]",A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer,6888
49,NCT03133390,Phase II,Recruiting,"[{'id': 4595, 'therapyName': 'Atezolizumab + Bevacizumab'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",Atezolizumab With or Without Bevacizumab in Cisplatin-ineligible Patients,6888
50,NCT03170960,Phase Ib/II,Recruiting,"[{'id': 6094, 'therapyName': 'Atezolizumab + Cabozantinib'}]",Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors,6888
51,NCT03237780,Phase II,Not yet recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 6098, 'therapyName': 'Atezolizumab + Eribulin'}]",Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer,6888
0,NCT02834013,Phase 0,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab in Treating Patients With Rare Tumors,4910
0,NCT00942331,Phase III,"Active, not recruiting","[{'id': 1295, 'therapyName': 'Gemcitabine + Bevacizumab + Cisplatin'}, {'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}]",Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer,734
1,NCT01366144,Phase I,Recruiting,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 954, 'therapyName': 'Veliparib'}, {'id': 1092, 'therapyName': 'Carboplatin'}]","Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction",734
2,NCT01688999,Phase II,"Active, not recruiting","[{'id': 998, 'therapyName': 'cabozantinib'}]",Cabozantinib for Advanced Urothelial Cancer,734
3,NCT03023319,Phase I,Recruiting,"[{'id': 5237, 'therapyName': 'Bosutinib + Pemetrexed'}]",Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors,734
4,NCT03171025,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Adjuvant Nivolumab Following Chemo-Radiation in Localized Muscle-Invasive Bladder Cancer (NEXT),734
0,NCT02834013,Phase 0,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab in Treating Patients With Rare Tumors,3750
0,NCT00942331,Phase III,"Active, not recruiting","[{'id': 1295, 'therapyName': 'Gemcitabine + Bevacizumab + Cisplatin'}, {'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}]",Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer,4013
1,NCT01108055,Phase II,Completed,"[{'id': 1143, 'therapyName': 'Pazopanib + Paclitaxel'}]",Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer,4013
2,NCT01174121,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 1167, 'therapyName': 'Aldesleukin'}]",Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer,4013
3,NCT01215136,Phase II,"Active, not recruiting","[{'id': 735, 'therapyName': 'Everolimus'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma,4013
4,NCT01326871,Phase Ib/II,"Active, not recruiting","[{'id': 2187, 'therapyName': 'ALT-801'}]",A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer,4013
5,NCT01780545,Phase II,Completed,"[{'id': 1807, 'therapyName': 'OGX-427'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer,4013
6,NCT02014337,Phase I,"Active, not recruiting","[{'id': 3053, 'therapyName': 'Eribulin + Mifepristone'}]",Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors,4013
7,NCT02108652,Phase II,"Active, not recruiting","[{'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study of MPDL3280A in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer,4013
8,NCT02122172,Phase II,Recruiting,"[{'id': 623, 'therapyName': 'Afatinib'}]",Afatinib in Advanced Refractory Urothelial Cancer,4013
9,NCT02178722,Phase Ib/II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2575, 'therapyName': 'Epacadostat'}]","A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Solid Tumors and Advanced NSCLC (INCB 24360-202 / MK-3475-037 / KEYNOTE-037)",4013
10,NCT02236195,Phase II,Completed,"[{'id': 3002, 'therapyName': 'Mocetinostat'}]",Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes,4013
11,NCT02240238,Phase Ib/II,Recruiting,"[{'id': 5626, 'therapyName': 'Gemcitabine + NC-6004'}]","Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer",4013
12,NCT02256436,Phase III,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045)",4013
13,NCT02300610,Phase I,"Active, not recruiting","[{'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]",Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer,4013
14,NCT02302807,Phase III,"Active, not recruiting","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 720, 'therapyName': 'Docetaxel'}]",A Study of MPDL3280A Compared With Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer,4013
15,NCT02334527,Phase II,Recruiting,"[{'id': 850, 'therapyName': 'Palbociclib'}]",Phase II Trial of Palbociclib (PD-0332991) in Patients With Metastatic Urothelial Cancer (UC) After Failure of First-Line Chemotherapy,4013
16,NCT02335424,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-52),4013
17,NCT02365766,Phase Ib/II,Recruiting,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",Study of Neoadjuvant Pembrolizumab in Combination With Gemcitabine Based Therapy in Cis-eligible or -Ineligible Subjects With Urothelial Cancer,4013
18,NCT02365818,Phase II,"Active, not recruiting","[{'id': 2523, 'therapyName': 'CG0070'}]",Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade Non-Muscle Invasive Bladder Cancer After BCG Failure,4013
19,NCT02387996,Phase II,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}]",A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder Cancer,4013
20,NCT02401542,Phase II,Recruiting,"[{'id': 2934, 'therapyName': 'B-701'}, {'id': 720, 'therapyName': 'Docetaxel'}]",A Phase 2 Study of B-701 in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma,4013
21,NCT02426125,Phase III,"Active, not recruiting","[{'id': 886, 'therapyName': 'Ramucirumab'}, {'id': 720, 'therapyName': 'Docetaxel'}]",A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer,4013
22,NCT02437370,Phase I,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer,4013
23,NCT02459119,Phase II,Recruiting,"[{'id': 890, 'therapyName': 'Regorafenib'}]",Study of Regorafenib for Urothelial Cancer Following Chemotherapy (UAB 1477),4013
24,NCT02479178,Phase II,Terminated,"[{'id': 3640, 'therapyName': 'BIND-014'}]","A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck  (iNSITE2)",4013
25,NCT02496208,Phase I,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 2067, 'therapyName': 'Cabozantinib + Nivolumab'}]",Cabozantinib Plus Nivolumab (CaboNivo) Alone or in Combination With Ipilimumab (CaboNivoIpi) in Patients With Advanced/Metastatic Urothelial Carcinoma and Other Genitourinary Tumors,4013
26,NCT02500121,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Testing the PD-1 Inhibitor Pembrolizumab After Initial Chemotherapy in Patients With Metastatic Bladder Cancer,4013
27,NCT02516241,Phase III,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 4686, 'therapyName': 'Carboplatin + Cisplatin + Gemcitabine'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",Study of MEDI4736 With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer,4013
28,NCT02553642,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260),4013
29,NCT02559492,Phase I,"Active, not recruiting","[{'id': 3096, 'therapyName': 'INCB039110 + INCB024360'}, {'id': 3097, 'therapyName': 'INCB039110 + INCB050465'}]",INCB039110 Combined With INCB024360 and/or INCB039110 Combined With INCB050465 in Advanced Solid Tumors,4013
30,NCT02567409,Phase II,Recruiting,"[{'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 3110, 'therapyName': 'Cisplatin + Gemcitabine + VX-970'}]",Cisplatin and Gemcitabine Hydrochloride With or Without ATR Kinase Inhibitor VX-970 in Treating Patients With Metastatic Urothelial Cancer,4013
31,NCT02581982,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer,4013
32,NCT02589717,FDA approved,Approved for marketing,"[{'id': 1201, 'therapyName': 'Atezolizumab'}]",An Expanded Access Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Urothelial Bladder Cancer After Failure With Platinum-Containing Chemotherapy,4013
33,NCT02612194,Phase II,Recruiting,"[{'id': 706, 'therapyName': 'Crizotinib'}]",LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer,4013
34,NCT02619253,Phase Ib/II,Recruiting,"[{'id': 3077, 'therapyName': 'Pembrolizumab + Vorinostat'}]",Phase I/Ib Study of Pembrolizumab With Vorinostat for Patients With Advanced Renal or Urothelial Cell Carcinoma,4013
35,NCT02646748,Phase I,Recruiting,"[{'id': 3088, 'therapyName': 'INCB050465 '}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2406, 'therapyName': 'INCB039110'}]",Pembrolizumab Combined With INCB039110 and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors,4013
36,NCT02788201,Phase II,Recruiting,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,4013
37,NCT02807636,Phase III,Recruiting,"[{'id': 4450, 'therapyName': 'Atezolizumab + Carboplatin + Gemcitabine'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}]",The Effect of Atezolizumab in Combination With Gemcitabine/Carboplatin and Gemcitabine/Carboplatin Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-based Therapy,4013
38,NCT02812420,Phase I,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]","Pre-Surgical Study Evaluating Anti-PD-L1 Antibody (Durvalumab) Plus Anti-CTLA-4 (Tremelimumab) in Patients With Muscle-Invasive, High-Risk Urothelial Carcinoma Who Are Ineligible for Cisplatin-based Neoadjuvant Chemotherapy",4013
39,NCT02853305,Phase III,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 4686, 'therapyName': 'Carboplatin + Cisplatin + Gemcitabine'}]",Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma (MK-3475-361/KEYNOTE-361),4013
40,NCT02897765,Phase I,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 4733, 'therapyName': 'NEO-PV-01 + poly ICLC'}]","A Personalized Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer",4013
41,NCT02925533,Phase I,Terminated,"[{'id': 4831, 'therapyName': 'B-701 + Pembrolizumab'}]",Ph 1B B-701 in Combination With Pembrolizumab in Metastatic Transitional Cell Carcinoma of the Urothelial Tract,4013
42,NCT02989584,Phase Ib/II,Recruiting,"[{'id': 5140, 'therapyName': 'Atezolizumab + Cisplatin + Gemcitabine'}]",A Pilot Safety Study of Atezolizumab Combination With Cisplatin + Gemcitabine in Pts With Metastatic Bladder Cancer,4013
43,NCT03093922,Phase II,Recruiting,"[{'id': 5140, 'therapyName': 'Atezolizumab + Cisplatin + Gemcitabine'}]",A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer,4013
44,NCT03133390,Phase II,Recruiting,"[{'id': 4595, 'therapyName': 'Atezolizumab + Bevacizumab'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",Atezolizumab With or Without Bevacizumab in Cisplatin-ineligible Patients,4013
45,NCT03170960,Phase Ib/II,Recruiting,"[{'id': 6094, 'therapyName': 'Atezolizumab + Cabozantinib'}]",Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors,4013
46,NCT03237780,Phase II,Not yet recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 6098, 'therapyName': 'Atezolizumab + Eribulin'}]",Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer,4013
0,NCT00959868,Phase I,Unknown status,"[{'id': 1807, 'therapyName': 'OGX-427'}]",A Study for Treatment of Superficial Bladder Cancer Using OGX-427,11054
1,NCT01730118,Phase I,Recruiting,"[{'id': 1404, 'therapyName': 'HER2 Vaccine'}]",Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing,11054
2,NCT01738815,Phase I,Unknown status,"[{'id': 1076, 'therapyName': 'Valproic acid'}]",Impact of Valproate on Angiogenesis and Histone Deacetylation in Bladder Cancer,11054
3,NCT01928394,Phase Ib/II,"Active, not recruiting","[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]","A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab in Subjects With Advanced or Metastatic Solid Tumors",11054
4,NCT01966445,Phase I,Completed,"[{'id': 2919, 'therapyName': 'GSK2849330'}]","Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors",11054
5,NCT01968109,Phase I,Recruiting,"[{'id': 4197, 'therapyName': 'BMS-986016 + Nivolumab'}, {'id': 4196, 'therapyName': 'BMS-986016'}]",Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors,11054
6,NCT01976741,Phase I,Recruiting,"[{'id': 2030, 'therapyName': 'Rogaratinib'}]",Phase I Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor,11054
7,NCT02043665,Phase I,Recruiting,"[{'id': 2974, 'therapyName': 'coxsackievirus A21'}]",Systemic Treatment Of Resistant Metastatic Disease Employing CVA21 and Pembrolizumab in Non-small Cell Lung Cancer and Bladder Cancer (STORM/ KEYNOTE-200) (STORM),11054
8,NCT02177695,Phase II,Recruiting,"[{'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 2564, 'therapyName': 'Aldoxorubicin + Cisplatin + Filgrastim + Methotrexate + Vinblastine'}]","S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer",11054
9,NCT02323191,Phase I,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 2004, 'therapyName': 'LY3022855'}]",A Study of RO5509554 and MPDL3280A Administered in Combination in Patients With Advanced Solid Tumors,11054
10,NCT02346955,Phase I,Terminated,"[{'id': 4246, 'therapyName': 'CM-24'}, {'id': 4247, 'therapyName': 'CM-24 + Pembrolizumab'}]",Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001),11054
11,NCT02351739,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1605, 'therapyName': 'Acalabrutinib'}]",Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum-refractory Metastatic Bladder Cancer,11054
12,NCT02360618,Phase II,Recruiting,"[{'id': 1829, 'therapyName': 'Metformin + Simvastatin'}]",Metformin and Simvastatin Use in Bladder Cancer,11054
13,NCT02365818,Phase II,"Active, not recruiting","[{'id': 2523, 'therapyName': 'CG0070'}]",Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade Non-Muscle Invasive Bladder Cancer After BCG Failure,11054
14,NCT02452424,Phase Ib/II,"Active, not recruiting","[{'id': 2736, 'therapyName': 'Pembrolizumab + PLX3397'}]",A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors,11054
15,NCT02528357,Phase I,Recruiting,"[{'id': 5177, 'therapyName': 'GSK3174998'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",GSK3174998 Alone or With Pembrolizumab in Subjects With Advanced Solid Tumors,11054
16,NCT02529553,Phase I,Recruiting,"[{'id': 3164, 'therapyName': 'LY3076226'}]",A Study of LY3076226 in Participants With Advanced or Metastatic Cancer,11054
17,NCT02543645,Phase Ib/II,Terminated,"[{'id': 3086, 'therapyName': 'Atezolizumab + Varlilumab'}]",A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer,11054
18,NCT02546661,Phase I,Recruiting,"[{'id': 654, 'therapyName': 'AZD4547'}, {'id': 1356, 'therapyName': 'Durvalumab'}]","Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer",11054
19,NCT02605863,Phase II,Recruiting,"[{'id': 1262, 'therapyName': 'Enzalutamide'}]",Enzalutamide for Bladder Cancer Chemoprevention,11054
20,NCT02643303,Phase Ib/II,Recruiting,"[{'id': 3385, 'therapyName': 'MEDI4736 + poly ICLC '}, {'id': 1652, 'therapyName': 'Tremelimumab'}]","A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers",11054
21,NCT02646319,Phase II,"Active, not recruiting","[{'id': 3380, 'therapyName': 'Nab-Rapamycin'}]",Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations,11054
22,NCT02655822,Phase I,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 3571, 'therapyName': 'CPI-444 '}]",Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers,11054
23,NCT02675829,Phase II,Recruiting,"[{'id': 1402, 'therapyName': 'trastuzumab emtansine'}]",Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers,11054
24,NCT02753309,Phase 0,Recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}]",A Study of Rapamycin Combined With Intravesical BCG in Patients With Non-muscle Invasive Bladder Cancer,11054
25,NCT02808143,Phase I,Recruiting,"[{'id': 4457, 'therapyName': 'BCG solution + Pembrolizumab'}]",Pembrolizumab and BCG Solution in Treating Patients With Recurrent Non-Muscle-Invasive Bladder Cancer,11054
26,NCT02880371,Phase Ib/II,Recruiting,"[{'id': 4608, 'therapyName': 'ARRY-382 + Pembrolizumab'}]",A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors,11054
27,NCT02952248,Phase I,Recruiting,"[{'id': 5692, 'therapyName': 'BI 754091'}]",A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours,11054
28,NCT03023319,Phase I,Recruiting,"[{'id': 5237, 'therapyName': 'Bosutinib + Pemetrexed'}]",Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors,11054
29,NCT03298958,Phase III,Not yet recruiting,"[{'id': 917, 'therapyName': 'Sirolimus'}]",Secondary Prevention Trial of Rapamycin in Patients With Resected Non-muscle Invasive Bladder Cancer,11054
0,NCT01182168,Phase I,Completed,"[{'id': 2296, 'therapyName': 'Cisplatin + Everolimus + Gemcitabine'}]",Gemcitabine and Split-Dose Cisplatin Plus Everolimus (RAD001) in Patients With Advanced Solid Tumor Malignancies,3996
1,NCT01848756,Phase Ib/II,Terminated,"[{'id': 866, 'therapyName': 'SNX-5422'}]",Safety and Efficacy of SNX-5422 in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Cancers,3996
2,NCT02192541,Phase I,Completed,"[{'id': 1665, 'therapyName': 'Ganetespib + Aflibercept'}]","Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas",3996
3,NCT02365597,Phase II,Recruiting,"[{'id': 1028, 'therapyName': 'JNJ-42756493'}]",An Efficacy and Safety Study of JNJ-42756493 in Participants With Urothelial Cancer,3996
4,NCT02675829,Phase II,Recruiting,"[{'id': 1402, 'therapyName': 'trastuzumab emtansine'}]",Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers,3996
5,NCT02928406,Phase III,Recruiting,"[{'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract,3996
6,NCT03084471,Phase III,Recruiting,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]","An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies. (STRONG)",3996
0,NCT02349958,Phase II,Recruiting,"[{'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy,363
1,NCT02646319,Phase II,"Active, not recruiting","[{'id': 3380, 'therapyName': 'Nab-Rapamycin'}]",Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations,363
2,NCT02874430,Phase II,Recruiting,"[{'id': 4610, 'therapyName': 'Metformin + Doxycycline'}]",Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer,363
3,NCT03206177,Phase I,Recruiting,"[{'id': 6265, 'therapyName': 'Carboplatin + Galunisertib + Paclitaxel'}]",Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary,363
4,NCT03241745,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",A Study of Nivolumab in Selected Uterine Cancer Patients,363
0,NCT02963831,Phase Ib/II,Recruiting,"[{'id': 4978, 'therapyName': 'ONCOS-102 + MEDI4736'}]","A Phase 1/2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies",6171
1,NCT03241745,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",A Study of Nivolumab in Selected Uterine Cancer Patients,6171
0,NCT00954174,Phase III,"Active, not recruiting","[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1125, 'therapyName': 'Paclitaxel + Ifosfamide'}]","Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritorium Cavity Cancer",5165
0,NCT01367002,Phase II,"Active, not recruiting","[{'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer,5750
1,NCT02491099,Phase II,Recruiting,"[{'id': 623, 'therapyName': 'Afatinib'}]",A Phase II Evaluation of Afatinib,5750
0,NCT02736435,Phase III,Not yet recruiting,"[{'id': 795, 'therapyName': 'Leuprolide'}]",Treatment of Uterine Fibroids With Magnetic Resonance Guided High Intensity Focused Ultrasound,13223
0,NCT02428192,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab in Treating Patients With Advanced Uterine Leiomyosarcoma,5289
1,NCT02963831,Phase Ib/II,Recruiting,"[{'id': 4978, 'therapyName': 'ONCOS-102 + MEDI4736'}]","A Phase 1/2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies",5289
2,NCT03241745,Phase II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",A Study of Nivolumab in Selected Uterine Cancer Patients,5289
0,NCT00489944,Phase II,Unknown status,"[{'id': 1963, 'therapyName': 'Sunitinib + Tamoxifen + Cisplatin'}]","Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular Melanoma",6039
1,NCT01200238,Phase II,"Active, not recruiting","[{'id': 745, 'therapyName': 'Ganetespib'}]",STA-9090(Ganetespib) in Metastatic Ocular Melanoma,6039
2,NCT01430416,Phase I,"Active, not recruiting","[{'id': 621, 'therapyName': 'AEB071'}]",Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients,6039
3,NCT01471054,Phase II,Terminated,"[{'id': 1480, 'therapyName': 'Dexamethasone intravitreal implant'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma,6039
4,NCT01585194,Phase II,Recruiting,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Phase II Study of Nivolumab in Combination With Ipilimumab for Uveal Melanoma,6039
5,NCT01587352,Phase II,Suspended,"[{'id': 1077, 'therapyName': 'Vorinostat'}]",Vorinostat in Treating Patients With Metastatic Melanoma of the Eye,6039
6,NCT01835145,Phase II,"Active, not recruiting","[{'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 998, 'therapyName': 'cabozantinib'}]",Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Melanoma of the Eye,6039
7,NCT01974752,Phase III,Completed,"[{'id': 1432, 'therapyName': 'Selumetinib + Dacarbazine'}]",Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT),6039
8,NCT01979523,Phase II,"Active, not recruiting","[{'id': 2, 'therapyName': 'Trametinib'}, {'id': 1298, 'therapyName': 'Trametinib + GSK2141795'}]",Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma,6039
9,NCT02068586,Phase II,Recruiting,"[{'id': 1076, 'therapyName': 'Valproic acid'}, {'id': 930, 'therapyName': 'Sunitinib'}]",Adjuvant Sunitinib or Valproic Acid in High-Risk Patients With Uveal Melanoma,6039
10,NCT02223819,Phase II,Recruiting,"[{'id': 706, 'therapyName': 'Crizotinib'}]",Adjuvant Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy,6039
11,NCT02273219,Phase I,Recruiting,"[{'id': 1861, 'therapyName': 'AEB071 + BYL719'}]",Trial of AEB071 in Combination With BYL719 in Patients With Melanoma,6039
12,NCT02359851,Phase II,"Active, not recruiting","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Treating Patients With Advanced Uveal Melanoma,6039
13,NCT02363283,Phase II,Recruiting,"[{'id': 3597, 'therapyName': 'Glembatumumab vedotin'}]",Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma,6039
14,NCT02570308,Phase I,Recruiting,"[{'id': 3847, 'therapyName': 'IMCgp100'}]",A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma,6039
15,NCT02768766,Phase I,Recruiting,"[{'id': 913, 'therapyName': 'Selumetinib'}]",Intermittent Selumetinib for Uveal Melanoma,6039
16,NCT02913417,Phase Ib/II,Recruiting,"[{'id': 4769, 'therapyName': 'Yttrium-90 + Nivolumab + Ipilimumab'}]","Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases",6039
17,NCT03022565,Phase I,Not yet recruiting,"[{'id': 1077, 'therapyName': 'Vorinostat'}]",Vorinostat in Patients With Class 2 High Risk Uveal Melanoma,6039
18,NCT03052127,Phase I,Recruiting,"[{'id': 5828, 'therapyName': 'AU-011'}]",Phase 1B Study in Subjects With Small to Medium Primary Choroidal Melanoma,6039
19,NCT03068624,Phase I,Recruiting,"[{'id': 5733, 'therapyName': 'Aldesleukin + Cyclophosphamide + Ipilimumab'}]",Study of Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells and Anti-CTLA4 for Patients With Metastatic Uveal Melanoma,6039
20,NCT03070392,Phase II,Recruiting,"[{'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 3847, 'therapyName': 'IMCgp100'}]",Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma,6039
21,NCT03207347,Phase II,Not yet recruiting,"[{'id': 832, 'therapyName': 'Niraparib'}]",A Trial of Niraparib in BAP1 and Other DNA Double-Strand Break Repair Deficient Neoplasms (UF-STO-ETI-001),6039
0,NCT02426892,Phase II,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab and HPV-16 Vaccination in Patients With HPV-16 Positive Incurable Solid Tumors,119
1,NCT02488759,Phase Ib/II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",A Study to Investigate the Safety and Efficacy of Nivolumab in Virus-associated Tumors (CheckMate358),119
2,NCT02812056,Phase I,Withdrawn,"[{'id': 4214, 'therapyName': 'Alisertib + MLN0128'}]",Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated Malignancies,119
3,NCT02963831,Phase Ib/II,Recruiting,"[{'id': 4978, 'therapyName': 'ONCOS-102 + MEDI4736'}]","A Phase 1/2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies",119
0,NCT02834013,Phase 0,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab in Treating Patients With Rare Tumors,50918
0,NCT02834013,Phase 0,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab in Treating Patients With Rare Tumors,138
1,NCT03074513,Phase II,Recruiting,"[{'id': 4595, 'therapyName': 'Atezolizumab + Bevacizumab'}]",Atezolizumab and Bevacizumab in Rare Solid Tumors,138
0,NCT03148275,Phase II,Recruiting,"[{'id': 2, 'therapyName': 'Trametinib'}]","Trametinib in Treating Patients With Epithelioid Hemangioendothelioma That Is Metastatic, Locally Advanced, or Cannot Be Removed by Surgery",175
0,NCT02831179,Phase I,Withdrawn,"[{'id': 4463, 'therapyName': 'Capecitabine + Veliparib + Temozolomide'}]","Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor",5574
0,NCT02834013,Phase 0,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab in Treating Patients With Rare Tumors,2098
0,NCT02426892,Phase II,"Active, not recruiting","[{'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab and HPV-16 Vaccination in Patients With HPV-16 Positive Incurable Solid Tumors,1245
1,NCT02812056,Phase I,Withdrawn,"[{'id': 4214, 'therapyName': 'Alisertib + MLN0128'}]",Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated Malignancies,1245
2,NCT02963831,Phase Ib/II,Recruiting,"[{'id': 4978, 'therapyName': 'ONCOS-102 + MEDI4736'}]","A Phase 1/2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies",1245
0,NCT02488759,Phase Ib/II,Recruiting,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",A Study to Investigate the Safety and Efficacy of Nivolumab in Virus-associated Tumors (CheckMate358),1294
1,NCT02628067,Phase II,Recruiting,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158),1294
0,NCT02834013,Phase 0,Recruiting,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab in Treating Patients With Rare Tumors,2101
1,NCT03074513,Phase II,Recruiting,"[{'id': 4595, 'therapyName': 'Atezolizumab + Bevacizumab'}]",Atezolizumab and Bevacizumab in Rare Solid Tumors,2101
0,NCT02978625,Phase II,Recruiting,"[{'id': 5080, 'therapyName': 'Talimogene laherparepvec + Nivolumab'}]",Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers,2072
0,NCT02576496,Phase I,Recruiting,"[{'id': 6104, 'therapyName': 'EDO-S101'}]","Study of EDO-S101, A First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies",60901
1,NCT03147885,Phase Ib/II,Recruiting,"[{'id': 1749, 'therapyName': 'Selinexor'}]",Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma,60901
2,NCT03162536,Phase I,Recruiting,"[{'id': 5224, 'therapyName': 'ARQ 531'}]","Safety, PK, PD, and Antitumor Activity of ARQ 531 in Hematologic Malignancies",60901
